The International Society on Thrombosis and Haemostasis

BOSTO

XXII Congress

The International Society on Thrombosis and Haemostasis

July 11-16 2009

NFinalProgram

55th Annual Meetingof the Scientific

and Standardization Committeeof the ISTH

XX

IIC

ongr

ess

of t

he I

nter

nati

onal

Soc

iety

on T

hrom

bos

is a

nd H

aem

osta

sis

Bo

sto

n -

Ju

ly 1

1-1

6 2

00

9

1

Venue and Contacts 2Welcome Messages 3Committees 7Congress Awards and Grants 15Other Meetings 19ISTH Information 20Program Overview 21SSC Meetings and

Educational Sessions 43

Scientific Program 89Monday 90– Plenary Lectures 90– State of the Art Lectures 90– Abstract Symposia Lectures 92– Oral Communications 100– Posters 118

Tuesday 185– Plenary Lectures 186– State of the Art Lectures 186– Abstract Symposia Lectures 188– Oral Communications 196

Table of ContentsWednesday 209– Plenary Lectures 210– State of the Art Lectures 210– Abstract Symposia Lectures 212– Oral Communications 219– Posters 239

Thursday 305– Plenary Lectures 306– State of the Art Lectures 306– Abstract Symposia Lectures 309– Oral Communications 316– Posters 331Nursing Program 383Special Symposia 389Satellite Symposia 401Technical Symposia Sessions 411Exhibition and Sponsors 415Exhibitor and Sponsor Profiles 423Congress Information 445Map of BCEC 446Hotel and

Transportation Information 447

ISTH 2009 Congress Information 452

Boston Information 458Social Events 463Excursions 465Authors’ Index 477

ISTH2009

Sponsorship & Exhibit Sales, IndustryRelationsRequests about sales opportunities orquestions by industry partners should bedirected to:Margo Price, ISTH Director ofCorporate RelationsLocal Number: +1 919 600 4095Email: [email protected]

Exhibition & Sponsorship Logistics and ManagementMCI Suisse SAChristophe de Rham Email: [email protected]

ISTH Headquarters610 Jones Ferry Road, Suite 205Carrboro, NC 27510, USA Phone: +1 919 929 3807 Fax: +1 919 929 3935 Website: www.isth.org Email: [email protected]

General Society InformationRequests for information about ISTH andits mission may be directed to:

Cathy Cole, ISTH Executive SecretaryEmail: [email protected]

Robert Cary Clark, SSC CoordinatorEmail: [email protected]

Sharon Overcash, ISTH MembershipSecretaryEmail: [email protected]

VenueBoston Convention & Exhibition Center415 Summer Street - Boston, Massachusetts 02210 - USA Phone: +1 617 954 2800 - Fax: +1 617 954 3326

The BCEC is only about 10 minutes by taxi from Boston Logan International Airport.

The 2009 Exhibition is located in Hall A and B of the Exhibit Level of the BCEC, along with postersand catering. Meeting rooms for oral presentations and symposia are located on the 1st and 2nd floors.

For further information about the BCEC, please visit www.massconvention.com/bcec.html

2

Venue & Contacts

Contacts

MCI Suisse is the official Congress Organizer forthe XXII Congress of the ISTH.

For further information contact:

ISTH 2009 Congress OrganizerMCI Suisse SARue de Lyon 751211 Geneva 13, Switzerland Local Number: +1 617 954 3360Phone: +41 22 33 99 587 Local Fax: +1 617 954 3379Fax: +41 22 33 99 601 Email: [email protected] Website: www.isth2009.com

Registration and Hotel AccommodationMCI Suisse SA Local Number: +1 617 954 3368Phone: +41 22 33 99 587 Local Fax: +1 617 954 3379Fax: +41 22 33 99 601 Email: [email protected]

Message from the Congress PresidentsDear Colleagues and Friends,

On behalf of the Local Organizing Committee, it is our great pleasure towelcome you to Boston and the XXII Congress of the ISTH. This biennial eventis one of the highlights of our professional activities, and we are confident thatyou will find the meeting enlightening and enjoyable.

We have worked to develop an array of topics, lectures and posterpresentations that will be of interest to a broad spectrum of physicians andscientists in our field, from students to seasoned practitioners, and coveringtopics in both basic and clinical science. A new Education Program, specialopportunities for trainees, grants to young scientists and attendees fromdeveloping countries, and geographic-specific programs, among otherinitiatives, are all intended to make this an inclusive meeting that embraces thegreat diversity of our field within the context of an international meeting.

We have had the privilege of working with a dedicated Local OrganizingCommittee and Program Committee, and we can’t thank them enough fortheir generous commitment of time and energy to this event. This Congress isthe result of their efforts, as well as the efforts of countless others, who haveshaped the program and tended to the myriad of arrangements that make upa successful meeting.

Thank you for joining us. We invite you to take advantage of the full range ofprogram offerings, as well as the exciting social events and opportunities tomeet or reconnect with colleagues from around the world.

BARBARA C. FURIE

PresidentXXII Congress of the ISTH

BRUCE FURIE

PresidentXXII Congress of the ISTH

3

Message from the Council Chairman Dear Colleagues and Friends,

Nearly 150 years ago, Boston was already renowned as a place oflearning in the United States, when Mark Twain remarked that inBoston someone was judged on what he knew, rather than on whathe was worth or who his parents were. It is therefore most appropriatethat in 2009 Boston is our place of learning, as it hosts our XXIICongress.

Our biennial Congress is an important event for the advancement ofour field, and I am delighted that you are participating. It is here thatprofessional colleagues from all over the world can come together tohear the latest developments in clinical medicine and basic science, aswell as have time to meet informally to share ideas and buildrelationships.

The Society is extremely grateful to the Congress Presidents, Barbaraand Bruce Furie, and their team, for taking on the task of organizing allaspects of this meeting. Their commitment and efforts are of greatbenefit to all of us.

The ISTH 2009 program is filled with topics important to us all, frombasic scientists to clinicians. I look forward to seeing you during thecourse of the Congress.

4

F. R. ROSENDAAL

MD PhDChairman of Council, ISTH

Message from the Executive Director of ISTH Dear Colleagues and Friends,

For the first time since the Washington Congress in 1999, the ISTHreturns to the United States – to Boston, the site of our 2002 SSCmeeting – for our XXII Congress and for the 55th SSC meeting.Congress Presidents Bruce and Barbara Furie and their organizingcommittee have worked hard and have developed an outstandingand unique program, including for the first time an educational com-ponent aimed at students, trainees, clinicians and basic scientistsinterested in our field. As always, the scientific program will featureinvited speakers and the latest in our science and medicine. The newconvention center set on Boston's Inner Harbor provides a beautifulsite for the meeting. The social program showcases the remarkablehistory and culture of the city. It promises to be a memorableCongress.

New England is a beautiful place in the summer. From the sand bea-ches of Cape Cod and the maritime islands, Nantucket, Martha'sVineyard, and the Elizabeth Islands, to the Berkshire region in westernMassachusetts, to Casco Bay and the dramatic coast of Maine andAcadia National Park, to the Allagash Wilderness in the North Woods,to the White Mountains of New Hampshire, to the crystal waters of LakeChamplain, it is a great place to explore before or after the meeting.

Take advantage of the excellent science offered here and becomepart of the tradition of the International Society on Thrombosis andHaemostasis.

5

GILBERT C. WHITE IIExecutive Director ISTH

Message from the Scientific ProgramCommittee Chairpersons Dear Colleagues and Friends,

We are very pleased to present to you the ISTH 2009 Scientific Program - afull array of lectures and programmatic elements that address the variedinterests of basic and clinical scientists. Our dedicated committee, withessential input from the distinguished International Scientific Advisory Board,has worked hard to ensure that each of our six core disciplines is well-represented and includes new voices and ground-breaking science.

The XXII Congress program includes several innovations. An Education Pro-gram has been developed in conjunction with the SSC meetings on Saturdayand Sunday, to provide a basic introduction to key topics. In addition to thetraditional Oral Communications, we have organized Abstract Symposiasessions where an invited speaker is paired with the presentation of severalabstracts on a related theme, and some of the most outstanding abstracts willbe showcased in a special Presidential Plenary Abstract session on Tuesdayafternoon. We will of course also hear from some exciting Plenary and Stateof the Art speakers throughout the Congress as well.

The success of each ISTH Congress is measured first and foremost by thequality of the scientific program, and we are confident that you will find the XXIIISTH Congress outstanding in this regard. We are enormously grateful to ourwonderful Scientific Program Committee, International Scientific AdvisoryBoard, Abstract Reviewers and Congress Organizers for all the hard work thatwent into making this program a reality.

Welcome. We look forward to your participation in ISTH 2009.

6

PAULA B. TRACY

Co-Chair Scientific ProgramCommittee (Basic Sciences)

KENNETH A. BAUERCongress Vice President and Chair, Education ProgramCo-Chair Scientific Program Committee (Clinical Sciences)

f Local OrganizingCommittee

From left to rightStanding:R. Handin, B. Furie,K. Bauer, K. Mann,R. Flaumenhaft, K. Plazak

Seated:D. Wagner, P. Tracy,B. Furie, M. Price

Congress CommitteesLocal Organizing Committee

Bruce Furie MDBarbara C. Furie PhDPresidents

Kenneth A. Bauer MDSenior Vice PresidentChair, Educational ProgramCo-Chair, Scientific ProgramCommittee (Clinical Sciences)

Robert I. Handin MDVice PresidentLiaison to SSC and Satellite Symposia

Paula B. Tracy PhDCo-Chair, Scientific ProgramCommittee (Basic Sciences)

Robert Flaumenhaft MD PhDEditor, State of the Art Book

Denisa D. Wagner PhDSecretary

Kenneth G. Mann PhDTreasurer

Margo Price MAISTH Director of Corporate Relations

Kathryn F. Plazak MBAISTH 2009 Congress Executive Director

International MembersIan PeakeXIX Congress President, 2003

Colin ChestermanXX Congress President, 2005

Henri BounameauxXXI Congress President, 2007

Yasuo IkedaXXIII Congress President, 2011

Gilbert C. White IIISTH Executive Director

Committees

7

Scientific Program CommitteePlatelets (Basic)Lawrence Brass, Chair (US)Joel S. Bennett (US)Joseph E. Italiano (US)Shaun Jackson (AU)Athan Kuliopulos (US)Satya P. Kunapuli (US)Jose A. Lopez (US)Peter J. Newman (US)Bernhardt Nieswandt (DE)Yukio Ozaki (JP)Mortimer Poncz (US)Zaverio Ruggeri (US)Sanford J. Shattil (US)Stephen Watson (UK)Donna Woulfe (US)

Coagulation and Fibrinolysis

Sriram Krishnaswamy, Chair (US)Jay L. Degen (US)Naomi L. Esmon (US)Gary Gilbert (US)Tilman Hackeng (NL)Katherine Hajjar (US)James A. Huntington (UK)Vicky Ploplis (US)Wolfram Ruf (US)Guido Tans (NL)

Vascular Biology

Roy L. Silverstein, Chair (US)William Aird (US)Kari Alitalo (FI)Yugiro Asada (JP)Lena Claesson-Welsh (SE)Stefanie Dimmeler (DE)Harold Dvorak (US)Timothy Hla (US)Klaus Ley (US)Keith R. McCrae (US)Michael Mendelsohn (US)William Sessa (US)Susan Smyth (US)Mervin Yoder (US)

Thrombotic Disorders

Mary Cushman, Chair (US)Trevor Baglin (UK)Sabine Eichinger (AT)Samuel Z. Goldhaber (US)Gerhard J. Johnson (US)Susan Kahn (CA)Ajay Kakkar (UK)

Committees

8

f Scientific ProgramCommittee

From left to right

Standing:S. Krishnaswamy, L. Brass,N. Key, R. Silverstein

Seated:C. Abrams, P. Tracy, M. Cushman, K. Bauer

Tetsuhito Kojima (JP)Marilyn J. Manco-Johnson (US)Saskia Middeldorp (NL)Paul Monagle (AU)Paul Ridker (US)Jeffrey Weitz (CA)Neil Zakai (US)Jeffrey Zwicker (US)

Hemorrhagic Disorders

Nigel S. Key, Chair (US)Andra H. James (US)David Lillicrap (CA)Pete Lollar (US)Michael Makris (UK)Catherine Manno (US)Pier Mannucci (IT)Ellis Neufeld (US)Johannes Oldenburg (DE)Alok Srivastava (IN)Edward G. D. Tuddenham (UK)Akira Yoshioka (JP)

Platelets (Clinical)

Charles Abrams, Chair (US)James B. Bussell (US)Doug Cines (US)Jorge Di Paola (US)Jane Freedman (US)Andreas Greinacher (DE)David Kuter (US)Alan Michelson (US)Adrian Newland (UK)Alan T. Nurden (FR)Chris Van Geet (BE)David Varon (IL)

ISTH CommitteesCouncil of ISTH Chairman of Council(2008-2010)Frits R. Rosendaal (NL)

Secretary/Chairman-Elect(2008-2010)Henri Bounameaux (CH)

ISTH Executive DirectorGilbert C. White, II (US)

Presidents of XXII CongressBruce Furie and Barbara Furie (US)

Senior Vice President, XXII CongressKenneth A. Bauer (US)Chairman, Scientific andStandardization CommitteeGerhard J. Johnson (US)Co-Editors, Journal of Thrombosisand HaemostasisMike Greaves (UK)David Lane (UK)

Council Class of 2010Ph. G. de Groot (NL)David Lane (UK)Ian Peake (UK)Uri Seligsohn (IL)Denisa Wagner (US)

9

Committees

10

Council Class of 2012Michael Berndt (AU)Henri Bounameaux (CH)Paquita Nurden (FR)Bjarne Østerud (NO)P.H. Reitsma (NL)

Council Class of 2014Nuala Ann Booth (UK)Jean-Marie Freyssinet (FR)Nigel S. Key (US)Robert R. Montgomery (US)Hugo Ten Cate (NL)

Scientific and StandardizationCommittee

Officers Chairman (2008-2010)Gerhard J. Johnson (US)

Secretary/Chairman-Elect(2008-2010)Anna Falanga (IT)

Special Assistant to the Chairman(2008-2010) Nuala A. Booth (UK)

Executive DirectorGilbert C. White II (US)

SSC Scientific Subcommittee ChairmenTrevor Baglin (UK)Marco Cattaneo (IT)Moniek de Maat (NL)Jean-Marie Freyssinet (FR)David Gailani (US)Andreas Greinacher (DE)Johan Heemskerk (NL)Anthony Hubbard (UK)Andra James (US)Gili Kenet (IL)David Lillicrap (CA)Colin Longstaff (UK)Gordon Lowe (UK)Mary Ann McLane (US)John McVey (UK)Tim Nichols (US)Vittorio Pengo (IT)Martin Prins (NL)Cheng-Hock Toh (UK)Alok Srivastava (IN)Herb Winna (US)

Committees

Members

SSC Class of 2009Trevor Baglin (UK)Joel S. Bennett (US)Beng Hock Chong (AU)Osamu Matsuo (JP)

SSC Class of 2010Dermot Kenny (IE)Claude Negrier (FR)Edward G. D. Tuddenham (UK)Ton van den Besselaar (NL)

11

Congress International Advisory Board

Giancarlo Agnelli (IT)

Jan Willem Akkerman (NL)

Lorenzo Alberio (CH)

Jack Ansell (US)

Valder Arruda (US)

Wadie Bahou (US)

Lazlo Bajzar (CA)

Carlo Balduini (IT)

Shannon Bates (CA)

Victoria Bautch (US)

Wolfgang Bergmeier (US)

Brad Berk (US)

Francesco Bernardi (IT)

Rogier Bertina (NL)

Joyce Bischoff (US)

Mark Blostein (CA)

Paul E Bock (US)

Susan Bock (US)

Annie Borel-Derlon (FR)

Beth Bouchard (US)

Edwin Bovill (US)

Paul Bray (US)

Benjamin Brenner (IL)

George Broze (US)

Kathleen Brummel-Ziedins (US)

Harry Büller (NL)

Tatiana Byzova (US)

Marina Camera (IT)

Rodney Camire (US)

Alan Cantor (US)

Francis J Castellino (US)

Jean-Pierre Cazenave (FR)

Alessandro Celi (IT)

Anthony Chan (CA)

Israel Charo (US)

Frank C Church (US)

Ken Clemetson (CH)

Barry Coller (US)

Peter Collins (UK)

John Cooke (US)

Shaun Coughlin (US)

Mark Crowther (CA)

Ola E Dahl (NO)

Bjorn Dahlback (SE)

Patricia D’Amore (US)

Raimondo De Cristofaro (IT)

Philip de Moerloose (CH)

Hans Deckmyn (BE)

Cécile Denis (FR)

Michael Detmar (CH)

Thomas Deuel (US)

Scott Diamond (US)

Enrico DiCera (US)

Françoise Dignat-George (FR)

Donna DiMichele (US)

Maria Benedetta Donati (IT)

Jing-Fei Dong (US)

Xiaoping Du (US)

Christophe Dubois (FR)

Bernd Engelmann (DE)

Gines Escolar (ES)

Anna Falanga (IT)

Richard Farndale (UK)

William Fay (US)

Philip Fay (US)

Garrett A Fitzgerald (US)

Charles Francis (US)

Paul Frenette (US)

Jean-Marie Freyssinet (FR)

Karen Furie (US)

Martha Furie (US)

Christian Gachet (FR)

David Gailani (US)

J.G.N. (Skip) Garcia (US)

Pablo Garcia (ES)

Jonathan Gibbins (UK)

Mark Ginsberg (US)

David Ginsburg (US)

Alison Helena Goodall (UK)

Anne Goodeve (UK)

Shinya Goto (JP)

Eric Grabowski (US)

Mike Greaves (UK)

Paolo Gresele (IT)

John Griffin (US)

Peter Gross (CA)

Tilo Grosser (US)

Yves Gruel (FR)

Paul Gurbel (US)

Stephen Hanson (US)

John Hartwig (US)

Johan W.M. Heemskerk (NL)

John Heit (US)

Coen Hemker (NL)

Ruth-Ann Henriksen (US)

Stanley Heptinstall (UK)

Committees

12

CongressInternational Advisory Board(continued)

Kathy High (US)

Maureane Hoffman (US)

Phil Hogg (AU)

Keith Hoots (US)

Marc Hoylaerts (BE)

Mingdong Huang (US)

Beverly Hunt (UK)

Licia Iacoviello (IT)

Yasuo Ikeda (JP)

Luisa Iruela-Arispe (US)

Mukesh Jain (US)

Martine Jandrot-Perrus (FR)

Nancy Jenny (US)

Walter Kahr (CA)

Michael Kalafatis (US)

Raghu Kalluri (US)

Cécile Kaplan (FR)

Simon Karpatkin (US)

Ken Kaushansky (US)

Beate Kehrel (DE)

Craig Kessler (US)

Benjamin Kile (AU)

Wolfgang Koenig (DE)

Barbara Konkle (US)

Thomas Kühne (CH)

Thomas Kunicki (US)

Paul Kyrle (AT)

David A Lane (UK)

Francois Lanza (FR)

John Lawler (US)

Dan Lawrence (US)

Jeff Lawson (US)

Bernard LeBonniec (FR)

Agnes Lee (CA)

Peter J. Lenting (NL)

Jack Levin (US)

Mark Levine (CA)

Howard Liebman (US)

Judith Lin (US)

Roberto Lorenzet (IT)

Gordon Lowe (UK)

Alice Ma (US)

Nigel Mackman (US)

Patricia Maguire (IE)

Elaine Majerus (US)

Aaron Marcus (US)

Ida Martinelli (IT)

Muriel Maurer (US)

John McVey (UK)

Koen Mertens (NL)

Dominique Meyer (FR)

Diego Mezzano (CL)

Tadashi Mitsuru (JP)

Stephan Moll (US)

Paul Monahan (US)

Manuel Monreal (ES)

McDougald Monroe (US)

Robson Monteiro (BR)

Bob Montgomery (US)

Jim Morrissey (US)

Michael Mosesson (US)

Laurent Mosnier (US)/(NL)

David Motto (US)

William Muller (US)

Claude Negrier (FR)

Gary Nelsestuen (US)

Debra Newman (US)

William Nichols (US)

Tim Nichols (US)

Diane Nugent (US)

Doyeun Oh (KR)

Ann-Kristin Ohlin (SE)

John Olson (US)

Steven Olson (US)

Tom Ortel (US)

Susanne Osanto (NL)

Bjarne Østerud (NO)

Willem H Ouwehand (UK)

Ingrid Pabinger (AT)

Joseph Palumbo (US)

Leslie Parise (US)

Carlo Patrono (US)

Cam Patterson (US)

Bernard Payrastre (FR)

Ian Peake (UK)

Ellinor Peerschke (US)

Raul Perez-Bianco (AR)

Egon Perrson (SE)

Petro Petrides (DE)

David Phillips (US)

Rob Pike (AU)

Steven Pipe (US)

Edward Plow (US)

Kathy Ponder (US)

Alistair Poole (UK)

Committees

Congress International Advisory Board(continued)

Paolo Prandoni (IT)Klaus Preissner (DE)Ed Pryzdial (CA)Bruce Psaty (US)Margaret Ragni (US)Koneti Rao (US)Katya Ravid (US)Mark Reding (US)Armin Reininger (DE)Pieter Reitsma (NL)Thomas Renne (DE)Fred Rickles (US)George Rivard (CA)Simon Robson (US)Francesco Rodeghiero (IT)Elliot Rosen (US)Frits R Rosendaal (NL)Jan Rosing (NL)Evan Sadler (US)Hatem Salem (AU)Charles - Marc Samama (FR)Michel Samama (FR)Andrew Schafer (US)Barbara Schick (US)Alvin Schmaier (US)Uri Seligsohn (IL)Sam Schulman (CA)Don Siegel (US)Paolo Simioni (IT)Daniel Simon (US)Nicholas Smith (US)C. Wayne Smith (US)

Stephanie Smith (US)Martha Sola-Visner (US)Steve Sommer (US)Henrik Sørensen (DK)Alex Spyropoulos (US)Darrel Stafford (US)Svetla Stoilova-McPhie (UK)Alison Street (AU)Dudley Strickland (US)Katsuo Sueishi (JP)Mark Taubman (US)Hugo Ten Cate (NL)Douglas Tollefsen (US)Mauro Torti (IT)Russell Tracy (US)JoAnn Trejo (US)Elena Tremoli (IT)Han-Mou Tsai (US)Dimitrios Tsakiris (CH)Alexander Turpie (CA)Tetsumei Urano (JP)Elizabeth van Cott (US)Doug Vaughan (US)Carla Vossen (DE)Thomas Wakefield (US)Ulrich Walter (DE)Chris M Ward (AU)Ted Warkentin (CA)Christian Weber (DE)Hartmut Weiler (US)Phil Wells (CA)

Andy Weyrich (US)

Richard H White (US)

Sidney (Wally) Whiteheart (US)

Ariella Zivelin (IL)

State of the Art Book AssociateEditors

William Aird (US)Tatiana Byzova (US)Beth Bouchard (US)Kevin Croce (US)Peter Gross (CA)Jonathon Gibbins (UK)John Heit (US)Joseph Italiano (US)Howard Leibman (US)Jose Lopez (US) (US)Nigel Mackman (US)Flora Peyvandi (IT)Denisa Wagner (US)Ted Warkentin (CA)Hartmut Weiler (US)Jeffrey Zwicker (US)

Committees

13

14

Committees

Presidents of Past Congresses

I 1970 Fritz Koller, Montreux, Switzerland

II 1971 Paul A. Owren, Oslo, Norway

III 1972 Kenneth M. Brinkhous, Washington, DC, United States

IV 1973 Erwin Deutsch, Vienna, Austria

V 1975 Jean-Pierre Soulier, Paris, France

VI 1977 Sol Sherry, Philadelphia, PA, United States

VII 1979 Gustav V. R. Born, London, United Kingdom

VIII 1981 J. Fraser Mustard, Toronto, Canada

IX 1983 Birger Blomback, Stockholm, Sweden

X 1985 Russel F. Doolittle, San Diego, CA, United States

XI 1987 Marc Verstraete, Brussels, Belgium

XII 1989 Takeshi Abe, Tokyo, Japan

XIII 1991 Jan Sixma, Amsterdam, The Netherlands

XIV 1993 Yale Nemerson, New York, NY, United States

XV 1995 Uri Seligsohn, Jeruslem, Israel

XVI 1997 Pier M. Mannucci, Florence, Italy

XVII 1999 Victor J. Marder, Washington, DC, United States

XVIII 2001 Dominique Meyer, Paris, France

XIX 2003 Ian R. Peake, Birmingham, United Kingdom

XX 2005 Colin Chesterman, Sydney, Australia

XXI 2007 Henri Bounameaux, Geneva, Switzerland

Presidents of Future Congresses

XXIII 2011 Yasuo Ikeda, Kyoto, Japan

XXIV 2013 Frits R. Rosendaal, Amsterdam, The Netherlands

XXV 2015 Sam Schulman, Toronto, Canada

ISTH AWARDS 2009

Robert P. Grant MedalThe highest award of the Society willbe presented at the XXII CongressOpening Ceremony on Sunday, July 12at 6:00 PM in the Grand Ballroom.

Marion I. Barnhart MemorialLecturerShaun JacksonWednesday, July 15 at 5:15 PM

Brinkhous Memorial LecturerEvan SadlerThursday, July 16 at 9:45 AM

ISTH Congress Plenary LecturerMade possible by a grant from the DésiréCollen FoundationRudolph JaenischThursday, July 16 at 5:15 PM

Pia Glas-Greenwalt MemorialLecturerAndreas GreinacherWednesday, July 15 at 9:45 AM

Shirley P. Johnson MemorialLecturerHelen HobbsMonday, July 13 at 9:45 AM

Oscar Ratnoff Memorial LecturerThis new award has been establishedthrough the generosity of Dr. HidehikoSaito, President of the 23rd Annual Meetingof the Japanese Society on Thrombosisand Hemostasis.Philip HoggTuesday, July 14 at 9:45 AM

Sol Sherry Memorial LecturerWilliam GeertsMonday, July 13 at 5:15 PM

Biennial Awards forContributions to Hemostasis:Investigator RecognitionAnna Falanga Jean-Marie Freyssinet Katherine High Clive Kearon Gordon Lowe To be presented during the AwardsPresentation Ceremony on Tuesday,July 14 at 4:00 PM

Biennial Awards forContributions to Hemostasis:Distinguished CareerHenri Bounameaux H Roger Lijnen Michael Nesheim Pieter Reitsma Sam Schulman To be presented during the AwardsPresentation Ceremony on Tuesday,July 14 at 4:00 PM

Roberts Medal for DistinguishedService to the SSCThis medal will be presented at theAwards Presentation Cermony onTuesday, July 14 at 4:00 PM.

2008 Journal of Thrombosis andHaemostasis, Pier M. MannucciYoung Investigator AwardsMichiel CoppensAdriana Franco Paes LemeJonathan George TardosXiao-lin Zang

sanofi-aventis/ISTH ResearchFellowship AwardsAwardees will be announced at theAwards Presentation Cermony onTuesday, July 14 at 4:00 PM.

Congress Awards and Grants

15

16

Young Investigator AwardsThe Young Investigator Awards were provided in the form of travel grants tomedical trainees and young scientists (under 35 years of age as of July 11, 2009)who have been chosen to present their highly rated abstracts at the Congress.These awards are part of the ISTH’s Reach the World initiative and have beenmade possible thanks to ISTH, the XXII Congress of the ISTH, and the followingcorporate sponsors: Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSLBehring, GlaxoSmithKline, Novo Nordisk, Wyeth.


Frédéric Adam (FR)Helena M. Andersson (UK)Guillemette Antoni (FR)Cihan Ay (AT)Bani M. Azari (US)Jennie Bäck (SE)Behnaz Bayat (DE)Markus Bender (DE)Florieke J. Berfelo (NL)Heike Bernhard (AT)Michelle A. Berny (US)Gerald Bertrand (FR)Irene D. Bezemer (NL)Wiebke Bielenberg (DE)Ruben Bierings (UK)Marc Blondon (CH)Anita N. Böing (NL)Elodie Boissier (FR)Knut H. Borch (NO)Keren S. Borensztajn (NL)Julian I. Borissoff (NL)Yacine Boulaftali (FR)Claire Bouvard (FR)

Sheryl R. Bowley (US)Karlien Buelens (BE)Sharene D. Bungay (CA)Laurent Burnier (CH)Yamini S. Bynagari (US)Robert A. Campbell (US)James E. Campbell (US)Jessica Cardenas (US)Sofia U. Carlsson (SE)Caterina Casari (IT)Luca Cecchetti (IT)Francesca Cesari (IT)Kan Chen (US)Elim Y. Cheung (NL)Robert B. Conley (US)Gregory C. Connolly (US)Judith Cosemans (NL)Mitali Das (US)Rebecca L. Davis-Harrison (US)Pavel Davizon-Castillo (US)Rens de Goot (UK)Bas de Laat (NL)Simon F. de Meyer (BE)

Olav R. de Peuter (NL)Sandrine Delignat (FR)Mieke Delvaeye (BE)Ingrid den Uijl (NL)Francesco Dentali (IT)Sukhdeep S. Dhadwar (CA)Leonardo Di Gennaro (IT)Renee A. Douma (NL)Connie Duckers (NL)Daniel Duerschmied (US)Ammon M. Fager (US)Neychelle L. Fernandes (US)Hendrik B. Feys (BE)Jonathan D. Finn (US)Linda E. Flinterman (NL)Jonathan H. Foley (CA)Daniel Frith (UK)Christian Furlan-Freguia (US)Kathryn C. Gersh (US)Nadine S. Gibson (NL)Karen Gilio (NL)Mia Golder (CA)Evelyn Groot (NL)

Congress Awards and GrantsPaul Gueguen (FR)Ina Hagedorn (DE)Justin R. Hamilton (AU)Daniel J. Hampshire (UK)Ellen Hanson (SE)Nicholas Hickson (UK)Lisa-Marie Holbrook (UK)Gregor Hron (AT)Vera Ignjatovic (AU)Miriam E. Jaax (DE)Ewa Jablonska (DE)Indu Jagannathan (US)Shashank Jain (US)Reema Jasuja (US)Sheng-Yu Jin (US)Matthew L. Jones (UK)Roman Kanz (AT)Anuja Khan (US)Paul Y. Kim (CA)Jenny Klintman (SE)Frederikus A. Klok (NL)Iris L. H. Knottnerus (NL)Jorine S. Koenderman (NL)Suzanne J. A. Korporaal (NL)Krystin Krauel (DE)Colin A. Kretz (CA)Michele P. Lambert (US)Danila Leontyev (CA)Willem M. Lijfering (NL)Luca A. Lotta (IT)Ester C. Lowenberg (NL)Brenda M. Luken (UK)Coen Maas (NL)Bakhtawar K. Mahmoodi (NL)David A. Manly (US)Nicola Martinelli (IT)Irene Martínez-Martíez (ES)Andreas C. Mauer (US)

Meadhbh McCall (IE)Mirjam E. Meltzer (NL)Xi Mo (US)Felicitas Mueller (DE)Eric S. Mullins (US)Keith B. Neeves (US)Reyhan Nergiz-nal, (NL)Chris Oschatz (DE)Cecilia Oslakovic (SE)Elena Osto (IT)Michael J. Page (US)Marta Palomo (ES)Peter R. Panizzi (US)Ronan Pendu (FR)Nicolas S. Petrera (CA)Irina Pleines (DE)Narcis I. Popescu (US)Ginta Pordes (AT)Wouter Pos (NL)Nicola Pozzi (IT)Cynthia M. Pruss (CA)Christoph Reinhardt (SE)Goran Rudez (NL)François Saller (CH)Francesca Santilli (IT)Steven L. Schadinger (CA)Marc Schindewolf (DE)Alec A. Schmaier (US)Marcel Schouten (NL)Joerg Schuettrumpf (DE)Sol Schulman (US)Hansjorg Schwertz (US)Olivier Segers (NL)Stefanie Seifert (DE)Ruchira Sengupta (CA)Bob Siegerink (NL)Kerrie A. Smith (UK)

Jaapjan D. Snoep (NL)Francesco Sofi (IT)Timothy J. Stalker (US)Brian M. Steele (IE)Katharina N. Steinitz (AT)Catherine Strassel (FR)Min K. ten Kate (US)Jonathan N. Thon (US)Ynse I. G. V. Tichelaar (NL)Lisa J. Toltl (CA)Erik Tournoij (NL)Rolf T. Urbanus (NL)Yascha W. van den Berg (NL)Maartje van den Biggelaar (NL)Lisa van den Hengel (NL)Frederiek F. van Doormaal (NL)Markus van Geffen (NL)Pauline M. van Helden (AT)Vielg Astrid van Hylckama (NL)Gwendolyn van Os (NL)Inge M. van Schouwenburg (NL)Geerte L. van Sluis (NL)Rainer Vormittag (AT)Natalya M. Vorobyeva (RU)J. W. Wang (NL)Jian-Guo Wang (US)Xiang Xu (US)Yuwna Yakura (JP)Takayuki Yamada (JP)Hong Yin (US)Yuana Yuana (NL)Melec G. Zeadin (CA)Erin Zekas (US)Wenhua Zhou (US)Xiao-Juan Zhu (CN)Majida Zidane (NL)

17

18


Developing World Scientist AwardsThe Developing World Scientist Awards provided travel grants to scientists fromdeveloping countries to support participation at the Congress.These awards are part of the ISTH’s Reach the World initiative and have beenmade possible thanks to ISTH, the XXII Congress of the ISTH and the followingcorporate sponsors: AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, BristolMyers Squibb, CSL Behring, GlaxoSmithKline, Novo Nordisk.

Yolanda P. Adamczuk (AR)Firdos Ahmad (IN)Dalila Aïtchafa Tadlaoui (DZ)Silvia Albanez (YE)Maha Aly Aldeen Abd

Elbasset Aly Mohamed (EG)Samina T. Amanat (PK)Angchaisuksiri Pantep (TH)Rumjana Apostolovska (MK)Omolade A. Awodu (NG)Xia Bai (CN)Bernát J. Béres (HU)Arijit Biswas (IN)Mariana Bonduel (AR)Wangwei Cai (CN)Jose M. Ceresetto (AR)Qiong Chen (CN)Yingyong Chinthammitr (TH)Ana M. Chudzinski-Tavassi (BR)Czeslaw S. Cierniewski (PL)Punsaldulam Dashnyam (MN)Gabriela F. de Larrañaga (AR)Kai-yang Ding (CN)Qiulan Ding (CN)Valentina J. Djordjevic (RS)Teresa B. Domagala (PL)Olena Dotsenko (UA)

Luci MS. Dusse (BR)Hejer Elmahmoudi (TN)Fernanda Faria (BR)Ana P. Fernandes (BR)Adriana Georgescu (RO)Francisco J. Goico (DO)Lyubov Gorbacheva (RU)Elena M. Gupalo (RU)Mohammad Bagher

Hashemi Soteh (IR)Hu Hu (CN)Baolai Hua (CN)Maria B. Irigoyen (AR)Mehrez M. Jadaon (KW)Ekaterina V. Kiseleva (RU)Grace W. Kitonyi (KE)Yeling Lu (CN)Eduard V. Lugovskoy (UA)Andrea Manzino (UY)Yulia A. Mikheeva (RU)Marija Milos (HR)Robson Q. Monteiro (BR)Elena G. Oganova (BY)Olga Panes (CL)Mikhail A. Panteleev (RU)Alfredo Perez Cuadra (MX)Marlien Pieters (ZA)

Ghasem Rastegarlari (IR)Shirin Ravanbod (IR)Maria A. Romaniuk (AR)Anna Rusanova (RU)Izabela Sacewicz (PL)Andrey Santos (BR)Mirta Schattner (AR)Tahereh Shashaani (IR)Ene Siigur (EE)Janaina B. J. Silva (BR)Elena I. Sinauridze (RU)Olga V. Sirotkina (RU)Olga A. Smirnova (RU)Svetlana Strukova (RU)Ayadurai Thiruchelvam (MY)Anettab Undas (PL)Nadezda A. Vorobyeva (RU)Xuefeng Wang (CN)Zhaoyue Wang (CN)Adriana I. Woods (AR)Shilong Xiong (CN)Erkan Yilmaz (TR)Tingting Yu (CN)Ziqiang Yu (CN)

Saturday July 11

SSC Members Meeting 6:30 PM - 9:30 PMWestin Boston Waterfront Hotel - Douglas and Alcott Rooms

Sunday July 12

APSTH Council Meeting 12:00 PM - 1:00 PM Room 155

ISFP Council Meeting 2:00 PM - 5:00 PMRoom 155

Monday July 13

MLTD Councilors Meeting 11:00 AM - 12:30 PMRoom 259B

MLTD General Assembly 12:30 PM - 2:00 PMRoom 259B

JTH Editorial Board Luncheon 12:30 PM - 2:15 PMWestin Boston Waterfront Hotel - Douglas Room

MLTD Foundation Meeting 2:00 PM - 3:30 PMRoom 259B

MLTD 21st Milan Congress Presentation 3:30 PM - 4:30 PMRoom 259B

ISTH Council Meeting 6:00 PM - 11:00 PM Westin Boston Waterfront Hotel, Douglas and Alcott Rooms

Tuesday July 14

ISTH General Membership Assembly 3:00 PM - 3:15 PM Grand Ballroom

Wednesday July 15

SSC Annual Business Meeting 1:00 PM - 3:30 PM Room 256

Thursday July 16

Industry Liaison Meeting 12:00 PM - 2:00 PMRoom 256

Other Meetings

19

20

The International Society on Thrombosis and Haemostasis, Inc. is organizedand operated exclusively for scientific and educational purposes. Its objectivesare to foster and advance science relating to the important medical problemsof thrombosis and abnormalities of hemostasis and vascular biology; toprovide a forum for discussion of these problems; to encourage research onthese problems by scientists of the relevant disciplines; to foster the diffusionand exchange of ideas through scientific meetings and publications; tostandardize nomenclature and methods as appropriate and timely.

k ISTH Headquarters610 Jones Ferry Road - Suite 205 - Carrboro, NC 27510 - USAPhone: +1 919 929 3807 - Fax: 1 919 929 3935Website: www.isth.org

k For information about sponsorships and industry participation in meetings,please contact:Margo Price, ISTH Director of Corporate RelationsDirect line: +1 919 929 2381Email: [email protected]

k For membership questions, please contact:Sharon Overcash, ISTH Membership SecretaryEmail: [email protected]

k For the ISTH website and SSC Information, please contact:Robert Cary Clark, ISTH Information ServicesEmail: [email protected]

k For general information about the ISTH, please contact:Cathy Cole, ISTH Executive SecretaryEmail: [email protected]

ISTH MembershipIf you are not yet a member of the ISTH and wish to join, youmay apply online at http://www.isth.org/Membership or contactthe Membership Secretary at [email protected] is by application and payment of annual dues,which are for the calendar year January through December.Membership dues for 2009 are $160.

ISTH Information

21

ProgramOverview

ISTH2009

Room104 ABC

Room107 ABC

Room153 ABC

Room156 ABC

SSC Meetings and Educational Sessions

8:00 - 12:00 P. 55

Factor VIII & IX

12:15 - 1:45 P. 57

APSTH / ISTHSymposium

2:00 - 4:30 P. 68

Animal Models

4:30 - 6:00 P. 69

Animal Models

8:00 - 9:30 P. 46

Hemostasis andMalignancy

9:30 - 12:00 P. 46

Hemostasis andMalignancy

12:15 - 1:45 P. 58

Genomics 101

2:00 - 3:00 P. 71

Biorheology

3:00 - 6:00 P. 71

Biorheology

8:00 - 11:00 P. 53

Platelet Immunology

11:00 - 12:00 P. 54

Platelet Immunology

12:15 - 1:45 P. 59

In silico Drug Design

2:00 - 3:30 P. 64

Factor VIII and IX

3:30 - 6:00 P. 65

Factor VIII and IX

8:00 - 9:30 P. 49

Predictive Variablesin Cardiovascular

Disease

9:30 - 12:00 P. 50

Predictive Variables in Cardiovascular

Disease

12:15 - 1:15 P. 60

The Illusion ofDisclosure

2:00 - 3:00 P. 61

Fibrinogen and Factor XIII

3:00 - 6:00 P. 62

Fibrinogen and Factor XIII

22

Room160 ABC

Room204 AB

Room102 AB

Room109 AB

Saturday, July 11, 2009

12:15 - 1:45 P. 60

Translating evidenceinto practice

2:00 - 4:30 P. 69

Lupus Anticoagulant /Phospholipid-

Dependent Antibodies

4:30 - 6:00 P. 70

Lupus Anticoagulant /Phospholipid-

Dependent Antibodies

8:00 - 9:30 P. 47

Vascular Biology

9:30 - 12:00 P. 48

Vascular Biology

12:00 - 2:00 P. 385

Nurses Meeting

8:00 - 10:30 P. 50

Women's Health in Thrombosis & Haemostasis

10:30 - 12:000 P. 51

Women's Health in Thrombosis & Haemostasis

2:00 - 3:30 P. 66

Perinatal/PediatricHemostasis

3:30 - 6:00 P. 67

Perinatal/PediatricHemostasis

4:30 - 6:00 P. 63

Plasma CoagulationInhibitors

2:00 - 4:30 P. 63

Plasma CoagulationInhibitors

23

SSC

& E

duca

tion

al

EducationalSessions

SCC Meetings

Room205 ABC

Room253 ABC

Room258 ABC

Room104 ABC

SSC Meetings and Educational Sessions

12:30 - 2:30 P. 391

Scienta HealthcareEducation®

(Baxter)

3:15 - 5:15 P. 393

Octapharma AG(CH)

12:30 - 2:30 P. 392

Bayer Healthcare

12:30 - 2:30 P. 392

sanofi-aventis US

3:15 - 5:15 P. 394

Medscape LLC(sanofi-aventis)

10:30 - 12:00 P. 79

Control ofAnticoagulation

8:00 - 10:30 P. 77

Control ofAnticoagulation

Room107 ABC

8:00 - 9:30 P. 73

Disease-SpecificMolecular

Mechanisms inDisseminatedIntravascularCoagulation

(DIC)

9:30 - 12:00 P. 74

Disease-SpecificMolecular

Mechanisms inDisseminatedIntravascularCoagulation

(DIC)

24

Sunday, July 12, 2009

25

SpecialSymposia

Room153 ABC

Room156 ABC

Room160 ABC

Room102 AB

8:00 - 11:00 P. 82

Platelet Physiology

11:00 - 12:00 P. 82

Platelet Physiology

8:00 - 10:30 P. 85

Registry ofExogenousHemostatic

Factors

10:30 - 12:00 P. 85

Registry ofExogenous

Hemostatic Factors

8:00 - 11:00 P. 83

Plasma Kallikrein-Kinin

System

11:00 - 12:00 P. 84

Plasma Kallikrein-Kinin

System

8:30 - 10:30 P. 80

Fibrinoloysis

10:30 - 12:00 P. 81

Fibrinoloysis

EducationalSessions

Room109 AB

8:00 - 9:30 P. 75

von WillebrandFactor (VWD)

9:30 - 12:00 P. 76

von WillebrandFactor (VWD)

SCC Meetings

SSC

& E

duca

tion

alThe Opening Ceremony will take place

on Sunday, July 12 at 6:00 PM in the BCEC's Grand Ballroom. For more information, please see page 87.

Grand Ballroom

A B

Ballroom210 ABC

Room205 ABC

Program Overview

10:30 - 11:00 COFFEE BREAK


12:30 - 2:15 LUNCH / POSTERS ATTENDED

8:00 - 9:30 P. 100

Risk Factors for Venous Thrombosis I

8:00 - 9:30 P. 117

Late Breaking Abstracts Session

11:00 - 12:30 P. 90

Pulmonary Embolism, 2009

11:00 - 12:30 P. 91

Von Willebrand Disease - NewDevelopments

11:00 - 12:30 P. 91

Novel Approaches to Understanding

Hemostasis

2:15 - 3:45 P. 93

Thrombophilia:Clinical Applications

4:00 - 5:00 P. 109

Venous Thrombosis:Clinical Course

6:30 - 8:00 P. 395

Scienta HealthcareEducation® (Baxter)

5.15 - 6:00 P. 90

Thromboprophylaxis as a key patient safety priority: Current approaches and future directions - W. Geerts

4:00 - 5:00 P. 109

Pre-clinical Studies of Novel Factor IX

Concentrates

2:15 - 3:45 P. 93

Interventions for Venous

Thromboembolism

11:00 - 12:30 P. 92

Endothelial and Vascular Signaling

9:45 - 10:30 P. 90

Cardiovascular genetics - H. Hobbs

8:00 - 9:30 P. 100

Resistance to Antiplatelet Therapy

26

Monday, July 13, 2009

Room253 ABC

Room258 ABC

Room157 ABC

Room104 ABC

Room107 ABC

Prog

ram

Ove

rvie

w




6:30 - 8:00 P. 399

Network for Continuing Medical

Education (NovoNordisk)

6:30 - 8:00 P. 396

Potomac Center forMedical Education

(BohringerIngelheim)

6:30 - 8:00 P. 397

ACCELMED® (Daiichi Sankyo,

Inc. and Lilly USA,LLC)

6:30 - 8:00 P. 397

CSL BehringGmbH

4:00 - 5:00 P. 110

Hormone Therapy in Women

4:00 - 5:00 P. 111

Thrombosis inCancer: Clinical

Course

4:00 - 5:00 P. 111

AnticoagulantReactions of

Activated Protein C

4:00 - 5:00 P. 112

Novel Mechanisms of Antiplatelet

Therapy

4:00 - 5:00 P. 112

Factor XI/XIa

2:15 - 3:45 P. 94

Biology of ADAMTS13

2:15 - 3:45 P. 94

Biology of vonWillebrand Factor

2:15 - 3:45 P. 95

Serpins-Inhibitors

2:15 - 3:45 P. 95

Women and Bleeding Disorders

2:15 - 3:45 P. 96

Platelets and Cancer

11:00 -12:30 P. 92

Inherited Platelet Disorders

11:00 - 12:30 P. 91

Inflammation and Coagulation

8:00 - 9:30 P. 101

Cancer and Thrombosis:

Clinical Aspects

8:00 - 9:30 P. 102

Genetics of Venous

Thrombosis I

8:00 - 9:30 P. 103Antiphospholid

Syndrome:Basic and Clinical

Aspects

8:00 - 9:30 P. 103

Hemophilia:Clinical I

8:00 - 9:30 P. 103

Diagnosis of PulmonaryEmbolus

State-of-the-ArtLectures

OralCommunications

PlenaryLectures

SpecialSymposia

Abstract SymposiaLectures

27

a

Room153 ABC

Room156 ABC

Room160 ABC

Room204 AB

Room102 AB

Program Overview

6:30 - 8:00 P. 399

Stago

6:30 - 8:00 P. 395

Bayer HealthCare AG and Ortho-

McNeilPharmaceuticals

6:30 - 8:00 P. 398

Grifols

6:30 - 8:00 P. 400

WyethPharmaceuticals

4:00 - 5:00 P. 113

Mechanisms of Platelet

Activation II

4:00 - 5:00 P. 113

AntiphospholipidSyndrome: Beta 2

Glycoprotein 1

4:00 - 5:00 P. 114

Fibrinolysis:Biochemistry

4:00 - 5:00 P. 114

Factor V

2:15 - 3:45 P. 96

Novel Approaches to UnderstandingPlatelet Biology

2:15 - 3:45 P. 97

Extrinsic Pathways of Coagulation

2:15 - 3:45 P. 97

Platelet Adhesionand Cohesion

8:00 - 9:30 P. 105

Mechanisms of Platelet Activation I

8:00 - 9:30 P. 106

Hospitalization and

Venous Thrombosis

8:00 - 9:30 P. 106

Regulation of the Initiation of

Coagulation

8:00 - 9:30 P. 107

Factors V and VIII

28



12:30 - 2:15 LUNCH / POSTERS ATTENDED 12:30 - 2:15 P. 385Nurses Meeting




Room109 AB

Room151 AB

Room162 AB

Room252 AB

Room257 AB

Prog

ram

Ove

rvie

w4:00 - 5:00 P. 115

Atherosclerosis:Plaque

Composition

4:00 - 5:00 P. 115

EndothelialDysfunction:

Vascular Signaling

4:00 - 5:00 P. 116

P2Y12

4:00 - 5:00 P. 116

Immune-mediatedThrombocytopenia

2:15 - 3:45 P. 98

PlateletTransfusions and Polymorphisms

2:15 - 3:45 P. 98

Inflammation andVascular

Pathobiology

2:15 - 3:45 P. 99

Angiogenesis

8:00 - 9:30 P. 108

Endothelial Cell Signaling

4:00 - 5:00 P. 108

Fibrin Clot Structure

29

Monday, July 13, 2009


OralCommunications

PlenaryLectures

SpecialSymposia

Abstract Symposia Lectures

Grand Ballroom

A B

Ballroom210 ABC

Room205 ABC

Program Overview



12:30 - 1:15 LUNCH

8:00 - 9:30 P. 196

Risk Factors for Venous Thrombosis II

11:00 - 12:30 P. 188Genomics and Vascular

Disease: What HaveWe Learned About

Thrombosis?

11:00 - 12:30 P. 187

Blood Coagulation-Systemic Effects

11:00 - 12:30 P. 187

Burning Questions inHemophilia Inhibitors

1:15 - 2:45 P. 188

Immunology andTreatment of ITP

P. 1953:00 - 3:15 ISTH General Membership Assembly 3:15 - 4:00 Presidential Plenary Abstracts 4:00 - 4:15 Awards Presentation 4:15 - 4:30 Presidential Plenary Abstracts

1:15 - 2:45 P. 189Post-thrombotic

Syndrome and otherOutcomes of Venous

Thrombosis

11:00 - 12:30 P. 186

Platelet Activation

9:45 - 10:30 P. 186

Contibution of allosteric disulfide bonds to regulation of hemostasis - P. Hogg

8:00 - 9:30 P. 196

Diagnosis of Venous Thromboembolism

30

Tuesday, July 14, 2009

Room253 ABC

Room258 ABC

Room157 ABC

Room104 ABC

Room107 ABC

Prog

ram

Ove

rvie

w



12:30 - 1:15 LUNCH

6:30 - 8:00 P. 413

Rovi

6:30 - 8:00 P. 414

Network forContinuing

Medical Education(Novo Nordisk)

1:15 - 2:45 P. 189

Update on GeneTherapy inHemophilia

1:15 - 2:45 P. 190

Cofactors

1:15 - 2:45 P. 190

Regulation ofCoagulation

1:15 - 2:45 P. 191

Platelets andSystemic Disorders

1:15 - 2:45 P. 191

IntracranialHemorrhage

11:00 -12:30 P. 186

ImmuneThrombocytopenia

11:00 - 12:30 P. 187Inflammation and Atherosclerosis:

Plaque Progression andRegression

8:00 - 9:30 P. 197

Risk of Thrombosisin Cancer

8:00 - 9:30 P. 198

Thrombo-prophylaxisin Surgery

8:00 - 9:30 P. 199

Platelets andSystemic Disorders

8:00 - 9:30 P. 199

Genetics ofCoagulation

8:00 - 9:30 P. 200

AntiphospholipidSyndrome: Basic

Apspects


OralCommunications

PlenaryLectures

TechnicalSessions


31

a

Room153 ABC

Room156 ABC

Room160 ABC

Room204 AB

Room102 AB

Program Overview

1:15 - 2:45 P. 192

Mechanisms ofPlatelet Activation

1:15 - 2:45 P. 192

Inflammation

1:15 - 2:45 P. 193

Platelets andMyleoproliferative

Syndromes

1:15 - 2:45 P. 193

PediatricThrombosis

8:00 - 9:30 P. 201

Platelet Biology I

8:00 - 9:30 P. 201

Atherosclerosis:Mouse Models

8:00 - 9:30 P. 202

Microparticles

8:00 - 9:30 P. 203

Venous Thrombosisin Pediatrics

8:00 - 9:30 P. 204Novel Assays inHemophilia andvon Willebrand

Disease

32



12:30 - 1:15 LUNCH

12:30 - 2:15 P. 386

Nurses Meeting


2:45- 3:00 COFFEE BREAK

12:30 - 1:15 LUNCH

Room109 AB

Room151 AB

Room162 AB

Room252 AB

Room257 AB

Prog

ram

Ove

rvie

w

1:15 - 2:45 P. 194

Regulation of GeneExpression inVascular Cells

8:00 - 9:30 P. 206

EndothelialDysfunction and

Biomarkers I

8:00 - 9:30 P. 207Membrane Binding andFuncion in

Coagulation

33

Tuesday, July 14, 2009


OralCommunications

PlenaryLectures

TechnicalSessions


8:00 - 9:30 P. 204Genotypes of

Hemophilia andvon Willebrand

Disease

8:00 - 9:30 P. 205

Serpin Structureand Function

Grand Ballroom

A B

Ballroom210 ABC

Room205 ABC

Program Overview




8:00 - 9:30 P. 219

Clinical Trials: Factor XaInhibitors

11:00 - 12:30 P. 212

ThrombopoietinReceptor Agonists

11:00 - 12:30 P. 211

Inflammation andAtherosclerosis:

A Paradigm Shift?

11:00 - 12:30 P. 210

Integrin Biology

2:15 - 3:45 P. 212

Hemophilia

6:30 - 8:00 P. 407

Institute for MedicalStudies (CME Provider),

(Lundbeck)

5.15 - 6:00 P. 210

Modern concepts of platelet activation during thrombus development

S. Jackson

4:00 - 5:00 P. 231

Genetics of VenousThrombosis II

2:15 - 3:45 P. 213

Stroke

11:00 - 12:30 P. 211

Cues to Create A MatureVasculature

9:45 - 10:30 P. 210

Heparin- induced thrombocytoperiaA. Greinacher

8:00 - 9:30 P. 219

ThromboticThrombocytopenic

Purpura I

34

Wednesday, July 15, 2009

Room253 ABC

Room258 ABC

Room157 ABC

Room104 ABC

Room107 ABC

Prog

ram

Ove

rvie

w




6:30 - 8:00 P. 408

Octapharma AG,(CH)

6:30 - 8:00 P. 403

CMEducationResources, LLC

(BMS)

6:30 - 8:00 P. 406

CSL Behring GmbH

6:30 - 8:00 P. 406

Loyola UniversityChicago

4:00 - 5:00 P. 231

Vascular DiseasePrevention

4:00 - 5:00 P. 232Cancer Treatment

Effects onHemostasis and

Thrombosis

4:00 - 5:00 P. 232

Fibrinolysis: CellBiology

4:00 - 5:00 P. 233

Stroke

4:00 - 5:00 P. 233

Hemophilia:Clinical II

2:15 - 3:45 P. 213

TTP andADAMTS13

2:15 - 3:45 P. 214

Microparticles

2:15 - 3:45 P. 214

ObstetricComplications

2:15 - 3:45 P. 215

Megakaryocytesand

Thrombopoiesis

2:15 - 3:45 P. 215

Platelet Biology

11:00 -12:30 P. 210

Fibrinogen/Fibrinolysis in the

Brain

11:00 - 12:30 P. 211

Factor XI Revisited

8:00 - 9:30 P. 220

Risk Factors forVenous Thrombosis

III

8:00 - 9:30 P. 221

Hemostasis andCancer

8:00 - 9:30 P. 222

Cell Biology of theExtrinsic Pathway

8:00 - 9:30 P. 222

Arterial DiseaseRisk Markers I

8:00 - 9:30 P. 223

ExperimentalStudies in

Thrombosis


OralCommunications

PlenaryLectures

SatelliteSymposia


35

a

Room153 ABC

Room156 ABC

Room160 ABC

Room204 AB

Room102 AB

Program Overview

6:30 - 8:00 P. 403

Biomerieux

6:30 - 8:00 P. 408

Siemens

6:30 - 8:00 P. 404

CMEducationResources, LLC

(Eisai)

6:30 - 8:00 P. 409

WyethPharmaceuticals

4:00 - 5:00 P. 234

Platelet Biology II

4:00 - 5:00 P. 234

Inflammation andCell Trafficking I

4:00 - 5:00 P. 235

ThromboticThrombocytopenic

Purpura II

4:00 - 5:00 P. 236

von WillebrandDisease

4:00 - 5:00 P. 236

Atherosclerosis:Risk factors I

2:15 - 3:45 P. 216

von WillebrandFactor: Structure

and Function

2:15 - 3:45 P. 216

Intrinsic Pathwayof Coagulation

2:15 - 3:45 P. 217

Fibrinogen andFibrinolysis

8:00 - 9:30 P. 224


III

8:00 - 9:30 P. 225

Novel Approachesto UnderstandingPlatelet Function

8:00 - 9:30 P. 225

BypassingTherapies

8:00 - 9:30 P. 226

Hemophilia:Basic Science

36



12:30 - 2:15 LUNCH / POSTERS ATTENDED 12:30 - 2:15 P. 387Nurses Meeting




Room109 AB

Room151 AB

Room162 AB

Room252 AB

Room257 AB

Prog

ram

Ove

rvie

w4:00 - 5:00 P. 237

Cell Biology of theActivated Protein C

Pathway

4:00 - 5:00 P. 237

FibrinogenStructure and

Function

4:00 - 5:00 P. 238

Megakaryocytesand

Thrombopoiesisa

2:15 - 3:45 P. 217

Blood VesselDevelopment

2:15 - 3:45 P. 218

Atherosclerosis

8:00 - 9:30 P. 229

EndothelialDysfunciton and

Biomarkers II

8:00 - 9:30 P. 228

Proteases:Structure and

Function

8:00 - 9:30 P. 228

Vitamin K Cycle

8:00 - 9:30 P. 227

Angiogenesis andVascular

Development

8:00 - 9:30 P. 230

PediatricThrombosis

37

Wednesday, July 15, 2009


OralCommunications

PlenaryLectures

SpecialSymposia


Grand Ballroom

A B

Ballroom210 ABC

Room205 ABC

Program Overview




8:00 - 9:30 P. 316

Risk Factors forRecurrent Venous

Thrombosis

11:00 - 12:30 P. 306Anticoagulation

Duration after IdiopathicVenous Thrombosis - the

Swinging Pendulum

11:00 - 12:30 P. 307

Acquired BleedingDisorders

11:00 - 12:30 P. 308

Platelet Physiology/-Pathophysiology

2:15 - 3:45 P. 309

Estrogens and VascularDisease

5.15 - 6:00 P. 306

Stem cells, pluripotency, and nuclearreprogramming

R. Jaenisch

4:00 - 5:00 P. 325

Health Services andOutcomes

2:15 - 3:45 P. 309

Pathophysiology ofHeparin-Induced

Thrombocytopenia

11:00 - 12:30 P. 307

Endothelial ProgenitorCell Biology

9:45 - 10:30 P. 306

Willebrand factors assembly and secretionJ. Sadler

8:00 - 9:30 P. 316

Clinical Trials:Anticoagulation

38

Thursday, July 16, 2009

Room253 ABC

Room258 ABC

Room157 ABC

Room104 ABC

Room107 ABC

Prog

ram

Ove

rvie

w




4:00 - 5:00 P. 325

Arterial DiseaseMechanisms

4:00 - 5:00 P. 326

PregnancyComplications

4:00 - 5:00 P. 326

Hemophilia: GeneTherapy

4:00 - 5:00 P. 327

Inflammation and Cell

Trafficking II

2:15 - 3:45 P. 310

New Products inHemophilia

2:15 - 3:45 P. 310

Signal Transductionin Vascular Cells

2:15 - 3:45 P. 311

Platelets as DrugTargets

2:15 - 3:45 P. 311

Treatment of DeepVein Thrombosis

2:15 - 3:45 P. 312

Platelet FunctionTests

11:00 -12:30 P. 307

Platelet Inhibition

11:00 - 12:30 P. 308

Novel RegulatoryReactions inCoagulation

8:00 - 9:30 P. 317

Health Services,Outcomes and

Patient Education

8:00 - 9:30 P. 318

Heparin-inducedThrombocytoperia I

8:00 - 9:30 P. 319

Artierial DiseaseRisk Markers II

8:00 - 9:30 P. 320Experimental

Studies inThrombosis:

Animal Models


OralCommunications

PlenaryLectures


39

a

Room153 ABC

Room156 ABC

Room160 ABC

Room204 AB

Room102 AB

Program Overview

4:00 - 5:00 P. 327


IV

4:00 - 5:00 P. 328

Platelet Biology IV

4:00 - 5:00 P. 328

Heparin-inducedThrombocytopenia

II

4:00 - 5:00 P. 329

Inhibitors ofCoagulation and

Fibrinolysis

2:15 - 3:45 P. 313

Contact Pathway

2:15 - 3:45 P. 313

Genetics of Platelet Disorders

2:15 - 3:45 P. 314

Protease:Structure-Function

2:15 - 3:45 P. 314

Neonatal/ PediatricHemostasis

8:00 - 9:30 P. 320

Platelet Biology III

8:00 - 9:30 P. 321

VascularProgenitors and

Stem Cells

8:00 - 9:30 P. 322

Inhibitors of Factor VIII and

Factor IX

8:00 - 9:30 P. 323

Antithrombtic -Systemic Effects

8:00 - 9:30 P. 323

Coagulation andInfection

40







Room109 AB

Room151 AB

Room162 AB

Room252 AB

Room257 AB

Prog

ram

Ove

rvie

w4:00 - 5:00 P. 330

Thrombin Acti-vatable Fibrinolysis

Inhibitor (TAFI)

4:00 - 5:00 P. 330

Atherosclerosis:Risk factors II

4:00 - 5:00 P. 329

Regulation ofCoagulation &Fribrinolysis1

2:15 - 3:45 P. 315

Shear-inducedSignaling

8:00 - 9:30 P. 324Trauma, Sepsis

and DisseminatedIntravascular

Coagulationvon

41

Thursday, July 16, 2009

State-of-the-Art

OralCommunications

PlenarySession

AbstractSymposia

NO

TE

S

43

SSC MeetingsandEducationalSessions

ISTH2009

55th Annual Meeting of the Scientific and Standardization Committee and Educational Program

The SSC Annual Meeting will be held on Saturday July 11 from 8:00 AM - 6:00 PM and on Sunday July 12 from 8:00 AM - 12:00 Noon.

An Education Program, sponsored jointly by the Congress and the SSC, willbe a part of individual SSC scientific subcommittee sessions, and will supple-ment topics not addressed in the main ISTH program. Speakers will provideattendees with an introduction to, and fundamentals of, a given subject.Additional education sessions will be held between 12:00 Noon and 2:00 PMon Saturday July 11.

Coffee BreaksCoffee will be served near the SSC Meeting Rooms. It will be possible to pur-chase coffee at various outlets throughout the BCEC as well.

Name BadgesName Badges can be picked up at the Registration Desk beginning on Friday,July 10 from 3:00 PM to 6:00 PM Name Badges must be worn at all timesthroughout the BCEC.

SSC Speakers Preview RoomSSC and Education Program Speakers are asked to bring their formattedPowerPoint presentations to the Speaker's Preview Room (Room 251) at leasttwo hours before their session. Files from key drives or CD-ROMs can betransferred to the Congress servers at that time. All conference rooms containstate-of-the-art technical equipment.

Speaker Preview Room Hours:Friday July 10, 2009 3:00 PM - 6:00 PM Saturday, July 11, 2009 7:30 AM - 7:00 PM Sunday July 12, 2009 7:30 AM - 7:00 PM

Scientific and Standardization CommitteeSee Page 9 for committee list

44

SSC

& E

duca

tion

alMessage from the SSC Chairman

Dear Colleagues and Friends:

Welcome to Boston! You have the privilege of participating in the world's lar-gest and most comprehensive gathering of investigators and practitioners inthe field of hemostasis and thrombosis. It begins with the Annual Meeting ofthe ISTH Scientific and Standardization Committee (SSC) and continues withthe XXII ISTH Congress. The SSC Annual Meeting has a valuable new educa-tional component, and the XXII Congress has been meticulously planned byPresidents Dr. Barbara Furie and Dr. Bruce Furie, with the assistance of theirLocal Organizing Committee, to be the best in a long sequence of outstandingscientific meetings.

As the Chairman of the SSC, it is my pleasure to invite you to participate in theSSC Subcommittee meetings on Saturday July 11th and Sunday July 12th.Each of the 20 SSC Subcommittees and Working Groups will have meetingsdevoted to the activities and projects in their respective areas. In addition, forthe first time at an SSC meeting held with an ISTH Congress, 19Subcommittees will have educational sessions. These carefully planned, outs-tanding educational presentations are the result of close collaboration betweenthe SSC Subcommittees and the ISTH Congress Vice Presidents, Dr. KennethBauer and Dr. Robert Handin. These educational opportunities effectivelycomplement the wide range of current basic and clinical science issues dis-cussed in Subcommittee business meetings. It is my expectation that the SSCmeetings will be one of the highlights of ISTH 2009. So, please join us for theSSC meetings. I am confident that you will benefit from the experience.

Best wishes for a productive and enjoyable visit!

45

Gerhard J. Johnson, M.D.ChairmanScientific and Standardization CommitteeISTH

Hemostasis and MalignancyChairperson: Martin H Prins (NL)

Co-Chairpersons: Giancarlo Agnelli (IT), Dominique Claire Farge (FR), CharlesW Francis (US), Alok A. Khorana (US), Agnes Y. Y. Lee (CA)

Educational Session 8:00 AM - 9:30 AM Room 107 ABC

Moderator: Martin H. Prins (NL)

Coagulation as a biological target for cancer therapyFrederick R. Rickles (US) 8:00 - 8:30 AM

Predicting cancer patients at risk for venous thromboembolism: Strategies for prophylaxisAlok A. Khorana (US) 8:30 - 9:00 AM

Diagnosis and management of cancer-associated thrombosisAgnes Y. Y. Lee (CA) 9:00 - 9:30 AM

This session will discuss the relationship between cancer and coagulation.Thrombosis is not only a common complication of cancer but coagulationmight also play a role as a biological target for cancer therapy. Experimentaland clinical evidence for the role of anticoagulants in cancer therapy will bediscussed. While it is clear that cancer patients who have surgery shouldreceive prophylaxis, it is unclear which cancer patient (if at all) deservesprophylaxis in the absence of surgery. Hence, it might be important to identifycancer patients at risk for venous thromboembolism to improve research instrategies for prophylaxis. Finally, the issues specific to cancer patients in thediagnosis and management of their thrombosis will be discussed.

SSC Business Session 9:30 AM - 12:00 PM Room 107 ABC

Program unavailable at time of printing. Go to www.isth.org for the most current program.

46

SATURDAY, JULY 11, 2009

Vascular BiologyChairperson: Jean-Marie Freyssinet (FR)

Co-chairpersons: Michael C. Berndt (IE), Françoise Dignat-George (FR), JohnH. Griffin (US), Peter J. Newman (US)


Shed proteins/receptors as clinical biomarkers of vascular diseaseModerator: Peter J. Newman (US)

Exploring the platelet sheddomeLawrence Brass (US) 8:00 - 8:30 AM

Translating the mechanism of GPVI shedding: Soluble GPVI as a clinical biomarkerMichael Berndt (IE) 8:30 - 9:00 AM

Platelet aging and ectodomain sheddingSimone Schoenwaelder (AU) 9:00 - 9:30 AM

There is growing realization that certain cell surface receptors are shed fromthe surface of blood and vascular cells as a result of their activation - perhapsas a mechanism to dampen the adhesive properties of the cell. A secondconsequence of platelet activation is the secretion of the contents ofspecialized granules, some of which have the potential to support endothelialcell growth, stem cell differentiation, and tumorigenesis. This 90 minutesession will highlight recent progress in the identification and characterizationof the so-called platelet sheddome and platelet secretome, with an emphasison how such fluid-phase proteins can both affect vascular physiology andreport vascular disease.

47


SSC

& E

duca

tion

al


Characterization of circulating endothelial progenitors

Chairpersons: Françoise Dignat-George (FR) and John Griffin (US)

Identification criteria of endothelial progenitor cellsMervin Yoder (US) 9:40 - 9:55 AM

Standardization of late endothelial progenitor cells culture from human blood David Smadja (FR) 9:55 - 10:10 AM

Determination and characterization of circulating microparticles

Chairpersons: Jean-Marie Freyssinet (FR) and Nigel Key (US)

Megakaryocyte-derived microparticles Joseph Italiano (US) 10:15 - 10:30 AM

The plasmin generation capacity of microparticles Romaric Lacroix (FR) 10:30 - 10:45 AM

Determination of microparticles by dynamic light scattering Paul Harrison (UK) 10:45 - 11:00 AM

Determination of microparticles by atomic force microscopy Yuana Yuana (NL) and Susanne Osanto (NL) 11:15 - 11:30 AM

Standardization off flow cytometry measurement, analysis, and reporting: Considerations for quantification of cell-derived membrane vesicles John Nolan (US) 11:30 - 11:45 AM

Progress on the standardization of microparticle enumeration by flow cytometry Françoise Dignat-George (FR) and Nigel Key (US) 11:45 - 12:00 PM

48


SSC

& E

duca

tion

al

Predictive Variables in Cardiovascular DiseaseChairperson: Gordon D. Lowe (UK)

Co-Chairpersons: James Douketis (CA), Veikko Salomaa (FI),Alberto Tosetto (IT)


Predictive hemostatic variables: A user's guide to applyingclinical/laboratory predictors of venous and arterial thromboembolismin everyday clinical practice

Moderators: Gordon Lowe (UK) and James Douketis (CA)

Interpreting studies of predictor variables and clinical outcomes: What does having a risk factor really mean?Mark Woodward (US) 8:00 - 8:30 AM

Developing a clinical-laboratory decision rule for recurrent venous thromboembolism: How do we get there?Marc A. Rodger (CA) 8:30 - 9:00 AM

Interpreting clinical-laboratory prediction rules: When is a Clinical Practice Guideline ready for prime time?Henri Bounameaux (CH) 9:00 - 9:30 AM

This educational program reviews the stages in development of clinical andlaboratory predictors of venous and arterial thromboembolism, and theirapplication to clinical practice. The first presentation considers analysis of theassociations of clinical and laboratory predictors with outcomes in prospectivestudies, their interpretation, and potential for risk stratification. The secondpresentation reviews the development of decision rules from such information,using prediction of recurrent venous thromboembolism as an example. Thefinal presentation addresses the application of such rules in clinical practiceguidelines, and in routine clinical care. This session will enable participants tocritically appraise new information on clinical risk management of thromboticdiseases, and apply it to everyday clinical practice.

49



Predictive Variables: Update

Chairpersons: Veikko Salomaa (FI) and Alberto Tosetto (IT)

Thrombophilias and recurrent venous thromboembolismTrevor Baglin (UK) 10:00 - 10:30 AM

Factor IX and venous thromboembolismFrits Rosendaal (NL) 10:30 - 11:00 AM

D-dimer and recurrent venous thromboembolism Alberto Tosetto (IT) 11:00 - 11:30 AM

Women's Health in Thrombosis and Hemostasis Chairperson: Andra H. James (US)

Co-Chairpersons: Margareta Blomback (SE), Benjamin Brenner (IL),Jacqueline Conard (FR), Sabine Eichinger (AT), Barbara A. Konkle (US),Claire McLintock (NZ), Claire S. Philipp (US)

SSC Business Session 8:00 AM - 10:30 AM Room 102 AB

Introduction and Overview

Chairperson: Andra H. James (US)

Welcome Purpose and function of SCC's What constitutes issues in women's health in thrombosis and hemostasis Introduction of co-chairs and their comments 8:00 - 8:15 AM

Educational Activities

Chairperson: Benjamin Brenner (IL)

Report on the Women's Health Issues in Thrombosis and HaemostasisSymposia 8:15 - 8:30 AM

Report on publications 8:30 - 8:45 AMUpdate on registries

50


SSC

& E

duca

tion

al

Pregnancy outcome in women with mechanical heart valves 8:45 - 8:55 AM

Mirena IUD for menorrhagia in women with bleeding disorders Rezan Kadir (UK) 8:55 - 9:05 AM

Corpus luteum bleeding in women with bleeding disorders Ron Hoffman (IL) 9:05 - 9:15 AM

Update on ongoing international collaborations

Menorrhagia in women affected by bleeding disorders Flora Peyvandi (IT) 9:15 - 9:25 AM

Other new and proposed projects including registries2 randomized trials of anticoagulation in women with a history of poor pregnancy

HEPRIN Anne McLeod (CA) 9:30 - 9:40 AM

TIPPS 9:40 - 9:50 AM

Laboratory analyses in habitual abortionMargareta Blombäck (SE) 9:50 - 10:00 AM

Break 10:00 - 10:30 AM

Educational Session 10:30 AM - 12:00 PM Room 102 AB

Moderator: Andra H. James (US)

Identifying women with menorrhagia for hemostatic evaluationClaire S. Philipp (US) 10:30 - 11:00 AM

Anticoagulation during pregnancy/ Debate: Inherited thrombophilia and pregnancy complications - anticoagulation? (Yes)Benjamin Brenner (IL) 11:00 - 11:30 AM

Anticoagulation during pregnancy/ Debate: Inherited thrombophilia and pregnancy complications - anticoagulation? (No)Marc A. Rodger (CA) 11:30 - 12:00 PM

51


Dr. Philipp will discuss her experience developing a screening tool for stratifyingwomen with unexplained menorrhagia for hemostatic testing for underlyingbleeding disorders. Recently, she and her colleagues completed a study of 146women with a physician diagnosis of menorrhagia who underwentcomprehensive hemostatic testing for the diagnosis of bleeding disorders,including von Willebrand disease, platelet dysfunction, and coagulation factordeficiencies. Bleeding symptoms with high predictive values for laboratoryhemostatic abnormalities were combined and used as single variables tocalculate sensitivity, specificity, and positive and negative predictive values inorder to develop a short screening tool. Dr. Phillip will discuss the results of thestudy. A combination of 8 questions in 4 categories resulted in a sensitivity of82% (95%CI 75-90) for bleeding disorders. Adding a pictorial bloodassessment chart score > 100 increased the sensitivity of the screening tool to95% (95%CI 91-99). Adding the PFA-100 did not increase the sensitivity forbleeding disorders overall, though sensitivity for VWD was increased.

Dr. Brenner will present one side of the debate: Inherited thrombophilia andpregnancy complications - anticoagulation? (Yes) Inherited thrombophilias areassociated with gestational vascular complications including three or more firsttrimester losses, two or more second trimester losses, or any stillbirth; early,severe or recurrent preeclampsia and severe intrauterine growth restriction.Furthermore, low-molecular-weight heparin is safe and effective in preventingpregnancy loss and decreasing the recurrence of placental-mediatedcomplications in women with both acquired and inherited thrombophilia.

Dr. Rodger will present one side of the debate: Inherited thrombophilia andpregnancy complications - anticoagulation? (No) Inherited thrombophilias arenot yet established as a cause of placenta-mediated pregnancy complications,such as fetal growth restriction, preeclampsia, abruption, and pregnancy loss.An inherited thrombophilia is only one of many factors that lead todevelopment of these diseases and is unlikely to be the unique factor thatshould drive management in subsequent pregnancies. The paucity of evidencefor benefit, coupled with a small potential for harm, suggests that lowmolecular weight heparin should be considered an experimental drug for theseindications until data from controlled trials are published. At present, womenwith a history of placenta-mediated pregnancy complications, with or withouta thrombophilia, should be followed closely without routine prophylactic lowmolecular weight heparin other than for prevention of venousthromboembolism in limited circumstances.

52


SSC

& E

duca

tion

al

Platelet Immunology Chairperson: Andreas Greinacher (DE)

Co-Chairpersons: Beng H. Chong (AU), Yves Gruel (FR), Volker Kiefel (DE),Hartmut Kroll (DE), Theodore Warkentin (CA)

SSC Business Session 8:00 AM - 11:00 AM Room 153 ABC

Welcome

Andreas Greinacher (DE) 8:00 - 8:05 AM

PART 1. Autoimmune thrombocytopenia

Chairpersons: Beng Chong (AU) and Hartmut Kroll (DE)

Standardization of terminology and definitions in ITP: On which topics has a consensus been reached and what are the open issuesFrancesco Rodeghiero (IT) 8:05 - 8:20 AM

Discussion: Does the Platelet Immunology Subcommittee agree with the consensus? 8:20 - 8:30 AM

Update: PARC study new lessons learned, new questions arising from systematically collecting and following ITP adult and pediatric ITP patientsPaul Imbach (CH) and T. Kühne (CH) 8:30 - 8:45 AM

Discussion: Are there specific questions of the Platelet Immunology Subcommittee which could be answered by the PARC study? 8:45 - 8:55 AM

Platelet antibodies in well-defined populations of patients with ITPDonald Arnold (CA) 8:55 - 9:05 AM

Discussion 9:05 - 9:10 AM

GPIIbIIIa and GPIbIX glycoproteins sufficient for platelet autoantibody testing? 9:10 - 9:20 AM


Break 9:25 - 9:35 AM

53


Discussion for a Statement of the Platelet Immunology Subcommittee on the role of platelet antibody testing in the time of new therapeutic options for ITP: Is there a role for platelet autoantibody testing in patients with ITP? Discussion 9:35 - 10:00 AM

Statement for the SSC chairVolker Kiefel (DE) 10:00 - 10:05 AM

PART 2. 10:05 - 10:45 AMHeparin-induced thrombocytopenia

Chairpersons: Yves Gruel (FR) and Theodore Warkentin (CA)

How to improve the clinical use of antigen assays in HITCombining quantitative interpretation of PF4-dependent EIA's and high heparinKarina Althaus (DE) 10:05 - 10:20 AM

Towards genetics in HITYves Gruel (FR) 10:20 - 10:35 AM

Last Minute Contributions 10:35 - 11:00 AM

Educational Session 11:00 AM - 12:00 PM Room 153 ABC

Moderator: Volker Kiefel (DE)

Laboratory testing for heparin-induced thrombocytopeniaTheodore E. Warkentin (CA) 11:00 - 11:30 AM

Drug-induced immune thrombocytopeniasRichard Aster (US) 11:30 - 12:00 PM

The educational session will focus on two important issues related to drug-induced immune reactions towards platelets. Heparin-induced thrombo-cytopenia is by far the most frequent drug induced antibody response, and thelecture will provide a comprehensive overview on the different assays currentlyavailable and an appraisal of their role in clinical practice. Drug-inducedimmune thrombocytopenias are less frequent but can be associated withsevere bleeding. Recent data provide new concepts on the understanding ofthe pathogenesis of the immune response. Both speakers are internationallyrespected experts in these topics.

54


SSC

& E

duca

tion

al

Factor VIII and IXChairperson: Alok Srivastava (IN)

Co-Chairpersons: Charles Hay (UK), Christine Lee (UK), Claude G. Negrier(FR), Johannes Oldenburg (DE), Flora Peyvandi (IT), Jean-Marie Saint-Remy(BE), Edward G D Tuddenham (UK)


Note: An additional Factor VIII and IX SSC Business Session, and EducationalProgram, will be held on Saturday 2:00 - 6:00 PM.

Part 1

Welcome and IntroductionAlok Srivastava (IN) 8:00 - 8:05 AM

Completed/Submitted reports and recommendationsAlok Srivastava (IN) 8:05 - 8:10 AM

Rare bleeding disorders

Chairpersons: Flora Peyvandi (IT) and Christine A. Lee (UK)

Overview Flora Peyvandi (IT) and Christine A. Lee (UK) 8:10 - 8:15 AM

European Network of Rare Bleeding Disorders (ENRBDs)Flora Peyvandi (IT) 8:15 - 8:30 AM

North American Registry of Rare Bleeding DisordersAmy Shapiro (US) 8:30 - 8:45 AM

Standardization of assays: FVII and FXISteven Kitchen (UK) 8:45 - 9:00 AM

Thrombin Generation in RBDs Waander van Heerde (NL) 9:00 - 9:15 AM

A new Factor X concentrate: Clinical issuesClive Dash (UK) 9:15 - 9:30 AM

Recombinant FXIII: Early dataKim Jacobsen (DK) 9:30 - 9:45 AM

General discussion / Future directions 9:45 - 9:55 AM

55


Break 9:55 - 10:00 AM

Factor VIII/IX: Clinical issues- I (Assay / EQA / Phenotype)

Chairpersons: Claude Negrier (FR) and Alok Srivastava (IN)

Overview: Tests of global hemostasis Claude Negrier (FR) and Alok Srivastava (IN) 10:10 - 10:15 AM

Systematic approach to the assay discrepancies between one and two-stage assaysJohannes Oldenburg (DE) 10:15 - 10:30 AM

Factor VIII assay - A new paradigmEdward Gomperts (US) and Kenneth Mann (US) 10:30 - 10:45 AM

Assays for global hemostasis in hemophilia: Correlation with adjuvant therapeutic optionsBenny Sorensen (UK) 10:45 - 11:00 AM

Comparison of TEG / TGT / Wave form analysis in clinical samples of hereditary bleeding disordersSukesh C. Nair (IN) 11:00 - 11:15 AM

Global hemostasis tests in hemophilia - Early data and a systematic study planClaude Negrier (FR) 11:15 - 11:30 AM

General discussion 11:30 - 11:40 AM

The agenda of the SSC: What are the priorities?

General discussion 11:40 - 12:00 PM

56


SSC

& E

duca

tion

al

APSTH-ISTH Symposium

Educational Session 12:15 PM - 1:45 PM Room 104 ABC

Moderator: Yukio Ozaki (JP)

Coagulopathy in MalariaPantep Angchaisuksiri (TH) 12:15 - 12:40 PM

Use of Asian snake venom inhibitors in studies of blood coagulation mechanismTakashi Morita (JP) 12:40 - 1:05 PM

Coagulopathy induced by snake bites and its managementGeoff Isbister (AT) 1:05 - 1:25 PM

Genetic disorders related to coagulopathy prevalent in the Far EastToshiyuki Miyata (JP) 1:25 - 1:45 PM

The Asian-Pacific Society on Thrombosis and Hemostasis (APSTH) wasfounded 11 years ago, and with the help of ardent activities of its members, ithas contributed immensely to the development of research and clinical studiesrelated to thrombosis and hemostasis in Asian-Pacific countries. The APSTH has the membership of more than 350 members fromAustralia, Cambodia, China, India, Indonesia, Japan, Korea, Malaysia, Mongol,Philippines, Singapore, Taiwan, Thailand, and Vietnam. We have had 5 APSTHConferences in Taiwan, Korea, Thailand, China, and Singapore, and the 6thConference of APSTH will be held in Indonesia in 2010. Please visit the websiteof APSTH: http://www.jsth.org/apsth/index.html The APSTH-ISTH jointsymposium was held at the Sydney ISTH Conference in 2005, and at theGeneva ISTH Conference in 2007, focusing on the diseases related tothrombosis and hemostasis prevalent in the Asian-Pacific area. The jointsymposium at the Boston ISTH Conference will deliver to the audiencecomprehensive introduction on coagulopathy in malaria, use of Asian snakevenom inhibitors in studies of blood coagulation mechanism, coagulopathyinduced by snake bites and its management, and genetic disorders related tocoagulopahty prevalent in the Far East.

57


Genomics 101


Moderator: Willem Ouwehand (UK)

The genetic architecture of thrombosis and bleeding: Rare mutations and common SNP'sPieter H. Reitsma (NL) 12:15 - 12:45 PM

The architecture of genome-wide SNP studies: New examples including fibrinogen, vWD, FVII and VFIIAndrew Johnson US) 12:45 - 1:15 PM

Small steps in a long journay: The discovery of risk loci for cardiovascular diseaseWillem Owehand (UK) 1:15 - 1:45 PM

A large number of common diseases have a substantial heritability. It hashowever until recently not been possible to identify loci which contribute todisease risk. The sequencing of the human genome, and the cataloguing ofsequence variation within and between populations, has provided theinformation which was needed for the design of genome-wide typing arrays.These high density arrays have been used to test large numbers of DNAsamples from cases with disease and healthy controls for common sequencevariation. Three distinguished speakers will review the results of the firstGenome-Wide Association Studies (GWAS) and how this type of study haslead to the discovery of novel loci implicated in cardiovascular disease,hemostasis and thrombosis. In a stepwise process you will be familiarized withthe principle categories and extent of common sequence variation, the designof GWAS and the statistical approach used for the analysis of large scalegenotyping results. Finally, we will show how these results have altered ourinsight in disease pathophysiology of thrombosis and hemostasis.

58


SSC

& E

duca

tion

al

In silico Drug Design


Moderator: Gerry AF Nicolaes (NL)

Application of in silico methods in blood coagulation research: From virtual proteins to wet protein chemistryGerry AF Nicolaes (NL) 12:15 - 12:45 PM

In silico screening of compound collections: Methods and applications for drug discovery and chemical biologyBruno Villoutreix (FR) 12:45 - 1:15 PM

Protein-Protein complexes: Druggable or undruggable targets?Xavier Morelli (FR) 1:15 - 1:45 PM

Structural bioinformatics meanwhile play a role across the entire drugdiscovery pipeline.A major application of structural bioinformatics is the design of ligands thatbind specifically and tightly to a binding site on a protein target. In silicotechniques such as molecular docking and virtual ligand screening (VLS) haveestablished themselves as novel computational techniques that can predictprotein-ligand interactions. Advances in calculation power of computersystems have made these techniques possible for researchers, both inacademia and in industry. During this session, the basic rules andconsiderations that are of importance to this rapidly developing field of sciencewill be discussed.

59


Translating Evidence into Practice

Educational Session 12:15 PM - 1:45PM Room 160 ABC

Moderators: Gerhard J. Johnson (US) and James Douketis (CA)

Developing Clinical Practice Guidelines - GRADE system experiencesRoman Jaeschke (CA) 12:15 - 1:00 PM

Incorporating practice guidelines into the realm of arterial and venous thromboembolism predictors: What do we have? What is missing? Gordon Lowe (UK) 1:00 - 1:45 PM

The session on 'translating evidence into practice' begins with a generaloverview of how evidence from clinical trials and observational studies isincorporated into clinical practice guidelines. This discussion will focus on thepractical aspects of developing practice guidelines, including how grades ofevidence are established and how guideline committees work to interpretavailable evidence, especially controversial evidence, in formulating simple andeasy-to-use practice guidelines. The session ends with a discussion of howclinical practice guidelines have been applied to the area of clinical predictorsof venous and arterial thromboembolism. This discussion will focus oncurrently used predictors and the evidence for their recommended use as wellas gaps in knowledge and future research.

The Illusion of Disclosure


Moderator: Bruce Furie (US)

The illusion of disclosure- Conflict of interests in clinical investigation: Perspectives of a journal editorRobert S. Schwartz, Deputy Editor, New England Journal of Medicine (US) 12:15 - 1:15 PM

This session will discuss the conflict of interest in medical publishing from aneditor's point of view, the recent Institute of Medicine report on conflict ofinterest, and some new questions about the tension between conflict ofinterest and ethical conduct of clinical trials.

60


SSC

& E

duca

tion

al

Fibrinogen and Factor XIIIChairperson: Moniek P. M. de Maat (NL)

Co-Chairpersons: Robert A S Ariens (UK), Aida Inbal (IL), Hans P. Kohler(CH), Jaap Koopman (NL), Muriel Maurer (US), Leonid Medved (US),Marguerite Neerman-Arbez (CH), Rainer Seitz (DE), John W. Weisel (US)


Moderator: Moniek deMaat (NL)

Fibrin gels and bioengineering/clinical applicationsJohn Weisel (US) 2:00 - 2:30 PM

Non-coagulation activities of Factor XIIIAida Inbal (IL) 2:30 - 3:00 PM

Weisel: Fibrin gels have unique structural and rheological properties that makethem well suited for numerous biomaterials applications in medicine andengineering. Fibrin is highly extensible with non-linear elasticity, andpolymerization can be modulated to produce a variety of soft substrates. Fibrinis commonly used as a sealant to stem bleeding and promote wound healing.Newer applications include its use as a matrix for drug delivery, cell migrationand differentiation, tissue engineering, and patterning.

Inbal: Factor XIII (FXIII) is a plasma transglutaminase that catalyzes the crosslink formation between fibrin chains to stabilize the clot. Beside its function inhemostasis FXIII has a role in wound healing and embryo implantation -processes that involve angiogenesis. In this review the role of FXIII inangiogenesis and wound repair as well as the molecular mechanismsunderlying these effects will be discussed. Finally, a novel activity of FXIII-protein disulfide isomerase (PDI) will be described.

61


SSC Business Session 3:00 PM - 6:00 PM Room 156 ABC

Factors XIII

Diagnosis of factor XIII deficiency; Outline of a position paperLaszlo Muszbek (HU) and Hans P. Kohler (CH) 3:00 - 3:20 PM

FXIII values in patients with heterozygous deficiencyVytautas Ivaskevicius (DE), Arijit Biswas (DE) and Johannes Oldenburg (DE) 3:20 - 3:40 PM

Measurement of Factor XIII activation peptide (FXIII-AP) in patients with acute ischemic stroke using a new FXIII-AP ELISAVerena Schroeder (UK), Elisabeth Ortner (CH) and Hans P. Kohler (CH) 3:40 - 4:00 PM

Measuring the B-unit in standardsRobert Ariens (UK) 4:00 - 4:20 PM

Break 4:20 - 4:40 PM

Fibrinogen

PT-derived and Clauss assay and dysfibrinogensWolfgang Miesbach (DE) 4:40 - 5:00 PM

Update CharacterizationMarguerite Neerman-Arbez (CH) 5:00 - 5:20 PM

Fibrin Structure Marlien Pieters (ZA) 5:20 - 5:40 PM

2nd International Standard Fibrinogen Plasma (98/612) - replacementSanj Raut (UK) 5:40 - 5:50 PM

1st International Standard Fibrinogen Concentrate (98/614) - replacementSanj Raut (UK) 5:50 - 6:00 PM

62


SSC

& E

duca

tion

al

Plasma Coagulation Inhibitors Chairperson: Herbert C. Whinna (US)

Co-chairpersons: Francesco Bernardi (IT), Elaine Gray (UK), Tilman M.Hackeng (NL), Steven Kitchen (UK), Richard Marlar (US), Piet Meijer (NL),Laurent O. Mosnier (US)

SSC Business Session 2:00 PM - 4:30 PM Room 109 AB

Report from the Working Party on Thrombin Generation Tests

Differences in protein S activity assay outcomes in the externalquality assessment program of the ECAT Foundation

Proposal for a scoring system of the analytical performance ofcoagulation inhibitor testing

Educational Session 4:30 PM - 6:00 PM Room 109 AB

Moderator: Elaine Gray (UK)

Antithrombin and heparin Co-factor II: Structure and functionTrevor Baglin (UK) 4:30 - 5:00 PM

Molecular mechanisms of thrombosis risk in protein S deficiencyElisabetta Castoldi (NL) 5:00 - 5:30 PM

Laboratory investigation of thrombophiliaSteven Kitchen (UK) 5:30 - 6:00 PM

The first presentation by Dr. Baglin will focus on how the structure ofantithrombin and heparin-cofactor II and their interactions with sulphatedpolysaccharides such as heparin influence their function as important serineprotease inhibitors. Dr. Castoldi will address the role of protein S, a majoranticoagulant protein that acts as a cofactor of both activated protein C andtissue factor pathway inhibitor. The increased risk of venous thrombosis as aresult of congenital protein S deficiency will be reviewed. Dr. Kitchen will coverthe standardization of laboratory tests for investigation of thrombophilia. Theadvantages/disadvantages of tests employing different principles of analysisincluding clotting/chromogenic PC assays, protein S activity assays, andantithrombin assays employing thrombin or factor Xa. The issues will beillustrated using genuine cases and data from external quality assessmentinvolving several hundred laboratories.

63


Factor VIII and IXChairperson: Alok Srivastava (IN)

Co-Chairpersons: Charles Hay (UK), Christine Lee (UK), Claude G. Negrier(FR), Johannes Oldenburg (DE), Flora Peyvandi (IT), Jean-Marie Saint-Remy(BE), Edward G D Tuddenham (UK)

Educational Session 2:00 PM - 3.30 PM Room 153 ABC

Moderator: Alok Srivastava (IN)

Management of hemophilia and assessment of outcomesKathelijn Fischer (NL) 2:00 - 2:30 PM

Factor concentrates for hemophilia - Current products and newer technologiesEdward G D Tuddenham (UK) 2:30 - 3:00 PM

Gene therapy of hemophilia B: Overview and new possibilitiesArun Srivastava (US) 3:00 - 3:30 PM

This program will review three important aspects of the management ofhemophilia. First, Dr. Fischer will discuss the different approaches toprophylactic factor replacement therapy, describe the assessment ofmusculoskeletal outcome after such therapy and tell us if we are anywherenear defining an optimal protocol. Dr. Tuddenham will then review the currentoptions of products for replacement therapy and discuss their advantages andpotential drawbacks. He will also mention some of the newer products andhow they may impact care of people with hemophilia. Finally, Dr. Srivastava willlook at the possibility of cure from this condition. He will review the possibilitiesfor gene therapy of hemophilia, describe the experience so far and discusssome of the ways to move this field forward.

64


SSC

& E

duca

tion

al

SSC Business Session 3:30 PM - 6.00 PM Room 153 ABC

Factor VIII/IX: Clinical issues- II (Inhibitors / Prophylaxis / NovelTherapies)

Chairpersons: Charles Hay (UK) and Jean-Marie Saint-Remy (BE)

OverviewCharles Hay (UK) and Jean-Marie Saint-Remy (BE) 3:30 - 3:35 PM

International ITI study: UpdateDonna DiMichele (US) 3:35 - 3:50 PM

Diagnosis and treatment of acquired hemophilia A:Recommendations of an International group Angela Huth-Kuhne (DE) 3:50 - 4:05 PM

Prophylactic factor replacement in hemophilia - What studies do we need to standardize practiceVictor Blanchette (CA) 4:05 - 4:20 PM

A simple, safe strategy for hemophilia gene therapy with plasmid DNAMichele Calos (US) 4:20 - 4:35 PM

General discussion / Future directions 4:35 - 4:45 PM

Factor VIII/IX: Standardization issues

Chairpersons: Edward Tuddenham (UK) and Johannes Oldenburg (DE)

OverviewEdward Tuddenham (UK) and Johannes Oldenburg (DE) 4:45 - 4:50 PM

6th International Standard for the FVIII / VWF plasmaAnthony Hubbard (UK) 4:50 - 5:05 PM

8th International Standard for FVIII Concentrate Sanj Raut (UK) 5:05 - 5:20 PM

Standardizing the FVIII inhibitor assay: Can it be done? Koen Mertens (NL) 5:20 - 5:35 PM

Standardizing assessment of musculoskeletal outcome in hemophiliaPradeep Poonnoose (IN) 5:35 - 5:50 PM

General discussion / Future directions 5:50 - 5:55 PM

Closing remarksAlok Srivastava (IN) 5:55 - 6:00 PM

65


Perinatal/Pediatric HemostasisChairperson: Gili Kenet (IL)

Co-chairpersons: Janna M. Journeycake (US), Prasad Mathew (US), PaulMonagle (AU), Wolgang Muntean (AT), Ulrike Nowak-Gottl (DE), NicoleSchlegel (FR)

Educational Session 2:00 PM - 3:30 PM Room 102 AB

Moderator: Gili Kenet (IL)

Developmental HemostasisGili Kenet (IL) 2:00 - 2:30 PM

Pediatric venous thromboembolism and thrombophiliaUlrike Nowak-Gottl (DE) 2:30 - 3:00 PM

Anticoagulant therapy in childrenPaul Monagle (AU) 3:00 - 3:30 PM

Kenet: Hemostasis is a dynamic process, which begins in-utero. The pro-coagulant capacity of new-borns is reduced. This fact, theoretically increasingthe risk of bleeding, is balanced by the protective physiologic deficiencies ofcoagulation inhibitors, as well as by decreased fibrinolytic capacity. Thevariations in levels and activity of hemostatic components affecting the clinicalsettings in neonates will be highlightened.

Nowak-Gottl: The annual incidence of venous thromboembolism (VTE) inchildren was estimated as 0.07 to 0.14 per 10,000 children, 5.3 per 10,000hospital admissions, and 24 per 10,000 admissions of neonates. VTE inchildren often occurs as a complication of a severe underlying medicalcondition. The potential role of inherited thrombophilias as risk factors, alsoaffecting recurrence rates in children, will be presented.

Monagle: The current standard anti-thrombotic therapy in children consists ofinitial short-term intravenous administration of either un-fractionated heparin(UFH) or LMWH, followed by long-term oral anticoagulants or continuedLMWH. New drugs deserve attention, yet data regarding their pharma-cokinetics, efficacy and safety in paediatric patients are to be elucidated. Thedifficulties and controversies regarding “tailoring” of anticoagulant treatment inchildren will be discussed.

66


SSC

& E

duca

tion

al

SSC Business Session 3:30 PM - 6:00 PM Room 102 AB

Anticoagulant trials

Chairpersons: Patricia Massicote (CA) and Wolfgang Munteau (AT)

Quality of Life tool for children receiving anticoagulant therapyAisha Bruce (CA) and Fiona Newall (AU) 3:30 - 3:45 PM

Trial design and outcomes for evaluation of anticoagulant drugs for use in childrenChristoph Male (AT) 3:45 - 4:05 PM

Break 4:05 - 4:20 PM

Pediatric thrombosis and stroke - Suggestions,definitions and trials

Chairpersons: Janna Journeycake (US) and Guy Young (US)

Limitations and definitions in pediatric thrombosis studiesLesley Mitchell (CA) 4:20 - 4:40 PM

A validated pediatric PTS outcome instrumentN Goldberg (US) 4:40 - 4:40 PM

Kids -DOTT trial N Goldberg (US) 4:40 - 4:50 PM

Genetic association studies for juvenile thrombosis and strokeMonika Stoll (DE) 4:50 - 5:00 PM

Neonatal Thrombosis

Chairpersons: Anthony K. Chan (CA) and Mariana Bonduel (AR)

Neonatal Renal Vein ThrombosisKeith Lau (CA) 5:00 - 5:15 PM

Neonatal Portal Vein ThrombosisSuzan Williams (CA) 5:15 - 5:30 PM

Neonatal CSVTMahendranath Moharir (CA) 5:30 - 5:45 PM

67


Animal Models Chairperson: Timothy Charles Nichols (US)

Co-chairpersons: Edward M. Conway (BE), Shaun Coughlin (US), Jay L.Degen (US), Nigel Mackman (US), Eva-Maria Muchitsch (AT), Susan Smyth(US), Hugo Ten Cate (NL), Hartmut Weiler (US)


Moderators: Nigel Mackman (US), Hartmut Weiler (US), Timothy C. Nichols (US)

Human gamma fibrinogen in mouse coagulationHartmut Weiler (US) 2:00 - 2:15 PM

Coagulation protease-inhibitor effects in models of cardiovascular disease Hugo Ten Cate (NL) 2:15 - 2:30 PM

Intra-articular factor IX protects hemophilia B mice from developing hemophilic synovitisPaul Monahan (US) 2:30 - 2:45 PM

Tissue factor and tissue-specific hemostasisNigel Mackman (US) 2:45 - 3:00 PM

Novel ultrasound methods to monitor hemostasisCaterina Gallippi (US) 3:00 - 3:30 PM

Hemophilia A in sheepGraca Almeida-Porada (US) 3:30 - 3:45 PM

Canine hemophilia A and BTimothy C. Nichols (US) 3:45 - 4:00 PM

Break 4:00 - 4:30 PM

68


SSC

& E

duca

tion

al


Moderators: Hartmut Weiler (US) and Timothy C. Nichols (US)

Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapiesThomas G. Diacovo (US) 4:30 - 5:00 PM

Key questions for animal models of hemostasis in developing new drugs and obtaining approvalEva-Marie Muchitsch (AT) 5:00 - 5:30 PM

Stressing the limits of mice models of hemophilia: When mice are not small peopleMortimer Poncz (US) 5:30 - 6:00 PM

The focus of this Animal Models Subcommittiee educational session is todiscuss the strengths and limitations of animal models in hemostasis research.The approach to cross species interactions of murine VWF and humanplatelets will be discussed by Dr. Diacovo. Issues to be considered in theutilization of animal models in developing new hemostatic agents and obtainingapproval for use will be discussed by Dr. Muchitsch. Dr. Poncz will discuss keydifferences between murine and human hemophilia.

Lupus Anticoagulant / Phospholipid-Dependent AntibodiesChairperson: Vittorio Pengo (IT)

Co-chairpersons: Ph G De Groot (NL), Thomas Ortel (US), Jacob H. Rand(US), Guido Reber (CH), Armando Tripodi (IT)

SSC Business Session 2:00 PM - 4:30 PM R oom 160 ABC

OpeningVittorio Pengo (IT) 2:00 - 2:15 PM

Round Table Chairperson: Armando Tripodi (IT)

Standard reference material for detecting antiphospholipidantibodies: Problems and possible solutionsKatrien Devreese (BE), Emmanuel Favaloro (AU), Elaine Gray (UK),Silvia Pierangeli (US), Guido Reber (CH) 2:15 - 3:00 PM

69


Laboratory diagnosis: Coagulation assays (new guidelines)Armando Tripodi (IT) 3:00 - 3:30 PM

Detection of antibodies against domain I of beta2- glycoprotein I improves the diagnosis of APS: An international multicenter studyBas de Laat (NL) 3:30 - 3:45 PM

Predictive value of the Antiphospholipid ScoreTatsuya Atsumi (JP) 3:45 - 4:00 PM

Break 4:00 - 4:30 PM


Moderator: Vittorio Pengo (IT)

Antiphospholipid antibodies: Historical backgroundThomas Ortel (US) 4:30 - 4:50 PM

Mechanism of action of antiphospholipid antibodiesJacob H. Rand (US) 4:50 - 5:10 PM

Laboratory diagnosisPh. G. de Groot (NL) 5:10 - 5 :30 PM

Clinical featuresVittorio Pengo (IT) 5:30 - 6:00 PM

Four speakers will cover all the relevant aspects of the antiphospholipidsyndrome. An Historical background will initially be given by Dr. Ortel startingfrom the discovery of antiphospholipid antibodies at the beginning of pastcentury. To follow Dr. Rand will describe the current hypotheses on thepathogenesis of the syndrome. Dr. de Groot will then discuss the veryimportant issue on the laboratory diagnosis of the syndrome and finally Dr.Pengo will describe the clinical features to diagnose the disease as well theinfrequent associated clinical manifestations.

70


SSC

& E

duca

tion

al

BiorheologyChairperson: Johan W.M. Heemskerk (NL)

Co-chairpersons: Thomas Diacovo (US), Marc Hoylaerts (BE), Michael King(US), Gerard B. Nash (UK), J. J. Zwaginga (NL)


Moderator: Johan W.M. Heemskerk (NL)

Adhesion of platelets and leukocytes to the vessel wall: Rheological principles and critical parametersGerard B. Nash (UK) 2:00 - 2:30 PM

Thrombus formation and the different ways to measure thisJohan W.M. Heemskerk (NL) 2:30 - 3:00 PM

The first lecture discusses key principles of blood flow-dependent processesand quantitative parameters of rheology, including (arterial and venous) shearstress and shear rate. Subsequently, an overview will be given of how theblood flow determines adhesion of platelets and leukocytes to the vessel wall.The second lecture overviews recent literature on the various stages of flow-dependent thrombus formation. In vivo, different procedures are used toprovoke thrombus formation experimentally. To study human thrombusformation ex vivo or in vitro, various types of flow-based devices (flowchambers, capillary systems) are developed. It will be discussed howthrombus formation can be measured in both in vivo and in vitro assays.


Section 1. Flow-dependent experimental thrombosis models andtranslation. How to use flow-dependent thrombosis models?

Chairpersons: Marc Hoylaerts (BE) and Johan Heemskerk (NL)

Novel molecular interactions in thrombus formationShaun Jackson (AU) 3:00 - 3:15 PM

Comparison of in vivo and in vitro thrombosis modelsBeatrice Hechler (FR) and Pierre Mangin (FR) 3:15 - 3:30 PM

Using flow-dependent models in vitro and in vivo to explore new ideas about platelet activationLawrence Brass (US) 3:30 - 3:45 PM

71


Limitations of animal thrombosis models: The need for alternativesMarc Hoylaerts (BE) 3:45 - 4:00 PM

Break 4:00 - 4:25 PM

Section 2. Determination of flow-dependent molecular interactions. Processes relying on flow

Chairpersons: Michael King (US) and Thomas Diacovo (US)

Platelet-fibrin-thrombus formation in arterial flow requires high and low shear regionsArmin Reininger (DE) 4:25 - 4:40 PM

Flow-based measurement of VWF binding to collagenBirte Fuchs (DE) 4:40 - 4:55 PM

Flow-dependent function of VWF after gene therapyKaren Vanhoorelbeke (BE) 4:40 - 5:10 PM

Section 3. Standardization of thrombus formation under flow. How to use flow devices?

Chairpersons: J.J. Zwaginga (NL) and Gerald Nash (UK)

Measurement of thrombus formation on (ruptured) atherosclerotic plaquesJudith Cosemans (NL) 5:10 - 5:25 PM

Use of quantitative flow assays to study unknown bleeding disordersMark Roest (NL) 5:25 - 5:40 PM

The analysis of shear-dependent thrombus deposition on synthetic collagen surfacesRichard Farndale (UK) 5:40 - 5:55 PM

72


SSC

& E

duca

tion

al

Disease-Specific Molecular Mechanisms inDisseminated Intravascular Coagulation (DIC)Chairperson: Cheng-Hock Toh (UK)

Co-chairpersons: Nigel S. Key (US), Hyun Kyung Kim (KR), Jorn DalsgaardNielsen (DK), Hideo Wada (JP)


Moderator: Cheng-Hock Toh (UK)

Role of IL-17 in SepsisPeter A. Ward (US) 8:00 - 8:30 AM

New concepts in trauma induced coagulopathyKarim Brohi (UK) 8:30 - 9:00 AM

Acute Promyelocytic Leukemia: Mechanisms of coagulopathyKatherine A. Hajjar (US) 9:00 - 9:30 AM

From the earliest clinical observations, it has long been recognized that theoutcome of any primary disease state is worsened by the development of acoagulopathy. In translating this into a standardized format of recognition, theISTH Scientific and Standardization Sub-Committee has developed a DICdiagnostic criteria that has now been well-validated. Studies have shown thatrecognizing DIC, irrespective of its aetiology, has clinical value in the improvedstratification of patient management. However, the emerging evidence is thatthe molecular pathogenesis of DIC can be different and can be disease-specific. This session is focused on understanding these differences in orderto enable the next stage of translational medicine, i.e. in facilitating pathway-specific therapy. Examples will be described of where complement-mediatedmechanisms, pro or anticoagulant pathways and fibrinolytic systems may bephysiologically important and clinically-relevant targets.

73

SUNDAY, JULY 12, 2009


Chairman's reportCheng-Hock Toh (UK) 10:00 - 10:15 AM

A. STANDARDIZATION

Evaluation of non-overt DIC criteria Hideo Wada (JP) 10:15 - 10:30 AM

Experience of evolving scores of hemostatic dysfunction in critical careGary Kinasewitz (US) 10:30 - 10:45 AM

Impact of the ISTH DIC score in children with critical illness Robinder Khemani (US) 10:45 - 11:00 AM

Impact of method for platelet count determination in DICHyun K. Kim (KR) 11:00 - 11:15 AM

B. COLLABORATIONS

With SSC in plasma coagulation inhibitors and UK NEQAS on Protein C and Antithrombin measurements Tina Dutt (UK)

With SSC in vascular biology on procoagulant microparticlesNigel Key (US)

Summation and Closing 11:45 - 12:00 PM

74


SSC

& E

duca

tion

al

von Willebrand Factor (VWD)Chairperson: David Lillicrap (CA)

Co-chairpersons: Thomas Abshire (US), Imre Bodo (HU), GiancarloCastaman (IT), Jorge DiPaola (US), Jeroen C.J. Eikenboom (NL), EmmanuelJ Favaloro (AU), Anne Goodeve (UK), Bernhard Lämmle (CH), ReinhardSchneppenheim (DE)

Educational Session 8:00 AM - 9:30 AM Room 109 AB

Moderator: David Lillicrap (CA)

Clinical aspects of VWD diagnosisFrancesco Rodeghiero (IT) 8:00 - 8:30 AM

Laboratory testing of the hemostatis phenotype in VWDRobert R. Montgomery (US) 8:30 - 9:00 AM

Genetic analysis as an aid in VWD diagnosisAnne Goodeve (UK) 9:00 - 9:30 AM

The diagnosis of the most common inherited bleeding disorder, von Willebranddisease (VWD), is often complicated. In theory, there are three components tothe diagnostic definition: a personal history of excessive mucocutaneousbleeding, a family history of the disease and a set of laboratory testsdemonstrating quantitative and/or qualitative abnormalities of von Willebrandfactor. In this educational session, experts in the field will address each ofthese diagnostic areas. Dr. Rodeghiero will discuss an optimal approach to theevaluation of the clinical symptoms manifest in VWD. Dr. Montgomery will thenreview the appropriate hemostasis testing strategy to evaluate quantitative andqualitative abnormalities of von Willebrand factor. Finally, Dr. Goodeve willdiscuss the role of molecular genetic analysis in making a diagnosis of (VWD).

75


SSC Business Session 9:30 AM - 12:00 PM Room 109 AB

1. VWF Assays for VWD Diagnosis

Chairperson: Emmanuel Favaloro (AU)

Standardization of ristocetin-based VWF assays

RIPAAugusto Federici (IT) 9:30 - 9:40 AM

Automated VWF: RCoAndreas Hillarp (SE) 9:40 - 9:50 AM

Alternative functional assays - GPIb binding assays:Robert Montgomery (US) 9:50 - 10:00 AMHans Deckmyn (BE) 10:00 - 10:10 AM


2. VWF Propeptide Studies

Chairperson: Jeroen Eikenboom (NL)

Standardization and Clinical utilityRobert Montgomery (US) 10:15 - 10:25 AMBas De Laat (NL) 10:25 - 10:35 AM


3. Standarized Bleeding Scores (joint session with Pediatric SSC)

Chairperson: Tom Abshire (US)

Bleeding scores

AdultFrancesco Rodeghiero (IT) 10:40 - 10:50 AM

PediatricPaula James (CA) 10:50 - 11:00 AM


76


SSC

& E

duca

tion

al

4. VWF Plasma and Concentrate StandardsChairperson: Anne Goodeve (UK)

DiscussantTony Hubbard (UK) 11:10 - 11:15 AM


5. ADAMTS13Chairperson: Bernhard Laemmle (CH)

ADAMTS13 assays Koichi Kokame (JP) 11:20 - 11:30 AM

ADAMTS13 antibody assays Bas De Laat (NL) 11:30 - 11 :40 AM


6. VWF and VWD RegistriesChairperson: Imre Bodo (HU)

Discussant

VWD registry Anne Goodeve (UK) 11:45 - 11:50 AM


Control of AnticoagulationChairperson: Trevor Patrick Baglin (UK)

Co-chairpersons: Walter Ageno (IT), Job Harenberg (DE), Clive Kearon (CA),Aharon Lubetsky (IL), John Olson (US), Gualtiero Palareti (IT), Sam Schulman(CA), A.M.H.P. van den Besselaar (NL)


Chairpersons: Trevor Baglin (UK) and Sam Schulman (CA)

Introduction and update on activities of the SSC including overviewof progress of Working Parties and future plansTrevor Baglin (UK) 8:00 - 8:10 AM

Registry Report - Splanchnic vein thrombosis Walter Ageno (IT) 8:10 - 8:20 AM

77


Discussion / Potential registry - Cerebral Vein Thrombosis - duration of anticoagulationWalter Ageno (IT) 8:20 - 8:30 AM

Working Party Report - Recommendation for requirements on biosimilar Anticoagulants / Working Party Report - Standardization of methods to determine direct factor Xa inhibitorsJob Harenberg (DE) 8:30 - 8:40 AM

Working Party Report - Results of international collaborative study for calibration of two candidates for International Standard for thromboplastin, human, plainTon Van Den Besselaar (NL) 8:40 - 8:50 AM

Working Party Report - Variability of INR in stabilized patients and requirements for INR analytical precisionTon Van Den Besselaar (NL) 8:50 - 9:00 AM

Discussion / New Working Party - Reporting INRs in liver diseaseArmando Tripodi (IT) 9:00 - 9:10 AM

New Oral Anticoagulants

Introduction to the Working Party: General and specific aimsTrevor Baglin (UK) 9:10 - 9:20 AM

Overview of drug development programsHarry Buller (NL) 9:20 - 9:35 AM

Monitoring, bleeding and reversalJeffrey Weitz (CA) 9:35 - 9:50 AM

Patient education, concordance and compliance (role of thrombosis centres / anticoagulation clinics)Jack Ansell (US) 9:50 - 10:00 AM

What to recommend for phase IV studies in collaboration between companies and anticoagulation clinicsGualtiero Palareti (IT) 10:00 - 10:10 AM

Break 10:10 - 10:30 AM

78


SSC

& E

duca

tion

al


Moderators: Trevor Baglin (UK) and Sam Schulman (CA)

Atrial fibrillation and antithrombotic therapy: Which drug and when?Elaine Hylek (US) 10:30 - 10:45 AM

Interruption of oral VKA therapy requires bridging therapy (for)David Keeling (UK) 10:45 - 11:00 AM

Interruption of oral VKA therapy requires bridging therapy (against)Clive Kearon (CA) 11:00 - 11:15 AM

Warfarin dosing and pharmacogenetic testing (for)Brian Gage (US) 11:15 - 11:30 AM

Warfarin dosing and pharmacogenetic testing (against)David A Garcia (US) 11:30 - 12:00 PM

This educational symposium focuses on three controversies frequentlyencountered in clinical practice: when to give vitamin K antagonists therapy foratrial fibrillation; how to initiate therapy; and when to bridge with heparin. Dr.Hylek will consider the issue of antithrombotic therapy in patients with atrialfibrillation in terms of which drug and when. How do clinical trial resultstranslate into treatment of individual patients? Dr. Gage and Dr. Garcia willdebate whether pharmacogenetic testing has a role when initiating oral VKAtherapy. Is there evidence of added value? Dr. Keeling and Dr. Kearon willdebate whether heparin bridging is ever necessary when oral VKA therapy isinterrupted. What is the clinical evidence? These issues are so common andrelevant to routine clinical practice that all three might be encountered inrelation to a single patient. It is hoped that the session will bring clarity andprovide guidance.

79


FibrinolysisChairperson: Colin Longstaff (UK)

Co-chairpersons: Carl-Erik H. Dempfle (DE), Ann Gils (BE), Dirk Hendriks(BE), Osamu Matsuo (JP), Michael E. Nesheim (CA), Tetsumei Urano (JP)


WHO International Standards

Report on a new WHO International Standard for StreptodornaseColin Longstaff (UK) 8:30 - 8:40 AM

Update on standardization of PAI-1 antigen determinations in plasmaColin Longstaff (UK) 8:40 - 8:50 AM

Approaches to dual labeling of International Standards for enzymes and inhibitorsCraig Thelwell (UK) 8:50 - 9:00 AM

TAFI/CPU

Update on the functional assay for plasma TAFIaMichael Nesheim (CA) 9:00 - 9:25 AM

Determination of CPU/TAFIa in plasma samplesEvelien Heylen (BE) and Dirk Hendriks (BE) 9:25 - 9:45 AM

D-dimer

Update on the NEQAS EQA for D-dimerIan Jennings (UK) 9:45 - 10:00 AM

General Discussion and Break 10:00 - 10:30 AM

80


SSC

& E

duca

tion

al


Moderator: Carl-Erik H. Dempfle (DE)

D-dimer in the emergency room (venous thromboembolism exclusion, aortic dissection)Carl-Eric Dempfle (US) 10:30 - 11:00 AM

Fibrin generation markers in the perioperative settingWolfgang Korte (CH) 11:00 - 11:30 AM

D-dimer as prognostic parameter in venous thromboemolism, pregnancy and cancerSaskia Middledorp (NL) 11:30 - 12:00 PM

D-dimer currently is the most prevalent marker for detection of coagulationactivation. Various assay systems are available, including automated assays forhigh throughput laboratory instrumentation, as well as point of care or nearpatient assays. Quantitative assays are the current standard. D-dimer maydiscriminate conditions associated with intravascular fibrin formation fromconditions without intravascular fibrin formation. Examples are exclusion ofvenous thrombosis or pulmonary embolism, or differential diagnosis of acutechest pain. In the perioperative setting, D-dimer and other markers of fibringeneration may identify patients with high clinical risk, including patients proneto thromboembolic complications. Finally, D-dimer measurement has emergedas a prognostic tool in secondary prevention of venous thromboembolism, formonitoring of pregnancy complications, and in cancer. The educationalsession will focus on the primary clinical applications of D-dimer and relatedassay systems from a practical perspective.

81


Platelet PhysiologyChairperson: Marco Cattaneo (IT)

Co-chairpersons: Joel S. Bennett (US), Paul Harrison (UK), Catherine P. M.Hayward (CA), Dermot Kenny (IE), Alan D. Michelson (US), Diane Nugent(US), Steve Watson (UK)


Chairpersons: Marco Cattaneo (IT) and Alan D. Michelson (US)

Discussion of the Consensus of Experts on LTA StandardizationMarco Cattaneo (IT), Chiara Cerletti (IT), Paul Harrison (UK),Catherine P.M. Hayward (CA), Dermot Kenny (IE),Alan D. Michelson (US), Diane Nugent (US), Paquita Nurden (FR), Koneti A. Rao (US), Alvin Schmeier (US), Steve Watson (UK) 8:00 - 9:45 AM

Proposal on formation of an SSC Working Party on Diagnosis of Platelet Function DisordersMarco Cattaneo (IT) 9:45 - 10:00 AM

Break 10:00 - 10:30 AM

Chairperson: Marco Cattaneo (IT)

New BCSH (British Committee for Standards in Haematology) guidelines for platelet function testingPaul Harrison (UK) 10:30 - 11:00 AM


Moderator: Marco Cattaneo (IT)

Platelet function as a guide to thrombotic riskAlan D. Michelson (US) 11:00 - 11:30 AM

Recent advances in the understanding and diagnosis of inherited platelet function disordersCatherine P. M. Hayward (CA) 11:30 - 12:00 PM

Platelets play an important role in hemostasis, because both inherited andacquired abnormalities of their number and/or function are associated withexcessive bleeding. Platelets also play an important pathogenic role in

82


SSC

& E

duca

tion

al

thrombosis, as shown by the results of several randomized clinical trials, whichshowed that drugs inhibiting platelet function reduce the risk of arterialthrombosis. Several laboratory methods for the evaluation of platelet functionare available. Aims of the Educational Session of the Platelet PhysiologySubcommittee of the Scientific and Standardization Committee of theInternational Society on Thrombosis and Haemostasis are the following: 1) toupdate on the diagnostic work-up of patients with clinical suspicion of inheritedplatelet function defects; 2) to review the clinical usefulness of the currentlyavailable platelet function tests in the identification of patients at risk ofthrombosis.

Plasma Kallikrein-Kinin systemChairperson: David Gailani (US)

Co-chairpersons: Keith R McCrae (US), Thomas Renné (SE), Alvin Schmaier (US)


Introduction. Description of the meeting organization. Business issue - Changing the name of Subcommittee to "Plasma Contact Activation System" Subcommittee David Gailani (US) 8:00 - 8:15 AM

The pathophysiology of hereditary angioedemaAlvin Davis (US) 8:15 - 8:45 AM

The platelet ApoER2' receptor and factor XI binding to plateletsOwen McCarty (US) 8:45 - 9:15 AM

Targeting factor XI in primate and murine models of pathologic coagulation Andras Gruber (US) 9:15 - 9:45 AM

Break 9:45 - 10:00 AM

Contact activation in arterial thrombosis - An update on clinical studies José Govers-Riemslag (NL) 10:00 - 10:30 AM

Assays for over-sulfated chondroitin sulfate in heparin Cornelius Kluft (NL) 10:30 - 11:00 AM

83



Moderator: David Gailani (US)

Misfolded proteins as a trigger for contact activationMartijn F.B.G. Gebbink (NL) 11:00 - 11:30 AM

Role of leukocytes and platelets in contact system activationThomas Renne (SE) 11:30 - 12:00 PM

The term Contact Activation describes the conversion of the plasma proteasezymogens factor XII, factor XI and prekallikrein (PK) to their active forms (factorXIIa, factor XIa and _-kallikrein, respectively) in the presence of an activatingsurface and the plasma protein high molecular weight kininogen (HK). Thisprocess can trigger activation of several host defense mechanisms includingvasoactive kinin formation and blood coagulation. Contact activation initiatesthrombin generation and fibrin formation in the classic cascade/waterfallmodels of coagulation, and in the partial thromboplastin time assay used toscreen for plasma coagulation defects in the clinical setting. However, for manyyears, the importance of this process has been considered minimal becauseof the absence of bleeding or other clinical disorders in patients with completedeficiency of factor XII, PK or HK. This school of thought is reflected in thedecision of the ISTH SSC on Contact Activation to change its name severalyears ago to the SSC on The Plasma Kallikrein-Kinin System. However, recentstudies with genetically engineered mice demonstrate that factor XII, while notrequired for normal hemostasis, makes important contributions to pathologiccoagulation in a number of vascular injury/thrombosis models. Similar resultswith factor XI deficient mice raise the distinct possibility that a process similarto classic contact activation is operating in these models. The nature of thetrigger for factor XII activation in vivo is an area of active research. Traditionalplasma assays typically use purified earths such as kaolin or celite to triggercontact activation. A number of physiologically relevant compounds includingcollagen, RNA, and polyphosphates from platelet granules have beenimplicated as triggers of factor XII activation at sites of vascular injuries. It is thegoal of this educational session to further explore biologically relevantmechanisms for factor XII activation. Our first speaker, Dr. Gebbink of theUniversity Medical Center in Utrecht will discuss the role of misfolded proteins,such as occur in amyloidosis, in activation of factor XII and prekallikrein. Then,Dr. Renné of the Karolinska Institute will speak on the role of platelets andleukocytes in initiating contact activation, and the implications for vascularthrombosis.

84


SSC

& E

duca

tion

al

Registry of Exogenous Hemostatic FactorsChairperson: Mary Ann McLane (US)

Co-Chairpersons: Kenneth J. Clemetson (CH), Manjunatha R. Kini, (SG),Francis S. Markland Jr. (US), Takashi Morita (JP)

SSC Business Session 8:00 AM - 10:30 AM Room 102 AB

Welcome

Record of last meeting (Vienna, 3 July 2008)

Progress report and planning for 4th International Conference on Exogenous Factors Affecting Thrombosis and Hemostasis (25th Anniversary), Boston 2009Mary Ann McLane (US)

Final Report on classification and nomenclature of C-type lectinsKenneth Clemetson (CH) and Takashi Morita (JP)

Interaction of disintegrins with natural killer cell activityMary Ann McLane (US)

Next Registry meeting (ISTH schedule: Cairo Egypt 5/22-5/25/2010)

Next EFATH meeting (ISTH schedule: Amsterdam, Netherlands 6/29 - 7/4/2013)

Future projects for the Registry: Nomenclature of VenomMetalloproteasesManjunatha Kini (SG)

Educational Session 10:30 AM - 12:00 PM Room 102 AB

Moderator: Mary Ann McLane (US)

Transcriptomics and functional genomics of salivary glands from hematophagous arthropodsIvo Francischetti (US) 10:30 - 11:15 AM

Fibrolase and its evolution to clinical trials: A long and winding roadFrancis S. Markland, Jr. (US) 11:15 - 12:00 PM

85


Francischette: Transcriptome and proteomic studies of the salivary gland fromblood sucking arthropods have provided new insights in our understanding ofsaliva pharmacopea. Currently available sialomes from mosquitoes, sand flies,bugs, soft and hard ticks indicate that protein families such as Kunitz inhibitorsare common to most hard ticks, while lipocalins are the most abundantproteins in soft ticks. Several proteins with unique sequences have also beenfound in distinct genera, and their functions have now been identified. Ixolarisinhibits the initiation of the coagulation cascade through inhibition of tissuefactor in a FX/FXa-dependent manner, while RPAI-1 binds with high affinity toADP and inhibits platelet aggregation. In addition, mosquito aegyptinspecifically binds to the collagen sequence that mediates its interaction withvon Willebrand factor (vWf). These molecules are being tested in vivo forinhibition of thrombus formation, cancer and metastasis. Markland: Fibrolase is a direct-acting fibrinolytic enzyme from southerncopperhead (Agkistrodon contortrix contortrix) snake venom. The enzyme hasno thrombin-like activity, does not activate protein C or platelets, does notactivate nor degrade plasminogen, and has no hemorrhagic or hemolyticactivity. Alfimeprase is the recombinant form of fibrolase made in yeast that isvirtually identical to fibrolase with respect to enzymatic activity. However, thealtered amino acid sequence stabilizes the structure of alfimeprase forprolonged shelf-life. In an acute carotid arterial thrombosis model,administration of alfimeprase produced significantly more rapid clot lysis thanurokinase (UK) in rats, piglets or dogs. In a porcine model of peripheral arterialocclusion of the carotid artery, alfimeprase (but not(UK)) achieved close tocomplete thrombus resolution and flow restoration within 30 min. However, inclinical trials for peripheral arterial occlusion, alfimeprase did not meet targetend points and further clinical development was ended in 2008.

McLane: Naturally occurring animal venoms from snakes, leeches, spiders,caterpillars, ticks and scorpions have been recognized for centuries assignificant modulators of thrombosis and hemostasis. It is only within the past40 years, however, that research techniques have allowed definitive insightsinto structure-function relationships of molecules from these sources, and theiradaptation for clinical use. This session will highlight recent advances inmolecular analyses and translational opportunities for proteins isolated fromthe southern copperhead viper (Agkistrodon contortrix contortrix) and bloodsucking arthropods (mosquitoes, sand flies, ticks).

86


Opening Ceremony

You are cordially invited to attend the XXII Congress'Opening Ceremony on Sunday, July 12 at 6:00 PMin the BCEC's Grand Ballroom, followed by the WelcomeReception, which will take you through the sights,sounds and tastes of Boston's historic 'Freedom Trail'.

l Welcome by Barbara and Bruce FuriePresidents of the XXII Congress of the ISTH

l Remarks by Gilbert C. White IIExecutive Director of ISTH

l Remarks and Presentation of the Grant Medalby Frits RosendaalChairman of the ISTH Council

l Closing Remarks by Barbara and Bruce FuriePresidents of the XXII Congress of the ISTH

Boston through Its MusicEntertainment by:Patriot Fife and Drum DuoDraw the LineAaron Goldberg TrioPALS Children's Chorus

87

NO

TE

S

89

ScientificProgram

ISTH2009

Monday,July 13, 2009

Plenary Lecture 9:45 AM – 10:30 AM

Shirley Johnson Memorial Lecture Grand Ballroom

Chairperson: Roy Silverstein (US)

Cardiovascular genetics PL-MO-001Helen H. Hobbs (US) 9:45 – 10:30 AM

Plenary Lecture 5:15 PM – 6:00 PM

Sol Sherry Memorial Lecture Grand Ballroom

Chairperson: Mary Cushman (US)

Thromboprophylaxis as a key patient safety priority: Currentapproaches and future directions PL-MO-002William H. Geerts (CA) 5:15 - 6:00 PM

State of the Art Lectures 11:00 AM - 12:30 PM

Pulmonary Embolism, 2009 Grand Ballroom A

Chairpersons: Phillip Wells (CA) and Samuel Goldhaber (US)

Short term prognosis of pulmonary embolism SA-MO-001Drahomir Aujesky (CH) 11:00 - 11:30 AM

Treatment strategies including thrombolysis and embolectomy SA-MO-002Samuel Goldhaber (US) 11:30 - 12:00 PM

Diagnostic management of pulmonary embolism SA-MO-003Menno Huisman (NL) 12:00 - 12:30 PM

90

MONDAY, JULY 13, 2009

Mon

day

Scie

nce

Novel Approaches to Understanding Hemostasis Ballroom 210 ABC

Chairpersons: Kenneth Kanushansky (US) and Joseph Italiano (US)

Empirical and theoretical phenotypic discrimination in hemostasis SA-MO-004Kathleen Brummel-Ziedins (US) 11:00 - 11:30 AM

Systems biology of platelets and coagulation SA-MO-005Scott Diamond (US) 11:30 - 12:00 PM

Selective sorting of platelet ?-granule contents SA-MO-006Joseph Italiano (US) 12:00 - 12:30 PM

Von Willebrand Disease - New Developments Grand Ballroom B

Chairpersons: Robert Montgomery (US) and Cécile Dennis (FR)

Reduced von Willebrand factor survival in von Willebrand disease: Pathophysiological and clinical relevance SA-MO-007Giancarlo Castaman (IT) 11:00 - 11:30 AM

Mouse models of von Willebrand disease SA-MO-008Cécile Denis (FR) 11:30 - 12:00 PM

Genotype/phenotype association in von Willebrand disease: Is the glass half full or half empty? SA-MO-009David Lillicrap (CA) 12:00 - 12:30 PM

Inflammation and Coagulation Room 258 ABC

Chairpersons: Charles Esmon (US) and Hartmut Weiler (US)

Critical roles for thrombin in acute and chronic inflammation SA-MO-010Anthony Dorling (UK) 11:00 - 11:30 AM

Dendritic cells and PAR signaling in Inflammation SA-MO-011Wolfram Ruf (US) 11:30 - 12:00 PM

Modulation of sepsis with activated protein C variants SA-MO-012Hartmut Weiler (US) 12:00 - 12:30 PM

91


Inherited Platelet Disorders Room 253 ABC

Chairpersons: Christel Van Geet (BE) and Charles Abrams (US)

Altered megakaryopoiesis in Type IIb von Willebrand disease SA-MO-013Alan Nurden (FR) 11:00 - 11:30 AM

Regulation of platelets biogenesis SA-MO-014Ramesh Shivdasani (US) 11:30 - 12:00 PM

Lesions in platelet signaling SA-MO-015Christel Van Geet (BE) 12:00 - 12:30 PM

Endothelial and Vascular Signaling Room 205 ABC

Chairpersons: William Aird (US) and Susan Smyth (US)

Systems approach to inflammation resolution: Identification of novel anti-inflammatory and pro-resolving lipid mediators SA-MO-016Charles N. Serhan (US) 11:00 - 11:30 AM

Molecular control of angiogenesis and remodeling SA-MO-017William Sessa (US) 11:30 - 12:00 PM

Regulation of vascular cell function by bioactive lysolipids SA-MO-018Susan Smyth (US) 12:00 - 12:30 PM

Abstract Symposia 2:15 PM - 3:45 PM

Abstract Symposia consist of an invited speaker and four highly ratedabstracts presented on a related general theme.

92


Mon

day

Scie

nce

Thrombophilia: Clinical Applications Room 210 ABC

Chairperson: Saskia Middeldorp (NL)

Thrombophilia testing in asymptomatic family members:More harm than good? AS-MO-001Saskia Middeldorp (NL) 2:15 - 2:45 PMAS-MO-002 2:45 - 3:00 PMA PROSPECTIVE COHORT STUDY ON THE ABSOLUTE RISK OF VENOUS THROMBOEMBOLISM INASYMPTOMATIC SUBJECTS WITH HEREDITARY DEFICIENCIES OF PROTEIN S, PROTEIN C ORANTITHROMBINB. K. Mahmoodi* (NL), J. Brouwer, M. ten Kate, W. Lijfering, N. Veeger, H. Kluin-Nelemans, J. van der Meer

AS-MO-003 3:00 - 3:15 PMMORTALITY IN THROMBOPHILIA: A CONTROLLED EVALUATION FROM THE EUROPEANPROSPECTIVE COHORT ON THROMBOPHILIA (EPCOT)I. Pabinger* (AT), C. Y. Vossen, J. Lang, J. Conard, C. García-Dabrio, W. Miesbach, G. Palareti, P. Svensson, A.Kaider, F. R. Rosendaal

AS-MO-004 3:15- 3:30 PMRISK OF RECURRENCE AMONG HETEROZYGOUS CARRIERS OF FACTOR II (FII) G20210A AND AFIRST UNPROVOKED VENOUS THROMBOEMBOLISM (VTE)G. Hron* (AT), L. Eischer, S. Eichinger, P. A. Kyrle

AS-MO-005 3:30 - 3:45 PMMULTIPLE SNP TESTING TO PREDICT RISK OF FIRST VENOUS THROMBOSISI. D. Bezemer* (NL), C. J. M. Doggen, S. Le Cessie, P. H. Reitsma, L. A. Bare, F. R. Rosendaal

Interventions for Venous Thromboembolism Room 205 ABC

Chairperson: Thomas Wakefield (US)

Aggressive therapies for DVT AS-MO-006Thomas Wakefield (US) 2:15 - 2:45 PMAS-MO-007 2:45 - 3:00 PMADDITIONAL CATHETER-DIRECTED VENOUS THROMBOLYSIS IN ILIOFEMORAL DEEP VEINTHROMBOSIS; SHORT-TERM RESULTS FROM THE CAVENT STUDY, A MULTICENTER,RANDOMIZED CONTROLLED TRIALT. R. Enden* (NO), C. E. Slagsvold, N. E. Kløw, P. M. Sandset

AS-MO-008 3:00 - 3:15 PMILIOFEMORAL VENOUS THROMBOSIS SUCCESSFULLY TREATED WITH CATHETER-DIRECTEDTHROMBOLYSISM. Jørgensen* (DK), S. Just, R. Broholm, N. Bækgaard, L. Panduro

AS-MO-009 3:15 - 3:30 PMTHE PAVIA ENDARTERECTOMY PROGRAM FOR THE MANAGEMENT OF PULMONARYENDARTERECTOMY (PEA) IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARYHYPERTENSION (CTEPH)F. Piovella* (IT), A. M. D’Armini, M. Barone, V. Emmi, C. Beltrametti, M. Viganò

AS-MO-010 3:30 - 3:45 PMCLINICAL SAFETY, EFFICACY & PHARMACOKINETICS OF INTRA-CLOT TPA FOR LOWEREXTREMITY DVTJ. N. Lozier* (US), R. Chang

93


Biology of ADAMTS13 Room 253 ABC

Chairperson: Jo’se Lo’pez (US)

ADAMTS13, TTP and related disorders AS-MO-011Jo’se Lo’pez (US) 2:15 - 2:45 PMAS-MO-012 2:45 - 3:00 PMCRYSTAL STRUCTURE OF THE EXOSITES-CONTAINING FRAGMENT OF ADAMTS13M. Akiyama* (JP), S. Takeda, K. Kokame, J. Takagi, T. Miyata

AS-MO-013 3:00 - 3:15 PMMOLECULAR MODELLING OF ADAMTS-13 METALLOPROTEINASE DOMAINR. de Cristofaro* (IT), S. Lancellotti, N. Pozzi, V. de Filippis

AS-MO-014 3:15 - 3:30 PMUNPRODUCTIVE BINDING OF ADAMTS13 TO VON WILLEBRAND FACTORH. B. Feys* (BE), P. J. Anderson, K. Vanhoorelbeke, J. E. Sadler

AS-MO-015 3:30 - 3:45 PMAMINO ACID RESIDUES R660, R661 AND Y662 WITHIN THE SPACER DOMAIN OF ADAMTS13 AREESSENTIAL FOR RECOGNITION AND CLEAVAGE OF VON WILLEBRAND FACTORS. Jin* (US), X. Zheng

Biology of von Willebrand Factor Room 258 ABC

Chairperson: Peter Lenting (NL)

Biology of von Willebrand factor AS-MO-016Peter Lenting (NL) 2:15 - 2:45 PMAS-MO-017 2:45 - 3:00 PMCLEARANCE OF VON WILLEBRAND FACTOR (VWF) IN TYPE 2 VON WILLEBRAND DISEASE (VWD):THE IMPLICATIONS OF VWF PROPEPTIDE (VWFPP) AND VWF:AG LEVELSS. L. Haberichter* (US), G. Castaman, P. D. James, P. A. Christopherson, F. Roheghiero, D. Lillicrap, R. R.Montgomery, for Canadian Vicenza and ZPMCB-VWD Study Groups

AS-MO-018 3:00 - 3:15 PMEXPRESSION OF HUMAN TYPE 2B VON WILLEBRAND DISEASE MUTANTS IN THE VWF KOMOUSE MODELM. Golder* (CA), C. M. Pruss, C. Hegadorn, K. Laverty, K. Sponagle, D. Lillicrap

AS-MO-019 3:15 - 3:30 PMASSOCIATIONS BETWEEN THE VON WILLEBRAND FACTOR GENE (VWF) VARIANT C.2771G>A(P.R924Q), VON WILLEBRAND FACTOR ANTIGEN (VWF:AG) AND FVIII ACTIVITY (FVIII:C) LEVELSAND ITS ROLE AS A RISK FACTOR FOR TYPE 1 VON WILLEBRAND DISEASE (VWD)N. Hickson* (UK), D. J. Hampshire, P. R. Winship, P. D. James, I. R. Peake, A. C. Goodeve, on behalf of the EU-VWD and ZPMCB-VWD Study Groups

AS-MO-020 3:30 - 3:45 PMTHE IMPACT OF VON WILLEBRAND FACTOR SEQUENCE CHANGES THAT AFFECT ADAMTS13-MEDIATED CLEAVAGE IN THE VWF KNOCKOUT MOUSE MODELC. M. Pruss* (CA), M. Golder, C. Hegadorn, K. Laverty, K. Sponagle, C. Notley, Y. Chirinian, D. Lillicrap

94


Mon

day

Scie

nce

Serpins - Inhibitors Room 157 ABC

Chairperson: George Broze (US)

Protein Z and ZPI: An update AS-MO-021George Broze (US) 2:15 - 2:45 PMAS-MO-022 2:45 - 3:00 PMACTIVATED PROTEIN C (APC) INHIBITS INFLAMMATION AND APOPTOSIS BY REGULATINGENDOPLASMIC RETICULUM (ER) STRESSL. J. Toltl* (CA), R. C. Austin, P. C. Y. Liaw

AS-MO-023 3:00 - 3:15 PMCRYSTAL STRUCTURES SHOW HOW PROTEIN Z CATALYSES ZPI INHIBITION OF FXa ONPHOSPHOLIPID SURFACESZ. Wei, Y. Yan, A. Zhou* (UK)

AS-MO-024 3:15 - 3:30 PMPLATELET TISSUE FACTOR PATHWAY INHIBITOR (TFPI) PREVENTS HEPATIC AND CEREBRALFIBRIN DEPOSITION IN MOUSE TISSUES AND LIMITS THROMBUS GROWTHS. A. Maroney* (US), J. P. Ferrel, B. C. Cooley, A. E. Mast

AS-MO-025 3:30 - 3:45 PMMECHANISMS OF COFACTOR-ASSISTED PROTEASE INHIBITION BY PROTEIN C INHIBITORW. Li* (UK), J. A. Huntington

Women and Bleeding Disorders Room 104 ABC

Chairperson: Rezan Kadir (UK)

Women and bleeding disorders: New perspectives AS-MO-026Rezan Kadir (UK) 2:15 - 2:45 PMAS-MO-027 2:45 - 3:00 PMINITIAL DEPLOYMENT OF A COMPREHENSIVE, ONTOLOGY-BACKED, WEB-BASED BLEEDINGHISTORY PHENOTYPING INSTRUMENT IN NORMAL INDIVIDUALSA. C. Mauer* (US), E. M. Barbour, N. A. Khazanov, N. Levenkova, S. A. Mollah, B. S. Coller

AS-MO-028 3:00 - 3:15 PMESTABLISHMENT OF A EUROPEAN NETWORK OF RARE BLEEDING DISORDERS (EN-RBDDATABASE): PRELIMINARY RESULTS ON 190 PATIENTSM. Menegatti* (IT), R. Palla, S. M. Siboni, M. Benedik-Dolnicar, C. Bidlingmaier, T. Celkan, P. Giangrande, R.Gilmore, J. Ingerslev, K. Peerlink, H. Pergantou, F. Suzan, M. Spreafico, R. Waha, P. Lanzi, F. Peyvandi

AS-MO-029 3:15 - 3:30 PMPREGNANCY AND DELIVERY IN WOMEN WITH VON WILLEBRAND DISEASE AND DIFFERENT VONWILLEBRAND FACTOR MUTATIONSG. Castaman* (IT), A. Tosetto, F. Rodeghiero

AS-MO-030 3:30 - 3:45 PMRISK OF POSTPARTUM HEMORRHAGE IN WOMEN RECEIVING THERAPEUTIC DOSES OF LOW-MOLECULAR-WEIGHT HEPARINS. Roshani* (NL), D. M. Cohn, A. Stehouwer, S. Hamers, H. Wolf, J. M. van der Post, H. R. Büller, P. W.Kamphuisen, S. Middeldorp

95


Platelets and Cancer Room 107 ABC

Chairperson: Jerry Ware (US)

The platelet paradigm in cancer AS-MO-031Jerry Ware (US) 2:15 - 2:45 PM

AS-MO-032 2:45 - 3:00 PMTHE EFFECT OF P2Y-MEDIATED ACTIVATION ON VEGF AND ENDOSTATIN RELEASE FROMPLATELETSN. M. Bambace* (US), J. E. Levis, C. E. Holmes

AS-MO-033 3:00 - 3:15 PMAN ASSOCIATION BETWEEN ANTI-PLATELET DRUG USE AND REDUCED CANCER PREVALENCEIN DIABETIC PATIENTS: RESULTS FROM THE VERMONT DIABETES INFORMATION SYSTEMC. E. Holmes* (US), M. E. Ramos-Nino, B. Littenberg

AS-MO-034 3:15 - 3:30 PMGENETIC VARIANTS OF PLATELET FUNCTION AND CANCER MORTALITY: A FOLLOW-UP STUDYJ. D. Snoep* (NL), C. E. Holmes, F. R. Rosendaal, J. G. van der Bom

AS-MO-035 3:30 - 3:45 PMPLASMA LEVELS OF MICROPARTICLE ASSOCIATED TISSUE FACTOR ACTIVITY IN PATIENTS WITHCLINICALLY SUSPECTED PULMONARY EMBOLISM WITH OR WITHOUT CANCERP. Garcia Rodriguez* (NL), H. C. J. Eikenboom, M. E. T. Tesselaar, M. V. Huisman, M. Nijkeuter, S. Osanto, R. M.Bertina

Novel Approaches to Understanding Platelet Biology Room 153 ABC

Chairperson: Angel Garcia (ES)

Novel strategies in platelet research: The proteomics approach AS-MO-036Angel Garcia, (ES) 2:15 - 2:45 PM

AS-MO-037 2:45 - 3:00 PMDEFINING THE FUNCTION OF NOVEL PLATELET GENES USING A LASER THROMBOSIS MODEL INDANIO RERIOI. I. Salles* (BE), M. N. O’Connor, A. Cvejic, N. A. Watkins, P. Burns, A. Walker, S. F. Garner, C. I. Jones, I. C.Macaulay, M. Steward, J. Zwaginga, S. L. Bray, F. Dudbridge, B. de Bono, A. H. Goodall, H. Deckmyn, D. L.Stemple, W. H. Ouwehand, on behalf of the Bloodomics consortium

AS-MO-038 3:00 - 3:15 PMTHE IDENTIFICATION OF ABI-1 AS NEW VASP EVH1 DOMAIN INTERACTING PARTNER IN HUMANPLATELETS BASED ON THE “PLATELETWEB” KNOWLEDGE BASEM. Dittrich, V. Strassberger, T. Jarchau, P. Tas, U. Lewandrowski, T. Dandekar, U. Walter, I. Birschmann* (DE)

AS-MO-039 3:15 - 3:30 PMSTUDY OF BIMOLECULAR INTEGRIN-FIBRINOGEN INTERACTIONS UNDER A CONSTANTUNBINDING FORCER. I. Litvinov* (US), H. Shuman, J. W. Weisel, J. S. Bennett

AS-MO-040 3:30 - 3:45 PMRAPID ADHESION KINETICS OF PLATELETS UNDER VERY HIGH SHEARD. N. Ku* (US), A. N. Para, D. L. Bark

96


Mon

day

Scie

nce

Extrinsic Pathway of Coagulation Room 156 ABC

Chairperson: Diego Mezzano (CL)

Regulation of platelet-expressed tissue factor AS-MO-041Diego Mezzano (CL) 2:15 - 2:45 PMAS-MO-042 2:45 - 3:00 PMCELLULAR SOURCES OF TISSUE FACTOR THAT CONTRIBUTE TO ACTIVATION OF COAGULATIONIN ENDOTOXEMIC MICER. Pawlinski* (US), N. Mackman

AS-MO-043 3:00 - 3:15 PMENDOTHELIAL TISSUE FACTOR CONTRIBUTES TO FIBRIN GENERATION DURING THROMBUSFORMATION IN LIVING MICE SUBJECTED TO LASER INJURYV. M. Chen* (US), T. H. David, G. Merrill-Skoloff, N. Mackman, S. R. Coughlin, B. C. Furie, B. Furie

AS-MO-044 3:15 - 3:30 PMLEVELS OF MICROPARTICLE TISSUE FACTOR ACTIVITY CORRELATE WITH COAGULATIONACTIVATION IN ENDOTOXEMIC MICEJ. Wang* (US), D. Manly, D. Kirchhofer, R. Pawlinski, N. Mackman

AS-MO-045 3:30 - 3:45 PMINHIBITION OF PROTEIN DISULPHIDE ISOMERASE ON ENDOTHELIAL CELLS ENHANCESCOAGULATION THROUGH PHOSPHATIDYLSERINE EXPOSUREN. I. Popescu* (US), C. Lupu, F. Lupu

Platelet Adhesion and Cohesion Room 160 ABC

Chairperson: Mark Ginsberg (US)

Dynamic regulation of cell-cell adhesion AS-MO-046Mark Ginsberg (US) 2:15 - 2:45 PMAS-MO-047 2:45 - 3:00 PMSEROTONIN STIMULATES PLATELET RECEPTOR SHEDDING BY TUMOR NECROSIS FACTOR-ALPHA-CONVERTING ENZYME (ADAM17)D. Duerschmied* (US), M. Canault, D. Lievens, A. Brill, S. Cifuni, M. Bader, D. D. Wagner

AS-MO-048 3:00 - 3:15 PMCADHERIN 6 MODULATES PLATELET FUNCTION THROUGH INTEGRIN αIIBβ3E. Dunne* (IE), M. C. Berndt, D. J. Kenny

AS-MO-049 3:15 - 3:30 PMTARGETING ONGOING ARTERIAL THROMBOSIS WITH PLATELET-SPECIFIC MICROPARTICLESZ. M. Ruggeri* (US), J. N. Orje, B. Molins, S. Harvey, S. Mitragorti, J. Smith

AS-MO-050 3:30 - 3:45 PMGI24R: A NOVEL MEMBER OF IMMUNOGLOBULIN RECEPTOR ON PLATELETSU. J. H. Sachs, S. Jessen, B. Kehrel, K. Clemetson, S. Santoso* (DE)

97


Platelet Transfusions and Polymorphisms Room 109 AB

Chairperson: Sherrill Slichter (US)

Current advances in platelet transfusion therapy AS-MO-051Sherrill Slichter (US) 2:15 - 2:45 PMAS-MO-052 2:45 - 3:00 PMMODIFIED MONOCLONAL PLATELET ANTIBODIES PREVENT ANTIBODY-MEDIATED CLEARANCEOF HUMAN PLATELETS IN AN IN VIVO MODEL OF IMMUNE THROMBOCYTOPENIAT. Bakchoul* (DE), B. Boylan, G. Bein, S. Santoso, P. J. Newman

AS-MO-053 3:00 - 3:15 PMTHE ALPHA2 INTEGRIN (GPIA) POLYMORPHISM: THE NEW PLATELET ALLOANTIGEN CABA AND 6NEW MUTATIONSG. Bertrand* (FR), V. Jallu, D. Saillant, D. Kervran, C. Martageix, C. Kaplan

AS-MO-054 3:15 - 3:30 PMASSESSMENT OF GENOTYPE-PHENOTYPE RELATIONSHIP FOR SIX COMMON PLATELETPOLYMORPHISMS IN 286 HEALTHY SUBJECTSC. Martínez, A. I. Antón, J. Corral, T. Quiroga, O. Panes, M. L. Lozano, R. González-Conejero, R. Teruel, L.Navarro-Núñez, J. Pereira, N. Navarro, D. Mezzano, V. Vicente, J. Rivera* (ES)

AS-MO-055 3:30 - 3:45 PMA PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (RAISE) OF ELTROMBOPAG FORTHE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)G. Cheng, M. N. Saleh, J. B. Bussel* (US), C. Marcher, S. Vasey, B. Mayer, M. Aivado, M. Arning, N. L. Stone

Inflammation and Vascular Pathobiology Room 252 AB

Chairperson: Ulrich Von Adrian (US)

Mechanisms and consequences of dendritic AS-MO-056cell migrationUlrich Von Adrian (US) 2:15 - 2:45 PMAS-MO-057 2:45 - 3:00 PMPECAM-1 POLYMORPHISM IN IG DOMAIN 6 (S536N) PLAYS A ROLE IN TRANSENDOTHELIALMIGRATION OF NEUTROPHILSB. Bayat* (DE), S. Werth, C. Andrei-Selmer, P. Newman, S. Santoso

AS-MO-058 3:00 - 3:15 PMA ROLE OF THE ENDOTHELIAL P2Y1 RECEPTOR IN MONOCYTE ADHESION TO ANDTRANSMIGRATION ACROSS MURINE MICROVASCULAR ENDOTHELIAL CELLS IN VITROM. Zerr-Fouineau* (FR), B. Hechler, I. Lanois, J. Cazenave, C. Gachet

AS-MO-059 3:15 - 3:30 PMHYPERCOAGULABILITY PROMOTES PLAQUE STABILITY DURING ATHEROGENESIS BYINHIBITING MONOCYTE MIGRATION THROUGH A PAR-1, PLC-BETA, PI3K, AND NO-DEPENDENTMECHANISMK. Shahzad, S. Seehaus, I. Vinnikov, H. Wang, M. Kashif, M. Thati, P. P. Nawroth, B. Isermann* (DE)

AS-MO-060 3:30 - 3:45 PMCD146 AND ITS SOLUBLE FORM REGULATE MONOCYTE TRANSENDOTHELIAL MIGRATIONN. Bardin* (FR), M. Blot-Chabaud, N. Despoix, A. Kebir, K. Harhouri, F. Vely, F. Dignat George

98


Mon

day

Scie

nce

Angiogenesis Room 257 AB

Chairperson: Holger Gerhardt (UK)

Molecular control of angiogenic sprouting AS-MO-061Holger Gerhardt (UK) 2:15 - 2:45 PM

AS-MO-062 2:45 - 3:00 PMVITRONECTIN PROMOTES ISCHEMIA-INDUCED ANGIOGENESISJ. Wu* (US), W. P. Fay

AS-MO-063 3:00 - 3:15 PMALTERNATIVELY SPLICED TISSUE FACTOR PROMOTES ANGIOGENESIS THROUGH INTEGRINLIGATIONY. W. van den Berg* (NL), L. G. van den Hengel, H. R. Myers, O. Ayachi, K. (JO)ova, W. Ruf, A. C. Spek, P. H.Reitsma, H. H. Versteeg

AS-MO-064 3:15 - 3:30 PMANGIOGENIC SIGNALING BY RAP1B IN ENDOTHELIAL CELLS INVOLVES ACTIVATION OFVASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 AND INTEGRIN ALPHAV/BETA3M. Chrzanowska-Wodnicka* (US)

AS-MO-065 3:30 - 3:45 PMIDENTIFICATION OF UPREGULATED PROANGIOGENIC GENES IN INTIMAL NEOVESSELS FROMHUMAN ADVANCED ATHEROSCLEROTIC PLAQUES USING LASER-CAPTURE MICROSCOPEM. M. Turu* (ES), L. Badimon, A. Luque, M. Baldellou, N. Rovira, J. Krupinski, M. Slevin

99


100

Risk Factors for Venous Thrombosis I Ballroom 210 ABC

Chairpersons: Thomas Ortel (US) and Bakhtawar Mahmoodi (NL)

OC-MO-001 8:00 AM - 8:15 AMMICROALBUMINURIA: A NOVEL RISK MARKER FOR VENOUSTHROMBOEMBOLISMB. K. Mahmoodi* (NL), R. Gansevoort, N. Veeger, A. Matthews, G. Navis, H. Hillege, J. van der Meer

OC-MO-002 8:15 AM - 8:30 AMUNIQUE WHOLE BLOOD GENE EXPRESSION PROFILES DISTINQUISHDIFFERENT CLINICAL PHENOTYPES OF VENOUS THROMBOEMBOLISMD. A. Lewis* (US), G. Stashenko, O. M. Akay, L. Price, A. Metjian, J. Chi, T. L. Ortel

OC-MO-003 8:30 AM - 8:45 AMFACTOR Xa GENERATION IN ADULT INDIVIDUALSK. Brummel-Ziedins* (US), T. Ashikaga, T. Orfeo, M. Gissel, K. G. Mann, F. R. Rosendaal

OC-MO-004 8:45 AM - 9:00 AMPROS1 GENE DELETIONS ARE RARE IN A POPULATION-BASED STUDY ON VENOUS THROMBOSISM. C. Pintao* (NL), A. A. Garcia, M. C. H. de Visser, C. J. M. Doggen, P. H. Reitsma, F. R. Rosendaal

OC-MO-005 9:00 AM - 9:15 AMTYPE III PROTEIN S DEFICIENCY IS ASSOCIATED WITH AHYPERCOAGULABLE STATE AND AN INCREASED RISK OF VENOUSTHROMBOSISE. Castoldi* (NL), L. F. Maurissen, D. Tormene, L. Spiezia, S. Gavasso, C. Radu, T. M. Hackeng, J. Rosing, P. Simioni

OC-MO-006 9:15 AM - 9:30 AMHETEROGENEOUS PRESENTATION OF FV IN FV LEIDENHETEROZYGOTESM. F. Whelihan* (US), M. Cushman, K. G. Mann

Resistance to Antiplatelet Therapy Room 205 ABC

Chairpersons: Koneti Rao (US) and Carlo Patrono (IT)

OC-MO-007 8:00 AM - 8:15 AMIMPACT OF THE CYP2C19*17 ALLELE ON PLATELET RESPONSE TOCLOPIDOGREL IN PATIENTS SUFFERING FROM NON–ST ELEVATIONACUTE CORONARY SYNDROMEC. Frere* (FR), T. Cuisset, P. Morange, L. Camoin-Jau, J. Bonnet, M. Alessi,J. Hulot

OC-MO-008 8:15 AM - 8:30 AMTHE RELATIVE CONTRIBUTION OF THE CYP2C19*2 POLYMORPHISM INTHE LOW RESPONSIVENESS TO CLOPIDOGREL IN THE VASP02STUDYB. Aleil, L. Jacquemin, F. de Poli, M. Zaehringer, J. P. Collet, G. Montalescot,C. Léon, J. P. Cazenave, M. C. Dickele, J. P. Monassier, C. Gachet* (FR)

MONDAY, JULY 13, 2009 8:00 AM - 9:30 AM

ORAL COMMUNICATIONS

* Presenting Author

Mon

day

Ora

ls

OC-MO-009 8:30 AM - 8:45 AMLONG TERM PROGNOSTIC VALUE OF ASPIRIN NON-RESPONSIVENESSAND PLATELET REACTIVITY AFTER ACUTE VASCULAR EVENTS: A POPULATION-BASE COHORT STUDYP. Harrison* (UK), L. Silver, H. Segal, A. Syed, Z. Mehta, P. Rothwell

OC-MO-010 8:45 AM - 9:00 AMCYTOCHROME P450 2C19 POLYMORPHISM AND CARDIOVASCULARRECURRENCES IN PATIENTS UNDER CLOPIDOGREL TREATMENT: A META-ANALYSISF. Sofi* (IT), B. Giusti, A. Gori, R. Marcucci, R. Abbate, G. Gensini

OC-MO-011 9:00 AM - 9:15 AMDIFFERENTIAL SENSITIVITY OF THE VARIOUS EX VIVO TESTSMONITORING FUNCTIONAL VARIABILITY OF PLATELET RESPONSE TOCLOPIDOGRELC. Bal Dit Sollier, N. Berge, B. Boval, L. Drouet* (FR)

OC-MO-012 9:15 AM - 9:30 AMRIFAMPICIN INCREASES THE EXTENT OF P2Y12 RECEPTORBLOCKADE ACHIEVED BY CLOPIDOGREL ADMINISTRATIONS. B. G. Patil* (UK), H. M. Judge, R. J. Buckland, J. A. Jakubowski, R. F. Storey

Cancer and Thrombosis: Clinical Aspects Room 253 ABC

Chairpersons: Paolo Simioni (IT) and Agnes Lee (CA)

OC-MO-013 8:00 AM - 8:15 AMWHAT IS THE LONG-TERM RISK FOR NEW CANCER IN PATIENTS WITHA FIRST EPISODE OF VENOUS THROMBOEMBOLISM?J. Douketis* (CA), C. Gu, A. Piccioli, A. Ghirarduzzi, V. Pengo, P. Prandoni

OC-MO-014 8:15 AM - 8:30 AMSCREENING FOR MALIGNANCY IN PATIENTS WITH IDIOPATHICVENOUS THROMBOSIS. THE TROUSSEAU INVESTIGATORSF. F. van Doormaal* (NL), J. M. M. B. Otten

OC-MO-015 8:30 AM - 8:45 AMCHRONIC WARFARIN USE AND INCIDENT CANCER: A POPULATION-BASED STUDYV. Pengo* (IT), F. Noventa, U. Gallo, A. Grion, G. Denas, S. Padayattil, P. Prandoni

OC-MO-016 8:45 AM - 9:00 AMRISK FACTORS FOR RECURRENT THROMBOSIS ANDANTICOAGULANT-RELATED BLEEDING IN CANCER PATIENTSA. Y. Lee* (CA), S. Parpia, J. Julian, F. Rickles, M. Prins, M. Levine

OC-MO-017 9:00 AM - 9:15 AMTHE EFFECT OF LOW MOLECULAR WEIGHT HEPARIN DALTEPARIN INNEWLY DIAGNOSED OVARIAN CANCER: A PHASE II RANDOMIZEDSTUDYA. Y. Lee* (CA), L. Elit, J. Julian, P. Hoskins, D. Julian, S. Parpia, M. Levine

MONDAY, JULY 13, 2009 8:00 AM - 9:30 AM

ORAL COMMUNICATIONS

101

102

OC-MO-018 9:15 AM - 9:30 AMPREVENTION OF THROMBOEMBOLIC EVENTS IN ADVANCED LUNGCANCER PATIENTS RECEIVING CHEMOTHERAPY: A COMBINEDANALYSIS FROM PROTECHT AND TOPIC-2 STUDIESM. Verso* (IT), G. Agnelli, G. Gussoni

Genetics of Venous Thrombosis I Room 258 ABC

Chairpersons: Pierre Morange (FR) and Astrid van Hylckama (NL)

OC-MO-019 8:00 AM - 8:15 AMPROTEIN S DEFICIENCY IN A LARGE PANEL OF SMALLTHROMBOPHILIA FAMILIES (GIFT STUDY)M. C. Pintao, J. Veth, R. van Minkelen, H. L. Vos, P. H. Reitsma, R. M. Bertina, M. C. H. de Visser* (NL)

OC-MO-020 8:15 AM - 8:30 AMSINGLE NUCLEOTIDE POLYMORPHISMS IN AKT3 ARE ASSOCIATEDWITH DEEP VEIN THROMBOSISL. A. Bare* (US), I. D. Bezemer, A. R. Arellano, C. H. Tong, P. H. Reitsma, J. J. Devlin, F. R. Rosendaal

OC-MO-021 8:30 AM - 8:45 AMA MULTI-STAGE / MULTI-DESIGN STRATEGY IDENTIFIES A NEW QTLFOR VON WILLEBRAND FACTOR ON CHROMOSOME 6–A POSSIBLELINK WITH VTE?G. Antoni* (FR), N. Saut, Y. Luo, G. Burgos, S. Heath, C. Perret, M.Desuremain, C. Biron-Andreani, J. Schved, G. Pernod, P. Galan, D. Zelenika,I. Juhan-Vague, M. Alessi, L. Drouet, S. Visvikis-Siest, M. Lathrop, P. S. Wells,J. Emmerich, F. Gagnon, P. Morange, D. Tregouet

OC-MO-022 8:45 AM - 9:00 AMFIBRINOGEN MUTATIONS SPECIFIC TO CHRONIC THROMBOEMBOLICPULMONARY HYPERTENSIONT. A. Morris* (US), J. J. Marsh, P. G. Chiles, N. Liang, V. L. Woods

OC-MO-023 9:00 AM - 9:15 AMGENETIC VARIATIONS AND ELEVATED LEVELS OF FIBRINOGEN ANDTHE RISK OF VENOUS THROMBOSISA. van Hylckama Vlieg* (NL), R. G. J. van der Voort, C. J. M. Doggen, F. R. Rosendaal

OC-MO-024 9:15 AM - 9:30 AMGENE DISCOVERY FOR VENOUS THROMBOSIS IN A LARGE PROTEINC DEFICIENT FAMILYC. Y. Vossen* (NL), S. J. Hasstedt, P. W. Callas, C. C. Elbers, B. P. C. Koeleman, F. R. Rosendaal, E. G. Bovill

MONDAY, JULY 13, 2009 8:00 AM - 9:30 AM

ORAL COMMUNICATIONS

Mon

day

Ora

ls

Antiphospholid Syndrome: Basic and Clinical Aspects Room 157 ABC

Chairpersons: Armando Tripodi (IT) and Vittorio Pengo (IT)

OC-MO-025 8:00 AM - 8:15 AMTISSUE FACTOR ACTIVITY IN MONOCYTES OF WHOLE BLOODINDUCED BY LUPUS ANTICOAGULANT - A POSSIBLE RISK FACTORFOR THROMBOSISD. T. Le, D. Ho, J. O. Olsen, B. Østerud* (NO)

OC-MO-026 8:15 AM - 8:30 AMPATHOGENIC EFFECTS OF ANTIPHOSPHOLIPID (APL) ANTIBODIES(ABS) ARE AMELIORATED IN ANNEXIN A2 DEFICIENT MICES. S. Pierangeli* (US), Z. Romay- Penabad, G. Montiel-Manzano, T. Shilagard, E. Papalardo, G. Vargas, K. Hajjar

OC-MO-027 8:30 AM - 8:45 AMHIGH LEVELS OF SERUM IMMUNOGLOBULIN G PREDICT THE RISK OFTHROMBOSIS IN PATIENTS WITH THE LUPUS ANTICOAGULANT (LAC)R. Vormittag* (AT), S. Panzer, C. Ay, P. Quehenberger, S. Koder, I. Pabinger

OC-MO-028 8:45 AM - 9:00 AMLONG-TERM CLINICAL COURSE OF PATIENTS WITHANTIPHOSPHOLIPID SYNDROME (APS) AND TRIPLE POSITIVELABORATORY TESTSV. Pengo* (IT), C. Legnani, F. Marongiu, P. Gresele, S. Testa, G. Denas, E. Bison, A. Banzato, S. Padayattil, D. Barcellona, A. Ruffatti

OC-MO-029 9:00 AM - 9:15 AMTHE RISK OF HEART VALVE DISEASE ASSOCIATED WITHANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH SYSTEMIC LUPUSERYTHEMATOSUS: A META-ANALYSIS OF ECHOCARDIOGRAPHICSTUDIESS. Zuily* (FR), P. Dotto, C. Perret-Guillaume, E. Bodé-Dotto, E. de Maistre, C. Selton-Suty, J. Bruntz, V. Regnault, T. Lecompte, D. Wahl

OC-MO-030 9:15 AM - 9:30 AMA RAPID ASSAY TO DISTINGUISH BETWEEN BETA2-GLYCOPROTEIN IDEPENDENT AND PROTHROMBIN DEPENDENT LUPUSANTICOAGULANTG. M. A. van Os* (NL), J. C. M. Meijers, R. T. Urbanus, R. H. W. M. Derksen,P. G. de Groot

Hemophilia: Clinical I Room 104 ABC

Chairpersons: Jorgen Ingerslev (DK) and Thomas Abshire (US)

OC-MO-031 8:00 AM - 8:15 AMFVIII PRODUCTION AFTER TRANSPLANTATION OF A HEMOPHILIADONOR LIVER INTO A NORMAL RECIPIENTC. L. Madeira, R. Layman, M. E. Devera, P. A. Fontes, M. V. Ragni* (US)

OC-MO-032 8:15 AM - 8:30 AMDETECTION OF PRPSC IN THE SPLEEN OF AN ADULT HAEMOPHILICPATIENT IN THE UKJ. W. Ironside* (UK), A. Peden, M. W. Head, D. M. Keeling, C. M. Millar, F. G. H. Hill

MONDAY, JULY 13, 2009 8:00 AM - 9:30 AM

ORAL COMMUNICATIONS

103

104

OC-MO-033 8:30 AM - 8:45 AMEXTENT OF EXPOSURE TO AND RISK STRATIFICATION OF UKPATIENTS REATED WITH PLASMA CONCENTRATES WITHCONTRIBUTION FROM A DONOR WHO DEVELOPED VCJDF. G. H. Hill* (UK), A. Zaman, N. Connor, C. Millar, J. Ironside, N. Gill

OC-MO-034 8:45 AM - 9:00 AMPRIMARY AND SECONDARY PROPHYLAXIS IN CHILDREN WITHHAEMOPHILIA A REDUCES BLEEDING FREQUENCY ANDARTHROPATHY DEVELOPMENT COMPARED TO ON-DEMANDTREATMENT: A 10-YEAR, RANDOMIZED, CLINICAL TRIALA. Gringeri* (IT), B. Lundin, S. von Mackensen, L. G. Mantovani, P. M. Mannucci

OC-MO-035 9:00 AM - 9:15 AMPLASMA DERIVED (PD) AND RECOMBINANT (R) FACTOR VIII (FVIII)CONCENTRATES INDUCE A DIFFERENT RATE OF INHIBITORDEVELOPMENT IN HEMOPHILIA A PATIENTS. A SYSTEMATIC REVIEWOF THE LITERATUREA. Iorio* (IT), M. Marcucci, E. Marchesini, P. Mannucci

OC-MO-036 9:15 AM - 9:30 AMA CASE-CONTROLLED DANISH-RUSSIAN COMPARATIVE STUDY OFCLINICAL OUTCOMES IN YOUNGER SEVERE HAEMOPHILIA PATIENTSTREATED WITH PROPHYLAXIS COMPARED TO THOSE MANAGED WITHON-DEMAND TREATMENTJ. Ingerslev* (DK), S. Lethagen, L. Hvitfeldt Poulsen, E. Lopatina, I. Tentsova,O. Yastrubinetskaya, O. P. Plyushch

Diagnosis of Pulmonary Embolus Room 107 ABC

Chairpersons: Menno Huisman (NL) and Marc Righini (CH)

OC-MO-037 8:00 AM - 8:15 AMTHE SAFETY OF EXCLUDING ACUTE PULMONARY EMBOLISM BASEDON AN UNLIKELY CLINICAL PROBABILITY BY THE WELLS RULE AND A NORMAL D-DIMER CONCENTRATIONF. A. Klok* (NL), J. D. Snoep, S. M. Pasha, I. C. M. Mos, S. Siragusa, R. J. Goekoop, M. A. Rodger, M. V. Huisman

OC-MO-038 8:15 AM - 8:30 AMCOMPARISON OF THE UNSTRUCTURED CLINICIAN GESTALT, THEWELLS SCORE AND THE REVISED GENEVA SCORE TO ESTIMATE THEPRETEST PROBABILITY FOR SUSPECTED PULMONARY EMBOLISMP. Roy* (FR), C. Coroller-Bec, S. Dambrine, M. Righini, J. Callahan, A. Perrier, H. Bounameaux, G. Le Gal

OC-MO-039 8:30 AM - 8:45 AMIMPLEMENTATION OF A DECISION RULE AND A D-DIMER ASSAY INTHE DIAGNOSIS OF PULMONARY EMBOLISMN. S. Gibson* (NL), R. A. Douma, M. Sohne, A. Squizzqato, H. R. Buller, V. E. A. Gerdes

MONDAY, JULY 13, 2009 8:00 AM - 9:30 AM

ORAL COMMUNICATIONS

Mon

day

Ora

ls

OC-MO-040 8:45 AM - 9:00 AMDETECTION OF PULMONARY EMBOLISM WITH PULMONARY MDCT-ANGIOGRAPHY OR VENTILATION/PERFUSION SPECT COMBINED WITHLOW-DOSE CTJ. Mortensen* (DK), H. Gutte, C. V. Jensen, P. V. D. Recke, C. L. Petersen, J. Kjærgaard, U. S. Kristoffersen, A. Kjær

OC-MO-041 9:00 AM - 9:15 AMCOMPLETE VENOUS ULTRASOUND IN OUTPATIENTS WITHSUSPECTED PULMONARY EMBOLISMM. Righini* (CH), G. Le Gal, D. Aujesky, P. Roy, O. Sanchez, F. Verschurren,L. Bressollette, G. Meyer, A. Perrier, H. Bounameaux

OC-MO-042 9:15 AM - 9:30 AMD-DIMER AND CLINICAL PROBABILITY TO RULE OUT PULMONARYEMBOLISM IN CANCER PATIENTS: AN EXPLORATIVE STUDY TOINCREASE THE CLINICAL UTILITYG. L. van Sluis* (NL), R. A. Douma, M. Sohne, P. W. Kamphuisen, F. W. G. Leebeek, H. R. Buller

Mechanisms of Platelet Activation I Room 153 ABC

Chairpersons: Wolfgang Bergmeier (US) and Jonathan N. Thon (US)

OC-MO-043 8:00 AM - 8:15 AMOSTEOACTIVIN POSITIVELY REGULATES PLATELET FUNCTIONTHROUGH INTEGRIN-MEDIATED SIGNALINGS. Kim* (US), J. Belcher, B. Nagy Jr, K. Bhavaraju, F. F. Safadi

OC-MO-044 8:15 AM - 8:30 AMHUMAN GAS6 CONTRIBUTES TO LATE INTEGRIN ALPHAIIBBETA3ACTIVATION AND THROMBUS STABILIZATION: INVOLVEMENT OF AKTJ. M. E. M. Cosemans* (NL), I. C. A. Munnix, L. J. Schurgers, A. Angelillo-Scherrer, M. F. Hoylaerts, P. Carmeliet, J. W. M. Heemskerk

OC-MO-045 8:30 AM - 8:45 AMANTAGONISTS OF INTEGRIN GPIIB/IIIA PARADOXICALLY ENHANCEGPVI-INDUCED PLATELET ACTIVATION, REVEALING A FEEDBACKSIGNALLING PATHWAY FROM INTEGRIN TO GPVI INVOLVING THEPROTEIN TYROSINE PHOSPHATASE PTP1BM. L. Jones* (UK), M. T. Harper, E. W. Aitken, A. W. Poole

OC-MO-046 8:45 AM - 9:00 AMJUNCTIONAL ADHESION MOLECULE-A NEGATIVELY REGULATESINTEGRIN ALPHA IIB BETA 3-DEPENDENT CONTRACTILE SIGNALINGIN PLATELETSU. P. Naik* (US), M. U. Naik

OC-MO-047 9:00 AM - 9:15 AMTHE MIGFILIN-FILAMIN INTERACTION REGULATES INTEGRINACTIVATIONM. Das* (US), S. Ithychanda, J. Qin, E. F. Plow

OC-MO-048 9:15 AM - 9:30 AMINTERACTIONS OF KINDLIN-2 AND TALIN WITH INTEGRIN BETACYTOPLASMIC TAILSK. Bledzka* (US), Y. Q. Ma, J. Qin, E. F. Plow

MONDAY, JULY 13, 2009 8:00 AM - 9:30 AM

ORAL COMMUNICATIONS

105

106

Hospitalization and Venous Thrombosis Room 156 ABC

Chairpersons: Patrick Mismetti (FR) and Alex Spyropoulos (US)

OC-MO-049 8:00 AM - 8:15 AMA RISK ASSESSMENT MODEL FOR THE IDENTIFICATION OFHOSPITALIZED MEDICAL PATIENTS AT RISK OF VENOUSTHROMBOEMBOLISMS. Barbar, D. Tormene, M. Perlati, B. Brandolin, P. Simioni, A. Pagnan, P. Prandoni* (IT)

OC-MO-050 8:15 AM - 8:30 AMBIOLOGICAL AND CLINICAL PREDICTORS OF BLEEDING IN 999PATIENTS TREATED WITH FONDAPARINUX AFTER MAJORORTHOPAEDIC SURGERY: THE POP-A-RIX STUDY FROM THEGETHCAM INVESTIGATORSP. Mismetti* (FR), E. Presles, X. Delavenne, P. Zufferey, J. Barré, P. Nguyen,J. Borg, N. Rosencher, S. Laporte

OC-MO-051 8:30 AM - 8:45 AMALIGNMENT TO PROPHYLAXIS GUIDELINES AND OCCURRENCE OFVENOUS THROMBOEMBOLISM AFTER TOTAL HIP AND KNEEREPLACEMENTR. Selby* (CA), B. Borah, H. McDonald, J. Henk, M. Crowther, P. Wells

OC-MO-052 8:45 AM - 9:00 AMVENOUS THROMBOEMBOLISM RISK FACTORS IN ACUTELY ILLHOSPITALIZED MEDICAL PATIENTS: FINDINGS FROM THE IMPROVEREGISTRYA. C. Spyropoulos* (US), F. A. Anderson, G. Fitzgerald, H. Decousus, V. Tapson

OC-MO-053 9:00 AM - 9:15 AMPREDICTORS OF VENOUS THROMBOEMBOLISM (VTE) AND BLEEDINGIN 3600 ACUTELY ILL MEDICAL PATIENTS RECEIVING THROMBO-PROPHYLAXISS. Laporte* (FR), G. F. Pineo, C. Chapelle, J. Liotier, F. Kleber, P. Mismetti

OC-MO-054 9:15 AM - 9:30 AMIMPACT OF AGE, BODY MASS INDEX, AND RENAL IMPAIRMENT ONVENOUS THROMBOEMBOLISM RISK AND PROPHYLAXIS PRACTICESIN THE ACUTE HOSPITAL CARE SETTING: A SUBANALYSIS OF THEENDORSE SURVEYF. Anderson* (US), A. Cohen, V. Tapson, J. Bergmann, S. Goldhaber, A. Kakkar

Regulation of the Initiation of Coagulation Room 160 ABC

Chairpersons: Bjarne Østerud(NO)and Christian Furlan-Freguia (US)

OC-MO-055 8:00 AM - 8:15 AMZINC-CONTAINING PROTEIN S INHIBITS EXTRINSIC FACTOR XACTIVATING COMPLEX INDEPENDENTLY OF TISSUE FACTORPATHWAY INHIBITORN. L. Fernandes* (US), M. J. Heeb

MONDAY, JULY 13, 2009 8:00 AM - 9:30 AM

ORAL COMMUNICATIONS

Mon

day

Ora

ls

OC-MO-056 8:15 AM - 8:30 AMREDOX PROPERTIES OF THE TISSUE FACTOR MEMBRANE-PROXIMALDISULFIDE BONDT. M. Brophy* (AU), H. H. P. Liang, P. J. Hogg

OC-MO-057 8:30 AM - 8:45 AMBETA3 INTEGRINS ARE REQUIRED FOR THE ACCUMULATION OFEXTRACELLULAR PROTEIN DISULFIDE ISOMERASE FOLLOWINGLASER-INDUCED VASCULAR INJURY IN LIVE MICEJ. Cho* (US), D. R. Kennedy, G. Merrill-Skoloff, B. C. Furie, B. Furie

OC-MO-058 8:45 AM - 9:00 AMELIMINATION OF HUMAN RECOMBINANT MAMMALIAN TISSUEFACTOR PATHWAY INHIBITOR IN A RAT MODELC. Øie* (NO), E. Brodin, I. Hilden, R. Appa, B. Smedsrød, J. B. Hansen

OC-MO-059 9:00 AM - 9:15 AMFACTOR VII RETAINS FUNCTION WHEN FUSED TO ALBUMIN ORANNEXIN V VIA A REPEATED ACTIVATION SITEA. Puchta* (CA), B. J. Clarke, W. P. Sheffield

OC-MO-060 9:15 AM - 9:30 AMTWO RESIDUES IN THE ACTIVATION PEPTIDE OF FACTOR XDETERMINE ITS HALF-LIFE IN VIVOP. Gueguen, I. Badirou, G. Cherel, R. Pendu, C. V. Denis, O. D. Christophe*(FR)

Factor V and Factor VIII Room 102 AB

Chairpersons: Koen Mertens (NL) and Laurent Burnier (CH)

OC-MO-061 8:00 AM - 8:15 AMFUNCTIONAL DIFFERENCES BETWEEN HUMAN AND BOVINEPROTHROMBINASE IN THE ACTIVATION OF PRETHROMBIN-1 CAN BEATTRIBUTED TO THE COOH-TERMINUS OF FACTOR Va HEAVY CHAINP. Y. Kim* (CA), R. Manuel, M. E. Nesheim

OC-MO-062 8:15 AM - 8:30 AMACTIVATED FACTOR X CLEAVES FACTOR VIII AT ARGININE 562LIMITING ITS COFACTOR EFFICIENCYJ. Plantier* (FR), V. Rolli, C. Ducasse, Y. Dargaud, N. Enjolras, H. Boukerche,C. Négrier

OC-MO-063 8:30 AM - 8:45 AMNOVEL APC-MEDIATED CLEAVAGE SITES FOUND IN THE HEAVYCHAIN OF COAGULATION FACTOR VaS. Tran* (SE), B. Dahlback

OC-MO-064 8:45 AM - 9:00 AMREDUCTION OF THE ANTI-FACTOR VIII HUMORAL IMMUNE RESPONSEIN FACTOR VIII-DEFICIENT MICE FOLLOWING MATERNO-FETALTRANSFER OF ANTI-FACTOR VIII IGGY. Meslier* (FR), S. André, M. Teyssandier, S. V. Kaveri, S. Lacroix-Desmazes

OC-MO-065 9:00 AM - 9:15 AMTHE ROLE OF N- LINKED GLYCANS IN THE EXPRESSION ANDINTRACELLULAR PROCESSING OF VWFT. A. J. McKinnon* (UK), A. C. K. Chion, G. Birdsey, M. A. Laffan

MONDAY, JULY 13, 2009 8:00 AM - 9:30 AM

ORAL COMMUNICATIONS

107

108

OC-MO-066 9:15 AM - 9:30 AMTHE ACTIVATED PLATELET MEMBRANE DIRECTS PROTHROMBINACTIVATION THROUGH A PATHWAY DISTINCT FROM THAT ONPHOSPHOLIPID VESICLESJ. P. Wood* (US), J. R. Silveira, P. B. Tracy

Endothelial Cell Signaling Room 252 AB

Chairpersons: Meghna Naik (US) and Magdalena Chrzanowska-Wolnicka (US)

OC-MO-067 8:00 AM - 8:15 AMROLE OF THE SMALL GTPASE RAB27A IN EXOCYTOSIS OF WEIBEL-PALADE BODIES FROM ENDOTHELIAL CELLSR. Bierings* (UK), B. Patel, L. Knipe, L. Hewlett, T. Carter, M. J. Hannah

OC-MO-068 8:15 AM - 8:30 AMDIFFERENTIAL VASP PHOSPHORYLATION CONTROLS ACTINCYTOSKELETON REMODELINGS. Seifert* (DE), P. M. Benz, C. Blume, S. Wilhelm, J. Waschke, K. Schuh, T. Muenzel, F. B. Gertler, T. Renné

OC-MO-069 8:30 AM - 8:45 AMA ROLE FOR THE ENDOTHELIAL TETRASPANIN TSPAN18 IN CALCIUMSIGNALLINGD. Colombo, V. L. Heath, J. M. J. Herbert, R. Bicknell, S. P. Watson, M. G. Tomlinson* (UK)

OC-MO-070 8:45 AM - 9:00 AMPHOSPHOLIPASE D, BUT NOT CALCIUM OR CYCLIC AMP, IS REQUIRED FOR REGULATED SECRETION OF VWF INDUCED BY B5 SUBUNITS OF SHIGA-LIKE TOXIN TYPE 2J. Huang* (US), F. Liu, E. Sadler

OC-MO-071 9:00 AM - 9:15 AMJAM-A NEGATIVELY REGULATES VASCULAR PERMEABILITY:ENHANCED VASCULAR PERMEABILITY IN JAM-A NULL MICE IS VEGF-DEPENDENTM. U. Naik* (US), U. P. Naik

OC-MO-072 9:15 AM - 9:30 AMANTI-DENGUE NS1 ANTIBODY INDUCES HEME OXYGENASE-1 GENE EXPRESSION IN ENDOTHELIAL CELLSP. Rahayu, S. Naidu, A. Rachman, S. Immenschuh, S. Santoso* (DE)

Fibrin Clot Structure Room 257 AB

Chairpersons: Susan Lord (US) and Rusten Litvinov (US)

OC-MO-073 8:00 AM - 8:15 AMTHE PROCOAGULANT PHENOTYPE OF THE CELL DICTATES FIBRINCLOT STRUCTURER. A. Campbell* (US), K. A. Overmyer, A. S. Wolberg

OC-MO-074 8:15 AM - 8:30 AMSELECTIVE DETECTION OF FREE PLASMIN USING A CHROMOGENICSUBSTRATE BOUND TO AGAROSE BEADST. A. Mewhort-Buist* (CA), L. R. Berry, A. K. C. Chan

MONDAY, JULY 13, 2009 8:00 AM - 9:30 AM

ORAL COMMUNICATIONS

Mon

day

Ora

ls

OC-MO-075 8:30 AM - 8:45 AMKINETICS OF FIBRIN DISSOLUTION INITIATED BY PLASMINOGENACTIVATION IN FIBRIN MATRICES OF VARYING ARCHITECTUREC. Longstaff* (UK), L. Szabó, K. Kolev

OC-MO-076 8:45 AM - 9:00 AMPOLYPHOSPHATE MODIFIES FIBRIN STRUCTURE AND INCREASESTHE RESISTANCE OF CLOTS TO FIBRINOLYSISN. J. Mutch* (UK), S. Uitte de Willige, R. Engel, H. Philippou, R. A. S. Ariens

OC-MO-077 9:00 AM - 9:15 AMINCREASED FIBRIN CLOT FORMATION AND SUSCEPTIBILITY TOTHROMBOSIS IN STAT5-DEFICIENT MICES. M. Nordstrom* (US), B. C. Sos, T. S. Fong, E. J. Weiss

OC-MO-078 9:15 AM - 9:30 AMELEVATED FIBRINOGEN GAMMA’ RATIO IS ASSOCIATED WITHCARDIOVASCULAR DISEASES, BUT NOT WITH ACUTE PHASEREACTION OR CLINICAL OUTCOMEE. Y. Cheung* (NL), H. L. Vos, M. J. Kruip, H. M. den Hertog, P. J. Koudstaal,R. M. Bertina, M. P. de Maat

Venous Thrombosis: Clinical Course Ballroom 210 ABC

Chairpersons: Marc Rodger (CA) and Linda Flinterman (NL)

OC-MO-079 4:00 PM - 4:15 PMMORTALITY AND RECURRENCE AFTER A FIRST VENOUSTHROMBOSISL. E. Flinterman* (NL), A. van Hylckama Vlieg, S. C. Cannegieter, F. R. Rosendaal

OC-MO-080 4:15 PM - 4:30 PMRECURRENT VENOUS THROMBOEMBOLISM (RVTE) AFTER SURGERY-ASSOCIATED VTE: COMPARISON WITH RVTE AFTERUNPROVOKED VTER. H. White* (US), B. Danielsen

OC-MO-081 4:30 PM - 4:45 PMTHE LONG-TERM CLINICAL COURSE OF CEREBRAL VEINTHROMBOSIS: A PROSPECTIVE COHORT STUDYI. Martinelli* (IT), P. Bucciarelli, S. Passamonti, T. Battaglioli, P. M. Mannucci

OC-MO-082 4:45 PM - 5:00 PMPOPULATION BASED COHORT STUDY ON THE RISK OF ARTERIALTHROMBOSIS IN SUBJECTS WITH PREVIOUS VENOUS THROMBOSISI. M. van Schouwenburg* (NL), B. K. Mahmoodi, R. T. Gansevoort, N. J. G. M. Veeger, M. M. Visser, W. Lijfering, J. van der Meer

Pre-clinical Studies of Novel Factor IX Concentrates Room 205 ABC

Chairpersons: Paul Monahan (US) and Jenny Goudemand (FR)

OC-MO-083 4:00 PM - 4:15 PMBIOCHEMICAL CHARACTERIZATION OF FACTOR IX-FC MONOMERG. Toby* (US), R. T. Peters, A. J. Bitonti

MONDAY, JULY 13, 2009 4:00 PM - 5:00 PM

ORAL COMMUNICATIONS

109

110

OC-MO-084 4:15 PM - 4:30 PMDOSE RESPONSE AND PROLONGED EFFECT OF 40K PEG-FIX ONBLEEDING IN HEMOPHILIA B MICET. Elm* (DK), H. Oestergaard, M. Tranholm

OC-MO-085 4:30 PM - 4:45 PMTHE PHARMACOKINETICS OF A LONG-ACTING FACTOR IX (40K PEG-RFIX) IN MINIPIGS SUGGESTS AT LEAST A ONCE-WEEKLYDOSING REGIMEL. Hansen, H. Ostergaard, M. Tranholm, H. Agersoe* (DK)

OC-MO-086 4:45 PM - 5:00 PMIB1001, A NEW RECOMBINANT FACTOR IX PREPARATION: INITIALSAFETY AND CHARACTERIZATIONE. D. Gomperts* (US), M. Lee, T. Nichols, M. Griffith

Hormone Therapy in Women Room 253 ABC

Chairpersons: Cornelis Kluft (NL) and Catherine Bagot (UK)

OC-MO-087 4:00 PM - 4:15 PMSHOULD WE CLASSIFY WOMEN WHO DEVELOP VENOUSTHROMBOSIS ON ESTROGEN AS HAVING PROVOKED ORUNPROVOKED VENOUS THROMBOEMBOLISM? RESULTS FROM THE REVERSE STUDYG. Le Gal* (FR), M. Carrier, M. Rodger

OC-MO-088 4:15 PM - 4:30 PMTHROMBIN GENERATION IS INCREASED IN POST MENOPAUSALWOMEN USING HORMONE REPLACEMENT THERAPY ADMINISTEREDBY THE ORAL BUT NOT THE TRANSDERMAL ROUTEC. N. Bagot* (UK), M. S. Marsh, M. Whitehead, R. Sherwood, L. Roberts, R. K. Patel, R. Arya

OC-MO-089 4:30 PM - 4:45 PMPEAK THROMBIN GENERATION CORRELATES WITH ESTRADIOLLEVELS IN WOMEN WHO USE HORMONE REPLACEMENT THERAPYADMINISTERED BY THE ORAL BUT NOT THE TRANSDERMAL ROUTEC. N. Bagot* (UK), M. S. Marsh, M. Whitehead, R. Sherwood, L. Roberts, R. K. Patel, R. Arya

OC-MO-090 4:45 PM - 5:00 PMTHE EFFECT OF MONOPHASIC ORAL CONTRACEPTIVE REGIMENS ONFACTOR VII-ACTIVATING PROTEASE - A RANDOMIZED MULTICENTRESTUDYJ. J. Sidelmann* (DK), S. O. Skouby, C. Kluft, U. Winkler, F. Vitzthum, H. Schwarz, J. Jespersen

MONDAY, JULY 13, 2009 4:00 PM - 5:00 PM

ORAL COMMUNICATIONS

Mon

day

Ora

ls

Thrombosis in Cancer: Clinical Course Room 258 ABC

Chairpersons: Charles Francis (US) and Francesco Dentali (IT)

OC-MO-091 4:00 PM - 4:15 PMASYMPTOMATIC VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: PREVALENCE AND CONSEQUENCER. A. Douma* (NL), M. G. M. Kok, L. M. Verberne, P. W. Kamphuisen, H. R. Büller

OC-MO-092 4:15 PM - 4:30 PMPROGNOSTIC RELEVANCE OF ASYMPTOMATIC VTE IN CANCERPATIENTSF. Dentali* (IT), J. Vitale, C. Nitti, D. Imberti, C. Becattini, A. Malato, A. Salvi,M. Giorgi Pierfranceschi, G. Agnelli, S. Siragusa, W. Ageno

OC-MO-093 4:30 PM - 4:45 PMRESIDUAL VEIN THROMBOSIS FOR ASSESSING THE OPTIMALDURATION OF ANTICOAGULANTS AFTER DEEP VEIN THROMBOSIS OF THE LOWER LIMBS IN CANCER PATIENTSS. M. Siragusa* (IT)

OC-MO-094 4:45 PM - 5:00 PMTHROMBOTIC DIATHESIS AND VASCULAR RISK FACTORS INPOLYCYTHEMIA VERA: GENDER RELATED DIFFERENCESL. di Gennaro* (IT), R. Marfisi, R. Marchioli, R. Landolfi

Anticoagulant Reactions of Activated Protein C Room 157 ABC

Chairpersons: Guido Tans (NL) and Laurent Mosnier (US)

OC-MO-095 4:00 PM - 4:15 PMDOWN REGULATION OF PROTHROMBINASE ACTIVITY BY ACTIVATEDPROTEIN C MEASURED IN REAL-TIME DURING PROTHROMBINACTIVATIONP. Y. Kim* (CA), M. E. Nesheim

OC-MO-096 4:15 PM - 4:30 PMMOUSE RECOMBINANT PROTEIN C VARIANTS WITH ENHANCEDMEMBRANE AFFINITY AND HYPER-ANTICOAGULANT ACTIVITY INMOUSE PLASMAM. J. Krisinger* (SE), L. J. Guo, G. Salvagno, G. C. Guidi, G. Lippi, B. Dahlbäck

OC-MO-097 4:30 PM - 4:45 PMGLA DOMAIN-MUTATED HUMAN PROTEINS C EXHIBIT ENHANCEDANTICOAGULANT ACTIVITY IN THROMBIN GENERATION ASSAYSYSTEMG. Salvagno* (IT), G. Lippi, M. Franchini, G. Guidi, B. Dahlback

OC-MO-098 4:45 PM - 5:00 PMGLA-DOMAIN MUTATED ACTIVATED PROTEIN C EXHIBITS ENHANCEDANTICOAGULANT ACTIVITY ON PLATELET SURFACESE. A. Norstrom* (SE), Y. Sun, B. Dahlback

MONDAY, JULY 13, 2009 4:00 PM - 5:00 PM

ORAL COMMUNICATIONS

111

112

Novel Mechanisms of Antiplatelet Therapy Room 104 ABC

Chairperson: Athan Kuliopulos (US) and Pamela Couley (US)

OC-MO-099 4:00 PM - 4:15 PMTHE NEW TYROSINE-KINASE INHIBITOR AND ANTI-CANCER DRUGDASATINIB REVERSIBLY AFFECTS PLATELET ACTIVATION IN VITROAND IN VIVOB. Payrastre, M. Gratacap* (FR), V. Martin, M. Valéra, S. Allart, C. Garcia, P. Sié, C. Recher

OC-MO-100 4:15 PM - 4:30 PMEP3 RECEPTOR BLOCKADE AND PLATELET FUNCTION IN MANS. Heptinstall* (UK), S. C. Fox, J. A. May, D. Hermann, D. Streiter, D. Hartman

OC-MO-101 4:30 PM - 4:45 PMTHE LECTIN-LIKE DOMAIN OF THROMBOMODULIN AND GRP78COMPLEX EXHIBITS NOVEL ANTI-THROMBOTIC PROPERTIESA. Sharma* (AU), X. Zhang, A. Samudra, S. Dezfouli, C. Selan, B. Michell, B. Kemp, A. D’Apice, P. Cowan, H. Nandurkar

OC-MO-102 4:45 PM - 5:00 PMTHE MECHANISM OF IVIG TREATMENT FOR IMMUNE-MEDIATEDPLATELET DESTRUCTION IS THROUGH INDUCTION OF INTERLEUKIN-11D. Leontyev* (CA), Y. Katsman, D. R. Branch

Factor XI/XIa Room 107 ABC

Chairpersons: Uri Seligsohn (US) and Coen Mass (NL)

OC-MO-103 4:00 PM - 4:15 PMSTRUCTURAL ANALYSIS OF APPLE DOMAIN MISSENSE MUTATIONSRELATED TO FACTOR XI DEFICIENCYP. A. McEwan, D. V. Kravtsov, M. Sun, D. Gailani, J. Emsley* (UK)

OC-MO-104 4:15 PM - 4:30 PMFACTOR XI ACTIVATION IN PLASMA IN THE ABSENCE OF FACTOR XIIAD. Gailani* (US), A. Matafonov, D. V. Kravtsov, E. I. Tucker, M. Sun, A. Gruber

OC-MO-105 4:30 PM - 4:45 PMDIMERIZATION OF HUMAN FACTOR XI IS NOT A PREREQUISITE FORITS SECRETION OR ACTIVATIONM. Zucker* (IL), A. Zivelin, M. Landau, N. Rosenberg, U. Seligsohn

OC-MO-106 4:45 PM - 5:00 PMREGULATION OF CONTACT ACTIVATION BY ANTITHROMBIN (AT) AND C1 INHIBITOR (C1INH)J. Bäck* (SE), G. Elgue, J. Sanchez, K. Nilsson Ekdahl, B. Nilsson

MONDAY, JULY 13, 2009 4:00 PM - 5:00 PM

ORAL COMMUNICATIONS

Mon

day

Ora

ls

Mechanisms of Platelet Activation II Room 153 ABC

Chairpersons: Yukio Ozaki (JP) and Timothy J. Stalker (US)

OC-MO-107 4:00 PM - 4:15 PMVAV GUANINE NUCLEOTIDE EXCHANGE FACTORS LINKHYPERLIPIDEMIA AND A PROTHROMBOTIC STATEK. Chen* (US), W. Li, M. Febbraio, R. Silverstein

OC-MO-108 4:15 PM - 4:30 PMROLE OF PDI IN THROMBUS FORMATION IN A COLLAGEN INDUCEDPATHWAYL. Bellido-Martin* (US), G. Merrill-Skoloff, B. Furie, B. C. Furie

OC-MO-109 4:30 PM - 4:45 PMPLATELET GPIB SENSES ENVIRONMENTAL CONDITIONS ANDMODULATES 14-3-3 AVAILABILITY AND OUTSIDE-IN SIGNALS ACROSSALPHAIIBBETA3 ACCORDINGLYJ. E. B. Fox* (US), Y. Zhang, K. Bialkowska

OC-MO-110 4:45 PM - 5:00 PMPATHOLOGICAL SHEAR RATES INCREASE LEVELS OF PLATELETRECEPTOR SHEDDINGM. Al-Tamimi* (AU), J. R. Hamilton, S. P. Jackson, A. Ludwig, M. C. Berndt, R. K. Andrews, E. E. Gardiner

Antiphospholipid Syndrome: Beta 2 Glycoprotein 1 Room 156 ABC

Chairpersons: Philip de Groot (NL) and Bas de Laat (NL)

OC-MO-111 4:00 PM - 4:15 PMPATIENT-DERIVED MONOCLONAL ANTIBODIES DIRECTED TOWARDSDOMAIN I OF BETA2-GLYCOPROTEIN I DISPLAY LAC ACTIVITYM. Boon-Spijker, I. Dienava* (NL), P. de Groot, J. Voorberg, K. Mertens, B. de Laat, R. Derksen

OC-MO-112 4:15 PM - 4:30 PMIMMUNE RESPONSES AGAINST DOMAIN I OF BETA2GPI AREDEPENDENT ON PROTEIN CONFORMATIONB. de Laat* (NL), C. Zappelli, M. van Berkel, B. Siregar, P. de Groot, K. Mertens, M. Gebbink, C. Maas

OC-MO-113 4:30 PM - 4:45 PMSYNTHESIS, CHARACTERIZATION AND ANTIBODY-BINDINGPROPERTIES OF DOMAIN I (1-64) OF BETA2-GLYCOPROTEIN I:IMPLICATION FOR THE ANTIPHOSPHOLIPID SYNDROME (APS)N. Pozzi* (IT), A. Banzato, E. Bison, S. Olivieri, A. Ruffatti, V. Pengo, V. de Filippis

OC-MO-114 4:45 PM - 5:00 PMIN VIVO INVOLVEMENT OF APOLIPOPROTEIN E RECEPTOR (APOER2’)ON THROMBOGENIC EFFECTS OF A DIMER OF BETA2GLYCOPROTEINI (BETA2GPI) AND OF ANTIPHOSPHOLIPID (APL) ANTIBODIESZ. Romay-Penabad, R. Urbanus, M. Pennings, E. Papalardo, G. Vargas, T. Shilagard, R. Derksen, P. de Groot, S. S. Pierangeli* (US)

MONDAY, JULY 13, 2009 4:00 PM - 5:00 PM

ORAL COMMUNICATIONS

113

114

Fibrinolysis: Biochemistry Room 160 ABC

Chairpersons: John Weisel (US) and Oleg Gorkun (US)

OC-MO-115 4:00 PM - 4:15 PMTHE ROLE OF THE FIBRINOGEN ALPHA CHAIN IN ENHANCING FXIIIACTIVATIONK. A. Smith* (UK), P. J. Adamson, R. J. Pease, A. J. Balmforth, R. A. S. Ariens, H. Philippou, P. J. Grant

OC-MO-116 4:15 PM - 4:30 PMTHE RELATIVE IMPORTANCE OF FINGER AND KRINGLE DOMAINS IN THE REGULATION OF TPA ACTIVITYS. Williams* (UK), C. Thelwell, C. Longstaff

OC-MO-117 4:30 PM - 4:45 PMPLASMIN-CATALYZED LYSIS IS ENHANCED IN FIBRIN VARIANTS WITH WEAKENED HOLE “B”B. A. Holliday* (US), S. R. Bowley, S. T. Lord

OC-MO-118 4:45 PM - 5:00 PMCOAGULATION FACTOR Xa DERIVATIVE, Xa33/13, ENHANCESPLASMINOGEN ACTIVATION AND CLOT LYSISK. Talbot, S. C. Meixner, E. L. G. Pryzdial* (CA)

Factor V Room 204 AB

Chairpersons: Francesco Bernardi (IT) and Beth Bouchard (US)

OC-MO-119 4:00 PM - 4:15 PMTHROMBIN GENERATION IN PATIENTS WITH SEVERE FACTOR VDEFICIENCY RELIES ON PLATELET FACTOR VC. Duckers* (NL), P. Simioni, C. Radu, L. Spiezia, S. Gavasso, J. Rosing, E. Castoldi

OC-MO-120 4:15 PM - 4:30 PMTHE PLATELET FACTOR V/Va POOL REMAINING TWO WEEKSSUBSEQUENT TO FFP ADMINISTRATION CORRECTS TOTAL PLASMAFACTOR V DEFICIENCYB. A. Bouchard* (US), K. E. Brummel-Ziedins, J. P. Wood, P. B. Tracy

OC-MO-121 4:30 PM - 4:45 PMDIRECT CORRELATION BETWEEN PLATELET AND PLASMA FACTOR VLEVELS IN HOMOZYGOUS AND HETEROZYGOUS FACTOR VDEFICIENT SUBJECTSL. Spiezia* (IT), C. Radu, G. Tognin, C. Bulato, M. Florean, P. Pradella, S. Gavasso, G. Barillari, V. de Angelis, P. Simioni

OC-MO-122 4:45 PM - 5:00 PMA DATABASE OF MUTATIONS AND POLYMORPHISMS IN AND AROUNDTHE FACTOR V GENE; AN UPDATEH. L. Vos* (NL)

MONDAY, JULY 13, 2009 4:00 PM - 5:00 PM

ORAL COMMUNICATIONS

Mon

day

Ora

ls

Atherosclerosis: Plaque Composition Room 109 AB

Chairpersons: Armin J. Reininger (DE) and Julian I. Borissoff (NL)

OC-MO-123 4:00 PM - 4:15 PMNON-INVASIVE IDENTIFICATION OF ATHEROSCLERTOTIC PLAQUESVIA TARGETED MOLECULAR IMAGING OF ACTIVATED VONWILLEBRAND FACTORR. B. Conley* (US), W. Shentu, A. Xie, Y. Qi, Y. Zhao, C. Carr, T. Belcik, P. G. de Groot, J. R. Lindner, O. McCarty

OC-MO-124 4:15 PM - 4:30 PMTHE INITIAL STEPS OF THROMBUS FORMATION INDUCED BY HUMANATHEROSCLEROTIC PLAQUESA. J. Reininger* (DE), I. Bernlochner, S. Penz, C. Ravanat, P. Smethurst, R. Farndale, C. Gachet, R. Brandl, W. Siess

OC-MO-125 4:30 PM - 4:45 PMTHE PROTHROMBOTIC STATE OF ATHEROSCLEROTIC LESIONS: A POSSIBLE ROLE FOR FXIIJ. I. Borissoff* (NL), S. Heeneman, P. Kassak, R. van Oerle, K. Hamulyák, M. Daemen, H. ten Cate, H. Spronk

OC-MO-126 4:45 PM - 5:00 PMMONOCYTE HETEROGENEITY IN OBESITY AND SUBCLINICALATHEROSCLEROSISG. H. Heine* (DE), K. S. Rogacev, C. Ulrich, L. Blömer, K. Oster, M. Ziegelin,Y. Grenner, J. Geisel, A. Schlitt, H. Köhler, M. Girndt, D. Flliser

Endothelial Dysfunction: Vascular Signaling Room 151 AB

Chairpersons: Tatiana Byzkova (US) and Mieke Delvaeya (NL)

OC-MO-127 4:00 PM - 4:15 PMTHROMBOMODULIN OVER-EXPRESSION PREVENTS VENOUSTHROMBOSIS AND PROLONGS CARDIAC XENOGRAFT SURVIVALX. Zhang* (AU), S. Crikis, S. Dezfouli, K. Dwyer, L. Murray-Segal, E. Salvaris,S. Robson, A. D’Apice, P. Cowan, H. Nandurkar

OC-MO-128 4:15 PM - 4:30 PMPROLYLCARBOXYPEPTIDASE MURINE HYPOMORPHS AREHYPERTENSIVE AND PROTHROMBOTICG. N. Adams* (US), Y. Zhou, G. Larusch, M. Nieman, B. Hoit, G. Jacobs, X. Yu, F. Mahdi, Z. Shariat-Madar, L. D’Alecy, Y. Okada, A. H. Schmaier

OC-MO-129 4:30 PM - 4:45 PMDIFFERENTIAL EXPRESSION AND SECRETION OF TISSUE FACTORAND TISSUE FACTOR PATHWAY INHIBITOR MODULATE ENDOTHELIALTHROMBORESISTANCE IN VITROJ. Madon, W. Ruf, S. Valsami, M. Leikauf, A. Kaech, L. M. Asmis* (CH)

OC-MO-130 4:45 PM - 5:00 PMMATRIX METALLOPROTEINASE-10 (MMP-10) IS UP-REGULATED BYTHROMBIN IN ENDOTHELIAL CELLS AND INCREASED IN PATIENTSWITH ENHANCED THROMBIN GENERATIONJ. Orbe* (ES), J. A. Rodriguez, C. Rodriguez, S. Martinez de Lizarrondo, J. Barrenetxe, J. Martinez-Gonzalez, J. C. Reverter, J. A. Paramo

MONDAY, JULY 13, 2009 4:00 PM - 5:00 PM

ORAL COMMUNICATIONS

115

116

P2Y12 Room 252 AB

Chairpersons: Jane Freedman (US) and David Varon (IL)

OC-MO-131 4:00 PM - 4:15 PMIDENTIFICATION OF TWO NOVEL P2Y12 ADP RECEPTOR GENEDEFECTS IN PATIENTS WITH TYPE 1 VON WILLEBRAND DISEASEM. E. Daly* (UK), B. B. Dawood, W. A. Lester, A. B. Federici, A. Artoni, I. R. Peake, A. D. Mumford, S. P. Watson, S. J. Mundell, on behalf of the EU-VWD Study Group

OC-MO-132 4:15 PM - 4:30 PMREPRODUCIBILITY OVER TIME OF PLATELET FUNCTION TESTS TOEVALUATE ASPIRIN AND CLOPIDOGREL RESPONSIVENESS: INSIGHTFROM THE ADRIE STUDY ON STABLE CARDIOVASCULAR PATIENTSJ. L. Reny* (FR), I. Barazer, C. Castelli, S. Nolli, P. Berdague, P. Fabbro-Peray, J. Schved, H. Bounameaux, F. Mach, P. de Moerloose, P. Fontana

OC-MO-133 4:30 PM - 4:45 PMCOMMON VARIATION IN THE PLATELET RECEPTOR P2RY12 GENE ISASSOCIATED WITH RESIDUAL ON-CLOPIDOGREL PLATELETREACTIVITY IN PATIENTS UNDERGOING ELECTIVE PCIG. Rudez* (NL), H. J. Bouman, J. W. van Werkum, F. W. G. Leebeek, A. Kruit,H. J. T. Ruven, J. M. ten Berg, M. P. M. de Maat, C. M. Hackeng

OC-MO-134 4:45 PM - 5:00 PMTHE INTERPRETATION OF LIGHT TRANSMITTANCE PLATELETAGGREGATION IS INCONSISTENT – RESULTS FROM ANINTERNATIONAL CHALLENGEK. A. Moffat* (CA), E. Plumhoff, E. Reyes, S. Hoffman, S. Israels, P. Meijer, C. P. M. Hayward

OC-MO-135 5:00 PM - 5:15 PMWHICH PLATELET FUNCTION TEST IS THE MOST SENSITIVE FOR THEIN VIVO EFFECTS OF CLOPIDOGREL? A PHARMACOKINETICANALYSISH. J. Bouman* (NL), J. W. van Werkum, N. J. Breet, C. M. Hackeng, J. M. ten Berg, D. Taubert

Immune-mediated Thrombocytopenia Room 257 AB

Chairpersons: Ming Hou (CN) and Samuel Machin (UK)

OC-MO-136 4:00 PM - 4:15 PMTHE EFFECT OF BAFF AND BAFF-R-FC FUSION PROTEIN IN CHRONICIMMUNE THROMBOCYTOPENIC PURPURAX. Zhu, Y. Shi, J. Sun, J. Peng, C. Guo, P. Qing, X. Zhang* (CN), X. Ji, L. Wang, M. Hou

OC-MO-137 4:15 PM - 4:30 PMMESENCHYMAL STEM CELL-MODULATED DENDRITIC CELLS INDUCEPLATELET-SPECIFIC T CELL-ANERGY IN IDIOPATHICTHROMBOCYTOPENIC PURPURAX. Zhang* (CN), J. Peng, Y. Shi, C. Guo, J. Sun, M. Hou

MONDAY, JULY 13, 2009 4:00 PM - 5:00 PM

ORAL COMMUNICATIONS

Mon

day

Ora

ls

OC-MO-138 4:30 PM - 4:45 PMTHE PHARMACOKINETICS OF RITUXIMAB IN ACUTE IDIOPATHICTHROMBOTIC THROMBOCYTOPENIC PURPURA (AITTP)V. McDonald* (UK), I. J. Mackie, K. Manns, S. J. Machin, M. A. Scully

OC-MO-139 4:45 PM - 5:00 PMROLE OF NEONATAL FC RECEPTOR (FCRN) IN FETAL AND NEONATALIMMUNE THROMBOCYTOPENIA (FNIT) AND FNIT THERAPYP. Chen, G. Zhu, J. Freedman, H. Ni* (CA)

Late Breaking Abstracts Grand Ballroom

Chairperson: Ken Bauer (US)

LB-MO-001 8:00 AM – 8:15 PMLATE BREAKING CLINICAL TRIAL: A RANDOMISED COMPARISON OFTHE QUALITY OF ANTICOAGULANT THERAPY WITH TWO VITAMIN KANTAGONISTS: WARFARIN VERSUS PHENPROCOUMON Y. van Leeuwen* (NL), E. P. A. Gebuis, F. J. M. van der Meer, F. R.Rosendaal

LB-MO-002 8:15 AM – 8:30 AMLATE BREAKING CLINICAL TRIAL: A RANDOMISED DOUBLE BLINDTRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PROLONGINGTHE THROMBOPROPHYLAXIS WITH BEMIPARIN IN PATIENTS UNDER-GOING CANCER ABDOMINAL OR PELVIC SURGERY (THE CANBESURESTUDY) V. V. Kakkar* (UK), J. Balibrea, J. Martinez-Gonzalez, P. Prandoni

LB-MO-003 8:30 AM – 8:45 AMLATE BREAKING CLINICAL TRIAL: A PROSPECTIVE, RANDOMIZEDTRIAL OF CHEMOTHERAPY WITH AND WITHOUT THE LOW MOLECU-LAR WEIGHT HEPARIN (LMWH) ENOXAPARIN IN ADVANCED PANCRE-ATIC CANCER PATIENTS H. B. Riess* (DE), U. Pelzer, B. Opitz, A. Hilbig, M. Strauch, S. Hahnfeld, G.Deutschinoff, J. Stieler, P. Reizig, H. Oettle

LB-MO-004 8:45 AM – 9:00 AMLATE BREAKING CLINICAL TRIAL: THE EFFECT OF THE LOW-MOLECU-LAR-WEIGHT HEPARIN NADROPARIN ON THE SURVIVAL IN PATIENTSWITH CANCER: A RANDOMIZED TRIAL (FOR THE INPACT INVESTIGA-TORS) H. R. Buller*(NL), M. H. Prins

LB-MO-005 9:00 AM – 9:15 AMLATE BREAKING CLINICAL TRIAL: THE ADVANCE - 2 STUDY: A RAN-DOMIZED DOUBLE-BLIND TRIAL COMPARING APIXABAN WITH ENOXA-PARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL KNEE REPLACE-MENT M. R. Lassen*(DK), A. S. Gallus, G. F. Pineo, G. E. Raskob

MONDAY, JULY 13, 2009 4:00 PM - 5:00 PM

ORAL COMMUNICATIONS

117

118

Mechanisms of Platelet Activation I

PP-MO-001 FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) ANALYSIS OF ACTIVATEDPLATELET INTEGRIN ALPHA IIB BETA 3 VARIANTS EXPRESSED IN HEK293 CELLSR. E. Scharf, A. El Khattouti* (DE), V. R. Stoldt, M. Gyenes

PP-MO-002 MODULATION OF PLATELET ADHESION BY DIFFERENTIAL PHOSPHORYLATION OFMULTIPLE GLYCOPROTEIN IB ALPHA SERINE AND THREONINE RESIDUESA. D. Munday* (US), R. A. Penkala, W. E. Thomas, J. A. Lopez

PP-MO-003 DO HUMAN PLATELETS HAVE A PERIMEMBRANE, EXTRACELLULAR CA2+ SOURCEWHICH CAN BE MOBILISED UPON THROMBIN STIMULATION?A. G. S. Harper* (UK), S. O. Sage

PP-MO-004 PLATELET SURFACE BINDING ENHANCES IMMUNE COMPLEX-INDUCED PLATELETAGGREGATIONM. L. Hatfield, J. Meyer, L. Robles-Carillo, A. Amirkhosravi* (US), T. Meyer, J. Francis

PP-MO-005 FRACTALKINE PROMOTES PLATELET ACTIVATION AND VASCULAR DYSFUNCTIONIN CHRONIC HEART FAILURE: A LINK TO IMPAIRED CLOPIDOGRELRESPONSIVENESSA. Schaefer* (DE), C. Schulz, D. Fraccarollo, S. Massberg, J. Bauersachs

PP-MO-006 LIPID RAFTS REGULATE PAR-1 SIGNALING LEADING TO PLATELET ACTIVATION ANDPLATELET-INDUCED MONOCYTE ACTIVATIONA. E. Schade* (US), E. Shick

PP-MO-007 INDUCTION OF INSULIN RESISTANCE BY ADIPOKINES IN HUMANMEGAKARYOCYTESA. J. Gerrits* (NL), E. Gitz, C. A. Koekman, F. L. Visseren, J. W. N. Akkerman

PP-MO-008 THE PLAQUE LIPID LYSOPHOSPHATIDIC ACID STIMULATES HUMANMEGAKARYOCYTIC CELLS VIA THE LPA5 RECEPTORA. L. Khandoga* (DE), P. Goyal, W. Siess

PP-MO-009 BINDING OF PLASMA FACTOR XIII TO THROMBIN-RECEPTOR ACTIVATED HUMANPLATELETSB. Nagy* (HU), Z. Simon, Z. Bagoly, L. Muszbek, J. Kappelmayer

PP-MO-010 STREPTOCOCCUS PYOGENES BACTERIA INDUCE PLATELET ACTIVATION ANDAGGREGATION VIA A FIBRINOGEN-DEPENDENT MECHANISMC. Liu* (TW), Y. Chen, L. Chang

PP-MO-011 PLATELET KAINIC ACID RECEPTOR SIGNALING PROMOTES THROMBOSIS BYSTIMULATING CYCLOOXYGENASE ACTIVATION IN A MAPK DEPENDENT MANNERH. Sun, A. Swaim, C. N. Morrell* (US)

PP-MO-012 CD40L PRIMES PLATELETS AND ENHANCES AGONIST-INDUCED ACTIVATION ANDAGGREGATION TROUGH CD40-MEDIATED SHAPE CHANGE AND FILOPODIAFORMATIOND. Yacoub* (CA), A. Hachem, J. F. Théorêt, M. Tabrizian, W. Mourad, Y. Merhi

PP-MO-013 HEMATOCRIT AND ERYTHROCYTE DEFORMABILITY AFFECT ADP PLATELETREACTIVITY IN PATIENTS WITH ACUTE CORONARY SYNDROMES ON DUALANTIPLATELET THERAPYE. Cecchi* (IT), R. Marcucci, R. Paniccia, B. Bandinelli, S. Valente, C. Giglioli, C. Lazzeri, G.Gensini, R. Abbate, L. Mannini


POSTER PRESENTATIONS

* Presenting Author

PP-MO-014 IDENTIFICATION OF G PROTEIN-COUPLED RECEPTORS (GPCRS) IN HUMANPLATELETS BY GENE EXPRESSION PROFILINGA. Hansen, B. Spath, C. Bokemeyer, B. Eifrig, F. Langer* (DE)

PP-MO-015 THROMBOXANE AND PROSTACYCLIN BIOSYNTHESIS IN HEART FAILURE OFISCHEMIC ORIGIN: EFFECTS OF DISEASE SEVERITY AND ASPIRIN TREATMENTF. Santilli* (IT), G. Davi, S. Basili, S. Lattanzio, A. Cavoni, G. Guizzardi, L. de Feudis, G.Traisci, C. Pettinella, P. Minuz, A. Meneguzzi, G. Ciabattoni, C. Patrono

PP-MO-016 POSTPRANDIAL HYPERGLYCEMIA IS AN IMPORTANT DETERMINANT OF PLATELETACTIVATION. EVIDENCE FROM BIOCHEMICAL MEASUREMENTS ANDPHARMACOLOGICAL INTERVENTION WITH ACARBOSEF. Santilli* (IT), G. Formoso, P. Sbraccia, M. Averna, R. Miccoli, P. di Fulvio, A. Ganci, N.Pulizzi, S. Lattanzio, G. Ciabattoni, A. Consoli, R. Lauro, C. Patrono, G. Davi

PP-MO-017 CROSS ACTIVATION OF PAR-1 AND -4 BY PAR-1 AND -4 AGONIST PEPTIDESL. L. Dewar, Y. Song, S. J. Craven, F. A. Ofosu* (CA)

PP-MO-018 A NOVEL SINERGISM BETWEEN EPINEPHRINE AND ADP STIMULATES PROTEINKINASE C AND RAP1B ACTIVATIONP. Lova, G. F. Guidetti* (IT), I. Canobbio, C. Balduini, M. Torti

PP-MO-019 INCREASED PLASMA PHOSPHOLIPID AND PLATELET MICROPARTICLES IN ACUTESTROKEG. Gilmore* (AU), J. Thom, G. Hankey, J. Eikelboom, R. Baker

PP-MO-020 DO YOUNG PLATELETS HAVE AN ENHANCED CAPACITY TO EXPOSEPROCOAGULANT PHOSPHATIDYLSERINE (PS) UPON ACTIVATION?M. L. Rand* (CA), H. Wang, K. W. Annie Bang, J. Freedman

PP-MO-021 PLATELET PAI-1 RELEASE IS DEPENDENT ON BOTH THROMBIN RECEPTOR PAR1AND PAR4M. Nylander* (SE), E. Löfgren, M. Grenegård, T. L. Lindahl

PP-MO-022 PROLACTIN DOES NOT AFFECT HUMAN PLATELET AGGREGATION OR SECRETIONA. Q. Reuwer, R. Nieuwland* (NL), I. Fernandez, V. Goffin, C. M. van Tiel, M. C. L. Schaap,R. Berckmans, J. J. P. Kastelein, M. Twickler

Platelet Biology I

PP-MO-023 NITRIC OXIDE INDUCES VASODILATOR-STIMULATED PHOSPHOPROTEINPHOSPHORYLATION BY PROTEIN KINASE G-DEPENDENT AND INDEPENDENTMECHANISMS: ROLE OF PROTEIN KINASE CA. A. Aburima* (UK), R. Riba, K. M. Naseem

PP-MO-024 REGULATION OF COLLAGEN MEDIATED PLATELET ADHESION AND AGGREGATIONUNDER CONDITIONS OF FLOW BY PROSTACYCLINA. Michno* (UK), W. Roberts, S. Homer-Vanniasinkam, K. M. Naseem

PP-MO-025 PLATELET-ACTIVE SUBSTANCES IN THE VENOM OF BOTHROPS MOOJENI SNAKE –AN EVALUATION USING WHOLE BLOOD AGGREGOMETRYC. Demler, B. Buehler, A. M. Perchuc* (DE)

PP-MO-026 THE PLASMA MEMBRANE CALCIUM ATPASE REGULATES CALCIUM HOMEOSTASISAND FUNCTION IN PLATELETSA. B. Solomon* (UK), S. Jones, D. Sanz-Rosa, M. Emerson

PP-MO-027 PLATELET RECEPTORS AND SIGNAL TRANSDUCTION MECHANISMS INVOLVED INERYTHROCYTE-AMPLIFIED PLATELET REACTIVITYA. Moscardo* (ES), J. Valles, M. A. Dasi, A. Latorre, M. T. Santos



119

Mon

day

Post

ers

120

PP-MO-028 CURCUMIN INHIBITS GPVI-MEDIATED PLATELET ACTIVATION BY INTERFERING WITHTHE KINASE ACTIVITY OF SYK AND THE SUBSEQUENT ACTIVATION OF PLCGAMMA2A. Mayanglambam* (US), J. L. Daniel, C. A. Dangelmaier, C. D. Reddy, D. Thomas, S. P.Kunapuli

PP-MO-029 HUMAN PLATELET GRANULE SECRETION INDUCED BY THROMBIN AND COLLAGENIS DIFFERENTIALLY MODULATED BY INTEGRINS: PLATELET FUNCTION OF APATIENT WITH LAD-1V/LAD-III SYNDROMEK. Jurk, A. S. Schulz, W. Friedrich, H. Schulze, H. Omran, R. Henschler, J. S. Scheele, B. E.Kehrel* (DE), B. Zieger

PP-MO-030 THE EXTRACELLULAR ADHERENCE PROTEIN (EAP) OF STAPHYLOCOCCUS AUREUSACTIVATES PLATELETS VIA THE ATP-GATED P2X1 CATION CHANNEL ANDFCGAMMA RIIAS. Niemann, M. Hussain, S. Pohl, T. Schifferdecker, A. Schulte, A. Bertling, C. Heilmann, B.E. Kehrel* (DE)

PP-MO-031 THE FUNGAL METABOLITE GLIOTOXIN INHIBITS PLATELET FUNCTION IN VITROA. Bertling, S. Niemann, A. Uekötter, C. Lass-Flörl, C. von Eiff, B. E. Kehrel* (DE)

PP-MO-032 A STRUCTURAL BASIS FOR THE INHIBITION OF SRC-FAMILY KINASE ACTIVITY BYDIETARY FLAVONOIDSB. Wright* (UK), J. A. Lovegrove, J. M. Gibbins

PP-MO-033 SEQUENCE DIFFERENCES IN THE N-TERMINAL REGION OF MOUSE GPIB? CHANGEPROTEASE SPECIFICITY AND PREVENT THROMBIN BINDINGC. Ravanat* (FR), V. Wurtz, C. Strassel, R. K. Andrews, S. Schuhler, C. Gachet, F. Lanza

PP-MO-034 PHOSPHOTYROSINE PROTEINS IN PLATELETS FROM PATIENTS WITH STICKYPLATELET SYNDROMED. M. Fries* (BR), C. S. S. S. Silva, V. Oliveira, L. Lopes, F. E. V. Barros, V. Debbas, M. L.

Santoro, E. A. D’Amico, T. J. C. Neiva, T. R. F. Rocha

PP-MO-035 EFFECT OF GLYCOPROTEIN IBALPHA CLUSTERING ON PLATELET CLEARANCE INVIVOD. E. van der Wal* (NL), S. Verhoef, J. W. N. Akkerman

PP-MO-036 ROLE OF GLYCOPROTEIN IBALPHA MOBILITY IN PLATELET FUNCTIOND. E. van der Wal* (NL), S. Verhoef, R. E. G. Schutgens, M. P. Peters, J. W. N. Akkerman

PP-MO-037 INTERRELATION BETWEEN PERIPHERAL PLATELET COUNT AND PLATELETACTIVATION DURING AND AFTER LIVER SURGERY IN PIGSA. H. Hussein, S. A. Kishta, E. A. A. Khaled* (EG)

PP-MO-038 EFFECT OF NYTROXYL AND NITRIC OXIDE ON THE OXIDATIVE STATUS IN NORMALPLATELETSE. Bermejo* (AR), M. F. Alberto, D. Saenz, S. Bari, M. A. Lazzari, R. Rosenstein

PP-MO-039 HUMAN FIBRINOGEN SUPPORTS NORMAL HEMOSTATIC FUNCTION IN A MOUSEPLATELET SYSTEME. S. Krystofiak* (US), J. A. Oliver

PP-MO-040 ACCURATE QUANTIFICATION OF MICROPARTICLES BY FLOW CYTOMETRY :IMPORTANT ISSUESF. Mullier* (BE), J. M. Dogné, N. Bailly, Y. Cornet, S. Robert, B. Chatelain

PP-MO-041 A ROLE FOR ADAP IN REGULATING INTEGRIN ALPHA2BETA1 IN PLATELETSG. E. Jarvis* (UK), S. Hamaia, D. Bihan, C. E. Rudd, R. W. Farndale

PP-MO-042 PLATELET PROTEIN DISULFIDE ISOMERASE IS RESTRICTED TO THE DENSETUBULAR SYSTEM AND NOT ASSOCIATED WITH THE CELL SURFACEH. E. van Nispen Tot Pannerden, S. M. van Dijk, V. Du, H. F. G. Heijnen* (NL)



Mon

day

Post

ers

PP-MO-043 REPLACEMENT OF PHE992 AND PHE993 WITH ALA IN THE INTEGRIN ALPHA IIBCYTOPLASMIC MOTIF CHANGES THE BINDING AFFINITY TO ITS INTERACTORSM. Raab, R. Moriarty, L. Parthasarathi, S. Allen, N. Moran, H. Daxecker* (IE)

PP-MO-044 PROTEIN INTERACTIONS WITH THE INTEGRIN ALPHA REGULATORY MOTIF: ACOMPARISON OF METHODSH. Daxecker* (IE), M. Raab, R. J. Edwards, D. Murphy, A. Treumann, N. Moran

PP-MO-045 A FUNCTIONAL POOL OF P2Y12 RECEPTORS EXPOSED UPON PLATELETACTIVATION PERSISTS IN MICE TREATED WITH HIGH DOSE CLOPIDOGREL, ANDCAN BE BLOCKED BY ELINOGREL, A DIRECT ACTING, REVERSIBLE P2Y12INHIBITORH. Haberstock-Debic* (US), P. Andre, S. M. Delaney, S. Mills, Y. Pak, D. R. Phillips, P. B.Conley

PP-MO-046 AMYLOID PRECURSOR PROTEIN PROTEOLYSIS IN HUMAN PLATELETS ISREGULATED BY CALMODULINI. Canobbio* (IT), S. Catricalà, L. Cipolla, C. Balduini, M. Torti

Platelet Adhesion and Cohesion I

PP-MO-047 PLATELET ADHESION TO PROTEINS IN MICROPLATES: FROM EXPERIMENTALRESEARCH TO CLINICAL EVALUATION OF PLATELET FUNCTIONA. C. Eriksson* (SE), P. A. Whiss

PP-MO-048 PLATELET ADHESION UNDER ARTERIAL FLOW CONDITIONS TO A VONWILLEBRAND FACTOR-BINDING PEPTIDE SEQUENCE PRESENT IN COLLAGEN IIIB. D. Maddox* (UK), G. E. Jarvis, R. W. Farndale

PP-MO-049 DIFFERENT BINDING CHARACTERISTICS OF THE INTEGRIN ALPHA 2 BETA 1 DUE TOI-DOMAIN MUTATIONSB. F. Iserbyt* (BE), S. Staelens, G. R. van de Walle, I. S. Salles, I. Pareyn, K. Vanhoorelbeke,H. Deckmyn

PP-MO-050 INFLUENCE OF THE NOVEL INTERACTORS SLAP-2 AND RHOGDI-α ON INTEGRINα2β1 BINDINGB. F. Iserbyt* (BE), S. Katsutani, S. Staelens, N. Vandeputte, I. Pareyn, K. Vanhoorelbeke, H.Deckmyn

PP-MO-051 PLATELET GPIIB/IIIA SUPPORTS ADHESION TO A NOVEL STREPTOCOCCUSGORDONII SURFACE PROTEINC. Keane* (IE), H. Petersen, M. Vickerman, D. Cox, H. F. Jenkinson, S. W. Kerrigan

PP-MO-052 OESTROGENIC AND ANDROGENIC MODULATION OF ITGA2 PROMOTER ACTIVITYAND INTEGRIN ALPHA 2 EXPRESSION LEVELF. M. Al-Zahrani* (UK), M. E. Daly, P. R. Winship

PP-MO-053 PLATELET ASSOCIATED TISSUE FACTOR ENHANCES THROMBUS FORMATION ONTHROMBOGENIC SURFACESI. Lopez-Vilchez* (ES), A. M. Galan, F. Navalon, L. Brunso, P. Molina, M. Diaz-Ricart, G.Escolar

PP-MO-054 CD9 TETRASPANIN IS A REPRESSOR OF GPIIB-IIIA ACTIVATIONJ. Kotha* (US), S. N. Hill, S. Grgurevich, S. Cholera, L. K. Jennings

PP-MO-055 INHIBITORY EFFECT OF QUERCETIN ON PLATELET SPREADING ON COLLAGEN ANDFIBRINOGEN AND ON MULTIPLE PLATELET KINASESL. Navarro-Núñez* (ES), M. Lozano, C. Martínez, V. Vicente, J. Castillo, J. Rivera



121

122

PP-MO-056 RELEASE OF PENTRAXIN-3 FROM ACTIVATED NEUTROPHIL MODULATES PLATELET-NEUTROPHIL CROSS-TALKN. Maugeri* (IT), R. Patrizia, D. Andrea, B. Barbara, C. Domenico, M. Attilio, M. Alberto, A. A.Manfredi

Novel Approaches to Understanding Platelet Biology I

PP-MO-057 THE PECULIAR PLATELET BEHAVIOR IN THE ARABIAN CAMEL (CAMELDROMEDARIUS)A. M. Abdelgadir* (SA), A. K. Al Ghomlas, A. Al Haidari, M. F. Husain, J. White

PP-MO-058 STRATEGY FOR THE USE OF SINGLE MOLECULE FORCE SPECTROSCOPY TOINVESTIGATE BINDING OF INTEGRIN ALPHA(2)BETA(1) AND COLLAGENA. M. C. Simpson* (UK), S. J. Attwood, D. Bihan, S. W. Hamaia, M. E. Welland, R. W.Farndale

PP-MO-059 POSSIBLE ROLE OF GNAS1 IMPRINTING IN A PROTHROMBOTIC PHENOTYPE:NESP55 HYPERMETHYLATION IN ISCHEMIC STROKE AT YOUNG AGEB. Izzi* (BE), R. Bouillon, K. Devriendt, C. van Geet, K. Freson

PP-MO-060 SOLUBLE AGONISTS AND SHEAR FORCES DIFFERENTIALLY ALTER THE LIQUIDORDER OF PLATELET MEMBRANES: QUANTITATIVE MEASURES AND PLATELETSUBPOPULATION DETECTIONB. Labarthe* (CA), A. Maguy, P. Theroux, A. Bonnefoy

PP-MO-061 ATORVASTATIN TREATMENT INCREASES THE LIQUID ORDER OF PLATELETMEMBRANESB. Labarthe* (CA), A. Maguy, R. Gallo, P. Theroux, A. Bonnefoy

PP-MO-062 REAL-TIME MEASUREMENT OF NON-LETHAL PLATELET THROMBOEMBOLICRESPONSES IN THE ANAESTHASIZED MICEC. Tymvios* (UK), C. Moore, M. Emerson

PP-MO-063 OPTIMIZATION OF INTRACELLULAR NITRIC OXIDE ASSESSMENT IN MONOCYTES BYFLOW CYTOMETRYN. C. C. Schachnik, V. Peruhype-Magalhães, F. Lucas-Junior, G. M. M. Paula, V. M. Freitas,O. A. Martins-Filho, L. M. S. Dusse* (BR)

PP-MO-064 TYPE OF AGONIST DETERMINES THE ROLE OF PLATELETS IN FIBRINOLYSIS.ASSEMBLY OF LRP-1, UPA, UPAR AND PAI-1 COMPLEX IN STIMULATED PLATELETSO. Panes* (CL), D. Flores, V. Matus, J. Pereira, D. Mezzano

PP-MO-065 MITOCHONDRIAL CONTROL OF PLATELET APOPTOSIS: ROLE OF THEMITOCHONDRIAL PERMEABILITY TRANSITION POREV. Leytin* (CA), A. Mutlu, D. J. Allen, A. V. Gyulkhandanyan, S. Mykhaylov, J. Freedman

Platelets and Systemic Disorders I

PP-MO-066 PLATELET TRANSFUSION INDEPENDENCE ACHIEVED WITH USE OF ATHROMBOPOIETIN RECEPTOR (TPO-R) AGONIST IN REFRACTORY SEVEREAPLASTIC ANEMIA (SAA)E. M. Bloch, A. Giermasz* (US), J. Knoche, P. F. Fogarty

PP-MO-067 THE D1424N AND R1933X MUTATIONS OF MYH9 RESULT IN AN ALTEREDPROPLATELET FORMATION BY HUMAN MEGAKARYOCYTESA. Pecci, A. Malara, S. Badalucco, V. Bozzi, C. L. Balduini, A. Balduini* (IT)

PP-MO-068 LACK OF ASPIRIN RESISTANCE IN PREGNANT WOMENA. Duncan* (US), A. Winkler, A. Ingle



Mon

day

Post

ers

PP-MO-069 A STUDY ON THE PATHOPHYSIOLOGY OF PREECLAMPSIA – THE PLATELETDYSFUNCTION. A SERIES OF 3 CASESM. Onisai, R. Vladareanu, A. Vladareanu* (RO), H. Bumbea, S. Radesi, M. Ciorascu, A.Nicolescu, I. Voican

PP-MO-070 TISSUE FACTOR EXPRESSION ON RECIPIENT PLATELETS AND PBMCS IS THE KEYFACTOR IN COAGULATION DYSFUNCTION IN PIG-TO-PRIMATE LIVERTRANSPLANTATIONC. Lin, B. Ekser, B. Gridelli, C. Long, G. Echeverri, H. Hara, M. Ezzelarab, D. Ayares, A.Dorling* (US), D. K. C. Cooper

PP-MO-071 DOES HEMODIALYSIS CAUSE BLOOD PLATELETS APOPTOSIS?A. Sobol, M. Kaminska, M. Stasiak, J. Szymanski, B. Walkowiak* (PL)

PP-MO-072 SELECTIVE SEROTONIN REUPTAKE INHIBITORS INFLUENCE AGONIST-INDUCEDPLATELET AGGREGATION. PRELIMINARY RESULTS FROM COMORBIDITY OFDEPRESSION AND CARDIOVASCULAR DISEASE STUDYE. Litinas* (US), J. Fareed, O. Iqbal

PP-MO-073 IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDREN WITH THERAPYMODALITIESG. Aydogan* (TR), M. Celik, D. Tugcu, Z. Salcioglu, F. Akici, A. Kiyak, A. Akcay, N. Canpolat,H. Sen

PP-MO-074 STUDIES FROM A PATIENT WITH A GRAY PLATELET SYNDROME: EVIDENCE FOR ANALPHA GRANULE LOCALIZATION OF OSTEOPROTEGERIN (OPG) IN PLATELETS ANDMEGAKARYOCYTES. EVALUATION OF MYELOFIBROSISM. E. Chollet* (FR), J. P. Brouland, C. Bal Dit Sollier, M. Lebret, F. Bauduer, L. Drouet, S.Bellucci

Mechanisms of Inherited and Acquired Defects of Platelet Number and Function I

PP-MO-075 MOLECULAR GENETIC BASIS OF INHERITED THROMBOCYTOPENIAA. O. Al-Marwani* (UK), D. Pearson, B. Wagner, A. C. Ong, M. Makris, M. E. Daly

PP-MO-076 IDENTIFICATION OF A NOVEL HOMOZYGOUS P2Y12 MUTATION IN A PATIENT WITH AMILD PLATELET-BASED BLEEDING DISORDERB. B. Dawood* (UK), M. Daly, M. Makris, A. Mumford, S. Watson, J. Wilde

PP-MO-077 FIRST CASE OF CONSTITUTIONAL GVI DEFECT IN A PATIENT HETEROZYGOUS FORTWO GPVI MUTATIONSB. Dumont* (FR), D. Lasne, C. Rothschild, M. Bouabdelli, V. Ollivier, N. Ajzenberg, B.Grandchamp, M. Jandrot-Perrus

PP-MO-078 PLATELET MYOSIN LIGHT CHAIN (MYL9) DEFICIENCY IN RUNX1 HAPLODEFICIENCY:MYL9 IS A DIRECT TRANSCRIPTIONAL TARGET OF RUNX1G. S. Jalagadugula* (US), G. Kaur, G. Mao, D. Dhanasekaran, A. K. Rao

PP-MO-079 ALPHA IIB CARRIES A NEW POLYMORPHISM, IN A+, INVOLVED IN NEONATALTHROMBOCYTOPENIAV. Jallu, M. Dusseaux, D. Granier, C. Kaplan, G. Bertrand* (FR)

PP-MO-080 PRESENCE OF PLATELET-ASSOCIATED ANTI-GPVI AUTOANTIBODIES ANDRESTORATION OF GPVI EXPRESSION IN PATIENTS WITH GPVI DEFICIENCYM. Akiyama, H. Kashiwagi* (JP), K. Todo, M. Moroi, M. C. Berndt, H. Kojima, Y. Kanakura, Y.Tomiyama

PP-MO-081 GATA-1,G208S MACROTHROMBOCYTES LACK TALINJ. G. White* (US), S. M. Burris, B. R. Crowe



123

124

PP-MO-082 VISUALIZING THE VON WILLEBRAND FACTOR/GLYCOPROTEIN IB-IX AXIS INPLATELET-TYPE VON WILLEBRAND DISEASEJ. A. Guerrero* (US), S. Russell, T. K. Gartner, B. Storrie, J. Ware

PP-MO-083 A CASE OF SEVERE THROMBOCYTOPENIA ASSOCIATED WITH PENTAMIDINE-DEPENDENT ANTIBODY SPECIFIC FOR GLYCPROTEIN IIBK. S. Heidinger* (DE), A. Giptner, R. Fischer, S. Santoso, G. Bein, U. Sachs

PP-MO-084 A POTENTIAL HOT SPOT FOR UNEQUAL HOMOLOGOUS RECOMBINATION WITHINEXON 24 OF THE MYH9 GENEK. Miyazaki* (JP), S. Kunishima, W. Fujii, M. Higashihara

PP-MO-085 DOMINANT INHERITANCE OF A NOVEL INTEGRIN BETA3 MUTATION ASSOCIATEDWITH HEREDITARY MACROTHROMBOCYTOPENIA AND PLATELET DYSFUNCTIONP. Gresele, E. Falcinelli, L. Bury* (IT), S. Giannini, P. D’Adamo, A. D’Eustacchio, T. Corazzi,A. Mezzasoma, F. di Bari, G. Guglielmini, L. Cecchetti, P. Noris, C. Balduini, A. Savoia

PP-MO-086 DOSE-DEPENDENT EFFECTS OF ASPIRIN ON PLATELET FUNCTIONM. Sobieraj-Teague* (CA), J. J. I. Weitz, J. J. S. Ginsberg, D. D. Sloane, S. S. Anand, J. J.W. Eikelboom

Basic Biology of ADAMTS13 I

PP-MO-087 DEPLETION OF NEUTRALIZING ANTI-ADAMTS13 ANTIBODY FROM ACQUIRED TTPPATIENT PLASMA BY ADAMTS13-SPECIFIC AFFINITY ADSORPTIONB. Plaimauer* (AT), S. Skalicky, M. Schmidt, M. Hasslacher, F. Scheiflinger

PP-MO-088 IN VITRO AND IN VIVO ACTIVITY OF TRUNCATED MURINE ADAMTS13 MUTANTSB. de Maeyer* (BE), S. F. de Meyer, H. B. Feys, H. Deckmyn, K. Vanhoorelbeke

PP-MO-089 STABILISATION OF THE VWF A2 DOMAIN BY INTRODUCTION OF A DISULPHIDEBOND PREVENTS BINDING TO AND CLEAVAGE BY ADAMTS13B. M. Luken* (UK), L. Y. N. Winn, J. Emsley, D. A. Lane, J. T. B. Crawley

PP-MO-090 VON WILLEBRAND FACTOR IS A MAJOR DETERMINANT OF ADAMTS-13 DECREASEDURING MOUSE SEPSIS INDUCED BY CECUM LIGATION AND PUNCTUREC. Dunois-Larde* (FR), N. Lerolle, I. Badirou, D. G. Motto, G. Hill, P. Bruneval, J. L. Diehl, C.V. Denis, D. Baruch

PP-MO-091 GLOBULAR VWF INTERACTION WITH C-TERMINAL DOMAINS OF ADAMTS13SUGGESTS A TWO SITE INTERACTION MECHANISM LEADING TO PROTEOLYSISS. Zanardelli, C. K. W. Chion, P. J. Lenting, E. Groot, D. A. Lane* (UK)

PP-MO-092 INTRAPLATELET LOCALIZATION OF ADAMTS13I. Garagiola, R. Lombardi, A. Artoni, R. de Cristofaro, M. Cattaneo, F. Peyvandi* (IT)

PP-MO-093 IMAGING ANALYSIS OF PLATELET THROMBUS FORMATION IN ADAMTS13-MUTANTMICEF. Banno* (JP), A. K. Chauhan, K. Kokame, J. Yang, S. Miyata, D. D. Wagner, T. Miyata

PP-MO-094 THE ADAMTS13 S119F MUTATION DECREASES ENZYME ACTIVITY BY ALTERINGSUBSITE ORIENTATIONH. B. Feys* (BE), I. Pareyn, R. Vancraenenbroeck, H. Deckmyn, M. de Maeyer, C. van Geet,K. Vanhoorelbeke



Mon

day

Post

ers

Novel Mechanisms of Antiplatelet Therapy I

PP-MO-095 ONGOING TREATMENT WITH CANGRELOR, BUT NOT TICAGRELOR, IS ASSOCIATEDWITH A SIGNIFICANT REDUCTION IN THE EFFICACY OF CLOPIDOGREL IN AN EX-VIVO CANINE MODELA. Ravnefjord* (SE), P. Delavaux, J. Tornvall, J. Weilitz, B. M. Emanuelsson, J. J. J. vanGiezen

PP-MO-096 THE EFFECTS OF MAJOR IN VIVO METABOLITES OF PRASUGREL ON HUMANPLATELET AGGREGATIONA. Sugidachi* (JP), Y. Niitsu, T. Ogawa, J. A. Jakubowski, M. Hasegawa, M. Hashimoto, K.Hagihara, A. Kurihara

PP-MO-097 THE EFFECT OF PLATELET AND PLASMA OXLDL AND PLATELET CHOLESTEROL ONTHE ASA-MEDIATED BLOOD PLATELET INHIBITION AND PLATELET PROTEINACETYLATION IN ATORVASTATIN-TREATED HYPERCHOLESTEROLEMIC PATIENTSB. Luzak* (PL), M. Boncler, J. Rywaniak, R. Wilk, L. Stanczyk, J. Rysz, C. Watala

PP-MO-098 INHIBITION OF PLATELET AGGREGATION AUGMENTS FIBRIN CLOT FORMATION INLARGE ARTERIES AND VEINSB. C. Cooley* (US)

PP-MO-099 CELLULAR BASES FOR THE EFFICACY OF EPOPROSTENOL IN PULMONARYHYPERTENSIONM. Crescente, C. Tamburrelli, M. Barisciano, W. Zamboni, M. B. Donati, G. de Gaetano, C.Cerletti* (IT)

PP-MO-100 SIMULTANEOUS DIRECT FACTOR Xa INHIBITION AND ACTIVATED PLATELETBLOCKAGE ALLOWS SUPERIOR ANTICOAGULATION WITHOUT BLEEDING TIMEPROLONGATIONC. E. Hagemeyer* (AU), S. U. Eisenhardt, N. Bassler, P. Stoll, M. Schwarz, Y. C. Chen, I.Ahrens, C. Bode, K. Peter

PP-MO-101 HARNESSING THE ANTIPLATELET EFFECTS OF PROSTAGLANDIN E2 BY EP3RECEPTOR BLOCKADED. Iyu* (UK), S. Heptinstall

PP-MO-102 SUPPRESSION OF PLATELET AGGREGATION CAUSED BY GLUCOSAMINESUPPLEMENTD. L. McGlasson* (US), G. A. Fritsma

PP-MO-103 STUDY OF PLATELET ACTIVITY IN ROUTINE AND ACUTE CORONOARYANGIOGRAPHYD. L. McGlasson* (US), G. Patino, B. J. Rubal, A. D. Shah

PP-MO-104 PLATELET MRP4 OVEREXPRESSION IS RESPONSIBLE FOR REDUCED CAMP-DEPENDENT INHIBITORY ACTION ON PLATELET FUNCTIONE. Trifiro’, A. Borgognone, D. di Pietrantonio, D. Reale, F. M. Pulcinelli* (IT)

PP-MO-105 SALVIANOLIC ACID A INHIBITS PLATELET ACTIVATION AND ARTERIAL THROMBOSISVIA THE INHIBITION OF AKT PHOSPHORYLATIONH. Hu* (CN), L. Zhu, Z. Huang, Y. Zhao, N. Li

PP-MO-106 P2Y12 ANTAGONISM INHIBITS SERUM THROMBOXANE GENERATION: IMPLICATIONSFOR COMBINATION THERAPY WITH ASPIRINK. Bhavaraju* (US), S. Kim, Y. Mao, J. Jin, S. Kunapuli



125

126

Extrinsic Pathway of Coagulation I

PP-MO-107 FUNCTIONAL BLOOD COAGULATION ASSAYS BASED ON THE LOCI® TECHNOLOGYA. Kappel* (DE), G. Christ

PP-MO-108 ALIMENTARY LIPEMIA IS ASSOCIATED WITH INCREASED PLASMA VIIaATCONCENTRATION AND THROMBIN GENERATIONA. Silveira* (SE), A. Carlo, B. J. Woodhams, A. Hamsten

PP-MO-109 HUMAN ALTERNATIVELY SPLICED TISSUE FACTOR IS NOT SECRETED AND DOESNOT TRIGGER COAGULATIONA. N. Böing* (NL), C. M. Hau, A. Sturk, R. Nieuwland

PP-MO-110 INR IN LIVER DISEASE: AN ISI DERIVED FROM LIVER DISEASE PATIENTS IMPROVESAGREEMENT BETWEEN INRS WITH DIFFERENT REAGENTSA. M. Sermon* (UK), J. M. Smith, R. Maclean, S. Kitchen

PP-MO-111 DISTURBED BLOOD FLOW INDUCES EROSIVE INJURY OF TISSUE FACTOR-RICHINTIMA AND PROMOTES THROMBUS FORMATIONT. Sumi, A. Yamashita* (JP), S. Matsuda, K. Nishihira, E. Furukoji, H. Sugimura, T. Imamura,K. Kitamura, S. Goto, Y. Asada

PP-MO-112 HOW TO OVERCOME THE INNER FILTER EFFECT IN FLUORESCENT SUBSTRATEACTIVITY ASSAYS?A. Carlo* (FR), C. Vauthier, E. Lebra, T. Fürle, M. Clabon, D. Drilhole, S. Kerdélo, G. Quentin,M. Gonidec, E. Arnaud, B. J. Woodhams

PP-MO-113 NMR STUDIES OF TISSUE FACTOR: SAMPLE PREPARATION AND PARTIALCHEMICAL SHIFT ASSIGNMENTSJ. M. Boettcher, B. D. Lahood, J. H. Morrissey, C. M. Rienstra* (US)

PP-MO-114 HYPERCOAGULABILITY IS INDEPENDENTLY ASSOCIATED WITH KYNURENINEPATHWAY ACTIVATION IN DIALYZED URAEMIC PATIENTSD. Pawlak* (PL), M. Mysliwiec, K. Pawlak

PP-MO-115 PRACTICE IN POINT OF CARE INR TESTING-REVIEW OF QUESTIONNAIRES FROM2001, 2004 AND 2007 OF UK NEQAS PARTICIPANTSD. P. Kitchen* (UK), S. Munroe, S. Kitchen, I. Jennings, T. Woods, I. Walker

PP-MO-116 ESTABLISHMENT OF AN EXTERNAL QUALITY ASSESSMENT PROGRAMME FORUSERS OF ACTIVATED CLOTTING TIMED. P. Kitchen* (UK), S. Munroe, S. Kitchen, I. Jennings, T. Woods, I. Walker

PP-MO-117 EPITOPE LOCALISATION AND FUNCTIONAL IMPACT OF A MONOCLONAL ANTIBODYRECOGNISING V158D/E296V/M298Q-FACTOR VIIaE. Persson* (DK)

PP-MO-118 SIGNIFICANCE OF COMPLETE GAMMA-CARBOXYLATION FOR DEVELOPMENT OF ALONG-ACTING GLYCOPEGYLATED COAGULATION FACTOR IX VARIANTJ. R. Bjelke* (DK), P. K. Holm, M. B. Hermit, A. A. Pedersen, J. M. Petersen, B. Kjær, T. N.Krogh, M. Nielsen, K. Vinther, H. Ostergaard

PP-MO-119 PREPARATION OF RECOMBINANT BOVINE TISSUE FACTOR EXPRESSED AS ANINTEGRAL MEMBRANE PROTEIN IN SILKWORM USING A BACULOVIRUSEXPRESSION SYSTEM, AND ITS APPLICATION IN AN OWREN-TYPE (II-VII-X, BOVINECOMBINED) REAGENTM. Okuda* (JP), T. Taniguchi, K. Kishi, Y. Hamaguchi, H. Nagaya, S. Murayama, A. Usami

PP-MO-120 ANTICOAGULATION OF A PATIENT WITH HYPERTROPHIC CARDIOMYOPATHY ANDFACTOR VII DEFICIENCYS. J. Davidson* (UK), N. Turner, L. Tillyer



Mon

day

Post

ers

PP-MO-121 CLEARANCE OF ACTIVATED RECOMBINANT HUMAN COAGULATION FACTOR VII(RFVIIa) IN RAT AND MOUSE LIVERT. Seested Johansen* (DK), H. M. Nielsen, E. I. Christensen, R. S. Appa

PP-MO-122 REABSORPTION OF RECOMBINANT ACTIVATED VII (RFVIIa) IN RENAL PROXIMALTUBULES OF THE KIDNEY IN RODENT MODELST. Seested Johansen* (DK), E. I. Christensen, C. Jacobsen, R. S. Appa

Intrinsic Pathway of Coagulation I

PP-MO-123 INHIBITION OF FACTOR XI REDUCES THROMBUS FORMATION IN RABBIT JUGULARVEIN UNDER CONDITIONS OF ENDOTHELIAL DENUDATION AND/OR BLOOD STASISA. Yamashita* (JP), M. Takahashi, S. Moriguchi-Goto, C. Sugita, S. Matsuda, Y. Sato, T.Kitazawa, K. Hattori, Y. Asada

PP-MO-124 THROMBELASTOGRAPHIC DETECTION OF FACTOR XII-LIKE ACTIVITY IN CITRATEDWHOLE BLOOD SAMPLES, BUT NOT IN PLASMA OF THE CHICKEN WHITE LEGHORNB. C. Prezoto* (BR), C. S. S. S. Silva, M. M. Rocha, G. Motta, T. R. F. Rocha

PP-MO-125 CONTINUOUS INFUSION IN THE MANAGEMENT OF SEVERE BLEEDING EPISODES INHAEMOPHILIA A CHILDRENB. Pautard Muchemble, B. Pautard* (FR), V. Li Thiao Te, T. Tinot, J. Notheaux Micheli, B.Roussel

PP-MO-126 GLYCOPROTEIN IB-ALPHA MODULATES FACTOR IXa-MEDIATED FACTOR Xa-GENERATION ON THE ACTIVATED PLATELET SURFACEC. Weeterings* (NL), P. G. de Groot, T. Lisman

PP-MO-127 FACTOR VIII CONTRIBUTES TO PLATELET-FIBRIN THROMBUS FORMATION VIATHROMBIN GENERATION UNDER LOW SHEAR CONDITIONSC. Sugita* (JP), A. Yamashita, S. Moriguchi-Goto, E. Furukoji, M. Takahashi, A. Harada, T.Soeda, T. Kitazawa, K. Hattori, S. Tamura, Y. Asada

PP-MO-128 FOUR NOVEL KLKB1 MUTATIONS IN SEVEN FAMILIES WITH SEVEREPREKALLIKREIN DEFICIENCYC. Geisen* (DE), J. Farac, D. Delev, M. Compes, B. Just, J. G. Kadar, A. Siegemund, B.Zieger, E. Seifried, J. Oldenburg

PP-MO-129 IMPACT OF ANALYTICAL VARIABLES ON INTRINSIC FACTOR ASSAYS RESULTS:NORTH AMERICAN SPECIAL COAGULATION LABORATORY ASSOCIATION(NASCOLA) PROFICIENCY TESTING FROM 2003-2007D. D. Castellone* (US), E. E. I. B. Peerschke

PP-MO-130 HEREDITARY ANGIOEDEMA DUE TO MISSENSE MUTATIONS IN THE COAGULATIONFACTOR XII GENE - THREE NOVEL CASESE. Aygören Pürsün* (DE), G. Dewald, E. Rusicke, I. Martinez-Saguer, W. Kreuz

PP-MO-131 PHOSPHATIDYLSERINE-INDEPENDENT PLATELET BINDING SITES FOR FACTOR VIIIG. E. Gilbert* (US), J. Shi, C. Bai, J. Lu, J. T. Rasmussen, C. W. Heegaard

PP-MO-132 THE RATIO BETWEEN THE ACTIVITIES OF COAGULATION FACTOR XII AND C1ESTERASE INHIBITOR MAY BE A RISK PREDICTOR FOR ANGIOEDEMAG. Moessmer* (DE)

Anticoagulant Pathways I

PP-MO-133 PLASMA PREDILUTION WITH ADDITION OF DEPLETED PLASMA IN A PT-REAGENTIMPROVES THE AGREEMENT BETWEEN DIFFERENT PROTHROMBIN TIME METHODSA. Osman* (SE), T. L. Lindahl



127

128

PP-MO-134 SEVERE BIOCHEMICAL AND FUNCTIONAL EFFECTS IN ANTITHROMBIN CAUSED BYACROLEINA. Ordóñez* (ES), S. Pedersen, J. A. Guerrero, A. Miñano, R. Teruel, C. Martínez, L.Velázquez, S. R. Kristensen, V. Vicente, J. Corral, I. Martínez-Martínez

PP-MO-135 THE INFLUENCE OF CYP2C9 GENETIC POLYMORPHISMS ON ORAL ANTICOAGULANTDOSE REQUIREMENTS IN THE LEBANESE POPULATIONN. Zgheib, M. Esmerian, Z. Mitri, G. Zaatari, S. Alam, H. Skouri, R. Mahfouz, A. Taher* (LB)

PP-MO-136 ASSAY DEPENDENT VARIATIONS IN THE USP POTENCY STANDARDIZEDUNFRACTIONATED HEPARINSA. Gray* (US), D. Hoppensteadt, L. Myers, O. Iqbal, C. Adiguzel, J. Fareed

PP-MO-137 COMPARISON OF A NOVEL ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHYTANDEM MASS SPECTROMETRY (UPLC-MS/MS) METHOD WITH THE ACTIVATEDPARTIAL THROMBOPLASTIN TIME (APTT) AND PROTHROMBIN TIME (PT)A. M. Winkler* (US), M. L. Synder, A. Duncan, R. J. Molinaro

PP-MO-138 DOWN-REGULATION OF PROTEIN S EXPRESSION BY 17BETA-ESTRADIOL IN HEPG2CELLSA. Suzuki* (JP), N. Sanda, K. Makita, Y. Miyawaki, Y. Fujimori, T. Yamada, A. Takagi, T.Murate, H. Saito, T. Kojima

PP-MO-139 DIFFERENTIAL THROMBIN GENERATION INHIBITION BY BRANDED AND GENERICLOW MOLECULAR WEIGHT HEPARINS (LMWHS) AS STUDIED BY USINGFLUORESCENCE SUBSTRATE BASED KINETIC METHODC. Adiguzel* (US), E. Litinas, J. Cunanan, D. Hoppensteadt, J. M. Walenga, J. Fareed

PP-MO-140 GENERIC VERSIONS OF ARGATROBAN CAN BE DIFFERENTIATED FROM BRANDEDARGATROBAN IN THE THROMBIN GENERATION ASSAYS (TGA)C. Adiguzel* (US), E. Litinas, O. Iqbal, J. Cunanan, W. Jeske, D. Hoppensteadt, J. Walenga,J. Fareed

PP-MO-141 TESTSTRIP-BASED GENOTYPING TO ASSIST IN THE PREDICTION OFANTICOAGULANT DOSE REQUIREMENTH. Puehringer, G. Klose, B. Schreyer, W. Krugluger, R. M. Loreth, C. Oberkanins* (AT)

PP-MO-142 VITAMIN K DEFICIENCY IN INJECTING DRUG USERSD. Dawson* (UK)

PP-MO-143 ACTIVATION OF PREKALLIKREIN BY CONTAMINATED HEPARINS, ISOLATEDCONTAMINANT AND RELATED HYPERSULFATED CHONDROITIN SULFATEPREPARATIONS: PHARMACOLOGIC IMPLICATIONSD. Hoppensteadt* (US), O. Iqbal, H. Messmore, C. Adiguzel, V. Bansal, J. Fareed

PP-MO-144 FIRST TYPE II ANTITHROMBIN DEFICIENCY CAUSED BY A LARGE INSERTION.STRUCTURAL AND FUNCTIONAL RELEVANCEI. Martínez-Martínez* (ES), T. Sevivas, N. Gómez, A. Ordóñez, A. Miñano, A. I. Antón, J.Padilla, M. E. de La Morena, R. González-Conejero, V. Vicente, J. Corral

PP-MO-145 ENCAPSULATION OF HEPARIN IN POLYMERIC NANOPATICLESC. Pazzini, P. D. Marcato, N. Durán, S. A. L. Montalvão, N. F. Höehr, J. M. Annichino-Bizzacchi* (BR)



Mon

day

Post

ers

Cofactors and Proteases I

PP-MO-146 THE INVESTIGATION OF PROTEIN-PROTEIN INTERACTIONS IN HEMOSTATIC SYSTEMUSING ENZYME ELECTROPHORESIS METHODA. I. Zhukova* (MN), I. Krasnobrysha, O. M. Savchuk, G. L. Volkov

PP-MO-147 INDUSTRIAL PURIFYING METHOD OF THROMBIN-LIKE ENZYMEB. B. Jonj* (MN), T. P. Buhan

PP-MO-148 PATIENTS WITH ENHANCED CLOT SOLUBILITY IN ACID CONDITIONS REQUIREDIFFERENTIATION BETWEEN RAISED PLASMA LEVELS OF THE ASPARTICPROTEASE PEPSINOGEN I AND INHIBITORY ANTIBODIES TO FACTOR XIIIE. M. Duncan* (AU), B. Dale, J. V. Lloyd

PP-MO-149 HAEMOSTASIS AFFECTING PROTEASES FROM VIPERA LEBETINA SNAKE VENOME. Siigur* Estonia, K. Tonismagi, M. Samel, H. Vija, K. Trummal, A. Aaspollu, J. Subbi, J.Siigur

PP-MO-150 RECOMBINANT HUMAN COAGULATION FACTOR IX (RFIX): INFLUENCE OF SERINEPHOSPHORYLATION AND TYROSINE SULFATION ON PHARMACOKINETICPROPERTIES IN FIX-KNOCK-OUT MICEE. Böhm* (AT), M. Dockal, M. Hasslacher, C. Konetschny, A. Mitterer, E. M. Muchitsch, M.Reiter, F. Scheiflinger

PP-MO-151 VARIATION AND CONSERVATION IN THE B-DOMAIN OF FACTOR VH. L. Vos* (NL), A. van Wijngaarden

PP-MO-152 CROSS-REACTIVITY OF RABBIT ANTI-BOVINE THROMBIN IGGS WITH HUMAN A-THROMBIN AND A RECOMBINANT VERSION OF HUMAN THROMBIN (RECOTHROMTM)H. Zhu* (US), D. Hoppensteadt, R. Wahi, J. Fareed

PP-MO-153 RELATIVE PURITY OF IMPROVED TOPICAL BOVINE THROMBIN PREPARATIONSH. Zhu* (US), D. Hoppensteadt, R. Wahi, J. Fareed

PP-MO-154 COMPARATIVE IMMUNOGENIC POTENTIALS OF CRUDE AND PURIFIED BOVINETHROMBIN PREPARATIONSH. Zhu* (US), D. Hoppensteadt, O. Iqbal, R. Wahi, J. Fareed

PP-MO-155 ROLE OF THE INTERACTION BETWEEN THE FACTOR VIII A1 DOMAIN CA2+ BINDINGSITE AND C2 DOMAIN ON ACTIVITY AND STABILITYH. Wakabayashi* (US), A. E. Griffiths, P. J. Fay

PP-MO-156 DEFINITION OF THE THROMBIN-BINDING SITE ON THE HUMAN FACTOR VIII C2DOMAINJ. C. Lin* (US), J. Schuman, S. M. Nakaya, K. P. Pratt

PP-MO-157 THROMBIN CLEAVAGE AT ARG1689 INFLUENCES HEAVY CHAIN CLEAVAGE DURINGACTIVATION OF FACTOR VIIIJ. L. Newell* (US), P. J. Fay

PP-MO-158 AN ENGINEERED COAGULATION FACTOR IX WITH AUGMENTED ACTIVITY: USINGMOUSE MODELS TO CHARACTERIZE THE CLOTTING FUNCTION IN VIVO ANDFURTHER EVALUATE THE THROMBOSIS RISKC. Y. Kao, C. N. Lin, I. S. Yu, S. R. Lin, M. H. Tao, H. L. Wu, G. Y. Shi, C. C. Fang, S. W. Lin*(TW)

PP-MO-159 SEQUENCE IN THE FIRST INTRON OF FXIII A SUBUNIT GENE IS INVOLVED INREGULATING THE EXPRESSION OF FXIII A SUBUNIT GENEW. Cai* (CN), L. L. H. Huang, X. X. L. Liu, G. G. L. Li



129

130

Inhibitors of Coagulation I

PP-MO-160 INHIBITORS IN CHILDREN DURING SECONDARY PROPHYLAXIS FOR HEMOPHILIA INA DEVELOPING COUNTRYA. Linares* Colombia, M. Aristizabal, I. Sarmiento, S. Castaño, M. Cortes

PP-MO-161 THE COMPLETE ISOLATED N-TERMINAL EXTENSION OF HEPARIN COFACTOR II ISREQUIRED FOR MAXIMAL THROMBIN BINDINGA. J. Boyle* (CA), V. Bhakta, W. P. Sheffield

PP-MO-162 MONITORING OF RIVAROXABAN: SUITABILITY OF A WELL-ESTABLISHEDCHROMOGENIC ANTI-FACTOR Xa ASSAYA. Karst* (DE), B. Bakowski-Enzian, E. Perzborn

PP-MO-163 LOW INHIBITOR INCIDENCE IN PREVIOUSLY UNTREATED HAEMOPHILIA A PATIENTSTREATED WITH OCTANATEA. Klukowska* (PL), P. Laguna, M. Jansen

PP-MO-164 CAN PROTEIN C AND PROTEIN S DEFICIENT PATIENTS BE IDENTIFIED DURINGORAL ANTICOAGULANT TREATMENT?A. B. Münster* (DK), J. J. Sidelmann, J. Gram, J. Jespersen

PP-MO-165 HEPARIN SULFATE FROM HUMAN FOLLICULAR FLUID CONTAINS ABUNDANT 3-O-SULFATED CHAINS WITH HIGH ANTICOAGULANT ACTIVITYA. I. de Agostini* (CH), A. Fischer, N. W. Shworak, L. Zhang, R. J. Linhardt

PP-MO-166 SUCCESSFUL MANAGEMENT OF MAJOR SURGERY WITH IVIG IN A PATIENT WITH APROGRESSIVE ACQUIRED VON WILLEBRAND FACTOR INHIBITOR ON THEBACKGROUND OF HEREDITARY TYPE 1 VON WILLEBRAND’S DISEASEB. Madan* (UK), G. W. Moore, P. Earnshaw, D. A. Gurney

PP-MO-167 RISK OF BLEEDING WITH DABIGATRAN ETEXILATE IN PATIENTS UNDERGOINGMAJOR ORTHOPAEDIC SURGERY IS NOT INCREASED BY CONCOMITANT USE OFNON-STEROIDAL ANTI-INFLAMMATORY DRUGS OR ACETYLSALICYLIC ACIDB. I. Eriksson* (SE), A. A. Kurth, R. J. Friedman, J. M. Schnee, A. Clemens, H. Noack, J. A.Caprini

PP-MO-168 RESULTS OF THE ECAT WORKSHOP ON THE DETECTION OF COAGULATIONINHIBITORSB. Verbruggen* (NL), P. Meijer

PP-MO-169 NON-PARALLELISM IN THE ONE-STAGE FACTOR ASSAYS IS A PHENOMENON OFLUPUS ANTICOAGULANTS AND NOT OF PARTICULAR FACTOR INHIBITORSJ. Ruinemans-Koerts, B. Verbruggen* (NL), I. Peterse-Stienissen

PP-MO-170 COMPARISON OF DIFFERENT MONITORING METHODS FOR DIRECT THROMBININHIBITOR, LEPIRUDINB. Salmela* Finland, L. Joutsi-Korhonen, R. Lassila

PP-MO-171 ACQUIRED HAEMOPHILIA A IN CHINA:REVIEW AND META-ANALYSIS FOCUSED ONCLINICAL CHARACTERS AND MANAGEMENTC. Zheng* (CN), J. Wu, K. Ding, W. Zhu, X. Cai

PP-MO-172 NANIPROIN, A NOVEL PROTHROMBINASE COMPLEX INHIBITOR FROM NAJANIGRICOLLIS VENOMC. Y. Koh* (SG), B. H. See, R. Kini

PP-MO-173 HEREDITARY ANTITHROMBIN DEFICIENCY CAUSED BY HETEROZYGOUSCAMBRIDGE II MUTATION IN COMBINATION WITH A LARGE GENE DELETIONC. Orlando* (BE), K. Jochmans, W. Lissens, I. Liebaers, M. de Waele



Mon

day

Post

ers

PP-MO-174 IDENTIFICATION OF LARGE GENE DELETIONS IN THE ANTITHROMBIN GENE BYMULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATIONC. Orlando* (BE), K. Jochmans, W. Lissens, I. Liebaers, M. de Waele

PP-MO-175 ANTICOAGULANT ACTIVITIES OF EP42675, SYNTHETIC DIRECT THROMBIN ANDINDIRECT FACTOR Xa INHIBITORC. Bal Dit Sollier* (FR), E. Neuhart, C. Krezel, M. Petitou, L. Drouet

PP-MO-176 ENHANCEMENT OF CLOT LYSIS BY ANTICOAGULANTS: DABIGATRAN IS MOREEQUAL THAN HEPARINC. T. Ammollo* (IT), F. Semeraro, C. Carrieri, R. Galasso, N. Semeraro, M. Colucci

PP-MO-177 UNFRACTIONATED HEPARIN PROMOTES ELIMINATION OF HUMAN RECOMBINANTMAMMALIAN TFPI IN A RAT MODELC. Øie* (NO), E. Brodin, I. Hilden, R. Appa, B. Smedsrød, J. B. Hansen

PP-MO-178 SOLUBLE EPCR INHIBITS THE PROCOAGULANT ACTIVITIES OF FACTOR VIIa: ANEXPLANATION FOR ITS ROLE IN THROMBOSISC. Puy* (ES), J. Lopez-Sagaseta, J. Hermida, R. Montes

PP-MO-179 DIRECT LOW-MOLECULAR FXa- AND/OR FIIa-INHIBITORS HAVE NO RISK FOR HITTYPE II: EFFECTS OF PF4 ON THROMBIN GENERATION INHIBITED BYRIVAROXABAN, DABIGATRAN AND NEW DUAL FIIA/FXa-INHIBITORSD. Pillitteri* (DE), T. Scholz, D. Westrup, M. Krause, C. M. Kirchmaier

PP-MO-180 ACQUIRED FACTOR XIII DEFICIENCY IN A CHILDC. Y. Hu, R. Saksena, R. Ricafort, D. Manwani* (US)

PP-MO-181 MECHANISMS OF INHIBITION OF FACTOR XIa AND TRYPSIN BY PROTEASE NEXIN 2AND BASIC PANCREATIC TRYPSIN INHIBITORD. Navaneetham* (US), D. Sinha, P. N. Walsh

PP-MO-182 NEW THROMBIN INHIBITORS: STRATEGY OF MOLECULAR DESIGN ANDEXPERIMENTAL TESTINGE. I. Sinauridze* (RU), A. N. Romanov, I. V. Gribkova, O. A. Kondakova, A. S. Gorbatenko, Y.V. Kuznetsov, A. A. Bogolyubov, M. Y. Manakov, V. B. Sulimov, F. I. Ataullakhanov

PP-MO-183 PROTHROMBIN COMPLEX CONCENTRATE REVERSES THE EFFECTS OF HIGH-DOSERIVAROXABAN IN RATSE. Perzborn* (DE), H. Tinel

PP-MO-184 INHIBITION OF THROMBIN GENERATION IN HUMAN PLASMA BY RIVAROXABAN, ANORAL, DIRECT FACTOR Xa INHIBITORE. Perzborn* (DE), M. Harwardt

PP-MO-185 ASSESSMENT OF FACTOR Xa CHROMOGENIC ASSAYS FOR MEASURING THEPHARMACODYNAMICS OF RIVAROXABAN – AN ORAL, DIRECT FACTOR XaINHIBITORE. Perzborn* (DE), M. Hardwardt, M. M. Samama

PP-MO-186 LOW PLASMA LEVELS OF FULL-LENGTH TISSUE FACTOR PATHWAY INHIBITOR INTYPE I PROTEIN S-DEFICIENT INDIVIDUALSE. Castoldi* (NL), P. Simioni, D. Tormene, J. Rosing, T. M. Hackeng

PP-MO-187 DESIGN OF A RECOMBINANT ANTITHROMBIN VARIANT AS A POTENT ANTIDOTEFOR FONDAPARINUX AND OTHER HEPARIN DERIVATIVESE. P. Bianchini* (FR), V. Picard, J. Fazavana, D. Borgel

PP-MO-188 COMPONENTS OF VARIABILITY OF THE EFFECT OF ACTIVATED PARTIALTHROMBOPLASTIN TIME VS. ANTI-FACTOR Xa ON UNFRACTIONATED HEPARINDOSE ADJUSTMENTSF. Guerrero* (FR), A. Faucher, V. Diemert, S. Voisin, P. Sié, A. Bura Rivière



131

132

PP-MO-189 PHOSPHOINOSITIDES INTERACT WITH PROTEIN C INHIBITOR (PCI)F. Wahlmüller* (AT), M. Furtmüller, B. Sokolikova, B. R. Binder, M. Geiger

PP-MO-190 NEBULIZED RECOMBINANT HUMAN TFPI ATTENUATES PULMONARYCOAGULOPATHY DURING STREPTOCOCCUS PNEUMONIAE PNEUMONIAF. E. van den Boogaard* (NL), J. H. Hofstra, C. van ‘t Veer, J. J. T. H. Roelofs, M. M. Levi, T.van der Poll, M. J. Schultz

PP-MO-191 NEBULIZED RECOMBINANT HUMAN TFPI ATTENUATES COAGULATION AND LIMITSBACTERIAL OUTGROWTH IN A RAT MODEL OF GRAM–NEGATIVE PNEUMONIAF. E. van den Boogaard* (NL), J. J. H. Hofstra, C. van ‘t Veer, J. J. T. H. Roelofs, M. M. Levi,T. van der Poll, M. J. Schultz

PP-MO-192 IDENTIFICATION OF MUTATIONS IN THE PROTEIN C GENE ASSOCIATED WITH THERISK OF VENOUS TROMBOSISP. Medina, S. Navarro, A. Vayá, F. Ferrando, M. T. Contreras, A. Estellés, F. Espana* (ES)

PP-MO-193 INFLUENCE OF THE HAPLOTYPE 1 OF THE ENDOTHELIAL PROTEIN C RECEPTORGENE ON THE CIRCULATING ACTIVATED PROTEIN C LEVELS DURING ORALANTICOAGULANT THERAPYS. Navarro, P. Medina, F. Ferrando, A. Vayá, M. T. Contreras, A. Estelles, F. Espana* (ES)

PP-MO-194 ANTI-FIBROGENIC EFFECTS OF THE DIRECT THROMBIN INHIBITOR DABIGATRAN INLUNG FIBROBLASTSG. S. Bogatkevich* (US), R. M. Silver

PP-MO-195 A C.-39C>T NOVEL POINT MUTATION IN THE 5’-UT REGION OF PROS-1 GENEASSOCIATED WITH PS DEFICIENCYS. Labrouche, C. Vergnes, G. Freyburger* (FR)

PP-MO-196 MLPA SCREENING OF THE PROS1 GENE: FINDING OF A NEW LARGE DELETION INTHREE PATIENTS WITH PROTEIN S DEFICIENCYS. Labrouche, C. Vergnes, C. Conri, J. Constans, G. F. Freyburger* (FR)

PP-MO-197 COMPARISON OF RECOMBINANT AND PLASMA-DERIVED ANTITHROMBINBIODISTRIBUTION IN VIVOL. R. Berry, B. Thong, H. M. Atkinson* (CA), A. K. C. Chan

PP-MO-198 EFFECT OF FOOD ON DISPOSITION OF DU-176B: PHARMACOKINETIC ANDPHARMACODYNAMIC EFFECTS IN CAUCASIAN AND JAPANESE HEALTHYVOLUNTEERSJ. Mendell* (US), M. Tachibana, M. Shi, S. Kunitada

PP-MO-199 RESISTANCE TO HEPARINS IN A SUBJECT WITH ANTITHROMBIN BUDAPEST IIIP. C. Cooper, K. P. Hickey* (UK), R. Jones, R. Krishna, S. Kitchen, R. M. Maclean, A.Goodeve, K. K. Hampton, J. van Veen, M. Makris

PP-MO-200 A CHROMOGENIC SCREENING ASSAY IDENTIFIES THROMBOBOTIC RISK FACTORSIN PRE-SURGERY PATIENTSM. Johnston* (CA), M. Rupwate, J. McGrath, M. Smirnov, O. Safa, M. Triscott

PP-MO-201 SYNERGISTIC EFFECT OF TAK-442, A DIRECT FACTOR Xa INHIBITOR, ANDANTIPLATELET AGENTS ON WHOLE BLOOD COAGULATION AND ARTERIALTHROMBOSIS IN RATSN. Konishi, K. Hiroe, E. Shinozawa, Y. Imaeda, K. Kubo, M. Kawamura* (US)

PP-MO-202 EFFECT OF A LOW MOLECULAR WEIGHT HEPARIN ON VASCULAR CELL TISSUEFACTOR EXPRESSIONE. Napoleone, A. Cutrone, G. Colavecchia, F. Calanni, G. de Gaetano, M. B. Donati, R.Lorenzet* (IT)



Mon

day

Post

ers

PP-MO-203 THE PREVALENCE AND GENETIC BACKGROUND OF FACTOR VIII INHIBITORS INCHINESE HEMOPHILIA A PATIENTSX. Wang* (CN), Q. Ding, R. Yang, Y. Zhao, J. Wu, J. Sun, X. Zhang, H. Wang

Fibrinogen I

PP-MO-204 SEVERE BLEEDING, CRYOFIBRINOGENAEMIA (CF) AND RHEUMATOID ARTHRITIS (RA)A. N. Blanco* (AR), S. Grosso, L. A. Bastos, J. Speroni, A. Sanchez Luceros, F. Alberto, M.Aixalá, S. Meschengieser, M. Lazzari

PP-MO-205 FACTOR XIII IN CEREBROSPINAL FLUIDA. Csapó* (HU), É. Katona, G. Szucs, G. Haramura, L. Muszbek

PP-MO-206 FIBRINOGEN KRAKOW: A HETEROZYGOUS CASE OF A NOVELHYPODYSFIBRINOGENEMIA (GASN325ILE) AFFECTING FIBRIN ARCHITECTURE ANDFUNCTIONA. Undas* (PL), J. Zdziarska, T. Iwaniec, E. Stepien, A. Skotnicki, P. de Moerloose, M.Neerman-Arbez

PP-MO-207 EFFECT OF CIGARETTE SMOKING ON PLASMA FIBRIN CLOT PROPERTIESA. Undas* (PL), E. Stepien, R. Topor-Madry, T. Miszalski-Jamka, W. Tracz, M. Pasowicz

PP-MO-208 FIBRINOGEN POLYMORPHISMS AND THE RISK OF ACUTE ONSET ISCHEMIC STROKEIN YOUNG ASIAN INDIANSA. Biswas* (IN), R. Ranjan, A. Meena, M. S. Akhter, B. K. Yadav, M. Behari, R. Saxena

PP-MO-209 FIBRINOGEN AND CHOLESTEROL PLASMATIC LEVELS ARE INDEPENDENTCARDIOVASCULAR RISK FACTORS? LIFESTYLE MODIFICATION CAN MODULATETHESE LEVELS?C. A. Villaverde* (ES), J. Rodriguez, C. Fernandez, D. Bleda, E. Peña

PP-MO-210 RETROSPECTIVE EVALUATION OF DYSFIBRINOGENAEMIC PATIENTS IN A SINGLECENTRE: CLINICAL FEATURES AND LABORATORY FINDINGSC. Santoro* (IT), A. Leporace, F. Biondo, R. Asselta, S. Duga, M. Menegatti, M. Platè, M.Mazzucconi

PP-MO-211 ADSORPTION-INDUCED FIBRINOGEN SELF-ASSEMBLY: EVIDENCE OF ESSENTIALALPHA-C DOMAIN AND «A» KNOB ROLESD. K. Galanakis* (US), J. Koo, B. Kudryk, M. Rafailovich

PP-MO-212 THE ROLE OF FRAGMENT BBETA121-138 IN FIBRIN PROTOFIBRIL LATERALASSOCIATIONE. V. Lugovskoy* (UA), P. G. Gritsenko, I. N. Kolesnikova, N. E. Lugovskaya, S. V.Komisarenko

PP-MO-213 FIBRINOGEN YECHEON : CONGENITAL DYSFIBRINOGENEMIA WITH GAMMAMETHIONINE-310 TO THREONINE SUBSTITUTIONE. Park* (KR), G. Park, R. Park, H. Kim, S. Lee, S. Park, Y. Cha

Fibrinolysis I

PP-MO-214 INDUCTION OF CATALYTIC ACTIVITY OF PLASMINOGEN BY MONOCLONALANTIBODY A5E10 IN THE PRESENCE OF PLASMINOGEN ACTIVATORSA. Maleki* (IR), M. Akrami, M. Mirshahi, A. Pourfathollah

PP-MO-215 EXPRESSION OF PROTEOLYTIC AND ANGIOGENIC FACTORS IN ENDOMETRIAL CELLCULTURE FROM ENDOMETRIOSIS. INFLUENCE OF PERITONEAL FLUIDR. Cosin, J. Gilabert-Estelles, L. A. Ramon, M. Gomez-Lechon, F. España, J. Gilabert, M.Chirivella, A. Estelles* (ES)



133

134

PP-MO-216 ALTERED FIBRIN CLOT STRUCTURE/FUNCTION IN PATIENTS WITH IDIOPATHICVENOUS THROMBOEMBOLISMA. Undas* (PL), K. Zawilska, M. Ciesla-Dul, A. Lehmann-Kopydlowska, A. Skubiszak, K.Ciepluch, W. Tracz

PP-MO-217 A HYPOFIBRINOLYTIC STATE IS ASSOCIATED WITH RETINAL VEIN OCCLUSIONA. Cellai* (IT), S. Fedi, D. Lami, B. Giambene, A. Sodi, U. Menchini, R. Marcucci, R. Abbate,G. Gensini, D. Prisco

PP-MO-218 RATIO BETWEEN TIME OF XIIa-DEPENDENT FYBRINOLYSIS (FS) AND ANTITHROMBINIII (AT) ACTIVITY AS A MARKER OF SEVERITY OF SEPSISA. V. Krechetova* (RU), G. M. Galstyan, E. B. Orel, S. A. Vasiliev, M. G. Alexanyan, V. M.Gorodetsky

PP-MO-219 CHARACTERIZATION AND APPLICATION OF MONOCLONAL ANTIBODIES TOWARDMOUSE PAI-1B. van de Craen* (BE), H. R. Lijnen, I. Scroyen, P. J. Declerck, A. Gils

PP-MO-220 DIAGNOSIS OF HYPERFIBRINOLYSIS : WHICH TEST(S) SHOULD BE USED ?S. Eeckhoudt, D. Latinne, C. Lambert* (BE), C. Hermans

PP-MO-221 THE EFFECTS OF HYPERGLYCAEMIA ON THROMBIN-ACTIVATABLE FIBRINOLYSISINHIBITORC. J. N. Verkleij* (NL), M. Nieuwdorp, V. E. A. Gerdes, M. Mörgelin, J. C. M. Meijers, P. F.Marx

PP-MO-222 PLASMA LEVELS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 ANDVITRONECTIN IN CHILDREN WITH SOLID TUMORSD. Tugcu, O. Devecioglu, A. Unuvar* (TR), O. B. Ekmekci, H. Ekmekci, A. Karatas, Z.Karakas, G. Ozturk, S. Anak, L. Agaoglu

PP-MO-223 EVALUATION OF THE INNOVANCE D-DIMER ANALYTICAL PERFORMANCED. Coen Herak* (HR), M. Milos, R. Zadro

PP-MO-224 IMPAIRED FIBRINOLYSIS AS A RISK FACTOR FOR BUDD-CHIARI SYNDROMEJ. Hoekstra, F. W. Leebeek, A. H. Guimaraes, S. D. Murad, J. J. Malfliet, A. Plessier, P.Langlet, E. Elias, J. Trebicka, M. Primignani, J. Garcia-Pagán, D. C. Valla, H. L. Janssen, D.C. Rijken* (NL)

PP-MO-225 IDENTIFICATION OF MONOCLONAL ANTIBODIES THAT IMPAIR THE ACTIVATION OFBOTH MOUSE AND HUMAN TAFI THROUGH DIFFERENT MECHANISMSE. Vercauteren* (BE), M. Peeters, P. J. Declerck, A. Gils

PP-MO-226 DERIVATION OF A CLINICAL PREDICTION RULE THAT INCLUDES D-DIMER TOIDENTIFY HIGH-RISK PATIENTS WITH PULMONARY EMBOLISM: FINDINGS FROM THERIETE REGISTRYE. Grau* (ES), J. Tenias, J. Ferrer, M. Guil, R. Sanchez, A. Riera, J. Sahuquillo, B. Vasco

PP-MO-227 D-DIMER AND SHORT-TERM CLINICAL OUTCOME OF PULMONARY EMBOLISM: ROLEOF PULMONARY ARTERY CLOT LOADE. Grau* (ES), M. Santos, R. Garcia, J. Ferrer, S. Isarria, J. Sanchez, S. Selfa, R. Molina, J.Tenias

PP-MO-228 FACTOR XIII LEVELS IN PATIENTS WITH DIFFERENT STAGES OF ALCOHOLIC LIVERCIRRHOSISÉ. Katona* (HU), B. Garai, I. Tornai, É. Csák, L. Muszbek

PP-MO-229 PROCARBOXYPEPTIDASE U (TAFI) CONSUMPTION IN ACUTE ISCHEMIC STROKECORRELATES WITH STROKE SEVERITY, EVOLUTION AND OUTCOMEE. Heylen* (BE), R. Brouns, J. Willemse, P. de Deyn, D. Hendriks



Mon

day

Post

ers

PP-MO-230 THROMBOLYTIC TREATMENT ALTERS THE PROCARBOXYPEPTIDASE U (TAFI)CONSUMPTION PROFILE IN ISCHEMIC STROKE PATIENTSE. Heylen* (BE), R. Brouns, J. Willemse, P. de Deyn, D. Hendriks

Regulation of Coagulation and Fibrinolysis I

PP-MO-231 O-LINKED GLYCOSYLATION OF VWF IS AN IMPORTANT MODULATOR OF ADAMTS13PROTEOLYSIS AND BINDING TO GPIBA. A. Nowak* (UK), G. Angus, M. A. Laffan, T. A. J. McKinnon

PP-MO-232 THE ROLE OF CAMP IN THE GENE EXPRESSION OF PLASMINOGEN ACTIVATORINHIBITOR-1 AND TISSUE FACTOR IN ADIPOCYTEA. Hayashi* (JP), N. Ono, A. Tomita, H. Takeya

PP-MO-233 STUDY OF D-DIMER LEVELS USING TWO DIFFERENT IMMUNOTURBIDOMETRICASSAYS AT DIFFERENT STAGES OF PREGNANCYA. A. Khalafallah* (AU), M. Morse, A. Dennis, J. Bates, G. Bates, L. Smith, G. Mishra, N.Blesingk, I. Robertson, D. Seaton, T. Brain

PP-MO-234 ANGIOTENSIN-(1-9) ENHANCES VENOUS THROMBOSIS DEVELOPMENT IN RAT BYINHIBITING FIBRINOLYTIC ACTIVITYA. Mogielnicki* (PL), K. Kramkowski, D. Pawlak, J. M. Hermanowicz, W. Buczko

PP-MO-235 REGULATORY FUNCTIONS OF POSITIVE FEEDBACKS OF FACTORS V AND VIIACTIVATION IN BLOOD CLOTTING INITIATIONA. N. Balandina* (RU), M. A. Panteleev, A. M. Shibeko, I. I. Shmirev, F. I. Ataullakhanov

PP-MO-236 ESTROGEN RECEPTORS MEDIATE CHANGES IN MOUSE PLASMA COAGULATIONFACTOR LEVELS AND HEPATIC TRANSCRIPT LEVELS INDUCED BY ORALETHINYLESTRADIOLA. C. A. Cleuren* (NL), I. K. van der Linden, P. H. Reitsma, B. J. M. van Vlijmen

PP-MO-237 PLATELET FACTOR 4 (CXCL4) SHIELDS PLASMA FACTOR V TO THROMBIN ANDRETARDS ACTIVATIONA. A. Amelot, M. Tagzirt, J. Libraire, B. F. Le Bonniec* (FR)

PP-MO-238 NATURAL COURSE OF ENDOGENOUS PLASMA ACTIVATED PROTEIN C LEVELS ANDEFFECT OF DROTRECOGIN ALFA (ACTIVATED) ON MARKERS OF COAGULATIONACTIVATION AND FIBRINOLYSIS IN ACUTE PULMONARY EMBOLISM TREATED WITHTHERAPEUTIC DOSE ENOXAPARIN: A RANDOMIZED, DOUBLE-BLIND STUDYC. H. Dempfle* (DE), A. Link, E. Elmas, N. Suvajac, V. Liebe, J. Janes, M. Borggrefe

PP-MO-239 INHIBITION OF GAMMA A AND GAMMA’ FIBRINOGEN SYNTHESIS BY INTERFERON-GAMMA OCCURS THROUGH A STAT1 MEDIATED MECHANISMC. M. Rein* (US), D. H. Farrell

PP-MO-240 COMPARISON OF CLOTTING FACTOR STABILITY IN LYOPHILIZED PLASMA AND S/D-PLASMA STORED FOR 6 DAYS AT 4°CC. von Heymann* (DE), M. K. Keller, A. Pruss, M. Sander, H. Schoenefeld, U. Kalus, C.Rosenthal, C. Spies

PP-MO-241 THE EFFECT OF THE ADDITION OF FXIII TO FRESH FROZEN PLASMA ONCOAGULATION AND CLOT FIRMNESS IN A MODEL OF DILUTIONAL COAGULOPATHYC. von Heymann* (DE), C. Rosenthal, M. K. Keller, M. Schuster, C. Spies

PP-MO-242 PLATELET PROTEIN S ANTIGEN LEVELS IN CONGENITAL PROTEIN S DEFICIENCYC. Radu* (IT), L. Spiezia, D. Tormene, C. Bulato, S. Gavasso, M. Perlati, M. Fadin, P. Simioni

PP-MO-243 DECREASED LEVELS OF PLATELET PROTEIN S IN PATIENTS UNDER TREATMENTWITH WARFARINC. Bulato* (IT), C. Radu, S. Gavasso, G. Tognin, L. Spiezia, P. Zerbinati, P. Simioni



135

136

PP-MO-244 THE NOVEL ANTICOAGULANT SOLULIN PROMOTES REPERFUSION AND REDUCESINFARCT VOLUME IN A THROMBOTIC MODEL OF STROKEE. J. Su* (US), M. Geyer, M. Wahl, M. Warnock, K. Mann, H. Brohmann, K. Petersen, D. A.Lawrence

PP-MO-245 THE NOVEL DIRECT THROMBIN INHIBITOR DABIGATRAN ACCELERATES PLASMAFIBRINOLYSIS THROUGH TAFI-DEPENDENT AND -INDEPENDENT MECHANISMSF. Semeraro* (IT), C. T. Ammollo, N. Semeraro, M. Colucci

PP-MO-246 QUENCHING OF THROMBIN GENERATION BY ANTITHROMBIN III (AT-III) ASMEASURED BY THROMBINOSCOPE IN NORMAL AND ALTERED CLOTTINGPROCESSESF. Carmassi* (IT), F. de Negri, F. Mori, I. Nardini

PP-MO-247 BLEEDING CONCERNS DRIVE PRACTICES OF ORTHOPEDIC SURGEONS INPREVENTION OF VENOUS THROMBOEMBOLISM IN PRIMARY HIP AND KNEEARTHROPLASTYF. A. Anderson* (US), D. Ayers, C. Colwell, F. Cushner, R. Friedman, M. Huo, G. Fitzgerald,L. Kwong

PP-MO-248 PRACTICES IN PREVENTION OF VENOUS THROMBOEMBOLISM IN PRIMARY HIP ANDKNEE ARTHROPLASTY VARY WITH SURGEON OPERATIVE VOLUME: FINDINGS FROMA SURVEY OF US ORTHOPEDIC SURGEONSF. A. Anderson* (US), J. Lieberman, V. D. Pellegrini, A. C. Spyropoulos, A. G. Turpie, G.Westrich, P. Franklin, D. Warwick

PP-MO-249 A QUANTITATIVE MODEL FOR THE HUMORAL COAGULATION NETWORKG. K. Isbister* (AU), T. Wajima, S. B. Duffull

PP-MO-250 THE ROLE OF BARRELS 1 AND 2 IN ENZYMATIC ACTIVITY OF FACTOR XIIIaE. L. Smith, P. J. Adamson, R. A. S. Ariëns, M. C. Maurer, P. J. Grant, H. Philippou* (UK)

PP-MO-251 CALIBRATED THROMBIN GENERATION FROM A SINGLE MEASURING WELLH. C. Hemker* (NL), R. Al Dieri, P. W. Hemker

PP-MO-252 INTRACELLULAR CYCLIC AMP UP-REGULATES EXPRESSION OF THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) IN CULTURED HUMAN HEPATOMAHEPG2 CELLSH. Ishii* (JP), Y. Masuda, K. Takada, K. Sugimoto

PP-MO-253 ACTIVATION OF FIBRINOLYSIS AND BLEEDING HISTORY IN PATIENTS WITHSYSTEMIC MASTOCYTOSISH. Seidel* (DE), H. J. Hertfelder, K. Alfter, U. W. Kolck, I. von Kügelgen, J. Homann, J.Oldenburg, G. J. Molderings

PP-MO-254 THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR GENETIC POLYMORPHISMS ASMARKERS OF THE TYPE OF ACUTE CORONARY SYNDROMED. Tassies, M. Roque, J. Monteagudo, T. Martorell, A. Sionis, D. Arzamendi, M. Heras, J. C.Reverter* (ES)

PP-MO-255 PROCOAGULANT EFFECT OF PLASMIN DEPENDENT ON FACTOR V AND FACTOR VIIIDURING THE BLOOD COAGULATION PROCESSK. Ogiwara* (JP), K. Nogami, K. Nishiya, M. Takeyama, M. Shima

PP-MO-256 OXYTOCIN INFLUENCE ON HAEMOSTASIS SYSTEM AND BEHAVIORAL REACTION INWHITE RAT BY NORMAL AND STRESSOGENIC CONDITIONM. Golubeva* (RU), M. Grigorjeva, O. Voscresenskaya

PP-MO-257 EFFECT OF, UMBILICAL CORD, BLOOD CELLS IN THE “EXPRESSION” OF PLATELETGLYCOPROTEIN RECEPTORSM. P. Makris* (GR), M. Moshou, D. Vasileiadou, G. Koliakos, P. E. Makris



Mon

day

Post

ers

PP-MO-258 CAN PROTEINS INDUCED BY VITAMIN K ABSENCE - PIVKA II - DETECT SUBCLINICALVITAMIN K DEFICIT IN MAJOR SURGERY?U. Schott* (SE), P. Anveden, K. Strandberg, P. Flisberg, M. Engström, A. Hillarp

Antiphospholipid Antibodies and Syndrome I

PP-MO-259 LONG-TERM FOLLOW-UP IN PATIENTS WITH POSITIVE ANTIPHOSPOLIPIDANTIBODIES – SINGLE CENTRE EXPERIENCEA. Bulikova* (CZ), D. Harustiakova, J. Zavrelova, L. Dusek, M. Penka

PP-MO-260 THE PARAMETERS OF IMMUNE INFLAMMATION AND HAEMOSTASIS IN PATIENTSWITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WITH ANTIPHOSPHOLIPIDSYNDROME (APS) AND WITHOUT APSA. V. Arshinov* (RU), V. I. Emanuylov, N. V. Zubova

PP-MO-261 ENDOGENOUS THROMBIN POTENTIAL (ETP) ANALYSIS OF LUPUS ANTICOAGULANTPLASMA WITH THE BMS (DADE BEHRING SIEMENS) SYSTEMA. D’Angelo* (IT), P. Della Valle, E. Pattarini, L. Crippa, A. Fattorini

PP-MO-262 THE LIPOPROTEIN DISTRIBUTION OF BETA-2-GLYCOPROTEIN I (APOLIPOPROTEINH)C. Agar* (NL), P. G. de Groot, J. H. M. Levels, J. A. Marquart, J. C. M. Meijers

PP-MO-263 THE LUPUS RATIO TESTS IMPROVE THE DIAGNOSIS OF LUPUS ANTICOAGULANTSC. Nougier* (FR), F. Sobas, G. Baud, C. Negrier

PP-MO-264 LABORATORY DIAGNOSIS OF LUPUS ANTICOAGULANT: HOW MANY TESTS?C. Nougier* (FR), Y. Chevalier, F. Sobas, C. Negrier

PP-MO-265 A LYOPHILIZED LUPUS ANTICOAGULANT NEGATIVE CONTROL PREPAREDACCORDING TO ISTH LA RECOMMENDATIONSD. Sanchez* (US), C. Cueto, J. Vasquez, R. Bottenus, M. Triscott

PP-MO-266 CEREBRAL MR AND SPECT ABNORMALITIES IN PATIENTS WITH DEEP VEINTHROMBOSIS OR STROKE IN ANTI-PHOSPHOLIPID SYNDROMED. Barcellona, A. Mameli, S. Cornacchini, L. Casciu, M. Piga, F. Marongiu* (IT)

PP-MO-267 IS LUPUS ANTICOAGULANT TESTING USEFUL IF APTT IS NORMAL?A. Mameli, D. Barcellona, L. Fenu, M. Vannini, F. Marongiu* (IT)

PP-MO-268 ANALYSIS OF LETHAL OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUSERYTHEMATOSUS (SLE) AND ANTIPHOSPHOLIPID SYNDROME (APS) BASED ONLONG-TERM FOLLOW-UPT. M. Reshetnyak, I. B. Shtivelband* (RU), E. N. Alexandrova, E. S. Mach, L. V. Kondratyeva,E. V. Ostryakova, A. A. Novikov, E. L. Nasonov

PP-MO-269 TUMOUR NECROSIS FACTOR ALPHA AND SOLUBLE INTERLEUKIN 2 RECEPTOR(SIL-2R) LEVELS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROMEJ. Swadzba* (PL), T. Iwaniec, J. Musial

PP-MO-270 FUNCTIONAL VARIANTS OF PLATELET GLYCOPROTEINS IA/IIA AND IIB/IIIA ANDVALINE/LEUCINE247 POLYMORPHISM OF BETA 2- GLYCOPROTEIN I AND A RISK OFARTERIAL THROMBOSIS IN PATIENTS WITH ANTIPHOSHOLIPID SYNDROMEJ. Swadzba* (PL), A. Matyja-Bednarczyk, M. Sanak, S. Dziedzina, T. Iwaniec, A. Bulikova, J.Musial

PP-MO-271 ARTERIAL THROMBOSIS IN PATIENTS WITH ANTIPHOSHOLIPID SYNDROMEJ. Swadzba* (PL), A. Matyja-Bednarczyk, T. Iwaniec, A. Bulikova, J. Musial



137

138

PP-MO-272 EVALUATION OF A NEW ENZYME IMMUNO ASSAY FOR DETECT ANDQUANTIFICATION OF HUMAN ANTICARDIOLIPIN ANTIBODIESJ. Needham* (UK), S. Knight, S. Rangarajan

PP-MO-273 PROSPECTIVE STUDY OF THE CLINICAL AND SEROLOGICAL CHARACTERISTICSAND LONG-TERM EVOLUTION OF THE ANTIPHOSPHOLIPID SYNDROME AT THEAMERICAN UNIVERSITY OF BEIRUT MEDICAL CENTERL. Bazzi* (LB), A. Taher, R. Mahfouz, I. Uthman

PP-MO-274 B2 GLYCOPROTEIN I (B2GPI) CONTAINING IGM IMMUNE-COMPLEXES (B2GPI-IGM IC)IN PATIENTS WITH IGM ANTICARDIOLIPIN ANTIBODIES (ACL IGM)M. F. Alberto* (AR), A. Sanchez Luceros, S. Meschengieser, M. A. Lazzari

PP-MO-275 THE IMPORTANCE OF APPROPRIATED CRITERIA FOR LUPUS ANTICOAGULANT (LA)DIAGNOSISM. E. Martinuzzo* (AR), G. Cerrato, M. Iglesias Varela, Y. Adamczuk, R. Forastiero

PP-MO-276 LUPUS ANTICOAGULANT IN NIGERIAN WOMEN WITH POOR OBSTETRICS HISTORYO. A. Awodu* (NG), A. O. Ejele, W. A. Shokunbi

Risk Factors and Epidemiology of Venous Thrombosis I

PP-MO-277 THROMBOPHILIC GENE MUTATION IN RECURRENT MISCARRIAGEZ. Mostafa* (EG), N. Abulata, S. Sahlab, A. Shams Eldin

PP-MO-278 HEMOSTASIS AND HEMATOLOGICAL THROMBOTIC RISK FACTORS IN YOUNGNIGERIAN SEMI VEGETARIANSA. A. Adeyemi* (NG), O. A. Omolade, Y. O. Makinde, O. I. Ajayi, O. A. Awodu, A. A. Famodu

PP-MO-279 JAK2 MUTATIONS OTHER THAN JAK2 V617F MAY BE ABSENT IN PATIENTS WITHUNUSUAL SITE THROMBOSISA. H. Tabares* (AR), A. L. Basquiera, N. Soria, M. Salguero, R. Ryser, J. J. García

PP-MO-280 DIFFERENCES IN VENOUS THROMBOEMBOLISM MANAGEMENT IN THREEEUROPEAN COUNTRIES: RESULTS FROM THE RIETE REGISTRYJ. P. Cambou, N. Hassairi, A. Bura* (FR)

PP-MO-281 VENOUS THROMBOEMBOLIC DISEASE IN MEN AND WOMEN: DATA FROM THE RIETEREGISTRYA. Bura* (FR), J. Ben Cheik, J. P. Cambou

PP-MO-282 VENOUS THROMBOEMBOLISM RECURRENCE AFTER A FIRST EPISODE OFPROVOKED VENOUS THROMBOSIS DUE TO A TRANSIENT RISK FACTOR. ASYSTEMATIC REVIEW OF THE LITERATUREA. Iorio* (IT), C. Kearon, E. Filippucci, M. Marcucci, V. Pengo, G. Agnelli, G. Palareti

PP-MO-283 FAVORABLE OUTCOMES WITH ONCE DAILY FONDAPARINUX 2.5MG VS.ENOXAPARIN 40MG FOR THROMBOPROPHYLAXIS AFTER ABDOMINAL OR MAJORORTHOPEDIC SURGERYA. F. Shorr* (US), R. V. Horblyuk, O. E. Lunacsek, L. A. Menditto, M. A. Franklin

PP-MO-284 ROLE OF LIPID LOWERING THERAPY (LLT) ON VENOUS THROMBOEMBOLISM (VTE)RISK: A POPULATION-BASED CASE-CONTROL STUDYA. A. Ashrani* (US), J. A. Heit, M. K. Barsoum, C. L. Leibson, T. M. Petterson, K. R. Bailey, L.J. Melton

PP-MO-285 THE RISK OF VENOUS THROMBOEMBOLIC EVENTS AFTER SPLENECTOMY.PROSPECTIVE OBSERVATIONAL COHORT STUDY IN 412 CONSECUTIVE PATIENTSA. Ghirarduzzi* (IT), F. Landini, S. Corradini, M. Iotti, I. Barbieri, F. Biolchini



Mon

day

Post

ers

PP-MO-286 INFLUENCE OF EXOGENOUS RISK FACTORS TO THE FACTOR V LEIDEN PARADOXIN MEN AND WOMEN – RESULTS FROM A RETROSPECTIVE THROMBOPHILIC FAMILYCOHORTA. B. U. Mäkelburg* (NL), W. M. Lijfering, N. J. G. M. Veeger, S. Middeldorp, K. Hamulyak, M.H. Prins, H. R. Büller, J. van der Meer

PP-MO-287 PROTEIN C DEFICIENCY AND RISK OF THROMBOSISA. Cafolla* (IT), E. Baldacci, N. Angelosanto, P. Pignoloni, F. Biondo, M. Mazzucconi

PP-MO-288 ANTIPHOSPHOLIPID ANTIBODIES IN WOMEN WITH A HISTORY OF PREGNANCY-RELATED VENOUS THROMBOSIS (VT) - A POPULATION-BASED CASE-CONTROLSTUDYA. Bergrem* (NO), E. M. Jacobsen, F. E. Skjeldestad, A. F. Jacobsen, P. M. Sandset

PP-MO-289 THROMBOPHILIA, HYPERCOAGULABILITY, AND ENVIRONMENT, AND THE RISK OFVENOUS THROMBO-EMBOLISM (THE-VTE STUDY)A. van Hylckama Vlieg* (NL), F. R. Rosendaal, C. A. Baglin, R. Luddington, T. P. Baglin

PP-MO-290 D-DIMER AND AGE AS RISK FACTORS FOR RECURRENCE AFTER A FIRST EPISODEOF VENOUS THROMBOEMBOLISM IN THE EXTENDED FOLLOW-UP OF THEPROLONG STUDYB. Cosmi* (IT), C. Legnani, V. Pengo, A. Ghirarduzzi, S. Testa, A. Alatri, P. Domenico, D. Poli,A. Tripodi, G. Palareti

PP-MO-291 D-DIMER AND SEX AS RISK FACTORS FOR RECURRENCE AFTER A FIRST EPISODEOF VENOUS THROMBOEMBOLISM IN THE EXTENDED FOLLOW-UP OF THEPROLONG STUDYB. Cosmi* (IT), C. Legnani, V. Pengo, A. Tosetto, A. Ghirarduzzi, A. Alatri, D. Prisco, D. Poli,A. Tripodi, G. Palareti

PP-MO-292 PRESENCE OF A PRO-THROMBOTIC STATE IN PATIENTS WITH CUSHING’SSYNDROME: A SYSTEMATIC REVIEW ON THE INFLUENCE OF ENDOGENOUSHYPERCORTISOLISM ON HEMOSTASIS AND VENOUS THROMBOSISB. van Zaane* (NL), E. Nur, A. Squizzato, O. M. Dekkers, M. T. H. B. Twickler, E. Fliers, V. E.A. Gerdes, H. R. Buller, D. P. M. Brandjes

PP-MO-293 THE EFFECT OF LEVOTHYROXINE ON COAGULATION AND FIBRINOLYSIS INHEALTHY VOLUNTEERS: A SINGLE BLINDED CROSSOVER RANDOMISEDCONTROLLED TRIALB. van Zaane* (NL), A. Squizzato, J. Debeij, O. M. Dekkers, J. C. M. Meijers, H. R. Buller, V.E. A. Gerdes, S. C. Cannegieter, D. P. M. Brandjes

PP-MO-294 RISK FACTORS FOR PULMONARY EMBOLISMB. Milli* (IT), A. Rocci, M. Riccò, M. Lombardi, R. Quintavalla

PP-MO-295 CYTOMEGALOVIRUS INFECTION IS ASSOCIATED WITH VENOUSTHROMBOEMBOLISM - A CASE-CONTROL STUDYS. Schimanski, B. Linnemann, B. Luxembourg, J. Rochon, E. Seifried, E. Lindhoff-Last, C. M.Schambeck* (DE)

PP-MO-296 PERFORMANCE CHARACTERISTICS OF AN ELISA FOR QUANTITATION OFADAMTS13 AUTOANTIBODIES IN HUMAN PLASMAC. J. Hoecke* (US), H. J. L. Fryer, E. Guinto, R. S. Greenfield

PP-MO-297 EVALUATION OF THROMBOSIS GENETIC PREDISPOSITION IN SÃO MIGUEL ISLANDHEALTHY POPULATIONC. C. Branco* (PT), T. Pereirinha, P. R. Pacheco, R. Cabral, L. Mota-Vieira



139

140

PP-MO-298 VENOUS THROMBOSIS IS ASSOCIATED WITH HYPERGLYCEMIA AT DIAGNOSIS: ACASE-CONTROL STUDYD. M. Cohn* (NL), J. Hermanides, J. H. Devries, P. W. Kamphuisen, R. Huijgen, J. C. M.Meijers, J. B. L. Hoekstra, H. R. Büller

PP-MO-299 SIMPLIFICATION OF THE PULMONARY EMBOLISM SEVERITY INDEX FORPROGNOSTICATING PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISMD. Jiménez* (ES), D. Aujesky, L. Moores, D. Marti, J. Lobo, F. Uresandi, R. Otero, M.Monreal, R. Yusen

PP-MO-300 PROTHROMBIN LEVELS ARE INCREASED IN TYPE II DIABETICSD. L. Sauls* (US), R. McFarland, A. Brogden, M. Hoffman

PP-MO-301 METABOLIC SYNDROME IS A RISK FACTOR FOR VENOUS THROMBOEMBOLISM INKOREAN POPULATIOND. Oh* (KR), M. Jang, W. Choi, S. Bang, T. Lee, Y. Kim, W. Ageno

PP-MO-302 IS THERE FAMILIAL CLUSTERING OF ELEVATED FACTOR VIII?E. Vagdatli* (GR), K. Mitsopoulou, F. Tsikopoulou, E. Pantziarela, O. Serafimidou, E.Protonotariou, E. Kazantzidou

PP-MO-303 HYPERHOMOCYSTEINEMIA AND RISK OF VENOUS THROMBOEMBOLISMRECURRENCE AFTER A FIRST EPISODE OF PULMONARY EMBOLISME. Grifoni* (IT), G. Ciuti, D. Poli, E. Antonucci, R. Marcucci, C. Arcangeli, M. Miniati, G.Gensini, R. Abbate, D. Prisco

PP-MO-304 OBESITY AS A POSSIBLE RISK FACTOR FOR INCOMPLETE RESTORATION OFPULMONARY PERFUSION AFTER PULMONARY EMBOLISM (PE)E. Grifoni* (IT), D. Poli, E. Antonucci, G. Ciuti, R. Marcucci, C. Arcangeli, G. Gensini, R.Abbate, D. Prisco, M. Miniati

PP-MO-305 TYPE AND LOCATION OF VENOUS THROMBOEMBOLISM IN FV LEIDEN CARRIERS;EXPERIENCE FROM A SINGLE CENTERE. Papadakis* (GR), A. Spyrou, S. Efraimidou, K. Loukidhs, H. Kartsios, M. Topalidou, I.Korantzis

PP-MO-306 HEMORRHAGE IN ACUTE CARE SETTING IS A RISK FACTOR FOR LATER VENOUSTHROMBOEMBOLISM IN REHABILITATION UNITE. Tincani* (IT), A. Bernardini, M. A. Crowther, M. Foroni

PP-MO-307 A GENOME WIDE ASSOCIATION STUDY TO IDENTIFY CANDIDATE GENES FOR HIGHFACTOR VIII LEVELS IN VENOUS THROMBOEMBOLISM: DO ABO-GLYCOSYLTRANSFERASES PLAY AN IMPORTANT ROLE?F. Thieme* (DE), A. Fiebig, T. Lu, B. Luxembourg, H. von Eller-Eberstein, B. Flesch, M.Spannagl, E. Lindhoff-Last, S. Schreiber, C. M. Schambeck

PP-MO-308 NATURAL HISTORY OF MESENTERIC VENOUS THROMBOSIS IN PATIENTS TREATEDWITH ORAL ANTICOAGULANTSF. Dentali* (IT), W. Ageno, D. Witt, A. Malato, N. Clark, D. Garcia, K. McCool, S. Siragusa, M.Crowther

PP-MO-309 JAK2V617F MUTATION FOR THE EARLY DIAGNOSIS OF PH- MYELOPROLIFERATIVENEOPLASMS IN PATIENTS WITH VENOUS THROMBOEMBOLISM. A META-ANALYSISF. Dentali* (IT), A. Squizzato, L. Brivio, L. Appio, L. Campiotti, M. Crowther, A. M. Grandi, W.Ageno

PP-MO-310 ELEVATED THROMBIN GENERATION IN RELATIVES OF PATIENTS WITHUNPROVOKED VENOUS THROMBOEMBOLISM AND NO DETECTABLETHROMBOPHILIAF. Couturaud* (FR), J. Duchemin, G. Quere, C. Kearon, J. Ginsberg, C. Leroyer, D. Mottier, J.Abgrall



Mon

day

Post

ers

PP-MO-311 CHRONOLOGY OF THE INCIDENCE OF VENOUS THROMBOEMBOLISM ALONG THEFIRST THREE MONTHS AFTER PROXIMAL FEMUR FRACTURE IN ELDERLY PATIENTSA. B. C. Machado, M. L. Sobreira, G. J. C. Pereira, J. E. Corrente, F. H. A. Maffei* (BR)

PP-MO-312 THE ITALIAN PULMONARY EMBOLISM REGISTRY “IPER”: PRELIMINARY RESULTSC. Becattini, F. Casazza* (IT), A. Rubboli, L. Roncon, P. Zonzin, C. D’Agostino, A.Bongarzoni, P. Favretto, G. Agnelli

PP-MO-313 HIGH LEVELS OF VON WILLEBRAND FACTOR ANTIGEN AND FACTOR VIII INPATIENTS WITH CHRONIC POSTTRAUMATIC STRESS DISORDERB. Makhoul, O. Rubichek, E. Klein, B. Brenner, G. Sarig* (IL)

PP-MO-314 TISSUE FACTOR ACTIVITY OF BLOOD MONONUCLEAR CELLS, BUT NOT PLASMAANTIGEN, IS INCREASED AFTER TOTAL KNEE ARTHROPLASTYG. J. Johnson* (US), L. A. Leis, R. R. Bach

PP-MO-315 VENOUS THROMBOEMBOLISM IN THE ELDERLY: EPIDEMIOLOGICAL DATAOVERVIEW BASED ON THE 2149-PATIENTS PROSPECTIVE OPTIMEV COHORTG. Pernod* (FR), J. Bosson, M. Sevestre, J. Labarere

PP-MO-316 KIDNEY DISEASE AND RISK OF VENOUS THROMBOSISG. Ocak* (NL), C. Y. Vossen, M. Verduijn, K. J. van Stralen, F. W. Dekker, C. J. M. Doggen,F. R. Rosendaal

PP-MO-317 INCIDENCE OF THROMBOPHILIC DISORDERS IN WOMEN OF CHILDBEARING AGEAND A HISTORY OF THROMBOEMBOLISM OR RECURRENT PREGNANT LOSS VS. AHEALTHY CONTROL GROUPH. Schinzel* (DE), E. Rolfes, L. Walter, A. Viertel, D. Peetz

PP-MO-318 ADEQUACY OF VENOUS THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICALPATIENTS (IMPART): PRELIMINARY REPORT OF A MULTISITE COMPARISON OFDIFFERENT DECISION SUPPORT SYSTEMSM. R. Nendaz, P. Chopard, C. Lovis, J. Doerffler, N. Kucher, L. Asmis, D. Spirk, H.Bounameaux* (CH)

PP-MO-319 LOW ADAMTS13 ANTIGEN AND ACTIVITY AND THE PRESENCE OF ADAMTS13AUTOANTIBODY SUGGEST ADAMTS13 MAY PLAY A ROLE IN VENOUSTHROMBOEMBOLISMH. J. L. Fryer* (US), C. J. Hoecke, J. R. Wu, E. Guinto, R. S. Greenfield

PP-MO-320 REFERENCE RANGES IN THROMBOPHILIA SCREENINGI. Jennings* (UK), D. P. Kitchen, S. Kitchen, T. A. L. Woods, I. D. Walker

PP-MO-321 LIVING NEAR MAJOR TRAFFIC ROADS AND RISK OF DEEP VEIN THROMBOSISI. Martinelli* (IT), A. Baccarelli, V. Pegoraro, P. A. Bertazzi, J. Schwartz, P. M. Mannucci

PP-MO-322 FACTOR V LEIDEN MUTATION INCREASES THE RISK FOR VENOUSTHROMBOEMBOLISM IN PATIENTS WITH MALIGNANCYI. Pabinger* (AT), D. Dunkler, R. Vormittag, C. Ay, C. Marosi, R. Simanek, C. Zielinski, C.Mannhalter

PP-MO-323 MUTATION SCREENING FOR THE C46T VARIANT IN THE F12 GENE BY MELTINGPOINT ANALYSIS WITH THE LIGHTCYCLER SYSTEM: ATYPICAL RESULTS,DETECTION OF THE VARIANT G47AI. Tirado* (ES), I. Coll, E. Martínez-Sánchez, A. Santamaría, E. Martí, J. Fontcuberta

PP-MO-324 RECURRENT THROMBOSIS IN NORTH INDIAN PATIENTS AND THE ROLE OFTHROMBOPHILIC RISK FACTORSJ. Ahluwalia* (IN), R. Das, P. Malhotra, N. Varma, S. Varma



141

142

PP-MO-325 PERSISTENT HIGH FACTOR VIII ACTIVITY LEADING TO INCREASED THROMBINGENERATIONJ. K. Ryland* (UK), A. S. Lawrie, S. J. Machin, I. J. Mackie

PP-MO-326 VENOUS THROMBOEMBOLISM IN THE EMERGENCY DEPARTMENT: INCIDENCE,DIAGNOSIS AND CLINICAL CHARACTERISTICS OF PATIENTSK. Hitos* (AU), A. Singh, N. Gunja, J. P. Fletcher

PP-MO-327 INFLUENCE OF PROCARBOXYPEPTIDASE U LEVEL AND THR325ILE POLYMORPHISMON CLINICAL EXPRESSION OF THROMBOPHILIA IN CARRIERS OF FV LEIDEN OR FII20210A MUTATIONP. S. Miljic* (RS), E. Heylen, J. L. Willemse, V. Djordjevic, M. Colovic, I. Elezovic, D. F.Hendriks

PP-MO-328 THROMBOTIC RISK FACTORS IN PATIENTS WITH LIVER CIRRHOSIS: CORRELATIONWITH MELD SCORING SYSTEM AND PORTAL VEIN THROMBOSIS DEVELOPMENTR. de Cristofaro* (IT), M. Zocco, E. di Stasio, S. Lancellotti, M. Pompili, G. Rapaccini, R.Landolfi, A. Gasbarrini

PP-MO-329 A COMMON GENETIC VARIANT OF FACTOR XIII A SUBUNIT VAL34LEU PREDISPOSESTO VENOUS THROMBOSIS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROMEM. Sanak, T. Iwaniec* (PL), S. Dziedzina, J. Musial

PP-MO-330 ASSOCIATION BETWEEN FACTOR XII C46T POLYMORPHISM AND THROMBOTICDISEASES IN TAIWAN AND ITS PARTICULAR ROLE IN MALE PATIENTSY. B. Yu* (TW), J. P. Gau, C. C. Chen, J. Y. You, H. C. Hsu, Y. C. Hong, C. Y. Liu, P. M. Chen,T. S. Lee, C. H. Tzeng

Arterial Vascular Diseases I

PP-MO-331 ASSESSMENT OF PULMONARY HYPERTENSION IN PATIENTS AFFECTED BYPULMONARY EMBOLISM (PE)A. Barchitta* (IT), L. Ruzza, F. Tosato, A. C. Pessina, V. Pengo

PP-MO-332 CARDIOVASCULAR AND THROMBO-EMBOLIC RISK FACTORS AND ANTECEDENTS INIDIOPATHIC SUDDEN SENSORINEURAL HEARING LOSS: THE ACOBRUSK STUDYA. Stepanian* (FR), I. Mosnier, F. Defay, G. Baron, F. Tankere, C. Bodenez, A. Robier, P.Bertholon, B. Fraysse, B. Meyer, O. Sterkers, D. de Prost

PP-MO-333 ABO BLOOD GROUP POLYMORPHISMS IN BRAZILIAN PATIENTS WITH VASCULARARTERIAL DISEASEA. P. Fernandes* (BR), A. P. Sabino, D. D. Ribeiro, G. G. Lages, M. S. Santos, T. Gadelha, L.S. Dusse, M. Carvalho

PP-MO-334 PLASMINOGEN ACTIVATOR INHIBITOR -1 (PAI-1) 4G5G POLYMORPHISM AND PAI-1ENZYME ACTIVITY IN YOUNG PATIENTS WITH ISCHEMIC STROKEM. S. Santos, A. P. Sabino, M. G. Carvalho, D. D. Ribeiro, T. Gadelha, L. S. Dusse, A. P.Fernandes* (BR)

PP-MO-335 EVALUATION OF POLYMORPHISMS IN APOLIPOPROTEIN B GENE AND THE RISK OFISCHEMIC STROKE IN YOUNG PATIENTSA. P. Fernandes* (BR), C. G. M. Santos, M. Carvalho, A. P. Sabino, D. D. Ribeiro, T.Gadelha, M. O. Sousa, K. B. Gomes

PP-MO-336 IMPACT OF THROMBOPHILIA IN YOUNG PATIENTS WITH ACUTE MYOCARDIALINFARCTIONA. Guida* (IT), A. Tufano, M. N. D. di Minno, M. di Capua, A. M. de Gregorio, G. Quintavalle,A. Russolillo, A. Coppola, E. Cimino, A. M. Cerbone, G. di Minno



Mon

day

Post

ers

PP-MO-337 THROMBIN GENERATION IS A MARKER OF CLINICAL OUTCOME AFTER ACUTEMYOCARDIAL INFARCTIONA. W. J. H. Dielis* (NL), M. Smid, H. M. H. Spronk, R. van Oerle, M. Winkens, K. Hamulyak,J. Rosing, M. H. Prins, J. Waltenberger, H. ten Cate

PP-MO-338 COAGULATION MARKERS LEVELS MEASURED DURING ACUTE INFECTION MAYPREDICT THE DEVELOPMENT OF LONG TERM CARDIO- AND CEREBRO-VASCULAREVENTS IN ELDERLYA. Winder* (IL), T. Bruzgol, I. Lichman, A. Herman, E. Leibovitz, E. Rachmilewitz, D. Gavish

PP-MO-339 RELEVANT RISK OF BLEEDING IN ATRIAL FIBRILLATION PATIENTS ON WARFARINWAITING FOR ELECTIVE CARDIOVERSIOND. Poli* (IT), E. Antonucci, E. Grifoni, G. Ciuti, R. Marcucci, S. Fedi, G. Gensini, R. Abbate, D.Prisco

PP-MO-340 BLEEDING RISK DURING ORAL ANTICOAGULATION IN ATRIAL FIBRILLATIONPATIENTS OLDER THAN 80 YEARSD. Poli* (IT), E. Antonucci, E. Grifoni, R. Marcucci, L. Mannini, R. Abbate, G. F. Gensini, D.Prisco

PP-MO-341 STROKE RISK IN ATRIAL FIBRILLATION PATIENTS ON WARFARIN: PREDICTIVEABILITY OF RISK STRATIFICATION SCHEMES FOR PRIMARY AND SECONDARYPREVENTIOND. Poli* (IT), E. Antonucci, E. Grifoni, G. Ciuti, R. Marcucci, L. Mannini, G. F. Gensini, R.Abbate, D. Prisco

PP-MO-342 ELEVATED D-DIMER LEVELS ARE ASSOCIATED WITH CORONARY ARTERY DISEASEAND CARDIOVASCULAR DEATH IN AN ANGIOGRAPHICALLY-STUDIED POPULATIOND. Girelli* (IT), N. Martinelli, A. Castagna, N. Campostrini, P. Guarini, S. Friso, F. Pizzolo, F.Busti, L. Annarumma, R. Corrocher, O. Olivieri

PP-MO-343 ASSOCIATION BETWEEN GENETIC VARIATION AT THE ADAMTS13 LOCUS ANDISCHEMIC STROKEE. Hanson* (SE), K. Jood, S. Nilsson, C. Blomstrand, C. Jern

PP-MO-344 A PEDIATRIC PATIENT WITH ACUTE STROKE DUE TO CEREBRAL ARTERYTHROMBOSISE. Turkkan* (TR), F. Pekun, D. Yalcin Atay

PP-MO-345 FIBRIN POLYMERIZATION RATE (FPR) AS A CARDIOVASCULAR RISK FACTOR ANDCORONARY RISK PREDICTORA. E. Ramirez, E. Cortina* (MX), R. A. Izaguirre

PP-MO-346 ANALYSIS OF THE ASSOCIATION BETWEEN THE POLYMORPHISM PLA1/A2 OF THEPLATELET GLYCOPROTEIN IIB/IIIA GENE AND THE RISK OF ISCHEMIC STROKE INYOUNG PATIENTSF. F. Coelho* (BR), A. P. Fernandes, K. B. Gomes, C. G. Miranda, M. G. Carvalho, A. P.Sabino, T. Gadelha

PP-MO-347 EFFECT OF THE DIRECT THROMBIN INHIBITOR, DABIGATRAN, ON ARTERIALTHROMBOSIS WHEN GIVEN IN COMBINATION WITH ASPIRIN (ASA) IN A CYCLICFLOW MODEL IN ANESTHETISED PIGSJ. van Ryn* (DE), T. Dietze, I. Kuritsch, M. Kink-Eiband, W. Wienen

PP-MO-348 DECREASE FACTOR VIIa/ANTITHROMBIN COMPLEXES IN CHILDREN WITH ISCHEMICSTROKEL. Spiezia* (IT), V. Rossetto, S. Gavasso, G. Tognin, B. Brandolin, B. Woodhams, P. Simioni

PP-MO-349 INCREASED FACTORS VIII AND VON WILLEBRAND IN TYPE 2 DIABETES WOMENAND THEIR ASSOCIATION TO MACROVASCULAR DISEASE EXTENTM. G. Carvalho* (BR), M. O. Sousa, M. A. Borges, P. W. Rosario, G. F. G. Lages, A.Fernandes, A. Soares



143

144

PP-MO-350 ASSOCIATION OF HAEMOSTATIC AND INFLAMMATORY MARKERS WITH FUTUREISCHEMIC CARDIOVASCULAR EVENTS IN PATIENTS WITH PERIPHERAL ARTERIALDISEASE - INITIAL LABORATORY RESULTS OF THE PREVENTION OF ISCHEMICEVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE (PIDM. Bedencic* (SI), A. Blinc, M. Bozic Mijovski, M. Stegnar, M. Kozak, M. Sabovic, P. Poredos,A. Kravos, B. Barbic-Zagar, M. Pohar-Perme, J. Stare

PP-MO-351 THROMBOPHILIC RISK FACTORS AND PERIPHERAL ARTERIAL DISEASE SEVERITYM. Sartori* (IT), E. Favaretto, C. Legnani, A. Amato, M. Cini, A. Caniato, M. Filippini, G.Palareti

PP-MO-352 PLASMA LEVELS OF FIBRINOLYTIC PROTEINS AND THE RISK OF MYOCARDIALINFARCTION IN MENM. E. Meltzer* (NL), C. J. M. Doggen, J. C. M. Meijers, P. G. de Groot, F. R. Rosendaal, T.Lisman

PP-MO-353 POLYMORPHISMS OF TUMOR NECROSIS FACTOR-ALPHA AND HYPOXIA INDUCIBLEFACTOR 1ALPHA GENES ARE ASSOCIATED WITH PLASMA HOMOCYSTEINE LEVELAND SUSCEPTIBILITY TO ISCHEMIC STROKE AND SILENT BRAIN INFARCTION (SBI)N. Kim* (KR), J. Lee, O. Kim, J. Choi, D. Rim, S. Lee, D. Oh

PP-MO-354 ACTIVATION OF COAGULATION SYSTEM AND ENDOTHELIAL MICROPARTICLES INCHILDREN WITH HENOCH SCHONLEIN PURPURAN. Sirachainan* (TH), W. Reakatanan, A. Chunharas, P. Kardkasam, N. Porntrasertsud,Tapaneya-Olarn, S. Treepongkarune, A. Chuansumrit

PP-MO-355 IMPROVEMENT OF PARAOXONASE 1 ACTIVITY IN PATIENTS WITH ACUTECORONARY SYNDROMESR. Januszek* (PL), T. B. Domagala, M. Rzeszutko, S. Dziedzina, M. Kaczor, A. Szczeklik

PP-MO-356 PREGNANCY-ASSOCIATED ISCHEMIC STROKE: PREVALENCE AND RISK OFRECURRENT STROKE COMPARED TO NON-PREGNANT WOMEN WITH ISCHEMICSTROKER. H. White* (US), A. Cheema, P. Verro

PP-MO-357 INFLUENCE OF THROMBOPHILIC RISK FACTORS ON PATENCY OF PERIPHERALARTERIAL BYPASSES IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVEDISEASE – A PROSPECTIVE STUDYR. Klamroth* (DE), S. Gottstein, C. Kubicek, M. Orlovic, I. Fritsche, H. Landgraf

PP-MO-358 PLASMINOGEN ACTIVATOR INHIBITOR-1 DEFICIENCY ENHANCES NEOINTIMAFORMATION IN A MURINE MODEL OF VEIN GRAFT DISEASEY. Ji* (US), W. P. Fay

PP-MO-359 STEM CELL THERAPY IN THE TREATMENT OF BUERGER’S DISEASE: A NEW ANDPROSPECTIVE APPROACHZ. Boda* (HU), K. Rázsó, M. Szarvas, M. Udvardy, Z. Oláh, P. Ilonczai, J. Tóth, L. Jámbor, T.Sipos, G. Kovács, J. Kappelmayer, K. Farkas, Z. Veréb, É. Rajnavölgyi

Hormones, Pregnancy and Women’s Issues I

PP-MO-360 PREVENTION OF RECURRENT PREECLAMPSIA IN WOMEN WITH THROMBOPHILIAA. D. Makatsariya* (RU), V. O. Bitsadze, S. M. Baimuradova, S. V. Akinshina

PP-MO-361 PREGNANCY MANAGEMENT IN WOMEN WITH HISTORY OF OBSTERICCOMPLICATIONS AND THROMBOPHILIAA. D. Makatsariya* (RU), V. O. Bitsadze, S. M. Baimuradova, S. V. Akinshina

PP-MO-362 FACTOR VIIIC AS CARDIOVASCULAR RISK IN DM2 SUBJECTS AND CORONARYHEART DISEASEA. Perez Cuadra* (MX), E. Cortina, R. A. Izaguirre



Mon

day

Post

ers

PP-MO-363 POLYMORPHISM (4G/5G) IN THE PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI1)PROMOTER GENE AND ITS RELATIONSHIP WITH THE PAI-1 PLASMA LEVELS INWOMEN UNDER ORAL HORMONE REPLACEMENT THERAPY (HRT)D. A. M. Guimarães, M. S. Santos, D. R. A. Rios, A. P. Sabino, J. E. Cardoso, K. B. Gomes,R. M. Franco, G. S. Teixeira, M. O. Sousa, L. M. S. Dusse, M. Carvalho, A. Fernandes* (BR)

PP-MO-364 ABO BLOOD GROUP, D-DIMER AND FACTOR VIII LEVELS IN POST MENOPAUSALWOMEN USING HORMONE REPLACEMENT THERAPYD. A. M. Guimarães, M. S. Santos, D. R. A. Rios, S. G. Paiva, J. E. Cardoso, K. B. Gomes,R. M. Franco, G. S. Teixeira, L. M. S. Dusse, M. Carvalho, A. Fernandes* (BR)

PP-MO-365 DIFFERENT METHODS OF THROMBIN GENERATION AS A PARAMETER TO MONITORPATIENTS WITH THROMBOPHILIA AND PREGNANCYA. Siegemund* (DE), T. Siegemund, I. Wittig, U. Scholz

PP-MO-366 OPPOSING TRENDS IN THROMBOPHILIA-INDUCED RECURRENT PREGNANCY LOSS:CONGENITAL IN CAUCASIANS, ACQUIRED IN ASIANSA. Thiruchelvam* (MY), M. Sekaran, K. Faraizah Karim, S. Z Omar

PP-MO-367 “NON-SPECIFIC ABNORMALITIES” - A CAUSE FOR RESISTANCE IN PROTEIN CPATHWAY IN MALAYSIAN WOMEN WITH RECURRENT FAILED PREGNANCIESA. Thiruchelvam* (MY), M. Sekaran, A. Faraizah Karim, S. Z. Omar

PP-MO-368 VARIATIONS IN THROMBOMODULIN, TISSUE FACTOR AND PROCOAGULANTPHOSPHOLIPID ACTIVITY IN EARLY AND LATE UNEXPLAINED FETAL LOSSP. VanDreden* (FR), A. Rousseau, B. J. Woodhams, R. Favier

PP-MO-369 ELEVATED CIRCULATING SOLUBLE THROMBOMODULIN ACTIVITY, TISSUE FACTORACTIVITY AND PROCOAGULANT PHOSPHOLIPIDS: NEW AND USEFUL MARKERSFOR PRE-ECLAMPSIA?A. Rousseau, R. Favier, P. van Dreden* (FR), B. J. Woodhams

PP-MO-370 PRELIMINARY RESULTS OF BASELINE THROMBIN GENERATION AND FIBRINOLYSISIN WOMEN WITH PREVIOUS PREGNANCY-ASSOCIATED VENOUS THROMBOSIS :THROMBIN GENERATION APPEARS INCREASED AND FIBRINOLYTIC ACTIVITYREDUCED COMPARED TO HEALTHY FEMALE CONTROLSB. Myers* (UK), N. Brook, R. Kirby

PP-MO-371 TINZAPARIN THROMBOPROPHYLAXIS FOR PROSTHETIC VALVES IN PREGNANCYC. J. Rea* (UK), S. Rangarajan, B. J. Hunt

PP-MO-372 LOW-MOLECULAR-WEIGHT HEPARIN FOR PREVENTION OF OBSTETRICCOMPLICATIONS IN WOMEN,CARRIERS OF FACTOR V LEIDEN OR PT–G20210AMUTATION, WITH PREVIOUS EARLY OR LATE OBSTETRIC COMPLICATIONSD. Tormene* (IT), E. Grandone, V. de Stefano, G. Palareti, G. Castaman, M. Margaglione, E.Rossi, C. Legnani, A. Tosetto, P. Simioni

PP-MO-373 ACTIVATED THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFIA) LEVELS INHIGH PREGNANCYD. Peetz* (DE), D. Dickemann, C. Interthal, E. Rolfes, H. Schinzel

PP-MO-374 CHANGES IN VON WILLEBRAND FACTOR AND ADAMTS-13 DURING IN VITROFERTILIZATIONE. Westerlund* (SE), P. Henriksson, H. Wallén, O. Hovatta, K. Persdotter Eberg, F. Mobarrez,M. Blombäck, A. Antovic

PP-MO-375 FETAL AND MATERNAL THROMBOPHILIA IN IUGR WITH OR WITHOUT MATERNALHYPERTENSIVE DISEASEE. Biguzzi* (IT), F. Franchi, P. Pileri, P. Antonazzo, I. Cetin, P. Mannucci



145

146

PP-MO-376 TREATMENT OF VENOUS THROMBOEMBOLISM DURING PREGNANCY WITH A ONCE-DAILY REGIMEN OF LMWHF. Parent* (FR), P. Deruelle, X. Jaïs, M. Wolf, F. Jilwan, O. Sanchez, G. Meyer, G.Simonneau

PP-MO-377 MENORRHAGIA IS COMMON IN PATIENTS ON ORAL ANTICOAGULATION WITHVITAMIN-K-ANTAGONIST PHENPROCOUMONH. Rott* (DE), G. Kappert, S. Halimeh

PP-MO-378 FOLATE DEFICIENCY STATE AND HYPERHOMOCYSTEINEMIA AS CAUSE OFANTENATAL FETAL DEATHI. N. Talalaeva* (RU), A. D. Makatsaria, L. N. Kiss

PP-MO-379 PREDICTIVE VALUE OF THROMBOPATH DETERMINATION IN WOMEN WITHPREGNANCY COMPLICATIONSP. Ferroni* (IT), F. La Farina, R. Palmirotta, F. Martini, V. Raparelli, C. Nigro, S. Riondino, M.Proietti, M. Rampini, S. Basili, F. Guadagni

PP-MO-380 TNF-ALPHA GENE POLYMORPHISMS AND SUSCEPTIBILITY TO RECURRENTPREGNANCY LOSS IN ITALIAN WOMENR. Palmirotta, F. La Farina, P. Ferroni* (IT), G. Ludovici, C. Nigro, A. Savonarola, V. Raparelli,B. Leone, M. R. Rampini, F. Guadagni, S. Basili

PP-MO-381 ALTERED REFERENCE RANGES FOR PROTEIN C AND PROTEIN S DURING EARLYPREGNANCY: IMPLICATIONS FOR DIAGNOSIS OF THEIR DEFICIENCY DURINGPREGNANCYJ. M. Said, V. Ignjatovic* (AU), P. Monagle, S. P. Walker, J. R. Higgins, S. P. Brennecke

Animal and Experimental Models I

PP-MO-382 S 35972, A NOVEL ORALLY ACTIVE THROMBIN INHIBITOR : IN VITRO AND EX VIVOANTICOAGULANT ACTIVITYA. Rupin* (FR), P. Mennecier, M. O. Vallez, P. Gloanec, G. de Nanteuil, T. J. Verbeuren

PP-MO-383 COAGULATION FACTOR CONCENTRATIONS ARE NOT HIGHER IN THE HEPATICVEINS THAN IN THE PERIPHERAL CIRCULATIONA. P. A. Gadisseur* (BE), J. Schouten, S. Franque, I. Vangenechten, M. van der Planken, P.Michielsen

PP-MO-384 HYPOXIA MAY BE A STIMULUS FOR VENOUS THROMBUS RESOLUTIONC. E. Evans, J. Humphries, A. Wadoodi, M. Waltham, K. Burnand, A. Smith* (UK)

PP-MO-385 THE USE OF MRI TO FOLLOW THE FIRST 3 HOURS OF THROMBUS DEVELOPMENTIN AR-H067637 TREATED RATSA. Ravnefjord* (SE), S. Pehrsson, A. W. Bidar, F. Risse, P. D. Hockings, M. Elg

PP-MO-386 HAEMOSTATIC RESPONSE TO IN VITRO ADDITION OF RECOMBINANT FACTOR VIIa,PROTHROMBIN COMPLEX CONCENTRATE, OR CONCENTRATE OF FACTOR IX/X INBLOOD SPIKED WITH A DIRECT Xa INHIBITORJ. B. Olesen, K. Christiansen, J. Ingerslev, B. Sørensen, A. Hvas* (DK)

PP-MO-387 PERMISSIVE HYPOTENSION AND DESMOPRESSIN ENHANCE CLOT FORMATIONJ. B. Rezende-Neto, M. V. Andrade, J. R. Cunha-Melo, D. D. Ribeiro* (BR), T. A. Lisboa, E.R. Camargos, P. Martins, S. B. Rizoli

PP-MO-388 ENOXAPARIN DOES NOT DECREASE TOTAL MICROPARTICLES TISSUE FACTORACTIVITY IN AN EXPERIMENTAL MODEL OF EARLY VENOUS THROMBOSIS IN MICEE. Ramacciotti* (US), J. A. Diaz, A. E. Hawley, D. M. Farris, N. E. Ballard, S. K. Wrobleski, D.D. Myers Jr, P. K. Henke, T. W. Wakefield



Mon

day

Post

ers

PP-MO-389 PLATELET UPREGULATION IN MICE EXPOSED TO AMBIENT PARTICULATE MATTERF. Tablin* (US), J. W. Norris, M. Pombo, H. Auh, M. W. Lame, D. W. Wilson

PP-MO-390 PHARMACOLOGIC CHARACTARIZATION OF THE ANTIHEMOSTATIC EFFECTS OFACYLHYDRAZONE DERIVATIVESF. S. Frattani* (BR), E. O. Coriolano, L. M. Lima, C. A. M. Fraga, E. J. Barreiro, R. B. Zingali

PP-MO-391 EFFICACY AND SAFETY OF PROTHROMBIN COMPLEX CONCENTRATE ANDRECOMBINANT ACTIVATED FACTOR VII VERSUS PLACEBO IN A RABBIT MODEL OFHEMODILUTION, BLEEDING AND THROMBOSIS: A BLIND STUDYF. Le Sache* (FR), B. Le Bonniec, B. Dizier, A. Godier, C. Bachelot-Loza, J. Emmerich, C. M.Samama

PP-MO-392 A NOVEL MURINE HEMOSTASIS MODEL: STUDIES ON RECOMBINANT FACTOR VIIaAND NN1731H. C. Whinna* (US), D. M. Monroe

PP-MO-393 NDRG4-NULL MICE ARE VULNERABLE TO CEREBRAL ISCHEMIAH. Yamamoto* (JP), K. Kokame, H. Yanamoto, T. Okuda, Y. Nakajo, S. Miyamoto, T. Miyata

PP-MO-394 ORAL SYSTEMIC ADMINISTRATION OF ANKAFERD BLOOD STOPPER HAS NOSHORT-TERM TOXICITY IN AN IN VIVO RABBIT EXPERIMENTAL MODELH. Bilgili, O. Captug, A. Kosar, M. Kurt, M. Kekilli, A. Shorbagi, O. K. Kurt, O. Ozdemir, H.Goker, I. C. Haznedaroglu* (TR)

PP-MO-395 THE DIRECT ORAL THROMBIN INHIBITOR S 35972 IS ANTITHROMBOTIC IN THEMICROVASCULATURE OF MICEI. Marx* (FR), M. O. Vallez, J. Paysant, G. de Nanteuil, A. Rupin, T. J. Verbeuren

PP-MO-396 PHARMACOEQUIVALENCE OF ENOXAPARIN AND CONTAMINATED ENOXAPARIN ASSTUDIED IN ANIMAL MODELS OF BLEEDING AND THROMBOSISJ. Kuziej* (US), W. Jeske, D. Hoppensteadt, E. Litinas, E. McGeehan, J. Fareed, R. Kennedy

PP-MO-397 IS THE APTT OR ANTI-Xa A MORE RELIABLE MEASURE OF HEPARINANTICOAGULATION IN THE ACUTE PHASE RESPONSE?J. Uprichard* (UK), R. A. Manning, A. Hann, M. A. Laffan

PP-MO-398 URBAN AND DIESEL PARTICULATE MATTER INDUCE LUNG INFLAMMATION BUTPOOR SECONDARY HEMOSTASIS ACTIVATION IN MICEJ. Emmerechts* (BE), B. Nemery, M. Hoylaerts

PP-MO-399 IMMUNOGENICITY OF LOW MOLECULAR WEIGHT HEPARINS AND BIOSIMILARSJ. M. Walenga* (US), D. Hoppensteadt, J. Cunanan, W. P. Jeske, C. Adiguzel, M. Bakhos

PP-MO-400 THROMBOGENESIS WITH CONTINUOUS BLOOD FLOW IN THE INFERIOR VENACAVA: A NOVEL MOUSE MODELJ. A. Diaz* (US), A. E. Hawley, A. M. Berguer, S. K. Wrobleski, B. R. Lucchesi, D. D. Myers Jr

PP-MO-401 EFFECTS OF 7 kDa STREPTOKINASE FRAGMENT: THE RABBIT MODEL OFHAEMOSTASIS SYSTEMS. P. Gavrylyuk* (UA), O. M. Savchuk, G. L. Volkov, L. I. Ostapchenko

Clinical Trials I

PP-MO-402 HIGHLIGHTING IN VITRO HYPERCOAGULABILITY DURING IDIOPATHIC PULMONARYARTERIAL HYPERTENSION WITH ENDOTHELIAL DYSFUNCTIONA. Brunette* (FR), J. Max, V. Regnault, A. Benetos, T. Lecompte, D. Wahl, F. Chabot

PP-MO-403 DERIVATION OF A MODEL FOR PREDICTING THE WARFARIN MAINTENANCE DOSE INPATIENTS WITH VENOUS THROMBOEMBOLISM BASED ON THE RESPONSE TO ASTANDARDIZED INITIATION NOMOGRAMA. Lazo-Langner* (CA), K. Monkman, M. J. Kovacs



147

148

PP-MO-404 QUALITY OF TELEPHONE-BASED MANAGEMENT OF ORAL ANTICOAGULATIONTREATMENTM. Gubensek, A. Mavri* (SI)

PP-MO-405 URINARY PROTHROMBIN FRAGMENT 1.2 (UF1.2) LEVELS IN PREGNANCIESCOMPLICATED BY PREECLAMPSIAA. S. Andersen* (DK), T. Bergholt, C. Sørensen, I. Deltour, J. G. Berthelsen, M. R. Lassen

PP-MO-406 EFFICACY OF 3-MG WARFARIN LOADING DOSE ON TIME TO THERAPEUTIC INR INADULT THAI PATIENTSB. Suwanawiboon* (TH), P. Kongtim, Y. Chinthammitr, T. Ruchutrakool, W. Wanachiwanawin

PP-MO-407 EFFECTS OF AGE AND GENDER ON THE SINGLE-DOSE PHARMACOKINETICS (PK)AND PHARMACODYNAMICS (PD) OF APIXABANC. E. Frost* (US), S. Nepal, Y. Barrett, F. Lacreta

PP-MO-408 LONG-TERM TREATMENT WITH AN ORAL DIRECT THROMBIN INHIBITOR CHANGESTHE PATTERN OF INFLAMMATORY MARKERS IN PATIENTS WITH MYOCARDIALINFARCTIONC. Christersson* (SE), J. Oldgren, L. Wallentin, A. Siegbahn

PP-MO-409 HOW USEFUL IS DETERMINATION OF ANTI FACTOR Xa ACTIVITY TO GUIDEBRIDGING THERAPY WITH ENOXAPARIN? A PILOT STUDYC. Hammerstingl* (DE), H. Omran, B. Pötzsch

PP-MO-410 AN EVALUATION OF THROMBOTIC CHANGES IN BEREAVEMENTM. C. Morel-Kopp, T. Buckley, Q. Chen, G. Tofler, S. McKinley, R. Bartrop, C. M. Ward* (AU)

PP-MO-411 LONG TERM EFFECT OF TOMATO JUICE AND FISH OIL ON PLATELET FUNCTIONAND THROMBUS FORMATIONM. C. Morel-Kopp, B. McEwen, Q. Chen, C. M. Ward* (AU)

PP-MO-412 ANTI-HUMAN, ANTI-BOVINE THROMBIN ANTI-BODIES AND FACTOR V/Va ANTI-BODIES IN NORMAL HUMAN SUBJECTSC. Paterson* (US), J. Fareed

PP-MO-413 EFFICACY AND SAFETY OF LONG TERM ADMINISTRATION OF BEMIPARIN INPATIENTS WHO NEED CRONIC ANTICOAGULATION AND HAVE SUFFERED SEVEREAND RECURRENT GASTROINTESTINAL BLEEDINGE. Marti* (ES), J. Mateo, A. Santamaria, J. C. Souto, C. Alvarez, C. Villanueva, J.Fontcuberta

PP-MO-414 SUPERVISED PATIENT SELF-TESTING OF WARFARIN THERAPY USING AN INTERNETBASED EXPERT SYSTEM - A FOLLOW UP STUDYF. Ryan, S. Byrne, S. Oshea* (IE)

PP-MO-415 FONDAPARINUX VERSUS LEPIRUDIN IN THE MANAGEMENT OF PATIENTS WITHSUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) WITH OR WITHOUTTHROMBOSIS (ON BEHALF OF THE FLHIT STUDY INVESTIGATORS)F. Piovella* (IT), M. Barone, C. Beltrametti, C. Piovella, S. Barco, M. de Amici, A. D’Angelo

PP-MO-416 LIMITED UTILITY OF PLATELET-THROMBIN ACTIVATION MARKERS IN THEASSESSMENT OF PATIENTS WITH CHEST PAIN OR SUSPICION OF VENOUSTHROMBOEMBOLISMS. El Ghannudi, S. Gayol, T. Kirchgesner, M. L. Wiesel, O. Morel, L. Calvel, P. Bareiss, J.Kopferschmitt, J. P. Cazenave, P. Ohlmann, C. Gachet, F. Lanza* (FR)

PP-MO-417 EFFICACY AND SAFETY OF FONDAPARINUX IN THE INITIAL TREATMENT OF VENOUSTHROMBOEMBOLISM (VTE) IN PATIENTS WITH MODERATE RENAL IMPAIRMENT(MRI)H. R. Buller* (NL)



Mon

day

Post

ers

PP-MO-418 ASSESSING IMMUNE RESPONSE AFTER REPEATED AVIDIN REVERSAL OF THE ANTI-Xa ACTIVITY OF IDRABIOTAPARINUX (BIOTINYLATED IDRAPARINUX)I. Paty* (FR), P. Cortez, M. Trellu, E. Sultan

PP-MO-419 NEW ASSAYS FOR MEASURING DIRECT THROMBIN INHIBITORS ON PLASMAJ. J. Amiral* (FR), A. M. Vissac, M. Peyrafitte

PP-MO-420 IDENTIFICATION OF COAGULATION PARAMETERS WHICH DETERMINE THECOMBINED EFFECT OF LOW-MOLECULAR-WEIGHT HEPARIN CERTOPARIN ANDPHENPROCOUMON IN PATIENTS UNDERGOING CARDIOVERSION FOR RECENTATRIAL FIBRILLATIONJ. Harenberg* (DE), J. Wierdak, C. Giese, C. Weiss, C. Abletshauser, U. Tebbe

PP-MO-421 WHICH BIOLOGICAL TEST BETTER REFLECTS THE POTENTIAL HEMORRHAGIC RISKASSOCIATED WITH STACK-ON UNFRACTIONATED HEPARIN: RESULTS FROM THESTACKENOX STUDYL. Drouet* (FR), C. Bal Dit Sollier, J. Martin

PP-MO-422 PREVENTION OF VENOUS THROMBOSIS IN CANCER PATIENTS: A PROSPECTIVE,RANDOMIZED, DOUBLE-BLIND STUDY COMPARING TWO DIFFERENT DOSAGES OFLOW-MOLECULAR WEIGHT HEPARINL. Traby* (AT), A. Kaider, R. Schmid, A. Kranz, P. Quehenberger, P. A. Kyrle, S. Eichinger

PP-MO-423 IN VIVO TAFI ACTIVATION IN OFF-PUMP CORONARY ARTERY BYPASS SURGERY(OPCAB): EFFECT OF DIFFERENT HEPARIN DOSAGES AND CORRELATION WITHTHROMBIN AND PLASMIN GENERATIONM. Colucci* (IT), F. Semeraro, C. T. Ammollo, D. Paparella, G. Scrascia, C. Fondacone, N.Semeraro

PP-MO-424 EFFICACY OF EARLY ANTITHROMBOTIC TREATMENT IN RETINAL VEIN OCCLUSIONA. Donà, M. T. Sartori, S. Piermarocchi, E. Pilotto, L. Pasetto, A. Pagnan, P. Prandoni* (IT)

Intravascular Devices and Interventions I

PP-MO-425 INFERIOR VENA CAVAL FILTER INSERTION – 5 YEAR EXPERIENCE IN A TERTIARYCARE HOSPITALJ. Saour* (SA), M. El Sherif, A. Al Harthi, E. Bakhsh, L. Mammo

PP-MO-426 FILTER FRACTURE AND MIGRATION OF A GUNTHER TULIP RETRIEVABLE INFERIORVENA CAVA FILTER 22 DAYS AFTER IN A PEDIATRIC PATIENT: A CASE REPORTJ. Y. K. Yang* (CA), A. K. C. Chan, L. R. Brandao, S. Williams

PP-MO-427 ARTERIOVENOUS (AV) FISTULA THROMBOSIS AND THROMBOPHILIAJ. I. Varughese* (US), M. Sandhu, S. Sachdev, S. Palekar, A. Cohen, A. Eisenberger

PP-MO-428 IMMOBILIZATION OF CORN TRYPSIN INHIBITOR REDUCES THE IN VITROPROCOAGULANT PROPERTIES OF CATHETERSJ. W. Yau* (CA), A. R. Stafford, J. C. Fredenburgh, J. L. Brash, J. I. Weitz

PP-MO-429 IMPACT OF IN VIVO PLATELET ACTIVITY ON SUBCLINICAL STENT THROMBOSIS: ANOPTICAL COHERENCE TOMOGRAPHY STUDYK. Komukai* (JP), A. Tanaka, H. Kitabata, T. Tanimoto, S. Takarada, N. Nakamura, K. Hirata,M. Mizukoshi, T. Imanishi, T. Akasaka

PP-MO-430 REAL TIME MEASURMENTS OF COAGULATION ON BACTERIAL CELLULOSEL. Faxälv* (SE), H. Fink, B. Risberg, P. Gatenholm, T. L. Lindahl, A. Sellborn

PP-MO-431 PROGNOSTIC ROLE OF HYPERHOMOCYSTEINEMIA IN PATIENTS UNDERGOINGCORONARY STENT IMPLANTATIONO. A. Smirnova* (RU), V. M. Shmeleva, L. P. Papayan, S. A. Boldueva



149

150

PP-MO-432 HAEMOPHILIA AND INVASIVE CORONARY PROCEDURESR. Santoro* (IT), S. Prejanò, P. Iannaccaro, G. Muleo

PP-MO-433 A HISTORY OF LATE STENT THROMBOSIS IS NOT ASSOCIATED WITH INCREASEDACTIVATION OF THE CONTACT PHASE SYSTEMV. Pönitz* (NO), J. W. P. Govers-Riemslag, H. ten Cate, R. van Oerle, P. Næsgaard, H.Grundt, D. Pritchard, A. Larsen, D. W. T. Nilsen

Pediatric Thrombosis I

PP-MO-434 INCREASED LEVELS OF VON WILLEBRAND FACTOR MULTIMERS AND VWF-CLEAVING PROTEASE (ADAMTS-13) IN TERM AND PRETERM NEONATEST. Strauss, A. Zivelin, B. Ravid, A. Lubetsky* (IL), I. Morag, J. Kuint, G. Kenet

PP-MO-435 DEVELOPMENT OF A PEDIATRIC QUALITY OF LIFE INVENTORY FOR CHILDRENREQUIRING LONG-TERM ANTICOAGULATIONA. A. K. Bruce* (CA), M. E. Bauman, A. S. Newton, M. Bauman, L. Bajzar, K. Black, L.Legge, M. Massicotte

PP-MO-436 INCIDENCE OF THROMBOTIC AND BLEEDING COMPLICATIONS DURING CARDIACCATHETERIZATION IN CHILDREN (HEARTCAT-STUDY)A. Hanslik* (AT), E. Kitzmüller, M. Haumer, H. Karapetian, K. Thom, U. Salzer-Muhar, I.Michel-Behnke, C. Male

PP-MO-437 THROMBIN GENERATION IN CHILDREN ON ORAL ANTICOAGULANTSA. Greenway* (AU), V. Ignjatovic, R. Summerhayes, F. Newall, J. Burgess, L. Derosa, P.Monagle

PP-MO-438 EVALUATION OF POINT OF CARE INR IN CHILDRENA. L. Greenway* (AU), V. Ignjatovic, R. Summerhayes, F. Newall, J. Burgess, L. Derosa, P. T.Monagle

PP-MO-439 EFFECTS OF L-ASPARAGINASE THERAPY ON THROMBIN GENERATION INCHILDREN WITH ACUTE LEUKEMIAA. Yamashita* (JP), C. Nagae, T. Shoji, S. Muto, M. Asahara, M. Morimoto, K. Kondo, A.Kinoshita, S. Yamazaki, S. Takayama, M. Taki

PP-MO-440 THROMBOCYTOPENIA ASSOCIATED MULTIPLE ORGAN FAILURE IN AN INFANT - ACHALLENGING CASEA. Unuvar* (TR), D. Demirkol, A. Nayir, M. Karabocuoglu, D. Yanni, O. Devecioglu

PP-MO-441 EVALUATION OF THROMBOTIC EFFECTS OF ASPARAGINASE IN CHILDREN WITHACUTE LYMPHOBLASTIC LEUKEMIA (ALL)C. Pawlik* (BE), A. Demulder, P. Lê, A. Ferster

PP-MO-442 CONCURRENT PAS AND CSVT IN THE NEWBORND. Telega, S. Ong, O. O. Zaidat, C. Amlie-Lefond* (US)

PP-MO-443 MAJOR BLEEDING COMPLICATIONS IN PEDIATRIC MECHANICAL VALVE PATIENTSDURING BRIDGING ANTICOAGULATION THERAPYC. I. Segbefia* (CA), S. Williams, L. Brandao

PP-MO-444 CATHETER-RELATED THROMBOSIS AND INFECTION IN CHILDREN WITH LONG-TERMTOTAL PARENTERAL NUTRITIONI. L. Vegting, M. M. Tabbers, M. A. Benninga, C. H. van Ommen* (NL)

PP-MO-445 A CLINICAL CASE OF HEMOGLOBIN C DISEASE, PROTEIN S DEFICIENCY ANDLEUKEMIAD. Aïtchafa Tadlaoui* (DZ), C. Touchrift, Z. Guechi



Mon

day

Post

ers

PP-MO-446 ADAMTS-13 ACTIVITY IS DECREASED IN CHILDREN WITH BETA-THALASSEMIAD. Sosothikul* (TH), P. Kuwatjanakul, Y. Kittikalayawong, C. Bubpachart, P. Seksarn

PP-MO-447 VENOUS STASIS ULCER IN PAEDIATRIC POST PHLEBITIC SYNDROME -MULTIDISCIPLINARY MANAGEMENT OF A CHRONIC CONDITIOND. Castle* (CA), L. Brandao, S. Williams

PP-MO-448 PROTEIN C REPLACEMENT DURING FEBRILE NEUTROPENIA IN PEDIATRICPATIENTS WITH CANCERP. Giordano, V. Cecinati, M. Grassi, L. P. Brescia, G. C. Del Vecchio, F. de Leonardis, G.Arcamone, N. Santoro, F.A. Badainah* (IT)

PP-MO-449 AGE-RELATED DIFFERENCES IN IN VIVO UFH RESPONSE IN CHILDRENF. H. Newall* (AU), V. Ignjatovic, L. Johnston, G. Lane, R. Summerhayes, P. Monagle

PP-MO-450 ANTI-Xa:ANTI-IIa RATIO VARIES WITH AGE AND UFH CONCENTRATION IN CHILDRENF. H. Newall* (AU), V. Ignjatovic, L. Johnston, G. Lane, R. Summerhayes, P. Monagle

PP-MO-451 CORRELATION OF UFH MEASURES OF EFFECT WITH PROTAMINE TITRATION INCHILDRENF. H. Newall* (AU), V. Ignjatovic, L. Johnston, G. Lane, R. Summerhayes, P. Monagle

PP-MO-452 PAEDIATRIC THROMBOSIS IN KENYAG. W. Kitonyi* (KE), J. W. Githanga, J. A. Rajab, W. O. Mwanda

PP-MO-453 THROMBOPHILIA IN CHILDRENL. Lokar* (SI), V. Urlep ?alinoviæ, O. Krajnc, L. ?olman

PP-MO-454 EMPOWARMENT: EDMONTON PEDIATRIC WARFARIN SELF-MANAGEMENT STUDYM. E. Bauman* (CA), K. L. Black, M. L. Bauman, S. Kuhle, L. Bajzar, M. P. Massicotte

PP-MO-455 ENOXAPARIN MONITORING: CHALLENGES OF CENTRAL LINE BLOOD SAMPLESM. P. Massicotte* (CA), M. E. Bauman, K. L. Black, L. Bajzar

PP-MO-456 CHALLENGES OF ANTICOAGULATION THERAPY IN CHILDREN: UFHCONTAMINATION OF ENOXAPARIN ANTI Xa LEVELS WHEN DRAWN THROUGH ACENTRAL LINEM. P. Massicotte* (CA), M. E. Bauman, M. L. Bauman, K. L. Black, L. Bajzar

Health Service and Outcomes I

PP-MO-457 COMPUTER ASSISTED VKA MONITORING WITH POINT OF CARE DEVICE BYGENERAL PRACTITIONERSM. Basileo, E. Filippucci, S. Iaboni, P. Grilli, M. Vecchioli, G. Agnelli, A. Iorio* (IT)

PP-MO-458 PROSPECTIVE ASSESSMENT OF CLINICAL ENDPOINTS OF VKA TREATMENT IN APRIMARY CARE COMPUTER ASSISTED MANAGEMENT MODELA. Iorio* (IT), E. Filippucci, M. Basileo, S. Iaboni, E. Paccamiccio, M. Vecchioli, G. Agnelli

PP-MO-459 PSYCHOSOCIAL OUTCOME IN PARENTS OF CHILDREN WITH HAEMOPHILIAS. Wiedebusch, B. Siegmund* (DE), H. Pollmann, F. Muthny

PP-MO-460 CURRICULUM DEVELOPMENT IN THROMBOSIS MEDICINEC. Gonsalves* (CA), P. Wells, A. Karovitch, L. Varpio, M. Marks, M. Rodger

PP-MO-461 STRUCTURED MANAGEMENT OF ORAL ANTICOAGULANT THERAPY BY GENERALPRACTITIONERSC. Manotti* (IT), C. Pattacini, R. Emanuele

PP-MO-462 EVALUATING THE FEASIBILITY OF LESS FREQUENT INR TESTING DURING CHRONICANTICOAGULATION THERAPYD. M. Witt* (US), T. Delate, N. P. Clark, M. A. Crowther, D. A. Garcia, W. Ageno, E. M. Hylek



151

152

PP-MO-463 INCIDENCE AND PREDICTORS OF SERIOUS BLEEDING FOLLOWING POLYPECTOMYIN PATIENTS RECEIVING AND NOT RECEIVING ORAL ANTICOAGULATION THERAPYD. M. Witt* (US), T. Delate, K. H. McCool, M. Dowd, N. P. Clark, M. A. Crowther, D. A. Garcia,W. Ageno, F. Dentali, E. M. Hylek, W. G. Rector

PP-MO-464 QUALITY OF ORAL ANTICOAGULATION MANAGEMENT IN PHARMACIST VS NURSEMANAGED MODELS OF CAREE. A. Nutescu, A. Bautista* (US), W. Gao, T. Stamos, W. Galanter, J. Garofalo, J. Bauman

PP-MO-465 ENOXAPARIN IS COST-SAVING COMPARED WITH UNFRACTIONATED HEPARIN (UFH)FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN PATIENTS WITH ACUTEISCHEMIC STROKE: AN ANALYSIS OF HOSPITAL COSTS FROM THE PREVAIL TRIALG. Pineo* (CA), J. Lin, L. Stern, T. Subrahmanian

PP-MO-466 ENOXAPARIN FOR VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS IN PATIENTSWITH ACUTE ISCHEMIC STROKE IS ASSOCIATED WITH LOWER COSTS TO THEPAYERS THAN UNFRACTIONATED HEPARIN (UFH): ANALYSIS FROM THE PREVAILTRIALG. Pineo* (CA), J. Lin, L. Stern, T. Subrahmanian

PP-MO-467 PERFORMANCE OF A LOW-VOLUME COAGULATION ANALYZER WITH EXPANDEDTEST MENUM. Sonnek, H. Su, G. A. Cutsforth* (US)

PP-MO-468 ECONOMIC COMPARISON OF RIVAROXABAN WITH ENOXAPARIN IN CANADIANPATIENTS UNDERGOING TOTAL HIP AND TOTAL KNEE REPLACEMENTP. Wells, A. Diamantopoulos, H. McDonald* (CA), F. Forster, M. Lees

PP-MO-469 INTERIM ANALYSIS OF TRIPLE INTERVENTION TO IMPROVE INR CONTROL INWARFARIN-TREATED PATIENTSH. I. Bussey* (US), M. B. Walker, K. L. Bussey Smith, C. Frei

PP-MO-470 INFREQUENT USE OF EMPIRIC ANTICOAGULATION OR FIBRINOLYSIS FOR SEVEREACUTE PULMONARY EMBOLISMJ. A. Kline* (US), B. Hiestand, D. Slattery, D. Schreibner, D. Schreibner, R. Pendleton

PP-MO-471 ARNICA MONTANA HAS NO EFFECT ON COAGULATION AND BLEEDING TIME IN VIVOJ. N. Mahlangu* (ZA), J. N. Mahlangu, B. Saunders, A. Reaves, T. Nkujani, M. Basson

PP-MO-472 MAINTAINED IMPACT OF AN ELECTRONIC ALERT SYSTEM FOR VENOUSTHROMBOEMBOLISM PREVENTION AMONG HOSPITALIZED PATIENTS: 3-YEAREXPERIENCER. Lecumberri, M. Marqués, E. Panizo, P. Rodríguez-Otero, C. Pegenaute, A. García-Mouriz,J. A. Páramo* (ES)

PP-MO-473 REAL-WORLD PATTERNS OF ARGATROBAN OR LEPIRUDIN USE IN PATIENTS WITHSUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIAA. F. Shorr, R. V. Horblyuk* (US), A. Basu, M. D. Zilberberg

Cancer and Thrombosis I

PP-MO-474 DIC AND THROMBOPHILIA PROPHYLAXIS DURING CHEMOTHERAPY INGYNECOLOGIC CANCER PATIENTSA. Vorobev* (RU), A. Makatsaria

PP-MO-475 TICK INHIBITORS MODULATING BLOOD CLOTTING AND CELL PROLIFERATIONA. M. Chudzinski-Tavassi* (BR), P. L. De-Sá-Júnior, S. M. Simons, D. G. L. Oliveira, J. S.Ventura, F. Faria, I. F. C. Batista, E. M. Reis



Mon

day

Post

ers

PP-MO-476 HEMOSTATIC VARIABLES IN CANCER PATIENTS RECEIVING LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) NADROPARIN OR PLACEBO DURING CHEMOTHERAPY INTHE PROTECHT TRIALA. Falanga* (IT), A. Vignoli, M. Marchetti, M. Mandalà, L. Russo, M. Kauling, G. Agnelli, C.Bianchini, and the PROTECHT Study Group

PP-MO-477 INCREASED THROMBIN GENERATION IN LUNG CANCER PATIENTS IS PARTIALLYREVERSED BY SURGICAL RESECTION AND ENOXAPARIN PROPHYLAXISC. Papageorgiou* (FR), E. Marret, Y. Ynineb, F. Bonnet, I. Elalamy, G. T. Gerotziafas

PP-MO-478 EFFECT OF POST-OPERATIVE PROPHYLAXIS WITH ENOXAPARIN ONTHOMBOELASTOGRPHIC PROFILE OF PATIENTS WITH LUNG CANCERC. Papageorgiou* (FR), E. Marret, Y. Ynineb, F. Bonnet, G. T. Gerotziafas, I. Elalamy

PP-MO-479 LOW MOLECULAR WEIGHT HEPARIN DOWNREGULATES TISSUE FACTOREXPRESSION AND SUPPRESSES PANCREATIC CANCER CELL INVASION IN VITROC. Ettelaie* (UK), A. Maraveyas, M. E. W. Collier

PP-MO-480 GENETIC POLYMORPHISMS IN CLOTTING FACTORS AND THE RISK OF COLORECTALCANCERC. Y. Vossen* (NL), M. Hoffmeister, J. Chang-Claude, F. R. Rosendaal, H. Brenner

PP-MO-481 LEPTIN ENHANCES TISSUE FACTOR SYNTHESIS IN THE HUMAN BREAST CANCERCELL LINE MCF7E. Napoleone* (IT), A. Cutrone, F. Zurlo, G. Colavecchia, M. Latella, L. Iacoviello, G. deGaetano, M. B. Donati, R. Lorenzet

PP-MO-482 CALIBRATED AUTOMATED THROMBOGRAM (CAT) IS A SUITABLE AND USEFULASSAY FOR IDENTIFICATION AND CHARACTERIZATION OF THE PROCOAGULANTACTIVITY (PCA) OF TUMOR CELLSE. Diani* (IT), M. Marchetti, E. Cantalino, H. ten Cate, A. Falanga

PP-MO-483 A PROBABILISTIC COST-EFFECTIVENESS ANALYSIS FOR DEEP-VEIN THROMBOSISPROPHYLAXIS ENOXAPARIN VERSUS NO INTERVENTION IN ONCOLOGY PATIENTSFOLLOWING SURGERY IN BRAZILE. de Meis* (BR), L. Schluckebier, R. A. Fernandes, E. Bernardina, R. A. Levy, F. F. Quintella

PP-MO-484 COAGULATION PROTEINS IN HEALTHY VERSUS MALIGNANT COLON TISSUEG. L. van Sluis* (NL), H. M. H. Spronk, R. van Oerle, J. Westerga, H. ten Cate, J. M. M. B.Otten

PP-MO-485 CANCER CELL-DERIVED MICROPARTICLES ACCELERATE THROMBUS FORMATIONIN VIVOG. M. Thomas* (FR), L. Panicot-Dubois, D. Lombardo, C. Dubois

PP-MO-486 MOLECULAR PATHWAYS INVOLVED IN THROMBUS FORMATION INDUCED BYCANCER CELL-DERIVED MICROPARTICLES IN VIVOG. M. Thomas* (FR), C. Dubois, R. Lacroix, F. Dignat-George, D. Lombardo, L. Panicot-Dubois

PP-MO-487 LOW RISK FOR SYMPTOMATIC VENOUS THROMBOEMBOLIC EVENTS (VTE) DURINGCYTOKINE ADMINISTRATION FOR PERIPHERAL BLOOD STEM CELL MOBILIZATIONH. V. K. Naina* (US), R. K. Pruthi, D. J. Inwards, M. R. Litzow, S. M. Ansell, D. Angela, W. J.Hogan, M. A. Gertz, D. A. Gastineau, M. A. Elliott, G. S. Nowakowski, S. K. Kumar

PP-MO-488 VENOUS THROMBOEMBOLISM (VTE) IN HOSPITALIZED CANCER PATIENTS:PROPHYLAXIS FAILURE OR FAILURE TO PROPHYLAX !H. N. Abdel-Razeq, F. A. Badainh* (JO), I. M. Treish, A. H. Mansour

PP-MO-489 A MECHANISM FOR THROMBIN-DEPENDENT LUNG METASTASIS IN PATIENTS WITHOSTEOSARCOMAK. S. Borensztajn* (NL), H. Aberson, A. P. Groot, M. P. Peppelenbosch, A. Spek



153

154

PP-MO-490 THE CHEMOTHERAPEUTIC METABOLITE ACROLEIN MODULATES PRO- ANDANTICOAGULANT PATHWAYS ON ENDOTHELIAL AND SMOOTH MUSCLE CELLSL. L. Swystun* (CA), P. C. Liaw

PP-MO-491 EFFECT OF L-ASPARAGINASE ADMINISTRATION ON TISSUEFACTOR,THROMBOMODULIN ACTIVITY AND PROCOAGULANT PHOSPHOLIPIDS INCHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)A. Rousseau, P. Schneider, P. Vandreden, J. Vannier, B. J. Woodhams, M. Vasse* (FR)

PP-MO-492 VENOUS THROMBOEMBOLISM AND BLEEDING IN CANCER PATIENTS ONBEVACIZUMAB THERAPY: A META-ANALYSISN. M. Kuderer* (US), T. L. Ortel, C. W. Francis, A. A. Khorana, M. S. Poniewierski, G. H.Lyman

PP-MO-493 VENOUS THROMBOEMBOLISM COMPLICATING MALIGNANCY:EFFECT OF TUMOURSUBTYPE AND THROMBOTIC LOAD ON SURVIVALT. Prestidge, S. Lee, L. Young, P. Harper, P. A. Ockelford* (NZ)

PP-MO-494 ELEVATED LEVELS OF FVIIa-AT FOLLOWING PREDNISONE MONOTHERAPY INCHILDREN WITH NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIAU. Athale* (CA), T. Nayiager, J. McGrath, A. Moghrabi, A. Chan

PP-MO-495 PREVALENCE OF HYPERHOMOCYSTEINEMIA IN PATIENTS WITH MULTIPLEMYELOMAV. M. Shmeleva* (RU), L. P. Papayan, K. M. Abdulkadirov

Venous Thrombosis: Diagnosis I

PP-MO-496 USEFULNESS OF VENOMETER TEST IN OUTPATIENT WITH CLINICAL SUSPICION OFDEEP VEIN THROMBOSISA. Alatri* (IT), O. Paoletti, L. Bassi, A. Zimmermann, E. Spotti, N. Delpero, S. Testa

PP-MO-497 CUT-OFF LEVEL OF SOLUBLE FIBRIN FOR DIAGNOSING VENOUSTHROMBOEMBOLISM USING NANOPIA®SFA. Suzuki* (JP), H. Yago, H. Wada, T. Matsumoto, N. Yamada, A. Sudo, T. Nobori

PP-MO-498 COMPARISON OF THE WELLS SCORE WITH THE SIMPLIFIED REVISED GENEVASCORE FOR ASSESSING PRETEST PROBABILITY OF PULMONARYA. Penaloza* (BE), C. Melot, S. Motte

PP-MO-499 “COCKADE THROMBUS”, A NEW ULTRASOUND DIAGNOSISM. Maufus, G. Le Gal, P. Quehe, A. Delluc* (FR), L. Bressollette

PP-MO-500 ”COCKADE” THROMBOSIS OF LOWER LIMBS IS ASSOCIATED WITH REDUCEDOCCURRENCE OF SYMPTOMATIC PULMONARY EMBOLISMA. Delluc* (FR), P. Quehe, E. Plat, M. Maufus, G. Le Gal, K. Lacut, E. Oger, D. Mottier, L.Bressollette

PP-MO-501 PERFORMANCE OF FIVE D-DIMER ASSAYS IN THE DIAGNOSIS OF SYMPTOMATICDISTAL LEG VEIN THROMBOSISB. Luxembourg* (DE), J. Schwonberg, C. Hecking, M. Schindewolf, D. Zgouras, S.Lehmeyer, E. Lindhoff-Last

PP-MO-502 PERFORMANCE CHARACTERISTICS OF A NEW AUTOMATED LATEXIMMUNOTURBIDIMETRIC ASSAY FOR DETERMINING D-DIMER CONCENTRATIONS INHUMAN PLASMAC. Silverstrim* (US), C. J. Hoecke, R. S. Greenfield, E. A. Lazarski, H. J. L. Fryer



Mon

day

Post

ers

PP-MO-503 IMPROVEMENT OF THE SPECIFICITY AND DIAGNOSTIC UTILITY OF A D- DIMER (DD)TEST FOR DEEP VEIN THROMBOSIS (DVT) EXCLUSION USING DIFFERENT CUT-OFFLEVELS ACCORDING TO AGE AND GENDERC. Legnani* (IT), M. Cini, M. Poggi, C. Abate, E. Favaretto, L. Piscitelli, G. Guazzaloca, G.Palareti

PP-MO-504 MULTICENTER EVALUATION OF A NEW QUANTITATIVE HIGHLY SENSITIVE LATEX D-DIMER ASSAY IN PATIENTS WITH CLINICALLY SUSPECTED VENOUSTHROMBOEMBOLISM (VTE)C. Legnani* (IT), M. Cini, D. Scarvelis, P. Toulon, J. Wu, G. Palareti

PP-MO-505 PREDICTION RULES FOR PULMONARY EMBOLISM: A META-ANALYSISE. Ceriani* (CH), C. Combescure, G. Le Gal, T. Perneger, H. Bounameaux, A. Perrier, M.Righini

PP-MO-506 UTILITY OF D-DIMER TESTING IN PATIENTS WITH CLINICALLY SUSPECTEDPULMONARY EMBOLISM AND IMPAIRED RENAL FUNCTIONF. A. Klok* (NL), R. Karami-Djurabi, J. Kooiman, S. I. Velthuis, M. Nijkeuter, M. V. Huisman

PP-MO-507 RIGHT VENTRICULAR REMODELING BY AND POTENTIAL USE OF CARDIAC MRI INTHE CLINICAL FOLLOW-UP OF PATIENTS WITH ACUTE PULMONARY EMBOLISMF. A. Klok* (NL), S. Romeih, J. J. M. Westenberg, L. J. M. Kroft, A. de Roos, M. V. Huisman

PP-MO-508 EVALUATION OF VENTILATION AND PERFUSION LUNG SPECT (SINGLE PHOTONEMISSION COMPUTED TOMOGRAPHY) IN THE DIAGNOSIS OF PULMONARYEMBOLISM: PRELIMINARY RESULTS BASED ON 100 CASESS. Querellou, P. Guillo, F. Couturaud, P. Salaun, G. Le Gal* (FR), K. Lacut, E. Oger, C.Leroyer, D. Mottier, A. Le Duc-Pennec

PP-MO-509 NON-IMPLEMENTATION OF GUIDELINE RECOMMENDATIONS FOR DIAGNOSIS OFDEEP VENOUS THROMBOSIS IN GERMANYH. E. Gerlach* (DE), S. M. Schellong, V. Hach-Wunderle, E. Rabe, H. B. Riess, H. Carnarius,S. Eberle, R. M. Bauersachs

PP-MO-510 PRO275SER HOMOZYGOUS MUTATION OF PROC GENE CAUSES TYPE II INHERITEDPROTEIN C DEFICIENCYJ. Wang* (CN), J. Dai, Q. Fu, T. Yu, X. Wang, H. Wang

PP-MO-511 COMPOUND HETEROZYGOUS MUTATIONS IN THE PROS1 GENE RESPONSIBLE FORQUANTITATIVE AND QUALITATIVE PROTEIN S DEFICIENCYJ. Yamanouchi* (JP), T. Hato, H. Fujiwara, Y. Yakushijin, M. Yasukawa

PP-MO-512 ANTICOAGULATION PRIOR TO DIAGNOSTIC CONFIRMATION IN PATIENTS WITHSUSPECTED PULMONARY EMBOLISMM. R. Marchick* (US), D. M. Courtney, C. Kabrhel, C. L. Moore, K. E. Nordenholz, J. A. Kline

PP-MO-513 ANTITHROMBIN DEFICIENCY: A GAP IN DIAGNOSTICSR. Fischer* (DE), K. Heidinger, A. Huth,Kühne, P. Staritz, R. Zimmermann, A. Pavlova, J.Oldenburg, B. Kemkes,Matthes

PP-MO-514 EVALUATION OF THE COMBINATION OF D-DIMER AND SOLUBLE FIBRINDETERMINATIONS IN PATIENTS WITH SUSPECTED VENOUS THROMBO-EMBOLISMS. Mirshahi* (FR), C. Soria, B. Kouchakji, G. Kierzek, J. Borg, L. Drouet, D. Elkharrat, R.Varin, J. Chidiac, M. Grimaux, C. Parry, B. J. Woodhams, J. Soria

PP-MO-515 A NEGATIVE IMMUNOTURBIDOMETRIC D-DIMER AS A STAND-ALONE TESTEXCLUDES PULMONARY EMBOLISMS. M. Bates* (CA), C. Kearon, J. A. Julian, J. Douketis, S. Schulman, B. MacKinnon, S.Parpia, J. S. Ginsberg



155

156

PP-MO-516 PREOPERATIVE SCREENING USING VENOUS DUPLEX SCANNING DOES NOT ALTERTHE OUTCOME IN PATIENTS AT HIGH RISK OF POSTOPERATIVE VENOUSTHROMBOEMBOLISMT. Yamaki* (JP), H. Sakurai, K. Soejima, T. Kono, A. Hamahata

Hemophilia I

PP-MO-517 FATAL POST SPLENECTOMY PULMONARY EMBOLISM IN MILD HAEMOPHILIA. AREPORT OF A CASEA. Davoodabadi* (IR), B. Keleidari

PP-MO-518 FUNCTIONAL MRI TECHNIQUES AS EARLY DIAGNOSTIC MARKERS IN HEMOPHILICARTHROPATHYA. Amirabadi* (CA), E. Miller, H. Gahunia, S. A. F. Peel, A. Zhong, R. Weiss, G. Detzler, A. S.Doria

PP-MO-519 BONE QUALITY IN PATIENTS WITH HAEMOPHILIA EVALUATED BY QUANTITATIVEULTRASOUNDA. Boban* (HR), D. Kastelan, S. Zupancic-Salek

PP-MO-520 ALLELIC VARIANTS OF HUMAN FACTOR VIII IN BRAZILIAN PATIENTS WITH SEVEREHEMOPHILIA A AND CORRELATION WITH THE RISK OF INHIBITORA. Santos* (BR), G. Damian, L. H. Siqueira, E. V. de Paula, J. M. Annichino-Bizzacchi, M. C.Ozelo

PP-MO-521 LOWER INCIDENCE OF IGGS SUBCLASSES OF ANTI-FVIII ANTIBODIES THATRECOGNIZE AN INTERMEDIATE-PURITY PLASMA DERIVED FACTOR VIII PRODUCT INSEVERE HEMOPHILIA A INHIBITOR POSITIVE PATIENTSA. Santos* (BR), S. A. L. Montalvão, L. H. Siqueira, G. B. Damian, S. Thomas, M. Veiga, D.E. Fujimoto, A. Streva, E. V. de Paula, J. M. Anicchino-Bizzacchi, M. C. Ozelo

PP-MO-522 CARDIOVASCULAR DISEASE IN PATIENTS WITH HEMOPHILIA BA. A. Sharathkumar* (US), M. Soucie, B. Trawinski, A. Griest, A. Shapiro

PP-MO-523 INHERITED BLEEDING DISORDERS: THE EMILIA ROMAGNA REGION REGISTRY, 2008UPDATEA. Tagliaferri* (IT), G. Rivolta, C. di Perna, C. Biasoli, L. Valdrè, G. Rodorigo, M. D’Incà, M.Serino, S. Macchi, D. Vincenzi, P. Pedrazzi, M. Arbasi, F. Riccardi, C. Pattacini

PP-MO-524 COMPARISON OF THREE DIFFERENT THROMBIN GENERATION ASSAYS IN PATIENTSWITH HAEMOPHILIAS. Aghighi, A. F. Riddell* (UK), P. Chowdary, A. Gatt

PP-MO-525 MANAGEMENT OF ACUTE CORONARY SYNDROMES IN HAEMOPHILIACS: A NEWCHALLENGE BETWEEN HAEMORRHAGIC AND THROMBOTIC RISKA. Coppola* (IT), G. F. Rivolta, M. Lapecorella, A. C. Molinari, C. Santoro, M. di Capua, M. N.D. di Minno, L. Banov, C. di Perna, E. Zanon, P. Schinco, R. Santoro, A. Tagliaferri

PP-MO-526 MULTIDISCIPLINARY APPROACH FOR OPTIMIZATION OF HAEMOPHILIA CARE INVENEZUELAA. Ruiz-Saez* (VE), A. Boadas, A. Arguello, N. de Bosch, A. Luque, C. Garrido

PP-MO-527 VARIABLE IMMUNE RESPONSE IN TWO BROTHERS WITH MILD/MODERATEHEMOPHILIA A CARRYING THE ARG2150HIS SUBSTITUTIONB. Fimbel* (FR), S. Regina, C. Pouplard, G. Lavigne-Lissalde, R. D’Oiron, Y. Gruel

PP-MO-528 SPORADIC VERSUS FAMILIAR SEVERE HAEMOPHILIA A RATIO IN A NEONATECOHORTC. Altisent* (ES), F. Vidal, L. Ramirez, M. Martorell, I. Corrales, R. Parra



Mon

day

Post

ers

PP-MO-529 DUPLICATION OF EXONS 1 TO 22 OF THE F8 GENE: À PROPOS OF A HAEMOHILIA APATIENTC. Costa* (FR), E. Bieth, P. Boisseau, S. Letourneau, F. Dastot, E. Girodon, M. Goossens

PP-MO-530 THE FRENCH BLOOD PRODUCTS SUPPLY DATABASE (MDSRAPPRO): AN EFFECTIVETOOL FOR LONG-TERM NATIONAL SURVEILLANCE OF COAGULATION FACTORSAND MANAGEMENT OF SUPPLY SHORTAGES A COORDINATION BETWEENPHARMACISTS, PHYSICIANS, PATIENTS ASSOCIATION, HEALTH AUTHORITIESP. Chocarne, M. Gensbittel, V. Chamouard, C. Rothschild, J. Goudemand, S. Clayessens, N.Ferré, B. Worms, J. Vernois, C. Vigneron, P. Arnaud, F. Suzan, C. Ratignier* (FR)

PP-MO-531 CARRIER AND PRENATAL DIAGNOSIS OF HEAMOPHILIA IN CHINESE PEDIGREED. Jing* (CN), Y. Lu, Q. Ding, H. Wang, X. Wang

PP-MO-532 MULTICENTRIC SELF-ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE INROMANIAN HAEMOPHILIACS, USING EQ-5DD. Lighezan* (RO), M. Mihailov, L. Pop, L. Ritli, C. Jinca, P. Stancu, A. Cucuianu, D. Baghiu,G. Olteanu, A. Lacatusu, E. Ursu, W. Schramm, M. Serban

PP-MO-533 DIFFERENTIAL EFFECT OF PROPHYLACTIC OR ON DEMAND TREATMENT REGIMESIN HEMOPHILIA A PATIENTS ON TAFI ACTIVATIOND. Mikovic* (RS), M. Holmström, B. J. Woodhams, J. Antovic

PP-MO-534 THE UK NEQAS GENETICS QA SCHEME FOR INHERITED BLEEDING DISORDERSD. J. Perry* (UK), T. Cumming, S. Kitchen, I. Jennings, A. Goodeve, M. Hill, I. Walker

PP-MO-535 PATTERNS OF BLEEDING IN CONGENITAL HEMOPHILIA PATIENTS WITH INHIBITORSAND VERY FREQUENT BLEEDING: ANALYSIS FROM THE HEMOPHILIA ANDTHROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRYE. J. Neufeld* (US), D. L. Cooper

PP-MO-536 MOLECULAR ANALYSIS OF HEMOPHILIA A IN MURCIA, SPAINF. García Candel* (ES), E. Tizzano, M. Moreno, E. Salido, M. Majado, J. Moraleda, C. Funes,A. Morales

PP-MO-537 THE RELATIONSHIP BETWEEN FACTOR LEVELS RADIOLOGICAL SCORE ANDACTIVE LIFE OF 14 PATIENTS WITH HEMOPHILIAC ARTHROPATHYS. Guler, F. Pekun, E. Turkkan* (TR), G. Korkmaz

PP-MO-538 A SERIES OF HEREDITARY FACTOR DEFICIENCIES PRESENTING WITH BLEEDING ATA PEDIATRIC HEMATOLOGY UNITF. Pekun, E. Turkkan* (TR), S. Guler, G. Korkmaz

PP-MO-539 12 NOVEL FACTOR IX MUTATIONS IDENTIFIED IN IRANIAN HAEMOPHILIA B PATIENTSG. Rastegarlari* (IR), M. Rassoulzadegan, S. Ravanbod, S. Hejazi, S. Enayat, F. A. Ala

PP-MO-540 IMPACT ON THROMBIN GENERATION OF DIFFERENT FACTOR VIII CONCENTRATESIN PATIENTS WITH ACQUIRED HAEMOPHILIAG. Salvagno* (IT), J. Astermark, M. Gunnarsson, M. Franchini, G. Poli, G. Guidi, G. Lippi, E.Berntorp

PP-MO-541 A PHARMACOKINETIC STUDY: IMPACT ON THROMBIN GENERATION OF TWORECOMBINANT FACTOR VIII CONCENTRATES IN SUBJECTS WITH HAEMOPHILIA AG. Salvagno* (IT), J. Astermark, M. Ekman, M. Franchini, G. Guidi, G. Lippi, R. Janco, E.Berntorp

PP-MO-542 COMPARISON OF THE RATES OF JOINT ARTHROPLASTY IN PATIENTS WITH SEVEREFACTOR VIII AND IX DEFICIENCY: AN INDEX OF DIFFERENT CLINICAL SEVERITY OFTHE TWO COAGULATION DISORDERSG. Tagariello* (IT), A. Iorio, E. Santagostino, M. Morfini, R. Bisson, M. Innocenti, M. Mancuso,M. Mazzucconi, G. Pasta, P. Radossi, G. Rodorigo, C. Santoro, R. Sartori, A. Scaraggi, L.Solimeno, P. Mannucci



157

158

PP-MO-543 HEPATITIS C IN HAEMOPHILIA – PREDICTIVE VALUES OF COAGULATION FACTORACTIVITIES IN PREDICTION OF FIBROSCAN VERIFIED CIRRHOSISG. Thomson* (UK), S. Trenchfield, D. Bevan, G. Moore, J. Ingerslev, S. Rangarajan, B.Sørensen

PP-MO-544 THROMBIN GENERATION: A COMPARISON OF ASSAYS USING PLATELET-POOR AND–RICH PLASMA SAMPLES FROM HEALTHY CONTROLS AND PATIENTS WITHHEMOPHILIAG. R. Lischetzki* (DE), H. Topf, M. Rauh

PP-MO-545 PRELIMINARY EVALUATION OF DAILY QOL ASSESSMENTS IN CONGENTIALHEMOPHILIA PATIENTS WITH ALLOANTIBODY INHIBITORSG. A. Young* (US), C. T. Wilke, D. L. Cooper, A. Pickard

PP-MO-546 IDENTIFICATION AND CHARACTERIZATION OF A NOVEL ADENINE TO GUANINETRANSITION IN INTRON 10 OF THE FACTOR VIII GENE AS A CANDIDATE CAUSATIVEMUTATION OF MILD HEMOPHILIA AH. Inaba* (JP), T. Koyama, K. Shinozawa, K. Fukutake

PP-MO-547 SUCCESSFUL LIVER TRANSPLANTATION IN A PATIENT WITH MILD HAEMOPHILIA AAND LOW-TITRE OF FACTOR VIII INHIBITOR TREATED WITH RECOMBINANT FACTORVIIa: THE FIRST ARGENTINIAN CASE STUDIEDH. A. Guglielmone* (AR), S. Minoldo, G. Jarchum

PP-MO-548 ALL ROUND UTILITY OF FACTOR VIII DEFICIENT PLASMA WITH VWFJ. Xia* (US), H. Patel, C. Kung, M. Triscott

PP-MO-549 UTILITY OF THROMBIN GENERATION IN SCREENING PATIENTS WITH HEMOPHILIAFACTOR DEFICIENCIESJ. R. Wu* (US), T. S. Smith, B. Bai

PP-MO-550 THE ROLE OF FIBROSCAN IN THE INVESTIGATION OF LIVER FIBROSIS INHAEMOPHILIACS WITH CHRONIC HEPATITIS C VIRUSS. Green, J. Vowles, D. Sheridan, M. L. Schmid, K. L. Talks* (UK)

PP-MO-551 FIRST EXPERIENCES WITH THE MEASUREMENT OF THROMBIN GENERATION(TGA)ON THE CEVERON®ALPHA IN THE ROUTINE LABL. Wagner* (AT), R. Luddington, A. Grigorov, L. Wiens, I. Hrachovinova, B. R. Binder

PP-MO-552 PREVALENCE AND MANAGEMENT OF INHERITED BLEEDING DISORDERS IN IRANM. Lak* (IR), R. A. Sharifian, M. R. Baghaiepour, H. Mansouritorghabeh

PP-MO-553 HEALTH-RELATED QUALITY OF LIFE IN RUSSIAN PATIENTS WITH HEREDITARYCOAGULOPATHIESP. A. Vorobyev, O. V. Borisenko, U. A. Zhulev, N. I. Zozulya* (RU), K. G. Kopylov, E. A.Telnova, A. A. Tonoyan

PP-MO-554 SAFETY AND EFFICACY OF RECOMBINANT FACTOR VIII FOR THE TREATMENT OFPREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA A IN CHINAR. Yang* (CN), Y. Zhao, J. Sun, J. Wu, X. Wang, M. Yu

PP-MO-555 GENETIC DEFECT ANALYSIS OF 104 HEMOPHILIA A PATIENTS IN TAIWANY. Chen* (TW), T. Chao, S. Hu, S. Cheng

Hemophilia Therapy I

PP-MO-556 PRION REDUCTION BY THE MANUFACTURING PROCESS OF A VWF/FVIII PRODUCTDEMONSTRATED BY BIOASSAY AND BIOCHEMICAL ASSAYA. Gröner* (DE), A. Buschmann, S. Rehberg, M. Groschup, W. Schäfer



Mon

day

Post

ers

PP-MO-557 MANUFACTURING PROCESSES OF PLASMA-DERIVED PRODUCTS REMOVE PRIONSA. Gröner* (DE), W. Schäfer

PP-MO-558 CHARACTERIZATION OF A NEW RECOMBINANT FVIII (N8) WITH ANTI-FVIIIMONOCLONAL ANTIBODIES (MAB)A. Gruhler* (DK), B. Vandahl, M. Kjalke

PP-MO-559 BIOPHYSICAL CHARACTERIZATION OF GLYCOPEGYLATED RECOMBINANT HUMANFVIIaA. D. Nielsen* (DK), C. Rischel

PP-MO-560 CONTINUOUS INFUSION PRACTICE IN 22 HAEMOPHILIA COMPREHENSIVE CARECENTRES IN 16 EUROPEAN COUNTRIESA. Batorova* (SK), P. Holme, A. Gringeri, K. Fijnvandraat, M. Richards, C. Hermans, C.Altisent, M. Lopez-Fernández

PP-MO-561 PERIPHERAL ARTERIO-VENOUS SHUNTS FOR VENOUS ACCESS IN CHILDREN WITHHAEMOPHILIAB. Raubal* (AT), K. Thom, T. Hölzenbein, N. Jones, K. Zwiauer, G. Endres, C. Male

PP-MO-562 EFFECTIVE HAEMOSTASIS WITHOUT FACTOR VIII - MAJOR CARDIAC SURGERY IN APATIENT WITH MILD HAEMOPHILIA A AND A HISTORY OF INHIBITOR DEVELOPMENTB. Sørensen* (UK), S. Rangarajan, S. McCorkell, S. Ferris, M. Mitchell, D. Bevan

PP-MO-563 FOUR YEARS OF EXPERIENCE WITH ADMINISTRATION OF THE RECOMBINANTFACTOR VIII ADVATE ® IN CHILDRENB. Blazek* (CZ), H. Ptoszkova, T. Kuhn

PP-MO-564 A GLYCOPEGYLATED LONG ACTING RFVIIa REDUCES BLEEDING IN HEMOPHILICRABBITSB. Lauritzen* (DK), M. Tranholm, M. Ezban

PP-MO-565 PURIFICATION AND CHARACTERISATION OF A NEW RECOMBINANT FVIII (N8)I. Thim, B. S. Vandahl* (DK), J. Karlsson, N. K. Klausen, J. Pedersen, T. N. Krogh, M. Kjalke,J. M. Petersen, L. B. Johnsen, G. Bolt, P. L. Nørby, J. J. Hansen, K. Kjaergaard, T. D.Steenstrup

PP-MO-566 EVALUATION OF SECONDARY PROPHYLAXIS WITH RFVIIa IN HEMOPHILIACPATIENTS WITH INHIBITORSC. Sedano* (ES), C. Altisent, F. Garcia-Candel, F. Gimenez, E. Mingot, R. Nuñez, M. Paloma,I. Soto, F. Velasco, A. Cid, M. López-Fernandez, V. Jimenez, M. Prieto

PP-MO-567 THE USE OF FEIBA DURING SURGERIES IN HEMOPHILIA PATIENTS WITHINHIBITORS: UPDATE FROM THE SURF INTERNATIONAL REGISTRYC. Negrier* (FR), R. Fleury, J. Ha Noh, F. Baghaei, S. Claeyssens, T. Yee, H. Gajek, D.Tolenaar, D. Stephens

PP-MO-568 FURTHER CLINICAL EXPERIENCE WITH A FACTOR XI CONCENTRATEC. H. Dash* (UK), E. W. Gascoigne, K. R. Gillanders

PP-MO-569 PHARMACOKINETIC (PK) EVALUATION OF A NEW RFVIII (N8) AFTER I.V.ADMINISTRATION OF DIFFERENT DOSE LEVELS TO FVIII KNOCK-OUT MICED. M. Karpf* (DK), M. Kjalke, T. D. Steenstrup, H. Pelzer, H. Agerso

PP-MO-570 PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) PROPERTIES OF A NEWRECOMBINANT FVIII (N8) IN HEMOPHILIA A DOGSD. M. Karpf* (DK), M. Kjalke, H. Pelzer, L. Thim, H. Agerso, E. P. Merricks, H. G. Franck, R.A. Raymer, T. C. Nichols, M. Ezban



159

160

PP-MO-571 A PHASE IV CLINICAL STUDY IN HAEMOPHILIA B PATIENTS USING AN ULTRAPUREFACTOR IX (FIX) PLASMA PRODUCTE. P. Mauser-Bunschoten, I. Kleine Budde* (NL), F. J. M. van der Meer, I. R. O. Nováková, P.Ypma, P. W. G. van der Linden, P. F. W. Strengers

PP-MO-572 EFFECTIVE INTRACRANIAL HAEMORRHAGE MANAGEMENT WITH CONTINUOUSINFUSION OF HIGHLY PURIFIED VWF/FVIII COMPLEX CONCENTRATE IN AN ADULTWITH SEVERE A HAEMOPHILIAF. Daniele* (IT), V. Rossi, C. Santoro

PP-MO-573 PROLONGED HAEMOSTATIC EFFECT OF 40K PEG-RFIX COMPARED TO RFIX IN AFECL3 INDUCED INJURY MODEL IN HEMOPHILIA B MICEF. Moeller* (DK), H. Oestergaard, M. Tranholm

PP-MO-574 CHARACTERISTICS OF THE FIRST HUMAN CELL LINE RECOMBINANT HUMANFACTOR VIII (HUMAN-CL RHFVIII)H. Sandberg* (SE), I. Agerkvist, C. Kannicht, M. Ramström, P. Stenlund, M. Dadaian

PP-MO-575 PROLONGED IN VIVO HALF-LIFE AND RETAINED ACTIVITY OF FACTOR IXGLYCOPEGYLATED IN THE ACTIVATION PEPTIDEP. K. Holm, L. C. Petersen, J. R. Bjelke, A. A. Pedersen, L. Hansen, M. B. Hermit, J. M.Petersen, T. N. Krogh, M. D. Andersen, M. Tranholm, S. E. Bjørn, H. Østergaard* (DK)

PP-MO-576 BENEFIT ANALYSIS OF A 750 IU RECOMBINANT FACTOR VIII POTENCY FOR THETREATMENT OF HEMOPHILIA A PATIENTSJ. D. Epstein* (US), J. H. Kwon

PP-MO-577 POSTMARKETING EXPERIENCE WITH SUCROSE-FORMULATED RECOMBINANTFACTOR VIII IN PATIENTS WITH HEMOPHILIA AK. Fukutake* (JP), R. Musso, J. Yong, C. Norenberg

PP-MO-578 GLYCOPEGYLATED HUMAN RECOMBINANT FACTOR IX SHOWED PROLONGEDHAEMOSTATIC ACTIVITY IN CYNOMOLGUS MONKEYSH. Offenberg, K. Abel, C. Sommer, H. Oestergaard, M. Tranholm* (DK), W. Beck, P. K. Holm

PP-MO-579 RESCUE IMMUNOTOLERANCE IN HAEMOPHILIAC PATIENTS TO A SERIOUS WITH AHIGHM. Quintana* (ES), J. Romero, M. Alvarez, P. Baltar, V. Jimenez, F. Navarro

PP-MO-580 IN VITRO ACTIVITY OF N8, A NEW RECOMBINANT FVIII COMPOUNDM. Kjalke* (DK), A. Bagger-Sørensen, L. F. Larsen, J. K. Rasmussen, N. K. Klausen, M.Ezban

PP-MO-581 CLINICAL USE OF WHOLE BLOOD THROMBELASTOGRAHY IN TAILORINGMANAGEMENT OF BYPASSING AGENTS IN HAEMOPHILIACS WITH INHIBITORSP. A. Holme* (NO), B. Sørensen

PP-MO-582 COMPARISON OF THE HAEMOSTATIC AND PROTHROMBOTIC ACTIVITIES OFDIFFERENT FACTOR IX PREPARATIONS BY MEANS OF THE THROMBIN GENERATIONTESTR. Al Dieri* (NL), H. C. Hemker

PP-MO-583 HIV POSITIVE PATIENT WITH SEVERE HEMOPHILIA A AND MALIGNANT LYMPHOMA:PROPHYLAXIS WITH RECOMBINANT FVIIIV. Geierova* (CZ), V. Pohlreichova, S. Rittich, K. Benesova, I. V. Hrachovinova, P. Cetkovsky,P. Salaj

PP-MO-584 DOES THERAPY OF HEMOPHILIA CHANGE IN THE ELDERLY ?W. Miesbach* (DE), S. Krekeler, G. Asmelash, B. Llugaliu, S. Alesci



Mon

day

Post

ers

Inhibitors: Pathogenesis, Prevention and Treatment I

PP-MO-585 SAFETY AND EFFICACY OF SEQUENTIAL COMBINED BYPASS THERAPY OF BLEEDSUNRESPONSIVE TO A SINGLE BYPASSING AGENTA. Gringeri* (IT), K. Fischer, A. Karafoulidou, M. López-Fernández

PP-MO-586 VWF/FVIII CONCENTRATES IN HIGH-RISK IMMUNOTOLERANCE: THE RESISTSTUDIESA. Gringeri* (IT), N. Ewing, M. A. Heisel-Kurth, K. Hoots, C. Negrier

PP-MO-587 IMMUNE TOLERANCE IN PATIENTS WITH HEMOPHILIA A AND LONGSTANDINGINHIBITORSA. L. Dunn* (US), S. L. Meeks, R. L. Chapman, C. L. Kempton

PP-MO-588 ROLE OF THE SPLEEN IN THE INITIATION OF THE IMMUNE RESPONSE TOTHERAPEUTIC FACTOR VIII IN HEMOPHILIA AA. Navarrete* (FR), S. Dasgupta, S. Delignat, Y. Repesse, S. Andre, Y. Meslier, M.Teyssandier, S. Kaveri, S. Lacroix-Desmazes

PP-MO-589 HIGH-DOSE IMMUNOTOLERANCE TREATMENT THREE TIMES A WEEK IN A SEVEREHAEMOPHILIA A PATIENTS. Haya, A. R. Cid* (ES), A. Moret, M. C. Carreras, P. Casaña, M. A. Dasi, J. A. Aznar

PP-MO-590 FVIII INHIBITOR EPITOPE MAPPING IN HAEMOPHILIA A PATIENTSA. Moret* (ES), S. Haya, M. Quintana, V. Jimenez-Yuste, C. Altisent, R. Parra, R. Perez, M.F. Lopez, F. Gimenez, J. J. Malcorra, M. J. Paloma, M. Prieto, C. Sedano, I. Soto, M. J.Gutierrez, V. Cortina, B. Galmes, M. Canaro, J. A. Aznar

PP-MO-591 IMMUNE TOLERANCE OUTCOME AND ECONOMICS RETROSPECTIVE REGISTRY(ITER-STUDY) OF PATIENTS WITH HAEMOPHILIA A (HA) AND FACTOR VIII INHIBITORSA. Rocino* (IT), A. Gringeri, T. Lambert, R. Klamroth, M. Lopez-Fernàndez F, M. Diniz

PP-MO-592 CORRELATION OF ITI COURSE TO EPITOPE LOCATION ON FACTOR VIII - AN INTERIMANALYSIS FROM THE OBSITI STUDYC. Königs* (DE), C. Kessel, C. Escuriola-Ettinghausen, K. Becker-Peters, K. Klich, F. Vorpahl,C. Heller, W. Kreuz

PP-MO-593 LOW INCIDENCE OF FACTOR VIII INHIBITOR DEVELOPMENT IN THE DUBLINHAEMOPHILIA A POPULATION FOLLOWING FVIII PRODUCT SWITCHC. L. Bacon* (IE), E. E. Singleton, B. White, B. Nolan, R. Gilmore, V. Jenkins, B. Brady, J.O’Donnell

PP-MO-594 ITI EXPERIENCE IN HEMOPHILIA A PATIENTS WITH INHIBITORS AND A POORPROGNOSISC. Berger* (FR), S. S. T. Thouvenin, J. J. R. Reynaud, C. C. L. Latour, J. J. L. S. Stephan

PP-MO-595 SUCCESSFUL IMMUNE TOLERANCE INDUCTION IN A YOUNG HEMOPHILIAC A WITHA HIGH RESPONDING INHIBITOR USING MOROCTOCOG ALFAC. M. Potthoff* (DE), S. Weinspach, B. Boxnick, H. Laws

PP-MO-596 NOVEL FACTOR VIII MUTATIONS IN U.S. HEMOPHILIA PATIENTS: RELATIONSHIP TOETHNICITY AND INHIBITOR HISTORYC. H. Miller* (US), C. Hooper, J. Benson, D. Ellingsen, J. Driggers, T. C. Abshire, P. L.Bockenstedt, D. B. Brettler, J. di Paola, G. Massey, A. T. Neff, A. D. Shapiro, M. Tarantino, B.M. Wicklund, M. J. Manco-Johnson, A. L. Dunn, C. Knoll, M. Creary, J. M. Soucie

PP-MO-597 INTENSIVE PERI-OPERATIVE USE OF FACTOR VIII AND THE MISSENSE MUTATIONARG593CYS ARE RISK FACTORS FOR FACTOR VIII INHIBITORS IN MILD ANDMODERATE HEMOPHILIA AC. L. Eckhardt* (NL), L. A. Menke, C. H. van Ommen, J. H. van der Lee, R. B. Geskus, P. W.Kamphuisen, M. Peters, K. Fijnvandraat



161

162

PP-MO-598 THE EFFICACY AND SAFETY OF RECOMBINANT FACTOR VIIa (RFVIIa) IN ADULTPATIENTS: THE EXPERIENCE OF THE HEMOPHILIA AND THROMBOSIS RESEARCHSOCIETY (HTRS) REGISTRY (2004-2008)C. M. Kessler* (US), D. L. Cooper, M. E. Carr

PP-MO-599 SUCCESSFUL TREATMENT OF INTRACRANIAL HAEMORRHAGE IN TWO PATIENTSWITH HAEMOPHILIA A AND INHIBITORSD. A. Antic* (RS), I. Elezovic, L. Davidovic, P. Djoric, P. Miljic

PP-MO-600 SAFETY OF HIGHER DOSES OF RECOMBINANT FACTOR VIIa (RFVIIa) >=250 MCG/KGIN PATIENTS WITH CONGENITAL HEMOPHILIA COMPLICATED BY INHIBITORS (CHWI):THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRYEXPERIENCE (2004-2008)E. J. Neufeld* (US), C. M. Kessler, J. C. Gill, C. T. Wilke, D. L. Cooper

PP-MO-601 PRIMARY PROPHYLAXIS WITH RECOMBINANT FACTOR VIIa (RFVIIa) IN ELEVENHAEMOPHILIA A PATIENTS WITH INHIBITORS YOUNGER THAN 3 YEARS OLDF. López Fernández* (ES), V. Jiménez Yuste, C. Altisent, F. Garcia Candel, C. Sedano, M.Prieto, A. Cid, E. Mingot, R. Nuñez, M. Paloma, I. Soto

PP-MO-602 PROSPECTIVE ADVATE IMMUNE TOLERANCE INDUCTION REGISTRY (PAIR):COLLECTING REAL-WORLD EXPERIENCE WITH PLASMA/ALBUMIN-FREERECOMBINANT FVIIIG. Spotts* (US), H. Luu, D. Stephens, B. Ewenstein

PP-MO-603 PROSPECTIVE STUDY OF INHIBITOR INCIDENCE WITH CONTINUOUS INFUSION OFFACTOR CONCENTRATES DURING AND AFTER SURGICAL PROCEDURES INPATIENTS WITH HAEMOPHILIA A, B, OR VON WILLEBRAND DISEASEG. Auerswald* (DE), A. Bade, J. Johne, K. Haubold, S. Masurat, C. Moorthi, D. Overberg

PP-MO-604 IDENTIFYING NONRESPONSIVE BLEEDING EPISODES IN PATIENTS WITHHEMOPHILIA AND INHIBITORS: A CONSENSUS DEFINITIONG. Young* (US), E. Berntorp, P. Collins, R. D’Oiron, N. Ewing, A. Gringeri, C. Négrier

PP-MO-605 GENERATION AND PHENOTYPIC CHARACTERIZATION OF A FACTOR VIII–SPECIFICHUMAN BCR TRANSGENIC C57BL/6 MOUSEA. Benhida, L. A. Vanderelst, F. G. Ectors, V. A. Carlier, J. G. Gilles* (BE), M. G. Jacquemin,J. R. Saint-Remy

PP-MO-606 THE VALUE OF EARLY TREATMENT IN PATIENTS WITH HAEMOPHILIA ANDINHIBITORSK. Kavakli* (TR), A. Yesilipek, B. Antmen, S. Aksu, C. Balkan, D. Yilmaz, A. Kupesiz, I.Sasmaz, P. Lindgren, J. Mesterton

PP-MO-607 INFLUENCE OF FACTOR VIII PRODUCTS, VIRAL INACTIVATION AND DOSAGEREGIMENS ON MEANINGFUL INHIBITOR DEVELOPMENT IN CHILDREN WITH SEVEREHEMOPHILIA A: RESULTS OF A NON-CONCURRENT COHORT STUDYC. Bidlingmaier, D. Manner, S. Halimeh, S. Holzhauer, K. Kurnik, M. Olivieri* (DE), U. Nowak-Gottl

PP-MO-608 RADIOSYNOVECTOMY IN CHILDREN WITH SEVERE HEMOPHILIA AND FACTOR VIIIOR IX INHIBITORP. Laguna* (PL), P. Zbikowski, J. Cwikla, A. Klukowska, M. Matysiak

PP-MO-609 FIRST LINE IMMUNOSUPPRESSIVE TREATMENT FOR ACQUIRED FACTOR VIIIANTIBODIES: RESULTS OF THE EUROPEAN ACQUIRED HAEMOPHILIA REGISTRY(EACH2)P. Collins* (UK), F. Baudo, A. Huth-Kuhne, P. Knobl, H. Levesque, P. Marco, L. Nemes, K.Peerlinck, L. Tengborn



Mon

day

Post

ers

von Willebrand Disease I

PP-MO-610 GENOTYPIC DIAGNOSIS OF VWD: PRELIMINARY RESULTS IN THE ANALYSIS OFEXON 28A. I. Woods* (AR), A. C. Kempfer, L. Keller, J. C. Calderazzo, A. Sanchez-Luceros, J. Paiva-Palomino, M. Lazzari

PP-MO-611 LOW REQUIREMENT OF VON WILLEBRAND FACTOR (VWF) THERAPEUTICCONCENTRATE FOR THE MANAGEMENT OF A VON WILLEBRAND DISEASE (VWD)TYPE 2M PATIENT WITH POST SPINAL FUSION SURGERY INDUCED SYSTEMICINFLAMMATORY RESPONSEA. Faradji* (FR), N. Salhi, L. Marcoux, C. Bopp, L. Grunebaum, D. Desprez, C. Caron, J.Clavert, M. Giacomelli

PP-MO-612 PROSPECTIVE ASSESSMENT OF BLEEDING SEVERITY IN CONSECUTIVE PATIENTSREFERRED FOR HEMOSTATIC EVALUATIONA. Tosetto* (IT), G. Castaman, F. Rodeghiero, J. Eikenboom

PP-MO-613 FACTOR VIII AND VON WILLEBRAND ACTIVITY ARE STRONGLY RELATED TO THEDESMOPRESSIN BIOLOGICAL RESPONSE IN VON WILLEBRAND DISEASEA. Sanchez-Luceros* (AR), A. I. Woods, S. S. Meschengieser, S. Grosso, M. A. Lazzari

PP-MO-614 SEGREGATION OF TYPE 1, TYPE 3, AND TYPE 2N VON WILLEBRAND DISEASE INTHREE GENERATIONS OF AN AFFECTED FAMILYA. M. Guilliatt* (UK), B. D. M. Theophilus, M. S. Enayat, M. D. Williams

PP-MO-615 IMPROVED AUTOMATED VWF:RCO ASSAY FOR VWF_FVIII CONCENTRATES ANDPLASMA SAMPLES BY ADJUSTMENT OF ASSAY REAGENTS, COMPOSITION ANDPERFORMANCE PARAMETERSM. Stadler, A. Hillarp* (SE), C. Haderer, C. Zapfl, K. Pock, J. Weinberger, J. Roemisch

PP-MO-616 SUCCESSFUL MANAGEMENT OF TOTAL KNEE REPLACEMENT SURGERY IN ANELDERLY PATIENT WITH 2A VWD AND HEREDITARY THROMBOPHILIA WITH APURIFIED VON WILLEBRAND FACTOR CONCENTRATEA. C. Molinari* (IT), P. Perutelli, P. Marino, U. Viesti, G. Barberis, A. Camera, L. Banov

PP-MO-617 HIGHLY PURIFIED VWFACTOR FOR THE MANAGEMENT OF A VON WILLEBRANDDISEASE (VWD) UNDERGOING REDO CARDIAC SURGERYA. C. Demulder* (BE), D. Rans, D. Noubouossié, A. Efira, A. Jeandriens, P. van der Linden

PP-MO-618 FOCUS ON LONG TERM PROPHYLAXIS IN VON WILLEBRAND DISEASE (VWD): DATAFROM A FRENCH CLINICAL POST-MARKETING SURVEY OF A HIGH-PURITY VONWILLEBRAND FACTOR CONCENTRATE WITH A LOW FACTOR VIII CONTENTA. Borel-Derlon* (FR), J. Goudemand, M. Bertrand, P. Sié, C. Boyer-Neumann, PostMarketing Study Group, C. Henriet, F. Bridey, C. Chatelanaz

PP-MO-619 EFFICACY AND SAFETY OF A VON WILLEBRAND FACTOR CONCENTRATE WITH ALOW FVIII CONTENT IN CHILDREN WITH VON WILLEBRAND DISEASE (VWD)A. Borel-Derlon* (FR), S. Aronis, H. Platokouki, P. Maes, Post Marketing Study Group, C.Chatelanaz, F. Bridey

PP-MO-620 IMPORTANCE OF MULTIMER SIZE FOR VON WILLEBRAND FACTOR FUNCTIONUNDER BLOOD FLOW – COMPARISON OF COMMERCIALLY AVAILABLE PRODUCTSA. J. Reininger* (DE), J. I. Angerer, M. Napoleone, M. Spannagl, M. F. Schneider

PP-MO-621 EVALUATION OF A NEW COLLAGEN BINDING ASSAYB. van Haren* (NL), S. Gijsen, B. Verbruggen



163

164

PP-MO-622 PHARMACOKINETICS AND PHARMACODYNAMICS OF THE APTAMER ARC1779, ASPECIFIC INHIBITOR OF VON WILLEBRAND FACTOR A1 DOMAINS. A PILOT STUDY INPATIENTS WITH TYPE 2B VON WILLEBRAND DISEASES. Schranz, B. Jilma* (AT), C. Firbas, J. C. Gilbert, R. Hutabarat, P. Knöbl

PP-MO-623 IDENTIFICATION OF A PSEUDOGENE CONVERSION IN THE VON WILLEBRANDFACTOR GENE AS THE CAUSE OF TYPE 3 VON WILLEBRAND DISEASEB. D. Theophilus* (UK), A. M. Guilliatt, D. Chandra, M. D. Williams

PP-MO-624 THE SPECTRUM OF VWD TYPE 2 PHENOTYPES ASSOCIATED WITH A1 DOMAINMUTATIONSC. M. Millar* (UK), A. F. Riddell, G. Mellors, T. T. Yee

PP-MO-625 VON WILLEBRAND DISEASE TREATMENT PATTERNS IN THE UNITED STATESC. Leissinger* (US), D. Nugent

PP-MO-626 AN ACCURATE AND ROUTINELY ADAPTED ENZYME-LINKED IMMUNOSORBENTASSAY FOR TYPE 2N VON WILLEBRAND DISEASE DIAGNOSISC. Caron* (FR), C. Ternisien, M. Wolf, E. Fressinaud, J. Goudemand, A. Veyradier

PP-MO-627 COST EFFECTIVENESS STRATEGY TO PREDICT POSTOPERATIVE BLEEDING IN VONWILLEBRAND DISEASE DEFINED BY VWF:RCO <30 IU/MLD. Delitto* (US), K. J. Smith, M. V. Ragni

PP-MO-628 A NOVEL MUTATION IN THE VWF A1 DOMAIN CAUSING TYPE 2B VWD WITH SEVERECHRONIC THROMBOCYTOPENIAD. H. Bevan* (UK), J. Cutler, M. Hadonou, M. J. Mitchell

PP-MO-629 LABORATORY CHARACTERISTICS OF AN AUTOMATED VON WILLEBRAND FACTORACTIVITY (VWF) ASSAYJ. I. Tange, D. Chen* (US), R. K. Pruthi, W. L. Nichols, J. A. Heit

PP-MO-630 CASE SERIES OF PATIENTS WITH INHERITED HEMORRHAGIC DISORDERS ANDRECURRENT SEVERE GASTROINTESTINAL BLEEDINGS – IMPORTANCE OFCAPSULE ENDOSCOPYD. Pulanic* (HR), S. Zupancic Salek, R. Pulanic, A. Boban, B. Labar

PP-MO-631 AN UNUSUAL CASE OF TYPE 2N VWDE. G. Merriman* (NZ), A. Laurie, M. Smith

PP-MO-632 ACQUIRED VON WILLEBRAND SYNDROME WITH A TYPE 2B PHENOTYPE:DIAGNOSTIC AND THERAPEUTIC DILEMMASE. Scepansky* (US), M. Othman, H. Smith

PP-MO-633 BLEEDING SEVERITY AND QUALITY OF LIFE IN VON WILLEBRAND DISEASEE. M. de Wee* (NL), E. P. Mauser-Bunschoten, J. G. van der Bom, M. E. L. Degenaar-Dujardin, H. C. J. Eikenboom, K. Fijnvandraat, A. de Goede-Bolder, K. Meijer, I. Nováková, F.W. G. Leebeek

PP-MO-634 A PROSPECTIVE STUDY ABOUT VON WILLEBRAND DISEASE IN WOMEN WITHOBSTETRIC AND GYNAECOLOGICAL PROBLEMSF. Gagliano* (IT), R. Amodeo, A. Martorana, R. Guido, G. Dantona

PP-MO-635 MONOZYGOTIC TWINS MONOCORIAL CHILDBIRTH IN A PRIMIPARA PATIENTSUFFERING FROM VON WILLEBRAND DISEASE. FOLLOW UP DURING PREGNANCYAND PROPHYLAXIS OF SURGICAL CAESAREANF. Gagliano* (IT), A. Maiorana, R. Amodeo, R. Guido, G. Dantona

PP-MO-636 VWF:CB AND VWF:RCO. ASSAY TO DIFFERENTIATE BETWEEN TYPE 1 AND TYPE 2VON WILLEBRAND DISEASE IN NATIONAL BLOOD CENTREF. Md. Afandi* (MY), S. Che Nordin, F. Abd.Karim, Y. Ayob, N. Asidin



Mon

day

Post

ers

PP-MO-637 UTILITY OF THE IMPEDANCE AGGREGOMETRY WITH MULTIPLE ELECTRODES (MEA)IN DIAGNOSIS OF VON WILLEBRAND DISEASE (VWD)F. Lopez Fernandez* (ES), F. Miras, M. Albors, L. Garcia Iglesias, A. Vale Lopez, M. CostaPinto Prego de Faria, J. Batlle

PP-MO-638 MUTATION SPECTRUM AND MOLECULAR STUDIES OF TYPE 2 VON WILLEBRANDDISEASEF. Ahmad* (IN), R. Schneppenheim, U. Budde, F. Oyen, T. Obser, I. Hasan, M. Kannan, R.Saxena

PP-MO-639 EXPANDED PHENOTYPE-GENOTYPE CORRELATIONS IN A PAEDIATRIC POPULATIONWITH TYPE 1 VON WILLEBRAND DISEASEJ. D. Robertson* (AU), P. R. Yenson, M. L. Rand, V. S. Blanchette, D. Lillicrap, P. D. James

PP-MO-640 SPECIES-DEPENDENT VARIABILITY OF ADAMTS13-MEDIATED PROTEOLYSIS OFHUMAN RECOMBINANT VWFK. Varadi, H. Rottensteiner, S. Vejda, E. M. Muchitsch, A. Weber, H. Gritsch, P. L. Turecek*(AT), H. J. Ehrlich, H. P. Schwarz

Other Inherited Coagulation Disorders I

PP-MO-641 INHERITED COAGULATION DISORDERS IN THE PUBLIC REFERENCE HEMOSTASISLABORATORY IN URUGUAYA. Manzino* (UY), L. Varela, I. M. I. Queijo

PP-MO-642 ALPHA1-ANTITRYPSIN PITTSBURGH IN A FAMILY WITH BLEEDING TENDENCYB. Hua* (CN), L. Fan, Y. Liang, Y. Zhao, E. G. D. Tuddenham

PP-MO-643 HOW SHOULD WE TREAT AFIBRINOGENAEMIA PATIENTS WITH THROMBOTICCOMPLICATIONSB. Brand* (CH), T. Pfammatter, B. Amann-Vesti, E. Bachli

PP-MO-644 SUCCESSFUL USE OF ACTIVATED RECOMBINANT FACTOR VII IN THE CEREBRALOPERATION FOR INTRACEREBRAL HEMORRHAGE IN A PATIENT WITH FACTOR VIIDEFICIENCYI. Sasmaz, B. Antmen* (TR), Y. Kilinc, G. Leblebisatan, B. S. Karagun, T. Erman

PP-MO-645 IDENTIFICATION OF FOUR NOVEL MUTATIONS IN COAGULATION FACTOR V GENEASSOCIATED WITH CONGENITAL FACTOR V DEFICIENCYM. Fretigny, V. Broyer, L. Rugeri, V. Guerin, P. de Moerloose, C. Negrier, C. Vinciguerra* (FR)

PP-MO-646 FIVE NOVEL FACTOR V GENE MUTATIONS ASSOCIATED WITH INHERITED FACTOR VDEFICIENCYD. Huang* (CN), X. Wang, Q. Ding, H. Wang, G. Xu, H. Chen, J. Dai, Y. Lu, T. Yu

PP-MO-647 SYMPTOMATIC CONGENITAL DISORDERS OF FIBRINOGEN – EFFECTIVETREATMENT WITH FIBRINOGEN CONCENTRATED. Overberg* (DE), W. Eberl, A. Bade, K. Haubold, J. Johne, C. Moorthi, G. Auerswald

PP-MO-648 MOLECULAR CHARACTERIZATION OF 9 GENETIC DEFECTS RESPONSIBLE FOR FVDEFICIENCYE. M. Paraboschi* (IT), I. Guella, S. Duga, F. Peyvandi, P. M. Mannucci, R. Asselta

PP-MO-649 TWO NOVEL AND ONE RECURRENT MISSENSE MUTATIONS CAUSING COMBINEDFACTOR V AND VIII DEFICIENCY IN TWO TUNISIAN PATIENTSH. Elmahmoudi, A. Jlizi, M. Ben Amor, E. Gouider* (TN), B. Meddeb, A. Ben Ammar Elgaaied

PP-MO-650 MOLECULAR CHARACTERIZATION OF 11 TUNISIAN FAMILIES WITH INHERITED FXIIIDEFICIENCYH. Elmahmoudi, M. Ben Amor, E. Gouider* (TN), R. Horchani, A. Ben Ammar Elgaaied



165

166

PP-MO-651 CONGENITAL FACTOR V DEFICIENCY: MALAYSIA EXPERIENCEF. Abdul Karim* (MY)

PP-MO-652 LOW PLASMA CONCENTRATION OF FIBRINOGEN AND FACTOR XIII ACTIVITY ARESYNERGISTICALLY ASSOCIATED WITH INCREASED BLEEDING AFTER CARDIACSURGERYF. Baghaei* (SE), L. Ternström, V. Radulovic, M. Karlsson, M. Hyllner, A. Jeppsson

PP-MO-653 T33P SUBSTITUTION AND W519X MUTATION IN TWO TURKISH PATIENTS WITH FXIDEFICIENCYH. Caglayan* (TR), S. Usluer, Y. Pekcelen, E. Berber, S. Aksu

PP-MO-654 MANAGEMENT OF KIDNEY TRANSPLANTATION IN A FACTOR VII-DEFICIENT PATIENTM. Lapecorella* (IT), M. Napolitano, A. Lucchesi, F. Pisani, P. di Cocco, V. Rizza, A. Famulari,C. Mazzotta, L. Aloisio, F. Bernardi, M. Pinotti, P. Ferraresi, G. Mariani

PP-MO-655 FREQUENCY OF INTRACRANIAL HEMORRHAGE AMONG IRANIAN PATIENTS WITHRARE BLEEDING DISORDERSM. Karimi* (IR), N. Cohan, M. Yavarian, Y. Ardeshiri, A. Vafafar

PP-MO-656 IMPACT OF THE C.-65G>C VARIANT ON THE F7 TRANSCRIPTIONAL REGULATIONM. Giansily-Blaizot* (FR), E. Lopez, J. Tapon-Bretaudière, O. Chafa, M. Claustres, M. C.Romey-Chatelain

PP-MO-657 NEW SEQUENCE VARIATIONS IN FACTOR VII GENE FOUND IN APPARENTLYHEALTHY ADULTS PRESENTING WITH TYPE 1 FACTOR VII DEFICIENCYN. I. Kolaitis* (GR), M. Giansily-Blaizot, P. Koliou, G. Vartholomatos, J. Schved

PP-MO-658 THROMBIN GENERATION TEST AND CLINICAL BLEEDING RISK IN FACTOR XIDEFICIENCYL. Rugeri, J. Bordet, H. Simpson, B. Chatard, C. Negrier, Y. Dargaud* (FR)

Acquired Coagulation Disorders and DIC I

PP-MO-659 THE EFFECT OF THYROID AUTOANTIBODIES ON WARFARIN STABILITY:RETROSPECTIVE INCEPTION COHORT STUDYA. Squizzato* (IT), E. Rancan, B. van Zaane, V. Gerdes, W. Ageno, F. Dentali

PP-MO-660 HUMAN PROTEIN C CONCENTRATE IN THE TREATMENT OF PURPURA FULMINANS:SAFETY AND OUTCOME IN 94 PATIENTSA. Veldman* (AU), D. Fischer, B. Eberspaecher, U. Mansmann, R. Schosser

PP-MO-661 COAGULOPATHY SECONDARY TO NIACIN THERAPYA. Ahmed, B. McJunkin, S. J. Jubelirer* (US)

PP-MO-662 SUCCESSFUL INHIBITOR-ELIMINATION WITH RITUXIMAB IN ONE PATIENT WITH ACARRIER STATE FOR HEMOPHILIA A, 9 PATIENTS WITH ACQUIRED HEMOPHILIA AAND ONE PATIENT WITH POSTPARTAL HEMOPHILIA AA. Huth-Kuehne* (DE), P. Staritz, P. Lages, M. Krause, R. Zimmermann

PP-MO-663 ACQUIRED INHIBITORS OF BLOOD COAGULATION: THE VENEZUELAN NATIONALHEMOPHILIA CENTER EXPERIENCEA. Boadas* (VE), C. Reyes, M. Mijares, N. de Bosch, M. Echenagucia, A. Torres, R. Borges,A. Ruiz-Saez

PP-MO-664 COMPARATIVE STUDY OF COAGULATION IN THE PORTAL AND SYSTEMICCIRCULATIONS OF CIRRHOTIC PATIENTSB. Delahousse* (FR), V. Labat, B. Hammamy, J. Perarnau, Y. Gruel



Mon

day

Post

ers

PP-MO-665 APPLICATION OF THROMBELASTOGRAPHY® FOR MONITORING HAEMOSTATICCHANGE IN RATS WITH LIPOPOLYSACCHARIDE-INDUCED DISSEMINATEDINTRAVASCULAR COAGULATIONH. Tsai, M. Liao, W. Liaw, C. Wu* (TW)

PP-MO-666 A CASE OF SEVERE ACQUIRED FACTOR VII DEFICIENCY WITH ANAPHYLAXIS ANDDISSEMINATED INTRAVASCULAR COAGULATION FOLLOWING ADMINISTRATION OFDIFFERENT FACTOR VII CONCENTRATESD. Lechner* (AT), S. Machherndl-Spandl, P. Knoebl

PP-MO-667 THE USE OF PROTHROMBIN COMPLEX CONCENTRATE IN PATIENTS UNDER ORALANTICOAGULATION OR WITH HEPATIC FAILURE: A PROSPECTIVE STUDYF. Campos* (PT), E. Cruz, C. Lau, R. Matos, N. Pinho, M. Miranda, S. Morais, M. Campos

PP-MO-668 CLINICAL EFFICACY AND SAFETY OF HIGH DOSES OF ANTITHROMBIM III (AT)TREATMENT OF SEVERE SEPSIS AND SEPTIC SHOCK IN NEUTROPENICTHROMBOCYTOPENIC PATIENTS (PTS)G. M. Galstyan* (RU), E. B. Orel, A. V. Krechetova, S. A. Vasiliev, M. G. Alexanyan, V. M.Gorodetsky

PP-MO-669 A PROGRESS REPORT ON THE PROSPECTIVE STUDY FOR THE DIAGNOSIS OF DICH. Wada* (JP), K. Kawasugi, S. Kushimoto, H. Tsuyoshi, T. Uchiyama, Y. Seki, K. Okamoto,T. Okamura, S. Madoiwa, S. Gando

PP-MO-670 IMPAIRED THROMBIN GENERATION AND FIBRIN CLOT FORMATION IN PATIENTSWITH DILUTIONAL COAGULOPATHY IN MAJOR SURGERYS. E. M. Schols* (NL), M. D. Lancé, M. A. H. Feijge, J. Damoiseaux, M. A. Marcus, K.Hamulyák, H. ten Cate, J. W. M. Heemskerk, E. C. M. van Pampus

PP-MO-671 ARE TEG PATTERN INTERPRETATIONS RELIABLET. Exner* (AU), K. Parsi

PP-MO-672 AUTOLOGOUS PLASMA FOR THE STUDY OF ANAPHYLATOXIN KINETICS IN MANU. Schott* (SE), R. Norda

PP-MO-673 POINT-OF-CARE COAGULATION MONITORS CALIBRATED FOR THE INTERNATIONALNORMALIZED RATIO FOR CIRRHOSIS (INRLIVER) CAN HELP TO IMPLEMENT THEINRLIVER FOR THE CALCULATION OF THE MELD SCOREV. Chantarangkul* (IT), A. Tripodi, M. Primignani, A. Dell’Era, M. Clerici, M. Cazzaniga, F.Iannuzzi, F. Salerno, P. M. Mannucci

PP-MO-674 THE SIGNIFICANCE OF SNAKE VENOM AND ANTIVENOM SPECIFICITY IN HUMANPLASMAS. Buschek, V. Ignjatovic* (AU), R. Summerhayes, R. Lowe

Consultative Hemostasis I

PP-MO-675 GENETIC DETERMINANTS OF RESPONSE TO WARFARIN IN OMANI PATIENTSA. V. Pathare* (OM), S. Alkindi, S. Alzadjali, R. Misquith, R. Krishnamoorthi

PP-MO-676 HEMOSTATIC MANAGEMENT IN JEHOVAH’S WITNESS PATIENT UNDERGOINGCOMPLEX CARDIAC SURGERYD. Bolliger* (US), G. Sreeram, R. J. Molinaro, F. Szlam, E. P. Chen, K. A. Tanaka

PP-MO-677 UNEXPLAINED MENORRHAGIA AND HEMOSTATIC EVALUATION INGYNAECOLOGICAL PRACTICE, A RETROSPECTIVE STUDYH. M. Knol* (NL), D. H. Bogchelman, K. Meijer, A. G. J. van der Zee, J. van der Meer



167

168

PP-MO-678 DIVERSE COAGULATION LABORATORY CHARACTERISTICS OF EDTA- VS. CITRATE-ANTICOAGULATED PLASMA SAMPLES AND A SIMPLE METHOD TO DIFFERENTIATETHEML. K. Cardel* (US), D. Chen, R. K. Pruthi, W. L. Nichols, J. A. Heit

PP-MO-679 COMBINATION OF RFVIIa AND FXIII IN AML PATIENTS WITH BLEEDING ANDTHROMBOCYTOPENIAP. A. Kotsi* (GR), A. Kouramba, M. Gavalaki, G. Georgiou, G. Kanellopoulou, K. Markakis, A.Karafoulidou

PP-MO-680 CLINICAL USE OF RECOMBINANT FACTOR VIIa: A SINGLE CENTRE EXPERIENCEP. Greaves* (UK), M. Madhani, S. Hallam, P. McCallum

Hemorrhagic Disorders in Children

PP-MO-681 TRANSFUSION REQUIREMENT IN CHILDREN WITH DENGUE VIRUS INFECTIONA. Chuansumrit* (TH), K. Tangnararatchakit, P. Kitpoka, R. Udomchaisakun, S. Yoksan, S.Kitjakornpa

PP-MO-682 IS COAGULATION WORK-UP REALLY NECESSARY IN CHILDREN BEFOREADENOIDECTOMY AND TONSILLECTOMYA. Samkova* (CZ), P. Dulicek, E. Parizkova

PP-MO-683 COMPARISON OF THE CLASSICAL AND THE MODIFIED TURKISH MODEL IN THECIRCUMCISION OF PEOPLE WITH HEMORRHAGIC DIATHESISB. Zulfikar* (TR), I. Karaman, F. Bezgal, F. Ovali

PP-MO-684 SCREENING CLOTTING TIMES AND COAGULOPATHIES IN CHILDREN WITHRECURRENT TONSILLITISG. Gamba* (IT), N. Montani, A. Trinchero, F. Pagella, M. Benazzo

PP-MO-685 CLOT FORMATION OF NEONATES TESTED BY THROMBOELASTOGRAPHYCORRELATES WITH GESTATIONAL AGET. Strauss, Y. Levy-Shraga, B. Ravid, I. Eisen-Schuchan, A. Maayan-Metzger, J. Kuint, G.Kenet* (IL)

PP-MO-686 THE USE OF THE PLATELET FUNCTION ASSAY (PFA) TO ASSESS BLEEDING RISK INA PEDIATRIC POPULATIONH. Henry* (CA), J. Berman, E. McBride, D. Barnard, L. Dickey, J. Gao, V. Price

PP-MO-687 LUPUS ANTICOAGULANT HYPOPROTHROMBINEMIA SYNDROME (LAHPS) ANDANTIPHOSPHOLIPID ANTIBODIES: REPORT OF FOUR CHILDREN WITH LONG TERMFOLLOW-UPG. Pieroni, M. Hepner* (AR), S. E. Annetta, G. Sciuccati, A. Feliú-Torres, M. Castañon, J.Frontroth, M. Bonduel

PP-MO-688 INTRACRANIAL BLEEDINGS IN CHILDREN WITH ITPA. V. Ageenkova, V. Y. Petrov, T. G. Plachuta, G. I. Soskov, P. V. Svirin* (RU

Immunology and Treatment of ITP I

PP-MO-689 RITUXIMAB TREATMENT FOR REFRACTORY CHRONIC AUTOIMMUNETHROMBOPENIA – SINGLE CENTRE EXPERIENCEA. Hlusi* (CZ), T. Papajik, J. Vondrakova, V. Krcova, L. Starostova, R. Zborilova

PP-MO-690 DIAGNOSTIC REVIEW OF CHILDREN WITH PRESUMED IMMUNETHROMBOCYTOPENIC PURPURA IN THE GREATER MANCHESTER AND LANCASHIREREGION (UKE. J. Searle* (UK), A. M. Will, J. D. Grainger



Mon

day

Post

ers

PP-MO-691 ROLE OF TLR7/BAFF/BAFF RECEPTORS PATHWAY IN ITP MICEY. Qing, W. Bo, Y. Lei, P. Jun, M. Daoxin, H. Ming* (CN)

PP-MO-692 NATIONAL SURVEY ON PREVALENCE AND TREATMENT OF IMMUNETHROMBOCYTOPENIC PURPURA IN POLAND – PLATE PROJECTK. M. Zawilska* (PL) on behalf of Haemostasis Group of PHiT, M. Podolak-Dawidziak, K.Chojnowski, J. Windyga, J. Zdziarska

PP-MO-693 PLATELET FUNCTION IN PATIENTS WITH ITP AFTER ELTROMBOPAG TREATMENTM. von Depka* (DE), M. Rieke, T. Hoebbel-Schnell, K. Lennemann, A. Czwalinna

PP-MO-694 NATURAL HISTORY AND ECONOMIC BURDEN OF ITP IN GERMANYM. Krych* (DE), A. Baumann, B. Ackermann, R. Shlaen, K. Berger, H. Ostermann

PP-MO-695 HIGH DOSE DEXAMETHASONE REGULATES INTERLEUKIN-18 AND INTERLEUKIN-18BINDING PROTEIN IN IDIOPATHIC THROMBOCYTOPENIC PURPURAN. Shan, X. Zhu, C. Wang, P. Qin, J. Peng, M. Hou* (CN)

PP-MO-696 COST OF TREATING PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA WITHANTI-D IMMUNE GLOBULIN AND INTRAVENOUS IMMUNE GLOBULIN: ARETROSPECTIVE DATABASE ANALYSIS OF OUTPATIENT CLAIMSP. O. Bonnet* (US), D. Dobler

Pathophysiology and Treatment of HIT I

PP-MO-697 PSEUDO-HIT ASSOCIATED WITH ANTIBODIES TO PROTAMINE SULFATEJ. J. Amiral, A. M. Vissac* (FR)

PP-MO-698 RELIABILITY AND ACCURACY OF 4T’S SYSTEM FOR THE DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)D. R. G. Junqueira* (BR), M. G. Carvalho, E. Perini

PP-MO-699 A NEW CLINICAL SCORE SYSTEM FOR HEPARIN-INDUCED THROMBOCYTOPENIA(HIT) DIAGNOSISD. R. G. Junqueira* (BR), E. Perini, M. G. Carvalho

PP-MO-700 IS HEPARIN-INDUCED THROMBOCYTOPENIA TYPE II (HIT II) AN AUTOIMMUNEDISEASEG. Nowak* (DE), T. Kaden, J. Hentrich

PP-MO-701 CAN WE IMPROVE CLINICAL SPECIFITY FOR HIT IMMUNOASSAYSJ. J. Amiral* (FR), A. M. Vissac

PP-MO-702 HOW TO MEASURE LEPIRUDIN CONCENTRATION: DIFFERENCES BETWEEN ASSAYSJ. J. van Veen* (UK), B. J. Hopkins, C. C. Watson

PP-MO-703 COMPARISON OF IMMUNOLOGICAL ASSAYS FOR DETECTION OF HEPARIN/PF4ANTIBODIES IN HIT PATIENTSJ. P. Antovic* (SE), J. Fareed, D. Hoppensteadt, M. Prechel, E. Norberg, M. Sten-Linder

PP-MO-704 RE-EXPOSURE TO HEPARIN IN UREMIC PATIENTS REQUIRING HEMODIALYISIS WITHHEPARIN-INDUCED THROMBOCYTOPENIAK. Wanaka* (JP), T. Matsuo, M. Matsuo, C. Kaneko, K. Miyashita, R. Asada, H. Matsushima,Y. Nakajima

PP-MO-705 HEPARIN-INDUCED SKIN LESIONS: RARE ASSOCIATION WITH HEPARIN-INDUCEDTHROMBOCYTOPENIAM. Schindewolf* (DE), H. Kroll, J. Garbaraviciene, R. Kaufmann, W. H. Boehncke, R. J.Ludwig, E. Lindhoff-Last



169

170

PP-MO-706 SIMULTANEOUS OCCURRENCE OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)AND DELAYED-TYPE HYPERSENSITIVITY (DTH) TO HEPARINM. Schindewolf* (DE), H. Kroll, M. Wolter, W. H. Boehncke, R. J. Ludwig, E. Lindhoff-Last

PP-MO-707 A FIVE-YEAR EXPERIENCE FROM 848 PATIENTS TESTED FOR HIT, IN A LARGEGREEK HOSPITALT. Theodoridis* (GR), C. Kalpodimou, M. El-Ali, D. Cokkinos, V. Christopoulou-Cokkinou

Pathophysiology and Clinical Studies of TTP I

PP-MO-708 HUMAN IMMUNODEFICIENCY VIRUS (HIV) RELATED THROMBOTICTHROMBOCYTOPENIC PURPURA (TTP) – FAVOURABLE OUTCOME WITH PLASMAEXCHANGE AND PROMPT INITIATION OF HIGHLY ACTIVE ANTIRETROVIRALTHERAPY (HAART)D. P. Hart* (UK), V. Macdonald, R. Sayer, S. J. Machin, M. Scully

PP-MO-709 A RAPID, SENSITIVE FRET ACTIVITY ASSAY USING ALEXA488/VWF84, A NOVELSUBSTRATE FOR QUANTIFICATION OF ADAMTS13 IN PLASMAE. R. Guinto* (US), M. Smirnov, H. J. L. Fryer, C. J. Hoecke, R. S. Greenfield

PP-MO-710 SEVERE MALARIA IS ASSOCIATED WITH A DEFICIENCY OF VON WILLEBRANDFACTOR CLEAVING PROTEASE, ADAMTS13E. C. Lowenberg* (NL), P. Charunwatthana, S. Cohen, B. van den Born, J. C. M. Meijers, E.B. Yunus, M. U. Hassan, G. Hoque, R. J. Maude, F. Nuchsongsin, M. Levi, A. M. Dondorp

PP-MO-711 ADAMTS13 ACTIVITY, ADAMTS13 AND VWF ANTIGEN CONCENTRATION AND THERISK OF MYOCARDIAL INFARCTIONH. Vetr* (AT), S. Geiter, M. Graf, B. Laemmle, M. Redondo, B. R. Binder

PP-MO-712 EXISTENCE OF LINEAR RELATIONSHIP BETWEEN ADAMTS13 AND PLATELETDYNAMICS EVEN BEFORE SEVERE THROMBOCYTOPENIAJ. Song* (KR), R. Park, K. Lee, J. Choi

PP-MO-713 EVALUATION OF AN ADAMTS13 ACTIVITY ELISAJ. Butler* (AU), J. J. Butler, E. Malan, J. Clifford, M. Wheeler, E. Gan

PP-MO-714 SUCCESSFUL PREGNANCY OUTCOME IN UPSHAW-SCHULMAN SYNDROME (USS)J. Windyga* (PL), B. Baran, E. Stefanska-Windyga, K. Bykowska, J. Kremer Hovinga

PP-MO-715 FOLLOW UP OF TTP PATIENTS AND RESULTS OF SPLENECTOMY IN RELAPSINGCASES. EXPERIENCE OF ONE CENTREK. Markakis* (GR), G. Kanellopoulou, I. Anastasopoulou, A. Marinaki, T. Adraktas, P. Kotsi, O.Katsarou, I. Karavokiros, A. Karafoulidou

PP-MO-716 EPISTATIC INTERACTION AMONG SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS)WITH PRO-INFLAMMATORY FUNCTIONS IN PREDICTING RECURRENCE OFTHROMBOTIC THROMBOCYTOPENIC PURPURAL. Beretta* (IT), R. Palla, M. Spreafico, C. Cristofalo, M. Pizzuti, P. Mannucci, F. Peyvandi

PP-MO-717 NATIONAL QUESTIONNAIRE SURVEY OF TMAN. Ito* (JP), H. Wada, M. Sugita, M. Matsumoto, Y. Fujimura, M. Murata, Y. Ikeda

Platelet Function Tests I

PP-MO-718 TIME-DEPENDENT ACTIVATION OF SHEAR-DEPENDENT PLATELET FUNCTION ANDCOAGULATION AFTER SINGLE-DOSE OF GRANULOCYTE COLONY-STIMULATINGFACTOR IN HEALTHY VOLUNTEERSA. O. Spiel* (AT), J. Siller-Matula, C. Firbas, J. Leitner, G. Russmüller, B. Jilma



Mon

day

Post

ers

PP-MO-719 THE FREQUENCY AND INTRA-INDIVIDUAL VARIATION OF CLOPIDOGREL NON-RESPONSIVENESS OVER TIME AS MEASURED BY VERIFYNOW IN PATIENTS WITHSTABLE CORONARY HEART DISEASEA. Pettersen* (NO), H. Arnesen, I. U. Njerve, M. T. Kase, I. Seljeflot

PP-MO-720 THE PERFORMANCE OF THE PLATELET FUNCTION ANALYZER IS INSUFFICIENT TORELIABLY DIAGNOSE AN INCREASED BLEEDING TENDENCY IN CHILDREN ANDADULT PATIENTSA. K. Stroobants* (NL), N. Dors, E. J. van den Dool, E. van der Neut, P. W. Kamphuisen

PP-MO-721 MEASUREMENT OF PROCOAGULANT PLATELET SUBPOPULATIONS IN WHOLEBLOOD: DEVELOPMENT OF AN ASSAY FOR POPULATION-BASED STUDIESA. K. Paradis, K. E. Brummel-Ziedins, B. A. Bouchard* (US)

PP-MO-722 THROMBUS FORMATION IN HIGHLY STENOTIC TUBES USING WHOLE BLOODA. N. Para, M. T. Wildes, J. Hurwitz, D. N. Ku* (US)

PP-MO-723 EVALUATION OF THE BIOLOGICAL RESPONSE IN PATIENTS TREATED WITHCLOPIDOGREL AND ASPIRIN. CONCORDANCE BETWEEN 3 TECHNIQUESA. Munier, J. Charniot, E. Martinod, F. Cymbalista, E. Mazoyer* (FR)

PP-MO-724 AN EXTERNAL QUALITY ASSESSMENT PROGRAM FOR THE PFA-100E. J. Favaloro* (AU), R. Bonar, K. Marsden

PP-MO-725 MAXIMAL AGGREGATION OR SLOPE: WHICH ONE SHOULD BE USED IN PLATELETAGGREGATION REPORTSE. V. de Paula* (BR), T. F. G. S. Machado, M. S. Pereira, F. Orsi, J. M. Annichino-Bizzacchi

PP-MO-726 ASSOCIATION BETWEEN PLATELET REACTIVITY AND GENETIC VARIATIONS INJAPANESE GENERAL POPULATIONH. Okada* (JP), T. Sakata, Y. Kokubo, T. Okamura, T. Miyata

PP-MO-727 PREDICTING RESPONSE TO ANTIPLATELET DRUGS WITH THE MULTPLATE®ANALYZERS. Park, H. Chi* (KR), S. Min, M. Choi, S. Jang, C. Park

PP-MO-729 OPTICAL IMAGING OF LIVING PLATELET ARCHITECTURE AND FUNCTION IN REALTIMEI. Vasilenko* (RU), V. Metelin, V. Tychinsky, T. Vishenskaya

PP-MO-730 ASSESSMENT OF RESPONSIVENESS TO ANTIPLATELET THERAPY BY LIGHTTRANSMITTANCE AGGREGOMETRY: AN ADJUSTMENT FOR PLATELET COUNT ISNOT NECESSARYJ. Schwonberg* (DE), B. Linnemann, S. Prochnow, H. Mani, E. Lindhoff-Last

PP-MO-731 EVALUATION OF PLATELET FUNCTION TESTS IN HEALTH SUBJECTS WITH ASPIRINOR CLOPIDOGREL INTAKEJ. Lee* (CN), Y. L. Cong

PP-MO-732 COMPARISON OF FOUR TESTS TO ASSESS PLATELET REACTIVITY IN PATIENTSUNDER DUAL ANTIPLATELET THERAPYL. Navarro-Núñez, F. Pastor, M. Lozano, F. Marín, J. Hurtado, V. Roldán, C. Martínez, V.Vicente, M. Valdés, J. Rivera* (ES)

PP-MO-733 USE OF THE VERIFYNOW(TM) P2Y12 POINT-OF-CARE DEVICE TO MONITORPLATELET FUNCTION WITH PRASUGREL AND CLOPIDOGREL: AN INTEGRATEDANALYSISJ. A. Jakubowski* (US), Y. G. Li, D. S. Small, C. D. Payne, D. E. Salazar, M. E. Tomlin, J.Luo, K. J. Winters



171

172

PP-MO-734 CLINICAL APPLICATION OF ADP-COATED BEAD COLUMNS FOR CLOPIDOGRELMONITORINGK. Satoh* (JP), I. Fukasawa, Y. Ozaki

PP-MO-735 REDUCING INTRAINDIVIDUAL VARIATION IN PLATELET AGGREGATION:IMPLICATIONS FOR PLATELET FUNCTION TESTINGA. J. Peace, K. Egan* (IE), G. F. Kavanagh, A. F. Tedesco, D. P. Foley, P. Dicker, M. C.Berndt, D. Kenny

PP-MO-736 DIAGNOSTIC VALUE OF PLATELET FLOW-CYTOMETRIC ANALYSIS IN PATIENTS WITHCLINICALLY RELEVANT BLEEDING DIATHESIS AND UNREVEALING LABORATORYWORK-UPT. Conte, M. Pavicic, M. Reusser, G. Barizzi, P. Keller, L. Alberio* (CH)

PP-MO-737 THE APPLICATION OF THROMBOELASTGRAPHY (TEG) IN THE STUDY OFHAEMOSTATIC DISORDERSM. Echenagucia* (VE), A. Boadas, A. Arguello, A. Quijada, M. Hernandez, J. Becerra, C.Reyes, N. Blumenfeld de Bosch, A. Ruiz-Saez

PP-MO-738 ASPIRIN RESISTANCE; AN INVESTIGATION AND EXPLANATIONM. McCall* (IE), A. F. Tedesco, A. Peace, D. Foley, D. Cox

PP-MO-739 PLATELET REACTIVITY TO ADENOSINE DIPHOSPHATE AND LONG-TERM ISCHEMICEVENTP. A. Gurbel* (US), M. J. Antonino, K. P. Bliden, J. Dichiara, T. A. Suarez, A. Singla, U. S.Tantry

PP-MO-740 DETERMINATION AND DIFFERENTIATION OF ASPIRIN AND CLOPIDOGRELEFFECTIVENESS BY 96-WELL PLATE AGGREGOMETRY AND MEASUREMENT OFTHROMBI ADHESIONP. C. J. Armstrong* (UK), A. A. Dhanji, N. J. Truss, Z. N. M. Zain, A. T. Tucker, J. A. Mitchell,T. D. Warner

PP-MO-741 URINARY 11-DEHYDRO-THROMBOXANE B2 AS A MARKER OF THE ANTI-PLATELETEFFECTS OF CLOPIDOGREL OR ASPIRIN THERAPY IN HEALTHY MALE VOLUNTEERSP. C. J. Armstrong* (UK), A. A. Dhanji, A. T. Tucker, J. A. Mitchell, T. D. Warner

PP-MO-742 COMPARISON OF SOLUBLE GLYCOPROTEIN V (SGPV) AND SOLUBLE CD40 LIGAND(SCD40L) AS PLASMA MARKERS OF PLATELET ACTIVATIONK. Javela, P. Mustonen* Finland

PP-MO-743 MONITORING PLATELET FUNCTION IN CORONARY HEART DISEASE PATIENTS ONCLOPIDOGREL THERAPY: WHOLE BLOOD MULTIPLATE IMPEDANCEAGGREGOMETER COMPARED TO CLASSICAL AND NEW PLATELET FUNCTIONMETHODSR. Paniccia* (IT), E. Antonucci, N. Maggini, M. Miranda, R. Marcucci, A. M. Gori, I.Romagnuolo, D. Prisco, R. Abbate, G. F. Gensini

PP-MO-744 ASSOCIATION BETWEEN ASPIRIN RESISTANCE AND PLATELET FUNCTION TESTSS. Genc* (TR), B. Saka, H. Eroglu, B. Omer, N. Erten, C. Tascıoglu

Diagnosis and Treatment of Inherited and Acquired Platelet Disorders I

PP-MO-745 PLATELET-FREE HEMOTHERAPY IN PATIENTS WITH BERNARD SOULIER SYNDROME(BSS): SUCCESSFUL BLEEDING PROPHYLAXIS WITH RECOMBINANT FACTOR VIIa(RFVIIa) FOR DENTAL EXTRACTIONR. E. Scharf, B. Bomke* (DE), T. Hoffmann



Mon

day

Post

ers

PP-MO-746 A COMPOUND HETEROZYGOUS THROMBASTHENIA GLANZMANN PATIENT WITH AMISSENSE MUTATION AND A FRAMESHIFT MUTATION IN THE GPIIIA-SUBUNITD. Westrup* (DE), A. Pilgrimm, R. Klamroth, T. Scholz, D. Pillitteri, M. Krause, C. M.Kirchmaier

PP-MO-747 CYCLICAL THROMBOCYTOPENIA AND NEUTROPENIA ASSOCIATED WITH REBOUNDTHROMBOCYTOSIS – A CASE REPORTD. E. Connor* (AU), J. E. Joseph

PP-MO-748 PLATELET DISORDERS IN PATIENTS WITH LOWE SYNDROME: EFFECT OFMUTATIONS IN THE OCRL GENE CODING FOR A PI(4,5)P2 5-PHOSPHATASE WITH ARHOGAP DOMAINT. Mirault, G. Baujat, R. Salomon, F. Grelac, J. Lunardi, C. Bachelot-Loza, D. Lasne* (FR)

PP-MO-749 ANTI-GPIIBIIIA-INDUCED ACQUIRED THROMBASTHENIA IN A PATIENT WITH SLED. Blickstein* (IL), R. Dardik, E. Rosenthal, J. Lahav, Y. Molad, O. Shpilberg, A. Inbal

PP-MO-750 MEAN PLATELET VOLUME AND PLATELET AGGREGATION: SCREENING TESTS FORWISKOTT-ALDRICH SYNDROMEF. Gagliano, M. Diquattro, S. Ditta, G. Mancuso* (IT)

PP-MO-751 THROMBIN GENERATION (TG) IS DECREASED IN SCOTT SYNDROME DOGSJ. L. Catalfamo* (US), M. B. Brooks, A. Bryon

PP-MO-752 INFLUENCE OF LOW-DOSE ASPIRIN ON LEUKOCYTE-PLATELET INTERACTION INPATIENTS WITH ESSENTIAL THROMBOCYTHEMIAM. Tybura, J. Trelinski, P. Smolewski, K. Chojnowski* (PL)

PP-MO-753 THE EFFECT OF DDAVP ON PLATELET FUNCTION: SELECTIVE ENHANCEMENT OFPLATELET PROCOAGULANT ACTIVITYT. Conte, M. Pavicic, C. Thuerlemann, G. Colucci, P. Keller, L. Alberio* (CH)

PP-MO-754 A MUTATION IN THE KINDLIN-3 GENE ASSOCIATED WITH COMBINED LEUKOCYTEAND PLATELET DYSFUNCTIONM. K. Boudreaux* (US), J. Wardrop, V. Kiklevich, P. Felsburg

PP-MO-755 THROMBOCYTOSIS ASSOCIATED WITH INFLAMMATORY DISEASE: A RISK FACTORFOR THROMBOEMBOLIC DISEASEP. L. Junqueira, A. K. Zeinad, E. Okazaki, P. R. Villaca* (BR), D. A. F. Chamone, E. A. D’Amico

PP-MO-756 ACQUIRED BERNARD SOULIER SYNDROME: SUCCESSFUL MANAGEMENT WITHPLASMAPHERESIS IN THE PERI-OPERATIVE SETTINGS. Nagalla* (US), P. Singh, G. Pullen, J. H. Herman, P. F. Bray

PP-MO-757 EFFICACY OF WHOLE BLOOD IMPEDANCE AGGREGOMETRY (WBIA) IN IDENTIFYINGPLATELET ABNORMALITIES RELEVANCE IN BLEEDING PATIENTSA. Mahaldar, Y. Shen* (US), K. Matevosyan, C. Burke, E. Frenkel, R. Sarode

Microparticles I

PP-MO-758 ANGIOTENSIN II INDUCES THE EXPRESSION OF PROCOAGULANT MICROPARTICLESBY HUMAN MONOCYTES/MACROPHAGESC. Cordazzo, T. Neri, M. Iorio, Y. Carmazzi, R. Vanacore, R. Pedrinelli, A. Celi* (IT)

PP-MO-759 THE INFLUENCE OF MICROPARTICLES ON CLOT FORMATION IN FRESH-FROZENPLASMA AS ASSESSED BY TWO FLUOROGENIC THROMBIN GENERATION TESTSA. S. Lawrie* (UK), P. Harrison, R. A. Cardigan, S. J. Machin, I. J. Mackie



173

174

PP-MO-760 ASSAY OF PROCOAGULANT MICROPARTICLES WITH A CALIBRATED AUTOMATEDTHROMBOGRAMB. A. Owen* (US), J. A. Heit

PP-MO-761 REDUCED EXPRESSION OF TISSUE FACTOR ON PLATELET DERIVEDMICROPARTICLES DURING ATORVASTATIN TREATMENT IN PATIENTS WITHPERIPHERAL ARTERY DISEASEF. Mobarrez* (SE), A. Antovic, A. Bröijersén, B. Wiklund, H. Wallén

PP-MO-762 A MULTICOLOR FLOW CYTOMETRIC ASSAY FOR THE DETECTION OF PLATELETDERIVED MICROPARTICLESF. Mobarrez* (SE), J. Antovic, N. Egberg, M. Hansson, H. Wallén

PP-MO-763 PHOSPHOLIPID-DEPENDENT CLOTTING TIME IS ABLE TO IDENTIFY CANCERPATIENTS WITH HIGH LEVELS OF CIRCULATING MICROPARTICLESF. F. van Doormaal* (NL), A. Kleinjan, H. R. Buller, P. Kamphuisen, R. J. Berckmans, R.Nieuwland

PP-MO-764 PLATELET-RELEASED PROTEIN DISULFIDE ISOMERASE ENHANCES TFPROCOAGULANT ACTIVITY ON ENDOTHELIAL CELL-DERIVED MICROVESICLES IN AREDOX INDEPENDENT MANNERL. G. van den Hengel* (NL), P. H. Reitsma, H. H. Versteeg

PP-MO-765 MICROPARTICLES PLASMA LEVELS IN PATIENTS WITH VENOUSTHROMBOEMBOLISM AND CANCERE. Campello, L. Spiezia* (IT), M. Castelli, C. Radu, S. Gavasso, P. Simioni

PP-MO-766 SENSITIVITY OF 2 FUNCTIONAL HAEMOSTASIS ASSAYS TO PLATELET-DERIVEDMICROPARTICLES (PMPM. Gonzalez* (FR), A. Carlo, P. Poncelet, D. Boulay-Moine, F. Nicham, E. Arnaud, G.Contant, B. J. Woodhams

PP-MO-767 THE PROTECTIVE EFFECTS OF FRESH THAWED PLASMA (FFP) ON ENDOTHELIALPERMEABILITY ARE CORRELATED WITH CHANGES IN THROMBOSPONDIN-1MICROPARTICLESN. Matijevic* (US), J. F. Dong, E. Hartwell, S. Pati, J. B. Holcomb

PP-MO-768 ACTIVATION OF COAGULATION IN SICKLE CELL TRAIT; POSSIBLE ROLE FORCIRCULATING MICROPARTICLE TISSUE FACTORN. S. Key* (US), C. Amin, J. Y. Chang, S. Adam, A. Kutlar, B. Hulkower, D. Esserman, N.Mackman, K. I. Ataga

PP-MO-769 MEASURING THE REAL CONTRIBUTION OF MICROPARTICLE-EXPOSEDPROCOAGULANT PHOSPHOLIPIDS TO COAGULATION: A NEW ASSAYR. J. Berckmans* (NL), E. J. van Beers, J. M. van den Goor, F. F. van Doormaal, J. M.Tushuizen, M. Diamant, B. J. Biemond, A. Sturk, R. Nieuwland

Patient-oriented Studies of Antiplatelet Therapy I

PP-MO-770 MINOR BLEEDING IN CHD PATIENTS RECEIVING DUAL ANTIPLATELET THERAPYA. B. Sumarokov* (RU), L. I. Buryachkovskaya, I. A. Uchitel, T. E. Shirokova

PP-MO-771 THE RELATION BETWEEN PLATELET REACTIVITY AND HBA1C IN DIABETICPATIENTS WITH CARDIOVASCULAR DISEASE ON MAINTENANCE ASPIRIN ANDCLOPIDOGREL THERAPYA. Singla* (US), M. Antonino, L. Lawal, S. Kotev, K. Bliden, P. A. Gurbel, U. Tantry

PP-MO-772 PLATELET ALPHA-2 ADRENERGIC RECEPTOR HAS A ROLE IN THIENOPYRIDINE-RESISTANCE OF STABLE CORONARY ARTERY DISEASE PATIENTS ONCONVENTIONAL DUAL ANTIPLATELET THERAPYB. J. Béres* (HU), E. Tóth-Zsámboki, K. Vargová, I. Préda, R. Kiss



Mon

day

Post

ers

PP-MO-773 PREDICTIVE ABILITY OF POST TREATMENT ADP-INDUCED AGGREGATION AND VASPINDEX ON STENT THROMBOSIS AFTER ACUTE CORONARY SYNDROME INCLOPIDOGREL-TREATED PATIENTS: A PROSPECTIVE STUDYC. Frere* (FR), T. Cuisset, J. Quilici, B. Gaborit, R. Poyet, L. Bali, P. Morange, J. Bonnet, M.Alessi

PP-MO-774 REDUCED PLATELET INHIBITION IN DIABETIC PATIENTS TREATED WITHCLOPIDOGREL IS INDEPENDENTLY RELATED TO FIBRINOGEN LEVEL BUT NOT TOGLYCEMIC CONTROLC. Frere* (FR), B. Gaborit, T. Cuisset, P. E. Morange, L. Camoin, A. Dutour, M. C. Alessi

PP-MO-775 COMPARISON OF VERIFYNOW-P2Y12 TEST AND FLOW CYTOMETRY FORMONITORING INDIVIDUAL PLATELET RESPONSE TO CLOPIDOGREL. WHAT IS THECUT-OFF VALUE FOR IDENTIFYING PATIENTS WHO ARE LOW RESPONDERS TOCLOPIDOGREL THERAPYC. Godino* (IT), L. Mendolicchio, F. Figini, A. Latib, A. Sharp, J. Cosgrave, G. Calori, M.Cera, A. Chieffo, A. Castelli, A. Maseri, Z. Ruggeri, A. Colombo

PP-MO-776 CAN WE REVERSE CLOPIDOGREL-INDUCED PLATELET DYSFUNCTIONF. Szlam* (US), K. A. Tanaka, D. Bolliger, B. Rumph, J. H. Levy

PP-MO-777 TREATMENT WITH ASPIRIN AND CLOPIDOGREL INHIBIT THROMBIN GENERATION INPATIENTS WITH STABLE CORONARY ARTERY DISEASEA. Bandi, L. Mosialos, N. Katsiki, J. Zarifis, C. Vassara, I. Kaprinis, D. Kiskinis, I. Elalamy, G.T. Gerotziafas* (FR)

PP-MO-778 IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE (CAD) RECEIVING ASPIRINAND CLOPIDOGREL PHARMACOLOGICAL RESPONSE TO CLOPIDOGREL ISASSOCIATED WITH INCREASED THROMBIN GENERATION. EVALUATION OFTHROMBIN GENERATIONA. Bandi, L. Mosialos, N. Katsiki, C. Vassara, J. Zarifis, I. Kaprinis, D. Kiskinis, A.Katsamouris, I. Elalamy, G. T. Gerotziafas* (FR)

PP-MO-779 PHARMACOLOGICAL RESISTANCE TO CLOPIDOGREL (PRC) STATUS IS MODIFIED INTIME AFTER PERCUTANEOUS CORONARY INTERVENTION. A PROSPECTIVE STUDYWITH REPEATED POINT OF CARE MONITORING WITH MULTIPLATE ANALYSERA. Banti, L. Mosialos, J. Zarifis, I. Kaprinis, C. Vassara, D. Kiskinis, I. Elalamy, G. T.Gerotziafas* (FR)

PP-MO-780 CANGRELOR INCREASES THE MAGNITUDE OF PLATELET INHIBITION AND REDUCESINTERINDIVIDUAL VARIABILITY IN CLOPIDOGREL-PRETREATED SUBJECTSH. J. Bouman* (NL), J. W. van Werkum, C. M. Hackeng, N. Clappers, J. M. ten Berg

PP-MO-781 THE INFLUENCE OF VARIATION IN THE P2Y12 RECEPTOR GENE ON THEMAGNITUDE OF IN VITRO PLATELET INHIBITION WITH THE DIRECT P2Y12ANTAGONIST CANGRELORH. J. Bouman* (NL), J. W. van Werkum, G. Rude?, F. W. G. Leebeek, A. Kruit, C. M.Hackeng, J. M. ten Berg, M. P. M. de Maat, H. J. T. Ruven

PP-MO-782 DIFFERENTIAL EFFECTS OF LOW-DOSE ASPIRIN TAKEN AT BEDTIME VERSUS ONAWAKENING ON PLASMA-RENIN ACTIVITY, CORTISOL AND CATECHOLAMINES INHYPERTENSIVE SUBJECTS: A RANDOMIZED CROSSOVER TRIALJ. D. Snoep* (NL), M. M. C. Hovens, S. M. Pasha, M. Frölich, H. Pijl, J. T. Tamsma, M. V.Huisman

PP-MO-783 AGE MODULATES THE LEVEL OF CLINICAL RISK ASSOCIATED WITH CLODIPOGRELBIOLOGICAL NON-RESPONSIVENESS IN CARDIOVASCULAR PATIENTS: A META-ANALYSIS ON 14 PROSPECTIVE STUDIESC. Combescure, P. Fontana, N. Mallouk, P. Berdague, C. Labruyere, I. Barazer, J. Gris, P.Fabbro-Peray, J. L. Reny* (FR)



175

176

PP-MO-784 A SURPLUS ANTIPLATELET ACTION OF CLOPIDOGREL IN CORONARY ARTERYDISEASE PATIENTS TREATED WITH ASPIRINJ. Dropinski* (PL), M. Sanak, B. Jakiela, W. Wegrzyn, J. Musial, A. Szczeklik

PP-MO-785 TAILORED CLOPIDOGREL LOADING DOSE ACCORDING TO PLATELET REACTIVITYMONITORING TO PREVENT ACUTE AND SUBACUTE STENT THROMBOSISL. Camoin-Jau* (FR), L. Bonello, S. Armero, O. Com, P. Barragan, F. Paganelli, F. DignatGeorge

PP-MO-786 IN VIVO IMAGING OF FIBROSIS USING A COLLAGEN TRACER MIMICKING PLATELETGPVIL. Sarda-Mantel, J. Muzard, S. Loyau, A. Meulemans, L. Louedec, J. Michel, D. Le Guludec,P. Billiald, M. Jandrot-Perrus* (FR)

PP-MO-787 COMPARISON OF A NOVEL ELISA-BASED VASP WHOLE BLOOD (WB) ASSAY WITHTHE FLOW CYTOMETRIC (FC) TECHNIQUEJ. A. Jakubowski, D. Boulay-Moine, N. Bourguet, A. Sugidachi, P. Barragan, M. Moulard* (FR)

PP-MO-788 THE EFFECT OF PLATELET REACTIVITY ON INFARCT RELATED ARTERY PATENCY INPATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTIONN. J. Breet* (NL), C. A. C. Pittens, H. J. Bouman, J. W. van Werkum, J. M. ten Berg, C. M.Hackeng

PP-MO-789 THE ANTI-PLATELET EFFECT OF ASPIRIN DOES NOT DECREASE AFTER 2-YEARINTERVALT. Ikeda* (JP), R. Taniguchi, H. Horiuchi

Atherosclerosis I

PP-MO-790 RESTORATION OF BLOOD FLOW IN UNILATERAL RENAL ARTERY STENOSISREDUCES AORTIC INFLAMMATION, LIPID DEPOSITION AND ATHEROMA FORMATIONA. S. Pathak* (US), M. Rojas, D. Fox, G. Stouffer

PP-MO-791 A 9p21 GENOMIC VARIANT ASSOCIATED WITH PREMATURE CORONARY ARTERYDISEASE IN ASIAN INDIANSA. Maitra* (IN), D. Dash, S. John, P. R. Sannappa, J. Shanker, V. S. Rao, H. Sridhara, V. V.Kakkar

PP-MO-792 ASSOCIATION OF THE GENETIC POLYMORPHISMS OF THE PITUITARY GROWTHHORMONE AND ITS RECEPTOR WITH PREMATURE CORONARY ARTERY DISEASE INASIAN INDIANSA. Maitra* (IN), D. Dash, S. John, P. R. Sannappa, S. Nagaraj, J. Shanker, V. S. Rao, H.Sridhara, V. V. Kakkar

PP-MO-793 UNDERSTANDING THE ROLE OF TOLL-LIKE RECEPTORS IN CORONARY ARTERYDISEASE IN ASIAN INDIANS: IMPLICATIONS FOR DISEASE ETIOPATHOLOGY ANDPREVENTIONA. Maitra* (IN), D. Dash, P. R. Sannappa, S. Nagaraj, S. John, J. Shanker, V. S. Rao, H.Sridhara, V. V. Kakkar

PP-MO-794 LIPOPROTEIN (A) AS A PREDICTOR OF FURTHER CLINICAL EVENTS IN PATIENTSWITH CORONARY DISEASEA. de la Peña* (MX), M. Baños, M. Peña, G. Cardoso, A. Bahena, B. Valente, E. Angles-Cano

PP-MO-795 ANTIINFLAMMATORY AND ANTIATHEROGENIC EFFECTS OF DIETARYSUPPLEMENTATION WITH A COMBINATION OF MARINE OIL AND EXTRA VIRGINOLIVE OIL IN APO-E-DEFICIENT MICE FED AN ATHEROGENOUS DIETK. Eilertsen, E. Elvevoll, J. Olsen, M. Hoylaerts, B. Østerud* (NO)



Mon

day

Post

ers

PP-MO-796 DENDRITIC CELLS (DCS) DIFFERENTIATED FROM CIRCULATING HEMATOPOIETICPROGENITOR CELLS (HPCS), INDUCED BY CD4+ T CELLS IS RESPONSIBLE FORINHIBITION OF REGULATORY T CELLS (TREGS) IN ATHEROSCLEROSISD. Chen* (UK), X. Lu, V. Kakkar

PP-MO-797 THE PROTEOMIC APPROACH OF OXIDATION AND INFLAMATION PROCESS ONINVITRO VASCULAR MODELD. F. Ozel Demiralp* (TR), C. Gumustekin, N. Yazihan

PP-MO-798 FIBRIN CLOT STRUCTURE IS ASSOCIATED WITH OXIDIZED LOW-DENSITYLIPOPROTEIN LEVELS IN PATIENTS WITH CORONARY ARTERY DISEASEE. Stepien* (PL), A. Undas, B. Kapelak, G. Tylko, J. Sadowski

PP-MO-799 DIFFERENT PATTERN OF MODIFICATIONS FOR HAEMATOPOIETIC ANDENDOTHELIAL PROGENITOR CELLS AFTER A STRENUOUS EXERCISE INSEDENTARY HEALTHY MENF. Cesari* (IT), F. Sofi, A. Capalbo, N. Pucci, R. Caporale, A. Gori, S. Califano, R. Abbate, G.Gensini

PP-MO-800 MODIFICATIONS OF RETICULOCYTES AND RETICULATED PLATELETS INSEDENTARY HEALTHY MEN AFTER AN ACUTE EPISODE OF STRENUOUS EXERCISEF. Cesari* (IT), F. Sofi, A. Capalbo, N. Pucci, A. Gori, R. Caporale, R. Abbate, G. Gensini

PP-MO-801 INFLUENCE OF ALCOHOL BEVERAGES AND DRINKING PATTERN ONHOMOCYSTEINE CONCENTRATIONSF. Sofi* (IT), F. Cesari, R. Marcucci, A. Gori, S. Fedi, I. Lapini, A. Casini, R. Abbate, G.Gensini

PP-MO-802 EFFECT OF SHORT-TERM CONSUMPTION OF BREAD OBTAINED BY A SELECTED“HEALTHY” ITALIAN GRAIN VARIETY ON LIPID, INFLAMMATORY ANDHAEMORHEOLOGICAL VARIABLES: AN INTERVENTION STUDYF. Sofi* (IT), F. Cesari, A. Gori, L. Mannini, L. Evangelisti, L. Ghiselli, S. Benedettelli, V.Vecchio, R. Abbate, G. Gensini

PP-MO-803 EFFECT OF A DIARY PRODUCT (PECORINO CHEESE) NATURALLY RICH IN CIS-9,TRANS-11 CONJUGATED LINOLEIC ACID ON LIPID, INFLAMMATORY ANDHAEMORHEOLOGICAL VARIABLES: AN INTERVENTION STUDYF. Sofi* (IT), A. Gori, F. Cesari, L. Mannini, A. Buccioni, M. Antongiovanni, A. Casini, R.Abbate, G. Gensini

PP-MO-804 HEMORHEOLOGICAL PROFILE IN PERIPHERAL ARTERIAL DISEASE PATIENTSF. Sofi* (IT), F. Cesari, L. Mannini, G. Pratesi, R. Pulli, C. Pratesi, R. Abbate, G. Gensini

PP-MO-805 ACE D/-240T HAPLOTYPE MODULATES THE PREDISPOSITION TO PERIPHERALARTERIAL DISEASEC. Fatini, E. Sticchi, A. Abdihakim, F. Sofi* (IT), I. Romagnuolo, G. Pratesi, R. Pulli, C.Pratesi, R. Abbate, G. Gensini

PP-MO-806 COLONY-FORMING UNITS OF MEGAKARYOCYTES IN INTIMA IN MAN WITHATHEROSCLEROSIS OF AORTAE. L. Soboleva, G. N. Potapova* (RU), S. P. Veselova

PP-MO-807 INTENSIVE LIPID LOWERING THERAPY ON PROGRESSION OF CORONARYATHEROSCLEROSIS AND STROKE IN HIGH RISK PATIENTSG. Corinaldesi* (IT), C. Corinaldesi

PP-MO-808 THE RELATIONSHIP BETWEEN TFPI AND TF EXPRESSION IN CIRCULATINGMONOCYTES AND WITHIN CAROTID ATHEROSCLEROTIC PLAQUES WITH DIFFERENTMORPHOLOGICAL COMPOSITIONG. B. Manjunath* (NO), M. Sovershaev, E. Egorina, V. Bogdanov, J. T. Fallon, N. Seredkina,F. X. Gruber, B. Østerud, J. Hansen



177

178

PP-MO-809 ENDOGENOUS CHOLESTEROL SYNTHESIS, BUT NOT CHOLESTEROL ABSORPTIONIS ASSOCIATED WITH EARLY ATHEROSCLEROSISG. H. Heine* (DE), O. Weingärtner, D. Lütjohann, K. S. Rogacev, L. Blömer, Y. Grenner, S.Gräber, C. K. Ulrich, M. Girndt, M. Böhm, D. Fliser, U. Laufs

PP-MO-810 SIGNIFICANCE OF SERUM INFLAMMATORY CYTOKINE AND BLOOD CLOTTINGFACTOR IN PATIENTS WITH ACUTE CEREBRAL INFARCTIONH. Gu* (CN), Y. Zhang, J. Gu

PP-MO-811 GENETIC ANALYSIS OF APOA1-APOC3-APOA5 GENE CLUSTER IN RELATION TOLIPIDS AND CORONARY ARTERY DISEASE IN THE ASIAN INDIAN POPULATIONJ. Shanker* (IN), V. S. Rao, S. John, S. Hebbagodi, B. Dhanakshmi, V. V. Kakkar

PP-MO-812 DISSECTION OF METABOLIC SYNDROME TRAIT IN ASIAN INDIAN FAMILIES WITHSTRONG HISTORY OF CORONARY ARTERY DISEASEJ. Shanker* (IN), K. Sibi, S. Hebbagodi, V. S. Rao, B. Dhanalakshmi, A. Mani, V. V. Kakkar

PP-MO-813 THE APOLIPOPROTEIN CI CONTENT OF VERY LOW DENSITY LIPOPROTEINS IS AKEY REGULATOR OF FASTING TRIGLYCERIDES AND POSTPRANDIAL LIPEMIA INHUMANSJ. B. Hansen* (NO), J. Fernandez, A. With Notø, H. Deguchi, J. Bjorkegren, E. Mathiesen

PP-MO-814 TISSUE FACTOR PATHWAY INHIBITOR-2 GENE METHYLATION IN CAROTIDATHEROSCLEROTIC PLAQUESC. Zawadzki, J. Breyne* (FR), N. Chatelain, M. Delestre, S. Susen, B. Quesnel, F. Juthier, E.Jeanpierre, R. Azzaoui, D. Corseaux, G. Torpier, B. Staels, E. van Belle, B. Jude

PP-MO-815 POTENTIAL ROLE OF TISSUE FACTOR IN HUMAN AORTIC VALVE STENOSISDEVELOPMENTJ. Breyne* (FR), F. Juthier, S. Maréchaux, D. Corseaux, C. Zawadzki, E. Jeanpierre, A.Vincentelli, T. Le Tourneau, B. Jude

PP-MO-816 FREQUENCY OF THE APOLIPOPROTEIN A5 -1131T> C POLYMORPHISM INDYSLIPIDEMIC SUBJECTS FROM MINAS GERAIS STATE - BRAZILK. B. Gomes* (BR), C. N. Ferreira, P. S. Pinheiro, K. F. Rodrigues, A. P. Fernandes, M. G.Carvalho, M. O. Sousa

PP-MO-817 IN VITRO MODEL FOR THE EVALUATION OF THE EFFICACY OF PUTATIVE VACCINESAGAINST ATHEROSCLEROSISL. A. Mundkur* (IN), K. Kumar, M. Varma, X. Lu, V. V. Kakkar

PP-MO-818 PLATELET REACTIVITY IN STABLE ATHEROSCLEROTIC DISEASE PATIENTS ONCHRONIC ANTIPLATELET TREATMENTR. Paniccia* (IT), E. Antonucci, N. Maggini, E. Romano, L. Lucarini, L. Rossi, C. Saracini, E.Sticchi, G. F. Gensini, R. Abbate

Regulation of Gene Expression in Vascular Cells

PP-MO-819 THE MOUSE SAPHENOUS VEIN: MORPHOLOGICAL CHARACTERISTICS OF VENOUSENDOTHELIUMB. Hemmeryckx* (BE), E. Bovill, E. Conway, M. Hoylaerts, R. Lijnen

PP-MO-820 MICROARRAY ANALYSIS OF GENE EXPRESSION IN GLUCOCORTICOID-INDUCEDOSTEONECROSIS USING A RAT MODEL: NEW INSIGHTS IN THE PATHOGENESIS OFOSTEONECROSISM. A. Kerachian, D. Cournoyer, E. J. Harvey, T. Y. Chow, L. R. Bégin, A. Nahal, C. Séguin*(CA)

PP-MO-821 INFLUENCE OF GENETIC VARIATIONS IN P-SELECTIN ON P-SELECTIN EXPRESSIONAND SECRETIONH. Ponniahpillai Subramanian, B. Subbarayal, C. Mannhalter* (AT)



Mon

day

Post

ers

PP-MO-822 RELATIONSHIP BETWEEN HAEMOSTASIS AND ANGIOGENESIS FACTORS INPLACENTAE FROM GESTATIONAL VASCULAR COMPLICATIONSE. Chinni, D. Colaizzo, G. Tiscia, D. Pisanelli, M. Tomaiuolo, G. Vecchione, P. Vergura, F.Cappucci, M. Margaglione, E. Grandone* (IT)

PP-MO-823 TISSUE FACTOR PROMOTER D/D HAPLOTYPE AMPLIFIES INFLAMMATORYRESPONSE VIA P38-MAPK IN NEONATAL COMPARED TO ADULT HUMANMICROVASCULAR ENDOTHELIAL CELLS (HMVECJ. S. Buzby* (US), S. A. Williams, K. L. Imfeld, D. J. Nugent

PP-MO-824 INTERACTION OF TF WITH ENDOTHELIAL CELLSS. Albrecht, M. Grosser* (DE), G. B. Baretton

PP-MO-825 ANALYSIS OF THE GENETIC EXPRESSION OF INFLAMMATORY MEDIATORS FROMDEEP VENOUS THROMBOSIS PATIENTSM. S. Rubin* (BR), A. C. Deckmann, M. F. Carazolle, L. P. Parizzi, G. A. G. Pereira, J. M.Annichino-Bizzacchi

PP-MO-826 ANALYSIS OF THE GENETIC EXPRESSION FROM ACUTE DEEP VENOUSTHROMBOSISM. S. Rubin* (BR), A. C. Deckmann, M. F. Carazzolle, L. P. Parizzi, G. A. G. Pereira, J. M.Annichino-Bizzacchi

PP-MO-827 RNASE ACTIVITY AND EXPRESSION IN THE VASCULAR SYSTEMM. Nishio* (JP), S. Fischer, S. Dadkhahi, T. Koyama, K. T. Preissner

PP-MO-828 TOWARDS AN UNDERSTANDING OF DIABETIC VASCULOPATHY: MECHANISMS OFHYPEROSMOLARITY-RELATED HYPERGLYCAEMIC DAMAGER. Madonna, E. Montebello, G. Lazzerini, R. de Caterina* (IT)

PP-MO-829 INTERLEUKIN-33, A NOVEL MEMBER OF THE INTERLEUKIN-1 FAMILY, IS UPREGULATED BY PRO INFLAMMATORY CYTOKINES IN HUMAN SMOOTH MUSCLECELLS IN VITROS. Demyanets* (AT), C. Kaun, K. Katsaros, K. Rychli, R. Hintenberger, S. Pfaffenberger, G.Maurer, K. Huber, J. Wojta

PP-MO-830 RETROVIRAL VECTOR-MEDIATED TRANSFER OF ENDOSTATIN INTO LEUKEMICCELLS AND ITS EFFECT ON CELL GROWTHX. Bai* (CN), J. Fu, X. Xie, Z. Wang, C. Ruan

PP-MO-831 PROGESTERONE AND HISTAMINE EXERT AN OPPOSITE EFFECT ON VWF/ADAMTS13TRANSCRIPTIONAL AND PROTEIN LEVELS IN HUVECY. P. Powazniak* (AR), A. C. Kempfer, J. C. Calderazzo, M. A. Carrivale, J. H. PaivaPalomino, L. Keller, M. A. Lazzari

PP-MO-832 VWF/ ADAMTS13 SYSTEM REGULATION BY ESTRADIOL AND HISTAMINEY. P. Powazniak* (AR), A. C. Kempfer, J. C. Calderazzo, J. H. Paiva Palomino, V. A. Zapata,L. Keller, M. A. Lazzari

Angiogenesis I

PP-MO-833 TRANSPLANTED LATE OUTGROWTH ENDOTHELIAL PROGENITOR CELLS AS CELLTHERAPY PRODUCT FOR STROKEC. Moubarik, B. Guillet* (FR), J. Codaccioni, F. Sabatier, M. Piercecchi-Marti, F. Dignat-George, P. Pisano

PP-MO-834 ANGIOGENIC EFFECT OF ALTERNATIVELY SPLICED AND FULL-LENGTH TISSUEFACTOR. INHIBITION BY TFPIC. Giannarelli* (US), M. M. Turu, G. Cimmino, V. Fuster, J. J. Badimon



179

180

PP-MO-835 ENDOTHELIAL PROGENITOR CELLS ARE SELECTIVELY MOBILIZED IMMEDIATELYAFTER CORONARY ARTERY BYPASS GRAFTING OR VALVE SURGERYD. M. Smadja* (FR), A. Godier, R. R. Packard, J. Fabiani, M. Aiach, P. Gaussem

PP-MO-836 BALANCE BETWEEN CIRCULATING ENDOTHELIAL PROGENITOR CELLS (EPCS) ANDMATURE CIRCULATING ENDOTHELIAL CELLS (CECS) IN RELATION TO THESEVERITY OF PERIPHERAL ARTERIAL DISEASEF. Cesari* (IT), F. Sofi, A. Gori, R. Caporale, G. Pratesi, R. Pulli, C. Pratesi, R. Abbate, G.Gensini

PP-MO-837 ROLE OF THROMBOMODULIN IN MONOCYTE ADHERENCE TO ENDOTHELIUMF. Rendu* (FR), P. Chieng Yane, B. Le Bonniec, M. David-Dufilho

PP-MO-838 GROWTH FACTOR INDUCED ENDOTHELIAL CELL MIGRATION REQUIRESUROKINASE RECEPTOR (UPAR) DEPENDENT INTEGRIN REDISTRIBUTIONG. W. Prager* (AT), M. Unseld, J. Breuss, J. Mihaly, C. C. Zielinski, B. R. Binder

PP-MO-839 DNAZYMES TO MOUSE BETA1 INTEGRIN MRNA IN VIVO - TARGETING THE TUMORVASCULATUREI. Sacewicz* (PL), M. Wiktorska, T. Wysocki, C. S. Cierniewski, J. Niewiarowska

PP-MO-840 A NOVEL COMPOUND, NP-184, INHIBITS THE VASCULAR ENDOTHELIAL GROWTHFACTOR INDUCED ANGIOGENESISK. Lin* (TW), C. Chung, T. Huang

PP-MO-841 THE EFFECT OF THE RATIO BETWEEN ANGIOGENIC AND ANTIANGIOGENICFACTORS ON PATIENTS’ SURVIVAL IN ADVANCED NONSMALL CELL LUNG CANCERV. Demir, M. Demir* (TR), I. Cicin, G. E. Pamuk, E. Ozturk, E. Tekgunduz, T. Caglar

PP-MO-842 NICKED BETA2-GLYCOPROTEIN I, BUT NOT INTACT BETA2-GLYCOPROTEIN I, BINDSPLASMINOGEN PROTEOLYSIS PRODUCT ANGIOSTATIN4.5 AND REDUCE ITSPHYSIOLOGICAL PROPERTIESS. Yasuda* (JP), H. Nakagawa, E. Matsuura, K. Kobayashi, M. Ieko, H. Kataoka, T. Horita, T.Atsumi, T. Koike

PP-MO-843 DOWNREGULATION OF MMP-7 BY SIRNA IN CANCER CELLS RESULTS INRETARDATION OF TUMOR GROWTH AND NEW BLOOD VESSELS FORMATION INVITRO AND IN VIVOT. Wysocki* (PL), M. Wiktorska, I. Saczewicz, C. S. Cierniewski, J. Niewiarowska

PP-MO-844 A NOVEL YC-1 DERIVATIVE, P95WU25, INHIBITED ANGIOGENESIS INDUCED BYVASCULAR ENDOTHELIAL GROWTH FACTORY. Chen* (TW), T. Huang

Extracellular Matrix and Cell-Matrix Interactions

PP-MO-845 CARDIOPROTECTIVE EFFECT OF ROSUVASTATIN IN WILD TYPE AND APOE MICEFED WITH HIGH FAT DIET-ROLE OF MATRIX METALLOPROTEINASE AND ITSINHIBITORSA. Siddiqui* (SE), T. Gustafsson, H. Fischer, M. Crisby

PP-MO-846 THE INTEGRIN ALPHA2BETA1 AS A NEW ANTI-ANGIOGENESIS TARGET FORREGULATING TUMOR ANGIOGENESIS BY AGGRETIN C-TERMINALC. Chung* (TW), C. Chang, T. Huang

PP-MO-847 ADHESION, PROLIFERATION AND MIGRATION OF HUMAN UMBILICAL VEINENDOTHELIAL CELLS ON FIBRINOGEN GAMMA A AND GAMMA’E. Y. Cheung* (NL), E. M. Weijers, P. Koolwijk, M. P. de Maat



Mon

day

Post

ers

PP-MO-848 PAI-1 INDUCES MALIGNANT PHENOTYPE MODULATING EXPRESSION AND ACTIVITYOF MAPK PATHWAY REGULATOR DUAL ACTIVITY PHOSPHATASES (DUSP)J. Mihaly* (AT), V. A. Carroll, J. M. Breuss, N. M. Geetha, G. W. Prager, B. R. Binder

PP-MO-849 THE ROLE OF A PROTHROMBIN ACTIVATOR BELONGING TO THE LIPOCALIN FAMILYON VASCULAR ENDOTHELIAL CELL SURVIVAL AND EXTRACELLULAR MATRIXREMODELINGL. C. Carrijo-Carvalho* (BR), J. S. Ventura, L. Wlian, A. M. Chudzinski-Tavassi

PP-MO-850 EXPRESSION OF INTEGRIN ALPHA(IIB)BETA3 IN PRIMARY HUMAN TROPHOBLASTSAND VILLI. POSSIBLE INVOLVEMENT OF FIBRIN AS A MATRIX LIGANDN. Lanir* (IL), B. Brenner, B. Paz, A. Snir

PP-MO-851 VON WILLEBRAND FACTOR-DEPENDENT PLATELET ADHESION FROM THE ASPECTOF HUMAN ARTERY WALL MORPHOLOGYN. Wohner* (HU), E. Komorowicz, Z. Keresztes, R. Machovich, K. Kolev

PP-MO-852 REGULATION OF ALPHA 2-I-DOMAIN AFFINITY BY HYDROPHOBIC INTERACTIONSS. W. Hamaia* (UK), D. G. Bihan, R. James, V. Bolanos-Garcia, R. W. Farndale

PP-MO-853 INHIBITION OF VSMC MIGRATION BY THE NON-INHIBITORY SERPIN, MASPIN,INVOLVES DIRECT INTERACTIONS WITH ?1 INTEGRINSR. Bass, L. Wagstaff, L. Ravenhill, V. Ellis* (UK)

PP-MO-854 PLATELET ADHESION TO LAMININ IS INHIBITED BY MONOCLONAL ANTIBODY TOVON WILLEBRAND FACTOR A3 DOMAIN UNDER HIGH SHEAR FLOWY. Zhao* (CN), T. Zhang, F. Shen, X. Bai, Y. He, C. Ruan

Endothelial Dysfunction I

PP-MO-855 ELEVATION OF ENDOTHELIAL AND PLATELET MICROPARTICLES IN PATIENTS WITHCHRONIC VENOUS INSUFFICIENCYA. Georgescu* (RO), N. Alexandru, D. Popov, M. Amuzescu, E. Andrei, M. Nemecz, C.Zamfir, A. Badila, M. Simionescu

PP-MO-856 ACTIVATION AND INJURY OF CULTURED ENDOTHELIAL CELLS IN HYPOXIA ANDREOXYGENATION. EFFECTS OF EXTRACELLULAR PHO. A. Antonova, S. A. Loktionova, Y. A. Romanov, O. N. Shustova, A. V. Mazurov* (RU)

PP-MO-857 INFLAMMATION AND ENDOTHELIAL DYSFUNCTION IN DEPRESSION: FACTORSCONTRIBUTING TO CARDIOVASCULAR DISEASE CO-MORBIDITYA. Halaris* (US), J. Fareed, J. Piletz, E. Litinas, O. Iqbal, D. Hoppensteadt, E. Tobin

PP-MO-858 HEMOSTATIC CHANGES IN CYANOTIC AND ACYANOTIC CONGENITAL HEARTDISEASESA. Ayaz Ozkul* (TR), A. Selime, U. Sevde, E. Murat, A. Hatemi, E. Kansiz, B. Guney

PP-MO-859 EXPRESSION OF ANNEXIN II IN PATIENTS WITH HEMATOLOGIC MALIGNANCIESM. Jiang, L. Zhang, M. Zhu, X. Bai, C. Ruan* (CN)

PP-MO-860 PLASMA FROM CHRONIC COCAINE CONSUMERS INDUCES ACTIVATION OFENDOTHELIAL CELLSC. G. Sáez* (CL), P. Olivares, P. Hidalgo, S. Belmont, D. Mezzano, T. Massardo, J.Pallavicini, J. Pereira

PP-MO-861 UPREGULATION OF INTEGRIN EXPRESSION IN HUVECS TRANSDUCED WITH AD-VEGF-D IS ASSOCIATED WITH SIGNIFICANT DOWNREGULATION OF A NUMBER OFCELL MEMBRANE PROTEINSC. S. Cierniewski* (PL), I. Papiewska-Pajak



181

182

PP-MO-862 COAGULATION ACTIVATION AND ENDOTHELIAL DYSFUNCTION IN PATIENTS WITHPAROXYSMAL NOCTURNAL HEMOGLOBINURIA. BENEFICIAL EFFECT OFECULIZUMAB TREATMENTD. Helley* (FR), R. Peffault de Latour, R. Porcher, C. A. Rodrigues, J. Matheron, I. Galy-Fauroux, A. Duval, G. Socié, A. M. Fischer

PP-MO-863 ASSESSMENT OF ENDOTHELIAL DYSFUNCTION IN PATIENTS OF DIFFERENT AGEWITH CHRONICAL RENAL FAILUREE. Vlasova* (RU), I. Vasilenko, V. Samoylenko, V. Suslov, I. Vaschuk

PP-MO-864 INHIBITION OF PAI-1 PRODUCTION BY TREATMENT OF HERBAL MEDICINE IN HUMANUMBILICAL VEIN ENDOTHELIAL CELLSG. Atsumi* (JP), N. Ohkura, A. Kurata, S. Kanai, T. Fukuda, J. Matsuda

PP-MO-865 NITRIC OXIDE PRODUCTION AND ANTIOXIDANT EFFECT OF APROPANOLAMINOESTROGEN DERIVATIVEG. Gonzalez* (MX), M. Flores, V. Gomez-Vidales, L. Del Valle, J. Fernandez-G, E. Pinzon, I.Torres, A. de La Peña

PP-MO-866 A RELIABLE MARKER OF ENDOTHELIAL CELL DYSFUNCTION AND VASCULARDAMAGE: LEGEND OR REALITYG. Corinaldesi* (IT), C. Corinaldesi

PP-MO-867 NITRIC OXIDE AND SOLUBLE PLASMA SELECTINS IN PATIENTS WITH ESSENTIALTHROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PVG. Cella* (IT), F. Vianello, M. Marchetti, A. Vignoli, M. Panova, T. Barbui, A. Falanga

PP-MO-868 SOLUBLE THROMBOMODULIN LEVEL IS NOT A MARKER OF ENDOTHELIAL INJURYIN DIABETIC PATIENTSJ. Kloczko* (PL), A. Blaszkowski, M. Galar, J. Sokolowski

PP-MO-869 ARECOLINE INDUCED CYTOTOXICITY, IL-8 PRODUCTION AND GENE EXPRESSION INHUMAN ENDOTHELIAL CELLSJ. H. Jeng* (TW), M. C. Chang

PP-MO-870 CIRCULATING ENDOTHELIAL CELLS IN DEEP VENOUS THROMBOSISA. M. Alessio, F. L. A. Orsi, L. F. Bittar, M. P. Beltrame, F. G. Pereira, E. V. de Paula, I.Lorand-Metze, J. M. Annichino-Bizzacchi* (BR)

PP-MO-871 NITRIC OXIDE ASSESSEMENT IN PREECLAMPSIAL. M. S. Dusse* (BR), L. C. Godoi, H. S. Madeira, B. A. Lwaleed, M. G. Carvalho

PP-MO-872 DIFFERENTIAL ROLES OF PAR-1 AND PAR-3 IN VASCULAR ENDOTHELIAL CELLSM. V. Skok* (UA), O. M. Kalashnyk, A. I. Zhukova, L. I. Mikhalovska, S. V. Mikhalovsky

PP-MO-873 ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH PULMONARY DISEASESN. V. Yahorava* (BY), I. S. Karpova, H. L. Hurevich

PP-MO-874 CORRECTION OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH PULMONARYDISEASESN. V. Yahorava* (BY), I. S. Karpova, H. L. Hurevich

Inflammation and Cell Trafficking I

PP-MO-875 ACTIVATED PROTEIN C INHIBITS HISTAMINE RELEASE AND ACTIVATION OF NF-KBIN MAST CELL FROM RATS UNDER NORMAL CONDITIONS AND ACUTEINFLAMMATIONA. Rusanova* (RU), S. Ishiwata, S. Strukova



Mon

day

Post

ers

PP-MO-876 PULMONARY FUNCTION, C-REACTIVE PROTEIN AND CARDIOVASCULAR RISK INTHE MOLI-SANI POPULATIONA. Arcari* (IT), D. Barbato, S. Costanzo, F. Bracone, A. de Curtis, M. Persichillo, R. diGiuseppe, L. Rago, A. di Castelnuovo, F. Zito, H. J. Schunemann, G. de Gaetano, M. Donati,L. Iacoviello

PP-MO-877 A BENZODIAZEPINES DERIVED COMPOUND, 4-(3-CHLOROPHENYL)-1,3-DIHYDRONAPHTHO [2,3-B][1,4]DIAZEPIN-2-ONE (ND700C), INHIBITS FMLP INDUCEDSUPEROXIDE ANION RELEASE BY ACTIVATING PROTEIN PHOSPHATASE 2A INHUMAN NEUTROPHILSC. Liao* (TW), C. Tseng, Y. Day, C. Chang, S. Kuo, S. Lin

PP-MO-878 A NOVEL MECHANISM OF INFLAMMATORY RESPONSE IN MACROPHAGE INDUCEDBY A SNAKE VENOM C-TYPE LECTIN PROTEIN, AGGRETINC. Chang* (TW), C. Chung, T. Huang

PP-MO-879 A DISINTEGRIN, RHODOSTOMIN, INHIBITS ACTIVITIES OF LPS-TREATEDMONOCYTES VIA ALPHAVBETA3 INTEGRINC. Hsu* (TW), T. Huang

PP-MO-880 CONTROL OF INNATE IMMUNITY BY ACTIVATED PROTEIN CE. J. Kerschen* (US), I. Hernandez, M. Zogg, S. Jia, M. J. Hessner, J. A. Fernández, L. O.Mosnier, J. H. Griffin, F. J. Castellino, H. Weiler

PP-MO-881 EFFICACY OF ACTIVATED PROTEIN C VARIANTS IN MURINE SEPSIS MODELSE. J. Kerschen* (US), I. Hernandez, M. Zogg, B. C. Cooley, J. A. Fernández, L. O. Mosnier, J.H. Griffin, F. J. Castellino, H. Weiler

PP-MO-882 ACTIVATED PROTEIN C (APC) PROMOTES PROLIFERATION OF RAT KERATINOCYTESVIA ACTIVATION OF PROTEASE-ACTIVATED RECEPTOR1 (PAR1) AND ENDOTHELIALPROTEIN C RECEPTOR (EPCRE. V. Kiseleva* (RU), L. R. Gorbacheva, O. N. Davydova, S. Ishiwata, S. M. Strukova

PP-MO-883 ARSENIC TRIOXIDE INHIBITS INVASIVE POTENTIAL OF NB4 CELLS THROUGH DOWNREGULATION OF ANNEXIN 2H. Bao* (CN), J. Ruan, M. Jiang, C. Ruan

PP-MO-884 ENDOTHELIAL THROMBIN-THROMBOMODULIN IN VASCULAR SYSTEM BOUNDS ANDCLEAVES HMGB1, AND PREVENTS SYSTEMIC INFLAMMATION AND INTRAVASCULARCOAGULATIONI. Maruyama* (JP), T. Ito, K. Kawahara, T. Hashiguchi

PP-MO-885 DYNORPHIN REGULATES THE PLASMA KALLIKREIN-KININ SYSTEM FUNCTION ONASTROCYTESJ. Mallela* (US), J. Yang, Z. Shariat-Madar



183

NO

TE

S

185

ScientificProgram

ISTH2009

Tuesday,July 14, 2009


Oscar Ratnoff Memorial Lecture Grand Ballroom

Chairperson: Paula Tracy (US)

Contribution of allosteric disulfide bonds to regulation of hemostasis PL-TU-001Philip Hogg (AU) 9:45 - 10:30 AM


Platelet Activation Room 205 ABC

Chairpersons: Edward Plow (US) and Joseph Italiano (US)

Novel molecules in calcium signaling in platelets SA-TU-001Wolfgang Bergmeier (US) 11:00 - 11:30 AM

The Y's that bind: Negative regulators of platelet activation SA-TU-002Debra Newman (US) 11:30 - 12:00 PM

Novel interactions in platelet biology SA-TU-003Yukio Ozaki (JP) 12:00 - 12:30 PM

Immune Thrombocytopenia Room 253 ABC

Chairpersons: Carlo Balduini (IT) and Mortimer Poncz (US)

Fetal and neonatal alloimmune thrombocytopenia SA-TU-004James Bussel (US) 11:00 - 11:30 AM

New insight into the mechanism of action of IV immunoglobulin SA-TU-005Alan Lazarus (CA) 11:30 - 12:00 PM

Pathogenesis of heparin-induced thrombocytopenia: Clinical implications SA-TU-006Mortimer Poncz (US) 12:00 - 12:30 PM

186

TUESDAY, JULY 14, 2009

Blood Coagulation: Systemic Effects Grand Ballroom B

Chairpersons: David Lane (US) and Francis Castellino (US)

The role of the protein C system in pathologic processes SA-TU-007

Francis Castellino (US) 11:00 - 11:30 AM

Modifier genes for disorders of thrombosis and hemostasis SA-TU-008David Ginsburg (US) 11:30 - 12:00 PM

The many faces of tissue factor SA-TU-009Nigel Mackman (US) 12:00 - 12:30 PM

Inflammation and Atherosclerosis: Room 258 ABC

Plaque Progression and Regression

Chairpersons: Yujiro Asada (JP) and Gwendalyn Randolph (US)

Dysfunctional HDL - Lipoprotein at the crossroads of inflammation, oxidant stress and reverse cholesterol transport SA-TU-0010Stanley Hazen (US) 11:00 - 11:30 AM

Dendritic cell and macrophage emigration from atheromatous plaque SA-TU-00011Gwendalyn Randolph (US) 11:30 - 12:00 PM

Progenitor cell trafficking to the vessel wall SA-TU-0012Christian Weber (DE) 12:00 - 12:30 PM

Burning Questions in Hemophilia Inhibitors Ballroom 210 ABC

Chairpersons: Marc Jacquemin (BE) and Birgit Reipert (AT)

The role of regulatory T cells in tolerance to coagulation factors SA-TU-0013Roland Herzog (US) 11:00 - 11:30 AM

Opportunities and limitations of mouse models humanized for HLA class II antigens SA-TU-0014Birgit Reipert (AT) 11:30 - 12:00 PM

Clinical prediction models for inhibitor development SA-TU-0015Marijke van den Berg (NL) 12:00 - 12:30 PM

187


Tues

day

Scie

nce

Genomics and Vascular Disease: Grand Ballroom A

What Have We Learned About Thrombosis?

Chairpersons: Russell Tracy (US) and Willem Ouwehand (UK)

The discovery of genes implicated in myocardial infarction SA-TU-0016Willem Ouwehand (UK) 11:00 - 11:30 AM

Genome wide association studies: Atherosclerosis and risk factors SA-TU-0017Bruce Psaty (US) 11:30 - 12:00 PM

Genetics of venous thrombosis SA-TU-0018Frits Rosendaal (NL) 12:00 - 12:30 PM

Abstract Symposia 1:15 - 2:45 PM

Abstract Symposia consist of an invited speaker and four highly rated abstracts presented on a related general theme.

Immunology and Treatment of ITP Room 210 ABC

Chairperson: Douglas Cines (US)

Controversies in ITP AS-TU-001Douglas Cines (US) 1:15 - 1:45 PMAS-TU-002 1:45 - 2:00 PMORAL ELTROMBOPAG REDUCES THE NEED FOR CONCOMITANT MEDICATIONS IN PATIENTSWITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)P. Fogarty, J. B. Bussel* (US), G. Cheng, M. N. Saleh, B. Meddeb, C. Bailey, A. Brainsky

AS-TU-003 2:00 - 2:15 PMSAFETY OF ALTERNATIVE TREATMENTS FOR ITP: META-ANALYSISN. Cooper* (UK), M. D. Tarantino

AS-TU-004 2:15 - 2:30 PMPLATELET VOLUME, PLATELET DIAMETER AND THROMBOPOIETIN LEVEL FORDIFFERENTIATING INHERITED THROMBOCYTOPENIAS FROM IDIOPATHIC THROMBOCYTOPENICPURPURAP. Noris* (IT), A. Pecci, L. Arcaini, V. Bozzi, A. di Cesare Merlone, F. Passamonti, F. Melazzini, M. Zecca, C.Balduini

AS-TU-005 2:30 - 2:45 PMSTORE-OPERATED CALCIUM ENTRY IS ESSENTIAL FOR FC GAMMA RECEPTOR ACTIVATIONAND AUTOIMMUNE THROMBOCYTOPENIAD. Stegner* (DE), A. Braun, S. N. Syed, S. Konrad, A. Berna-Erro, D. Varga-Szabo, J. E. Gessner, B. Nieswandt

188


Tues

day

Scie

nce

Post-thrombotic Syndrome and Other Outcomes

of Venous Thrombosis Room 205 ABC

Chairperson: Susan Kahn (US)

The post-thrombotic syndrome: Epidemiology and management AS-TU-006Susan Kahn (US) 1:15 - 1:45 PMAS-TU-007 1:45 - 2:00 PMRISK FACTORS FOR VENOUS INSUFFICIENCY THAT RESEMBLES POST-THROMBOTICSYNDROMEM. Cushman* (US), P. W. Callas, M. H. Criqui, J. O. Denenberg, E. G. Bovill

AS-TU-008 2:00 - 2:15 PMMILD SIGNS OF POST-THROMBOTIC SYNDROME ARE NOT RARE IN CHILDHOOD CANCERSURVIVORS TREATED WITH HICKMAN CATHETERSM. Menahem, M. Weintraub, S. Revel-Vilk* (IL)

AS-TU-009 2:15 - 2:30 PMPROGNOSTIC FACTORS OF PULMONARY EMBOLISM. A PROSPECTIVE MULTICENTER COHORTSTUDY. THE PREP STUDYO. Sanchez, L. Trinquart, V. Caille, F. Couturaud, G. Pacouret, N. Meneveau, F. Verschuren, P. Roy, F. Parent,A. Perrier, C. Lorut, B. Tardy, M. Benoit, G. Chatellier, G. Meyer* (FR)

AS-TU-010 2:30 - 2:45 PMRIGHT VENTRICULAR EJECTION FRACTION MEASURED BY ELECTROCARDIOGRAPHY-SYNCHRONIZED MULTI-DETECTOR ROW CT ANGIOGRAPHY PREDICTS CLINICAL OUTCOME INPATIENTS WITH ACUTE PULMONARY EMBOLISM - THE PROBE STUDYF. A. Klok* (NL), N. van der Bijl, A. de Roos, L. J. M. Kroft, M. V. Huisman

Update on Gene Therapy in Hemophilia Room 253 ABC

Chairperson: Amit Nathwani (UK)

Gene therapy for haemophilia B AS-TU-011Amit Nathwani (UK) 1:15 - 1:45 PMAS-TU-012 1:45 - 2:00 PMENCAPSULATED FETAL MOUSE MYOBLASTS SECRETING FVIII AS A GENE THERAPY STRATEGYFOR HEMOPHILIA AR. Sengupta* (CA), H. Matsui, J. Wen, D. Lillicrap, G. Hortelano

AS-TU-013 2:00 - 2:15 PMINDUCTION OF IMMUNO TOLERANCE TO CANINE FVIII (CFVIII) USING LIVER DIRECTED, AAVMEDIATED EXPRESSION OF CFVIII IN HEMOPHILIA A DOGS WITH INHIBITOR ANTIBODIESJ. D. Finn* (US), D. E. Sabatino, M. C. Ozelo, S. Zhou, D. Lillicrap, H. H. Kazazian, T. C. Nichols, V. R. Arruda

AS-TU-014 2:15 - 2:30 PMIMPLANTING GENETICALLY ENGINEERED ENDOTHELIAL PROGENITOR CELLS IN THE OMENTUMOF DOGS RESULTS IN PERSISTENT FVIII EXPRESSION AND CELL VIABILITYM. C. Ozelo* (CA), H. Matsui, M. McMurray, C. Hegadorn, L. Harpell, S. Powell, C. Hough, D. Lillicrap

AS-TU-015 2:30 - 2:45 PMSUBSTANTIAL IMPACT OF THE GENETIC MUTATION AND THE GENE TRANSFER PROTOCOL ONIMMUNE RESPONSES TO FACTOR IX IN AAV-BASED THERAPY FOR HEMOPHILIA BB. E. Hoffman* (US), O. Cao, B. Moghimi, S. Nayak, M. Cooper, S. Zhou, H. Ertl, K. A. High, R. W. Herzog

189


Cofactors Room 258 ABC

Chairperson: Pete Lollar (US)

The immune response to factor VIII AS-TU-016Pete Lollar (US) 1:15 - 1:45 PMAS-TU-017 1:45 - 2:00 PMFACTOR V IS A COFACTOR FOR ACTIVATION OF FACTOR XI BY THROMBINC. Maas* (NL), J. C. M. Meijers, C. Weeterings, P. G. de Groot, R. T. Urbanus

AS-TU-018 2:00 - 2:15 PMNOVEL ROLE FOR CONNEXIN37 IN FVIII SECRETION AND COAGULATIONL. Burnier* (CH), A. Pfenniger, R. Sugamele, I. Roth, M. Delmar, P. Fontana, B. R. Kwak, A. Angelillo-Scherrer

AS-TU-019 2:15 - 2:30 PMACTIVATED PROTEIN C COFACTOR FUNCTION OF PROTEIN S: A CRITICAL ROLE FOR THE EGF1-LIKE DOMAINH. M. Andersson* (UK), M. J. Arantes, J. T. B. Crawley, B. M. Luken, D. A. Lane, S. M. Rezende

AS-TU-020 2:30 - 2:45 PMPLG-RKT, A NOVEL, STRUCTURALLY UNIQUE, AND DEVELOPMENTALLY REGULATEDTRANSMEMBRANE RECEPTOR FOR PLASMINOGENL. A. Miles* (US), N. M. Andronicos, E. I. Chen, N. Baik, H. Bai, M. P. Kamps, J. R. Yates Iii, R. J. Parmer

Regulation of Coagulation Room 157 ABC

Chairperson: Bernd Engelmann (DE)

Activation of tissue factor-triggered coagulation by proteindisulfide isomerase AS-TU-021Bernd Engelmann (DE) 1:15 - 1:45 PMAS-TU-022 1:45 - 2:00 PMPLATELET INDEPENDENT ENDOTHELIUM-DERIVED PROTEIN DISULFIDE ISOMERASE ISREQUIRED FOR FIBRIN GENERATION DURING THROMBUS FORMATION IN VIVOR. Jasuja* (US), G. Merrill-Skoloff, B. Furie, B. C. Furie

AS-TU-023 2:00 - 2:15 PMENDOTHELIAL CELL REGULATION OF BLOOD COAGULATION: A MODEL FOR VENOUS STASISJ. E. Campbell* (US), M. F. Whelihan, K. E. Brummel-Zeidens, T. Orfeo, J. Krudysz-Amblo, S. Butenas, K. G. Mann

AS-TU-024 2:15 - 2:30 PMANTITHROMBOTIC AND ANTIFIBRINOLYTIC EFFECTS OF PLATELET PROTEASE NEXIN-1Y. Boulaftali* (FR), F. Adam, L. Venisse, S. Loyau, V. Ollivier, M. Alessi, M. Bryckaert, R. Favier, V. Arocas, M. Jandrot-Perrus, M. Bouton

AS-TU-025 2:30 - 2:45 PMCRYSTAL STRUCTURE OF A TERNARY COMPLEX OF VITAMIN K EPOXIDE REDUCTASEW. Li* (US), S. Schulman, R. Dutton, D. Boyd, J. Beckwith, T. Rapoport

190


Tues

day

Scie

nce

Platelets and Systemic Disorders Room 104 ABC

Chairperson: David Phillips (US)

New directions in antithrombotic drug discovery AS-TU-026David Phillips (US) 1:15 - 1:45 PMAS-TU-027 1:45 - 2:00 PMIN VIVO ANTI-THROMBOTIC EFFECT OF AN INHIBITOR OF PLATELET GLYCOPROTEIN IB-IX-14-3-3 INTERCTION AND ITS THERAPEUTIC ACTION IN ENDOTOXEMIC MOUSE MODELSH. Yin* (US), J. Lu, Z. Wang, X. Du

AS-TU-028 2:00 - 2:15 PMGENETIC DELETION OF SEMAPHORIN 4D (SEMA4D) AMELIORATES PLATELETHYPERSENSITIVITY IN DYSLIPIDEMIA AND CONFERS PROTECTION AGAINST THEDEVELOPMENT OF ATHEROSCLEROSIST. J. Stalker* (US), L. Zhu, K. P. Fong, H. Jiang, A. Tran, I. Crichton, E. K. Lee, K. B. Neeves, S. F. Maloney, A. Kumanongoh, E. Pure, S. L. Diamond, L. F. Brass

AS-TU-029 2:15 - 2:30 PMTHROMBUS STABILIZATION BY P2Y12 RECEPTORS CONTRIBUTES TO ATHEROTHROMBOSISAND IS RESTRICTED TO HIGH SHEAR FLOW CONDITIONSR. Nergiz-Unal* (NL), J. M. E. M. Cosemans, P. J. E. van der Meijden, M. A. H. Feijge, M. G. A. Oude Egbrink,J. W. M. Heemskerk, M. J. E. Kuijpers

AS-TU-030 2:30 - 2:45 PMMATERNAL IMMUNE RESPONSE TO FETAL PLATELET GPIBALPHA CAUSES MORE FREQUENTMISCARRIAGE THAT CAN BE PREVENTED BY BOTH IVIG AND ANTIBODIES AGAINST THENEONATAL FC RECEPTORC. Li* (CA), S. Piran, P. Chen, G. Zhu, S. Lang, J. Ware, Z. Ruggeri, J. Freedman, H. Ni

Intracranial Hemorrhage Room 107 ABC

Chairperson: Thorsten Steiner (DE)

Intracranial hemorrhage: Threats and chances AS-TU-031Thorsten Steiner (DE) 1:15 - 1:45 PMAS-TU-032 1:45 - 2:00 PMINTRACRANIAL HAEMORRHAGE IN HAEMOPHILIA A AND B: AN ITALIAN RETROSPECTIVESURVEYE. Zanon* (IT), L. Spiezia, E. Santagostino, A. Coppola, A. Tagliaferri, G. Rossetti, A. Iorio, R. Santoro, A. Dragani, A. Giuffrida, R. Musso, G. Mancuso, G. Castaman, G. Gamba, G. Mazzucconi, M. Lapecorella

AS-TU-033 2:00 - 2:15 PMCENTRAL NERVOUS SYSTEM (CNS) BLEEDING IN PATIENTS WITH RARE BLEEDING DISORDERS (RBDS)S. M. Siboni, E. Zanon, G. Sottilotta, D. Mikovic, A. Iorio, G. Castaman, M. Mazzucconi, P. M. Mannucci, F. Peyvandi* (IT)

AS-TU-034 2:15 - 2:30 PMWHEN SHOULD WARFARIN BE RESTARTED AFTER INTRACRANIAL HEMORRHAGE?A. Majeed, Y. Kim, M. Holmström, S. Schulman* (CA)

AS-TU-035 2:30 - 2:45 PMSERIAL CHANGES IN VON WILLEBRAND FACTOR AND ADAMTS13 IN PATIENTS WITH ANDWITHOUT DELAYED CEREBRAL ISCHEMIA AFTER ANEURYSMAL SUBARACHNOID HEMORRHAGEK. Bakhtiari* (NL), M. D. I. Vergouwen, N. van Geloven, M. Vermeulen, Y. B. W. E. Roos, J. C. M. Meijers

191


Mechanisms of Platelet Activation Room 153 ABC

Chairperson: Stephen Watson (UK)

Comparison of the proximal events in glycoprotein receptorsignaling in platelets AS-TU-036 Stephen Watson (UK) 1:15 - 1:45 PMAS-TU-037 1:45 - 2:00 PMROLE OF PLATELET ORAI1 AND STIM1 IN GPVI-DEPENDENT AND GPVI-INDEPENDENTTHROMBUS FORMATION AND PROCOAGULANT ACTIVITYK. Gilio, R. van Kruchten* (NL), A. Braun, M. Elvers, P. E. J. van der Meijden, M. A. H. Feijge, M. J. E. Kuijpers,D. Stegner, J. W. M. Heemskerk, B. Nieswandt

AS-TU-038 2:00 - 2:15 PMSIGNAL ACCELERATION BY THE GLYCOPROTEIN VI PROLINE-RICH DOMAIN ENABLES ANIMMUNE-TYPE RECEPTOR TO ADOPT A HEMOSTATIC ROLEA. A. Schmaier* (US), Z. Zou, K. B. Neeves, S. F. Maloney, K. P. Fong, A. Kazlauskas, S. L. Diamond, K. Saksela, M. L. Kahn

AS-TU-039 2:15 - 2:30 PMTRAF4 (TNF-RECEPTOR ASSOCIATED FACTOR 4): A NOVEL LINK BETWEEN GLYCOPROTEIN IBAND GLYCOPROTEIN VI AND REDOX-DEPENDENT SIGNALING PATHWAYS IN HUMAN PLATELETSJ. F. Arthur* (AU), Y. Shen, E. E. Gardiner, D. Kenny, R. K. Andrews, M. C. Berndt

AS-TU-040 2:30 - 2:45 PMSTIM1, BUT NOT STIM2 REGULATES CALCIUM STORE CONTENT IN PLATELETSA. Braun* (DE), D. Varga-Szabó, A. Berna-Erro, I. Hagedorn, B. Nieswandt

Inflammation Room 156 ABC

Chairperson: Paul Fox (US)

Post-transcriptional regulation of inflammatory gene expression AS-TU-041Paul Fox (US) 1:15 - 1:45 PMAS-TU-042 1:45 - 2:00 PMGLYCOGEN SYNTHASE KINASE-3 NEGATIVELY REGULATES TISSUE FACTOR GENE EXPRESSIONIN MONOCYTES INTERACTING WITH ACTIVATED PLATELETS. A NOVEL MECHANISM LINKINGTHROMBOTIC RISK AND METABOLIC DISORDERSA. di Santo, C. Amore, S. Manarini, V. Evangelista* (IT)

AS-TU-043 2:00 - 2:15 PMVASCULAR AND INNATE IMMUNE CELL SIGNALING CONTRIBUTE TO LETHALITY PROTECTIONBY ACTIVATED PROTEIN C IN MURINE SEPSIS MODELSC. Furlan-Freguia* (US), F. Niessen, J. A. Fernández, L. O. Mosnier, F. J. Castellino, H. Rosen, H. Weiler, J. H. Griffin, W. Ruf

AS-TU-044 2:15 - 2:30 PMCONTRIBUTION OF EGFR TO LPS-INDUCED INFLAMMATION AND COAGULATIONR. Pawlinski* (US), N. Mackman

AS-TU-045 2:30 - 2:45 PMREDUCTION OF PROTHROMBIN IN MICE ATTENUATES THE DEVELOPMENT OF PARALYSISASSOCIATED WITH EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITISE. S. Mullins* (US), K. W. Kombrinck, M. J. Flick, J. S. Palumbo, K. E. Talmage, M. A. Shaw, K. Akassaglou, J. L. Degen

192


Tues

day

Scie

nce

Platelets and Myeloproliferative Syndromes Room 160 ABC

Chairperson: Alessandro Vannucchi (IT)

Mechanisms of thrombosis in myeloproliferative AS-TU-046neoplasmsAlessandro Vannucchi (IT) 1:15 - 1:45 PMAS-TU-047 1:45 - 2:00 PMEVALUATION OF HAEMOSTASIS AND THROMBOSIS RESPONSES IN A THROMBOCYTOSISMOUSE MODELC. Strassel* (FR), P. Mangin, M. Freund, J. Cazenave, R. Skoda, G. Chrisitian, F. Lanza

AS-TU-048 2:00 - 2:15 PMCHARACTERIZATION OF THE THROMBIN GENERATION (TG) POTENTIAL OF PLATELETS FROMESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) PATIENTSM. Panova-Noeva* (IT), M. Marchetti, H. Spronk, G. Finazzi, A. Rambaldi, T. Barbui, H. ten Cate, A. Falanga

AS-TU-049 2:15 - 2:30 PMCIRCULATING ENDOTHELIAL PROGENITOR CELLS AND RESIDUAL IN VIVO THROMBOXANEBIOSYNTHESIS IN LOW-DOSE ASPIRIN-TREATED POLYCYTHEMIA VERA PATIENTSF. Santilli* (IT), M. Romano, A. Recchiuti, A. Dragani, A. Falco, G. Lessiani, F. Fioritoni, S. Lattanzio, D. Mattoscio, R. de Cristofaro, B. Rocca, G. Davì

AS-TU-050 2:30 - 2:45 PMMONOCYTE (MNC) HEMOSTATIC PROFILE IN ESSENTIAL THROMBOCYTHEMIA (ET) ORPOLYCYTHEMIA VERA (PV) PATIENTS IS INFLUENCED BY JAK2V617F MUTATIONAL LOADA. Vignoli* (IT), M. Marchetti, L. Russo, M. Panova-Noeva, S. Salmoiraghi, T. Barbui, A. Rambaldi, H. ten Cate,A. Falanga

Pediatric Thrombosis Room 102 AB

Chairperson: Neil Goldenberg (US)

Neonatal and childhood arterial ischemic stroke AS-TU-051Neil Goldenberg (US) 1:15 - 1:45 PMAS-TU-052 1:45 - 2:00 PMANTIPHOSPHOLIPID ANTIBODIES OF INFANTS WITH CEREBRAL EVENTS - A UNIQUE ENTITY ORVARIANT OF ANTIPHOSPHOLIPID SYNDROME?Y. Berkun, M. Simchen, T. Strauss, S. Menashku, S. Padeh, G. Kenet* (IL)

AS-TU-053 2:00 - 2:15 PMGENETIC VARIATION IN THE C-REACTIVE PROTEIN GENE AND THE IL4-IL13 GENE CLUSTER ISASSOCIATED WITH VASCULAR STROKE IN CHILDRENU. Nowak-Gottl, A. Huge, S. Thedieck, M. Stoll* (DE)

AS-TU-054 2:15 - 2:30 PMIN PEDIATRIC PATIENTS, AGE HAS MORE IMPACT ON ORAL ANTICOAGULANT DOSE THANVKORC1 OR CYP2CP GENOTYPESU. Nowak Göttl, K. Dietrich, N. Eldin, Y. Yasui, C. Geissen, L. G. Mitchell* (CA)

AS-TU-055 2:30 - 2:45 PMA SIGNIFICANT INCREASE IN VENOUS THROMBOEMBOLISM IN HOSPITALIZED CHILDREN INTHE UNITED STATES FROM 2001 TO 2007L. J. Raffini* (US), Y. Huang, C. Witmer, C. Feudtner

193


Regulation of Gene Expression in Vascular Cells Room 109 AB

Chairperson: Philip Marsden (CA)

Regulation of vascular endothilial gene expression: The role of epigenetics AS-TU-056Philip Marsden (CA) 1:15 - 1:45 PMAS-TU-057 1:45 - 2:00 PMMIRNA-DEPENDENT REGULATION OF SMOOTH MUSCLE CELL FUNCTIONW. Bielenberg* (DE), A. Prock, H. Tillmanns, D. G. Sedding

AS-TU-058 2:00 - 2:15 PMTHE TRANSCRIPTIONAL MACHINERY RESPONSIBLE FOR THE TISSUE-SPECIFIC EXPRESSION OFTHE MURINE MVWF1 GENE IS CONSERVED IN ZEBRAFISHY. Kalish* (US), J. Johnsen, D. Ginsburg

AS-TU-059 2:15 - 2:30 PMBIO-MECHANICAL REGULATION OF MICRORNA EXPRESSION AND ENDOTHELIAL CELLPHENOTYPE IN VITROA. Murphy* (IE), M. Britto, P. Fitzpatrick, N. Barron, D. O'Gorman, N. Moyna, P. Cummins, R. P. Murphy

AS-TU-060 2:30 - 2:45 PMGAS6 REGULATES DIFFERENT INFLAMMATORY RESPONSES TO TNF AND LPS IN ENDOTHELIALCELLSL. Bellido-Martin* (ES), P. Garcia de Frutos

194


Tues

day

Scie

nce

Presidential Plenary Abstracts 3:15 PM - 5:00 PM

Introducer: Edwin Bovill (US)PL-TU-001 3:20 - 3:30 PMGENOME-WIDE SCAN IN AFFECTED SIBLING PAIRS (GIFT STUDY) IDENTIFIES A NOVELSUSCEPTIBILITY REGION FOR VENOUS THROMBOEMBOLISMM. C. H. de Visser* (NL), R. van Minkelen, V. van Marion, M. den Heijer, J. C. J. Eikenboom, H. L. Vos, P. E.Slagboom, J. J. Houwing-Duistermaat, R. M. Bertina

Introducer: Kenneth Kaushansky (US)PL-TU-002 3:35 - 3:45 PMEXAMINATION OF THE FINAL STAGES OF PLATELET PRODUCTIONJ. N. Thon* (US), A. Montalvo, S. R. Patel, J. L. Richardson, J. H. Hartwig, J. E. Italiano

Introducer: George Broze (US)PL-TU-003 3:50 - 4:00 PMFEEDBACK ACTIVATION OF FACTOR XI BY THROMBIN IS ESSENTIAL FOR HAEMOSTASIS IN VIVOH. M. H. Spronk* (NL), S. Wilhelm, J. W. M. Heemskerk, H. ten Cate, M. L. Knetsch, D. Gailani, R. Pawlinski,N. Mackman, T. Renné

ISTH 2009 Awards Presentation 4:00 PM - 4:15 PM

Presidential Plenary Abstracts 4:15 PM - 5:00 PM

Introducer: Pete Lollar (US)PL-TU-004 4:20 - 4:30 PMEVIDENCE OF THE FIRST X-LINKED THROMBOPHILIA DUE TO A NOVEL MUTATION IN CLOTTINGFACTOR IX GENE RESULTING IN HYPERFUNCTIONAL FIX: FACTOR IX ARGININE 338 LEUCINE(FACTOR IX PADUA)P. Simioni* (IT), D. Tormene, G. Tognin, S. Gavasso, C. Bulato, N. Iacobellis, J. Finn, L. Spiezia, C. Radu, V. Arruda

Introducer: Mark Ginsberg (US)PL-TU-005 4:35 - 4:45 PMKINDLIN3 IN INTEGRIN ACTIVATIONT. V. Byzova* (US), N. Malinin, J. Choi, A. Ciocea, L. Zhang, E. Podrez, M. Tosi, D. Lennon, A. Caplan, E. Plow, S. Shurin

Introducer: Hartmut Weiler (US) PL-TU-006 4:50 - 5:00 PMTHROMBOMODULIN MUTATIONS PREDISPOSE TO ATYPICAL HEMOLYTIC-UREMIC SYNDROMEVIA IMPAIRED COMPLEMENT REGULATIONM. Delvaeye* (BE), M. Noris, A. de Vriese, C. T. Esmon, N. L. Esmon, D. Lambrechts, G. Remuzzi, E. M. Conway


195

* Presenting Author

Risk Factors for Venous Thrombosis II Ball Room 210 ABC

Chairpersons: Peter MacCallum (UK) and Mirjam Meltzer (NL)

OC-TU-001 8:00 AM - 8:15 AMHYPOFIBRINOLYSIS AS A RISK FACTOR FOR THROMBOSIS ANDLINKAGE ANALYSIS OF CLOT LYSIS TIME IN A PROTEIN C DEFICIENTKINDREDM. E. Meltzer* (NL), S. J. Hasstedt, C. J. M. Doggen, P. G. de Groot, F. R. Rosendaal, T. Lisman, E. G. Bovill

OC-TU-002 8:15 AM - 8:30 AMAIR TRAVEL AND RISK OF VENOUS THROMBOEMBOLISM: ACOMMUNITY-BASED STUDYP. K. MacCallum* (UK), S. Mt-Isa, K. Whyte, L. Letley, J. Martin, M. R. Vickers, E. M. Hennessy, D. Ashby

OC-TU-003 8:30 AM - 8:45 AMEVALUATING THROMBIN GENERATION IN A FAMILY WITH PROTEIN C DEFICIENCYK. Brummel-Ziedins* (US), P. W. Callas, T. Orfeo, M. Gissel, M. F. Hockin, K. G. Mann, E. G. Bovill

OC-TU-004 8:45 AM - 9:00 AMPROSPECTIVE STUDY OF BODY MASS INDEX AND THE RISK OFPULMONARY EMBOLISM IN WOMENC. Kabrhel* (US), R. Varraso, S. Z. Goldhaber, E. Rimm, C. A. Camargo

OC-TU-005 9:00 AM - 9:15 AMTALLER MEN HAVE INCREASED RISK OF VENOUSTHROMBOEMBOLISM – THE TROMSO STUDYK. H. Borch* (NO), S. Kufaas-Braekkan, E. Mathiesen, I. Njolstad, T. Wilsgaard, J. Stormer, J. Hansen

OC-TU-006 9:15 AM - 9:30 AMHDL CHOLESTEROL AND FUTURE RISK OF VENOUSTHROMBOEMBOLISM – THE TROMSO STUDYK. H. Borch* (NO), S. Kufaas-Braekkan, E. Mathiesen, I. Njolstad, T. Wilsgaard, J. Stormer, J. Hansen

Diagnosis of Venous Thromboembolism Room 205 ABC

Chairpersons: Gregoire LeGal (FR) and Nadine Gibson (NL)

OC-TU-007 8:00 AM - 8:15 AMPROSPECTIVE MULTI-CENTER ASSESSMENT OF INTEROBSERVERAGREEMENT FOR RADIOLOGIST INTERPRETATION OF 64-CHANNELCT ANGIOGRAPHY FOR PULMONARY EMBOLISMD. M. Courtney* (US), N. T. Klekowski, C. D. Miller, H. A. Smithline, M. M. Hogg, J. A. Kline

TUESDAY, JULY 14, 2009 08:00 - 09:30

ORAL COMMUNICATIONS

196

OC-TU-008 8:15 AM - 8:30 AMAN ALTERNATIVE DIAGNOSTIC STRATEGY WITH LOWER RADIATIONRISK IN YOUNG WOMEN WITH SUSPECTED PULMONARY EMBOLISMR. A. Douma* (NL), P. W. Kamphuisen, A. J. M. Rijnders, B. Hendrickx, M. ten Wolde, H. R. Büller

OC-TU-009 8:30 AM - 8:45 AMDETECTION OF PULMONARY EMBOLI WITH 99MTC-LABELED ANTI-FIBRIN FAB’ FRAGMENTS (THROMBOVIEW): PHASE II STUDYT. A. Morris* (US), M. Gerometta, R. H. White, R. D. Yusen, J. D. Douketis, S. S. Kaatz, J. S. Ginsberg

OC-TU-010 8:45 AM - 9:00 AMSAFETY AND SENSITIVITY OF TWO ULTRASOUND STRATEGIES INPATIENTS WITH CLINICALLY SUSPECTED DEEP VENOUSTHROMBOSIS; A PROSPECTIVE MANAGEMENT STUDYN. S. Gibson* (NL), S. M. Schellong, D. Y. El Kheir, J. Beyer, A. S. Gallus, S. McRae, R. E. G. Schutgens, F. Piovella, V. E. A. Gerdes, H. R. Buller

OC-TU-011 9:00 AM - 9:15 AMVALIDATION OF A DIAGNOSTIC APPROACH TO EXCLUDE RECURRENTVENOUS THROMBOEMBOLISMG. Le Gal* (FR), M. J. Kovacs, M. Carrier, K. Do, S. R. Kahn, P. S. Wells, D. A. Anderson, I. Chagnon, S. Solymoss, M. Crowther, M. Righini, A. Perrier,R. H. White, L. Vickars, M. Rodger

OC-TU-012 9:15 AM - 9:30 AMCOMMON ALTERNATIVE DIAGNOSES AFTER EXCLUSION OF DEEPVENOUS THROMBOSIS IN SYMPTOMATIC PATIENTS IN GENERALPRACTICEA. J. ten Cate-Hoek* (NL), H. R. Büller, A. W. Hoes, K. M. G. Moons, R. Oudega, D. B. Toll, E. van der Velde, H. van Weert, M. H. Prins, H. E. J. H. Stoffers

Risk of Thrombosis in Cancer Room 253 ABC

Chairpersons: Alok A. Khorana (US) and Richard White (US)

OC-TU-013 8:00 AM - 8:15 AMELEVATED C-REACTIVE PROTEIN (CRP) LEVELS ARE ASSOCIATEDWITH RISK OF OCCURRENCE OF VENOUS THROMBOEMBOLISM (VTE)IN CANCER PATIENTS – RESULTS FROM THE VIENNA CANCER ANDTHROMBOSIS STUDY (CATS)R. Kanz* (AT), T. Vukovich, C. Ay, D. Dunkler, R. Vormittag, J. Haselboeck, C. Zielinski, I. Pabinger

OC-TU-014 8:15 AM - 8:30 AMINCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS WITHLYMPHOMAS. J. Conlon* (US), R. H. White, H. K. Chew, T. Wun

OC-TU-015 8:30 AM - 8:45 AMPREDICTION OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTSBY MEASURING THROMBIN GENERATION - RESULTS FROM THEVIENNA CANCER AND THROMBOSIS STUDY (CATS)C. Ay* (AT), R. Simanek, D. Dunkler, J. Thaler, S. Koder, O. Wagner, C. Zielinski, I. Pabinger

TUESDAY, JULY 14, 2009 08:00 - 09:30

ORAL COMMUNICATIONS

197

Tues

day

Ora

ls

OC-TU-016 8:45 AM - 9:00 AMBIOMARKERS IMPROVE THE RISK SCORING MODEL FOR PREDICTIONOF CANCER-ASSOCIATED THROMBOSISC. Ay* (AT), A. L. Chiriac, D. Dunkler, R. Vormittag, R. Simanek, P. Quehenberger, C. Zielinski, I. Pabinger

OC-TU-017 9:00 AM - 9:15 AMINCREASED MICROPARTICLE TISSUE FACTOR ACTIVITY IN CANCERPATIENTS WITH VENOUS THROMBOEMBOLISMD. A. Manly* (US), J. Wang, R. Kasthuri, H. Liebman, N. S. Key, N. Mackman

OC-TU-018 9:15 AM - 9:30 AMLEUKOCYTOSIS, THROMBOSIS AND MORTALITY IN CANCERG. C. Connolly* (US), N. M. Kuderer, E. Culakova, C. W. Francis, G. H. Lyman, A. A. Khorana

Thromboprophylaxis in Surgery Room 258 ABC

Chairpersons: David Bergqvist (SE) and Cecilia Becattini (IT)

OC-TU-019 8:00 AM - 8:15 AMEVALUATION OF DURATION OF THROMBOEMBOLIC PROPHYLAXISAFTER MAJOR ORTHOPEDIC SURGERY: THE ETHOS REGISTRYD. Bergqvist* (SE), J. Arcelus, P. Felicissimo

OC-TU-020 8:15 AM - 8:30 AMBURDEN OF ILLNESS OF VENOUS THROMBOEMBOLISM AFTER TOTALHIP AND KNEE REPLACEMENT IN CANADAR. Selby* (CA), D. Becker, H. McDonald, S. Cartier, M. Crowther, P. Wells

OC-TU-021 8:30 AM - 8:45 AMVARIATION IN MAJOR BLEEDING DEFINITIONS IN PHASE IIIORTHOPEDIC VTE PROPHYLAXIS TRIALS AND THE IMPACT ONMAJOR BLEEDING FREQUENCYR. D. Hull* (CA), R. D. Yusen, D. Bergvist

OC-TU-022 8:45 AM - 9:00 AMULTRASOUND SCREENING OF DEEP VENOUS THROMBOSIS (DVT)AND DURATION OF THROMBOPROPHYLAXIS AFTER TOTAL KNEEARTHROPLASTY (TKA): THE RANDOMIZED MULTICENTER PROTHEGESTUDY ON 878 PATIENTSM. T. Barrellier* (FR), B. Lebel, P. Mismetti, J. Parienti, J. Dutheil, C. H. Vielpeau

OC-TU-023 9:00 AM - 9:15 AMAN ASSESSMENT OF SURGICAL THROMBOPROPHYLAXIS IN ATERTIARY CARE CENTERC. Robinson-Cohen* (US), V. Tagalakis, M. Dubois, D. Pilon

OC-TU-024 9:15 AM - 9:30 AMANTITHROMBOTIC PROPHYLAXIS FOR LAPAROSCOPICCHOLECYSTECTOMY: A META-ANALYSISC. Becattini* (IT), F. Rondelli, G. Manina, G. Noya, G. Agnelli

TUESDAY, JULY 14, 2009 08:00 - 09:30

ORAL COMMUNICATIONS

198

Tues

day

Ora

ls

Platelets and Systemic Disorders Room 157 ABC

Chairpersons: Alison H. Goodall (UK) and Kan Chen (US)

OC-TU-025 8:00 AM - 8:15 AMPLATELET TRANSCRIPTOME PROFILING IN STABLE ANGINA ANDNON-ST ELEVATION ACUTE CORONARY SYNDROMEK. Gertow, G. Marenzi, G. Colombo, M. Brambilla, L. Ruggiero, M. de Metrio,E. Tremoli, M. Camera* (IT)

OC-TU-026 8:15 AM - 8:30 AMPLATELET PROTEINS AS A MEMORY FOR THE BLOOD PRESSURESTATUS IN ANGIOTENSIN-II-INDUCED HYPERTENSIONS. Gebhard* (DE), L. Steil, M. Gesell-Salazar, B. Kuttler, J. Peters, R. Rettig, U. Völker, A. Greinacher

OC-TU-027 8:30 AM - 8:45 AMPLATELET ACTIVATION AND INCREASED ADHESION TOPOLYMORPHONUCLEAR NEUTROPHILS ACTIVATES OXIDATIVE BURSTIN THE NY1DD TRANSGENIC MOUSE MODEL OF SICKLE CELLDISEASER. K. Polanowska-Grabowska* (US), K. Wallace, R. Figler, L. Chen, A. R. L. Gear, J. Linden

OC-TU-028 8:45 AM - 9:00 AMPLATELET-ASSOCIATED COMPLEMENT FACTOR H IN NORMALINDIVIDUALS AND PATIENTS WITH ATYPICAL HUSC. Licht* (CA), F. G. Pluthero, P. F. Zipfel, W. H. A. Kahr

OC-TU-029 9:00 AM - 9:15 AMINCREASE IN MRNA LEVELS OF PLATELET-SPECIFIC GENES WITHINAN ARTERIAL THROMBUSJ. R. Wright, P. Ellis, C. Landford, N. A. Watkins, W. H. Ouwehand, A. H. Goodall* (UK)

OC-TU-030 9:15 AM - 9:30 AMMLCK1A IS EXPRESSED IN ZEBRAFISH THROMBOCYTES AND ANESSENTIAL COMPONENT FOR THROMBUS FORMATIONE. Tournoij* (NL), G. J. Weber, J. N. Akkerman, P. G. de Groot, L. I. Zon, F. L. Moll, S. Schulte-Merker

Genetics of Coagulation Room 104 ABC

Chairpersons: Katherine High (US) and Randal Westrick (US)

OC-TU-031 8:00 AM - 8:15 AMIDENTIFICATION OF HEMOSTATIC MODIFIER GENES RESCUING FVIIDEFICIENT MICEE. D. Rosen* (US)

OC-TU-032 8:15 AM - 8:30 AMINFLUENCE OF THE GENETIC STATUS ON ENDOTHELIAL CELLPROTEIN C RECEPTOR (EPCR) MRNA FORMS FROM PERIPHERALBLOOD MONONUCLEAR CELLS (PBMC), AND ON SOLUBLE EPCR(SEPCR) LEVELSB. Saposnik, P. Gaussem, A. Lokajczyk, J. L. Reny, M. Aiach, S. Gandrille* (FR)

TUESDAY, JULY 14, 2009 08:00 - 09:30

ORAL COMMUNICATIONS

199

OC-TU-033 8:30 AM - 8:45 AMTWO SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) IN THEENDOTHELIAL PROTEIN C RECEPTOR (EPCR) GENE ARE ASSOCIATEDWITH LOWER SOLUBLE EPCR (SEPCR), LOW COMPLEMENT C4 ANDTHROMBOTIC RISK IN PATIENTS WITH LUPUS (SLE)J. T. Merrill* (US), S. Kamp, K. Thomas, B. J. Woodhams, N. L. Esmon

OC-TU-034 8:45 AM - 9:00 AMGENOME-WIDE ASSOCIATION STUDY REVEALS MULTIPLE NOVELGENETIC LOCI WITH PLASMA LEVELS OF COAGULATION FACTOR VII,FACTOR VIII, AND VON WILLEBRAND FACTOR: THE COHORTS FORHEART AND AGING RESEARCH IN GENOME EPIDEMIOLOGY (CHARGE)CONSORTIUMN. L. Smith* (US), W. Tang, M. de Maat, W. L. McArdle, M. Chen, A. Peters,W. Koenig, E. G. Bovill, S. Basu, J. C. M. Witteman, D. Strachan, C. J. O’Donnell

OC-TU-035 9:00 AM - 9:15 AMANNEXIN V GENE INVOLVEMENT IN THE OCCURRENCE OFGESTATIONAL VASCULAR DISORDERSG. L. Tiscia, D. Colaizzo, E. Chinni, D. Pisanelli, N. Scianname’, G. Favuzzi,M. Margaglione, E. Grandone* (IT)

OC-TU-036 9:15 AM - 9:30 AMFINE MAPPING OF MOUSE CHROMOSOME 11 THROMBOSISMODIFIERS USING CONGENIC MOUSE STRAINSQ. Sa* (US), J. L. Hoover-Plow

Antiphospholipid Syndrome: Basic Aspects Room 107 ABC

Chairpersons: Nathalie Satta-Poschung (CH) and Jacob Rand (US)

OC-TU-037 8:00 AM - 8:15 AMANTIPHOSPHOLIPID ANTIBODIES STIMULATE HUMAN CELLS VIA TLR2 AND CD14N. Satta* (CH), S. Dunoyer-Geindre, F. Boehlen, G. Reber, E. K. O. Kruithof,P. de Moerloose

OC-TU-038 8:15 AM - 8:30 AMINDUCTION OF PATHOGENIC ANTIPHOSPHOLIPID ANTIBODIES IN VIVO ARE DEPENDENT ON EXPRESSION OF MHC-II GENESS. S. Pierangeli* (US), E. Papalardo, Z. Romay-Penabad, A. Ibarra, P. Christadoss

OC-TU-039 8:30 AM - 8:45 AMASSOCIATION OF ANTI-B2GPI DOMAIN I IGG AND RESISTANCE TOANNEXIN A5 WITH OBSTETRICAL ANTIPHOSPHOLIPID SYNDROME:EVIDENCE FOR A SPECIFIC MECHANISM IN A PATIENT SUBSETB. J. Hunt* (UK), X. Wu, B. de Laat, A. A. Arslan, K. Parmar, S. Stuart-Smith,J. H. Rand

OC-TU-040 8:45 AM - 9:00 AMANTI- BETA2- GLYCOPROTEIN I ANTIBODIES DIRECTED TO DOMAIN IIN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME (APS) AND TRIPLELABORATORY POSITIVITYA. Banzato* (IT), N. Pozzi, V. Defilippis, E. Bison, M. Tonello, A. Ruffatti, V. Pengo

TUESDAY, JULY 14, 2009 08:00 - 09:30

ORAL COMMUNICATIONS

200

Tues

day

Ora

ls

OC-TU-041 9:00 AM - 9:15 AMCOVALENTLY ASSOCIATED DIMERS AND MULTIMERS OF B2-GLYCOPROTEIN IT. Matsui* (JP), A. Hayashi, Y. Yakura, S. Matsumoto, H. Takeya

OC-TU-042 9:15 AM - 9:30 AMMODULATION OF KLF2 AND KLF4 BY ANTIPHOSPHOLIPID ANTIBODIESK. L. Allen* (US), D. Kawanami, M. K. Jain, K. R. McCrae

Platelet Biology I Room 153 ABC

Chairpersons: Joel Bennett (US) and Matthew Jones (UK)

OC-TU-043 8:00 AM - 8:15 AMSTRUCTURE OF THE GLYCOPROTEIN IB-BETA ECTODOMAINP. A. McEwan, X. Zheng, R. Li, J. Emsley* (UK)

OC-TU-044 8:15 AM - 8:30 AMFUNCTIONAL THROMBIN MODULATION IN VIVO BY PLATELETGLYCOPROTEIN IBA. Zampolli* (US), J. R. Roberts, P. Marchese, Z. M. Ruggeri

OC-TU-045 8:30 AM - 8:45 AMOXIDATIVE STRESS ACTIVATES ADAM17 (TACE) IN PLATELETS ANDINDUCES GPIB-ALPHA SHEDDING IN A P38 KINASE-DEPENDENTFASHIONA. Brill* (US), A. K. Chauhan, M. Canault, M. T. Walsh, W. Bergmeier, D. D. Wagner

OC-TU-046 8:45 AM - 9:00 AMTRANS-SUBUNIT REGULATION OF ECTODOMAIN SHEDDING OFGLYCOPROTEIN IB-ALPHAX. Mo* (US), N. X. Nguyen, H. Fan, M. C. Berndt, R. Li

OC-TU-047 9:00 AM - 9:15 AMMEGAKARYOCYTES AND PLATELETS DIFFERENTIALLY EXPRESS AND SYNTHESIZE MMP/TIMP FAMILY MEMBERSL. Cecchetti* (IT), N. Tolley, A. S. Weyrich, P. Gresele

OC-TU-048 9:15 AM - 9:30 AMACCELERATED THROMBOSIS IN A MOUSE MODEL WITH IMPAIREDMITOCHONDRIAL SIGNALINGS. M. Jobe* (US), W. Clemmons

Atherosclerosis: Mouse Models Room 156 ABC

Chairpersons: Victoria A. Ploplis (US) and Peter Panizzi (US)

OC-TU-049 8:00 AM - 8:15 AMATHEROSCLEROTIC LESIONS DEVELOPMENT IS NOT PREVENTED IN THE GPIBBETA-/-APOE-/- DOUBLE KNOCKOUT MICEC. Strassel* (FR), B. Hechler, A. Bull, M. Freund, J. Cazenave, C. Gachet, F. Lanza

TUESDAY, JULY 14, 2009 08:00 - 09:30

ORAL COMMUNICATIONS

201

OC-TU-050 8:15 AM - 8:30 AMA PLASMINOGEN DEFICIENCY ATTENUATES ATHEROSCLEROSIS AS A RESULT OF ALTERED LIPOPROTEIN PROCESSINGT. Iwaki, D. L. Donahue, M. J. Sandoval-Cooper, F. J. Castellino, V. A. Ploplis* (US)

OC-TU-051 8:30 AM - 8:45 AMA SYNERGISTIC ROLE OF COMBINATION OF APOB AND HHSP60EPITOPES IN REGRESSION OF ATHEROSCLEROTIC LESIONX. Lu* (UK), V. Endresz, M. Xia, D. Chen, G. Qi, I. Faludi, K. Burián, A. Csanadi, A. Miczák, E. Gonczol, V. Kakkar

OC-TU-052 8:45 AM - 9:00 AMALPHA-LINOLENIC ACID DIMINISHES ATHEROTHROMBOSIS, REDUCES RED CELL ARACHIDONIC ACID AND ENDOTHELIALTISSUE FACTOR EXPRESSIONC. M. Matter, C. Lohmann, F. C. Tanner, E. W. Holy, E. K. Richter, F. Leiber, T. F. Lüscher, M. Forestier* (CH), J. H. Beer

OC-TU-053 9:00 AM - 9:15 AMWARFARIN INDUCES VASCULAR CALCIFICATION AS AN UNWANTEDSIDE-EFFECTL. J. Schurgers* (NL), R. Westenfeld, T. Krueger, S. Oelenberg, C. Vermeer,C. P. Reutelingsperger

OC-TU-054 9:15 AM - 9:30 AMTISSUE TRANSGLUTAMINASE IS NOT ESSENTIAL FOR ARTERIALCALCIFICATION IN THE APOLIPOPROTEIN E KNOCKOUT MOUSER. J. Pease* (UK), H. Williams, R. M. Graham, C. L. Jackson, P. J. Grant

Microparticles Room 160 ABC

Chairpersons: Benjamin Brenner (IL) and Rienk Nieuwland (NL)

OC-TU-055 8:00 AM - 8:15 AMCASPASE 3 IS SORTED INTO MICROPARTICLES FROM MCF-7 CELLSA. N. Böing* (NL), G. B. Afink, C. Ris, A. Sturk, R. Nieuwland

OC-TU-056 8:15 AM - 8:30 AMAPPLICATION OF DYNAMIC LIGHT SCATTERING TO THEMEASUREMENT OF MICROPARTICLESP. Harrison* (UK), R. Dragovic, A. Albanyan, A. S. Lawrie, M. Murphy, I. Sargent

OC-TU-057 8:30 AM - 8:45 AMTHE ROLE OF MICROPARTICLES (MPS) IN DIABETIC VASCULARCOMPLICATIONSA. Aharon* (IL), G. Tsimerman, A. Rugin, E. Melamed, A. Bachar, B. Brenner

OC-TU-058 8:45 AM - 9:00 AMMICROPARTICLES AFFECT ANGIOGENESIS AND INFLAMMATIONBALANCE– IN HEALTHY PREGNANCIES AND GESTATIONALVASCULAR COMPLICATIONSA. Aharon* (IL), E. Shomer, S. Katzenell, B. Brenner

TUESDAY, JULY 14, 2009 08:00 - 09:30

ORAL COMMUNICATIONS

202

Tues

day

Ora

ls

OC-TU-059 9:00 AM - 9:15 AMCIRCULATING ERYTHROCYTE-DERIVED MICROPARTICLES AREASSOCIATED WITH COAGULATION ACTIVATION IN SICKLE CELLDISEASEE. J. van Beers* (NL), M. C. L. Schaap, R. J. Berckmans, R. Nieuwland, A. Sturk, F. F. van Doormaal, J. C. M. Meijers, B. J. Biemond

OC-TU-060 9:15 AM - 9:30 AMPROTEOMICS OF HUMAN MICROPARTICLES AFTER DEEP VENOUSTHROMBOSISE. Ramacciotti* (US), A. E. Hawley, S. K. Wrobleski, D. D. Myers Jr, J. R. Strahler, P. C. Andrew, P. K. Henke, T. W. Wakefield

Venous Thrombosis in Pediatrics Room 204 AB

Chairpersons: Marilyn Manco-Johnson (US) and Susanne Holzhauer (DE)

OC-TU-061 8:00 AM - 8:15 AMINCIDENCE AND RISK FACTORS OF CATHETER-RELATED ARTERIALTHROMBOSIS IN CHILDRENM. Albisetti* (CH), B. Brotschi, D. Neuhaus, C. Bürki, B. Latal, W. Knirsch, O. Kretschmar, S. Kroiss, M. Schmugge, M. Hug

OC-TU-062 8:15 AM - 8:30 AMPREVALENCE OF THROMBOPHILIA AND INCIDENCE OF SYMPTOMATICTHROMBOEMBOLISM IN FIRST DEGREE RELATIVES OF PEDIATRICINDEX CASES: A PROSPECTIVE COHORT STUDYS. Holzhauer* (DE), M. Stoll, S. Thedieck, A. Huge, G. de Angelis, D. Manner,R. Mesters, U. Nowak-Göttl

OC-TU-063 8:30 AM - 8:45 AMNEONATAL SINOVENOUS THROMBOSIS: CLINICAL PRESENTATION,RISKFACTORS, IMAGING RESULTS, OUTCOMEF. J. Berfelo* (NL), T. R. de Haan, F. Groenendaal, L. S. de Vries, P. Govaert,C. van Ommen

OC-TU-064 8:45 AM - 9:00 AMANTIPHOSPHOLIPID SYNDROME (APS) IN A PEDIATRIC COHORTWITH VENOUS THROMBOEMBOLISMM. Bonduel* (AR), M. Hepner, G. Sciuccati, G. Pieroni, S. E. Annetta, A. Feliú-Torres, M. Castañon, J. Frontroth

OC-TU-065 9:00 AM - 9:15 AMINCIDENCE AND RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN CRITICALLY ILL CHILDREN WITH CARDIAC DISEASES. J. Hanson* (US), R. C. Punzalan, N. S. Ghanayem, P. L. Havens

OC-TU-066 9:15 AM - 9:30 AMWARFARIN THERAPY INDUCED COAGULOPATHY IN CHILDREN:ASSESSMENT OF A CONSERVATIVE APPROACHK. L. Black, M. E. Bauman, S. Kuhle, L. Bajzar, M. P. Massicotte* (CA)

TUESDAY, JULY 14, 2009 08:00 - 09:30

ORAL COMMUNICATIONS

203

Novel Assays in Hemophilia and von Willebrand Disease Room 102 AB

Chairpersons: Michael Makris (UK) and Evelyn Groot (NL)

OC-TU-067 8:00 AM - 8:15 AMQUANTIFICATION OF LOW LEVELS OF FUNCTIONAL FACTOR VIII IN PLASMA BY TURBIDITYP. Y. Kim* (CA), A. C. Ma, V. A. Ward, M. E. Nesheim

OC-TU-068 8:15 AM - 8:30 AMDOES HETEROGENEITY IN MEASURED CALIBRATED THROMBINGENERATION ASSAY OR FVIII ACTIVITY (<1%) EXPLAIN CLINICALHETEROGENEITY IN SEVERE HEMOPHILIA A?G. D. Sinclair* (CA), V. Blanchette, R. T. Card, A. K. C. Chan, S. Israels, D. Lillicrap, G. Rivard, S. Robinson, L. Vickars, Z. Williams, J. K. M. Wu, M. Poon

OC-TU-069 8:30 AM - 8:45 AMTAFI ACTIVATION IN THE WHOLE BLOOD OF PATIENTS WITHHEMOPHILIA AJ. H. Foley* (CA), M. E. Nesheim, G. E. Rivard, K. E. Brummel-Ziedins

OC-TU-070 8:45 AM - 9:00 AMPREDICTED FREQUENCY OF JOINT BLEEDS BASED ON RESIDUALCLOTTING FACTOR LEVELSI. E. M. den Uijl* (NL), K. Fischer, J. G. van der Bom, D. E. Grobbee, F. R. Rosendaal, I. Plug

OC-TU-071 9:00 AM - 9:15 AMFUNCTIONAL ASSAYS FOR THE DISCRIMINATION OF TYPE 2 VWDVARIANTSV. H. Flood* (US), P. A. Morateck, P. A. Christopherson, J. C. Gill, K. D. Friedman, R. R. Montgomery

OC-TU-072 9:15 AM - 9:30 AMNANOBODY AU/VWF-A11: AN ADDITIONAL TOOL FOR A BETTERCHARACTERIZATION OF DIFFERENT TYPES OF VON WILLEBRANDDISEASEE. Groot* (NL), A. B. Federici, M. Solimando, M. Punzo, P. J. Lenting, F. Rezzonico, L. Baronciani, P. G. de Groot

Genotypes of Hemophilia and von Willebrand Disease Room 109 AB

Chairpersons: David Lillicrap (CA) and Daniel Hampshire (UK)

OC-TU-073 8:00 AM - 8:15 AMSTUDY OF 7 LARGE DELETIONS OF BEGINNING OR END OF F8 GENE IN SEVERE HEMOPHILIA A PATIENTSR. Chatelain, M. Fretigny, H. Chambost, J. Goudemand, C. Zawadzki, B. Guillet, Y. Gruel, T. Lambert, C. Negrier, C. Vinciguerra* (FR)

OC-TU-074 8:15 AM - 8:30 AMFVIII MRNA ANALYSIS IN MILD HEMOPHILIA A PATIENTS WITH SPLICE SITE CHANGES OR WITHOUT GENOMIC MUTATIONSS. Sanna, S. Giacomelli, M. Mancuso, E. Santagostino, P. Mannucci, F. Rodeghiero, G. Castaman* (IT)

TUESDAY, JULY 14, 2009 08:00 - 09:30

ORAL COMMUNICATIONS

204

Tues

day

Ora

ls

OC-TU-075 8:30 AM - 8:45 AMFACTOR VIII GENE (F8) MUTATIONS AS A PREDICTOR OF OUTCOME INIMMUNE TOLERANCE INDUCTION (ITI) IN HEMOPHILIA A PATIENTSWITH HIGH-RESPONDING INHIBITORSA. Coppola* (IT), M. Margaglione, E. Santagostino, A. Rocino, F. Scaraggi, A. Tagliaferri, G. Castaman, M. Messina, M. E. Mancuso, A. Iorio, P. Schinco,E. Zanon, R. Musso, G. Mancuso, G. di Minno, P. Mannucci

OC-TU-076 8:45 AM - 9:00 AMFUNCTIONAL CHARACTERISATION OF 13-BP DELETION MUTATION (-1255 DEL) IN THE VWF GENE PROMOTER CAUSING TYPE 1 VONWILLEBRAND DISEASEM. Othman* (CA), Y. Chirinian, C. Brown, C. Notely, S. Buckley, S. N. Waddington, A. H. Baker, D. Lillicrap

OC-TU-077 9:00 AM - 9:15 AMIDENTIFICATION OF THREE ADDITIONAL MUTATIONS IN PATIENTSENROLLED IN THE EUROPEAN STUDY, MOLECULAR AND CLINICALMARKERS FOR THE DIAGNOSIS AND MANAGEMENT OF TYPE 1 VWD(MCMDM-1VWD)G. J. Burghel, J. C. J. Eikenboom, R. Schneppenheim, U. Budde, I. R. Peake,A. C. Goodeve, D. J. Hampshire* (UK), on behalf of the EU-VWD StudyGroup

OC-TU-078 9:15 AM - 9:30 AMTYPE 1 AND TYPE 3 VON WILLEBRAND DISEASE ASSOCIATED WITH A NOVEL RECURRENT DELETION MUTATIONM. S. Sutherland, A. M. Cumming, M. Bowman, P. H. B. Bolton-Maggs, D. J. Bowen, P. W. Collins, C. R. M. Hay, A. Will, S. Keeney* (UK)

Serpin Structure and Function Room 151 AB

Chairpersons: Bernard LeBonniec (FR) and Daniel Johnson (UK)

OC-TU-079 8:00 AM - 8:15 AMPOINT MUTATIONS IN PROTEIN Z DEPENDENT PROTEASE INHIBITORIMPAIR INHIBITORY FUNCTIONL. Young, N. van de Water, P. Ockelford, A. Horvath, P. Coughlin, P. Browett,N. Birch, P. L. Harper* (NZ)

OC-TU-080 8:15 AM - 8:30 AMCITRULLINATION OF ANTITHROMBIN: PROTEOMICCHARACTERIZATION AND CORRELATION WITH FUNCTIONAL ANDCONFORMATIONAL EFFECTSA. Ordóñez* (ES), F. J. Corrales, I. Martínez-Martínez, C. Miqueo, A. Miñano,V. Vicente, J. Corral

OC-TU-081 8:30 AM - 8:45 AMINTRACELLULAR INTERACTION PARTNERS OF PROTEIN C INHIBITOR (PCI)M. Furtmüller* (AT), B. Sokolikova, F. Wahlmüller, J. Schmid, H. Linder, B. Binder, M. Geiger

TUESDAY, JULY 14, 2009 08:00 - 09:30

ORAL COMMUNICATIONS

205

OC-TU-082 8:45 AM - 9:00 AMANTITHROMBIN MURCIA (K241E) REVEALS A NEW MECHANISM FOR ANTITHROMBIN DEFICIENCY INDIRECTLY AFFECTINGGLYCOSYLATIONI. Martínez-Martínez* (ES), A. Ordóñez, J. Navarro-Fernández, Á. Pérez-Lara,R. Gutiérrez-Gallego, R. Giraldo, C. Martínez, E. Llop, V. Vicente, J. Corral

OC-TU-083 9:00 AM - 9:15 AMSURFACE EXPOSED LYSINE RESIDUES, BUT NOT ARGININERESIDUES, CONTRIBUTE TO LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN INTERACTIONM. van den Biggelaar* (NL), J. W. T. M. Klein Gebbinck, K. Mertens, A. B. Meijer

OC-TU-084 9:15 AM - 9:30 AMLYSINE RESIDUES IN THE ANTIPLASMIN C-TERMINUS MEDIATE ONLY A PART OF THE INTERACTION WITH PLASMINB. Lu, T. Sofian, P. B. Coughlin* (AU), A. Horvath

Endothelial Dysfunction and Biomarkers I Room 252 AB

Chairpersons: Francoise Dignat-George (FR) and Michael Tomlinson (UK)

OC-TU-085 8:00 AM - 8:15 AMMARKERS OF ENDOTHELIAL FUNCTION IN LACUNAR STROKEI. L. H. Knottnerus* (NL), H. ten Cate, J. W. P. Govers-Riemslag, R. van Oerle, R. P. W. Rouhl, J. Staals, H. M. H. Spronk, J. Lodder, R. van Oostenbrugge

OC-TU-086 8:15 AM - 8:30 AMTHROMBIN GENERATION AND MICROPARTICLES PLASMA LEVELS IN PATIENTS WITH VASCULITISM. Castelli, L. Spiezia* (IT), V. Rossetto, V. Carraro, C. Radu, F. Schiavon, S. Todesco, A. Pagnan, P. Simioni

OC-TU-087 8:30 AM - 8:45 AMINCREASED LEVELS OF MICROPARTICLES ORIGINATING FROMENDOTHELIUM, PLATELET AND ERYTHROCYTE IN SUBJECTS WITHMETABOLIC SYNDROME: RELATIONSHIP WITH OXIDATIVE STRESSO. Helal, C. Defoort, S. Robert, C. Marin, N. Lesavre, J. Lopez-Miranda, U. Riserus, S. Basu, J. Lovegrove, J. McMonagle, F. Sabatier, H. Roche, D. Lairon, F. Dignat-George* (FR)

OC-TU-088 8:45 AM - 9:00 AMDECREASED PLASMA SOLUBLE RAGE IN PATIENTS WITHHYPERCHOLESTEROLEMIA: EFFECTS OF STATINSN. Vazzana* (IT), F. Santilli, L. G. Bucciarelli, D. Noto, A. B. Cefalù, V. Davì,E. Ferrante, C. Pettinella, M. Averna, G. Ciabattoni, G. Davì

OC-TU-089 9:00 AM - 9:15 AMIMPACT OF IMMUNOSUPPRESSIVE TREATMENT ON ENDOTHELIALBIOMARKERS AFTER KIDNEY TRANSPLANTATIONL. Camoin-Jau* (FR), H. Vacher Coponat, P. Paul, L. Arnaud, S. Robert, Y. Berland, F. Dignat George

TUESDAY, JULY 14, 2009 08:00 - 09:30

ORAL COMMUNICATIONS

206

Tues

day

Ora

ls

OC-TU-090 9:15 AM - 9:30 AMIMBALANCE BETWEEN CIRCULATING ENDOTHELIAL CELLS ANDPROGENITORS IN PRIMITIVE AND POST EMBOLIC PULMONARYHYPERTENSIOND. M. Smadja* (FR), L. Mauge, D. Israel-Biet, P. Gaussem, O. Sanchez

Membrane Binding and Function in Coagulation Room 257 AB

Chairpersons: Gary Gilbert (US) and Rinku Majumder (US)

OC-TU-091 8:00 AM - 8:15 AMSOLID-STATE NMR STUDIES OF NANOSCALE PHOSPHOLIPIDBILAYERS USING ISOTOPICALLY-LABELED PHOSPHATIDYLSERINER. L. Davis-Harrison* (US), J. M. Boettcher, A. J. Nieuwkoop, A. Z. Kijac, S. G. Sligar, C. M. Rienstra, J. H. Morrissey

OC-TU-092 8:15 AM - 8:30 AMUNIQUE STRUCTURAL MODELS OF PROTHROMBINASE ASSEMBLED ON THE ACTIVATED PLATELET MEMBRANEA. M. Fager* (US), P. B. Tracy, S. J. Everse

OC-TU-093 8:30 AM - 8:45 AMNEW INSIGHT INTO THE ROLE OF MEMBRANE IN THEPROTHROMBINASE COMPLEXS. H. Qureshi* (US), L. Yang, C. Manithody, A. R. Rezaie

OC-TU-094 8:45 AM - 9:00 AMDYNAMICAL VIEW OF MEMBRANE BINDING AND COMPLEXFORMATION OF HUMAN TISSUE FACTOR AND FACTOR VIIaE. Tajkhorshid* (US), Y. Z. Ohkubo

OC-TU-095 9:00 AM - 9:15 AMDYNAMICS OF FACTOR VIII C2 DOMAIN IN RELATION TO MEMBRANE BINDINGD. Pantazatos* (US), C. R. Gessner, V. L. Woods, G. E. Gilbert

OC-TU-096 9:15 AM - 9:30 AMANIONIC PHOSPHOLIPIDS LOSE THEIR PROCOAGULANT PROPERTIES WHEN INCORPORATED INTO HIGH-DENSITYLIPOPROTEINSC. Oslakovic* (SE), M. J. Krisinger, A. Andersson, M. Jauhiainen, C. Ehnholm, B. Dahlbäck

TUESDAY, JULY 14, 2009 08:00 - 09:30

ORAL COMMUNICATIONS

207

NO

TE

S

209

ScientificProgram

ISTH2009

Wednesday,July 15, 2009


Pia Glas-Greenwalt Memorial Lecture Grand Ballroom

Chairperson: Nigel Key (US)

Heparin-induced thrombocytopenia PL-WE-001Andreas Greinacher (DE) 9:45 - 10:30


Marion Barnhart Memorial Lecture Grand Ballroom

Chairperson: Lawrence Brass (US)

Modern concepts of platelet activation during thrombus development PL-WE-002Shaun Jackson (AU) 5:15 - 6:00


Fibrinogen/Fibrinolysis in the Brain Room 253 ABC

Chairpersons: Jay Degen (US) and Katerina Akassoglou (US)

Fibrinogen signal transduction in the nervous system SA-WE-001Katerina Akassoglou (US) 11:00 - 11:30 AM

tPA and neurovascular coupling in stroke SA-WE-002Daniel Lawrence (US) 11:30 - 12:00 PM

The role of fibrin in Alzheimer's Disease SA-WE-003Sidney Strickland (US) 12:00 - 12:30 PM

Integrin Biology Ballroom 210 ABC

Chairpersons: Sanford Shattil (US) and Shaun Jackson (US)

Integrin structure SA-WE-004Joel S Bennett (US) 11:00 - 11:30 AM

Integrins in platelet activation SA-WE-005Bernhardt Nieswandt (DE) 11:30 - 12:00 PM

Platelets and integrin signaling SA-WE-006Sanford Shattil (US) 12:00 - 12:30 PM

210

WEDNESDAY, JULY 15, 2009

Wed

nesd

ay S

cien

ce

Inflammation and Atherosclerosis: Grand Ballroom B

A Paradigm Shift?

Chairpersons: Gordon Lowe (UK) and Paul Ridker, (US)

Epidemiology of inflammation and coronary heart disease SA-WE-007John Danesh (UK) 11:00 - 11:30 AM

Inflammation and atherosclerosis: Pathophysiology SA-WE-008Goran Hansson (SE) 11:30 - 12:30 PM

Clinical interventions for inflammation SA-WE-009Paul Ridker (US) 12:00 - 12:30 PM

Cues to Create A Mature Vasculature Room 205 ABC

Chairpersons: Harold Dvorak (US) and Anne Eichman (US)

Receptors involved in guiding vascular cells SA-WE-010Anne Eichman (FR) 11:00 - 11:30 AM

Guidance signals that promote vascular stability SA-WE-011Dean Li (US) 11:30 - 12:00 PM

Signaling pathways regulating angiogenesis SA-WE-012Brant Weinstein (US) 12:00 - 12:30 PM

Factor XI Revisited Room 258 ABC

Chairpersons: Paul Bock (US) and Thomas Renné (DE)

Structural and functional features of factor XI SA-WE-013David Gailani (US) 11:00 - 11:30 AM

Factor XI deficiency in animal models SA-WE-014Thomas Renné (DE) 11:30 - 12:00 PM

Factor XI deficiency in humans SA-WE-015Uri Seligsohn (IL) 12:00 - 12:30 PM

211


Thrombopoietin Receptor Agonists Grand Ballroom A

Chairpersons: Diana Beardsley (US) and Yasuo Ikeda (JP)

Development of thrombopoietin receptor agonists for clinical use SA-WE-016Yasuo Ikeda (JP) 11:00 - 11:30 AM

Molecular mechanisms of thrombopoietin signaling SA-WE-017Kenneth Kaushansky (US) 11:30 - 12:00 PM

Regulation of megakaryocyte maturation and platelet formation SA-WE-018William Vainchenker (FR) 12:00 - 12:30 PM


Abstract Symposia consist of an invited speaker and four highly ratedabstracts presented on a related general theme.

Hemophilia Room 210 ABC

Chairperson: Alok Srivastava (IN)

Hemophilia and rare bleeding disorders AS-WE-001Alok Srivastava (IN) 2:15 - 2:45 PM

AS-WE-002 2:45 - 3:00 PMFVIII ASSAY DISCREPANCY - HEMOPHILIA A VARIANTS ESCAPING THE TWO-STAGE ASSAYH. Brondke* (DE), U. Herbiniaux, J. Oldenburg

AS-WE-003 3:00 - 3:15 PMLONG TERM (10 YEAR) RESULTS FROM THE CANADIAN HEMOPHILIA PRIMARY PROPHYLAXISSTUDYV. S. Blanchette* (CA), P. Babyn, A. Chan, R. Card, C. Demers, K. Gill, S. Israels, R. Klaassen, N. Laferriere, D.Lillicrap, K. Luke, M. McLimont, M. Pai, M. C. Poon, V. Price, G. E. Rivard, S. Robinson, M. Steele, J. K. M.Wu, B. M. Feldman

AS-WE-004 3:15 - 3:30 PMCONTRIBUTION OF POLYMORPHISMS IN THE IL-10, TNF-ALPHA, CTLA-4 GENES AND HLA CLASSII MOLECULES TO THE RISK OF INHIBITOR DEVELOPMENT: A CASE-CONTROL STUDY ON 260PATIENTS WITH SEVERE HAEMOPHILIA AA. Pavlova* (DE), D. Delev, M. Mende, R. Fimmers, R. Schwaab, J. Oldenburg

AS-WE-005 3:30 - 3:45 PMTYPE OF FVIII PRODUCT AND INHIBITOR RISK IN PATIENTS WITH SEVERE HEMOPHILIA A ANDNULL MUTATIONS IN THE FACTOR VIII GENEE. Santagostino* (IT), M. E. Mancuso, A. Rocino, A. Tagliaferri, M. Margaglione, P. Mannucci

212


Wed

nesd

ay S

cien

ce

Stroke Room 205 ABC

Chairperson: Shunichi Homma (US)

Paradoxical embolus and treatment of patent AS-WE-006foramen ovale Shunichi Homma (US) 2:15 - 2:45 PM

AS-WE-007 2:45 - 3:00 PMYOUNG PATIENTS WITH STROKE, PFO (PATENT FORAMEN OVALE) AND THROMBOPHILIAC. Lodigiani* (IT), D. Mari, P. Ferrazzi, M. Minaudo, L. Librè, E. Morenghi, L. L. Rota

AS-WE-008 3:00 - 3:15 PMANTIPHOSPHOLIPID ANTIBODIES AND THE RISK OF MYOCARDIAL INFARCTION AND ISCHEMICSTROKE IN YOUNG WOMENR. T. Urbanus* (NL), B. Siegerink, M. Roest, F. R. Rosendaal, P. G. de Groot, A. Algra

AS-WE-009 3:15 - 3:30 PMASSOCIATION OF COAGULATION AND INFLAMMATION RELATED GENES AND FACTOR 7 LEVELSWITH ISCHEMIC STROKE: THE CARDIOVASCULAR HEALTH STUDYN. A. Zakai* (US), A. P. Reiner, L. A. Lang, W. T. Longstreth, E. O'Meara, J. Kelley, M. Fornage, D. A.Nickerson, M. Cushman

AS-WE-010 3:30 - 3:45 PMPOLYMORPHISMS ASSOCIATED WITH NONCARDIOEMBOLIC STROKE IN THREE CASE-CONTROLSTUDIESM. M. Luke, K. Berger, C. M. Rowland, J. J. Catanese, C. H. Tong, D. A. Ross, V. Garcia, C. R. Pullinger, M.J. Malloy, S. G. Ellis, J. P. Kane, J. J. Devlin, W. Lalouschek, C. Mannhalter* (AT)

TTP and ADAMTS13 Room 253 ABC

Chairperson: Flora Peyvandi (IT)

Congenital and acquired TTP AS-WE-011Flora Peyvandi (IT) 2:15 -2:45 PM

AS-WE-012 2:45 - 3:00 PMTTP AUTOANTIBODIES DEFINE A VWF BINDING SITE IN THE ADAMTS13 SPACER DOMAINB. M. Luken* (UK), W. Pos, J. Voorberg, J. T. B. Crawley, D. A. Lane

AS-WE-013 3:00 - 3:15 PMRESIDUES ARG660, TYR661 AND TYR665 IN THE SPACER DOMAIN PROVIDE A COMMONANTIGENIC CORE REQUIRED FOR BINDING OF ANTI-ADAMTS13 ANTIBODIES IN PATIENTS WITHACQUIRED TTPW. Pos* (NL), E. A. M. Turenhout, B. de Laat, R. Fijnheer, J. Voorberg

AS-WE-014 3:15 - 3:30 PMSAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ANTI VON WILLEBRANDFACTOR APTAMER ARC1779 IN PATIENTS WITH ACUTE THROMBOTIC THROMBOCYTOPENICPURPURA (TTP)B. Jilma, P. Jilma, J. C. Gilbert, R. Hutabarat, J. Siller, A. Spiel, M. Gorczyca, P. Knoebl* (AT)

AS-WE-015 3:30 - 3:45 PMRECOMBINANT ADAMTS13 EFFICACY TO OVERWHELM INHIBITING ANTI-ADAMTS13AUTOANTIBODY IN ACQUIRED TTP PATIENT PLASMAB. Plaimauer* (AT), S. Skalicky, M. Hasslacher, M. Wolfsegger, F. Scheiflinger

213


Microparticles Room 258 ABC

Chairperson: Shosaku Nomura (JP)

New outlook on the clinical significance AS-WE-016of microparticles Shosaku Nomura (JP) 2:15 - 2:45 PM

AS-WE-017 2:45 - 3:00 PMTISSUE FACTOR AND PROTEIN DISULFIDE ISOMERASE CO-LOCALIZE IN NON-CAVEOLAR RAFTSIN MICROPARTICLESA. N. Böing* (NL), C. M. Hau, A. Sturk, R. Nieuwland

AS-WE-018 3:00 - 3:15 PMPROTEOMIC ANALYSIS OF MICROPARTICLES/MICROVESICLES FROM HUMAN B (LG2) CELLSINFECTED WITH VIRUSN. de Bosch, A. Becerra, K. J. Martin, M. Woda, K. J. Xhaja, I. Bosch* (US)

AS-WE-019 3:15 - 3:30 PMTHE DETECTION OF NANOSIZED BLOOD MICROPARTICLES BY ATOMIC FORCE MICROSCOPYY. Yuana* (NL), T. H. Oosterkamp, S. Bahatyrova, B. Ashcroft, P. Garcia Rodriguez, R. M. Bertina, S. Osanto

AS-WE-020 3:30 - 3:45 PMLARGER VON WILLEBRAND FACTOR MULTIMERS PLAY A ROLE IN GENERATING PLATELETMICROPARTICLESA. Artoni* (IT), A. Lecchi, M. Mancuso, E. Santagostino, A. B. Federici, P. Mannucci

Obstetric Complications Room 157 ABC

Chairperson: Ananth Karumanchi (US)

Pathogenesis of pre-eclampsia AS-WE-021Ananth Karumanchi (US) 2:15 - 2:45 PM

AS-WE-022 2:45 - 3:00 PMTHE ASSOCIATION OF FVL AND PGM AND PLACENTA MEDIATED PREGNANCY COMPLICATIONS.A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE COHORT STUDIESM. A. Rodger* (CA), M. Betancourt, M. Carrier

AS-WE-023 3:00 - 3:15 PMLOW-MOLECULAR-WEIGHT HEPARIN FOR PREVENTION OF OBSTETRIC COMPLICATIONS INCARRIERS OF FACTOR V LEIDEN OR PT-G20210A MUTATIOND. Tormene* (IT), E. Grandone, V. de Stefano, G. Palareti, G. Castaman, M. Margaglione, A. Ciminello, L.Valdre, A. Tosetto, P. Simioni

AS-WE-024 3:15 - 3:30 PMINCREASED THROMBOXANE PRODUCTION IN PREECLAMPSIA - INFLUENCE OF ASPIRINTREATMENTC. Perneby* (SE), K. Bremme, M. Vahter, M. Daleskog, P. Hjemdahl

AS-WE-025 3:30 - 3:45 PMSEARCH FOR AN ASSOCIATION BETWEEN V249I AND T280M CX3CR1 GENETICPOLYMORPHISMS, ENDOTHELIAL INJURY AND PREECLAMPSIA: THE ECLAXIR STUDYA. Stepanian* (FR), S. Benchenni, T. Beillat-Lucas, S. Omnes, F. Defay, E. Peynaud-

214


Wed

nesd

ay S

cien

ce

Megakaryocytes and Thrombopoiesis Room 104 ABC

Chairperson: John Hartwig (US)

Megakarycytes and thrombopoiesis AS-WE-026John Hartwig (US) 2:15 - 2:45 PM

AS-WE-027 2:45 - 3:00 PMLOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN-1 (LRP1) IS TRANSIENTLYEXPRESSED DURING MEGAKARYOPOIESIS AND IS THE RECEPTOR BY WHICH PLATELETFACTOR 4 (PF4) INHIBITS MEGAKARYOCYTE DEVELOPMENTM. P. Lambert* (US), Y. Wang, K. Bdeir, Y. Nguyen, M. A. Kowalska, M. Poncz

AS-WE-028 3:00 - 3:15 PMANUCLEATE PLATELETS GENERATE FUNCTIONAL PROGENYH. Schwertz* (US), S. Koster, W. H. A. Kahr, L. W. Kraiss, G. A. Zimmerman, A. S. Weyrich

AS-WE-029 3:15 - 3:30 PMADF / N-COFILIN-DEPENDENT ACTIN TURNOVER IS ESSENTIAL FOR PLATELET FORMATIONM. Bender* (DE), M. Elvers, I. Pleines, C. Gurniak, G. Krohne, W. Witke, B. Nieswandt

AS-WE-030 3:30 - 3:45 PMMEGAKARYOCYTE-SPECIFIC DELETION OF RAC1 AND CDC42 ABROGATES PROPLATELETFORMATION IN VITRO AND IN VIVOI. Pleines* (DE), M. Elvers, M. Rhomdhane, A. Eckly, I. Hagedorn, M. Bender, X. Wu, A. Chrostek, G. Krohne,N. Debili, C. Gachet, C. Brakebusch, B. Nieswandt

Platelet Biology Room 107 ABC

Chairperson: Donna Woulfe (US)

Arrestin-2: Regulating platelet responses to agonist AS-WE-031Donna Woulfe (US) 2:15 -2:45 PM

AS-WE-032 2:45 - 3:00 PMTWO DISTINCT PATHWAYS REGULATE PLATELET PHOSPHATIDYLSERINE EXPOSURE ANDPROCOAGULANT FUNCTIONS. M. Schoenwaelder* (AU), Y. Yuan, E. C. Josefsson, M. J. White, E. Gardiner, R. Andrews, M. Hua, Y. Yao,K. D. Mason, L. A. O'Reilly, K. J. Henley, A. Ono, S. Hsiao, A. Willcox, A. W. Roberts, D. C. S. Huang, H. H.Salem, B. T. Kile, S. P. Jackson

AS-WE-033 3:00 - 3:15 PMCRITICAL ROLE FOR CD148 IN HAEMOSTASIS AND PLATELET FORMATION IN VIVOY. A. Senis* (UK), M. G. Tomlinson, S. Ellison, A. Mazharian, Y. Zhao, N. Kalia, J. Zhu, A. Weiss, S. P. Watson

AS-WE-034 3:15 - 3:30 PMPLATELET-POLYPHOSPHATES ARE PRO-COAGULANT AND PRO-INFLAMMATORY BY PLASMACONTACT ACTIVATION IN VIVOF. Mueller* (DE), N. J. Mutch Mueller, W. A. Schenk, W. A. Gahl, J. H. Morrissey, T. Renné

AS-WE-035 3:30 - 3:45 PMCANONICAL WNT SIGNALLING IN PLATELETS NEGATIVELY REGULATES THEIR FUNCTIONB. M. Steele* (IE), I. C. Macaulay, M. T. Harper, R. Habas, A. Poole, D. J. Fitzgerald, P. B. Maguire

215


von Willebrand Factor: Structure and Function Room 153 ABC

Chairperson: Zaverio Ruggeri (US)

Structure and function of von Willebrand factor: AS-WE-036Facts and myths Zaverio Ruggeri (US) 2:15 - 2:45 PM

AS-WE-037 2:45 - 3:00 PMTRANSITION FROM LATENT TO ACTIVE CONFORMATION OF VON WILLEBRAND FACTOROCCURS UPON EXOCYTOSISE. Groot* (NL), R. Fijnheer, S. Sebastian, P. J. Lenting, P. G. de Groot

AS-WE-038 3:00 - 3:15 PMHOMOZYGOUS AND HETEROZYGOUS EXPRESSION OF TYPE 2A VON WILLEBRAND DISEASE(VWD) VARIANTS: NEGATIVE IMPACT ON MECHANISMS CRITICAL FOR VON WILLEBRANDFACTOR (VWF) PROCESSING AND SECRETIONP. M. Jacobi* (US), J. C. Gill, K. D. Friedman, R. R. Montgomery, S. L. Haberichter

AS-WE-039 3:15 - 3:30 PMCELLULAR MODELS OF A DOMINANT-NEGATIVE VWF GENE DELETION: A BREAKPOINT SPECIFICRNAI RESTORES SECRETION OF FUNCTIONAL VWFC. Casari* (IT), M. Pinotti, A. Casonato, S. Calzavarini, D. Gemmati, F. Bernardi

AS-WE-040 3:30 - 3:45 PMINTRACELLULAR STORAGE AND REGULATED SECRETION OF VON WILLEBRAND FACTOR INQUANTITATIVE VON WILLEBRAND FACTOR DEFECTSJ. W. Wang* (NL), H. C. de Boer, K. M. Valentijn, R. J. Dirven, P. H. Reitsma, H. C. J. Eikenboom

Intrinsic Pathway of Coagulation Room 156 ABC

Chairperson: Jacky Chi Ki Ngo (HK)

Crystal structure of B-domain deleted factor VIII and AS-WE-041implications for the formation of the tenase complex Jacky Chi Ki Ngo (HK) 2:15 - 2:45 PM

AS-WE-042 2:45 - 3:00 PMLOSS OF FACTOR IX BINDING TO COLLAGEN IV RESULTS IN ABNORMAL IN VIVO HEMOSTASISAND THROMBOSISP. E. Monahan* (US), T. Gui, A. Reheman, H. Ni, P. L. Gross, F. Yin, D. M. Monroe, D. W. Stafford

AS-WE-043 3:00 - 3:15 PMINHIBITION OF MITOCHONDRIAL PERMEABILITY TRANSITION IMPROVES SECRETION OFCOAGULATION FACTOR VIIIJ. D. Malhotra* (US), H. Miao, S. W. Pipe, R. J. Kaufman

AS-WE-044 3:15 - 3:30 PMHETEROGENEOUS LOCALIZATION OF COAGULATION FACTORS IN AN EX VIVO MODEL OFTHROMBUS FORMATIONM. A. Berny* (US), I. C. A. Munnix, S. E. M. Schols, P. E. Bock, O. J. McCarty, J. W. M. Heemskerk

AS-WE-045 3:30 - 3:45 PMIDENTIFICATION OF CRITICAL RESIDUES IN THE 558-LOOP OF FACTOR VIIIA A2 SUBUNIT IN THEINTERACTION WITH FACTOR IXAI. Jagannathan* (US), H. Ichikawa, S. Chadha, T. Kruger, P. Fay

216


Wed

nesd

ay S

cien

ce

Fibrinogen and Fibrinolysis Room 160 ABC

Chairperson: Katherine Hajjar (US)

Fibrinolysis and cellular functions: AS-WE-046Implications for health and disease Katherine Hajjar (US) 2:15 - 2:45 PM

AS-WE-047 2:45 - 3:00 PMCRYSTAL STRUCTURES OF A SOLUBLE UROKINASE RECEPTOR MUTANT IN ITS LIGAND-FREEFORM AND IN COMPLEX WITH ITS LIGAND UPAX. Xu* (US), H. Gårdsvoll, M. Ploug, M. Huang

AS-WE-048 3:00 - 3:15 PMVISUALIZATION OF STRUCTURES EARLY IN FIBRIN POLYMERIZATIONI. N. Chernysh, C. Nagaswami, J. W. Weisel* (US)

AS-WE-049 3:15 - 3:30 PMSTRUCTURAL AND DYNAMIC PROPERTIES OF THE KRINGLE 2 DOMAIN OF HUMANPLASMINOGEN IN COMPLEX WITH A PEPTIDE DERIVED FROM THE STREPTOCOCCAL SURFACEPROTEIN, PAMM. Wang, J. Zajicek, M. Prorok* (US), F. J. Castellino

AS-WE-050 3:30 - 3:45 PMENDOTHELIAL MICROPARTICLES PLASMIN GENERATION: A NEW MECHANISM REGULATINGENDOTHELIUM PROTEOLYTIC ACTIVITIESR. Lacroix* (FR), F. Sabatier, A. Mialhe, A. Basire, R. Pannell, H. Borghi, S. Robert, E. Lamy, L. Plawinski, L.Camoin-Jau, V. Gurewich, E. Angles-Cano, F. Dignat-George

Blood Vessel Development Room 252 AB

Chairperson: Victoria Bautch (US)

Integrating cellular processes to make a blood vessel AS-WE-051Victoria Bautch (US) 2:15 - 2:45 PM

AS-WE-052 2:45 - 3:00 PMMAKING ANTI-THROMBOTIC BYPASS VESSELS FROM SELECTED POPULATIONS OF VASCULARSMOOTH MUSCLE CELLSA. A. Dhanji* (UK), F. Y. Ali, L. S. Harrington, A. Shipolini, J. A. Mitchell, T. D. Warner

AS-WE-053 3:00 - 3:15 PMCROSS-COUPLING OF THE TRANSCRIPTION FACTORS NF-E2 AND AP-1 REGULATES CELL-AUTONOMOUSLY TROPHOBLAST SYNCYTIUM FORMATION AND PLACENTAL VASCULARISATIONM. Kashif, A. Hellweg, M. Thati, K. Shahzad, P. P. Nawroth, B. Isermann* (DE)

AS-WE-054 3:15 - 3:30 PMTHE GUT MICROBES TRIGGER SMALL INTESTINAL MICROVESSEL FORMATION VIACYTOPLASMIC TAIL-DEPENDENT TISSUE FACTOR SIGNALINGC. Reinhardt* (SE), G. Östergren-Ludén, F. Schaffner, W. Ruf, F. Bäckhed

AS-WE-055 3:30 - 3:45 PMTISSUE FACTOR PROMOTES AND STABILIZES THE VASCULAR PHENOTYPE OF NEWLY FORMCAPILLARIESG. Arderiu, E. Peña, L. Badimon* (ES)

217


Atherosclerosis Room 257 AB

Chairperson: Timothy Hla (US)

Vascular cell signaling by sphingosine-1-phosphate: AS-WE-056Implications for atherosclerosis Timothy Hla (US) 2:15 - 2:45 PM

AS-WE-057 2:45 - 3:00 PMATHEROSCLEROSIS-ASSOCIATED LY-6CHI BLOOD MONOCYTOSIS IMPAIRS WOUND HEALING INMICE WITH MYOCARDIAL INFARCTIONP. R. Panizzi* (US), F. K. Swirski, J. Figueiredo, P. Waterman, D. E. Sosnovik, E. Aikawa, P. Libby, M. Pittet, R.Weissleder, M. Nahrendorf

AS-WE-058 3:00 - 3:15 PMGENETICALLY ALTERED LEVELS OF THROMBIN GENERATION DEMONSTRATE AN IMPACT ONATHEROSCLEROTIC PROGRESSION IN APOE-NULL MICEJ. I. Borissoff* (NL), S. Heeneman, P. Leenders, R. van Oerle, H. Weiler, J. Degen, M. Marchetti, K. Hamulyák,M. Daemen, H. ten Cate, H. Spronk

AS-WE-059 3:15 - 3:30 PMEVALUATION OF SPLA2 TYPE IIA AS A MARKER OF CORONARY ARTERY DISEASE AND ITSPREDICTIVE VALUE FOR FUTURE CORONARY EVENTS AMONG ASIAN INDIANSV. S. Rao, B. K. Natesha, H. Sridhara, J. Shibu, V. V. Kakkar* (IN)

AS-WE-060 3:30 - 3:45 PMELEVATED FIBRINOGEN LEVELS AND SUBCLINICAL CARDIOVASCULAR DISEASE IN MIDDLE-AGE: THE CARDIA STUDYD. Green* (US), C. Chan, J. Kang, K. Liu, P. J. Schreiner, N. S. Jenny, R. P. Tracy

218


Wed

nesd

ay O

rals

* Presenting Author

Clinical Trials: Factor Xa Inhibitors Ball Room 210 ABC

Chairpersons: Sam Schulman (CA) and Robert Giugliano (US)

OC-WE-001 8:00 AM - 8:15 AMEFFICACY AND SAFETY OF FONDAPARINUX IN THE INITIALTREATMENT OF VENOUS THROMBOEMBOLISM (VTE) IN PATIENTSAGED 75 YEARS OR ABOVEH. R. Buller* (NL)

OC-WE-002 8:15 AM - 8:30 AMFONDAPARINUX 1.5 MG IN PATIENTS WITH MODERATE TO SEVERERENAL IMPAIRMENT UNDERGOING MAJOR ORTHOPEDIC SURGERY:THE PROPICE STUDYP. Mismetti* (FR), N. Rosencher, C. Samama, C. Vielpeau, P. Nguyen, B. Deygas, E. Presles, S. Laporte

OC-WE-003 8:30 AM - 8:45 AMTHE RELATIONSHIP BETWEEN ORAL FACTOR Xa (FXa) INHIBITOR DU-176B PHARMACOKINETICS (PK) AND THE PROBABILITY OFBLEEDING EVENTS (BE) IN PATIENTS WITH ATRIAL FIBRILLATION (AF)R. Giugliano* (US), S. Rohatagi, H. Kastrissios, M. Green, T. J. Carrothers, J. Mendell, E. Antman, D. Salazar

OC-WE-004 8:45 AM - 9:00 AMPOOLED ANALYSIS OF FOUR RIVAROXABAN STUDIES: EFFECTS ON SYMPTOMATIC EVENTS AND BLEEDINGA. G. G. Turpie* (CA), M. R. Lassen, A. K. Kakkar, B. I. Eriksson, M. Gent

OC-WE-005 9:00 AM - 9:15 AMECONOMIC COMPARISON OF RIVAROXABAN WITH DABIGATRAN INCANADIAN PATIENTS UNDERGOING TOTAL HIP REPLACEMENTP. Wells* (CA), A. Diamantopoulos, H. McDonald, F. Forster, C. Lereun, F. Rasul, M. Lees

OC-WE-006 9:15 AM - 9:30 AMREVERSIBILITY OF THE ANTICOAGULANT ACTIVITY OFIDRABIOTAPARINUX (BIOTINYLATED IDRAPARINUX) BY AVIDIN INHEALTHY SUBJECTS AND PATIENTSI. Paty* (FR), M. Trellu, J. Destors, P. Cortez, E. Boëlle, G. Sanderink

Thrombotic Thrombocytopenic Purpura I Room 205 ABC

Chairpersons: Toshiyuki Miyata (JP) and X. Long Zheng (US)

OC-WE-007 8:00 AM - 8:15 AMANTI-THROMBOTIC EFFECTS OF AN ANTI-VON WILLEBRAND FACTORA1 DOMAIN APTAMER IN BLOOD FROM PATIENTS UNDER ASPIRINAND CLOPIDOGREL THERAPYD. Arzamendi* (CA), F. Dandachli, G. Ducroq, J. F. Théorêt, W. Mourad, J. Gilbert, R. Schaub, J. F. Tanguay, Y. Merhi

WEDNESDAY, JULY 15, 2009 8:00 AM - 9:30 AM

ORAL COMMUNICATIONS

219

OC-WE-008 8:15 AM - 8:30 AMIDENTIFICATION OF 41 JAPANESE PATIENTS WITH UPSHAW-SHULMANSYNDROME, WITH SPECIAL REFERENCE TO ITS GENOTYPE-PHENOTYPE ANALYSISY. Fujimura* (JP), K. Kokame, M. Matsumoto, A. Isonishi, S. Kato, H. Hiura, T. Miyata

OC-WE-009 8:30 AM - 8:45 AMADAMTS13 ACTIVITY, RACE, AND AGE AS PREDICTORS OFEXACERBATION IN PATIENTS WITH IDIOPATHIC TTPS. R. Cataland* (US), S. Yang, L. Witkoff, E. H. Kraut, S. Lin, J. N. George, H. M. Wu

OC-WE-010 8:45 AM - 9:00 AMRESPONSIVENESS OF VON WILLEBRAND FACTOR (VWF) TO SHEARSTRESS MAY AFFECT THE THROMBOTIC PHENOTYPE OF ADAMTS13DEFICIENCYW. Zhou* (US), H. Tsai

OC-WE-011 9:00 AM - 9:15 AMTHE ANTI VON WILLEBRAND FACTOR APTAMER ARC1779 INCREASESPLATELET COUNTS IN A PATIENT WITH FAMILIAL THROMBOTICTHROMBOCYTOPENIC PURPURA (TTP)C. Firbas, B. Jilma* (AT), J. C. Gilbert, S. Schranz, P. Knöbl

OC-WE-012 9:15 AM - 9:30 AMECULIZUMAB IN CONGENITAL RELAPSING AHUS/TTPR. A. Gruppo* (US), V. Fremeaux-Bacchi, R. P. Rother

Risk Factors for Venous Thrombosis III Room 253 ABC

Chairpersons: Pieter Kamphuisen (NL) and Suzanne Cannegieter (NL)

OC-WE-013 8:00 AM - 8:15 AMINCREASED LEVELS OF THYROXIN INCREASE THE RISK OF VENOUSTHROMBOSISS. C. Cannegieter* (NL), J. Debeij, O. M. Dekkers, S. C. Christiansen, I. Naess, B. O. Asvold, J. Hammerstrom, F. R. Rosendaal

OC-WE-014 8:15 AM - 8:30 AMNONSTEROIDAL ANTI-INFLAMMATORY DRUGS INCREASE THE RISKOF PULMONARY EMBOLISMS. Rafi* (NL), M. di Nisio, E. Porreca, A. de Boer, P. C. Souverein, H. R. Buller, P. W. Kamphuisen

OC-WE-015 8:30 AM - 8:45 AMCOAGULATION FACTORS AND BLOOD GROUP AS RISK FACTORS FORVENOUS THROMBOSIS OF THE UPPER EXTREMITYL. E. Flinterman* (NL), A. van Hylckama Vlieg, F. R. Rosendaal, C. J. M. Doggen

OC-WE-016 8:45 AM - 9:00 AMPLASMA LEVELS OF FIBRINOLYTIC PROTEINS AND THE RISK OFVENOUS THROMBOSISM. E. Meltzer* (NL), T. Lisman, J. C. M. Meijers, P. G. de Groot, C. J. M. Doggen, F. R. Rosendaal


ORAL COMMUNICATIONS

220

Wed

nesd

ay O

rals

OC-WE-017 9:00 AM - 9:15 AMASSOCIATION OF INFLUENZA VACCINATION WITH REDUCED RISK OFVENOUS THROMBOEMBOLISMJ. Emmerich* (FR), T. Zhu, L. Carcaillon, I. Martinez, J. Cambou, X. Kyndt, K. Guillot, M. Vergnes, P. Scarabin

OC-WE-018 9:15 AM - 9:30 AMPREVALENCE OF VENOUS THROMBOEMBOLISM IN THE USA: NOWAND FUTURES. Deitelzweig* (US), J. Lin, B. H. Johnson, K. L. Schulman

Hemostasis and Cancer Room 258 ABC

Chairpersons: Chris Holmes (US) and Ajay Kakkar and (UK)

OC-WE-019 8:00 AM - 8:15 AMENDOGENOUS ACTIVATED PROTEIN C PROTECTS AGAINSTEXPERIMENTAL METASTASIS THROUGH SPHINGOSINE 1- PHOSPHATERECEPTOR-1 MEDIATED VASCULAR ENDOTHELIAL BARRIERPROTECTIONG. L. van Sluis* (NL), T. M. H. Niers, W. Tigchelaar Gutter, C. T. Esmon, D. J. Richel, H. R. Buller, C. J. F. van Noorden, C. A. Spek

OC-WE-020 8:15 AM - 8:30 AMPLATELET GLYCOPROTEIN VI FACILITATES MURINE EXPERIMENTALMETASTASISS. Jain* (US), S. Russell, J. Ware

OC-WE-021 8:30 AM - 8:45 AMMDA-9/SYNTENIN PROMOTES ACTIVE TISSUE-FACTOR/FVIIa COMPLEXASSEMBLY AND MEDIATES TUMOR CELL MIGRATION AND INVASIONC. Prévost, H. Aissaoui, J. C. Bordet, J. L. Plantier, Y. Dargaud, C. Negrier, P. B. Fisher, H. Boukerche, H. Boukerche* (FR)

OC-WE-022 8:45 AM - 9:00 AMA TISSUE PLASMINOGEN ACTIVATOR DEFICIENCY ENHANCESADENOMA GROWTH AND ANGIOGENESIS IN A MODEL OF FAMILIALADENOMATOUS POLYPOSISV. A. Ploplis* (US), H. Tipton, S. Chapman, M. J. Sandoval-Cooper, R. D. Balsara, A. Carmony, H. Menchen, F. J. Castellino

OC-WE-023 9:00 AM - 9:15 AMCOAGULATION ACTIVATION AND INFLAMMATION IN APROMYELOCYTIC LEUKEMIC MICE MODELM. C. Pintao* (BR), B. A. A. Santana-Lemos, F. G. Mangolini, L. L. Figueiredo-Pontes, F. P. Saggioro, C. L. A. Silva, P. S. Scheucher, G. A. S. Santos, M. S. Baggio, A. B. Garcia, A. A. Garcia, E. M. Rego

OC-WE-024 9:15 AM - 9:30 AMDOWN REGULATION OF THE EXPRESSION OF KEY GENESFOLLOWING TREATMENT OF BREAST CANCER CELLS WITH HEPARINM. F. Scully, G. Dawson, C. Goodwin, T. Razzaq, A. K. Kakkar* (UK)


ORAL COMMUNICATIONS

221

Cell Biology of the Extrinsic Pathway Room 157 ABC

Chairpersons: Wolfram Ruf (US) and Vivien Chen (US)

OC-WE-025 8:00 AM - 8:15 AMTISSUE FACTOR (TF) LOCALIZATION AND ACTIVITIES IN BLOODCELLS: MONOCYTES THE ONLY CELL POSSESSING TF ACTIVITYAND ANTIGEN AND MICROPARTICLES ARE FREE OF TFB. Osterud* (NO), J. Olsen

OC-WE-026 8:15 AM - 8:30 AMACTIVATION OF TISSUE FACTOR-DEPENDENT CLOTTING PATHWAYIN HUMAN PLATELETS IS AGONIST-SPECIFIC, USES SRC-LYNSIGNALING PATHWAY, IS NOT INHIBITED BY TFPI AND IS NOTINDUCED BY PKC-SIGNALING AGONISTSD. Mezzano* (CL), G. Valenzuela, V. Matus, J. Pereira, O. Panes

OC-WE-027 8:30 AM - 8:45 AMHIGH MOBILITY GROUP BOX 1 PROTEIN INDUCES TISSUE FACTOREXPRESSION IN VASCULAR ENDOTHELIAL CELLS VIA ACTIVATION OF NFB AND EGR-1F. Chen* (CN), B. Lv, H. Wang, Y. Tang, X. Xiao

OC-WE-028 8:45 AM - 9:00 AMDYNAMIN2- MEDIATED CAVEOLAE INTERNALIZATION CONTROLS THECELL SURFACE ACTIVITY OF TISSUE FACTOR PATHWAY INHIBITOR INENDOTHELIAL CELLSC. Lupu* (US), N. I. Popescu, R. Silasi-Mansat, H. Zhu, F. Lupu

OC-WE-029 9:00 AM - 9:15 AMROLE OF THE RENIN ANGIOTENSIN SYSTEM IN THE MODULATION OFTISSUE FACTOR EXPRESSION BY TNF-ALPHA-STIMULATED HUMANUMBILICAL VEIN ENDOTHELIAL CELLSA. Del Fiorentino, S. Cianchetti, C. Armani, R. Pedrinelli, A. Celi* (IT)

OC-WE-030 9:15 AM - 9:30 AMASSEMBLY OF THE PROTHROMBINASE COMPLEX IN THE PRESENCEOF TSP1 ON THE FIBROBLAST SURFACE INDUCES UPREGULATIONOF CTGF BY TWO SEPARATE SIGNALING PATHWAYSM. C. Rico* (US), J. J. Rough, J. M. Manns, S. P. Kunapuli, R. A. Dela Cadena

Arterial Disease Risk Markers I Room 104 ABC

Chairpersons: Nancy Jenny (US) and Francesco Sofi (IT)

OC-WE-031 8:00 AM - 8:15 AMHOMOCYSTEINE, B-GROUP VITAMINS (VITAMIN B6 AND FOLIC ACID)AND RHEOLOGICAL PARAMETERS AS INDEPENDENT RISK FACTORSFOR RETINAL VEIN OCCLUSIONF. Sofi* (IT), R. Marcucci, L. Mannini, B. Giambene, A. Sodi, U. Menchini, R. Abbate, G. Gensini, D. Prisco


ORAL COMMUNICATIONS

222

Wed

nesd

ay O

rals

OC-WE-032 8:15 AM - 8:30 AMHIGH LIPOPROTEIN (A) LEVELS ARE ASSOCIATED WITH ANINCREASED RISK OF RETINAL VEIN OCCLUSIONF. Sofi* (IT), R. Marcucci, S. Fedi, B. Giambene, A. Sodi, U. Menchini, R. Abbate, G. Gensini, D. Prisco

OC-WE-033 8:30 AM - 8:45 AMCOAGULATION ACTIVATION MARKERS ARE ASSOCIATED WITHCARDIOVASCULAR EVENTS AND DEATH IN THE ELDERLY AT RISK:PROSPER STUDY COHORTA. Rumley* (UK), G. Lowe, D. Stott, P. Welsh, M. Robertson, H. Murray, I. Ford, N. Sattar, R. Westendorp, T. de Craen

OC-WE-034 8:45 AM - 9:00 AMFACTOR XIII ACTIVATION PEPTIDE AND SUBUNIT ANTIGEN LEVELS IN PATIENTS WITH ACUTE ISCHAEMIC STROKEE. Ortner, H. P. Kohler, M. Mono, A. Galimanis, N. Meier, O. Findling, M. Arnold, H. P. Mattle, V. Schroeder* (CH)

OC-WE-035 9:00 AM - 9:15 AMNON-SELECTIVE BETA-BLOCKERS DECREASE THROMBOTIC EVENTSIN PATIENTS WITH HEART FAILUREO. R. de Peuter* (NL), P. C. Souverein, O. H. Klungel, A. de Boer, H. R. Büller, P. W. Kamphuisen

OC-WE-036 9:15 AM - 9:30 AMACTIVATION OF THE INTRINSIC COAGULATION PROTEINS AND THE RISK OF ARTERIAL THROMBOSIS IN YOUNG WOMENB. Siegerink* (NL), J. W. P. Govers-Riemslag, F. R. Rosendaal, H. ten Cate,A. Algra

Experimental Studies in Thrombosis Room 107 ABC

Chairpersons: David Motto (US) and Roger Lijnen (BE)

OC-WE-037 8:00 AM - 8:15 AMGENERATION AND PHENOTYPIC ANALYSIS OF PROTEIN S-DEFICIENT MICEF. Saller* (CH), A. C. Brisset, M. Azevedo, R. Chrast, M. Schapira, A. Angelillo-Scherrer

OC-WE-038 8:15 AM - 8:30 AMDIRECT EFFECTS OF PROTEIN S IN AMELIORATING ACUTE LUNGINJURYT. Takagi* (JP), E. C. Gabazza, J. Morser, S. Aoki, H. Fujimoto, C. N. D’Alessandro-Gabazza, M. Toda, A. Fujiwara, Y. Takei, O. Taguchi

OC-WE-039 8:30 AM - 8:45 AMA SENSITIZED SUPPRESSOR SCREEN TO IDENTIFY MODIFIER GENESFOR FACTOR V LEIDEN-DEPENDENT THROMBOSIS IN THE MOUSER. J. Westrick* (US), S. L. Manning, G. Zhu, D. R. Siemieniak, D. Ginsburg

OC-WE-040 8:45 AM - 9:00 AMDEFICIENCY OF VON WILLEBRAND FACTOR PROTECTS MICE FROMISCHEMIC STROKES. F. de Meyer* (BE), C. Kleinschnitz, T. Schwarz, M. Austinat, K. Vanhoorelbeke, B. Nieswandt, H. Deckmyn, G. Stoll


ORAL COMMUNICATIONS

223

OC-WE-041 9:00 AM - 9:15 AMSCANNING ELECTRON MICROSCOPY STUDY OF ENDOTHELIALINJURY AND THROMBUS FORMATION IN WT AND VWF-DEFICIENTMICEJ. D. Barr* (US), D. G. Motto

OC-WE-042 9:15 AM - 9:30 AMA MURINE MODEL TO TEST ANTITHROMBOTIC DRUGS TARGETINGHUMAN VON WILLEBRAND FACTORR. Pendu* (FR), I. Marx, P. J. Lenting, O. D. Christophe, C. V. Denis

Mechanisms of Platelet Activation III Room 153 ABC

Chairpersons: Satya Kunapuli (US) and Yotis Senis (UK)

OC-WE-043 8:00 AM - 8:15 AMTHE MITOGEN-ACTIVATED PROTEIN KINASE JNK1 IS INVOLVED INPLATELET FUNCTION AND THROMBUS GROWTHF. Adam* (FR), A. Kauskot, E. Sulpice, M. F. Hoylaerts, R. J. Davis, J. Rosa,M. Bryckaert

OC-WE-044 8:15 AM - 8:30 AMTHE CONTRIBUTION OF THROMBIN-INDUCED PLATELET ACTIVATIONTO THROMBOSIS IS DEPENDENT ON BLOOD SHEAR RATEJ. R. Hamilton* (AU), H. Lee, S. A. Sturgeon, A. Ono, H. H. Salem, S. P. Jackson

OC-WE-045 8:30 AM - 8:45 AMA ROLE FOR MICRO-RNA IN THE REGULATION OF HUMAN VAMP8EXPRESSION AND PLATELET REACTIVITYA. Kondkar* (US), S. Nagalla, M. Bray, C. Shaw, S. Leal, Y. Jin, S. Whiteheart, P. F. Bray

OC-WE-046 8:45 AM - 9:00 AMTHE HDL RECEPTOR SR-BI MODULATES PLATELET FUNCTION ANDSUSCEPTIBILITY TO THROMBOSIS IN VIVOS. J. A. Korporaal* (NL), I. Meurs, M. Vergeer, A. Hauer, R. B. Hildebrand, D. Praticò, J. N. Akkerman, T. J. C. van Berkel, J. Kuiper, J. A. Kuivenhoven,M. van Eck

OC-WE-047 9:00 AM - 9:15 AMSTREPTOCOCCUS PNEUMONIAE TRIGGERS PLATELET ACTIVATIONVIA TOLL LIKE RECEPTOR 2A. Cunningham, C. Keane, D. Cox, A. Kadioglu, H. F. Jenkinson, S. W. Kerrigan* (IE)

OC-WE-048 9:15 AM - 9:30 AMTHE ROLE OF FIBROUS COLLAGEN STRUCTURE IN DETERMINING ITSABILITY TO BIND AND ACTIVATE PLATELETSR. W. Farndale* (UK), A. B. Herr


ORAL COMMUNICATIONS

224

Wed

nesd

ay O

rals

Novel Approaches to Understanding Platelet Function Room 156 ABC

Chairpersons: Scott Diamond (US) and Danila Leontyev (CA)

OC-WE-049 8:00 AM - 8:15 AMA MICROFLUIDIC-BASED FOCAL INJURY MODEL PROVIDES APLATFORM TO INVESTIGATE DRUG RESPONSE REGIMES ONTHROMBUS FORMATION AND STABILITYS. F. Maloney* (US), S. L. Diamond

OC-WE-050 8:15 AM - 8:30 AMCONFORMATION CHANGE IN HUMAN BLOOD PROTEIN VONWILLEBRAND FACTOR INDUCED BY FLUID SHEARS. Neelamegham* (US), I. Singh, L. Porcar, E. Themistou

OC-WE-051 8:30 AM - 8:45 AMMEMBRANE ELASTICITY AND CYTOSKELETAL STRUCTUREDETERMINE PLATELET TETHER AND MICROPARTICLE FORMATIONUNDER SHEAR STRESSA. J. Reininger* (DE), J. I. Angerer, M. Napoleone, A. Kern, M. F. Schneider

OC-WE-052 8:45 AM - 9:00 AMIMMUNOSELECTION OF ZEBRAFISH YOUNG AND MATURETHROMBOCYTES AND IDENTIFICATION OF NOVEL G-PROTEINCOUPLED RECEPTORS (GPCRS)V. Kulkarni* (US), S. Kim, L. Zafreen, P. Jagadeeswaran

OC-WE-053 9:00 AM - 9:15 AMA MICROFLUIDIC METHOD FOR CONTROLLING THE FLUX OFPLATELET AGONISTS INTO FLOWING BLOODK. B. Neeves* (US), S. L. Diamond

OC-WE-054 9:15 AM - 9:30 AMREALTIME IMAGING ANALYSIS OF PHOSPHATIDYLSERINE EXPOSUREON PLATELET THROMBUS USING INTRA-VITAL CONFOCALMICROSCOPYT. Urano* (JP), M. Rybaltowski, T. Hayashi, Y. Suzuki, H. Mogami

Bypassing Therapies Room 160 ABC

Chairpersons: Elena Santagostino (IT) and Olivier Christophe (FR)

OC-WE-055 8:00 AM - 8:15 AMSAFETY AND PHARMACOKINETICS OF A LONG-ACTINGGLYCOPEGYLATED RFVIIa DERIVATIVE: A FIRST HUMAN DOSE TRIALIN HEALTHY SUBJECTSJ. Møss* (DK), A. Rosholm, A. Laurén

OC-WE-056 8:15 AM - 8:30 AMPROLONGED EFFECT OF A LONG ACTING RFVIIa ON BLEEDING INHAEMOPHILIC MICE COMPARED WITH RFVIIaH. L. Holmberg* (DK), T. Elm, M. Tranholm, M. Ezban


ORAL COMMUNICATIONS

225

OC-WE-057 8:30 AM - 8:45 AMENHANCED AND PROLONGED EFFICACY OF A NOVEL RECOMBINANTFVIIa VARIANT (BAY86-6150) FOR ACUTE AND PROPHYLACTICTREATMENTS IN HEMOPHILIA A (HEMA) MICET. Liu, X. Zhang, J. Pan, D. Sim, K. McLean, Z. Cui, J. M. Sommer, J. Haaning, X. Zhao, J. E. Murphy, G. F. Pierce, H. Jiang* (US)

OC-WE-058 8:45 AM - 9:00 AMHEMOSTATIC THERAPY IN ACQUIRED HAEMOPHILIA: DATA FROM THE EUROPEAN ACQUIRED HAEMOPHILIA (EACH2) REGISTRYF. Baudo* (IT), P. Collins, A. Huth-Kühne, P. Knoebl, H. Lévesque, M. Pascual, L. Nemes, K. Peerlinck, L. Tengborn

OC-WE-059 9:00 AM - 9:15 AMBINDING TO ACTIVATED PLATELETS AND ENHANCED CLOTTINGPROPERTIES OF THE RECOMBINANT FVIIa ANALOGUE BAY7J. Pan* (US), J. Kim, D. Zhu, E. Blank, X. Zhang, T. Liu, J. Wu, D. Schneider,K. McLean, X. Zhao, D. Sim, H. Jiang, H. Apeler, J. E. Murphy, J. Haaning, G. F. Pierce, J. M. Sommer

OC-WE-060 9:15 AM - 9:30 AMTHROMBIN GENERATION TEST OPTIMIZED TO MEASURE TREATMENTOF FACTOR VIII DEFICIENCY WITH RECOMBINANT FACTOR VIIaP. L. A. Giesen* (NL), R. van Oerle, H. M. H. Spronk

Hemophilia: Basic Science Room 102 AB

Chairpersons: Steven Pipe (US) and Pauline van Helden (AT)

OC-WE-061 8:00 AM - 8:15 AMWOUND HEALING IN HEMOPHILIA: PROGRESSIVE IMPROVEMENTWITH LONGER TREATMENTD. M. Monroe* (US), M. Hoffman, J. Brock, M. Ezban, H. R. Roberts, U. Hedner

OC-WE-062 8:15 AM - 8:30 AMTRANSGENIC MURINE MODEL FOR EVALUATING THEIMMUNOGENICITY OF BIOENGINEERED FACTOR VIII VARIANTSH. Z. Miao, C. H. Miao, R. J. Kaufman, S. W. Pipe* (US)

OC-WE-063 8:30 AM - 8:45 AMTOWARDS A NEW HEMOPHILIC MOUSE MODEL FOR THE DETECTIONOF NEO-ANTIGEN FORMATION IN HUMAN FACTOR VIIIP. M. van Helden* (AT), S. Unterthurner, M. Schuster, G. Antoine, R. U. Ahmad, C. Hermann, E. M. Muchitsch, H. J. Ehrlich, H. Schwarz, B. M. Reipert

OC-WE-064 8:45 AM - 9:00 AMTNF-ALPHA ANTAGONISTS AUGMENT FACTOR REPLACEMENT TO PREVENT ARTHROPATHY IN HEMOPHILIC MICEJ. Sun* (US), G. Hu, P. E. Monahan


ORAL COMMUNICATIONS

226

Wed

nesd

ay O

rals

OC-WE-065 9:00 AM - 9:15 AMWEAK AGREEMENT BETWEEN COMPUTER SIMULATION AND IN VITROBINDING ASSAYS FOR IDENTIFYING FACTOR VIII 15MER PEPTIDESTHAT BIND TO THE MHC-CLASS II HAPLOTYPE HLA-DRB1*1501K. N. Steinitz* (AT), P. M. van Helden, M. Wolfsegger, H. Ehrlich, H. P. Schwarz, B. M. Reipert

OC-WE-066 9:15 AM - 9:30 AMACCUMULATION OF THERAPEUTIC FACTOR VIII IN THE MARGINALZONE OF THE SPLEEN OF FACTOR VIII-DEFICIENT MICES. Delignat* (FR), A. Navarrete, S. Dasgupta, Y. Repesse, S. André, Y. Meslier, M. Teyssandier, S. Kaveri, S. Lacroix-Desmazes

Angiogenesis and Vascular Development Room 109 AB

Chairpersons: Raffaele de Caterina (IT) and Bernard Binetruy (FR)

OC-WE-067 8:00 AM - 8:15 AMEXPRESSION OF TF AND PARS ON SMOOTH MUSCLE VASCULARPROGENITORS DEFINES A PATTERN OF CD34+ MOBILISATIONASSOCIATED WITH INTIMAL HYPERPLASIA POST-TRANSPLANTATIOND. Chen* (UK), J. M. Abrahams, J. H. McVey, A. Dorling

OC-WE-068 8:15 AM - 8:30 AMALLOGENEIC MESENCHYMAL STEM CELLS CONFER VASCULARPROTECTION AFTER BALLOON ANGIOPLASTY IN RABBIT CAROTIDSP. Liu, L. Zhang* (CN), W. Liao, W. Du, D. Gu, M. Liu, J. Xu, S. Lu, W. Xing,S. Yang, B. Zhou, Z. Han

OC-WE-069 8:30 AM - 8:45 AMTUMOR BLOOD VESSEL FORMATION IS AFFECTED BY THE HUMANCARCINOEMBRYONIC ANTIGEN (CEA)K. Braemswig, M. Poettler, M. Cabaravbic, B. Binder, C. C. Zielinski, G. W. Prager* (AT)

OC-WE-070 8:45 AM - 9:00 AMPROTEASE NEXIN-1 IS ANTI-ANGIOGENIC IN VITRO INDEPENDENTLYOF ITS ANTI-PROTEASE ACTIVITYV. Arocas* (FR), F. Azibani, S. Iatmanen, Y. Boulaftali, M. Bouton, M. Jandrot-Perrus

OC-WE-071 9:00 AM - 9:15 AMTHE OMEGA-3 FATTY ACID DOCOSAHEXAENOATE ATTENUATESINSULIN-INDUCED CD36 EXPRESSION IN HUMAN MICROVASCULARENDOTHELIAL CELLSR. Madonna, D. Schiavone, R. de Caterina* (IT)

OC-WE-072 9:15 AM - 9:30 AMRESTRICTION OF GAMMA-GLUTAMYL CARBOXYLASE EXPRESSIONTO THE LIVER LEADS TO MINERALIZATION IN BLOOD VESSEL WALLAND HEARTM. M. Bronstein* (US), H. Sun, G. Merrill-Skoloff, M. Rishavy, B. Furie, K. Berkner, B. C. Furie, D. Ginsburg


ORAL COMMUNICATIONS

227

Vitamin K Cycle Room 151 AB

Chairpersons: Darrel Stafford (US) and Weikai Li (US)

OC-WE-073 8:00 AM - 8:15 AMGAMMA-GLUTAMYL CARBOXYLASE IS A CARGO RECEPTOR FORVITAMIN K-DEPENDENT PROTEINSM. Souri* (JP), H. Iwata, W. Zhang, T. Nakagaki, A. Ichinose

OC-WE-074 8:15 AM - 8:30 AMIN VITRO RECONSTITUTION OF VKOR-DEPENDENT DISULFIDE BRIDGEFORMATIONS. Schulman* (US), W. Li, R. Dutton, D. Boyd, J. Beckwith, T. Rapoport

OC-WE-075 8:30 AM - 8:45 AMINVESTIGATION OF RESIDUES L394, Y395, AND W399 ROLES INLINKAGE AMONG THE GAMMA-GLUTAMYL CARBOXYLASE (GGCX)SUBSTRATE BINDING SITESV. P. Mutucumarana* (US), S. L. Higgins-Gruber, D. W. Stafford, D. L. Straight

OC-WE-076 8:45 AM - 9:00 AMPHENOTYPE OF VKORC1 KNOCKOUT-MICEG. Spohn* (DE), A. Kleinridders, M. Watzka, F. T. Wunderlich, F. Zaucke, K. Blumbach, C. Geisen, E. Seifried, C. Müller-Reible, M. Paulsson, J. C. Brüning, J. Oldenburg

OC-WE-077 9:00 AM - 9:15 AMHEREDITARY WARFARIN RESISTANCE IN 16 PATIENTS DUE TO NINENOVEL AND THREE KNOWN VKORC1 MUTATIONSC. Geisen* (DE), M. Watzka, K. Sittinger, G. Spohn, D. M. Dimichele, H. Haubelt, M. Heistinger, J. G. Kadar, B. Kemkes-Matthes, R. Klamroth, P. Lages, E. Lindhoff-Last, B. Luxembourg, B. Mansouri Taleghani, H. Pollmann, M. Spannagl, S. Struve, R. Zimmermann, E. Seifried, J. Oldenburg

OC-WE-078 9:15 AM - 9:30 AMTHE VITAMIN K-DEPENDENT CARBOXYLASE ACHIEVES EFFICIENTCOUPLING OF VITAMIN K EPOXIDATION AND GLUTAMATECARBOXYLATION USING A CONCERTED MECHANISM OF CARBANION-AND GAMMA-CARBOXYLATED GLUTAMATE FORMATIONM. A. Rishavy* (US), K. L. Berkner

Proteases: Structure and Function Room 162 AB

Chairpersons: James Huntington (UK) and Neychelle Fernandes (US)

OC-WE-079 8:00 AM - 8:15 AMEXOSITE 2-DIRECTED LIGANDS MODULATE THE FUNCTION OFEXOSITE 1 ON THROMBINN. S. Petrera* (CA), A. R. Stafford, B. A. Leslie, J. C. Fredenburgh, J. I. Weitz

OC-WE-080 8:15 AM - 8:30 AMFLUORESCENCE RESONANCE ENERGY TRANSFER STUDIES OFPROTHROMBIN RECOGNITION BY PROTHROMBINASEE. Zekas* (US), S. Krishnaswamy


ORAL COMMUNICATIONS

228

Wed

nesd

ay O

rals

OC-WE-081 8:30 AM - 8:45 AMEFFECT OF GLYCOSYLATION ON THROMBIN STRUCTURE, STABILITY AND FUNCTIONR. Frasson* (IT), N. Pozzi, D. J. D. Johnson, J. A. Huntington, V. de Filippis

OC-WE-082 8:45 AM - 9:00 AMCONTRIBUTION OF PROTHROMBIN DOMAINS AND ACTIVE SITELABELING TO CONFORMATIONAL ACTIVATION OF PROTHROMBIN BY VON WILLEBRAND FACTOR-BINDING PROTEINH. K. Kroh* (US), P. E. Bock

OC-WE-083 9:00 AM - 9:15 AMFRAGMENT-BASED ENZYME DESIGN OF COAGULATION FACTORACTIVITYM. J. Page* (US), E. di Cera

OC-WE-084 9:15 AM - 9:30 AMFACTOR VII-ACTIVATING PROTEASE (FSAP): DOES IT ACTIVATEFACTOR VII?F. Stavenuiter* (NL), E. Sellink, H. J. M. Brinkman, A. B. Meijer, K. Mertens

Endothelial Dysfunction and Biomarkers II Room 252 AB

Chairpersons: Christopher Jackson (AU) and David Smadja (FR)

OC-WE-085 8:00 AM - 8:15 AMIMPACT OF SMOKING PROHIBITION IN BARS, RESTAURANTS ANDDISCOTHEQUES ON EMPLOYEES’ ENDOTHELIAL FUNCTION: THE DILATER STUDYA. Bura* (FR), S. Labro, N. Vaysse, D. Thomas, J. P. Cambou

OC-WE-086 8:15 AM - 8:30 AMACTIVATION OF THE HEMOSTATIC SYSTEM AND ENDOTHELIALDYSFUNCTION IN CHRONIC COCAINE CONSUMERS: ASSOCIATIONWITH BRAIN PERFUSION DEFECTSJ. Pereira* (CL), C. G. Sáez, P. Olivares, N. Moreno, M. J. Cabrera, O. Panes, P. Hidalgo, T. Massardo, J. Pallavicini, R. Jaimovich, J. C. Quintana, D. Mezzano

OC-WE-087 8:30 AM - 8:45 AMHUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION, AND NOTSHORT-TERM HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, INDUCESENDOTHELIAL DYSFUNCTIONS. Giannini* (IT), D. Francisci, F. Baldelli, M. Leone, B. Belfiori, G. Guglielmini,L. Malincarne, P. Gresele

OC-WE-088 8:45 AM - 9:00 AMPLASMA MARKERS OF ENDOTHELIAL CELL ACTIVATION IN PATIENTSWITH SECONDARY PULMONARY HYPERTENSION RELATED TOCONNECTIVE TISSUE DISEASES: EFFECT OF BOSENTANE. Osto* (IT), F. Vianello, F. Tona, F. Cozzi, H. Marotta, G. Saggiorato, O. Iqbal, J. Fareed, G. Cella


ORAL COMMUNICATIONS

229

OC-WE-089 9:00 AM - 9:15 AMCIRCULATING ENDOTHELIAL CELLS ARE A NEW CANDIDATEBIOMARKER OF IRREVERSIBLE PULMONARY HYPERTENSIONSECONDARY TO CONGENITAL HEART DISEASED. M. Smadja* (FR), P. Gaussem, L. Mauge, F. Dignat-George, D. Bonnet, M. Levy

OC-WE-090 9:15 AM - 9:30 AMINCREASED LEVELS OF CIRCULATING ENDOTHELIAL CELLS INPATIENTS WITH MAJOR DEPRESSIONC. G. Sáez* (CL), J. Pereira, L. Risco, P. Olivares, O. Panes, V. Araya, T. Galleguillos, T. Massardo, C. Liberman

Pediatric Thrombosis Room 257 AB

Chairpersons: Paul Monagle (AU) and Sharene Bungay (CA)

OC-WE-091 8:00 AM - 8:15 AMCOAGULATION ABNORMALITIES IN LEGG-CALVÉ-PERTHES DISEASEJ. S. Koenderman* (NL), A. Vosmaer, R. Rodrigues Pereira, F. R. Rosendaal,S. C. Cannegieter

OC-WE-092 8:15 AM - 8:30 AMOVERWEIGHT YOUTH HAVE A DECREASED FIBRINOLYTIC CAPACITY:A POTENTIAL NOVEL RISK FACTOR FOR CARDIOVASCULAR DISEASEIN CHILDRENG. Ball, K. Dietrich, S. Qayyum, L. G. Mitchell* (CA)

OC-WE-093 8:30 AM - 8:45 AMDOSING OF LMWH (ENOXAPARIN) THERAPY IN CHILDRENV. Ignjatovic* (AU), S. Najid, F. Newall, R. Summerhayes, P. Monagle

OC-WE-094 8:45 AM - 9:00 AMENOXAPARIN POPULATION- PHARMACOKINETIC MODELLING [POP-PK] IN CHILDREN – PRELIMINARY RESULTSL. Mitchell* (CA), A. Krumpel, J. Barett, U. Nowak-Gottl

OC-WE-095 9:00 AM - 9:15 AMMODELLING THROMBIN GENERATION IN DEVELOPMENTALHEMOSTASISS. D. Bungay* (CA), A. K. Chan

OC-WE-096 9:15 AM - 9:30 AMDECREASED GLOBAL FIBRINOLYTIC CAPACITY IN CHILDREN POSTCARDIOPULMONARY BYPASS SURGERY FOR REPAIR OFCONGENITAL HEART DEFECTS: A PROSPECTIVE COHORT STUDYL. G. Mitchell* (CA), K. Dietrich, I. Rebeyka, D. Ross, S. Qayyum


ORAL COMMUNICATIONS

230

Wed

nesd

ay O

rals

Genetics of Venous Thrombosis II Room 205 ABC

Chairpersons: Tetsuhito Kojima (JP) and Neil Zakai (US)

OC-WE-097 4:00 PM - 4:15 PMFUNCTIONAL ANALYSIS OF COMMON HAEMOSTATIC GENEPOLYMORPHISMS USING CALIBRATED AUTOMATEDTHROMBOGRAPHYO. Segers* (NL), R. van Oerle, H. ten Cate, J. Rosing, E. Castoldi

OC-WE-098 4:15 PM - 4:30 PMA GENOME WIDE LINKAGE SCAN FOR THROMBOSIS SUSCEPTIBILITYGENES IDENTIFIES A NOVEL PROTHROMBIN MUTATIONM. K. ten Kate* (US), C. He, I. M. van Schouwenburg, G. van der Steege, R. Mulder, C. Wijmenga, A. B. Mulder, H. C. Kluin-Nelemans, D. J. D. Johnson, J. A. Huntington, J. Ott, J. van der Meer

OC-WE-099 4:30 PM - 4:45 PMIN PT G20210A CARRIERS THE GENETIC MUTATION AND THE HISTORYOF VENOUS THROMBOSIS CONTRIBUTE BOTH TO THROMBINGENERATION INDEPENDENTLY OF FII PLASMA LEVELSG. Lavigne Lissalde* (FR), C. Castelli, C. Sanchez, S. Alonso, E. Mazoyer, C. Bal Dit Sollier, L. Drouet, I. Juhan Vague, J. C. Gris, M. C. Alessi, P. E. Morange

OC-WE-100 4:45 PM - 5:00 PMRISK OF RECURRENT VENOUS THROMBOSIS IN HOMOZYGOUSCARRIERS, AND DOUBLE HETEROZYGOUS CARRIERS OF FACTOR VLEIDEN AND PROTHROMBIN G20210AW. M. Lijfering* (NL), N. J. G. M. Veeger, S. Middeldorp, K. Hamulyák, M. H. Prins, H. R. Büller, J. van der Meer

Vascular Disease Prevention Room 253 ABC

Chairpersons: Henny Billett (US) and Gun Jorneskog (SE)

OC-WE-101 4:00 PM - 4:15 PMLMWH BRIDGING IN ATRIAL FIBRILLATIONH. H. Billett* (US), E. R. Giannattasio, B. A. Scorizello, H. W. Cohen

OC-WE-102 4:15 PM - 4:30 PMGENDER DIFFERENCES IN STROKE RISK OF ATRIAL FIBRILLATIONPATIENTS ON ORAL ANTICOAGULANT TREATMENTD. Poli* (IT), E. Antonucci, E. Grifoni, G. Ciuti, R. Marcucci, L. Mannini, G. F. Gensini, R. Abbate, D. Prisco

OC-WE-103 4:30 PM - 4:45 PMPREVALENCE, CHARACTERISTICS AND MORTALITY RATES OFINDIVIDUALS ELIGIBLE FOR LIPID LOWERING USING THE JUPITERCRITERIA IN A GENERAL POPULATION SAMPLEM. Cushman* (US), L. A. McClure, S. G. Lakoski, N. S. Jenny

OC-WE-104 4:45 PM - 5:00 PMEFFECTS OF ATORVASTATIN ON HAEMOSTASIS IN PATIENTS WITHTYPE 1 DIABETESS. Tehrani* (SE), F. Mobarrez, A. Antovic, P. Santesson, P. Lins, U. Adamson,P. Henriksson, H. Wallén, G. Jörneskog

WEDNESDAY, JULY 15, 2009 4:00 PM - 5:00 PM

ORAL COMMUNICATIONS

231

Cancer Treatment Effects on Hemostasis and Thrombosis Room 258 ABC

Chairpersons: Javier Corral (ES) and Ulrike Nowak-Gottl (DE)

OC-WE-105 4:00 PM - 4:15 PMA PIVOTAL ROLE OF PROTEASE-ACTIVATED RECEPTOR-2 INBLEOMYCIN-INDUCED PULMONARY FIBROSISK. S. Borensztajn* (NL), P. Bresser, J. von der Thusen, B. van den Blink, A. P. Groot, J. Daalhuisen, M. P. Peppelenbosch, A. Spek

OC-WE-106 4:15 PM - 4:30 PMA PREDICTIVE MODEL FOR INDENTIFYING CHILDREN AT RISK FORSYMPTOMATIC THROMBOEMBOLISM DURING ACUTELYMPHOBLASTIC LEUKEMIA TREATMENT – RESULTS OF A MULTICENTER COHORT STUDYS. Flege, L. Mitchell, G. Kenet, M. Fruhwald, R. Schobess, U. Nowak-Gottl* (DE)

OC-WE-107 4:30 PM - 4:45 PMDEXAMETHASONE INDUCES A HEAT-STRESS RESPONSE THATAMELIORATES THE CONFORMATIONAL CONSEQUENCES ONANTITHROMBIN OF L-ASPARAGINASE TREATMENT AND HELPS TOEXPLAIN THE REDUCED RISK OF THROMBOSISD. Hernández-Espinosa, A. Miñano, A. Ordóñez, R. Mota, I. Martínez-Martínez, V. Vicente, J. Corral* (ES)

OC-WE-108 4:45 PM - 5:00 PMDEFIBROTIDE BLUNTS THE PRO-THROMBOTIC EFFECT OFTHALIDOMIDE ON ENDOTHELIAL CELLSC. Echart, S. Somaini, P. G. Richardson, J. Fareed* (US), M. Iacobelli

Fibrinolysis: Cell Biology Room 157 ABC

Chairpersons: Edward Pryzdial (CA) and Eric Mullins (US)

OC-WE-109 4:00 PM - 4:15 PMREGULATION OF MOUSE THROMBIN-ACTIVABLE FIBRINOLYSISINHIBITOR GENE EXPRESSION BY INFLAMMATORY CYTOKINESM. Garand* (CA), N. Jiang, C. E. Hill, M. L. Koschinsky, M. B. Boffa

OC-WE-110 4:15 PM - 4:30 PMEPIGENETIC CONTROL OF TISSUE-TYPE PLASMINOGEN ACTIVATOREXPRESSION BY HUMAN ENDOTHELIAL CELLSS. Dunoyer-Geindre* (CH), E. K. O. Kruithof

OC-WE-111 4:30 PM - 4:45 PMPLASMIN FORMATION ON NEURONS STIMULATES THE RELEASE OF NEURON-DERIVED MICROPARTICLES BEARING PROTEOLYTICACTIVITYL. Doeuvre* (FR), L. Plawinski, O. Nicole, D. Goux, F. Toti, E. Anglés-Cano


ORAL COMMUNICATIONS

232

Wed

nesd

ay O

rals

OC-WE-112 4:45 PM - 5:00 PMRBC-BOUND PLASMINOGEN ACTIVATORS INITIATE AND PROPAGATE EFFICIENT FIBRINOLYSISK. C. Gersh* (US), S. Zaitsev, D. B. Cines, V. Muzykantov, J. W. Weisel

Stroke Room 104 ABC

Chairpersons: Peter Grant (UK) and Christina Jern (SE)

OC-WE-113 4:00 PM - 4:15 PMDETERMINANTS OF CAROTID INTIMA-MEDIA THICKNESS AMONG HIVPOSITIVE PERSONS: A THREE YEARS PROSPECTIVE COHORT STUDYE. Fourn, E. Pasquier, A. Delluc* (FR), L. Bressollette, L. de Saint Martin

OC-WE-114 4:15 PM - 4:30 PMFIBRIN STRUCTURE/FUNCTION IN RELATION TO STROKE SUB-TYPESAND POST-STROKE MORTALITYA. M. Carter* (UK), D. Kirby, N. A. Englyst, R. A. Ajjan, J. M. Bamford, C. Byrne, P. J. Grant

OC-WE-115 4:30 PM - 4:45 PMPLASMA LEVELS OF VON WILLEBRAND FACTOR IN ETIOLOGICALSUBTYPES OF ISCHEMIC STROKEE. Hanson* (SE), K. Jood, P. Redfors, S. Nilsson, C. Blomstrand, C. Jern

OC-WE-116 4:45 PM - 5:00 PMIS COAGULATION ACTIVATION A RISK FACTOR FOR COGNITIVEDECLINE IN OLDER PEOPLE?G. D. O. Lowe* (UK), D. J. Stott, A. Rumley, P. Welsh, M. Robertson, I. Ford,N. Sattar, R. Westendorp, T. J. M. de Craen, J. Shepherd

Hemophilia: Clinical II Room 107 ABC

Chairpersons: Wolfgang Schramm (DE) and Barbara Konkle (US)

OC-WE-117 4:00 PM - 4:15 PMEVIDENCE FOR INCREASED INHIBITOR INCIDENCE IN CHILDREN WITHSEVERE HEMOPHILIA A TREATED WITH RECOMBINANT FACTOR VIIIPRODUCTS: A SYSTEMATIC REVIEW&META-ANALYSISS. Halimeh* (DE), C. Bindlingmaier, C. Escuriola Ettinghausen, N. Goldenberg, S. Holzhauer, G. Kenet, K. Kurnik, D. Manner, U. Nowak-Goettl

OC-WE-118 4:15 PM - 4:30 PMMANAGEMENT OF HAEMOPHILIA PATIENTS WITH INHIBITORS:OPTIMAL CARE IN TIMES OF LIMITED RESOURCESK. Berger* (DE), D. Eheberg, W. Schramm


ORAL COMMUNICATIONS

233

OC-WE-119 4:30 PM - 4:45 PMTHE EUROPEAN STUDY OF CLINICAL, HEALTH ECONOMIC ANDQUALITY OF LIFE OUTCOMES IN 1,426 HAEMOPHILIA PATIENTSW. Schramm* (DE), K. Berger, B. Bullinger, A. Crispin, P. Giangrande, A. Giebl, A. Gringeri, R. Ljung, L. Nemes, S. von Mackensen, L. Mantovani, M. Serban

OC-WE-120 4:45 PM - 5:00 PMIMPROVED CONCEPT OF FACTOR IX ALBUMIN FUSION PROTEINSH. J. Metzner* (DE), T. Weimer, U. Kronthaler, W. Lang, S. Schulte

Platelet Biology II Room 153 ABC

Chairpersons: Peter Newman (US) and Steven W. Kerrigan (IE)

OC-WE-121 4:00 PM - 4:15 PMFIBRINOGEN-BETA3 INTEGRIN INTERACTION IS REQUIRED FORMAINTENANCE OF PLATELET P-SELECTIN EXPRESSIONH. Yang, S. Lang* (CA), Z. Zhai, L. Li, W. H. A. Kahr, P. Chen, J. Brkic, C. M. Spring, M. J. Flick, J. L. Degen, J. Freedman, H. Ni

OC-WE-122 4:15 PM - 4:30 PMTHE ROLE OF PI 3-KBETA IN GLYCOPROTEIN VI-MEDIATED AKTACTIVATION IN PLATELETSS. Kim* (US), P. Mangin, C. Dangelmaier, R. Lillian, S. P. Jackson, J. L. Daniel, S. P. Kunapuli

OC-WE-123 4:30 PM - 4:45 PMDIVERGENT ROLES OF CONVENTIONAL AND NOVEL PKC ISOFORMSIN PLATELET ACTIVATION TOWARDS THROMBUS FORMATIONK. Gilio* (NL), M. T. Harper, J. M. E. M. Cosemans, K. J. Hall, O. Konopatskaya, I. C. A. Munnix, J. D. Molkentin, M. Leitges, J. W. M. Heemskerk, A. W. Poole

OC-WE-124 4:45 PM - 5:00 PMIDENTIFICATION OF A RHEOLOGICAL-DEPENDENT MECHANISMSTABILIZING DISCOID PLATELET AGGREGATION INDEPENDENT OFSOLUBLE AGONISTSE. Westein* (AU), W. S. Nesbitt, F. Jia, S. P. Jackson

Inflammation and Cell Trafficking I Room 156 ABC

Chairpersons: Sandip Kanse (DE) and Virgilio Evangelista (IT)

OC-WE-125 4:00 PM - 4:15 PMFXIIIa ADOPTS A PERINUCLEAR DISTRIBUTION IN MONOCYTIC-CELLSAND TRANSFECTED COS CELLSP. A. Cordell* (UK), P. J. Grant, R. J. Pease


ORAL COMMUNICATIONS

234

Wed

nesd

ay O

rals

OC-WE-126 4:15 PM - 4:30 PMPLATELET SOLUBLE MEDIATORS INDUCE A MONOCYTE GENEEXPRESSION PROFILE THAT IS ANTI-INFLAMMATORY,ANTITHROMBOTIC AND PRO-ANGIOGENICJ. R. Wright, U. Krishnan, R. Farrugia, N. A. Watkins, P. Ellis, C. Langford, W. H. Ouwehand, A. H. Goodall* (UK)

OC-WE-127 4:30 PM - 4:45 PMNEUTROPHILS PHAGOCYTOSE ACTIVATED PLATELETS IN VIVO: APHOSPHATIDYLSERINE, P-SELECTIN AND ß2 INTEGRIN-DEPENDENTCELL CLEARANCE PROGRAMN. Maugeri* (IT), P. Rovere-Querini, A. Capobianco, L. Totani, V. Evangelista,A. Maseri, A. A. Manfredi

OC-WE-128 4:45 PM - 5:00 PMFACTOR SEVEN ACTIVATING PROTEASE (FSAP) – INFLAMMATION ANDCOAGULATION CROSS-TALK IN PATIENTS WITH CORONARY ARTERYDISEASEM. Parahuleva, R. Maj, A. Staubitz, H. Hoelscherman, H. Tillmanns, A. Erdogan, S. Kanse* (DE)

Thrombotic Thrombocytopenic Purpura II Room 160 ABC

Chairpersons: J. Evan Sadler (US) and Luca Lotta (IT)

OC-WE-129 4:00 PM - 4:15 PMTITLE: OBJECTIVE DOCUMENTATION OF NEUROLOGIC INJURY INPATIENTS WITH IDIOPATHIC THROMBOTIC THROMBOCYTOPENICPURPURA (TTP)S. R. Cataland* (US), J. Paskavitz, P. Maruff, L. Witkoff, M. Jin, J. C. Gilbert,H. M. Wu

OC-WE-130 4:15 PM - 4:30 PMLONGITUDINAL PERFORMANCES OF ADAMTS13 ANTIGEN ANDACTIVITY OVER THE COURSE OF IDIOPATHIC TTPS. Yang, M. Jin, S. Lin, S. R. Cataland, H. M. Wu* (US)

OC-WE-131 4:30 PM - 4:45 PMINFLUENCE OF THE VON WILLEBRAND FACTOR (VWF) SUBSTRATEON ADAMTS13 ACTIVITY MEASUREMENTR. Palla* (IT), C. Valsecchi, M. Spreafico, M. T. Bajetta, F. Peyvandi

OC-WE-132 4:45 PM - 5:00 PMINFLUENCE OF ADAMTS13 GENOTYPE ON THE AGE OF ONSET OFCONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)L. A. Lotta* (IT), I. Garagiola, R. Palla, A. Cairo, R. Klaassen, A. Metin, A. Gurgey, F. Peyvandi


ORAL COMMUNICATIONS

235

von Willebrand Disease Room 204 AB

Chairperson: Emmanuel Favaloro (AU) and Augusto Federici (T)

OC-WE-133 4:00 PM - 4:15 PMREDUCED VWF SURVIVAL IN TWO LARGE COHORTS OF TYPE 1 VWD PATIENTS FROM THE CANADIAN TYPE 1 VWD AND US VWD(ZPMCB-VWD) STUDIESS. L. Haberichter* (US), P. D. James, P. A. Christopherson, D. Lillicrap, R. R. Montgomery, for the Canadian Type 1 VWD and ZPMCB-VWD Study

OC-WE-134 4:15 PM - 4:30 PMCANADIAN PLATELET-TYPE VON WILLEBRAND DISEASE (PT-VWD)PROJECT: PROGRESS AND UPDATEM. Othman* (CA), M. C. Ozelo, H. Brown, J. Leggo, C. Notley, E. J. Favaloro, S. Enayat, J. P. Frontroth, A. Angelillo, H. Smith, J. Olson, D. Lillicrap

OC-WE-135 4:30 PM - 4:45 PMUSE OF IN SILICO AND IN VITRO ANALYSIS TO IDENTIFY VWF 5’REGULATORY ELEMENTSD. J. Hampshire* (UK), P. R. Winship, D. Lillicrap, I. R. Peake, A. C. Goodeve,on behalf of the EU-VWD and ZPMCB-VWD Study Groups

OC-WE-136 4:45 PM - 5:00 PMHOMOZYGOUS R854W VON WILLEBRAND FACTOR IS POORLYSECRETED AND CAUSES A SEVERE VON WILLEBRAND DISEASEPHENOTYPEG. Castaman* (IT), S. Giacomelli, T. Obser, U. Budde, R. Schneppenheim, F. Rodeghiero

Atherosclerosis: Risk factors I Room 102 AB

Chairpersons: John-Bjarne Hansen (NO) and David Green (US)

OC-WE-137 4:00 PM - 4:15 PMIMPACT OF SERUM OSTEOPROTEGERIN AND SRANKL ON CAROTIDATHEROSCLEROTIC PLAQUE FORMATION AND GROWTH IN AGENERAL POPULATION – THE TROMSØ STUDYA. Vik, E. Mathiesen, S. Johnsen, J. Brox, T. Wilsgaard, I. Njølstad, J. Hansen* (NO)

OC-WE-138 4:15 PM - 4:30 PMENDOGENOUS THROMBIN POTENTIAL IS ASSOCIATED WITH CAROTIDINTIMA MEDIA THICKNESS IN SUBJECTS YOUNGER THAN 45 YEARSH. Bernhard* (AT), P. Wipfler, B. Leschnik, J. Kraus, M. Novak, G. Pilz, G. Ladurner, W. Muntean

OC-WE-139 4:30 PM - 4:45 PMINTERLEUKIN-6 GENE POLYMORPHISMS IN ASIAN INDIAN FAMILIESWITH PREMATURE CORONARY ARTERY DISEASEA. Maitra* (IN), J. Shanker, D. Dash, S. John, P. R. Sannappa, V. S. Rao, V. V. Kakkar


ORAL COMMUNICATIONS

236

Wed

nesd

ay O

rals

OC-WE-140 4:45 PM - 5:00 PMRELATIONS BETWEEN SERUM OSTEOPROTEGERIN AND CAROTIDINTIMA MEDIA THICKNESS IN A GENERAL POPULATION – THE TROMSØ STUDYA. Vik, E. Mathiesen, S. Johnsen, J. Brox, T. Wilsgaard, I. Njølstad, J. Hansen* (NO)

Cell Biology of the Activated Protein C Pathway Room 151 AB

Chairpersons: Bjorn Dahlback (SE) and Jasimuddin Ahamed (US)

OC-WE-141 4:00 PM - 4:15 PMIMPORTANCE OF PROTEIN S FOR EXPRESSION OF THE C4B-BINDINGPROTEIN -?-CHAINS. U. Carlsson* (SE), B. Dahlbäck

OC-WE-142 4:15 PM - 4:30 PMMODULATION OF ACTIVATED PROTEIN C CYTOPROTECTIVE EFFECTSBY CELLULAR THERAPY USING GPI-LINKED ENDOTHELIAL CELLPROTEIN C RECEPTORL. O. Mosnier* (US)

OC-WE-143 4:30 PM - 4:45 PMACTIVATED PROTEIN C PREVENTS THE NF-KB ACTIVATION ATGLUTAMATE- AND THROMBIN- INDUCED TOXICITYS. Strukova* (RU), L. Gorbacheva, I. Savinkova, V. Pinelis, S. Ishiwata, G. Reiser

OC-WE-144 4:45 PM - 5:00 PMPROTEIN C DEPLETION ENHANCES BACTERIAL OUTGROWTH ANDINFLAMMATION IN MURINE E. COLI PERITONITISM. Schouten* (NL), C. van ‘T Veer, C. T. Esmon, M. M. Levi, T. van der Poll

Fibrinogen Structure and Function Room 162 AB

Chairpersons: Margareta Blomback (SE) and Sheryl Bowley (US)

OC-WE-145 4:00 PM - 4:15 PMIMPAIRED POLYMERIZATION OF FIBRINOGEN GAMMA-N308K IS DUE TO ALTERED D:D AND “A:A” INTERACTIONSS. R. Bowley* (US), N. Okumura, S. T. Lord

OC-WE-146 4:15 PM - 4:30 PMSTRUCTURAL BASIS FOR FIBRIN MECHANICAL PROPERTIES AND ITS POTENTIAL CLINICAL SIGNIFICANCEA. E. X. Brown, R. I. Litvinov, D. E. Discher, P. K. Purihit, J. W. Weisel* (US)

OC-WE-147 4:30 PM - 4:45 PMFORCED RUPTURE OF FIBRIN ‘A-A’ KNOB-HOLE INTERACTION ISACCOMPANIED BY UNFOLDING IN THE DISTAL D REGION OF THEMOLECULEO. V. Gorkun* (US), L. E. Averett, B. B. Akhremitchev, M. H. Schoenfisch


ORAL COMMUNICATIONS

237

OC-WE-148 4:45 PM - 5:00 PMFIBRINOGEN SHAPE IN SOLUTION: A MULTI-RESOLUTION STUDYB. Cardinali* (IT), C. Rosano, A. Profumo, O. Byron, M. Roessle, N. Volkmann, M. Rocco

Megakaryocytes and Thrombopoiesis Room 257 AB

Chairperson: Hansjorg Schwertz (US) and Anna Kowalska (US)

OC-WE-149 4:00 PM - 4:15 PMDYNAMIC UPREGULATION OF HUMAN PLATELET PRODUCTION BY HIGH SHEAR RATESC. Dunois-Larde, C. Capron, S. Fichelson, E. Cramer-Borde, D. Baruch* (FR)

OC-WE-150 4:15 PM - 4:30 PMABNORMAL MEGAKARYOCYTE AND PROPLATELET FORMATION INMEGAKARYOCYTE-RESTRICTED MYH9 INACTIVATIONA. Eckly, C. Strassel, M. Freund, J. Cazenave, F. Lanza, C. Gachet, C. Léon* (FR)

OC-WE-151 4:30 PM - 4:45 PMCLINICAL IMPLICATIONS OF THE NEGATIVE PARACRINE EFFECT OFPLATELET FACTOR 4 (PF4) ON THROMBOPOIETIN (TPO) TREATMENTIN RADIATION-INDUCED THROMBOCYTOPENIA (RIT)M. P. Lambert* (US), Y. Nguyen, M. A. Kowalska, M. Poncz

OC-WE-152 4:45 PM - 5:00 PMGENE EXPRESSION DIFFERENCES BETWEEN FETAL LIVER AND ADULTBONE MARROW-DERIVED MURINE MEGAKARYOCYTE PROGENITORS:IMPLICATIONS FOR DOWN SYNDROME MEGAKARYOBLASTICLEUKEMIAK. Wieland, A. B. Cantor* (US)


ORAL COMMUNICATIONS

238

Wed

nesd

ay P

oste

rs

Mechanisms of Platelet Activation II

PP-WE-001 PLATELET ACTIVATION AND THROMBOSIS BY ANTI-CD40L IMMUNE COMPLEXESL. Robles, A. Amirkhosravi* (US), T. Meyer, H. Desai, M. Davila, F. Langer, M. Amaya, J.Francis

PP-WE-002 RETICULATED PLATELETS AND PLATELET REACTIVITY IN RENAL TRASPLANTRECIPIENTS ON ANTIPLATELET THERAPYF. Cesari* (IT), R. Marcucci, A. Gori, F. Sofi, R. Caporale, R. Paniccia, E. Antonucci, M.Salvadori, G. Gensini, R. Abbate, M. Zanazzi

PP-WE-003 PLATELET AGGREGABILITY IS MODULATED BY ENOS LOCUS IN NON-TYPE 2DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROMEC. Fatini, E. Sticchi, F. Sofi* (IT), P. Bolli, R. Marcucci, B. Giusti, R. Paniccia, A. Gori, G.Gensini, R. Abbate

PP-WE-004 DIRECT INTERACTION BETWEEN GALPHA13 AND INTEGRIN BETA3 SUBUNITMEDIATES INTEGRIN OUTSIDE-IN SIGNALLINGH. Gong* (US), P. Flevaris, C. Chow, S. Lam, T. Voyno-Yasenetskaya, T. Kozasa, X. Du

PP-WE-005 ARE PLATELETS PHAGOCYTES OR COVERCYTES? AN ULTRASTRUCTURAL STUDYOF INTERACTION BETWEEN PORPHYROMONAS GINGIVALIS, AN ORAL BACTERIUMAND HUMAN PLATELETSH. Suzuki* (JP), X. Li, H. Nakamura, Y. Inoue, Y. Chen, M. Umeda, T. Iwai

PP-WE-006 RHO GTPASES RAC1 AND RHOA DIFFERENTIALLY REGULATE PLATELET ACTINREORGANIZATION, SECRETION AND AGGREGATIONH. Akbar* (US), K. Funk, R. Perveen, X. Shang, Y. Zheng

PP-WE-007 THE ROLE AND REGULATION OF MTOR IN HUMAN PLATELETSR. W. Hunter, I. Hers* (UK)

PP-WE-008 RAPID PROCOAGULANT PHOSPHATIDYLSERINE EXPOSURE RELIES ON HIGHCYTOSOLIC CALCIUM RATHER THAN ON MITOCHONDRIAL DEPOLARIZATIONA. Arachiche, D. Kerbiriou-Nabias, I. Garcin, T. Letellier, J. Dachary-Prigent* (FR)

PP-WE-009 INFLUENCE OF CORNARY STENT IMPLANTATION ON PLATELET ACTIVATIONJ. Gu* (CN), X. Gu, H. Gu, L. Wang

PP-WE-010 POST-ACTIVATION SIGNALING BY ALPHAIIBBETA3 NECESSITATES PDI-MEDIATEDDISULFIDE EXCHANGEO. Romanenko, V. Sheptovitsky, R. Mor Cohen, N. Rosenberg, J. Lahav* (IL)

PP-WE-011 INTEGRIN3 MEMBRANE-PROXIMAL AND -DISTAL RESIDUES COOPERATIVELYREGULATE TALIN-MEDIATED IIB3 ACTIVATIONJ. Yamanouchi* (JP), T. Hato, H. Fujiwara, Y. Yakushijin, M. Yasukawa

PP-WE-012 REGULATION OF PLATELET THROMBOXANE GENERATION DOWNSTREAM OFG12/13 PATHWAYS THROUGH FOCAL ADHESION KINASEK. Bhavaraju* (US), P. Lakhani, R. Dorsam, J. Jin, A. Sanjay, S. Kunapuli

PP-WE-013 THE NOVEL S527F MUTATION IN THE INTEGRIN BETA3 CHAIN INDUCES A HIGHAFFINITY (ALPHA)IIB(BETA)3 RECEPTOR BY HINDERING ADOPTION OF THE BENTCONFORMATIONK. Vanhoorelbeke* (BE), S. F. de Meyer, I. Pareyn, C. Melchior, S. Plançon, C. Margue, O.Pradier, P. Fondu, N. Kieffer, T. A. Springer, H. Deckmyn



239

* Presenting Author

PP-WE-014 PLATELET THROMBIN RECEPTORS PAR1 AND PAR4 ACT IN A SYNERGISTICMANNERK. V. Öberg* (SE), S. Kulsum, N. Boknäs, S. Ramström, T. L. Lindahl

PP-WE-015 AN INHIBITORY ROLE OF PLATELET CD109 IN PLATELET FUNCTIONK. Matsumoto* (JP), Y. Matsubara, H. Hoshino, K. Yokoyama, G. Watanabe, T. Shibano, N.Suzuki, Y. Ikeda, M. Murata

PP-WE-016 CALDAG-GEFI: AT THE NEXUS OF CALCIUM-DEPENDENT PLATELET ACTIVATIONL. Stefanini* (US), R. C. Roden, W. Bergmeier

PP-WE-017 EVALUATION OF DIFFERENT BLOOD DRAWING TECHNIQUES ON THE RESULTS OFPLATELET FUNCTION TESTSM. D. Lance* (NL), Y. M. C. Henskens, H. M. S. Theunissen, R. van Oerle, K. Hamulyak, H.ten Cate, M. A. E. Marcus

PP-WE-018 COOPERATIVE CALCIUM SIGNALING ELICITED BY GLICOPROTEINS (GP)IB-IX-V, GPVIAND INTEGRIN ALPHA2BETA1 DURING PLATELET ADHESION TO COLLAGEN UNDERFLOWM. R. Cozzi, M. Battiston, M. Mazzucato, M. Jandrot Perrus, Z. M. Ruggeri, L. de Marco* (IT)

PP-WE-019 A ROLE FOR SHIP1 IN PLATELET INTERNAL CONTRACTION VIA THE CONTROL OFACTOMYOSIN AND MICROTUBULE DYNAMICSM. Gratacap* (FR), S. Severin, G. Chicanne, V. Martin, S. Allart, A. Eckly, M. Plantavid, B.Payrastre

PP-WE-020 PKC ALPHA REGULATES GPVI-DEPENDENT CALCIUM SIGNALLING ANDPHOSPHATIDYLSERINE EXPOSURE IN PLATELETSM. T. Harper* (UK), A. W. Poole

PP-WE-021 PRE-OPERATIVE PLATELET CD40 LIGAND EXPRESSION PREDICTS ADVERSECARDIAC EVENTS AFTER ORTHOPAEDIC SURGERYM. J. Ray* (AU), D. Walters, S. Crawford, D. Enever, L. Calabro, T. Sirisena, R. Crawford

PP-WE-022 EFFECTS OF THE 5-HT4 RECEPTOR AGONIST, TEGASEROD, ON IN VITRO HUMANPLATELET AGGREGATIONV. L. Serebruany, M. El Mouelhi* (US), H. Pfannkuche, K. Rose, M. Marro, D. J. Angiolillo

Platelet Biology II

PP-WE-023 PROTEIN KINASE A PHOSPHORYLATES MULTIPLE GPIB ALPHA; CYTOPLASMICRESIDUES: IMPLICATIONS RECEPTOR REGULATIONA. D. Munday* (US), J. A. Lopez

PP-WE-024 TISSUE FACTOR PRE-MRNA SPLICING IN PLATELETS FROM HEALTHY SUBJECTSAND TYPE 2 DIABETES MELLITUS PATIENTSA. J. Gerrits* (NL), C. A. Koekman, J. W. N. Akkerman

PP-WE-025 USE OF THE PLATELET INDICES FOR DIFFERENTIAL DIAGNOSIS OF PEDIATRICIMMUNE THROMBOCYTOPENIC PURPURA ( ITPH. Nakadate* (JP), M. Kaida, S. Furukawa, M. Ishii, M. Higashihara

PP-WE-026 LEVELS OF VON WILLEBRAND FACTOR AS MEASURE OF ENDOTHELIALDYSFUNCTION ARE INCREASED IN ELDERLY PATIENTS WITH ATRIAL FIBRILLATIONI. Seljeflot* (NO), S. Ulimoen, S. Enger, H. Arnesen, A. Tveit

PP-WE-027 EFFECTS OF ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE POLYMORPHISMS ANDPLATELET-DERIVED NITRIC OXIDE ON PLATELET AGGREGATIONJ. Kim* (KR), S. Park, E. Park, Y. Koo, J. Kim, I. Kim, S. Yoon, H. Yun-Choi, S. Park



240

Wed

nesd

ay P

oste

rs

PP-WE-028 MMP-13: A NOVEL PLATELET PROTEIN AND A POTENT INHIBITOR OF PLATELETAGGREGATIONJ. Howes* (UK), N. Pugh, R. W. Farndale

PP-WE-029 BOTROCETIN-DEPENDENT BINDING OF VON WILLEBRAND FACTOR TO THEPLATELET RECEPTOR GLYCOPROTEIN IB ALPHA CHAIN IS ENHANCED BY THECENTRAL MACROGLYCOPEPTIDE REGION OF THE RECEPTORT. K. Biswas, J. L. Miller* (US)

PP-WE-030 DIMINISHED SYK PHOSPHORYLATION IN PLATELETS UNDERLIES IMPAIREDTHROMBUS GROWTH IN RESPONSE TO COLLAGEN IN MICE LACKING SEMAPHORIN4DK. M. Wannemacher* (US), L. Zhu, H. Jiang, K. Fong, T. J. Stalker, D. Lee, A. Tran, K.Neeves, S. Maloney, A. Kumanogoh, D. Hammer, S. L. Diamond, L. F. Brass

PP-WE-031 EFFECT OF ASPIRIN ADMINISTRATION ON GPIB ALPHA SHEDDING: ASSOCIATIONOF GLYCOCALICIN LEVEL WITH PLATELET SENSITIVITY TO ASPIRINK. Yamaji* (JP), Y. Matsubara, H. Hoshino, N. Suzuki, Y. Ikeda, M. Murata

PP-WE-032 SRC AND PI3-KINASE TRANSMIT SIGNALS LEADING TO CK2 ACTIVATION IN PAR1-AP-STIMULATED PLATELETSK. Nakanishi* (JP), M. Ido, Y. Komada, T. Hayashi, K. Suzuki

PP-WE-033 MODULATION OF PLATELET REACTIVITY TO THROMBIN BY FLAVONOIDS:INTERFERENCE ON PAR1 AND PAR4 SIGNALINGL. Navarro-Núñez* (ES), M. Lozano, J. Guerrero, C. Martínez, V. Vicente, J. Castillo, J.Rivera

PP-WE-034 EFFICACY OF MODIFIED C-REACTIVE PROTEIN IN THE MODULATION OF PLATELETFUNCTION UNDER DIFFERENT EXPERIMENTAL CONDITIONSM. Boncler* (PL), J. Rywaniak, B. Rychlik, C. Watala

PP-WE-035 ROLE OF GALECTIN-8 AS A MODULATOR OF PLATELET ACTIVATIONM. A. Romaniuk* (AR), M. V. Tribulatti, V. Cattaneo, J. Etulain, O. Campetella, M. Schattner

PP-WE-036 STORAGE OF BLOOD COMPONENTS DOES NOT DECREASE THEIR HEMOSTATIOCPOTENTIAL: IN VITRO ASSESSMENT OF FRESH VERSUS STORED BLOODCOMPONENTS USING THROMBOELASTOGRAPHYM. H. Ellis* (IL), G. Bartfeld, A. Lubetzky, V. Yahalom, G. Kenet

PP-WE-037 THROMBOGENIC MUTATIONS IN GLANZMANN’S THROMBASTHENIA PATIENTSM. Kannan* (IN), B. K. Yadav, F. Ahmad, J. Fareed, R. Saxena

PP-WE-038 TIME COURSE OF ASPIRIN EFFECT ON PLATELET FUNCTION EXAMINED BYBLEEDING TIME, PFA-100 AND WHOLE BLOOD AGGREGOMETRYK. von Pape, C. Jambor, M. Spannagl* (DE), H. Weisser

PP-WE-039 MULTIPLE ELECTRODE PLATELET AGGREGOMETRY FOR THE EVALUATION OF VONWILLEBRAND DISEASES. Lison, A. Dick, A. Giebl, T. Kauke, A. Perchuc, M. Spannagl* (DE)

PP-WE-040 PPAR-GAMMA AGONISTS 15D-PGJ2, ROSIGLITAZONE AND CIGLITAZONE ENGAGE INNON-GENOMIC SIGNALLING PATHWAYS THAT INHIBIT HUMAN PLATELET FUNCTIONIN PPAR-GAMMA -DEPENDENT MECHANISMSM. Spyridon* (UK), L. A. Moraes, W. J. Kaiser, C. I. Jones, J. M. Gibbins

PP-WE-041 PROTEOMICS OF PLATELET SECRETOME IN PATIENTS WITH DELTA STORAGE POOLDISEASEM. di Michele* (BE), C. Thys, W. D’Hertog, E. Waelkens, R. de Vos, K. Peerlinck, C. vanGeet, K. Freson



241

PP-WE-042 EXTRACELLULAR ACIDOSIS PROMOTES PLATELET-MEDIATED INFLAMMATORYRESPONSESM. Schattner* (AR), M. A. Romaniuk, J. Etulain, L. P. D´atri, E. Malaver, S. Negrotto, R.Pozner

PP-WE-043 DARK CHOCOLATE EFFECT ON PLATELET ACTIVITY, C-REACTIVE PROTEIN ANDLIPID PROFILE:A PILOT STUDYM. Hamed* (US), S. Gambert, K. Bliden, O. Bailon, A. Singla, M. Antonino, F. Hamed, U.Tantry, P. A. Gurbel

PP-WE-044 SHEAR INDUCED PLATELET ADHESION STIMULATES CORTACTIN TYROSINEPHOSPHORYLATIONN. Savion* (IL), I. Budnik, B. Shenkman

PP-WE-045 DETECTION OF P2Y14 RECEPTOR PROTEIN ON PLATELETS AND INVESTIGATION OFTHE ROLE OF P2Y14 IN PLATELET FUNCTIONN. Dovlatova* (UK), Y. D. Wijeyeratne, S. C. Fox, P. Manolopoulos, A. J. Johnson, A. E.White, L. Latif, V. Ralevic, S. Heptinstall

PP-WE-046 CONVERSION OF LYMPHOCYTES CHROMATINE AND NEUTROPHILES UNDERCONDITIONS OF THE HEAT SHOCK IN VITRO: POSSIBLE CONNECTION WITHPLATELETS MORPHOLOGYN. G. Kruchynsky* (BY), S. Vishnevskaya

Platelet Adhesion and Cohesion II

PP-WE-047 FINE MAPPING THE VWF A1 DOMAIN BY PHAGE DISPLAYA. Yee* (US), F. Tan, D. Ginsburg

PP-WE-048 PLATELET ACTIVATION AND PLATELET-LEUKOCYTE MIXED CONJUGATES INPATIENTS WITH ATRIAL FIBRILLATIONS. Alberti, G. Angeloni, C. Tamburrelli, A. Pampuch, B. Izzi, L. Messano, Q. Parisi, M.Santamaria, M. B. Donati, G. de Gaetano, C. Cerletti* (IT)

PP-WE-049 EFFECT OF COATING CONDITIONS ON COLLAGEN MATRIX FORMATION AND TO THEVON WILLEBRAND FACTOR AND PLATELET BINDING TO ITS. Mendelboum Raviv, K. Szekeres-Csiki, A. Jenei, J. Nagy, B. Shenkman, N. Savion, J.Harsfalvi* (HU)

PP-WE-050 PROTEASE-ACTIVATED RECEPTORS 1 AND 2 ACTIVATION INDUCES TISSUE FACTORTHROUGH MITOCHONDRIAL REACTIVE OXYGEN SPECIESC. Banfi, M. Brioschi, S. S. Barbieri, S. Eligini, S. Barcella, E. Tremoli, S. Colli, L. Mussoni*(IT)

PP-WE-051 FECL3-INDUCED THROMBUS FORMATION IN THE INFERIOR VENA CAVA OF MICEREQUIRES PLATELETS, GLYCOPROTEIN IB-IX, AND VON WILLEBRAND FACTORM. Joglekar* (US), J. Ware, T. K. Gartner

PP-WE-052 INVESTIGATION OF THE EFFECT OF DIFFERENTIAL PLATELET RECEPTORENGAGEMENT ON THROMBUS FORMATION USING COLLAGEN PEPTIDESN. Pugh* (UK), D. G. Bihan, R. W. Farndale

PP-WE-053 CIB1 CONTROLS INTEGRIN ALPHA IIB BETA 3-DEPENDENT PLATELET SPREADINGBY REGULATING FAK ACTIVATIONU. P. Naik* (US), M. U. Naik

PP-WE-054 ENHANCED SHEAR-INDUCED ADHESION ACTIVITY AND DECREASEDMICROMOBILITY OF PLATELETS RELATED TO THE ALPHA2 807TT VARIANT OFINTEGRIN ALPHA2 BETA1R. E. Scharf, V. R. Stoldt* (DE)



242

Wed

nesd

ay P

oste

rs

PP-WE-055 CD40L MODULATES PLATELET THROMBUS FORMATION UNDER ARTERIAL FLOWCONDITIONSR. E. Scharf, E. Reiff, V. R. Stoldt* (DE)

PP-WE-056 ROLE OF THE D’D3 SUBUNIT OF VON WILLEBRAND FACTOR IN THE SHEARENHANCED BINDING OF PLATELETS UNDER FLOW CONDITIONSR. A. Penkala* (US), A. Tu, A. D. Munday, P. Lenting, H. Deckmyn, J. A. Lopez, W. Thomas

Novel Approaches to Understanding Platelet Biology II

PP-WE-057 CD3 IS EXPRESSED AND SYNTHESIZED BY HUMAN PLATELETSC. G. Sáez* (CL), V. Matus, O. Panes, J. Pereira, D. Mezzano

PP-WE-058 PLATELETS ABILITY TO PHAGOCYTOSIS DEPENDS ON THEIR FUNCTIONALACTIVITY AND GPIIB/IIIAE. M. Gupalo* (RU), L. L. I. Buryachkovskaya, A. A. B. Sumarokov

PP-WE-059 A NOVEL ANALYSIS OF INITIAL PLATELET-ADHESION IN FLOWING BLOODG. R. Meade* (IE), B. Lincoln, A. J. Ricco, N. Kent, L. Basabe-Desmonts, S. O’Brien, L. P.Lee, B. D. MacCraith, D. Kenny

PP-WE-060 NOVEL MOUSE ANTI-MOUSE GPIBALPHA MONOCLONAL ANTIBODIES:DEVELOPMENT AND CHARACTERIZATION OF NEW REAGENTS FOR RESEARCH INTHROMBOSIS AND HEMOSTASISG. Zhu* (CA), S. Lang, C. Li, A. Reheman, P. Chen, J. Ware, Z. Ruggeri, J. Freedman, H. Ni

PP-WE-061 HIGH RESOLUTION EM-TOMOGRAPHY OF A VITRIFIED PLATELETH. E. van Nispen Tot Pannerden, F. de Haas, H. F. G. Heijnen* (NL)

PP-WE-062 THE ROLE OF ANTIPHOSOLIPID AND ANTIPLATELET ANTIBODIES IN PLATELETDYSFUNCTION: COMPUTER-AIDED VISUALIZATIONI. Vasilenko* (RU), I. Kastrikina, V. Metelin, T. Reshetnyak

PP-WE-063 PLATELET CALCIUM AND PHOSPHOINOSITIDE SIGNALING THROUGHCOMPUTATIONAL MODELINGJ. E. Purvis* (US), M. S. Chatterjee, R. Radhakrishnan, L. F. Brass, S. L. Diamond

PP-WE-064 MULTIPLE ANTIBODY FLOW CYTOMETRY FOR FAST AND EFFICIENT EVALUATION OFPLATELET SURFACE ANTIGENS AND ACTIVATION MARKERSJ. van Velzen* (NL), W. L. van Heerde, J. Boezeman

PP-WE-065 TLT-1 INDUCTION DURING DENGUE FEVER MAY PROMOTE PLATELET ENDOTHELIALCELL INTERACTIONJ. Morales* (PR), K. Vila, J. Gattis, K. Colon, J. Lubkowski, P. Sanabria, R. Hunter, A.Washington

PP-WE-066 FIVE NOVEL MUTATIONS IDENTIFIED IN THE GLICOPROTEINS IBA, IBB AND 9 GENESAMONG 15 UNRELATED PATIENTS WITH BERNARD SOULIER SYNDROME IN BRAZILL. H. Siqueira* (BR), A. Santos, M. Perlingeiro Beltrame, V. Oliveira Duarte, E. Vinícius dePaula, J. Maria Annichino-Bizzacchi, M. Castro Ozelo

Platelets and Systemic Disorders II

PP-WE-067 THE ROLE OF CHEMOKINES, GROWTH FACTORS AND ELECTRON MICROSCOPY INDIAGNOSIS OF DIABETIC NEPHROPATHYE. A. A. Khaled* (EG), A. H. Hussein, E. A. Waked, S. A. Badr, K. A. Younis

PP-WE-068 PLATELET FUNCTIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLEJ. Maly* (CZ), P. Bradna, Z. Hrncir, T. Soukup, P. Dulicek, M. Pecka, R. Maly



243

PP-WE-069 RISK FACTORS FOR THROMBOTIC OR HEMORRHAGIC COMPLICATIONS INESSENTIAL THROMBOCYTHEMIA (ET) PATIENTS (PTSJ. Park* (KR), B. Kim, H. Kim, S. Bang, I. Kim, S. Yoon, D. Lee, J. Lee, S. Park, B. Kim

PP-WE-070 SERIOUS CONGENITAL DEFICIENCY OF FVII AND ACQUIRED ITP - THE RARECOMBINATION OF TWO BLEEDING DISORDERSJ. Slechtova* (CZ), Z. Hajsmanova

PP-WE-071 PLATELET SECRETION CONTRIBUTES TO THE DEVELOPMENT OFATHEROSCLEROSISJ. M. Patton* (US), R. A. McNamee, S. M. King, H. Mehta, G. L. Reed

PP-WE-072 A CASE CONTROL STUDY ON PLATELET RESPONSE TO ANTIPLATELET THERAPY INSURVIVORS OF LATE STENT THROMBOSISK. Winckers* (NL), V. Poenitz, R. van Oerle, K. Noordermeer, H. ten Cate, D. W. T. Nilsen

PP-WE-073 EVALUATION OF A NEW KIT FOR QUANTITATION OF PLATELET ASSOCIATEDIMMUNOGLOBULINSL. Le Flem* (FR), F. Ballon, S. Aguilar

PP-WE-074 EVALUATION OF THE INCIDENCE, MATERNAL AND NEONATAL COMPLICATIONS OFTHE HELLP SYNDROME AND ITS RISK FACTORSM. Kashanian* (IR), N. Sohrabi, E. Rafiee Khoshnood

PP-WE-075 PLATELETS AGGREGATION CHANGES IN PATIENTS WITH RENDU OSLER DISEASE –BRIEF REPORTV. I. Popov* (RO), C. Socoliuc, H. Bumbea, M. Onisai, A. Vladareanu, T. Savopol, E. Kovacs

Megakaryocytes and Thrombopoiesis I

PP-WE-076 MEGAKARYOCYTE MIGRATION AND THROMBOPOIESIS ARE REGULATED BY SRCKINASES AND PLCGAMMA2, BUT NOT BY THE GPVI-FCRGAMMA-CHAINA. Mazharian* (UK), T. S. Dhanjal, Y. Zhao, C. D. Buckley, S. P. Watson

PP-WE-077 DIFFERENTIAL ROLES OF CAMP AND CGMP IN MEGAKARYOCYTE MATURATIONAND PLATELET FORMATIONA. Jurak Begonja* (US), S. Gambaryan, H. Schulze, S. Patel Hett, J. E. Italiano, J. H.Hartwig, U. Walter

PP-WE-078 ROLE OF THE HSP40 DNAJC10 IN ALPHAIIB-BETA3 BIOGENESISA. Chen, M. Yazdani-Abyaneh, B. Mitchell* (US)

PP-WE-079 DISABLED-2 IS A KEY REGULATOR DURING MESODERMAL DIFFERENTIATION ANDMEGAKARYOPOIESIS OF MURINE EMBRYONIC STEM CELLSC. Huang* (TW), J. Cheng, C. Lin, C. Tseng

PP-WE-080 SYNTHESIS OF PROTEIN S BY HUMAN MEGAKARYOCYTESC. Radu* (IT), C. Bulato, L. Spiezia, S. Gavasso, G. Tognin, M. Fadin, P. Simioni

PP-WE-081 IN VITRO ADHESION CULTURES OF HUMAN MEGAKARYOCYTES AS A TOOL FORSTUDYING MEGAKARYOCYTIC DEVELOPMENT AND PROPLATELETS FORMATIONC. Radu* (IT), P. Simioni

PP-WE-082 DIRECTED DIFFERENTIATION OF THE MEGAKARYOCYTE LINEAGE FROM HUMAN ESCELLSD. L. French* (US), M. Jirouskova, B. S. Coller, M. Kennedy, G. Keller

PP-WE-083 MEGAKARYOCYTOPOIESIS IN C-MPL KNOCKOUT NEONATAL VS. ADULT MICEF. Ferrer-Marin* (US), Z. Hu, Z. Liu, W. Slayton, M. Bailey, R. K. Gutti, M. Sola-Visner



244

Wed

nesd

ay P

oste

rs

PP-WE-084 HUMAN PLATELETS PRODUCED IN NOD/SCID MICE UPON TRANSPLANTATION OFHUMAN CORD BLOOD CD34+ CELLS ARE FUNCTIONALLY ACTIVE IN AN EX VIVOFLOW MODEL OF THROMBOSISI. I. Salles* (BE), T. Thijs, C. Brunaud, S. F. de Meyer, J. Thys, K. Vanhoorelbeke, H.Deckmyn

PP-WE-085 THROMBOPOIETIC EFFECT OF VPAC1 INHIBITION IN MURINE AND HUMANTHROMBOPOIESISK. Peeters* (BE), I. I. Salles, M. F. Hoylaerts, H. Deckmyn, C. van Geet, K. Freson

Basic Biology of ADAMTS13 II

PP-WE-086 PROTEOLYSIS OF ADAMTS13 IN ACUTE PHASE THROMBOTIC THROMBOCYTOPENICPURPURAH. B. Feys* (BE), N. Vandeputte, K. Peerlinck, F. Peyvandi, K. Vanhoorelbeke

PP-WE-087 ADAMTS-13 ACTIVITY AND ANTIGEN IN COMMERCIAL VON-WILLEBRAND-FACTOR(VWF) CONCENTRATESI. Scharrer* (DE), T. Vigh, M. Böhm-Weigert

PP-WE-088 MONOCLONAL ANTI-VON WILLEBRAND FACTOR ANTIBODY-SZ-34 INHIBITSPROTEOLYTIC CLEAVAGE OF VWF BY ADAMTS13 UNDER SHEAR STRESSJ. Zhang* (CN), N. Dong, Z. Ma, C. Ruan

PP-WE-089 SPECTRUM OF ADAMTS13 GENE MUTATIONS IN 19 PATIENTS WITH ADAMTS13DEFICIENCYJ. C. Calderzzo* (AR), A. C. Kempfer, L. Keller, A. Sánchez Luceros, A. I. Woods, Y. P.Powazniak, M. A. Lazzari

PP-WE-090 PROTECTIVE PROPERTY OF ADAMTS13 IN A MOUSE-MODEL OF ISCHEMIC STROKEK. Nishio* (JP), M. Fujioka, K. Hayakawa, K. Mishima, M. Fujiwara, F. Banno, K. Kokame, T.Miyata, Y. Shida, M. Sugimoto, T. Ueyama, H. Fukushima, K. Okuchi

PP-WE-091 PLATELET FUNCTION AND THE VON WILLEBRAND FACTOR PROTEOLYSIS BYRADAMS13L. I. Buryachkovskaya* (RU), N. E. Dovlatova, I. A. Uchitel, A. B. Sumarokov, E. Limonov

PP-WE-092 ADAMTS13 AND VWF ANTIGENS ASSESSMENT IN PATIENTS UNDERGOINGHEMODIALYSIS WITH AND WITHOUT THROMBOTIC COMPLICATIONSD. R. A. Rios, M. G. Carvalho, D. A. Guimarães, A. C. S. Silva, E. M. Lima, R. A. Souza, L.M. S. Dusse* (BR)

PP-WE-093 STUDY OF ADAMTS13 ISOFORMS IN HUVECM. A. Carrivale* (AR), V. A. Zapata, L. Keller, A. Sánchez Luceros, A. C. Kempfer, M. A.Lazzari

PP-WE-094 REAL TIME QUANTITATIVE PCR OF ADAMTS 13 IN PLATELETS AND HUMANENDOTHELIAL CELLSM. A. Carrivale* (AR), A. C. Kempfer, Y. P. Powazniak, A. Sánchez Luceros, V. A. Zapata, M.A. Lazzari

Novel Mechanisms of Antiplatelet Therapy II

PP-WE-095 THE PROTEIN TYROSINE KINASE INHIBITOR DASATINIB INHIBITS P2Y12 AND PAR-1MEDIATED PLATELET ACTIVATION AND GRANULE RELEASE INDEPENDENTLY OFSRC FAMILY KINASE INHIBITIONA. E. Schade* (US), E. Shick



245

PP-WE-096 SIMVASTATIN INHIBITS TXA2 SYNTHESIS IN PLATELETS REGULATING CPLA2PHOSPHORYLATION AND CALCIUM MOVEMENTSA. Moscardo* (ES), M. T. Santos, B. Cortina, A. Latorre, J. Valles

PP-WE-097 MODERATE PHARMACOLOGICAL PLATELET COUNT REDUCTION PREVENTS ACUTETHROMBOTIC VASCULAR GRAFT OCCLUSION IN PRIMATESE. I. Tucker* (US), U. M. Marzec, S. Hurst, A. Gruber, S. R. Hanson

PP-WE-098 PRODUCTION OF A RECOMBINANT PUTATIVE INHIBITOR OF PLATELETAGGREGATION FROM HAEMENTERIA DEPRESSA LEECHF. Faria* (BR), J. Lacerda-Alves, A. M. Chudzisnki-Tavassi

PP-WE-099 CONSTRUCTION AND CHARACTERIZATION OF A CHIMERIC ANTI-PLATELETGLYCOPROTEIN IB ALPHA MONOCLONAL ANTIBODYJ. Yang* (CN), S. Ji, N. Dong, C. Ruan

PP-WE-100 BLEEDING RESPONSE INDUCED BY ANTI-THROMBOTIC DOSES OFPHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR IN MICEJ. E. Bird* (US), P. L. Smith, J. S. Bostwick, W. A. Schumacher

PP-WE-101 P2RY1 GENE POLYMORPHISMS ARE ASSOCIATED WITH ASPIRIN RESISTANCE INPATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTIONP. P. Aung, G. Murugesan, L. Zhang, J. Barnard, Y. Hu, Q. Wang, K. Kottke-Marchant* (US)

PP-WE-102 BRIEF ANTECEDENT ‘PRECONDITIONING’ ISCHEMIA ATTENUATES RECURRENTPLATELET-MEDIATED THROMBOSIS: LOSS OF EFFICACY IN AGING RATSK. Przyklenk* (US), P. Whittaker

PP-WE-103 DISPERSAL OF PLATELET AGGREGATES BY P2Y12 ANTAGONIST ARC-69931MXH. E. Speich, J. D. Caughran, L. T. Lands, L. K. Jennings* (US)

PP-WE-105 VITAMIN C INFUSION BLUNTS CD40L UP-REGULATION IN PATIENTS UNDERGOINGCORONARY STENTP. Pignatelli* (IT), S. Basili, G. Tanzilli, R. Carnevale, S. di Santo, L. Loffredo, A. Celestini, E.Mangieri, F. Violi

PP-WE-106 A SMALL MOLECULE INHIBITOR OF P2Y1 BLOCKS ADP-INDUCED AGGREGATIONBUT DOES NOT SHAPE CHANGE VIA AN ALLOSTERIC MECHANISMR. Mairuhu* (US), L. Dowal, J. R. Dilks, P. Blair, R. Flaumenhaft

Extrinsic Pathway of Coagulation II

PP-WE-107 FIBRIN PRESENCE AND TISSUE FACTOR EXPRESSION IN AORTIC VALVES INPATIENTS WITH AORTIC STENOSIS AND AORTIC INSUFFICIENCY: ASSOCIATIONWITH PLASMA MARKERS OF FIBRIN TURNOVER AND THROMBIN GENERATIONA. Undas* (PL), J. Natorska, G. Marek, M. Hlawaty, J. Sadowski, W. Tracz

PP-WE-108 DETECTION OF TISSUE FACTOR ACTIVITY IN WHOLE BLOOD BY A FLUOROGENICTHROMBIN GENERATION ASSAYE. Coll* (US), A. Amirkhosravi, J. Francis

PP-WE-109 INTRACELLULAR PROCESSING AND SECRETION OF COAGULATION FACTOR VIISTUDIED BY PULSE-CHASE ANALYSISG. Bolt* (DK), T. D. Steenstrup, C. Kristensen

PP-WE-110 IMPACT OF ANTICOAGULANTS ON PLATELET-MONOCYTE COMPLEX FORMATIONAND REGULATION OF PROCOAGULANT FUNCTION OF MONOCYTES ISOLATEDFROM HUMAN BLOODG. B. Manjunath* (NO), F. X. Gruber, M. Sovershaev, B. Østerud, J. Hansen



246

Wed

nesd

ay P

oste

rs

PP-WE-111 EVALUATION OF A NEW AUTOMATED ANALYSER FOR HAEMOSTASIS ANDTHROMBOSIS ANALYSISJ. Needham* (UK), H. Lewis, S. Rangarajan, A. Roy

PP-WE-112 LOCAL ANESTHETICS ATTENUATE TISSUE FACTOR EXPRESSION IN ACTIVATEDMONOCYTES VIA NF-KB-MEDIATED INHIBITION OF MRNA SYNTHESISJ. Kim* (KR), K. Kim, K. Han, H. Kim

PP-WE-113 METFORMIN DECREASES FACTOR VII EXPRESSIONJ. A. Carew* (US), K. R. Cronin

PP-WE-114 EVALUATION OF THE ENDOGENOUS THROMBIN POTENTIAL (ETP) ASSAYJ. P. Antovic* (SE), A. Kallner, N. M. H. Soutari, M. Sten-Linder

PP-WE-115 THE IMPACT OF LOCAL MEAN NORMAL PROTHROMBIN TIME VARIABILITY ON INRWITH LESS RESPONSIVE THROMBOPLASTIN REAGENTS AS DEMONSTRATED BYLOCAL ISI CALIBRATION WITH A NEW SET OF CERTIFIED PLASMASJ. Hammelburger* (US), R. Bottenus, M. Triscott, M. Johnston, M. Lauzon

PP-WE-116 A POSITIVE APTT BIPHASIC WAVE FORM IS AN EARLY PREDICTOR OF RENALIMPAIRMENT IN PATIENTS ON THE INTENSIVE CARE UNITK. Sullivan* (UK), J. Thachil, C. Downey, T. Dutt, J. Harper, C. H. Toh

PP-WE-117 CLINICAL AND LABORATORY EVALUATIONS OF A HIGH-SENSITIVITY LIQUID HUMANTHROMBOPLASTIN FOR USE WITH AUTOMATED COAGULATION ANALYZERSK. M. Cawthern* (US), R. Bottenus, J. Vasquez, D. Diaz, M. X. Triscott

PP-WE-118 ENDOGENOUS THROMBIN POTENTIAL AS A NOVEL METHOD FORCHARACTERISATION OF PROCOAGULANT SNAKE VENOMSL. F. Lincz* (AU), D. Woods, S. Alley, M. A. O’Leary, M. Seldon, G. Isbister

PP-WE-119 ANIONIC LIPID DOMAIN FORMATION ON THE NANOMETER SCALEM. A. McLean* (US), I. G. Denisov, S. G. Sligar

PP-WE-120 FACTOR VII ACTIVATION BY FACTOR IXa-ALPHA VERSUS FACTOR IXa-BETAM. L. Morgret* (US), J. H. Morrissey

PP-WE-121 INVERSE CORRELATION BETWEEN PLASMA AND PLATELET CHOLESTEROLCONCENTRATION WITH PLATELET TISSUE FACTOR-DEPENDENT CLOTTINGACTIVITYO. Panes* (CL), V. Matus, M. Acevedo, J. Pereira, D. Mezzano

PP-WE-122 DETECTING TISSUE FACTOR-POSITIVE CELLS IN A MIXED POPULATION BYSCANNING ELECTRON MICROSCOPYV. Strogolov* (US), L. G. Westrick, J. A. Oliver

Intrinsic Pathway of Coagulation II

PP-WE-123 THE COMMON AND FUNCTIONAL F12 -4 C>T POLYMORPHISM COUPLED WITH LOWFXII LEVELS SIGNIFICANTLY ASSOCIATED WITH REDUCED FVIIC AND FIXC LEVELS,PROLONGED APTT, AND LESS THROMBIN GENERATIONJ. Corral* (ES), A. I. Antón, T. Quiroga, R. González-Conejero, J. Pereira, V. Roldán, V.Vicente, D. Mezzano

PP-WE-124 THE IMPACT OF COLLECTION TUBE FILL VOLUME ON INTERNATIONALNORMALISED RATIOJ. J. Potgieter* (ZA), R. Pool, E. M. D. Botha, A. Prinsloo, S. Olorunju

PP-WE-125 THROMBIN GENERATION: CORN TRYPSIN INHIBITOR CHANGES RELATIONSHIPSBETWEEN NORMAL AND THROMBOTIC SAMPLESJ. K. Ryland* (UK), A. S. Lawrie, S. J. Machin, I. J. Mackie



247

PP-WE-126 CHANGES OF INHIBITORY COMPLEXES OF THE PLASMA KALLIKREIN-KININ SYSTEMFOLLOWING PERCUTANEOUS CORONARY INTERVENTION OR THROMBOLYTICTHERAPY WITH TENECTEPLASEJ. W. P. Govers-Riemslag* (NL), V. Pönitz, T. Brügger-Andersen, H. Grundt, H. ten Cate, D.W. T. Nilsen

PP-WE-127 DOES FACTOR XI ACTIVITY CORRELATE WITH THROMBIN GENERATIONL. Elreda* (US), O. U. Ogbata, M. Drejka, A. J. Cohen

PP-WE-128 TOTAL LAB AUTOMATION AND COAGULATION TESTINGM. Deckers* (NL), G. Bulut, T. Hofman, J. de Kok

PP-WE-129 BIOLOGICAL EVALUATION OF SYNTHETIC LINEAR ANALOGUE PEPTIDES OF 1811-1818 LOOP OF THE A3 SUBUNIT OF THE LIGHT CHAIN A3-C1-C2 OF FVIII BLOODCOAGULATIONM. P. Makris* (GR), K. Patsialas, C. Koutsas, M. Liakopulu, P. E. Makris

PP-WE-130 INSIGHTS INTO THE MECHANISM UNDERLYING POLYPHOSPHATE STIMULATEDAUTOACTIVATION OF FACTOR XIIR. Engel, R. A. S. Ariens, H. Philippou, N. J. Mutch* (UK)

PP-WE-131 GENETIC POLYMORPHISM OF BLOOD COAGULATION FACTOR IX GENE IN GREEKPATIENTS WITH THROMBOPHILIAM. S. Iskas, R. M. Papi, G. E. Mimikakou, D. A. Kyriakidis, P. E. Makris* (GR)

PP-WE-132 FACTOR VIII LEVELS DURING AND AFTER ORAL ANTICOAGULANT THERAPYS. Passamonti, I. Martinelli, P. Bucciarelli* (IT), P. M. Mannucci

PP-WE-133 STANDARDIZATION OF THROMBIN GENERATION TEST – II. WHICH REFERENCEPLASMA FOR TGT? : AN INTERNATIONAL MULTICENTER STUDYY. Dargaud* (FR), R. Luddington, E. Gray, V. Regnault, T. Siegemund, T. Baglin, J. Hogwood,T. Lecompte, A. Siegemund, C. Negrier

Anticoagulant Pathways II

PP-WE-134 INHIBITION OF THROMBIN VERSUS FACTOR Xa FOR VENOUS THROMBUSREDUCTIONB. C. Cooley* (US)

PP-WE-135 EFFECT OF LMWH OF FIRST AND SECOND GENERATION ON THE THROMBINGENERATION (TG) PARAMETERSC. L. Duboscq* (AR), J. J. Ceresetto, C. Shanley, G. Stemmelin, O. Rabinovich, C. Doti, N.Cazap, E. Bullorsky

PP-WE-136 ENDOTHELIAL PROTEIN C RECEPTOR GENE SILENCING AFFECTS MDA-MB-231BREAST CANCER CELL INVASIVENESSG. Fontana, C. Razzari, S. Ferrero, E. M. Faioni* (IT)

PP-WE-137 MONITORING OF LOW MOLECULAR WEIGHT HEPARIN IN PATIENTS WITH CHRONICRENAL FAILURE BY USING CPME. Vlasova* (RU), I. Vasilenko, V. Suslov

PP-WE-138 INFLUENCE LOW MOLECULAR WEIGHT HEPARIN ON PLATELETSE. Vlasova* (RU), I. Vasilenko, V. Samoylenko, V. Suslov

PP-WE-139 A NOVEL METHOD TO ANALYZE ENDOTHELIAL CELL PROTEIN C RECEPTOREXPRESSION IN VITROE. Ducros* (FR), S. Mirshahi, C. Bermot, M. Mirshahi



248

Wed

nesd

ay P

oste

rs

PP-WE-140 THE EFFECTS OF PHOSPHOLIPID AND TISSUE FACTOR CONCENTRATIONS ON THEAPC ANTICOAGULANT ACTIVITY IN A THROMBIN GENERATION ASSAYG. Salvagno* (IT), G. Lippi, M. Franchini, G. Guidi, B. Dahlback

PP-WE-141 INFECTIVITY AND POSSIBLE GAIN OF FUNCTION OF P1 MUTANTS OFANTITHROMBINI. Martínez-Martínez* (ES), A. Ordóñez, A. Miñano, L. Velázquez, R. Teruel, J. Padilla, C.Martínez, R. Lecumberri, H. Cano, C. de Cos, V. Vicente, J. Corral

PP-WE-142 LABORATORY MONITORING OF DABIGATRAN DURING ORTHOPEDIC SURGERYJ. Ulehlova* (CZ), L. Slavik, V. Krcova, J. Prochazkova, A. Hlusi, L. Cech

PP-WE-143 MOLECULAR AND FUNCTIONAL HETEROGENEITY IN CONTAMINANTS ISOLATEDFROM RECALLED HEPARIN. IMPACT ON ANTICOAGULATION AND POTENTIALADVERSE REACTIONSJ. Fareed* (US), D. Hoppensteadt, W. Jeske, C. Adiguzel, O. Iqbal, J. Walenga

PP-WE-144 EVALUATION OF A NOVEL QUANTITATIVE ASSAY FOR FACTOR V LEIDEN (FVLK. P. Hickey* (UK), P. C. Cooper, S. Kitchen

PP-WE-145 C1173T POLYMORPHISM IN THE VKORC1 GENE AND WARFARIN SENSITIVITYL. A. Bastos* (AR), A. N. Blanco, S. Meschengieser, M. A. Lazzari

PP-WE-146 FREQUENCY OF VKORC1 POLYMORPHISM C1173T IN A GROUP OF NORMALINDIVIDUALS AND PATIENTS UNDER ANTICOAGULANT TREATMENT IN ARGENTINAL. A. Bastos* (AR), A. N. Blanco, S. Meschengieser, M. A. Lazzari

PP-WE-147 THROMBIN GENERATION IN CARRIERS OF INHERITED CLOTTING INHIBITORSDEFECTSV. Rossetto* (IT), L. Spiezia, G. Sabrina, P. Dabrilli, C. Abalotti, S. Barbar, D. Tormene, P.Simioni

Cofactors and Proteases II

PP-WE-148 SUBSTRATE SPECIFICITY OF NATTOKINASE : APPLICATION TO THE ASSAY OF ITSPOTENCYH. Sumi* (JP), C. Yatagai, S. Naito, T. Ohsugi, J. Saito

PP-WE-149 FERMENTATION OF ROYAL JELLY AND BEE POLLEN : NATTOKINASE FIBRINOLYSISAND VITAMIN K2 CONTENTH. Sumi* (JP), M. Imai, Y. Yanagisawa

PP-WE-150 INFLUENCE OF FACTOR X ON IN VITRO AND IN VIVO GENE DELIVERY BY AD5 ANDAD35 VECTORSJ. A. Greig, S. N. Waddington, S. M. K. Buckley, A. L. Parker, D. Bhella, R. Pink, T. Morita, J.Custers, J. Goudsmit, S. A. Nicklin, J. H. McVey* (UK), A. H. Baker

PP-WE-151 SELECTED MODIFICATION OF THE ADENOVIRUS TYPE 5 HEXON MODULATESINTERACTION WITH COAGULATION FACTOR X AND HEPATOCYTE TRANSDUCTIONIN VIVOR. Alba, A. C. Bradshaw, A. L. Parker, D. Bhella, S. A. Nicklin, S. N. Waddington, J. Custers,J. Goudsmit, N. van Rooijen, D. H. Barouch, J. H. McVey* (UK), A. H. Baker

PP-WE-152 THE INFLUENCE OF GLYCOSYLATION ON TISSUE FACTOR ACTIVITYJ. Krudysz-Amblo* (US), K. G. Mann, S. Butenas

PP-WE-153 MAPPING FACTOR VIII C1 DOMAIN AMINO ACIDS THAT COOPERATE WITH EPITOPESOF THE C2 DOMAIN IN MEMBRANE BINDINGJ. Lu* (US), S. W. Pipe, H. Z. Miao, M. G. Jacquemin, G. E. Gilbert



249

PP-WE-154 EFFECT OF ANTITHROMBIN (AT) COMPLEX FORMATION ON THEPHARMACOKINETICS OF RECOMBINANT FACTOR VIIa (RFVII) AND NN1731 INBEAGLE DOGSL. C. Petersen* (DK), D. M. Karpf, H. Pelzer, M. B. Hermit, M. Ezban

PP-WE-155 ENDOTHELIAL PROTEIN C RECEPTOR AND PROTEASE ACTIVATED RECEPTOR 1ARE REQUIRED FOR NEUROPROTECTIVE ACTION OF ACTIVATED PROTEIN CL. Gorbacheva* (RU), O. Davidova, V. Pinelis, G. Reiser, S. Strukova

PP-WE-156 THROMBIN RESIDUES IN THE BETA-INSERTION LOOP AND THE S2 POCKETCONTRIBUTE TO RECOGNIZING FACTOR XIII ACTIVATION PEPTIDESM. A. Jadhav* (US), R. C. Lucas, M. C. Maurer

PP-WE-157 IDENTIFICATION AND CHARACTERISATION OF FACTOR VIII-MEMBRANEINTERACTION INHIBITORSM. Kulharia* (FR), O. Sperandio, J. Voorberg, S. Wielders, J. Rosing, B. O. Villoutreix, G. A.F. Nicolaes

PP-WE-158 CONFORMATIONAL CHANGES THAT OCCUR WHEN THROMBIN BINDS EXOSITE-DIRECTED LIGANDS IN SOLUTIONM. V. Malovichko* (US), T. M. Sabo, M. C. Maurer

PP-WE-159 SUBSTRATE SPECIFICITY OF VKORC1M. Marinova* (DE), M. Watzka, P. Westhofen, M. Hass, D. Luetjohann, J. Oldenburg

PP-WE-160 ADHESIVES PROPERTIES OF A HEMOLIN FROM LONOMIA OBLIQUA CATERPILLARBRISTLES AND MECHANISMS OF ACTIVATION OF HUMAN FACTOR XM. P. Flores* (BR), O. H. Ramos, A. M. Chudzinski-Tavassi

PP-WE-161 TRANSCRIPTIONAL REGULATION OF PROTEIN ZM. Ben-Hasan* (UK), P. R. Winship, A. J. Hall

PP-WE-162 BINDING OF THE C2 DOMAIN OF FACTOR V AND FACTOR VIII TO ANIONICPHOSPHOLIPID BILAYERSY. Z. Ohkubo* (US), E. Tajkhorshid

Inhibitors of Coagulation II

PP-WE-163 NATURAL ANTICOAGULANTS CAN BE USEFUL PREDICTORS OF SEVERITY INCHRONIC LIVER DISEASEA. M. Abdelgadir* (SA), A. A. Abdo, F. M. Al Sania, N. Azzam, K. Al Sawat, M. Al Duhgyal, A.K. Al Ghumlas, A. Hersi

PP-WE-164 THE USE OF POLYBRENE FOR HEPARIN NEUTRALISATION IN THE THROMBINGENERATION TESTA. Carlo* (FR), E. Arnaud, B. J. Woodhams

PP-WE-165 VENOUS THROMBOSIS RELATED TO RESISTANCE TO TISSUE FACTOR PATHWAYINHIBITORB. Tardy- Poncet* (FR), M. Piot, C. Chapelle, P. Morange, J. Reynaud, K. Rivron-Guillot, O.Garraud, L. Campos, H. Decousus, P. Mismetti, B. Tardy

PP-WE-166 INCREASED LEVELS OF ANAPHYLATOXIN (C5A) AND BRADYKININ IN END-STAGERENAL DISEASE PATIENTS ON MAINTENANCE HEMODIALYSIS. POTENTIALRELEVANCE TO HEPARIN MEDIATED HEMODYNAMIC RESPONSESC. Adiguzel* (US), V. Bansal, E. Litinas, D. Hoppensteadt, J. Fareed

PP-WE-167 INHIBITORY POWERS MOLECULES OF SPECIFICS SITES IN THE HAEMOSTATICSYSTEM FROM SALIVARY GLANDS LEECH HAEMENTERIA VIZOTTOI (VIZOTTO, 1967D. G. L. Oliveira* (BR), A. Miranda, A. M. Chudzinski-Tavassi



250

Wed

nesd

ay P

oste

rs

PP-WE-168 EFFECT OF NU172 AND BIVALIRUDIN ON ECARIN CLOTTING TIME IN HUMANPLASMA AND WHOLE BLOODE. K. Waters* (US), J. Richardson, R. G. Schaub, J. C. Kurz

PP-WE-169 COMPONENTS OF VARIABILITY OF ACTIVATED PARTIAL THROMBOPLASTIN TIME(APTT) VS. ANTI-FACTOR Xa (AXa) ON UNFRACTIONATED HEPARIN (UFH) DOSEADJUSTMENTSF. Guerrero* (FR), A. Faure, V. Diemert, S. Voisin, P. Sié, A. Bura Rivière

PP-WE-170 THROMBIN GENERATION IN PATIENTS (PTS) WITH SEVERE SEPSIS AND SEPTICSHOCK DURING THE TREATMENT WITH HIGH DOSES OF ANTITHROMBIN III (ATG. M. Galstyan* (RU), A. V. Krechetova, M. G. Alexanyan, E. I. Sinauridze, V. M. Gorodetsky,S. A. Vasiliev

PP-WE-171 USE OF ALBUMIN TO REPLACE FVIII DEFICIENT PLASMA IN THE BETHESDA ASSAYFOR FACTOR VIII INHIBITORS: COMPARISON TO THE NIJMEGEN BETHESDA ASSAYG. W. Kershaw* (AU), D. Jayakodi, A. Belin, S. Dunkley, D. Joshua

PP-WE-172 EXPOSURE DEPENDENT EFFECTS ON COAGULATION ASSAYS BY THE ORALDIRECT THROMBIN INHIBITOR AZD0837 IN PATIENTS WITH ATRIAL FIBRILLATION.RESULTS FROM TWO PHASE II STUDIESG. Y. H. Lip* (UK), B. Olsson, L. H. Rasmussen, A. Tveit, E. Jensen, U. G. Eriksson, M. Elg,P. Weissman, K. Wåhlander

PP-WE-173 ANTICOAGULANT MECHANISMS OF ANTITHROMBIN-HEPARIN STUDIED BY TEGH. M. Atkinson* (CA), T. A. Mewhort-Buist, L. R. Berry, A. K. C. Chan

PP-WE-174 NOVEL HEPARIN COFACTOR II-DERMATAN SULFATE COVALENT COMPLEXFORMATION SELECTS FOR DERMATAN SULFATE WITH HIGHER MOLECULARWEIGHTH. H. W. Chan* (CA), D. L. French, L. R. Berry, A. K. C. Chan

PP-WE-175 ANTITHROMBIN ALA383PRO: A NEW MISSENSE VARIANT IDENTIFIED IN A PATIENTWITH VENOUS THROMBOSISI. Tirado* (ES), M. Borrell, D. Llobet, I. Coll, C. Vallvé, P. Fuentes, J. Mateo, J. Fontcuberta

PP-WE-176 LOW MOLECULAR WEIGHT HEPARIN INHIBITS TUMOR ASSOCIATED ANGIOGENESISIN VIVOI. M. C. Debergh* (BE), N. van Damme, P. Pattyn, M. Peeters, W. P. Ceelen

PP-WE-177 COVALENTLY LINKING ANTITHROMBIN TO HEPARIN ENHANCES THE INHIBITION OFFXa IN THE PROTHROMBINASE COMPLEXI. Stevic* (CA), T. A. Kentner, L. R. Berry, A. K. C. Chan

PP-WE-178 PHARMACOKINETICS AND SAFETY OF A NOVEL ULTRA LOW MOLECULAR WEIGHTHEPARIN (RO-14) IN HEALTHY VOLUNTEERS – A FIRST TIME IN HUMAN (FTIH)SINGLE ASCENDING DOSE STUDYR. M. Antonijoan, S. Rico, M. Puntes, M. Borrell, J. Fontcuberta, M. Monreal, J. Martinez-Gonzalez* (ES), M. J. Barbanoj

PP-WE-179 THE FACTOR Xa INHIBITOR DU-176B IS SAFE IN HEALTHY SUBJECTS 24 HOURSPOST WARFARIN TREATMENT: A RANDOMIZED, DOUBLE-BLIND STUDYJ. Mendell* (US), R. J. Noveck, I. Rubets, R. Luo, M. Shi, D. Salazar

PP-WE-180 IN-VITRO CHARACTERISATION OF A BIVALENT FUSION APTAMER TARGETINGHUMAN THROMBINJ. Müller* (DE), B. Wulffen, G. Mayer, B. Pötzsch

PP-WE-181 EFFECTS OF DIRECT THROMBIN OR FACTOR Xa INHIBITION ON CLOTTHROMBOGENICITY IN VITRO: COMPARISON OF DABIGATRAN WITH RIVAROXABANAND APIXABANJ. van Ryn* (DE), M. Kink-Eiband, I. Kuritsch, W. Wienen



251

PP-WE-182 ATTITUDES TOWARDS TREATMENT WITH VITAMIN-K ANTAGONISTS IN RELATION TOPERSONALITY TRAITS IN PATIENTS ON STABLE ORAL ANTICOAGULANT THERAPYM. Felten, J. Harenberg* (DE), L. Frölich, C. Weiss

PP-WE-183 GENETIC POLYMORPHISMS OF VKORC1 AND CYP2C9 CONTRIBUTES TO STEADY-STATE DOSE REQUIREMENTS OF PATIENTS ON PHENPROCOUMONJ. Harenberg* (DE), W. Wu, C. Weiss, S. Stehle, J. Kirchheiner, U. Fuhr, C. Gleiter

PP-WE-184 FUCOSYLATED CHONDROITIN SULFATE INHIBITS PLASMA THROMBIN GENERATIONVIA TARGETING OF THE FACTOR IXa HEPARIN-BINDING EXOSITEJ. P. Sheehan* (US), Y. Buyue

PP-WE-185 ECT MEASUREMENT AFTER DIFFERENT STORAGE CONDITIONS OF AR-H067637,THE ACTIVE METABOLITE OF AZD0837, IN WHOLE BLOOD AND PLASMAK. Wåhlander* (SE), F. Wågberg, M. Elg

PP-WE-186 EFFECTS OF CYTOCHROME P450 2C9 (CYP2C9) AND VITAMIN K EPOXIDEREDUCTASE (VKORC1) GENOTYPES ON FLUINDIONE ANTICOAGULATION STATUSK. Lacut* (FR), C. Verstuyft, L. Gourhant, E. Poulhazan, L. Becquemont, D. Mottier

PP-WE-187 PROTAMINE INHIBITS PROPAGATION OF THROMBIN GENERATIONK. A. Tanaka* (US), D. Bolliger, J. H. Levy, F. Szlam

PP-WE-188 ASSOCIATION OF THE SINGLE NUCLEOTIDE POLYMORPHISM RS2227589 IN THESERPINC1 GENE WITH INHERITED ANTITHROMBIN DEFICIENCYK. Jochmans* (BE), C. Orlando, W. Lissens, I. Liebaers, M. de Waele

PP-WE-189 ANTIDOTE REVERSAL OF A NOVEL PROTHROMBIN APTAMER ANTICOAGULANTK. M. Bompiani* (US), S. Oney, F. C. Church, B. A. Sullenger

PP-WE-190 COMPARISON OF DABIGATRAN, UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN IN PREVENTING THROMBUS FORMATION ONMECHANICAL HEART VALVES: RESULTS OF AN IN VITRO STUDYL. Maegdefessel* (DE), T. Linde, F. Krapiec, U. Steinseifer, J. van Ryn, B. Hauroeder, U.Raaz, M. Buerke, K. Werdan, A. Schlitt

PP-WE-191 MECHANISM UNDERLYING PROTEIN C DEFICIENCY IN A PATIENT WITH ANALA267THR MUTATIONL. Tjeldhorn* (NO), N. Iversen, P. Sandset, G. Skretting

PP-WE-192 WHAT IS THE BEST WAY TO MONITOR TINZAPARIN TREATMENT? A COMPARISONBETWEEN ASSAYSL. Lanning* (UK), A. Riddell, A. Griffioen, S. Brooks, P. Chowdary, A. Gatt

PP-WE-193 COVALENT LINKAGE OF HEPARIN TO ANTITHROMBIN INCREASES LUNG CELLPROLIFERATIONL. R. Berry* (CA), I. Tseu, M. Post, A. K. C. Chan

PP-WE-194 EFFECT OF SUBSTRATE AND ANTICOAGULANT ON THE FLUOROGENIC DETECTIONOF DYNAMIC THROMBIN ACTIVITY IN WHOLE BLOODM. S. Chatterjee* (US), S. L. Diamond

PP-WE-195 PERFORMANCE OF A NEW KCT ASSAY AND COMPARISON TO THE DRVVT FORDETECTION OF LAM. D. Goldford* (US), S. R. Raval

PP-WE-196 RANDOMIZED, PARALLEL GROUP, WARFARIN CONTROL, MULTICENTER PHASE IISTUDY EVALUATING SAFETY OF DU-176B IN JAPANESE SUBJECTS WITH NON-VALVULAR ATRIAL FIBRILLATION (NVAFM. Yasaka* (JP), H. Inoue, Y. Kawai, T. Yamaguchi, S. Uchiyama, M. Matsumoto, S. Ogawa,Y. Koretsune, T. Yamashita



252

Wed

nesd

ay P

oste

rs

PP-WE-197 VENOUS THROMBOEMBOLISM PROPHYLAXIS METHODS IN THE TRAUMA ANDEMERGENCY SURGERY INTENSIVE CARE UNIT PATIENTSM. Kurtoglu* (TR), K. Serin, H. Yanar, Y. Ozdenkaya

PP-WE-198 EFFECTS OF RIVAROXABAN, A NOVEL, ORAL, DIRECT FACTOR Xa INHIBITOR, ONCOAGULATION ASSAYSM. M. Samama* (FR), L. L. Fem, C. Guinet, E. Perzborn, J. Martinoli, F. Depasse

PP-WE-199 SUITABILITY OF CHROMOGENIC ANTI-FACTOR Xa METHODS TO MEASURERIVAROXABAN IN HUMAN PLASMAM. M. Samama* (FR), L. L. Flem, C. Guinet, E. Perzborn, J. Amiral, F. Depasse

PP-WE-200 EFFECTS OF THE ORAL DIRECT THROMBIN INHIBITOR AZD0837 AND VKA ON FIBRINFORMATION IN A PERFUSION CHAMBER MODEL OF THROMBOSIS IN PATIENTSWITH ATRIAL FIBRILLATIONM. Wolzt* (AT), S. Kapiotis, K. Schützer, M. Holmberg, U. Eriksson, K. Wahlander

PP-WE-201 DOSE-DEPENDENT INHIBITION OF EX VIVO FIBRIN FORMATION BY THE ORALDIRECT THROMBIN INHIBITOR AZD0837 IN PATIENTS WITH ATRIAL FIBRILLATIONM. Wolzt* (AT), S. Kapiotis, K. Schützer, M. Holmberg, U. Eriksson, K. Wahlander

PP-WE-202 ROLE OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) AS A PREDICTOR OFDISSEMINATED INTRAVASCULAR COAGULOPATHY (DIC) AMONG CHILDREN WITHSEPSIS SYNDROMEM. A. F. Ragab* (EG), F. M. Hafez

PP-WE-203 PROPHYLACTIC TREATMENT WITH RECOMBINANT ACTIVATED FACTOR VII INPAEDIATRIC PATIENTS WITH HAEMOPHILIA A AND INHIBITORSM. A. Cermelj* (AR), A. M. Ferro, S. M. Ouvina, J. A. Pollola, G. B. Paoloski

PP-WE-204 DELAY IN INITIATING PROPHYLACTIC TREATMENT WITH DABIGATRAN ETEXILATEFOLLOWING TOTAL HIP OR KNEE REPLACEMENT SURGERY DID NOT AFFECTEFFICACY. POOLED ANALYSIS OF TWO EUROPEAN PHASE III TRIALSO. E. Dahl* (NO), A. A. Kurth, N. Rosencher, J. M. Schnee, A. Clemens, S. Hantel, B. I.Eriksson

PP-WE-205 DABIGATRAN ETEXILATE 150 MG ONCE DAILY FOR THE PREVENTION OF VENOUSTHROMBOEMBOLISM AFTER TOTAL KNEE OR HIP REPLACEMENT SURGERY IN THEELDERLY AND THOSE WITH MODERATE RENAL IMPAIRMENTO. E. Dahl* (NO), A. A. Kurth, N. Rosencher, A. Clemens, M. Feuring, H. Noack, B. I.Eriksson

Fibrinogen II

PP-WE-206 PROPHYLACTIC FIBRINOGEN INFUSION REDUCES BLEEDING AFTER CORONARYARTERY BYPASS SURGERY: A PROSPECTIVE RANDOMIZED PILOT STUDYF. Baghaei* (SE), M. Karlsson, L. Ternström, M. Hyllner, A. Flinck, S. Skrtic, A. Jeppsson

PP-WE-207 INTER-RELATIONSHIP OF DIRECT THROMBIN INHIBITOR CONCENTRATIONS WITHTHROMBIN CONCENTRATION AND CLAUSS FIBRINOGEN LEVELSJ. B. Callahan* (US), K. Distasio, H. Lin, M. Doyle, M. Triscott

PP-WE-208 SEX-SPECIFIC GENETIC DETERMINATION OF FIBRINOGEN PLASMA LEVELSM. Sabater-Lleal, I. Arbesú, A. Buil, J. Souto, J. Blangero, J. Fontcuberta, L. Almasy, J. Soria*(ES)

PP-WE-209 GENETIC VARIANTS UNDERLAYING FIBRINOGEN LEVELS: FROM LINKAGEANALYSIS TO FINE MAPPING ON CHROMOSOME 12Q24I. Arbesú, M. Sabater-Lleal, A. Buil, J. Souto, S. Lopez, L. Rib, J. Blangero, J. Fontcuberta, L.Almasy, J. Soria* (ES)



253

PP-WE-210 GENETIC, LABORATORY AND CLINICAL CHARACTERIZATION OF 45 FAMILIES WITHCONGENITAL DYSFIBRINOGENEMIAK. Sittinger* (DE), W. Miesbach, C. Heller, D. Weiss, A. Lauricella, M. Vega-Ostertag, C.Bidlingmaier, U. Harbrecht, C. Sucker, B. Zieger, E. Seifried, J. Oldenburg, C. Geisen

PP-WE-211 IMPAIRED THROMBIN SCAVENGING MAY LEAD TO THROMBOEMBOLICCOMPLICATIONS IN AFIBRINOGENEMIA: A CASE REPORTK. Peter* (CH), S. Gretener, B. Laemmle, F. Demarmels Biasiutti, L. Alberio

PP-WE-212 ALA312THR POLYMORPHISM IS NOT ASSOCIATED WITH CHANGES IN CLOTSTRUCTURE IN A RECOMBINANT SYSTEM: PITFALLS IN ANALYZING PLASMA-PURIFIED PROTEINK. F. Standeven* (UK), S. Dolling, F. P. Phoenix, K. Gersh, J. W. Weisel, R. A. S. Ariens, R.A. Ajjan

PP-WE-213 FUNCTIONAL CHARACTERIZATION OF FIBRINOGEN POZNAN: A PREMATURETRUNCATING MUTATION IN FGG ASSOCIATED WITH HYPOFIBRINOGENEMIA ANDMILD BLEEDING TENDENCYK. Zawilska* (PL), A. Undas, L. Malendowicz-Portala, P. de Moerloose, R. Fish, M.Neerman-Arbez

PP-WE-214 GENETIC MUTATIONS ASSOCIATED WITH DYSFIBRINOGENEMIA IN A UK COHORTM. Hill* (UK), R. C. Tait, M. Williams, G. Dolan

PP-WE-215 FIBRINOGEN BIRMINGHAM II - A NOVEL VARIANT ASSOCIATED WITHHYPODYSFIBRINOGENEMIA, DUE TO COMPOUND HETEROZYGOSITY FORTRP334CYS AND ASN335TYR IN THE FIBRINOGEN A ALPHA CHAINM. Hill* (UK), N. Thompson, B. Gordon, R. Ajjan, R. A. S. Ariens, M. Williams, G. Dolan

PP-WE-216 FIBRIN IN BLOOD CLOTS FORMS NATURAL AMYLOIDB. Bouma, C. Maas, L. M. J. Kroon-Batenburg, O. Kranenburg, Y. Wu, M. F. B. G. Gebbink* (NL)

Fibrinolysis II

PP-WE-217 EVALUATION OF MARKERS OF INFLAMMATION, HEMOSTASIS AND FIBRINOLYSIS INOBESE ASTHMATIC ADOLESCENTSF. Huang* (MX), B. Del-Rio-Navarro, J. Perez-Ontiveros, S. Torres-Alcantara, Toussaint-Martinez de Castro

PP-WE-218 REPROGRAMMED STREPTOKINASES DEVELOP FIBRIN-TARGETING AND DISSOLVEBLOOD CLOTS WITH MORE POTENCY THAN TISSUE PLASMINOGEN ACTIVATORI. Y. Sazonova* (US), R. A. McNamee, A. K. Houng, S. M. King, L. Hedstrom, G. L. Reed

PP-WE-219 MARKERS OF FIBRINOLYSIS IN FIRST-EVER LACUNAR STROKEI. L. H. Knottnerus* (NL), J. W. P. Govers-Riemslag, K. Hamulyak, R. van Oerle, R. P. W.Rouhl, H. M. H. Spronk, J. Staals, H. ten Cate, J. Lodder, R. J. van Oostenbrugge

PP-WE-220 THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR IN PATIENTS WITH DIABETESMELLITUS TYPE 2J. Stasko* (SK), P. Chud?, P. Holl?, P. Galajda, P. Kubisz

PP-WE-221 ABNORMALITIES IN FIBRINOLYTIC FACTORS CONTRIBUTE TO HYPERCOAGULABLESTATES AND ARE QUANTIFIABLE UTILIZING THE OVERALL HAEMOSTATICPOTENTIAL (OHP) ASSAYJ. L. Curnow* (AU), M. C. Morel-Kopp, C. M. Ward

PP-WE-222 NORMALIZATION OF CYTOKINES IN PULMONARY HYPERTENSION IN MICEDEFICIENT IN THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITORJ. Morser* (JP), P. Gil Bernabe, S. Aoki, L. Qin, D. Boveda Ruiz, T. Takagi, C. N.D’Alessandro-Gabazza, O. Taguchi, Y. Takei, E. C. Gabazza



254

Wed

nesd

ay P

oste

rs

PP-WE-223 HYPERFIBRINOLYSIS AND KYNURENINE PATHWAY IN CHRONIC RENAL FAILUREPATIENTSK. Pawlak* (PL), A. Buraczewska-Buczko, M. Mysliwiec, D. Pawlak

PP-WE-224 URINE FIBRINOLYTIC ACTIVITY IN ELDERLY PATIENTS WITH HYPERTENSIONL. V. Podorolskaya* (RU), L. A. Alekseeva, E. L. Chumakova

PP-WE-225 PRELIMINARY CRYSTALLOGRAPHIC STUDY OF HUMAN C4.4A, A SRUCTURAL UPARHOMOLOGUEL. Lin* (US), H. Gardsvoll, B. Jacobsen, M. Ploug, M. Huang

PP-WE-226 FIBRINOLYSIS AND ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERYDISEASE (CAD): IS THERE A LINKA. B. Fernandes, L. M. Lima, M. O. Sousa, V. P. C. Toledo, M. G. Carvalho* (BR)

PP-WE-227 TAFI PLASMA LEVELS ASSESSMENT IN DYSLIPIDEMIC SUBJECTS IN MINAS GERAISSTATE, BRAZILM. G. Carvalho* (BR), M. O. Sousa, A. P. Fernandes, C. N. Ferreira

PP-WE-228 FIBRINOLYTIC CAPACITY FOLLOWING A SINGLE MODERATE ETHANOL DOSE, ASMEASURED BY TPA ACT, PAI-1 ACT AND TWO GLOBAL FIBRINOLYTIC CAPACITYASSAYSM. Pieters* (ZA), H. H. Vorster, J. C. Jerling, C. S. Venter, R. C. M. Kotze, J. J. Malfliet, D. C.Rijken

PP-WE-229 PLASMIN INHIBITOR AND PAI-1 INHIBITION KINETICS IN FIBRIN CLOTSM. Silva* (UK), C. Thelwell, K. Kolev, C. Longstaff

PP-WE-230 CHARACTERIZATION OF ANTIBODIES TO TISSUE-TYPE PLASMINOGEN ACTIVATOR(T-PA) IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED WITH THERECOMBINANT PROTEINM. Cugno* (IT), R. Castelli, G. Bisiani, A. Calini, P. M. Mannucci

PP-WE-231 THE INFLUENCE OF ALPHA-2-ANTIPLASMIN POLYMORPHISM ARG6TRP ONFIBRINOLYSIS; THE LEEDS FAMILY STUDYS. Uitte de Willige* (UK), A. M. Carter, K. F. Standeven, H. Philippou, P. J. Grant, R. A. S.Ariëns

PP-WE-232 THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) DURINGCARDIOPULMONARY BYPASSS. J. Davidson* (UK), D. A. Lindsey, L. Tillyer, B. J. Woodhams

Regulation of Coagulation and Fibrinolysis II

PP-WE-233 THE INFLUENCE OF THE DIRECT FACTOR Xa INHIBITOR RIVAROXABAN ON TWODIFFERENT THROMBIN GENERATION ASSAYS IN PATIENTS WITH THROMBOPHILIAA. Siegemund* (DE), T. Siegemund, U. Scholz

PP-WE-234 HAEMOSTATIC FACTOR PROFILE DURING ORTHOPAEDIC REPLACEMENT SURGERYIN A HEALTHY POPULATIONC. Altisent* (ES), M. Colomina, J. Massons, C. Fernández, M. Melado, R. Parra

PP-WE-235 COMPARISON OF TWO CHROMOGENIC FVIII ACTIVITY ASSAYS TO A STANDARDCLOT-BASED FVIII ACTIVITY ASSAYD. L. McGlasson* (US), G. A. Fritsma

PP-WE-236 SUSCEPTIBILITY AND CLINICAL INVOLVEMENT OF 4G/5G POLYMORPHISM OFPLASMINOGEN ACTIVATOR INHIBITOR-1 (4G/5G PAI-1) GENE IN SYSTEMIC LUPUSERYTHEMATOSUS (SLE). PRELIMINARY RESULTS OF A MULTICENTRE STUDYG. F. de Larrañaga* (AR), S. Perés Wingeyer, A. Allievi, S. Muñoz, R. Trobo, A. Orden, J.Barreira, A. Álvarez, A. Eimon



255

PP-WE-237 REDISTRIBUTION OF RECOMBINANT ACTIVATED FACTOR VII INTO PLATELETS ANDTHE VASCULAR BED: IMPLICATIONS ON HEMOSTATIC MECHANISMSI. Lopez-Vilchez* (ES), J. Tusell, U. Hedner, C. Altisent, G. Escolar, A. M. Galan

PP-WE-238 PROFIBRINOLYTIC EFFECT OF THROMBIN FORMATION DURING FIBRINOLYSISJ. R. Ha* (CA), A. Klompas, P. Massicotte, M. Bauman, P. L. Swanson, L. Bajzar

PP-WE-239 APO(A) INCREASES CLOT STABILITY IN TRANSGENIC MICEJ. L. Hoover-Plow* (US), E. Hart, J. Saraniti

PP-WE-240 EFFECT OF IN-VITRO CRYSTALLOID DILUTION ON COAGULATION IN HEALTHYVOLUNTEERS AND PATIENTS WITH A HISTORY OF VENOUS THROMBOSIS ORHEPATIC CIRRHOSIS USING THROMBOELASTOGRAPY (TEGJ. Kaur* (UK), N. Jones, A. Riddell, C. Melikian, S. Mallett

PP-WE-241 IDENTIFICATION OF HUMAN THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR INVARIOUS VASCULAR CELL TYPESJ. H. Lin* (CA), M. Garand, S. Schadinger, M. B. Boffa, M. L. Koschinsky

PP-WE-242 DIAGNOSIS OF NONOVERT, PRECLINICAL DIC USING CRITERIA FROM THEINTERNATIONAL SOCIETY ON THROMBOSIS AND HEMOSTASISJ. Lee* (KR), J. Song

PP-WE-243 PLEIOTROPIC EFFECTS IN THROMBOTIC-RELATED TRAITS USING BIVARIATEVARIANCE COMPONENTS MODELSA. Buil, Á. Martínez, J. Souto, J. Blangero, L. Rib, M. Borrell, J. Fontcuberta, L. Almasy, J.Soria* (ES)

PP-WE-244 COAGULATION FACTORS DURING LIVER REGENERATION IN MICEK. Tatsumi* (JP), K. Ohashi, Y. Sakurai, T. Okano, M. Shima

PP-WE-245 REGULATION OF PLASMA THROMBIN GENERATION BY VASCULAR ENDOTHELIALCELLSL. Pepler* (CA), P. C. Liaw

PP-WE-246 GENETIC REGULATION OF INFLAMMATION-MEDIATED HAEMOSTASIS ACTIVATION: AFAMILY-BASED APPROACHL. Iacoviello* (IT), B. Vohnout, F. Gianfagna, A. di Castelnuovo, L. Nanni, E. Napoleone, M.Crescente, A. de Curtis, A. Cutrone, C. Tamburrelli, F. Zurlo, R. Lorenzet, C. Cerletti, M. Arca,G. de Gaetano, M. B. Donati

PP-WE-247 WHOLE BLOOD THROMBOELASTOMETRY PROFILE IN FACTOR V LEIDEN SUBJECTSAFTER IN VITRO ADDITION OF HUMAN ACTIVATED PROTEIN CL. Spiezia* (IT), D. Bertini, D. Tormene, C. Radu, V. Rossetto, M. Perlati, F. Dalla Valle, P.Simioni

PP-WE-248 WHOLE BLOOD THROMBOELASTOMETRY IN HUMAN AND CYNOMOLGUS MONKEYSL. Spiezia* (IT), D. Bertini, M. Boldrin, S. Gavasso, C. Radu, P. Zerbinati, C. Bulato, E.Ancona, E. Cozzi, P. Simioni

PP-WE-249 TAFI-DEPENDENT INHIBITION OF FIBRINOLYSIS BY PLATELETS EVALUATED INWHOLE BLOOD BY THROMBOELASTOGRAPHYM. Colucci* (IT), C. Carrieri, R. Galasso, F. Semeraro, C. T. Ammollo, F. Incampo, N.Semeraro

PP-WE-250 ANTI-A2 MONOCLONAL ANTIBODY ENHANCING THROMBIN (AND FACTOR Xa)-CATALYZED FACTOR VIII ACTIVITYM. Takeyama* (JP), K. Nogami, T. Soeda, K. Ogiwara, K. Nishiya, M. Shima

PP-WE-251 CYP2C9 GENOTYPES AND RESPONSE TO WARFARIN DURING INITIALANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATIONM. Bedencic* (SI), E. Zemljic, M. Bozic, P. Peternel, M. Stegnar



256

Wed

nesd

ay P

oste

rs

PP-WE-252 ESTIMATION OF THROMBIN PRODUCTION IN DIFFERENT SUBJECTSM. Makris* (GR), P. Makris

PP-WE-253 TASK-ORIENTED MODULAR ANALYSIS OF THE BLOOD COAGULATION NETWORK:THE ROLE OF FACTOR V FEEDBACK ACTIVATION IN TRIGGERING CLOT FORMATIONM. A. Panteleev* (RU), A. N. Balandina, M. V. Ovanesov, E. N. Lipets, F. I. Ataullakhanov

PP-WE-254 IMPORTANCE OF LIFELONG ORAL ANTICOAGULANT THERAPY IN ADOLESCENTWITH CONGENITAL THROMBOPHILLIAM. Jovic* (RS), D. Redzic, O. Serbic, D. Aleksic, D. Djokic

PP-WE-255 A NOVEL FLUOROMETRIC ASSAY OF SIMULTANEOUS THROMBIN AND PLASMINGENERATION DETECTS ABNORMAL COAGULATION AND FIBRINOLYSIS IN PLASMAM. L. Grunzke* (US), N. A. Goldenberg, W. E. Hathaway, L. J. Jacobson, C. G. Bombardier,H. A. Hathaway, M. J. Manco-Johnson

PP-WE-256 SYNERGY BETWEEN PHOSPHATIDYLSERINE AND OTHER PHOSPHOLIPIDS INBLOOD COAGULATIONN. Tavoosi* (US), R. L. Davis-Harrison, J. H. Morrrissey

PP-WE-257 EVALUATION OF SOME HEMOSTATIC PARAMETERS IN PATIENTS WITH END-STAGERENAL DISEASE: RELATION TO DYSLIPIDEMIA AND HEMODIALYSIS THERAPYN. K. H. A. Y. R. A. T. Abousamra, T. S. Selim, N. K. Abousamra* (EG), S. M. Elshaarawy

PP-WE-258 PLASMA FACTOR XIIIA LEVELS ARE NOT MAINTAINED BY CIRCULATING PLATELETSDURING THEIR LIFETIMEP. A. Cordell* (UK), B. T. Kile, P. J. Grant, R. J. Pease

PP-WE-259 THE EFFECT OF BLOOD COAGULATION FACTOR XIII ON FIBRIN CLOT STRUCTUREAND FUNCTIONE. L. Smith, R. H. Abou-Saleh, S. D. Connell, K. F. Standeven, P. J. Grant, H. Philippou, R. A.S. Ariëns* (UK)

PP-WE-260 NEW ROLE OF PLATELETS IN INDUCING FIBRIN FORMATION UNDER FLOWS. E. M. Schols* (NL), M. A. Berny, J. M. E. M. Cosemans, K. Gilio, M. A. H. Feijge, H.Deckmyn, J. W. M. Heemskerk

PP-WE-261 FIBRINOKINETIC DEFICIT IN CHRONIC KIDNEY DISEASE AND END STAGE RENALDISEASE PATIENTS CONTRIBUTES TO THE HEMOSTATIC ABNORMALITIESV. Bansal* (US), C. Adiguzel, J. Cunanan, D. Hoppensteadt, O. Iqbal, J. Fareed

PP-WE-262 IN VIVO NEUTRALIZATION OF HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN BYA NOVEL SALICYLAMIDE DERIVATIVEJ. Kuziej, E. Litinas, W. P. Jeske* (US), D. Hoppensteadt, J. M. Walenga, J. Fareed

Antiphospholipid Antibodies and Syndrome II

PP-WE-263 PLASMA LEVELS OF VEGF, PLGF AND SDF-1 ARE DIFFERENTLY MODULATEDDURING THE ANTIPHOSPHOLIPID SYNDROMED. M. Smadja* (FR), P. Gaussem, A. Fischer, J. Emmerich, L. Darnige

PP-WE-264 AUTOANTIBODIES AGAINST THE FIBRINOLYTIC RECEPTOR, ANNEXIN A2, INCEREBRAL VENOUS THROMBOSISG. N. Cesarman-Maus* (MX), F. Barinagarrementería, R. Villa, E. García-Latorre, E. Reyes,K. A. Hajjar, C. Cantu-Brito

PP-WE-265 CLINICAL MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME IN OBSTETRICPRACTICEJ. Khizroeva* (RU), A. A. D. Makatsaria



257

PP-WE-266 ANTICARDIOLIPIN ANTIBODIES AND LUPUS ANTICOAGULANT IN CHILDREN WITHSYSTEMIC LUPUS ERYTHEMATOSUS - THE NORTH INDIAN EXPERIENCEJ. Ahluwalia* (IN), S. Singh, S. Naseem, D. Suri

PP-WE-267 CLINICAL PERFORMANCE OF NEW AND QUANTITATIVE ASSAYS FOR THEDIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME (APS) ON A FULLY AUTOMATED,CHEMILUMINESCENT ANALYZERJ. Serra* (ES), R. G. Barry, K. A. Morin, C. V. Manion, J. Musial, J. Arnout, M. van Russelt, P.de Moerloose, G. Reber, N. Ruiz, J. Puig

PP-WE-268 CALIBRATED AUTOMATED THROMBOGRAPHY IN QUANTITATION OF LUPUSANTICOAGULANTS IN THE DIAGNOSIS OF THE ANTIPHOSPHOLIPID SYNDROMEK. M. J. Devreese* (BE), K. Peerlinck, M. F. Hoylaerts

PP-WE-269 THE P38 MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) PATHWAY MEDIATES THEINDUCTION OF TISSUE FACTOR AND ADHESION MOLECULE EXPRESSIONS ONENDOTHELIAL CELLSK. Oku* (JP), T. Atsumi, O. Amengual, E. Miyamoto, Y. Fujieda, K. Otomo, M. Kato, H.Kataoka, T. Horita, S. Yasuda, T. Koike

PP-WE-270 ANALYTICAL PERFORMANCE OF NEW AND QUANTITATIVE ASSAYS FOR THEDIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME ON A FULLY AUTOMATED,CHEMILUMINESCENT ANALYZERK. A. Morin* (US), R. G. Barry, J. F. Guasch, N. Ruiz, J. Puig, J. Musial, J. Arnout, G. Reber,P. de Moerloose

PP-WE-271 PREDICTIVE VALUE OF THE ANTIPHOSPHOLIPID SCORE (APL-S) FOR THROMBOTICEVENTS IN PATIENTS WITH AUTOIMMUNE DISEASESK. Otomo* (JP), T. Atsumi, Y. Fujieda, M. Kato, E. Miyamoto, K. Oku, O. Amengual, H.Kataoka, T. Horita, S. Yasuda, T. Koike

PP-WE-272 RELAPSING CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME ASSOCIATED WITHEARLY ONSET HELLP SYNDROME AND LIVER INFARCTIONSL. Schliamser* (IL), R. Gonen, M. Carlebach, E. Schiff, D. Attias

PP-WE-273 THE EFFECT OF LUPUS ANTI-COAGULANTS ON ANTI-COAGULANT THERAPYMONITORINGL. Slavik* (CZ), J. Ulehlova, V. Krcova, A. Hlusi, J. Prochazkova

PP-WE-274 DRUG-INDUCED ANTIPHOSPHOLIPID ANTIBODY SYNDROME - TIME TO RESOLUTIONM. Kennedy* (US), J. S. Dlott

PP-WE-275 MONOCLONAL IGM PARAPROTEIN WITH LUPUS ANTICOAGULANT ACTIVITY –INFLUENCE ON COAGULATION TESTINGM. Milos* (HR), D. Coen Herak, D. Matisic, R. Zadro

PP-WE-276 CLINICAL AND LABORATORY PICTURE OF APS IN A NATIONAL REGISTRYM. Puurunen* Finland, P. Makkonen, P. Mustonen

PP-WE-277 SIGNIFICANCE OF DELTA TIME VALUE IN THE LAB BY HEXAGONAL ASSAY FORANTIPHOSPHOLIPID SYNDROMEM. Samonte* (US), O. Tcherniantchouk

PP-WE-278 COMBINED ANTIPLATELET AGENTS MIGHT HELP PREVENT ARTERIALTHROMBOSES IN ANTIPHOSPHOLIPID SYNDROMEM. Yamazaki* (JP), Y. Kadohira, M. Maekawa, T. Hayashi, E. Morishita, H. Asakura, S. Nakao

PP-WE-279 A SERIOUS PROBLEM IN NEW REAGENT LOTS OF BETA(2)- GLYCOPROTEIN I IGGASSAYK. Javela, P. Mustonen* Finland



258

Wed

nesd

ay P

oste

rs

PP-WE-280 SUCCESSFUL TREATMENT OF A CASE OF CATASTROPHIC ANTIPHOSPHOLIPIDSYNDROME WITH AUTOLOGOUS BONE MARROW TRANSPLANTATIONT. M. Owaidah* (SA), F. Al Mohareeb, A. Al Harthi, H. Al Zahrani

Risk Factors and Epidemiology of Venous Thrombosis II

PP-WE-281 THE AVAIL ME PROJECT: A FIRST REGIONAL EVALUATION OF VENOUSTHROMBOEMBOLISM (VTE) RISK AND PROPHYLAXIS PRACTICEA. Taher* (LB), P. Salameh, G. Dabar, M. Waked, G. Chaar, M. Itani, E. Elias, R. Abdelkarim,A. Alfahim, S. Haggag, N. Shahrour, A. Khoury, M. Aghili, A. Aldeshev, M. Begaliyev, T.Sultanaliev, S. Tuganbekova, A. Vasheghani, R. Vardosanidze, T. Charkviani, J. Aoun

PP-WE-282 THROMBOPHILIA SCREENING IN THE ACUTE PHASE OF DEEP VENOUS THROMBOSISA. B. Münster* (DK), J. J. Sidelmann, J. Gram

PP-WE-283 TRANSTHORACIC ECHOCARDIOGRAPHY IN PATIENTS WITH A FIRST EPISODE OFPULMONARY EMBOLISM (PE) FOR THE DETECTION OF CHRONICTHROMBOEMBOLIC PULMONARY HYPERTENSION (CTPH)D. Poli* (IT), E. Antonucci, E. Grifoni, G. Ciuti, M. Miniati, G. Gensini, D. Prisco, R. Abbate, C.Arcangeli

PP-WE-284 DEMOGRAPHIC FEATURES, FUNCTIONAL STATUS AND OUTCOMES OF A LARGESAMPLE OF PATIENTS DIAGNOSED WITH PULMONARY EMBOLISM IN EMERGENCYDEPARTMENTS IN THE UNITED STATESJ. Hernandez* (US), C. V. Pollack, J. A. Kline, B. Hiestand, D. Slattery, D. Schrieber, R.Pendleton

PP-WE-285 INHERITED THROMBOPHILIA IN NORMAL SAUDI ARABIAN AND THOSE WITHVENOUS THROMBOSIS-THE SAUDI THROMBOSIS AND FAMILIAL TROMBOPHILIA (S -TAFT) REGISTRYJ. Saour* (SA), A. Sheereen, T. Saour, M. Shoukri, L. Mammo

PP-WE-286 DOES THE CLINICAL PRESENTATION OF VENOUS THROMBOEMBOLISM PREDICTTHE RISK FOR AND TYPE OF THROMBOSIS RECURRENCEJ. Douketis* (CA), A. Iorio, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D.Poli, C. Tait, A. Tosetto

PP-WE-287 SUPERFICIAL THROMBOPHLEBITIS – WHICH CASES ARE MORE RISKYJ. Hirmerova* (CZ), J. Seidlerova, I. Subrt

PP-WE-288 RIGHT ATRIAL THROMBOSIS IN INFANTS AND CHILDREN: LITERATURE REVIEWFROM 1981 TO 2008J. Y. K. Yang* (CA), S. Williams, L. R. Brandao, A. K. C. Chan

PP-WE-289 THE ROLE OF P4-P3’ RESIDUES IN FACILITATING ACTIVATED PROTEIN C CLEAVAGEOF THE FACTOR VIIIa A1 DOMAINJ. P. Deangelis* (US), F. Varfaj, H. Wakabayashi, P. J. Fay

PP-WE-290 ROLE OF P16INK4A-MEDIATED CELLULAR SENESCENCE IN IDIOPATHIC, AGE-RELATED VENOUS THROMBOSISJ. Cardenas* (US), N. Sharpless, H. Whinna, F. Church

PP-WE-291 SCREENING PATIENTS WITH FACTOR V LEIDEN MUTATION AND PROTEIN SDEFICIENCY AND PROTEIN C DEFICIENCY BY MEASURING THROMBIN GENERATIONJ. R. Wu* (US), B. Bai, T. S. Smith

PP-WE-292 BASAL AND LIPOPOLYSACCHARIDE-STIMULATED MONONUCLEAR CELL TISSUEFACTOR PROCOAGULANT ACTIVITY IN PATIENTS WITH PRIOR VENOUSTHROMBOEMBOLISMA. Xue, J. A. Heit* (US), R. Miller, J. Larson, T. M. Petterson, W. G. Owen



259

PP-WE-293 RELATIONSHIP BETWEEN THE PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) 4G/5GPOLYMORPHISM AND CEREBRAL VENOUS THROMBOSIS (CVT). ANOTHER BRICK INTHE WALLJ. M. Ceresetto* (AR), C. Duboscq, C. Doti, F. Bottaro, O. Rabinovich, C. Shanley, G.Stemmelin, E. Bullorsky

PP-WE-294 MOLECULAR CHANGES IN VWF AND ADAMTS13 GENES AND THEIR CORRELATIONWITH PLASMA LEVELS OF FVIII AND VWF IN PATIENTS WITH DEEP VENOUSTHROMBOSISL. F. Bittar, L. H. Siqueira, E. V. de Paula, F. L. A. Orsi, J. M. Annichino-Bizzacchi* (BR)

PP-WE-295 INCREASED ACTIVITY OF COAGULATION FACTORS FVII AND FIX ASSOCIATED WITHRECURRENT THROMBOSIST. M. Melo, F. A. Orsi, E. V. de Paula, M. C. Ozelo, J. M. Annichino-Bizzacchi* (BR)

PP-WE-296 THE FACTOR VIII D1241E POLYMORPHISM, LEVELS OF FACTOR VIII AND RISK OFDEEP VENOUS THROMBOSIS IN A BRAZILIAN POPULATIONT. B. T. Mello, L. H. S. Siqueira, S. A. L. Montavão, D. S. P. Paixão, J. M. Annichino-Bizzacchi* (BR)

PP-WE-297 ANTITHROMBIN (AT) DEFICIENCY: EFFECT OF PERIOPERATIVETHROMBOPROPHYLACTIC APPROACH ON VENOUS THROMBOEMBOLIC EVENT(VTE) RATET. Sooriyakumar, S. Bretherton, J. K. Phillips* (NZ)

PP-WE-298 A PROSPECTIVE STUDY OF QUANTITATIVE D-DIMER AND ENDOGENOUS THROMBINPOTENTIAL MEASUREMENTS IN INDIVIDUALS STOPPING ORAL ANTICOAGULANTSFOR ACUTE VENOUS THROMBOEMBOLISM; ROLE IN PREDICTING RISK OFRECURRENT THROMBOTIC EVENTSS. P. Green, E. Hynes, K. Knaggs, J. Hanley, P. Kesteven, K. L. Talks* (UK)

PP-WE-299 USE OF CALIBRATED AUTOMATED THROMBOGRAPHY TO DETECTHYPERCOAGULABILITYK. R. Machlus* (US), E. A. Colby, J. R. Wu, G. G. Koch, N. S. Key, A. S. Wolberg

PP-WE-300 BLEEDING COMPLICATIONS WITH PHARMACOLOGICAL PROPHYLAXIS FOLLOWINGGYNAECOLOGICAL ONCOLOGY SURGERYK. Hitos* (AU), G. V. Wain, J. P. Fletcher

PP-WE-301 VENOUS THROMBOEMBOLISM PROPHYLAXIS FOLLOWING LAPAROSCOPICSURGERYK. Hitos* (AU), J. P. Fletcher

PP-WE-302 THERE IS NO INCREASE IN THROMBIN GENERATION IN PATIENTS WITH IDIOPATHICINTRACRANIAL HYPERTENSIONK. Hickey* (UK), S. Dhungana, B. Sharrack, P. C. Cooper, M. Makris

PP-WE-303 THE EFFECT OF AGING ON VENOUS VALVESK. van Langevelde* (NL), A. Srámek, A. de Roos, J. H. C. Reiber, F. R. Rosendaal

PP-WE-304 PHYSICAL ACTIVITY AND RISK OF VENOUS THROMBOEMBOLISM -THE TROMSOSTUDYK. H. Borch* (NO), S. Kufaas-Braekkan, E. Mathiesen, I. Njolstad, T. Wilsgaard, J. Stormer, J.Hansen

PP-WE-305 ANTHROPOMETRIC MEASURES OF OBESITY AND RISK OF VTE - THE TROMSOSTUDYK. H. Borch* (NO), S. Kufaas-Braekkan, E. Mathiesen, I. Njolstad, T. Wilsgaard, J. Stormer, J.Hansen



260

Wed

nesd

ay P

oste

rs

PP-WE-306 ELEVATED FACTOR IX LEVELS AS A RISK FACTOR FOR ARTERIAL AND VENOUSTHROMBOSISK. J. Smock* (US), R. A. Crist, K. K. Murphy, A. R. Wilson, G. M. Rodgers

PP-WE-307 ABDOMINAL VEIN THROMBOSIS AS THE FIRST CLINICAL FEATURE OFMYELOPROLIFERATIVE SYNDROMEK. M. Zawilska* (PL), M. M. Jamrozek-Jedlinska, A. M. Grzywacz

PP-WE-308 INHERITED THROMBOPHILIA IN PATIENTS WITH THROMBOEMBOLIC DISEASEL. Lokar* (SI), V. Urlep Salinoviæ, B. Bizjak, B. Majcen Vivod, I. Maraèiè, E. Kava?

PP-WE-309 RISK OF RECURRENT VENOUS THROMBOEMBOLISM – EFFECT OF AGEL. Eischer* (AT), S. Eichinger, P. A. Kyrle

PP-WE-310 ROLE OF GENETIC MUTATIONS IN VASCULAR ACCESS THROMBOSIS AMONGHEMODIALYSIS PATIENTSD. R. A. Rios, D. A. Guimarães, K. B. Gomes, A. P. Fernandes, D. Reis, M. G. Carvalho, L.M. S. Dusse* (BR)

PP-WE-311 OBESITY, POOR MUSCLE STRENGTH AND THE RISK OF VENOUSTHROMBOEMBOLISM IN OLDER PERSONS: THE INCHIANTI STUDYM. di Nisio* (IT), A. di Iorio, E. Porreca, M. Abate, S. Bandinelli, J. Guralnik, R. Molino-Lova,F. Cuccurullo, L. Ferrucci

PP-WE-312 RISK-ASSESSMENT OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED PATIENTS:PRELIMINARY RESULTS FROM A LARGE PROSPECTIVE STUDYM. Debastos* (BR), J. Caiafa, T. Bogutchi, S. Barreto, S. Rezende

PP-WE-313 INCIDENCE OF CARDIOVASCULAR EVENTS AFTER VENOUS THROMBOEMBOLISM. ASYSTEMATIC REVIEW AND META-ANALYSISM. C. Vedovati* (IT), C. Becattini, W. Ageno, F. Dentali, G. Agnelli

PP-WE-314 RETINAL VEIN THROMBOSIS (RVO) AND THROMBOPHILIAM. S. Bellia* (GR), A. J. Gafou, E. Nomikou, V. Tsevrenis, C. Zafiri, G. Apergis, G.Theodosiadis

PP-WE-315 ANTHROPOMETRY AND VENOUS THROMBOEMBOLISM: A DANISH FOLLOW-UPSTUDYM. T. Severinsen* (DK), S. R. Kristensen, S. P. Johnsen, K. Overvad

PP-WE-316 PREVALENCE OF THROMBOPHILIA IN A COHORT OF 2607 WOMEN: IMPACT OF THECALF OR PROXIMAL LOCALIZATION OF DEEP VEIN THROMBOSISM. Horellou* (FR), J. Conard, V. Olié, C. Flaujac, M. Fontenay, G. Plu-Bureau

PP-WE-317 N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE CORRELATES WITH THEPERCENTAGE OF PULMONARY VASCULAR OBSTRUCTION IN PATIENTS WITH ACUTEPULMONARY EMBOLISMM. J. Agterof* (NL), R. E. G. Schutgens, J. F. Verzijlbergen, M. M. C. van Buul, E. A. M.Tromp, M. H. Prins, D. H. Biesma

PP-WE-318 RISK STRATIFICATION OF PATIENTS WITH PULMONARY EMBOLISM BASED ONPULSE RATE AND D-DIMER CONCENTRATIONM. J. Agterof* (NL), E. R. van Bladel, R. E. G. Schutgens, R. J. Snijder, E. A. M. Tromp, M. H.Prins, D. H. Biesma

PP-WE-319 A CASE OF SEVERE INHERITED HYPERHOMOCYSTEINEMIA IN A YOUNG MALEHAVING VENOUS THROMBOEMBOLISM AND CLAUDICATION SUCCESSFULLYTREATED WITH VITAMIN B6 AND B9M. Andersen* (DK), J. Dalsgaard, S. Stender



261

PP-WE-320 THE METABOLIC SYNDROME AND THE RISK OF IDIOPATHIC VENOUSTHROMBOEMBOLISMM. N. D. di Minno* (IT), A. Guida, A. Tufano, A. Coppola, A. M. de Gregorio, M. di Capua, E.Cimino, A. M. Cerbone, G. di Minno

PP-WE-321 LACK OF CHANGE IN INSULIN LEVELS AS A BIOLOGICAL MARKER OF PAI-1LOWERING IN 60 GROWTH HORMONE (GH) DEFICIENT ADULTS ON RECOMBINANTHUMAN GH (R-HGH) REPLACEMENT THERAPY: A PROSPECTIVE STUDYM. N. D. di Minno* (IT), V. Palmieri, G. Lombardi, S. Pezzullo, F. Cirillo, A. Meola, C. diSomma, P. Beck-Peccoz, G. di Minno

PP-WE-322 SAFETY OF VITAMIN K ANTAGONISTS IN PULMONARY ARTERIAL HYPERTENSIONM. V. Huisman* (NL), T. A. Hazenoot, I. R. Henkens, H. W. Vliegen, A. Boonstra, P. E.Postmus, A. Vonk Noordegraaf

PP-WE-323 DECREASED HEME OXYGENASE-1 EXPRESSION IN PATIENTS WITH PULMONARYHYPERTENSION FOLLOWING PULMONARY EMBOLISMM. R. Marchick* (US), J. A. Kline

PP-WE-324 A COMPARISON OF THE PREVALENCE OF HEREDITARY NATURAL ANTICOAGULANTPATHWAY DEFECTS BETWEEN PATIENTS WITH DVT, PE AND THROMBOSIS ATUNUSUAL SITESM. Ahmadinejad* (IR), D. Bashash, T. Ahmadinejad, S. Zolfaghari, M. Tabatabaii, K. Atarodi,L. Seyed Mortaz, S. Baluch

PP-WE-325 CORONARY ARTERY DISEASE AND-OR CEREBRAL NON-FATAL ISCHEMIC STROKEFOLLOWING RETINAL VEIN OCCLUSION: A 8-YEAR FOLLOW-UPM. di Capua* (IT), M. N. D. di Minno, A. Guida, A. M. de Gregorio, C. Cuccaro, M. Loffredo,A. Tufano, E. Ciminno, A. Coppola, A. M. Cerbone, G. di Minno

PP-WE-326 STATIN USE IN PATIENTS WITH NEPHROTIC SYNDROME IS ASSOCIATED WITH RISKREDUCTION OF VENOUS THROMBOEMBOLISMM. Resh* (NL), B. Mahmoodi, G. Navis, N. Veeger, W. Lijfering, J. van der Meer

PP-WE-327 ENOS POLYMORPHISMS MAY BE A RISK FACTOR FOR DEEP VEIN THROMBOSIS ININDIAN ASIAN POPULATIONM. S. Akhter* (IN), A. Biswas, R. Ranjan, A. Meena, A. Sharma, S. Kumar, R. Saxena

PP-WE-328 EPIDEMIOLOGY OF AND RISK FACTORS FOR UPPER EXTREMITY VENOUSTHROMBOSIS IN THE POPULATION-BASED MALMO TROMBOPHILIA STUDY, (MATS)N. Isma* (SE), P. J. Svensson, A. Gottsäter, B. Lindblad

PP-WE-329 PHYSICIAN COMPLIANCE WITH ADVANCED NON-INTERRUPTIVE ELECTRONICALERTS FOR PREVENTING VENOUS THROMBOEMBOLISM AMONG HOSPITALIZEDMEDICAL PATIENTSN. Kucher* (CH), M. Puck, D. Spirk, G. Bucklar, E. Eschmann, T. F. Lüscher

PP-WE-330 ANTHROPOMETRIC AND HAEMOSTATIC CARDIOVASCULAR RISK IN YOUNGNIGERIAN SEMI VEGETARIANSO. A. Awodu* (NG), A. A. Adeyemi, O. A. Omolade, Y. O. Makinde, O. I. Ajayi, A. A. Famodu

PP-WE-332 RISK ASSESSMENT AND MANIFESTATION OF VENOUS THROMBOSIS (VT) INPREGNANCY AMONG CARRIERS OF THE FACTOR V LEIDEN AND THEPROTHROMBIN GENE 20210GA MUTATIONS – A POPULATION-BASED CASE-CONTROL STUDYA. F. Jacobsen, F. E. Skjeldestad, A. Bergrem, P. M. Sandset* (NO)

PP-WE-333 PERFORMANCE OF THE HEMOSIL THROMBOPATH ASSAY IN THE SCREENING FORPROTEIN C PATHWAY ABNORMALITIES. PRELIMINARY RESULTS IN 352UNSELECTED PATIENTS WITH A HISTORY OF THROMBOSISP. A. Toulon* (FR), I. Martin Toutain, A. Ankri



262

Wed

nesd

ay P

oste

rs

PP-WE-334 FACTOR V LEIDEN AND THROMBIN GENERATION AND RISK OF RECURRENTTHROMBOTIC EPISODES IN A PATIENT COHORT WITH VENOUSTHROMBOEMBOLISM. THE LIST STUDYR. Chaireti, C. Jennersjö, T. L. Lindahl* (SE)

Arterial Vascular Diseases II

PP-WE-335 HAEMOSTATIC GENE FACTORS AND RISK OF VASCULAR EVENTS IN RUSSIANPATIENTS WITH STABLE CORONARY ARTERY DISEASE: THE RESULTS OF 4 YEARSFOLLOW-UPA. L. Komarov* (RU), O. Shakhmatova, D. Rebrikov, I. Kofiady, D. Stambolsky, A. Deev, E.Panchenko

PP-WE-336 THE HEMOSTATIC SYSTEM IN PATIENTS WITH TYPE 2 DIABETES WITH ANDWITHOUT CARDIOVASCULAR DISEASEC. J. N. Verkleij* (NL), V. E. A. Gerdes, R. de Bruijn, J. C. M. Meijers, P. F. Marx

PP-WE-337 HAEMOSTATIC AND INFLAMMATORY BIOMARKERS IN CHRONIC HEART FAILUREE. G. Oganova* (BY), S. F. Zolotukhina, S. M. Komissarova, O. A. Petruk

PP-WE-338 AGE IS MORE IMPORTANT TO PREDICT CAROTID STENOSIS AMENABLE OFSURGICAL CORRECTION THAN FOCAL NEUROLOGICAL SYMPTOMSF. Verlato* (IT), G. Verlato, M. Marzolo, G. Camporese, F. Rosso, F. Busonera, M. Nardi, G.Andreozzi

PP-WE-339 INCREASED ACTIVE VON WILLEBRAND FACTOR IN YOUNG WOMEN WITH ACUTEMYOCARDIAL INFARCTIONF. Peyvandi* (IT), M. J. Hollestelle, R. Palla, M. F. M. de Rooij, H. Feys, D. Ardissino, P.Merlini, P. J. Lenting, P. M. Mannucci

PP-WE-340 JAK2V617F MUTATION IN PATIENTS WITH ARTERIAL THROMBOSIS IN THE ABSENCEOF OVERT MYELOPROLIFERATIVE DISEASEF. Dentali* (IT), A. Squizzato, L. Appio, L. Brivio, W. Ageno

PP-WE-341 RISK OF ARTERIAL CARDIOVASCULAR EVENTS IN PATIENTS AFTER ACUTEPULMONARY EMBOLISMF. A. Klok* (NL), I. C. M. Mos, L. Broek, J. T. Tamsma, F. R. Rosendaal, A. de Roos, M. V.Huisman

PP-WE-342 STATIN THERAPY MAY HAVE BEEN INVOLVED IN THE REDUCTION OFCARDIOVASCULAR EVENTS VIA SUPPRESSION OF ENHANCED THROMBOXANEPRODUCTIONH. Omori* (JP), K. Murasaki, Y. Uetsuka, N. Hagiwara

PP-WE-343 PREVALENCE OF C677T AND A1298C POLYMORPHISMS INMETHYLENETETRAHYDROFOLATE REDUCTASE GENE IN PATIENTS WITHCORONARY HEART DISEASES. Park, H. Chi* (KR), S. Min, S. Jang, C. Park

PP-WE-344 PREDICTION OF CARDIOVASCULAR EVENTS BY MMP-9 IN ELDERLY MENT. Weiss, I. Seljeflot* (NO), E. B. Furenes, H. Arnesen

PP-WE-345 LOCAL PROCOAGULANT STATE IN THE LEFT ATRIUM OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATIONI. V. Hrachovinová* (CZ), P. Sulc, M. Zemanova, V. Melenovsk?, D. Wichterle, G. Y. H. Lip, J.Kautzner

PP-WE-346 VON WILLEBRAND FACTOR DOES NOT PREDICT OUTCOME IN UNSTABLE ANGINAJ. E. van Loon* (NL), J. W. Jukema, F. W. G. Leebeek, M. P. M. de Maat



263

PP-WE-347 FREQUENCY OF THE POLYMORPHISM -1131T> C IN APOLIPOPROTEIN A5 (APOA5)GENE IN SUBJECTS IN MINAS GERAIS STATE - BRAZILK. B. Gomes* (BR), A. P. Fernandes, N. G. Cruz, F. F. Coelho, I. R. Santos, K. F. Rodrigues,P. S. Pinheiro, D. A. Guimarães, M. O. Sousa

PP-WE-348 A POSSIBLE MECHANISM OF FASTER ONSET OF PRASUGREL - THE INTESTINE ASAN IMPORTANT CONTRIBUTOR TO THE ACTIVE METABOLITE FORMATION IN VIVO -K. Hagihara* (JP), M. Kazui, H. Ikenaga, T. Nanba, K. Fusegawa, A. Kurihara, O. Okazaki

PP-WE-349 COULD D-DIMER IN THE TYPE 2 DIABETIC PATIENTS BE A MARKER OF THEMACROVASCULAR COMPLICATIONSK. Yokoyama* (JP), Y. Tsukada, Y. Matsubara, T. Kawai, Y. Oikawa, A. Shimada, H. Itoh, M.Murata, Y. Ikeda

PP-WE-350 FACTOR XIII A SUBUNIT VAL34LEU POLYMORPHISM IN PATIENTS SURVIVING ORNOT SURVIVING ISCHEMIC STROKEL. Muszbek* (HU), A. H. Shemirani, B. Antalfi, E. Pongrácz, R. Ádány

PP-WE-351 LOOKING FOR EARLY SIGNS OF ATHEROSCLEROTIC ALTERATIONS IN CARRIERSOF INHERITED THROMBOPHILIAL. Valdre* (IT), C. Legnani, B. Cosmi, M. Cini, E. Favaretto, G. Palareti

PP-WE-352 DETERMINANTS OF THROMBIN GENERATION IN ACUTE MYOCARDIAL INFARCTIONM. Smid* (NL), A. W. J. H. Dielis, R. van Oerle, J. W. P. Govers-Riemslag, H. M. H. Spronk,K. Hamulyák, M. Prins, J. Rosing, J. Waltenberger, H. ten Cate

PP-WE-353 REDUCED THROMBIN GENERATION IS ASSOCIATED WITH MYOCARDIALINFARCTION IN THE GLASGOW MYOCARDIAL INFARCTION STUDY (GLAMISM. Smid* (NL), M. Woodward, R. van Oerle, H. M. H. Spronk, A. Rumley, H. ten Cate, G.Lowe

PP-WE-354 PLASMA GLUTATHIONE PEROXIDASE (GPX-3) AND APOLIPOPROTEIN (A) (APOA) INYOUNG PATIENTS WITH NON-EMBOLIC ISCHEMIC STROKE (IS): A SUB-GROUPANALYSISM. F. Alberto* (AR), P. Casais, L. Jones, G. Campregher, S. Meschengieser, M. A. Lazzari

PP-WE-355 ENDOTHELIAL CELL ACTIVATION MEASURED BY VON WILLEBRAND FACTORPROPEPTIDE IN ISCHEMIC STROKE PATIENTSM. C. van Schie* (NL), M. P. M. de Maat, A. A. Hyseni, D. W. J. Dippel, P. J. Lenting, P. G. deGroot, F. W. G. Leebeek, M. J. Hollestelle

PP-WE-356 PLATELET BEHAVIOUR IN PATIENTS WITH DRUG-ELUTING STENTS AFTERTHIENOPYRIDINE TREATMENT DISCONTINUATIONM. Camera* (IT), D. Trabattoni, D. Villa, A. Bartorelli, P. Bogani, M. Brambilla, E. Tremoli

PP-WE-357 INCREASED INNATE AND ADAPTIVE IMMUNE CELL CONCENTRATIONS IN BLOODPREDICT AN INCREASED CARDIOVASCULAR DISEASE INCIDENCEM. Roest* (NL), H. B. Bueno-De-Mesquita

PP-WE-358 PLASMA FACTOR AND INHIBITOR COMPOSITION CONTRIBUTES TO THROMBINGENERATION DYNAMICS IN ACUTE CEREBROVASCULAR EVENTSM. Gissel* (US), A. Undas, A. Slowik, K. G. Mann, K. Brummel-Ziedins

PP-WE-359 THROMBOPHILIC RISK FACTORS AND OUTCOME IN PATIENTS UNDERGOINGENDOVASCULAR INTERVENTION FOR PERIPHERAL ARTERIAL DISEASEM. Sartori* (IT), E. Conti, E. Favaretto, C. Legnani, G. Guazzaloca, L. Valdre’, C. Pili, G.Palareti

PP-WE-360 MAJOR BLEEDING EVENTS IN STABLE OUTPATIENTS WITH CORONARY,CEREBROVASCULAR OR PERIPHERAL ARTERY DISEASE. FINDINGS FROM THEFRENA REGISTRYT. Gadelha, J. Bisbe, J. Toril, J. N. Alcalá Pedrajas, C. Sanclemente, T. Pascual, M. Manuel* (ES)



264

Wed

nesd

ay P

oste

rs

PP-WE-361 MOLECULAR GENETICS ANALYSIS IN CORONARY ARTERY DISEASEO. A. Smirnova* (RU), V. M. Shmeleva, S. I. Kapustin, N. A. Klenkova, M. N. Blinov, L. P.Papayan

PP-WE-362 FACTOR XIa AND TISSUE FACTOR ACTIVITY IN PATIENTS WITH CARDIOVASCULARAND INFLAMMATORY DISEASESS. Butenas* (US), A. Undas, M. Gissel, K. G. Mann

Hormones, Pregnancy and Women’s Issues II

PP-WE-363 FONDAPARINOX FOR A PREGNANT WOMAN WITH DEEP VEIN THROMBOSIS ANDHEPARIN ALLERGYA. M. Almomen* (SA), A. M. Abdel Gader

PP-WE-364 ABO BLOOD GROUP GENOTYPING AND VENOUS THROMBOSIS IN BRAZILIANWOMEN USING ESTROGENM. S. Santos, D. A. M. Guimarães, S. G. Paiva, A. P. Sabino, M. G. Carvalho, D. D. Ribeiro,K. B. Gomes, L. M. S. Dusse, A. P. Fernandes* (BR)

PP-WE-365 LIPIDS AND APOLIPOPROTEINS (APO B/APO A-I RATIO) IN POST-MENOPAUSALWOMEN UNDER HORMONE REPLACEMENT THERAPYD. A. M. Guimarães, D. Diniz, K. B. Gomes, M. S. Santos, R. M. Franco, G. S. Teixeira, M.Carvalho, A. Fernandes* (BR), M. O. Sousa

PP-WE-366 SPORADIC MUTATIONS WITHIN THE EXON 8 OF PROTEIN Z ARE SIGNIFICANTLYASSOCIATED WITH THE OCCURRENCE OF FETAL LOSSG. Favuzzi, D. Colaizzo, V. de Stefano, E. Rossi, D. Pisanelli, F. Cappucci, T. Za, R.Santacroce, M. Margaglione, E. Grandone* (IT)

PP-WE-367 JAK2 V617F MUTATION IS NOT ASSOCIATED WITH PREGNANCY LOSS: A NESTEDCASE-CONTROL STUDYD. Colaizzo, P. Vergura, G. Favuzzi, G. Vecchione, A. Iannaccone, L. Greco, L. Mazzarelli, P.Martinelli, G. D’ Andrea, M. Margaglione, E. Grandone* (IT)

PP-WE-368 LOCALISATION AND PERIOD OF VENOUS THROMBOSIS OCCURRENCE INTHROMBOPHILIC WOMEN WITH PREGNANCY AND PUERPERIUM RELATED VENOUSTHROMBOEMBOLIC DISEASEG. Mitic* (RS), M. Kovac, L. Povazan, V. Djordjevic, Z. Magic, I. Salatic, N. Antonijevic, A.Novakov Mikic

PP-WE-369 PREDICTION OF ANTI Xa ACTIVITY LEVEL IN PREGNANT WOMEN RECEIVING LOWMOLECULAR WEIGHT HEPARIN USING ARTIFICIAL NEURAL NETWORK ANDSUPPORT VECTOR MACHINESG. Mitic* (RS), M. Scekic, D. Jurisic, L. Povazan, R. Tesic, M. Petkovic, B. Jakovljevic, Z. D.Jelicic

PP-WE-370 REFERENCE RANGES FOR THE DETERMINATION OF D-DIMERS IN PREGNANCYG. Kappert* (DE), S. Halimeh, H. Rott

PP-WE-371 THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) LEVELS, TAFI GENEPOLYMORPHISMS AND CLOT LYSIS TIME IN PREGNANT PATIENTS: RELATIONSHIPWITH PREECLAMPSIA AND/OR INTRAUTERINE FETAL GROWTH RESTRICTIOND. Tassies, M. A. Martinez, J. Monteagudo, C. Freire, J. Pijoan, F. Carmona, J. Balasch, J. C.Reverter* (ES)

PP-WE-372 ENDOGENOUS THROMBIN POTENTIAL: PROFILES IN NORMAL PREGNANCY ANDPRO-THROMBOTIC PREGNANT WOMENE. Hynes, K. Knaggs, S. McCourt, C. Bomken, A. D. Loughney, P. Kesteven, J. P. Hanley*(UK)



265

PP-WE-373 EFFECT OF GENISTEIN VERSUS OESTROGEN ON HAEMOSTATIC GENE EXPRESSIONIN OVARIECTOMISED RATSL. A. Kelly* (IE), W. Wuttke, J. J. O’Leary, L. A. Norris

PP-WE-374 GESTATIONAL VASCULAR COMPLICATIONS: SCREENING FOR CONGENITALTHROMBOPHILIAS. Morais, C. Laranjeira, S. Faria, L. Lima, R. Lopes, M. Pereira, L. Moreira, F. Oliveira, E.Valente, A. Cunha, J. Braga, M. Campos* (PT)

PP-WE-375 THROMBOPROPHYLAXIS WITH LOW MOLECULAR WEIGHT HEPARIN AFTERCAESAREAN SECTION: A DECISION ANALYSISM. Blondon* (CH), M. Righini, A. Perrier, M. Nendaz, F. Boehlen, M. Boulvain, P. deMoerloose

PP-WE-376 ALTERNATIVE ANTICOAGULATION WITH FONDAPARINUX IN PREGNANT PATIENTSWITH HEPARIN-INTOLERANCEM. Schindewolf* (DE), B. Linnemann, B. Luxembourg, E. Lindhoff-Last

PP-WE-377 PREDICTORS OF CARDIOVASCULAR DISEASE IN PRE-ECLAMPSIAM. G. Macey* (UK), S. Bevan, S. Alam, L. Verghese, S. G. Agrawal, S. Beski, R.Thuraisingham, P. K. MacCallum

PP-WE-378 THE SIGNIFICANCE OF ENDOTHELIAL MARKERS ACTIVATION IN THE PREDICTIONOF SUBSEQUENT DEVELOPMENT OF PREECLAMPSIAM. Procházka* (CZ), J. Procházková, R. Pilka, L. Slavík, J. Úlehlová, A. Mechurová, O.Simetka, A. Hlusí

PP-WE-379 THROMBOPHILIA PRESENCE AMONG WOMEN WITH PREGNANCY-ASSOCIATEDCOMPLICATIONS: FETAL LOSS OR PREGNANCY RELATED VENOUSTHROMBOEMBOLISMM. Kovac* (RS), G. Mitic, Z. Mikovic, V. Djordjevic, V. Mandic, L. Rakicevic, D. Mikovic, D.Radojkovic

PP-WE-380 HAEMOLYTIC URAEMIC SYNDROME (HUS) WITHIN TWO HOURS POSTPARTUMM. M. Tea* (AT), R. Kroiss, D. Bikas, T. Wagner

PP-WE-381 VIRAL INFECTIONS, INFLAMMATION, PATHOLOGY OF HEMOSTASIS AND PLACENTALFAILUREN. V. Dolgushina* (RU), A. Makatsaria

PP-WE-382 ROLE OF ACTIVATED RECOMBINANT FACTOR VII IN MASSIVE POSTPARTUMHEMORRHAGEN. Hossain* (PK), T. Shamsi, S. Haider, N. Khan, E. Triche, C. Lockwood, M. Paidas

PP-WE-383 GESTATION AGE SPECIFIC REFERENCE INTERVALS FOR COAGULATION TESTSDURING UNCOMPLICATED PREGNANCY DELIVERY AND EARLY POSTPARTUMPERIODP. B. Szecsi* (DK), M. Jørgensen, A. Klajnbard, N. P. Colov, M. R. Andersen, A. Barfoed, K.Haahr, B. Bjørngaard, S. Stender

Animal and Experimental Models II

PP-WE-384 IMMUNOLOGICAL CHARACTERIZATION AND ANALYSIS OF SEQUENCE ALIGNMENTOF THE COAGULATION PROTEINS IN PRIMATES AND PIGSC. Bulato* (IT), C. Radu, G. Cozza, M. Boldrin, L. Spiezia, S. Gavasso, E. Cozzi, P. Simioni

PP-WE-385 INCREASED ANTITHROMBOTIC AND BLEEDING EFFECTS OF CONTAMINATEDHEPARINS; HEMATOLOGICAL IMPLICATIONSE. Litinas* (US), C. Adiguzel, W. Jeske, D. Hoppensteadt, H. Messmore, J. Walenga, J.Fareed



266

Wed

nesd

ay P

oste

rs

PP-WE-386 EVALUATION OF BOTH ANTI- AND PRO-THROMBOTIC EFFECTS IN A DOG MODEL OFARTERIAL THROMBOSIS, MODIFIED FOLTS MODELJ. Björkman* (SE), A. Bulhak, H. Zachrisson

PP-WE-387 FIBRIN CLOT FORMATION DIFFERS IN THE PRESENCE OF BRANDED AND GENERICENOXAPARINSJ. M. Walenga* (US), C. Adiguzel, O. Iqbal, D. Hoppensteadt, J. Cunanan, M. Bakhos

PP-WE-388 BODY DISTRIBUTION OF IDRAPARINUX AND IDRABIOTAPARINUX IN RATSJ. Herault* (FR), F. Hurbin, M. Pasdelou, B. Remandet, M. Trellu

PP-WE-389 THE ROLE OF THE VWF A1 DOMAIN IN MURINE MODELS OF TTP AND HEMOSTASISJ. Y. Barr* (US), D. G. Motto

PP-WE-390 COMPARISON OF THE ANTITHROMBOTIC AND BLEEDING EFFECTS OF THE DIRECTTHROMBIN INHIBITOR, DABIGATRAN, WITH ENOXAPARIN, HEPARIN AND WARFARININ RATSJ. van Ryn* (DE), I. Kuritsch, M. Kink-Eiband, H. Priepke, W. Wienen

PP-WE-391 ERYTHROCYTE HEMOLYSIS AND HEMOGLOBIN OXIDATION PROMOTE FERRICCHLORIDE INDUCED VASCULAR INJURYK. J. Woollard* (AU), S. Sturgeon, J. Chin-Dusting, H. Salem, S. P. Jackson

PP-WE-392 ANTITHROMBOTIC ACTIVITY OF ORAL HEPARINS IN A PORCINE MODELL. M. Hiebert* (CA), T. Ping, S. M. Wice

PP-WE-393 TRANSPORT OF HEPARINS ACROSS RAT GASTRIC MUCOSA: DOES IT DEPEND ONACTIVE TRANSPORTB. Moazed, L. M. Hiebert* (CA)

PP-WE-394 WHY DO THROMBI STOP GROWING? - FIBRIN POLYMERIZATION MAY LIMIT CLOTGROWTHM. Kamocka* (US), Z. Xu, J. Mu, X. Liu, M. Alber, D. Chen, E. D. Rosen

PP-WE-395 FALSE-POSITIVE HIT-ELISA SPECIMENS MAY CONTAIN ANTIBODIES THATRECOGNIZE NON-SPECIFIC HEPARIN-BOUND CATIONIC PEPTIDESM. Prechel* (US), V. Escalante, J. M. Walenga

PP-WE-396 ANTITHROMBOTIC PROPERTIES OF S 35972, A NEW ORALLY ACTIVE THROMBININHIBITORM. O. Vallez* (FR), P. Gloanec, G. de Nanteuil, A. Rupin, T. J. Verbeuren

PP-WE-397 THE PREVENTION OF EXPERIMENTAL THROMBUS FORMATION UNDER THEINFLUENCE OF PRO-GLY-PRO-ARGM. Grigorjeva* (RU), T. Obergan

PP-WE-398 EFFECTS OF TAK-442, A DIRECT FACTOR Xa INHIBITOR, AND FONDAPARINUX ONPLATELET-ASSOCIATED PROTHROMBINASE IN THE BALLOON INJURED ARTERY OFRATSN. Konishi, H. Katsuhiko, Y. Imaeda, T. Fujimoto, K. Kubo, M. Kawamura* (US)

PP-WE-399 EFFECTS OF ACTIVATED RECOMBINANT FACTOR VII (RFVIIa) ON COAGULATIONPARAMETERS IN HEMORRHAGED ACIDOTIC AND PH CORRECTED SWINEM. A. Dubick* (US), D. N. Darlington, M. R. Scherer, W. Z. Martini, B. S. Kheirabadi

PP-WE-400 ANTITHROMBOTIC PROFILES OF TAK-442, A NOVEL ORAL FACTOR Xa INHIBITOR, INVENOUS AND ARTERIAL THROMBOSIS MODELSN. Konishi* (JP), K. Hiroe, E. Shinozawa, K. Shofuda, K. Matsuda, Y. Imaeda, T. Fujimoto, K.Kubo, M. Kawamura

PP-WE-401 DETECTION OF CANINE COATED PLATELETS BY THREE COLOR FLOW CYTOMETRYT. Knudsen* (DK), M. Kjalke, M. Tranholm, A. L. Jensen, A. T. Kristensen



267

PP-WE-402 EFFECTS OF SHORT-TERM GLUCOCORTICOIDS ON VON WILLEBRAND FACTOR INMICE. PRELIMINARY RESULTSV. A. Zapata* (AR), A. C. Kempfer, J. H. Paiva Palomino, O. G. Astudillo, H. Costa, M. A.Lazzari, A. Sánchez Luceros

Clinical Trials II

PP-WE-403 A RANDOMIZED, PROSPECTIVE, OPEN-LABEL STUDY ON DISTAL VEIN THROMBOSIS(LOW-MOLECULAR-WEIGHT HEPARIN VERSUS WARFARIN FOR SIX WEEKS): THETODI STUDYA. Ghirarduzzi* (IT), G. Camporese, S. Siragusa, D. Imberti, E. Bucherini, F. Landini, W.Ageno, P. Prandoni

PP-WE-404 POOLED ANALYSIS OF FOUR RIVAROXABAN STUDIES: NSAIDS, ASA AND PLATELETINHIBITORSB. I. Eriksson* (SE), A. G. G. Turpie, M. R. Lassen, A. K. Kakkar, M. Gent

PP-WE-405 A POOLED EFFICACY AND SAFETY ANALYSIS OF THE USE OF ANTITHROMBIN(RECOMBINANT) IN HEREDITARY AT DEFICIENT PATIENTS IN HIGH-RISK SITUATIONSC. Tait* (UK), M. J. Paidas, J. Frieling

PP-WE-406 LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS) FOR PROPHYLAXIS OF VTE INPATIENTS WITH SEVERE RENAL INSUFFICIENCY: AN ANALYSIS OF RECENTCLINICAL TRIALSE. Nutescu* (US), A. C. Spyropoulos

PP-WE-407 BUNGEE JUMPING LEADS TO ACTIVATION OF COAGULATION AND VASCULARENDOTHELIUME. C. Lowenberg* (NL), D. J. van Westerloo, G. Choi, A. F. de Vos, J. C. M. Meijers, T. vander Poll, M. Levi

PP-WE-408 SMOKING INDUCES AN EPIGENETIC MODIFICATION OF PLATELET SEROTONINCATABOLISMF. Rendu* (FR), M. Del Pino, G. Chironi, J. Callebert, K. Peoc’H, A. Simon, J. Launay

PP-WE-409 VENOUS THROMBOEMBOLISM PROPHYLAXIS GUIDELINE IMPLEMENTATION ISIMPROVED BY A DEDICATED NURSE PRACTITIONER IN MEDICAL PATIENTSH. Gibbs* (AU), J. Fletcher, P. Blombery, R. Collins, T. Glennane

PP-WE-410 FONDAPARINUX 2.5 MG FOR THE TREATMENT OF SYMPTOMATIC, ISOLATEDSUPERFICIAL THROMBOPHLEBITIS (ST): PRELIMINARY DATA FROM THERANDOMIZED PLACEBO-CONTROLLED CALISTO TRIAL (ON BEHALF OF THECALISTO INVESTIGATORSH. Décousus* (FR), A. Leizorovicz, P. Prandoni

PP-WE-411 DETERMINATION OF PT-INR BY NEW PORTABLE DEVICE (COAGUCHECK XSH. Iwahashi* (JP), T. Tashiro, N. Morishige, K. Tacheuchi, M. Nishimi, Y. Hayashida, N. Ito, G.Kuwahara

PP-WE-412 IMPROVING ANTICOAGULATION CONTROL IN HOSPITALIZED ELDERLY PATIENTS ONWARFARINI. Gouin-Thibault* (FR), C. Levy, E. Pautas, J. Cambus, L. Drouet, I. Mahé, C. Bal Dit Sollier,M. Horellou, J. Golmard, V. Siguret

PP-WE-413 NO INTERACTION OF IDRAPARINUX AND ASPIRIN WHEN CO-ADMINISTERED TOHEALTHY SUBJECTSI. Paty* (FR), M. Trellu

PP-WE-414 COMBINED USE OF D-DIMER AND THE EXHALED CO2/O2 EXCLUDE PULMONARYEMBOLISMJ. A. Kline* (US), D. M. Courtney, C. D. Miller, H. A. Smithline, R. Lanier, M. M. Hogg



268

Wed

nesd

ay P

oste

rs

PP-WE-415 PHARMACOKINETICS AND SAFETY OF BEMIPARIN AFTER MULTIPLEPROPHYLACTIC AND SINGLE THERAPEUTIC DOSES IN YOUNG AND ELDERLYHEALTHY VOLUNTEERS – NO NEED FOR DOSE ADJUSTMENTS. Rico, R. M. Antonijoan, J. Martinez-Colomer, M. Borrell, J. Fontcuberta* (ES), M. Monreal,J. Martinez-Gonzalez, M. J. Barbanoj

PP-WE-416 ALX-0081 A NOVEL ANTI-THROMBOTIC: FIRST RESULTS OF A MULTIPLE DOSEPHASE 1 STUDY IN PATIENTS WITH STABLE ANGINA UNDERGOING PCIJ. Holz* (BE), J. Bartunek, E. Barbato, K. Vercruysse, S. Pullan, G. Heyndrickxs

PP-WE-417 ACCURACY AND PRECISION OF INRATIO 2 - A NEW GENERATION OF A POINT OFCARE COAGULOMETERJ. Engelsen* (DK), J. Dalsgaard Nielsen

PP-WE-418 PLATELET COX-2 EXPRESSION IS A STRONG PREDICTOR FOR FUTURECARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMEK. M. Murasaki* (JP), H. Omori, A. Kobayashi, Y. Uetsuka, N. Hagiwara

PP-WE-419 DECREASING WARFARIN SENSITIVITY DURING THE FIRST THREE MONTHS AFTERHEART VALVE SURGERY: IMPLICATIONS FOR DOSINGK. Meijer* (CA), Y. Kim, S. Schulman

PP-WE-420 INCREASED LEVELS OF PLATELET-DERIVED MICROPARTICLES IN SEPTIC PATIENTSWITH DICK. Kawasugi* (JP), R. Shirasaki, H. Tashiro, N. Shirafuji, C. Shimazu, Y. Miyazawa

PP-WE-421 EFFECTS OF AGE, WEIGHT, GENDER AND RENAL FUNCTION IN A POOLED ANALYSISOF FOUR RIVAROXABAN STUDIESK. A. Bauer* (US), A. G. G. Turpie, M. R. Lassen, A. K. Kakkar, B. I. Eriksson, M. Gent

PP-WE-422 POLYUNSATURATED FATTY ACIDS,VITAMIN E, AND COENZYME Q10 IN THERAPY OFMETABOLIC SYNDROMEL. V. Lyutova* (RU), V. M. Panchenko, G. S. Simowchenko, A. A. Ershov, V. A. Isaev

PP-WE-423 SINGLE ADMINISTRATION OF IDRABIOTAPARINUX HAS NO EFFECT ON DIGOXINPHARMACOKINETICS IN HEALTHY SUBJECTSM. Trellu* (FR), S. Cartot-Cotton, D. Ibghi, I. Paty, G. Sanderink

PP-WE-424 PORTAL VEIN THROMBOSIS MANAGEMENT IN CANDIDATES FOR LIVERTRANSPLANTATION (LT)M. T. Sartori* (IT), C. Ferronato, P. Boccagni, D. Gasparini, U. Cillo, M. Senzolo

PP-WE-425 CONVENIENCE OF AND SATISFACTION WITH THE NEW LONG-ACTINGANTICOAGULANT IDRAPARINUX (IDRA) VS. VITAMIN K ANTAGONIST (VKA) INPATIENTS WITH DEEP VENOUS THROMBOSIS (DVT), PULMONARY EMBOLISM (PE)AND ATRIAL FIBRILLATION (AFM. H. Prins* (NL), P. Leguet, H. Gilet, B. Arnould

PP-WE-426 LABORATORY MONITORING OF HEPARINEMYR. Apostolovska* (MK), S. Kostovska, V. Dejanova, V. Neceva, T. Balkanov, S. Atanasova, S.Useini, I. Nikoloska

PP-WE-427 SURVEY OF CURRENT MANAGEMENT OF ISOLATED DISTAL DEEP VEINTHROMBOSISN. Blest, R. Fitridge, S. J. McRae* (AU)



269

Patient Education and Knowledge Transfer

PP-WE-428 SURVEY ON PHYSICIANS’ ADHERENCE TO DEEP VENOUS THROMBOSISPROPHYLAXIS GUIDELINES IN A TERTIARY HOSPITALG. V. Alemany* (PH), C. C. Budhrani, A. P. Bautista, E. B. Madronio, E. C. Santos

PP-WE-429 BARRIERS TO AND POTENTIAL SOLUTIONS TOWARD OPTIMAL PROPHYLAXISAGAINST DEEP VEIN THROMBOSIS FOR HOSPITALIZED MEDICAL PATIENTS: ASURVEY OF HEALTHCARE PROFESSIONALSN. S. Lloyd* (CA), J. D. Douketis, J. Cheng, H. J. Schunemann, D. J. Cook, L. Thabane, M.Pai, F. A. Spencer, R. Haynes

PP-WE-430 PATIENTS AT HIGHEST RISK FOR VENOUS THROMBOEMBOLISM ARE NOTRECEIVING SPECIFIC DISCHARGE INSTRUCTIONS WARNING FOR SIGNS ANDSYMPTOMS OF VTE: A DOUBLE SETBACKO. Dabbagh* (US), W. A. Parker, M. A. Philpot, M. B. Keegan, J. P. Bosanquet

PP-WE-431 DEVELOPMENT OF FACTOR V LEIDEN BROCHURER. E. Goldsmith* (CA), A. K. C. Chan, W. M. Seroski, L. Wizowski

PP-WE-432 AN EXPLORATION OF THE LIVED EXPERIENCES OF PATIENTS LIVING WITH CHRONICIDIOPATHIC THROMBOCYTOPENIC PURPURAV. Ragoonanan* (UK)

PP-WE-433 INFLUENCE OF PUBLIC AWARENESS ABOUT DVT SYMPTOMS AND BURDEN ON THERATE OF CONFIRMED DVT EVENTSW. Z. Tomkowski* (PL), P. Andziak, M. Dybowska, A. Jawien, P. Kuca, K. Ziaja, G. Malek, M.Gorska

PP-WE-434 SELF ADMINISTRATION OF C1-INHIBITOR-CONCENTRATE IN PATIENTS WITHHEREDITARY ANGIODEMA (HAE)W. Kreuz* (DE), E. Rusicke, I. Martinez-Saguer, C. Heller, E. Aygören-Pürsün, T. Klingebiel

Pediatric Thrombosis II

PP-WE-435 ASSOCIATION BETWEEN C-REACTIVE PROTEIN AND ARTERIAL ISCHEMIC STROKEIN CHILDREND. Coen Herak* (HR), M. Milos, J. Lenicek Krleza, R. Zrinski Topic, S. Dodig, V. Duranovic,R. Zadro

PP-WE-436 D-DIMER CONCENTRATIONS IN UMBILICAL CORD BLOOD OF NORMAL NEONATESE. Grau* (ES), P. Correcher, J. Tenias, R. Garcia, M. Santos, E. Monteagudo, F. Calvo

PP-WE-437 DO BOLUS DOSES OF UFH CONTRIBUTE TO INCREASED BLEEDING RISKS INCHILDRENF. H. Newall* (AU), V. Ignjatovic, L. Johnston, G. Lane, P. Monagle

PP-WE-438 UNFRACTIONATED HEPARIN HAS AN AGE-DEPENDENT PHARMACOKINETICPROFILE IN CHILDRENF. H. Newall* (AU), V. Ignjatovic, L. Johnston, G. Lane, R. Summerhayes, N. Cranswick, P.Monagle

PP-WE-439 THE ROLE OF THROMBIN GENERATION IN CHILDREN WITH INFLAMMATORY BOWELDISEASEH. Bernhard* (AT), A. Deutschmann, B. Leschnik, M. Novak, A. Hauer, H. Haidl, A.Rosenkranz, W. Muntean

PP-WE-440 PRESUMED PERINATAL ISCHAEMIC STROKEH. Platokouki* (GR), H. Pergantou, A. Komitopoulou, P. Xafaki, S. Aronis



270

Wed

nesd

ay P

oste

rs

PP-WE-441 TREATMENT OF DEEP VEIN THROMBOSIS WITH CONTINUOUS INTRAVENOUSINFUSION OF LMWH IN CHILDREN – AN UPDATEJ. Blatny* (CZ), V. Fiamoli

PP-WE-442 HEREDITARY THROMBOPHILIA AND HYPOFIBRINOLYSIS IN A FAMILY WITHMULTIPLE PROTHROMBOTIC RISK FACTORS - A CASE REPORTJ. Lenicek Krleza* (HR), G. Jakovljevic, D. Coen Herak, A. Bronic, R. Zadro, M. Nakic

PP-WE-443 CEREBRAL SINUS VENOUS THROMBOSIS IN PAEDIATRIC ACUTE LYMPHOBLASTICLEUKAEMIA: A SINGLE CENTRE EXPERIENCEJ. D. Robertson* (AU), C. Ryan, D. Castle, S. Williams, L. Brandao

PP-WE-444 EVALUATION OF VON WILLEBRAND FACTOR AND ADAMTS13 IN CHILDREN WITHALL DURING INDUCTION THERAPYJ. D. A. Carneiro* (BR), E. A. D’Amico, T. R. F. Rocha, C. S. S. S. Silva, V. Odone-Filho, D. A.F. Chamone

PP-WE-445 SYSTEMATIC LITERATURE REVIEW OF ILIAC VEIN COMPRESSION SYNDROME INPEDIATRIC PATIENTSB. H. L. Tam, A. K. Chan, S. Williams, L. Brandao* (CA)

PP-WE-446 ADVERSE OUTCOMES FOLLOWING NON-CEREBRAL ARTERIAL THROMBOSES INNEONATES: A CASE-SERIES REPORTJ. Franco, S. Williams, G. Chaudry, B. Connonly, D. Castle, L. R. Brandao* (CA)

PP-WE-447 THE IMPACT OF PROPHYLACTIC CRYOPRECIPITATE AND FRESH FROZEN PLASMAON THE INCIDENCE OF CNS THROMBOSES IN CHILDREN WITH ACUTELYMPHOBLASTIC LEUKEMIA (ALL) RECEIVING ASPARAGINASEV. Price, L. S. Abbott* (CA), M. Deveeska, D. R. Barnard, C. V. Fernandez, M. Yhap, C.Fitzgerald, D. Dix, J. N. Berman

PP-WE-448 COMPARISON OF HEMOCLOT TO STANDARD COAGULATION ASSAYS FORMONITORING THE DIRECT THROMBIN INHIBITOR (DABIGATRAN) IN PEDIATRICPATIENTS: AN IN VITRO STUDYL. G. Mitchell* (CA), K. Dietrich, L. Stang, W. Etches, S. Qayyum

PP-WE-449 LACK OF ASSOCIATION OF PROTHROMBIN 20112A, FACTOR V LEIDEN, LP(A) ORVIII:C WITH THROMBOSIS IN CHILDREN UNDERGOING SURGERY FOR CORRECTIONOF CONGENITAL HEART DISEASEL. G. Mitchell* (CA), K. Dietrich, I. Rebeyka, D. Ross, S. Qayyum

PP-WE-450 THE EFFECT OF THE TOPICAL ANAESTHETIC MAXILENE ON ENOXAPARINMETABOLISM AS MEASURED BY PEAK ANTI-Xa LEVELSM. E. Bauman* (CA), S. Duncan, L. Ray, L. Bajzar, S. Kuhle, M. P. Massicotte

PP-WE-451 DEVELOPMENT AND VALIDATION OF A COMPLEMENTARY ALTERNATIVE MEDICINEEDUCATIONAL HANDOUT AND PERFORMANCE EVALUATION TOOL FORANTICOAGULATED CHILDRENM. E. Bauman* (CA), G. Mack, A. Bruce, K. L. Black, M. P. Massicotte

PP-WE-452 ADMINISTRATION OF ANTITHROMBIN CONCENTRATE AND EFFECT ONANTICOAGULATIONM. E. Bauman* (CA), M. L. Bauman, K. L. Black, L. Bajzar, M. P. Massicotte

PP-WE-453 MANAGEMENT OF SUBCUTANEOUS PROTEIN C SUBSTITUTION IN CHILDREN WITHSEVERE PROTEIN C DEFICIENCYM. Olivieri* (DE), C. Bidlingmaier, W. Behnisch, I. Engelsberger, A. Kienast, A. Krümpel, U.Nowak-Göttl, M. Sigl-Kraetzig, K. Kurnik



271

PP-WE-454 POOLED ANALYSIS OF TWO RANDOMIZED STUDIES COMPARING FONDAPARINUX2.5MG AND ENOXAPARIN 40MG FOR PREVENTING VENOUS THROMBOEMBOLISM(VTE) IN HIP SURGERY USING NEW STUDY ENDPOINTSM. R. Lassen* (DK)

PP-WE-455 THROMBOTIC RISK IN THALASSEMIC PATIENTSN. Dhouib, N. Ben Romdhane* (TN), F. Mallouli, S. Mahjoub, H. Kallel, R. Ellouze, M. Bejaoui

PP-WE-456 STUDY OF INHERITED AND ACQUIRED PROTHROMBOTIC RISK FACTORS INPEDIATRIC PATIENTS WITH THROMBOSISJ. Ahluwalia, S. Naseem* (IN), R. Das, P. Singhi, B. Thapa, S. Singh, N. Varma

Post-thrombotic Syndrome

PP-WE-457 INCIDENCE OF PTS AFTER INDIVIDUALLY TAILORED DURATION OF ELASTICCOMPRESSION THERAPYA. J. ten Cate-Hoek* (NL), H. ten Cate, J. Tordoir, K. Hamulyák, M. H. Prins

PP-WE-458 VENOUS THROMBOSIS RISK FACTORS ARE ASSOCIATED WITH RISK OF VENOUSINSUFFICIENCYM. Cushman* (US), P. W. Callas, M. H. Criqui, J. O. Denenberg, E. G. Bovill

PP-WE-459 FREQUENCY OF HEREDITARY THROMBOPHILIC RISK FACTORS IN IRANIANPATIENTS WITH DEEP VEIN THROMBOSISM. Karimi* (IR), M. Yavarian, M. Ramzi, M. Zakernia, M. Dehgani, A. Afrasiabi, H. NouraniKhojaste

PP-WE-460 THROMBOPHILIA DOES NOT INCREASE THE RISK OF THE POST-THROMBOTICSYNDROME. A PROSPECTIVE COHORT STUDYL. Spiezia, E. Campello, E. Giolo, D. Tormene, P. Simioni, S. Villalta, P. Prandoni* (IT)

PP-WE-461 MEASUREMENT PROPERTIES OF THE VILLALTA SCALE TO DEFINE AND CLASSIFYTHE SEVERITY OF THE POST-THROMBOTIC SYNDROMES. R. Kahn* (CA)

PP-WE-462 FEASIBILITY OF RECRUITMENT AND RETENTION IN AN UNBLINDED RANDOMIZEDCONTROLLED TRIAL OF EXERCISE TRAINING FOR THE POST-THROMBOTICSYNDROMES. R. Kahn* (CA), A. Houweling, S. Shapiro, A. Muladzanov, I. Shrier, A. M. Hirsch, R. Reid,C. Kearon, M. A. Rodger, M. J. Kovacs, D. Anderson, P. S. Wells

PP-WE-463 INCREASED CALF MUSCLE DEOXYGENATION DURING LIGHT-INTENSITY EXERCISESUGGESTS INCREASED VENOUS REFLUX FLOW IN ADVANCED HUMAN CHRONICVENOUS DISEASET. Yamaki* (JP), M. Nozaki, H. Sakurai, K. Soejima, A. Hamahata, K. Kim

Health Service and Outcomes II

PP-WE-464 USE OF WARFARIN AND DRUGS WITH POTENTIAL INTERACTION IN A HEALTHMAINTENANCE ORGANIZATION (HMO) FROM CÓRDOBA, ARGENTINAA. H. Tabares* (AR), A. I. Casanegra

PP-WE-465 APPROPRIATE VTE PROPHYLAXIS, COMPARED WITH PARTIAL VTE PROPHYLAXIS,LEADS TO LOWER VTE RECURRENCE AND COST IN US MEDICAL PATIENTSA. N. Amin* (US), M. Hussein, D. Battleman, J. Lin, S. Stemkowski, G. J. Merli

PP-WE-466 REAL-WORLD EFFECTIVENESS OF ANTITHROMBOTIC AGENTS FOR INTPATIENTTREATMENT OF VENOUS THROMBOEMBOLISMA. F. Shorr* (US), M. M. Bonafede, B. H. Johnson, R. V. Horblyuk



272

Wed

nesd

ay P

oste

rs

PP-WE-467 CHARACTERISTICS OF HOSPITAL ADMISSIONS FROM A LARGE NATIONWIDESAMPLE OF PULMONARY EMBOLISM PATIENTS IN THE UNITED STATES:PREVALENCE, OUTCOME, AND CHARGESD. M. Courtney* (US), R. K. Khare

PP-WE-468 APPARENT OVERUTILIZATION OF THROMBOPHILIA SCREENING PANELS: ANANALYSIS OF PHYSICIAN ORDERING PATTERNS AT AN URBAN ACADEMIC MEDICALCENTERK. P. Patel, J. Somma, H. Rose, I. I. Sussman, J. H. Rand* (US)

PP-WE-469 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE 150MG IN CANADA FOR THEPREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTALKNEE OR HIP ARTHROPLASTY THAT HAVE MODERATE IMPAIRMENT OF RENALFUNCTIONC. Bradley-Kennedy, S. E. Wolowacz, N. S. Roskell, A. Clemens, J. M. Plumb* (DE)

PP-WE-470 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE IN CANADA FOR THE PRIMARYPREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTALHIP REPLACEMENT SURGERYC. Bradley-Kennedy, S. E. Wolowacz, N. S. Roskell, J. M. Plumb* (DE)

PP-WE-471 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE IN CANADA FOR THE PRIMARYPREVENTION OF VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS UNDERGOINGTOTAL KNEE REPLACEMENT SURGERY (TKR)C. Bradley-Kennedy, S. E. Wolowacz, N. S. Roskell, J. M. Plumb* (DE)

PP-WE-472 ECONOMIC COMPARISON OF RIVAROXABAN WITH ENOXAPARIN IN THE UK ANDSWEDENL. Ryttberg* (SE), I. Bjorholt, A. Diamantopoulos, L. Gilmour, M. Lees

PP-WE-473 COST-EFFECTIVENESS OF RIVAROXABAN FOR PREVENTION OF VENOUSTHROMBOEMBOLISM (VTE) AFTER TOTAL HIP OR KNEE REPLACEMENT (THR, TKR)IN THE USL. Kwong* (US), A. Duran, A. Diamantopoulos, N. Sengupta, M. Lees

PP-WE-474 EVALUATION OF CLOTTING TESTS USING A NEW HIGH THROUGHPUT HEMOSTASISANALYZERM. McInerney* (IE), N. Kelly, E. Kearney, J. Landowska, J. Grace

PP-WE-475 THE QUALITY OF ANTICOAGULANT THERAPY IN THE INITIAL TREATMENT PERIODOF PATIENTS WITH PULMONARY EMBOLISMM. J. Agterof* (NL), E. R. van Bladel, B. Frijling, R. van der Griend, M. H. Prins, R. E. G.Schutgens, D. H. Biesma

PP-WE-476 PERFORMANCE OF A PORTABLE MONITOR OF PROTHROMBIN TIME IN AUNIVERSITY ANTICOAGULATION CLINIC IN BRAZILM. M. Fiusa, M. S. Pereira* (BR), E. V. de Paula, F. A. Orsi, S. Custodio, J. M. Annichino-Bizzacchi

PP-WE-477 THROMBOPROPHYLAXIS WITH DALTEPARIN IN BARIATRIC SURGERY: ARETROSPECTIVE CHART REVIEW OF 2,138 PATIENTSM. Snyder* (US)

PP-WE-478 IMPACT OF VENOUS THROMBOEMOLISM IN US MEDICARE PATIENTS UNDERGOINGTOTAL HIP AND TOTAL KNEE REPLACEMENT SURGERYO. Baser* (US), D. Supina, N. Sengupta, L. Wang, L. M. Kwong

PP-WE-479 RENAL DYSFUNCTION IN OLDER PATIENTS IS ASSOCIATED WITH REDUCEDWARFARIN MAINTENANCE DOSE AND DECREASED ANTIOCOAGULATION STABILITYP. Whittaker* (US), C. L. Garwood, M. E. Kleinow, K. Curtis, J. L. Clemente



273

PP-WE-480 DEVELOPMENTAL DIFFERENCES IN PROCOAGULANTPHOSHOLIPID/MICROPARTICLE CONCENTRATIONR. Summerhayes* (AU), V. Ignjatovic, P. Monagle

Cancer and Thrombosis II

PP-WE-481 AVE5026: A NEW HEMISYNTHETIC ULTRA LOW MOLECULAR WEIGHT HEPARIN WITHENRICHED ANTI-Xa ACTIVITY AND ENHANCED ANTITHROMBOTIC ACTIVITY FORMANAGEMENT OF CANCER ASSOCIATED THROMBOSISA. Gray* (US), D. Hoppensteadt, W. Jeske, J. M. Walenga, J. Fareed

PP-WE-482 UPREGULATION OF PROCALCITONIN IN CANCER PATIENTS WITH VENOUSTHROMBOSISD. Hoppensteadt* (US), O. Iqbal, C. Adiguzel, J. Cunanan, J. Fareed

PP-WE-483 STANDARDS, OPTIONS : RECOMMENDATIONS 2008 THROMBOEMBOLIC EVENTSTREATMENT IN CANCER PATIENTSD. Farge Bancel* (FR), L. Bosquet, P. Mismetti, I. Mahe, F. Cajfinger, H. Desmurs Clavel, G.Meyer, C. Grange, H. Hocini, J. Renaudin, H. Levesque, P. Debourdeau

PP-WE-484 PROTEIN C PATHWAY VALUES, HOMOCYSTEINE AND ANTIPHOSPHOLIPIDANTIBODIES IN PATIENTS WITH NEWLY DIAGNOSED MYELOPROLIFERATIVEDISORDERSE. Papadakis* (GR), S. Efraimidou, K. Loukidhs, K. Kokoviadou, M. Speletas, I. Korantzis, M.Sion

PP-WE-485 ROLE OF TISSUE FACTOR (TF) IN LEUKEMIA-ASSOCIATED COAGULATIONACTIVATION AND VEGF EXPRESSIONB. Spath, A. Amirkhosravi, J. L. Francis, C. Bokemeyer, B. Eifrig, F. Langer* (DE)

PP-WE-486 INCREASED ACQUIRED ACTIVATED PROTEIN C RESISTANCE IN UNSELECTEDPATIENTS WITH HEMATOLOGIC MALIGNANCIESH. F. S. Negaard* (NO), P. O. Iversen, B. Østenstad, M. Mowinckel, P. M. Sandset

PP-WE-487 REGULATORS OF EXTRACELLULAR MATRIX TURNOVER ARE NOT STRONGLYCORRELATED WITH HEMOSTATIC PARAMETERS IN PATIENTS WITH HEMATOLOGICMALIGNANCIESH. F. S. Negaard* (NO), K. Svennevig, S. O. Kolset, P. O. Iversen, B. Østenstad, N. Iversen,P. M. Sandset

PP-WE-488 SUCCESSFUL THERAPY OF AN EXTENSIVE VENA CAVA SUPERIOR THROMBOSISWITH INTRAVENOUS LOW MOLECULAR WEIGHT HEPARIN (DALTEPARIN)H. Schinzel* (DE), S. Schadmand-Fischer, T. Achenbach, D. Peetz, K. Fruth

PP-WE-489 APIXABAN IN PATIENTS WITH METASTATIC CANCER: A RANDOMIZED PHASE IIFEASIBILITY STUDYH. Liebman* (US), M. N. Levine, D. Deitchman, J. Julian, C. P. Escalante, M. C. O’Brien, L.M. Ramirez, L. Weise-Kelly, S. Solymoss

PP-WE-490 ALTERATION OF THE LMWHS INHIBITORY EFFECT ON THROMBIN GENERATION BYDIFFERENT HISTOLOGICAL TYPES OF CANCER CELLS. AN IN VITRO STUDYV. Galea, M. Mbemba, A. Khaterchi, C. Prengel, J. Bernaudin, M. Hatmi, I. Elalamy* (FR), G.T. Gerotziafas

PP-WE-491 PROTEIN C, THROMBOMODULIN AND ENDOTHELIAL PROTEIN C RECEPTOR INACUTE MYELOBLASTIC LEUKAEMIAM. Galar, J. Sokolowski, K. Mazgajska-Barczyk, J. Kloczko* (PL)

PP-WE-492 PROTEIN Z IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMAJ. Oleksiuk, E. Luksza, J. Kloczko* (PL), M. Galar



274

Wed

nesd

ay P

oste

rs

PP-WE-493 PROCOAGULANT PROPERTIES OF CANCER CELLSJ. C. Bordet* (FR), K. Villaume, J. Y. Scoazec, C. Negrier

PP-WE-494 THE ROLE OF SOLUBLE FIBRIN IN LYMPHOCYTE AND LAK CELL ADHERENCE TOAND DIAPEDESIS ACROSS ENDOTHELIAL CELLS: IMPLICATIONS FORIMMUNOTHERAPY AND CANCERJ. P. Biggerstaff* (US), B. L. Weidow

PP-WE-495 HYPERCOAGULATION IN MALIGNANCY LOCALIZED BY THROMBOELASTOGRAPHYTO THE HUMORAL PHASE OF COAGULATIONK. A. Schwartz* (US), S. Nagpal, E. A. Faber, D. Estrada, D. Schwartz, A. Cziffer, C.Puttarajappa

PP-WE-496 VENOUS THROMBOEMBOLISM IN GASTRIC CANCER: INCIDENCE AND CLINICALCHARACTERISTICSK. Lee* (KR), S. Bang, Y. Kim, J. Kim, H. Kim, D. Park, J. Lee

PP-WE-497 MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY, VENOUSTHROMBOEMBOLISM AND POOR SURVIVAL IN PANCREATIC CANCER PATIENTSM. E. T. Tesselaar* (NL), F. Romijn, P. Garcia-Rodrigues, I. van der Linden, R. Bertina, S.Osanto

PP-WE-498 THROMBOTIC COMPLICATIONS IN ADULT PATIENTS WITH LYMPHOMA: A META-ANALYSISV. Caruso, A. di Castelnuovo, V. C. Lein, G. de Gaetano, M. A. Lazzari, S. Storti, L. Iacoviello,M. B. Donati* (IT)

PP-WE-499 JAK2 V617F ALLELE BURDEN AND HEMOSTATIC PROFILE OF ESSENTIALTHROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) PATIENTSM. Marchetti* (IT), E. Castoldi, L. Russo, A. Vignoli, J. Rosing, H. ten Cate, A. Falanga

PP-WE-500 EVALUATING RISK FOR RECURRENT VENOUS THROMBOEMBOLISM (VTE)ACCORDING TO MALIGNANCY CHARACTERISTICS IN PATIENTS WITH CANCER-ASSOCIATED-THROMBOSIS: A SYSTEMATIC REVIEW OF OBSERVATIONAL ANDINTERVENTION STUDIESM. L. Louzada* (CA), H. H. M. Majeed, V. V. D. Dao, P. P. W. Wells

PP-WE-501 ACTIVATION OF COAGULATION BY ANTINEOPLASTIC DRUGS FOR MULTIPLEMYELOMAM. Nishio* (JP), A. Hoshi, J. Chung, A. Matsumoto, T. Koyama

PP-WE-502 EPOPROSTENOL INHIBITS TISSUE FACTOR EXPRESSION IN HUMAN CANCER ANDTUMOR-ASSOCIATED HOST CELLSA. Cutrone, E. Napoleone, G. Colavecchia, W. Zamboni, G. de Gaetano, M. B. Donati, R.Lorenzet* (IT)

PP-WE-503 INCIDENTAL SPLANCHNIC THROMBOSIS IN CANCER PATIENTSS. M. Ramasamy* (UK), G. Bozas, G. Avery, A. Maraveyas

PP-WE-504 VENOUS THROMBOEMBOLISM (VTE) RISK STRATIFICATION IN HOSPITALIZEDCANCER PATIENTSS. B. Hijjawi* (JO), S. G. Jallad, B. A. Ababneh, H. N. Abdel-Razeq

PP-WE-505 PLASMA SOLUBLE FIBRIN LEVEL, A CLINICALLY USEFUL PREDICTOR OFTHROMBOSIS IN CANCER PATIENTSS. Mirshahi* (FR), C. Soria, J. Chidiac, R. Varin, K. Khalfi, E. Pujade-Lauraine, M. Mirshahi,B. J. Woodhams, J. Soria

PP-WE-506 DEVELOPMENT OF A NOVEL HEPARANASE ACTIVITY ASSAY AND IDENTIFICATIONOF POTENT HEPARANASE INHIBITORSS. Alban* (DE), S. Schiemann



275

PP-WE-507 PRODUCTION OF VWF MAY MEDIATE LYMPHOBLAST INDUCED THROMBINACTIVATION IN CHILDREN WITH NEWLY DIAGNOSED ALLU. Athale* (CA), A. Moghrabi, T. Nayiger, D. Yves-Line, L. Thabane, A. Chan

Venous Thrombosis: Diagnosis II

PP-WE-508 IS COCKADE DEEP VEIN THROMBOSIS OF THE LOWER LIMBS ASSOCIATED WITHAN INCREASED FIBRINOLYTIC POTENTIALA. Delluc* (FR), A. Rousseau, P. Quehe, G. Le Gal, K. Lacut, E. Oger, P. vanDreden, D.Mottier, L. Bressollette

PP-WE-509 D-DIMER (DD) LEVELS AT DIAGNOSIS IN RELATION TO THE SITE AND EXTENSION OFLEG DEEP VEIN THROMBOSIS (DVT)C. Legnani* (IT), M. Cini, K. Cavallaroni, G. Rodorigo, S. Cavazza, L. Valdrè, A. Amato, G.Palareti

PP-WE-510 VALIDITY OF ANGULAR SUM AS PLANAR EXTRACTION TECHNIQUE OF LUNGVENTILATION-PERFUSION SPECT DATAP. Cambefort, A. Le Duc-Pennec, P. Guillo, F. Couturaud, S. Querellou, R. Abgral, G. Le Gal*(FR), D. Mottier, C. Leroyer, P. Salaun

PP-WE-511 ILEO-FEMORAL THROMBOSIS IN A PATIENT WITH ELEVATED HOMOCYSTEINE DUETO THREE POLYMORPHISMS IN THE MTHFR GENEH. A. Guglielmone* (AR), S. Minoldo, G. Jarchum

PP-WE-512 SAFETY OF RULING OUT ACUTE PULMONARY EMBOLISM BY NEGATIVE CTPULMONARY ANGIOGRAPHY IN PATIENTS WITH A STRICT INDICATION FOR CT:SYSTEMATIC REVIEW AND META-ANALYSISI. C. M. Mos* (NL), F. A. Klok, L. J. M. Kroft, A. de Roos, O. M. Dekkers, M. V. Huisman

PP-WE-513 CONTRAST INDUCED NEPHROPATHY FOLLOWING CT-PULMONARY ANGIOGRAPHYFOR CLINICALLY SUSPECTED PULMONARY EMBOLISMJ. Kooiman* (NL), F. A. Klok, I. C. M. Mos, J. T. Tamsma, Y. W. J. Sijpkens, M. V. Huisman

PP-WE-514 CLINICAL EVALUATION OF NEW QUANTITATIVE D-DIMER ASSAYS FOR EXCLUSIONOF DEEP VEIN THROMBOSISJ. L. Elf* (SE), K. Strandberg, P. J. Svensson

PP-WE-515 DIAGNOSTIC PERFORMANCE OF AQT90 FLEX D-DIMER IN PATIENTS SUSPECTEDFOR DEEP VENOUS THROMBOSIS - COMPARISON WITH FOUR WELL-ESTABLISHEDD-DIMER TESTSJ. J. Sidelmann* (DK), J. Gram, J. Jespersen

PP-WE-516 DEEP VENOUS THROMBOEMBOLISM IN A PATIENT OF FACTOR V DEFICIENCYK. Nishiya* (JP), K. Nogami, Y. Kikukawa, K. Shinozawa, H. Yada, K. Fukutake, M. Shima

PP-WE-517 PROTEIN C AND S LEVELS CAN BE ACCURATELY MEASURED DURING AN ACUTEVENOUS THROMBOEMBOLISM (VTE)L. Minuk, A. Lazo-Langner* (CA), M. Kovacs

PP-WE-518 FREQUENCY OF FACTOR V LEIDEN AND PROTHROMBIM 20210A AS THROMBOTICAND GENETIC RISK FACTORS FOR PREECLAMPSIA IN THE SOUTH IRANIANPROVINCEM. Yavarian* (IR), S. Karimi, L. Ahmadian, M. Karimi

PP-WE-519 EVALUATION OF PRECISION, ACCURACY AND SUITABILITY OF EDTA PLASMA FOR ANEW ROCHE D-DIMER ASSAYA. Busse Grawitz, M. Mueller, G. Honauer, H. Maier, M. Wilmer* (CH), A. Hubbuch



276

Wed

nesd

ay P

oste

rs

PP-WE-520 FIBRIN MONOMER: DOES IT HELP IMPROVE THE SENSITIVITY AND SPECIFICITY OFTHE D-DIMER ASSAY FOR IDENTIFICATION OF VENOUS THROMBOEMBOLISMM. Johnston* (CA), E. Ali, N. McEwen, S. Bates

PP-WE-521 HIGH PERCENTAGE OF NON-DIAGNOSTIC COMPRESSION ULTRASONOGRAPHYRESULTS IN THE DIAGNOSIS OF IPSILATERAL RECURRENT DEEP VEINTHROMBOSISM. Tan* (NL), S. I. Velthuis, C. J. van Rooden, R. E. Westerbeek, M. V. Huisman

PP-WE-522 THE UTILITY AND FEASIBILITY OF SCREENING FOR DEEP VENOUS THROMBOSIS INPRIMARY CARE PRACTICEM. D. Creagh* (UK), P. Carson, S. Herbert, M. Kazi, A. McSorley

PP-WE-523 FACTORS WHICH INFLUENCE PRIMARY CARE PHYSICIANS WHEN REFERRINGPATIENTS TO A HOSPITAL OUTPATIENT DVT SCREENING SERVICEM. D. Creagh* (UK), H. Bond, S. Gupta, A. McSorley

PP-WE-524 CEREBRAL VENOUS THROMBOSIS RISK FACTORS AND INCIDENCE OF JAK2 V617FMUTATIONM. Kostál* (CZ), P. Dulísek, J. Maly’, D. Krajísková

PP-WE-525 PERFORMANCE OF A NEW TURBIDIMETRIC D-DIMER ASSAY ADAPTED TOAUTOMATED COAGULOMETERSB. Arza, T. Sánchez, L. Del Toro, M. Sales* (ES), J. Arnout

PP-WE-526 PROLONGATION OF ENOXAPARIN THERAPY TO ONE MONTH ACCELERATESRECANALIZATION OF DEEP VEIN THROMBOSISN. M. Vorobyeva* (RU), E. P. Panchenko, A. B. Dobrovolsky, A. I. Kirienko, T. V. Balakhonova

PP-WE-527 THE VALUE OF 64-DETECTOR ROW COMPUTED TOMOGRAPHY FOR THE DIAGNOSISOF PULMONARY EMBOLISMR. Pesavento, G. de Conti, I. Minotto, F. Maurizi, M. Mongiat, A. Pagnan, P. Prandoni* (IT)

PP-WE-528 MALE PREDOMINANCE IN CHILDHOOD STROKE AND VENOUS THROMBOEMBOLISMREVISITED: U. Nowak-Gottl* (DE), S. Normann, M. Fobker, C. Langer, R. Strater, G.Deveber

Hemophilia II

PP-WE-529 BONE MINERAL DENSITY IN HEMOPHILIA PATIENTS: A META-ANALYSISM. Marcucci, G. Fabbriciani, M. Brozzetti, A. Iorio* (IT)

PP-WE-530 FUNCTIONAL LIMITATIONS IN HEMOPHILIA A: COMPARISON OF A SELF-ASSESSMENT TOOL AND JOINT ROMA. Zakarija* (US), J. Brewer, S. Harris, D. Green

PP-WE-531 THROMBIN GENERATION AND FIBRINOLYSIS PARAMETERS IN BOYS WITH SEVEREHAEMOPHILIA AA. Greenway* (AU), V. Ignjatovic, R. Summerhayes, C. Barnes, J. Furmedge, J. Ekert, P.Monagle

PP-WE-532 DETECTION OF LARGE REARRANGEMENTS BY MLPA IN SEVERE HEMOPHILIA APATIENTSN. Lannoy, I. Abinet, C. Lambert* (BE), C. Vermylen, K. Dahan, C. Hermans

PP-WE-533 UNUSUAL INTRON 1 INVERSION WITH CONCOMITANT LARGE DUPLICATION WITHINTHE F8 GENE IN A SEVERE HEMOPHILIA A PATIENTM. Badoz, D. Pellechia, M. Fretigny, V. Roussel-Robert, N. Stieltjes, C. Negrier, C.Vinciguerra* (FR)



277

PP-WE-534 EVALUATING THERAPY IN HEMOPHILIA: DEVELOPMENT OF AN MRI PROTOCOLI. E. M. den Uijl* (NL), A. M. A. de Schepper, D. E. Grobbee, K. Fischer

PP-WE-535 PROSPECTIVE EVALUATION OF SAFETY AND EFFICACY OF RADIOSYNOVIORTHESISWITH HYDROXYAPATITE-YTTRIUM IN CHRONIC SYNOVITIS IN HEMOPHILIA:PRELIMINARY RESULTSJ. B. J. Silva* (BR), J. M. Annichino-Bizzacchi, R. G. Pagnano, H. Hong, M. A. P. Matta, A. L.A. Sambo, R. G. Roveri, E. Bortoletto, J. Mengatti, C. D. Ramos, A. O. Santos, M. C. Ozelo,E. V. de Paula

PP-WE-536 ANALYSIS OF INTRON 1 AND INTRON 22 INVERSION IN FACTOR VIII GENE INPATIENTS WITH HAEMOPHILIA AJ. Wu* (CN), T. Li, J. Dai, Q. Ding, X. Wang, K. Ding, C. Zheng

PP-WE-537 THE RELATIVE BURDEN OF HEMOPHILIA ON HEALTH RELATED QUALITY OF LIFEJ. D. Epstein* (US), J. M. Li-McLeod, A. S. Yarlas, G. C. Hammond

PP-WE-538 THE IMPACT OF TARGET JOINT DEVELOPMENT ON HEALTH RELATED QUALITY OFLIFE FOR ADULT HEMOPHILIA A PATIENTS: RESULTS FROM THE PASS STUDYJ. D. Epstein* (US), J. M. Li-McLeod, A. S. Yarlas

PP-WE-539 INCIDENCE OF PORT INFECTIONS IN A COHORT OF BOYS WITH HAEMOPHILIA –IMPACT OF RIGOROUS ANTISEPTIC TECHNIQUE TRAINING IN THE HOMEJ. Mitchell* (UK), D. Bevan, S. Rangarajan, B. Sørensen

PP-WE-540 HIGHER CD4+CD25HIGH TREG CELLS IN HAEMOPHILIA PATIENTS WITH FVIIIINHIBITORK. Ding* (CN), J. Wu, T. Li, Y. Sheng

PP-WE-541 LONG-TERM BLEEDING HISTORY AS A TOOL FOR HEMOPHILIA MANAGEMENTK. L. Strike, A. K. C. Chan, T. M. Almonte, K. P. Decker* (CA), R. E. Goldsmith Rn, I. Walker,M. J. Wright

PP-WE-542 RESOURCE CONSUMPTION IN HAEMOPHILIA CARE - THE ESCHQOL STUDY(EUROPEAN STUDY OF CLINICAL, HEALTH ECONOMIC AND QUALITY OF LIFEOUTCOMES IN HAEMOPHILIA TREATMENTK. Berger* (DE), M. Bullinger, P. Giangrande, A. Giebl, A. Gringeri, R. Ljung, L. Nemes, S.von Mackensen, L. Mantovani, M. Serban, M. Shlaen, W. Schramm

PP-WE-543 SKEW RATIOS OF FEMALE HEMOPHILIA PATIENTS IN KOREAK. Y. Yoo* (KR), S. Kwon, M. Lee

PP-WE-544 GENETIC MUTATIONS IN MILD HAEMOPHILIA A FAMILIES IN SOUTH AUSTRALIAL. H. Tay* (AU), S. Rodgers, S. McRae, Z. Rudzki, E. Duncan, J. Lloyd

PP-WE-545 SEVERE HEMOPHILIA B DUE TO AN APPROXIMATELY 100 KB FACTOR IX GENEDELETION INVOLVING THREE DISTAL EXONSL. Kokabee* (IR), N. Karimi, S. Zeinali, M. Karimipoor

PP-WE-546 HYPERMOBILITY AND ARTHROPATHY IN HEMOPHILIA: A RETROSPECTIVEEVALUATION OF JOINT HYPERMOBILITY AS A RISK FACTOR FOR ARTHROPATHY INSEVERE AND MODERATE HEMOPHILIAL. A. Skeith* (CA), S. C. Jackson, J. Brooks, M. Poon

PP-WE-547 HAEMOPHILIA A PATIENTS WITH DISCORDANT FVIII LEVELS BY 1-STAGE &CHROMOGENIC ASSAYS SHOW REDUCED THROMBIN GENERATION & INCREASEDBLEEDINGL. T. Khoo* (AU), G. W. Kershaw, J. Curnow, M. Morel-Kopp, S. Matthews, C. Waite, S.Dunkley



278

Wed

nesd

ay P

oste

rs

PP-WE-548 THE INVERSE ASSOCIATION BETWEEN HEMOPHILIA AND CARDIOVASCULARMORTALITY IS NOT EXPLAINED BY DIFFERENCES IN CARDIOVASCULAR RISKPROFILEM. A. Baarslag* (NL), S. Rafi, M. J. H. A. Kruip, M. Peters, P. W. Kamphuisen

PP-WE-549 LOCOMOTOR STATUS – CLINICAL EXPRESSION OF THE QUALITY OF CARE INHEMOPHILIA - MULTICENTRIC STUDYM. Serban* (RO), L. Pop, L. Ritli, P. Stancu, H. Ionita, D. Mihailov, D. Baghiu, A. Cucuianu, V.Uscatescu, E. Ursu, A. Lacatusu, L. Barna, D. Poenaru, W. Schramm

PP-WE-550 INTEGRAL ASSESSMENT OF FEMALE HEMOPHILIA CARRIERSM. E. Mingot* (ES), A. Palomo, A. Heiniger

PP-WE-551 HEMOPHILIAC PATIENT SERUM BANK: EVALUATION OF THE INFLUENCE OFEMERGING PATHOGENS AND INFECTIOUS RISKS ASSOCIATED TO REPLACEMENTTHERAPY AFTER TWO YEARS FOLLOW-UPM. E. Mingot* (ES), M. García, J. A. Fernández, A. Palomo, A. Heiniger, J. Camacho

PP-WE-552 HAEMOPHILIA ACTIVITIES LIST-USEFUL INSTRUMENT IN SELF-ASSESSMENT OFMUSCULOSKELETAL FUNCTION IN ROMANIAN HEMOPHILIACSM. Mihailov* (RO), L. Pop, R. Ladislau, G. Miculschi, C. Jinca, D. Lighezan, A. Lacatusu, E.Ursu, W. Schramm, M. Serban

PP-WE-553 RISK FACTORS OF BLEEDING SEVERITY IN YOUNG BOYS WITH SEVEREHEMOPHILIA A ON TAILORED PROPHYLAXIS: LONG-TERM (10-YEAR) RESULTSFROM THE CANADIAN HEMOPHILIA PRIMARY PROPHYLAXIS STUDYM. X. Hang* (CA), V. S. Blanchette, E. Pullenayegum, P. Babyn, R. Card, A. Chan, C.Demers, K. Gill, S. Israels, R. Klaassen, N. Laferriere, D. Lillicrap, K. Luke, M. McLimont, M.Pai, M. Poon, V. Price, G. E. Rivard, S. Robinson, M. Steele, J. K. M. Wu, B. Feldman

PP-WE-554 HEMOPHILIA A AND CARDIOVASCULAR EVENTS: A CASE SERIESM. Zwiers* (NL), W. M. Lijfering, K. Meijer, J. D. Lefrandt, A. J. Smit, J. van der Meer

PP-WE-555 DIFFERENTIATION OF PATIENTS WITH SEVERE HEMOPHILIA A BY FACTOR VIIIACTIVITY: A MASS SPECTROMETRY APPROACHM. van Geffen* (NL), B. Verbruggen, M. E. Mancuso, B. Laros-Vangorkom, E. Santagostino,W. L. van Heerde

PP-WE-556 THE DIFFERENTIAL PREDICTIVE VALUE OF THROMBIN GENERATION INHAEMOPHILIA A AND B DEPENDANT ON TISSUE FACTORM. W. Besser* (UK), R. Luddington, T. Baglin

PP-WE-557 A THROMBIN GENERATION TEST IN FVIII-DEFICIENT MOUSE PLASMAM. Dockal* (AT), R. Hartmann, M. Fries, E. Panholzer, A. Schiviz, E. M. Muchitsch, F.Scheiflinger

PP-WE-558 CARRIER DETECTION USING THREE POLYMORPHIC DNA MARKERS IN HEMOPHILIAA FAMILIES FROM MAZANDARAN, NORTHERN PROVINCE OF IRANM. Hashemi Soteh* (IR), Z. Hosseini Khah, M. Bagherian, R. Mohseni, E. Siami, F. ValiZadeh, R. Zaki Zadeh

PP-WE-559 AFIBRINOGENAEMIA; AN IRANIAN EXPERIENCEM. R. Baghaipour* (IR)

PP-WE-560 HAEMOPHILIA A IN FEMALE PATIENTSM. Martin-Salces* (ES), M. Alvarez, I. Fernandez, N. Butta, I. Muñoz, M. Garcia, I. Rivas, V.Jimenez, F. Hernandez

PP-WE-561 EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN RUSSIA: PATIENT-REPORTEDDATAP. A. Vorobyev, O. V. Borisenko, U. A. Zhulev, K. G. Kopylov, E. A. Telnova, A. A. Tonoyan, N.I. Zozulya* (RU)



279

PP-WE-562 CASE OF AN INFANT WITH A SEVERE HEMOPHILIA A DIAGNOSED DUE TO THEDEVELOPMENT OF SPINAL EPIDURAL HEMATOMAS. Muto* (JP), C. Nagae, T. Shoji, A. Yamashita, J. Hiramoto, S. Yamazaki, M. Taki

PP-WE-563 LINGUISTIC VALIDATION OF THE HAEMO-QOL AND HAEM-A-QOL IN RUSSIAN ANDBULGARIAN FOR USE IN A PHASE III CLINICAL TRIALI. Gil-Campos, P. O. Bonnet, S. von Mackensen* (DE)

PP-WE-564 TITRE : EVALUATION OF THE OCCURRENCE INCIDENCE OF ANTI-F VIII INHIBITORSIN HAEMOPHILIA : ALGERIAN STUDYT. K. Taouli* (DZ), B. K. Bendedouche, A. S. Ayad, M. N. Mesli

PP-WE-565 HEMOPHILIA B PATIENT, TRAUMA OR SPONTANEOUS BLEEDINGV. V. Jovanoska* (MK), I. I. J. Jovanoski

PP-WE-566 THE PROMINENT MUTATION OF INVERSION INTRON 22 AMONG SPORADICHEMOPHILIA: IS IT WORTH FOR ANTENATAL SCREENINGW. Sasanakul* (TH), A. Chuansumrit

Hemophilia Therapy II

PP-WE-567 PROPHYLAXIS VS ON-DEMAND THERAPY THROUGH ECONOMIC REPORT(P.O.T.T.E.R.) STUDYA. Tagliaferri* (IT), G. Rivolta, A. Coppola, G. Feola, E. Boeri, C. Santoro, G. Mancuso, R.Musso, M. Mancuso, E. Zanon, L. Valdrè, G. Piseddu

PP-WE-568 EFFECTIVITY OF INTRAARTICULAR HYALURONIC ACID IN HEMOPHILICARTROPATHYB. Zulfikar* (TR), O. Taser, O. Kilicoglu, F. Dikici, A. Atalar, F. Bezgal

PP-WE-569 A NON-HUMAN PRIMATE MODEL OF HEMOPHILIA AE. K. Waters* (US), J. L. Parker, J. R. Preiss, J. C. Kurz, K. McGinness, J. Chung, R. M.Hutabarat, R. G. Schaub

PP-WE-570 A PROSPECTIVE, RANDOMIZED TRIAL OF DAILY PROPHYLAXIS IN HEMOPHILIAE. Berntorp* (SE), K. Lindvall, J. Astermark, L. Kampf, K. Steen Carlsson, R. Ljung, S.Björkman

PP-WE-571 THE COMPREHENSIVE, MULTIDISCIPLINARY TEAM FOR THE TREATMENT OFHAEMOPHILIA: ISTANBUL EXPERIENCEG. Aydogan* (TR), M. Altun, Z. Salcioglu, F. Pekun, E. Turkkan, H. Sen, T. Ozulker, C. Timur,Y. Yildirmak, N. Sarper, T. Sahin, A. Akcay, D. Yalcin Atay, F. Akici, D. Tugcu

PP-WE-572 GENERATION OF RECOMBINANT FVIII PURIFICATION ANTIBODY FORMANUFACTURING OF N8J. J. Hansen* (DK), G. Bolt, K. Kjærgaard, C. Kristensen, T. D. Steenstrup

PP-WE-573 A CASE OF PERICARDIOCENTESIS FOR HEMOPHILIA A PATIENT WITHTUBERCULOUS PERICARDIAL EFFUSIONJ. Park* (KR), Y. Park, S. Lee

PP-WE-574 POST-AUTHORIZATION SAFETY SURVEILLANCE (PASS) FOR RAHF-PFM: FINAL EUAND US SAFETY AND EFFICACY RESULTSJ. Oldenburg* (DE), H. Luu, G. Spotts, H. Gajek, A. Kriukov, D. Stephens, R. Berg, K. Barker,B. Ewenstein

PP-WE-575 FACTOR IX PRODUCTION STEPS EFFECTIVELY REMOVE A TRANSMISSIBLESPONGIFORM ENCEPHALOPATHY (TSE) MODEL AGENTJ. M. Diez, S. Caballero, F. Belda, M. Otegui, R. Gajardo, J. I. Jorquera* (ES)



280

Wed

nesd

ay P

oste

rs

PP-WE-576 EFFECTIVE REMOVAL OF A TSE-MODEL AGENT DURING FVIII/VWF PURIFICATIONS. Caballero, F. Belda, M. Otegui, J. M. Diez, R. Gajardo, J. I. Jorquera* (ES)

PP-WE-577 LONG-TERM EVALUATION OF CHROMOSOMAL BREAKAGES AFTER RADIOISOTOPESYNOVECTOMY FOR TREATMENT OF TARGET JOINTS IN PATIENTS WITHHEMOPHILIAK. Kavakli* (TR), O. Cogulu, S. Aydogdu, H. Ozkilic, B. Durmaz, C. Balkan, D. Yilmaz, Y. Ay

PP-WE-578 ANTIVIRAL TREATMENT OF HCV INFECTED YOUNG HAEMOPHILIACS – AN UPDATEOF 16 YEARS EXPERIENCEK. Koehler-Vajta* (DE), G. Froesner, R. Zachoval

PP-WE-579 INHIBITOR FORMATION WITH SUCROSE-FORMULATED RECOMBINANT FACTOR VIIIIN PATIENTS WITH HEMOPHILIA A: RESULTS FROM POSTMARKETINGSURVEILLANCE STUDIESK. Fukutake* (JP), R. Musso, J. Young, C. Norenberg

PP-WE-580 HUMAN HEPATOCYTE PROPAGATION IN MICE: POTENTIAL FOR CELL SOURCE FORCOAGULATION FACTOR DEFICIENCIESK. Ohashi* (JP), K. Tatsumi, C. Tateno, K. Yoshizato, M. Shima, T. Okano

PP-WE-581 THE EFFECT OF N8 AND RFVIII ON NEEDLE INDUCED HEMARTHROSIS INHEMOPHILIA A MICEK. Øvlisen* (DK), M. Kjalke, M. Tranholm

PP-WE-582 ACTIVATION AND INACTIVATION RATES OF A NEW RECOMBINANT FVIII (N8) ARESIMILAR TO FVIII EXPRESSED AS FULL LENGTH MOLECULEK. W. Balling* (DK), M. Kjalke

PP-WE-583 ASSESSING THE BENEFITS APCC PROPHYLAXIS IN HEMOPHILIA PATIENTS WITHINHIBITORSL. A. Valentino* (US)

PP-WE-584 FACTOR VIII PROPHYLAXIS FOR ADULT PATIENTS WITH SEVERE HEMOPHILIA A:RESULTS OF A US SURVEY OF ATTITUDES AND PRACTICESC. E. Walsh, L. A. Valentino* (US)

PP-WE-585 ANALYSIS AND CHARACTERIZATION OF GLYCOPEGYLATED RECOMBINANT HUMANFVIIaL. Palm* (DK), T. Jepsen, S. F. Garmer, J. Malmstrom, A. D. Nielsen, W. Chen, S. Valentin

PP-WE-586 ANALYSES OF 40K POLYETHYLENE GLYCOL USED FOR GLYCOPEGYLATEDRECOMBINANT HUMAN FVIIaL. Palm* (DK), T. S. Hoeg, J. Ström, J. Malmstrom, W. Chen, A. D. Nielsen

PP-WE-587 RELATIONSHIP BETWEEN GENETIC MUTATION AND DDAVP RESPONSIVENESS INMILD/MODERATE HEMOPHILIA AM. E. Seary, D. Feldman, A. M. Stain, M. D. Carcao* (CA)

PP-WE-588 PROPHYLATIC TREATMENT OF HAEMOPHILIA A PATIENTS WITH INHIBITORSM. B. Antunes* (PT), A. Santos, M. Diniz

PP-WE-589 FUNCTIONAL CHARACTERIZATION OF A NEW RECOMBINANT FVIII (N8)M. Kjalke* (DK), M. S. Christiansen, K. W. Balling, L. F. Larsen, E. Persson, I. Hilden, B. B.Sørensen, D. Viuff, S. Segel, M. Ezban, S. Lethagen, T. D. Steenstrup

PP-WE-590 EFFECT OF 40K PEG-RFIX IN BLOOD FROM HEMOPHILIA B PATIENTS USINGTHROMBOELASTOGRAPHY (TEG®M. L. S. Christiansen* (DK), B. B. Sorensen, D. Viuff, H. Ostergaard, S. Segel, S. Lethagen



281

PP-WE-591 EFFECT OF A NEW RFVIII COMPOUND N8 USING BLOOD FROM HEMOPHILIA A (HA)PATIENTS EVALUATED BY THROMBOELASTOGRAPHY (TEG®M. L. S. Christiansen* (DK), B. B. Sorensen, D. Viuff, M. Kjalke, M. Ezban, S. Segel, S.Lethagen

PP-WE-592 SUCCESSFUL NEUROSURGERY OF A MALIGNANT GLIONEURONAL TUMOR (MGT)UNDER RECOMBINANT ACTIVATED FACTOR VII (RFVIIa) COVER IN A SEVEREHEMOPHILIA A PATIENT WITH A HIGH TITER INHIBITOR (SHHIA. Aouba, E. Dezamis, C. Rothschild, M. Torchet* (FR)

PP-WE-593 THE FIRST 2 YEARS OF A MOBILE ELECTRONIC PATIENT DIARY IN HEMOPHILIA –INSIGHTS FROM ADOPTION RATES AND USAGE DATAW. Mondorf, R. Klamroth, B. Siegmund, M. Westfeld* (DE), M. Kosch, J. Tuischer, H.Pollmann

PP-WE-594 A PHARMACOVIGILANCE EVALUATION OF B-DOMAIN DELETED RECOMBINANTFACTOR VIII – INTERIM RESULTS AFTER NINE YEARSH. Pollmann, M. Westfeld* (DE), B. Eifrig, R. Klamroth, W. Kreuz, H. Lenk, J. Oldenburg, I.Pabinger, W. Schramm, T. Schwarz, N. Zavazava, R. Zimmermann

PP-WE-595 THE STUDY ON THE POTENCY TEST FOR HUMAN BLOOD COAGULATION FACTORVIIIS. Y. Kang* (KR), N. Lee, S. N. Kim, H. J. Oh, D. J. Shin

Inhibitors: Pathogenesis, Prevention and Treatment II

PP-WE-596 FACTOR XI INHIBITOR ASSOCIATED WITH AUTOIMMUNE HEPATITIS ANDULCERATIVE COLITIS-CASE REPORTA. Bulikova* (CZ), L. Husova, J. Zavrelova, M. Penka

PP-WE-597 MODELING COSTS AND OUTCOMES OF GUIDELINES ADHERENCE IN THETREATMENT OF PROBLEM BLEEDS IN PATIENTS WITH SEVERE HAEMOPHILIA AAND HIGH-TITRE INHIBITORSA. Gringeri* (IT), E. Gomperts, C. Leissinger, R. D’Oiron, J. Teitel, G. Young, B. Ewenstein, P.O. Bonnet, E. Berntorp

PP-WE-598 IMMUNE TOLERANCE INDUCTION WITH FVIII/VWF CONCENTRATE IN AN ELDERLYSEVERE HAEMOPHILIA A PATIENT WITH HIGH-RESPONDING INHIBITORA. Tagliaferri* (IT), G. Rivolta, C. di Perna, F. Riccardi, L. Ippolito, M. Lombardi, M. Franchini

PP-WE-599 ITALIAN EXPERIENCE OF IMMUNE TOLERANCE INDUCTION (ITI) WITH A FVIIICONCENTRATE AT HIGH VWF CONTENT IN HAEMOPHILIACS WITH PREVIOUSUNSUCCESSFUL ITI AND/OR NEGATIVE PREDICTORS OF ITI RESPONSEA. Coppola* (IT), C. Biasoli, G. Mancuso, A. Tagliaferri, M. Schiavulli, M. Morfini, E.Santagostino, F. A. Scaraggi

PP-WE-600 A SINGLE CAUSATIVE MUTATION IN THE PROMOTER REGION OF F8 GENEASSOCIATED WITH FVIII INHIBITOR DEVELOPMENTC. Costa* (FR), Y. Repesse, P. Gautier, M. Goossens, A. Borel-Derlon

PP-WE-601 THE USEFULNESS OF REGISTRY DATA FOR UNDERSTANDING TREATMENTPRACTICES AND CLINICAL OUTCOMES IN HEMOPHILIA: THE EXPERIENCE OF THEHEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY (2004-2008C. M. Kessler* (US), J. C. Gill, D. L. Cooper

PP-WE-602 DOSING AND EFFECTIVENESS OF RECOMBINANT FVIIa (RFVIIa) IN CONGENITALHEMOPHILIA WITH INHIBITORS BY BLEED TYPE AND LOCATION: THE EXPERIENCEOF THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY(2004-2008G. A. Young* (US), D. L. Cooper, R. Gut



282

Wed

nesd

ay P

oste

rs

PP-WE-603 THE ONE REGISTRY: DESIGN AND BASELINE DATAH. Chambost* (FR) for the Steering Committee of the ONE Registry

PP-WE-604 ACQUIRED HAEMOPHILIA: DESCRIPTIVE DATA OF THE EUROPEAN ACQUIREDHAEMOPHILIA REGISTRY (EACH2)H. Levesque* (FR), P. Collins, F. Baudo, A. Huth-Kuhne, P. Knoebl, P. Marco, L. Nemes, L.Tengborn

PP-WE-605 EVALUATION OF FIBRIN CLOT FORMED FROM FVIII-DEPLETED PLASMA WITHFVIIa/FX MIXTUREH. Miyazaki* (JP), K. Tomokiyo, S. Nishimura, Y. Nakatomi, T. Nakashima, E. Takami, M.Tsuji, E. Kusumoto, A. Takaki, T. Hamamoto, T. Nakagaki

PP-WE-606 THE JAPANESE GUIDELINE FOR THE HEMOSTATIC THERAPY OF PATIENTS WITHCONGENITAL HEMOPHILIA AND INHIBITORSI. Tanaka* (JP), K. Amano, M. Taki, T. Oka, M. Sakai, A. Shirahata, N. Takata, J. Takamatsu,H. Takedani, H. Hanabusa, S. Higasa, K. Fukutake, T. Fujii, T. Matsushita, J. Mimaya, A.Yoshioka, M. Shima

PP-WE-607 INGUINAL HERNIA OPERATION AND CIRCUMCISION IN A HEMOPHILIA A PATIENTWITH INHIBITORI. Sasmaz* (TR), B. Antmen, G. Leblebisatan, Y. Kilinc, A. Aridogan

PP-WE-608 SAFETY, PHARMACOKINETICS AND EFFICACY OF FACTOR VIIa FORMULATED WITHPEGYLATED LIPOSOMES IN HEMOPHILIA A PATIENTS WITH INHIBITORS TO FACTORVIIIM. Baru, J. Spira* (IL), O. Plyushch, N. Zozulya, R. Yatuv, I. Dayan, M. Robinson

PP-WE-609 QUALITY OF LIFE IN PATIENTS WITH SEVERE HAEMOPHILIA A AND INHIBITORS ONPDFVIIID. Furby, A. Phillott, A. Roy, S. Rangarajan, J. Alamelu* (UK)

PP-WE-610 FUNCTIONAL REACTIVITY OF A HUMAN BCR-TRANSGENE MOUSE SPECIFIC TOFACTOR VIIIW. K. Hoots, S. Y. Grailly, V. A. Carlier, M. G. Jacquemin, J. G. Gilles* (BE), J. R. Saint-Remy

PP-WE-611 APCC IN COMBINATION WITH FVIII POTENTIATE IN VITRO THROMBIN PRODUCTIONIN INHIBITOR PLASMAJ. Klintman* (SE), J. Astermark, M. Ekman, E. Berntorp

PP-WE-612 APCC VERSUS RFVIIa IN TREATMENT OF HEMOPHILIA PATIENTS WITH INHIBITORS:A STRUCTURED REVIEW OF THE PHARMACOECONOMIC LITERATUREJ. W. Hay* (US), Z. Zhou

PP-WE-613 INHIBITOR SURVEILLANCE AND MUTATION ANALYSIS IN HEMOPHILIA B PATIENTSJ. M. Soucie* (US), M. Creary, T. C. Abshire, D. B. Brettler, P. L. Bockenstedt, J. di Paola, G.Massey, A. T. Neff, A. D. Shapiro, M. Tarantino, B. M. Wicklund, M. J. Manco-Johnson, A. L.Dunn, C. Knoll, S. J. Platt, J. Driggers, D. Ellingsen, J. Benson, C. Hooper, C. H. Miller

PP-WE-614 PHYSICOCHEMICAL CHARACTERIZATION OF FACTOR VIII NEUTRALIZATION BY ANINHIBITORY ANTIBODYJ. D. Dimitrov* (FR), L. T. Roumenina, B. P. Atanasov, M. Jacquemin, J. Saint-Remy, S. V.Kaveri, S. Lacroix-Desmazes

PP-WE-615 A SINGLE CENTRE EXPERIENCE OF PROPHYLACTIC RFVIIa IN PAEDIATRICPATIENTS WITH SEVERE HAEMOPHILIA AND INHIBITORSK. A. Breen* (IE), M. Kavanagh, I. Kelly, B. Nolan, I. Regan, C. McMahon

PP-WE-616 STABILIZATION OF FIBRIN CLOTS BY FEIBA AND TXA IN FVIII INHIBITOR PLASMAL. Dai* (UK), S. Rangarajan, D. Bevan, B. Sorensen, M. Mitchell



283

PP-WE-617 UNDERSTANDING REAL-WORLD EXPERIENCE WITH INHIBITOR BY-PASS THERAPY:FEIBA NF POST-AUTHORIZATION SAFETY SURVEILLANCE (PASS)M. Pirck* (AT), G. Spotts, H. Gajek, B. Ewenstein

PP-WE-618 A FLOW CYTOMETRY EVALUATION OF ANTI-FVIII ANTIBODIES: CORRELATION WITHELISA AND BETHESDA ASSAYSM. B. Irigoyen* (AR), L. Primiani, M. Felippo, M. Candela, R. Perez Bianco, M. E de Bracco,N. Galassi

PP-WE-619 NEW ASSAY FOR QUANTIFYING FUNCTIONAL DOMAIN-SPECIFIC INHIBITORSAGAINST HUMAN VWF IN PLASMAK. Varadi, G. Schrenk, S. Langlet, N. Martineau, E. Arnaud, H. Rottensteiner, P. L. Turecek*(AT), H. J. Ehrlich, H. P. Schwarz

PP-WE-620 IMPROVED VENOUS ACCESS AND BLEEDING MANAGEMENT IN AN EIGHT-YEAR OLDBOY WITH LONG-LASTING INHIBITOR AGAINST FACTOR VIIIS. Gottstein, A. Hinrichs, S. Seibt, R. Klamroth* (DE)

PP-WE-621 INHIBITOR DEVELOPMENT IN TWO PATIENTS WITH MILD HAEMOPHILIA AS. E. Reitter* (AT), K. Lechner, R. Sunder-Plassmann, I. Pabinger-Fasching, C. Mannhalter

PP-WE-622 THE USE OF FVIII PREPARATIONS IN THE BETHESDA INHIBITOR ASSAY – A PITFALLT. Siegemund* (DE), U. Scholz, A. Siegemund

von Willebrand Disease II

PP-WE-623 SUCCESSFUL MANAGEMENT OF PREGNANCIES IN THREE SISTERS WITH VARYINGPHENOTYPES OF VON WILLEBRAND’S DISEASEB. Madan* (UK), C. Rea, A. Dunkerley, D. Holloway, L. Chappell

PP-WE-624 VON WILLEBRAND FACTOR FUNCTION UNDER PHYSIOLOGICAL FLOW CONDITIONS:COMPARISON OF FIVE VWF-CONTAINING CONCENTRATES IN AN IN VITRO FLOW-CHAMBER MODELB. Fuchs* (DE), C. Fisseau, L. Trawnicek, R. Kuhelj, C. Kannicht

PP-WE-625 CONGENITAL AND ACQUIRED DEFECTS OF FVIII BINDING TO VON WILLEBRANDFACTOR: RESULTS OF A COHORT STUDY ON 48 ITALIAN PATIENTSM. T. Canciani, G. Cozzi, S. La Marca, V. Rubini, F. Rezzonico* (IT), L. Baronciani, P. M.Mannucci, A. B. Federici

PP-WE-626 PLATELET VON WILLEBRAND FACTOR (VWF) MRNA ANALYSIS IN PATIENTS WITHVON WILLEBRAND DISEASE (VWD) AND NULL MUTATIONS IN VWF GENES. Giacomelli, F. Rodeghiero, G. Castaman* (IT)

PP-WE-627 A NOVEL MUTATION AT THE PHYSIOLOGICAL TERMINATION CODON OF VONWILLEBRAND FACTOR (VWF) GENE PRODUCES A LONGER VWF PROTEING. Castaman* (IT), S. Giacomelli, F. Rodeghiero

PP-WE-628 THE COMPLEX RELATIONSHIP BETWEEN PHENOTYPE AND GENOTYPE IN VONWILLEBRAND DISEASE: COEXISTENCE IN THE SAME FAMILY OF SEEMINGLYHOMOZYGOUS P1266Q/L VON WILLEBRAND FACTOR GENE MUTATIONSG. Castaman* (IT), S. Giacomelli, F. Rodeghiero

PP-WE-629 CHARACTERISATION OF TWO NOVEL VON WILLEBRAND FACTOR (VWF) MUTATIONS(C2190Y AND R2663C) WITH LOSS OR GAIN OF CYSTEINE RESIDUES IN VWFG. Castaman* (IT), S. Giacomelli, T. Obser, U. Budde, R. Schneppenheim, F. Rodeghiero

PP-WE-630 TRANSIENT EXPRESSION OF TWO NOVEL VON WILLEBRAND FACTOR MUTATIONS(I1343V AND A1716P) IN THE COLLAGEN BINDING DOMAINS OF THE PROTEING. Castaman* (IT), S. Giacomelli, T. Obser, U. Budde, R. Schneppenheim, F. Rodeghiero



284

Wed

nesd

ay P

oste

rs

PP-WE-631 MOLECULAR ASSESSMENT OF FVIII BINDING SITE IN VON WILLEBRAND FACTORGENE IN SUSPECTS PATIENTS OF VON WILLEBRAND DISEASE TYPE 2NG. B. Damian* (BR), A. Santos, C. Oliveira di Migueli, L. Siqueira, A. Prezoti, E. di Paula, J.Bizzacchi, M. Ozelo

PP-WE-632 FREQUENCY OF HAEMORRHAGIC DISORDERS IN NORTH EASTERN IRANH. Mansouritorghabeh* (IR), L. Manavifar, A. Mobalegh

PP-WE-633 UPDATE ON EFFICACY AND TOLERABILITY OF A NEW GENERATION VWF/FVIIICONCENTRATE IN VON WILLEBRAND’S DISEASE FROM A PROSPECTIVE POST-MARKETING SURVEILLANCEI. Scharrer* (DE), S. Halimeh, J. Kadar, U. Nowak-Göttl, M. von Depka Prondzinski, J.Feddern

PP-WE-634 ACQUIRED VON WILLEBRAND SYNDROME IN PATIENTS WITH MULTIPLE MYELOMAI. S. Djunic* (RS), I. Elezovic, N. Milosevic Jovcic, V. Ilic, D. Antic, A. Vidovic, D. Tomin

PP-WE-635 THE IDENTIFICATION OF A REPEAT NOVEL FRAMESHIFT MUTATION IN THE VWFGENE WITH AN UNPREDICTED EFFECTJ. A. Cutler* (UK), M. Hadonou, B. Madan, M. Laffan, M. J. Mitchell

PP-WE-636 QUANTITATIVE TRAIT LOCI (QTL) FOR VON WILLEBRAND FACTOR (VWF) LEVELS INA LARGE PEDIGREE WITH VON WILLEBRAND DISEASE (VWD)J. di Paola* (US), D. Abbott, K. Wang, J. Hinckley, J. Murray, B. Nixon, T. L. Burns, A. Shapiro

PP-WE-637 USE OF LOW-DOSE RISTOCETIN INDUCED PLATELET AGGREGATION (RIPA) AS AFIRST-STEP SCREENING TOOL IN THE DIAGNOSIS OF TYPE 2B VON WILLEBRANDAND PLATELET-TYPE VON WILLEBRAND DISEASE IN CHILDRENJ. P. Frontroth* (AR), M. D. Hepner, G. Sciuccati, G. Pieroni, A. Feliu-Torres, M. Bonduel

PP-WE-638 THE EVALUATION OF A NEW VWF:CB KIT FOR QUANTITATIVE DETERMINATION OFVWF ACTIVITY IN THE DIAGNOSIS OF VWDK. Sukhu* (UK), V. Heath, J. Beavis, D. Keeling

PP-WE-639 HAEMOSTATIC MANAGEMENT OF POST SURGICAL SEVERE BLEEDING USING LOWDOSES OF FVIII/VWF CONCENTRATE IN TYPE 3 VON WILLEBRAND DISEASEK. W. Chennoukh* (DZ), S. Nekkal, M. Adjali, S. Bourada, N. Zidani, M. Belhani

PP-WE-640 GENETIC CONTROL OF PLASMA VON WILLEBRAND FACTOR LEVELS IN HUMANS:THE GENES AND BLOOD CLOTTING STUDYK. C. Desch* (US), J. Li, K. E. Metzger, D. Siemieniak, D. Ginsburg

PP-WE-641 THE CONTRIBUTION OF A REDUCED VON WILLEBRAND FACTOR SURVIVAL IN TYPE2 VON WILLEBRAND DISEASEL. Gallinaro* (IT), M. G. Cattini, E. Pontara, F. Sartorello, V. Daidone, R. Padrini, A.Bertomoro, A. Pagnan, A. Casonato

PP-WE-642 UNIPARENTAL ISODISOMY OF CHROMOSOME 12: A NOVEL AND ORIGINALMECHANISM FOR A CASE OF VON WILLEBRAND DISEASE TYPE 3M. Fouassier, P. Boisseau, A. Lefrançois, C. Thomas, M. Sigaud, C. Ternisien, S. Bezieau, M.Trossaërt* (FR)

PP-WE-643 TREATMENT AT DELIVERY AND IN THE POST-PARTUM PERIOD OF WOMEN WITHVON WILLEBRANDS DISEASEM. Holmström* (SE), D. Näslin, M. Bruzelius, E. Nord, K. Bremme

PP-WE-644 MANAGEMENT OF PERI-SURGICAL HAEMOSTASIS IN VWD PATIENTS – CLINICALEXPERIENCE WITH A HIGH-PURITY DOUBLE VIRUS-INACTIVATED VWF/FVIII-CONCENTRATEM. von Depka Prondzinski* (DE), T. Hoebbel-Schnell, S. Doepke, M. Rieke



285

PP-WE-645 VON WILLEBRAND FACTOR PROPEPTIDE RATIO FOR EVALUATING VWF SURVIVALAND CHARACTERIZING TYPE 1 AND TYPE 2 VON WILLEBRAND DISEASEM. Sztukowska* (IT), L. Gallinaro, M. G. Cattini, E. Pontara, F. Sartorello, V. Daidone, A.Pagnan, A. Casonato

PP-WE-646 ESTABLISHMENT OF A CLINICAL ROUTINE ASSAY, WHICH CAN DETECT MILDDEFECTS IN COAGULATION FACTOR VIII – VON WILLEBRAND FACTOR BINDINGM. Karlman* (SE), B. Wiman

PP-WE-647 DUODENAL AND GASTRIC DIEULAFOY’S LESIONS IN TWO UNRELATED PATIENTSWITH TYPE 2A VON WILLEBRAND’S DISEASE: IS THIS A CASUAL ASSOCIATIONR. de Cristofaro* (IT), M. Riccioni, M. Basso, S. Lancellotti, A. Federici, C. Spada, G.Costamagna, R. Landolfi

PP-WE-648 RECOVERY STUDY IN A CHILD WITH VWD TYPE 3 ON PROPHYLAXISS. I. Heine* (DE), T. Krenn, N. Graf

PP-WE-649 MONITORING VON WILLEBRAND FACTOR REPLACEMENT THERAPY IN THE SETTINGOF ORTHOTOPIC LIVER TRANSPLANTATION USING A RAPID LATEX VWF ACTIVITYASSAYS. V. Brooks* (UK), L. Lanning, S. Unadkat, A. Condez, J. O’Beirne, A. Gatt, P. Chowdary

PP-WE-650 MUTATIONS IN TYPE 2 VON WILLEBRAND DISEASE IN SOUTH AFRICAS. M. Mothabeng* (ZA), A. de Kock, M. Meiring

PP-WE-651 STRONG BLEEDING TENDENCY IN A FAMILY WITH MODERATETHROMBOCYTOPENIA - LABORATORY DIAGNOSTIC WORK-UP OF SEVEN FAMILYMEMBERSJ. Zdziarska, T. Iwaniec* (PL), A. B. Skotnicki, R. Schneppenheim, K. Kentouche, U. Budde

PP-WE-652 PK COMPARABILITY OF VWF/FVIII CONCENTRATES AFTER REPEATED DOSINGU. Kronthaler* (DE), M. Stockschlaeder

PP-WE-653 TREATMENT OF PAEDIATRIC VON WILLEBRAND’S DISEASE PATIENTS WITH HIGHPURITY DOUBLE VIRUS INACTIVATED VWF/FVIII CONCENTRATE – EXPERIENCEFROM CLINICAL STUDIESU. Nowak-Göttl* (DE), S. Halimeh, A. Russo, I. Scharrer, M. Sigl-Kraetzig, J. Feddern

PP-WE-654 PARALLEL DECREASES OF INTRAPLATELET VON WILLEBRAND FACTOR (VWF) ANDPLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) MAY DETERMINE THE BLEEDINGPHENOTYPE OF TYPE 1 VON WILLEBRAND DISEASE (VWD)V. Matus* (CL), O. Panes, S. Acuña, J. Pereira, D. Mezzano

Other Inherited Coagulation Disorders II

PP-WE-655 VALUE OF A PROTHROMBIN COMPLEX CONCENTRATE IN THE MANAGEMENT OFPERIOPERATIVE HAEMORRHAGIC RISK IN A FACTOR X-DEFICIENT WOMANA. Faradji* (FR), E. Baulon-Thaveau, J. P. Mole, L. Grunebaum, D. Deprez, J. L. Poplavsky

PP-WE-656 MANAGEMENT OF 118 SURGERIES IN CONGENITAL FVII DEFICIENCY. A SINGLECENTRE EXPERIENCEA. Batorova* (SK), V. Cupanik, B. Steno, M. Borovsky, D. Horvathova, D. Jankovicova

PP-WE-657 MUTATIONAL SCREENING OF 25 UNRELATED FV-DEFICIENT PATIENTS FROM 6COUNTRIESI. Guella* (IT), E. M. Paraboschi, S. Duga, F. Peyvandi, D. Gemmati, N. Ciavarella, P. M.Mannucci, R. Asselta



286

Wed

nesd

ay P

oste

rs

PP-WE-658 INHIBITORY ANTIBODIES AGAINST FACTOR VII:C IN FACTOR VII DEFICIENCY. 2009INTERIM DATA ANALYSIS REPORT FROM THE CENTRAL LABORATORY FACILITY OFTHE SEVEN TREATMENT EVALUATION REGISTRY (STER)J. Ingerslev* (DK), L. Norengaard, K. Christiansen, B. Sørensen, G. Mariani

PP-WE-659 NEW CLASSIFICATION OF MISSENSE MUTATIONS IN FVII USING STRUCTURE ANDSEQUENCE ANALYSESJ. L. Pellequer* (FR), M. Giansily-Blaizot, S. W. Chen

PP-WE-660 FACTOR XI DEFICIENCY – A STUDY OF ONE FAMILYJ. Windyga* (PL), A. Pavlova, B. Baran, A. Buczma, J. Oldenburg

PP-WE-661 MOLECULAR AND GENETIC ANALYSIS OF PROTHROMBIN-CHUNGHWA: A DOUBLEHETEROZYGOTE MUTATIONJ. Young* (TW), J. Lin

PP-WE-662 CHARACTERISTICS OF A HIGH PURITY FACTOR X CONCENTRATEJ. Lloyd* (UK), J. R. Mead, E. John

PP-WE-663 DEFICIENCY OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 (PAI-1) AND ALPHA2-ANTIPLASMIN (APL) ACTIVITY IN PATIENTS WITH A BLEEDING TENDENCY OFUNKNOWN ORIGINJ. Haselböck* (AT), C. Laczkovics, C. Ay, R. Simanek, P. Quehenberger, I. Pabinger

PP-WE-664 SHOULD WE SCREEN COAGULATION IN WOMEN WITH MENORRHAGIAS. M. Djukic, N. Andjelkovic, P. Djurdjevic, A. Djukic, J. Antovic* (SE)

PP-WE-665 HIGHER THAN EXPECTED PREVALENCE OF RARE COAGULATION DISORDERS INTHE ISLE OF TENERIFE (CANARY ISLANDS, SPAIN)J. Garcia-Talavera* (ES), C. Marrero, A. Leon, S. Jover, T. Bello, M. Trujillo, M. Herrera, M.Mesa, A. Cabello, A. Oliva, M. Rios, N. Hernan

PP-WE-666 THE SEVERITY OF BLEEDING SYMPTOMS IN FACTOR V DEFICIENCY CAUSED BY ANOVEL COMPOUND HETEROZYGOUS MUTATION (P1618R AND IVS7+5 G>C)K. Shinozawa* (JP), D. Imanishi, K. Amano, Y. Miyazaki, M. Tomonaga, T. Suzuki, A. Tanaka,H. Inaba, K. Fukutake

PP-WE-667 MOCULAR BASIS OF FACTOR XI DEFICIENCY IN FIFTEEN FAMILIES FROM CHINA:FOUR NOVEL MUTATIONSL. Dong* (CN), X. Wang

PP-WE-668 GYNECOLOGIC AND OBSTETRIC PATHOLOGIES IN WOMEN WITH SEVERE BLEEDINGDISORDERS: EXPERIENCE AT A REFERENCE COAGULOPATHIES UNIT IN SPAINL. Abad-Franch* (ES), A. R. Cid, S. Haya, P. Casaña, N. Cabrera, A. Moret, J. A. Aznar

PP-WE-669 LONG TERMN RECOMBINANT FACTOR VIIa IN PREGNANAT WOMEN WITH FACTORVII DEFICIENCY AND BLEEDING IN THE FIRST TRIMESTERS. Halimeh* (DE), H. Rott, G. Kappert

PP-WE-670 PROPHYLACTIC THERAPY OF PATIENTS WITH INHERITED FIBRINOGEN DEFICIENCYWITH HAEMOCOMPLETAN P/RIASTAPS. Halimeh* (DE), R. Eisert, H. Rott, B. Siegmund, A. Tiede, H. Pollmann

PP-WE-671 A NOVEL HOMOZYGOUS MISSENSE MUTATION IN THE LMAN1 GENE IN A JAPANESEPATIENT WITH COMBINED FACTORS V AND VIII DEFICIENCYT. Yamada* (JP), Y. Fujimori, A. Suzuki, Y. Miyawaki, A. Takagi, M. Sano, T. Matsushita, H.Saito, T. Kojima



287

Acquired Coagulation Disorders and DIC II

PP-WE-672 EVALUATION OF AN AUTOMATED ASSAY FOR SOLUBLE FIBRIN MONOMERSA. Duncan* (US), A. Winkler, A. Ingle, K. Hostetler

PP-WE-673 THROMBOELASTROGRAPHY (TEG) IN ORTHOTOPIC LIVER TRANSPLANTATION (OLT)S. Roullet, J. Pillot, P. Revel, A. Quinart, F. Sztark, S. Labrouche, G. Freyburger* (FR)

PP-WE-674 DAUNORUBICIN ENHANCES PROCOAGULANT ACTIVITY OF RBCJ. Zhou, Y. Zheng, H. Li, Y. Fu, W. Li, X. Zhang, J. Hou, G. E. Gilbert, J. Shi* (US)

PP-WE-675 AN EXPERIMENTAL MODEL TO STUDY DISSAMINATED INTRAVACULARCOAGULATION IN SHEEPJ. M. Siller-Matula* (AT), R. Plasenzotti, B. Jilma

PP-WE-676 COST-EFFECTIVENESS OF PROTHROMBIN COMPLEX CONCENTRATE COMPAREDTO FRESH FROZEN PLASMA IN EMERGENCY WARFARIN REVERSAL IN THE UKJ. F. Guest, H. G. Watson* (UK), S. Limaye

PP-WE-677 DEVELOPMENT OF A LABORATORY MODEL OF POST CARDIAC COAGULOPATHYM. Tang* (DK), K. Christiansen, J. Ingerslev, V. Hjortdal, B. Sørensen

PP-WE-678 DISSEMINATED INTRAVASCULAR COAGULATION SYNDROME IN SEVERE BURNSM. V. Presnyakova* (RU), A. N. Sidorkina, V. G. Sidorkin

PP-WE-679 ROLE OF GENETIC MONITORING OF HAEMOSTASIS IN SEVERE DIC SYNDROMEN. A. Vorobyeva* (RU)

PP-WE-680 OFF LABEL USE OF RECOMBINANT FACTOR VIIa IN THE HEMATOLOGY WARDN. V. Rajic, N. V. Rajic* (RS), S. Popovic, A. Savic, I. Savic, I. Urosevic, B. Zeravica, N.Vlaisavljevic, D. Agic, I. Percic

PP-WE-681 ASSESSING THE FUNCTION OF CLOTTING SYSTEM AND SEARCHING FORPROGNOSTIC TESTS IN LIVER CIRRHOSISN. I. Kolaitis* (GR), A. Oikonomou, G. Vartholomatos, G. Baltayiannis, E. V. Tsianos

PP-WE-682 PROLONGED COAGULOPATHY RELATED TO ANTICOAGULANT SUPERWARFARINRODENTICIDES OVERDOSEO. Paoletti* (IT), A. Alatri, L. Bassi, A. Zimmermann, M. Stramezzi, A. Cogrossi, S. Testa

PP-WE-683 THE PROCOAGULANT EFFECT OF VITAMIN-K ANTAGONISTS IN PATIENTS WITHATRIAL FIBRILLATION, ATHEROSCLEROSIS AND DEEP VENOUS THROMBOSISR. Al Dieri* (NL), A. J. ten Cate-Hoek, H. ten Cate, H. C. Hemker

PP-WE-684 ASSOCIATION OF VASOPRESSIN INDUCED IMPAIRMENT OF MICROCIRCULATIONWITH A DROP-OFF IN ADAMTS13 ACTIVITY IN PATIENTS WITH SEPTIC SHOCKR. A. Claus* (DE), S. Klinzing, P. Reuken, C. L. Bockmeyer, T. Schuerholz, K. Reinhart, G.Marx, W. Losche, M. Bauer

PP-WE-685 DIFFERING EFFECTS OF THREE PROTHROMBIN COMPLEX CONCENTRATES ONANTICOAGULATED PLASMA AS MEASURED BY CALIBRATED AUTOMATEDTHROMBOGRAPHYR. M. Gilmore* (IE), S. Harmon, G. Keane, C. Gannon, M. Byrne, B. White, J. S. O’Donnell

PP-WE-686 USE OF RECOMBINANT ACTIVATED FACTOR VII IN PEDIATRIC PATIENTS WITHOUTHEMOPHILIAS. A. Muwakkit* (LB), M. M. Majdalani, K. M. Musallem, R. Saab, M. Abboud



288

Wed

nesd

ay P

oste

rs

PP-WE-687 DISSEMINATED INTRAVASCULAR COAGULATION WITH A FIBRINOLYTIC PHENOTYPEMODIFIED THROUGH FIBRINOGENOLYSIS AT AN EARLY PHASE OF TRAUMAPREDICTS MORTALITYS. Gando* (JP), A. Sawamura, M. Hayakawa, N. Kubota, M. Sugano, T. Wada, K. Katabami

Consultative Hemostasis II

PP-WE-688 AUDIT OF THE CLINICAL USE OF FRESH-FROZEN PLASMA IN UMBRIA: STUDYDESIGN AND RESULTSM. Basileo, M. Marchesi, E. Marchesini, M. Materazzi, A. Germani, L. Rocchetti, C. Silvani, A.Iorio* (IT)

PP-WE-689 A GLOBAL TEST (THROMBOELASTOGRAPHY) REFLECTS THE CONVENTIONALCOAGULOGRAM AND PLATELET COUNT BEFORE LIVER TRANSPLANTATIOND. D. Ribeiro* (BR), A. S. Lima, M. D. Faria, C. Caram

PP-WE-690 PRACTICAL-HAEMOSTASIS.COM - : A WEB-BASED RESOURCE FOR LABORATORYHAEMOSTASISD. J. Perry* (UK), T. Todd

PP-WE-691 WHY DO WE EVALUATE PT AND APTT BEFORE DELIVERYE. Biguzzi* (IT), F. Franchi, B. Ibrahim, B. Acaia, T. Radaelli, P. Bucciarelli, P. Mannucci

PP-WE-692 ROTATIONAL THROMBOELASTOGRAPHY (ROTEM) AS A TOOL FOR ASSESSING THECLINICAL RESPONSE TO HEMOSTATIC AGENTS IN BLEEDING DISORDERSM. Echenagucia* (VE), A. Boadas, A. Arguello, A. Quijada, M. Hernandez, J. Becerra, C.Reyes, N. Blumenfeld de Bosch, A. Ruiz-Saez

PP-WE-693 RESCUE RFVIIa ADMINISTRATION FOR INTRACTABLE BLEEDING IN CARDIACSURGERYO. Katsarou* (GR), V. Panagiotakopoulos, A. Koumarianou, A. Kouraba, T. Sakellaridis, P.Kotsi, K. Markakis, C. Charitos, A. Karafoulidou

PP-WE-694 THROMBOCYTOPENIA DOES NOT INCREASE THE RISK OF PERI-PROCEDURALHEMORRHAGIC OR VASCULAR COMPLICATIONS ASSOCIATED WITH CARDIACCATHETERIZATIONP. Vidwan* (US), J. Bumgarner, C. Stalls, J. Rossi, G. Stouffer

PP-WE-695 PREVALENCE OF SUSPECTED COLLAGEN DISORDERS IN THE ADULT BLEEDINGDISORDER CLINICS. C. Jackson* (CA), R. T. Card, M. Brown, C. Spitzer, M. Poon

PP-WE-696 IS ROUTINE SCREENING FOR COAGULATION ABNORMALITIES PRIOR TO OVAEXTRACTION NEEDEDS. Revel-Vilk* (IL), Y. Schejter-Dinur, A. Revel

Innovative Therapies for Hemorrhagic Disorders I

PP-WE-697 EFFICACY AND LONG-TERM SAFETY OF A PASTEURISED NANOFILTRATEDPROTHROMBIN COMPLEX CENCENTRATE (BERIPLEX® P/NA. A. Hanke* (DE), L. Rodewald, C. Joch, K. Görlinger

PP-WE-698 MECHANISMS OF DILUTIONAL COAGULOPATHYC. Fenger-Eriksen* (DK), E. Tonnesen, J. Ingerslev, B. Sorensen

PP-WE-699 IMMEDIATE REVERSAL OF ORAL ANTICOAGULATION IN A SEVERERETROPERITONEAL BLEEDING AND ABDOMINAL COMPARTIMENT SYNDROME: AREPORT OF FOUR CASESM. Quintana* (ES), M. Sánchez Casado, S. Martinez, S. Fabra



289

PP-WE-700 OFF-LABEL USE OF RECOMBINANT ACTIVATED FACTOR VII IN INTRACTABLEHAEMORRHAGE AFTER CARDIOVASCULAR SURGERY: AN OBSERVATIONAL STUDYOF FRENCH PRACTICES (2005-2007)M. Hacquard* (FR), M. Durand, T. Lecompte, J. Carteaux, on behalf of the French Societieson CV Surgery Anesthesiology and IC T&H/Haematology

PP-WE-701 THE USE OF ACTIVATED FACTOR VII IN HAEMORRHAGIC DISEASES- THE STUDY OF09 CASESN. Mesli* (DZ), S. Bereksi Reguig, K. Taouli, H. Hemche

PP-WE-702 THE COMBINATION OF RECOMBINANT FACTOR VIIa AND FIBRINOGEN CORRECTSCOAGULATION IN A MODEL OF WHOLE BLOOD THROMBOCYTOPENIAO. H. Larsen* (DK), J. Ingerslev, B. Sørensen

PP-WE-703 KERATIN HYDROGEL HEMOSTASIS - CELLULAR AND MOLECULAR MECHANISMSC. Orebaugh, M. Bahawdory, M. C. Stahle, J. Rouse, L. Burnett, M. van Dyke, R. R.Hantgan* (US)

Immunology and Treatment of ITP II

PP-WE-704 VARIABLE PLATELET RESPONSIVENESS TO SEQUENTIAL THROMBOPOIETINRECEPTOR AGONISTS (TPO-RA) ADMINISTRATION IN CHRONIC IMMUNETHROMBOCYTOPENIC PURPURA (ITPP. Olszynski* (US), C. Cromwell, M. P. Russin, L. M. Aledort, P. F. Fogarty

PP-WE-705 IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) IN TWO MEMBERS OF A FAMILY:FAMILIAL ITP OR COINCIDENCEP. L. Junqueira, E. Okazaki, A. K. Zeinad, P. R. Villaca* (BR), D. A. F. Chamone, E. A. D’Amico

PP-WE-706 PLASMA APRIL LEVELS IN CHINESE PATIENTS WITH CHRONIC IDIOPATHICTHROMBOCYTOPENIC PURPURAD. Gu, W. Du, J. Ge, Z. Chen, H. Zhao, L. Zhang, R. Yang* (CN)

PP-WE-707 THE ROLE OF TIM-3 POLYMORPHISMS IN IDIOPATHIC THROMBOCYTOPENICPURPURAW. Du, D. Wang, H. Zhao, J. Xu, D. Gu, F. Xue, J. Ge, R. Yang* (CN)

PP-WE-708 PARAOXONASE-1 L/M 55 GENE POLYMORPHISM IN THE CASES OF IDIOPATHICTHROMBOCYTOPENIC PURPURAO. Cakici, S. Akarsu* (TR), D. Erol, B. Ustundag, H. Yuce

PP-WE-709 ENOS GLU298ASP GENE POLYMORPHISM IN THE CASES OF IDIOPATHICTHROMBOCYTOPENIC PURPURAF. Arslan, S. Akarsu* (TR), M. Kara, B. Ustundag, H. Yuce

PP-WE-710 SUCCESSFUL USE OF CYCLOSPORINE AS AN ADJUNCTIVE IMMUNOSUPPRESSIVEAGENT IN AN INFANTILE EVANS SYNDROME: A CASE REPORT AND LITERATUREREVIEWS. Hutspardol* (TH), S. Soonsawad, S. Wattanatittan, P. Siripattanapong

PP-WE-711 IMMUNOMODULATORY THERAPY FOR REFRACTORY ITP WITH ALL-TRANS RETINOICACIDZ. Wang* (CN), W. Liu, X. Bai, L. Cao, C. Ruan



290

Wed

nesd

ay P

oste

rs

Pathophysiology and Treatment of HIT II

PP-WE-712 HEPARIN-INDUCED THROMBOCYTOPENIA: COMPARISON BETWEEN THE STANDARDGEL-PARTICLE ASSAY AND THE FUNCTIONAL FLOW CYTOMETRIC ASSAYA. Tomer* (IL), G. Abslander, S. Fleisher

PP-WE-713 DETECTION OF ANTI PLATELET FACTOR 4/HEPARIN ANTIBODIES USINGCOMMERCIAL ELISA ASSAYSA. F. Riddell* (UK), S. Brooks, A. Davenport, P. Chowdary

PP-WE-714 PERFORMANCE OF ANTI-HEPARIN/PLATELET FACTOR 4-ASSAYS IN THE DIAGNOSISOF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) DEFINED BY CLINICAL CRITERIAN. Schwarz, B. Luxembourg* (DE), H. Kroll, M. Schindewolf, E. Lindhoff-Last

PP-WE-715 PERFORMANCE OF TWO NEW EIA ASSAYS FOR DETECTION OF IGG ANTI-PF4/HEPARIN ANTIBODIES (ABS) IN PATIENTS SUSPECTED OF HAVING HEPARIN-INDUCED THROMBOCYTOPENIA (HITC. Legnani* (IT), M. Cini, M. Frascaro, O. Boggian, F. Bettini, M. Poggi, B. Cosmi, G. Palareti

PP-WE-716 CLINICAL ASSESSMENT AND LABORATORY TESTING FOR HEPARIN INDUCEDTHROMBOCYTOPAENIA (HIT); CURRENT PRACTICE AMONGST UK NEQAS (BLOODCOAGULATION) PARTICIPANTSI. Jennings* (UK), D. P. Kitchen, S. Kitchen, T. A. L. Woods, D. Keeling, I. D. Walker

PP-WE-717 VARIABILITY OF ANTI-PF4/HEPARIN ANTIBODY RESULTS OBTAINED BY THE RAPIDTESTING SYSTEM ID-H/PF4-PAGIAG. Colucci, S. Schneiter, I. Sulzer, G. Barizzi, B. Laemmle, L. Alberio* (CH)

PP-WE-718 A CASE OF SPONTANEOUS HEPARIN INDUCED THROMBOCYTOPENIA ANDTHROMBOSISM. T. Desancho* (US), K. S. Carlson, A. Mallik

PP-WE-719 THE UTILITY OF A PF4-DEPENDENT ENZYME IMMUNOASSAY TO DIAGNOSEHEPARIN-INDUCED THROMBOCYTOPENIA IN CHILDRENP. R. Yenson* (CA), A. K. Chan, S. Williams, L. R. Brandao

PP-WE-720 ARGATROBAN ANTICOAGULANT THERAPY WITH LOW INITIAL DOSAGE INCARDIOVASCULAR DISEASE PATIENTS WITH HEPARIN-INDUCEDTHROMBOCYTOPENIAS. Miyata* (JP), H. Yamamoto, Y. Ohkita, N. Yamada, T. Shimokawa, K. Myojin, H. Tomoike

PP-WE-721 AN EVALUATION OF MONITORING POSSIBILITIES OF ARGATROBAN USINGROTATIONAL THROMBOELASTOMETRY AND APTTU. Schott* (SE), M. Rundgren, M. Engström

Pathophysiology and Clinical Studies of TTP II

PP-WE-722 CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA IN TWO POLISHFAMILIESA. Klukowska* (PL), E. Niewiadomska, U. Budde, F. Oyen, R. Schneppenheim

PP-WE-723 THROMBOTIC MICROANGIOPATHY (TMA) DURING PERIPHERAL BLOOD STEM CELLMOBILIZATIONH. V. K. Naina* (US), M. A. Gertz, M. A. Elliott

PP-WE-724 DETERMINATION OF ADAMTS-13 AND VWF ANTIGEN AND ACTIVITY LEVELS INPATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA AND OTHERTHROMBOCYTOPENIC DISORDERS IN KUWAITM. M. Jadaon* (KW), A. M. Al-Awadhi, H. A. Al-Jafar, H. J. Al-Wazzan



291

PP-WE-725 PREDICTIVE VALUE OF PATIENT CHARACTERISTICS IN THE DIAGNOSIS OFCLINICALLY-SUSPECTED TTPM. J. Bentley* (US), A. R. Wilson, G. M. Rodgers

PP-WE-726 ADAMTS13 LEVELS IN HIV INFECTED PATIENTS WITH AND WITHOUT TTPM. Meiring* (ZA), B. van Staden, K. van Hoorelbeke, H. Deckmyn, P. Badenhorst

PP-WE-727 MATERNAL DEATHS DUE TO ACQUIRED THROMBOTIC THROMBOCYTOPENICPURPURA (TTP) IN LONDON, ENGLAND 2003-7R. R. Thomas-Dewing* (UK), S. B. Lucas, B. J. Hunt

PP-WE-728 CLINICAL ANALYSIS OF INTRACRANIAL HEMORRHAGE IN THE FIRST EPISODEIDIOPATHIC THROMBOCYTOPENIC PURPURA CHILDRENR. Wu* (CN), H. Ma

PP-WE-729 SUB-CLINICAL CARDIAC AND RENAL COMPLICATIONS IN PATIENTS WITH MULTIPLERELAPSES OF THROMBOTIC THROMBOCYTOPENIC PUPURA DURING LONG-TERMFOLLOW-UPS. Viswanathan* (US), B. H. Rovin, G. B. Shidham, S. V. Raman, J. N. George, H. M. Wu, S.R. Cataland

PP-WE-730 ADAMTS13 IN THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) EVALUATION OF11 CASES REVEALS 2 NEW MUTATIONST. Fidalgo* (PT), P. Martinho, R. Salvado, T. Sevivas, C. Silva Pinto, D. Marques, E.Gonçalves, N. Martins, M. Ribeiro

PP-WE-731 ELEVATED INTERLUKIN-21 AND IFN-R IN PATIENTS WITH CHRONIC IMMUNETHROMBOCYTOPENIC PURPURAX. Zhu, D. Ma, J. Zhang, J. Peng, M. Hou* (CN)

PP-WE-732 THROMBOTIC THROMBOCYTOPENIC PURPURA AND HEMOLYTIC UREMICSYNDROME IN PREGNANCY: A REPORT OF FIVE CASESY. He* (CN), Y. Zhang, Y. Zhao, J. Hu, J. Zu, J. Yan, W. Yang

Platelet Function Tests II

PP-WE-733 MONITORING OF ANTIPLATELET AGENTS – NECESSARY IN PATIENTS WITHCARDIOVASCULAR DISEASES A. Siegemund* (DE), I. Körner, U. Scholz

PP-WE-734 IN VITRO ASSAY FOR THE DETECTION OF NON CLASSICAL PLATELET DISORDERSAND FOR MONITORING THE EFFECT OF RECOMBINANT FACTOR VIIaK. Jurk, M. F. Brodde, S. Niemann, B. E. Kehrel* (DE)

PP-WE-735 TEN YEAR EXPERIENCE WITH WHOLE BLOOD AGGREGOMETRY IN THE DIAGNOSISOF THROMBOCYTOPATHYT. de Boer, R. Polenewen, I. Novakova, B. Verbruggen* (NL)

PP-WE-736 EFFECTS OF DIFFERENT WAVELENGTH ULTRAVIOLET IRRADIATION ON PLATELETFUNCTIONC. Terada* (JP), H. Okazaki, Y. Tani, M. Satake, K. Tadokoro

PP-WE-737 THE CLINICAL SIGNIFICANCE OF HEPARIN/PLATELET FACTOR 4 ANTIBODIES AFTERCARDIAC SURGERYD. C. Filipescu* (RO), A. Calugareanu, M. Luchian, O. Ghenu, S. Marin, L. Dima, V.Uscatescu, H. Ghomchi, L. Iliuta, V. Iliescu



292

Wed

nesd

ay P

oste

rs

PP-WE-738 PLATELET CYCLOOXYGENASE INHIBITION BY LOW-DOSE ASPIRIN IS NOTREFLECTED CONSISTENTLY BY PLATELET FUNCTION ASSAYS. IMPLICATIONS FORASPIRIN ‘RESISTANCE’F. Santilli* (IT), B. Rocca, R. de Cristofaro, S. Lattanzio, L. Pietrangelo, A. Habib, C.Pettinella, A. Recchiuti, E. Ferrante, G. Ciabattoni, G. Davi, C. Patrono

PP-WE-739 PREVALENCE AND PROFILE OF ASPIRIN RESISTANCE IN PATIENTS WITHCARDIOVASCULAR DISEASES IN COMPARISON TO HEALTHY VOLUNTEERST. Kaden, J. Hentrich, G. Nowak* (DE)

PP-WE-740 STORED PLATELET POOLS LOSE THEIR ABILITY TO FACILITATE AGGREGATION BUTMAINTAIN THEIR SUPPORT OF CLOT FORMATION AS EVALUATED IN A MODEL OFWHOLE BLOOD THROMBOCYTOPENIAM. Andersen* (DK), J. Ingerslev, B. Sørensen, B. Møller

PP-WE-741 THE INFLUENCE OF CLINICAL CHARACTERISTICS, LABORATORY ANDINFLAMMATORY MARKERS ON “HIGH ON-TREATMENT PLATELET REACTIVITY” ASMEASURED WITH DIFFERENT PLATELET FUNCTION TESTSN. J. Breet* (NL), J. W. van Werkum, R. M. A. van de Wal, C. A. Zomer, H. J. Bouman, F. W.A. Verheugt, J. M. ten Berg, C. M. Hackeng

PP-WE-742 THE CONE-AND-PLATE(LET) ANALYZER FOR THE MONITORING OF CLOPIDOGRELTHERAPY: A COMPARISON WITH THE FLOWCYTOMETRIC VASP ASSAY ANDOPTICAL AGGREGOMETRYN. J. Breet* (NL), J. W. van Werkum, H. J. Bouman, E. H. A. M. Elsenberg, S. Postma, J. M.ten Berg, C. M. Hackeng

PP-WE-743 PLATELET CYCLOOXYGENASE-1 ACTIVITY IN NONSTEROIDAL ANTI INFLAMMATORYDRUG TREATED PATIENTS WITH CHRONIC PERICARDIAL EFFUSIONN. V. Lomakin* (RU), A. Gruzdev, D. Privalov

PP-WE-744 DETERMINANTS OF RESIDUAL PLATELET REACTIVITY IN A COHORT OF 750 STABLECARDIOVASCULAR PATIENTS TREATED WITH ASPIRIN AND/OR CLOPIDOGREL:INSIGHT FROM THE ADRIE STUDY ON STABLE CARDIOVASCULAR PATIENTSP. Fontana* (CH), I. Barazer, C. Castelli, S. Nolli, P. Berdagué, P. Fabbro-Peray, J. Schved,H. Bounameaux, F. Mach, P. de Moerloose, J. Reny

PP-WE-745 EFFECT ON LIGHT TRANSMITTANCE AGGREGATION OF ADJUSTMENT OF PLATELETCOUNT IN PLATELET-RICH PLASMA IN PATIENTS ON DUAL ANTIPLATELET THERAPYR. Paniccia* (IT), E. Antonucci, E. Romano, N. Maggini, A. M. Gori, P. Bolli, D. Lami, I. Lapini,G. F. Gensini, R. Abbate

PP-WE-746 PLATELET AGGREGATION IN WHOLE BLOOD: SODIUM CITRATE OR HIRUDIN ASANTICOAGULANTR. Paniccia* (IT), E. Antonucci, N. Maggini, E. Romano, A. Abdullahi Said, F. Sofi, L. Rossi,D. Prisco, R. Abbate, G. F. Gensini

PP-WE-747 PLATELET FUNCTION ASSESSMENT BY MULTIPLE ELECTRODE WHOLE BLOODAGGREGOMETRY IN HIGH RISK PATIENTS WITH CORONARY ARTERY DISEASE ONANTIPLATELET THERAPYR. Paniccia* (IT), E. Antonucci, N. Maggini, E. Romano, R. Marcucci, F. Cesari, A. M. Gori, D.Prisco, R. Abbate, G. F. Gensini

PP-WE-748 COMPARISON OF WHOLE BLOOD MULTIPLATE IMPEDANCE AGGREGOMETRY WITHPLATELET FUNCTION TESTS TO ASSESS RESIDUAL PLATELET REACTIVITYR. Paniccia* (IT), E. Antonucci, N. Maggini, M. Miranda, R. Marcucci, A. M. Gori, A. Vestrini,D. Prisco, G. F. Gensini, R. Abbate

PP-WE-749 PLATELET AGGREGATION AND ATP RELEASE STUDIES IN DRUG-FREE NORMALSDEMONSTRATE HIGH FALSE-POSITIVE RATES WITH MULTIPLE INSTRUMENTSS. F. Stein* (US), A. Rice, K. Lindstrom, C. H. Miller



293

PP-WE-750 ASSESSMENT OF PLATELET FUNCTION IN NORMAL ADULTS: GENDER AND RACEDIFFERENCES IN PLATELET AGGREGATION AND ATP RELEASES. F. Stein* (US), A. Rice, K. Lindstrom, C. H. Miller

PP-WE-751 SPONTANEOUS THROMBOLYTIC ACTIVITY IN CORONARY ARTERY DISEASES. Saraf, S. Sharma* (UK), D. Gorog

PP-WE-752 UNIVERSAL NORMAL RANGES FOR LIGHT TRANSMITTANCE AGGREGOMETRY ANDPLATELET FUNCTION ANALYZER (PFA-100S. Nagalla* (US), J. F. Dong, P. F. Bray

PP-WE-753 PFA100: A RELIABLE TOOL TO EVALUATE PATIENTS COMPLIANCE TO ASPIRINTHERAPYS. Basili* (IT), P. Pignatelli, R. Carnevale, S. di Santo, L. Loffredo, F. Violi

PP-WE-754 PLATELET FUNCTION DETERMINATION IN PLATELET CONCENTRATES FORTRANSFUSIONS. Thomas* (UK)

PP-WE-755 ASSESSMENT OF CLOPIDOGREL AND ASPIRIN THERAPY USING REMOTE PLATELETTESTINGS. C. Fox* (UK), J. A. May, A. Shah, U. Neubert, S. Heptinstall

PP-WE-756 MULTIPLATE WHOLE BLOOD IMPEDANCE AGGREGOMETRY: REFERENCE VALUES INHEALTHY INFANTS, CHILDREN AND ADOLESCENTSS. Halimeh* (DE), G. Deangelis, C. Edelbusch, S. Thedieck, U. Nowak-Gottl

PP-WE-757 PLATELET FUNCTION IN PATIENTS UNDERGOING AORTO-CORONARY ARTERYBYPASS SURGERYT. A. Suarez* (US), K. P. Bliden, M. J. Antonino, E. Mahla, A. Sequeria, P. W. Cho, U. S.Tantry, P. A. Gurbel

PP-WE-758 PROTHROMBIN COMPLEX CONCENTRATE AND EFFECTS ON THE CONE AND PLATEANALYSERU. Schott* (SE), L. Jirgård, K. Strandberg, A. Hillarp

PP-WE-759 PLATELET REACTIVITY BEFORE AND AFTER ASPIRIN TREATMENTY. Lee* (KR), H. Kim, H. Kang

Diagnosis and Treatment of Inherited and Acquired Platelet Disorders II

PP-WE-760 PREGNANCY-RELATED COMPLICATIONS IN WOMEN WITH RARE PRODUCTION-DEFECT THROMBOCYTOPENIASB. Myers* (UK), D. Elliott, S. Pavord

PP-WE-761 MINIMALLY-INVASIVE PARATHYROIDECTOMY WITH RECOMBINANT ACTIVATED FVIIIN GLANZMANN´S THROMBASTHENIAC. Altisent* (ES), J. Baena, J. Ayats, J. Escoll, N. Purroy, M. Martorell, R. Parra

PP-WE-762 JAK2V617F MUTATION IS ASSOCIATED WITH SPEEDED THROMBIN GENERATIONA. Bauters, N. Cambier, N. Trillot, E. Jeanpierre, C. Caron* (FR), B. Jude, A. Renneville, C.Preudhomme

PP-WE-763 THREE UNRELATED THROMBASTHENIA GLANZMANN PATIENTS WITH A SPLICINGDONOR SIDE MUTATION OF GPIIB EXON 29D. Westrup* (DE), R. Eisert, T. Scholz, D. Pillitteri, M. Krause, C. M. Kirchmaier



294

Wed

nesd

ay P

oste

rs

PP-WE-764 MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF NOVEL MUTATIONS IN GPIXAND BETA3 INTEGRIN GIVING RISE TO BERNARD-SOULIER SYNDROME AND TO ANATYPICAL GLANZMANN’S THROMBASTHENIA-LIKE SYNDROME IN TWO PATIENTSMISDIAGNOSED WITH IDIOPATHIC THROMBOCYTOPENIC PURPUA. Antón, L. Navarro-Núñez, M. Lozano, C. González-Manchón, A. Jayo, C. Martínez, V.Roldán, V. Vicente, J. Rivera* (ES)

PP-WE-765 ANTI-CD20 AS ALTERNATIVE TO SPLENECTOMY IN PATIENTS WITH REFRACTORYIMMUNE THROMBOCYTOPENIC PURPURA. TWO YEARS FOLLOW-UPM. Alvarez* (ES), V. Jimenez, M. Martin, I. Fernandez, N. Butta, I. Muñoz, I. Rivas, M. Garcia,F. Hernandez

PP-WE-766 GASTROINTESTINAL BLEEDING DUE TO ANGIODYSPLASIA IN PATIENTS WITHINHERITED PLATELET FUNCTION DISORDERSN. R. Farquharson* (UK), R. N. Maclean, K. K. Hampton, M. McAlindon, J. J. van Veen, M.Makris

PP-WE-767 RECOMBINANT FACTOR VIIa IS EFFECTIVE FOR BLEEDING AND SURGERY INPATIENTS WITH GLANZMANN THROMBASTHENIAR. J. Nuñez* (ES), R. Perez-Garrido

PP-WE-768 NEW AUTOMATED CHEMILUMINESCENT ANTI-HEPARIN/PF4 IMMUNOASSAY:ANALYTICAL PERFORMANCE IN HIT SUSPECTED PATIENTSS. Faraudo, A. Martinez, S. Morcillo, F. Robert, A. Katerchi, R. G. Barry* (US), I. Elalamy

PP-WE-769 FATAL OUTCOME IN A PATIENT WITH BERNARD SOULIER SYNDROME: CASEREPORTS. Stankovic* (MK), L. B. Hadzi-Pecova, T. Smilevska, L. Cevreska, T. Sotirova, A. Ljatifi, D.Dukovski, S. Trajkova

PP-WE-770 IDENTIFICATION OF EIGHT NOVEL MUTATIONS AMONG TEN UNRELATED CHINESEPATIENTS WITH GLANZMANN THROMBASTHENIAT. Yu* (CN), X. Wang, Q. Ding, J. Dai, Y. Lu, X. Xi, H. Wang

PP-WE-771 DEVELOPMENT OF A SEVERE VON WILLEBRAND FACTOR/ADAMTS13 DYSBALANCEDURING LIVER TRANSPLANTATIONI. T. A. Pereboom, J. Adelmeijer, Y. van Leeuwen, H. G. D. Hendriks, R. J. Porte, T. Lisman*(NL)

PP-WE-772 EFFECT OF HELICOBACTER PYLORI ERADICATION IN THAI ADULT PATIENTS WITHIDIOPATHIC THROMBOCYTOPENIC PURPURAY. Chinthammitr* (TH), N. Thongtanyong, Y. Nakkinkun, T. Ruchutrakool, B. Suwanawiboon,W. Wanachiwanawin

PP-WE-773 CLINICAL STUDY OF HEMORRHAGE IN THE EARLY PHASE OF HEMATOPOIETICSTEM CELL TRANSPLANTATIONY. Han* (CN), D. Wu, A. Sun, Z. Wang, C. Ruan

PP-WE-774 VARIANT TYPE GLANZMANN THROMBASTHENIA: MOLECULAR GENETIC, PRENATALAND PROTEIN DIAGNOSTICSZ. Bagoly* (HU), F. Fazakas, A. Marosi, J. Tóth, J. Kappelmayer, L. Muszbek

Microparticles II

PP-WE-775 CD11B-POSITIVE MICROPARTICLES ARE AN INDEPENDENT PREDICTOR OFCARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ARTERY DISEASED. Faille, C. Frere* (FR), T. Cuisset, J. Quilici, P. Morange, I. Juhan-Vague, J. Bonnet, M.Alessi



295

PP-WE-776 PHOSPHOLIPID-DEPENDENT PROCOAGULANT ACTIVITY OF PLATELET-DERIVEDMICROPARTICLES IS RESTRICTED TO THE ANNEXIN V BINDING SUBPOPULATIOND. E. Connor* (AU), T. Exner, D. D. F. Ma, J. E. Joseph

PP-WE-777 THROMBOGENIC FUNCTION OF CIRCULATING MICROPARTICLES DOES NOTCORRELATE WITH MICROPARTICLE NUMBERH. Vetr* (AT), T. Perkmann, M. Graf, S. Geiter, V. Kaufmann, J. Mager, C. J. Binder, B. R.Binder

PP-WE-778 A SHIFT FROM LOW NUMBERS OF CELLULAR MICROPARTICLES WITH HIGHSPECIFIC PROCOAGULANT ACTIVITY TO HIGH NUMBERS WITH LOW SPECIFICPROCUAGULANT ACTIVITY DURING CHEMOTHERAPEUTIC LEUKEMIA TREATMENT:BEHAVIOUR OF BLAST-DERIVED MICROPARTICLES IN A PHOSPHOLIPID- AM. C. Trappenburg, M. van Schilfgaarde* (NL), P. J. Molenaar, W. E. Terpstra, A. Leyte

PP-WE-779 ELEVATED LEVELS AND DIFFERENT SUBSETS OF PROCOAGULANTMICROPARTICLES IN BREAST CANCER PATIENTS USING HORMONAL THERAPYM. C. Trappenburg, M. van Schilfgaarde* (NL), H. M. Spronk, H. ten Cate, A. Leyte, W. E.Terpstra

PP-WE-780 STANDARDIZED METHODOLOGY FOR IDENTIFICATION AND CHARACTERIZATION OFMICROVESICLESM. Jayachandran* (US), V. M. Miller, W. G. Owen

PP-WE-781 ADIPONECTIN-DEPENDENT EFFECTS OF PITAVASTATIN ON PLATELET-DERIVEDMICROPARTICLES, SOLUBLE CD40 LIGAND AND MCP-1 IN HYPERLIPIDEMICPATIENTSN. Inami* (JP), S. Nomura, A. Shouzu, S. Omoto, T. Shimazu, D. Satoh, T. Kajiura, K.Yamada, T. Iwasaka

PP-WE-782 PROTEOMIC ANALYSIS OF MICROPARTICLES DERIVED FROM HUMAN B CELLSINFECTED WITH DENGUE VIRUSN. de Bosch* (US), J. Evans, A. Becerra, K. Giaya, K. Green, K. J. Martin, I. Bosch

PP-WE-783 MICROPARTICLES WITH PROCOAGULANT POTENTIAL IN THE ASPIRATE FROM THECULPRIT CORONARY ARTERY OF PATIENTS WITH ACUTE MYOCARDIAL INFRACTIONP. Min* (KR), S. Kang, H. Doh, S. Hong, H. Mun, J. Kim, E. Choi, B. Lee, Y. Yoon, B. Hong,S. Rim, K. Chung, H. Kwon

PP-WE-784 FEMALE STEROID HORMONES AND ENDOTHELIAL FUNCTION IN IVF/ICSI PATIENTSB. Toth, A. Rank, U. Jeschke, K. Friese, C. Thaler, R. Nieuwland* (NL)

PP-WE-785 STANDARDIZATION OF FLOW CYTOMETRY-BASED ENUMERATION OF PLATELETMICROPARTICLES USING CALIBRATED BEADS: RESULTS OF INSTRUMENTQUALIFICATIONR. Lacroix* (FR), P. Poncelet, S. Robert, N. S. Key, F. Dignat-George, on behalf of the ISTHSSC Workshop

PP-WE-786 EFFECT OF NEEDLE GAUGE, SHEAR RATE AND ANTICOAGULANT ON PLATELETACTIVATION IN BLOOD COLLECTIONT. Exner* (AU), K. Parsi

PP-WE-787 INCREASED LEVELS OF CIRCULATING MICROPARTICLES IN AUTOIMMUNEDISEASES AND RELATION TO DISEASE ACTIVITYV. Proulle* (FR), J. Sellam, A. Jungel, M. Ittah, C. Miceli-Richard, J. Gottenberg, F. Toti, J.Benessiano, S. Gay, J. Freyssinet, X. Mariette



296

Wed

nesd

ay P

oste

rs

Patient-oriented Studies of Antiplatelet Therapy II

PP-WE-788 REDUCED PLATELET RESPONSE TO ASPIRIN IN PATIENTS WITH CORONARYARTERY DISEASE AND TYPE 2 DIABETES MELLITUSS. B. Mortensen, S. B. Larsen, E. L. Grove, S. D. Kristensen, A. Hvas* (DK)

PP-WE-789 PERSISTENT THROMBOXANE-A2 PRODUCTION IN TYPE 1 AND TYPE 2 DIABETICPATIENTS UNDER CHRONIC ASPIRIN TREATMENTF. M. Pulcinelli* (IT), L. M. Biasucci, S. Riondino, S. Giubilato, A. Leo, L. di Renzo, E. Trifiro’,D. Pitocco, F. Crea

PP-WE-790 CROCODILE SMILE: BENEFIT AND RISKS OF COMBINED ANTICOAGULANT ANDANTIPLATELET THERAPY IN CVDG. Corinaldesi* (IT), C. Corinaldesi

PP-WE-791 RESISTANCE TO CLOPIDOGREL DETECTED BY REAL TIME EVALUATION OFPLATELET THROMBUS FORMATIONG. L. Mendolicchio* (IT), D. Zavalloni, E. Corrada, M. Rossi, M. Marconi, M. Bacci, P.Presbitero, L. Rota, Z. M. Ruggeri

PP-WE-792 VARIABILITY OF RESIDUAL PLATELET FUNCTION DESPITE CLOPIDOGRELTREATMENT IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE - APROSPECTIVE STUDYJ. Schwonberg* (DE), B. Linnemann, S. W. Toennes, H. Mani, E. Lindhoff-Last

PP-WE-793 EVALUATION OF ASPIRIN RESISTANCE IN ASPIRIN-FREE PATIENTS WITH SEVERETYPE-2 DIABETES MELLITUSK. Takano* (JP), Y. Kimura, K. Sato, K. Aida, T. Kobayashi, Y. Ozaki

PP-WE-794 THE ANTIPLATELET RESPONSE TO CLOPIDOGREL IN DIABETIC PATIENTSUNDERGOING ELECTIVE CORONARY STENTINGK. P. Bliden* (US), L. Lawal, A. Singla, S. Yadav, J. Dichiara, M. J. Antonino, U. S. Tantry, J.F. Saucedo, P. A. Gurbel

PP-WE-795 COMPLICATIONS OF DUAL ANTIPLATELET THERAPY COMBINED WITH ORALANTICOGULATION IN PATIENTS POST ACUTE CORONARY SYNDROMESM. Banaszewski* (PL), J. Stepinska

PP-WE-796 ATORVASTATIN REDUCES PERSISTENT PLATELET TXA2 SYNTHESIS IN ASPIRIN-TREATED PATIENTS WITH ACUTE MYOCARDIAL INFARCTIONM. T. Santos* (ES), M. P. Fuset, M. Ruano, A. Moscardó, J. Valles

PP-WE-797 ASPIRIN RESPONSIVENESS MEASURED BY COX-1 SPECIFIC AND COX-1 NON-SPECIFIC METHODS IN HEALTHY SUBJECTS: CLARIFYING THE DEBATE ON ASPIRIN«RESISTANCE»M. J. Antonino* (US), K. P. Bliden, R. Coppolecchia, M. Gesheff, P. A. Gurbel, A. Singla, L.Lawal, S. Kotev, U. S. Tantry, P. Gurbel

PP-WE-798 EFFECT OF EPTIFIBATIDE ADDED TO BIVALIRUDIN ON PERIPROCEDURALINFLAMMATION AND PLATELET FUNCTION IN ELECTIVE STENTINGM. J. Antonino* (US), K. P. Bliden, T. A. Suarez, W. R. Herzog, A. K. Bassi, M. S. Hamed, T.Gesheff, S. Yadav, U. S. Tantry, P. A. Gurbel

PP-WE-799 EFFECT OF LONG-TERM CLOPIDOGREL TREATMENT ON PLATELET FUNCTION ANDINFLAMMATION IN PATIENTS UNDERGOING CORONARY ARTERIAL STENTINGM. J. Antonino* (US), E. Mahla, K. Bliden, U. S. Tantry, P. A. Gurbel

PP-WE-800 URINE 11DEHYDRO-THROMBOXANEB2 CONCENTRATIONS ARE HIGHER POST CABGCOMPARED WITH HEALTHY CONTROLSN. C. Raju* (CA), M. Teague, H. Jung, J. Sun, S. Anand, J. Eikelboom



297

PP-WE-801 THE ANTIPLATELET EFFECT OF A NEW, DIRECT ACTING, REVERSIBLE P2Y12INHIBITOR, ELINOGREL (PRT060128) IN PATIENTS WITH HIGH PLATELET REACTIVITYDURING CLOPIDOGREL THERAPYP. A. Gurbel* (US), K. Bliden, M. Antonino, P. Andre, G. Stephens, D. Gretler, M. Jurek, A.Hutchaleelaha, A. Singla, T. Suarez, P. Conely, U. Tantry

PP-WE-802 CYTOCHROME P450 2C19 GENOTYPE IS A MAJOR DETERMINANT OF CLOPIDOGRELRESPONSE AND A PREDICTOR OF POST-STENTING ISCHEMIC EVENT OCCURRENCEP. A. Gurbel* (US), K. Bliden, K. Ryan, W. Herzog, M. Antonino, U. Tantry, A. Shuldiner

PP-WE-803 PA32520 (SINGLE-TABLET OF IMMEDIATE-RELEASE OMEPRAZOLE 20 MG +ENTERIC-COATED ASPIRIN 325 MG): SAFER ASPIRIN THERAPY WITH GREATERTHROMBOXANE SUPPRESSIONP. A. Gurbel* (US), J. G. Fort, E. Orlemans, J. Planchetka

PP-WE-804 COMPARISON OF THE DIFFERENT METHODS OF MONITORING THE EFFECT OFASPIRIN AND CLOPIDOGREL IN PATIENTS WITH PERCUTANEOUS CORONARYINTERVENTIONP. Smejkal* (CZ), P. Kala, J. Zavrelova, M. Poloczek, J. Spinar, M. Penka

PP-WE-805 ENDOTHELIN-1 DUAL RECEPTOR ANTAGONIST AND THE EFFECT ON PLATELETFUNCTION IN PULMONARY ARTERIAL HYPERTENSIONS. J. Davidson* (UK), S. J. Wort, L. A. Parfitt, T. J. Corte, J. Park, C. Harries, M. Gatzoulis

PP-WE-806 IMMUNE THROMBOCYTOPENIC PURPURA-RELATED HEMOTYMPANUM PRESENTINGWITH HEARING LOSST. Fisgin* (TR), S. Atmaca, F. Duru, E. Ozyurek, R. Cetin, D. Albayrak

Atherosclerosis II

PP-WE-807 MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: A BURNING QUESTIONG. Corinaldesi* (IT), C. Corinaldesi

PP-WE-808 MATRIX GLA-PROTEIN: A RISK MARKER FOR VASCULAR CALCIFICATION THAT CANBE MODIFIED BY VITAMIN KL. J. Schurgers* (NL), E. C. M. Cranenburg, C. Vermeer

PP-WE-809 THE NUCLEAR RECEPTOR FXR AS A NOVEL REGULATOR OF PLATELET FUNCTIONL. A. Moraes* (UK), M. Spyridon, D. Bishop-Bailey, J. M. Gibbins

PP-WE-810 FBM PIGS: HUMAN-SIZED PIGS WITH HUMAN-LIKE ATHEROSCLEROSISC. Bal Dit Sollier, T. Thim, M. Bonneau, C. Kang, J. Brouland, N. Berge, M. Beauchaton-Piallat, C. Chaabane, E. Falk, L. Drouet* (FR)

PP-WE-811 ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS (SNP) IN METHIONINESYNTHASE (MTR) AND BETAINE-HOMOCYSTEINE METHYL TRANSFERASE (BHMT)GENES WITH CORONARY ARTERY DISEASE (CAD): ROLE OF DIETARY FACTORS ONHOMOCYSTEINEM. S. Mukherjee* (IN), P. R. Singh, K. R. Shetty

PP-WE-812 LIPID PENTAD INDEX IN NORMOLIPIDEMIC PATIENTS UNDERGOING CORONARYANGIOGRAPHYL. M. Lima, M. Carvalho* (BR), M. O. Sousa

PP-WE-813 IDENTIFICATION OF BIOMARKERS FOR VULNERABLE PLAQUEM. P. Brennan* (IE), J. Padickakudi, G. Kirwan, C. L. Jackson, D. Cox

PP-WE-814 POLYMORPHISM -1131T> C IN THE APOLIPOPROTEIN A5 (APOA5) GENE IN YOUNGSUBJECTS WITH DYSLIPIDEMIAS IN MINAS GERAIS STATE, BRAZILM. O. Sousa* (BR), D. D. V. Brito, F. F. Coelho, N. G. Cruz, I. R. Santos, A. P. Fernandes, K.B. Gomes



298

Wed

nesd

ay P

oste

rs

PP-WE-815 EFFECTS OF APOLIPOPROTEIN E POLYMORPHISMS ON LIPID PLASMA LEVEL INCHILDREN AND TEENAGERS IN MINAS GERAIS STATE, BRAZILM. O. Sousa* (BR), D. D. V. Brito, K. B. Gomes, A. P. Sabino, J. E. Cardoso, A. P. Fernandes

PP-WE-816 EFFECTS OF APOLIPOPROTEIN E C.471T>C AND C.609C>T POLYMORPHISMS ONLIPID- LIPOPROTEIN PLASMA LEVELS IN DYSLIPIDEMIC AND/OR ISCHEMICPATIENTSM. O. Sousa* (BR), P. Alía, M. Navarro, E. Corbella, X. Pintó

PP-WE-817 THE EFFECT OF LEPTIN ON VASCULAR CALCIFICATION IN APOLIPOPROTEIN E -DEFICIENT MICEM. G. Zeadin* (CA), M. Butcher, G. H. Werstuck, M. I. Khan, C. K. Yee, S. G. Shaughnessy

PP-WE-818 PLATELET-DEPENDENT LYMPHOCYTE ADHESION UNDER ARTERIAL FLOWCONDITIONS: EVIDENCE FROM IN VITRO AND IN VIVO STUDIESL. Zhu, H. Hu, Q. Ji, N. Li* (SE)

PP-WE-819 ASSOCIATION OF BLOOD CELLULAR MARKERS WITH CAROTID PLAQUE SIZE ANDCOMPOSITIONN. Matijevic* (US), K. K. Wu, A. G. Howard, B. Wasserman, W. Wang, A. R. Folsom, R.Sharrett

PP-WE-820 HIGH-RISK ATHEROSCLEROSIS OF MOGILEV SCHOOLCHILDRENN. V. Akulich* (BY), N. G. Kruchinsky

PP-WE-821 ASSOCIATION STUDY BETWEEN VARIANTS IN GAS6-TAM GENES AND ATHEROMACAROTID PLAQUEB. Hurtado, N. Abasolo, X. Muñoz, N. Garcia, J. Krupinski, P. Garcia de Frutos* (ES), N. Sala

PP-WE-822 PROTEIN S AND TYROSINE KINASE RECEPTORS TYRO3, AXL AND MERTK AREDIFFERENTIALY ESPRESSED IN CAROTID ATHEROSCLEROTIC PLAQUESB. Hurtado, X. Muñoz, N. Garcia, J. Krupinski, N. Sala, P. Garcia de Frutos* (ES)

PP-WE-823 HUMAN ATHEROSCLEROTIC PLAQUES POTENTIATE PLATELET AGGREGATION:ROLE OF MMP-2P. Gresele* (IT), M. Pompili, M. Lenti, E. Falcinelli, G. Giordano, T. Corazzi, P. Cao

PP-WE-824 VASCULAR ENDOTHELIAL GROWTH FACTOR GENE POLYMORPHISMS ANDMICROVASCULAR COMPLICATIONS IN PATIENTS WITH ESSENTIAL HYPERTENSIONR. Palmirotta, P. Ferroni* (IT), G. Ludovici, F. Martini, A. Savonarola, M. Ciancia, V. Raparelli,M. Proietti, A. Scarno, S. Riondino, S. Basili, F. Guadagni

PP-WE-825 FACTOR VII HYPERCOAGULANT ACTIVITY AND HYPERLEPTINEMIA AMONGABDOMINALLY OBESE HYPERTENSIVESR. A. Karatela* (IN), G. Sainani

PP-WE-826 ASSOCIATION OF FACTOR VII HYPERCOAGULANT ACTIVITY WITH INSULINRESISTANCE IN CORONARY HEART DISEASER. A. Karatela* (IN), G. Sainani

PP-WE-827 EICOSAPENTAENOIC ACID IMPROVES ADIPONECTIN, ENDOTHELIAL CELL-DERIVEDMICROPARTICLES AND ANGIOPOIETIN-2 IN PATIENTS WITH TYPE 2 DIABETESS. Nomura* (JP), N. Inami, S. Omoto, A. Shouzu, T. Ueba

PP-WE-828 IDENTIFICATION AND PREDICTION OF RISK FOR CORONARY ARTERY DISEASE INPREDISPOSED ASIAN INDIAN FAMILIESS. Hebbagodi* (IN), V. S. Rao, K. Sibi, S. John, J. Shanker, V. V. Kakkar

PP-WE-829 THE VALUE OF D-DIMER AND FIBRIN MONOMER AS PROGNOSTIC MARKERS OFDEATH AT 30 DAYS FOLLOW-UP IN CHEST PAIN PATIENTS WITH SUSPECTED ACUTECORONARY SYNDROMET. Brügger-Andersen* (NO), V. Pönitz, H. Staines, H. Grundt, D. Nilsen



299

PP-WE-830 WOULD THE USE OF N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE AS APROGNOSTIC MARKER HAVE CHANGED OUR CLINICAL JUDGEMENTT. Brügger-Andersen* (NO), H. Aarsetøy, H. Grundt, D. W. T. Nilsen

PP-WE-831 EVALUATION OF PLAQUE DESTABILIZATION BY PREGNANCY-ASSOCIATED PLASMAPROTEIN A (PAPPA) AND COAGULANT ACTIVITY DID NOT PREDICT RECCURENTTROPONIN-T POSITIVE CARDIAC EVENTS FOLLOWING AN ACUTE MYOCARDIALINFARCTIONT. Brügger-Andersen* (NO), H. Aarsetøy, H. Grundt, D. W. T. Nilsen

PP-WE-832 USEFULNESS OF C-REACTIVE PROTEIN AS A MARKER FOR PREDICTION OFFUTURE CORONARY EVENTS IN THE ASIAN INDIAN POPULATIONV. S. Rao, B. K. Natesha, H. Sridhara, J. Shibu, V. V. Kakkar* (UK)

PP-WE-833 ASSOCIATION OF SOLUBLE TWEAK WITH CORONARY ARTERY DISEASE IN THEASIAN INDIAN POPULATIONV. S. Rao, B. K. Natesha, S. Niladri, H. Sridhara, J. Shibu, V. V. Kakkar* (UK)

PP-WE-834 UTILITY OF CYTOMETRIC BEAD ASSAY FOR SIMULTANEOUS DETECTION OFMULTIPLE INFLAMMATORY MARKERS IN URINE SAMPLES: THE INDIANATHEROSCLEROSIS RESEARCH STUDYV. S. Rao, B. K. Natesha, U. Balakrishnan, V. V. Kakkar* (UK)

PP-WE-835 DEPLETION OF ANTIOXIDANT CAPACITY IN HYPERHOMOCYSTEINEMIC PATIENTSWITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASEV. M. Shmeleva* (RU), L. P. Rybakova

PP-WE-836 IMMUNE RESPONSE IN BALB/C MICE BY USING A MULTIFUNCTIONAL EPITOPESINTRODUCED INTO A DENDROASPIN PROTEIN SCAFFOLDX. Lu* (UK), V. Endresz, M. Xia, G. Qi, D. Chen, I. Faludi, K. Burián, A. Csanadi, A. Miczák,E. Gonczol, V. Kakkar

Signal Transduction in Vascular Cells

PP-WE-837 SERINE 253 REGULATES THE INCORPORATION OF TISSUE FACTOR AND RELEASEAS MICROPARTICLESC. Ettelaie* (UK), M. E. W. Collier

PP-WE-838 RAP1 REGULATES VASCULAR SMOOTH MUSCLE CELL ADHESION, SPREADING ANDPROLIFERATION, MIGRATION AND RESPONSE TO THROMBIN: IMPLICATION FORNEOINTIMAL FORMATIONJ. Huang* (US), G. A. Stouffer

PP-WE-839 FXa-INDUCED INTRACELLULAR SIGNALING LINKS COAGULATION TONEOANGIOGENESIS: POTENTIAL IMPLICATIONS FOR FIBROSISK. S. Borensztajn* (NL), H. Aberson, M. Peppelenbosch, A. Spek

PP-WE-840 EXOGENOUS TISSUE FACTOR STIMULATES VASCULAR ENDOTHELIAL CELLPROLIFERATION THROUGH ACTIVATION OF THE ERK1/2 PATHWAYM. E. W. Collier* (UK), C. Ettelaie

PP-WE-841 THE HYALURONIC ACID-BINDING PROTEASE HABP STIMULATES MMP-2 AND UPAACTIVITY IN FIBROBLASTS, BUT INITIATES CELL INVASION IN AN UPA-INDEPENDENT WAYM. Etscheid* (DE), N. Beer, R. Seitz, J. Dodt

PP-WE-842 “MODULATION OF UPAR SIGNALING TO ERK/MAPK BY ENDOCYTIC RECEPTORS OFTHE LDLR FAMILY”N. Geetha* (AT), J. Mihaly, B. R. Binder



300

Wed

nesd

ay P

oste

rs

PP-WE-843 VEGF- INDUCED INITIAL ENDOTHELIAL CELL MIGRATION REQUIRES UROKINASERECEPTOR FOR INTEGRIN REDISTRIBUTIONR. A. Alexander* (AT), J. M. Breuss, G. W. Prager, B. R. Binder

PP-WE-844 ROLE OF CERAMIDE 1-PHOSPHATE ON NEOINTIMAL HYPERPLASIAT. Kim* (KR), Y. Lim, H. Han, H. Lee, M. Song, M. Chung, Y. Kim, H. Yoo, Y. Yun

PP-WE-845 THE FLAVONE CHRYSIN INHIBITS PDGF- AND OXIDATIVE STRESS-INDUCEDSIGNALING IN VASCULAR SMOOTH MUSCLE CELLSW. Wu* (TW), H. Lo, M. Wu

PP-WE-846 INFLUENCE OF ANGIOTENSIN-(1-7) ON THE EXPRESSION OF TISSUE FACTORINDUCED BY LPS AND ITS MECHANISMS IN VASCULAR ENDOTHELIAL CELLSX. He* (CN), J. Hu, H. Wang, X. Shen, S. He, Z. Wen

Angiogenesis II

PP-WE-847 CELL-DRIVEN ANGIOGENESIS AND NEUROGENESIS AFTER STROKE IS REGULATEDBY PLATELET MICROPARTICLESD. Varon* (IL), Y. Hayun, A. Brill, R. Leker

PP-WE-848 NEOINTIMAL CELLS IN TRANSPLANT ARTERIOSCLEROSIS RESEMBLE A SPECIFICSUBSET OF SMOOTH MUSCLE PROGENITOR CELLS FOUND CIRCULATING POST-TRANSPLANTATIOND. Chen* (UK), J. M. Abrahams, J. H. McVey, A. Dorling

PP-WE-849 REGENERATIVE REPAIR AFTER ENDOLUMINAL INJURY ASSOCIATED WITHINHIBITION OF TISSUE FACTOR ACTIVITY ON A SPECIFIC SUBPOPULATION OFSMOOTH MUSCLE PROGENITORSD. Chen* (UK), J. M. Abrahams, J. H. McVey, A. Dorling

PP-WE-850 PROGENITOR CELLS ARE RELATED TO VASCULAR INJURY AND UREMIC TOXINS INHEMODIALYSIS PATIENTSN. Jourde-Chiche, L. Dou, F. Sabatier, R. Calaf, C. Cerini, P. Brunet, F. Dignat-George* (FR)

PP-WE-851 EFFECTS OF ASPIRIN ON CIRCULATING HEMATOPOIETIC STEM CELLS ANDENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH TYPE 2 DIABETES: ARANDOMIZED CROSSOVER TRIALM. M. C. Hovens* (NL), H. de Boer, J. D. Snoep, J. T. Tamsma, A. van Zonneveld, T. J.Rabelink, M. V. Huisman

PP-WE-852 ALTERED TRAFFICKING OF BONE MARROW-DERIVED CXCR4+ PROGENITOR CELLSFOLLOWING CARDIAC SURGERY WITH THE USE OF CARDIOPULMONARY BYPASSO. Dotsenko* (UK), Q. Xiao, Q. Xu, M. Jahangiri

PP-WE-853 PATTERN OF CIRCULATORY VASCULAR ENDOTHELIAL GROWTH FACTORRECEPTORS ( VEGFR-1 AND VEGFR-2 ) IN PATIENTS WITH B-CELL CHRONICLYMPHOCYTIC LEUKEMIAO. Elbaz* (EG), A. M. Eldemeri, M. S. Elashry

PP-WE-854 ANGIOTENSIN II RECEPTOR BLOCKADE INCREASES ENDOTHELIAL REPAIRPOTENTIAL IN YOUNGER ADULTS WITH SEVERE PERIPHERAL ARTERIAL DISEASE(PAD)P. J. Levy* (US), W. B. Strawn, K. B. Brosnihan, L. C. Moore, J. B. Holbrook, K. J. Hansen,C. M. Ferrario

PP-WE-855 VASCULOGENIC MIMICRY OF ACUTE LEUKEMIC BONE MARROW STROMAL CELLS.ROLE OF IGF-1P. Mirshahi* (FR), A. Rafii, L. Vincent, A. Berthaut, R. Varin, G. Kalantar, C. Marzac, O.Calandini, J. Marie, C. Soria, J. Soria, M. Mirshahi



301

PP-WE-856 AGE-DEPENDENT IMPAIRMENT OF NUMBER AND ANGIOGENIC POTENTIAL OFADIPOSE TISSUE – DERIVED PROGENITOR CELLSR. Madonna, F. Renna, C. Cellini, R. Cotellese, N. Picardi, P. Innocenti, R. de Caterina* (IT)

PP-WE-857 CHANGES OF COAGULATION AND INFLAMMATION BY TRANSPLANTATION OF TFSILENCED HUMAN EPCS IN ENDOTOXEMIC MICES. Xiong* (CN), Q. Wang, L. Zheng, J. Bao, X. Huang, J. Liu, F. Zeng, Y. Qiu

PP-WE-858 THE PRESENCE OF BONE MARROW CELLS-DERIVED MICROPARTICLES IMPAIRSTHE EFFICACY OF CARDIAC CELL THERAPYS. Susen* (FR), G. Lemesle, C. Charbonnel, C. Delhaye, D. Corseaux, T. Le Tourneau, O.Fabre, P. Marchetti, R. Nevière, E. vanBelle, B. Jude, F. Mouquet

PP-WE-859 LINEAGE NEGATIVE MONONUCLEAR CELLS : A MAJOR SOURCE OF MURINEENDOTHELIAL PROGENITOR CELLSV. Barbay* (FR), V. Richard, J. Borg, O. Boyer, C. Thuillez, E. Brakenhielm

Shear-induced Signaling

PP-WE-860 A MICROFLUDIC SYSTEM DESIGNED TO OBSERVE PLATELET BEHAVIOR UNDERCONTROLLED SHEAR IN REAL TIMEC. G. Conant* (US), M. Schwartz, C. Ionescu-Zanetti

PP-WE-861 PLATELET ADHERENCE TO PROTEINS UNDER SHEAR FLOW CONDITIONSJ. L. Berry, R. R. Hantgan* (US), M. Guthold, D. C. Sane, P. J. Nelli, N. Wajih

PP-WE-862 ENHANCED OUTSIDE-IN SIGNALING RELATED TO THE PRO33 (HPA-1B) VARIANT OFPLATELET INTEGRIN ALPHAIIB BETA3R. E. Scharf, M. Gyenes* (DE), M. Hasse, V. R. Stoldt

PP-WE-863 INTRAVENOUS OZON IN MULTI-DRUG RESISTANT PULMONARY TUBERCULOSISN. V. Yahorava* (BY), H. L. Hurevich, A. M. Skrahina, E. E. Konstantinova, E. V. Mironova, D.A. Milyutina

PP-WE-864 CORRECTION OF MICROCIRCULATORY AND RHEOLOGICAL DISORDERS INPATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASEN. V. Yahorava* (BY), E. E. Konstantinova, H. L. Hurevich, E. V. Mironova, D. A. Milyutina

PP-WE-865 THE HPA-1B (PRO33) VARIANT OF INTEGRIN ALPHAIIB BETA3 INCREASES THERESISTANCE OF ADHERENT PLATELETS UPON EXPOSURE TO SHEAR STRESSR. E. Scharf* (DE), V. R. Stoldt

Endothelial Dysfunction II

PP-WE-866 TADALAFIL IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULARRISK FACTORS: EFFECTS ON PLATELETS AND ENDOTHELIUME. de Bon, G. Bonanni, P. Bassi, G. Saggiorato, S. Imbergamo, C. Giuseppe* (IT), O. Iqbal,J. Fareed

PP-WE-867 INCIDENCE, RISK FACTORS, COAGULATION DISTURBANCES AND OUTCOME OFPEDIATRIC PATIENTS WITH VOD AFTER SCT – A SINGLE CENTRE EXPERIENCED. M. Jevtic* (RS), D. Vujic, Z. Zecevic, D. Veljkovic, S. Gazikalovic, I. Elezovic

PP-WE-868 INFLAMMATORY CYTOKINES PRESENT IN SMOKERS’ SERUM MODULATECYCLOOXYGENASE-2 EXPRESSION VIA NADPH-OXIDASE IN ENDOTHELIAL CELLSS. S. Barbieri, E. Zacchi, S. Gianellini, P. Amadio, B. B. Weksler, E. Tremoli* (IT)



302

Wed

nesd

ay P

oste

rs

PP-WE-869 PLASMA THROMBOMODULIN IN PREECLAMPSIAL. M. S. Dusse* (BR), L. C. Godoi, H. S. Madeira, B. A. Lwaleed, M. G. Carvalho

PP-WE-870 THE PLASMA HYPERCOGULABILITY AND VASCULAR ENDOTHELIUM ABNORMALCYTOKINES’ RELEASE MAY INFLUENCE THE PROGRESSION OF THE OSTEOPATHYIN HOMOZYGOUS BETA THALASSEMIA PATIENTSM. Musso* (IT), D. Cultrera, A. Cipolla, M. Rosso, G. Colletta, M. Ferro, B. Ximenes, G.Guido, R. Musso

PP-WE-871 CONTRIBUTION OF BOTH UREMIA AND SUBSTITUTIVE THERAPIES IN THEDEVELOPMENT OF ENDOTHELIAL DYSFUNCTION IN PATIENS WITH CHRONIC RENALFAILUREM. Diaz-Ricart* (ES), M. Palomo, A. Cases, P. Molina, F. Navalon, G. Escolar

PP-WE-872 GENETIC POLYMORPHISMS OF ENDOTHELIN-RELATED GENES ASSOCIATED WITHTWENTY-FOUR HOURS BLOOD PRESSURE VARIATIONS IN JAPANESEHYPERTENSIVESM. Banno* (JP), K. Kamide, T. Horio, T. Miyata, Y. Kawano

PP-WE-873 INCUBATION OF ENDOTHELIAL CELLS WITH CRP RESULTS IN ALTERATIONS INSURFACE FC GAMMA RI EXPRESSIONM. Shahidi* (UK), L. Powell, E. Oviedo-Orta, K. Bodman-Smith

PP-WE-874 X-RAY MOLECULAR STRUCTURE AND ANTIOXIDANT EFFECT OF ABUTYLAMINOESTROGEN DERIVATIVEM. Flores* (MX), L. Del Valle, B. Valente, L. Quintanar, J. Fernandez-G, V. Salgado, A. de La Peña

PP-WE-875 PKC-MMP-14 AXIS REGULATES ENDOTHELIAL SOLUBLE TIE-2 (STIE-2)PRODUCTION: INVOLVEMENT OF STIE-2 IN DIABETES MELLITUS-ASSOCIATEDVASCULAR COMPLICATIONSM. Onimaru* (JP), Y. Murakami, Y. Ikeda, T. Ishibashi, K. Sueishi

PP-WE-876 SOLUBLE ENDOTHELIAL PROTEIN C RECEPTOR AND HIGH SENSITIVE CRP LEVELSIN OBESITYB. Taskiran, S. Guldiken, M. Demir* (TR), T. Kilic-Okman

PP-WE-877 ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE POLYMORPHISMS (-786T>C, 4A4B,894G>T) AND HAPLOTYPES IN PATIENTS WITH IDIOPATHIC RECURRENTSPONTANEOUS ABORTION (RSA)N. Kim* (KR), S. Shin, D. Choi, J. Lee, J. Choi, S. Shim, D. Oh

PP-WE-878 EFFECTS OF CHILDHOOD OBESITY ON ENDOTHELIAL DYSFUNCTION ANDCOAGULATIVE ACTIVATION IN OBESE CHILDREN AND ADOLESCENTSM. F. Faienza, P. Giordano* (IT), V. Cecinati, M. Grassi, M. Delvecchio, L. P. Brescia, M.Altomare, L. Piacente, L. Cavallo, D. de Mattia

PP-WE-879 PROTEOME OF ENDOTHELIAL CELL IS CHANGED AFTER CONTACT WITHARTIFICIAL SURFACES OF BIOMATERIALSP. Komorowski* (PL), H. Jerczynska, Z. Pawlowska, B. Walkowiak

PP-WE-880 EVALUATION OF HEMATOLOGIC FACTORS IN YOUNG AND ELDERLY CANDIDATESFOR CORONARY ARTERY BYPASS GRAFTINGS. Ayaz* (TR), A. Aksöyek, U. Tutun, T. A. Ulus, S. B. Guney

PP-WE-881 LP(A) LIPOPROTEIN,ADHESION MOLECULE AND CYTOKIN:ROLE AND INTERACTIONIN RESTENOSIS AFTER PCIS. M. Pantovic* (ME), E. Pejovic

PP-WE-882 GAP JUNCTION PROTEIN, CONNEXIN32 IS EXPRESSED IN VASCULAR ENDOTHELIALCELLS AND MODULATES TUMOR NECROSIS FACTOR-ALPHA-INDUCEDENDOTHELIAL INFLAMMATIONT. Okamoto* (JP), T. Hayashi, K. Suzuki



303

PP-WE-883 ENDOTHELIAL DYSFUNCTION AND TNF-ALPHA IN YOUNG MEN WITH MULTIPLECARDIOVASCULAR RISK FACTORST. B. Domagala* (PL), R. Januszek, K. Kotula-Horowitz, J. Dropinski, T. Iwaniec, A. Szczeklik

PP-WE-884 IMPROVEMENT OF ENDOTHELIAL FUNCTION AND REDUCTION OFPROINFLAMMATORY MARKERS IN SIMVASTATIN TREATMENTT. B. Domagala* (PL), R. Januszek, K. Kotula-Horowitz, T. Iwaniec, M. Kaszuba, S. Polanski,A. Szczeklik

PP-WE-885 HIGH LEVELS OF CIRCULATING ENDOTHELIAL CELLS IN HEART FAILUREV. Martínez-Sales* (ES), V. Vila, I. Sánchez-Lázaro, L. Almenar, T. Contreras, E. Reganon

Inflammation and Cell Trafficking II

PP-WE-886 ACE INHIBITION REDUCES MONOCYTE MFG-E8 AND MCP-1 EXPRESSION IN RATSWITH CHRONIC HEART FAILUREJ. Pfrang* (DE), D. Fraccarollo, J. Bauersachs, A. Schaefer

PP-WE-887 ACTIVE VON WILLEBRAND FACTOR (VWF) IN PLASMA OF SICKLE CELL PATIENTS ISAN INDICATOR OF DISEASE SEVERITYJ. Chen* (US), W. Hobbs, J. Le, P. Lenting, P. G. de Groot, J. A. Lopez

PP-WE-888 THROMBOSPONDIN-1 INDUCES TNF ALPHA AND IL-6 GENE EXPRESSION ON HUMANFIBROBLASTSM. C. Rico* (US), J. J. Rough, F. E. Del Carpio-Cano, F. F. Safadi, S. P. Kunapuli, R. A. DelaCadena

PP-WE-889 THE RELATIONSHIPS BETWEEN VASCULAR ENDOTHELIAL GROWTH FACTORS,PARAMETERS OF INFLAMMATION AND PATIENTS’ SURVIVAL IN ADVANCEDNONSMALL CELL LUNG CANCERV. Demir, M. Demir* (TR), I. Cicin, G. E. Pamuk, E. Ozturk, E. Tekgunduz, T. Caglar

PP-WE-890 PLATELETS ENHANCE T HELPER CELL ACTIVATIONN. Gerdes* (SE), M. Ersoy, G. K. Hansson, P. Hjemdahl, N. Li

PP-WE-891 IMMATURE MYELOID DENDRITIC CELLS INTERACT WITH ACTIVATED PLATELETS INSUSPENSION AND ON PREFORMED THROMBI UNDER REDUCED FLOW CONDITIONSB. Maître, P. Mangin* (FR), A. Eckly, V. Heim, J. Cazenave, D. Hanau, F. Lanza, C. Gachet

PP-WE-892 DOMAIN SWAPPING OF CCR1 AND CCR5 REVEALS DEFINED FUNCTIONS OF THEEXTRACELLULAR REGIONS IN CELL RECRUITMENTR. R. Koenen* (DE), B. K. Kramp, A. Sarabi, S. Winkler, C. Weber

PP-WE-893 METABOLIC ALTERATION OF GLYCOSYLATION IN LEUKOCYTE PSGL-1 ANDREDUCTION IN SELECTIN BINDING FUNCTION USING ANALOGS OF NATURALLYOCCURRING MONOSACCHARIDESS. Neelamegham* (US), D. D. Marathe, A. Buffone, E. V. Chandrasekaran, J. Xue, M.Nasirikenari, J. T. Y. Lau, K. L. Matta

PP-WE-894 INFLAMMATORY BIOMARKER CRP: ASSOCIATION WITH MICROVESSEL OCCLUSIONIN PEDIATRIC SICKLE CELL DISEASES. Krishnan* (US), Y. B. N. Setty, C. Dampier, A. Rao, S. Gayen-Betal, M. Stuart

PP-WE-895 EFFECT OF A NOVEL ANTI-INFLAMMATORY COMPOUND, PCPC07F2, ON LPS-INDUCED CYTOKINES RELEASE OF MACROPHAGET. Huang* (TW), T. Huang

PP-WE-896 THE CONTRIBUTION OF PROTEASE-ACTIVATED RECEPTOR 4 TO PLATELETACTIVATION AND INFLAMMATION DURING CEREBRAL ISCHEMIC/REPERFUSIONY. Mao* (US), M. Zhang, R. F. Tuma, S. P. Kunapuli



304

305

ScientificProgram

ISTH2009

Thursday,July 16, 2009


Brinkhous Memorial Lecture Grand Ballroom

Chairperson: Sriram Krishnaswamy (US)

von Willebrand factor assembly and secretion PL-TH-001J. Evan Sadler (US) 9:45 - 10:30 AM

Plenary Lecture 5:15 PM – 6:00 PM

ISTH Congress Plenary Lecture, made possible Grand Ballroom

by a grant from the Désiré Collen Foundation

Chairperson: Charles Abrams (US)

Stem cells, pluripotency, and nuclear reprogramming PL-TH-002Rudolf Jaenisch (US) 5:15 - 6:00 PM


Anticoagulation Duration after Idiopathic Grand Ballroom A

Venous Thrombosis - the Swinging Pendulum

Chairpersons: Henri Bounameaux (CH) and Trevor Baglin (US)

What happens after venous thromboembolism? SA-TH-001Trevor Baglin (UK) 11:00 - 11:30 AM

Risk assessment to predict recurrence SA-TH-002Sabine Eichinger (AT) 11:30 - 12:00 PM

Balancing risks and benefits of extended anticoagulation SA-TH-003Clive Kearon (US) 12:00 - 12:30 PM

306

THURSDAY, JULY 16, 2009

Thur

sday

Sci

ence

Platelet Inhibition Room 253 ABC

Chairpersons: Marco Cattaneo (IT) and Alan Michelson (US)

The evolution of platelet-directed pharmacotherapy SA-TH-004Richard Becker (US) 11:00 - 11:30 AM

New P2Y12 antagonists SA-TH-005Marco Cattaneo (IT) 11:30 - 12:00 PM

Aspirin: 110 years later SA-TH-006Carlo Patrono (IT) 12:00 - 12:30 PM

Endothelial Progenitor Cell Biology Room 205 ABC

Chairpersons: Keith McCrae (US) and Lena Claesson-Welsh (SE)

Embryonic stem cell-derived endothelial cells: Properties and potential SA-TH-007Lena Claesson-Welsh (SE) 11:00 - 11:30 AM

Regulation of stem cell niche by endothelium SA-TH-008Shahin Rafii (US) 11:30 - 12:00 PM

Defining and characterizing human endothelial progenitor cells SA-TH-009Marvin Yoder (US) 12:00 - 12:30 PM

Acquired Bleeding Disorders Grand Ballroom B

Chairpersons: Michael Greaves (UK) and Marcel Levi (NL)

Bleeding with the new anticoagulants: Management options SA-TH-0010Mark Crowther (CA) 11:00 - 11:30 AM

Prediction and management of bleeding after cardiac surgery SA-TH-0011George Despotis (US) 11:30 - 12:00 PM

Epidemiology and management of bleeding in patients using vitamin K antagonists SA-TH-0012Marcel Levi (NL) 12:00 - 12:30 PM

307


Platelet Physiology/Pathophysiology Ballroom 210 ABC

Chairpersons: Bernhardt Nieswandt (DE) and Garret FitzGerald (US)

Bioactive lipids and atherothrombosis SA-TH-013Garret A FitzGerald (US) 11:00 - 11:30 AM

The role of the intrinsic apoptosis pathway in platelet biogenesis, life and death SA-TH-014Benjamin Kile (AU) 11:30 - 12:00 PM

Platelet hyperreactivity, scavenger receptors and atherothrombosis SA-TH-0015Eugene Podrez (US) 12:00 - 12:30 PM

Novel Regulatory Reactions in Coagulation Room 258 ABC

Chairpersons: Kenneth Mann (US) and Tilman Hackeng (NL)

Regulation of TFPI function by protein S SA-TH-0016Tilman Hackeng (NL) 11:00 - 11:30 AM

Protease allostery in hemostasis SA-TH-0017James Huntington (UK) 11:30 - 12:00 PM

Blood clotting reactions on nanoscale bilayers SA-TH-0018James Morrissey (US) 12:00 - 12:30 PM

308


Thur

sday

Sci

ence


Abstract Symposia consist of an invited speaker and four highly ratedabstracts presented on a related general theme period.

Estrogens and Vascular Disease Room 210 ABC

Chairperson: Joseph Emmerich (FR)

Estrogens and vascular disease: AS-TH-001Non-oral postmenopausal hormones and risk of thrombosis Joseph Emmerich (FR) 2:15 - 2:45 PM

AS-TH-002 2:45 - 3:00 PMTHE RISK OF VENOUS THROMBOSIS ASSOCIATED WITH NON-ORAL HORMONALCONTRACEPTIVESA. van Hylckama Vlieg* (NL), F. M. Helmerhorst, J. P. Vandenbroucke, C. J. M. Doggen, F. R. Rosendaal

AS-TH-003 3:00 - 3:15 PMIS PROGESTERONE AN INDEPENDENT RISK FACTOR FOR INCIDENT VENOUSTHROMBOEMBOLISM (VTE)? A POPULATION-BASED CASE-CONTROL STUDYM. Barsoum, J. A. Heit* (US), A. A. Ashrani, C. L. Leibson, T. M. Petterson, K. R. Bailey, L. J. Melton III

AS-TH-004 3:15 - 3:30 PMDIFFERENTIAL IMPACT OF CONVENTIONAL AND LOW DOSE ORAL HORMONE THERAPY (HT) ONSEX HORMONE BINDING GLOBULIN (SHBG)A. L. Eilertsen* (NO), E. Hoibraaten, C. M. Lofthus, M. C. Mowinckel, P. M. Sandset

AS-TH-005 3:30 - 3:45 PMDOES PATIENT SEX AND PRIOR HORMONAL THERAPY PREDICT RISK FOR THROMBOSISRECURRENCE AFTER A FIRST VENOUS THROMBOEMBOLISM?J. Douketis* (CA), A. Iorio, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, A.Tosetto

Pathophysiology of Heparin-Induced Room 205 ABC

Thrombocytopenia

Chairperson: Gowthami Arepally (US)

Heparin-induced thrombocytopenia: AS-TH-006Insights from murine models Gowthami Arepally (US) 2:15 - 2:45 PM

AS-TH-007 2:45 - 3:00 PMPLATELET FACTOR 4 BINDS TO GRAM POSITIVE BACTERIA AND INDUCES ANTIBODIES CROSS-REACTING WITH PF4/HEPARINK. Krauel* (DE), C. Pötschke, B. Fürll, W. Keßler, J. Bagemühl, B. M. Bröker, A. Greinacher

309


AS-TH-008 3:00 - 3:15 PMA MODEL OF HOW PLATELET FACTOR 4 (PF4) CONTRIBUTES TO PHYSIOLOGIC ANDPATHOLOGIC THROMBOSISM. A. Kowalska* (US), T. Turoczi, J. Hirsch, L. Rauova, D. Cines, H. Weiler, R. Camire, S. Krishnaswamy, M.Poncz

AS-TH-009 3:15 - 3:30 PMANTIBODY-INDEPENDENT, ALPHAIIBBETA3-MEDIATED ACTIVATION OF HUMAN PLATELETS BYUNFRACTIONATED HEPARINC. Gao* (US), B. Boylan, J. Fang, D. A. Wilcox, D. K. Newman, P. J. Newman

AS-TH-010 3:30 - 3:45 PMSIGNIFICANCE OF HIGH CONCENTRATION OF HEPARIN-INDUCED PLATELET ANTIBODIESK. M. Javela, R. Kekomäki* Finland, S. Koskinen

New Products in Hemophilia Room 253 ABC

Chairperson: Claude G. Negrier (FR)

Can we improve upon nature to design products AS-TH-011with enhanced efficacy for treating hemophilia and von Willebrand disease? Claude G. Negrier (FR) 2:15 - 2:45 PM

AS-TH-012 2:45 - 3:00 PMREPEAT ORAL ADMINISTRATION OF CHITOSAN FVIII DNA NANOPARTICLES RESULTS IN FVIIIANTIGEN IN BLOOD OF HEMOPHILIA A MICES. S. Dhadwar* (CA), J. Wen, G. Hortelano

AS-TH-013 3:00 - 3:15 PMZYMOGEN-LIKE FACTOR Xa VARIANTS IMPROVE HEMOSTASIS IN HEMOPHILIA MICEL. Ivanciu* (US), R. Toso, A. Schlachterman, H. Downey, J. Liu, V. R. Arruda, R. M. Camire

AS-TH-014 3:15 - 3:30 PMFACTOR IX VARIANTS WITH FACTOR VIII INHIBITOR BYPASSING ACTIVITYJ. Schuettrumpf* (DE), P. Milanov, D. Abriss, T. Tonn, E. Seifried

AS-TH-015 3:30 - 3:45 PMDEVELOPMENT OF A NOVEL TENASE-BYPASSING AGENT WITH A PROLONGED HALF-LIFE IN VIVOP. Gueguen* (FR), G. Cherel, L. Panicot-Dubois, R. Pendu, I. Badirou, C. Dubois, C. V. Denis, O. D. Christophe

Signal Transduction in Vascular Cells Room 258 ABC

Chairperson: Michael Mendelsohn (US)Estrogen signaling in endothelium AS-TH-016Michael Mendelsohn (US) 2:15 - 2:45 PM

AS-TH-017 2:45 - 3:00 PMENDOGENOUS PROTEIN C IS ESSENTIAL FOR THE FUNCTIONAL INTEGRITY OF HUMANENDOTHELIAL CELLSM. Xue, N. Minhas, P. N. Sambrook, L. March, C. J. Jackson* (AU)

AS-TH-018 3:00 - 3:15 PMVISCERAL STROMAL SECRETOME INDUCES ENDOTHELIAL DAMAGE AND ACTIVATION INOBESITYM. Palomo* (ES), F. Hanzu, P. Molina, P. Gomez, M. Garaulet, G. Escolar, R. Gomis, M. Diaz-Ricart

310


Thur

sday

Sci

ence

AS-TH-019 3:15 - 3:30 PMMETABOLIC AND VASCULAR CONSEQUENCES OF NEPRILYSIN DEFICIENCY: STUDIES IN AMURINE MODELK. F. Standeven* (UK), K. A. Hess, N. Y. Yuldasheva, A. J. Balmforth, S. B. Wheatcroft, N. M. Hooper, P. J.Grant

AS-TH-020 3:30 - 3:45 PMACTIVATED FACTOR X CLEAVES PAR1 AND MEDIATES SIGNALING DEPENDENT ON BINDING TOTHE ENDOTHELIAL PROTEIN C RECEPTORR. A. Schuepbach, M. Riewald* (US)

Platelets as Drug Targets Room 157 ABC

Chairperson: Christian Gachet (FR)

Purinergic and other receptors as targets AS-TH-021for old and new drugs Christian Gachet (FR) 2:15 - 2:45 PM

AS-TH-022 2:45 - 3:00 PMCLOPIDOGREL AND PRASUGREL PROLONG PRIMARY HEMOSTASIS IN THE MOUSE BEYONDLEVELS ASSOCIATED WITH P2Y12 INHIBITIONP. Andre* (US), F. Deguzman, S. Mills, Y. Pak, M. Inagaki, A. Pandey, S. Hollenbach, D. Phillips, P. Conley

AS-TH-023 3:00 - 3:15 PMIN VIVO AND IN VITRO EFFECT OF A NEW THROMBIN PROTEASE-ACTIVATED RECEPTOR (PAR-1)ANTAGONISTM. Dumas* (FR), F. Nadal-Wollbold, F. Grelac, M. Aiach, B. Le Grand, P. Gaussem, C. Bachelot-Loza

AS-TH-024 3:15 - 3:30 PMANTI-THROMBOTIC DRUG CANDIDATE ALX-0081 SHOWS SUPERIOR PRECLINICAL EFFICACYAND SAFETY COMPARED TO CURRENT MARKETED ANTIPLATELET DRUGSH. Ulrichts, A. Schoolmeester* (BE), S. Hoefman, M. Lauwereys, P. Casteels, P. Stanssens, J. Baumeister, J.Roodt, P. P. T. de Jaegere, J. Holz

AS-TH-025 3:30 - 3:45 PMDEVELOPMENT OF RSOLCD39-PSGL AS A NOVEL THERAPEUTIC WITH ANTI-THROMBOTIC ANDANTI-INFLAMMATORY EFFECTSS. Dezfouli* (AU), X. Zhang, S. Crikis, K. Dwyer, C. Selan, S. Robson, A. D'Apice, P. Cowan, H. Nandurkar

Treatment of Deep Vein Thrombosis Room 104 ABC

Chairperson: Suresh Vedantham (US)

Best use of vena cava filters AS-TH-026Suresh Vedantham (US) 2:15 - 2:45 PM

AS-TH-027 2:45 - 3:00 PMRETRIEVABLE IVC FILTERS ARE NOT BEING RETRIEVED. WHERE IS THE GAP?D. Bearelly* (US), N. Nagam, R. Chitima-Matsiga, S. Bearelly, O. Dabbagh

AS-TH-028 3:00 - 3:15 PMINFERIOR VENA CAVA FILTER OCCLUSION AND SYMPTOMATIC VENOUS THROMBOEMBOLISMRISK IN FULLY ANTICOAGULATED PATIENTS: A PROSPECTIVE, OBSERVATIONAL CONTROLLEDSTUDYB. Hajduk* (PL), W. Z. Tomkowski, G. Malek, B. L. Davidson

311


AS-TH-029 3:15 - 3:30 PMA PROSPECTIVE BLIND STUDY ON DIAGNOSIS AND CLINICAL RISK OF ISOLATED CALF DEEPVEIN THROMBOSIS IN SYMPTOMATIC OUTPATIENTS (THE CALTHRO STUDY; NCT00816920)G. Palareti* (IT), B. Cosmi, G. Lessiani, G. Rodorigo, G. Guazzaloca, C. Brusi, E. Conti, M. Filippini, M. Sartori,C. Legnani

AS-TH-030 3:30 - 3:45 PMABSENCE OF RESIDUAL VEIN THROMBOSIS AFTER AN EPISODE OF IDIOPATHIC DEEP VEINTHROMBOSIS: SHORT-TERM ANTICOAGULATION IS SAFE. THE “EXTENDED DACUS STUDY”S. M. Siragusa* (IT), A. Malato, G. Saccullo, G. Pizzo, D. Caramazza, L. Lo Coco, G. Baiardi, G. Milio, A. Pinto

Platelet Function Tests Room 107 ABC

Chairperson: Catherine Hayward (CA)

Platelet function tests in the assessment AS-TH-031of bleeding problems Catherine Hayward (CA) 2:15 -2:45 PM

AS-TH-032 2:45 - 3:00 PMPREVALENCE AND CHARACTERISTICS OF DUAL NON RESPONSIVENESS TO ASPIRIN ANDCLOPIDOGREL IN A COHORT OF 430 STABLE CARDIOVASCULAR PATIENTS. INSIGHT FROM THEADRIE STUDY ON STABLE CARDIOVASCULAR PATIENTSP. Fontana* (CH), I. Barazer, C. Castelli, S. Nolli, P. Berdagué, P. Fabbro-Peray, J. Schved, H. Bounameaux, F.Mach, P. de Moerloose, J. Reny

AS-TH-033 3:00 - 3:15 PMMEAN PLATELET VOLUME AS A PREDICTOR OF CARDIOVASCULAR RISK: A META-ANALYSISS. G. Chu, R. C. Becker, P. B. Berger, D. L. Bhatt, J. W. Eikelboom, B. Konkle, E. R. Mohler, J. S. Berger*(US)

AS-TH-034 3:15 - 3:30 PMCARDIOVASCULAR DEATH AND NONFATAL MYOCARDIAL INFARCTION IN ACUTE CORONARYSYNDROME PATIENTS ARE PREDICTED BY RESIDUAL PLATELET REACTIVITY TO ADP IN THEABSENCE OF CYP2C19*2 ALLELE: BEYOND GENETIC SCREENINGR. Marcucci* (IT), B. Giusti, A. Gori, R. Paniccia, C. Saracini, A. Vestrini, C. Nanna, A. Cordisco, E. Antonucci,G. Gensini, R. Abbate

AS-TH-035 3:30 - 3:45 PMGENETIC VARIANTS OF PLATELET FUNCTION AND CARDIOVASCULAR EVENTS: RESULTS FROMTHE SMILE-PLATELETS PROJECTJ. D. Snoep* (NL), J. Emmerich, P. Gaussem, J. C. J. Eikenboom, J. J. Zwaginga, H. L. Vos, P. G. de Groot, F.R. Rosendaal, J. G. van der Bom

312


Thur

sday

Sci

ence

313


Contact Pathway Room 153 ABC

Chairperson: Alvin Schmaier (US)

Animal models of the plasma kallikrein/kinin system: AS-TH-036Modulation of arterial thrombosis Alvin Schmaier (US) 2:15 - 2:45 PM

AS-TH-037 2:45 - 3:00 PMFACTOR XII IS A NOVEL MITOGENIC FACTOR FOR LUNG FIBROBLASTS IN LUNG FIBROSISE. Jablonska* (DE), P. Markart, I. Henneke, T. Renné, A. Günther, K. T. Preissner, M. Wygrecka

AS-TH-038 3:00 - 3:15 PMMISFOLDED PROTEINS ACTIVATE FACTOR XII IN HUMANS, LEADING TO KALLIKREINFORMATION WITHOUT INITIATING COAGULATIONC. Maas* (NL), J. W. P. Govers-Riemslag, B. Bouma, B. Schiks, B. P. C. Hazenberg, H. M. Lokhorst, P.Hammarström, H. ten Cate, P. G. de Groot, B. N. Bouma, M. F. B. G. Gebbink

AS-TH-039 3:15 - 3:30 PMFACTOR XI ACTIVATION BY FACTOR XIIa IN A MURINE THROMBOSIS MODELA. Gruber* (US), E. I. Tucker, Q. Cheng, I. Sisler, A. Matafonov, M. Sun, T. Renné, D. Gailani

AS-TH-040 3:30 - 3:45 PMRHA-INFESTIN, A COAGULATION FACTOR XIIa INHIBITOR, PROTECTS MICE FROM ARTERIALTHROMBOSIS AND ISCHEMIC STROKE WITHOUT IMPAIRING HEMOSTASISI. Hagedorn* (DE), U. Kronthaler, I. Pleines, C. Kleinschnitz, G. Stoll, B. Nieswandt

Genetics of Platelet Disorders Room 156 ABC

Chairperson: Paul Bray (US)

Pathways to variation in platelet reactivity AS-TH-041Paul Bray (US) 2:15 - 2:45 PM

AS-TH-042 2:45 - 3:00 PMDISRUPTION OF GATA-1/FOG-1 INTERACTION WITH THE NURD COMPLEX RESULTS IN AMACROTHROMBOCYTOPENIA AND ABSENT ALPHA-GRANULESY. Wang* (US), A. Miccio, G. D. Gregory, W. Hong, G. A. Blobel, M. Poncz

AS-TH-043 3:00 - 3:15 PMMYH9-RELATED DISEASE (MYH9-RD), FROM ONE THING TO THE OTHER: 11 NOVEL MUTATIONSAND 3 NEW EXONS AFFECTEDB. Saposnik* (FR), S. Binard, S. Elbaz, C. Trichet, C. Pouplard, V. Roussel-Robert, V. Leymarie, E. de Maistre,B. Royer, N. Djafari, C. Fagnou, H. Charlanne, P. Nurden, A. Nurden, N. Schlegel

AS-TH-044 3:15 - 3:30 PMRUNX1 REGULATES PLATELET/MEGAKARYOCYTE PKC-THETA : DECREASED PLATELET PKC-THETA EXPRESSION IN HUMAN RUNX1 HAPLODEFICIENCYG. S. Jalagadugula* (US), G. Kaur, G. Mao, D. Dhanasekaran, A. K. Rao

AS-TH-045 3:30 - 3:45 PMINDIVIDUALS WITH QUEBEC PLATELET DISORDER HAVE A TANDEM DUPLICATION OF THEUROKINASE PLASMINOGEN ACTIVATOR GENE (PLAU)A. Paterson, J. Rommens, B. Baraj, I. Wong, J. Blavignac* (CA), M. Diamandis, J. S. Waye, G. E. Rivard, C. P.M. Hayward

Protease Structure-Function Room 160 ABC

Chairperson: Rodney Camire (US)

Novel factor Xa Variant for improving Hemostasis AS-TH-046in Hemophilia Rodney Camire (US) 2:15 - 2:45 PMAS-TH-047 2:45 - 3:00 PMSUBSTRATE GEOMETRY GOVERNS ACTIVE SITE DOCKING AND REGULATES THE ACTION OFPROTHROMBINASE ON THE TWO CLEAVAGE SITES IN PROTHROMBINH. N. Bradford* (US), J. A. Micucci, S. Krishnaswamy

AS-TH-048 3:00 - 3:15 PMIN-VITRO SELECTION AND CHARACTERISATION OF DNA-APTAMERS THAT SPECIFICALLY BINDTO HUMAN ACTIVATED PROTEIN CJ. Müller* (DE), G. Mayer, B. Isermann, J. Oldenburg, B. Pötzsch

AS-TH-049 3:15 - 3:30 PMTHROMBIN CONTAINS A CRYPTIC LRP BINDING SITED. J. D. Johnson* (UK), K. S. Larsen, H. Stennicke, J. A. Huntington

AS-TH-050 3:30 - 3:45 PMCONFORMATIONAL ACTIVATION OF ZYMOGEN-LIKE THROMBIN VARIANTS BY TIGHT BINDINGLIGANDSA. Khan* (US), P. Panizzi, H. K. Kroh, P. E. Bock, S. Krishnaswamy

Neonatal and Pediatric Hemostasis Room 204 AB

Chairperson: Anthony Chan (CA)

Neonates: Are they more prone to clotting or bleeding? AS-TH-051Anthony Chan (CA) 2:15 - 2:45 PM

AS-TH-052 2:45 - 3:00 PMROLE OF 18 FUNCTIONAL HEMOSTATIC POLYMORPHISMS IN MUCOCUTANEOUS BLEEDINGA. Antón* (ES), R. González-Conejero, V. Roldán, T. Quiroga, C. Martínez, M. Lozano, L. Navarro-Núñez, B.Sánchez-Vega, J. Rivera, J. Corral, D. Mezzano, V. Vicente

AS-TH-053 3:00 - 3:15 PMIDENTIFICATION OF CHILDREN WITH SIGNIFICANT MUCOCUTANEOUS BLEEDING: COMPARISONOF THE HOSPITAL FOR SICK CHILDREN (HSC) CRITERIA AND A QUANTITATIVE PEDIATRIC-SPECIFIC BLEEDING QUESTIONNAIRE (PBQ)T. T. Biss* (CA), V. S. Blanchette, D. S. Clark, C. D. Wakefield, D. Lillicrap, P. D. James, M. L. Rand

AS-TH-054 3:15 - 3:30 PMMAJOR HAEMORRHAGE IN NEONATES WITH HAEMOPHILIA, FREQUENCY AND RISK FACTORS. AEUROPEAN COHORT STUDYM. Richards* (UK), K. Fijnvandraat, G. Lavigne-Lissalde

AS-TH-055 3:30 - 3:45 PMEVALUATION OF FAMILY HISTORIES IN PEDIATRIC PATIENTS WITH HEREDITARYTHROMBOCYTOPATHIES: RESULTS FROM THE THROMKID-STUDYR. Knoefler* (DE), M. Olivieri, S. Weickardt, W. Eberl, W. Streif

314


Shear-induced Signaling Room 257 AB

Chairperson: Martin A. Schwartz (US)

Fluid shear stress signaling in endothelial cells: AS-TH-056Role of integrins and extracellular matrix Martin A. Schwartz (US) 2:15 - 2:45 PM

AS-TH-057 2:45 - 3:00 PMVON WILLEBRAND FACTOR SELF-ASSEMBLY UNDER ELEVATED SHEAR STRESS FOSTERSACTIVATION-INDEPENDENT PLATELET STRING FORMATIONA. J. Reininger* (DE), J. I. Angerer, M. Fallah, M. F. Schneider

AS-TH-058 3:00 - 3:15 PMFACTOR SEVEN ACTIVATING PROTEASE (FSAP); A KEY REGULATOR OF PERICELLULARPROTEOLYSISJ. Daniel, O. Uslu, K. Hersemeyer, O. Rannou, L. Muhl, K. T. Preissner, D. Sedding, S. M. Kanse* (DE)

AS-TH-059 3:15 - 3:30 PMPHOSPHODIESTERASE-TYPE IV-CAMP-PKA AXIS REGULATES SFK-PYK2 PATHWAY, PMN/PLATELET ADHESION AND PMN ACCUMULATION AT THE SITE OF VASCULAR INJURYL. Totani, Z. Pamuklar, A. Piccoli, R. Pecce, L. Federico, N. Martelli, S. Manarini, V. Evangelista, S. S. Smyth*(US)

AS-TH-060 3:30 - 3:45 PMCD40 LIGAND (CD40L) INCREASES PLATELET THROMBUS STABILITY AND OUTSIDE-INSIGNALING THROUGH INTEGRIN ALPHAIIB BETA3R. E. Scharf* (DE), M. Hasse, E. Reiff, M. Gyenes, V. R. Stoldt

315


Thur

sday

Sci

ence

316

Risk Factors for Recurrent Venous Thrombosis Ball Room 210 ABC

Chairpersons: James Douketis (CA) and Gregor Hron (AT)

OC-TH-001 8:00 AM - 8:15 AMINCREASING LEVELS OF THROMBIN GENERATION PRECEDERECURRENT DVTA. J. ten Cate-Hoek* (NL), A. J. W. H. Dielis, H. M. H. Spronk, R. van Oerle,K. Hamulyák, M. H. Prins, H. ten Cate

OC-TH-002 8:15 AM - 8:30 AMD-DIMER TO PREDICT THROMBOSIS RECURRENCE AFTERUNPROVOKED VENOUS THROMBOEMBOLISM: EFFECT OF PATIENT-AND D-DIMER-RELATED FACTORS ON RECURRENCE PREDICTIONA. Iorio* (IT), J. Douketis, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger,G. Palareti, D. Poli, C. Tait, A. Tosetto

OC-TH-003 8:30 AM - 8:45 AMD-DIMER TIME COURSE AFTER STOPPING ANTICOAGULATION AFTERA FIRST EPISODE OF IDIOPATHIC VENOUS THROMBOEMBOLISM: THE PROLONG II PROSPECTIVE STUDYB. Cosmi* (IT), C. Legnani, A. Tosetto, V. Pengo, A. Ghirarduzzi, A. Alatri, S. Testa, D. Prisco, D. Poli, A. Tripodi, G. Palareti

OC-TH-004 8:45 AM - 9:00 AMCLINICAL PREDICTION GUIDE TO PREDICT THROMBOSISRECURRENCE AFTER A FIRST UNPROVOKED VENOUSTHROMBOEMBOLISMA. Tosetto* (IT), A. Iorio, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, J. Douketis

OC-TH-005 9:00 AM - 9:15 AMRISK FACTOR FOR THE PREDICTION OF RECURRENT VENOUSTHROMBOEMBOLISMJ. Emmerich* (FR), T. Zhu, L. Carcaillon, I. Martinez, V. Olie, V. Remones, F. Dali-Ali, P. Scarabin

OC-TH-006 9:15 AM - 9:30 AMD-DIMER AND COMORBIDITIES AS RISK FACTORS FOR RECURRENCEAFTER A FIRST EPISODE OF VENOUS THROMBOEMBOLISM IN THEEXTENDED FOLLOW-UP OF THE PROLONG STUDYB. Cosmi* (IT), C. Legnani, V. Pengo, A. Ghirarduzzi, S. Testa, A. Alatri, D. Prisco, D. Poli, A. Tripodi, G. Palareti

Clinicial Trials: Anticoagulation Room 205 ABC

Chairpersons: Samuel Goldhaber (US) and Walter Ageno (IT)

OC-TH-007 8:00 AM - 8:15 AMSINGLE-DOSE ADJUSTMENT VERSUS NO ADJUSTMENT OF WARFARININ STABLY ANTICOAGULATED PATIENTS WITH AN OCCASIONALLEVEL OUT OF RANGES. Schulman* (CA), A. Melinyshyn, D. Ennis, L. Rudd-Scott

THURSDAY, JULY 16, 2009 8:00 AM - 9:30 AM

ORAL COMMUNICATIONS

* Presenting Author

OC-TH-008 8:15 AM - 8:30 AMFREQUENCY OF MAJOR BLEEDING IN PATIENTS TREATED WITH LOWMOLECULAR WEIGHT HEPARIN FOR DEEP-VEIN THROMBOSIS ORPULMONARY EMBOLISM- A STUDY IN ROUTINE CLINICAL PRACTICEM. Zidane* (NL), E. P. C. Plompen, F. Cluitmans, F. J. M. van der Meer, E. V. Planken, M. V. Huisman

OC-TH-009 8:30 AM - 8:45 AMLOW-INTENSITY ADJUSTED-DOSE WARFARIN FOR THE PREVENTIONOF MECHANICAL MALFUNCTION OF DOUBLE-LUMEN HAEMODIALYSISCATHETERS: A RANDOMIZED CONTROLLED TRIALC. M. Clase, M. A. Crowther* (CA), T. J. Wilkieson, S. D. Soroka, R. Nagai, K. K. Jindal, A. J. Ingram

OC-TH-010 8:45 AM - 9:00 AMBLEEDING RISK WITH FIXED DOSE SUBCUTANEOUS LOWMOLECULAR WEIGHT HEPARIN COMPARED TO INTRAVENOUSADJUSTED DOSE UNFRACTIONATED HEPARIN: A METANALYSISG. Podda* (IT), G. Costantino, E. Ceriani, A. Rusconi, G. Casazza, N. Montano, P. Duca, M. Cattaneo

OC-TH-011 9:00 AM - 9:15 AMLMWH VS ASPIRIN FOR THE TREATMENT OF ACUTE RETINAL VEINOCCLUSIONW. Ageno* (IT), R. Cattaneo, E. Manfredi, A. Ghirarduzzi, E. Filippucci, G. Scannapieco, F. Rubbi, D. Imberti

OC-TH-012 9:15 AM - 9:30 AMPREDICTION OF THE WARFARIN MAINTENANCE DOSE AFTERCOMPLETION OF THE 10 MG INITIATION NOMOGRAMG. Le Gal* (FR), M. Carrier, S. Tierney, H. Majeed, M. Rodger, P. S. Wells

Health Services, Outcomes and Patient Education Room 258 ABC

Chairperson: Mark Crowther (CA) and Alex Spyropoulos (US)

OC-TH-013 8:00 AM - 8:15 AMTHE ROLE OF NEW EDUCATIONAL MATERIAL IN PATIENTSKNOWLEDGE OF ANTICOAGULANT THERAPYN. Ostasevski Fernandez* (SI), A. Kramaric, A. Mavri

OC-TH-014 8:15 AM - 8:30 AMMULTIDETECTOR COMPUTED TOMOGRAPHY TO ASSESS CLINICALOUTCOME IN HEMODYNAMICALLY STABLE PATIENTS WITH ACUTEPULMONARY EMBOLISMC. Becattini* (IT), M. C. Vedovati, S. Grifoni, F. Casazza, R. Douma, M. Bianchi, A. Salvi, S. Konstantinides, S. Vanni, W. Ageno, P. Kamphuisen,C. Nitti, R. Poggio, M. Duranti, G. Agnelli


ORAL COMMUNICATIONS

Thur

sday

Ora

ls

317

318

OC-TH-016 8:30 AM - 8:45 AMVENOUS THROMBOEMBOLISM PHARMACY INTERVENTIONMANAGEMENT PROGRAMC. E. Mahan* (US), M. A. Hussein, A. N. Amin, A. C. Spyropoulos

OC-TH-017 8:45 AM - 9:00 AMCOST-EFFECTIVENESS OF RULING OUT DEEP VENOUS THROMBOSIS(DVT) IN PRIMARY CAREA. J. ten Cate-Hoek* (NL), H. E. J. H. Stoffers, E. van der Velde, H. C. vanWeert, D. B. Toll, H. R. Büller, A. W. Hoes, K. G. M. Moons, R. Oudega, M. H. Prins, M. Joore

OC-TH-018 9:00 AM - 9:15 AMEFFECT OF A COMPUTERIZED HANDHELD CLINICAL DECISIONSUPPORT SYSTEM ON THE APPROPRIATENESS OF PULMONARYEMBOLISM DIAGNOSIS IN EMERGENCY DEPARTMENTS. A CLUSTERCONTROLLED CLINICAL TRIALP. Roy* (FR), P. Durieux, F. Guillaizeau, C. Legall, A. Armand-Perroux, L. Martino, M. Hachelaf, A. Dubart, J. Schmidt, M. Cristiano, J. Chretien, A. Perrier, G. Meyer

Heparin-induced Thrombocytopenia I Room 157 ABC

Chairpersons: Raj Kasthuri (IN) and Christilla Bachelot-Loza (FR)

OC-TH-019 8:00 AM - 8:15 AMA HIGHER PREVALENCE OF HIT ANTIBODIES IN HEMODIALYSISPATIENTS MAY BE DUE TO CONTAMINATED HEPARINJ. M. Walenga* (US), D. Hoppensteadt, J. Cunanan, C. Adiguzel, O. Iqbal, J. Fareed

OC-TH-020 8:15 AM - 8:30 AMHEPARIN ANTIBODY COMPLEXES ACTIVATE MONOCYTES ANDINDUCE THE RELEASE OF TISSUE FACTOR POSITIVEMICROPARTICLESR. S. Kasthuri* (US), S. Glover, G. Arepally, N. Key, N. Mackman

OC-TH-021 8:30 AM - 8:45 AMTHROMBIN GENERATION RELATED TO HEPARIN-INDUCEDTHROMBOCYTOPENIAB. Tardy- Poncet* (FR), M. Piot, C. Chapelle, L. Campos, O. Garraud, H. Decousus, P. Mismetti, B. Tardy

OC-TH-022 8:45 AM - 9:00 AMTHE RISK OF HEPARIN-INDUCED THROMBOCYTOPENIA IS INCREASEDIN PATIENTS HOMOZYGOUS FOR THE GNB3 825T ALLELEE. Boissier* (FR), D. Lasne, C. Pouplard, S. Gandrille, M. Alhenc-Gelas, F. Grelac, P. Gaussem, Y. Gruel, C. Bachelot-Loza

OC-TH-023 9:00 AM - 9:15 AMANTIBODIES OF PATIENTS WITH HEPARIN-INDUCEDTHROMBOCYTOPENIA RECOGNIZE COMPLEXES FORMED BYPLATELET FACTOR 4 AND NUCLEIC ACIDSM. E. Jaax* (DE), K. Krauel, B. Fürll, T. Marschall, B. Appel, S. Müller, S. Fischer, K. T. Preissner, A. Greinacher


ORAL COMMUNICATIONS

Thur

sday

Ora

ls

OC-TH-024 9:15 AM - 9:30 AMIMPROVING THE CAPABILITY OF THE ANTI-PF4/HEPARIN ENZYMEIMMUNOSORBENT ASSAY TO RULE OUT PLATELET ACTIVATINGPF4/HEPARIN ANTIBODIESK. Althaus* (DE), U. Strobel, B. Fuerll, A. Greinacher

Arterial Disease Risk Markers II Room 104 ABC

Chairpersons: Hugo Ten Cate (NL) and Veikko Salomaa (FI)

OC-TH-025 8:00 AM - 8:15 AMHIGH PLATELET REACTIVITY AND THE RISK OF MYOCARDIALINFARCTION IN YOUNG WOMENJ. D. Snoep* (NL), M. Roest, A. Barendrecht, F. R. Rosendaal, J. G. van der Bom

OC-TH-026 8:15 AM - 8:30 AMHEREDITARY DEFICIENCY OF NATURAL INHIBITORS OFCOAGULATION( ANTITROMBIN, PROTEIN C OR PROTEIN S) CONFERSINCREASED RISK OF ARTERIAL THROMBOEMBOLIC EVENTS.RESULTS FROM A PROSPECTIVE FAMILY COHORT STUDYD. Tormene* (IT), M. Perlati, V. Ferri, M. Facchin, S. Gavasso, P. Simioni

OC-TH-027 8:30 AM - 8:45 AMANTITHROMBIN CAMBRIDGE II (A384S) SUPPORTS A ROLE FORANTITHROMBIN DEFICIENCY IN ARTERIAL THROMBOSISV. Roldán, A. Ordóñez, F. Marín, E. Zorio, J. M. Soria, A. Miñano, F. España,R. González-Conejero, J. Pineda, A. Estellés, J. Fontcuberta, V. Vicente, J. Corral* (ES)

OC-TH-028 8:45 AM - 9:00 AMA COMMON POLYMORPHISM IN LOW-DENSITY LIPOPROTEINRECEPTOR GENE IS A PREDICTOR OF FACTOR VIII ACTIVITY LEVELSAND IS ASSOCIATED WITH CORONARY ARTERY DISEASEN. Martinelli* (IT), B. Lunghi, D. Girelli, M. Pinotti, G. Marchetti, M. Bisi, O. Olivieri, F. Manzato, R. Corrocher, F. Bernardi

OC-TH-029 9:00 AM - 9:15 AMVARIATION IN THE VON WILLEBRAND FACTOR GENE IS ASSOCIATEDWITH THE RISK OF CARDIOVASCULAR DISEASES AT YOUNG AGE: A HAPLOTYPE APPROACHM. C. van Schie* (NL), J. E. van Loon, D. W. J. Dippel, J. W. Deckers, D. D. Poldermans, M. P. M. de Maat, F. W. G. Leebeek

OC-TH-030 9:15 AM - 9:30 AMHIGH PLASMA APOLIPOPROTEIN C-III LEVELS PREDICT TOTAL ANDCARDIOVASCULAR MORTALITY IN PATIENTS WITHANGIOGRAPHICALLY DEFINED CORONARY ARTERY DISEASEN. Martinelli* (IT), D. Girelli, S. Friso, F. Pizzolo, P. Guarini, A. Bassi, G. Guidi,R. Corrocher, O. Olivieri


ORAL COMMUNICATIONS

319

320

Experimental Studies in Thrombosis: Animal Models Room 107 ABC

Chairpersons: Beatrice Hechler (FR) and Pieter Rietsma (NL)

OC-TH-031 8:00 AM - 8:15 AMEFFICACY OF FULL-LENGTH RECOMBINANT HUMAN PLASMIN IN A PORCINE MODEL OF ARTERIOVENOUS GRAFT THROMBOSISI. Hoefer, E. S. G. Stroes, G. Pasterkamp, M. Levi, J. A. Reekers, H. J. M. Verhagen, J. C. Meijers, J. E. Humphries* (US), J. I. Rotmans

OC-TH-032 8:15 AM - 8:30 AMBLOOD CELL-DERIVED MATRIX METALLOPROTEINASE TYPE 2 (MMP-2) PLAYS A ROLE IN ATHEROGENESISS. Momi* (IT), S. Giannini, P. Gresele

OC-TH-033 8:30 AM - 8:45 AMLOCALIZED ARTERIAL THROMBOSIS ON RUPTUREDATHEROSCLEROTIC PLAQUES OF APOE-/- MICE AFTER VASCULARINJURY WITH ULTRASOUNDB. Hechler* (FR), A. Eckly, S. Magnenat, M. Freund, J. P. Cazenave, F. Lanza, C. Gachet

OC-TH-034 8:45 AM - 9:00 AMFURTHER PHARMACOLOGICAL AND HISTOLOGICALCHARACTERIZATION OF A MODEL OF LASER-INDUCED LOCALIZEDTHROMBOSIS IN MESENTERIC ARTERIOLES WITH STANDARDIZEDMODERATE AND SEVERE INJURIESB. Hechler* (FR), A. Eckly, C. Nonne, S. Magnenat, C. Ravanat, M. Freund,C. Denis, J. P. Cazenave, F. Lanza, C. Gachet

OC-TH-035 9:00 AM - 9:15 AMHISTOLOGICAL CHARACTERIZATION OF MOUSE CAROTID ARTERYALTERATION FOLLOWING FERRIC CHLORIDE-INDUCED INJURYA. Eckly* (FR), M. Freund, M. Zerr Fouineau, J. Cazenave, F. Lanza, B. Hechler, C. Gachet

OC-TH-036 9:15 AM - 9:30 AMTLT-1 PROMOTES THROMBOSIS IN MICEL. Rivera* (PR), R. Hernández, O. González, J. Simon, A. Washington

Platelet Biology III Room 153 ABC

Chairpersons: Jonathan Gibbins (UK) and Michelle Lambert (US)

OC-TH-037 8:00 AM - 8:15 AMCHARACTERISATION OF NOVEL PLATELET SURFACE THIOLISOMERASE ENZYMESL. Holbrook* (UK), K. L. Jones, N. A. Watkins, C. I. Jones, W. H. Ouwehand, J. M. Gibbins

OC-TH-038 8:15 AM - 8:30 AMCIB1 IS A KEY REGULATOR OF PLATELET INTEGRIN IIB3-DEPENDENT RETRACTILE SIGNALINGM. U. Naik* (US), U. P. Naik


ORAL COMMUNICATIONS

Thur

sday

Ora

ls

OC-TH-039 8:30 AM - 8:45 AMA GAIN-OF-FUNCTION MUTATION IN THE PHOSPHOLIPASE C GAMMA 2 GENE ENHANCES INTEGRIN OUTSIDE-IN SIGNALING ANDLEADS TO A PROTHROMBOTIC PHENOTYPE IN MICEM. Elvers* (DE), R. Pozgaj, D. Varga-Szabo, F. May, P. Yu, B. Nieswandt

OC-TH-040 8:45 AM - 9:00 AMC-CBL NEGATIVELY REGULATES PLATELET GPVI SIGNALING VIA ANINTERACTION WITH THE HISTIDINE PHOSPATASE TULA-2 AND SYKD. H. Thomas* (US), C. A. Dangelmaier, J. Jin, A. Y. Tsygankov, S. P. Kunapuli, J. L. Daniel

OC-TH-041 9:00 AM - 9:15 AMIDENTIFICATION OF A NOVEL PLATELET THROMBOXANE A2RECEPTOR p.D304N VARIANT WITH REDUCED LIGAND BINDINGA. D. Mumford* (UK), B. B. Dawood, M. E. Daly, J. C. Spalton, S. J. Mundell,S. P. Watson, M. D. Williams

OC-TH-042 9:15 AM - 9:30 AMSUBSTITUTIONS OF THE UNIQUE BETA3-ARG261 HAVE DIFFERENTEFFECTS ON INTEGRINS ALPHAIIB-BETA3 AND ALPHAV-BETA3H. Hauschner* (IL), N. Rosenberg, M. Landau, U. Seligsohn

Vascular Progenitors and Stem Cells Room 156 ABC

Chairpersons: Anthony Dorling (UK) and Christoph Reinhardt (SE)

OC-TH-043 8:00 AM - 8:15 AMCOMPLETE INHIBITION OF TRANSPLANT ARTERIOSCLEROSIS BYINHIBITING TISSUE FACTOR ON VASCULAR PROGENITOR CELLSD. Chen* (UK), S. Shrivastava, D. J. Coe, J. Chai, D. M. Scott, J. H. McVey, A. Dorling

OC-TH-044 8:15 AM - 8:30 AMEFFECT OF ACUTE INFLAMMATION INDUCED BY PROLONGEDEXERCISE ON CIRCULATING STEM/PROGENITOR CELLS THATMEDIATE TISSUE REPAIRI. Papassotiriou, A. Spiropoulos, M. Tsironi, K. Skenderi* (GR), A. Margeli, P. Baltopoulos, E. Goussetis

OC-TH-045 8:30 AM - 8:45 AMREGULATION OF MOUSE EMBRYONIC STEM CELL COMMITMENT INTO THE ENDOTHELIAL LINEAGE BY P38 MITOGEN-ACTIVATEDPROTEIN KINASEE. Barruet, F. Peiretti, O. Hadadeh, I. Juhan-Vague, M. Alessi, B. Binetruy* (FR)

OC-TH-046 8:45 AM - 9:00 AMALPHA-6 INTEGRIN SUBUNIT PLAYS A MAJOR ROLE INPROANGIOGENIC PROPERTIES OF ENDOTHELIAL PROGENITORCELLSC. Bouvard* (FR), B. Gafsou, B. Dizier, I. Galy-Fauroux, A. Lokajczyk, C. Boisson-Vidal, A. M. Fischer, D. Helley


ORAL COMMUNICATIONS

321

322

OC-TH-047 9:00 AM - 9:15 AMBONE MARROW-DERIVED PROGENITOR CELLS IN ISCHEMIC STROKEPATIENTS: RELATIONSHIP BETWEEN INFARCT SIZE, NEUROLOGICALIMPAIRMENT AND DISCHARGE OUTCOMEF. Cesari* (IT), A. Gori, R. Marcucci, F. Sofi, V. Palumbo, G. Pracucci, P. Nencini, D. Inzitari, G. Gensini, R. Abbate

OC-TH-048 9:15 AM - 9:30 AMEX VIVO PRETREATMENT OF ENDOTHELIAL PROGENITOR CELLSWITH FUCOIDAN ENHANCES THEIR FUNCTIONAL ACTIVITY FOR CELLTHERAPYC. Boisson-Vidal* (FR), F. Zemani, G. Sarlon, J. P. Duong, B. Dizier, A. Lokajczyk, I. Galy-Fauroux, P. Bruneval, S. Colliec-Jouault, A. M. Fischer,J. Emmerich

Inhibitors of Factor VIII and Factor IX Room 160 ABC

Chairperson: Jenny Klintman (SE) and Donna Dimichele (US)

OC-TH-049 8:00 AM - 8:15 AMNOVEL TOLERANCE PROTOCOL FOR FACTOR VIIIB. Moghimi* (US), B. Sack, S. Nayak, C. Mah, R. Herzog

OC-TH-050 8:15 AM - 8:30 AMNON-INHIBITORY ANTIBODIES IN THE MIBS COHORTJ. Klintman* (SE), A. Hillarp, E. Berntorp, J. Astermark

OC-TH-051 8:30 AM - 8:45 AMINTRATHYMIC ADMINISTRATION OF FACTOR VIII RESULTS IN IMMUNETOLERANCE BY INDUCTION OF FACTOR VIII-SPECIFIC REGULATORYT CELLS IN MURINE HEMOPHILIA AS. Madoiwa* (JP), T. Yamauchi, E. Kobayashi, Y. Kashiwakura, A. Ishiwata, T. Ohmori, J. Mimuro, Y. Sakata

OC-TH-052 8:45 AM - 9:00 AMMAPPING THE FVIII BINDING SITE OF THE MONOCLONAL ANTI-FACTOR VIII ANTIBODY ESH-8 BY MASS SPECTROMETRYM. van Geffen* (NL), A. Loof, B. Verbruggen, W. van Heerde

OC-TH-053 9:00 AM - 9:15 AMDISTINCT T CELL AND B CELL IMMUNE RESPONSES IN BALB/C AND C57BL/6 MICE INFLUENCE THE ANTI-FVIII ANTIBODY TITRE INHEMOPHILIA A MICEM. Qadura, B. Waters* (CA), E. Burnett, R. Chegeni, M. Othman, D. Lillicrap

OC-TH-054 9:15 AM - 9:30 AMTHE RESIDENCE OF FVIII-SPECIFIC MEMORY B CELLS IN HEMOPHILICMICE AFTER INTRAVENOUS APPLICATION OF FVIIIG. Pordes* (AT), A. Trbic, C. Hausl, E. M. Muchitsch, R. U. Ahmad, H. J. Ehrlich, H. P. Schwarz, B. M. Reipert


ORAL COMMUNICATIONS

Thur

sday

Ora

ls

Antithrombotics - Systemic Effects Room 204 AB

Chairpersons: Jeffery Weitz (CA) and Irene Martinez-Martinez (ES)

OC-TH-055 8:00 AM - 8:15 AMASPIRIN AND CARDIOVASCULAR DISEASE: A CYCLOOXYGENASE-INDEPENDENT MODE OF ACTIONR. A. Ajjan* (UK), K. F. Standeven, K. Naseem, M. Khanbhai, F. Phoenix, K. Gersh, J. W. Weisel, R. A. S. Ariens, M. T. Kearney, P. J. Grant

OC-TH-056 8:15 AM - 8:30 AMTHROMBOSTATIN COMPOUNDS-INHBITION OF PROSTATE CANCER IN VITRO AND IN VIVOM. T. Nieman* (US), Y. Zhou, G. Larusch, G. Adams, A. H. Schmaier

OC-TH-057 8:30 AM - 8:45 AMTHROMBOGRAM ANALYSIS OF THE LONG-ACTING ANTICOAGULANTEFFECT OF TB-402, A HUMAN ANTI-FVIII ANTIBODY, AND OF ITSINTERACTIONS WITH RHFVIII, LMWH AND WARFARIN IN HEALTHYVOLUNTEERSP. Verhamme* (BE), S. Pakola, S. Glazer, J. Stassen, G. Cahillane, T. J. Jensen, J. Saint-Remy, E. Sonesson, P. Giessen, M. Hoylaerts, M. Jacquemin

OC-TH-058 8:45 AM - 9:00 AMRIVAROXABAN SUPPRESSES PLATELET-RICH THROMBUSFORMATION IN A RAT ARTERIOLAR, LASER-INDUCED INJURY MODELC. Gerdes* (DE), M. Schumacher

OC-TH-059 9:00 AM - 9:15 AMMAST CELLS INCREASE VASCULAR PERMEABILITY BY HEPARIN-INITIATED BRADYKININ FORMATION IN VIVOC. Oschatz* (DE), B. Lecher, T. Tradler, M. Paschke, R. Sedlmeier, S. Cichon,S. Hammerschmidt, W. Mueller-Esterl, T. Renné

OC-TH-060 9:15 AM - 9:30 AMIN VITRO AND IN VIVO ANTITHROMBOTIC EFFECTS OF DIANNEXIN, A NOVEL HOMODIMER OF ANNEXIN A5M. L. Rand* (CA), P. L. Gross, H. Wang, A. C. Allison, F. G. Pluthero, W. H. Kahr

Coagulation and Infection Room 102 AB

Chairpersons: David Ginsburg (US) and Mettine Bos (US)

OC-TH-061 8:00 AM - 8:15 AMINHIBITION OF GROUP A STREPTOCOCCUS VIRULENCE BY SMALLCOMPOUNDS AS NOVEL ANTIMICROBIAL REAGENTSH. Sun* (US), Y. Xu, M. Lapadatescu, S. Larsen, D. Ginsburg

OC-TH-062 8:15 AM - 8:30 AMPROTEIN C DEPLETION ENHANCES BACTERIAL OUTGROWTH ANDINCREASES MORTALITY IN MURINE PNEUMOCOCCAL SEPSISM. Schouten* (NL), C. van ‘T Veer, C. T. Esmon, M. M. Levi, T. van der Poll

OC-TH-063 8:30 AM - 8:45 AMPROLONGED SURVIVAL FOLLOWING MICROBIAL INFECTION IN MICEEXPRESSING THE THROMBIN ANTICOAGULANT MUTANT W215/E217AM. J. Flick* (US), A. K. Chauhan, E. S. Mullins, J. S. Palumbo, S. Thornton, X. Zheng, N. L. Esmon, C. T. Esmon, D. D. Wagner, J. L. Degen


ORAL COMMUNICATIONS

323

324

OC-TH-064 8:45 AM - 9:00 AMTHROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR IS DEGRADED BY PLASMINOGEN ACTIVATOR PLA OF YERSINIA PESTISM. Valls Serón* (NL), J. Haiko, P. F. Marx, T. K. Korhonen, P. G. de Groot, J. C. M. Meijers

OC-TH-065 9:00 AM - 9:15 AMINTERACTIONS OF PLASMIN WITH TISSUE FACTOR PATHWAYINHIBITOR (TFPI) IN A MOUSE MODEL OF ENDOTOXEMIAF. Lupu* (US), O. Herlea, N. I. Popescu, H. Tang, C. Lupu, C. T. Esmon, H. R. Lijnen

OC-TH-066 9:15 AM - 9:30 AMPROTEIN C DEPLETION ENHANCES INFLAMMATION AND DELAYSMORTALITY IN MURINE LETHAL INFLUENZA A INFECTIONM. Schouten* (NL), K. van der Sluijs, C. van ‘T Veer, C. T. Esmon, M. M. Levi, T. van der Poll

Trauma, Sepsis and Disseminated Intravascular Coagulation Room 109 AB

Chairpersons: Carl-Erik Dempfle (DE) and Daniel Frith (UK)

OC-TH-067 8:00 AM - 8:15 AMACUTE TRAUMATIC COAGULOPATHY IS DEPENDENT ON BOTHINJURY SEVERITY AND SHOCK: CLINICAL AND EXPERIMENTALVALIDATIOND. Frith* (UK), S. Stanworth, C. Gaarder, M. Maegele, C. Goslings, P. I. Johansson, S. Allard, M. J. Cohen, R. M. Pearse, C. Thiemermann, K. Brohi

OC-TH-068 8:15 AM - 8:30 AMFACTOR V LEIDEN MUTATION ENHANCES FIBRIN FORMATION ANDDISSOLUTION IN VIVO IN A HUMAN ENDOTOXEMIA MODELC. H. Dempfle* (DE), N. Suvajac, E. Elmas, B. Jilma, H. Weiler, M. Borggrefe

OC-TH-069 8:30 AM - 8:45 AMEFFICACY AND SAFETY OF RECOMBINANT ACTIVATED FACTOR VII IN THE MANAGEMENT OF HEMORRHAGIC SHOCK DUE TO TRAUMAC. J. Hauser, K. D. Boffard, R. P. Dutton* (US), G. R. Bernard, M. A. Croce, J. B. Holcomb, A. K. Leppaniemi, M. J. A. Parr, J. L. Vincent, B. J. Tortella, J. Dimsits, B. Bouillon, for the CONTROL Study Group

OC-TH-070 8:45 AM - 9:00 AMEBOLA VIRUS INFECTION MODULATES THE BALANCE BETWEEN TISSUEFACTOR AND THROMBOMODULIN ON ENDOTHELIAL CELLS: RELEVANCEFOR DYSFUNCTIONAL HAEMOSTASIS IN VIRAL INFECTIONSA. Shibamiya, M. Schuemann, T. Schmidt-Woell, K. T. Preissner, E. Muehlberger, S. M. Kanse* (DE)

OC-TH-071 9:00 AM - 9:15 AMTEMPORAL ASSOCIATION OF ALPHA-1-PROTEASE INHIBITORINACTIVATION WITH INCREASED ELASTASE DURING EXPERIMENTALSEPSISJ. A. Samis* (CA), K. A. Stewart, M. E. Nesheim, F. B. Taylor Jr

OC-TH-072 9:15 AM - 9:30 AMTEMPORAL ASSOCIATION OF COAGULATION FACTOR INACTIVATIONWITH INCREASED ELASTASE DURING EXPERIMENTAL SEPSISJ. A. Samis* (CA), K. A. Stewart, M. E. Nesheim, F. B. Taylor Jr


ORAL COMMUNICATIONS

Thur

sday

Ora

ls

Health Services and Outcomes Room 205 ABC

Chairpersons: Clive Kearon (CA) and Michael Streiff (US)

OC-TH-073 4:00 PM - 4:15 PMCARDIAC BIOMARKERS FOR RISK STRATIFICATION IN NON MASSIVEPULMONARY EMBOLISM: A MULTICENTER PROSPECTIVE STUDYN. Vuilleumier* (CH), G. Le Gal, F. Verschuren, A. Perrier, H. Bounameaux, N. Turck, J. Sanchez, N. Mensi, T. Perneger, D. Hochstrasser, M. Righini

OC-TH-074 4:15 PM - 4:30 PMEXTENT OF CLINICALLY IMPORTANT DIFFERENCES BETWEEN TWOMEASURES OF THE INTERNATIONAL NORMALIZED RATIO (INR)K. M. Shermock, B. L. Pinto, P. S. Kraus, M. B. Streiff* (US)

OC-TH-075 4:30 PM - 4:45 PMSTANDARDIZED LOW MOLECULAR WEIGHT HEPARIN BRIDGINGREGIMEN IN OUTPATIENTS ON ORAL ANTICOAGULANTSUNDERGOING INVASIVE PROCEDURE OR SURGERY: AN INCEPTIONCOHORT MANAGEMENT STUDYV. Pengo, U. Cucchini, G. Denas* (IT), N. Erba, G. Guazzaloca, L. La Rosa,V. de Micheli, S. Testa, R. Frontoni, D. Prisco, S. Iliceto

OC-TH-076 4:45 PM - 5:00 PMASSESSING THE UPTAKE OF NATIONAL INITIATIVES TO IMPROVEVENOUS THROMBOEMBOLISM PATIENT CARE IN THE UKR. Arya* (UK), A. McManus, S. Paneesha, N. Scriven, T. Nokes, T. Farren, A. Nieland, P. Rose, S. Bacon, D. O’Shaughnessy

Arterial Disease Mechanisms Room 253 ABC

Chairpersons: Aleksandra Antovic (SE) and Mark Taubman (US)

OC-TH-077 4:00 PM - 4:15 PMVASCULAR SMOOTH MUSCLE-DERIVED TISSUE FACTOR MEDIATESDEVELOPMENT OF ABDOMINAL AORTIC ANEURYSM INDUCED BYANGIOTENSIN II INFUSIONL. Wang* (US), D. L. Rateri, C. M. Miller, A. Daugherty, M. B. Taubman

OC-TH-078 4:15 PM - 4:30 PMPLASMA CONCENTRATIONS OF GROWTH ARREST SPECIFIC PROTEIN6 (GAS6) AND THE SOLUBLE FORM OF ITS TYROSINE KINASERECEPTOR AXL AS MARKERS OF LARGE ABDOMINAL AORTICANEURYSMSC. Ekman* (SE), D. Flondell, A. Gottsäter, B. Lindblad, B. Dahlbäck

OC-TH-079 4:30 PM - 4:45 PMGLYCEMIC CONTROL IS OF MAJOR IMPORTANCE FOR FIBRIN CLOTSTRUCTURE IN TYPE 1 DIABETESA. Antovic* (SE), F. Mobarrez, S. Tehrani, P. Lins, U. Adamson, N. Wallen, G. Jörneskog

THURSDAY, JULY 16, 2009 4:00 PM - 5:00 PM

ORAL COMMUNICATIONS

325

326

OC-TH-080 4:45 PM - 5:00 PMASSOCIATIONS OF THROMBIN GENERATION WITH RISK OFCARDIOVASCULAR DISEASE IN THE GLASGOW MONICA STUDYM. Smid* (NL), M. Woodward, A. Rumley, R. van Oerle, H. M. H. Spronk, H. ten Cate, G. Lowe

Pregnancy Complications Room 258 ABC

Chairpersons: Andra James (US) and Marc Blondon (CH)

OC-TH-081 4:00 PM - 4:15 PMPATERNAL THROMBOPHILIA AS A RISK FACTOR FOR DEEP VEINTHROMBOSIS (DVT) DURING PREGNANCY AND POSTPARTUM:INFLUENCE OF THE PATERNAL A3 HAPLOTYPE OF THE EPCR GENEON MATERNAL DVT OCCURRENCEJ. Galanaud* (FR), E. Cochery-Nouvellon, S. Alonso, C. Chauleur, E. Mercier,G. Lissalde-Lavigne, P. Fabbro-Péray, P. Marés, J. Daurés, M. Dauzat, I. Quéré, J. Gris

OC-TH-082 4:15 PM - 4:30 PMINCREASED LEVELS OF SOLUBLE ENDOTHELIAL CELL PROTEIN CRECEPTOR (SEPCR) IN WOMEN WITH PREECLAMPSIA: WITNESSESOF ENDOTHELIUM DAMAGE, OR NEW RISK FACTOR FORPREECLAMPSIA?B. Saposnik* (FR), E. Peynaud-Debayle, A. Stepanian, S. Benchenni, M. Simansour, G. Baron, M. Fontenay, A. Le Querrec, L. Mandelbrot, D. de Prost, S. Gandrille, on behalf of the ECLAXIR Study

OC-TH-083 4:30 PM - 4:45 PMHIGH-DOSE ANTITHROMBIN SUPPLEMENTATION IN EARLY PRE-ECLAMPSIA: A DOUBLE-BLIND, PLACEBO CONTROLLED STUDY(ON BEHALF OF THE ATIII-EPAS STUDY GROUP)L. Valsecchi, A. D’Angelo* (IT)

OC-TH-084 4:45 PM - 5:00 PMMATERNAL TOBACCO SMOKE EXPOSURE IN WOMEN WITH PREECLAMP-SIA IS ASSOCIATED WITH HIGHER BIRTHWEIGHT FOR GESTATIONAL AGES. R. Kahn* (CA), N. Almeida, G. Koren, M. Dahou, H. McNamara, R. Platt,M. S. Kramer

Hemophila: Gene Therapy Room 104 ABC

Chairpersons: Edward Tuddenham (UK) and Jonathan Finn (US)

OC-TH-085 4:00 PM - 4:15 PMINTRAVENOUS INFUSION OF GENETICALLY-MODIFIED ENDOTHELIALPROGENITOR CELLS FOR THE TREATMENT OF HEMOPHILIA A: INITIALTRIALS IN THE HEMOPHILIA A DOG MODELH. Matsui* (CA), M. Ozelo, A. Labelle, S. Powell, L. Harpell, C. Hegadorn, P. Thompson, C. Hough, D. Lillicrap

OC-TH-086 4:15 PM - 4:30 PMREDUCED IMMUNOLOGICAL RESPONSE TO FACTOR VIII IN HEMOPHILIAA MICE ASSOCIATED WITH SUBCUTANEOUS IMPLANTATION OFLENTIVIRALLY-ENGINEERED ENDOTHELIAL PROGENITOR CELLSH. Matsui* (CA), A. Labelle, C. Hegadorn, P. Thompson, E. Burnett, C. Hough, D. Lillicrap


ORAL COMMUNICATIONS

Thur

sday

Ora

ls

OC-TH-087 4:30 PM - 4:45 PMADENO-ASSOCIATED VIRUS VECTOR EXPRESSION OF LARGE GENESIS ENHANCED BY PROTEASOME INHIBITORS AS MODELED INHEMOPHILIA A MICE AND DOGSP. E. Monahan* (US), J. Sun, C. D. Lothrop Jr, R. J. Samulski

OC-TH-088 4:45 PM - 5:00 PMDEVELOPMENT OF HUMAN ARTIFICIAL CHROMOSOME VECTORS FOR GENE THERAPY OF HEMOPHILIA AY. Yakura* (JP), C. Ishihara, A. Hayashi, T. Matsui, S. Matsumoto, H. Kurosaki, M. Oshimura, T. Doi, N. Komatsu, H. Takeya

Inflammation and Cell Trafficking II Room 107 ABC

Chairpersons: Lina Badimon (ES) and Elena Osto (IT)

OC-TH-089 4:00 PM - 4:15 PMCOMPLEMENT C3 IS A SUBSTRATE FOR FACTOR XIII AND ISINCORPORATED INTO FIBRIN CLOTS – A NOVEL LINK BETWEENINFLAMMATION AND THROMBOSISV. Schroeder* (UK), V. Polkinghorne, K. F. Standeven, P. J. Grant, A. M. Carter

OC-TH-090 4:15 PM - 4:30 PMTISSUE FACTOR LOCALIZES IN THE LEADING EDGE OF MIGRATINGHUMAN VASCULAR SMOOTH MUSCLE CELLS AND ITS DOWN-REGULATION SIGNIFICANTLY REDUCES MIGRATIONE. Peña, G. Arderiu, L. Badimon* (ES)

OC-TH-091 4:30 PM - 4:45 PMCRP-VLDL COMPLEXES IN SEPSISG. Wang* (UK), S. Abrams, C. Dowsey, J. Thachil, C. Toh

OC-TH-092 4:45 PM - 5:00 PMF11R/JAM-A IS REQUIRED FOR PLATELET ADHESION TO INFLAMEDENDOTHELIAL CELLS (EC): ROLE IN THROMBOGENESIS ANDATHEROSCLEROSISB. M. Azari* (US), J. D. Marmur, E. Kornecki, Y. H. Ehrlich, M. O. Salifu, A. Babinska

Mechanisms of Platelet Activation IV Room 153 ABC

Chairpersons: Johan Heemskerk (NL) and Justin Hamilton (AU)

OC-TH-093 4:00 PM - 4:15 PMCLUSTERING OF PECAM-1 INHIBITS MULTIPLE PLATELET SIGNALINGPATHWAYS AND RESULTS IN SIGNIFICANT REDUCTION OF THROMBUSFORMATIONC. I. Jones* (UK), S. F. Garner, L. A. Moraes, W. J. Kaiser, A. Rankin, W. H. Ouwehand, A. H. Goodall, J. M. Gibbins

OC-TH-094 4:15 PM - 4:30 PMROLE OF PKC ISOFORMS ETA AND EPSILON IN ADP-INDUCEDPLATELET FUNCTIONAL RESPONSES – PHARMACOLOGICAL ANDGENE KNOCKOUT STUDIESY. S. Bynagari* (US), B. Nagy, K. Bhavaraju, S. Kim, D. Woulfe, S. Kunapuli


ORAL COMMUNICATIONS

327

328

OC-TH-095 4:30 PM - 4:45 PMTHE ROLE OF PGRMC1 IN PLATELET FUNCTIONY. Jin* (US), W. Hong, D. Woulfe, D. Kenny, P. F. Bray

OC-TH-096 4:45 PM - 5:00 PMMECHANISM OF THROMBIN BINDING TO PLATELET GLYCOPROTEIN IBA. Zarpellon* (US), A. Zampolli, R. A. McClintock, J. R. Roberts, Z. M. Ruggeri

Platelet Biology IV Room 156 ABC

Chairpersons: Paquita Nurden (FR) and Judith Cosemans (NL)

OC-TH-097 4:00 PM - 4:15 PMTHERE IS A HIGH MORTALITY RATE IN MICE WHEN PLATELETINTEGRIN ? IIB?3 IS LOCKED-IN ITS HIGH AFFINITY STATED. A. Wilcox* (US), J. Fang, P. North, P. Nurden, A. T. Nurden, N. Valentin

OC-TH-098 4:15 PM - 4:30 PMIMPAIRED ACTIVATION OF PLATELETS LACKING PROTEIN KINASE CTHETA ISOFORMB. Nagy* (US), K. Bhavaraju, T. Getz, Y. B. Bynagari, S. Kim, S. P. Kunapuli

OC-TH-099 4:30 PM - 4:45 PMA ROLE OF PLATELET MEMBRANE MICRODOMAINS IN CLEC-2-MEDIATED SIGNAL TRANSDUCTIONK. Suzuki-Inoue* (JP), O. Inoue, Y. Ozaki

OC-TH-100 4:45 PM - 5:00 PMA NOVEL ROLE OF GAB1-SHP2-PI3K COMPLEX ON PECAM-1SIGNALLING IN PLATELETSL. A. Moraes* (UK), C. I. Jones, J. M. Gibbins

Heparin-induced Thrombocytopenia II Room 160 ABC

Chairpersons: Andreas Greinacher (DE) and Yves Gruel (FR)

OC-TH-101 4:00 PM - 4:15 PMQUANTITATIVE INTERPRETATION OF OPTICAL DENSITYMEASUREMENTS OF IGG ANTIBODIES AGAINST HEPARIN/PF 4-COMPLEX IN COMPARISON WITH RESULTS OF OUR FUNCTIONALASSAY – IS THERE A BETTER CUTOFF VALUE?F. Bergmann* (DE), C. Bruns, C. Platzer, S. Krell, B. Arndt, A. Gröning

OC-TH-102 4:15 PM - 4:30 PMFALSE POSITIVE TESTS FOR HEPARIN INDUCEDTHROMBOCYTOPENIA IN PATIENTS WITH ANTIPHOSPHOLIPIDSYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUSR. Pauzner* (IL), A. Greinacher, K. Selleng, K. Althaus, B. Shenkman, U. Seligsohn

OC-TH-103 4:30 PM - 4:45 PMBIOMARKER PROFILING OF PLASMA SAMPLES FROM SUSPECTEDHEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS USING APROTEIN CHIP ARRAY METHODJ. Fareed* (US), H. Zhu, J. Walenga, J. Cunanan, D. Hoppensteadt


ORAL COMMUNICATIONS

Thur

sday

Ora

ls

OC-TH-104 4:45 PM - 5:00 PMHOW FREQUENTLY DO EMERGENCY DEPARTMENT PHYSICIANSDOCUMENT RISK ASSESSMENT FOR HEPARIN-INDUCEDTHROMBOCYTOPENIA?R. L. Levine* (US), R. T. Funk, G. W. Hergenroeder, M. J. Hursting

Inhibitors of Coagulation and Fibrinolysis Room 102 AB

Chairpersons: Naomi Esmon (US) and Michael Page (US)

OC-TH-105 4:00 PM - 4:15 PMSTRUCTURE-FUNCTION RELATIONSHIPS OF VARIEGIN: A NOVELCLASS OF THROMBIN INHIBITORSC. Y. Koh* (SG), S. Kumar, K. Swaminathan, P. Uvaraj, P. Jagadeeswaran, R. M. Kini

OC-TH-106 4:15 PM - 4:30 PMHD1 INHIBITS THROMBIN GENERATION BY ATTENUATINGPROTHROMBIN ACTIVATION AND THROMBIN FEEDBACKC. A. Kretz* (CA), K. K. Cuddy, A. R. Stafford, J. C. Fredenburgh, J. I. Weitz

OC-TH-107 4:30 PM - 4:45 PMRECONSTRUCTED RECOMBINANT FACTOR Xa AS AN ANTIDOTE TOREVERSE ANTICOAGULATION BY FACTOR Xa INHIBITORSG. Lu* (US), P. Luan, S. J. Hollenbach, K. Abe, F. R. Deguzman, G. Siu, A. Hutchaleelaha, M. Inagaki, P. B. Conley, D. R. Phillips, U. Sinha

OC-TH-108 4:45 PM - 5:00 PMANTITHROMBOTIC EFFECTS OF A FACTOR VII ANTISENSEOLIGONUCLEOTIDE IN MICEJ. R. Crosby* (US), D. Gao, C. Zhao, A. Siwkowski, H. Zhang, A. R. MacLeod, B. P. Monia

Regulation of Coagulation and Fibrinolysis Room 109 AB

Chairpersons: Dennis Galanakis (US) and Maartje van den Biggelaar (NL)

OC-TH-109 4:00 PM - 4:15 PMSYSTEMS BIOLOGY MODEL OF COMBINED PLATELET ACTIVATIONAND BLOOD COAGULATION TESTED OVER A MULTIVARIATEEXPERIMENTAL SPACEM. S. Chatterjee* (US), W. S. Denney, H. Jing, D. Jager, S. L. Diamond

OC-TH-110 4:15 PM - 4:30 PMTHE MARBURG I POLYMORPHISM (G534E) OF FACTOR VII ACTIVATINGPROTEASE (FSAP) PREVENTS FVII ACTIVATION, BUT CONTRIBUTESTO THROMBOEMBOLIC RISK DUE TO FVIII ACTIVATIONM. Etscheid* (DE), L. Muhl, D. Pons, K. T. Preissner, W. Ruf, W. Jukema, S. M. Kanse

OC-TH-111 4:30 PM - 4:45 PMINACTIVATION OF PAI-1 BY ACTIVATED FACTOR XII PLAYS A ROLE INTHE CONTACT PHASE DEPENDENT ENHANCEMENT OF FIBRINOLYSISA. Tanaka* (JP), Y. Suzuki, N. Kanayama, T. Urano

OC-TH-112 4:45 PM - 5:00 PMEXPRESSION OF HEMOSTATIC PROTEINS IN THE LYMPHATICVASCULATURE OF HEALTHY AND SEPTIC BABOONSC. Lupu, G. A. Harris, R. Silasi-Mansat, L. Ivanciu, F. B. Taylor, G. T. Kinasewitz, F. Lupu* (US)


ORAL COMMUNICATIONS

329

330

Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Room 151 AB

Chairpersons: Michael Nesheim (CA) and Mary Prorok (US)

OC-TH-113 4:00 PM - 4:15 PMIN VIVO AND IN VITRO PROFIBRINOLYTIC EFFECT OF MMP-10MEDIATED BY TAFI: A NEW ROLE FOR MMPS ON FIBRINOLYSIS?J. Orbe* (ES), J. A. Rodriguez, C. Orset, J. Barrenetxe, R. Serrano, E. Angles-Cano, D. Vivien, M. Belzunce, J. A. Paramo

OC-TH-114 4:15 PM - 4:30 PMSTIMULATION OF THE INTRINSIC ENZYMATIC ACTIVITY OF TAFIATTENUATES CLOT LYSISK. Buelens* (BE), G. H. Hassanzadeh, S. Muyldermans, A. Gils, P. J. Declerck

OC-TH-115 4:30 PM - 4:45 PMACTIVE PLATELET-DERIVED TAFI ATTENUATES PLATELET-RICHTHROMBUS LYSIS IN VITROS. L. Schadinger* (CA), M. B. Boffa

OC-TH-116 4:45 PM - 5:00 PMCARBOXYPEPTIDASE N: AN ANTIFIBRINOLYTICCARBOXYPEPTIDASE?P. L. Swanson* (CA), T. Binette, P. Scott, C. Peterson, L. Bajzar

Atherosclerosis: Risk factors II Room 162 AB

Chairpersons: Gunnar Heine (DE) and V. V. Kakkar, (UK)

OC-TH-117 4:00 PM - 4:15 PMASSOCIATIONS OF CIRCULATING NATURAL KILLER CELLS WITHCARDIOVASCULAR DISEASE RISK FACTORS: THE MULTI-ETHNICSTUDY OF ATHEROSCLEROSIS (MESA)N. S. Jenny* (US), M. Doyle, R. Kronmal, S. Huber, B. M. Psaty, R. P. Tracy

OC-TH-118 4:15 PM - 4:30 PMHIGH ANTIBODY LEVELS TO PATHOGENS, HEAT SHOCK PROTEINSAND THE RISK OF CORONARY ARTERY DISEASE IN INDIANPOPULATIONV. S. Rao, L. A. Mundkur* (IN), J. Shanker, H. Sridhara, J. Shibhu, K. Sibi, K. Hemapriya, V. Ravi Kumar, B. Dhanalakshmi, A. Mani, V. V. Kakkar

OC-TH-119 4:30 PM - 4:45 PMTHE RHEUMATOID FACTOR MAY BE AN INDEPENDENT RISK FACTORFOR CORONARY ARTERY DISEASE IN METABOLIC SYNDROME MENG. Jong* (TW), T. Ma, L. Tien, M. Chang

OC-TH-120 4:45 PM - 5:00 PMCALU A29809G POLYMORPHISM ROLE IN CORONARYATHEROTHROMBOTIC PLAQUES AND PROGNOSTIC INVOLVEMENTV. Pérez Andreu* (ES), R. Gonzalez Conejero, J. Ruiz Nodar, D. HernandezRomero, F. Marín, A. Tello Montoliu, A. Antón, V. Vicente, V. Roldan


ORAL COMMUNICATIONS

Thur

sday

Pos

ters

Mechanisms of Platelet Activation III

PP-TH-001 THE EFFECT OF HYDROGEN SULPHIDE ON PLATELET ACTIONN. J. Truss* (UK), F. Y. Ali, P. C. J. Armstrong, T. D. Warner

PP-TH-002 NITRIC OXIDE INHIBITS PLATELET AGGREGATION INDEPENDENTLY FROMFORMATION OF THROMBOXANE A2N. J. Truss* (UK), P. C. J. Armstrong, S. K. Shinhmar, T. D. Warner

PP-TH-003 HOMOCYSTEINE INDUCES CHANGES IN PLATELET CALCIUM MOBILIZATION ANDFUNCTION IN TYPE 2 DIABETES MELLITUSN. Alexandru* (RO), I. Jardín, D. Popov, M. Simionecu, J. García- Estañ, G. M. Salido, J. A.Rosado

PP-TH-004 LOCAL DISTRIBUTION OF CYTOSOLIC CALCIUM ION IN PLATELET FORMINGTHROMBI ON COLLAGEN FIBRILS AND VON WILLEBRAND FACTOR UNDERCONTROLLED BLOOD FLOW CONDITIONN. Tamura* (JP), H. Ishida, S. Goto

PP-TH-005 SOLUBLE ELASTIN INHIBITS PLATELET ACTIVATION MEDIATED THROUGHGLYCOPROTEIN IBO. Inoue* (JP), K. Suzuki-Inoue, Y. Ozaki

PP-TH-006 STUDY OF THE RESISTANCE IN ASPIRIN, BY DETERMINATION OF GLYCOPROTEINON THE PLATELET MEMBRANEP. E. Makris* (GR), M. Moshou, M. P. Makris, G. Koliakos

PP-TH-007 INTEGRIN ALPHAIIBBETA3 OUTSIDE-IN SIGNALING VIA SYK INDUCES PLATELETPROCOAGULANT ACTIVITYP. E. J. van der Meijden* (NL), M. A. H. Feijge, K. Gilio, K. Hamulyak, J. W. M. Heemskerk

PP-TH-008 CHARACTERIZATION OF PLATELET NITRIC OXIDE PRODUCTION TRIGGERED BYPLATELET ADHESION UNDER FLOW USING IMAGE SEQUENCE ANALYSISG. Guglielmini, M. Cozzi, M. Battiston, M. Mazzucato, P. Gresele* (IT), L. de Marco

PP-TH-009 THE DYNAMICS OF PLATELET ACTIVATION IN VIVOP. L. Gross* (CA), R. Ni, B. Esposito, M. L. Rand, J. I. Weitz

PP-TH-010 IDENTIFICATION OF FIVE NOVEL 14-3-3 ISOFORMS INTERACTING WITH THEPLATELET GPIB-IX COMPLEXP. Mangin* (FR), N. Receveur, V. Wurtz, C. Gachet, F. Lanza

PP-TH-011 MOLECULAR MECHANISMS UNDERLYING THE DIFFERENTIAL REGULATION OFPLATELET DENSE GRANULE SECRETION BY PROTEIN KINASE C-DELTAR. Chari* (US), S. Kim, S. Murugappan, A. Sanjay, J. L. Daniel, S. P. Kunapuli

PP-TH-012 OUTSIDE-IN SIGNALING INDUCED BY THROMBOSPONDIN-1 ENHANCES THROMBUSFORMATION: INVOLVEMENT OF CD36R. Nergiz-Ünal* (NL), M. J. E. Kuijpers, I. C. A. Munnix, J. F. Glatz, J. W. M. Heemskerk

PP-TH-013 SPECIFIC CYSTEINES IN THE EGF DOMAINS OF BETA3 AFFECT DIFFERENTLYALPHAVBETA3 AND ALPHAIIBBETA3 RECEPTOR FUNCTIONR. Mor-Cohen* (IL), N. Rosenberg, U. Seligsohn

PP-TH-014 AKT REGULATES WEAK-AGONIST MEDIATED RAP1B ACTIVATION VIA A GSK-3INDEPENDENT SIGNALLING PATHWAY IN PLATELETSR. N. Sumathipala* (UK), K. V. Patel, S. Rahman, Y. Nishino, I. G. Webb, S. Rangarajan, W.J. Kaiser, J. M. Gibbins, Y. M. Patel



331

* Presenting Author

PP-TH-015 INTEGRIN-LINKED KINASE ASSOCIATED WITH INTEGRIN ACTIVATIONS. Honda* (JP), H. Shirotani-Ikejima, S. Tadokoro, Y. Maeda, T. Kinoshita, Y. Tomiyama, T.Miyata

PP-TH-016 ELECTRON MICROSCOPY CHARACTERIZATION OF PLATELET INTERACTION WITHCARBON NANOMATERIALSS. H. Lacerda* (US), J. Semberova, O. Simakova, K. Holada, M. P. Gelderman, J. Simak

PP-TH-017 PLATELETS INTERACTION WITH PHOSPHOLIPASE A2 PURIFIED FROM THEAGKISTRODON BLOMHOFFII USSURIENSIS SNAKE VENOMS. B. Otgontaij* (MN), E. E. Altantsetseg

PP-TH-018 GPIB ALPHA IS A COFACTOR BINDING THROMBIN AND THUS FACILITATING PAR1CLEAVAGEL. Faxälv, S. Nylander, R. Chaireti, F. Pettersson, T. L. Lindahl* (SE)

PP-TH-019 FRACTALKINE DESENSITIZES PLATELETS TO PLATELET INHIBITION BY THEENDOGENOUS PLATELET INHIBITOR PROSTACYCLINU. Flierl* (DE), J. Bauersachs, A. Schaefer

PP-TH-020 NITRIC-OXIDE MEDIATED INHIBITION OF PLATELET FUNCTION IS REVERSED BYTHROMBOSPONDIN-1W. Roberts* (UK), R. Riba, K. M. Naseem

PP-TH-021 CD148 ENHANCES PLATELET RESPONSIVENESS TO COLLAGEN AND FIBRINOGENBY MODULATING SRC FAMILY KINASE ACTIVITYS. Ellison, A. Barr, M. G. Tomlinson, J. Zhu, A. Weiss, S. P. Watson, Y. A. Senis* (UK)

PP-TH-022 BF0801, A NOVEL PLATELET PHOSPHODIESTERASE INHIBITORS. Zhang, Y. Zhang, X. Yu, K. Bhavaraju, L. Hu, J. Jin, H. Du, S. P. Kunapuli, Z. Ding* (CN)

Platelet Biology III

PP-TH-023 HEAT SHOCK IN VITRO MODEL: POSSIBLE RELATIONSHIP WITH PLATELETSMORPHOLOGY LYMPHOCYTES AND NEUTROPHILS LEUKOCYTES CHROMATINREALIGNMENTN. G. Kruchynsky* (BY), S. Vishnevskaya

PP-TH-024 PLATELET AGGREGATION AND SECRETION MEDIATED BY GPVI ACTIVATION ARENOT ACCOMPANIED WITH INCREASE OF TISSUE FACTOR-DEPENDENTPROCOAGULANT ACTIVITY (PCAO. Panes* (CL), V. Matus, J. Pereira, D. Mezzano

PP-TH-025 THE P2Y1, P2Y12, GPIIB AND GPIIIA GENE EXPRESSIONS IN PLATELETS OFHEALTHY DONORS AND PATIENTS WITH MYOCARDIAL INFARCTIONO. V. Sirotkina* (RU), N. A. Bogankova, A. L. Schwarzman, T. V. Vavilova

PP-TH-026 PLATELET REACTIVITY IN DIFFERENT ETHNICITIES AND GENDER (PRIDE G) PILOTTRIALO. Bailon* (US), A. Singla, M. Antonino, J. Dichiara, K. Bliden, M. Hamed, T. Suarez, P. A.Gurbel, L. Lawal, U. S. Tantry

PP-TH-027 ADP-MEDIATED AGGREGATION AS A PHARMACODYNAMIC ASSAYUNDERESTIMATES THE ANTITHROMBOTIC ACTIVITY OF ELINOGREL, ACOMPETITIVE, REVERSIBLE P2Y12 INHIBITOR, RELATIVE TO CLOPIDOGRELP. B. Conley* (US), P. Andre, G. Stephens, H. Haberstock-Debic, M. Jurek, D. Gretler, D. R.Phillips

PP-TH-028 CALPAIN CLEAVES ANTI-APOPTOTIC PROTEINS IN ACTIVATED PLATELETSP. A. Cordell* (UK), P. J. Grant, R. J. Pease



332

Thur

sday

Pos

ters

PP-TH-029 PLATELET AGGREGATION INHIBITOR FROM AGKISTRODON BLOMHOFFIIUSSURIENSIS VENOMP. Dashnyam* (MN), B. Jugder, A. Nemekh

PP-TH-030 REVERSIBLE BINDING OF CANGRELOR TO THE P2Y12 RECEPTOR PREVENTS THEBINDING OF CLOPIDOGREL AND PRASUGREL ACTIVE METABOLITESR. J. Buckland, H. M. Judge, A. Sugidachi, J. A. Jakubowski, R. F. Storey* (UK)

PP-TH-031 SYSTEMATIC IDENTIFICATION AND INTERPRETATION OF PLATELET PROTEINLOCALISATIONR. G. Stanley* (UK), B. Wright, W. J. Kaiser, J. M. Gibbins

PP-TH-032 PALMITOYLATION SUPPORTS THE ASSOCIATION OF TETRASPANIN CD63 WITH CD9AND WITH THE ACTIN CYTOSKELETON IN THROMBIN-ACTIVATED PLATELETSS. J. Israels* (CA), E. M. McMillan-Ward

PP-TH-033 ALTERATIONS IN THE EXTERNAL REDOX POTENTIAL OF THE PLATELETENVIRONMENT IMPACTS ON PLATELET REACTIVITYS. O Neill* (IE), D. Murphy

PP-TH-034 MARKERS OF HUMAN PLATELET ACTIVATION IN HYPERHOMOCYSTEINAEMICSTATESS. O Neill* (IE), S. A. McGarrigle, N. Moran, I. G. Graham, M. T. Cooney, A. Monavari, P.Mayne, P. B. Collins

PP-TH-035 DIMERIC-SPECIFIC CONFORMATION OF THE COLLAGEN-RECEPTOR GLYCOPROTEIN(GP) VI CONTAINS THE COLLAGEN-BINDING SITE OF NATIVE PLATELETS: DIRECTEVIDENCE PROVIDED BY A RECOMBINANT FAB SPECIFIC FOR DIMERIC GPVIS. M. Jung* (JP), M. Moroi

PP-TH-036 USE OF MEMBRANE-PERMEABLE ITAM-PEPTIDES TO INVESTIGATE THE INITIALREACTIONS OF PLATELET ACTIVATION INDUCED THROUGH THE PLATELETCOLLAGEN RECEPTOR GLYCOPROTEIN (GP) VIS. M. Jung* (JP), M. Moroi

PP-TH-037 APOLIPOPROTEIN E RECEPTOR 2 IS A PLATELET RECEPTOR FOR COAGULATIONFACTOR XIT. C. White-Adams* (US), M. A. Berny, E. I. Tucker, J. Pang, D. Gailani, R. T. Urbanus, P. G.de Groot, A. Gruber, O. J. T. McCarty

PP-TH-038 ENDOTHELIAL CELL SPECIFIC ADHESION MOLECULE (ESAM) LOCALIZES TO CELL-CELL JUNCTIONS VIA A HOMOPHILIC INTERACTION BETWEEN ADJACENT CELLS,INDEPENDENT OF ITS C-TERMINAL PDZ-DOMAIN BINDING MOTIFT. J. Stalker* (US), J. Wu, M. S. Chatterjee, S. L. Diamond, L. F. Brass

PP-TH-039 FIBRINOLYTIC CROSS-TALK: PLATELET-BOUND PLASMINOGEN IS ACTIVATED BYMONOCYTE UPAT. de Jouvencel* (FR), L. Doeuvre, L. Plawinski, R. Lijnen, E. Angles-Cano

PP-TH-040 DIFFERENTIAL ACTIVATION AND FUNCTIONAL ROLE OF MYOSIN LIGHT CHAIN(THR)18 AND (SER)19 PHOSPHORYLATIONS IN PLATELETST. M. Getz* (US), C. C. D. Dangelmaier, J. J. D. Daniel, S. S. P. K. Kunapuli

PP-TH-041 BIOCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF ASP1645, A NOVELSELECTIVE P2Y12 RECEPTOR ANTAGONISTT. Uemura* (JP), T. Kawasaki, Y. Moritani, C. Sakata, F. Takamura, J. Takasaki, Y. Koga, H.Ito, S. Mutoh

PP-TH-042 THE ANTIPLATELET EFFECT OF ASP1645, A NOVEL P2Y12 RECEPTOR ANTAGONIST,COMPARED WITH CLOPIDOGRELT. Uemura* (JP), T. Kawasaki, C. Sakata, T. Shigenaga, Y. Moritani, J. Takasaki, Y. Koga, H.Ito, S. Mutoh



333

PP-TH-043 HUMAN PLATELETS EXPRESS MRNA AND SYNTHESIZE UPAR, BUT NOT UPAV. Matus* (CL), O. Panes, E. Torres, C. G. Sáez, J. Pereira, D. Mezzano

PP-TH-044 ABSOLUTE QUANTITATION OF VWF MRNA FROM HUMAN NORMAL PLATELETSV. A. Zapata* (AR), A. C. Kempfer, M. A. Carrivale, J. H. Paiva Palomino, A. Vellicce, Y. P.Powazniak, M. A. Lazzari

PP-TH-045 BINDING OF PLATELET GLYCOPROTEIN IB-BETA THROUGH THE CONVEX SURFACEOF LEUCINE-RICH REPEATS DOMAIN OF GLYCOPROTEIN IXX. Mo* (US), N. X. Nguyen, P. A. McEwan, X. Zheng, J. A. López, J. Emsley, R. Li

PP-TH-046 AN IN VITRO MODEL TO VISUALIZE AND QUANTIFY PHAGOCYTOSIS OF PLATELETSAND VWFY. P. Wu* (NL), D. E. van der Wal, P. G. de Groot, J. W. N. Akkerman

Novel Approaches to Understanding Platelet Biology III

PP-TH-047 SEROTONIN IMPROVES CLOT FORMATION AND VISCOELASTIC PROPERTIESA. M. Galan* (ES), I. Lopez-Vilchez, F. Navalon, M. Pino, C. Gasto, G. Escolar

PP-TH-048 HUMAN BLOOD PLATELET FUNCTION AND PROTEOME FOLLOWING CHRONICINTAKE OF ORANGE JUICEA. Della Corte, S. Marcone, M. Crescente, L. Giordano, W. Coletta, C. Tamburrelli, M.Barisciano, A. de Curtis, L. Iacoviello, R. Lorenzet, G. de Gaetano, M. B. Donati, C. Cerletti*(IT), D. Rotilio

PP-TH-049 A HIGH THROUGHPUT STUDY OF PLATELET CALCIUM RESPONSE TO PAIRWISECOMBINATION FROM A 6-DIMENSIONAL AGONIST SPACE ALLOWS TRAINING OF ASYSTEMS BIOLOGY NEURAL NETWORK “PLATELET BARCODE”M. S. Chatterjee* (US), J. E. Purvis, S. L. Diamond

PP-TH-050 INHERITED HUMAN NOX2 DEFICIENCY IS ASSOCIATED WITH IMPAIREDISOPROSTANE FORMATION AND REDUCED PLATELET RECRUITMENTP. Pignatelli* (IT), R. Carnevale, S. di Santo, S. Bartimoccia, V. Sanguigni, A. Plebani, S.Basili, F. Violi

PP-TH-051 CLOCK REGULATES CIRCADIAN PLATELET ACTIVITYS. Horie* (JP), N. Ohkura, Y. Sudo, H. Hayashi, K. Shikata, N. Ishida, J. Matsuda, K. Oishi

PP-TH-052 BLOOD VOLUME IS SIGNIFICANTLY REDUCED IN A NOVEL PARALLEL PLATE FLOWCHAMBERS. O’Brien* (IE), N. Kent, A. J. Ricco, D. Kenny, G. Meade

PP-TH-053 CAPTURE AND ASSAY OF INDIVIDUAL ADHERING PLATELETSS. Ramstrom* (IE), L. Basabe-Desmonts, A. Lopez-Alonso, A. J. Ricco, J. O’Donnell, D.Kenny

PP-TH-054 THE CHS-4 CHROMATIN INSULATOR SEQUENCE PROTECTS CLONAL DOMINANCEOF HEMATOPOIETIC STEM CELLS TRANSDUCED WITH A SELF-INACTIVATING SIVVECTOR IN PLATELET-DIRECTED GENE THERAPYT. Ohmori* (JP), S. Madoiwa, Y. Kashiwakura, A. Ishiwata, E. Akiba, M. Hasegawa, J.Mimuro, Y. Sakata

PP-TH-055 DEVELOPMENT OF A MODEL TO STUDY PLATELET FUNCTION UNDER CONDITIONSOF FLOWV. X. Du* (NL), H. F. G. Heijnen, P. G. de Groot, A. Barendracht, M. Roest



334

Thur

sday

Pos

ters

Platelets and Systemic Disorders III

PP-TH-056 FC GAMMA RIIA AND ALPHAIIB BETA3 SYNERGY IN PLATELET ADHESION TOIMMUNOGLOBULIN GM. P. Brennan* (IE), M. Thai Trung King, S. Kerrigan, D. Cox

PP-TH-057 PLASMA LEVELS OF PLATELET-DERIVED MICROPARTICLES (PDMP) MIGHTCOMPRISE A USEFUL INDICATOR FOR ANTIPLATELET THERAPY INANTIPHOSPHOLIPID SYNDROME (APS)M. Yamazaki* (JP), Y. Kadohira, M. Maekawa, T. Hayashi, E. Morishita, H. Asakura, S. Nakao

PP-TH-058 P-CRESOL INHIBITS PLATELET AGGREGATION AND INDUCES ENDOTHELIAL CELLIL-8 PRODUCTIONM. C. Chang* (TW), J. H. Jeng

PP-TH-059 EFFECT OF SOLUBLE CD40L ON THE ACTIVITY OF MATRIXMETALLOPROTEINASE 9OF MEG-01 CELLSN. Butta* (ES), E. Arias-Salgado, M. Alvarez, M. Martin, I. Fernandez, V. Jimenez-Yuste, F.Hernandez

PP-TH-060 PLATELET AGGREGATION AND COAGULATION DISORDERS IN EHLERS-DANLOSSYNDROMEP. Martinez* (AR), P. Martinez, H. Caferri, M. Facchini, P. Iommi, E. Agriello, M. Brandt, S.Garbiero, L. Roumeque, D. di Paolo

PP-TH-061 RACIAL DIFFERENCES IN THROMBOTIC STATUS MAY EXPLAIN THE INCREASEDINCIDENCE OF HAEMORRHAGIC STROKE IN JAPANS. Saraf, H. Ishii, J. Yamamoto, Y. Yamori, D. Gorog, S. Sharma* (UK)

PP-TH-062 VALIDATION OF RAPID AND AUTOMATED METHOD FOR MEASUREMENT OFADAMTS-13 ACTIVITY AND AUTO ANTIBODIEST. M. Owaidah, M. Ahmed* (SA), R. Al Nounou, N. Rasheed

PP-TH-063 ALTERATIONS OF PLATELET FUNCTION IN PATIENTS WITH CHRONIC MYELOIDLEUKEMIAV. Popov* (RO), H. Bumbea, A. Vladareanu, C. Saftoiu, S. Radesi, A. Nicolescu, T. Savopol,E. Kovacs

Megakaryocytes and Thrombopoiesis II

PP-TH-064 INFLAMMATORY MODULATION OF MEGAKARYOCYTES AND THROMBOPOIESISTHROUGH TLR2 AND IL1RL. M. Beaulieu* (US), E. Lin, N. Mavrogiorgos, R. Ingalls, J. E. Freedman

PP-TH-065 THE EFFECT OF IMMUNE THROMBOCYTOPENIC PURPURA (ITP) PLASMA ONMEGAKARYOCYTOPOIESIS IN VITRO: COMPARISON OF PRE VERSUS POSTDIAGNOSIS PLASMAM. Chang* (US), P. A. Nakagawa, S. A. Williams, K. L. Imfeld, J. S. Buzby, D. J. Nugent

PP-TH-066 NPLATE EXPANDS AND DIFFERENTIATES MEGAKARYOCYTIC CELLS IN UMBILICALCORD BLOOD CULTURESM. Chang* (US), P. A. Nakagawa, J. S. Buzby, D. J. Nugent

PP-TH-067 MICRORNA EXPRESSION SIGNATURES ARE DIFFERENT IN HUMAN NEONATALCOMPARED TO ADULT MEGAKARYOCYTESR. K. Gutti* (US), H. Sallmon, M. Bailey, Z. Liu, M. C. Sola-Visner

PP-TH-068 EFFECT OF BLOOD CLOTS ON THE MEGAKARYOCYTIC POTENTIAL OF THAWEDCORD BLOOD UNITSS. Juutistenaho* Finland, S. Möttönen, M. Eskola, K. Aranko, R. Kekomäki



335

PP-TH-069 HIGH GLUCOSE CONCENTRATIONS RAPIDLY UPREGULATE CYCLOOXYGENASE-2(COX-2) EXPRESSION IN HUMAN MEGAKARYOCYTES (MK)T. Corazzi* (IT), P. Gresele, L. Bury, G. B. Bolli

PP-TH-070 HEMATOPOIETIC STEM CELL STIMULATORS THROMBOPOIETIN , ARP ANDFIBRONECTIN PROVIDE A NOVEL STRATEGY FOR EXPANSION OF EARLYHEMATOPOIETIC AND MEGAKARYOCYTE-PROGENITOR CELLS FROM CORD BLOODV. R. Deutsch* (IL), E. Hubel, S. Kay, T. Ohayon, B. Katz, E. Naparstek, D. Grisaru

PP-TH-071 APOPTOTIC PROCESS IS INVOLVED IN THE EARLY PHASE OF MEGAKARYOPOIESIS,BUT NOT IN PLATELET PRODUCTION FROM MEGAKARYOCYTESY. Kozuma* (JP), H. Ninomiya, T. Kono, H. Y. Mukai, H. Kojima

PP-TH-072 GSK-3 NEGATIVELY REGULATES THROMBOPOIESIS IN AN IN VITRO NORMALHUMAN CD34-POSITIVE CELL-DERIVED DIFFERENTIATION SYSTEMM. Ono, Y. Matsubara* (JP), T. Shibano, Y. Ikeda, M. Murata

PP-TH-073 THROMBOPOIETIN STIMULATES THE CYTOPLASMIC MATURATION OF LOW-PLOIDYNEONATAL MEGAKARYOCYTES THROUGH THE MTOR PATHWAYZ. Liu* (US), M. Bailley, R. Gutti, H. Sallmon, M. Sola-Visner

Mechanisms of Inherited and Acquired Defects of Platelet Number and Function II

PP-TH-074 GLANZMANN THROMBASTHENIA (GT): A SERIES OF 12 GENETIC VARIANTS - 11NOVEL- IN ITGB3 AND ITGA2B GENES IN 16 INDIVIDUALS FROM FRANCE ANDGERMANYB. Saposnik, M. Simansour, S. Binard, M. Hurtaud-Roux, V. Proulle, M. Gerard-Blanluet, D.de Prost, A. Nurden, U. Nowak Göttl And, N. Schlegel* (FR)

PP-TH-075 STRUCTURAL ANALYSIS OF THE HUMAN PLATELET ANTIGENSN. Rosenberg* (IL), M. Landau

PP-TH-076 ESTIMATION OF INCIDENCE OF THROMBOCYTOSIS-INDUCED BY HEPARIN IN 1861MEDICAL PATIENTSM. Epinat, N. Moulin, E. Presles, T. Monatte, C. Guy, S. Laporte, P. Mismetti* (FR)

PP-TH-077 RITUXIMAB FOR REFRACTORY AND RELAPSING THROMBOTICTHROMBOCYTOPENIC PURPURAP. N. Knoebl* (AT), P. Distelmaier, S. Koder, P. Schellongowski, P. Quehenberger

PP-TH-078 DECREASED EXPRESSION OF MBD2 AND MBD4 GENE AND GENOMIC-WIDEHYPOMETHYLATION IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENICPURPURAZ. Chen, D. Gu, X. Chen, Z. Zhou, Z. Guo, J. Ge, H. Zhao, R. Yang* (CN)

PP-TH-079 CONGENITAL OR ACQUIRED ADAMTS13 DEFICIENCY OR BOTH – THAT’S THEQUESTIONS. C. Meyer* (CH), I. Sulzer, G. Mäder, J. N. George, B. Lämmle, J. A. Kremer Hovinga

PP-TH-080 HETEROZYGOUS ADAMTS13 MUTATIONS IN IDIOPATHIC TTP WITH SEVEREACQUIRED ADAMTS13 DEFICIENCYS. C. Meyer* (CH), S. Jin, W. Cao, W. Pos, J. Voorberg, X. L. Zheng, B. Lämmle, J. A.Kremer Hovinga

PP-TH-081 A HETEROZYGOUS ITGA2B R995W MUTATION CAUSES CONSTITUTIVE ACTIVATIONOF THE IIB 3 RECEPTOR AND RESULTS IN CONGENITALMACROTHROMBOCYTOPENIAS. Kunishima* (JP), H. Kashiwagi, Y. Ito, Y. Fujimori, Y. Miyajima, Y. Takamatsu, J. Suzumiya,Y. Tomiyama, H. Saito



336

Thur

sday

Pos

ters

PP-TH-082 A NOVEL CASE OF SELECTIVE ENZYMATIC DEFECT OF CYCLOOXYGENASE-1ASSOCIATED WITH HAEMORRHAGIC DIATHESISS. Pascale* (IT), A. Dragani, D. Mattoscio, E. Ferrante, L. Mucci, I. di Marzio, G. Davì, B.Rocca

PP-TH-083 CLINICAL MANIFESTATIONS OF DISORDERS ASSOCIATED WITH MYH9 MUTATIONSS. Rittich* (CZ), D. Provaznikova, V. Geierova, D. Mikulenkova, I. Hrachovinova, P. Salaj

PP-TH-084 A NOVEL MUTATION OF A HIGHLY CONSERVED RESIDUE ASN2ASP OF INTEGRINALPHA-IIB CAUSES GLANZMANN THROMBASTHENIAW. Mansour* (IL), N. Rosenbreg, H. Haushner, A. Koren, U. Seligsohn

Basic Biology of ADAMTS13 III

PP-TH-085 FORMATION OF METHIONINE-SULFOXIDE AT POSITION 1606 OF VON WILLEBRANDFACTOR INHIBITS CLEAVAGE BY ADAMTS-13 WITHOUT AFFECTING PLATELETINTERACTION: A NEW PROTHROMBOTIC MECHANISM PROMOTED BY OXIDATIVESTRESSR. de Cristofaro* (IT), S. Lancellotti, V. de Filippis, N. Pozzi, F. Peyvandi, R. Palla, B. Rocca,S. Rutella, P. Mannucci

PP-TH-086 RENAL THROMBOTIC MICROANGIOPATHY WITH SEVERE ARTERIAL NECROSIS IN ASEPTIC PORCINE 2-HIT MODELC. L. Bockmeyer, K. Kentouche, P. Reuken, S. Krause, C. Krusche, G. Marx, W. Losche, J.Becker, R. A. Claus* (DE)

PP-TH-087 DIFFERENTIAL TRANSCRIPTION OF MRNA CODING THE VWF-CLEAVING PROTEASEADAMTS13 UNDER PROINFLAMMATORY STIMULATION IN ENDOTHELIAL ANDSTELLATE CELLSR. A. Claus* (DE), F. Conradi, C. L. Bockmeyer, K. Kentouche, M. W. Sieber, P. Recknagel,W. Losche, S. Friedman, M. Bauer

PP-TH-088 EIGHT NOVEL ADAMTS13 MISSENSE MUTATIONS IN CHILDHOOD AND ADULT ONSETCONGENITAL TTPR. S. Camilleri* (UK), I. J. Mackie, R. Liesner, W. J. Chen, K. Manns, S. J. Machin, M. Scully

PP-TH-089 ADAMTS13 METALLOPROTEASE DOMAIN SUBSITES CONTROL CLEAVAGE SITESPECIFICITYR. de Groot* (UK), D. A. Lane, J. T. B. Crawley

PP-TH-090 IDENTIFICATION OF A FUNCTIONAL EXOSITE IN THE ADAMTS13 DISINTEGRIN-LIKEDOMAINR. de Groot* (UK), N. Ramroop, A. Bardhan, J. T. B. Crawley, D. A. Lane

PP-TH-091 IN VIVO ABSENCE OF ADAMTS13 DOES NOT ABROGATE VWF SIZE HETEROGENEITYS. F. de Meyer* (BE), U. Budde, H. Deckmyn, K. Vanhoorelbeke

PP-TH-092 HYPOCHLOROUS ACID INACTIVATES ADAMTS13: AN OXIDATIVE MECHANISM FORREGULATING ADAMTS13 ACTIVITY DURING INFLAMMATIONX. Fu* (US), Y. Wang, J. Chen, M. Ling, J. D. Kulman, J. A. López, D. W. Chung

PP-TH-093 ESTIMATION OF THE ADAMTS13 ACTIVITY IN PLASMA UNDER SHEAR STRESSUSING NOVEL MONOCLONAL ANTIBODIES TO VWFZ. Ma* (CN), N. Dong, J. Zhang, A. Wang, C. Ruan



337

Novel Mechanisms of Antiplatelet Therapy III

PP-TH-094 GALLIC ACID COMPETES WITH ASPIRIN, RESVERATROL AND QUERCETIN FORPLATELET COX-1: FUNCTIONAL AND MOLECULAR MODELLING STUDIESM. Crescente, S. Momi, G. Jessen, M. Leone, H. D. Höltje, P. Gresele, C. Cerletti* (IT), G. deGaetano

PP-TH-095 ANTI-DIABETIC SMALL MOLECULE 1,2,3,4,6-PENTA-<I>O</I>-GALLOYL-?-D-GLUCOPYRANOSE INHIBITS PLATELET ACTIVATION BY PREVENTING GI?2-MEDIATED SIGNAL TRANSDUCTIONH. Akbar* (US), K. Funk, S. Wulf, R. Perveen, Y. Cao, X. Chen

PP-TH-096 THROMBOXANE A2 RECEPTOR ANTAGONISM BY FLAVONOIDS: STRUCTURE-ACTIVITY RELATIONSHIPSL. Navarro-Núñez* (ES), J. Castillo, M. Lozano, C. Martínez, O. Benavente-García, V.Vicente, J. Rivera

PP-TH-097 PLATELET AGGREGATION REVERSAL BY GPIIB-IIIA ANTAGONISTS: DEPENDENCEUPON AGONIST AND AGGREGATE AGEH. E. Speich, A. D. Earhart, S. N. Hill, T. J. Kueter, M. M. White, L. K. Jennings* (US)

PP-TH-098 ANTIPLATELET EFFECTS OF PARTHENOLIDE, THE SESQUITERPENE LACTONEFROM FEVERFEW (THANACETUM PARTHENIUM)M. Helinska* (PL), M. Rozalski, B. Rychlik, C. Watala

PP-TH-099 ARONIA MELANOCARPA EXTRACT MAY LEAD TO PLATELET ACTIVATION WHENUSED AT HIGH CONCENTRATIONSJ. Golanski, M. Helinska* (PL), M. Rozalski, £. Kraszula, C. Watala

PP-TH-100 AN “IN VITRO” STUDY ABOUT THE COMBINED ANTIPLATELET EFFECTS OFCILOSTAZOL AND ASPIRINM. F. Alberto* (AR), S. Meschengieser, P. Pieczanski, J. Rodriguez Moncalvo, M. A. Lazzari

PP-TH-101 ANTIPLATELET EFFECTS OF ASPIRIN WITH PHYTOSTEROLS: COMPARISON WITHNON-ENTERIC COATED ASPIRIN ALONEM. J. Antonino* (US), R. Coppolecchia, E. Mahla, K. P. Bliden, U. S. Tantry, P. A. Gurbel

PP-TH-102 DEVELOPMENT OF FC-GAMMA-RIIA ANTAGONISTM. Thai Trung King* (IE), M. Adamo, M. Brennan, D. Cox

PP-TH-103 EV-077-3201-2TBS, A REVERSIBLE DUAL THROMBOXANE RECEPTOR ANTAGONISTAND THROMBOXANE SYNTHASE INHIBITOR, IS MORE POTENT THAN ASPIRIN ININHIBITING ARACHIDONIC ACID AND COLLAGEN-INDUCED HUMAN PLATELETAGGREGATION IN VITROP. Alberts* (CH), P. Fontana, K. S. Sakariassen, H. Bounameaux, J. P. Meyer, A. SantanaSorensen

PP-TH-104 THE REVERSIBLY BINDING P2Y<SUB>12</SUB> RECEPTOR ANTAGONISTTICAGRELOR REDUCES EFFECT OF NEWLY FORMED PLATELETS UNDER LAMINARFLOW CONDITIONSR. Megens* (NL), M. Oude Egbrink, E. Nikookhesal, J. Heemskerk, J. J. J. van Giezen

PP-TH-105 INTEGRIN PRIMING DYNAMICSR. R. Hantgan* (US), M. C. Stahle



338

Thur

sday

Pos

ters

Extrinsic Pathway of Coagulation III

PP-TH-106 A PRAGMATIC APPROACH FOR THE MEASUREMENT OF THE INR IN LIVER PATIENTSA. F. Riddell* (UK), V. Calvaruso, E. G. Tuddenham, A. Burroughs, A. Gatt

PP-TH-107 THE EFFECT OF PLASMA-DILUTION ON THROMBIN GENERATIONE. de Smedt* (NL), R. Wagenvoord, C. Hemker

PP-TH-108 CODING AND PROMOTER REGION POLYMORPHISMS OF FACTOR VII (FVII) GENE INASIAN INDIANS VIS-À-VIS OTHER POPULATIONS OF THE WORLD: ALLELEFREQUENCIES, LINKAGE DISEQUILIBRIUM, FVII COAGULANT ACTIVITY (FVII:C) ANDCORONARY ARTERY DISEASE (CAD)M. S. Mukherjee* (IN), C. S. Deshpande, S. S. Joshi, K. R. Shetty

PP-TH-109 REGULATION OF TISSUE FACTOR-INITIATED THROMBIN GENERATION IN PLASMABY FACTOR VII AND ACTIVATED FACTOR VIIM. V. Ovanesov* (US), T. K. Lee

PP-TH-110 TISSUE FACTOR AND GULF WAR-ASSOCIATED CHRONIC COAGULOPATHIESR. R. Bach* (US), B. C. S. Slater

PP-TH-111 HAEMOSTATIC PROFILE AND DETERMINANTS OF RHEOLOGY IN NIGERIAN PRE-ECLAMPTICSR. A. Anyanwu* (NG), O. A. Awodu, A. B. Ande

PP-TH-112 OBSERVATION ON TISSUE FACTOR EXPRESSION OF MONOCYTES IN PATIENTSWITH ACUTE CEREBROCARDIAC THROMBOTIC DISEASESR. Wang* (CN), L. Li, B. Z. Wen, D. Zhong, Y. T. Ma, P. Pen

PP-TH-113 COMPUTER MODELISATION OF THE PROTHROMBIN TIME TEST. CONCEPTION,VALIDATION AND POTENTIAL OF APPLICATIONS. Kerdelo* (FR), P. Redou, J. Tisseau, J. Abgrall

PP-TH-114 EFFECT OF PUERARIN ON THE EXPRESSION OF TISSUE FACTOR INDUCED BYANGIOTENSIN II AND ITS MECHANISM IN VASCULAR ENDOTHELIAL CELLSS. He* (CN), H. Wang, J. Hu, X. Shen, X. He, Z. Wen

PP-TH-115 FACTOR VIIa-ANTITHROMBIN COMPLEXES DURING CARDIOPULMONARY BYPASSSURGERYS. J. Davidson* (UK), B. J. Woodhams

PP-TH-116 CANINE TISSUE FACTOR (TF) BINDS HUMAN AND CANINE FVII WITH SIMILAR HIGHAFFINITY WHICH CONTRASTS THE LOW AFFINITY FOR BINDING OF HUMAN TF TOCANINE FVIIT. Knudsen* (DK), B. B. Sørensen, H. R. Stennicke, L. C. Petersen, A. T. Kristensen

PP-TH-117 TISSUE FACTOR INDUCES PROMMP9 RELEASE AND ACTIVATES PROMMP2 INOSTEOSARCOMAT. Stokol* (US), J. L. Daddona, V. Rathnam

PP-TH-118 FREQUENCY AND GENDER DIFFERENCES OF POLYMORPHISMS IN THE TF AND TFPIGENES, AS RELATED TO PHENOTYPES IN PATIENTS WITH CORONARY HEARTDISEASET. B. Opstad* (NO), A. Pettersen, S. Åkra, H. Arnesen, I. Seljeflot

PP-TH-119 DETECTION OF ENDOGENOUS TISSUE FACTOR LEVELS IN PLASMA USING THECALIBRATED AUTOMATED THROMBOGRAM ASSAYV. Ollivier* (FR), D. A. Manly, J. Wang, K. R. Machlus, A. S. Wolberg, M. Jandrot-Perrus, N.Mackman



339

PP-TH-120 VALIDATION OF THE INR CALIBRATION OF COAGUCHEK XS PT TEST STRIP MASTERLOTS AND ROUTINE PRODUCTION LOTSW. Plesch* (DE), B. Scheffler, P. Herbel, A. Jünschke, T. Wickert

PP-TH-121 RFVIIa TREATMENT IN FACTOR VII DEFICIENCY : A SINGLE CENTRE EXPERIENCEZ. Salcioglu* (TR), G. Aydogan, F. Akici, A. Akcay, D. Tugcu, H. S. Sen, Z. Baslar

Intrinsic Pathway of Coagulation III

PP-TH-122 ACTIVATION OF THE INTRINSIC PATHWAY OF BLOOD COAGULATION BYPARTICULATE MATTER IN VITROE. Kilinc* (NL), H. M. H. Spronk, I. Gosens, R. van Oerle, J. W. P. Govers-Riemslag, M. E.Gerlofs-Nijland, F. R. Cassee, H. ten Cate

PP-TH-123 EVALUATION OF NORMAL PLASMA MIXING STUDIES ON PROLONGED ACTIVATEDPARTIAL THROMBOPLASTIN TIME IN CHINESEJ. Lin* (TW), S. Kuo, S. Yang, S. Chio, M. Shen

PP-TH-124 DIFFERENT SEVERITY OF CLINICAL MANIFESTATION IN PATIENTS WITH SEVEREHEMOPHILIA AM. Faranoush* (IR), N. Danaie, R. Ghorbani, M. Rahmani, M. Jazebi, T. Shashaani, A.Mehrvar, A. Hedayatiasl, P. Vossough

PP-TH-125 HEMODYNAMIC EFFECTS OF COAGULATION BETA-FXIIa IN CONSCIOUS RATSP. C. Papageorgiou* (CA), P. H. Backx, C. T. Chan, E. L. Yeo, J. S. Floras

PP-TH-126 STUDY OF THE MOLECULAR MECHANISM OF THE COAGULATION FACTOR XDEFICIENCY IN THREE CHINESE PEDIGREESQ. Chen* (CN), Q. Ding, X. Wang

PP-TH-127 CHARACTERIZATION OF TWO NOVEL MUTATIONS (VAL384ALA AND VAL384PHE)CAUSING FACTOR X DEFICIENCY IN TWO UNRELATED CHINESE FAMILIESQ. Ding* (CN), X. Wang, T. Yu, H. Wang

PP-TH-128 FACTOR VIII AND VON WILLEBRAND FACTOR – THE CONFUSION OF THE 70’SPERSISTS TODAYR. R. Montgomery* (US), S. L. Haberichter, M. Jozwiak, S. Fahs, Q. Shi

PP-TH-129 DEVELOPMENT OF NEW ASSAYS TO IDENTIFY THE CRP-VLDL COMPLEXS. T. Abrams* (UK), C. Downey, J. Thachil, G. Wang, C. H. Toh

PP-TH-130 FACTOR XIIa INHIBITORS PREVENT FE(III)-CHLORIDE INDUCED THROMBOSIS INMICES. Schmidbauer* (DE), C. Nerlich, T. Weimer, U. Kronthaler, H. Metzner, S. Schulte

PP-TH-131 THE PLASMA KALLIKREIN-KININ SYSTEM AND CLINICAL OUTCOME DURINGFOLLOW-UP IN CHEST-PAIN PATIENTSV. Pönitz* (NO), J. W. P. Govers-Riemslag, J. Konings, T. Brügger-Andersen, H. Grundt, H.ten Cate, H. Staines, D. W. T. Nilsen

PP-TH-132 GENETIC ANALYSIS OF A PEDIGREE WITH COMBINED FACTOR XII AND FACTRO XIDEFICIENCYX. Ye* (CN), Y. Feng

PP-TH-133 MOLECULAR SIGNALING PATHWAY REGULATING PROLYLCARBOXYPEPTIDASE-DEPENDENT KININ GENERATING CASCADE IN INFLAMMATIONZ. Shariat-Madar* (US), M. Ngo, D. Kolte, F. Mahdi



340

Thur

sday

Pos

ters

Anticoagulant Pathways III

PP-TH-134 MEASUREMENT OF THE PHARMACODYNAMIC EFFECT OF DABIGATRAN ETEXILATE:THROMBIN CLOTTING TIMEJ. Stangier, K. Wetzel, W. Wienen, J. van Ryn* (DE), K. Rathgen

PP-TH-135 COVALENT ANTITHROMBIN-HEPARIN AND THE PROTEIN C PATHWAYM. C. van Walderveen* (CA), L. R. Berry, A. K. C. Chan

PP-TH-136 VALIDATION OF AN AUTOMATED CLOTTING ASSAY FOR MONITORING PLASMAARGATROBAN LEVELS IN COMPARISON WITH A NOVEL ULTRA-PERFORMANCELIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (UPLC-MS/MS)METHODM. L. Snyder* (US), A. M. Winkler, F. Brierre, R. J. Molinaro

PP-TH-137 DIFFERENTIAL EFFECTS OF GENERIC ARGATROBANS ON THE PT/INRO. Iqbal* (US), S. Masood, A. Gray, D. Hoppensteadt, J. Fareed

PP-TH-138 DIFFERENTIAL EFFECTS OF GENERIC ARGATROBANS ON WHOLE BLOODACTIVATION AND THROMBIN GENERATION MARKERSO. Iqbal* (US), S. Masood, D. Hoppensteadt, J. Fareed

PP-TH-139 DETERMINANTS OF HIGH PROTEIN C LEVELS IN A LARGE DUTCH FAMILYS. Roshani* (NL), M. C. Pintão, M. C. H. de Visser, C. Tieken, M. W. Tanck, H. R. Büller, I. M.Wichers, J. C. M. Meijers, S. Middeldorp, P. H. Reitsma

PP-TH-140 BIOPHYSICAL CHARACTERIZATION OF A DYSFUNCTIONAL ANTITHROMBIN VARIANTS. Pedersen* (DK), M. Thomsen, S. R. Kristensen, A. Stensballe, D. E. Otzen

PP-TH-141 EFFECTS OF THROMBIN- OR Xa-INHIBITORS ON THE END PRODUCT OFCOAGULATION: INCREASED POROSITY OF THE FIBRIN NETWORK CONTRIBUTES TOFIBRINOLYSISS. He, M. Blombäck* (SE), N. Bark, H. Jonhsson, H. Wallen

PP-TH-142 DRUG INTERACTIONS OF ORAL ANTITHROMBIN AND ANTI-Xa AGENTS WITHHEPARINIZED AND ORAL ANTICOAGULANT TREATED PATIENTSS. Masood* (US), J. Cunanan, D. Hoppensteadt, D. van Thiel, J. Fareed

PP-TH-143 IDENTIFICATION OF MUTATION SITE AND FUNCTIONAL CHARACTERIZATION OFABNORMAL PROTEIN C-TOTTORIT. Hayashi* (JP), Y. Tanaka, Y. Okuyama, K. Yoshida, T. Okamoto, K. Iijima, K. Suzuki

PP-TH-144 GENETIC INFLUENCE OF CYP2C9 AND VKORC1 ON WARFARIN DOSE IN TWOGROUPS OF PATIENTS WITH DIFFERENT INR TARGET RANGES. (RELEVANCE OF APREVIOUSLY DESCRIBED ALGORITHM FOR LOW INR RANGEV. Le Cam-Duchez* (FR), M. Fretigny, N. Cailleux, Y. Benhamou, V. Barbay, H. Levesque, J.Borg

PP-TH-145 CONTAMINANTS IN HEPARIN! A CALL FOR SUBSTITUTE ANTICOAGULANTSV. Bansal* (US), E. Litinas, D. Hoppensteadt, C. Adiguzel, J. Fareed

PP-TH-146 EFFECT OF ANGIOTENSIN(1-7) ON THE EXPRESSION OF E-SELECTIN INDUCED BYANGIOTENSIN II AND ITS MECHANISM IN VASCULAR ENDOTHELIAL CELLX. H. Shen* (CN), Z. B. Wen, X. F. He, N. Li, S. L. He

PP-TH-147 THE EFFECTS OF TANSHINONE 2A ON PLATELETS AND MEGAKARYOCYTES INIMMUNE VASCULITISX. Li* (CN), M. Zhou, X. Li, M. Yang



341

Cofactors and Proteases III

PP-TH-148 MEASUREMENT OF THROMBIN-ALPHA-2-MACROGLOBULIN COMPLEXESGENERATED IN PLASMAH. Vetr* (AT), S. Geiter, M. Graf, S. Knapp, B. R. Binder

PP-TH-149 CORRELATION BETWEEN PLASMA ACTIVITY OF ADAMTS-13 AND COAGULOPATHY,AND PROGNOSIS IN DISSEMINATED INTRAVASCULAR COAGULATIONJ. Kim* (KR), J. Hyun, S. Park, H. Cho, H. Kim

PP-TH-150 CLEARANCE OF RECOMBINANT AND PLASMA DERIVED HUMAN FACTOR VIII IN APERFUSED RAT LIVER MODELR. Appa* (DK), C. Theill, L. Hansen

PP-TH-151 INVESTIGATION OF CLEARANCE OF RECOMBINANT HUMAN FACTOR VIIa AND ITSVARIANTS IN A PERFUSED RAT LIVER MODELR. Appa* (DK), L. Hansen, C. Theill

PP-TH-152 THE DETECTION OF PROS1 DELETIONS, A COMMON CAUSE OF PROTEIN SDEFICIENCYR. B. Wheeler* (UK), J. Cutler, M. Mitchell

PP-TH-153 FACTOR VII-ACTIVATING PROTEASE IS ACTIVATED IN SEPSISS. Zeerleder* (NL), I. Bulder, F. Stephan, M. de Kruif, J. Hoogerwerf, T. van der Poll, L.Aarden

PP-TH-154 REEVALUATION OF “NORMAL” FACTOR VIII CONCENTRATION IN PLASMAS. Butenas* (US), B. Parhami-Seren, A. Undas, K. G. Mann

PP-TH-155 THROMBIN GENERATION IN A THIN LAYER OF WHOLE BLOODS. Nijhuis* (NL), R. Apitz-Castro, C. H. Hemker

PP-TH-156 EVOLUTION OF PRIMARY HEMOSTASIS: ROLE OF TRYPSINS IN GILL HEMOSTASISS. Kim* (US), S. Rajpurohit, M. Carrillo, V. Kulkarni, P. Jagadeeswaran

PP-TH-157 DETERMINATION OF RISTOCETIN COFACTOR ACTIVITY: EYES ON BOTH DIRECTIONSS. A. L. Montalvão* (BR), J. M. Annichino-Bizzacchi, M. S. Pereira, T. M. Machado, M. C.Ozelo, E. V. de Paula

PP-TH-158 ANTI-INFLAMMATORY EFFECT OF THROMBOLYTIC PREPARATION LONGOLYTINT. N. Serebryakova* (RU), T. S. Sharkova, L. V. Podorolskaya, I. S. Chromov

PP-TH-159 MEMBRANE BINDING OF FACTOR VIII C2 DOMAIN INHIBITED BY PHYSIOLOGICSALINE IMPLYING A PROCESSIVE BINDING MECHANISMV. A. Novakovic* (US), D. B. Cullinan, J. B. Baleja, G. E. Gilbert

PP-TH-160 ISOLATION AND CHARACTERIZATION OF A NOVEL FIBRINO(GENO)LYTIC SERINEPROTEINASE FROM AGKISTRODON BLOMHOFFII USSURIENSIS SNAKE VENOMV. L. Karbovskyy* (UA), V. N. Skalka, A. N. Savchuk, G. L. Volkov

PP-TH-161 MOUSE THROMBIN IS UNIQUELY INSENSITIVE TO SODIUM ION AMONGREPRESENTATIVES OF MAMMALIAN, AVIAN AND REPTILIAN THROMBINSN. Goli, W. G. Owen* (US)

PP-TH-162 AGE-RELATED REFERENCE RANGES OF C1-INH ACTIVITY AND ANTIGEN AREIMPORTANT FOR EARLY DIAGNOSIS IN PAEDIATRIC HAE PATIENTSW. Kreuz* (DE), E. Rusicke, I. Martinez-Saguer, E. Aygören-Pürsün, T. Klingebiel



342

Thur

sday

Pos

ters

Inhibitors of Coagulation III

PP-TH-163 PROTEIN Z LEVELS AND THROMBOTIC DISEASES – A META-ANALYSISF. Sofi* (IT), F. Cesari, S. Fedi, G. Broze, R. Abbate, G. Gensini

PP-TH-164 FUNCTIONAL STUDIES OF THE 5’UTR AND INTRON 7 SNPS OF THE TFPI GENEG. Skretting* (NO), B. Stavik, C. F. Myklebust, P. Sandset, N. Iversen

PP-TH-165 KNOCK DOWN OF TFPI EXPRESSION IN SUM102 BREAST CANCER CELLS LEADS TOPRO-ANGIOGENIC PHENOTYPESB. Stavik, G. Skretting* (NO), M. Sletten, E. Frengen, P. Sandset, N. Iversen

PP-TH-166 DEFIBROTIDE AUGMENTS THE ANTICOAGULANT ACTIONS OF HEPARIN AND LOWMOLECULAR WEIGHT HEPARINSJ. Fareed* (US), J. Cunanan, D. Hoppensteadt, O. Iqbal, C. Adiguzel

PP-TH-167 TYPE OF ANAESTHESIA DID NOT AFFECT THE EFFICACY AND SAFETY PROFILE OFDABIGATRAN ETEXILATE COMPARED WITH ENOXAPARIN FOR PRIMARY VENOUSTHROMBOEMBOLISM PREVENTION FOLLOWING TOTAL KNEE OR HIPREPLACEMENT SURGERYN. Rosencher* (FR), H. Noack, M. Feuring, A. Clemens, R. Friedman, B. I. Eriksson

PP-TH-168 DIFFERENTIAL EFFECTS OF TAK-442, A FACTOR Xa INHIBITOR, ANDXIMELAGATRAN, A THROMBIN INHIBITOR ON FACTOR V-MEDIATED FEEDBACK ONCOAGULATION CASCADE AND BLEEDINGN. Konishi* (JP), K. Hiroe, Y. Imaeda, T. Fujimoto, K. Kubo, M. Kawamura

PP-TH-169 IN PATIENTS PREDISPOSED TO CARDIOVASCULAR EVENTS, STANDARD DOSES OFDABIGATRAN ETEXILATE PREVENT POST-OPERATIVE VENOUSTHROMBOEMBOLISM EFFECTIVELY AND WITH A GOOD SAFETY PROFILEO. E. Dahl* (NO), C. Francis, A. Kurth, N. Rosencher, M. Feuring, A. Clemens, H. Noack, B.I. Eriksson, J. A. Caprini

PP-TH-170 STANDARD DOSE OF DABIGATRAN ETEXILATE IN PATIENTS UNDERGOING TOTALHIP OR KNEE REPLACEMENT SURGERY WHO ARE PREDISPOSED TO POST-OPERATIVE VENOUS THROMBOEMBOLISM: EFFECTIVE AND GOOD SAFETYPROFILEO. E. Dahl* (NO), C. Francis, A. Kurth, N. Rosencher, M. Feuring, H. Noack, B. I. Eriksson, J.A. Caprini

PP-TH-171 EVALUATION OF CLOTTING TIME ASSAYS FOR MONITORING ANTITHROMBOTICACTIVITIES OF THE FACTOR Xa INHIBITORS, APIXABAN AND RIVAROXABAN, ANDTHE THROMBIN INHIBITOR DABIGATRAN IN THE RABBITP. C. Wong* (US), E. J. Crain, C. A. Watson

PP-TH-172 MULTIPLEXED ANALYSIS OF IMMUNOGLOBULIN CLASS/ SUBCLASS AND EPITOPESPECIFICITY OF ANTI-FVIII ANTIBODIES IN SIX CASES OF POSTPARTUM ACQUIREDHEMOPHILIAP. Lapalud* (FR), S. Grosbrois, S. André, J. Borg, B. Guillet, Y. Gruel, M. Trossaert, B.Polack, C. Rotschild, J. Schved, H. Levesque, S. Lacroix-Desmazes, C. Granier, G. Lavigne-Lissalde

PP-TH-173 INTERFERENCE OF PLATELETS IN PLASMA ON THE APTT MIXING TESTR. Ikeda* (JP), C. Morikawa, H. Yago

PP-TH-174 RIVAROXABAN DOWN REGULATES THE COAGULANT ACTIVITY INDUCED BYACTIVATED MONOCYTES. COMPARISON WITH FONDAPARINUXM. Laurent, U. Joimel, H. Li, S. Mirshahi, V. Lecam-Duchez, J. Borg, L. Cazin, J. Soria, C.Soria, R. Varin* (FR)



343

PP-TH-175 MAMMALIAN CELL SURFACE DISPLAY OF A FUNCTIONAL THROMBIN-INHIBITORYSERPINR. F. Gierczak* (CA), J. S. Sutherland, V. Bhakta, W. P. Sheffield

PP-TH-176 IN CALIBRATED AUTOMATED THROMBINOSCOPY, A DIRECT THROMBIN INHIBITOR(AR-H067637) CAUSES A SPURIOUS INCREASE OF THROMBIN GENERATION, DUE TOA TRANSIENT ALPHA2-MACRO-GLOBULIN-THROMBIN PEAKR. J. Wagenvoord* (NL), J. Deinum, M. Elg, C. Hemker

PP-TH-177 ASSESSMENT OF THE EFFECT OF AR-H067637 ON THE ETP AS OBTAINED BYCALIBRATED AUTOMATED THROMBINOSCOPYR. J. Wagenvoord* (NL), J. Deinum, M. Elg, C. Hemker

PP-TH-178 EFFECTS OF OVERSULFATED AND FUCOSYLATED CHONDROITIN SULFATES ONCOAGULATION. CHALLENGES IN STUDIES OF ANTICOAGULANTPOLYSACCHARIDESR. J. C. Fonseca* (BR), S. M. C. G. Oliveira, V. H. Pomin, A. S. Mecawi, I. G. Araújo, P. A. S.Mourão

PP-TH-179 BOTHROJARACIN A PROTHROMBIN INHIBITOR WITH POTENT ANTI-THROMBOTICACTIVITYR. B. Zingali* (BR), R. R. Q. Monteiro, F. F. S. Frattani, M. Assafim

PP-TH-180 EVALUATION OF MIXING STUDIES INTERPRETATION CRITERIA AND LUPUSANTICOAGULANTS (LA) CONFIRMATORY TEST IN PEDIATRIC PATIENTSS. Estelle* (US), M. Chitlur, L. Llanto, J. Thul, L. Kodali, M. Rajpurkar, J. M. Lusher

PP-TH-181 THE ANTI-COAGULANTS ASIS OR APC DO NOT PROTECT AGAINST RENALISCHEMIA/ REPERFUSION INJURYS. T. B. G. Loubele* (NL), A. C. Spek, P. Leenders, K. Hamulyak, R. A. Matthijsen, W. A.Buurman, C. J. Peutz-Kootstra, H. M. H. Spronk, H. ten Cate

PP-TH-182 EVALUATION OF A GENOTYPING TEST DETECTING VKORC1 AND CYP2C9POLYMORPHISMS ASSOCIATED WITH COUMARIN-BASED ANTICOAGULANTSENSITIVITY IN PATIENTSS. Campbell* (US), T. Patno, W. Cork

PP-TH-183 INFLUENCE OF A FLUOROGENIC SUBSTRATE ON THROMBIN GENERATION: WHENIN SILICO SIMULATIONS PREDICT IN VITRO EXPERIMENTSA. Carlo, S. Kerdélo* (FR), M. Gonidec, E. Arnaud, B. J. Woodhams

PP-TH-184 EFFECTS OF NOVEL FACTOR Xa INHIBITOR YM150 ON IN VITRO HUMAN PLATELETACTIVATION AND AGGREGATIONS. Kaku* (JP), K. Suzuki, M. Sasamata, K. Miyata

PP-TH-185 PROTEIN Z/PROTEIN Z-DEPENDENT PROTEASE INHIBITOR COMPLEX IS A POORINHIBITOR OF FACTOR Xa IN A PLASMA MILIEUS. Mirshahi* (FR), C. Soria, M. Adam, J. Soria, B. J. Woodhams

PP-TH-186 EFFECTS ON FIBRIN NETWORK POROSITY OF ANTICOAGULANTS WITH DIFFERENTMODES OF ACTIONS. He, M. Blombäck* (SE), N. Bark, H. Wallén, M. Elg

PP-TH-187 EVALUATION OF A NEW ANTI-Xa HEPARIN ASSAYS. J. Davidson* (UK)

PP-TH-188 THROMBIN GENERATION IN ACQUIRED AND INHERITED PROTEIN S DEFICIENCYA. Wong, S. Rodgers, T. Stanford, E. Duncan, B. Dale, R. Baker, S. J. McRae* (AU)



344

Thur

sday

Pos

ters

PP-TH-189 INFLUENCE OF THE ENDOTHELIAL CELL PROTEIN C RECEPTOR (EPCR) GENE(PROCR) ON PROTEIN C DEFICIENCY EXPRESSIONB. Saposnik, M. Alhenc-Gelas, J. F. Abgrall, M. F. Aillaud, C. Boinot, P. de Moerloose, M.Dreyfus, J. Emmerich, M. Gouault-Heilman, B. Jude, C. Ternisien, B. Tardy, C. Vergnes, M.Aiach, S. Gandrille* (FR)

PP-TH-190 PROFILING OF DIFFERENTIALLY EXPRESSED GENES ASSOCIATED WITH INHIBITORDEVELOPMENT IN HEMOPHILIA AS. Hwang* (KR), H. C. Kim, H. Lee, K. Yoo, H. J. Kim, H. Kim

PP-TH-191 MASS TRANSPORT PROPERTIES OF ANTITHROMBIN III ISOFORMS SUGGESTINTRODUCTION OF ALPHA-ANTITHROMBIN AT THE TELEOST TO TETRAPODTRANSITION WAS ADAPTIVE IN THE CONTEXT OF THE EVOLUTIONARY SWITCH TOHIGH-PRESSURE DOUBLE CIRCULATORY SYSTEMS, WHICH REQUIRE RAPIDS. C. Bock* (US), B. Leng

PP-TH-192 A FLUORESCENCE MICROPLATE ASSAY FOR DIRECT QUANTIFICATION OFHEPARINS AND OTHER SULFATED CARBOHYDRATESS. Alban* (DE), S. Lühn

PP-TH-193 PROTHROMBIN TIME AS A SIMPLE SCREENING METHOD TO IDENTIFY HEPARINSCONTAMINATED WITH OSCS AND SIMILAR COMPOUNDSS. Alban* (DE), S. Lühn

PP-TH-194 ACTIVATION OF ANTITHROMBIN BY TWO SITES MUTATIONST. Koide* (JP), H. Kawajiri, E. Ooe, Y. Shoya

PP-TH-195 INHIBITION OF THROMBIN GENERATION IN HUMAN PLASMA BY THE ORAL DIRECTFACTOR Xa INHIBITOR DU-176B IN VITROT. Furugohri* (JP), C. Kamisato-Matsumoto, Y. Morishima, T. Shibano

PP-TH-196 COMPUTATIONAL MODELING OF WARFARIN THERAPYT. Orfeo* (US), K. Brummel-Ziedins, M. Gissel, S. Butenas, K. G. Mann

PP-TH-197 ACTIVATED PROTEIN C REGULATES CARDIOMYOCYTE FUNCTION VIA EPCR ANDPAR1T. Dutt* (UK), E. Dubuis, M. Perez-Casal, G. Wang, G. Hart, C. Toh

PP-TH-198 ENOXAPARIN ATTENUATES ENDOTHELIAL DAMAGE WITH LESS BLEEDINGCOMPARED TO UNFRACTIONATED HEPARIN IN ENDOTOXEMIC RATST. Iba* (JP)

PP-TH-199 THROMBIN GENERATION IN THE ASSESSMENT OF SUSPECTED ANTIBODIES TOFACTOR XT. H. Tran* (CH), G. Favre, G. A. Marbet

PP-TH-200 CLINICAL SITE EVALUATION OF A NEW LIQUID HEPARIN ASSAYV. Krougliak* (US), J. Gabbeta, C. Kung, M. Triscott

PP-TH-201 EX VIVO NEUTRALIZATION OF ENOXAPARIN IN PRIMATES BY A NOVEL HEPARINANTAGONISTW. P. Jeske* (US), E. Litinas, J. Emanuele, D. Hoppensteadt, E. McAllister

PP-TH-202 EVALUATION OF THE DIRECT FACTOR Xa INHIBITOR APIXABAN IN RAT MODELS OFTHROMBOSIS AND HEMOSTASISW. A. Schumacher* (US), J. S. Bostwick, A. B. Stewart, B. Xin, P. C. Wong

PP-TH-203 THE PREVALENCE AND GENETIC BACKGROUND OF FACTOR VIII INHIBITORS INCHINESE HEMOPHILIA A PATIENTSX. Wang* (CN), Q. Ding, R. Yang, Y. Zhao, J. Wu, J. Sun, X. Zhang, H. Wang



345

PP-TH-204 ACQUIRED FACTOR X DEFICIENCY: DIFFICULTIES TO ESTABLISH ETIOLOGICDIAGNOSISZ. Kaci* (DZ), H. Ahmidatou, N. Zidani, K. Chennoukh, Y. Berkouk, M. Belhani

PP-TH-205 PROLONGATION OF THE APTT MAY DEPEND ON INHIBITION OF CONTACT FACTORSZ. Volovyk* (US), D. M. Monroe, M. Hoffman

Fibrinogen III

PP-TH-206 OBESITY INCREASES FIBRINOGEN LEVELS IN PREGNANCYM. P. Smrtka* (US), B. H. Thames, M. Beckman, P. Rawlins, A. H. James

PP-TH-207 THE EFFICACY OF FIBRINOGEN CONCENTRATE IN TREATING EXCESSIVE BLEEDINGIN AORTIC SURGERYN. Rahe-Meyer* (DE), K. Tanaka, C. Solomon, A. Osthaus, K. Goerlinger, S. Piepenbrock, M.Pichlmaier

PP-TH-208 RECOVERY OF FIBRINOGEN PLASMA LEVEL AFTER ADMINISTRATION OFFIBRINOGEN CONCENTRATE FOR HEMOSTATIC THERAPY IN AORTIC SURGERYN. Rahe-Meyer* (DE), K. Tanaka, K. Goerlinger, M. Pichlmaier, A. Osthaus, S. Piepenbrock,C. Solomon

PP-TH-209 EFFECTS OF ANTI-RETROVIRAL THERAPY ON HAEMOSTATIC ANDHAEMORHEOLOGICAL PARAMETERS IN HIV/AIDS PATIENTSO. A. Awodu* (NG), A. O. Adebayo, A. A. Famodu

PP-TH-210 IN VITRO PROPERTIES OF BLOOD BANK PRODUCED FIBRIN SEALANTS FROMSINGLE DONOR HUMAN PLASMAP. Eshghi* (IR), A. Hashemi, N. Amirizadeh, H. Abolghasemi

PP-TH-211 DETERMINATION OF ACTIVATED FACTOR XIII IN PLASMA AS A MARKER OFACTIVATION OF COAGULATIONS. Mirshahi* (FR), C. Soria, J. Chidiac, G. Kierzek, R. Varin, R. Batista, L. Drouet, B. J.Woodhams, J. Soria

PP-TH-212 ANALYSIS OF FIBRIN STRUCTURE AND FUNCTION IN MAN EXPOSED TO TRANSIENTDIESEL EXHAUSTS. Metassan* (UK), M. N. Routledge, A. J. Lucking, J. A. Scott, N. L. Mills, D. E. Newby, R. A.S. Ariëns

PP-TH-213 KINETICS OF FIBRINOPEPTIDES RELEASE FROM FIBRINOGEN ADSORBED ON ASURFACET. Riedel* (CZ), E. Brynda, M. Houska, J. Suttnar, J. E. Dyr

PP-TH-214 MOLECULAR SIMULATIONS OF FORCED UNFOLDING OF FIBRIN MONOMERSV. Barsegov* (US), R. Dima, J. W. Weisel, R. I. Litvinov, A. Zhmurov

PP-TH-215 CRYPTIC HEPATOPATHY AND HYPOFIBRINOGENEMIA IN A PATIENT COMPOUNDHETEROZYGOUS FOR A KNOWN MUTATION IN THE FIBRINOGEN GAMMA CHAIN(ARG375TRP) AND A NOVEL MUTATION IN THE FIBRINOGEN BETA CHAIN (PRO70SERW. A. Hassenpflug* (DE), K. Franke, E. Grabhorn, H. Schäfer, R. Schneppenheim, M. Meyer

PP-TH-216 FACTOR XIII SUBUNITS IN NON-STIMULATED AND STIMULATED HUMAN TEARS ANDIN TEARS PRODUCED FOLLOWING PENETRATING KERATOPLASTYZ. Z. Orosz* (HU), É. Katona, A. Facskó, A. Berta, L. Muszbek



346

Thur

sday

Pos

ters

Fibrinolysis III

PP-TH-217 FIBRINOLYTIC SYSTEM ASSESSMENT IN HEMODIALYSIS PATIENTS WITH ANDWITHOUT THROMBOTIC COMPLICATIONSL. M. S. Dusse* (BR), D. R. A. Rios, A. C. Simões E Silva, V. Rodrigues, A. V. Santos, B. A.Lwaleed, M. G. Carvalho

PP-TH-218 FIBRINOLYSIS IN PREECLAMPSIAL. C. Godoi, L. S. Dusse* (BR), H. S. Madeira, B. A. Lwaleed, M. G. Carvalho

PP-TH-219 ROLE OF KRINGLES OF PLASMINOGEN (PG) AND PLASMIN-STAPHYLOKINASEACTIVATOR COMPLEX (PM-STA) IN TERNARY ENZYME-SUBSTRATE COMPLEXFORMATIONM. Y. Levashov* (RU), R. Aisina, R. Kramor, K. Gershkovich, S. Varfolomeyev

PP-TH-220 SYSTEMIC PRIMARY FIBRINOLYSIS DUE TO TISSUE PLASMINOGEN ACTIVATOR(TPA) PRODUCING METASTATIC BREAST CANCERH. V. K. Naina, M. M. Patnaik* (US), U. Ali, A. Behfar, C. Dong, A. A. Ashrani

PP-TH-221 IS THERE ANY EFFECT OF OBESITY ON THROMBIN ACTIVATABLE FIBRINOLYSISINHIBITOR LEVELS IN POSTMENOPAUSAL WOMENB. Taskiran, S. Guldiken, M. Demir* (TR), T. Kilic-Okman, E. Arikan, B. Turgut, A. Tugrul

PP-TH-222 THE PLASMA LEVELS OF THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR INPATIENTS WITH PRIMARY HYPOTHYROIDISM BEFORE AND AFTER TREATMENTN. Ermantas, S. Guldiken, M. Demir* (TR), A. Tugrul

PP-TH-223 UNFRACTIONATED HEPARIN OR FONDAPARINUX IN ELDERLY PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME: DIFFERENT EFFECT ONFIBRINOLYTIC STATUS AT DAY 8O. Averkov* (RU), L. Skutnitskaya, Z. Kobalava

PP-TH-224 THE EXTREME C-TERMINUS OF ANTIPLASMIN IS MOST IMPORTANT INACCELERATING THE PLASMIN-ANTIPLASMIN INTERACTIONT. Sofian, B. Lu, C. Hitchen, A. J. Horvath, P. B. Coughlin* (AU)

PP-TH-225 TREATMENT OF CENTRAL CATHETER RELATED VENOUS THROMBOSIS WITH LOWDOSE INTRACLOT INJECTIONS OF TPAR. Chang, R. Chang* (US), A. W. Kam, E. Chen, J. N. Lozier, M. K. Horne

PP-TH-226 MECHANISM OF THE ACTION OF THE PLASMINOGEN MODULATOR SMTPR. Narasaki* (JP), H. Koide, H. Shiraishi, K. Hasumi

PP-TH-227 MECHANISM OF INHIBITORY ACTION OF ANGIOSTATIN ON PLASMINOGEN (PG)ACTIVATION BY TISSUE PLASMINOGEN ACTIVATOR (TPA) AND UROKINASE (UPAR. B. Aisina* (RU), L. Mukhametova, N. Prisyazhnaya, D. Gulin, K. Gershkovich, S.Varfolomeyev

PP-TH-228 INFLUENCE OF HEAT-PROOF SUBSTANCE CONTAINED IN NATTO ON BLOODCIRCULATIONT. Ohsugi* (JP), E. Sumida, H. Sumi

PP-TH-229 UROKINASE-TYPE PLASMINOGEN ACTIVATOR INDUCES HEPATIC DIFFERENTIATIONOF EMBRYONIC STEM CELLT. Seki* (JP), Y. Hasebe, G. Watanabe, H. Nakashima, K. Sawada, S. Hanazawa, M.Harashima, Y. Ito, N. Okumura, T. Ariga

PP-TH-230 IN VITRO COMPARISON OF FIBRINOLYTIC PROPERTIES OF DIRECTTHROMBOLYTICSV. Novokhatny* (US), J. Nixon, C. Li, J. Bromirski, J. Hunt, P. Scuderi, S. R. Petteway



347

PP-TH-231 A UNIQUE RECOMBINANT PLASMIN MOLECULE LACKING KRINGLES 2-5 EXHIBITSCOMPARABLE HEMOSTATIC SAFETY AND EFFICACY AS FULL-LENGTH, PLASMA-DERIVED PLASMINV. J. Marder* (US), S. Manyak, T. Gruber, J. Hunt, J. Bromirski, A. Goyal, P. Scuderi, S. R.Petteway Jr, V. Novokhatny

PP-TH-232 DOSE RESPONSE STUDY OF INTRA-ARTERIAL PLASMIN TO RECANALIZE THETHROMBO-OCCLUDED RABBIT MIDDLE CEREBRAL ARTERYR. Jahan, T. Gruber, A. Goyal, V. Arora, V. J. Marder* (US)

PP-TH-233 DEVELOPMENT OF NOVEL TECHNOLOGY TO ANALYZE THE PROCESS OFINTRAVASCULAR THROMBOLYSISY. Magari* (JP)

Regulation of Coagulation and Fibrinolysis III

PP-TH-234 ROTEM® THROMBOELASTOMETRY IN LIVER TRANSPLANTATION: COULD ITPREDICT POSTRANSPLANTATION GRAFT PERFORMANCEA. F. Minou* (BY), A. M. Dzyadzko

PP-TH-235 SELECTION OF A FLUOROGENIC MARKER FOR USE IN WHOLE BLOOD (WB)ENZYMATIC ASSAYSE. Lebra, A. Carlo* (FR), H. Apan, V. El Qacemi, G. Quentin, B. J. Woodhams, E. Arnaud

PP-TH-236 TESTING OF LOW MOLECULAR WEIGHT HEPARIN DURING HEMODIALYSISE. Vlasova* (RU), I. Vasilenko, V. Samoylenko, V. Suslov

PP-TH-237 PIVOTAL ROLE OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) FOR LOCALREGULATION OF TISSUE FACTOR (TF) -INDUCED THROMBIN GENERATION INMONOCYTES ISOLATED FROM HUMAN BLOODG. B. Manjunath* (NO), F. X. Gruber, M. Sovershaev, H. I. Appelbom, B. Østerud, L. C.Petersen, S. Pankiv, J. Hansen

PP-TH-238 THE EFFECT OF THYROXINE AND THYROTROPIN (TSH) LEVELS ON THECOAGULATION SYSTEMJ. Debeij* (NL), S. C. Cannegieter, B. van Zaane, J. W. A. Smit, N. P. M. van der Kley-Corssmit, F. R. Rosendaal, J. A. Romijn, O. M. Dekkers

PP-TH-239 CARBON MONOXIDE RELEASING MOLECULE 3 (CORM-3) INHIBITS ARTERIALTHROMBOSIS IN RATSK. Kramkowski* (PL), A. Mogielnicki, R. Motterlini, S. Chlopicki, W. Buczko

PP-TH-240 BIOLOGICAL VARIABILITY OF COAGULATION TESTSM. W. Besser* (UK), L. Figueiredo, T. Baglin, R. Luddington

PP-TH-241 QUANTIFICATION OF PROTHROMBIN FRAGMENT 1+2 BY LOCI® TECHNOLOGY*M. Ehm* (DE), H. Althaus, B. Fischer, A. Muth, M. Pfeiff, S. Teigelkamp

PP-TH-242 EFFECT OF IN-VITRO CRYSTALLOID DILUTION ON ENDOGENOUS THROMBINPOTENTIAL (ETP) IN HEALTHY VOLUNTEERS (HV) AND PATIENTS WITH A HISTORYOF VENOUS THROMBOSIS (VT) OR HEPATIC CIRRHOSIS (HC)N. Jones* (UK), J. Kaur, A. Riddell, C. Melikian, S. Mallett

PP-TH-243 THROMBIN REDUCES TIME TO PEAK ON TISSUE FACTOR INDUCED THROMBINGENERATION IN HUMAN AORTIC SMC VIA ACTIVATION OF PAR 3 AND 4 RECEPTORSP. Vidwan* (US), A. Pathak, S. Sheth, G. A. Stouffer

PP-TH-244 FURTHER CHARACTERISATION OF AN ANDROGEN RESPONSE ELEMENT IN THEHUMAN PROTEIN C GENE PROMOTERK. Korfi, K. J. Cameron, P. R. Winship* (UK)



348

Thur

sday

Pos

ters

PP-TH-245 RESPONSES TO LOW-DOSE VITAMIN K TREATMENT FOR WARFARIN OVERDOSEAND VKORC1 SINGLE NUCLEOTIDE POLYMORPHISM (SNP)R. Deoisares, P. Rojnuckarin* (TH)

PP-TH-246 HIGH PROCOAGULANT ACTIVITY IN SUBRETINAL FLUID IN PRIMARY RETINALDETACHMENT DISORDERR. Al Dieri* (NL), L. J. A. G. Ricker, E. C. La Heij, A. Kijlstra, H. C. Hemker

PP-TH-247 FAST QUANTITATIVE AND GLYCOMIC VARIATIONS OF ANTITHROMBIN AFTER BIRTHR. Teruel* (ES), J. Corral, I. Martínez-Martínez, A. Miñano, A. Ordóñez, B. Sánchez-Vega, V.Vicente, C. Martínez

PP-TH-248 WHOLE BLOOD PROCOAGULANT ACTIVITY IN HEALTHY VOLUNTEERS ISDECREASED FOLLOWING ORANGE JUICE INTAKEE. Napoleone, A. Cutrone, F. Zurlo, G. Colavecchia, A. di Castelnuovo, L. Giordano, A. deCurtis, L. Iacoviello, C. Cerletti, D. Rotilio, G. de Gaetano, M. B. Donati, R. Lorenzet* (IT)

PP-TH-249 WHOLE BLOOD PROCOAGULANT ACTIVITY AS A POSSIBLE CELLULAR MARKER OFCARDIOVASCULAR RISKE. Napoleone, A. Cutrone, F. Zurlo, A. de Curtis, F. Gianfagna, B. Vohnout, L. Iacoviello, G.de Gaetano, M. B. Donati, R. Lorenzet* (IT)

PP-TH-250 THE ARTERIO-VENOUS DIFFERENCE OF HEMOSTASIS PARAMETERS IN VARIOUSTYPES OF ENERGY DEFICIENCYS. V. Sinkov* (RU), I. B. Zabolotskikh, K. D. Zybin, S. V. Grigoriev

PP-TH-251 THE ROLE OF INSTRUMENTAL DIAGNOSTIC TECHNIQUES IN THE ASSESSMENT OFTHE DEGREE OF HEMOSTATIC DYSFUNCTIONS. V. Sinkov* (RU), I. B. Zabolotskikh, S. A. Shaposhnikov

PP-TH-252 IDENTIFICATION AND CHARACTERIZATION OF HIGH AFFINITY SMALL MOLECULEINACTIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1S. Li* (US), J. M. Cale, M. Warnock, C. Emal, D. A. Lawrence

PP-TH-253 CALIBRATED AUTOMATED THROMBOGRAPHY (CAT) IN PLATELET POOR PLASMA INADULTSS. Petros* (DE), T. Schneider, T. Siegemund, R. Siegemund

PP-TH-254 THROMBIN GENERATION IN PATIENTS WITH SEPSISS. Petros* (DE), P. Kliem, T. Siegemund, R. Siegemund, S. Kindler

PP-TH-255 EFFECT OF IN VIVO REDUCTION IN RED CELL MASS ON RESULTS OF CANINEWHOLE BLOOD THROMBOELASTOMETRYS. A. Smith* (US), M. McMichael, A. Galligan, K. Swanson, J. H. Morrissey

PP-TH-256 DIFFERENTIAL EFFECTS OF POLYPHOSPHATE ON BLOOD CLOTTINGS. A. Smith* (US), S. H. Choi, J. Huyck, J. H. Morrissey

PP-TH-257 HEPARIN ACCELERATES FIBRINOLYTIC AND THROMBOLYTIC FUNCTION OFLONGOLYTINT. S. Sharkova* (RU), L. V. Podorolskaya, T. N. Serebryakova

PP-TH-258 LOW-MOLECULAR-WEIGHT HEPARIN AND TRANEXAMIC ACID FOR CHRONIC DIC INPROSTATE CANCER - A CASE REPORTT. Vucemilo* (HR), D. Sturm, M. Banoviæ, G. Krajaèiæ,Karas

PP-TH-259 THE (GT)N LOCUS OF THE VON WILLEBRAND FACTOR (VWF) GENE PROMOTERPREDICTS INCREASED VWF LEVELS IN RESPONSE TO GLUCOCORTICOID EXCESSV. Daidone* (IT), F. Sartorello, M. Cattini, E. Pontara, L. Gallinaro, A. Pagnan, A. Casonato



349

PP-TH-260 PLASMIN-INDUCED THROMBIN FORMATION EXPLAINS MILD HAEMORRHAGE INFIBRINOLYTIC DISORDERSW. L. van Heerde* (NL), S. Croockewit, P. Lap, A. Loof, K. Verbeek, J. Boezeman, I.Novakova, M. van Kraaij, B. Verbruggen

PP-TH-261 FACTOR VA C1 AND C2 DOMAINS PARTICIPATE IN PHOSPHATIDYLETHANOLAMINEMEMBRANE BINDINGX. Liang* (US), M. Quinn-Allen, W. H. Kane

PP-TH-262 FURTHER STUDIES ON HEMOSTATIC ACTIVATION IN SICKLE CELL DISEASE : ROLEOF HEMOLYSIS AND TYPE-II PHOSPHATIDYLSERINE-POSITIVE ERYTHROCYTESY. B. Setty* (US), N. S. Key, M. J. Stuart

Antiphospholipid Antibodies and Syndrome III

PP-TH-263 ANTICARDIOLIPIN AND ANTI-BETA 2 GLYCOPROTEIN 1 ANTIBODIES ARE REQUIREDFOR THE CLINICAL DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROMEC. Gardiner* (UK), J. Hills, S. J. Machin, H. Cohen

PP-TH-264 PHOSPHOLIPID COMPOSITION IMPACT ON DILUTE THROMBOPLASTIN SENSITIVITYTO LUPUS ANTICOAGULANTSK. M. Cawthern* (US), R. Bottenus, D. Diaz, M. X. Triscott

PP-TH-265 CATASTROPHIC ANTIPHOSPHOLIPID ANTIBODY SYNDROME (CAPS) IN CHILDREN:SUCCESSFUL MANAGEMENT WITH AGGRESSIVE DIRECT THROMBIN INHIBITION,PHARMACOMECHANICAL THROMBOLYSIS, AND IMMUNOMODULATORY THERAPYM. J. Manco-Johnson* (US), M. Wang, N. A. Goldenberg, J. Soep, E. Pounder, C. Knoll

PP-TH-266 BIOPHYSICAL CHARACTERIZATION OF THE COMPLEXES BETWEEN B2GPI AND THELIGAND-BINDING LA MODULES FROM THE LIPOPROTEIN RECEPTORSC. Lee, A. de Biasio, N. Beglova* (US)

PP-TH-267 MARKERS OF INFLAMMATION AND ENDOTHELIAL CELLS ACTIVATION IN PATIENTSWITH ANTIPHOSPHOLIPID SYNDROME DEPENDING ON THROMBOSIS LOCALIZATIONN. V. Seredavkina* (RU), T. M. Reshetnyak, E. N. Alexandrova, A. A. Novikov, E. S. Much, M.V. Cherkasova, E. L. Nasonov

PP-TH-268 ASSOCIATION BETWEEN HOMOCYSTEINE, ANTICARDIOLIPIN AND ANTIBETA2GLYCOPROTEIN-I ANTIBODIES IN PATIENTS WITH CORONARY ARTERY DISEASEO. A. Smirnova* (RU), V. M. Shmeleva, V. A. Kobilyanskaya, L. P. Papayan

PP-TH-269 CLINICAL MANIFESTATIONS OF LUPUS ANTICOAGULANTS IN CHILDRENO. M. Serbic* (RS), M. Kuzmanovic, G. Vlahovic, D. Veljkovic, S. Pasic, D. Micic

PP-TH-270 TISSUE FACTOR -603A/G POLYMORPHISM AND TISSUE FACTOR LEVELS INPATIENTS WITH ANTIPHOSPHOLIPID SYNDROMER. Kahraman, V. Hancer, R. Diz-Kucukkaya* (TR)

PP-TH-271 THE MANAGEMENT OF ELEVATED APL IN PREGNANCYR. Apostolovska* (MK), T. Balkanov, V. Dejanova, K. Dimitrovski, S. Atanasova, I. Nikoloska,L. Stojanovska-Trajkovska, V. Neceva

PP-TH-272 LUPUS ANTICOAGULANT IN A CHILD WITH CELIAC DISEASE- AN UNCOMMONASSOCIATIONS. Naseem* (IN), J. Ahluwalia, D. Suri, S. Singh

PP-TH-273 ANTI-BETA-2-GLYCOPROTEIN-I IGG ANTIBODIES AND ANTI-CARDIOLIPIN IGGANTIBODIES DO NOT PREDICT THROMBOSIS IN PATIENTS WITH A PERSISTENTLUPUS ANTICOAGULANTS. Koder* (AT), R. Vormittag, C. Zoghlami, S. Panzer, P. Quehenberger, I. Pabinger



350

Thur

sday

Pos

ters

PP-TH-274 ROLE OF CALCIUM IONS IN THE BINDING OF BETA2-GLYCOPROTEIN I TOCARDIOLIPIN IN AN ELISA ASSAYS. Olivieri* (IT), M. Tonello, A. Cavazzana, A. Bontadi, A. Banzato, E. Bison, V. Pengo, A.Ruffatti

PP-TH-275 LUPUS ANTICOAGULANT – WITH HYPOPROTHROMBINAEMIA: A REPORT OF 2CASESS. C. Nair* (IN), N. Arora, N. V. Patkar, S. Baidya, L. G. Mattew, P. D. Moses

PP-TH-276 SEVERE BLEEDING DUE TO ACQUIRED HYPOPROTHROMBINEMIA-LUPUSANTICOAGULANT SYNDROME.CAS REPORT AND REVIEW OF LITERATURET. K. Dib* (DZ), C. Abi-Ayad, S. Ayad, M. Gheras, S. Brixi, A. Reghis

PP-TH-277 THROMBOCYTOPENIA IN ANTIPHOSPHOIPID SYNDROMET. M. Reshetnyak* (RU), I. B. Shtivelband, E. N. Alexandrova, A. A. Novikov, N. V.Seredavkina, L. V. Kondratieva, E. V. Ostryakova, E. L. Nasonov

PP-TH-278 CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME AND OBSTETRIC COMPLICATIONSV. O. Bitsadze* (RU), S. M. Baimuradova, D. H. Hizroeva, S. V. Akinshina, A. D. Makatsariya

PP-TH-279 INTIMA-MEDIA THICKNESS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROMEG. Malek, W. Z. Tomkowski* (PL), P. Kuca, M. Dybowska, J. Burakowski, M. Meissner

PP-TH-280 CORONARY ARTERIES CALCIUM SCORING IN PATIENTS WITH ANTIPHOSPHOLIPIDSYNDROMEP. Kuca, W. Z. Tomkowski* (PL), G. Malek, M. Dybowska, J. Burakowski, M. Meissner

PP-TH-281 THE EFFECT OF LUPUS ANTICOAGULANTS AND APC RESISTANCE ON PROTEIN SACTIVITY ASSAYZ. Cao* (US), R. Bottenus, D. Sanchez, M. Triscott

Risk Factors and Epidemiology of Venous Thrombosis III

PP-TH-282 INHERITED OR ACQUIRED THROMBOPHILIC ALTERATIONS (TAS) IN PATIENTS WITHSUPERFICIAL VEIN THROMBOSIS (SVT)C. Legnani* (IT), M. Cini, C. Pili, G. Lo Manto, M. Frascaro, O. Boggian, G. Palareti

PP-TH-283 ASSESSMENT OF RACE, GENDER AND MORTALITY FROM A LARGE NATIONWIDESAMPLE OF PATIENTS ADMITTED FOR PULMONARY EMBOLISM IN THE UNITEDSTATESD. M. Courtney* (US), R. K. Khare

PP-TH-284 VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER MAJOR ORTHOPEDICSURGERY: A MULTI-CENTER PROSPECTIVE OBSERVATIONAL STUDYF. Altintas* (TR), ?. Öztürk, B. Atilla, R. Tözün, F. Pestilci

PP-TH-285 AUTOMATIZATION OF GENETIC ANALYSIS: FACTOR V LEIDEN, F2G20210A, F12C46TAND MTHFR C667T BY REAL TIME PCRI. Coll, I. Tirado* (ES), E. Martínez-Sánchez, J. Souto, V. Orantes, J. Fontcuberta

PP-TH-286 HYPERTHYROIDISM IS ASSOCIATED WITH AN INCREASED RISK OF VENOUSTHROMBOSISJ. Debeij* (NL), B. van Zaane, O. M. Dekkers, J. W. A. Smit, J. A. Romijn, V. E. A. Gerdes, A.P. van Zanten, D. P. M. Brandjes, H. R. Büller, F. R. Rosendaal, S. C. Cannegieter

PP-TH-287 FUNCTIONAL CONSEQUENCES OF THE PROTHROMBOTIC SERPINC1 RS2227589POLYMORPHISM ON ANTITHROMBIN LEVELSA. I. Antón, R. Teruel, J. Corral* (ES), A. Miñano, I. Martínez-Martínez, A. Ordóñez, V.Vicente, B. Sánchez-Vega



351

PP-TH-288 COMPARISON OF THE CLINICAL HISTORY OF SYMPTOMATIC ISOLATED DISTALDEEP-VEIN THROMBOSIS VERSUS PROXIMAL DEEP-VEIN THROMBOSIS IN 11086PATIENTS: RESULTS FROM THE RIETE REGISTRYJ. Galanaud* (FR), S. Quenet, K. Guillot, I. Quéré, J. Sanchez Munoz-Torrero, C. Tolosa, M.Monreal, A. The Riete Investigators

PP-TH-289 QUANTITATIVE TRAIT LOCI INVOLVED IN THE REGULATION OF LIPOPROTEIN A (LPA)LEVELS: GENOME-WIDE LINKAGE ANALYSIS FROM THE GAIT PROJECTS. López, A. Buil, J. Souto, J. Ordoñez, J. Blangero, F. Blanco-Vaca, J. Fontcuberta, L.Almasy, J. Soria* (ES)

PP-TH-290 QUANTITATIVE TRAIT NUCLEOTIDE ANALYSIS IN THE NNMT GENE: A GENETICDETERMINANT FOR HOMOCYSTEIN LEVELSM. Sabater-Lleal, J. Martín, A. Buil, M. Chillón, J. Souto, J. Blangero, J. Fontcuberta, F.Blanco-Vaca, J. Soria* (ES), L. Almasy

PP-TH-291 LIPID-LOWERING DRUGS, LIPID PARAMETERS AND VENOUS THROMBOEMBOLISMK. Lacut* (FR), J. Malecot, A. Delluc, F. Couturaud, H. Kerspern, J. Carre, D. Mottier, E. Oger

PP-TH-292 CASE FATALITY RATE OF RECURRENT VENOUS THROMBOEMBOLISM AND MAJORBLEEDING DURING AND FOLLOWING ANTICOAGULATION THERAPYM. Carrier* (CA), G. Le Gal, P. S. Wells, M. A. Rodger

PP-TH-293 IS SCREENING FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION INPATIENTS WITH A PREVIOUS PULMONARY EMBOLISM INDICATEDN. S. Gibson* (NL), S. Surie, V. E. A. Gerdes, B. J. Bouma, B. L. F. van Eck-Smit, H. R.Buller, P. Bresser

PP-TH-294 ASSOCIATION OF THE VEGF POLYMORPHISMS AND HAPLOTYPES WITH THE RISKOF OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURES INPOSTMENOPAUSAL WOMENN. Kim* (KR), Y. Chung, S. Hong, D. Shin, J. Lee

PP-TH-295 DIFFERENCES IN AETIOLOGICAL AND CLINICAL MANIFESTATIONS IN UPPER ANDLOWER LIMB DEEP VENOUS THROMBOSIS PATIENTS FROM INDIAN. Pai* (IN), S. Shetty, B. Kulkarni, K. Ghosh

PP-TH-296 PROTHROMBOTIC TENDENCY IN PATIENTS WITH HYPERTHYROIDISMN. M. Antonijevic* (RS), B. Stojanovic, D. Mikovic, M. Kovac, S. Popovic, M. Petakov, B.Jakovljevic, A. Beletic, V. Djordjevic, B. Trbojevic, N. Radovanovic, I. Elezovic

PP-TH-297 THROMBOPHILIA MARKERS IN PORTAL VEIN THROMBOSISN. Ben Romdhane* (TN), S. Mahjoub, H. Kallel, R. Ellouze, H. Baccouche, Z. Manai

PP-TH-298 THROMBOPHILIC ABNORMALITIES IN TUNISIAN PATIENTS WITH INFLAMMATORYBOWEL DISEASEN. Ben Romdhane* (TN), R. Ellouze, S. Mahjoub, H. Kallel, L. Kallel, A. Filali

PP-TH-299 THROMBOPROPHYLAXIS IN HOSPITALIZED PATIENTS: CAN WE DO IT BETTERP. Marchena Yglesias* (ES), E. Pesantes, R. Rey Santos, J. Burillo Lorente, F. Castro, F.Ribó Crusat, X. Martret Redrado, C. Paytubí Garí, J. Pérez Más, A. Domènech, M. BioscaGómez de Tejada

PP-TH-300 HIGH FACTOR VIII IN EXTRA-HEPATIC PORTAL VEIN OBSTRUCTIONP. Bucciarelli* (IT), I. Martinelli, M. Primignani, R. Reati, F. Fabris, T. Battaglioli, A. Dell’Era, P.M. Mannucci

PP-TH-301 RELATIONSHIP BETWEEN HYPERHOMOCYSTEINEMIA AND LOW BONE MINERALDENSITYP. Bucciarelli* (IT), G. Martini, I. Martinelli, R. Nuti, P. M. Mannucci



352

Thur

sday

Pos

ters

PP-TH-302 PROSPECTIVE COHORT STUDY ON CARDIOVASCULAR RISK IN RETINAL VEINOCCLUSIONM. T. Sartori, A. Donà, S. Piermarocchi, E. Pilotto, G. Saggiorato, A. Pagnan, P. Prandoni*(IT)

PP-TH-303 RISK STRATIFICATION AND OUTCOMES IN HEMODYNAMICALLY STABLE PATIENTSWITH ACUTE PULMONARY EMBOLISM. A PROSPECTIVE MULTICENTRE COHORTSTUDY WITH THREE MONTHS OF FOLLOW-UPC. Bova, R. Pesavento, A. Marchiori, A. Palla, I. Enea, V. Pengo, A. Visonà, A. Noto, P.Prandoni* (IT)

PP-TH-304 HEART DISEASES AS A POTENTIAL SOURCE OF PULMONARY EMBOLISM. FINDINGSFROM A CROSS-SECTIONAL SURVEYP. Prandoni* (IT), R. Pesavento, H. T. Sorensen, N. Gennaro, F. Dalla Valle, I. Minotto, F.Perina, V. Pengo, A. Pagnan

PP-TH-305 STICKY PLATELET SYNDROME : ROLE OF FLOW CYTOMETRYP. Kubisz* (SK), L. Bartosová, J. Fedorová, P. Holly, J. Stasko

PP-TH-306 NATIONAL REGISTRY OF THROMBOPHILIC STATES IN SLOVAK REPUBLICP. Kubisz* (SK), I. Plamenová, J. Chudej, K. Gregorová, L. Bartosová, M. Dobrotová, P.Chudy’, J. Stasko

PP-TH-307 A ONE-DAY SURVEY OF ANTICOAGULANT USE IN A FRENCH GENERAL HOSPITALP. Girard* (FR), C. Christidis, J. Cosserat, N. Cathala, D. Czitrom, J. Le Guillou, A. Lebuisson

PP-TH-308 FACTOR V LEIDEN IS MOST COMMONLY FOUND IN CATHETER-RELATED UPPEREXTREMITY DEEP VEIN THROMBOSIS; DATA FROM THE RIETE REGISTRYP. di Micco, A. A. Visonà* (IT), V. V. Roldan, R. R. Lecumberri, A. A. Tirado, A. A. Niglio, M. M.Monreal

PP-TH-309 COMMON SUSCEPTIBILITY ALLELE ARE UNLIKELY TO CONTRIBUTE AS STRONGLYAS THE FV AND ABO LOCI TO VTE RISK: RESULTS FROM A GWAS APPROACHD. Tregouet, S. Heath, N. Saut, C. Biron, J. Schved, G. Pernod, P. Galand, L. Drouet, D.Zelenika, I. Juhan-Vague, M. Alessi, L. Tiret, M. Lathrop, J. Emmerich, P. E. Morange* (FR)

PP-TH-310 INCIDENCE OF VENOUS THROMBOTIC EVENTS IN A DIVERSE AMERICAN PEDIATRICINTENSIVE CARE UNIT POPULATIONR. A. Higgerson* (US), S. Hanson, K. A. Lawson, L. M. Christie, B. Totapally, J. McArthur, A.Brown

PP-TH-311 THE PREDICTIVE VALUE OF ICD-9-CM CODING FOR DEEP-VENOUS THROMBOSIS(DVT) AND PULMONARY EMBOLISM (PE)R. H. White* (US), M. Garcia, B. Sadeghi, D. Tancredi, P. Zrelak, P. S. Romano

PP-TH-312 INFLUENCE OF GENDER ON THE CLINICAL PRESENTATION AND DIAGNOSIS OFDEEP-VEIN THROMBOSIS. FINDINGS FROM THE TULIPA REGISTRYR. M. Bauersachs* (DE), H. Riess, V. Hach-Wunderle, H. Gerlach, H. Carnarius, S. Eberle, E.Rabe, S. M. Schellong

PP-TH-313 GENETIC RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN YOUNG WOMENFROM NORTH-WESTERN RUSSIAS. I. Kapustin* (RU), V. A. Kobilyanskaya, N. B. Saltykova, V. M. Shmeleva, M. N. Blinov

PP-TH-314 IS A LOW LEVEL OF APOLIPOPROTEIN A1 A RISK FACTOR FOR THROMBOSIS INBUDD-CHIARI SYNDROMES. Talens* (NL), J. Hoekstra, S. P. G. Dirkx, S. Darwish Murad, J. Garcia-Pagan, D. C. Valla,H. L. A. Janssen, F. W. G. Leebeek, D. C. Rijken



353

PP-TH-315 NATIONAL PROSPECTIVE COHORT STUDY OF VENOUS THROMBOEMBOLISM (VTE)MANAGEMENT IN THE CANADIAN OUTPATIENT SETTING: RECOVERY REGISTRYS. R. Kahn* (CA), S. Schulman, J. Martineau, N. Komari, A. McLeod, C. Strulovitch, M.Blostein, J. Faucher, G. Gamble, W. Gordon, P. Kagoma, M. Miron

PP-TH-316 HOMOCYSTEINE PLASMA LEVELS AND MTHFR C677T MUTATIONS. M. Ouviña* (AR), A. La Greca, C. Mardaraz, G. Araujo, F. Negro, A. Ferro

PP-TH-317 LONG-TERM SURVIVAL AFTER VENOUS THROMBOEMBOLISM: A COHORT STUDYAMONG YOUNG WOMENS. E. Reitter* (AT), C. Laczkovics, T. Waldhoer, C. Vutuc, I. Pabinger-Fasching

PP-TH-318 PLASMA HOMOCYSTEINE LEVEL AND MTHFR MUTATION IN IRANIAN PATIENTS WITHTHROMBOTIC EVENTST. Shashaani* (IR), M. Faranoush, S. Hejazi, M. Jazebi, F. Ala, N. Danaie

PP-TH-319 PRESENCE OF LOWER LIMB DEEP VEIN THROMBOSIS AND PROGNOSIS INPATIENTS WITH SYMPTOMATIC PULMONARY EMBOLISMT. Yamaki* (JP), H. Sakurai, K. Soejima, T. Kono, A. Hamahata

PP-TH-320 TYPE I ANTITHROMBIN DEFICIENCY IS MORE CLOSELY ASSOCIATED WITH VENOUSTHROMBOEMBOLISM THAN TYPE II ANTITHROMBIN DEFICIENCYT. Sakata, S. Kameda, M. Mitsuguro, A. Okamoto, M. Sano, Y. Kokubo, Y. Tsutsumi, T.Miyata* (JP)

PP-TH-321 THROMBOPHILIC RISK PROFILE IN PATIENTS WITH VENOUS THROMBOEMBOLISMIN NORTH-WESTERN RUSSIAV. M. Shmeleva* (RU), S. I. Kapustin, M. N. Blinov

PP-TH-322 THE RISK OF VENOUS THROMBOSIS, INCLUDING CEREBRAL VEIN THROMBOSIS,AMONG WOMEN WITH THROMBOPHILIA AND ORAL CONTRACEPTIVE USE: A META-ANALYSISN. Dayan, V. Tagalakis* (CA), C. Holcroft

PP-TH-323 THE EFFECT OF CASE DEFINITION ON THE APPARENT INCIDENCE OF VENOUSTHROMBOEMBOLISM WITHIN A LARGE ADMINISTRATIVE HEALTH CLAIMSDATABASE IN QUÉBEC, CANADAV. Tagalakis* (CA), S. R. Kahn, Y. Moride, J. Bovin

PP-TH-324 THE RELATIONSHIP BETWEEN THE A6963G EPCR POLYMORPHISM AND VENOUSTHROMBOEMBOLISM IN AMERICAN WHITES AND BLACKS: THE GATE STUDYC. Destareck, C. Lally, J. Benson, D. Ellingsen, H. Austin, W. C. Hooper* (US)

PP-TH-325 THE RELATIONSHIP OF TWO POLYMORPHISMS OF THE TCF7L2 GENE AND VENOUSTHROMBOEMBOLISM IN AMERICAN WHITES AND BLACKS: THE GATE STUDYC. J. Bean, C. Lally, J. Benson, H. Austin, W. C. Hooper* (US)

PP-TH-326 LACK OF ASSOCIATION BETWEEN THE PHE204 ALLELE OF FACTOR XIII WITHVENOUS THROMBOEMBOLISM AND MYOCARDIAL INFARCTIONH. Austin, C. Lally, M. Pyle, W. C. Hooper* (US)

PP-TH-327 FACTOR V LEIDEN AND VENOUS THROMBOEMBOLISM RISK AMONG IDIOPATHICAND PROVOKED CASES IN THE GATE STUDYC. Lally, H. Austin, M. Beckman, M. Pyle, W. C. Hooper* (US)

PP-TH-328 POLYMORPHISMS IN THE THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR GENEAND RISK OF VENOUS THROMBOEMBOLISMW. C. Hooper* (US), N. Dowling, C. Destaercke, C. Whitsett, C. Miller, M. Beckman, H. Austin



354

Thur

sday

Pos

ters

PP-TH-329 CONTRIBUTION OF HIGH LEVELS OF FACTORS VIII, IX AND XI TO THE RISK OFRECURRENT VENOUS THROMBOSIS IN HETEROZYGOUS FACTOR V LEIDENCARRIERSW. M. Lijfering* (NL), S. C. Christiansen, F. R. Rosendaal, S. C. Cannegieter

PP-TH-330 IMPLEMENTATION OF AN ELECTRONIC RISK ASSESSMENT TOOL WITH RULE BASEDRECOMMENDATIONS FOR PREVENTION OF HOSPITAL ACQUIRED VENOUSTHROMBOEMBOLISMG. C. Moore, I. Clark, N. Gautam, G. Jeskins, N. Suggett, W. Lester* (UK)

PP-TH-331 COMBINED OCCURRENCE OF HEREDITARY PROTEIN C AND PROTEIN S DEFICIENCYIN TWO CHINESE FAMILIES WITH VENOUS THROMBOSISY. Wu* (CN), G. Xu, Q. Ding, X. Xi, X. Wang, H. Wang

PP-TH-332 INFLAMMATORY STATE IN PATIENTS PRESENTING WITH VENOUS THROMBOSISY. I. G. V. Tichelaar* (NL), W. M. Lijfering, H. G. M. Niesters, N. J. G. M. Veeger, A. B. Mulder,J. C. Kluin-Nelemans

PP-TH-333 ABO BLOOD GROUP AS A RISK FACTOR FOR VENOUS THROMBOSISY. P. Adamczuk* (AR), M. L. Iglesias Varela, M. E. Martinuzzo, G. S. Cerrato, R. R. Forastiero

PP-TH-334 A NOVEL MUTATION (G2172?C) OF FACTOR V GENE IN A CHINESE FAMILY WITHACTIVATED PROTEIN C RESISTANCE ASSOCIATED WITH VENOUSTHROMBOEMBOLISMH. Cai, B. Hua, L. Fan, Q. Wang, S. Wang, Y. Zhao* (CN)

PP-TH-335 SIGNIFICANCE OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) IN THE EARLYDEVELOPMENT OF HSCT-ASSOCIATED THROMBOTIC COMPLICATIONSY. Han* (CN), D. Wu, A. Sun, Z. Wang, C. Ruan

Arterial Vascular Diseases III

PP-TH-336 ASYMPTOMATIC MRI BRAIN ABNORMALITIES IN PATIENTS WITH THALASSEMIAINTERMEDIAA. Taher* (LB), K. M. Musallam, W. Nasreddine, A. Beydoun

PP-TH-337 TISSUE FACTOR POLYMORPHISMS, TISSUE FACTOR LEVELS AND RISK FORCRYPTOGENIC ISCHEMIC STROKEA. Undas* (PL), D. Potaczek, M. Mazur, M. Pieculewicz, P. Podolec, W. Tracz

PP-TH-338 G-455A POLYMORPHISM OF B-FIBRINOGEN GENE AND THE RISK OF PREMATUREMYOCARDIAL INFARCTIONA. E. Gialeraki* (GR), L. Rallidis, M. Politou, E. Merkouri, D. Kremastinos, A. Travlou

PP-TH-339 GENETIC VARIATION IN COAGULATION FACTOR XIII AND THE RISK OF ARTERIALTHROMBOSIS: DIFFERENCES BETWEEN MYOCARDIAL INFARCTION AND ISCHAEMICSTROKEB. Siegerink* (NL), F. R. Rosendaal, A. Algra

PP-TH-340 EFFECT OF A PERSONALIZED PHYSICAL ACTIVITY PROGRAMME ON WEIGHTREDUCTION AND ENDOTHELIAL PROGENITOR CELLS IN OVERWEIGHT SUBJECTSF. Cesari* (IT), F. Sofi, I. Corsani, N. Pucci, R. Caporale, R. Abbate, G. Gensini, A. Casini

PP-TH-341 CLOPIDOGREL NONRESPONSIVENESS AND RISK OF CARDIOVASCULAR MORBIDITY– AN UPDATED META-ANALYSISF. Sofi* (IT), R. Marcucci, A. Gori, B. Giusti, R. Abbate, G. Gensini

PP-TH-342 THE FIRE UNDER THE ASH: WHICH ARE THE PREDICTORS OF RELAPSE AFTERISCHEMIC HEART DISEASEG. Corinaldesi* (IT), C. Corinaldesi



355

PP-TH-343 PLATELET GLYCOPROTEIN IIB/IIIA POLYMORPHISM AND RISK OF CARDIOVASCULAREVENTS IN ASPIRIN-TREATED PATIENTS WITH STABLE CORONARY ARTERYDISEASEI. Elalamy* (FR), T. Chakroun, F. Addad, Z. Dridi, F. Abderrazak, S. Hamdi, M. Hassine, M.Hassine, F. Betbout, G. Gerotziafas, M. Hatmi, H. Gamra

PP-TH-344 A RETROSPECTIVE CASE CONTROL STUDY ON THE ROLE OFHYPERCOAGULABILITY IN LATE STENT THROMBOSISK. Winckers* (NL), V. Poenitz, R. van Oerle, H. Spronk, T. M. Hackeng, D. W. T. Nilsen, H.ten Cate

PP-TH-345 THE ACTIVITY OF THROMBOMODULIN, TISSUE FACTOR AND CIRCULATINGPROCOAGULANT PHOSPHOLIPIDS AS MARKERS FOR ACUTE MYOCARDIALINFARCTION (AMI)P. Vandreden, A. Rousseau, B. Lenormand, S. Fontaine, B. J. Woodhams, M. Vasse* (FR)

PP-TH-346 GENETIC POLYMORPHISM OF THE HOMOCYSTEINE AND FOLATE METABOLIZINGENZYMES: ASSOCIATION WITH PLASMA HOMOCYSTEINE AND PERIPHERALARTERIAL DISEASE RISKN. A. Klenkova* (RU), S. I. Kapustin, A. A. Gyrgy, V. M. Shmeleva, L. P. Papayan, N. B.Saltykova, M. N. Blinov

PP-TH-347 ASSOCIATION OF ENDOGENOUS THROMBIN POTENTIAL (ETP) WITH CORONARYARTERY DISEASE. AN ANGIOGRAPHY-BASED STUDYN. Martinelli* (IT), O. Olivieri, N. Campostrini, A. Castagna, S. Friso, F. Pizzolo, P. Guarini, L.Annarumma, F. Busti, R. Corrocher, D. Girelli

PP-TH-348 ANTITHROMBOTIC EFFECTS OF BETA2-ADRENERGIC RECEPTOR BLOCKADE ONTOP OF BETA1-RECEPTOR BLOCKADE IN PATIENTS WITH ACUTE CORONARYSYNDROME OR HEART FAILURE; A SYSTEMATIC REVIEWO. R. de Peuter* (NL), F. Lussana, R. J. Peters, H. R. Büller, P. W. Kamphuisen

PP-TH-349 ELEVATED PLASMA FIBRIN D-DIMER AS A RISK FACTOR FOR VASCULARDEMENTIA:THE THREE-CITY COHORT STUDYL. Carcaillon, P. Gaussem* (FR), P. Ducimetière, M. Giroud, C. Tzourio, K. Ritchie, J.Dartigues, P. Scarabin

PP-TH-350 PROSPECTIVE EPIDEMIOLOGICAL STUDY OF THROMBOPHILIA AND INFLAMMATIONMARKERS IN YOUNG HISPANIC PATIENTS WITH ARTERIAL THROMBOSISP. Casais* (AR), M. F. Alberto, L. Jones, G. Campregher, A. I. Woods, J. Paiva-Patiño, L.Keller, A. C. Kempfer, A. N. Blanco, S. S. Meschengieser, M. A. Lazzari

PP-TH-351 CLOTTING FACTORS, INFLAMMATORY MARKERS AND GLYCEMIC CONTROL INDIABETES: ROLE IN CLOT STRUCTURE AND FIBRINOLYSISR. A. Ajjan* (UK), K. F. Standeven, S. Mughal, K. Hess, F. Phoenix, A. M. Carter, R. A. S.Ariens, P. J. Grant

PP-TH-352 CLOSE MONITORING OF HEMOSTASIS BY THROMBOELASTOMETRY DURINGEXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)R. Paniccia* (IT), E. Antonucci, N. Maggini, S. Bevilacqua, M. Bonacchi, G. Sani, G. Olivo, D.Prisco, R. Abbate, G. F. Gensini

PP-TH-353 LOW-DOSE ASPIRIN THERAPY AFTER KIDNEY TRANSPLANTATIONR. Paniccia* (IT), E. Antonucci, M. Zanazzi, N. Maggini, N. Paudice, I. Ricci, R. Marcucci, L.Mannini, G. F. Gensini, R. Abbate

PP-TH-354 ACUTE ISCHEMIC CEREBROVASCULAR ACCIDENT (CVA) AFTER BEVACIZUMABTHERAPY. CASE REPORT & REVIEW OF THE LITERATURER. M. Biswar* (US), S. J. Jubelirer, J. G. Rosencrance



356

Thur

sday

Pos

ters

PP-TH-355 THE HPA-1B (PRO33) VARIANT OF PLATELET INTEGRIN ALPHAIIB BETA3 CANINDUCE A PROTHROMBOTIC STATER. E. Scharf* (DE), V. R. Stoldt

PP-TH-356 A SYSTEMATIC REVIEW OF THE EFFECTS OF HEMOPHILIA AND VON WILLEBRANDDISEASE ON ARTERIAL TROMBOSISS. Rafi* (NL), M. Zwiers, M. Peters, J. van der Meer, F. R. Rosendaal, H. R. Buller, P. W.Kamphuisen

PP-TH-357 CHADS2 SCORE PREDICTION OF POST-OPERATIVE STROKE IN PATIENTS WITH ANDWITHOUT ATRIAL FIBRILLATIONS. Kaatz* (US), B. F. Gage, J. D. Douketis, R. H. White

PP-TH-358 CLINICAL BACKGROUND OF ACUTE ISCHEMIC STROKE PATIENTS WITH EXTREMELYHIGH LEVEL OF SERUM D-DIMERT. Nagao* (JP), A. Nogami, M. Okamura, N. Umesato, M. Inoue, M. Komine-Kobayashi, C.Nohara, N. Yoshimura, T. Ohtake, K. Hirabayashi, M. Yokochi, Y. Katayama, H. Takubo

PP-TH-359 COMPARISON OF TWO DIFFERENT HEPARIN DOSES IN PERIPHERAL VASCULARSURGERYU. Schott* (SE), D. Winstedt

PP-TH-360 GENETIC VARIATION IN THE PLASMA GLUTATHIONE PEROXIDASE (GPX-3) GENE ISASSOCIATED WITH VASCULAR, BUT NOT THROMBOEMBOLIC, STROKE INCHILDRENU. Nowak-Gottl* (DE), S. Thedieck, T. Seehafer, M. Stoll

PP-TH-361 ACTIVATION OF HAEMOSTASIS IN ELDERLY PATIENTS WITH CHRONIC HEARTFAILUREV. M. Shmeleva* (RU), O. N. Semenova

PP-TH-362 TISSUE FACTOR PATHWAY INHIBITOR: A NEW LINK BETWEEN ARTERIAL STIFFNESSAND THROMBIN GENERATIONV. Regnault* (FR), A. Kearney-Schwartz, J. Max, T. Lecompte, A. Benetos, P. Lacolley

PP-TH-363 INFLAMMATION AND COAGULATION MARKERS IN HEART FAILURE PATIENTS:TRANSITION FROM ACUTE DECOMPENSATED TO CHRONIC HEART FAILUREV. Vila* (ES), V. Martinez-Sales, I. Sanchez-Lazaro, L. Almenar, E. Reganon

PP-TH-364 CHARACTERIZATION OF CANDIDATE GENETIC DETERMINERS FOR MYOCARDIALINFARCTION IN A GENETIC HOMOGENEOUS POPULATIONJ. Cui, E. Randell, R. James, F. Y. Han, G. Sun, C. Butt, J. Hwa, Y. G. Xie* (CA)

PP-TH-365 RELATION BETWEEN CYTOCHROME P450 2C19 681 G>A POLYMORPHISM, PLATELETRESPONSIVENESS TO ADP AND CLINICAL OUTCOME AFTER ELECTIVEPERCUTANEOUS CORONARY INTERVENTION IN PATIENTS TREATED WITHCLOPIDOGRELC. Pouplard, E. Blicq, S. Regina, A. de Labriolle, B. Charbonnier, Y. Gruel* (FR)

PP-TH-366 INTERACTION BETWEEN HOMOCYSTEINE AND LIPOPROTEIN(A) INCREASES THERISK OF CORONARY SCLEROSIS/MYOCARDIAL INFARCTION IN WOMENZ. Bereczky* (HU), É. Katona, E. Balogh, K. Kósa, I. Czuriga, I. Édes, L. Muszbek



357

Hormones, Pregnancy and Women’s Issues III

PP-TH-367 ROLE OF NATURAL PROGESTERONE IN PROPHYLAXIS OF RECURRENTPREGNANCY LOSS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROMEE. N. Shakhovskaya* (RU), A. D. Makatsaria

PP-TH-368 MONITORING OF HAEMOCOAGULATION CHANGES DURING LONG-TERM LOWMOLECULAR WEIGHT HEPARIN PROTECTION OF PREGNANCYP. Sigutova* (CZ), Z. Hajsmanova, J. Slechtova, Z. Ulcova-Gallova

PP-TH-369 VENOUS THROMBOEMBOLISM IN CZECH WOMEN IN ASSOCIATION WITH ORALCONTRACEPTIVE USE: FREQUENCY, ETIOLOGY AND THERAPY OF BUDD-CHIARISYNDROMEP. Dulicek* (CZ), J. J. M. Maly’, T. T. F. Fejfar, R. R. M. Maly’, F. F. V. Vrbacky’

PP-TH-370 INTRAPARTUM BRIDGING THERAPY USING LOW MOLECULAR WEIGHT HEPARIN INPREGNANT PATIENTS REQUIRING A HIGH DEGREE OF ANTICOAGULATIONR. S. Chitsike* (ZA), G. Toweel, S. Moodley, H. A. Rhemtula, P. Manga, B. F. Jacobson

PP-TH-371 IS DOSAGE ADJUSTMENT OF LOW MOLECULAR WEIGHT HEPARIN NECESSARY ANDSAFE FOR PREGNANCIES AT GREATEST RISK OF THROMBOSISR. S. Chitsike* (ZA), H. A. Rhemtula, P. Manga, B. F. Jacobson

PP-TH-372 MODULATION OF COAGULATION FACTOR LEVELS AND THROMBIN GENERATIONPARAMETERS BY A HEALTHY DIET IN PRE-MENOPAUSAL MIDDLE-AGED WOMENWITH MODERATE CARDIOVASCULAR RISKS. Calzavarini* (IT), S. Volpato, P. Caruso, A. Passaro, R. Fellin, F. Bernardi

PP-TH-373 PREVALENCE OF JAK2V617F MUTATION IN WOMEN WITH UNEXPLAINEDRECURRENT MISCARRIAGES. P. Kaandorp, M. N. Lauw, C. van der Schoot, M. Goddijn, F. van der Veen, H. R. Koene, B.J. Biemond, S. Middeldorp* (NL)

PP-TH-374 PREVENTION OF VENOUS THROMBOEMBOLISM IN PREGNANT WOMEN:MANAGEMENT STRATEGY ON A LARGE HEALTH CARE AREAS. Testa* (IT), O. Paoletti, E. Ronca, A. Rigolli, A. Alatri, A. Zimmermann, A. Riccardi

PP-TH-375 LOW MOLECULAR WEIGHT HEPARINS LABORATORY MONITORING: VARIABILITY INRELATION TO CALIBRATION AND ANTITHROMBIN PLASMA LEVELS. Testa* (IT), O. Paoletti, L. Bassi, A. Alatri, A. Zimmermann, A. Cogrossi, M. Stramezzi

PP-TH-376 STRATEGY OF THROMBUS REMOVAL FOR ILIOFEMORAL DVT OF PREGNANCYS. Thakur* (US), A. J. Comerota, J. L. Martinez Trabal, R. Disalle, S. N. Kazanjian, D. M.Sepanski, Z. Assi

PP-TH-377 CHANGES IN THE COAGULATION SYSTEM IN HUMANS AND MICE DURINGPREGNANCYS. N. Tchaikovski* (NL), B. van Vlijmen, M. L. G. D. Thomassen, E. Castoldi, L. L. Peeters,G. Tans, J. Rosing

PP-TH-378 ROLE OF THROMBOPHILIA IN PROSTHETIC VALVE THROMBOSIS DURINGPREGNANCYS. V. Akinshina* (RU), A. D. Makatsariya, V. O. Bitsadze, S. M. Baimuradova

PP-TH-379 PREGNANCY IN WOMEN WITH HISTORY OF STROKE: PATHOGENETIC PROPHYLAXISIS POSSIBLES. V. Akinshina* (RU), A. D. Makatsariya, V. O. Bitsadze, S. M. Baimuradova

PP-TH-380 THROMBOPHILIC AND PROINFLAMMATORY STATES IN PREGNANT WOMEN WITHMETABOLIC SYNDROMET. B. Pshenichnikova* (RU), E. B. Perederyaeva, Z. Gadaeva, A. D. Makatsariya



358

Thur

sday

Pos

ters

PP-TH-381 MICROPARTICLES‘ PROCOAGULANT ACTIVITY AND SCD40L CONCENTRATIONDURING PREGNANCY IN HEALTHY WOMEN AND WOMEN WITH ANTIPHOSPHOLIPIDSYNDROMEM. Celinska-Lowenhoff, T. Iwaniec* (PL), A. Grzyb, J. Musial

PP-TH-382 INCREASED THROMBIN GENERATION DURING PREGNANCYV. Rossetto* (IT), P. Dabrilli, L. Spiezia, M. Castelli, E. Campello, M. Perlati, S. Gavasso, P.Simioni

PP-TH-383 MILD RESISTANCE TO THROMBOPROPHYLAXIS WITH LMWH DURING PREGNANCYV. Rossetto* (IT), P. Dabrilli, L. Spiezia, F. Dalla Valle, E. Campello, S. Gavasso, P. Simioni

PP-TH-384 ANTI-Xa MONITORING IS REQUIRED IN PREGNANT WOMEN ON LOW MOLECULARWEIGHT HEPARIN (LMWH)V. M. A. Simpson* (UK), M. Pescott, D. Peebles, H. Cohen

PP-TH-385 MANAGEMENT OF PREGNANCIES WITH HIGH RISK OF THROMBOSIS: AMULTICENTER PROSPECTIVE STUDYY. Dargaud* (FR), L. Rugeri, M. C. Vergnes, B. Arnuti, P. Miranda, C. Negrier, A. Bestion, H.Desmurs Clavel, J. Ninet, P. Gaucherand, C. R. Rudigoz, M. Berland, F. Champion, M. C.Trzeciak

PP-TH-386 ENDOGENOUS THROMBIN POTENTIAL, D DIMERS AND F 1+2 IN NORMALPREGNANCYY. Dargaud* (FR), S. Hierso, L. Rugeri, B. Chatard, C. Battie, P. Gaucherand, C. Negrier

PP-TH-387 INVOLVEMENT OF HEPARANASE IN EARLY PREGNANCY LOSSESY. Nadir* (IL), I. Henig, I. Vlodavsky, B. Brenner

Animal and Experimental Models III

PP-TH-388 FACTOR XI ANTISENSE THERAPY REDUCES THROMBUS FORMATION IN MICEE. C. Lowenberg* (NL), J. C. M. Meijers, H. Zhang, J. R. Crosby, E. S. Stroes, B. P. Monia,M. Levi

PP-TH-389 EXTENDED ADMINISTRATION OF DEFIBROTIDE IN NON-IMMUNOGENIC EXTENDEDSTUDIES IN RATS AND DOGSJ. Fareed* (US), D. Hoppensteadt, J. Cunanan, H. Zhu, C. Echart, M. Iacobelli

PP-TH-390 BIOAVAILABILITY OF OVER SULFATED CHONDROITIN SULFATE. IMMUNOLOGICIMPLICATIONSC. Adiguzel, D. Hoppensteadt, H. Messmore, J. M. Walenga, R. Wahi, J. Fareed* (US)

PP-TH-391 SUSTAINED ANTITHROMBOTIC ACTIVITY OF LMWHS COMPARED TO FXAINHIBITORSJ. M. Walenga* (US), W. P. Jeske, E. Litinas, J. Emanuele, D. Hoppensteadt, J. Cunanan, M.Bakhos

PP-TH-392 AUTOTAXIN/LYSOPHOSPHATIDIC ACID AXIS: IN VIVO EVIDENCE FOR A ROLE INOBESITY PREDISPOSITIONL. Federico* (US), S. Liu, P. Muller, G. B. Mills, A. J. Morris, S. S. Smyth

PP-TH-393 THROMBOELASTOGRAPHIC (TEG) EVALUATION OF HEMOSTASIS IN A RAT MODELOF OBSTRUCTIVE SLEEP APNEAM. Othman* (CA), S. P. Gordon, S. Iscoe

PP-TH-394 EFFICACY AND SAFETY OF RFVIIa IN AN ACUTE ARTERIAL BLEEDING MODEL INHEALTHY RABBIT: A BLIND STUDYM. Durand* (FR), A. Godier, V. Notet, M. Hacquard, O. Collignon, G. Corbonnois, F. Plénat, J.P. Carteaux, T. Lecompte



359

PP-TH-395 THE INFLUENCE OF STREPTOKINASE ON PLATELET LINK OF HAEMOSTATICSYSTEMN. Burlova-Vasilieva* (UA), O. Savchuk, I. Krasnobrizha, G. Volkov

PP-TH-396 METHODS TO EVALUATE THE PHARMACOKINETICS OF TAL6003, A SIMPLIFIEDVERSION OF PLASMINC. Cruz, K. Yarbrough, B. Sandy, P. Vandeberg* (US)

PP-TH-397 NEW INSIGHT INTO THE FUNCTION OF VKORC1L1P. Westhofen* (DE), M. Watzka, M. Marinova, M. Hass, J. Oldenburg

PP-TH-398 PASSENGER GENE POINT MUTATION: DISCOVERY OF A SPONTANEOUS IRS1MUTATION IN LINKAGE WITH PAI2 DEFICIENCYR. J. Westrick* (US), K. L. Mohlke, G. Zhu, S. L. Manning, D. Ginsburg

PP-TH-399 EVALUATION OF ANTI HUMAN PLATELET GLYCOPROTEIN GPIIIA THERAPEUTICCHIMERIC ANTIBODY F(AB)2 FRAGMENT IN BEAGLE DOGSS. Ji* (CN), M. Jiang, Y. Zhao, W. Fang, J. Yang, C. Ruan

PP-TH-400 DEVELOPMENT AND EVALUATION OF AN IMMUNOASSAY FOR THE MONITORING OFA NEW ANTI-PLATELET DRUG CHIMERIC MONOCLONAL SZ21 F(AB)2S. Ji* (CN), N. Wen, Z. Li, C. Ruan

PP-TH-401 FUNCTIONAL ROLES OF THROMBOXANE A2 ON PREECLAMPSIAC. Pai, I. Yu, S. Lin, S. Lin* (TW)

PP-TH-402 A MILD ARTERIAL DAMAGE FACILITATES DOWNSTREAM THROMBUS FORMATIONBY PRIMING PLATELET ACTIVATIONS. Momi* (IT), S. Giannini, P. Gresele

PP-TH-403 PRECLINICAL TOXICOLOGY AND SAFETY PHARMACOLOGY OF PLASMIN (HUMAN)V. Arora* (US), G. A. Baumbach, P. Scuderi, S. R. Petteway

PP-TH-404 SALICYLAMIDE DERIVATIVES AS ANTAGONISTS FOR LOW MOLECULAR WEIGHTHEPARIN AND HEPARIN-LIKE DRUGSC. Schroeder, M. Prechel, J. M. Walenga, W. P. Jeske* (US), M. Bakhos

PP-TH-405 EFFICACY OF ASPIRIN ON IMPROVEMENT OF PERIPHERAL BLOOD CIRCULATION INMICEW. K. Jeon* (KR), B. K. Yoo, B. S. Ko, J. Y. Ma

PP-TH-406 TREATMENT OF VENOUS THROMBOSIS WITH THE ORAL DIRECT FACTOR XaINHIBITOR DU-176B IN CONSCIOUS RATSY. Morishima* (JP), Y. Honda, C. Kamisato-Matsumoto, T. Shibano

Clinical Trials III

PP-TH-407 ATTENUATED ELEVATION OF SP-SELECTIN IN PATIENTS WITH RECENTMYOCARDIAL INFARCTION IS RELATED TO BLEEDING EVENTS DURINGANTITHROMBOTIC TREATMENTC. Christersson* (SE), J. Oldgren, L. Wallentin, A. Siegbahn

PP-TH-408 GOAL-DIRECTED INTRAVENOUS HEPARIN (IVH) VERSUS SUBCUTANEOUS HEPARIN(SQH) IN PREVENTING THROMBOEMBOLISM IN POST-SURGICAL SICU PATIENTSK. E. Nordenholz* (US), C. Hamiel, S. Cheng, A. Baer, D. Matero, N. Pearlman, P.Wischmeyer

PP-TH-409 CO-ADMINISTRATION OF IDRAPARINUX AND WARFARIN IN HEALTHY SUBJECTSM. Trellu* (FR), I. Paty



360

Thur

sday

Pos

ters

PP-TH-410 EFFICACY AND SAFETY OF ENOXAPARIN FOR THE PREVENTION OF VENOUSTHROMBOEMBOLISM IN JAPANESE PATIENTS UNDERGOING MAJOR ABDOMINALSURGERYM. Sakon* (JP)

PP-TH-411 CLINICAL EVALUATION OF FONDAPARINUX FOR PREVENTION OF VENOUSTHROMBOEMBOLISM IN JAPANESE PATIENTS UNDERGOING ABDOMINAL SURGERYM. Sakon* (JP), T. Kobayashi

PP-TH-412 D-DIMER TO PREDICT THROMBOSIS RECURRENCE: COMPARISON OF AGGREGATEDATA AND INDIVIDUAL PATIENT DATA META-ANALYSESM. Marcucci* (IT), A. Iorio, J. Douketis, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D.Poli, C. Tait, A. Tosetto

PP-TH-413 ENOXAPARIN VERSUS DABIGATRAN ETEXILATE OR RIVAROXABAN FORTHROMBOPROPHYLAXIS AFTER HIP OR KNEE ARTHROPLASTYM. V. Huisman* (NL), D. J. Quinlan, O. E. Dahl, S. Schulman

PP-TH-414 OPTIMAL MAINTENANCE OF AT ACTIVITY DURING HIGH-RISK SITUATIONS FORTHROMBOSIS WITH THE USE OF ANTITHROMBIN (RECOMBINANT)M. J. Paidas* (US), C. Tait, J. Frieling

PP-TH-415 POTENTIAL IMPACT OF RIVAROXABAN ON LONG-TERM SAFETY OUTCOMES AFTERTOTAL HIP OR KNEE REPLACEMENT SURGERYM. R. Lassen* (DK), A. G. G. Turpie, A. K. Kakkar, B. I. Eriksson, M. Gent

PP-TH-416 DECREASE OF INTRAOPERATIVE TRANSFUSION, ESPECIALLY FRESH FROZENPLASMA, DURING CARDIOVASCULAR SURGERY LEADS TO DECREASE THE RISK OFTHE POSTOPERATIVE INFECTIONM. Iwade* (JP), M. Nomura, K. Iwade

PP-TH-417 LACK OF EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HIGH-RISKPATIENTS UNDERGOING MAJOR ORTHOPEDIC OR MAJOR CANCER SURGERY:ELECTRONIC ASSESSMENT OF VTE PROPHYLAXIS IN HIGH-RISK SURGICALPATIENTS AT DISCHARGE FROM SWISS HOSPITALS (ESSENTIAL)N. Kucher* (CH), D. Spirk, K. Siebenrock, U. Metzger, D. Sterzing, M. Zuber, E. Mouhsine, C.Kalka

PP-TH-418 EVALUATION OF PERIPROCEDURAL ANTICOAGULATION MANAGEMENT IN PATIENTSON LONG TERM ORAL ANTICOAGULANTSN. Ostasevski Fernandez* (SI), A. Mavri

PP-TH-419 UNFRACTIONATED HEPARIN UFH VERSUS LOW MOLECULAR WEIGHT HEPARINLMWH FOR BRIDGING DURING WARFARIN INTERRUPTION: A METAANALYSIS OFCONTROLLED CLINICAL TRIALSO. Dabbagh* (US), M. P. Lent, S. R. Bearelly

PP-TH-420 PORTAL AND SPLANCNIC VEIN THROMBOSIS: STUDY ON RISK FACTORS ANDTREATMENT ALGORITHMM. T. Sartori, M. Senzolo, C. Ferronato, P. Burra, P. Boccagni, D. Gasparini, S. Gavasso, G.Saggiorato, P. Simioni* (IT)

PP-TH-421 PLATELET AGGREGATION AND ENDOGENOUS THROMBIN CAPACITY (ETC) ARE NOTINCREASED IN PATIENTS AFTER HEART TRANSPLANTATIONP. Staritz* (DE), A. Huth-Kühne, R. Zimmermann, T. J. Dengler, B. T. Ivandic

PP-TH-422 THE EFFECT OF VITAMIN K RICH DIET ON THE INR, VITAMIN K DEPENDENTFACTORS ACTIVITY, AND D-DIMER IN PATIENTS USING WARFARINP. Kessler* (CZ), M. Kusnierova, H. Poul, A. Komarek, E. Vlckova



361

PP-TH-423 PHARMACOKINETICS AND PHARMACODYNAMICS OF EP42675, A NEW SYNTHETICANTICOAGULANT WITH A DUAL MECHANISM OF ACTIONP. Gueret* (FR), C. Krezel, P. L. M. van Giersbergen, M. Petitou, E. Neuhart

PP-TH-424 PHYSICIAN ALERTS TO PREVENT SYMPTOMATIC VENOUS THROMBOEMBOLISM INHOSPITALIZED PATIENTSG. Piazza, E. J. Rosenbaum, W. Pendergast, J. O. Jacobson, R. C. Pendleton, G. D.McLaren, C. Elliott, S. M. Stevens, W. F. Patton, O. Dabbagh, M. D. Paterno, E. Catapane, S.Z. Goldhaber* (US)

PP-TH-425 THROMBOPROPHYLAXIS WITH CERTOPARIN IN ACUTELY ILL, NON-SURGICALPATIENTS – CERTAIN STUDYS. Schellong* (DE), S. Haas, A. Greinacher, C. Abletshauser, H. Riess

PP-TH-426 TOWARDS THE REDUCTION OF THE INCIDENCE OF MAJOR BLEEDING UNDERANTICOAGULANT DRUGS IN MAJOR ORTHOPAEDIC SURGERY. MYTH OR REALITYS. Laporte* (FR), P. Zufferey, P. Mismetti

PP-TH-427 LEFT VENTRICULAR (LV) THROMBUS FORMATION IN SPITE OF INTENSIVEANTIPLATELET TREATMENT IN PATIENTS WITH ACUTE ANTERIOR WALL ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) TREATED WITH PCIS. Solheim* (NO), I. Seljeflot, K. Lunde, R. Bjørnerheim, S. Aakhus, K. Forfang, H. Arnesen

PP-TH-428 COMPARISON OF TWO INFUSION RATES OF ANTITHROMBIN CONCENTRATE INCARDIOPULMONARY BYPASS SURGERYU. Schott* (SE), T. Carlsson, P. Lund

PP-TH-429 THE INFLUENCE OF GENETIC BESIDES NON GENETIC FACTORS ON WARFARINRESPONSE IN 300 VERY ELDERLY INPATIENTSV. Siguret* (FR), C. Moreau, I. Gouin-Thibault, J. L. Golmard, I. Mahe, P. Beaune, E. Pautas,M. A. Loriot

PP-TH-430 BLEEDING EVENTS IN THE EARLY PHASE OF THROMBOPROPHYLAXIS: A POOLEDANALYSIS OF FOUR RIVAROXABAN STUDIESW. D. Fisher* (CA), M. R. Lassen, A. G. G. Turpie, A. K. Kakkar, B. I. Eriksson, M. Gent

PP-TH-431 THE GENETIC PREDICTORS OF BLEEDINGS DURING WARAFRIN THERAPY (THEDATA BASED ON FIVE YEAR PROSPECTIVE STUDYY. A. Mikheeva* (RU), E. S. Kropacheva, D. A. Sichev, A. B. Dobrovolsky, E. P. Panchenko

Intravascular Devices and Interventions II

PP-TH-432 HAEMOSTATIC PARAMETERS IN PATIENTS WITH SUBCLAVIAN CATHETER-ASSOCIATED THROMBOSISL. Petit, V. Cottenceau, F. Masson, S. Labrouche, G. Freyburger* (FR)

PP-TH-433 INFLAMMATORY AND COAGULATION MARKERS IN PATIENTS WITH ATRIALFIBRILATION TREATED WITH RF ABLATIONJ. Kyselovic* (SK), P. Musil, L. Urban, P. Krenek, R. Hatala

PP-TH-434 COAGULATION LABORATORY SCREENING IS NOT A GOOD PREDICTOR FORBLEEDING COMPLICATIONS IN PEDIATRIC PATIENTS REQUIRING PERIPHERALLYINSERTED CENTRAL CATHETERSJ. Woodley-Cook* (CA), J. Amaral, B. Connolly, L. Brandao

PP-TH-435 BIOMATERIAL SURFACE MODIFICATION WITH AN ANTITHROMBIN-HEPARINCOVALENT COMPLEX FOR IMPROVED INTRAVASCULAR DEVICESK. N. Sask* (CA), J. L. Brash, A. K. C. Chan, L. R. Berry, W. G. McClung



362

Thur

sday

Pos

ters

PP-TH-436 TROMBIN GENERATION AS HEMOSTASIS INDICATOR: VALIDATION IN A CVVHSETTINGM. van Schilfgaarde* (NL), H. M. Oudemans,van Straaten, P. J. Molenaar, N. R. Wiertz, J. P.J. Wester, A. Leyte

PP-TH-437 PREDICTIVE VALUE OF COAGULATION MARKER (D-DIMER) AND PLASMA MARKERSOF MYOCARDIAL DAMAGE ON SUCCESS RATE OF RADIOFREQUENCY ABLATION OFATRIAL FIBRILLATIONP. Musil* (SK), J. Kyselovic, P. Krenek, L. Urban, R. Hatala

PP-TH-438 TREATMENT OF ILEOFEMORAL DEEP VEIN THROMBOSIS IN PUERPERIUM USINGCATHETER-DIRECTED THROMBOLYSISR. Maly* (CZ), V. Chovanec, A. Krajina, J. Raupach, M. Lojik, P. Dulicek, L. Vodickova, M.Solar, J. Fridrich, J. Vojacek

PP-TH-439 IN VITRO EVALUATION OF ARTIFICIAL MEMBRANE BIOCOMPATIBILITYS. C. Minkin* (US), M. Benner, M. Beeler, B. Curry, P. Iakova, J. Biggerstaff, P. Cahalan, L.Cahalan

PP-TH-440 EFFICACY OF ENOXAPARIN, CERTOPARIN, AND DALTEPARIN IN PREVENTINGCARDIAC CATHETER THROMBOSIS: AN IN VITRO APPROACHU. Raaz* (DE), M. Buerke, M. Busshardt, L. Maegdefessel, A. Plehn, B. Hauroeder, K.Werdan, A. Schlitt

Pediatric Thrombosis III

PP-TH-441 EXPERIENCE OF TREATING PEDIATRIC VENOUS THROMBOEMBOLISM WITH LOWMOLECULAR WEIGHT HEPARIN (LMWH) IN AN INSTITUTE LACK OF ANTI-XaMONITORING SUPPORTJ. Y. K. Yang* Hong Kong Special Administrative Region of (CN), M. L. G. Wong, A. K. C.Chan, R. C. H. Li, A. C. W. Lee

PP-TH-442 COMPLIANCE OF ANTITHROMBOTIC MANAGEMENT WITH PAEDIATRIC GUIDELINESF. H. Newall, J. Doan* (AU), T. Wallace, V. Ignjatovic, P. Monagle

PP-TH-443 PLATELET AGGREGATES AND LEUCOCYTES IN THE LUNG CAPILLARIES OF CASESOF SUDDEN INFANT DEATH SYNDROMEL. Jørgensen* (NO), T. Hanssen

PP-TH-444 CEREBRAL VENOUS THROMBOSIS IN CHILDREN: EVALUATION OF THEASSOCIATION WITH PROTHROMBOTIC RISK FACTORSL. R. Goncalves* (PT), M. Carvalho, M. M. Campos, R. Vaz, L. M. Ribeiro

PP-TH-445 HIGHER ENDOGENOUS THROMBIN POTENTIAL VALUE AS PROTHROMBOTICMARKER IN NEWLY DIAGNOSED PEDIATRIC CANCER PATIENTSM. Aly Aldeen Abd Elbasset Aly Mohamed* (EG), R. M. Edwards, D. Cooper, I. Tjia, M.Hesham, U. Roshdy Elsafy, M. Badr, L. Bomgaars, A. Pappo, M. Chintagumpala, J. Teruya

PP-TH-446 OUTCOME OF CATHETER-RELATED ARTERIAL THROMBOSIS IN CHILDRENS. Kroiss, O. Kretschmar, I. Forster, M. Schmugge, M. Albisetti* (CH)

PP-TH-447 THE RATIO ACTIVITY/ANTIGENIC LEVEL OF SOLUBLE THROMBOMODULIN AS AMARKER OF VASCULAR INJURY IN CHILDHOOD BONE MARROWTRANSPLANTATIONA. Rousseau, P. Schneider, P. van Dreden, J. P. Vannier, M. Vasse* (FR)

PP-TH-448 INHIBITION OF THROMBIN GENERATION BY RIVAROXABAN IN NEONATAL PLASMAM. Novak* (AT), H. Bernhard, M. Koestenberger, D. Ulrich, B. Leschnik, S. Schweintzger, W.Muntean



363

PP-TH-449 PROPHYLAXIS FOR SEVERE PROTEIN C DEFICIENCY: A NOVEL APPROACHM. D. Williams* (UK), D. Marshall, P. Nyatanga

PP-TH-450 RECURRENT PULMONARY EMBOLISM IN A 14 YEAR OLD BOY WITHANTIPHOSPHOLIPID SYNDROMEM. Girisch* (DE), R. Rauch, G. Wiegand, M. Hofbeck

PP-TH-451 CEREBRAL THROMBOEMBOLISM IN CHILDREN WITH ACUTE LYMPHOBLASTICLEUKEMIAN. Conde, N. Conde* (ES), T. Toll, R. Berrueco, A. Català, S. Rives, J. Estella

PP-TH-452 OUTCOME AFTER CENTRAL VENOUS LINES RELATED VENOUS THROMBOSIS (CVL-VT) IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A SINGLECENTRE PROSPECTIVE STUDYP. Saracco* (IT), L. L. Garbarini, N. N. Bertorello, E. E. Barisone, S. S. Longo, L. L. Artesani,L. L. Farinasso

PP-TH-453 A RETROSPECTIVE AND PROSPECTIVE SINGLE CENTRE STUDY ON APPLICABILITYOF THE PROPOSED WRAIGE CLASSIFICATION FOR SUBTYPES OF ARTERIALISCHEMIC STROKE (AIS) IN CHILDRENP. Saracco* (IT), M. Agostini, A. Tocchet, R. Vittorini, V. Licari, C. Marinaccio, L. Pagana, B.Bobba, B. Bassi

PP-TH-454 FACTORS OF EXTRACEREBRAL NON CATHETHER RELATED THROMBOSIS INCHILDRENP. V. Svirin* (RU), V. V. Vdovin, G. A. Sukchanova, T. G. Plachuta, L. E. Larina, E. A. Shiller,E. A. Yatzenko, A. V. Ageenkova, E. K. Doniusch

PP-TH-455 VALIDITY OF PAEDIATRIC THROMBOSIS DIAGNOSES IN A NATIONAL REGISTRY OFPATIENTSR. Tuckuviene* (DK), J. Helgestad, S. P. Johnsen, S. R. Kristensen

PP-TH-456 INHERITED THROMBOPHILIA IN CHILDHOOD STROKE: EXPERIENCE OF A TERTIARYCARE CENTER IN LEBANONS. A. Muwakkit* (LB), M. Majdalani, R. Hourani, Z. Otrock, R. Saab, M. Abboud, M. Mikati

PP-TH-457 MANAGEMENT OF VENOUS THROMBOEMBOLIC EVENTS IN PEDIATRIC ICUPATIENTSS. J. Hanson* (US), K. A. Lawson, A. Brown, L. M. Christie, B. Totapally, J. McArthur, R. A.Higgerson

PP-TH-458 EFFECTIVENESS AND LONG-TERM OUTCOME OF THE USE OF RECOMBINANTTISSUE PLASMINOGEN ACTIVATOR (RT-PA) IN CHILDREN WITH LIFE-THREATENINGTHROMBOSISS. J. Russell* (AU), G. D. Williams, J. J. Brereton, A. Numa

PP-TH-459 EQUIVALENCY OF TINZAPARIN AND ENOXAPARIN CHILDREN: A SINGLE CENTREREPORT ON EFFICACY AND SAFETYA. Al-Zahrani* (SA), P. Komwilaisak, L. Brandao, W. H. A. Kahr, A. K. C. Chan, S. Williams

PP-TH-460 PROTHROMBOTIC GENETIC RISK FACTORS IN STROKE: A POSSIBLE DIFFERENTROLE IN PEDIATRIC AND ADULT PATIENTSV. J. Djordjevic* (RS), M. Stankovic, V. Brankovic-Sreckovic, L. Rakicevic, T. Damnjanovic, N.Antonijevic, D. Radojkovic

PP-TH-461 LOW MOLECULAR WEIGHT HEPARIN (LMWH) RESPONSE IN CHILDRENV. Ignjatovic* (AU), C. Cuman, R. Summerhayes, F. Newall, P. Monagle

PP-TH-462 AGE-RELATED DIFFERENCES IN THE BINDING OF UNFRACTIONATED HEPARIN (UFH)TO PLASMA PROTEINSE. Straka, V. Ignjatovic* (AU), R. Summerhayes, P. Monagle



364

Thur

sday

Pos

ters

PP-TH-463 EXTENSIVE CEREBRAL SINUS VENOUS THROMBOSIS IN THE SETTING OFHYPERTHYROIDISM IN A CHILDV. F. van Eimeren* (CA), L. Billinghurst, E. Yiu, R. Askalan, T. Soman, S. Laughlin, L. R.Brandão, S. Williams, W. H. A. Kahr

Health Service and Outcomes III

PP-TH-464 A 4-YEAR FOLLOW-UP OF ADVERSE EFFECTS WITH FONDAPARINUX TREATMENT:RESULTS FROM THE FRENCH PHARMACOVIGILANCE SURVEYA. Lillo-Le Louet, D. M. Smadja* (FR), C. Le Beller

PP-TH-465 THROMBOPHILIA TESTING - A COMPARATIVE STUDYL. Mammo, T. Saour, A. Sheereen, J. Saour* (SA)

PP-TH-466 RARE VKORC1 MUTATIONS IN AFRICAN BRAZILIAN PATIENTS TAKING ORALANTICOAGULANT THERAPYF. A. Orsi, K. Weck, E. V. de Paula, J. Evans, M. C. Ozelo, J. M. Annichino-Bizzacchi* (BR)

PP-TH-467 MONITORING OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) THERAPY BY ANTI-XaASSAY. A LABORATORY PERSPECTIVE USING HEPARIN SPECIFIC STANDARDSP. A. Kotsi* (GR), A. Chanos, I. Anastasopoulou, C. Tsoukala, K. Markakis, A. Karafoulidou

PP-TH-468 EVALUATION OF OPTIMAL SAMPLING METHODS FOR MICROPARTICLES IN STOREDRED BLOOD CELLSP. Davizon-Castillo* (US), J. A. Lopez, T. R. Watkins

PP-TH-469 TIR - RESULTS FROM THE NATIONAL QUALITY REGISTRY FOR ANTICOAGULATIONTREATMENT IN SWEDENP. J. Svensson* (SE), V. Frykman, A. Själander, M. Rosenqvist, L. Wallentin

PP-TH-470 ARE CITRATED PARTIAL-DRAW POLYMER COLLECTION TUBES ADEQUATE FORBASIC COAGULATION TESTSP. A. Toulon* (FR), V. Eschvege, M. Dreyfus, T. Boutekedjiret, V. Proulle

PP-TH-471 A VTE PREVENTION PROGRAM IMPLEMENTED BY A VTE NURSE SPECIALIST LEADSTO A MARKED AND SUSTAINED IMPROVEMENT IN APPROPRIATE VTE PROPHYLAXISR. D. Collins* (AU), H. Gibbs, J. Gibbs, J. Schluter, L. Tewhatu

PP-TH-472 SIGNIFICANT IMPROVEMENT OF VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXISIN A TERTIARY REFERRAL HOSPITAL DOES NOT LEAD TO AN INCREASE ININAPPROPRIATE VTE PROPHYLAXIS IN PATIENTS NOT AT RISKR. D. Collins* (AU), H. Gibbs, J. Gibbs, J. Schluter, L. Tewhatu

PP-TH-473 PRECISION AND ACCURACY STUDY OF A TABLE TOP COAGULATION ANALYZERWITH EXPANDED TEST MENUR. Porche-Sorbet* (US), J. Hughes, P. Barnes, G. Cutsforth, K. Whelchel, C. S. Eby

PP-TH-474 ASSESSMENT OF QUALITY CONTROL AND ACCURACY OF PORTABLECOAGULOMETERS FOR MONITORING ORAL ANTICOAGULANT TREATMENT INANTICOAGULATION CLINICR. Paniccia* (IT), D. Poli, E. Antonucci, M. Pagliuca, D. Lami, I. Ricci, A. Alessandrello Liotta,D. Prisco, R. Abbate

PP-TH-475 AUTOMATED ANTI-FACTOR IIA ASSAY FOR MONITORING UNFRACTIONATEDHEPARIN (UFHR. Summerhayes* (AU), V. Ignjatovic, F. Newall, P. Monagle

PP-TH-476 MEASURES TO IMPROVE SAFETY OF WARFARINIZED PATIENTS FOLLOWINGHOSPITAL DISCHARGES. R. Hossain* (UK), M. Madhani, G. Varma, P. K. MacCallum



365

PP-TH-477 A RETROSPECTIVE REVIEW OF BRIDGING THERAPY IN A COMMUNITY BASED OUTPATIENT ANTICOAGULATION CLINICS. Beaudoin* (US), S. C. Johnson, M. Mukon, D. Kapur, M. Dhami, D. E. Slater

PP-TH-478 EVALUATION OF COMPLIANCE WITH LOW DOSE UNFRACTIONATED HEPARIN FORVENOUS THROMBOEMBOLISM PROPHYLAXIS IN MEDICALLY ILL HOSPITALIZEDPATIENTS AT AN ACADEMIC MEDICAL CENTERS. H. Bhatt* (US)

PP-TH-479 HEMOPHILIA IN UKRAINE:PROBLEMS AND PROSPECTSS. V. Vydyborets* (UA), G. I. Moroz, S. M. Gaydukova

PP-TH-480 OUTPATIENT DVT TREATMENT – AN AUDIT OF SAFETY INDICATORS FOR PATIENTSON ORAL ANTICOAGULANT TREATMENTS. Bacon* (UK), S. Chadwick

PP-TH-481 PHARMACOGENETIC RELEVANCE OF CYP4F2 V433M POLYMORPHISM ONACENOCOUMAROL THERAPYV. Pérez Andreu* (ES), V. Roldan, A. Anton, N. Garcia Barbera, J. Corral, V. Vicente, R.Gonzalez Conejero

Cancer and Thrombosis III

PP-TH-482 A PROSPECTIVE ANALYSIS OF PLASMA TISSUE FACTOR IN PATIENTS WITHOVARIAN TUMORSA. Amirkhosravi* (US), G. Bigsby Iv, E. Coll, H. Desai, M. Amaya, L. Robles, P. Faust, A.Drexler, F. Langer, E. Reyes, J. Francis

PP-TH-483 VENOUS THROMBOEMBOLISM DURING THE COURSE OF PANCREATIC CANCER:IMPLICATION OF TISSUE FACTORA. Delluc* (FR), A. Rousseau, C. Delluc, E. Le Moigne, G. Le Gal, K. Lacut, E. Oger, P. vanDreden, D. Mottier

PP-TH-484 METASTASIS PROMOTING EFFECTS OF DIRECT THROMBIN INHIBITORST. M. H. Niers, G. L. van Sluis* (NL), L. W. Bruggeman, R. D. Liu, H. H. Versteeg, H. R.Buller, C. J. F. van Noorden, P. H. Reitsma, C. A. Spek, D. J. Richel

PP-TH-485 CANCER CELLS ACCELERATE IN VITRO THROMBIN GENERATION IN HUMANPLASMA BUT THEIR EFFECT IS DETERMINED BY THE HISTOLOGICAL TYPE OF THECANCERG. T. Gerotziafas* (FR), V. Galea, E. Mbemba, A. Khaterchi, F. Couppey, C. Prengel, M.Hatmi, J. Bernaudin, I. Elalamy

PP-TH-486 CLINICALLY RELEVANT CONCENTRATIONS OF FONDAPARINUX EFFICIENTLY INHIBITIN VITRO THROMBIN GENERATION TRIGGERED BY DIFFERENT HISTOLOGICALTYPES OF CANCER CELLSG. T. Gerotziafas* (FR), V. Galea, E. Mbemba, A. Khaterchi, C. Prengel, M. Hatmi, J.Bernaudin, I. Elalamy

PP-TH-487 PROCOAGULANT PHOSPHOLIPIDS IN PATIENTS WITH VENOUSTHROMBOEMBOLISM AND CANCERL. Spiezia* (IT), E. Campello, S. Gavasso, V. Rossetto, C. Abalotti, B. Woodhams, P. Simioni

PP-TH-488 HYPOFIBRINOLYSIS IN PATIENTS WITH VENOUS THROMBOEMBOLISM AND CANCERL. Spiezia* (IT), E. Campello, S. Gavasso, V. Rossetto, F. Dalla Valle, S. Barbar, B.Woodhams, P. Simioni

PP-TH-489 DOSE ESCALATION OF LOW MOLECULAR WEIGHT HEPARIN TO MANAGERECURRENT VENOUS THROMBOEMBLIC EVENTS DESPITE SYSTEMICANTICOAGULATION IN CANCER PATIENTSM. Carrier* (CA), G. Le Gal, R. Cho, S. Tierney, M. A. Rodger, A. Y. Lee



366

Thur

sday

Pos

ters

PP-TH-490 D-DIMER AS A POSSIBLE PROGNOSTIC MARKER OF BREAST CANCER INHORMONAL RECEPTOR NEGATIVE PATIENTSM. G. Carvalho* (BR), A. P. Fernandes, C. P. Figueiredo, E. C. Bueno, M. A. Ribeiro, K. B.Gomes, L. M. S. Dusse, A. P. B. Batschauer

PP-TH-491 TUMOR CELL-DERIVED MICROPARTICLES: DOES SIZE MATTERM. Davila* (US), A. Amirkhosravi, C. H. Baker, J. Colon, J. Francis

PP-TH-492 LACK OF PROPHYLAXIS PRIOR TO THE ONSET OF ACUTE VENOUSTHROMBOEMBOLISM AMONG HOSPITALIZED CANCER PATIENTSN. Kucher* (CH), D. Spirk, C. Kalka, L. Mazzolai, D. Nobel, M. Banyai, B. Frauchiger, H.Bounameaux

PP-TH-493 MAGNETIC RESONANCE IMAGING: IS IT USEFUL FOR DIAGNOSIS OFASYMPTOMATIC CEREBRAL THROMBOEMBOLIC EVENTS IN CHILDREN WITH ACUTELYMPHOBLASTIC LEUKAEMIAP. Giordano* (IT), M. Grassi, V. Cecinati, G. C. Del Vecchio, F. Dicuonzo, M. Palma, G.Arcamone, N. Santoro, D. de Mattia

PP-TH-494 PROGNOSTIC VALUE OF THROMBOPATH DETERMINATION FOR CHEMOTHERAPY-ASSOCIATED VENOUS THROMBOEMBOLISMP. Ferroni* (IT), F. Martini, I. Portarena, I. Grenga, S. Riondino, A. Spila, R. D’Alessandro, M.G. Pera, A. Laudisi, M. Roselli, F. Guadagni

PP-TH-495 KUNITZ TYPE INHIBITOR (RKTI) INDUCES CHANGES IN GENE EXPRESSION,PROTEASOME INHIBITION AND APOPTOSIS IN CANCER CELLSP. L. De-Sá-Júnior* (BR), E. M. Reis, S. A. Barreto, E. M. Akagi, S. M. Simons, M. Demasi, A.M. Chudzinski-Tavassi

PP-TH-496 DEEP VEIN THROMBOSIS – WHAT LIES BENEATHP. Braude* (UK), B. Prathibha

PP-TH-497 STANDARDS, OPTIONS : RECOMMENDATIONS 2008 PROPHYLAXIS AND TREATMENTOF CENTRAL VENOUS CATHETER THROMBOSIS IN CANCER PATIENTSP. Debourdeau* (FR), D. Kassab Chahmi, E. Desruennes, M. Douard, I. Kriegel, A. Elias, I.Elalamy, G. Legal, M. Pavic, M. Scroboachi, I. Quere, D. Farge Bancel

PP-TH-498 THE INCIDENCE OF VENOUS THROMBOEMBOLISM AND ITS IMPACT ON SURVIVAL INPATIENTS WITH BLADDER CANCERR. K. Sandhu* (US), R. H. White, T. Wun, H. K. Chew

PP-TH-499 PROCOAGULANT PROPERTIES OF MELANOMA MICROVESICLES SUGGEST THEIRINVOLVEMENT IN CANCER-ASSOCIATED THROMBOSISR. Q. Monteiro* (BR), R. Chammas, C. P. Vicente, M. A. Barcinski, L. G. Lima

PP-TH-500 HAEMOSTATIC AND HAEMORHEOLOGICAL CHANGES IN AFRICAN PATIENTS WITHCHRONIC MYELOID LEUKAEMIAS. O. Abegunde* (NG), A. A. Famodu, O. A. Awodu, I. O. Ajayi, F. A. Ojeokun

PP-TH-501 HAEMOSTATIC AND HAEMORHEOLOGICAL CHANGES IN AFRICAN PATIENTS WITHACUTE LYMPHOBLASTIC LEUKAEMIAS. O. Abegunde* (NG), A. A. Famodu, O. A. Awodu, I. O. Ajayi, F. A. Ojeokun

PP-TH-502 THE ROLE OF TISSUE FACTOR-FACTOR VIIa-PROTEASE ACTIVATED RECEPTOR 2SIGNALING IN BREAST CANCER PROGRESSIONT. McEachron* (US), F. Church, N. Mackman

PP-TH-503 DECREASED OVERALL SURVIVAL AND INCREASED RISK OF THROMBOSIS INCHILDREN WITH CANCER AND CENTRAL VENOUS LINE (CVL) DYSFUNCTIONU. Athale* (CA), S. Siciliano, J. Cheng, L. Thabane, A. K. C. Chan



367

PP-TH-504 LOW INCIDENCE OF THROMBOEMBOLISM IN KOREAN PATIENTS WITH MULTIPLEMYELOMA TREATED WITH THALIDOMIDEY. Koh* (KR), S. Bang, J. Lee, H. Yoon, Y. Do, H. Ryoo, N. Lee, S. Kim, K. Kim, H. Kim, S.Yoon, J. Won, Y. Mun, M. Lee, K. Rhee, H. Eom, M. Kim, H. Shin

Venous Thrombosis: Diagnosis III

PP-TH-505 DIAGNOSTIC PERFORMANCE OF THE VIDAS D-DIMER IN A PROSPECTIVE STUDY OFINPATIENTS AND EMERGENCY PATIENTS EVALUATED FOR PULMONARY EMBOLISMWITH ANALYSIS OF PERCENT OBSTRUCTIOND. M. Courtney* (US), N. T. Klekowski, C. D. Miller, H. A. Smithline, M. M. Hogg, J. A. Kline

PP-TH-506 THROMBOPHILIC RISK FACTORS IN PATIENTS UNDERGOING MAJOR ABDOMINALSURGERY AND THEIR RELEVANCE TO DEEP VENOUS THROMBOSISE. A. A. Khaled* (EG), F. M. Essawy, E. M. Esmat, N. A. Hussein, S. E. Sabaie, A. S.Hassanien, N. E. Mikhail

PP-TH-507 AGREEMENT OF PERFUSION SCINTIGRAPHY AND CT-ANGIOGRAPHY IN DETECTINGRESIDUAL THROMBOEMBOLI AFTER PULMONARY EMBOLISMF. Dentali* (IT), M. Donadini, B. Cosmi, S. Bozzato, A. Squizzato, C. Neri, W. Ageno

PP-TH-508 DIAGNOSIS OF DEEP VEIN THROMBOSIS BY COMPRESSION ULTRASONOGRAPHYDURING PREGNANCY AND THE POSTPARTUM PERIOD: A MANAGEMENT OUTCOMESTUDYG. Le Gal* (FR), M. Righini, G. Kercret, L. Bressollette, P. Louis, C. Bohec, M. Labalette, D.Mottier, ANGIO-GETBO Group

PP-TH-509 EVALUATION OF THE INNOVANCE® D-DIMER ASSAY ON THE SYSMEX® CA-7000SYSTEMS. Park, H. Chi* (KR), S. Chun, S. Jang, C. Park

PP-TH-510 PROSPECTIVE AUDIT OF THE MEDICAL DOCUMENTATION AND OUTCOMES OFPATIENTS EVALUATED WITH THE PULMONARY EMBOLISM RULE-OUT CRITERIAJ. A. Kline* (US), C. Peterson, M. T. Steuerwald

PP-TH-511 RESULTS OF A MULTICENTER, CROSS-SECTIONAL VENOUS THROMBOSISSCREENING STUDY IN IZMIRM. Karacelik* (TR), E. Kara, I. Erdinc, A. B. Ozelci, C. S. Atalay, E. O∂uz, M. Sen, G.Albayrak, S. T. Kutlu, E. Bahtiyar, C. Sert, A. Gurbuz, T. Calkavur, Karabay

PP-TH-512 ROLE OF CONGENITAL THROMBOPHILIC CONDITIONS IN THE DEVELOPMENT OFTHROMBUS FLOTATIONN. A. Vorobyeva* (RU), M. G. Anisimov

PP-TH-513 LEVEL OF D-DIMER AND DURATION OF SYMPTOMS OF VENOUSTHROMBOEMBOLISMN. M. Vorobyeva* (RU), E. P. Panchenko, A. B. Dobrovolsky, E. V. Titaeva, A. I. Kirienko

PP-TH-514 FATAL PULMONARY EMBOLISM IN YOUNG PEOPLE: RISK FACTORS AND CLINICALPRESENTATIONO. V. Fesenko* (RU), A. V. Glechikov

PP-TH-515 VALIDATION OF 9 DIFFERENT PROTEIN S ASSAYS IN A FAMILY COHORT WITH APROS1 MUTATIONR. Mulder* (NL), M. K. ten Kate, A. B. Mulder, H. C. Kluin-Nelemans, J. van der Meer

PP-TH-516 CALIBRATED AUTOMATED THROMBOGRAPHY IN THE PRESENCE AND ABSENCE OFTHROMBOMODULIN TO ASSESS THE PROTHROMBOTIC STATER. Mulder* (NL), M. K. ten Kate, H. M. H. Spronk, R. van Oerle, H. ten Cate, A. B. Mulder, H.C. Kluin-Nelemans, J. van der Meer



368

Thur

sday

Pos

ters

PP-TH-517 COMPARISON OF 4- AND 64-SLICE CT SCANNING IN THE DIAGNOSIS OFPULMONARY EMBOLISMR. A. Douma* (NL), H. M. A. Hofstee, C. Schaefer-Prokop, J. H. T. M. van Waesberghe, R.Lely, P. W. Kamphuisen, V. E. A. Gerdes, M. H. H. Kramer, H. R. Büller

PP-TH-518 AGE-ADJUSTED D-DIMER CUT-OFF LEVELS INCREASE THE CLINICAL UTILITY OFRULING OUT PULMONARY EMBOLISM IN ELDERLY PATIENTSR. A. Douma* (NL), G. Le Gal, M. Söhne, M. Righini, P. W. Kamphuisen, A. Perrier, M. J. H.A. Kruip, H. Bounameaux, H. R. Büller, P. M. Roy

PP-TH-519 UTILITY OF D-DIMER ASSAY FOR DIAGNOSING PULMONARY EMBOLISM: SINGLEINSTITUTE STUDYR. Park* (KR), Y. Seo, S. Yoon, J. Shin, T. Choi, S. Lee, S. Uh, Y. Kim

PP-TH-520 NEW AUTOMATED CHEMILUMINESCENT D-DIMER IMMUNOASSAY: ANALYTICAL ANDCLINICAL PERFORMANCE IN PATIENTS SUSPECTED OF VTER. G. Barry* (US), J. F. Guasch, Z. Pascual, J. Serra, K. A. Morin, J. Arnout, M. Vanrusselt, P.de Moerloose, G. Reber

PP-TH-521 D-DIMER TEST FOR DIAGNOSIS OF DEEP VENOUS THROMBOSIS (DVT) IN THE ICUR. Moroi* (JP), A. Yaguchi, M. Takeda, M. Abe, T. Harada, T. Yamaki

PP-TH-522 DEVELOPMENT OF A CLINICAL CUT-POINT FOR A NEW AUTOMATED D-DIMERS. M. Bates* (CA), M. Johnston, E. Ali, J. S. Ginsberg

PP-TH-523 RETROSPECTIVE EVALUATION OF AN IMMUNOTURBIDOMETRIC D-DIMER ASSAY ASA STAND-ALONE TEST TO EXCLUDE VENOUS THROMBOEMBOLISMS. M. Bates* (CA), M. Johnston, E. Ali, J. S. Ginsberg

PP-TH-524 INTEROBSERVER REPRODUCIBILITY OF CLINICAL PROBABILITY ASSESSMENT INSUSPECTED PULMONARY EMBOLISM: REVISED GENEVA SCORE AND WELLSSCORES. Dambrine* (FR), F. Verschuren, G. Le Gal, J. Callahan, N. Delvau, C. Coroller-Bec, M.Righini, D. Aujesky, O. Sanchez, A. Perrier, F. Thys, P. Roy

PP-TH-525 OUTCOME OF 205 VTE PATIENTS, PATICULAR REFERENCE TO NATIONAL PATIENTSAFETY ALERT 18 - SAFER ANTICOAGULATIONS. B. Bacon* (UK), S. Chadwick

PP-TH-526 ELEVATED LEVELS OF SOLUBLE FIBRIN IN PATIENTS WITH VENOUSTHROMBOEMBOLISMT. Matsumoto* (JP), H. Wada, A. Tsuji, S. Ota, N. Yamada, T. Sugiyama, K. Ohishi, A. Sudo,Y. Abe, N. Ito, K. Onishi, K. Nakatani, A. Uchida, K. Suzuki, M. Ito, N. Katayama, T. Nobori

Hemophilia III

PP-TH-527 VENOUS THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH SEVERECOAGULOPATHY UNDERGOING MAJOR SURGERYA. Malato* (IT), A. Tagliaferri, P. Redossi, P. Solimeno, G. Saccullo, L. Lo Coco, G. Tagariello,S. M. Siragusa

PP-TH-528 USE OF A COMMERCIAL FVIII ANTIBODY SCREEN ELISAA. F. Riddell* (UK), S. Brooks, T. Yee

PP-TH-529 THE INTERACTIONS OF A NEW RFVIII (N8) WITH VWF AND LRPI. Hilden* (DK), E. Persson

PP-TH-530 TWENTY YEARS OF IMPROVEMENT IN THE TREATMENT OF CHILDREN WITHHAEMOPHILIA IN THE CZECH REPUBLICJ. Blatny* (CZ), O. Zapletal, V. Komrska



369

PP-TH-531 DOSING AND SAFETY OF ANTITHROMBIN CONCENTRATE IN PEDIATRIC PATIENTSWHO REQUIRE HEPARIN ANTICOAGULATIONM. E. Bauman* (CA), K. L. Black, A. Bruce, S. Kuhle, L. Bajzar, M. P. Massicotte

PP-TH-532 SPONTANEOUS CERVICAL EPIDURAL HAEMATOMA IN HAEMOPHILIA: ANIMPORTANT DIFFERENTIAL DIAGNOSIS OF UNSPECIFIC BACK PAINM. S. Pereira* (BR), G. C. Duarte, E. V. de Paula, F. A. Orsi, M. C. Ozelo, J. M. Annichino-Bizzachi

PP-TH-533 MAGNETIC RESONANCE IMAGING (MRI) IDENTIFIES EARLIEST JOINT DAMAGE INCLINICALLY ASYMPTOMATIC PATIENTS WITH HEMOPHILIA A, HEMOPHILIA B ANDVON WILLEBRAND DISEASE DESPITE PROPHYLAXISM. Olivieri* (DE), C. Bidlingmaier, K. Kurnik

PP-TH-534 THE IMPACT OF INHIBITORS ON THE COST OF CLOTTING FACTOR REPLACEMENTTHERAPY IN HEMOPHILIA A IN SOUTH OF IRANM. Karimi* (IR), A. Ahmadkia Daliri, K. Pourmohammadi, P. Bastani

PP-TH-535 QUALITY OF LIFE IN HEMOPHILIA COMPLICATED BY INHIBITORSM. Karimi* (IR), K. Pourmohamadi, P. Bastani

PP-TH-536 ENHANCEMENT OF HAEMOSTATIC EFFICACY OF PLASMA-DERIVED FVIII BYFORMULATION WITH PEGYLATED LIPOSOMESM. Baru* (IL), I. Dayan, M. Robinson

PP-TH-537 TRANSIENT ELASTOGRAPHY DISCLOSES IDENTICAL DISTRIBUTION OF LIVERFIBROSIS IN HAEMOPHILIACS WITH HCV-MONO- AND HCV/HIV-COINFECTIONN. Vidovic* (DE), R. Lochowski, F. Grünhage, G. Goldmann, B. Niemann, S. Horneff, J.Schröder, U. Spengler, T. Sauerbruch, J. Oldenburg

PP-TH-538 BONE MINERAL DENSITY IN CHILDREN WITH SEVERE HAEMOPHILIA RECEIVINGREGULAR FVIII PROPHYLAXISN. B. Heaney, A. Gibson, S. Khanna, F. Ahmed, E. Chalmers* (UK)

PP-TH-539 ECONOMIC ASSESSMENT OF HOME TREATMENT VERSUS HOSPITAL TREATMENTWITH APCC IN INHIBITOR PATIENTSP. A. Holme* (NO), K. Nyhus, J. Sverre, G. Tjønnfjord

PP-TH-540 DETECTION OF F8 MUTATIONS BY HIGH RESOLUTION MELTING (HRM) ANALYSISP. A. Bignell* (UK), D. Keeling, P. Giangrande

PP-TH-541 DETECTION OF DUPLICATIONS AND DELETIONS WITHIN THE FACTOR VIII GENE BYMPLAP. A. Bignell* (UK), D. Keeling, P. Giangrande

PP-TH-542 INTRAMURAL URETERAL HEMORRHAGE ASSOCIATED WITH CONTRALATERALILIOPSOAS HEMATOMA IN A PATIENT WITH HEMOPHILIA A WITH INHIBITOR: CASEREPORTP. R. Villaca* (BR), C. L. Dinardo, L. F. Botelho, E. P. N. Sandoval, P. L. Junqueira, E.Okazaki, A. K. Zeinad, C. S. S. S. Silva, T. R. F. Rocha, D. A. F. Chamone, E. A. D’ Amico

PP-TH-543 HEAMOPHILIA EPIDEMIOLOGY ASSESSMENT IN CENTRAL AND EAST EUROPEANCOUNTRIES PROVIDED BY ONLINE CLINICAL REGISTRYP. Brabec* (CZ), P. Salaj, T. Pavlík

PP-TH-544 PHENOTYPE-GENOTYPE CORRELATION IN MILD HEMOPHILIA AP. Casaña* (ES), N. Cabrera, A. R. Cid, S. Haya, A. Moret, L. Abad-Franch, J. A. Aznar

PP-TH-545 CURRENT PRACTICE IN MANAGEMENT OF MUSCLE HAEMATOMA IN PATIENTS WITHSEVERE HAEMOPHILIAR. Beyer* (DK), J. Ingerslev, B. Sørensen



370

Thur

sday

Pos

ters

PP-TH-546 ISCHEMIC HEART DISEASE IN HAEMOPHILIAC PATIENTSR. Santoro* (IT), S. Prejanò, P. Iannaccaro, G. Muleo

PP-TH-547 LUPUS ANTICOAGULANT IN A PATIENT WITH HAEMOPHILIA AR. Santoro* (IT), S. Prejanò, P. Iannaccaro, G. Muleo

PP-TH-548 JOINT BLEEDING AND ARTHROPATHY EVOLUTION IN CHINESE CHILDRENHEMOPHILIAS WITHOUT ROUTINE TREATMENT AND DISCUSSION FOR CUREOPPORTUNITYR. Wu* (CN), N. Zhang, L. Zhao, X. Wu

PP-TH-549 ASSESSMENT OF THROMBIN GENERATION IN MILD HAEMOPHILIA A WITH FACTORVIII ASSAY DISCREPANCYR. M. Gilmore* (IE), S. Harmon, C. Gannon, M. Byrne, B. White, J. S. O’Donnell, P. V.Jenkins

PP-TH-550 MALIGNANT GONADAL GERM CELL TUMOR WITH PARANEOPLASTIC PULMONARYEMBOLISM IN A PATIENT WITH SEVERE HEMOPHILIA AS. Struve* (DE), M. Griesshammer

PP-TH-551 DIFFERENT ONE STAGE FVIII ACTIVITY RESULTS IN A PATIENT WITH MODERATEHAEMOPHILIA A DEPENDING ON THE TYPE OF APTT REAGENT USEDS. V. Brooks* (UK), S. Aghighi, K. Gomez, G. Mellars, M. Mathias

PP-TH-552 URINARY EXCRETION OF 8-ISO-PGF2 IN HEMOPHILIA A PATIENTS WITH ORWITHOUT INHIBITOR DURING ACUTE JOINT BLEEDING, AND STATE OF FACTORTHERAPYS. Cheng* (TW), C. Yc

PP-TH-553 DETECTION OF 101 NOVEL MUTATIONS IN THE FACTOR 8 GENE OF IRANIANSHEMOPHILIA A PATIENTSS. Ravanbod* (IR), G. Rastegarlari, M. Rassoulzadegan, F. Ala, S. Enayat

PP-TH-554 SCREENING LABORATORY BRAZILIAN PROGRAM OF HAEMOPHILIA ANDINHIBITORSS. A. L. Montalvão* (BR), E. V. de Paula, S. Thomas, J. M. Annichino-Bizzacchi, M. C. Ozelo

PP-TH-555 FACTOR VIII GENE MUTATIONS IN PATIENTS WITH SEVERE HEMOPHILIA A ANDINHIBITORS FROM VENEZUELAS. Albanez* (VE), N. de Bosch, A. Boadas, A. Sáez, A. Porco

PP-TH-556 ABERRANT DIAGNOSTIC PATTERN IN A BRAZILIAN PATIENT WITH SEVEREHEMOPHILIA A EXPLAINABLE BY AN INT1H-RELATED INVERSION COMBINED WITH ADELETION IN F8C. Mühle, S. F. Pio, D. Zouain, G. Correa, S. M. Rezende* (BR)

PP-TH-557 LOW-DOSE THROMBOPROPHYLAXIS IN A HEMOPHILIC PATIENT UNDERGOING HIPSURGERYS. Stankovic* (MK), A. Stojanovic, T. Smilevska, Z. Stojanovski, T. Sotirova, S. Trajkova, A.Ljatifi, D. Dukovski, L. Cevreska

PP-TH-558 HEALTH-RELATED QUALITY OF LIFE IN ELDERLY HAEMOPHILIA PATIENTSS. von Mackensen* (DE), A. Gringeri, S. Siboni, M. Ferretti, F. Tradati, M. Franchini, A.Tagliaferri, E. Santagostino, P. Mannucci

PP-TH-559 A HAEMOPHILIA-SPECIFIC AQUA-TRAINING FOR HAEMOPHILIA PATIENTS –RESULTS OF THE WATERCISE - QUALITY OF LIFE STUDY (WAT-QOL)S. von Mackensen* (DE), A. Wieloch, D. Zäch, B. Eifrig, J. Kalnins, W. Zeller

PP-TH-560 IMPACT OF HAEMOPHILIA EDUCATION ON PATIENTS AND FAMILIES IN ADEVELOPING COUNTRYT. Zafar* (PK)



371

PP-TH-561 PROLONGED HALF-LIFE OF RECOMBINANT FACTOR VIIa FUSION PROTEIN - SINGLEDOSE STUDY IN RABBITSU. Kronthaler* (DE), S. Schmidbauer, U. Liebing, W. Lang, H. J. Metzner, T. Weimer, S.Schulte

PP-TH-562 PREVALENCE OF THE FACTOR VIII GENE INTRON 1 INVERSION IN CHINESEHAEMOPHILIAC AND ITS APPLICATION TO THE CARRIER DETECTION ANDPRENATAL DIAGNOSISY. Lu* (CN), X. Wang, Q. Ding, J. Dai, X. Xi, H. Wang

PP-TH-563 HAEMOPHILIA A IN A FEMALE WITH DE NOVEL INV22 AND SKEWED X-CHROMOSOME INACTIVATIONY. Lu* (CN), X. Wang, J. Dai, Q. Ding, X. Xi, H. Wang

PP-TH-564 COMBINED HAEMOPHILIA A AND B IN A PEDIGREE WITH MOSAICISM OF THE F9GENE MUTATION IN HB INDEX’S MATERNAL GRANDFATHERY. Lu* (CN), X. Wang, Q. Ding, J. Dai, X. Xi, B. Xie, M. Wang, H. Wang

PP-TH-565 HAEMOPHILIA A IN A FEMALE WITH INV 1 AND SKEWED X-CHROMOSOMEINACTIVATIONY. Lu* (CN), X. Wang, Q. Ding, J. Dai, X. Xi, H. Wang

Hemophilia Therapy III

PP-TH-566 VISUALISING THE COAGULATION PROCESS AND HEMOPHILIA IN 3D, A UNIQUE ANDVALUABLE EDUCATIONAL TOOL FOR PATIENTS AND HEALTH CAREPROFESSIONALSC. Hermans, C. Lambert* (BE)

PP-TH-567 EFFECTS OF RFVIIa ANALOGUE (NN1731) ON PLATELET FUNCTION, CLOTSTRUCTURE AND CLOT KINETICS IN WHOLE BLOOD FROM PATIENTS WITHHEMOPHILIA AD. F. Brophy* (US), E. J. Martin, M. E. Nolte, J. G. Kuhn, M. Ezban

PP-TH-568 NO EVIDENCE FOR NEONATIGENS FORMATION IN DIFFERENTS BATCHES OF ADOUBLE-VIRUS INACTIVATED FACTOR VIII CONCENTRATE MANUFACTURED INARGENTINAH. A. Guglielmone* (AR), F. Farias, C. Moya, D. Navarro, M. Vitali

PP-TH-569 UPDATE OF A LONG-TERM PHARMACOVIGILANCE SURVEILLANCE: REC. FVIII FORTHE TREATMENT OF HEMOPHILIA AJ. Oldenburg* (DE), P. Petrini, A. Tagliaferri, A. Faradji, E. Zanon, I. Pabinger, M. Broder, C.Zacharias, H. Lenk

PP-TH-570 THE NUMBER OF FACTOR VIII DOSAGE STRENGTHS OFFERED IS ASSOCIATED WITHTHE NUMBER OF VIALS NEEDED TO TREAT HEMOPHILIAJ. D. Epstein* (US), M. P. Luo

PP-TH-571 RETROSPECTIVE ANALYSIS OF FACTOR VIII UTILIZATION IN MATCHED HEMOPHILIAA PATIENTS TREATED WITH EITHER FULL-LENGTH OR B DOMAIN-DELETEDRECOMBINANT FACTOR VIIIJ. D. Epstein* (US), J. M. Li-McLeod

PP-TH-572 IMPACT OF FVIII PRODUCT CHANGE IN SEVERE HAEMOPHILIA A PATIENTSPREVIOUSLY TREATED WITH PLASMA-DERIVED FVIIIM. E. Mingot* (ES), A. I. Heiniger, M. García, J. A. Fernández

PP-TH-573 INFLUENCE OF RECOMBINANT ACTIVATED FVII ON CLOT STABILITY: ATHROMBOELASTOGRAPHIC STUDY IN NORMAL AND HAEMOPHILIC BLOODM. Colucci* (IT), R. Galasso, C. Carrieri, R. Marino, F. A. Scaraggi, N. Semeraro



372

Thur

sday

Pos

ters

PP-TH-574 MARKERS OF BLOOD CELL ACTIVATION AND COMPLEMENT ACTIVATION IN FACTORVIII OR VWF CONCENTRATESM. Brodde* (DE), B. E. Kehrel

PP-TH-575 EVALUATION OF SAFETY AND EFFICACY OF RECOMBINANT FACTOR IX IN DAILYCLINICAL PRACTICE: RESULTS OF THE FIRST YEARM. Westfeld* (DE), H. Pollmann, C. Niekrens, H. Laws, M. Girisch, S. Halimeh, M. Ries, K.Severin, A. Huth-Kuehne, J. Oldenburg

PP-TH-576 POST-AUTHORIZATION SAFETY SURVEILLANCE (PASS) PROGRAM OFANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD(RAHF-PFM) FOR JAPANESE HEMOPHILIA A PATIENTSM. Taki* (JP), K. Fukutake, H. Hanabusa, J. Takamatsu, M. Shima, A. Shirahata, G. AdvatePass Study

PP-TH-577 FORMULATION DESIGN AND STABILITY OF LONG ACTING RFVIIa (40KGLYCOPEGYLATED FACTOR VIIaM. B. Jensen* (DK), L. Kragelund

PP-TH-578 KEY ASPECTS IN THE MANAGEMENT OF ACUTE HAEMARTHROSIS IN HAEMOPHILIA:A EUROPEAN SURVEYM. Richards* (UK), P. de Moerloose, K. Fischer, K. Holstein, R. Klamroth, T. Lambert, G.Lavigne-Lissalde, R. Perez, G. Dolan, C. Hermans

PP-TH-579 PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) PROPERTIES OF A NEWRECOMBINANT LONG ACTING FACTOR IX (40KPEG-RFIX) PRODUCT AFTERINTRAVENOUS (IV) ADMINISTRATION TO HEMOPHILIA B DOGSM. Ezban* (DK), M. B. Hermit, P. K. Holm, L. Hansen, H. Østergaard, M. Tranholm, E. P.Merricks, H. G. Franck, R. A. Raymer, T. C. Nichols

PP-TH-580 PATIENTS WITH SEVERE HAMOPHILIA ON LONG-TERM PROPHYLAXIS ARE ASPHYSICALLY ACTIVE AS THE GENERAL SWEDISH POPULATIONM. M. Khawaji* (SE), E. Berntorp

PP-TH-581 INDICATORS FOR ASSESSING EFFECTIVENESS OF THE STATE PROGRAM ON DRUGSUPPLY FOR PATIENTS WITH HEREDITARY COAGULOPATHIES:P. A. Vorobyev, O. V. Borisenko, U. A. Zhulev, E. A. Telnova, A. A. Tonoyan, V. U. Zorenko, N.I. Zozulya* (RU)

PP-TH-582 TREATMENT OF HAEMOPHILIA A PATIENTS WITH INHIBITORS AND A POORPROGNOSIS: ITI WITH OCTANATE®N. I. Zozulya* (RU)

PP-TH-583 MANAGEMENT OF CORONARY ARTERY DISEASES IN PATIENTS WITH HAEMOPHILIAOR WILLEBRAND DISEASEN. Trillot* (FR), F. Mouquet, B. Wibaut, O. Equine, B. Jude, E. van Belle, S. Susen, J.Goudemand

PP-TH-584 EFFICACY OF SECONDARY PROPHYLACTIC VERSUS ON-DEMAND SUCROSE-FORMULATED RECOMBINANT FACTOR VIII TREATMENT IN ADULTS WITH SEVEREHEMOPHILIA A WITH AND WITHOUT TARGET JOINTSP. Collins* (UK), A. Faradji, M. Morfini, M. Maas Enriquez, L. Schwartz

PP-TH-585 IMPACT OF FACTOR VIII HALF LIFE ON PROPHYLACTIC DOSING IN CHILDREN ANDADULTS WITH SEVERE HAEMOPHILIA AP. W. Collins* (UK), K. Fischer, V. Blanchette, S. Björkman, M. Oh, P. Schroth, S. Fritsch, K.Casey, G. Spotts, B. Ewenstein

PP-TH-586 A NOVEL DISPLAY OF PATIENT TREATMENT RECORDS AND ASSOCIATED BLEEDINGPATTERNS FOR PROPHYLAXIS REGIMENSP. Schroth* (US), L. Huang, W. Knowlton, S. Fritsch



373

PP-TH-587 PLASMA DERIVED FACTOR VIII IN THE TREATMENT OF PATIENTS WITH HEMOPHILIAA: UPDATE OF A LONG-TERM PHARMACOVIGILANCER. Klamroth* (DE), R. Zimmermann, B. Schütz, C. Zacharias, M. Broder, K. Kurnik

PP-TH-588 STRUMECTOMY IN A PATIENT WITH HEMOPHILIA B USING A REASONABLE AMOUNTOF RECOMBINANT FACTOR IX FOR REPLACEMENT THERAPYS. Gottstein, K. Unger, R. Klamroth* (DE)

PP-TH-589 PHARMACOKINETIC PROPERTIES OF A HIGH PURITY PLASMA-DERIVED FIXCONCENTRATE IN HAEMOPHILIA B ADULTS AND CHILDREN – AN OVERVIEW OFCLINICAL DATAR. Kuhelj* (CH), M. Jansen, J. Feddern

PP-TH-590 TRANSCATHETER ARTERIAL EMBOLIZATION OF CONCURRENT SPONTANEOUSHEMATOMAS OF THE RECTUS AND OBLIQUE LEFT ABDOMINAL MUSCLES IN AMODERATE HAEMOPHILIA B PATIENTR. R. M. Musso* (IT), D. Cultrera, A. Basile, M. Musso, A. Cipolla

PP-TH-591 LC-ESI-MS/MS ANALYSIS OF Y1680 SULFONATION IN RECOMBINANT FVIIICONCENTRATESS. Grancha* (ES), R. Navajas, A. Nardi, A. Paradela, J. P. Albar, J. I. Jorquera

PP-TH-592 THE JAPANESE GUIDELINE FOR THE PRACTICAL REPLACEMENT THERAPY FORACUTE BLEEDING AND SURGICAL PROPHYLAXIS IN HEMOPHILIA WITHOUTINHIBITORST. Matsushita* (JP), K. Amano, M. Taki, T. Oka, M. Sakai, A. Shirahata, N. Takata, J.Takamatsu, H. Takedani, H. Hanabusa, A. Higasa, K. Fukutake, T. Fujii, I. Tanaka, J. Mimaya,A. Yoshioka, M. Shima

PP-TH-593 SECONDARY PROPHYLAXIS WITH ACTIVATED PROTHROMBIN COMPLEXCONCENTRATES (APCC) REDUCES BLEEDING FREQUENCY IN HAEMOPHILIA APATIENTS WITH INHIBITORST. Lambert* (FR), C. Rothschild, J. Goudemand, C. Négrier, S. Girault, P. Moreau, M.Trossaërt

PP-TH-594 EFFICACY OF A NEW RECOMBINANT FVIII (N8) IN A TAIL BLEEDING MODEL INHEMOPHILIA A MICET. Elm* (DK), M. Kjalke, H. Pelzer, M. Tranholm

PP-TH-595 AVAILABILITY OF PERIPHERAL INSERTED CENTRAL CATHETERS IN SEVEREHEMOPHILIA PATIENTSY. Park* (KR), J. Park

Inhibitors: Pathogenesis, Prevention and Treatment III

PP-TH-596 HOW CAN THE RIGHT FVIII DOSAGE TO NEUTRALISE LOW TITRE INHIBITOR BECALCULATEDC. Altisent* (ES), A. Cid, V. Jiménez, M. López, E. Mingot, R. Nuñez, M. Paloma, M. Prieto,C. Sedano, I. Soto

PP-TH-597 SUCCESSFUL TOLERIZATION WITH HIGH VON WILLEBRAND FACTOR / FACTOR VIIICONTENT RATIO CONCENTRATE OF CHILDREN WITH SEVERE HAEMOPHILIA A ANDHIGH RESPONDING INHIBITORH. Platokouki* (GR), H. Pergantou, P. Xafaki, A. Komitopoulou, S. Aronis

PP-TH-598 IMMUNE TOLERANCE INDUCTION IN CONGENITAL HEMOPHILIA A WITH HIGH TITREINHIBITOR - CASE REPORTJ. Stasko* (SK), I. Plamenová, P. Holly’, P. Kubisz



374

Thur

sday

Pos

ters

PP-TH-599 CASE STUDY IMMUNE-TOLERANCE IN HAEMOPHILIA A USING PLASMA-DERIVEDFACTOR VIII CONCENTRATEJ. Needham* (UK), A. Roy, S. Knight, Y. Stebbings, S. Rangarajan

PP-TH-600 ECONOMIC COMPARISON OF APCC VS RFVIIa FOR MILD-TO-MODERATE BLEEDINGEPISODES IN HEMOPHILIA PATIENTS WITH INHIBITORSJ. W. Hay* (US), Z. Zhou, G. Young

PP-TH-601 DOSING AND EFFECTIVENESS OF RECOMBINANT FVIIa (RFVIIa) IN SURGICAL ANDDENTAL PROCEDURES IN CONGENITAL HEMOPHILIA WITH INHIBITORS: THEEXPERIENCE OF THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS)REGISTRY (2004-2008)L. A. Valentino* (US), D. L. Cooper

PP-TH-602 HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY DATA TOUNDERSTAND DIFFERENCES IN RECOMBINANT FACTOR VIIa (RFVIIa) DOSING ANDCLINICAL OUTCOMES FOR THE TREATMENT OF SPECIFIC JOINT BLEEDS INHEMOPHILIAL. A. Valentino* (US), D. L. Cooper

PP-TH-603 THROMBELASTOGRAPHY ROTATIONAL (ROTEM®) UTILITY FOR MONITORINGPATIENTS WITH HAEMOPHILIA AND FACTOR VIII INHIBITORS TREATED WITH FEIBA®M. Garcia-Rodriguez* (ES), M. Martin-Salces, M. Alvarez, I. Fernandez, N. Butta, I. Muñoz, I.Rivas, V. Jimenez-Yuste, F. Hernandez-Navarro

PP-TH-604 THROMBELASTOGRAPHY ROTATIONAL (ROTEM®) UTILITY FOR MONITORINGPATIENTS WITH HAEMOPHILIA AND FACTOR VIII INHIBITORS TREATED WITH RFVIIa(NOVOSEVENj)M. Garcia-Rodriguez* (ES), M. Alvarez, M. Martin-Salces, I. Fernandez, N. Butta, I. Rivas, I.Muñoz, V. Jimenez-Yuste, F. Hernandez-Navarro

PP-TH-605 USE OF PLASMA DERIVED FVIII FOR IMMUNE TOLERANCE: A SINGLE CENTREEXPERIENCEM. C. Mathias* (UK), R. Liesner, K. Khair

PP-TH-606 RECOMBINANT ACTIVATED FACTOR VII PROPHYLACTIC TREATMENT FORINTRACRANIAL HEMORRHAGE IN A HEMOPHILIA PATIENT WITH INHIBITORSM. Martinez* (AR), M. A. Costa, R. Fernandez, V. Schuttenberg, L. Alba, F. Cuello, M. Aznar,S. Formisano, A. Fynn, S. Arguello

PP-TH-607 TREATMENT OF AQUIRED HAEMOPHILIA A WITH RECOMBINANT ACTIVATED FVIIM. A. Cermelj* (AR), S. Ouviña, A. Guzmán, O. Torres, A. Ferro

PP-TH-608 RADIOISOTOPE SYNOVECTOMY IN HAEMOPHILIA WITH INHIBITORSN. Mesli, S. Bereksi Reguig, N. Mesli* (DZ), H. Hemche, H. Bezzou, K. Taouli, A. Slama

PP-TH-609 SEQUENTIAL THERAPY WITH RFVIIa AND ACTIVATED PROTHROMBIN COMPLEXCONCENTRATES (APCCS) IN HAEMOPHILIA B PATIENT WITH INHIBITOR AND LIFETHREATENING BLEEDINGO. Katsarou* (GR), A. Kouraba, I. Anastasopoulou, P. Kotsi, M. Gavalaki, K. Markakis, A.Karafoulidou

PP-TH-610 A RETROSPECTIVE CLAIMS DATABASE ANALYSIS OF HAEMOPHILIA PATIENTS WITHINHIBITORS FOCUSING ON COST OUTLIERSP. O. Bonnet* (US)

PP-TH-611 NEW INSIGHTS INTO THE ROLE OF HEMOSTATIC COMPONENTS (FEIBA®K. Varadi, P. Montsch, B. Keil, P. L. Turecek* (AT), H. J. Ehrlich, H. P. Schwarz



375

PP-TH-612 PROPHYLACTIC TREATMENT WITH RECOMBINANT FACTOR VIIa IN PATIENT WITHADVANCED HAEMOPHILIAC ARTHROPATHYP. Smejkal* (CZ), G. Chlupova, M. Matyskova, A. Bulikova, J. Kissova, M. Slechtova, M.Penka

PP-TH-613 RECOMBINANT FACTOR VIIa IN TREATMENT OF BLEEDS IN HEMOPHILIACS WITHINHIBITOR IN RELATION TO TIME TO TREATMENT AND DOSEP. Smejkal* (CZ), P. Brabec, M. Matyskova, A. Bulikova, M. Slechtova, G. Chlupova, J.Kissova, T. Pavlik, M. Penka

PP-TH-614 RECOMBINANT FVIIa IN THE MANAGEMENT OF PORT-A-CATH ACCESS IN A BOYWITH SEVERE HEMOPHILIA A AND HIGH-TITRE INHIBITOR:WAS IT PROPHYLAXISS. I. Heine* (DE), T. Krenn, N. Graf

PP-TH-615 MANAGEMENT OF PATIENTS WITH INTRACRANIAL BLEED IN MGUS ASSOCIATED AVWSJ. Laurie, J. Chacko, J. Mainwaring, R. Scott, S. Rangarajan* (UK)

PP-TH-616 TETRAMER-GUIDED ANALYSIS OF T-CELL RESPONSES IN MONOZYGOTIC TWINSWITH SEVERE HEMOPHILIA A DISPLAYING A DISCORDANT ANTIBODY RESPONSE TOFACTOR VIIIS. D. van Haren* (NL), E. Herczenik, E. A. James, H. van den Berg, K. Fischer, K. Pratt, J. Voorberg

PP-TH-617 USE OF RECOMBINANT FACTOR VIIa (RFVIIa) IN INDIVIDUALS WITH CONGENITALHEMOPHILIA B COMPLICATED BY ALLOANTIBODY INHIBITORS TO FACTOR IX:ANALYSIS OF DATA CAPTURE FROM THE HEMOPHILIA AND THROMBOSISRESEARCH SOCIETY (HTRS) REGISTRY (2004-2008)S. W. Pipe* (US), D. L. Cooper

PP-TH-618 PREVENTION AND TREATMENT OF INHIBITOR FORMATION IN GENE THERAPY FORHEMOPHILIA BS. Nayak* (US), O. Cao, R. W. Herzog

PP-TH-619 POLYMORPHISMS IN THE VWF GENE AND DEVELOPMENT OF FVIII INHIBITORS INPATIENTS WITH SEVERE HEMOPHILIA AY. Repesse* (FR), E. Farrokhi, C. Costa, A. Borel-Derlon, R. D’Oiron, J. Oldenburg, A.Pavlova, C. Rothschild, C. Vinciguerra, S. Kaveri, S. Lacroix-Desmazes

PP-TH-620 INHIBITOR TITER PREDICTS THE OCCURRENCE BUT NOT THE SEVERITY OFBLEEDING IN ACQUIRED HEMOPHILIA A PATIENTS: SINGLE INSTITUTIONEXPERIENCE IN TAIWANY. B. Yu* (TW), H. C. Hsu, J. P. Gau, C. H. Ho, W. K. Chau, C. C. Chen, J. Y. You, Y. C.Hong, C. H. Tzeng

PP-TH-621 AN ELISA-BASED ASSAY FOR ALLOANTIBODIES AGAINST FACTOR VIII IN PATIENTSWITH HEMOPHILIA AZ. Yu* (CN), L. Zhang, W. Zhang, Y. Zhao, Z. Wang, X. Bai, C. Ruan

von Willebrand Disease III

PP-TH-622 INTERIM ANALYSIS OF A PROSPECTIVE OBSERVATIONAL STUDY ON ITALIAN VWDPATIENTS, MONITORING EFFICACY AND SAFETY DURING A FORMULATION SHIFT OFA PASTEURIZED FVIII/VWF CONCENTRATEM. Morfini, A. Coppola* (IT), E. Zanon, E. Boeri, R. Musso, S. Siragusa

PP-TH-623 DISTRIBUTION OF VON WILLEBRAND DISEASE (VWD) TYPES IN 94 FAMILIES FROMTHE FRENCH NATIONAL REFERENCE CENTER FOR VWD (CRMW) : TYPE 1 IS NOTTHE MOST FREQUENT WITHIN «TRUE» VWDJ. Goudemand* (FR), E. Fressinaud, P. Boisseau, C. Ternisien, C. Caron, M. Trossaert, N.Itzhar, A. Borel-Derlon, M. Dreyfus, C. Boyer-Neumann, T. Lambert, V. Proulle, C. Zawadzki,D. Meyer, A. Veyradier



376

Thur

sday

Pos

ters

PP-TH-624 PERI- AND POST-OPERATIVE HEMATOLOGIC MANAGEMENT IN A PATIENT WITHTYPE II VON WILLEBRANDS DISEASE UNDERGOING MITRAL VALVE REPLACEMENTJ. E. Arnason* (US), M. T. Desancho

PP-TH-625 NEW AUTOMATED CHEMILUMINESCENT VWF:AG AND VWF:RCO ASSAYS:PRELIMINARY ANALYTICAL AND CLINICAL PERFORMANCEJ. Tous, R. G. Barry, J. Arnout, M. Vanrusselt, Z. Pascual, J. Serra* (ES)

PP-TH-626 RETROSPECTIVE ANALYSIS OF DESMOPRESSIN RESPONSES IN TYPE 1 AND TYPE 2VON WILLEBRAND DISORDER, AND HAEMOPHILIA A IN SOUTH AUSTRALIAK. Bavishi, E. Duncan, S. Rodgers, S. McRae, L. H. Tay* (AU), J. Lloyd

PP-TH-627 MENORRHAGIA IN WOMEN WHIT VON WILLEBRAND DISEASE: EXPERIENCE IN AREFERENCE CONGENITAL COAGULOPATHIES UNIT IN SPAINL. Abad-Franch* (ES), A. R. Cid, S. Haya, P. Casaña, N. Cabrera, A. Moret, J. Gilabert, J. A.Aznar

PP-TH-628 PHENOTYPIC AND GENOTYPIC CHARACTERIZATION OF A CANADIAN COHORT OFTYPE 3 VON WILLEBRAND DISEASE (VWD) PATIENTSM. Bowman* (CA), A. Tuttle, M. Hemostasis Research Lab Members, A. H.C.D.C., V. S.Blanchette, D. Lillicrap, P. James

PP-TH-629 DENTAL DISEASE IN TYPE 3 VON WILLEBRAND DISEASE; A NEGLECTED PROBLEMM. E. Seary, L. Winter, P. Judd, M. J. Casas, A. M. Stain, M. D. Carcao* (CA)

PP-TH-630 MUTATIONS CAUSING PREMATURE TERMINATION CODONS IN THE VONWILLEBRAND FACTOR GENE ARE ASSOCIATED WITH ALLELE-SPECIFIC ANDPOSITION-DEPENDENT MRNA DECAYM. Platè* (IT), S. Duga, L. Baronciani, A. B. Federici, R. Asselta

PP-TH-631 SUPRAPHYSIOLOGICAL LEVELS OF PLASMA VON WILLEBRAND FACTOR DO NOTSUPPORT PRIMARY HEMOSTASIS IN VON WILLEBRAND FACTOR KNOCK-OUT MICEM. Golder* (CA), C. M. Pruss, C. Hegadorn, K. Laverty, K. Sponagle, J. Mewburn, J. Meens,D. Lillicrap

PP-TH-632 CORRELATION OF A STANDARDISED BLEEDING SCORE FOR VON WILLIBRANDDISEASE PATIENTS WITH INTERVENTIONS AND BLEEDING EVENTS BY A 10 YEARCOHORT STUDYM. D. Creagh* (UK), R. Kalathara, S. Johns, S. Wallace

PP-TH-633 NOVEL EVALUATION METHOD FOR DENSITOMETRIC CURVES OF VON WILLEBRANDFACTOR MULTIMERS AND A NEW PARAMETER TO DESCRIBE THE DEGREE OF THEMULTIMERZATIONM. L. Udvardy* (HU), K. Szekeres-Csiki, J. Hársfalvi

PP-TH-634 NOVEL MUTATION IN THE VON WILLEBRAND FACTOR GENE OF TYPE 2 VONWILLEBRAND DISEASE SEEN IN TAIWANM. C. Shen* (TW), B. D. Lin, H. Y. Lin, W. Tsai, J. S. Lin, S. F. Kuo, M. H. Hong, Y. C. Wang

PP-TH-635 NEW AUTOMATED RISTOCETIN COFACTOR ACTIVITY ASSAY TO DISTINGUISH TYPE1 AND TYPE 2 VON WILLEBRAND DISEASE (VWD)M. Piñol, T. Sánchez, M. Sales* (ES), M. Vanrusselt, J. Arnout

PP-TH-636 MOLECULAR ANALYSIS OF TYPE 2 VON WILLEBRAND DISEASE IN IRANIANPATIENTSM. Hashemi Soteh* (IR), M. Jazebi, S. Ravanbod, G. Rastegar-Lari, F. Ala

PP-TH-637 DETECTION OF TYPE 1 VON WILLEBRAND DISEASE WITH INCREASED VONWILLEBRAND FACTOR CLEARANCEM. Meiring* (ZA), P. Setlaba, M. Coetzee



377

PP-TH-638 FUT3 GENE DETERMINING LEWIS BLOOD GROUP ANTIGEN EXPRESSIONINFLUENCES VWF:AG LEVELS IN PLASMAN. Hickson* (UK), D. J. Hampshire, P. R. Winship, P. D. James, I. R. Peake, A. C. Goodeve,on behalf of the EU-VWD and ZPMCB-VWD Study Groups

PP-TH-639 COMPARATIVE ANALYSIS OF VON WILLEBRAND FACTOR MULTIMERS FROM THECANADIAN TYPE 1 VWD STUDYP. James* (CA), C. Hegadorn, J. Grabell, E. Ong, D. Rapson, Association of HemophiliaClinic Directors of Canada, U. Budde, D. Lillicrap

PP-TH-640 DEVELOPMENT OF A CONVENIENT LECTIN-BASED METHOD FOR THEDISCRIMINATION OF PLASMA-DERIVED AND RECOMBINANT VON WILLEBRANDFACTORA. Weber, E. Minibeck, P. L. Turecek* (AT), H. J. Ehrlich, H. P. Schwarz

PP-TH-641 IN VITRO CLEAVAGE OF RECOMBINANT AND PLASMA-DERIVED VWF UNDER STATICCONDITIONS AND UNDER SHEAR STRESSH. Rottensteiner, K. Varadi, S. Vejda, J. Schreiner, H. Gritsch, P. L. Turecek* (AT), H. J.Ehrlich, H. P. Schwarz

PP-TH-642 PURIFICATION AND CHARACTERIZATION OF RECOMBINANT MOUSE VONWILLEBRAND FACTORR. Pendu* (FR), E. Westein, I. Marx, P. J. Lenting, C. V. Denis, O. D. Christophe

PP-TH-643 VWF:AG AND FVIII LEVELS IN THE PATIENTS WITH VON WILLEBRAND DISEASE: ASINGLE CENTER STUDYS. T. Amanat* (PK), N. Ikram, T. Zafar

PP-TH-644 MONITORING OF DIFFERENT VON WILLEBRAND PARAMETERS AFTERADMINISTRATION OF VWF/FVIII-CONCENTRATESS. R. Alesci* (DE), K. Bickhardt, B. Llugaliu, G. Asmelash, W. Miesbach

PP-TH-645 GENETIC CHARACTERISATION OF TYPE 3 VON WILLEBRAND DISEASE IN THENORTH-WEST OF ENGLAND PATIENT POPULATIONM. S. Sutherland, S. Keeney* (UK), P. H. B. Bolton-Maggs, C. R. M. Hay, A. Will, A. M. Cumming

PP-TH-646 CASE REPORT: 7-YEAR OLD PATIENT WITH SEVERE VWD TYPE 3 AND INHIBITORSAGAINST FVIII AND VWFS. Halimeh* (DE), H. Rott, B. Faeser, M. Bicker, S. Eisert, W. Kreuz, H. Laws, U. Budde

PP-TH-647 SUCCESFUL PROPHYLACTIC TREATMENT OF PAEDIATRIC VON WILLEBRANDDISEASE (VWD) TYPE 2 AND 3 WITH TWO DIFFERENT VON WILLEBRAND FACTORCONCENTRATE- A CHORT STUDYS. Halimeh* (DE), H. Rott, A. Kruempel, N. Bogdanova, G. Kappert, U. Nowak-Goettl

PP-TH-648 PREVALENCE OF VON WILLEBRAND DISEASE IN WOMEN WITH MENORRHAGIAN. Hossain, T. Shamsi* (PK), A. A. N. Naz, M. M. B. Borhany

PP-TH-649 DETECTION AND CHARACTERIZATION OF VON WILLEBRAND DISEASE: A CRUCIALSTEP PRIOR TO MAJOR SURGERYV. Proulle* (FR), T. Boutekedjiret, J. Pottecher, C. Court, J. Missenard, M. Dreyfus

PP-TH-650 WHOLE BLOOD IMPEDANCE AGGREGOMETRY: A NEW TOOL FOR VON WILLEBRANDDISEASE CHARACTERIZATIONV. Proulle* (FR), V. Valarche, T. Boutekedjiret, M. Dreyfus

PP-TH-651 PROSPECTIVE CRITERIA FOR SIDE EFFECTS OF DDAVPW. Miesbach* (DE), O. Dück, B. Llugaliu, G. Asmelash, S. Krekeler, J. Schüttrumpf, S. Alesci,R. Grossmann



378

Thur

sday

Pos

ters

PP-TH-652 PERIODONTAL TREATMENT IN A PATIENT WITH AGGRESSIVE PERIODONTITIS ANDVON WILLEBRAND DISEASE: A CASE REPORTW. Miesbach* (DE), P. Eickholz, K. Himmer, S. Alesci, M. Wohlfeil

PP-TH-653 TYPE 2A VON WILLEBRAND DISEASE IN TAIWAN: 2 PATIENTS REPORT WITHFAMILIAL STUDIESY. Chen* (TW), S. Cheng, S. Hu, T. Huang, T. Chao

Other Inherited Coagulation Disorders III

PP-TH-654 MULTICENTRIC EVALUATION OF CURRENT DOSING PRACTICE OF RECOMBINANTFIX IN ITALYA. Lorio* (IT), A. Rocca, S. Pizzinelli

PP-TH-655 THROMBIN GENERATION AND FIBRIN CLOT FORMATION IN PATIENTS WITH SICKLECELL DISEASE (SCD)A. S. Wolberg* (US), C. Amin, S. Adam, A. Kutlar, B. Hulkower, L. Gray, J. Y. Chang, K. I.Ataga, N. S. Key

PP-TH-656 MONITORING OF CARDIAC SURGERY IN FACTOR XI DEFICIENCY: A CASE REPORTA. Siegemund* (DE), J. Oppermann, C. Kämpfert, U. Scholz

PP-TH-657 STRUCTURAL ANALYSIS OF 8 NOVEL AND 109 PREVOUSLY REPORTED MISSENSEMUTATIONS IN THE INTERACTIVE FXI MUTATION DATABASE REVEALS NEW INSIGHTON FXI DEFICIENCYR. E. Saunders, N. Shiltagh, K. Gomez, G. Mellars* (UK), C. Cooper, D. J. Perry, E. G.Tuddenham, S. J. Perkins

PP-TH-658 INHERITED COMBINED DEFICIENCY OF VITAMIN K-DEPENDENT COAGULATIONFACTORS (VKCFD1) DIAGNOSED IN A 54-YEAR-OLD MALEJ. Windyga* (PL), M. Watzka, B. Baran, K. Owczarska, J. Oldenburg

PP-TH-659 PHENOTYPIC AND GENOTYPIC CHARACTERIZATION OF FACTOR VII DEFICIENCYPATIENTS FROM WESTERN INDIAK. Ghosh* (IN), L. Mota, S. Shetty

PP-TH-660 PHENOTYPIC AND GENOTYPIC DIVERSITY OF FACTOR X DEFICIENCY FROMWESTERN INDIAK. Ghosh* (IN), S. Shetty, L. Mota

PP-TH-661 FIRST INDEL MCFD2 MUTATION FROM ARGENTINA AND NOVEL/RECURRENTVARIATIONS IN F5F8D: RESULTS OF A SCREENING STRATEGY BASED ON THEETHNIC ORIGIN OF NINE PATIENTSK. Sittinger* (DE), M. Vega-Ostertag, R. Eisert, E. Seifried, J. Oldenburg, C. Geisen

PP-TH-662 SUCCESSFUL MANAGEMENT OF TWO PATIENTS WITH CONGENITAL FACTOR VIIDEFICIENCY UNDERGOING TONSILLECTOMY WITH RFVIIa - NORMALIZATION OFTHROMBIN GENERATIONM. Krause* (DE), D. Pillitteri, T. Scholz, D. Westrup, C. M. Kirchmaier

PP-TH-663 BRUISING IN INHERITED DISORDERS OF PRIMARY HEMOSTASIS: RESULTS FROM APROSPECTIVE STUDYM. Pai* (CA), G. T. Wang, Y. Liu, K. E. Webert, N. Heddle, C. P. M. Hayward

PP-TH-664 FACTOR XIII DEFICIENCY: EFFECTIVE HAEMOSTASIS DESPITE TREATMENT FOR THEWRONG DIAGNOSISN. R. Farquharson* (UK), R. M. Maclean, K. K. Hampton, S. Kitchen, J. J. van Veen, M.Makris



379

PP-TH-665 RESULTS OF TREATMENT WITH LONG TERM HAEMOCOMPLETTAN IN TWOPATIENTS WITH CONGENITAL AFIBRINOGENEMIA AND MULTIPLE BONE CYSTSP. Brons* (NL), R. Thomson, B. Verbruggen, J. de Rooy, R. Veth

PP-TH-666 FACTOR XIII DEFICIENCY IN A NEWBORN OF A NON CONSANGUINEOUS CAUCASIANCOUPLEP. Lê* (BE), A. Ferster, L. Leenders, A. Tarantino, T. Khalil, M. Demaegd, A. Demulder

PP-TH-667 SEVERE COAGULATION FACTOR X DEFICIENCY CAUSED BY TWO DE NOVELHETEROZYGOUS MISSENSE MUTATIONS IN FACTOR X GENE AND CONSTRUCTIONOF MUTANT EXPRESSION VECTORSR. Zhou* (CN), J. Ou-Yang, D. Chang

PP-TH-668 EFFECT OF CO-INHERITED THROMBOPHILIA GENES ON THE CLINICAL SEVERITY OFRARE BLEEDING DISORDERS SUCH AS FACTOR VII AND FACTOR X DEFICIENCYS. Shetty* (IN), L. Mota, K. Ghosh

PP-TH-669 OCCULT BLOOD COAGULATION DISORDERS AND MASSIVE OBSTETRICALBLEEDINGV. V. Smurygina* (RU), A. D. Makatsarya

PP-TH-670 CHARACTERIZATION OF THE GENETIC BASIS OF FXI DEFICIENCY IN FOURTEENUNRELATED PATIENTSV. Rimoldi* (IT), I. Guella, S. Spena, N. Ciavarella, F. Peyvandi, R. Asselta, P. M. Mannucci,S. Duga

PP-TH-671 STRUCTURAL ANALYSIS OF SIX NOVEL COAGULATION FACTOR XIII SUBUNIT AMISSENSE MUTATIONSV. Ivaskevicius* (DE), V. Schroeder, H. Kohler, H. Rott, P. Petrides, A. Biswas, R. Knoefler, J.Oldenburg

Acquired Coagulation Disorders and DIC III

PP-TH-672 ASSOCIATION BETWEEN ETIOLOGY OF CIRRHOSIS, CHILD’S CLASSIFICATION,PRESENCE OF ASCITES AND CONVENTIONAL COAGULOGRAM, AND THEIMMEDIATE PREOPERATIVE THROMBOELASTOGRAPHIC PROFILES IN PATIENTSSUBMITTED TO LIVER TRANSPLANTATIOND. D. Ribeiro* (BR), T. C. A. Ferrari, A. S. Lima, P. R. S. Rocha

PP-TH-673 PREDICTING FIBRINOLYISIS DURING LIVER TRANSPLANTATION BY CLINICAL ANDLABORATORIAL CHARACTERISTICS OF THE RECEPTOR IMMEDIATELY BEFORE THEBEGINNING OF TRANSPLANTD. D. Ribeiro* (BR), A. S. Lima, M. D. Faria, C. Caram

PP-TH-674 CLINICAL AND LABORATORIAL CHARACTERISTICS OF LIVER TRANSPLANTATIONRECEPTORS AND THEIR RELATION WITH THE USE OF BLOOD PRODUCTSD. D. Ribeiro* (BR), A. S. Lima, M. D. Faria, C. Caram

PP-TH-675 BENEFITS AND RISKS OF RECOMBINANT ACTIVATED FACTOR VII (RFVIIa) INMASSIVE BLEEDING: A SINGLE CENTRE STUDYE. Panizo, R. Lecumberri, P. Rodríguez-Otero, M. Hernández, C. Pegenaute, J. A. Páramo*(ES)

PP-TH-676 MASSIVE PULMONARY EMBOLISM NECESSITATING CARDIOPULMONARYRESUSCITATION IS FREQUENTLY ASSOCIATED WITH OVERT DISSEMINATEDINTRAVASCULAR COAGULATIONJ. M. Leitner* (AT), K. Janata, A. O. Spiel, F. Sterz, A. N. Laggner, B. Jilma



380

Thur

sday

Pos

ters

PP-TH-677 EFFECT OF DIFFERENT TOPICAL AGENTS ON CLOTTING TIMES IN A WHOLE BLOODMODEL OF ACIDOSIS MEDIATED COAGULOPATHYK. A. Moskowitz* (US), D. Manly, N. Mackman

PP-TH-678 EFFECT OF TOPICAL HEMOSTATIC AGENTS ON CLOTTING TIMES IN A WHOLEBLOOD MODEL OF DILUTIONAL COAGULOPATHYK. A. Moskowitz* (US), D. Manly, N. Mackman

PP-TH-679 PATIENTS WITH PULMONARY HYPERTENSION HAVE HIGHER THROMBINGENERATION COMPARED TO ATRIAL FIBRILLATION INDIVIDUALS WITH THE SAMEINRK. P. Hickey* (UK), A. Gatt, P. Sephton, D. G. Kiely, C. A. Elliot, P. C. Cooper, M. Makris

PP-TH-680 ACQUIRED SEVERE BIOLOGICAL VON WILLEBRAND SYNDROME WITHOUTBLEEDING: ROLE OF PLATELET VON WILLEBRAND FACTORM. E. Chollet, C. Caron, B. Boval, S. Bellucci, C. Bal Dit Sollier, A. Hadj-Ali, M. Yakoubi, C.Soria, L. Drouet* (FR)

PP-TH-681 FACTOR V IN PLASMA OF CIRRHOTIC PATIENTS HAS NO SYSTEMATIC VARIATIONBETWEEN LABORATORIES: A MULTICENTER STUDYM. E. Martinuzzo* (AR), G. Cerrato, A. Ruf, F. Cairo, C. Duboscq, S. Ouviña, L. Chavez, F.Villamil, R. Forastiero

PP-TH-682 DYNAMIC CHANGES IN CLOT ELASTIC MODULUS DURING HEMORRHAGIC SHOCK INA SWINE MODELN. J. White* (US), E. J. Martin, K. R. Ward

PP-TH-683 MANAGEMENT OF ACQUIRED HAEMOPHILIA A - A SINGLE CENTRE EXPERIENCEP. Kanagasabapathy* (UK), H. Greensmith, D. H. Bevan, S. Austin

PP-TH-684 ISTH DIC SCORE: INTEREST OF FIBRIN RELATED MARKERS IN ICU PATIENTSP. Cauchie* (BE), S. Ollieuz, B. Woodhams, P. Biston, K. Zouaoui Boudjeltia, N. Deschepper,C. Cauchie, M. Daune

PP-TH-685 ACUTE TRAUMATIC COAGULOPATHY: FUNCTIONAL CHARACTERISATION BYROTATIONAL THROMBOLELASTOMETRYR. A. Davenport* (UK), S. Allard, A. Coates, C. Thiemermann, J. Pasi, R. Pearse, K. Brohi

PP-TH-686 MEASUREMENT OF THE PROCOAGULANT ACTIVITY OF FACTOR VII IN PATIENTSWITH LIVER CIRRHOSIS AND NORMAL PROTHROMBIN ACTIVITY : EVALUATION OFTHE BLEEDING RISKS. Ayaz* (TR), N. Mengi, S. B. Guney

PP-TH-687 CHANGES IN THROMBIN GENERATION KINETICS FOLLOWING SEVEREHEMORRHAGE AND LR RESUSCITATION IN PIGSW. Z. Martini* (US), S. Colvin, M. A. Dubick

PP-TH-688 PATHOLOGICAL FINDINGS OF DIC AND TMA IN A PATIENT WITH BONE MARROWMETASTASIS OF GASTRIC CANCERY. Seki* (JP), K. Wakagi

PP-TH-689 EFFICACY AND SAFETY OF RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN INSEPTIC ANTITHROMBIN SUBSTITUTION-RESISTANT DISSEMINATEDINTRAVASCULAR COAGULATION:RESULTS OF A PILOT STUDYY. Eguchi* (JP), T. Saotome, K. Matsumura, Y. Tsujita, T. Hamamoto, K. Fujino, K. Hayafuji, I.Fuse, S. Furukawa



381

Innovative Therapies for Hemorrhagic Disorders II

PP-TH-690 PERI-INTERVENTIONAL CONTROL OF HEMOSTASIS WITH RECOMBINANT ACTIVATEDFACTOR VII IN A PATIENT WITH COMBINED COAGULATION FACTOR V- AND FACTORVIII-DEFICIENCY AND ANAPHYLAXIS TO FRESH FROZEN PLASMAD. Lechner* (AT), R. Kotz, H. A. Wanivenhaus, P. A. Kyrle, S. Eichinger

PP-TH-691 CORRECTION OF ABNORMAL CLOTTING BY A TOPICAL HEMOSTATIC AGENT IN AWHOLE BLOOD MODEL OF DRUG-INDUCED COAGULOPATHYK. A. Moskowitz* (US), D. Manly, N. Mackman

PP-TH-692 LOW-DOSE RECOMBINANT FACTOR VIIa FOR LIFE-THREATENING BLEEDING ISEFFICACIOUS EVEN AT LOW FIBRINOGEN LEVELSP. Schmid, A. Mordasini, B. Laemmle, L. Alberio* (CH)

PP-TH-693 COMPARATIVE STUDY OF THE HEMOSTATIC POTENCY OF THREE PREPARATIONSOF THERAPEUTIC PLASMAM. Hacquard* (FR), B. Belcour, T. Lecompte, T. Schneider

PP-TH-694 SORAFENIB IS A FEASIBLE THERAPEUTIC OPTION IN HAEMOPHILIACS WITHHEPATOCELLULAR CARCINOMAM. Lapecorella* (IT), M. Napolitano, M. Tudini, G. Bruera, A. Lucchesi, A. V. Giordano, G.Mariani, E. Ricevuto

PP-TH-695 BEDSIDE POINT OF CARE COAGULATION TESTING FOR INDIVIDUALIZEDANTIVITAMIN K REVERSAL IN EMERGENCY SURGERYU. Schott* (SE), D. Winstedt, P. Anveden

PP-TH-696 CONSTRUCTION OF A NEW HELPER VECTOR FOR THE PRODUCTION OF HELPER-DEPENDENT ADENOVECTORS FOR THE USE IN HEMOPHILIA A GENE THERAPYZ. A. Aburubaiha* (DE), M. Srour, H. Fenchner, J. Oldenburg, R. Schwaab



382

383

NursingProgram

ISTH2009

The Nursing Program at ISTH 2009 provides a forum for nurses world-wide toidentify issues that directly impact their role pertaining to disorders ofhemostasis and thrombosis in both pediatric and adult populations. The goalis to provide free exchange of knowledge, experience, and practice patternsneeded to standardize and improve the quality of hands-on participation in theart and science of medicine focused on disorders of hemostasis andthrombosis.

384

Nursing Program

Nur

sing

Pro

gram

385

SATURDAY, JULY 11, 2009 12:00 PM - 2:00 PM

Nursing Committee Meeting Room 204 AB

Mission and Future SessionsDivision of Workload

MONDAY, JULY 13, 2009 12:30 PM - 2:15 PM

A Workshop on Bleeders and Clotters in Pediatric and Adult

Populations: Challenges in Treatment Management Room 204 AB

Moderators: Maura Malone (US), Fiona Newall (AU)

Welcome and IntroductionMaura Malone (US) 12:30 - 12:35 PM

Nurse driven research-nurses as PIFiona Newall (AU) 12:35 - 12:45 PM

A review of incidence of Intracranial Hemorrhage in bleeding and clotting disorders and long-term implicationsJen Maahs (US) 12:45 - 1:00 PM

Managing an infant with mitral valve replacement on warfarinKathy Harney (US) 1:00 - 1:10 PM

Iron reduction for paroxysmal atrial fibrillation in hemophilia ALaurel Mckernan (US) 1:10 - 1:20 PMQ&A Discussion 1:20 - 1:25 PMBreak 1:25 - 1:35 PMCase TBDDebi Smith (NZ) 1:35 - 1:45 PMVenous stasis ulcer in pediatric patient with post- phlebitic syndrome (selected abstract for oral presentation)Darlene Castles (CA) 1:45 - 1:55 PMMenorrhagia: alternative treatment regimens considered for patients with hemostasis and thrombosis disordersRuthann Kirschman (US) 1:55 - 2:05 PMQ&A DiscussionFiona Newall (AU) 2:05 - 2:10 PMClosing Remarks / Evaluations / Topic Suggestions 2:10 - 2:15 PMMaura Malone (US)

TUESDAY, JULY 14, 2009 12:30 PM - 2:15 PM

Haemostasis and Thrombosis: Partners for Adolescent Care:

Adherence and Transition Challenges Room 204 AB

Moderators: Mary Bauman (IE), Anna O'Sullivan (IE)

Welcome and IntroductionMary Bauman (CA) 12:30 - 12:35 PM

Psycho social issues of adolescents with chronic illness (selected abstract for oral presentation)Anna O'Sullivan (IE) 12:35 - 12:45 PM

Development of a Quality of Life tool in children with chronic illnessAisha Bruce (CA) 12:45 - 12:55 PM

Cultural challenges in translation and application of QOL toolsCindy Wakefield (CA) 12:55 - 1:05 PM

Challenges for managing the athletic adolescent clotterMarilyn Blumstein (US) 1:05 - 1:15 PM

Patient education and knowledge transfer(selected abstract for oral presentation)Rebecca Goldsmith (US) 1:45 - 1:55 PM

Q & A Discussion 1:25 - 1:30 PM

Break 1:30 - 1:35 PM

Adolescents with/or at risk for thrombosis: Transition to adult careKarina Black (US) 1:35 - 1:45 PM

Hemostasis: Transition Programs ReviewedRhonda Fritz (US) 1:45 - 1:55 PM

Optimizing Adherence Regina Butler (US) 1:55 - 2:05 PM

Q&A DiscussionAnna O'Sullivan (IE) 2:05 - 2:10 PM

Closing Remarks, Evaluations / Topic SuggestionsMary Bauman (CA) 2:10 - 2:15 PM

386

Nur

sing

Pro

gram

387


Controversies in Thrombosis and Hemostasis Room 204 AB

Moderators: Bunis Packman (UK), Kathy Harney (US)

Welcome and IntroductionBunis Packman (UK) 12:30 - 12:35 PM

Standard thromboprophylaxis for all patients admitted into hospital: National standards reviewedBunis Packman (UK) 12:35 - 12:45 PM

US: Joint Commission: Patient Safety Goals Chris A. DiPaola (US) 12:45 - 12:55 PM

Q&A Discussion 12:55 - 1:00 PM

Break 1:00 - 1:10 PM

Moderators: Regina Butler (US), Marie Mahoney (US))

Toward standard disease management for hemophiliaJen Maahs (US) 1:10 - 1:30 PM

The American Thrombosis and Hemostasis Network (ATHN): one model of a secured national data base for bleeding and clotting disorders: a look at the pros and consPam Bryant (US) 1:30 - 1:40 PM

Pharmacogenomics: Determining Coumadin sensitivity/resistance with blood tests - should this be done prior to initiation of therapy?Lory Luchtman (CA) 1:40 - 1:50 PM

Don't see Red: Complementary Alternative Medicines (CAM) in patients with coagulopathies(selected abstract for oral presentation)Mary Bauman (CA) 1:50 - 2:00 PM

Q&A DiscussionMarie Mahoney (US) 2:00 - 2:10 PM

Closing Remarks, Evaluations / Topic Suggestions 2:10 - 2:15 PMRegina Butler (US)

NO

TE

S

389

SpecialSymposia

ISTH2009

390

Special SymposiaSpecial Symposia take place on:

SUNDAY, JULY 12, 2009 12:30 PM - 2:30PM

Scienta Healthcare Education® Room 205 ABCSupported by an educational grant from Baxter

Bayer HealthCare Room 253 ABC

sanofi-aventis (US) Room 258 ABC

SUNDAY, JULY 12, 2009 3:15 PM - 5:15 PM

Octapharma AG (CH) Room 205 ABC

Medscape LLCSupported by an educational grant Room 258 ABCfrom sanofi-aventis

MONDAY, JULY 13, 2009 6:30 PM - 8:00 PM

Scienta Healthcare Education®Supported by Baxter Healthcare Room 205 ABC

Bayer HealthCare AG and Ortho-McNeilPharmaceuticals Inc. Division of Ortho-McNeilJanssen Pharmaceuticals, Inc., administered byOrtho-McNeil Janssen Scientific Affairs, LLC. Room 156 ABC

Potomac Center for Medical Education Room 258 ABCSupported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

CSL Behring Room 107 ABC

ACCELMED® and Postgraduate Institute for Medicine®Supported by an educational grant from Room 104 ABCDaiichi Sankyo Inc. and Lilly USA, LLC

Grifols International Room 160 ABC

Network for Continuing Medical EducationSupported by an unrestricted educational grant Room 253 ABCfrom Novo Nordisk Healthcare AG

Stago Room 153 ABC

Wyeth Pharmaceuticals Room 204 AB

Spec

ial S

ympo

sia

SUNDAY, JULY 12, 2009 12:30 PM - 2:30PM

Sponsored by Scienta 12:30 PM - 2:30 PM Room 205 ABC

Healthcare Education®

Supported by an educational grant from Baxter

Update on Factor VIII Immunogenicity: Risk Factors, Prediction Modeling, and Implications for Clinical Practice

Chairperson: Gilbert C. White II (US)

Welcome and introductionsGilbert C. White II (US) 12:30 - 12:40 PM

Risk factors for development of Factor VIII inhibitorsJan Astermark (SE) 12:40 - 1:10 PM

Prediction models for inhibitor development in previously untreated patientsJohanna G. van der Bom (NL) 1:10 - 1:40 PM

Improving and utilizing prediction models: implications for clinical research and practiceGilbert C. White II (US) 1:40 - 2:10 PM

Concluding remarksGilbert C. White II (US) 2:10 - 2:15 PM

Questions and answersChairperson and faculty 2:15 - 2:30 PM

391

SUNDAY, JULY 12, 2009 12:30 PM - 2:30 PM

Bayer HealthCare 12:30 PM - 2:30 PM Room 253 ABC

Hemophilic Arthropathy: New Insights into Mechanisms, Prevention, and Management

Chairperson: Leonard A Valentino (US)

Welcome and introduction Leonard A Valentino (US) 12:30 - 12:35 PM

Biology of joint disease Leonard A Valentino (US) 12:35 - 1:00 PM

Reducing joint bleeding and arthropathy in children Marilyn Manco-Johnson (US) 1:00 - 1:25 PM

When medical management fails to prevent arthropathy Carlos Rodriguez-Merchan (ES) 1:25 - 1:50 PM

Clinical investigations of long-acting rFVIII formulation and improved rFVIIa product Georg Lemm (DE) 1:50 - 2:00 PM

Next-generation coagulation factors John Murphy (US) 2:00 - 2:10 PM

Questions and discussion Panel 2:10 - 2:25 PM

Concluding remarks Leonard A Valentino (US) 2:25 - 2:30 PM

sanofi-aventis US 12:30 PM - 2:30 PM Room 258 ABC

Across the Clinical and Temporal Continuum: Defining Successful Strategies for Venous Thromboprophylaxis

Chairpersons: Ajay K. Kakkar (UK) and Samuel Z. Goldhaber (US)

Welcome and IntroductionSamuel Z. Goldhaber (US) 12:30 - 12:35 PM

Clinical presentations and mechanisms of thrombogenesis in VTE:implications for therapyHenri Bounameaux (CH) 12:35 - 12:50 PM

392

Spec

ial S

ympo

sia

SUNDAY, JULY 12, 2009 12:30 PM - 2:30 PM

Learning from our failures: Lessons from the registriesVictor Tapson (US) 12:50 - 1:05 PM

Defining clinical strategies for improving thromboprophylaxisSamuel Z. Goldhaber (US) 1:05 - 1:20 PM

Thromboprophylaxis in special populationsAjay K. Kakkar (UK) 1:20 - 1:35 PM

Approaching pharmacologic prophylaxisRoger D. Yusen (UK) 1:35 - 1:50 PM

Panel discussion / Questions and answersModerator: Ajay K. Kakkar (UK) 1:50 - 2:25 PM

Concluding remarksAjay K. Kakkar (UK) 2:25 - 2:30 PM

SUNDAY, JULY 12, 2009 3:15 PM - 5:15 PM

Octapharma AG (CH) 3:15 PM to 5:15 PM Room 205 ABC

Prevention and Eradication of FVIII Inhibitors: Bridging Lab and Field Research

Chairpersons: Georges E. Rivard (CA) and David Lillicrap (CA)

Welcome and introduction Georges E. Rivard (CA) and David Lillicrap (CA) 3:15 - 3:20 PM

Immune response to FVIIIDavid Lillicrap (CA) 3:20 - 3:35 PM

After a 30-year experience with immune tolerance therapy. Still room for improvement?Wolfhart Kreuz (DE) 3:35 - 3:55 PM

Can inhibitor profile and thrombin generation assay help optimize individual immune tolerance induction treatment? Christoph Königs (DE) 3:55 - 4:10 PM

Immune monitoring of Haemophilia A patients undergoing immune tolerance inductionSebastien Lacroix-Desmazes (FR) 4:10 - 4:25 PM

393

SUNDAY, JULY 12, 2009 3:15 PM - 5:15 PM

How I prevent and treat FVIII inhibitors in Hemophilia A patients Georges E. Rivard (CN) 4:25 - 4:45 PM

Incidence of FVIII inhibitors in PUPs with hemophilia Carmen Escuriola-Ettingshausen (DE) 4:45 - 5:00 PM

Concluding remarks Georges E. Rivard (CA) and David Lillicrap (CA) 5:00 - 5:05 PM

Questions and answersChairperson and Faculty 5:05 - 5:15 PM

Medscape LLC 3:15 PM - 5:15 PM Room 258 ABC

Supported by an educational grant from sanofi-aventis

Meeting the Challenges in Long-Term Anticoagulation: Opportunities to Improve Patient Care

Chairpersons: Elaine Hylek (US) and Ander Cohen (UK)

Welcome and introduction Elaine Hylek (US) 3:15 - 3:20 PM

Real world, real patients: Understanding the burden of venous and arterial thromboembolic diseasesGreg Lip (UK) 3:20 - 3:40 PM

Recognizing the gaps: Opportunities for addressing the patient's need and improving the continuum of careElaine Hylek (US) 3:40 - 4:00 PM

Emerging treatment options in long-term anticoagulation: Gateway to the future of clinical careAnder Cohen (UK) 4:00 - 4:20 PM

New and ongoing anticoagulant trials: what does the future hold?Jack Ansell (US) 4:20 - 4:40 PM

Panel Discussion (Questions and answers) 4:40 - 5:00 PM

Concluding remarks Ander Cohen (UK) 5:00 - 5:15 PM

394

Spec

ial S

ympo

sia

Supported by Scienta 6:30 PM - 8:00 PM 205 ABC

Healthcare Education®

Supported by an educational grant from Baxter

Challenges in Clinical Decision-Making for Patients with Hemophilia A and Inhibitors: The Role of Laboratory Assays

Chairperson: Claude Negrier (FR)

Introduction: Challenges in clinical decision-making for patients with hemophilia A and inhibitors Claude Négrier (FR) 6:30- 6:45 PM

Validating the role of thromboelastography and the thrombin generation: Assay for routine clinical care in inhibitor patients Yesim Dargaud (FR) 6:45- 7:15 PM

New insights into laboratory monitoring: Novel assays for monitoring bypassing therapyKenneth Mann (US) 7:15 - 7:45 PM

Questions and answers 7:45 - 8:00 PM

Bayer HealthCare AG and 6:30 PM - 8:00 PM 156 ABC

Ortho-McNeil Pharmaceuticals Inc. Division of

Ortho-McNeil Janssen Pharmaceuticals, Inc.,

administered by Ortho-McNeil Janssen Scientific Affairs, LLC

Meeting the Unmet Needs in Anticoagulant Therapy

Chairpersons: Jeffrey I. Weitz (CA) and Harry R. Büller (NL)

Welcome and introductionJeffrey I. Weitz (CA) 6:30 - 6:40 PM

Extended thromboprophylaxis: Defining the case, refining the approachAlexander G.G. Turpie (CA) 6:40 - 7:00 PM

395

MONDAY, JULY 13, 2009 6:30 PM - 8:00 PM

Advancing the treatment of VTE Harry R. Büller (NL) 7:00 - 7:20 PM

Long-term anticoagulation in cardiovascular indications: Where do we go from here?C. Michael Gibson (US) 7:20 - 7:40 PM

Panel Discussion / Questions and answersGiancarlo Agnelli (IT) 7:40 - 7:55 PM

Concluding remarksGiancarlo Agnelli (IT) 7:55 - 8:00 PM

Potomac Center for Medical Education 6:30 PM - 8:00 PM 258 ABC

Supported by an educational grant from Boehringer Ingelheimpharmaceuticals, Inc.

Thrombosis and Thromboembolism: Emerging Therapies

Chairperson: John Heit (US)

Welcome and introduction

Anticoagulants and antithrombotics: The current situationJohn Heit (US) 7:00 - 7:10 PM

Therapies for stroke prevention in atrial fibrillationGiuseppe Di Pasquale (IT) 7:10 - 7:30 PM

Therapies for prevention and treatment of venous thromboembolismShannon Bates (US) 7:30 - 7:50 PM

Questions and answersAll faculty 7:50 - 8:00 PM

396

MONDAY, JULY 13, 2009 6:30 PM - 8:00 PM

Spec

ial S

ympo

sia

CSL Behring GmbH 6:30 pm - 8:00 pm 107 ABC

Diagnosis and Management of Inherited von Willebrand Disease in the Next Decade: A Clinical Perspective

Chairpersons: Peter Kouides (US) and Wolfhart Kreuz (DE)

Welcome and introductionPeter Kouides (US) and Wolfhart Kreuz (DE) 6:30 - 6:40 PM

Classification of von Willebrand disease and implications in clinical practice Augusto Federici (IT) 6:40 - 7:00 PM

Awareness and diagnosis of von Willebrand disease: state of the art Andra James (US) 7:00 - 7:20 PM

Haemate P/ Humate-P: A systematic reviewErik Berntorp (SE) 7:20 - 7:40 PM

The role of prophylaxis in the management of von Willebrand disease: Today and tomorrowThomas Abshire (US) 7:40 - 8:00 PM

ACCELMED® and Postgraduate 6:30 PM-8:00 PM 104 ABC

Institute for Medicine®

Supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

Variability, Testing, and Treatment: What is the Future of Antiplatelet Therapy?

Chairperson: Paul A.Gurbel (US)

Welcome and OverviewPaul A. Gurbel (US) 6:30 - 6:35 PMAntiplatelet respons variability: A review of the literaturePaul A. Gurbel (US) 6:35 - 7:00 PMPlatelet function testing: The future standard of care?Gilles Montalescot (FR) 7:00- 7:15 PM Emerging antiplatelet therapies: The potential impact on response variabilityPaul A. Gurbel (US) 7:15 - 7:40 PMQuestions and answers Panel discussion 7:40 - 8:00 PM

397

MONDAY, JULY 13, 2009 6:30 PM - 8:00 PM

Grifols 6:30 PM - 8:00 PM Room 160 ABC

Managing Hemophilia B: How can we Optimize Treatment from a Laboratory and Clinical Perspective?

Chairperson: Lou M. Aledort (US)

Welcome and introduction Lou M. Aledort (US) 6:30 - 6:40 PM

Grifols' Factor IX concentrates: New findings in biochemical characteristics and safety profilesSteve Herring (US) 6:40 - 6:55 PM

New insights from Factor IX activation studies with chromogenic assays What are the implications of disparate results between different products?Trevor Barrowcliffe (UK) 6:55 - 7:10 PM

Clinical challenges in hemophilia B patients undergoing surgery, when a reliable Factor IX level is required. Doris Quon (US) 7:10 - 7:30 PM

Prophylaxis in hemophilia B patients: Unresolved issues andpharmacoeconomic implications.Elena Santagostino (IT) 7:30 - 7:50 PM

Concluding remarks Lou M. Aledort (US) 7:50 - 7:55 PM


398

MONDAY, JULY 13, 2009 6:30 PM - 8:00 PM

Spec

ial S

ympo

sia

Network for Continuing 6:30 PM - 8:00 PM Room 253 ABC

Medical Education

Supported by an unrestricted educational grant from Novo Nordisk Health Care AG

Applying the Latest Clinical Trial Data to Control Bleeding in the Management of Haemophilia Patients with Inhibitors

Chairperson: Nigel Key (US)

Welcome and introduction Nigel Key (US) 6:30 - 6:35 PM

Clot structure/stability, histology, anatomy, and inflammatory status in patients with haemophilia with inhibitors: May choice and dosage of by-passing agent play a role?Nigel Key (US) 6:35 - 6:55 PM

An update of clinical studies in by-passing therapy of inhibitor HaemophiliaGili Kenet (IL) 6:55 - 7:15 PM

Early on-demand treatment versus prophylaxis for patients with haemophilia with inhibitors Guy Young (US) 7:15 - 7:35 PM

Monitoring by-passing agents: achievements and future challengesBenny Sørensen (DK) 7:35 - 7:55 PM


Stago 6.30 PM - 8:00 PM Room 153 ABC

Thrombosis, Inflammation and Haemostasis: Is it Time to Revisit the Concept?

Chairperson: Françoise Dignat-George (FR)

Welcome and introduction Françoise Dignat-George (FR) 6:30 - 6 :35 PM

399

MONDAY, JULY 13, 2009 6:30 PM - 8:00 PM

The vessel wall and its interaction Paul S. Frenette (US) 6:35 - 7:00 PM

Platelets and inflammation Alan Nurden (FR) 7:00 - 7:25 PM

The protein C pathway: The interface between coagulation and inflammationCharles T. Ermon (US) 7:25 - 7 :50 PM

Panel discussionModerator: Françoise Dignat-George (FR) 7:50 - 8 :00 PM

Wyeth Pharmaceuticals 6.30 PM - 8:00 PM Room 204 AB

Hemophilia Treatment: The Past, Present & Future

Chairperson: Christopher Ludlam ((UK)

Chairperson’s Welcome and IntroductionChristopher Ludlam (UK) 6:30 - 6:35 PM

An early history of hemophilia and product developmentJeanne Lusher (US) 6:35 - 6:45 PM

Clinical perspectives of pathogens in bleeding disorders Christopher Ludlam (UK) 6:45 - 7:05 PM

Prions: Another reason for robust pharmacovigilanceJames Ironside (UK) 7:05 - 7:25 PM

Strategies for addressing the safety of treatment in bleeding disordersRiita Lassila (FI) 7:25 - 7:40 PM

Concluding Questions and answers Christopher Ludlam (UK) 7:40 - 7:55 PM

Chairperson’s SummaryChristopher Ludlam (UK) 7:55 - 8:00 PM

400

MONDAY, JULY 13, 2009 6:30 PM - 8:00 PM

401

SatelliteSymposia

ISTH2009

Satellite Symposia

Satellite Symposia take place on:


Biomérieux Room 153 ABC

CMEducation Resources, LLCSupported by an educational grant Room 157 ABCfrom BMS

CMEducation Resources, LLCSupported by an educational grant Room 160 ABCfrom EISAI

CSL Behring GmbH Room 104 ABC

Loyola University Chicago Room 107 ABC

Institute for Medical Studies (CME provider)Supported by an educational grant Room 205 ABCfrom Lundbeck Inc.

Octapharma AG (CH) Room 253 ABC

Siemens Room 156 ABC

Wyeth Pharmaceuticals Room 204 AB

402

Sate

llite

Sym

posi

a

Biomérieux 6:30 PM -8:00 PM Room 153 ABC

D-dimer in the Management of Venous Thromboembolism (VTE): Current and Future Perspectives

Chairperson: Arnaud Perrier (CH)

IntroductionArnaud Perrier (CH) 6:30 - 6:40 PM

What makes a good D-dimer assay for VTE exclusion?Guido Reber (CH) 6:40 - 7:00 PM

How should the clinician use D-dimer in the diagnosis of VTE?Grégoire Le Gal (FR) 7:00 - 7:20 PM

Is there a role for D-dimer to determine the duration of anticoagulant therapy in unprovoked VTE?Marc Roger (CN) 7:20 - 7:40 PM

DiscussionModerator: Arnaud Perrier (CH) 7:40 - 7:50 PM

Questions and answersModerator: Arnaud Perrier (CH) 7:50 - 8:00 PM

CMEducation Resources, LLC 6:30 PM - 8:00 PM Room 157 ABC

Supported by an educational grant from BMS

The Practical and Research Dimensions of VTE Prevention and Management in Cancer and Associated Conditions

Chairperson: John H. Alexander (US)

Welcome and Introduction - Goals and objectives of program

Prophylaxis of thromboembolism across the arteriovenous risk spectrum: VTE, acute coronary syndrome, and atrial fibrillation- new challenges and emerging advances for the cardiovascular and thrombosis specialistStavros Konstantinides (DE) 6:30 - 6:45 PM

403


The emerging role of factor Xa inhibition in the setting of cardiovascular disease and VTE: Novel approaches to residual risk reductionDeepak L. Bhatt (US) 6:45 - 7:10 PM

Acute Coronary Syndrome (ACS) - Achieving effective prevention of thrombosis-related events: Factor Xa inhibition and the optimal balancebetween anti-ischemic efficacy and bleeding risk reduction John H. Alexander (US) 7:10 - 7:35 PM

Challenges and new dimensions to stroke prevention in the setting of Atrial Fibrillation: Current deficiencies and future opportunitiesSunil V. Rao (US) 7:35 - 7:55 PM

Questions and answers:Faculty and participants debate results and implications of current trials focused on factor Xa inhibitionModerator: Stavros Konstantinides (DE) 7:55 - 8:00 PM

CMEducation Resources, LLC 6:30 PM - 8:00 PM Room 160 ABC

Supported by an educational grant from EISAI

The Practical and Research Dimensions of VTE Prevention andManagement in Cancer and Associated Conditions: Focus onOptimal, Best Practice Strategies for DVT Management in theInpatient and Outpatient Setting

Chairperson: Craig M. Kessler (US)

Welcome and introduction

Clotting and cancer: Controversies and questions-critical challenges and landmark advances in venous thromboembolism (VTE)-A look at the contemporary landscapeCraig M. Kessler (US) 6:30 - 6:45 PM

404


Sate

llite

Sym

posi

a

The interface of cancer and coagulation: The evolving science, research, and foundation role of low molecular weight heparin (LWMH) in malignancypreventing VTE and optimizing mortality outcomes with pharmacologic agents in the setting of malignancy-What does the research tell us about LMWHs?Craig M. Kessler (US) 6:45 - 7:10 PM

Cancer, thrombosis, and the biology of malignancy: A science-to-clinical strategy perspective-how do clinical trials guide us?

Approaches to optimizing DVT prophylaxis in the setting of cancer at the front lines of patient care-focus on LMWHs and evidence-based medicineFrederick Rickles (UK) 7:10 - 7:35 PM

VTE prophylaxis in the cancer patient-national guidelines NCCN, ASCO, and ACCP)

Optimizing long-term VTE prevention at the front lines of practice: Focus on compliance, challenging patients, and special populations Edith Nutescu (US) 7:35 - 7:55 PM

Questions and answers

International experts in thrombosis and cancer articulate, illuminate and debate key issues

Interactive analysis of case-based management of patients with cancer and VTEModerator: Craig M. Kessler (US) 7:55 - 8:00 PM

405


CSL Behring GmbH 6:30 PM - 8:00 PM Room 104 ABC

Treatment of Congenital Bleeding Disorders: Future Trends in Management

Chairpersons: Pier Mannucci (IT) and Donna DiMichele (US)

Welcome and introductionPier Mannucci (IT) and Donna DiMichele (US) 6:30 - 6:40 PM

Visions in hemophilia careSteven Pipe (US) 6:40 - 7:00 PM

Half-life extension through albumin fusion technologiesStefan Schulte (DE) 7:00 - 7:20 PM

Results of international, multi-center pharma-cokinetics trial in congenital fibrinogen deficiencyFlora Peyvandi (IT) 7:20 - 7:40 PM

Cryo: no longer the best choice for congenital Factor Deficiencies?David Bevan (UK) 7:40 - 8:00 PM

Loyola University Chicago 6:30 PM - 8:00 PM Room 107 ABC

Anticoagulant Therapy in Transition. Heparin and Oral Anticoagulants Challenged

Chairpersons: Lilia Talarico (US) and Charles Francis (US)

Moderator: Gary Raskob (US)

Welcome and introductionRichard Kennedy (US) 6:30 - 6:40 PM

Newer developments in heparin related drugs from heparin to pentasaccharidesJawed Fareed (US) 6:40 - 6:55 PM

Future oral anticoagulants in the next decadeHenry I. Bussey (US) 6:55 - 7:10 PM

Antithrombin and anti-factor Xa drugs. Current developmentsCharles Francis (US) 7:10 - 7.25 PM

406


Sate

llite

Sym

posi

a

Newer and conventional anticoagulants in the management of thrombosisJob Harenberg (US) 7:25 - 7:40 PM

Transitions in anticoagulant therapy. What do we learn from clinical trials?Russell Hull (CN) 7:40 - 7:55 PM

Concluding remarksGary Raskob (US) 7:55 - 8:00 PM

Institute for Medical Studies 6:30 PM - 8:00 PM Room 205 ABC

(CME Provider)

Supported by an educational grant from Lundbeck Inc.

Exploring the Diverse Role of Antithrombin Deficiency in Thromboembolic Disease

Chairperson: Stephan Moll (US)

Welcome and introduction Stephan Moll (US) 6:30 - 6:35 PM

Defining unmet pathologic and clinical needs involving antithrombin disordersStephan Moll (US) 6:35 - 6:50 PM

Clinical issues in patients at riskMichael J. Paidas (US) 6:50 - 7:05 PM

Acquired antithrombin deficiency associated with cardiac surgery and cardiopulmonary bypassJerrold H. Levy (US) 7:05 - 7:25 PM

Dosing strategies of antithrombin to optimize safety and efficacyR. Campbell Tait (UK) 7:25 - 7:40 PM

DiscussionModerator: Stephan Moll (US) 7:40 - 7:55 PM

Concluding remarks Stephan Moll (US) 7:55 - 8:00 PM

407


Octapharma AG (CH) 6:30 PM - 8:00 PM Room 253 ABC

From Human to Humans - Introducing the First Recombinant FVIII Produced From a Human Cell-Line

Chairpersons: Edward G.D. Tuddenham (UK) and Johannes Oldenburg (DE)

Welcome and introduction Edward G.D. Tuddenham (UK) 6:30 - 6:40 PM

The human cell-line as a superior expression system - what are the benefits?Christoph Kannicht (DE) 6:40 - 7:00 PM

Characterization and functional properties of the new human cell-line derived recombinant FVIII Irene Agerkvist (SE) 7:00 - 7:20 PM

The clinical development of the first recombinant FVIII from a human cell-lineSigurd Knaub (DE) 7:20 - 7:35 PM

First clinical experiences from a crossover pharmacokinetic studyNadezhda Zozulya (RU) 7:35 - 7:45 PM

Concluding remarksJohannes Oldenburg (DE) 7:45 - 7:50 PM

Questions and answersAll Faculty 7:50 - 8:00 PM

Siemens 6:30 PM - 8:00 PM Room 156 ABC

Beyond the Clot - Innovations Targeting Primary and Secondary Hemostasis in Cardiovascular Disease

Chairperson: Thomas Kickler (US)

Welcome and introduction Thomas Kickler (US) 6:00 - 6:35 PM

Targeting platelets in acute experimental strokeBernhard Nieswandt (DE) 6:35 - 7:00 PM

408


Sate

llite

Sym

posi

a

Markers of platelet hyper-reactivity and aspirin resistance predict early vein graft thrombosis after coronary artery bypass surgeryJeffrey Rade (US) 7:00 - 7:25 PM

New anticoagulants, thrombocyte antagonists and plasma expanders: How do they influence diagnostics?Edelgard Lindhoff-Last (DE) 7:25 - 7:50 PM

Questions and answersModerator: Thomas Kickler (US) 7:50 - 8:00 PM

Wyeth Pharmaceuticals 6:30 PM - 8:00 PM Room 204 AB

Recombinant Therapy and Advances in Manufacturing and Purification Processes

Chairperson: Robert Janco (US)

Chairperson's Welcome and IntroductionRobert Janco (US) 6:30 - 6:35 PM

The history of recombinant therapyJørgen Ingerslev (DK) 6:35 - 6:50 PM

Modifications in factor manufacturing processesBrian Colvin (US) 6:50 - 7:10 PM

Recombinant therapy in clinical practiceVictor Blanchette (CA) 7:10 - 7:40 PM

Concluding Questions and Answers Robert Janco (US) 7:40 - 7:55 PM

Chairperson's SummaryRobert Janco (US) 7:55 - 8:00 PM

409


NO

TE

S

411

TechnicalSymposiaSessions

ISTH2009

Technical Symposia

Technical Sessions take place on:


Rovi Room 104 ABC

Network for Continuing Medical Education Room 107 ABCSupported by an unrestricted educational grant from Novo Nordisk Healthcare AG

412

Tech

nica

l Sym

posi

a Se

ssio

ns

Rovi 6:30 PM - 7:30 PM Room 104 ABC

Latest Advances in Cancer and Low Molecular Weight Heparins

Chairperson: Vijay Kakkar (UK)

Welcome and introductionVijay Kakkar (UK) 6:30 - 6:35 PM

Scientific guidelines on thromboprophylaxis in cancer surgeryVijay Kakkar (UK) 6:35 - 6:50 PM

Prolonged thromboprophylaxis with bemiparin in cancer surgeryPaolo Prandoni (IT) 6:50 - 7:15 PM

Effects of low molecular weight heparin in cancerAna Falanga (IT) 7:15 - 7:25 PM

Concluding remarksVijay Kakkar (UK) 7:25 - 7:30 PM

413


Network for Continuing 6:30 PM - 7:30 PM Room 107 ABC

Medical Education

Supported by an unrestricted educational grant from Novo Nordisk Healthcare AG

Evolving Pathogenic Threats to the Global Blood Supply: Impact an Haemophilia Treatment

Chairperson: Roshni Kulkarni (US)

Welcome and introductionRoshni Kulkarni (US) 6:30 - 6:35 PM

Blood supply safety issues, emerging pathogens and surveillance– The US picture– The global pictureRoger Y. Dodd (US) 6:35 - 6:50 PM

The UK experience with variant Creutzfeldt-Jakob disease and surveillanceMaura Ricketts (CN) 6:50 - 7:05 PM

Current and emerging recombinant clotting factors for aemophilia with and without inhibitorsRoshni Kulkarni (US) 7:05 - 7:20 PM

Question and answer session and panel discussionAll faculty 7:20 - 7:30 PM

414


415

ExhibitionandSponsors

ISTH2009

416

Sponsors ISTH 2009 would like to thank the following

PLATINUM SPONSORS

GOLD SPONSORS

417

Exhi

biti

on a

nd S

pons

ors

Sponsors ISTH 2009 would like to thank the following

SILVER SPONSORS

BRONZE SPONSORS

Loyola UniversityMedical Center

418

ISTH 2009 Partners

4 S Dawn Clinical SoftwareAccumetricsAffinity BiologicalsAmerican Diagnostica Inc.AstraZenecaArteriosclerosis , Thrombosis and

Vascular BiologyBeckman Coulter Inc.Bio / Data CorporationBio Products LaboratoryBiocascade Inc.Biogen Idec HemophiliaBiomérieuxBiotest AGBiovitrumChrono-log Corp.Corgenix Inc.Diapharma Group Inc.ElsevierEnzyme Research Laboratories Inc.Esoterix Inc.Fluxion BiosciencesGTI DiagnosticsHaematologic Technologies Inc.Haemonetics Corp.HPS NetworkHyphen Biomed SASInnovative Research

Intelligent Imaging Innovations Inc.Inverness MedicalInvitrox Inc.ISTH ISTH 2011Journal of Thrombosis and HaemostasisKedrionMedirox ABMLTD & MLTD FoundationMultitplate Services GmbHNHLBI-NIHNorth American Thrombosis ForumNovo Nordisk Haemophilia FoundationPentapharm DSM Nutritional Products AGPrecision Biologic Inc.R2 Diagnostics Inc.Roche Diagnostics GmbHRotem Inc.S. Karger Publishers Inc.Saringer Life Science Technologies IncSchattauer GmbHSSC 2010Syntonix SubsidiaryTechnoclone GmbHThrombinoscope BVTrinity Biotech PLCVascular Disease FoundationWiley Blackwell World Federation of Hemophilia

POST

ERS

ARE

A

FOO

D C

OU

RT

REG

ISTR

ATIO

N A

REA

MA

IN E

NTR

AN

CE &

EXI

T

ENTR

AN

CETO

PO

STER

ARE

AW

HEN

EXH

IBIT

ION

IS C

LOSE

D

HO

SPIT

ALI

TY S

UIT

ESExhibition Area

An Exhibition is held concurrently with the ISTH 2009 Congress. The coffee break and lunchareas are located adjacent to the booths. Thanks to exhibitors from all over the world,attendees will have a complete overview of new findings in the domain of Vascular Medicine,Thrombosis and Haemostasis.

Exhi

biti

on a

nd S

pons

ors

419

4 S Dawn Clinical Software 867Accumetrics 917Affinity Biologicals 915Alexion Pharmaceuticals Inc. 711 American Diagnostica Inc. 869Arteriosclerosis, Thrombosis and Vascular Biology 1108Baxter Healthcare 660, 960 & 1063Bayer HealthCare 1131Bayer HealthCare & Ortho McNeil 1145Beckman Coulter Inc. 517Bio / Data Corp. 912Bio Products Laboratory 1539Biocascade Inc. 1173Biogen Idec Hemophilia 611Biomérieux 618Biotest AG 139Biovitrum 611Boehringer Ingelheim 131Chrono-log Corp. 1016Corgenix Inc. 909CSL Behring GmbH 345DiaPharma Group Inc. 923Eisai Inc. 1101Elsevier 1011Enzyme Research Laboratories Inc. 1008Esoterix Inc. 1014Fluxion Biosciences 1172Future Event’s Knosk 1005GlaxoSmithKline 361Grifols International SA 315 BGTI Diagnostics 811 Haematologic Technologies Inc. 908Haemonetics Corp. 614HPS Network 368 Hyphen BioMed SA 1309Innovative Research 913Instrumentation Laboratory 315 AIntelligent Imaging Innovations Inc. 910Inverness Medical 809

420

Exhibition ListExhibitors

as ofJune 2009

COMPANY NAME Exhibition Stand N°

Invitrox Inc. 110ISTH 161 ISTH 2011 360Journal of Thrombosis and Haemostasis 1002Kedrion 145Laboratorios Farmaceuticos Rovi SA 123Leo Pharma 1531LFB 1339Lundbeck Inc. 801 & 901Medirox AB 515MLDT & MLTD Foundation 267Multiplate Services 616NHLBI-NIH 364North American Thrombosis Forum 362Novo Nordisk Haemophilia Foundation 523, 622 & 624Novo Nordisk Health Care AG 239 & 331Octapharma AG 1345Pentapharm DSM Nutritional Products AG 919Pfizer 1201Precision Biologic Inc. 124R2 Diagnostics Inc. 1010Roche Diagnostics GmbH 1545Rotem Inc. 1166 S. Karger Publishers Inc. 1110sanofi-aventis 617 & 819Saringer Life Science Technologies Inc. 1164Schattauer GmbH 1009Siemens Healthcare Diagnostics Products 1551SSC 2010 Cairo 162Stago 151Syntonix Subsidiary 611Sysmex Corp. 1551Talecris Biotherapeutics 1321Technoclone GmbH 923Thrombinoscope BV 1069Trinity Biotech PLC 1019Vascular Disease Foundation 366Wiley Blackwell 1004World Federation of Hemophilia 269Wyeth Pharmaceuticals 1331

Exhibition ListExhibitorsas ofJune 2009

421

COMPANY NAME Exhibition Stand N°

N O T E S

423

Exhibitorand SponsorProfiles

ISTH2009

4S DAWN CLINICAL SOFTWARE BOOTH N°867

4 The Square MilnthorpeCumbria LA7 7QJCaliforniaUnited KingdomWebsite: www.4s-dawn.com

4S was founded in 1984 and has been involved in medical applications since start-up. Currently, we have16 staff members, and over 350 clients in 17 countries worldwide. An estimated 500,000 patients aremanaged using our software. Our Software helps Clinicians manage patients in the following areas:Anticoagulation - Clinical Haematology - Hepatitis - Anaemia - Diabetes - Rheumatology

ACCUMETRICS BOOTH N° 917

3985 Sorrento Valley Blvd San Diego 92121 CaliforniaUnited StatesWebsite: www.accumetrics.com

Accumetrics is committed to advancing medical understanding of platelets and enhancing quality of carefor patients who are at risk of cardiovascular disease by providing industry-leading diagnostic tests toassess response to antiplatelet therapy. With Accumetrics' family of VerifyNow® tests, which addressevery major type of antiplatelet therapy, including aspirin, P2Y12 inhibitors (Plavix®) and GP IIa/IIIbinhibitors (e.g. ReoPro® and Integrilin®), it provides physicians with a rapid, easy and valuable tool to helpguide treatment decisions.

AFFINITY BIOLOGICALS BOOTH N° 915

1395 Sandhill Drive L9G 4V5 AncasterOntarioCanadaWebsite: www.affinitybiologicals.com

Affinity Biologicals, Inc. is a primary manufacturer of products used worldwide in thrombosis andhaemostasis research as well as medical diagnostics. Products include an extensive line of antibodiesand conjugates, immunoassay products, the VisuLize™ line of complete ELISA kits, and a full line ofhuman plasma products including affinity-depleted factor-deficient plasmas (Factors II through XIII, PC,PS, ATIII), calibrators and controls. Affinity is registered to ISO 13485, holds license(s) with the CanadianTherapeutic Products Directorate (TPD) and is FDA QSR compliant.

ALEXION PHARMACEUTICALS INC. BOOTH N° 711

352 Knotter DriveCheshire, CT 6410USAWebsite: www.alxn.com

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Alexion isengaged in the discovery, development and commercialization of therapeutic products aimed at treatingpatients with a wide array of severe disease states, including hematologic and kidney diseases,transplant, cancer, and autoimmune disorders. Soliris is Alexion's first marketed product, approved in theU.S. and Europe in 2007, and Canada and Australia in 2009.

EXHIBITOR AND SPONSOR PROFILES

424

AMERICAN DIAGNOSTICA INC. BOOTH N° 869

500 West Avenue PO Box 110215 Stamford 06911-0215 ConnecticutUnited StatesWebsite: www.americandiagnostica.com

American Diagnostica Inc. is now a member of the Sekisui Group and is a subsidiary of Sekisui MedicalCo. Ltd. in Tokyo, Japan. We are displaying our World Class products, including tests for LupusAnticoagulants, including the first commercial dPT test and ACTICLOT® LA Complete™, combineddRVVT and dilute PT assays. Also kits for Protein S, Protein C, ATIII, D-dimer, activity and ELISA kits forvWF, PAI-1 and ADAMTS13, ELISA kits for APS, TF, TFPI, uPA, etc. We are a leader in new productssuch as FSAP (Factor V Activating Protease) and 12 LOX (12-Lipoxygenase), to name a few.

ARTERIOSCLEROSIS, THROMBOSIS BOOTH N° 1108

AND VASCULAR BIOLOGY

University of Rochester, 10 Circle Drive, Ste 12 North Liberty 52317 United StatesWebsite: atvb.ahajournals.org

The Editorial Office of Arteriosclerosis, Thrombosis and Vascular Biology, journal of the American HeartAssociation, is available to discuss submissions, policies, and provide additional journal information,including journals and reprints. Visit us today or online at atvb.ahajournals.org!

ASTRAZENECA SPONSOR

S-431 83 Mölndal,SwedenTelephone: 0046 317761000Websites: www.astrazeneca.com

BAXTER HEALTHCARE BOOTH N° 660, 960 & 1063

One Baxter WayWestlake VillageCA 91362United Stateswww.Baxter.com

Baxter's BioScience business is a leading producer of recombinant and plasma-based proteins to treathemophilia and other bleeding disorders. Baxter continues to innovate, advancing science andtechnology to drive better patient care.


425

Exhi

bito

r an

d Sp

onso

r Pr

ofile

s

BAYER HEALTHCARE BOOTH N° 1131 & 1145

6 West Belt Wayne 07470 6806 New JerseyUnited StatesWebsite: www.pharma.bayer.com

About Bayer HealthCare Pharmaceuticals. Bayer HealthCare Pharmaceuticals is among the top tenspecialty pharmaceutical companies worldwide. Its research and business activities are focused on thefollowing areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. Withinnovative products, Bayer HealthCare Pharmaceuticals aims for leading positions in specialized marketsworldwide. Using new ideas, Bayer HealthCare Pharmaceuticals aims to make a contribution to medicalprogress and strives to improve the quality of life.

BECKMAN COULTER, INC. BOOTH N° 517

200 S. Kraemer Blvd. Brea 92822 CaliforniaUnited StatesWebsite: www.beckmancoulter.com

Beckman Coulter offers hemostasis solutions scaled to your laboratory's needs-today and in the future.Our easy-to-use, fully automated ACL* systems offer superior performance and reliability along with thewidest range of routine and specialty assays. Our instruments also offer unsurpassed service and supportto help your lab increase productivity and improve patient care.*ACL is a registered trademark ofInstrumentation Laboratory

BIO / DATA CORPORATION BOOTH N° 912

155 Gibraltar Road, PO Box 347 Horsham, PA 19044-0347 USAWebsite: www.biodatacorp.com

Bio/Data Corporation is a leading manufacturer, marketer, and worldwide distributor of thrombosis,hemostasis, and platelet function products. Our Company focuses on providing high quality instruments,reagents, controls, accessories and disposables. Bio/Data Corporation also offers specialized, studyspecific products for clinical trials. New this year: vW Select™, Ristocetin CoFactor Assay Kit. It is the only complete test system designedto help laboratories comply with regulatory requirements for test system verification and calibration.An ISO 9001:2000, ISO 13485:2003 Registered Company.

BIO PRODUCTS LABORATORY BOOTH N° 1539

Dagger Lane Elstree WD6 3BX United KingdomWebsite: www.bpl.co.uk

BPL is the United Kingdom's national plasma fractionator and is a part of the National Health ServiceBlood and Transplant (NHSBT).BPL is committed to providing a continuous supply of high quality, safeplasma-derived products to a growing global market through investing in the latest research, technologyand manufacturing methods.


426

Exhi

bito

r an

d Sp

onso

r Pr

ofile

s

BIOCASCADE INCORPORATED BOOTH N° 1173

107 Skyline Drive P.O. Box 98 Arlington 53911 WisconsinUnited StatesWebsite: www.biocascade.com

Biocascade, a global leader in coagulation testing, provides the following services and products to theresearch, pharmaceutical and medical device manufacturing sectors:-Chromogenic heparin, LMW-heparin, and antithrombotic testing-Kinetichrome Anti-Xa and Anti-IIa test kits-Method development andvalidation studies-Custom and specialty test development services-Contract manufacture of proteins,reagents, and test kits-Immobilized heparin testing of medical devices.

BIOMÉRIEUX BOOTH N° 618

Chemin de l'Orme France 69280 FranceWebsite: www.biomerieux.com

bioMérieux is a world leader in the field of in vitro diagnostics for clinical and industrial applications. OurVIDAS® Emergency range provides high medical value results and a unique menu for the diagnosis ofcardiovascular diseases and bacterial infection. The upcoming VIDAS® D-Dimer Exclusion™ II assay is anew, more rapid version of the internationally recognized VIDAS® D-Dimer Exclusion™ test - the firstFDA-cleared/CE-marked test for use in conjunction with a clinical Pre-Test Probability assessment modelto safely exclude out-patients with suspected venous thromboembolism (VTE).

BIOTEST AG BOOTH N° 139

Landsteinerstrasse 3-5 Dreieich 63303 GermanyWebsite: www.biotest.com

Biotest is a German research-based pharmaceutical and diagnostics company, dedicated to the areas ofimmunology and haematology. Biotest's plasma protein division develops and markets variousimmunoglobulin preparations, clotting factor concentrates and albumins, which all are purified fromhuman plasma. The main focus of clinical investigation is on recent developments in the field ofbiotherapeutics, including innovative monoclonal antibody therapies against rheumatoid arthritis, multiplemyeloma and psoriasis.


427

428

BIOGEN IDEC HEMOPHILIA/ SYNTONIX

SUBSIDIARY & BIOVITRUM BOOTH N°611

Biogen Idec Hemophilia Biovitrum AB (publ)Syntonix Subsidiary SE-112 76 Stockholm9 Fourth Avenue SwedenWaltham, MA 02451 Website: www.biovitrum.comUnited States

Biogen Idec's Syntonix Subsidiary with development partner Biovitrum AB (publ) has developed severalFc fusion molecules by coupling a therapeutic agent to the Fc domain of an antibody to extend the plasmahalf-life of the therapeutic agent. The lead investigational compound of this collaboration, FIXFc, is arecombinant fusion molecule that combines the Fc domain of antibody to clotting factor IX. Clinicalevaluation of the potentially long-acting FIX product is underway.

BOEHRINGER INGELHEIM GMBH BOOTH N° 131

Binger Strasse 173 Ingelheim 55216 GermanyWebsite: www.boehringer-ingelheim.com

The Boehringer Ingelheim Group has become one of the top 20 leading pharmaceutical companies in theworld since it was founded in 1885. Headquartered in Ingelheim, Germany, with more then 40.000employees, it operates globally with 135 affiliates in companies spread around the globe. The family-owned company is committed to researching, developing, manufacturing and marketing novel productsof high therapeutic value for human and veterinary medicine. In 2008, Boehringer Ingelheim posted netsales of over 11,6 billion Euros, while spending one-fifth of net sales on research and development.

BRISTOL-MYERS SQUIBB SPONSOR

Corporate Headquarters345 Park AvenueNew YorkNew York 10154Website: www.bms.com

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhancehuman life. Bristol-Myers Squibb employees are dedicated to discovering, developing and providinginnovative medicines that help patients prevail against serious diseases.

CHRONO-LOG CORP. BOOTH N° 1016

2 West Park Road Havertown 19083 PennsylvaniaUnited StatesWebsite: www.chronolog.comChrono-log Corp. manufactures systems for quickly screening the anti-platelet effect of drugs such asAspirin and Plavix. Systems with disposable impedance probes [Models 700, 591A and 592A], plus theability to test platelets in Whole Blood, greatly reduce hands-on and significantly improve turn-aroundtime. Systems with Disposable probes are rated CLIA-moderate and tests are reimbursable. Visit BoothNo. 1016 to also learn more about Chrono-log systems with Luminescence used to detect specificplatelet disorders such as Secretion and Storage Pool Disorders. See you in Boston!


Exhi

bito

r an

d Sp

onso

r Pr

ofile

s

429

CORGENIX, INC. BOOTH N° 909

11575 Main Street Suite 400 Broomfield 80020 ColoradoUnited StatesWebsite: www.corgenixonline.com

Corgenix develops, manufactures and markets diagnostic products for the worldwide healthcare market.The REAADS ELISA products include the new AspirinWorks® Test for measuring aspirin effect, andassays for selected autoimmune, vascular and liver disorders, such as Antiphospholipid Syndrome andvon Willebrand Disease. Corgenix also offers contract R&D and manufacturing services.

CSL BEHRING GMBH BOOTH N° 345

P.0.Box 1230 Marburg 35002 GermanyWebsite: http://www.cslbehring.com

CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improvingthe quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in thetreatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disordersand inherited emphysema. The company also operates one of the world's largest plasma collectionnetworks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company.

DAIICHI SANKYO INC AND LILLY USA, LLC SPONSOR

Lilly Corporate Center Daiichi Sankyo, Inc.46285 Indianapolis, IN Two Hilton CourtUnited States 07054 Parsippony, NYwww.lilly.com United States

www.dsus.com

DIAPHARMA GROUP, INC. BOOTH N° 923

8948 Beckett Road West Chester 45069 United StatesWebsite: www.diapharma.com

DiaPharma distributes test kits and reagents for thrombophilia diagnosis, anticoagulation monitoring,bleeding disorder management, and hemostasis research. We pride ourselves in providing supportivecustomer service and a highly trained team of technical representatives to discuss specialized productapplications. Please visit Diapharma, and see our newest diagnostic tools for measuring thrombingeneration, ADAMTS13, microparticles, and platelet function.


430

EISAI INC. BOOTH N° 1101

100 Tice Blvd. Woodcliff LakeNew Jersey 07677United StatesWebsite: www.eisai.com

Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc)company that discovers, develops and markets products throughout the world. Eisai focuses its effortsin three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

ELSEVIER BOOTH N° 1011

1600 JFK Blvd. Suite 1800 Philadelphia 19103 PennsylvaniaUnited StatesWebsite: www.elsevierhealth.com

Elsevier is the leading international publisher of medical journals, books, and electronic products. Stopby our booth to browse our latest selections in the field of Thrombosis and Haemostasis.

ENZYME RESEARCH LABORATORIES INC. BOOTH N° 1008

1801 Commerce Drive South Bend 46628 IndianaUnited StatesWebsite: www.enzymeresearch.com

Enzyme Research Laboratories provides coagulation and fibrinolytic proteins from human plasma, othersource plasmas and platelets. Additionally, we offer monoclonal and polyclonal antibodies, immu-nodepleted plasmas and ELISA reagents. Custom purifications and contract services are also available.

ESOTERIX, INC BOOTH N° 1014

4509 Freidrich Ln Bldg. 1, Ste. 100 Austin 78744 TexasUnited StatesWebsite: www.esoterix.com

Esoterix is a national reference laboratory and a recognized leader in coagulation testing. Through aconsultative approach, Esoterix's services become a seamless extension to a client's current laboratorycapabilities. Esoterix's extensive test menu and staff expertise ensure that clients have the resources topredict, diagnose, and manage even the most unusual bleeding and clotting disorders. Esoterix is awholly owned subsidiary of Laboratory Corporation of America where its laboratories operate as Centersof Excellence for specialized services and esoteric testing.


Exhi

bito

r an

d Sp

onso

r Pr

ofile

s

431

FLUXION BIOSCIENCES BOOTH N° 1172

384 Oyster Point Blvd Suite 6 SSF 94080 CaliforniaUnited StatesWebsite: www.fluxionbio.com

Fluxion's microfluidic technologies provide simple high throughput live cell assays under shear flow andhigh throughput ion channel screening. Our technologies bridge the gap between biochemical screeningassays and in vivo studies to provide more powerful, predictive assays and higher quality lead compounds.

GLAXOSMITHKLINE BOOTH N° 361

100 Route de Versailles Marly-Le-Roi 78163 Cedex FranceWebsite: www.gsk.com

GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerfulcombination of skills and resources that provides a platform for delivering strong growth in today's rapidlychanging healthcare environment.Our mission is to improve the quality of human life by enabling peopleto do more, feel better and live longer.At the ISTH, GSK will demonstrate its continued commitment tothrombosis and cardiovascular disease by providing a range of information on its product portfolio.Pleasecome visit us at our exhibition booth if you would like further information.

GRIFOLS INTERNATIONAL, S.A. BOOTH N° 315B

C/ de la Marina, 16-18, Torre Mapfre, planta 30 Barcelona 8005 SpainWebsite: www.grifols.com

Grifols is a group of healthcare companies which serves health professionals and patients in over 90countries around the world. We research, develop, manufacture and market plasma derivatives, IVtherapy, enteral nutrition, diagnostic systems and medical materials. In the hemostasis field, our productsrange from Diagnostics to Therapy: the Diagnostic Division offers reagents, instrumentation and softwareto make possible a clear and precise diagnosis while the Bioscience Division provides high quality plasmaderivatives to treat patients, save lives and improve life expectancy.

GTI DIAGNOSTICS BOOTH N° 811

20925 Crossroads Circle Waukesha 53186 WisconsinUnited StatesWebsite: www.gtidiagnostics.com

GTI Diagnostics designs, manufactures and markets worldwide a variety of in vitro diagnostic assays forBlood Bank, Coagulation and HLA laboratories. Many of our assays are configured for manual use or areautomated for use on the QuickStep instrument. GTI Diagnostics also offers select OEM services tointerested partners.


432

HAEMATOLOGIC TECHNOLOGIES, INC. BOOTH N° 908

57 River Road Unit 1021 Essex Junction 5452 United StatesWebsite: www.haemtech.com

Haematologic Technologies, Inc. (HTI) is a primary manufacturer of research reagents, specializing in theisolation and characterization of plasma proteins involved in the regulation of blood coagulation andfibrinolysis. Our product line of highly purified proteins includes zymogens, enzymes, cofactors, andinhibitors as well as monoclonal and polyclonal antibodies. Services available by contract include: customprotein purification, assay development, and contract research.

HAEMONETICS CORPORATION BOOTH N° 614

400 Wood Road Braintree 2184MassachusettsUnited StatesWebsite: www.haemonetics.com

Haemonetics assists you in understanding your unique blood management needs and applying the rightcombinations of technologies and services to help you improve patient outcomes and decrease costs.When the options seem limitless but the right ones aren't clear, you need a partner to help make thechanges that are right for your hospital's blood management program.

HPS NETWORK BOOTH N° 368

One South RoadOyster BayNew York 11771-1905United StatesWebsite: www.hpsnetwork.org

HYPHEN BIOMED SAS BOOTH N° 1309

155 Rue d'Eragny Neuville sur Oise 95000 FranceWebsite: www.hyphen-biomed.com

HYPHEN BioMed is a scientific and technical company, expert in biological reagents for haemostasis,thrombosis, fibrinolysis and auto-immune disorders. It is a privileged laboratory partner for anti-thromboticdrug discovery, manufacturing processes and QC of anticoagulant drugs. Through its worldwide distri-bution network, and expert partner companies (Aniara Diagnostica, Biogenic, Coachrom, Diagnostica CZ,Quadratech, Nodia, Endotell and Cabru), research and IVD reagents (CE and 510(k) cleared) can beapplied to all automatic platforms available, with a full service for instrument applications.


Exhi

bito

r an

d Sp

onso

r Pr

ofile

s

433

INNOVATIVE RESEARCH BOOTH N° 913

46430 Peary Court Novi 48377 MichiganUnited StatesWebsite: www.innov-research.com

For over a decade, researchers around the world have trusted Innovative Research to provide them withthe highest quality biomedical products and services available today. Our focus on providing dependablehuman and animal biologicals, coagulation proteins, antibodies and ELISA kits remains our goal. Wecontinually strive to provide our researchers with the tools they need to achieve a competitive advantagein their respective field of research and we will continue do our best to continue to exceed yourexpectations with every product.

INSTRUMENTATION LABORATORY BOOTH N° 315A

180 Hartwell Road Bedford 01730 MassachusettsUnited StatesWebsite: www.ilus.com

IL's exhibit features: the new ACL AcuStar™, the first fully automated, chemiluminescent analyzer forhemostasis specialty testing; ACL TOP® Family of Hemostasis Testing Systems, including ACL TOP 500CTS, ACL TOP 700 CTS and LAS - all fully automated, random-access analyzers that deliver “Testing ProcessAutomation”; and the ACL ELITE system. Combined with the HemosIL® line of reagents, a comprehensivepanel of fully automated assays, IL offers complete disease state management for the hemostasis lab.

INTELLIGENT IMAGING INNOVATIONS, INC. BOOTH N° 910

5124 N. Washington Street Denver 80216 United StatesWebsite: www.intelligent-imaging.com

3i manufactures research level live cell and intravital microscopy imaging systems based on our NEWLYreleased 64-bit native SlideBook 5.0 software. Come see our VIVO line of intravital imaging systems, idealfor a variety of live animal imaging techniques including transmitted light, multi-channel widefieldfluorescence, spinning disk confocal, and 2-photon microscopy. Representatives will be available todiscuss high speed and multi-dimensional imaging during vascular damage, cellular rolling and trafficking,single molecule tracking, or general microscopy as it pertains to your research.


434

INVERNESS MEDICAL BOOTH N° 809

3347 Investment Boulevard Hayward 94545 CaliforniaUnited StatesWebsite: www.invernessmedicalpd.com

HemoSense®, a subsidiary of Inverness Medical, develops, manufactures and sells easy-to-use,handheld blood coagulation monitoring systems for use by patients and healthcare professionals in themanagement of warfarin medication. Warfarin is an oral anticoagulant, or blood thinning drug given topatients to prevent potentially lethal blood clots from forming. HemoSense's INRatio® PT/INR MonitoringSystem consists of a small, portable monitor and disposable test strips and provides a quick and accuratemeasurement of a patient's blood clotting time, known as a PT/INR value.

INVITROX INC. BOOTH N° 110

104 TW Alexander Dr. Bdlg. #6 Research Triangle Park RTP 27709 United StatesWebsite: www.invitrox.com

Invitrox, a diagnostic company founded in 2003, provides clinical lab services to pharmaceutical andbiotechnology companies. The company has filed multiple patents for two medical instruments capableof uniquely identifying and characterizing suspended particles, e.g., microparticles, platelets, circulatingtumor cells, and microbes. Invitrox's most advanced technology, a cell size and surface antigen detector- MPAD, provides an analysis capability not yet available in the market.

ISTH 2011 BOOTH N° 360

Secretariat of ISTH2011c/o Japan Convention Services, Inc.1-4-2 Kasumigaseki, Chiyoda-ku Tokyo Japan 100-0013Website: www.isth2011.com

XXIIIrd Congress of the International Society on Thrombosis and Haemostasis(ISTH 2011) and 57thAnnual SSC Meeting will be held in Kyoto, Japan. Kyoto is a charming city jeweled by over 2000 templesand shrines. The experience in this city which had been the capital of Japan for over eleven centuries willbe precious and unforgettable. See you in two years!

JTH BOOTH N° 1002

Commonwealth Bldg, 5 th Floor, Du Cane RdLondon, W12 0NNUKWebsite: www.journalth.com

Visit the Journal of Thrombosis and Haemostasis booth to find out more about the official journal of theISTH and one of the leading titles in the field. Now with an Impact Factor of 5.947 (2007), the Journal ofThrombosis and Haemostasis is the essential resource for all involved in thrombosis, bleeding disordersand vascular biology. Pick up your sample copy and speak to a member of the editorial team. For moreinformation visit www.journalth.com


Exhi

bito

r an

d Sp

onso

r Pr

ofile

s

435

KEDRION BOOTH N° 145

Loc. ai Conti Castelvecchio Pascoli - Barga 55051 ItalyWebsite: www.kedrion.com

Kedrion is a biopharmaceutical company specialized in the development, production, commercializationand distribution of plasma-derived products. Production is carried out in three authorized productionplants: Bolognana, near Lucca -I- S. Antimo, near Naples -I- GödöllQ, near Budapest -Hu- Kedrionworks in four business areas: ·production and commercialization of plasma-derived products·commercialization of flu vaccines and synthetic pharmaceutical products ·plasma collection andcommercialization in foreign markets ·other activities: in particular transfer of technological know-how.

LABORATORIOS FARMACÉUTICOS ROVI, S.A. BOOTH N° 123

Julián Camarillo, 35 Madrid 28037 SpainWebsite: www.rovi.es

Bemiparin, a second generation LMWHBemiparin has an unique and innovative pharmacological profileresulting from a patented exclusive fractionation process.Just in time for the prevention of VTE:theunequivocal LMWH licensed in EU for a post-op initiation of thromboprophylaxis 6 hours after general andorthopaedic surgery and as effective and safe as enoxaparin.For the treatment of DVT with or without PE:more effective than UFH in reducing thrombus size during the acute phase of DVT and represents a cost-effective strategy. 10 years of post-marketing experience: in 35 countries with over 7 million patientsexposed to bemiparin.

LEO PHARMA BOOTH N° 1531

Industriparken 55 Ballerup 2750 DenmarkWebsite: leo-pharma.com

In 1991, LEO Pharma launched the low molecular weight heparin (LMWH), Innohep® (tinzaparin sodium).Innohep® is one of the leading low molecular weight heparins used in the treatment and prevention ofpulmonary embolism and deep vein thrombosis.LEO Pharma also supplies the heparin antidote,Protamine Sulphate LEO Pharma, in a number of markets.LEO Pharma is one of the few research-basedcompanies which maintain its own integrated manufacturing from extraction of raw material from animaltissue to production of finished product.LEO Pharma is an independent pharmaceutical company 100%owned by the LEO Foundation.


436

LFB BOOTH N° 1339

3 Avenue des Tropiques BP 305 Les Ulis ZA Courtaboeuf Les Ulis 91958 FranceWebsite: www.lfb.fr

LFB is a biopharmaceutical group that develops,manufactures and markets medicinal products for thetreatment of serious and often rare diseases in several major therapeutic fields:Hemostasis,Immunologyand Intensive Care.LFB is the leading manufacturer of plasma-derived medicinal products in France andthe 6th player worldwide.It is also among the leading European companies for the development ofmonoclonal antibodies and new-generation proteins based on biotechnologies.With its strong focus oninnovation,LFB is developing a growth strategy expanding its business activities in international marketsand offering new therapeutics.

LUNDBECK INC. BOOTH N° 801 & 901

Four Parkway NorthSuite 200Deerfield, IL 60015United StatesWebsite: www.lundbeckinc.com

Lundbeck Inc. has proven success in developing and commercializing high-need treatments. Thecompany is committed to providing innovative therapies that fulfill unmet medical needs of people withsevere, and often rare, disorders for which few, if any, effective treatments are available. More information about the company, its products and full prescribing information may be found atwww.lundbeckinc.com.

MEDIROX AB BOOTH N° 515

SE 611 82 Nykoeping Nykoping SE 611 82 SwedenWebsite: www.medirox.se

MediRox produces high quality instruments, diagnostic reagents and quality control material used in the areasof visco-elasticity and coagulation diagnostics since 1998. MediRox is constantly searching for commiteddistribution partners for our product portfolio. We are also OEM/ Private labelling bulk supply to well knowncompanies including Siemens/DADE, Trinity, Teco, Helena Lab and others.Products;oCoagControlsBasicMulti incl D-DimerMulti PLUS incl D-Dimer, Prot S&CoCoag ReagentsPT D-DimerATIII FXa APTTLR oInstrumentsAdvanced coag. Thromboelastography analysers.See www.medirox.se for more information.


Exhi

bito

r an

d Sp

onso

r Pr

ofile

s

437

MULTIPLATE SERVICES GMBH BOOTH N° 616

Reichenbachstr. 27 Munich 80469 GermanyWebsite: www.multiplate.net

The Multiplate® platelet function analyzer is highly sensitive for the detection of aspirin®, clopidogrel,prasugrel, IIb/IIIa receptor antagonists and acquired platelet disorders. The largest study to date evaluatingthe clinical impact of clopidogrel resistance (JACC 2008;53(10):849-56) has shown that patients, stratifiedas inadequate responders according to Multiplate analysis exhibited a 9.4 fold increased risk of early stentthrombosis. With over 500 installations in the market Multiplate® is among the most widely applied plateletfunction analyzers in Europe. Multiplate® is available for research use in the USA.

NHLBI-NIH BOOTH N° 364

Two Rockledge Center6701 Rockledge Drive Suite 9030 Bethesda 20892, MD United StatesWebsite: www.nhlbi.nih.gov

The National Heart, Lung, and Blood Institute (NHLBI) provides leadership for a national program in diseasesof the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Since October 1997, theNHLBI has also had administrative responsibility for the NIH Woman's Health Initiative. The Institute plans, conducts, fosters, and supports an integrated and coordinated program of basic research,clinical investigations and trials, observational studies, and demonstration and education projects. Research isrelated to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases;and sleep disorders.

NORTH AMERICAN THROMBOSIS FORUM BOOTH N° 362

1620 Tremont Street, Suite 3022 Roxbury Crossing 02120-1613 MassachusettsUnited StatesWebsite: www.NATFonline.org

The North American Thrombosis Forum (NATF) is a non profit agency with the vision of improving patientcare, outcomes, and public health by utilizing a multi-disciplinary approach to advance thrombosisresearch and education. NATF's mission is to focus on unmet needs and issues related to thrombosisand cardiovascular diseases such as deep vein thrombosis, pulmonary embolism, myocardial infarction,peripheral arterial occlusive disease, and stroke. NATF's five areas of major focus are: 1) Basictranslational research; 2) Clinical research; 3) Prevention and education; 4) Public policy; 5) Advocacy.


438

NOVO NORDISK HAEMOPHILIA FOUNDATION BOOTH N° 523

Andreasstrasse 15 Zürich 8050 SwitzerlandWebsite: www.nnhf.org

The Novo Nordisk Haemophilia Foundation (NNHF) was created in 2005, in Zurich, Switzerland, as anindependent, non-profit entity to address the significant need for improving haemophilia care in the developingworld. An estimated 75% of the global haemophilia population resides in the developing world wherehaemophilia is not a healthcare priority and many people go undiagnosed or are inadequately treated. NNHFfunds development programmes to deliver capacity building, patient education, diagnosis and registries in thedeveloping world - aiming to bridge the gap between the developed and the developing worlds.

NOVO NORDISK HEALTH CARE AG BOOTH N° 239 & 331

Andreasstrasse 15 Zurich 8050 SwitzerlandWebsite: www.novonordisk.com

Novo Nordisk is a global healthcare company with a leading position in haemostasis management,providing treatment of spontaneous and surgical bleedings in haemophilia A and B patients with inhibitorsagainst factors VIII and IX respectively.For more information on what Novo Nordisk are doing to ChangePossibilities in Haemophilia, visit us at our booth in the exhibition hall.

OCTAPHARMA AG BOOTH N° 1345

Seidenstrasse 2 Lachen 8853 SwitzerlandWebsite: www.octapharma.com

Octapharma is an independent, Swiss-based biopharmaceutical company operating worldwide in 28countries, with 3,000 employees and 5 modern, state-of-the-art production facilities in Austria, France,Germany, Sweden, and Mexico. Octapharma's overall mission is to provide safe and optimal use ofhuman proteins to patients in need of lifesaving therapies covering coagulation disorders, immunediseases and medical emergencies. Octapharma will highlight the following products in ISTH: wilate®,octanate®, octanine F®, nanotiv®, and octaplex®, including its new recombinant factor VIII concentrateproduced from a human cell line.

PENTAPHARM DSM NUTRITIONAL PRODUCTS AG BOOTH N° 919

Engelgasse 109 Basel 4002 SwitzerlandWebsite: www.pentapharm.com

Pentapharm is a manufacturer of reagents for blood coagulation diagnostics:Test kits e.g. Pefakit® APC-R Factor V Leiden, PiCT® (for anti-FIIa and FXa drug monitoring), Reptilase Time, in-TDT®, FXIIIfunctional assay, TAFI or OEM products.Reagents (from research to bulk quantities) including customdevelopment and production: synthetic chromogenic and fluorogenic substrates, inhibitors, snake venomenzymes. Active pharmaceutical ingredients: aprotinin, peptides and snake venom derived enzymes(Batroxobin; Haemocoagulase ) and custom synthesis of peptides and small organic molecules.


Exhi

bito

r an

d Sp

onso

r Pr

ofile

s

439

PFIZER BOOTH N° 1201

235 E. 42nd Street MS 219-7-1New York 10017 - 5755New YorkUnited StatesWebsite: www.pfizer.com

Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking newapproaches to better health. We discover, develop, manufacture and deliver quality, safe and effectiveprescription medicines to treat and help prevent disease for both people and animals.

PRECISION BIOLOGIC INC. BOOTH N° 124

140 Eileen Stubbs Ave Dartmouth B0J2E0 CanadaWebsite: www.precisionbiologic.com

In the coagulation lab, you want confidence in the results you are reporting. You want to do things quicklyand get them right the first time. At Precision BioLogic, we're committed to making it easier for you toachieve the productivity you need. Through years of extensive collaboration with lab managers andtechnologists, we've developed and manufactured a range of innovative products used in clinicalcoagulation laboratories around the world. Known for their integrity, simplicity, and relevance, ourdiagnostic kits, controls and specialty plasmas have become favorites in many laboratories.

R2 DIAGNOSTICS, INC. BOOTH N° 1010

1801 Commerce Drive South Bend 46628 IndianaUnited StatesWebsite: www.r2diagnostics.com

r2 Diagnostics, a sister company to Enzyme Research Laboratories, provides general purpose andspecialty reagents to the clinical coagulation laboratory. Our products include robust PT, APTT, ProteinS, Lupus Screen and Confirm, KCT, Thrombin Time, and Fibrinogen kits manufactured with ERL's highpurity proteins and with “end to end” control over materials and processes. r2 invests in the developmentof specialty reagents and kits, and can provide the laboratory with an expanding menu of diagnosticassays for hemostasis.

ROCHE DIAGNOSTICS GMBH BOOTH N° 1545

Sandhofer Strasse 116 Mannheim 68305 GermanyWebsite: www.roche-diagnostics.com

About Roche headquartered in Basel, Switzerland, Roche is one of the world's leading research-focusedhealthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotechcompany the Group contributes on a broad range of fronts to improving people's health and quality of life.Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a marketleader in virology. It is also active in other major therapeutic areas such as autoimmune diseases,inflammatory and metabolic disorders and diseases of the central nervous system.


440

ROTEM, INC. BOOTH N° 1166

1009 Slater Road Suite 450 Durham 27703 North CarolinaUnited StatesWebsite: www.roteminc.com

ROTEM, Inc. distributes whole blood haemostasis analysis systems, consumables, and reagents for theROTEM® Systems, based on rotation thromboelastometry®. ROTEM, Inc., newly established in the US,will provide anesthesiologists central laboratory and peri-operative bleeding management systems.

S. KARGER PUBLISHERS, INC. BOOTH N°1110

26 W. Avon Rd.P.O. Box 529Unionville, CT 06085United StatesWebsite: www.karger.com

Publications on display include the journals Acta Haematologica, Cardiology, Cerebrovascular Diseases,Journal of Vascular Research, and Pathophysiology of Haemostasis and Thrombosis.

SANOFI-AVENTIS BOOTH N° 617 & 819

174 Avenue de France Paris 75013 FranceWebsite: www.sanofi-aventis.com

Sanofi-aventis, a global leader in the pharmaceutical industry, researches and develops medicines andvaccines to help improve the lives of the greatest possible number of people. R&D explores a broadspectrum of innovative approaches, and develops new products in the key areas of therapeutic expertise:Thrombosis, Cardiovascular diseases, Diabetes,Vaccines, Oncology, Central Nervous System disordersand Internal Medicine. By virtue of its commitments, sanofi-aventis constantly adapts its developmentmodel to the world's emerging human and economic problems.

SARINGER LIFE SCIENCE TECHNOLOGIES INC BOOTH N° 1164

2345 Wyecroft Road Unit 2 Oakville l6l 6l8 CanadaWebsite: www.saringer.com

Venowave is a portable, non-invasive, external venous pump designed to provide improved vascular andlymphatic flow of the lower limbs using a patented wave technology.


Exhi

bito

r an

d Sp

onso

r Pr

ofile

s

441

SCHATTAUER GMBH BOOTH N° 1009

3 HoelderlinstrasseStuttgart 70174 GermanyWebsite: www.thrombosis-online.com

THROMBOSIS AND HAEMOSTASIS publishes original articles with a broad scope in basic research andclinical studies in vascular biology and medicine. Categories include: blood coagulation, fibrinolysis andcellular haemostasis; platelets and blood cells; wound healing and inflammation/infection; endotheliumand vascular development; cardiovascular biology and cell signalling; cellular proteolysis and oncology;new technologies, diagnostic tools and drugs.

SIEMENS HEALTHCARE DIAGNOSTICS BOOTH N° 1551

AND SYSMEX CORPORATION

511 Benedict Avenue Tarrytown 10591 New YorkUnited StatesWebsite: www.diagnostics.siemens.com

www.sysmex.com

Since 1995, the partnership between Siemens Healthcare Diagnostics & Sysmex Corporation hasprovided hemostasis solutions to laboratories worldwide. Siemens' portfolio of performance-drivensystems, unmatched menu offering, and IT solutions, in conjunction with highly responsive service, isdesigned to streamline workflow, enhance operational efficiency and support improved patient care.Sysmex is a leading international manufacturer of diagnostic systems, involved in the development ofclinical laboratory testing devices, reagents and software for hematology, hemostasis, immuno-chemistry,particle counting, urinalysis and life sciences.

SSC 2010 BOOTH N° 263

Venue address:Grand Hyatt CairoCorniche El Nile, Garden CityP.O. Box 2288El Roda islandEgyptWebsite: www.ssc2010.org

The Scientific & Standardization Committee of the ISTH is the working arm of the Society. Since 1954, theSSC has supported the collaboration of experts worldwide on matters related to blood coagulation,hemorrhagic disorders and standards and methods of research related to these medical problems. TheSSC is comprised of 20 scientific subcommittees, registries and working groups that meet annually topresent public reports of their work in progress and to address problems and issues that require expertconsideration. The 56th Annual Meeting of the Scientific & Standardization Committee of the ISTH willtake place in Cairo, Egypt from 22 to 25 May, 2010.


442

STAGO BOOTH N° 151

9 rue des Frères Chausson Asnières sur Seine 92600 FranceWebsite: www.stago.com

Stago dedicates its research and innovative skills to develop and improve the accuracy of the medicaldiagnostic. The firm formulates, manufactures and markets worldwide, a broad range of reagents (routine& research) and fully automated systems for haemostasis & thrombosis.Thanks to its haemostasisexpertise, Stago is recognized and is in position to cooperate with the scientific community worldwide.Affiliates in USA, China, UK, Australia/NZ, Canada - wide network of distributors (> 100 countries)BioCytex, a Stago group company, develops advanced research tools in field of cellular biology.

TALECRIS BIOTHERAPEUTICS BOOTH N° 1321

79 TW Alexander Drive 4101 Research Commons Research Triangle Park 27709 North CarolinaUnited StatesWebsite: www.talecris.com

Talecris Biotherapeutics is dedicated to the development and delivery of life-saving and life-enhancingprotein therapies to markets throughout the world. Visit booth #1321 to learn more about our products.

TECHNOCLONE GMBH BOOTH N° 923

Brunner Str. 59/5 Vienna 1230 AustriaWebsite: www.technoclone.com

TECHNOCLONE is a world leading producer of global and special coagulation tests. Ceveron alpha offersthe unique feature of fully automated thrombin generation measurement in the routine. Another innovationis the Ceveron MFU 500, a microparticle filtration unit which can identify microparticles thombogenicity inconjunction with the Technothrombin MP. Furthermore Technoclone provides a complete range ofADAMTS13 ELISAs and FXIII assays. With the new TECHNOVIEW control and calibration plasma productrange we were able to expand the portfolio for anticoagulant therapy monitoring.


Exhi

bito

r an

d Sp

onso

r Pr

ofile

s

443

THROMBINOSCOPE BV BOOTH N° 1069

Oude Maasstraat 47 Maastricht 6229 BC NetherlandsWebsite: www.thrombinoscope.com

Thrombinoscope BV offers the Calibrated Automated Thrombogram(CAT) assay which is intended to measure thrombin generation forresearch purposes. The assay can be measured in platelet-rich orplatelet-poor plasma, and has a unique and patented calibration which makes a proper measurement ofeach individual patient possible. The CAT assay is the most commonly used thrombin generation assaybecause of its reproducibility and correct calculation of thrombin in time. This overall physiologicalfunction test of the coagulation system is used to monitor anticoagulant treatment and is sensitive to boththrombotic and bleeding tendencies.

TRINITY BIOTECH PLC BOOTH N° 1019

One Southern Cross Road IDA Business Park Bray Co. Wicklow IrelandWebsite: www.trinitybiotech.com

Trinity Biotech develops, acquires, manufactures, and markets diagnostic products for the clinicallaboratory and point-of-care diagnostic market. Trinity Biotech is an Irish company with headquarters inDublin. It has direct affiliate distribution in UK, Germany and USA and is represented by distributorpartnerships globally in over 80 countries. Trinity provides a broad line of haemostasis reagents andinstruments which are used to detect blood coagulation disorders. Trinity now launches its new highthrough put 'Destiny Max' analyser which is the latest innovation.

VASCULAR DISEASE FOUNDATION BOOTH N° 366

1075 S Yukon Street, Ste 320 Lakewood 80226 ColoradoUnited StatesWebsite: www.VDF.org, VenousDiseaseCoalition.org

A division of the Vascular Disease Foundation, the Venous Disease Coalition (VDC) is a collaborativenetwork of professional and public organizations united to increase public and health professionalawareness, and promote efforts to improve the survival rates and quality of life of individuals with, or atrisk for, venous disease. Join our efforts for a common campaign and messages and help improve patientoutcomes. Visit www.VenousDiseaseCoalition.org or call 888.833.4463 for more information.


WILEY BLACKWELL BOOTH N° 1004

9600 Garsington RoadOxford Business ParkOxford, OX2 4DQUKWebsite: www.wiley.com

Wiley-Blackwell is a leading publisher in hematology and other related areas. We publish many of the topjournals in the field including; the official journal of the ISTH, the Journal of Thrombosis and Haemostasisand the British Journal of Haematology. Come and pick up your free sample copy. We also have manyleading book titles - all with an exclusive 20% discount. For more information, visit: www.interscience.wiley.com

WORLD FEDERATION OF HEMOPHILIA BOOTH N° 269

1425 René Lévesque Blvd West, Suite 1010 Montreal H3G 1T7 CanadaWebsite: www.wfh.org

The World Federation of Hemophilia is the leading international organization representing the inheritedbleeding disorders community. With a global network of patient organizations in 113 countries, the WFHworks to provide treatment for all people with bleeding disorders through education and training,advocacy, and product donations. Visit the WFH booth for a chance to win free registration for theHemophilia 2010 World Congress in Buenos Aires, Argentina, 10-14 July 2010.

WYETH PHARMACEUTICALS BOOTH N° 1331

500 Arcola Road Collegeville 19426 PennsylvaniaUnited StatesWebsite: www.wyeth.com

Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE)*, has leading products in the areas of women'shealth care, infectious disease, gastrointestinal health, central nervous system, inflammation,transplantation, hemophilia, oncology, vaccines and nutritional products.


444

ISTH2009

CongressInformation

445

Layout of the Congress Venue

446

Grand Ballroom Level Two Meeting Rooms

Level One Meeting Rooms Exibit Level

Registration

Fee On-site

ISTH Member $ 950

ISTH Non Member $ 1,200

Trainees / Students* $ 350up to the age of 38

Exhibitors $ 410

Accompanying Persons $ 280

SSC Meeting attendance only Free Saturday July 11, Sunday July 12, 2009

Fees payable in USD only.

* For trainees and students, a letter ofconfirmation from the Head ofDepartment on departmental letter-head must be presented with theregistration form. Students older than38 can request a waiver from this agerestriction by providing a briefexplanation and a letter from theHead of Department confirming theirstudent status.

Cong

ress

Info

rmat

ion

447

Hotel and Transportation Information

Delegates’ Registration Fee includes:Admission to all Scientific SessionsCongress BagFinal ProgramState of the Art Book and CD-ROMAbstract CD-ROMOpening CeremonyWelcome ReceptionAccess to Exhibition AreaScheduled Coffee BreaksUse of the Congress Shuttle Service to the Official Congress Hotels

Accompanying Persons’ Registration Fee includes:Opening CeremonyWelcome ReceptionAccess to Exhibition AreaScheduled coffee breaksNeighborhoods of Boston Excursion TourUse of the Congress Shuttle Service to the official Congress Hotels

Modification or Cancellation of Registration All cancellations must be sent to MCI Suisse SA in writing (fax, letter oremail). For cancellations received before May 6, 2009, deposits will berefunded less USD 100 for administrative costs. For cancellations after May 6, 2009, no refund will be available. A handlingfee of USD 50 per registration will be charged for every registration modifi-cation received after June 10, 2009.

On-site Registration HoursThe Registration Desk at the BCEC will be open as follows: Friday July 10, 2009 3:00 PM - 6:00 PM Saturday July 11, 2009 7:00 AM - 6:00 PM Sunday July 12, 2009 7:30 AM - 7:30 PM Monday July 13, 2009 7:30 AM - 6:30 PM Tuesday July 14, 2009 7:30 AM - 6:30 PM Wednesday July 15, 2009 7:30 AM - 6:30 PM Thursday July 16, 2009 7:30 AM - 6:30 PM

Please also note that availability of hotel accommodation at the time ofon-site registration may be limited.

448

HotelsMCI Suisse SA hasreserved a large numberof rooms in different hotelcategories and offersdiscounted room rates forCongress participants.Only reservations madethrough MCI Suisse SAwill benefit from theserates. All of these hotelsare located in the CityCenter, or near theConvention Center.Rates are in US dollars(USD) and are per room,per night. Please also note thatavailability of hotelaccommodations at thetime of on-site registrationmay be limited.

Boston Hotel MapPlease note that hotelavailability will be limitedfor those registering on site.

Hotel Check-in/Check-outTimeCheck-in time is 3:00 PMor later. If you are arrivingafter 6:00 PM, pleasenotify MCI Suisse SA inadvance. Check-out timeis noon.


Cong

ress

Info

rmat

ion

449

Methods of PaymentPayment by personal checks cannot be accepted.All payments are in US dollars (USD). For hotel bookings, a deposit paymentfor the first night must accompany the hotel accommodation form. Additionalexpenses such as mini-bar, laundry, etc. must be paid directly to the hotelwhen checking out.

Changes of Hotel BookingFor any changes to hotel reservations please inquire at the Hotel Desk in theRegistration Area. A handling fee of USD $50 per hotel room will be chargedfor hotel modifications made at this time. In the case of cancellations, wereserve the right to charge the full stay if the hotel room cannot be re-sold.


HOTELS IN BOSTON

HOTELS 5* Telephone NUMBER SINGLE DOUBLE LOCATIONRATE RATE

1 The Langham +1 (617) 451 1900 276 276 City Center18 Mandarin Oriental Boston +1 (617) 535 8888 394 394 Back Bay19 The Ritz-Carlton, Boston Common +1 (617) 574 7100 343 343 City Center

HOTELS 4*

2 Boston Marriott Copley Place +1 (617) 236 5800 258 286 Back Bay3 The Boston Park Plaza Hotel & Towers +1 (617) 426 2000 225 248 Back Bay4 The Colonnade Hotel Boston +1 (617) 424 7000 269 269 Back Bay5 The Hilton Boston Back Bay +1 (617) 236 1100 247 247 Back Bay6 Hilton Boston Financial District +1 (617) 556 0006 254 254 City Center7 Hyatt Harborside +1 (617) 568 1234 242 242 Airport8 The Back Bay Hotel (formerly Jurys Boston) +1 (617) 266 7200 270 270 Back Bay9 The Omni Parker House Hotel +1 (617) 227 8600 247 247 City Center10 Renaissance Boston Waterfront +1 (617) 338 4111 281 281 Congress Center11 The Seaport Hotel +1 800 440 3318 258 258 Congress Center12 Sheraton Boston Hotel +1 (617) 236 2000 239 261 Back Bay13 The Westin Copley Place Boston +1 (617) 262 9600 288 311 Back Bay14 The Copley Square Hotel +1 (617) 536 9000 269 269 Back Bay20 The Westin Boston Waterfront +1 (617) 532 4600 275 297 Congress Center

HOTELS 3* Superior16 Boston Marriott Long Wharf +1 (617) 227 0800 321 321 City Center

HOTELS 3*15 Courtyard Boston Tremont +1 (617) 426 1400 214 214 City Center

HOTELS 2*17 MidTown Hotel +1 (617) 262 1000 191 191 Back Bay

Rates include 12,45% City Tax and apply for Standard rooms; other room types like Deluxe rooms,Junior Suites, Suites etc. may be available upon request. Rates are in USD $.


450

TransportationThere will be a shuttle bus system available ONLY from/to the hotelsbooked through the Congress. The Congress Organizers have worked toensure convenient and timely transportation between the Congress Hotels andthe BCEC with the following arrangements:

Departures from Hotels or Defined Pick-Up Points to the BCECEvery 10 minutes starting 7:00 AM

Departures from the BCEC to Hotels and Defined Drop-Off PointsEvery 10 minutesFor more information, please refer to the Transportation Guide.

Following the All Congress PartyShuttle buses will transport participants back to Congress Hotels.

Transportation to the AirportThe MBTA will offer direct service for the attendees from the BCEC to LoganAirport terminals with ADA accessible, luggage friendly Silver Line vehicles. Ashuttle will be available for $2 per person from the BCEC to Boston’s LoganAirport on Thursday, July 16 from 2:30 PM to 6:30 PM. Inquire at the HotelDesk in the Registration area for more information.Many hotels also offer shuttle service to and from the airport. Please checkwith your hotel if this is available.

For any questions, kindly inquire at the Hotel Desk in the Registration area or contact:MCI Suisse SAPhone: Local Number +1 617 954 3360

DisclaimerMCI Suisse SA as the Congress Organizer, ISTH and committee members andofficers of the XXII Congress of the ISTH claim no liability for the act of anysupplier to this meeting, nor liability for: personal injury, the safety of anyattendee while in transit to or from this event, for any loss or damage, fordelays in transport by air, sea, rail, road, weather, in case of strikes, sickness,war or other causes.

Cong

ress

Info

rmat

ionHotel and Transportation Information

“How To get there” South Boston Waterfront Driving Directions and Local Parking Options

Local Parking Lots and Pedestrian Access to the BCEC Silver Line Entrance

Pedestrian Routes

Stairs to Summer Street

Entrance/Exit to Parking Lot

Parking Lot

From Logan International Airportand Route 1A South:• I-90 West/Ted Williams Tunnel to Exit 25

“South Boston”.• Bear left at end of ramp.• Go straight onto B Street.

From Western Massachusetts:• Massachusetts Turnpike /I-90 East to

Exit 25, “South Boston”.• Bear left at split onto East Service Road.

I-93 Southbound:• I-93 South to Exit 23 “Purchase Street”.• Take left at top of ramp.• Go straight onto Seaport Boulevard.

I-93 Northbound:• I-93 North to Exit 20 “I-90 East/

Logan Airport”.• Massachusetts Turnpike/I-90 East to

Exit 25 “South Boston”.• Bear left at split onto East Service Road.

Public parking lots and garages can bereached from Northern Avenue, Congress Street,Seaport Boulevard and connecting streets.

LP Parking Lots

For updated information on trafficclosures visit www.masspike.com

Boston Convention & Exhibition Center415 Summer Street, Boston, MA 02210Additional information about the BCEC:www.massconvention.com : 617.954.2000

451

452

Abstract CD-RomThe Abstract CD-Rom is inside the Congress Bag andincludes all submitted abstracts as well as the abstractsof the Plenary, State-of-the-Art and Symposia Sessions.It will also be included in the August issue of the Journalof Thrombosis and Haemostasis.

ATM (Automatic Teller Machine)There are ATM’s located at the BCEC. Please ask the Registration Desk forfurther information.

BadgesCongress Name Badges are issued upon check in at the Congress site andmust be visible and used at all times throughout the BCEC for access to themeetings and official social functions.

CMEAMA PRA Credits The Congress has been reviewed by the American Medical Association andapproved for a maximum of 29.75 AMA PRA Category 1 Credits™. Creditclaim forms will be available in your Conference bag. In order to receive credityou must complete the claim form, pay the $35 USD processing fee ( waivedfor AMA members), and return the form to the AMA monitor's desk during theCongress or fax the form to AMA headquarters after the conference. A creditcertificate will be emailed to physicians within 4 weeks of receipt of the claimform. Physicians should only claim credit commensurate with the extent oftheir participation in the activity. One credit may be claimed for each hour ofparticipation in approved sessions. If you should have any questions about thisprocess, you may contact the AMA directly (Mindi Daiga, [email protected] phone: 312.464-5196 fax: 312-464-5830). Further information canbe obtained under the AMA website.

Congress BagThe Congress Bag will be distributed to registered participants at theRegistration Desk.

Congress DocumentsThe Congress documents should be collected on-site at the Registration Deskat the BCEC.

ISTH 2009 Congress Information

Cong

ress

Info

rmat

ion

Congress NewsThe ISTH 2009 Congress will feature a newspaper that will include scientifichighlights. A new issue will be distributed each day from Monday, July 13 toThursday, July 16.

Congress OrganizerMCI Suisse SARue de Lyon 751211 Geneva 13SwitzerlandLocal PhonePhone: +41 22 33 99 587Fax: +41 22 33 99 601Email: [email protected] / Web: www.isth2009.com

Duplicating / RecordingAny form of duplication (recording, audio taping, digital taping, photographyand video) of sessions including Poster Presentations is prohibited without theexpressed written consent of the Congress Organizers.

ExhibitionExhibition Area InformationThe Congress Exhibition, featuring commercial displays of internationalorganizations, sponsor pharmaceutical companies, media publishers andscientific societies, catering and lounge areas will be located in Halls A & B1 ofthe BCEC.

Exhibition Area ScheduleMonday July 13, 2009 10:00 AM - 5:00 PM Tuesday July 14, 2009 10:00 AM - 5:00 PM Wednesday July 15, 2009 10:00 AM - 5:00 PM Thursday July 16, 2009 10:00 AM - 4:00 PM


453

454

Food & BeverageCoffee BreaksCoffee breaks are included in the registration fee. Coffee will be served todelegates in several locations, including the Exhibition Area, from Monday toThursday during the session breaks. (For times, please see the ProgramOverview on page 26). Coffee breaks will be provided outside the meetingrooms during the SSC Annual Meeting and Education Program on Saturdayand Sunday. It will also be possible to purchase coffee at various outletsthroughout the BCEC.

Future MeetingsA Future Meetings table is located in the Exhibition Area

InternetWifi is provided throughout the BCEC. Please inquire at theRegistration Desk for more information. Two Cyber Cafésare situated inside the Exhibition.

ISTH General Membership AssemblyThe ISTH Membership Meeting will take place on Tuesday July 14, from 3:00-3:15 PM in the Grand Ballroom.

ISTH SecretariatThe International Society on Thrombosis and Haemostasis Secretariat islocated in Room 255 on the 2nd Floor of the BCEC.

LanguageEnglish is the official Congress language, and no translation services areoffered.

LunchOn Saturday, July 11 and Sunday, July 12 lunch may be purchased at the FoodCourt of the BCEC.

From Monday, July 13 to Thursday, July 16 lunch may be purchased at theFood Court of the BCEC, as well as at various locations in the Exhibition Area.


Cong

ress

Info

rmat

ion

For those who purchased lunch boxes for Monday through Thursday as partof your registration, these may be collected at designated outlets in theExhibition Area upon presentation of your voucher. (Note: Advance purchasewas required for the lunch boxes.)

MessagesParticipants can use the message options available at the Cyber Café locatedin the Exhibition Area.

Massachusetts RegulationsPlease note that Massachusetts regulations, effective July 1, 2009, prohibitMassachusetts-licensed health care providers from accepting gifts (pens, etc)or refreshments from pharmaceutical or medical device companies.

Media / Press RoomThe Media Room is located in Room 209 on the second floor of the BCEC.

Mini ProgramA Mini Program will be handed out to participants.

ParkingPlease refer to page 451 that shows the plan of the parking areas.

Poster Help DeskA Poster Help Desk will be available at the Registration Desk as well as in thePoster Area.

Poster SessionsPoster sessions will take place in Hall B2 of the BCEC, adjacent to theExhibition Area, on Monday, Wednesday and Thursday from 12:30 PM to 2:15PM. Posters should be mounted on the assigned board in the Poster Displayarea. The poster presenting authors should be present in the Poster Area from12:30 PM to 2:15 PM on the day of their poster presentation for opendiscussion. Support staff will be at available for help at the Registration Deskand in the Poster Area.


455

456

Registration DeskThe Registration Desk at the BCEC will be open as follows: Friday July 10, 2009 3:00 PM - 6:00 PM Saturday July 11, 2009 7:00 AM - 6:00 PM Sunday July 12, 2009 7:30 AM - 7:30 PM Monday July 13, 2009 7:30 AM - 6:30 PM Tuesday July 14, 2009 7:30 AM - 6:30 PM Wednesday July 15, 2009 7:30 AM - 6:30 PM Thursday July 16, 2009 7:30 AM - 6:30 PM

RulesSmoking PolicyThe ISTH 2009 Congress is a non-smoking event. Participants are kindlyrequested to refrain from smoking in the BCEC, including the Exhibition Area.

Mobile PhonesDelegates are kindly requested to keep their mobile phones silenced in therooms where scientific and educational sessions are being held, as well asduring poster sessions.

Speaker’s Preview Room Speakers are asked to bring their formattedPowerPoint presentations to the Speaker’s PreviewRoom (Room 251) at least two hours before theirsession. Files from keydrives or CD-ROMs can be transferred to the Congressservers at that time. All conference rooms contain state-of-the-art technicalequipment.

The Speakers’ Preview Room will be open as follows:Friday July 10, 2009 3:00 PM - 6:00 PM Saturday July 11, 2009 7:30 AM - 7:00 PM Sunday July 12, 2009 7:30 AM - 7:00 PM Monday July 13, 2009 7:30 AM - 7:00 PM Tuesday July 14, 2009 7:30 AM - 7:00 PM Wednesday July 15, 2009 7:30 AM - 7:00 PM Thursday July 16, 2009 8:00 AM - 12:00 PM


Cong

ress

Info

rmat

ion

457

State-of-the-Art Book and CD-RomThe State-of-the-Art Book and CD-Rom are inside the CongressBag. The CD-Rom will also be included in the July issue of theJournal of Thrombosis and Haemostasis.

TransportationA complimentary shuttle service between theBCEC and official Congress Hotels will be availableto participants from Saturday, July 11 to Thursday,July 16. More information on the schedule can beobtained from the Transportation Guide, which is handed out upon registrationat the Registration Desk at the BCEC.

Trainee Hospitality SuiteRoom 101 on the 1st floor of the BCEC has been designated as a HospitalitySuite for all delegates registered as Trainees. The Hospitality Suite will serve asa place for informal meeting, relaxing and networking. Senior mentors will beavailable to answer questions Sunday afternoon, and during morning andlunch breaks Monday through Thursday. (A specific schedule is posted in theSuite.) The Suite will be open from 8:00 AM to 6:00 PM through Thursday,July 16.

Website of ISTH 2009Updated information and the on-line itinerary plan-ner are available on the website: www.isth2009.com


458

About BostonBoston is one of America’s oldest cities and the economic and cultural hub ofNew England. Home to about 600,000 residents, its population is augmentedby the more than 250,000 students from around the world who attenduniversities and colleges in the greater Boston area. Finance, health care andeducation are among the mainstays of the city’s economic life. Tourism is oneof New England’s major industries, with 1.2 million visitors annually. WhileBoston over the last several decades has developed a modern skyline, it hasmaintained its architectural heritage with vibrant neighborhoods each with theirunique personality and appeal. Boston is also home to many fine culturalinstitutions, some of the world’s finest hospitals, and world class professionalsports organizations.

For more information, please visit the Boston Information Booth at theRegistration Desk and the following websites:www.cityofboston.govwww.bostontourism.com

Getting to BostonBy Air: Logan Airport is located in East Boston. There are several options forgetting from Logan Airport to the Boston Convention and Exhibition Center

Boston Information

Cong

ress

Info

rmat

ion

and the official Congress Hotels, including rapid transit bus and subwayservice provided by the Metropolitan Boston Transit Authority (MBTA),Logan/Boston Hotel Shuttle van service, water transport and taxi service. Formore detailed information please go to: www.massport.com.

By car: There are 3 main routes into Boston:I-90 (Massachusetts Turnpike) from the west I-95 from the north and south I-93 from the north and south

By Subway and Bus (Local): The MBTA offers an online trip planner usefulfor figuring out how to get around by subway, local bus, and train. For moreinformation, please go to: www.mbta.com.

By Bus (Regional): Nationwide bus companies including Greyhound andPeter Pan stop downtown at South Station. Several regional bus companiesoffer scheduled service from Boston to New Hampshire, Cape Cod, RhodeIsland, Connecticut, and New York City. The MBTA’s Silver Line provides aneasy connection from South Station to the BCEC.

By Train: Amtrak has scheduled train service to Boston from New York andother points in the Northeast Corridor. The trip from New York City takes 3 1/2hours on Acela Express trains, about 4 hours on other trains. Trains arrive atSouth Station, with easy connection to the BCEC via the MBTA’s Silver Line.

For more information, we invite you to visit:www.cityofboston.gov/visitors/gettinghere.asp

Getting AroundChances are you’ve heard Boston referred to as «the walking city.» Boston’scompact downtown area provides opportunities to walk from Congress Hotelsto many attractions, including shopping and historic sights. Several CongressHotels are within walking distance of the BCEC.WalkBoston has developed a Downtown/Back Bay/South Boston Seaportwalking map to help commuters and visitors get around town.

For more information, we invite you to visit the following websites:www.walkboston.org/resources/maps.htmwww.mbta.comwww.massport.com/default.aspx

Boston Information

459

460

Driving around Boston can be difficult, and parking expensive. Most hotelshave parking facilities, with rates ranging from USD $20 to USD $40.

For more information, please go to:http://www.cityofboston.gov/transportation/accessboston/ parking.asp

Parking is also available at the BCEC for USD $10. A free shuttle serviceprovides transportation from the parking lot to the BCEC entrance.

For more information, please go to:http://www.massconvention.com/bcec_dir_par.html

TaxiFor taxi fares, please go to:

http://www.massport.com/logan/getti_typeo_taxis.html.

FoodBoston has many excellent restaurants. Visitors have their choice of popularBoston restaurants in many areas of the city such as the narrow alleys of theNorth End and the bustling avenues of the Back Bay. The city is home topeople from around the world who have enriched the local New Englandcuisine, providing a wide array of dining opportunities.

For restaurant information, please see the following websites:

http://www.bostonusa.com/visitor/geninfo.htmhttp://www.yelp.com/c/boston/restaurants

BanksOnly major banks exchange foreign currency. ATMs are widespread and creditcards and travelers’ checks are widely accepted. Travelers’ checks should beissued in US dollars for maximum convenience. Banking hours are Monday toFriday 9AM to 3PM. There are several ATM’s at the BCEC.

ClimateBoston has a continental climate with very changeable weather patterns suchas wide temperature swings in a matter of days.Summers are usually sunny, hot and humid. In July the average temperaturesare a high of 82°F (28°C) and a low of 65°F (18°C).

Boston Information

Cong

ress

Info

rmat

ion

CurrencyThe US dollar (USD) is the unit of currency and is divided into 100 cents.

Credit CardsAll major credit cards are accepted in the majority of hotels, restaurants andshops.

Dress CodeThe dress code for the Welcome Reception and the All Congress Party iscasual attire. The dress code for the meetings is business casual.

Electricity120 volts, 60 Hz. Plugs are mainly the two, flat-pin type, though three-pinplugs are also widely used. Appliances without dual voltage capabilities willrequire an adapter, which can be purchased in most major departure airports.

Boston Information

461

462

ShopsShops are generally open from 10:00 AM - 7:00 PM from Monday to Saturday.Most large stores will also open on Sunday but generally with shorter openinghours.

TaxesMassachusetts has a sales tax of 5% that is applied to the price of goods atcheckout. Clothing under USD $175 and food purchased in grocery stores areexempt. There is no VAT.

TimeStandard time zone: UTC/GMT -5 hoursDaylight saving time: +1 hourBoston is on EDT (Eastern Daylight Time).

TippingA 15% tip is expected by taxidrivers, bartenders, hairdressersand waiters, but don’t tip in fast-food or self-service restaurants. It isnormal to tip staff in hotels. Mostservices are customarily tipped ifthe service is good.

Travel InsuranceA travel insurance policy to covertheft, loss and medical problems isrecommended. The Congress willnot be held liable for illness,accidents or thefts suffered byparticipants or accompanyingpersons during the Congress ortheir stay in USA before or after theCongress.

Boston Information

Cong

ress

Info

rmat

ion

Opening Ceremony and Welcome ReceptionSunday July 12, 2009, 6:00 PMIncluded in the registration fee. This event will take place at the BCEC in theGrand Ballroom. From 9:00 PM until 9:30 PM bus departures are scheduledto all official ISTH 2009 Congress Hotels.

Presidents’ DinnerJohn F. Kennedy Library, Boston

Tuesday, July 14, 2009, 6:00 PMThis function is by invitation only. At 6:30 PM sharp, a boat will leave for a harbor tour before dropping offguests at the John F Kennedy Library. Please meet in the Registration Area at6:00 PM. At 10:00 PM, a bus departure is scheduled back to the WestinWaterfront Hotel.

Social Events

463

464

All Congress PartyBank of America Pavilion, 290 Northern Ave, Boston

Thursday July 16, 2009, 6:30 PM

A reservation fee of USD $35 must be paid in advance. While the event isan easy walk from the Convention Center, bus transfers are available from theBCEC to the Pavilion between 6:00 PM and 6:45 PM. After the event, a bustransfer back to the official Congress Hotels will be available from 9:30 PM to12:00 PM.

If you would still like to register for the All Congress Party onsite, pleaseinquire at the Registration Desk.

Accompanying Persons’ Program/ExcursionsAll excursions depart from and return to the BCEC, Level 0.

Excursions will take place only if a minimum of participants is met (please referto the Excursions’ counter at the Registration Desk for more information).The Neighborhoods of Boston Tour is included in the registration fee forAccompanying Persons.

Trainee ReceptionBCECSaturday July 11 from 6:30 PM to 10:00 PM

Included in the registration fee for Trainees. Reception, brief program andlight dinner, followed by music and dancing, at the BCEC. All those who haveregistered as Trainees are welcome to attend.

Social Events

ISTH 2009 Excursion Overview

Saturday July 11Neighborhoods of Boston 9:00 AM – 12:00 PM Tall Ships 1:00 PM – 04:00 PM

Sunday July 12Tall Ships 9:00 AM – 12:00 PMHometown Favorites 1:00 PM – 04:00 PMNeighborhoods of Boston 1:00 PM – 04:00 PM

Monday July 13Neighborhoods of Boston 9:00 AM – 12:00 PM Ducks, Sharks and Penguins 1:00 PM – 05:00 PMWhale of a Tail 2:30 PM – 05:30 PM

Tuesday July 14Veni, Veidi, Vice 9:00 AM – 12:00 PMThe Gilded Age of Newport 9:00 AM – 05:00 PMDucks, Sharks and Penguins 1:00 PM – 05:00 PM

Wednesday July 15Pleasurable Provincetown 8:30 AM – 06:00 PMJFK Legacy Tour 9:00 AM – 01:00 PM

Thursday July 16Veni, Veidi, Vice 9:00 AM – 12:00 PMArt and Architecture 1:00 PM – 04:00 PM

Cancellation of ExcursionsThere will be no refunds for cancellations after May6, 2009. Full refunds will be made if an activity iscancelled due to insufficient numbers of participants. For any cancellations or more information, pleaseaddress inquiries to the Registration Desk.

Excursions

465

Cong

ress

Info

rmat

ion

466

Excursions

Neighborhoods of BostonTour of the City

Saturday July 11, 2009 9:00 AM - 12:00 PM Sunday July 12, 2009 1:00 PM - 04:00 PM Monday July 13, 2009 9:00 AM - 12:00 PM 3 hours

Boston is a city rich in American history, neighborhoods and education. Tomany, Boston is known as “Beantown,” Boston is our nation’s oldest major citywith world famous medical centers, industry and finance at our fingertips, andendless faith in the beloved Red Sox. A city of seasons makes the snow-covered rooftops of Beacon Hill or the flower-filled public gardens somethingto see for any season.Begin your trip with the Back Bay, an area rich in Victorian architecture as wellas modern marvels such as the Prudential Center and Hancock Tower. Driveby the Boston Public Library, the Trinity Church, the Boston Common and thePublic Gardens on the way to Beacon Hill. Beacon Hill’s 19th Centuryneighborhood impresses locals and tourists alike with its charming streets,brick sidewalks lined with antique gas lamps, hidden gardens, unique doors,doorknockers, and detailed iron balconies. From Beacon Hill to the Freedom Trail, see King’s Chapel and Burying Ground,Granary Burying Ground, the Old Corner Bookstore, the Old South MeetingHouse, the Old State House, the site of the Boston Massacre and Faneuil Hall. From Faneuil Hall, Quincy Market and the statue of Samuel Adams, move toBoston’s North End. The area today is largely populated by those of Italiandescent, whose many cafes, delis and restaurants make it one of the city’smost distinct communities! Hanover and Salem Streets are the main arteries ofthe area with the Old North Church at the top of Salem Street. Built in 1723,this is Boston’s oldest religious building and most famous for the part it playedin Paul Revere’s midnight ride. Just south is North Square, site of the PaulRevere House. From the North End look across the harbor and view “OldIronsides,” the USS Constitution, and the Bunker Hill Monument, which is thelast stop along the Freedom Trail. The only stops where guests disembark arethe North End and a harbor view of the Constitution.

This Tour Includes:Round trip Motor Coach transportation - Uniformed Conventures, Inc. Guide All applicable taxes and gratuities Cost: $55.00 per personBased on a 35 person minimum per coach

Cong

ress

Info

rmat

ion

The Veni, Veidi, Vice TourNorth End Market Tour and Tasting

Tuesday July 14, 2009 9:00 AM - 12:00 PM Thursday July 16, 2009 9:00 AM - 12:00 PM 3 hours

Come see, taste and conquer the North End! If you have a passion for food,wine and all things Italian, you won’t want to miss out on this unique tourexperience. Your guide is trained by Michele Topor who has been featured onFood Network’s “The Best Of “for her knowledge of the food and markettraditions of Italy. Follow your guide through the cobblestone paths ofAmerica’s most European neighborhood to some of the best Italian marketsthis side of Rome. You’ll discover the pasticceria, the greengrocer, the deli, anenoteca , and a spice and confection store that stocks the ingredients that canmake your meals memorable. Enjoy the colorful sights, tantalizing aromas andauthentic tastes of pastries, cured meats, cheeses, the freshest seasonalproduce, and a little liquori in this Old World community. Learn cookingsecrets, sample authentic flavors and discover Mediterranean traditions as youget an “insider’s view” of one of the premier food neighborhoods in the country.It’s like visiting Italy, no passport required. Andiamo!

This Tour Includes:Round Trip Transportation via DeluxeMotor Coach North End Market Tour and Tasting Uniformed Conventures, Inc. guide All applicable taxes and gratuities This tour does involve walking, and guests are advised to wear comfortable footwear and clothing.

Cost: $115.00 per personBased on a minimum of 30 per coach

Excursions

467

468

Art & ArchitectureThe Isabella Stewart Gardner Museum, Boston Public Library and Trinity Church

Thursday July 16, 2009 1:00 PM - 4:00 PM 3 hours

Your first stop will be the Isabella Stewart Gardner Museum. Isabella StewartGardner, a Boston socialite, opened the museum on January 1st, 1903, with amusical and visual arts celebration. It now contains more than 2,500 paintings,sculptures, tapestries, furniture, manuscripts, rare books and decorative arts.The galleries house works by well-known artists, including John Singer Sargentand James McNeill Whistler. The spirit of the architecture, the personalcharacter of the arrangements and the artistic display of the enchantingcourtyard in full bloom all create an atmosphere that distinguishes the IsabellaStewart Gardner Museum as an intimate and culturally rich treasure.The next stop will be the Boston Public Library. Founded in 1848, the librarywas the first large free municipal library in the United States. The presentCopley Square location has been its home since 1895, when architect CharlesFollen McKim completed his “palace for the people.” A must see is thesumptuous Abbey Room with its luxurious beauty. The room’s dominatingfeature is the series of splendid and richly colored mural paintings, “The Questof the Holy Grail“, by the American artist, Edwin Austin Abbey. The ceiling isremarkable for its heavy ornamental rafters. Across the street is Trinity Church. Ask any architect, architectural historian, orcritic and they’ll tell you that Trinity is a masterpiece of American architecture.Dedicated in 1877, Trinity presented a bold, fresh new face and feeling forecclesiastical architecture in America. The church continues to be heraldedtoday as a celebrated example of “Richardsonian Romanesque“ design,named after its architect, H. H. Richardson.

This Tour Includes:Round Trip Transportation via Deluxe Mini or Motor Coach Entrance and Tour of Gardner, Library and Church Uniformed Conventures, Inc. guide All applicable taxes and gratuities This tour does involve walking, and guests are advised to wear comfortablefootwear and clothing.

Cost: $80 per personBased on a minimum of 35 guests per coach

Excursions

Cong

ress

Info

rmat

ion

Ducks, Sharks and PenguinsDuck Tour and New England Aquarium

Monday July 13, 2009 1:00 PM - 5:00 PM Tuesday July 14, 2009 1:00 PM - 5:00 PM 4 hours

The fun begins as soon as you board your “DUCK“, an authentic, renovatedWorld War II amphibious landing vehicle. You will receive a souvenir duckwhistle so you will not lose your voice quacking through the streets of Boston.Cruise by all the places that make Boston the birthplace of Freedom and a Cityof Firsts! From the golden-domed State House to Bunker Hill and the TDBanknorth Garden, to Boston Common and Copley Square, GovernmentCenter, fashionable Newbury Street, Quincy Market, the Prudential Tower, andmore. Once you’ve seen all of Boston by land, you’ll enter the Charles River forbreathtaking views of Boston and Cambridge from the water. The Duck will then drop you off at The New England Aquarium. Designed in1969, the aquarium’s core encloses a vast four-story ocean tank, whichcontains a wide array of marine animals. A curving walkway runs around theoutside of the tank and provides close-up viewpoints of the interior of the tankfrom different levels. Colonies of penguins, a Tropical Fish Gallery and anoutdoor tank – homes to a lively colony of harbor seals - are some of the otherfascinating exhibits.

This Tour Includes:Round Trip Transportation via Deluxe Motor Coach The Famous Boston DuckTour – Exclusive charter (not a public Duck Tour) Admission to the NewEngland Aquarium Uniformed Conventures, Inc.guide All applicable taxes andgratuities

Cost: $115.00 per personBased on a minimum andmaximum of 32 utilizing 1Private Duck

Excursions

469

470

Hometown FavoritesFenway Park and Faneuil Hall

Sunday July 12, 2009 9:00 AM - 1:00 PM 4 hours

Visit America’s most beloved ballpark, Fenway Park, where the Boston RedSox, 2004 and 2007 World Series Baseball Champions play ball! Thoughgenerations have come and gone, Fenway Park remains, much like it did theday it opened on April 20, 1912. The home of the Red Sox resounds withechoes of the past from some of the great players like Cy Young, Babe Ruth,Ted Williams, Carlton Fisk and Carl Yastrzemski to name a few. Soak up therich history; hear the echoes of the past. Visit the Green Monster, imaginebeing one of the “Knights of the Keyboard“ as you see the view from the PressBox, visit the State Street Pavilion Club before strolling around Fenway Park.With the stories of all the legends that have played here for more than eightdecades, Fenway remains an important link to baseball’s past.After the tour, enjoy a walk around the most popular tour attraction in Boston,Faneuil Hall and Quincy Market. For over 250 years, this marketplace hasplayed an important role in the life of Boston’s residents. The marketplace hasmore than 100 wonderful shops and carts and 17 restaurants and pubsincluding Cheers!

This Tour Includes:Round Trip Transportation via Deluxe Mini or Motor Coach Entrance and Tour of Fenway Park Tour of Faneuil Hall and free time Uniformed Conventures, Inc. guide All applicable taxes and gratuities This tour does involve walking, and guests are advised to wear comfortablefootwear and clothing.

Cost: $66 per personBased on a minimum of 35 per coach

Excursions

Cong

ress

Info

rmat

ion

John F. Kennedy Legacy Tour

Wednesday July, 15, 2009 9:00 AM - 1:00 PM 4 hours

Tour the John F. Kennedy Presidential Library and Museum, which portrays thelife, leadership, and legacy of President Kennedy. Experience Kennedy’sjourney from the campaign trail through his presidency. The striking I.M. Peiwhite and black modern building stands sentinel on Columbia Point near themouth of the harbor. Its interior is equally as dramatic with a 50 foot wall ofglass overlooking the sea. Several rooms recreate key chambers of theExcursions White House during the Kennedy administration including the OvalOffice. The combination of artifacts, displays and television footage evoke boththe euphoria of “Camelot” and the numb horror of the assassination.Afterwards, experience Harvard, one of the world’s most renowned academicinstitutions, and walk the same paths John F. Kennedy once traveled. The tourguide will elaborate on the history, incredible architecture and famouslandmarks in the old yard. While at Harvard, pass by the JFK School ofGovernment, a lasting tribute to one of our country’s most dedicated leaders.This beautiful campus will enchant everyone with its charming brickarchitecture and elegant style.

This Tour Includes:Round Trip Transportation via Deluxe Mini Coach or Motor Coach Tour of the John F. Kennedy Library and Museum Tour of Harvard University Uniformed Conventures, Inc. guide All applicable taxes and gratuities


Excursions

471

472

The Majesty of the Tall Ships

Saturday July 11, 2009 1:00 PM - 4:00 PM Sunday July 12, 2009 9:00 AM - 12:00 PM 3 hours

A Tall Ship is a large rigged sailing vessel. Most of the Tall Ships are mannedby a largely cadet or trainee crew who are partaking in sail training. Fiftypercent of these crew members must be aged between 15 and 25 and do nothave any previous sailing experience!Boston is hosting a “Tall Ships Celebration” in July of 2009. With over 50 of theworld’s remaining large sailing ships in port, a very special opportunity is opento the attendees of the International Society on Thrombosis and HaemostasisCongress.A motorcoach will pick up those interested attendees at the BCEC and transferthem to and from Boston Harbor private dock areas.The group will board one of the Harbor Cruise boats reserved exclusively forthem, and enjoy a magnificent water view tour of the Tall Ships in port. Yourguide will tell you which country each is from, how long they are and some oftheir fascinating maritime history. Afterwards, you will be able to board one ofthe ships (without waiting in the public lines!), meet some of the crew, tour thevessel and take pictures of these great sailing ships from another era. A oncein a lifetime experience!

This Tour Includes:Round Trip Transportation via Motorcoach Admission aboard a Cruise thru the Harbor Tour of a Tall Ship Uniformed Conventures, Inc. guide All applicable taxes and gratuities

Cost: $124.00 per personBased on a 35 person minimum per coach

Excursions

Cong

ress

Info

rmat

ion

The Gilded Age Newport Mansions TourTuesday July 14, 2009 9:00 AM - 5:00 PM 8 hours

Experience the grandiose Newport “cottages” built at the apex of the GildedAge spurred by the Industrial Revolution. Home to spectacular coastal scenery,awe-inspiring architecture, a thriving waterfront downtown and welcominghospitality, Newport, Rhode Island is considered by many to be a shining gemin the coastal crown of New England. The grandest of Newport Mansions, theBreakers, is your first stop. Railroad industrialist Commodore CorneliusVanderbilt built this estate as a symbol of the family’s social and financialpreeminence. All 70 rooms covering 138,000 square-feet abound with RobertMorris Hunt’s architecture and furnishings inspired by the 16th century ItalianRenaissance palazzos. To this day, the Breakers remains one of the mostextravagant indications of the Vanderbilt family’s fortune.Afterwards, relax with lunch at The Mooring Seafood Kitchen and Bar locatedon the waterfront at Sayer’s Wharf, directly off America’s Cup Avenue indowntown Newport. The meal will include a cup of New England clamchowder, choice of entree, dessert and beverage. One of the waterfront’sfinest restaurants, The Mooring is the perfect location for a break during thisenchanting day. As the restaurant is within easy walking distance of many ofthe local shops and attractions, guests will have about an hour to peruse thevarious boutiques along the waters edge. Your final visit will be the magnificent Marble House. The Marble House wasbuilt between 1888 and 1892 for Mr. and Mrs. William K. Vanderbilt, a summerhouse, or “cottage“, as Newporters called them in remembrance of themodest houses of the early 19th century. However, Marble House was muchmore; it was a social and architectural landmark that set the pace forNewport’s subsequent transformation from a quiet summer colony of woodenhouses to the legendary resort of opulent stone palaces.

This Tour Includes:

Round Trip Transportation via Deluxe Mini Coach or Motor Coach Guided Tour of Two Newport Mansions: 1) Breakers; and, 2) Marble House Catered lunch at The Mooring Alcoholic Beverages are not Included Uniformed Conventures, Inc. guide All applicable taxes and gratuities Cost: $138.00 per personBased on a minimum of 35 per coach

Excursions

473

474

A Whale of a TailWhale Watching Excursion

Monday July 13, 2009 2:30 PM - 5:30 PM 3 hours

Venture out on the water for an exiting day of Humpback whale watching.Cruise out to sea on a comfortable high-speed catamaran that will provide youwith more viewing time and less travel time. You will travel aboard a pristinevessel complete with climate-controlled cabins, three viewing decks,restrooms and a full service snack bar. You will find Humpback whales are anamazing species to watch. These whales are some of the largest mammals onEarth, and it is incredible to see these huge creatures leap many feet out of thewater. Humpbacks are also known for their “singing”. On board you will enjoya professional researcher from the Whale Center of New England to narrateyour tour.A whale of a good time!

This Tour Includes:Round Trip Transportation via Deluxe Motor Coach Public Whale Watching Excursion Uniformed Conventures, Inc. guide All applicable taxes and gratuities


Pleasurable Provincetown

Wednesday July 15, 2009 8:30 AM - 6:00 PM 9.5 hours

Zoom to Provincetown in 90 minutes on the newest, most luxurious ferry fromBoston. The state of the art catamaran, the Provincetown III, has amplecomfortable seating and an enclosed, air-conditioned lower deck. You will be awed by the amazing sand dunes on the Provincetown Cape CodNational Seashore protected lands during this special tour. Expert guides willentertain you with their knowledge and history of these special dunes as youride in a comfortable SUV. Enjoy dunes that stretch as far as you can see withwispy beach grass, dark green pine trees and deep red beach plums nestled

Excursions

Cong

ress

Info

rmat

ion

in hollows, which are brought together by a silhouette of blue sky. Your journeyalong the shoreline will enlighten you about the “dune shacks” that inspiredsuch famous artists and writers as Eugene O’Neill and Harry Kemp. Enjoy thislovely tour as a peaceful retreat from metropolitan Boston. Satisfy your hunger with lunch at the famed Lobster Pot. For all you fishconnoisseurs, enjoy the fresh lobster rolls, clam roll, and various seafooddishes. If fish is not your preference, there are many options available. After thisrelaxing stop, get ready for the next excursion.Enter the Provincetown Art Association and Museum (PAAM) where you willview their phenomenal collections spanning an 80-year period. This is one ofthe premier art museums in the country, and includes a permanent collectionof regional art. PAAM was founded by artists in 1914 to be the focal point ofthe new summer art colony. The Museum has flourished over the years; itscollection now numbers 2,000 works, and its reputation is recognized acrossthe country and internationally. PAAM averages 35 exhibitions year-round infour galleries. In today’s less competitive atmosphere, it’s not unusual to seean acknowledged master sharing space with a less-skilled upstart. Juriedmembers’ shows usually accompany the in-depth retrospectives, so there arealways new discoveries to be made. After these intriguing adventures, yourgroup will have the opportunity to explore the quaint shops and galleries inProvincetown on their own. Enjoy finding your own Provincetown treasures!

This Tour Includes:Round Trip Transportation Boston-Provincetown via Provincetown III ferry Private Guided Tour of the Provincetown Cape Cod National SeashoreDunes via car Lunch at the Lobster Pot Admission and Guided Tour of the Provincetown Art Association andMuseum (PAAM) Uniformed Conventures, Inc. Guide All applicable taxes and gratuities


Excursions

475

N O T E S

477

AuthorsIndex

ISTH2009

Aakhus S., PP-TH-427

Aarden L., PP-TH-153

Aarsetøy H., PP-WE-830, PP-WE-831

Aaspollu A., PP-MO-149

Ababneh B. A., PP-WE-504

Abad-Franch L., PP-TH-627,PP-WE-668, PP-TH-544

Abalotti C., PP-TH-487, PP-WE-147

Abasolo N., PP-WE-821

Abate C., PP-MO-503

Abate M., PP-WE-311

Abbate R., AS-TH-034, OC-MO-010, OC-TH-047, OC-WE-031, OC-WE-032, OC-WE-102, PP-MO-013, PP-MO-217, PP-MO-303, PP-MO-304, PP-MO-339, PP-MO-340, PP-MO-341, PP-MO-743, PP-MO-799, PP-MO-800, PP-MO-801, PP-MO-802, PP-MO-803, PP-MO-804, PP-MO-805, PP-MO-818, PP-MO-836,

Abbott D., PP-WE-636

Abbott L. S., PP-WE-447

Abboud M., PP-TH-456, PP-WE-686

Abd.Karim F., PP-MO-636

Abdel Gader A. M., PP-WE-363

Abdelgadir A. M., PP-MO-057,PP-WE-163

Abdelkarim R., PP-WE-281

Abdel-Razeq H. N.,PP-MO-488, PP-WE-504

Abderrazak F., PP-TH-343

Abdihakim A., PP-MO-805

Abdo A. A., PP-WE-163

Abdul Karim F., PP-MO-651

Abdulkadirov K. M.,PP-MO-495

Abdullahi Said A., PP-WE-746

Abe K., OC-TH-107

Abe M., PP-TH-521

Abe Y., PP-TH-526

Abegunde S. O., PP-TH-500,PP-TH-501

Abel K., PP-MO-578

Aberson H., PP-MO-489, PP-WE-839

Abgral R., PP-WE-510

Abgrall J. F., PP-TH-189

Abgrall J., PP-TH-113, PP-MO-310

Abi-Ayad C., PP-TH-276

Abinet I., PP-WE-532

Abletshauser C., PP-MO-420,PP-TH-425

Abolghasemi H., PP-TH-210

Abou-Saleh R. H., PP-WE-259

Abousamra N. K., PP-WE-257

Abousamra N. K., PP-WE-257

Abrahams J. M., OC-WE-067,PP-WE-848, PP-WE-849

Abrams S. T., PP-TH-129

Abrams S., OC-TH-091

Abriss D., AS-TH-014

Abshire T. C., PP-MO-596, PP-WE-613

Abslander G., PP-WE-712

Abulata N., PP-MO-277

Aburima A. A., PP-MO-023

Aburubaiha Z. A., PP-TH-696

Acaia B., PP-WE-691

Acevedo M., PP-WE-121

Achenbach T., PP-WE-488

Ackermann B., PP-MO-694

Acuña S., PP-WE-654

Adam F., OC-WE-043, AS-TU-024

Adam M., PP-TH-185

Adam S., PP-MO-768, PP-TH-655

Adamczuk Y. P., PP-TH-333

Adamczuk Y., PP-MO-275

Adamo M., PP-TH-102

Adams G. N., OC-MO-128

Adams G., OC-TH-056

Adamson P. J., OC-MO-115,PP-MO-250

Adamson U., OC-TH-079, OC-WE-104

Ádány R., PP-WE-350

Addad F., PP-TH-343

Adebayo A. O., PP-TH-209

Adelmeijer J., PP-WE-771

Adeyemi A. A., PP-MO-278,PP-WE-330

Adiguzel C., OC-TH-019, PP-MO-136, PP-MO-139, PP-MO-140, PP-MO-143, PP-MO-399, PP-TH-145, PP-TH-166, PP-TH-390, PP-WE-143, PP-WE-166, PP-WE-261, PP-WE-385, PP-WE-387, PP-WE-482

Adjali M., PP-WE-639

Adraktas T., PP-MO-715

Advate Pass Study G.,PP-TH-576

Afink G. B., OC-TU-055

Afrasiabi A., PP-WE-459

Agaoglu L., PP-MO-222

Agar C., PP-MO-262

Ageenkova A. V., PP-MO-688,PP-TH-454

Ageno W., OC-MO-092, OC-TH-011, OC-TH-014, PP-MO-301, PP-MO-308, PP-MO-309, PP-MO-462, PP-MO-463, PP-MO-659, PP-TH-507, PP-WE-313, PP-WE-340, PP-WE-403

Agerkvist I., PP-MO-574

Agerso H., PP-MO-569, PP-MO-570

Agersoe H., OC-MO-085

Aghighi S., PP-MO-524, PP-TH-551

Aghili M., PP-WE-281

Agic D., PP-WE-680

Agnelli G. G. A., PP-MO-312

Agnelli G., OC-MO-018, OC-MO-092, OC-TH-014, OC-TU-024, PP-MO-282, PP-MO-457, PP-MO-458, PP-MO-476, PP-WE-313

Agostini M., PP-TH-453

Agrawal S. G., PP-WE-377

Agriello E., PP-TH-060

Agterof M. J., PP-WE-317, PP-WE-318, PP-WE-475

Aguilar S., PP-WE-073

Aharon A., OC-TU-057, OC-TU-058

AUTHORS INDEX

478

Aut

hors

Inde

x

Ahluwalia J., PP-MO-324, PP-TH-272, PP-WE-266, PP-WE-456

Ahmad F., PP-MO-638, PP-WE-037

Ahmad R. U., OC-TH-054, OC-WE-063

Ahmadian H., PC-042

Ahmadian L., PP-WE-518

Ahmadinejad M., PP-WE-324

Ahmadinejad T., PP-WE-324

Ahmadkia Daliri A., PP-TH-534

Ahmed A., PP-MO-661

Ahmed F., PP-TH-538

Ahmed M., PP-TH-062

Ahmidatou H., PP-TH-204

Ahrens I., PP-MO-100

Aiach M., AS-TH-023, OC-TU-032, PP-MO-835, PP-TH-189

Aida K., PP-WE-793

Aikawa E., AS-WE-057

Aillaud M. F., PP-TH-189

Aisina R. B., PP-TH-227

Aisina R., PC-005, PP-TH-219

Aissaoui H., OC-WE-021

Aïtchafa Tadlaoui D., PC-018,PP-MO-445

Aitken E. W., OC-MO-045

Aivado M., AS-MO-055

Aixalá M., PP-MO-204

Ajayi I. O., PC-009, PP-TH-500,PP-TH-501, PC-008

Ajayi I. O., PC-008

Ajayi O. I., PP-MO-278, PP-WE-330

Ajjan R. A., OC-TH-055, OC-WE-114, PP-TH-351, PP-WE-212

Ajjan R., PP-WE-215

Ajzenberg N., PP-MO-077

Akagi E. M., PP-TH-495

Akar N., PC-001

Akarsu S., PP-WE-708, PP-WE-709

Akasaka T., PP-MO-429

Akassaglou K., AS-TU-045

Akassoglou K., SA-WE-001

Akay O. M., OC-MO-002

Akbar H., PP-TH-095, PP-WE-006

Akcay A., PP-MO-073, PP-TH-121, PP-WE-571

Akdogan M., PC-003

Akhremitchev B. B.,OC-WE-147

Akhter M. S., PP-MO-208, PP-WE-327

Akhvlediani M., PC-019

Akiba E., PP-TH-054

Akici F., PP-MO-073, PP-TH-121, PP-WE-571

Akinshina S. V., PC-017, PP-MO-360, PP-MO-361, PP-TH-278, PP-TH-378, PP-TH-379

Akiyama M., AS-MO-012, PP-MO-080

Akkerman J. N., OC-TU-030,OC-WE-046

Akkerman J. W. N., PP-MO-007, PP-MO-035, PP-MO-036,PP-TH-046, PP-WE-024

Åkra S., PP-TH-118

Akrami M., PP-MO-214

Akria L., PC-053

Aksöyek A., PP-WE-880

Aksu S., PP-MO-606, PP-MO-653

Akulich N. V., PP-WE-820

Al Dieri R., PP-MO-251, PP-MO-582, PP-TH-246, PP-WE-683

Al Duhgyal M., PP-WE-163

Al Ghomlas A. K., PP-MO-057

Al Ghumlas A. K., PP-WE-163

Al Haidari A., PP-MO-057

Al Harthi A., PP-MO-425, PP-WE-280

Al Mohareeb F., PP-WE-280

Al Nounou R., PP-TH-062

Al Sania F. M., PP-WE-163

Al Sawat K., PP-WE-163

Al Zahrani H., PP-WE-280

Ala F. A., PP-MO-539

Ala F., PP-TH-318, PP-TH-553,PP-TH-636

Alam S., PP-MO-135, PP-WE-377

Alamelu J., PP-WE-609

Alatri A., OC-TH-003, OC-TH-006, PP-MO-290, PP-MO-291,PP-MO-496, PP-TH-374, PP-TH-375, PP-WE-682

Al-Awadhi A. M., PP-WE-724

Alba L., PP-TH-606

Alba R., PP-WE-151

Alban S., PP-TH-192, PP-TH-193, PP-WE-506

Albanez S., PP-TH-555

Albanyan A., OC-TU-056

Albar J. P., PP-TH-591

Albayrak D., PP-WE-806

Albayrak G., PP-TH-511

Albayram S., PC-039

Alber M., PP-WE-394

Alberio L., PP-MO-736, PP-MO-753, PP-TH-692, PP-WE-211, PP-WE-717

Alberti S., PP-WE-048

Alberto F., PP-MO-204

Alberto M. F., PP-MO-038, PP-MO-274, PP-TH-100, PP-TH-350, PP-WE-354

Alberto M., PP-MO-056

Alberts P., PP-TH-103

Albisetti M., OC-TU-061, PP-TH-446

Albors M., PP-MO-637

Albrecht S., PP-MO-824

Alcalá Pedrajas J. N.,PP-WE-360

Aldeshev A., PP-WE-281

Aledort L. M., PP-WE-704

Aleil B., OC-MO-008

Alekseeva L. A., PP-WE-224

Aleksic D., PP-WE-254

Alemany G. V., PP-WE-428

Alesci S. R., PP-TH-644

Alesci S., PP-MO-584, PP-TH-651, PP-TH-652

Alessandrello Liotta A.,PP-TH-474

AUTHORS INDEX

479

Alessi M. C., OC-WE-099, PP-MO-774

Alessi M., AS-TU-024, OC-MO-007, OC-MO-021, OC-TH-045, PP-MO-773, PP-TH-309, PP-WE-775

Alessio A. M., PP-MO-870

Alexander R. A., PP-WE-843

Alexandrova E. N., PP-MO-268, PP-TH-267, PP-TH-277

Alexandru N., PP-MO-855, PP-TH-003

Alexanyan M. G., PP-MO-218,PP-MO-668, PP-WE-170

Alfahim A., PP-WE-281

Alfter K., PP-MO-253

Algra A., AS-WE-008, OC-WE-036, PP-TH-339

Alhenc-Gelas M., OC-TH-022,PP-TH-189, AS-TH-001

Ali E., PP-TH-522, PP-TH-523,PP-WE-520

Ali F. Y., AS-WE-052, PP-TH-001

Ali U., PP-TH-220

Alía P., PP-WE-816

Al-Jafar H. A., PP-WE-724

Alkindi S., PP-MO-675

Allard S., OC-TH-067, PP-TH-685

Allart S., OC-MO-099, PP-WE-019

Allen D. J., PP-MO-065

Allen K. L., OC-TU-042

Allen S., PP-MO-043

Alley S., PP-WE-118

Allievi A., PP-WE-236

Allison A. C., OC-TH-060

Al-Marwani A. O., PP-MO-075

Almasy L., PP-TH-289, PP-TH-290, PP-WE-208, PP-WE-209, PP-WE-243

Almeida N., OC-TH-084

Almenar L., PP-TH-363, PP-WE-885

Almomen A. M., PP-WE-363

Almonte T. M., PP-WE-541

Aloisio L., PP-MO-654

Alonso S., OC-TH-081, OC-WE-099

Al-Tamimi M., OC-MO-110

Altantsetseg E. E., PP-TH-017

Althaus H., PP-TH-241

Althaus K., OC-TH-024, OC-TH-102

Altintas F., PP-TH-284

Altisent C., PP-MO-528, PP-MO-560, PP-MO-566, PP-MO-590, PP-MO-601, PP-TH-596, PP-WE-234, PP-WE-237, PP-WE-761

Altomare M., PP-WE-878

Altun M., PP-WE-571

Álvarez A., PP-WE-236

Alvarez C., PP-MO-413

Alvarez M., PC-048, PP-MO-579, PP-TH-059, PP-TH-603, PP-TH-604, PP-WE-560, PP-WE-765

Al-Wazzan H. J., PP-WE-724

Aly Aldeen Abd Elbasset AlyMohamed M., PP-TH-445

Alzadjali S., PP-MO-675

Al-Zahrani A., PP-TH-459

Al-Zahrani F. M., PP-MO-052

Amadio P., PP-WE-868

Amanat S. T., PP-TH-643

Amann-Vesti B., PP-MO-643

Amano K., PP-TH-592, PP-WE-606, PP-WE-666

Amaral J., PP-TH-434

Amato A., PP-MO-351, PP-WE-509

Amaya M., PP-TH-482, PP-WE-001

Amelot A. A., PP-MO-237

Amengual O., PP-WE-269, PP-WE-271

Amin A. N., OC-TH-016, PP-WE-465

Amin C., PP-MO-768, PP-TH-655

Amirabadi A., PP-MO-518

Amiral J. J., PP-MO-419, PP-MO-697, PP-MO-701

Amiral J., PP-WE-199

Amirizadeh N., PP-TH-210

Amirkhosravi A., PP-MO-004,PP-TH-482, PP-TH-491, PP-WE-001, PP-WE-108, PP-WE-485

Amlie-Lefond C., PP-MO-442

Ammollo C. T., PP-MO-176,PP-MO-245, PP-MO-423, PP-WE-249

Amodeo R., PP-MO-634, PP-MO-635

Amore C., AS-TU-042

Amuzescu M., PP-MO-855

Anak S., PP-MO-222

Anand S. S., PP-MO-086

Anand S., PP-WE-800

Anastasopoulou I., PP-MO-715, PP-TH-609, PP-TH-467

Anastasovska L., PC-028

Anastasovski S., PC-028

Ancona E., PP-WE-248

Ande A. A., PC-008

Ande A. B., PP-TH-111

Andersen A. S., PP-MO-405

Andersen M. D., PP-MO-575

Andersen M. R., PP-WE-383

Andersen M., PP-WE-319, PP-WE-740

Anderson D. A., OC-TU-011

Anderson D., PP-WE-462

Anderson F. A., OC-MO-052,PP-MO-247, PP-MO-248

Anderson F., OC-MO-054

Anderson P. J., AS-MO-014

Andersson A., OC-TU-096

Andersson H. M., AS-TU-019

Andjelkovic N., PP-WE-664

Andrade M. V., PP-MO-387

Andre P., AS-TH-022, PP-MO-045, PP-TH-027, PP-WE-801, AS-TU-026

Andre S., PP-MO-588

André S., OC-MO-064, OC-WE-066, PP-TH-172

Andrea D., PP-MO-056

Andrei E., PP-MO-855

Andrei-Selmer C., AS-MO-057

AUTHORS INDEX

480

Aut

hors

Inde

x

Andreozzi G., PP-WE-338

Andrew P. C., OC-TU-060

Andrews R. K., AS-TU-039,OC-MO-110, PP-MO-033

Andrews R., AS-WE-032

Andronicos N. M., AS-TU-020

Andziak P., PP-WE-433

Angela D., PP-MO-487

Angelillo-Scherrer A.,AS-TU-018, OC-MO-044, OC-WE-037, OC-WE-134

Angeloni G., PP-WE-048

Angelosanto N., PP-MO-287

Angerer J. I., AS-TH-057, OC-WE-051, PP-MO-620

Angio-Getbo Group A.,PP-TH-508

Angiolillo D. J., PP-WE-022

Angles-Cano E., AS-WE-050,OC-TH-113, PP-MO-794, PP-TH-039

Anglés-Cano E., OC-WE-111

Angus G., PP-MO-231

Anicchino-Bizzacchi J. M.,PP-MO-521

Anisimov M. G., PP-TH-512

Ankri A., PP-WE-333

Annarumma L., PP-MO-342,PP-TH-347

Annetta S. E., OC-TU-064, PP-MO-687

Annichino-Bizzacchi J. M.,PC-046, PP-MO-145, PP-MO-520, PP-MO-725, PP-MO-825, PP-MO-826, PP-MO-870, PP-TH-157, PP-TH-466, PP-TH-554, PP-WE-294, PP-WE-295, PP-WE-296, PP-WE-476, PP-WE-535

Annichino-Bizzachi J. M.,PP-TH-532

Annie Bang K. W., PP-MO-020

Ansell S. M., PP-MO-487

Antalfi B., PP-WE-350

Antic D. A., PP-MO-599

Antic D., PP-WE-634

Antman E., OC-WE-003

Antmen B., PP-MO-606, PP-MO-644, PP-WE-607

Antoine G., OC-WE-063

Antón A. I., AS-MO-054, PP-MO-144, PP-TH-287, PP-WE-123

Anton A., PP-TH-481

Antón A., AS-TH-052, OC-TH-120, PP-WE-764

Antonazzo P., PP-MO-375

Antongiovanni M., PP-MO-803

Antoni G., OC-MO-021

Antonijevic N. M., PP-TH-296

Antonijevic N., PP-TH-460, PP-WE-368

Antonijoan R. M., PP-WE-178,PP-WE-415

Antonino M. J., PP-MO-739,PP-TH-101, PP-WE-757, PP-WE-794, PP-WE-797, PP-WE-798, PP-WE-799

Antonino M., PP-MO-771, PP-TH-026, PP-WE-043, PP-WE-801, PP-WE-802

Antonova O. A., PP-MO-856

Antonucci E., AS-TH-034, OC-WE-102, PP-MO-303, PP-MO-304, PP-MO-339, PP-MO-340, PP-MO-341, PP-MO-743, PP-MO-818, PP-TH-352, PP-TH-353, PP-TH-474, PP-WE-002, PP-WE-283,PP-WE-745, PP-WE-746, PP-WE-747, PP-WE-748

Antovic A., OC-TH-079, OC-WE-104, PP-MO-374, PP-MO-761

Antovic J. P., PP-MO-703, PP-WE-114

Antovic J., PP-MO-533, PP-MO-762, PP-WE-664

Antunes M. B., PP-WE-588

Anveden P., PP-MO-258, PP-TH-695

Anyanwu R. A., PP-TH-111

Aoki S., OC-WE-038, PP-WE-222

Aouba A., PP-WE-592

Aoun J., PP-WE-281

Apan H., PP-TH-235

Apeler H., OC-WE-059

Apergis G., PP-WE-314

Apitz-Castro R., PP-TH-155

Apostolovska R., PC-014, PC-027, PC-028, PP-TH-271,PP-WE-426

Appa R. S., PP-MO-121, PP-MO-122

Appa R., OC-MO-058, PP-MO-177, PP-TH-150, PP-TH-151

Appel B., OC-TH-023

Appelbom H. I., PP-TH-237

Appio L., PP-MO-309, PP-WE-340

Arachiche A., PP-WE-008

Aranko K., PP-TH-068

Arantes M. J., AS-TU-019

Araujo G., PP-TH-316

Araújo I. G., PP-TH-178

Araya V., OC-WE-090

Arbasi M., PP-MO-523

Arbesú I., PP-WE-208, PP-WE-209

Arbuthnot C., OC-TH-015

Arca M., PP-WE-246

Arcaini L., AS-TU-004

Arcamone G., PP-MO-448, PP-TH-493

Arcangeli C., PP-MO-303, PP-MO-304, PP-WE-283

Arcari A., PP-MO-876

Arcelus J., OC-TU-019

Archarit N., PC-052

Arderiu G., AS-WE-055, OC-TH-090

Ardeshiri Y., PC-044, PP-MO-655

Ardissino D., PP-WE-339

Arellano A. R., OC-MO-020

Arepally G. M., AS-TH-006

Arepally G., OC-TH-020

Arguello A., PP-MO-526, PP-MO-737, PP-WE-692

Arguello S., PP-TH-606

Arhan M., PC-003

Arias-Salgado E., PP-TH-059

Aridogan A., PP-WE-607

Ariens R. A. S., OC-MO-076,OC-MO-115, OC-TH-055, PP-TH-351, PP-WE-130, PP-WE-212, PP-WE-215

AUTHORS INDEX

481

Ariëns R. A. S., PP-MO-250,PP-TH-212, PP-WE-231, PP-WE-259

Arif A., AS-TU-041

Ariga T., PP-TH-229

Arikan E., PP-TH-221

Arina G. A., PC-041

Aristizabal M., PP-MO-160

Armand-Perroux A.,OC-TH-018

Armani C., OC-WE-029

Armero S., PP-MO-785

Armstrong P. C. J.,PP-MO-740, PP-MO-741, PP-TH-001, PP-TH-002

Arnason J. E., PP-TH-624

Arnaud E., PP-MO-112, PP-MO-766, PP-TH-183, PP-TH-235, PP-WE-164, PP-WE-619

Arnaud L., OC-TU-089

Arnaud P., PP-MO-530

Arndt B., OC-TH-101

Arnesen H., PP-MO-719, PP-TH-118, PP-TH-427, PP-WE-026, PP-WE-344

Arning M., AS-MO-055

Arnold M., OC-WE-034

Arnould B., PP-WE-425

Arnout J., PP-TH-520, PP-TH-625, PP-TH-635, PP-WE-267,PP-WE-270, PP-WE-525

Arnuti B., PP-TH-385

Arocas V., AS-TU-024, OC-WE-070

Aronis S., PP-TH-597, PP-WE-440, PP-MO-619

Arora N., PP-TH-275

Arora V., PP-TH-232, PP-TH-403

Arruda V. R., AS-TH-013, AS-TU-013

Arruda V., PL-TU-004, AS-TH-046

Arshinov A. V., PP-MO-260

Arslan A. A., OC-TU-039

Arslan F., PP-WE-709

Artesani L. L., PP-TH-452

Arthur J. F., AS-TU-039

Artoni A., AS-WE-020, OC-MO-131, PP-MO-092

Arya R., OC-MO-088, OC-MO-089, OC-TH-076

Arza B., PP-WE-525

Arzamendi D., OC-WE-007,PP-MO-254

Asada R., PP-MO-704

Asada Y., PP-MO-111, PP-MO-123, PP-MO-127

Asahara M., PP-MO-439

Asakura H., PP-TH-057, PP-WE-278

Ashby D., OC-TU-002

Ashcroft B., AS-WE-019

Ashikaga T., OC-MO-003

Ashrani A. A., AS-TH-003, PP-MO-284, PP-TH-220

Asidin N., PP-MO-636

Askalan R., PP-TH-463

Asmelash G., PP-MO-584, PP-TH-644, PP-TH-651

Asmis L. M., OC-MO-129

Asmis L., PP-MO-318

Assafim M., PP-TH-179

Asselta R., PP-MO-210, PP-MO-648, PP-TH-630, PP-TH-670, PP-WE-657

Assi Z., PP-TH-376

Astermark J., OC-TH-050, PP-MO-540, PP-MO-541, PP-WE-570, PP-WE-611

Astudillo O. G., PP-WE-402

Asvold B. O., OC-WE-013

Ataga K. I., PP-MO-768, PP-TH-655

Atalar A., PP-WE-568

Atalay C. S., PP-TH-511

Atanasov B. P., PP-WE-614

Atanasova S., PP-TH-271, PP-WE-426

Atarodi K., PP-WE-324

Ataullakhanov F. I.,PP-MO-182, PP-MO-235, PP-WE-253

Athale U., PP-MO-494, PP-TH-503, PP-WE-507

Atilla B., PP-TH-284

Atkinson H. M., PP-MO-197,PP-WE-173

Atmaca S., PP-WE-806

Atsumi G., PP-MO-864

Atsumi T., PP-MO-842, PP-WE-269, PP-WE-271

Attias D., PP-WE-272

Attilio M., PP-MO-056

Attwood S. J., PP-MO-058

Auerswald G., PP-MO-603, PP-MO-647

Auh H., PP-MO-389

Aujesky D., SA-MO-001, OC-MO-041, PP-MO-299, PP-TH-524

Aung P. P., PP-WE-101

Austin H., PP-TH-324, PP-TH-325, PP-TH-326, PP-TH-327, PP-TH-328

Austin R. C., AS-MO-022

Austin S., PP-TH-683

Austinat M., OC-WE-040

Averett L. E., OC-WE-147

Averkov O., PP-TH-223

Averna M., OC-TU-088, PP-MO-016

Avery G., PP-WE-503

Awodu O. A., PP-MO-276, PP-MO-278, PP-TH-111, PP-TH-209, PP-WE-330, PP-TH-500, PP-TH-501

Ay C., OC-MO-027, OC-TU-013, OC-TU-015, OC-TU-016, PP-MO-322, PP-WE-663

Ay Y., PP-WE-577

Ayachi O., AS-MO-063

Ayad A. S., PP-WE-564

Ayad S., PP-TH-276

Ayares D., PP-MO-070

Ayats J., PP-WE-761

Ayaz Ozkul A., PP-MO-858

Ayaz S., PP-TH-686, PP-WE-880

Aydogan G., PP-MO-073, PP-TH-121, PP-WE-571

Aydogdu S., PP-WE-577

Ayers D., PP-MO-247

AUTHORS INDEX

482

Aut

hors

Inde

x

Aygören Pürsün E.,PP-MO-130

Aygören-Pürsün E.,PP-TH-162, PP-WE-434

Ayob Y., PP-MO-636

Azari B. M., OC-TH-092

Azevedo M., OC-WE-037

Azibani F., OC-WE-070

Aznar J. A., PP-MO-589, PP-MO-590, PP-TH-544, PP-TH-627, PP-WE-668

Aznar M., PP-TH-606

Azzam N., PP-WE-163

Azzaoui R., PP-MO-814

B. Johnsen L., PP-MO-565

Baarslag M. A., PP-WE-548

Babinska A., OC-TH-092

Babyn P., AS-WE-003, PP-WE-553

Baccarelli A., PP-MO-321

Bacci M., PP-WE-791

Baccouche H., PP-TH-297

Bach R. R., PP-MO-314, PP-TH-110

Bachar A., OC-TU-057

Bachelot-Loza C., AS-TH-023,OC-TH-022, PP-MO-391, PP-MO-748

Bachli E., PP-MO-643

Bäck J., OC-MO-106

Bäckhed F., AS-WE-054

Backx P. H., PP-TH-125

Bacon C. L., PP-MO-593

Bacon S. B., PP-TH-525

Bacon S., OC-TH-076, PP-TH-480

Badainh F. A., PP-MO-488

Badalucco S., PP-MO-067

Bade A., PP-MO-603, PP-MO-647

Badenhorst P., PP-WE-726

Bader M., AS-MO-047

Badila A., PP-MO-855

Badimon J. J., PP-MO-834

Badimon L., AS-MO-065, AS-WE-055, OC-TH-090

Badirou I., AS-TH-015, OC-MO-060, PP-MO-090

Badoz M., PP-WE-533

Badr M., PP-TH-445

Badr S. A., PP-WE-067

Bækgaard N., AS-MO-008

Baena J., PP-WE-761

Baer A., PP-TH-408

Bagemühl J., AS-TH-007

Bagger-Sørensen A.,PP-MO-580

Baggio M. S., OC-WE-023

Baghaei F., PP-MO-567, PP-MO-652, PP-WE-206

Baghaiepour M. R.,PP-MO-552

Baghaipour M. R., PP-WE-559

Bagherian M., PP-WE-558

Baghiu D., PP-MO-532, PP-WE-549

Baglin C. A., PP-MO-289

Baglin T. P., PP-MO-289

Baglin T., SA-TH-001, AS-TH-005, OC-TH-002, OC-TH-004, PP-TH-240, PP-TH-412, PP-WE-133, PP-WE-286, PP-WE-556

Bagoly Z., PP-MO-009, PP-WE-774

Bagot C. N., OC-MO-088, OC-MO-089

Bahatyrova S., AS-WE-019

Bahawdory M., PP-WE-703

Bahena A., PP-MO-794

Bahtiyar E., PP-TH-511

Bai B., PP-MO-549, PP-WE-291

Bai C., PP-MO-131

Bai H., AS-TU-020

Bai X., PP-MO-830, PP-MO-854, PP-MO-859, PP-TH-621, PP-WE-711

Baiardi G., AS-TH-030

Baidya S., PP-TH-275

Baik N., AS-TU-020

Bailey C., AS-TU-002

Bailey K. R., AS-TH-003, PP-MO-284

Bailey M., PP-TH-067, PP-WE-083

Bailley M., PP-TH-073

Bailly N., PP-MO-040

Bailon O., PP-TH-026, PP-WE-043

Baimuradova S. M., PC-017,PP-MO-360, PP-MO-361, PP-TH-278, PP-TH-378, PP-TH-379

Bajetta M. T., OC-WE-131

Bajzar L., OC-TH-116, OC-TU-066, PP-MO-435, PP-MO-454,PP-MO-455, PP-MO-456, PP-TH-531, PP-WE-238, PP-WE-450, PP-WE-452

Bakchoul T., AS-MO-052

Baker A. H., OC-TU-076, PP-WE-150, PP-WE-151

Baker C. H., PP-TH-491

Baker R., PP-MO-019, PP-TH-188

Bakhos M., PP-MO-399, PP-TH-391, PP-TH-404, PP-WE-387

Bakhsh E., PP-MO-425

Bakhtiari K., AS-TU-035

Bakowski-Enzian B.,PP-MO-162

Bal Dit Sollier C., OC-MO-011,PP-MO-074, PP-MO-175, PP-MO-421, PP-TH-680, PP-WE-412, PP-WE-810, OC-WE-099

Balakhonova T. V., PP-WE-526

Balakrishnan U., PP-WE-834

Balandina A. N., PP-MO-235,PP-WE-253

Balasch J., PP-WE-371

Baldacci E., PP-MO-287

Baldelli F., OC-WE-087

Baldellou M., AS-MO-065

Balduini A., PP-MO-067

Balduini C. L., PP-MO-067

Balduini C., AS-TU-004, PP-MO-018, PP-MO-046, PP-MO-085

Baleja J. B., PP-TH-159

Bali L., PP-MO-773

Balibrea J., LB-MO-002

AUTHORS INDEX

483

Balkan C., PP-MO-606, PP-WE-577

Balkanov T., PP-TH-271, PP-WE-426

Ball G., OC-WE-092

Ballard N. E., PP-MO-388

Balling K. W., PP-WE-582, PP-WE-589

Ballon F., PP-WE-073

Balmforth A. J., AS-TH-019,OC-MO-115

Balogh E., PP-TH-366

Balsara R. D., OC-WE-022

Baltar P., PP-MO-579

Baltayiannis G., PP-WE-681

Baltopoulos P., OC-TH-044

Baluch S., PP-WE-324

Bambace N. M., AS-MO-032

Bamford J. M., OC-WE-114

Banaszewski M., PP-WE-795

Bandi A., PP-MO-777, PP-MO-778

Bandinelli B., PP-MO-013

Bandinelli S., PP-WE-311

Banfi C., PP-WE-050

Bang S., PP-MO-301, PP-TH-504, PP-WE-069, PP-WE-496

Banno F., PP-MO-093, PP-WE-090

Banno M., PP-WE-872

Baños M., PP-MO-794

Banov L., PP-MO-525, PP-MO-616

Banoviæ M., PP-TH-258

Bansal V., PP-MO-143, PP-TH-145, PP-WE-166, PP-WE-261

Banti A., PP-MO-779

Banyai M., PP-TH-492

Banzato A., OC-MO-028, OC-MO-113, OC-TU-040, PP-TH-274

Bao H., PP-MO-883

Bao J., PP-WE-857

Baraj B., AS-TH-045

Baran B., PP-MO-714, PP-TH-658, PP-WE-660

Barazer I., AS-TH-032, OC-MO-132, PP-MO-783, PP-WE-744

Barbanoj M. J., PP-WE-178,PP-WE-415

Barbar S., OC-MO-049, PP-TH-488, PP-WE-147

Barbara B., PP-MO-056

Barbato D., PP-MO-876

Barbato E., PP-WE-416

Barbay V., PP-TH-144, PP-WE-859

Barberis G., PP-MO-616

Barbic-Zagar B., PP-MO-350

Barbieri I., PP-MO-285

Barbieri S. S., PP-WE-050, PP-WE-868

Barbour E. M., AS-MO-027

Barbui T., AS-TU-048, AS-TU-050, PP-MO-867

Barcella S., PP-WE-050

Barcellona D., OC-MO-028,PP-MO-266, PP-MO-267

Barchitta A., PP-MO-331

Barcinski M. A., PP-TH-499

Barco S., PP-MO-415

Bardhan A., PP-TH-090

Bardin N., AS-MO-060

Bare L. A., AS-MO-005, OC-MO-020

Bareiss P., PP-MO-416

Barendracht A., PP-TH-055

Barendrecht A., OC-TH-025

Barett J., OC-WE-094

Baretton G. B., PP-MO-824

Barfoed A., PP-WE-383

Bari S., PP-MO-038

Barillari G., OC-MO-121

Barinagarrementería F.,PP-WE-264

Baris M., PC-039

Baris S., PC-039

Barisciano M., PP-MO-099,PP-TH-048

Barisone E. E., PP-TH-452

Barizzi G., PP-MO-736, PP-WE-717

Bark D. L., AS-MO-040

Bark N., PP-TH-141, PP-TH-186

Barker K., PP-WE-574

Barna L., PP-WE-549

Barnard D. R., PP-WE-447

Barnard D., PP-MO-686

Barnard J., PP-WE-101

Barnes C. D., PC-043

Barnes C., PP-WE-531

Barnes P., PP-TH-473

Baron G., AS-WE-025, PP-MO-332,

Baronciani L., OC-TU-072, PP-TH-630, PP-WE-625

Barone M., AS-MO-009, PP-MO-415

Barouch D. H., PP-WE-151

Barr A., PP-TH-021

Barr J. D., OC-WE-041

Barr J. Y., PP-WE-389

Barragan P., PP-MO-787, PP-MO-785

Barré J., OC-MO-050

Barreira J., PP-WE-236

Barreiro E. J., PP-MO-390

Barrellier M. T., OC-TU-022

Barrenetxe J., OC-MO-130,OC-TH-113

Barreto S. A., PP-TH-495

Barreto S., PP-WE-312

Barrett Y., PP-MO-407

Barron N., AS-TU-059

Barros F. E. V., PP-MO-034

Barruet E., OC-TH-045

Barry R. G., PP-TH-520, PP-TH-625, PP-WE-267, PP-WE-270, PP-WE-768

Barsegov V., PP-TH-214

Barsoum M. K., PP-MO-284

Barsoum M., AS-TH-003

Bartfeld G., PP-WE-036

Bartimoccia S., PP-TH-050

Bartorelli A., PP-WE-356

Bartosová L., PP-TH-305, PP-TH-306

Bartrop R., PP-MO-410

AUTHORS INDEX

484

Aut

hors

Inde

x

Bartunek J., PP-WE-416

Baru M., PP-TH-536, PP-WE-608

Baruch D., OC-WE-149, PP-MO-090

Basabe-Desmonts L.,PP-TH-053, PP-WE-059

Baser O., PP-WE-478

Bashash D., PP-WE-324

Basile A., PP-TH-590

Basileo M., PP-MO-457, PP-MO-458, PP-WE-688

Basili S., PP-MO-015, PP-MO-379, PP-MO-380, PP-TH-050,PP-WE-105, PP-WE-753, PP-WE-824

Basire A., AS-WE-050

Baslar Z., PP-TH-121

Basquiera A. L., PP-MO-279

Bass R., PP-MO-853

Bassi A. K., PP-WE-798

Bassi A., OC-TH-030

Bassi B., PP-TH-453

Bassi L., PP-MO-496, PP-TH-375, PP-WE-682

Bassi P., PP-WE-866

Bassler N., PP-MO-100

Basso M., PP-WE-647

Basson M., PP-MO-471

Bastani P., PP-TH-534, PP-TH-535

Bastos L. A., PC-047, PP-MO-204, PP-WE-145, PP-WE-146

Basu A., PP-MO-473

Basu S., OC-TU-034, OC-TU-087

Bates G., PP-MO-233

Bates J., PP-MO-233

Bates S. M., PP-MO-515, PP-TH-522, PP-TH-523

Bates S., PP-WE-520

Batista I. F. C., PP-MO-475

Batista R., PP-TH-211

Batlle J., PP-MO-637

Batorova A., PP-MO-560, PP-WE-656

Batschauer A. P. B.,PP-TH-490

Battaglioli T., OC-MO-081, PP-TH-300

Battie C., PP-TH-386

Battiston M., PP-TH-008, PP-WE-018

Battleman D., PP-WE-465

Baud G., PP-MO-263

Baudo F., OC-WE-058, PP-MO-609, PP-WE-604

Bauduer F., PP-MO-074

Bauer K. A., PP-WE-421

Bauer M., PP-TH-087, PP-WE-684

Bauersachs J., PP-MO-005,PP-TH-019, PP-WE-886

Bauersachs R. M., PP-MO-509,PP-TH-312

Baujat G., PP-MO-748

Baulon-Thaveau E.,PP-WE-655

Bauman J., PP-MO-464

Bauman M. E., OC-TU-066,PP-MO-435, PP-MO-454, PP-MO-455, PP-MO-456, PP-TH-531, PP-WE-450, PP-WE-451, PP-WE-452

Bauman M. L., PP-MO-454,PP-MO-456, PP-WE-452

Bauman M., PP-MO-435, PP-WE-238

Baumann A., PP-MO-694

Baumbach G. A., PP-TH-403

Baumeister J., AS-TH-024

Bautch V. L., AS-WE-051

Bauters A., PP-WE-762

Bautista A. P., PP-WE-428

Bautista A., PP-MO-464

Bavishi K., PP-TH-626

Bayat B., AS-MO-057

Bazzi L., PP-MO-273

Bdeir K., AS-WE-027

Bean C. J., PP-TH-325

Bearelly D., AS-TH-027

Bearelly S. R., PP-TH-419

Bearelly S., AS-TH-027

Beauchaton-Piallat M.,PP-WE-810

Beaudoin S., PP-TH-477

Beaulieu L. M., PP-TH-064

Beaune P., PP-TH-429

Beavis J., PP-WE-638

Becattini C., OC-MO-092, OC-TH-014, OC-TU-024, PP-MO-312, PP-WE-313

Becerra A., AS-WE-018, PP-WE-782

Becerra J., PP-MO-737, PP-WE-692

Beck W., PP-MO-578

Becker D., OC-TU-020

Becker J., PP-TH-086

Becker R. C., AS-TH-033

Becker R., SA-TH-004

Becker-Peters K., PP-MO-592

Beckman M., PP-TH-206, PP-TH-327, PP-TH-328

Beck-Peccoz P., PP-WE-321

Beckwith J., AS-TU-025, OC-WE-074

Becquemont L., PP-WE-186

Bedencic M., PP-MO-350, PP-WE-251

Beeler M., PP-TH-439

Beer J. H., OC-TU-052

Beer N., PP-WE-841

Begaliyev M., PP-WE-281

Bégin L. R., PP-MO-820

Beglova N., PP-TH-266

Begonia A., AS-WE-026

Behari M., PP-MO-208

Beheshtipoor N., PC-044

Behfar A., PP-TH-220

Behnisch W., PP-WE-453

Beillat-Lucas T., AS-WE-025

Bein G., AS-MO-052, PP-MO-083

Bejaoui M., PP-WE-455

Belcher J., OC-MO-043

Belcik T., OC-MO-123

Belcour B., PP-TH-693

Belda F., PP-WE-575, PP-WE-576

Beletic A., PP-TH-296

Belfiori B., OC-WE-087

AUTHORS INDEX

485

Belhani M., PP-WE-639, PP-TH-204

Belin A., PP-WE-171

Bellia M. S., PP-WE-314

Bellido-Martin L., AS-TU-060,OC-MO-108

Bello T., PP-WE-665

Bellucci S., PP-MO-074, PP-TH-680

Belmont S., PP-MO-860

Beltrame M. P., PP-MO-870

Beltrametti C., AS-MO-009,PP-MO-415

Belzunce M., OC-TH-113

Ben Ammar Elgaaied A.,PP-MO-649, PP-MO-650

Ben Amor M., PP-MO-649, PP-MO-650

Ben Cheik J., PP-MO-281

Ben Romdhane N., PP-TH-297,PP-TH-298, PP-WE-455

Benavente-García O.,PP-TH-096

Benazzo M., PP-MO-684

Benchenni S., AS-WE-025,OC-TH-082

Bendaoud H., PC-018

Bendedouche B. K.,PP-WE-564

Bender M., AS-WE-029, AS-WE-030

Benedettelli S., PP-MO-802

Benedik-Dolnicar M.,AS-MO-028

Benesova K., PP-MO-583

Benessiano J., PP-WE-787

Benetos A., PP-MO-402, PP-TH-362

Benhamou Y., PP-TH-144

Ben-Hasan M., PP-WE-161

Benhida A., PP-MO-605

Benner M., PP-TH-439

Bennett J. S., AS-MO-039

Bennett J., SA-WE-004

Benninga M. A., PP-MO-444

Benoit M., AS-TU-009

Benson J., PP-MO-596, PP-TH-324, PP-TH-325, PP-WE-613

Bentley M. J., PP-WE-725

Benz P. M., OC-MO-068

Berber E., PP-MO-653

Berckmans R. J., OC-TU-059,PP-MO-763, PP-MO-769

Berckmans R., PP-MO-022

Berdague P., OC-MO-132, PP-MO-783

Berdagué P., AS-TH-032, PP-WE-744

Bereczky Z., PP-TH-366

Bereksi Reguig S., PP-TH-608,PP-WE-701

Béres B. J., PP-MO-772

Beretta L., PP-MO-716

Berfelo F. J., OC-TU-063

Berg R., PP-WE-574

Berge N., OC-MO-011, PP-WE-810

Berger C., PP-MO-594

Berger J. S., AS-TH-033

Berger K., AS-WE-010, OC-WE-118, OC-WE-119, PP-MO-694, PP-WE-542

Berger M. G., PC-013

Berger P. B., AS-TH-033

Bergholt T., PP-MO-405

Bergmann F., OC-TH-101

Bergmann J., OC-MO-054

Bergmeier W., SA-TU-001, OC-TU-045, PP-WE-016

Bergqvist D., OC-TU-019

Bergrem A., PP-MO-288, PP-WE-332

Berguer A. M., PP-MO-400

Bergvist D., OC-TU-021

Berkner K. L., OC-WE-078

Berkner K., OC-WE-072

Berkouk Y., PP-TH-204

Berkun Y., AS-TU-052

Berland M., PP-TH-385

Berland Y., OC-TU-089

Berman J. N., PP-WE-447

Berman J., PP-MO-686

Bermejo E., PP-MO-038

Bermot C., PP-WE-139

Berna-Erro A., AS-TU-005, AS-TU-040

Bernard G. R., OC-TH-069

Bernardi F., AS-WE-039, OC-TH-028, PP-MO-654, PP-TH-372

Bernardina E., PP-MO-483

Bernardini A., PP-MO-306

Bernaudin J., PP-TH-485, PP-TH-486, PP-WE-490

Berndt M. C., AS-MO-048, AS-TU-039, OC-MO-110, OC-TU-046, PP-MO-080, PP-MO-735

Bernhard H., OC-WE-138, PP-TH-448, PP-WE-439

Bernlochner I., OC-MO-124

Berntorp E., OC-TH-050, PP-MO-540, PP-MO-541, PP-MO-604, PP-TH-580, PP-WE-570, PP-WE-597, PP-WE-611

Berny M. A., AS-WE-044, PP-TH-037, PP-WE-260

Berrueco R., PP-TH-451

Berry J. L., PP-WE-861

Berry L. R., OC-MO-074, PP-MO-197, PP-TH-135, PP-TH-435, PP-WE-173, PP-WE-174, PP-WE-177, PP-WE-193

Berta A., PP-TH-216

Bertazzi P. A., PP-MO-321

Berthaut A., PP-WE-855

Berthelsen J. G., PP-MO-405

Bertholon P., PP-MO-332

Bertina R. M., AS-MO-035, AS-WE-019, OC-MO-019, OC-MO-078, PL-TU-001

Bertina R., PP-WE-497

Bertini D., PP-WE-247, PP-WE-248

Bertling A., PP-MO-030, PP-MO-031

Bertomoro A., PP-WE-641

Bertorello N. N., PP-TH-452

Bertrand G., AS-MO-053, PP-MO-079

AUTHORS INDEX

486

Aut

hors

Inde

x

Bertrand M., PP-MO-618

Beski S., PP-WE-377

Besser M. W., PP-TH-240, PP-WE-556

Bestion A., PP-TH-385

Betancourt M., AS-WE-022

Betbout F., PP-TH-343

Bettini F., PP-WE-715

Bevan D. H., PP-MO-628, PP-TH-683

Bevan D., PP-MO-543, PP-MO-562, PP-WE-539, PP-WE-616

Bevan S., PP-WE-377

Bevilacqua S., PP-TH-352

Beydoun A., PP-TH-336

Beyer J., OC-TU-010

Beyer R., PP-TH-545

Bezemer I. D., AS-MO-005, OC-MO-020

Bezgal F., PP-MO-683, PP-WE-568

Bezieau S., PP-WE-642

Beznos O., PC-005

Bezzou H., PP-TH-608

Bhakta V., PP-MO-161, PP-TH-175

Bhatt D. L., AS-TH-033

Bhatt S. H., PP-TH-478

Bhavaraju K., OC-MO-043,OC-TH-098, PP-MO-106, PP-TH-022, PP-WE-012, OC-TH-094

Bhella D., PP-WE-150, PP-WE-151

Bialkowska K., OC-MO-109

Bianchi M., OC-TH-014

Bianchini C., PP-MO-476

Bianchini E. P., PP-MO-187

Biasoli C., PP-MO-523, PP-WE-599

Biasucci L. M., PP-WE-789

Bicker M., PP-TH-646

Bickhardt K., PP-TH-644

Bicknell R., OC-MO-069

Bidar A. W., PP-MO-385

Bidlingmaier C., AS-MO-028,PP-MO-607, PP-TH-533, PP-WE-210, PP-WE-453

Bielenberg W., AS-TU-057

Biemond B. J., OC-TU-059,PP-MO-769, PP-TH-373

Bierings R., OC-MO-067

Biesma D. H., PP-WE-317, PP-WE-318, PP-WE-475

Bieth E., PP-MO-529

Bigetti L., PC-034

Biggerstaff J. P., PP-WE-494

Biggerstaff J., PP-TH-439

Bignell P. A., PP-TH-540, PP-TH-541

Bigsby Iv G., PP-TH-482

Biguzzi E., PP-MO-375, PP-WE-691

Bihan D. G., PP-MO-852, PP-WE-052

Bihan D., PP-MO-041, PP-MO-058

Bikas D., PP-WE-380

Bilgili H., PP-MO-394

Billett H. H., OC-WE-101

Billiald P., PP-MO-786

Billinghurst L., PP-TH-463

Binard S., AS-TH-043, PP-TH-074

Binder B. R., PP-MO-189, PP-MO-551, PP-MO-711, PP-MO-838, PP-MO-848, PP-TH-148, PP-WE-777, PP-WE-842, PP-WE-843

Binder B., OC-TU-081, OC-WE-069

Binder C. J., PP-WE-777

Bindlingmaier C., OC-WE-117

Binetruy B., OC-TH-045

Binette T., OC-TH-116

Binevski P., PC-005

Biolchini F., PP-MO-285

Biondo F., PP-MO-210, PP-MO-287

Biosca Gómez De Tejada M.,PP-TH-299

Birch N., OC-TU-079

Bird J. E., PP-WE-100

Birdsey G., OC-MO-065

Biron C., PP-TH-309

Biron-Andreani C.,OC-MO-021

Birschmann I., AS-MO-038

Bisbe J., PP-WE-360

Bishop-Bailey D., PP-WE-809

Bisi M., OC-TH-028

Bisiani G., PP-WE-230

Bison E., OC-MO-028, OC-MO-113, OC-TU-040, PP-TH-274

Biss T. T., AS-TH-053

Bisson R., PP-MO-542

Biston P., PP-TH-684

Biswar R. M., PP-TH-354

Biswas A., PP-MO-208, PP-TH-671, PP-WE-327

Biswas T. K., PP-WE-029

Bitonti A. J., OC-MO-083

Bitsadze V. O., PC-017, PP-MO-360, PP-MO-361, PP-TH-278, PP-TH-378, PP-TH-379

Bittar L. F., PP-MO-870, PP-WE-294

Bizjak B., PP-WE-308

Bizzacchi J., PP-WE-631

Bjelke J. R., PP-MO-118, PP-MO-575

Bjorholt I., PP-WE-472

Bjorkegren J., PP-MO-813

Björkman J., PP-WE-386

Björkman S., PP-TH-585, PP-WE-570

Bjørn S. E., PP-MO-575

Bjørnerheim R., PP-TH-427

Bjørngaard B., PP-WE-383

Black K. L., OC-TU-066, PP-MO-454, PP-MO-455, PP-MO-456, PP-TH-531, PP-WE-451, PP-WE-452

Black K., PP-MO-435

Blair P., PP-WE-106

Blanchette V. S., AS-TH-053,AS-WE-003, PP-MO-639, PP-TH-628, PP-WE-553

AUTHORS INDEX

487

Blanchette V., OC-TU-068, PP-TH-585

Blanco A. N., PP-MO-204, PP-TH-350, PP-WE-145, PP-WE-146

Blanco A., PC-047

Blanco-Vaca F., PP-TH-289,PP-TH-290

Blangero J., PP-TH-289, PP-TH-290, PP-WE-208, PP-WE-209, PP-WE-243

Blank E., OC-WE-059

Blaszkowski A., PP-MO-868

Blatny J., PP-TH-530, PP-WE-441

Blavignac J., AS-TH-045

Blazek B., PP-MO-563

Bleda D., PP-MO-209

Bledzka K., OC-MO-048

Blesingk N., PP-MO-233

Blest N., PP-WE-427

Blickstein D., PP-MO-749

Blicq E., PP-TH-365

Bliden K. P., PP-MO-739, PP-TH-101, PP-WE-757, PP-WE-794, PP-WE-797, PP-WE-798

Bliden K., PP-MO-771, PP-TH-026, PP-WE-043, PP-WE-799, PP-WE-801, PP-WE-802

Blinc A., PP-MO-350

Blinov M. N., PP-TH-313, PP-TH-321, PP-TH-346, PP-WE-361

Blobel G. A., AS-TH-042

Bloch E. M., PP-MO-066

Blombäck M., PP-MO-374, PP-TH-141, PP-TH-186

Blombery P., PP-WE-409

Blömer L., OC-MO-126, PP-MO-809

Blomstrand C., OC-WE-115,PP-MO-343

Blondon M., PP-WE-375

Blostein M., PP-TH-315

Blot-Chabaud M., AS-MO-060

Blumbach K., OC-WE-076

Blume C., OC-MO-068

Blumenfeld De Bosch N., PP-MO-737, PP-WE-692

Bo W., PP-MO-691

Boadas A., PP-MO-526, PP-MO-663, PP-MO-737, PP-TH-555, PP-WE-692

Boban A., PP-MO-519, PP-MO-630

Bobba B., PP-TH-453

Boccagni P., PP-TH-420, PP-WE-424

Bock P. E., AS-TH-050, AS-WE-044, OC-WE-082

Bock S. C., PP-TH-191

Bockenstedt P. L., PP-MO-596,PP-WE-613

Bockmeyer C. L., PP-TH-086,PP-TH-087, PP-WE-684

Boda Z., PP-MO-359

Bode C., PP-MO-100

Bodé-Dotto E., OC-MO-029

Bodenez C., PP-MO-332

Bodman-Smith K., PP-WE-873

Boehlen F., OC-TU-037, PP-WE-375

Boehncke W. H., PP-MO-705,PP-MO-706

Boëlle E., OC-WE-006

Boeri E., PP-TH-622, PP-WE-567

Boettcher J. M., OC-TU-091,PP-MO-113

Boezeman J., PP-TH-260, PP-WE-064

Boffa M. B., OC-TH-115, OC-WE-109, PP-WE-241

Boffard K. D., OC-TH-069

Bogani P., PP-WE-356

Bogankova N. A., PP-TH-025

Bogatkevich G. S., PP-MO-194

Bogchelman D. H., PP-MO-677

Bogdanov V., PP-MO-808

Bogdanova N., PP-TH-647

Boggian O., PP-TH-282, PP-WE-715

Bogolyubov A. A., PP-MO-182

Bogutchi T., PP-WE-312

Bohec C., PP-TH-508

Böhm E., PP-MO-150

Böhm M., PP-MO-809

Böhm-Weigert M., PP-WE-087

Böing A. N., AS-WE-017, OC-TU-055, PP-MO-109

Boinot C., PP-TH-189

Boisseau P., PP-MO-529, PP-TH-623, PP-WE-642

Boissier E., OC-TH-022

Boisson-Vidal C., OC-TH-046,OC-TH-048

Bokemeyer C., PP-MO-014,PP-WE-485

Boknäs N., PP-WE-014

Bokuchava M., PC-019

Bolanos-Garcia V., PP-MO-852

Boldrin M., PP-WE-248, PP-WE-384

Boldueva S. A., PP-MO-431

Bolli G. B., PP-TH-069

Bolli P., PP-WE-003, PP-WE-745

Bolliger D., PP-MO-676, PP-MO-776, PP-WE-187

Bolt G., PP-MO-565, PP-WE-109, PP-WE-572

Bolton-Maggs P. H. B.,OC-TU-078, PP-TH-645

Bombardier C. G., PP-WE-255

Bomgaars L., PP-TH-445

Bomke B., PP-MO-745

Bomken C., PP-WE-372

Bompiani K. M., PP-WE-189

Bonacchi M., PP-TH-352

Bonafede M. M., PP-WE-466

Bonanni G., PP-WE-866

Bonar R., PP-MO-724

Boncler M., PP-MO-097, PP-WE-034

Bond H., PP-WE-523

Bonduel M., OC-TU-064, PP-MO-687, PP-WE-637

Bonello L., PP-MO-785

Bongarzoni A. A. B.,PP-MO-312

Bonneau M., PP-WE-810

AUTHORS INDEX

488

Aut

hors

Inde

x

Bonnefoy A., PP-MO-060, PP-MO-061

Bonnet D., OC-WE-089

Bonnet F., PP-MO-477, PP-MO-478

Bonnet J., OC-MO-007, PP-MO-773, PP-WE-775

Bonnet P. O., PP-MO-696, PP-TH-610, PP-WE-563, PP-WE-597

Bontadi A., PP-TH-274

Boon-Spijker M., OC-MO-111

Boonstra A., PP-WE-322

Bopp C., PP-MO-611

Borah B., OC-MO-051

Borch K. H., OC-TU-005, OC-TU-006, PP-WE-304, PP-WE-305

Bordet J. C., OC-WE-021, PP-WE-493

Bordet J., PP-MO-658

Borel-Derlon A., PP-MO-618,PP-MO-619, PP-TH-619, PP-TH-623, PP-WE-600

Borensztajn K. S., OC-WE-105, PP-MO-489, PP-WE-839

Borg J., OC-MO-050, PP-MO-514, PP-TH-144, PP-TH-172, PP-TH-174, PP-WE-859

Borgel D., PP-MO-187

Borges M. A., PP-MO-349

Borges R., PP-MO-663

Borggrefe M., OC-TH-068, PP-MO-238

Borghi H., AS-WE-050

Borgognone A., PP-MO-104

Borhany M. M. B., PP-TH-648

Borisenko O. V., PP-MO-553,PP-TH-581, PP-WE-561

Borissoff J. I., AS-WE-058,OC-MO-125

Borovsky M., PP-WE-656

Borrell M., PP-WE-175, PP-WE-178, PP-WE-243, PP-WE-415

Bortoletto E., PP-WE-535

Bosanquet J. P., PP-WE-430

Bosch I., AS-WE-018, PP-WE-782

Bosquet L., PP-WE-483

Bosson J., PP-MO-315

Bostwick J. S., PP-TH-202,PP-WE-100

Botelho L. F., PP-TH-542

Botha E. M. D., PP-WE-124

Bottaro F., PP-WE-293

Bottenus R., PP-MO-265, PP-TH-264, PP-TH-281, PP-WE-115, PP-WE-117

Bouabdelli M., PP-MO-077

Bouchard B. A., OC-MO-120,PP-MO-721

Boudreaux M. K., PP-MO-754

Bouillon B., OC-TH-069

Bouillon R., PP-MO-059

Boukerche H., OC-WE-021,OC-WE-021, OC-MO-062

Boulaftali Y., AS-TU-024, OC-WE-070

Boulay-Moine D., PP-MO-766,PP-MO-787

Boulvain M., PP-WE-375

Bouma B. J., PP-TH-293

Bouma B. N., AS-TH-038

Bouma B., AS-TH-038, PP-WE-216

Bouman H. J., OC-MO-133,OC-MO-135, PP-MO-780, PP-MO-781, PP-MO-788, PP-WE-741, PP-WE-742

Bounameaux H., AS-TH-032,OC-MO-038, OC-MO-041, OC-MO-132, OC-TH-073, PP-MO-318, PP-MO-505, PP-TH-103, PP-TH-492, PP-TH-518, PP-WE-744

Bourada S., PP-WE-639

Bourguet N., PP-MO-787

Boutekedjiret T., PP-TH-470,PP-TH-649, PP-TH-650

Bouton M., AS-TU-024, OC-WE-070

Bouvard C., OC-TH-046

Bova C., PP-TH-303

Boval B., OC-MO-011, PP-TH-680

Boveda Ruiz D., PP-WE-222

Bovill E. G., AS-TU-007, OC-MO-024, OC-TU-001, OC-TU-003, OC-TU-034, PP-WE-458

Bovill E., PP-MO-819

Bovin J., PP-TH-323

Bowen D. J., OC-TU-078

Bowley S. R., OC-MO-117, OC-WE-145

Bowman M., OC-TU-078, PP-TH-628

Boxnick B., PP-MO-595

Boyd D., AS-TU-025, OC-WE-074

Boyer O., PP-WE-859

Boyer-Neumann C., PP-MO-618, PP-TH-623

Boylan B., AS-MO-052, AS-TH-009

Boyle A. J., PP-MO-161

Bozas G., PP-WE-503

Bozic M., PP-WE-251

Bozic Mijovski M., PP-MO-350

Bozzato S., PP-TH-507

Bozzi V., AS-TU-004, PP-MO-067

Brabec P., PP-TH-543, PP-TH-613

Bracone F., PP-MO-876

Bradford H. N., AS-TH-047

Bradley-Kennedy C., PP-WE-469, PP-WE-470, PP-WE-471

Bradna P., PP-WE-068

Bradshaw A. C., PP-WE-151

Brady B., PP-MO-593

Braemswig K., OC-WE-069

Braester A., PC-053

Braga J., PP-WE-374

Brain T., PP-MO-233

Brainsky A., AS-TU-002

Brakebusch C., AS-WE-030

Brakenhielm E., PP-WE-859

Brambilla M., OC-TU-025, PP-WE-356

Branch D. R., OC-MO-102

Branco C. C., PP-MO-297

AUTHORS INDEX

489

Brand B., PP-MO-643

Brandao L. R., PP-MO-426,PP-WE-288, PP-WE-446, PP-WE-719

Brandão L. R., PP-TH-463

Brandao L., PP-MO-443, PP-MO-447, PP-TH-434, PP-TH-459, PP-WE-443, PP-WE-445

Brandjes D. P. M., PP-MO-292,PP-MO-293, PP-TH-286

Brandl R., OC-MO-124

Brandolin B., OC-MO-049, PP-MO-348

Brandt M., PP-TH-060

Brankovic-Sreckovic V., PP-TH-460

Brash J. L., PP-MO-428, PP-TH-435

Brass L. F., AS-TU-028, PP-TH-038, PP-WE-030, PP-WE-063

Braude P., PP-TH-496

Braun A., AS-TU-005, AS-TU-037, AS-TU-040

Bray M., OC-WE-045

Bray P. F., OC-TH-095, OC-WE-045, PP-MO-756, PP-WE-752,AS-TH-041

Bray S. L., AS-MO-037

Breen K. A., PP-WE-615

Breet N. J., OC-MO-135, PP-MO-788, PP-WE-741, PP-WE-742

Bremme K., AS-WE-024, PP-WE-643

Brennan M. P., PP-TH-056, PP-WE-813

Brennan M., PP-TH-102

Brennecke S. P., PP-MO-381

Brenner B., OC-TU-057, OC-TU-058, PP-MO-313, PP-MO-850, PP-TH-387

Brenner H., PP-MO-480

Brereton J. J., PP-TH-458

Brescia L. P., PP-MO-448, PP-WE-878

Bresser P., OC-WE-105, PP-TH-293

Bressollette L., OC-MO-041,OC-WE-113, PP-MO-500, PP-WE-508, PP-MO-499, PP-TH-508

Bretherton S., PP-WE-297

Brettler D. B., PP-MO-596, PP-WE-613

Breuss J. M., PP-MO-848, PP-WE-843

Breuss J., PP-MO-838

Brewer J., PP-WE-530

Breyne J., PP-MO-815, PP-MO-814

Brezinova J., PC-022

Bridey F., PP-MO-619, PP-MO-618

Brierre F., PP-TH-136

Brill A., AS-MO-047, OC-TU-045, PP-WE-847

Brinkman H. J. M., OC-WE-084

Brioschi M., PP-WE-050

Brisset A. C., OC-WE-037

Brito D. D. V., PP-WE-814, PP-WE-815

Britto M., AS-TU-059

Brivio L., PP-MO-309, PP-WE-340

Brixi S., PP-TH-276

Brkic J., OC-WE-121

Brock J., OC-WE-061

Brodde M. F., PP-WE-734

Brodde M., PP-TH-574

Broder M., PP-TH-569, PP-TH-587

Brodin E., OC-MO-058, PP-MO-177

Broek L., PP-WE-341

Brogden A., PP-MO-300

Brohi K., OC-TH-067, PP-TH-685

Brohmann H., PP-MO-244

Broholm R., AS-MO-008

Bröijersén A., PP-MO-761

Bröker B. M., AS-TH-007

Bromirski J., PP-TH-230, PP-TH-231

Brondke H., AS-WE-002

Bronic A., PP-WE-442

Brons P., PP-TH-665

Bronstein M. M., OC-WE-072

Brook N., PP-MO-370

Brooks J., PP-WE-546

Brooks M. B., PP-MO-751

Brooks S. V., PP-TH-551, PP-WE-649

Brooks S., PP-TH-528, PP-WE-192, PP-WE-713

Brophy D. F., PP-TH-567

Brophy T. M., OC-MO-056

Brosnihan K. B., PP-WE-854

Brotschi B., OC-TU-061

Brouland J. P., PP-MO-074

Brouland J., PP-WE-810

Brouns R., PP-MO-229, PP-MO-230

Brouwer J., AS-MO-002

Browett P., OC-TU-079

Brown A. E. X., OC-WE-146

Brown A., PP-TH-310, PP-TH-457

Brown C., OC-TU-076

Brown H., OC-WE-134

Brown M., PP-WE-695

Brox J., OC-WE-137, OC-WE-140

Broyer V., PP-MO-645

Broze - Jr. G. J., AS-MO-021

Broze G., PP-TH-163

Brozzetti M., PP-WE-529

Bruce A. A. K., PP-MO-435

Bruce A., PP-TH-531, PP-WE-451

Bruera G., PP-TH-694

Bruggeman L. W., PP-TH-484

Brügger-Andersen T., PP-TH-131, PP-WE-126, PP-WE-829,PP-WE-830, PP-WE-831

Brummel-Ziedins K., SA-MO-004, OC-MO-003, OC-TU-003, PP-TH-196, PP-WE-358, AS-TU-023, OC-MO-120, OC-TU-069, PP-MO-721

Brunaud C., PP-WE-084

AUTHORS INDEX

490

Aut

hors

Inde

x

Brunet P., PP-WE-850

Brunette A., PP-MO-402

Bruneval P., OC-TH-048, PP-MO-090

Brüning J. C., OC-WE-076

Bruns C., OC-TH-101

Brunso L., PP-MO-053

Bruntz J., OC-MO-029

Brusi C., AS-TH-029

Bruzelius M., PP-WE-643

Bruzgol T., PP-MO-338

Bryckaert M., OC-WE-043, AS-TU-024

Brynda E., PP-TH-213

Bryon A., PP-MO-751

Bubpachart C., PP-MO-446

Bucciarelli L. G., OC-TU-088

Bucciarelli P., OC-MO-081, PP-TH-300, PP-TH-301, PP-WE-132, PP-WE-691

Buccioni A., PP-MO-803

Bucherini E., PP-WE-403

Buckland R. J., OC-MO-012,PP-TH-030

Bucklar G., PP-WE-329

Buckley C. D., PP-WE-076

Buckley S. M. K., PP-WE-150

Buckley S., OC-TU-076

Buckley T., PP-MO-410

Buczko W., PP-MO-234, PP-TH-239

Buczma A., PP-WE-660

Budde U., OC-TU-077, OC-WE-136, PP-MO-638, PP-TH-091, PP-TH-639, PP-TH-646, PP-WE-629, PP-WE-630, PP-WE-651, PP-WE-722

Budhrani C. C., PP-WE-428

Budnik I., PP-WE-044

Buehler B., PP-MO-025

Buelens K., OC-TH-114

Bueno E. C., PP-TH-490

Bueno-De-Mesquita H. B., PP-WE-357

Buerke M., PP-TH-440, PP-WE-190

Buffone A., PP-WE-893

Buhan T. P., PP-MO-147

Buil A., PP-TH-289, PP-TH-290, PP-WE-208, PP-WE-209, PP-WE-243

Bulato C., OC-MO-121, PL-TU-004, PP-MO-242, PP-MO-243, PP-WE-080, PP-WE-248, PP-WE-384

Bulder I., PP-TH-153

Bulhak A., PP-WE-386

Bulikova A., PP-MO-259, PP-MO-270, PP-MO-271, PP-TH-612, PP-TH-613, PP-WE-596

Bull A., OC-TU-049

Buller H. R., LB-MO-004, OC-MO-039, OC-MO-042, OC-TU-010, OC-WE-001, OC-WE-014, OC-WE-019, PP-MO-292, PP-MO-293, PP-MO-417, PP-MO-763, PP-TH-293, PP-TH-356, PP-TH-484

Büller H. R., AS-MO-030, OC-MO-091, OC-TH-017, OC-TU-008, OC-TU-012, OC-WE-035, OC-WE-100, PP-MO-286, PP-MO-298, PP-TH-139, PP-TH-286, PP-TH-348, PP-TH-517, PP-TH-518

Bullinger B., OC-WE-119

Bullinger M., PP-WE-542

Bullorsky E., PP-WE-135, PP-WE-293

Bulut G., PP-WE-128

Bumbea H., PP-MO-069, PP-TH-063, PP-WE-075

Bumgarner J., PP-WE-694

Bunce M., AS-TH-046

Bungay S. D., OC-WE-095

Bura A., OC-WE-085, PP-MO-280, PP-MO-281

Bura Rivière A., PP-MO-188,PP-WE-169

Buraczewska-Buczko A., PP-WE-223

Burakowski J., PP-TH-279,PP-TH-280

Burgess J., PP-MO-437, PP-MO-438

Burghel G. J., OC-TU-077

Burgos G., OC-MO-021

Burián K., OC-TU-051, PP-WE-836

Burillo Lorente J., PP-TH-299

Burke C., PP-MO-757

Bürki C., OC-TU-061

Burlova-Vasilieva N., PP-TH-395

Burnand K., PP-MO-384

Burnett E., OC-TH-053, OC-TH-086

Burnett L., PP-WE-703

Burnier L., AS-TU-018

Burns P., AS-MO-037

Burns T. L., PP-WE-636

Burra P., PP-TH-420

Burris S. M., PP-MO-081

Burroughs A., PP-TH-106

Bury L., PP-MO-085, PP-TH-069

Buryachkovskaya L. I., PP-MO-770, PP-WE-091

Buryachkovskaya L. L. I., PP-WE-058

Buschek S., PP-MO-674

Buschmann A., PP-MO-556

Busonera F., PP-WE-338

Busse Grawitz A., PP-WE-519

Bussel J. B., AS-MO-055, AS-TU-002

Bussel J., SA-TU-004

Bussey H. I., PP-MO-469

Bussey Smith K. L., PP-MO-469

Busshardt M., PP-TH-440

Busti F., PP-MO-342, PP-TH-347

Butcher M., PP-WE-817

Butenas S., AS-TU-023, PP-TH-154, PP-TH-196, PP-WE-152, PP-WE-362

Butler J. J., PP-MO-713

Butler J., PP-MO-713

Butt C., PP-TH-364

Butta N., PC-048, PP-TH-059,PP-TH-603, PP-TH-604, PP-WE-560, PP-WE-765

AUTHORS INDEX

491

Buurman W. A., PP-TH-181

Buyue Y., PP-WE-184

Buzby J. S., PP-MO-823, PP-TH-065, PP-TH-066

Bykowska K., PP-MO-714

Bynagari Y. B., OC-TH-098

Bynagari Y. S., OC-TH-094

Byrne C., OC-WE-114

Byrne M., PP-TH-549, PP-WE-685

Byrne S., PP-MO-414

Byron O., OC-WE-148

Byzova T. V., PL-TU-005

Caballero S., PP-WE-575, PP-WE-576

Cabaravbic M., OC-WE-069

Cabello A., PP-WE-665

Cabral R., PP-MO-297

Cabrera M. J., OC-WE-086

Cabrera N., PP-TH-627, PP-WE-668, PP-TH-544

Caferri H., PP-TH-060

Cafolla A., PP-MO-287

Caglar T., PP-MO-841, PP-WE-889

Caglayan H., PP-MO-653

Cahalan L., PP-TH-439

Cahalan P., PP-TH-439

Cahillane G., OC-TH-057

Cai H., PP-TH-334

Cai W., PP-MO-159

Cai X., PP-MO-171

Caiafa J., PP-WE-312

Caille V., AS-TU-009

Cailleux N., PP-TH-144

Cairo A., OC-WE-132

Cairo F., PP-TH-681

Cajfinger F., PP-WE-483

Cakici O., PP-WE-708

Calabro L., PP-WE-021

Calaf R., PP-WE-850

Calandini O., PP-WE-855

Calanni F., PP-MO-202

Calderazzo J. C., PP-MO-610,PP-MO-831, PP-MO-832

Calderzzo J. C., PP-WE-089

Cale J. M., PP-TH-252

Califano S., PP-MO-799

Calini A., PP-WE-230

Calkavur T., PP-TH-511

Callahan J. B., PP-WE-207

Callahan J., OC-MO-038, PP-TH-524

Callas P. W., AS-TU-007, OC-MO-024, OC-TU-003, PP-WE-458

Callebert J., PP-WE-408

Calori G., PP-MO-775

Calugareanu A., PP-WE-737

Calvaruso V., PP-TH-106

Calvel L., PP-MO-416

Calvo F., PP-WE-436

Calzavarini S., AS-WE-039,PP-TH-372

Camacho J., PP-WE-551

Camargo C. A., OC-TU-004

Camargos E. R., PP-MO-387

Cambefort P., PP-WE-510

Cambier N., PP-WE-762

Cambou J. P., OC-WE-085, PP-MO-280, PP-MO-281

Cambou J., OC-WE-017

Cambus J., PP-WE-412

Camera A., PP-MO-616

Camera M., OC-TU-025, PP-WE-356

Cameron K. J., PP-TH-244

Camilleri R. S., PP-TH-088

Camire R. M., AS-TH-013, AS-TH-046

Camire R., AS-TH-008

Camoin L., PP-MO-774

Camoin-Jau L., OC-TU-089,PP-MO-785, AS-WE-050, OC-MO-007

Campbell J. E., AS-TU-023

Campbell P. J., OC-TH-015

Campbell R. A., OC-MO-073

Campbell S., PP-TH-182

Campello E., PP-MO-765, PP-TH-382, PP-TH-383, PP-TH-487, PP-TH-488, PP-WE-460

Campetella O., PP-WE-035

Campiotti L., PP-MO-309

Camporese G., PP-WE-338,PP-WE-403

Campos F., PP-MO-667

Campos L., OC-TH-021, PP-WE-165

Campos M. M., PP-TH-444

Campos M., PP-MO-667, PP-WE-374

Campostrini N., PP-MO-342,PP-TH-347

Campregher G., PP-TH-350,PP-WE-354

Canaro M., PP-MO-590

Canault M., AS-MO-047, OC-TU-045

Canciani M. T., PP-WE-625

Candela M., PP-WE-618

Caniato A., PP-MO-351

Cannegieter S. C., OC-MO-079, OC-WE-013, OC-WE-091, PP-MO-293, PP-TH-238, PP-TH-286, PP-TH-329

Cano H., PP-WE-141

Canobbio I., PP-MO-018, PP-MO-046

Canpolat N., PP-MO-073

Cantalino E., PP-MO-482

Cantor A. B., OC-WE-152

Cantu-Brito C., PP-WE-264

Cao L., PP-WE-711

Cao O., AS-TU-015, PP-TH-618

Cao P., PP-WE-823

Cao W., PP-TH-080

Cao Y., PP-TH-095

Cao Z., PP-TH-281

Capalbo A., PP-MO-799, PP-MO-800

Caplan A., PL-TU-005

Capobianco A., OC-WE-127

Caporale R., PP-MO-799, PP-MO-800, PP-MO-836, PP-TH-340, PP-WE-002

Cappucci F., PP-MO-822, PP-WE-366

AUTHORS INDEX

492

Aut

hors

Inde

x

Caprini J. A., PP-MO-167, PP-TH-169, PP-TH-170

Capron C., OC-WE-149

Captug O., PP-MO-394

Caram C., PP-TH-673, PP-TH-674, PP-WE-689

Caramazza D., AS-TH-030

Carazolle M. F., PP-MO-825

Carazzolle M. F., PP-MO-826

Carcaillon L., OC-TH-005, OC-WE-017, PP-TH-349

Carcao M. D., PP-TH-629, PP-WE-587

Card R. T., OC-TU-068, PP-WE-695

Card R., AS-WE-003, PP-WE-553

Cardel L. K., PP-MO-678

Cardenas J., PP-WE-290

Cardigan R. A., PP-MO-759

Cardinali B., OC-WE-148

Cardoso G., PP-MO-794

Cardoso J. E., PP-MO-363, PP-MO-364, PP-WE-815

Carew J. A., PP-WE-113

Carlebach M., PP-WE-272

Carlier V. A., PP-MO-605, PP-WE-610

Carlo A., PP-MO-108, PP-MO-112, PP-MO-766, PP-TH-183,PP-TH-235, PP-WE-164

Carlson K. S., PP-WE-718

Carlsson S. U., OC-WE-141

Carlsson T., PP-TH-428

Carmassi F., PP-MO-246

Carmazzi Y., PP-MO-758

Carmeliet P., OC-MO-044

Carmona F., PP-WE-371

Carmony A., OC-WE-022

Carnarius H., PP-MO-509, PP-TH-312

Carneiro J. D. A., PP-WE-444

Carnevale R., PP-TH-050, PP-WE-105, PP-WE-753

Caron C., PP-MO-611, PP-MO-626, PP-TH-623, PP-TH-680, PP-WE-762

Carr C., OC-MO-123

Carr M. E., PP-MO-598

Carraro V., OC-TU-086

Carre J., PP-TH-291

Carreras M. C., PP-MO-589

Carrier M., OC-MO-087, OC-TH-012, OC-TU-011, AS-WE-022, PP-TH-292, PP-TH-489

Carrieri C., PP-MO-176, PP-TH-573, PP-WE-249

Carrijo-Carvalho L. C., PP-MO-849

Carrillo M., PP-TH-156

Carrivale M. A., PP-MO-831,PP-TH-044, PP-WE-093, PP-WE-094

Carroll V. A., PP-MO-848

Carrothers T. J., OC-WE-003

Carson P., PP-WE-522

Carteaux J. P., PP-TH-394

Carteaux J., PP-WE-700

Carter A. M., OC-TH-089, OC-WE-114, PP-TH-351, PP-WE-231

Carter T., OC-MO-067

Cartier S., OC-TU-020

Cartot-Cotton S., PP-WE-423

Caruso P., PP-TH-372

Caruso V., PP-WE-498

Carvalho M. G., PP-MO-334,PP-MO-346, PP-MO-349, PP-MO-698, PP-MO-699, PP-MO-816, PP-MO-871, PP-TH-217, PP-TH-218, PP-TH-490, PP-WE-092, PP-WE-226, PP-WE-227, PP-WE-310, PP-WE-364, PP-WE-869

Carvalho M., PP-MO-333, PP-MO-335, PP-MO-363, PP-MO-364, PP-TH-444, PP-WE-365, PP-WE-812

Casais P., PP-TH-350, PP-WE-354

Casaña P., PP-TH-627, PP-WE-668, PP-MO-589, PP-TH-544

Casanegra A. I., PP-WE-464

Casari C., AS-WE-039

Casas M. J., PP-TH-629

Casazza F. F. C., PP-MO-312

Casazza F., OC-TH-014

Casazza G., OC-TH-010

Casciu L., PP-MO-266

Cases A., PP-WE-871

Casey K., PP-TH-585

Casini A., PP-MO-801, PP-MO-803, PP-TH-340

Casonato A., AS-WE-039, PP-TH-259, PP-WE-641, PP-WE-645

Cassee F. R., PP-TH-122

Castagna A., PP-MO-342, PP-TH-347

Castaman G. G. C., AS-WE-023, PP-MO-372

Castaman G., SA-MO-007, AS-MO-017, AS-MO-029, AS-TU-032, AS-TU-033, OC-TU-074, OC-TU-075, OC-WE-136, PP-MO-612, PP-WE-626, PP-WE-627, PP-WE-628, PP-WE-629, PP-WE-630

Castaño S., PP-MO-160

Castañon M., OC-TU-064, PP-MO-687

Casteels P., AS-TH-024

Castellano R., PC-015

Castelli A., PP-MO-775

Castelli C., AS-TH-032, OC-MO-132, OC-WE-099, PP-WE-744

Castelli M., OC-TU-086, PP-MO-765, PP-TH-382

Castelli R., PP-WE-230

Castellino F. J., AS-TU-043,AS-WE-049, OC-TU-050, OC-WE-022, PP-MO-880, PP-MO-881

Castellino F., SA-TU-007

Castellone D. D., PP-MO-129

Castillo J., PP-MO-055, PP-TH-096, PP-WE-033

Castle D., PP-MO-447, PP-WE-443, PP-WE-446

Castoldi E., OC-MO-005, OC-MO-119, OC-WE-097, PP-MO-186, PP-TH-377, PP-WE-499

AUTHORS INDEX

493

Castro F., PP-TH-299

Castro Ozelo M., PP-WE-066

Català A., PP-TH-451

Cataland S. R., OC-WE-009,OC-WE-129, OC-WE-130, PP-WE-729

Catalfamo J. L., PP-MO-751

Catanese J. J., AS-WE-010

Catapane E., PP-TH-424

Cathala N., PP-TH-307

Catricalà S., PP-MO-046

Cattaneo M., SA-TH-005, OC-TH-010, PP-MO-092

Cattaneo R., OC-TH-011

Cattaneo V., PP-WE-035

Cattini M. G., PP-WE-641, PP-WE-645

Cattini M., PP-TH-259

Cauchie C., PP-TH-684

Cauchie P., PP-TH-684

Caughran J. D., PP-WE-103

Cavallaroni K., PP-WE-509

Cavallo L., PP-WE-878

Cavazza S., PP-WE-509

Cavazzana A., PP-TH-274

Cavoni A., PP-MO-015

Cawthern K. M., PP-TH-264,PP-WE-117

Cazap N., PP-WE-135

Cazenave J. P., OC-MO-008,OC-TH-033, OC-TH-034, PP-MO-416

Cazenave J., AS-MO-058, AS-TU-047, OC-TH-035, OC-TU-049, OC-WE-150, PP-WE-891

Cazin L., PP-TH-174

Cazzaniga M., PP-MO-673

Cecchetti L., OC-TU-047, PP-MO-085

Cecchi E., PP-MO-013

Cech L., PP-WE-142

Cecinati V., PP-MO-448, PP-TH-493, PP-WE-878

Ceelen W. P., PP-WE-176

Cefalù A. B., OC-TU-088

Celestini A., PP-WE-105

Celi A., OC-WE-029, PP-MO-758

Celik M., PP-MO-073

Celinska-Lowenhoff M., PP-TH-381

Celkan T., AS-MO-028, PC-039

Cella G., OC-WE-088, PP-MO-867

Cellai A., PP-MO-217

Cellini C., PP-WE-856

Cera M., PP-MO-775

Cerbone A. M., PP-MO-336,PP-WE-320, PP-WE-325

Ceresetto J. J., PP-WE-135

Ceresetto J. M., PP-WE-293

Ceriani E., OC-TH-010, PP-MO-505

Cerini C., PP-WE-850

Cerletti C., PP-MO-099, PP-TH-048, PP-TH-094, PP-TH-248, PP-WE-048, PP-WE-246

Cermelj M. A., PP-TH-607, PP-WE-203

Cerrato G. S., PP-TH-333

Cerrato G., PP-MO-275, PP-TH-681

Cesari F., OC-TH-047, PP-MO-799, PP-MO-800, PP-MO-801, PP-MO-802, PP-MO-803, PP-MO-804, PP-MO-836, PP-TH-163, PP-TH-340, PP-WE-002, PP-WE-747

Cesarman-Maus G. N., PP-WE-264

Cetin I., PP-MO-375

Cetin R., PP-WE-806

Cetkovsky P., PP-MO-583

Cevreska L., PP-TH-557, PP-WE-769

Cha Y., PP-MO-213

Chaabane C., PP-WE-810

Chaar G., PP-WE-281

Chabot F., PP-MO-402

Chacko J., PP-TH-615

Chadha S., AS-WE-045

Chadwick S., PP-TH-480, PP-TH-525

Chafa O., PP-MO-656

Chagnon I., OC-TU-011

Chai J., OC-TH-043

Chaim E. E. A. C., PC-046

Chaireti R., PP-TH-018, PP-WE-334

Chakroun T., PP-TH-343

Chalmers E., PP-TH-538

Chambost H., OC-TU-073, PP-WE-603

Chammas R., PP-TH-499

Chamone D. A. F., PP-MO-755,PP-TH-542, PP-WE-444, PP-WE-705

Chamouard V., PP-MO-530

Champion F., PP-TH-385

Chan A. K. C., OC-MO-074,OC-TU-068, PP-MO-197, PP-MO-426, PP-TH-135, PP-TH-435, PP-TH-441, PP-TH-459, PP-TH-503, PP-WE-173, PP-WE-174, PP-WE-177, PP-WE-193, PP-WE-288, PP-WE-431, PP-WE-541, AS-TH-051

Chan A. K., OC-WE-095, PP-WE-445, PP-WE-719

Chan A., AS-WE-003, PP-MO-494, PP-WE-507, PP-WE-553

Chan C. T., PP-TH-125

Chan C., AS-WE-060

Chan H. H. W., PP-WE-174

Chandra D., PP-MO-623

Chandrasekaran E. V., PP-WE-893

Chang C., PP-MO-846, PP-MO-877, PP-MO-878

Chang D., PP-TH-667

Chang J. Y., PP-MO-768, PP-TH-655

Chang L., PP-MO-010

Chang M. C., PP-MO-869, PP-TH-058

Chang M., OC-TH-119, PP-TH-065, PP-TH-066

Chang R., AS-MO-010, PP-TH-225, PP-TH-225

Chang-Claude J., PP-MO-480

AUTHORS INDEX

494

Aut

hors

Inde

x

Chanos A., PP-TH-467

Chantarangkul V., PP-MO-673

Chao T., PP-MO-555, PP-TH-653

Chapelle C., OC-MO-053, OC-TH-021, PP-WE-165

Chapman R. L., PP-MO-587

Chapman S., OC-WE-022

Chappell J. C., AS-WE-051

Chappell L., PP-WE-623

Charbonnel C., PP-WE-858

Charbonnier B., PP-TH-365

Chari R., PP-TH-011

Charitos C., PP-WE-693

Charkviani T., PP-WE-281

Charlanne H., AS-TH-043

Charnaya M. A., PC-010, PC-011, PC-051

Charniot J., PP-MO-723

Charunwatthana P., PP-MO-710

Chatard B., PP-MO-658, PP-TH-386

Chatelain B., PP-MO-040

Chatelain N., PP-MO-814

Chatelain R., OC-TU-073

Chatelanaz C., PP-MO-619,PP-MO-618

Chatellier G., AS-TU-009

Chatterjee M. S., OC-TH-109,PP-TH-038, PP-TH-049, PP-WE-063, PP-WE-194

Chau W. K., PP-TH-620

Chaudry G., PP-WE-446

Chauhan A. K., OC-TH-063,OC-TU-045, PP-MO-093

Chauleur C., OC-TH-081

Chaunsamrit A., PC-052

Chavez L., PP-TH-681

Chavez M., AS-WE-031

Che Nordin S., PP-MO-636

Cheema A., PP-MO-356

Chegeni R., OC-TH-053

Chen A., PP-WE-078

Chen C. C., PP-MO-330, PP-TH-620

Chen D., OC-TH-043, OC-TU-051, OC-WE-067, PP-MO-629, PP-MO-678, PP-MO-796, PP-WE-394, PP-WE-836, PP-WE-848, PP-WE-849

Chen E. I., AS-TU-020

Chen E. P., PP-MO-676

Chen E., PP-TH-225

Chen F., OC-WE-027

Chen H., PP-MO-646

Chen J., PP-TH-092, PP-WE-887, AS-MO-011

Chen K., OC-MO-107

Chen L., OC-TU-027

Chen M., OC-TU-034

Chen P. M., PP-MO-330

Chen P., AS-TU-030, OC-MO-139, OC-WE-121, PP-WE-060

Chen Q., PP-MO-410, PP-MO-411, PP-TH-126

Chen S. W., PP-WE-659

Chen V. M., AS-MO-043

Chen W. J., PP-TH-088

Chen W., PP-WE-585, PP-WE-586

Chen X., PP-TH-078, PP-TH-095

Chen Y. C., PP-MO-100

Chen Y., PP-MO-010, PP-MO-555, PP-MO-844, PP-TH-653, PP-WE-005

Chen Z., PP-TH-078, PP-WE-706

Cheng G., AS-MO-055, AS-TU-002

Cheng J., PP-TH-503, PP-WE-079, PP-WE-429

Cheng Q., AS-TH-039

Cheng S., PP-MO-555, PP-TH-408, PP-TH-552, PP-TH-653

Chennoukh K. W., PP-WE-639

Chennoukh K., PP-TH-204

Cherel G., AS-TH-015, OC-MO-060

Cherkasova M. V., PP-TH-267

Chernysh I. N., AS-WE-048

Chesnokova N., PC-005

Cheung E. Y., OC-MO-078, PP-MO-847

Chevalier Y., PP-MO-264

Chew H. K., OC-TU-014, PP-TH-498

Chi H., PP-MO-727, PP-TH-509, PP-WE-343

Chi J., OC-MO-002

Chicanne G., PP-WE-019

Chidiac J., PP-MO-514, PP-TH-211, PP-WE-505

Chieffo A., PP-MO-775

Chieng Yane P., PP-MO-837

Chiesa R., PC-015

Chiles P. G., OC-MO-022

Chillón M., PP-TH-290

Chin-Dusting J., PP-WE-391

Chinni E., OC-TU-035, PP-MO-822

Chintagumpala M., PP-TH-445

Chinthammitr Y., PP-MO-406,PP-WE-772

Chio S., PP-TH-123

Chion A. C. K., OC-MO-065

Chion C. K. W., PP-MO-091

Chiriac A. L., OC-TU-016

Chirinian Y., AS-MO-020, OC-TU-076

Chirivella M., PP-MO-215

Chironi G., PP-WE-408

Chitima-Matsiga R., AS-TH-027

Chitlur M., PP-TH-180

Chitsike R. S., PP-TH-370, PP-TH-371

Chlopicki S., PP-TH-239

Chlupova G., PP-TH-612, PP-TH-613

Cho H., PP-TH-149

Cho J., OC-MO-057

Cho P. W., PP-WE-757

Cho R., PP-TH-489

Chocarne P., PP-MO-530

Choi D., PP-WE-877

Choi E., PP-WE-783

Choi G., PP-WE-407

Choi J., PL-TU-005, PP-MO-353, PP-MO-712, PP-WE-877

AUTHORS INDEX

495

Choi M., PP-MO-727

Choi S. H., PP-TH-256

Choi T., PP-TH-519

Choi W., PP-MO-301

Chojnowski K., PP-MO-692,PP-MO-752

Cholera S., PP-MO-054

Chollet M. E., PP-MO-074, PP-TH-680

Chopard P., PP-MO-318

Chovanec V., PP-TH-438

Chow C., PP-WE-004

Chow T. Y., PP-MO-820

Chowdary P., PP-MO-524, PP-WE-192, PP-WE-649, PP-WE-713

Chrast R., OC-WE-037

Chretien J., OC-TH-018

Chrisitian G., AS-TU-047

Christ G., PP-MO-107

Christadoss P., OC-TU-038

Christensen E. I., PP-MO-121,PP-MO-122

Christersson C., PP-MO-408,PP-TH-407

Christiansen K., PP-MO-386,PP-WE-658, PP-WE-677

Christiansen M. L. S., PP-WE-590, PP-WE-591

Christiansen M. S., PP-WE-589

Christiansen S. C., OC-WE-013, PP-TH-329

Christidis C., PP-TH-307

Christie L. M., PP-TH-310, PP-TH-457

Christophe O. D., AS-TH-015,OC-MO-060, OC-WE-042, PP-TH-642

Christopherson P. A., AS-MO-017, OC-TU-071, OC-WE-133

Christopoulou-Cokkinou V.,PP-MO-707

Chromov I. S., PP-TH-158

Chrostek A., AS-WE-030

Chrzanowska-Wodnicka M.,AS-MO-064

Chu S. G., AS-TH-033

Chuansumrit A., PP-MO-354,PP-MO-681, PP-WE-566

Chudej J., PP-TH-306

Chudy’ P., PP-TH-306, PP-WE-220

Chudzinski-Tavassi A. M., PP-MO-475, PP-MO-849, PP-WE-160, PP-WE-167, PP-TH-495, PP-WE-098

Chumakova E. L., PP-WE-224

Chun S., PP-TH-509

Chung C., PP-MO-840, PP-MO-846, PP-MO-878

Chung D. W., PP-TH-092

Chung D., AS-MO-011

Chung J., PP-WE-501, PP-WE-569

Chung K., PP-WE-783

Chung M., PP-WE-844

Chung Y., PP-TH-294

Chunharas A., PP-MO-354

Church F. C., PP-WE-189

Church F., PP-TH-502, PP-WE-290

Ciabattoni G., OC-TU-088, PP-MO-015, PP-MO-016, PP-WE-738

Cianchetti S., OC-WE-029

Ciancia M., PP-WE-824

Ciavarella N., PP-TH-670, PP-WE-657

Cichon S., OC-TH-059

Cicin I., PP-MO-841, PP-WE-889

Cid A. R., PP-MO-589, PP-TH-544, PP-MO-566, PP-MO-601, PP-TH-596, PP-TH-627, PP-WE-668

Ciepluch K., PP-MO-216

Cierniewski C. S., PP-MO-839,PP-MO-843, PP-MO-861

Ciesla-Dul M., PP-MO-216

Cifuni S., AS-MO-047

Cillo U., PP-WE-424

Ciminello A. A. C., AS-WE-023

Ciminno E., PP-WE-325

Cimino E., PP-MO-336, PP-WE-320

Cimmino G., PP-MO-834

Cines D. B., OC-WE-112, AS-TU-001

Cines D., AS-TH-008

Cini M., PP-MO-351, PP-MO-503, PP-MO-504, PP-TH-282, PP-WE-351, PP-WE-509, PP-WE-715

Ciocea A., PL-TU-005

Ciorascu M., PP-MO-069

Cipolla A., PP-TH-590, PP-WE-870

Cipolla L., PP-MO-046

Cirillo F., PP-WE-321

Ciuti G., OC-WE-102, PP-MO-303, PP-MO-304, PP-MO-339, PP-MO-341, PP-WE-283

Clabon M., PP-MO-112

Claesson-Welsh L., SA-TH-007

Claeyssens S., PP-MO-567

Clappers N., PP-MO-780

Clark D. S., AS-TH-053

Clark I., PP-TH-330

Clark N. P., PP-MO-462, PP-MO-463

Clark N., PP-MO-308

Clarke B. J., OC-MO-059

Clase C. M., OC-TH-009

Claus R. A., PP-TH-086, PP-TH-087, PP-WE-684

Claustres M., PP-MO-656

Clavert J., PP-MO-611

Clayessens S., PP-MO-530

Clemens A., PP-MO-167, PP-TH-167, PP-TH-169, PP-WE-204, PP-WE-205, PP-WE-469

Clemente J. L., PP-WE-479

Clemetson K., AS-MO-050

Clemmons W., OC-TU-048

Clerici M., PP-MO-673

Cleuren A. C. A., PP-MO-236

Clifford J., PP-MO-713

Cluitmans F., OC-TH-008

Coates A., PP-TH-685

Cochery-Nouvellon E., OC-TH-081

AUTHORS INDEX

496

Aut

hors

Inde

x

Codaccioni J., PP-MO-833

Coe D. J., OC-TH-043

Coelho F. F., PP-MO-346, PP-WE-347, PP-WE-814

Coen Herak D., PP-MO-223,PP-WE-275, PP-WE-435, PP-WE-442

Coetzee M., PP-TH-637

Cogrossi A., PP-TH-375, PP-WE-682

Cogulu O., PP-WE-577

Cohan N., PC-044, PP-MO-655

Cohen A. J., PP-WE-127

Cohen A., OC-MO-054, PP-MO-427

Cohen H. W., OC-WE-101

Cohen H., PP-TH-263, PP-TH-384

Cohen M. J., OC-TH-067

Cohen S., PP-MO-710

Cohn D. M., AS-MO-030, PP-MO-298

Cokkinos D., PP-MO-707

Colaizzo D., PP-MO-822, PP-WE-366, PP-WE-367, OC-TU-035

Colavecchia G., PP-MO-202,PP-MO-481, PP-TH-248, PP-WE-502

Colby E. A., PP-WE-299

Coletta W., PP-TH-048

Coletti V., PC-030

Coll E., PP-TH-482, PP-WE-108

Coll I., PP-MO-323, PP-TH-285,PP-WE-175

Coller B. S., AS-MO-027, PP-WE-082

Collet J. P., OC-MO-008

Colletta G., PP-WE-870

Colli S., PP-WE-050

Colliec-Jouault S., OC-TH-048

Collier M. E. W., PP-MO-479,PP-WE-837, PP-WE-840

Collignon O., PP-TH-394

Collins P. B., PP-TH-034

Collins P. W., OC-TU-078, PP-TH-585

Collins P., OC-WE-058, PP-MO-604, PP-MO-609, PP-TH-584, PP-WE-604

Collins R. D., PP-TH-471, PP-TH-472

Collins R., PP-WE-409

Colombo A., PP-MO-775

Colombo D., OC-MO-069

Colombo G., OC-TU-025

Colomina M., PP-WE-234

Colon J., PP-TH-491

Colon K., PP-WE-065

Colov N. P., PP-WE-383

Colovic M., PP-MO-327

Colucci G., PP-MO-753, PP-WE-717

Colucci M., PP-MO-176, PP-MO-245, PP-MO-423, PP-TH-573, PP-WE-249

Coluccia A., PC-034

Colvin S., PP-TH-687

Colwell C., PP-MO-247

Com O., PP-MO-785

Combescure C., PP-MO-505,PP-MO-783

Comerota A. J., PP-TH-376

Compes M., PP-MO-128

Conant C. G., PP-WE-860

Conard J., AS-MO-003, PP-WE-316

Conde N., PP-TH-451, PP-TH-451

Condez A., PP-WE-649

Conely P., PP-WE-801

Cong Y. L., PP-MO-731

Conley P. B., OC-TH-107, PP-MO-045, PP-TH-027

Conley P., AS-TH-022, AS-TU-026

Conley R. B., OC-MO-123

Conlon S. J., OC-TU-014

Connell S. D., PP-WE-259

Connolly B., PP-TH-434

Connolly G. C., OC-TU-018

Connonly B., PP-WE-446

Connor D. E., PP-MO-747, PP-WE-776

Connor N., OC-MO-033

Conradi F., PP-TH-087

Conri C., PP-MO-196

Consoli A., PP-MO-016

Constans J., PP-MO-196

Contant G., PP-MO-766

Conte T., PP-MO-736, PP-MO-753

Conti E., AS-TH-029, PP-WE-359

Contreras M. T., PP-MO-192,PP-MO-193

Contreras T., PP-WE-885

Conway E. M., PL-TU-006

Conway E., PP-MO-819

Cook D. J., PP-WE-429

Cooley B. C., AS-MO-024, PP-MO-098, PP-MO-881, PP-WE-134

Cooney M. T., PP-TH-034

Cooper C., PP-TH-657

Cooper D. K. C., PP-MO-070

Cooper D. L., PP-MO-535, PP-MO-545, PP-MO-598, PP-MO-600, PP-TH-601, PP-TH-602, PP-TH-617, PP-WE-601, PP-WE-602

Cooper D., PP-TH-445

Cooper M., AS-TU-015

Cooper N., AS-TU-003

Cooper P. C., PP-MO-199, PP-TH-679, PP-WE-144, PP-WE-302

Coppola A., AS-TU-032, OC-TU-075, PP-MO-336, PP-MO-525, PP-TH-622, PP-WE-320, PP-WE-567, PP-WE-599, PP-WE-325

Coppolecchia R., PP-TH-101,PP-WE-797

Corazzi T., PP-MO-085, PP-TH-069, PP-WE-823

Corbella E., PP-WE-816

Corbonnois G., PP-TH-394

Cordazzo C., PP-MO-758

Cordell P. A., OC-WE-125, PP-TH-028, PP-WE-258

Cordisco A., AS-TH-034

AUTHORS INDEX

497

Corinaldesi C., PC-016, PC-054, PP-MO-807, PP-MO-866, PP-TH-342, PP-WE-790, PP-WE-807

Corinaldesi G., PC-016, PC-054, PP-MO-807, PP-MO-866, PP-TH-342, PP-WE-790, PP-WE-807

Coriolano E. O., PP-MO-390

Cork W., PP-TH-182

Cornacchini S., PP-MO-266

Cornet Y., PP-MO-040

Coroller-Bec C., OC-MO-038,PP-TH-524

Corrada E., PP-WE-791

Corradini S., PP-MO-285

Corral J., AS-MO-054, AS-TH-052, OC-TH-027, OC-TU-080, OC-TU-082, OC-WE-107, PP-MO-134, PP-MO-144, PP-TH-247, PP-TH-287, PP-TH-481, PP-WE-123, PP-WE-141

Corrales F. J., OC-TU-080

Corrales I., PP-MO-528

Correa G., PP-TH-556

Correcher P., PP-WE-436

Corrente J. E., PP-MO-311

Corrocher R., OC-TH-028, OC-TH-030, PP-MO-342, PP-TH-347

Corsani I., PP-TH-340

Corseaux D., PP-MO-814, PP-MO-815, PP-WE-858

Corte T. J., PP-WE-805

Cortes M., PP-MO-160

Cortez P., OC-WE-006, PP-MO-418

Cortina B., PP-WE-096

Cortina E., PP-MO-345, PP-MO-362

Cortina V., PP-MO-590

Cosemans J. M. E. M., AS-TU-029, OC-MO-044, OC-WE-123, PP-WE-260

Cosgrave J., PP-MO-775

Cosin R., PP-MO-215

Cosmi B., AS-TH-029, OC-TH-003, OC-TH-006, PP-MO-290, PP-MO-291, PP-TH-507, PP-WE-351, PP-WE-715

Cosserat J., PP-TH-307

Costa C., PP-MO-529, PP-TH-619, PP-WE-600

Costa H., PP-WE-402

Costa M. A., PP-TH-606

Costa Pinto Prego De FariaM., PP-MO-637

Costamagna G., PP-WE-647

Costantino G., OC-TH-010

Costanzo S., PP-MO-876

Cotellese R., PP-WE-856

Cottenceau V., PP-TH-432

Coughlin P. B., OC-TU-084,PP-TH-224

Coughlin P., OC-TU-079

Coughlin S. R., AS-MO-043

Couppey F., PP-TH-485

Cournoyer D., PP-MO-820

Court C., PP-TH-649

Courtney D. M., OC-TU-007,PP-MO-512, PP-TH-283, PP-TH-505, PP-WE-414, PP-WE-467

Couturaud F., AS-TU-009, PP-MO-310, PP-WE-510, PP-MO-508, PP-TH-291

Cowan P., AS-TH-025, OC-MO-101, OC-MO-127

Cox D., OC-WE-047, PP-MO-051, PP-MO-738, PP-TH-056, PP-TH-102, PP-WE-813

Cozza G., PP-WE-384

Cozzi E., PP-WE-248, PP-WE-384

Cozzi F., OC-WE-088

Cozzi G., PP-WE-625

Cozzi M. R., PP-WE-018

Cozzi M., PP-TH-008

Crain E. J., PP-TH-171

Cramer-Borde E., OC-WE-149

Cranenburg E. C. M., PP-WE-808

Cranswick N., PP-WE-438

Craven S. J., PP-MO-017

Crawford R., PP-WE-021

Crawford S., PP-WE-021

Crawley J. T. B., AS-TU-019,AS-WE-012, PP-MO-089, PP-TH-089, PP-TH-090

Crea F., PP-WE-789

Creagh M. D., PP-TH-632, PP-WE-522, PP-WE-523

Creary M., PP-MO-596, PP-WE-613

Crescente M., PP-MO-099, PP-TH-048, PP-TH-094, PP-WE-246

Crichton I., AS-TU-028

Crikis S., AS-TH-025, OC-MO-127

Crippa L., PP-MO-261

Criqui M. H., AS-TU-007, PP-WE-458

Crisby M., PP-MO-845

Crispin A., OC-WE-119

Crist R. A., PP-WE-306

Cristiano M., OC-TH-018

Cristofalo C., PP-MO-716

Croce M. A., OC-TH-069

Cromwell C., PP-WE-704

Cronin K. R., PP-WE-113

Croockewit S., PP-TH-260

Crosby J. R., OC-TH-108, PP-TH-388

Crowe B. R., PP-MO-081

Crowther M. A., OC-TH-009,PP-MO-306, PP-MO-462, PP-MO-463

Crowther M., SA-TH-010, OC-MO-051, OC-TU-020, PP-MO-308, PP-MO-309,

Cruz C., PP-TH-396

Cruz E., PP-MO-667

Cruz N. G., PP-WE-347, PP-WE-814

Csák É., PP-MO-228

Csanadi A., OC-TU-051, PP-WE-836

Csapó A., PP-MO-205

Cuccaro C., PP-WE-325

AUTHORS INDEX

498

Aut

hors

Inde

x

Cucchini U., OC-TH-075

Cuccurullo F., PP-WE-311

Cucuianu A., PP-MO-532, PP-WE-549

Cuddy K. K., OC-TH-106

Cuello F., PP-TH-606

Cueto C., PP-MO-265

Cugno M., PP-WE-230

Cui J., PP-TH-364

Cui Z., OC-WE-057

Cuisset T., OC-MO-007, PP-MO-773, PP-MO-774, PP-WE-775

Culakova E., OC-TU-018

Cullinan D. B., PP-TH-159

Cultrera D., PP-TH-590, PP-WE-870

Cuman C., PP-TH-461

Cumming A. M., OC-TU-078,PP-TH-645

Cumming T., PP-MO-534

Cummins P., AS-TU-059

Cunanan J., OC-TH-019, OC-TH-103, PP-MO-139, PP-MO-140, PP-MO-399, PP-TH-142, PP-TH-166, PP-TH-389, PP-TH-391, PP-WE-261, PP-WE-387, PP-WE-482

Cunha A., PP-WE-374

Cunha-Melo J. R., PP-MO-387

Cunningham A., OC-WE-047

Cupanik V., PP-WE-656

Curnow J. L., PP-WE-221

Curnow J., PP-WE-547

Curry B., PP-TH-439

Curtis K., PP-WE-479

Cushman M., AS-TH-005, AS-TU-007, AS-WE-009, OC-MO-006, OC-TH-002, OC-TH-004, OC-WE-103, PP-TH-412, PP-WE-286, PP-WE-458

Cushner F., PP-MO-247

Custers J., PP-WE-150, PP-WE-151

Custodio S., PP-WE-476

Cutler J. A., PP-WE-635

Cutler J., PP-MO-628, PP-TH-152

Cutrone A., PP-MO-202, PP-MO-481, PP-TH-248, PP-TH-249, PP-WE-246, PP-WE-502

Cutsforth G. A., PP-MO-467

Cutsforth G., PP-TH-473

Cvejic A., AS-MO-037

Cwikla J., PP-MO-608

Cymbalista F., PP-MO-723

Cziffer A., PP-WE-495

Czitrom D., PP-TH-307

Czuriga I., PP-TH-366

Czwalinna A., PP-MO-693

D’ Amico E. A., PP-MO-755,PP-TH-542, PP-WE-705

D’ Andrea G., PP-WE-367

D. Steenstrup T., PP-MO-565

D´atri L. P., PP-WE-042

D’Apice A., OC-MO-101

Daalhuisen J., OC-WE-105

Dabar G., PP-WE-281

Dabbagh O., AS-TH-027, PP-TH-419, PP-TH-424, PP-WE-430

Dabrilli P., PP-TH-382, PP-TH-383, PP-WE-147

Dachary-Prigent J., PP-WE-008

Dadaian M., PP-MO-574

D’Adamo P., PP-MO-085

Daddona J. L., PP-TH-117

Dadkhahi S., PP-MO-827

Daemen M., AS-WE-058, OC-MO-125

D’Agostino C. C. D. A., PP-MO-312

Dahan K., PP-WE-532

Dahl O. E., PP-TH-169, PP-TH-170, PP-TH-413, PP-WE-204, PP-WE-205

Dahlback B., OC-MO-063, OC-MO-097, OC-MO-098, PP-WE-140

Dahlbäck B., OC-MO-096, OC-TH-078, OC-TU-096, OC-WE-141

Dahou M., OC-TH-084

Dai J., PP-MO-510, PP-TH-562,PP-TH-563, PP-TH-564, PP-TH-565, PP-WE-536, PP-WE-770, PP-MO-646

Dai L., PP-WE-616

Daidone V., PP-TH-259, PP-WE-641, PP-WE-645

Dale B., PP-MO-148, PP-TH-188

D’Alecy L., OC-MO-128

Daleskog M., AS-WE-024

D’Alessandro R., PP-TH-494

D’Alessandro-Gabazza C. N.,OC-WE-038, PP-WE-222

Dali-Ali F., OC-TH-005

Dalla Valle F., PP-TH-304, PP-TH-383, PP-TH-488, PP-WE-247

Dalsgaard J., PP-WE-319

Dalsgaard Nielsen J., PP-WE-417

Daly M. E., OC-MO-131, OC-TH-041, PP-MO-052, PP-MO-075

Daly M., PP-MO-076

Dambrine S., OC-MO-038, PP-TH-524

Damian G. B., PP-MO-521, PP-WE-631

Damian G., PP-MO-520

D’Amico E. A., PP-WE-444,PP-MO-034

Damnjanovic T., PP-TH-460

Damoiseaux J., PP-MO-670

Dampier C., PP-WE-894

Danaie N., PP-TH-124, PP-TH-318

Dandachli F., OC-WE-007

Dandekar T., AS-MO-038

Danesh J., SA-WE-007

Dangelmaier C. A., OC-TH-040, PP-MO-028

Dangelmaier C. C. D., PP-TH-040

Dangelmaier C., OC-WE-122

D’Angelo A., OC-TH-083, PP-MO-261, PP-MO-415

AUTHORS INDEX

499

Daniel J. J. D., PP-TH-040

Daniel J. L., OC-TH-040, OC-WE-122, PP-MO-028, PP-TH-011

Daniel J., AS-TH-058

Daniele F., PP-MO-572

Danielsen B., OC-MO-080

Dantona G., PP-MO-634, PP-MO-635

Dao V. V. D., PP-WE-500

Daoxin M., PP-MO-691

D’Apice A., AS-TH-025, OC-MO-127

Dardik R., PP-MO-749

Dargaud Y., OC-MO-062, OC-WE-021, PP-MO-658, PP-TH-385, PP-TH-386, PP-WE-133

Darlington D. N., PP-WE-399

D’Armini A. M., AS-MO-009

Darnige L., PP-WE-263

Dartigues J., PP-TH-349

Darwish Murad S., PP-TH-314

Das M., OC-MO-047

Das R., PP-MO-324, PP-WE-456

Dasgupta S., OC-WE-066, PP-MO-588

Dash C. H., PP-MO-568

Dash D., OC-WE-139, PP-MO-791, PP-MO-792, PP-MO-793

Dashnyam P., PP-TH-029

Dasi M. A., PP-MO-027, PP-MO-589

Dastot F., PP-MO-529

Daugherty A., OC-TH-077

Daune M., PP-TH-684

Dauphin C., PC-021

Daurés J., OC-TH-081

Dauzat M., OC-TH-081

Davenport A., PP-WE-713

Davenport R. A., PP-TH-685

Davi G., PP-MO-015, PP-MO-016, PP-WE-738

Davì G., AS-TU-049, OC-TU-088, PP-TH-082

Davì V., OC-TU-088

David T. H., AS-MO-043

David-Dufilho M., PP-MO-837

Davidoff A. M., AS-TU-011

Davidova O., PP-WE-155

Davidovic L., PP-MO-599

Davidson B. L., AS-TH-028

Davidson S. J., PP-MO-120,PP-TH-115, PP-TH-187, PP-WE-232, PP-WE-805

Davila M., PP-TH-491, PP-WE-001

Davis R. J., OC-WE-043

Davis-Harrison R. L., OC-TU-091, PP-WE-256

Davizon-Castillo P., PP-TH-468

Davoodabadi A., PP-MO-517

Davydova O. N., PP-MO-882

Dawood B. B., OC-MO-131,OC-TH-041, PP-MO-076

Dawson D., PP-MO-142

Dawson G., OC-WE-024

Daxecker H., PP-MO-043, PP-MO-044

Day Y., PP-MO-877

Dayan I., PP-TH-536, PP-WE-608

Dayan N., PP-TH-322

De Agostini A. I., PP-MO-165

De Amici M., PP-MO-415

De Angelis G., OC-TU-062

De Angelis V., OC-MO-121

De Biasio A., PP-TH-266

De Boer A., OC-WE-014, OC-WE-035

De Boer H. C., AS-WE-040

De Boer H., PP-WE-851

De Boer T., PP-WE-735

De Bon E., PP-WE-866

De Bono B., AS-MO-037

De Bosch N., AS-WE-018, PP-MO-526, PP-MO-663, PP-TH-555, PP-WE-782

De Bruijn R., PP-WE-336

De Caterina R., OC-WE-071,PP-MO-828, PP-WE-856

De Conti G., PP-WE-527

De Cos C., PP-WE-141

De Craen T. J. M., OC-WE-116

De Craen T., OC-WE-033

De Cristofaro R., AS-MO-013,AS-TU-049, PP-MO-092, PP-MO-328, PP-TH-085, PP-WE-647, PP-WE-738

De Curtis A., PP-TH-248, PP-TH-249, PP-WE-246, PP-MO-876, PP-TH-048

De Deyn P., PP-MO-229, PP-MO-230

De Feudis L., PP-MO-015

De Filippis V., AS-MO-013, OC-MO-113, OC-WE-081, PP-TH-085

De Gaetano G., PP-MO-099,PP-MO-202, PP-MO-481, PP-MO-876, PP-TH-048, PP-TH-094, PP-TH-248, PP-TH-249, PP-WE-048, PP-WE-246, PP-WE-498, PP-WE-502

De Goede-Bolder A., PP-MO-633

De Gregorio A. M., PP-MO-336, PP-WE-320, PP-WE-325

De Groot P. G., AS-TH-035, AS-TH-038, AS-TU-017, AS-WE-008, AS-WE-037, OC-MO-030, OC-MO-123, OC-TH-064, OC-TU-001, OC-TU-030, OC-TU-072, OC-WE-016, PP-MO-126, PP-MO-262, PP-MO-352, PP-TH-037, PP-TH-046, PP-TH-055, PP-WE-887, PP-WE-355

De Groot P., OC-MO-111, OC-MO-112, OC-MO-114

De Groot R., PP-TH-089, PP-TH-090

De Haan T. R., OC-TU-063

De Haas F., PP-WE-061

De Jaegere P. P. T., AS-TH-024

De Jouvencel T., PP-TH-039

De Kock A., PP-WE-650

De Kok J., PP-WE-128

De Kruif M., PP-TH-153

De La Morena M. E., PP-MO-144

De La Peña A., PP-MO-794,PP-MO-865, PP-WE-874

AUTHORS INDEX

500

Aut

hors

Inde

x

De Laat B., AS-WE-013, OC-MO-111, OC-MO-112, OC-TU-039

De Labriolle A., PP-TH-365

De Larrañaga G. F., PP-WE-236

De Leonardis F., PP-MO-448

De Maat M. P. M., OC-MO-133,PP-MO-781, PP-WE-346, OC-MO-078, PP-MO-847, OC-TH-029, PP-WE-355, OC-TU-034

De Maeyer B., PP-MO-088

De Maeyer M., PP-MO-094

De Maistre E., AS-TH-043, OC-MO-029

De Marco L., PP-WE-018, PP-TH-008

De Mattia D., PP-MO-448, PP-TH-493, PP-WE-878

De Meis E., PP-MO-483

De Metrio M., OC-TU-025

De Meyer S. F., OC-WE-040,PP-MO-088, PP-TH-091, PP-WE-013, PP-WE-084

De Micheli V., OC-TH-075

De Moerloose P., AS-TH-032,OC-MO-132, OC-TU-037, PP-MO-206, PP-MO-645, PP-TH-189, PP-TH-520, PP-TH-578, PP-WE-213, PP-WE-267, PP-WE-270, PP-WE-744, PP-WE-375

De Nanteuil G., PP-MO-382,PP-MO-395, PP-WE-396

De Negri F., PP-MO-246

De Paula E. V., PP-MO-520,PP-MO-521, PP-TH-466, PP-WE-295, PP-WE-535, PP-MO-725, PP-MO-870, PP-TH-157, PP-TH-532, PP-TH-554, PP-WE-294, PP-WE-476

De Peuter O. R., OC-WE-035,PP-TH-348

De Poli F., OC-MO-008

De Prost D., AS-WE-025, PP-MO-332, OC-TH-082, PP-TH-074

De Rooij M. F. M., PP-WE-339

De Roos A., AS-TU-010, PP-MO-507, PP-WE-303, PP-WE-341, PP-WE-512

De Rooy J., PP-TH-665

De Rossi G., PC-030

De Saint Martin L., OC-WE-113

De Schepper A. M. A., PP-WE-534

De Smedt E., PP-TH-107

De Stefano V. V. D. S., AS-WE-023, PP-MO-372

De Stefano V., PP-WE-366

De Visser M. C. H., OC-MO-004, OC-MO-019, PL-TU-001, PP-TH-139

De Vos A. F., PP-WE-407

De Vos R., PP-WE-041

De Vries L. S., OC-TU-063

De Vriese A., PL-TU-006

De Waele M., PP-MO-173, PP-MO-174, PP-WE-188

De Wee E. M., PP-MO-633

Deangelis G., PP-WE-756

Deangelis J. P., PP-WE-289

Debastos M., PP-WE-312

Debbas V., PP-MO-034

Debeij J., OC-WE-013, PP-MO-293, PP-TH-238, PP-TH-286

Debergh I. M. C., PP-WE-176

Debili N., AS-WE-030

Debourdeau P., PP-TH-497,PP-WE-483

Decker K. P., PP-WE-541

Deckers J. W., OC-TH-029

Deckers M., PP-WE-128

Deckmann A. C., PP-MO-825,PP-MO-826

Deckmyn H., AS-MO-037, OC-WE-040, PP-MO-049, PP-MO-050, PP-MO-088, PP-MO-094, PP-TH-091, PP-WE-013, PP-WE-056, PP-WE-084, PP-WE-085, PP-WE-260, PP-WE-726

Declerck P. J., OC-TH-114, PP-MO-219, PP-MO-225

Decousus H., OC-MO-052, OC-TH-021, PP-WE-165

Décousus H., PP-WE-410

Deev A., PP-WE-335

Defay F., AS-WE-025, PP-MO-332

Defilippis V., OC-TU-040

Defoort C., OC-TU-087

Degen J. L., AS-TU-045, OC-TH-063, OC-WE-121

Degen J., AS-WE-058

Degenaar-Dujardin M. E. L.,PP-MO-633

Deguchi H., PP-MO-813

Deguzman F. R., OC-TH-107

Deguzman F., AS-TH-022

Dehbozorgian J., PC-044

Dehgani M., PP-WE-459

Deinum J., PP-TH-176, PP-TH-177

Deitchman D., PP-WE-489

Deitelzweig S., OC-WE-018

Dejanova V., PC-028, PP-TH-271, PP-WE-426

Dekker F. W., PP-MO-316

Dekkers O. M., OC-WE-013,PP-MO-292, PP-MO-293, PP-TH-238, PP-TH-286, PP-WE-512

Del Carpio-Cano F. E., PP-WE-888

Del Fiorentino A., OC-WE-029

Del Pino M., PP-WE-408

Del Toro L., PP-WE-525

Del Valle L., PP-MO-865, PP-WE-874

Del Vecchio G. C., PP-MO-448,PP-TH-493

Dela Cadena R. A., OC-WE-030, PP-WE-888

Delahousse B., PP-MO-664

Delaney S. M., PP-MO-045

Delate T., PP-MO-462, PP-MO-463

Delavaux P., PP-MO-095

Delavenne X., OC-MO-050

Delestre M., PP-MO-814

Delev D., AS-WE-004, PP-MO-128

Delhaye C., PP-WE-858

Delignat S., OC-WE-066, PP-MO-588

AUTHORS INDEX

501

Delitto D., PP-MO-627

Della Corte A., PP-TH-048

Della Valle P., PP-MO-261

Dell’Era A., PP-MO-673, PP-TH-300

Delluc A., OC-WE-113, PP-MO-500, PP-TH-483, PP-WE-508, PP-MO-499, PP-TH-291

Delluc C., PP-TH-483

Delmar M., AS-TU-018

Delpero N., PP-MO-496

Del-Rio-Navarro B., PP-WE-217

Deltour I., PP-MO-405

Delvaeye M., PL-TU-006

Delvau N., PP-TH-524

Delvecchio M., PP-WE-878

Demaegd M., PP-TH-666

Demarmels Biasiutti F., PP-WE-211

Demasi M., PP-TH-495

Dementieva I. I., PC-011, PC-051

Demers C., AS-WE-003, PP-WE-553

Demir M., PP-MO-841, PP-TH-221, PP-TH-222, PP-WE-876, PP-WE-889

Demir V., PP-MO-841, PP-WE-889

Demirkol D., PP-MO-440

Demler C., PP-MO-025

Dempfle C. H., OC-TH-068, PP-MO-238

Demulder A. C., PP-MO-617

Demulder A., PP-MO-441, PP-TH-666

Demyanets S., PP-MO-829

Den Heijer M., PL-TU-001

Den Hertog H. M., OC-MO-078

Den Uijl I. E. M., OC-TU-070,PP-WE-534

Denas G., OC-MO-015, OC-MO-028, OC-TH-075

Denenberg J. O., AS-TU-007,PP-WE-458

Dengler T. J., PP-TH-421

Denis C. V., AS-TH-015, OC-MO-060, OC-WE-042, PP-MO-090, PP-TH-642

Denis C., SA-MO-008, OC-TH-034

Denisov I. G., PP-WE-119

Denney W. S., OC-TH-109

Dennis A., PP-MO-233

Dentali F., OC-MO-092, PP-MO-308, PP-MO-309, PP-MO-463, PP-MO-659, PP-TH-507, PP-WE-313, PP-WE-340

Deoisares R., PP-TH-245

Depasse F., PP-WE-198, PP-WE-199

Deprez D., PP-WE-655

Derksen R. H. W. M., OC-MO-030

Derksen R., OC-MO-111, OC-MO-114

Derosa L., PP-MO-437, PP-MO-438

Deruelle P., PP-MO-376

Desai H., PP-TH-482, PP-WE-001

De-Sá-Júnior P. L., PP-TH-495,PP-MO-475

Desancho M. T., PP-TH-624,PP-WE-718

Desch K. C., PP-WE-640

Deschepper N., PP-TH-684

Deshpande C. S., PP-TH-108

Desmurs Clavel H., PP-WE-483, PP-TH-385

Despoix N., AS-MO-060

Desposit G., SA-TH-011

Desprez D., PP-MO-611

Desruennes E., PP-TH-497

Destaercke C., PP-TH-328

Destareck C., PP-TH-324

Destors J., OC-WE-006

Desuremain M., OC-MO-021

Detzler G., PP-MO-518

D’Eustacchio A., PP-MO-085

Deutsch V. R., PP-TH-070

Deutschinoff G., LB-MO-003

Deutschmann A., PP-WE-439

Deveber G., PP-WE-528

Devecioglu O., PP-MO-222,PP-MO-440

Deveeska M., PP-WE-447

Devera M. E., OC-MO-031

Devlin J. J., AS-WE-010, OC-MO-020

Devreese K. M. J., PP-WE-268

Devriendt K., PP-MO-059

Devries J. H., PP-MO-298

Dewald G., PP-MO-130

Dewar L. L., PP-MO-017

Deygas B., OC-WE-002

Dezamis E., PP-WE-592

Dezfouli S., AS-TH-025, OC-MO-101, OC-MO-127

Dhadwar S. S., AS-TH-012

Dhami M., PP-TH-477

Dhanakshmi B., PP-MO-811

Dhanalakshmi B., OC-TH-118,PP-MO-812

Dhanasekaran D., AS-TH-044,PP-MO-078

Dhanjal T. S., PP-WE-076

Dhanji A. A., AS-WE-052, PP-MO-740, PP-MO-741

D’Hertog W., PP-WE-041

Dhouib N., PP-WE-455

Dhungana S., PP-WE-302

Di Bari F., PP-MO-085

Di Capua M., PP-MO-336, PP-MO-525, PP-WE-320, PP-WE-325

Di Castelnuovo A., PP-MO-876, PP-TH-248, PP-WE-246, PP-WE-498

Di Cera E., OC-WE-083

Di Cesare Merlone A., AS-TU-004

Di Cocco P., PP-MO-654

Di Fulvio P., PP-MO-016

Di Gennaro L., OC-MO-094

Di Giuseppe R., PP-MO-876

Di Iorio A., PP-WE-311

Di Marzio I., PP-TH-082

Di Micco P., PP-TH-308

Di Michele M., PP-WE-041

AUTHORS INDEX

502

Aut

hors

Inde

x

Di Minno G., OC-TU-075, PP-MO-336, PP-WE-320, PP-WE-321, PP-WE-325

Di Minno M. N. D., PP-MO-336,PP-MO-525, PP-WE-320, PP-WE-321, PP-WE-325

Di Nisio M., OC-WE-014, PP-WE-311

Di Paola J., PP-MO-596, PP-WE-613, PP-WE-636

Di Paolo D., PP-TH-060

Di Paula E., PP-WE-631

Di Perna C., PP-MO-523, PP-MO-525, PP-WE-598

Di Pietrantonio D., PP-MO-104

Di Renzo L., PP-WE-789

Di Santo A., AS-TU-042

Di Santo S., PP-TH-050, PP-WE-105, PP-WE-753

Di Somma C., PP-WE-321

Di Stasio E., PP-MO-328

Diamandis M., AS-TH-045

Diamant M., PP-MO-769

Diamantopoulos A., OC-WE-005, PP-MO-468, PP-WE-472, PP-WE-473

Diamond S. L., SA-MO-005,AS-TU-028, AS-TU-038, OC-TH-109, OC-WE-049, OC-WE-053, PP-TH-038, PP-WE-030, PP-WE-063, PP-WE-194, PP-TH-049

Diani E., PP-MO-482

Diaz D., PP-TH-264, PP-WE-117

Diaz J. A., PP-MO-388, PP-MO-400

Diaz-Ricart M., AS-TH-018, PP-MO-053, PP-WE-871

Dib T. K., PP-TH-276

Dichiara J., PP-MO-739, PP-WE-794, PP-TH-026

Dick A., PP-WE-039

Dickele M. C., OC-MO-008

Dickemann D., PP-MO-373

Dicker P., PP-MO-735

Dickey L., PP-MO-686

Dicuonzo F., PP-TH-493

Diehl J. L., PP-MO-090

Dielis A. J. W. H., OC-TH-001

Dielis A. W. J. H., PP-MO-337,PP-WE-352

Diemert V., PP-MO-188, PP-WE-169

Dienava I., OC-MO-111

Dietrich K., AS-TU-054, OC-WE-092, OC-WE-096, PP-WE-448, PP-WE-449

Dietze T., PP-MO-347

Diez J. M., PP-WE-575, PP-WE-576

Dignat-George F., AS-WE-050,OC-TU-087, OC-WE-089, PP-MO-486, PP-WE-850, PP-MO-833, AS-MO-060, OC-TU-089, PP-MO-785, PP-WE-785

Dikici F., PP-WE-568

Dilks J. R., PP-WE-106

Dima L., PP-WE-737

Dima R., PP-TH-214

Dimichele D. M., OC-WE-077

Dimitrov J. D., PP-WE-614

Dimitrovski K., PP-TH-271

Dimsits J., OC-TH-069

Dinardo C. L., PP-TH-542

D’Incà M., PP-MO-523

Ding Q., PP-MO-203, PP-TH-127, PP-TH-203, PP-TH-331, PP-TH-562, PP-TH-563, PP-TH-564, PP-TH-565, PP-WE-536, PP-WE-770, PP-MO-646, PP-TH-126, PP-MO-531

Ding Z., PP-TH-022

Diniz D., PP-WE-365

Diniz M., PP-MO-591, PP-WE-588

Dippel D. W. J., OC-TH-029,PP-WE-355

Diquattro M., PP-MO-750

Dirkx S. P. G., PP-TH-314

Dirven R. J., AS-WE-040

Disalle R., PP-TH-376

Discher D. E., OC-WE-146

Distasio K., PP-WE-207

Distelmaier P., PP-TH-077

Ditta S., PP-MO-750

Dittrich M., AS-MO-038

Dix D., PP-WE-447

Dizier B., OC-TH-046, OC-TH-048, PP-MO-391

Diz-Kucukkaya R., PP-TH-270

Djafari N., AS-TH-043

Djanguidze M. V., PC-017

Djokic D., PP-WE-254

Djordjevic V. J., PP-TH-460

Djordjevic V., PP-MO-327, PP-TH-296, PP-WE-368, PP-WE-379

Djoric P., PP-MO-599

Djukic A., PP-WE-664

Djukic S. M., PP-WE-664

Djunic I. S., PP-WE-634

Djurdjevic P., PP-WE-664

Dlott J. S., PP-WE-274

Do K., OC-TU-011

Do Y., PP-TH-504

Doan J., PP-TH-442

Dobler D., PP-MO-696

Dobrotová M., PP-TH-306

Dobrovolsky A. B., PP-TH-431,PP-TH-513, PP-WE-526

Dockal M., PP-MO-150, PP-WE-557

Dodig S., PP-WE-435

Dodt J., PP-WE-841

Doepke S., PP-WE-644

Doerffler J., PP-MO-318

Doeuvre L., PP-TH-039, OC-WE-111

Doggen C. J. M., AS-MO-005,AS-TH-002, OC-MO-004, OC-MO-023, OC-TU-001, OC-WE-015, OC-WE-016, PP-MO-316, PP-MO-352

Dogné J. M., PP-MO-040

Dogru O., PC-039

Doh H., PP-WE-783

Doi T., OC-TH-088

D’Oiron R., PP-MO-604, PP-TH-619, PP-MO-527, PP-WE-597

Dojcinoski A., PC-028

Dolan G., PP-TH-578, PP-WE-214, PP-WE-215

AUTHORS INDEX

503

Dolgushina N. V., PP-WE-381

Dolling S., PP-WE-212

Domagala T. B., PP-MO-355,PP-WE-883, PP-WE-884

Domènech A., PP-TH-299

Domenico C., PP-MO-056

Domenico P., PP-MO-290

Donà A., PP-MO-424, PP-TH-302

Donadini M., PP-TH-507

Donahue D. L., OC-TU-050

Donati M. B., PP-MO-099, PP-MO-202, PP-MO-481, PP-TH-048, PP-TH-248, PP-TH-249, PP-WE-048, PP-WE-246, PP-WE-498, PP-WE-502

Donati M., PP-MO-876

Dondorp A. M., PP-MO-710

Dong C., PP-TH-220

Dong J. F., PP-MO-767, PP-WE-752

Dong L., PP-WE-667

Dong N., PP-TH-093, PP-WE-088, PP-WE-099

Doniusch E. K., PP-TH-454

Doria A. S., PP-MO-518

Dorling A., SA-MO-010, OC-TH-043, OC-WE-067, PP-MO-070, PP-WE-848, PP-WE-849

Dors N., PP-MO-720

Dorsam R., PP-WE-012

Doti C., PP-WE-135, PP-WE-293

Dotsenko O., PP-WE-852

Dotto P., OC-MO-029

Dou L., PP-WE-850

Douard M., PP-TH-497

Douketis J. D., OC-TU-009,PP-TH-357, PP-WE-429

Douketis J., AS-TH-005, OC-MO-013, OC-TH-002, OC-TH-004, PP-MO-515, PP-TH-412, PP-WE-286

Douma R. A., OC-MO-039, OC-MO-042, OC-MO-091, OC-TU-008, PP-TH-517, PP-TH-518

Douma R., OC-TH-014

Dovlatova N. E., PP-WE-091

Dovlatova N., PP-WE-045

Dowal L., PP-WE-106

Dowd M., PP-MO-463

Dowling N., PP-TH-328

Downey C., PP-TH-129, PP-WE-116

Downey H., AS-TH-013, AS-TH-046

Dowsey C., OC-TH-091

Doyle M., OC-TH-117, PP-WE-207

Dragani A., AS-TU-032, AS-TU-049, PP-TH-082

Dragovic R., OC-TU-056

Drejka M., PP-WE-127

Drexler A., PP-TH-482

Dreyfus M., AS-WE-025, PP-TH-189, PP-TH-470, PP-TH-623, PP-TH-649, PP-TH-650

Dridi Z., PP-TH-343

Driggers J., PP-MO-596, PP-WE-613

Drilhole D., PP-MO-112

Dropinski J., PP-MO-784, PP-WE-883

Drouet L., OC-MO-011, OC-MO-021, OC-WE-099, PP-MO-074, PP-MO-175, PP-MO-421, PP-MO-514, PP-TH-211, PP-TH-309, PP-TH-680, PP-WE-412, PP-WE-810

Du H., PP-TH-022

Du V. X., PP-TH-055

Du V., PP-MO-042

Du W., OC-WE-068, PP-WE-706, PP-WE-707

Du X., AS-TU-027, PP-WE-004

Duarte G. C., PP-TH-532

Dubart A., OC-TH-018

Dubick M. A., PP-TH-687, PP-WE-399

Dubois C., AS-TH-015, PP-MO-485, PP-MO-486

Dubois M., OC-TU-023

Duboscq C. L., PP-WE-135

Duboscq C., PP-TH-681, PP-WE-293

Dubuis E., PP-TH-197

Duca P., OC-TH-010

Ducasse C., OC-MO-062

Duchemin J., PP-MO-310

Ducimetière P., PP-TH-349

Dück O., PP-TH-651

Duckers C., OC-MO-119

Ducroq G., OC-WE-007

Ducros E., PP-WE-139

Dudbridge F., AS-MO-037

Duerschmied D., AS-MO-047

Duffull S. B., PP-MO-249

Duga S., PP-MO-210, PP-MO-648, PP-TH-630, PP-TH-670, PP-WE-657

Dukovski D., PP-TH-557, PP-WE-769

DulíčEk P., PP-WE-524

Dulicek P., PP-MO-682, PP-TH-369, PP-TH-438, PP-WE-068

Dumas M., AS-TH-023

Dumont B., PP-MO-077

Duncan A., PP-MO-068, PP-MO-137, PP-WE-672

Duncan E. M., PP-MO-148

Duncan E., PP-TH-188, PP-TH-626, PP-WE-544

Duncan S., PP-WE-450

Dunkerley A., PP-WE-623

Dunkler D., OC-TU-013, OC-TU-015, OC-TU-016, PP-MO-322

Dunkley S., PP-WE-171, PP-WE-547

Dunn A. L., PP-MO-587, PP-MO-596, PP-WE-613

Dunne E., AS-MO-048

Dunois-Larde C., OC-WE-149,PP-MO-090

Dunoyer-Geindre S., OC-TU-037, OC-WE-110

Duong J. P., OC-TH-048

Duran A., PP-WE-473

Durán N., PP-MO-145

AUTHORS INDEX

504

Aut

hors

Inde

x

Durand M., PP-TH-394, PP-WE-700

Duranovic V., PP-WE-435

Duranti M., OC-TH-014

Durieux P., OC-TH-018

Durmaz B., PP-WE-577

Duru F., PP-WE-806

Dusek L., PP-MO-259

Dusse L. M. S., PP-MO-063,PP-MO-363, PP-MO-364, PP-MO-871, PP-TH-217, PP-TH-490, PP-WE-092, PP-WE-310, PP-WE-364, PP-WE-869

Dusse L. S., PP-MO-333, PP-MO-334, PP-TH-218

Dusseaux M., PP-MO-079

Dutheil J., OC-TU-022

Dutour A., PP-MO-774

Dutt T., PP-TH-197, PP-WE-116

Dutton R. P., OC-TH-069

Dutton R., AS-TU-025, OC-WE-074

Duval A., PP-MO-862

Dwyer K., AS-TH-025, OC-MO-127

Dybowska M., PP-TH-279, PP-TH-280, PP-WE-433

Dyr J. E., PP-TH-213

Dziedzina S., PP-MO-270, PP-MO-329, PP-MO-355

Dzyadzko A. M., PP-TH-234

E De Bracco M., PP-WE-618

Earhart A. D., PP-TH-097

Earnshaw P., PP-MO-166

Eberl W., AS-TH-055, PP-MO-647

Eberle S., PP-MO-509, PP-TH-312

Eberspaecher B., PP-MO-660

Eby C. S., PP-TH-473

Echart C., OC-WE-108, PP-TH-389

Echenagucia M., PP-MO-663,PP-MO-737, PP-WE-692

Echeverri G., PP-MO-070

Eckhardt C. L., PP-MO-597

Eckly A., AS-WE-030, OC-TH-033, OC-TH-034, OC-TH-035, OC-WE-150, PP-WE-019, PP-WE-891

Ectors F. G., PP-MO-605

Edelbusch C., PP-WE-756

Édes I., PP-TH-366

Edwards R. J., PP-MO-044

Edwards R. M., PP-TH-445

Eeckhoudt S., PP-MO-220

Efira A., PP-MO-617

Efraimidou S., PP-MO-305,PP-WE-484

Egan K., PP-MO-735

Egberg N., PP-MO-762

Egorina E., PP-MO-808

Eguchi Y., PP-TH-689

Eheberg D., OC-WE-118

Ehm M., PP-TH-241

Ehnholm C., OC-TU-096

Ehrlich H. J., OC-TH-054, OC-WE-063, PP-MO-640, PP-TH-611, PP-TH-640, PP-TH-641, PP-WE-619

Ehrlich H., OC-WE-065

Ehrlich Y. H., OC-TH-092

Eichinger S., SA-TH-002, AS-MO-004, AS-TH-005, OC-TH-002, OC-TH-004, PP-MO-422, PP-TH-412, PP-TH-690, PP-WE-286, PP-WE-309

Eichman A., SA-WE-010

Eickholz P., PP-TH-652

Eifrig B., PP-MO-014, PP-TH-559, PP-WE-485, PP-WE-594

Eikelboom J. J. W., PP-MO-086

Eikelboom J. W., AS-TH-033

Eikelboom J., PP-MO-019, PP-WE-800

Eikenboom H. C. J., AS-MO-035, AS-WE-040, PP-MO-633

Eikenboom J. C. J., AS-TH-035, OC-TU-077, PL-TU-001

Eikenboom J., PP-MO-612

Eilertsen A. L., AS-TH-004

Eilertsen K., PP-MO-795

Eimon A., PP-WE-236

Eischer L., AS-MO-004, PP-WE-309

Eisenberger A., PP-MO-427

Eisenhardt S. U., PP-MO-100

Eisen-Schuchan I., PP-MO-685

Eisert R., PP-TH-661, PP-WE-670, PP-WE-763

Eisert S., PP-TH-646

Ejele A. O., PP-MO-276

Ekert J., PP-WE-531

Ekman C., OC-TH-078

Ekman M., PP-MO-541, PP-WE-611

Ekmekci H., PP-MO-222

Ekmekci O. B., PP-MO-222

Ekser B., PP-MO-070

El Ghannudi S., PP-MO-416

El Khattouti A., PP-MO-001

El Kheir D. Y., OC-TU-010

El Mouelhi M., PP-WE-022

El Qacemi V., PP-TH-235

El Sherif M., PP-MO-425

Elagroudi A., PC-035

Elalamy I., PP-TH-343, PP-TH-497

Elalamy I., PP-MO-477, PP-MO-478, PP-MO-777, PP-MO-778, PP-MO-779, PP-TH-485, PP-TH-486, PP-WE-490, PP-WE-768, PP-MO-707

Elashry M. S., PP-WE-853

Elbaz O., PC-035, PC-038, PP-WE-853

Elbaz S., AS-TH-043

Elbers C. C., OC-MO-024

Eldemeri A. M. H., PC-038

Eldemeri A. M., PP-WE-853

Eldin N., AS-TU-054

Elezovic I., PP-MO-327, PP-MO-599, PP-TH-296, PP-WE-634, PP-WE-867

Elf J. L., PP-WE-514

AUTHORS INDEX

505

Elg M., PP-MO-385, PP-TH-176, PP-TH-177, PP-TH-186, PP-WE-172, PP-WE-185

Elgue G., OC-MO-106

Elias A., PP-TH-497

Elias E., PP-MO-224, PP-WE-281

Eligini S., PP-WE-050

Elit L., OC-MO-017

Elkharrat D., PP-MO-514

Ellingsen D., PP-MO-596, PP-TH-324, PP-WE-613

Elliot C. A., PP-TH-679

Elliott C., PP-TH-424

Elliott D., PP-WE-760

Elliott M. A., PP-MO-487, PP-WE-723

Ellis M. H., PP-WE-036

Ellis P., OC-TU-029, OC-WE-126

Ellis S. G., AS-WE-010

Ellis V., PP-MO-853

Ellison S., AS-WE-033, PP-TH-021

Ellouze R., PP-TH-297, PP-TH-298, PP-WE-455

Elm T., OC-MO-084, OC-WE-056, PP-TH-594

Elmahmoudi H., PP-MO-649,PP-MO-650

Elmas E., OC-TH-068, PP-MO-238

Elreda L., PP-WE-127

Elsenberg E. H. A. M., PP-WE-742

Elshaarawy S. M., PP-WE-257

Elvers M., AS-TU-037, AS-WE-029, AS-WE-030, OC-TH-039

Elvevoll E., PP-MO-795

Emal C., PP-TH-252

Emanuele J., PP-TH-201, PP-TH-391

Emanuele R., PP-MO-461

Emanuelsson B. M., PP-MO-095

Emanuylov V. I., PP-MO-260

Emerson M., PP-MO-026, PP-MO-062

Emmerechts J., PP-MO-398

Emmerich J., AS-TH-035, OC-MO-021, OC-TH-005, OC-TH-048, OC-WE-017, PP-MO-391, PP-TH-189, PP-TH-309, PP-WE-263, AS-TH-001

Emmi V., AS-MO-009

Emsley J., OC-MO-103, OC-TU-043, PP-MO-089, PP-TH-045

Enayat M. S., PP-MO-614

Enayat S., OC-WE-134, PP-MO-539, PP-TH-553, PP-TH-636

Enden T. R., AS-MO-007

Endres G., PP-MO-561

Endresz V., OC-TU-051, PP-WE-836

Enea I., PP-TH-303

Enever D., PP-WE-021

Engel R., OC-MO-076, PP-WE-130

Engelmann B., AS-TU-021

Engelsberger I., PP-WE-453

Engelsen J., PP-WE-417

Enger S., PP-WE-026

Englyst N. A., OC-WE-114

Engström M., PP-MO-258, PP-WE-721

Enjolras N., OC-MO-062

Ennis D., OC-TH-007

Eom H., PP-TH-504

Epinat M., PP-TH-076

Epstein J. D., PP-MO-576, PP-TH-570, PP-TH-571, PP-WE-537, PP-WE-538

Equine O., PP-TH-583

Erba N., OC-TH-075

Erdinc I., PP-TH-511

Erdogan A., OC-WE-128

Eriksson A. C., PP-MO-047

Eriksson B. I., OC-WE-004,PP-MO-167, PP-TH-167, PP-TH-169, PP-TH-170, PP-TH-415, PP-TH-430, PP-WE-204, PP-WE-205, PP-WE-404, PP-WE-421

Eriksson U. G., PP-WE-172

Eriksson U., PP-WE-200, PP-WE-201

Erman T., PP-MO-644

Ermantas N., PP-TH-222

Eroglu H., PP-MO-744

Erol D., PP-WE-708

Ershov A. A., PP-WE-422

Ersoy M., PP-WE-890

Erten N., PP-MO-744

Ertl H., AS-TU-015

Escalante C. P., PP-WE-489

Escalante V., PP-WE-395

Eschmann E., PP-WE-329

Eschvege V., PP-TH-470

Escolar G., AS-TH-018, PP-MO-053, PP-TH-047, PP-WE-237, PP-WE-871

Escoll J., PP-WE-761

Escuriola Ettinghausen C.,OC-WE-117

Escuriola-Ettinghausen C.,PP-MO-592

Eshghi P., PP-TH-210

Eskola M., PP-TH-068

Esmat E. M., PP-TH-506

Esmerian M., PP-MO-135

Esmon C. T., OC-TH-062, OC-TH-063, OC-TH-065, OC-TH-066, OC-WE-019, OC-WE-144, PL-TU-006

Esmon N. L., OC-TH-063, OC-TU-033, PL-TU-006

Espana F., PP-MO-192, PP-MO-193

España F., OC-TH-027, PP-MO-215

Esposito B., PP-TH-009

Essawy F. M., PP-TH-506

Esserman D., PP-MO-768

Estella J., PP-TH-451

Estelle S., PP-TH-180

Estelles A., PP-MO-193, PP-MO-215

Estellés A., OC-TH-027, PP-MO-192

Estrada D., PP-WE-495

AUTHORS INDEX

506

Aut

hors

Inde

x

Etches W., PP-WE-448

Etscheid M., OC-TH-110, PP-WE-841

Ettelaie C., PP-MO-479, PP-WE-837, PP-WE-840

Etulain J., PP-WE-035, PP-WE-042

Evangelista V., AS-TH-059, AS-TU-042, OC-WE-127

Evangelisti L., PP-MO-802

Evans C. E., PP-MO-384

Evans J., PP-TH-466, PP-WE-782

Everse S. J., OC-TU-092

Ewenstein B., PP-MO-602, PP-TH-585, PP-WE-574, PP-WE-597, PP-WE-617

Ewing N., PP-MO-586, PP-MO-604

Exner T., PP-MO-671, PP-WE-776, PP-WE-786

Ezban M., OC-WE-056, OC-WE-061, PP-MO-564, PP-MO-570, PP-MO-580, PP-TH-567, PP-TH-579, PP-WE-154, PP-WE-589, PP-WE-591

Ezzelarab M., PP-MO-070

Fabbriciani G., PP-WE-529

Fabbro-Peray P., AS-TH-032,OC-MO-132, PP-MO-783, PP-WE-744

Fabbro-Péray P., OC-TH-081

Faber E. A., PP-WE-495

Fabiani J., PP-MO-835

Fabra S., PC-031, PC-032, PC-033, PP-WE-699

Fabre O., PP-WE-858

Fabris F., PP-TH-300

Facchin M. M. F., OC-TH-026

Facchini M., PP-TH-060

Facskó A., PP-TH-216

Fadin M., PP-MO-242, PP-WE-080

Faeser B., PP-TH-646

Fager A. M., OC-TU-092

Fagnou C., AS-TH-043

Fahs S., PP-TH-128

Faienza M. F., PP-WE-878

Faille D., PP-WE-775

Faioni E. M., PP-WE-136

Falanga A., AS-TU-048, AS-TU-050, PP-MO-476, PP-MO-482, PP-MO-867, PP-WE-499

Falcinelli E., PP-MO-085, PP-WE-823

Falco A., AS-TU-049

Falet H., AS-WE-026

Falk E., PP-WE-810

Fallah M., AS-TH-057

Fallon J. T., PP-MO-808

Faludi I., OC-TU-051, PP-WE-836

Famodu A. A., PP-MO-278, PP-TH-209, PP-WE-330, PC-009, PP-TH-500, PP-TH-501

Famulari A., PP-MO-654

Fan H., OC-TU-046

Fan L., PP-MO-642, PP-TH-334

Fang C. C., PP-MO-158

Fang J., AS-TH-009, OC-TH-097

Fang W., PP-TH-399

Farac J., PP-MO-128

Faradji A., PP-TH-569, PP-TH-584, PP-WE-655, PP-MO-611

Faraizah Karim A., PP-MO-367

Faraizah Karim K., PP-MO-366

Faranoush M., PP-TH-124, PP-TH-318

Faraudo S., PP-WE-768

Fareed J., OC-TH-019, OC-TH-103, OC-WE-088, OC-WE-108, PP-MO-072, PP-MO-136, PP-MO-139, PP-MO-140, PP-MO-143, PP-MO-152, PP-MO-153, PP-MO-154, PP-MO-396, PP-MO-412, PP-MO-703, PP-MO-857, PP-TH-137, PP-TH-138, PP-TH-142, PP-TH-145, PP-TH-166, PP-TH-389, PP-TH-390, PP

Farge Bancel D., PP-TH-497,PP-WE-483

Faria F., PP-MO-475, PP-WE-098

Faria M. D., PP-TH-673, PP-TH-674, PP-WE-689

Faria S., PP-WE-374

Farias F., PP-TH-568

Farinasso L. L., PP-TH-452

Farkas K., PP-MO-359

Farndale R. W., OC-WE-048,PP-MO-041, PP-MO-048, PP-MO-058, PP-WE-028, PP-WE-052, PP-MO-852

Farndale R., OC-MO-124

Farquharson N. R., PP-TH-664, PP-WE-766

Farrell D. H., PP-MO-239

Farren T., OC-TH-076

Farris D. M., PP-MO-388

Farrokhi E., PP-TH-619

Farrugia R., OC-WE-126

Fatini C., PP-MO-805, PP-WE-003

Fattorini A., PP-MO-261

Faucher A., PP-MO-188

Faucher J., PP-TH-315

Faure A., PP-WE-169

Faust P., PP-TH-482

Favaloro E. J., OC-WE-134,PP-MO-724

Favaretto E., PP-MO-351, PP-MO-503, PP-WE-351, PP-WE-359

Favier R., AS-TU-024, PP-MO-368, PP-MO-369

Favre G., PP-TH-199

Favretto P. P. F., PP-MO-312

Favuzzi G., PP-WE-366, PP-WE-367, OC-TU-035

Faxälv L., PP-MO-430, PP-TH-018

Fay P. J., PP-MO-155, PP-MO-157, PP-WE-289

Fay P., AS-WE-045

Fay W. P., AS-MO-062, PP-MO-358

Fazakas F., PP-WE-774

Fazavana J., PP-MO-187

Febbraio M., OC-MO-107

Feddern J., PP-TH-589, PP-WE-633, PP-WE-653

AUTHORS INDEX

507

Federici A. B., AS-WE-020,OC-MO-131, OC-TU-072, PP-TH-630, PP-WE-625

Federici A., PP-WE-647

Federico L., AS-TH-059, PP-TH-392

Fedi S., OC-WE-032, PP-MO-217, PP-MO-339, PP-MO-801, PP-TH-163

Fedorová J., PP-TH-305

Feijge M. A. H., AS-TU-029,AS-TU-037, PP-MO-670, PP-TH-007, PP-WE-260

Fejfar T. T. F., PP-TH-369

Feldman B. M., AS-WE-003

Feldman B., PP-WE-553

Feldman D., PP-WE-587

Felicissimo P., OC-TU-019

Felippo M., PP-WE-618

Feliu-Torres A., PP-WE-637

Feliú-Torres A., OC-TU-064,PP-MO-687

Fellin R., PP-TH-372

Felsburg P., PP-MO-754

Felten M., PP-WE-182

Fem L. L., PP-WE-198

Fenchner H., PP-TH-696

Feng Y., PP-TH-132

Fenger-Eriksen C., PP-WE-698

Fenu L., PP-MO-267

Feola G., PP-WE-567

Fernandes A. B., PP-WE-226

Fernandes A. P., PP-MO-333,PP-MO-334, PP-MO-335, PP-MO-346, PP-MO-816, PP-TH-490, PP-WE-227, PP-WE-310, PP-WE-347, PP-WE-364, PP-WE-814, PP-WE-815

Fernandes A., PP-MO-349, PP-MO-363, PP-MO-364, PP-WE-365

Fernandes N. L., OC-MO-055

Fernandes R. A., PP-MO-483

Fernandez C. V., PP-WE-447

Fernandez C., PP-MO-209

Fernández C., PP-WE-234

Fernandez I., PC-048, PP-MO-022, PP-TH-059, PP-TH-603, PP-TH-604, PP-WE-560, PP-WE-765

Fernández J. A., AS-TU-043,PP-MO-880, PP-MO-881, PP-TH-572, PP-WE-551

Fernandez J., PP-MO-813

Fernandez R., PP-TH-606

Fernandez-G J., PP-MO-865,PP-WE-874

Ferrando F., PP-MO-192, PP-MO-193

Ferrante E., OC-TU-088, PP-TH-082, PP-WE-738

Ferraresi P., PP-MO-654

Ferrari T. C. A., PP-TH-672

Ferrario C. M., PP-WE-854

Ferrazzi P., AS-WE-007

Ferré N., PP-MO-530

Ferreira C. N., PP-MO-816, PP-WE-227

Ferrel J. P., AS-MO-024

Ferrer J., PP-MO-226, PP-MO-227

Ferrer-Marin F., PP-WE-083

Ferrero S., PP-WE-136

Ferretti M., PP-TH-558

Ferri V. V. F., OC-TH-026

Ferris S., PP-MO-562

Ferro A. M., PP-WE-203

Ferro A., PP-TH-316, PP-TH-607

Ferro M., PP-WE-870

Ferronato C., PP-TH-420, PP-WE-424

Ferroni P., PP-MO-379, PP-MO-380, PP-TH-494, PP-WE-824

Ferrucci L., PP-WE-311

Ferster A., PP-MO-441, PP-TH-666

Fesenko O. V., PP-TH-514

Feudtner C., AS-TU-055

Feuring M., PP-TH-167, PP-TH-169, PP-TH-170, PP-WE-205

Feys H. B., AS-MO-014, PP-MO-088, PP-MO-094, PP-WE-086

Feys H., PP-WE-339

Fiamoli V., PP-WE-441

Fichelson S., OC-WE-149

Fidalgo T., PP-WE-730

Fiebig A., PP-MO-307

Figini F., PP-MO-775

Figler R., OC-TU-027

Figueiredo C. P., PP-TH-490

Figueiredo J., AS-WE-057

Figueiredo L., PP-TH-240

Figueiredo-Pontes L. L., OC-WE-023

Fijnheer R., AS-WE-013, AS-WE-037

Fijnvandraat K., AS-TH-054,PP-MO-560, PP-MO-597, PP-MO-633

Filali A., PP-TH-298

Filipescu D. C., PP-WE-737

Filippini M., AS-TH-029, PP-MO-351

Filippucci E., OC-TH-011, PP-MO-282, PP-MO-457, PP-MO-458

Fimbel B., PP-MO-527

Fimmers R., AS-WE-004

Finazzi G., AS-TU-048

Findling O., OC-WE-034

Fink H., PP-MO-430

Finn J. D., AS-TU-013

Finn J., PL-TU-004

Fioritoni F., AS-TU-049

Firbas C., OC-WE-011, PP-MO-622, PP-MO-718

Fischer A. M., OC-TH-046, OC-TH-048, PP-MO-862

Fischer A., PP-MO-165, PP-WE-263

Fischer B., PP-TH-241

Fischer D., PP-MO-660

Fischer H., PP-MO-845

Fischer K., OC-TU-070, PP-MO-585, PP-TH-578, PP-TH-585, PP-TH-616, PP-WE-534

AUTHORS INDEX

508

Aut

hors

Inde

x

Fischer R., PP-MO-083, PP-MO-513

Fischer S., OC-TH-023, PP-MO-827

Fisgin T., PP-WE-806

Fish R., PP-WE-213

Fisher P. B., OC-WE-021

Fisher W. D., PP-TH-430

Fisseau C., PP-WE-624

Fitridge R., PP-WE-427

Fitzgerald C., PP-WE-447

Fitzgerald D. J., AS-WE-035

Fitzgerald G., SA-TH-013, OC-MO-052, PP-MO-247

Fitzpatrick P., AS-TU-059

Fiusa M. M., PP-WE-476

Flaujac C., PP-WE-316

Flaumenhaft R., PP-WE-106

Flege S., OC-WE-106

Fleisher S., PP-WE-712

Flem L. L., PP-WE-199

Flesch B., PP-MO-307

Fletcher J. P., PP-MO-326, PP-WE-300, PP-WE-301

Fletcher J., PP-WE-409

Fleury R., PP-MO-567

Flevaris P., PP-WE-004

Flick M. J., AS-TU-045, OC-TH-063, OC-WE-121

Flierl U., PP-TH-019

Fliers E., PP-MO-292

Flinck A., PP-WE-206

Flinterman L. E., OC-MO-079,OC-WE-015

Flisberg P., PP-MO-258

Fliser D., PP-MO-809

Flliser D., OC-MO-126

Flondell D., OC-TH-078

Flood V. H., OC-TU-071

Floras J. S., PP-TH-125

Florean M., OC-MO-121

Flores D., PP-MO-064

Flores M. P., PP-WE-160

Flores M., PP-MO-865, PP-WE-874

Fobker M., PP-WE-528

Fogarty P. F., PP-MO-066, PP-WE-704

Fogarty P., AS-TU-002

Foley D. P., PP-MO-735

Foley D., PP-MO-738

Foley J. H., OC-TU-069

Folsom A. R., PP-WE-819

Fondacone C., PP-MO-423

Fondu P., PP-WE-013

Fong K. P., AS-TU-028, AS-TU-038

Fong K., PP-WE-030

Fong T. S., OC-MO-077

Fonseca R. J. C., PP-TH-178

Fontaine S., PP-TH-345

Fontana G., PP-WE-136

Fontana P., AS-TH-032, AS-TU-018, OC-MO-132, PP-MO-783, PP-TH-103, PP-WE-744

Fontcuberta J., OC-TH-027,PP-MO-323, PP-MO-413, PP-TH-285, PP-TH-289, PP-TH-290, PP-WE-175, PP-WE-178, PP-WE-208, PP-WE-209, PP-WE-243, PP-WE-415

Fontenay M., PP-WE-316, OC-TH-082

Fontes P. A., OC-MO-031

Forastiero R. R., PP-TH-333

Forastiero R., PP-MO-275, PP-TH-681

Ford I., OC-WE-033, OC-WE-116

Forestier M., OC-TU-052

Forfang K., PP-TH-427

Formisano S., PP-TH-606

Formoso G., PP-MO-016

Fornage M., AS-WE-009

Foroni M., PP-MO-306

Forster F., OC-WE-005, PP-MO-468

Forster I., PP-TH-446

Fort J. G., PP-WE-803

Fouassier M., PP-WE-642

Fourn E., OC-WE-113

Fox D., PP-MO-790

Fox J. E. B., OC-MO-109

Fox P. L., AS-TU-041

Fox S. C., OC-MO-100, PP-WE-045, PP-WE-755

Fraccarollo D., PP-MO-005,PP-WE-886

Fraga C. A. M., PP-MO-390

Franchi F., PP-MO-375, PP-WE-691

Franchini M., OC-MO-097, PP-MO-540, PP-MO-541, PP-TH-558, PP-WE-140, PP-WE-598

Francis C. W., OC-TU-018, PP-MO-492

Francis C., PP-TH-169, PP-TH-170

Francis J. L., PP-WE-485

Francis J., PP-MO-004, PP-TH-482, PP-TH-491, PP-WE-001, PP-WE-108

Francisci D., OC-WE-087

Franck H. G., PP-MO-570, PP-TH-579

Franco J., PP-WE-446

Franco R. M., PP-MO-363, PP-MO-364, PP-WE-365

Frangov M., PC-028

Franke K., PP-TH-215

Franklin M. A., PP-MO-283

Franklin P., PP-MO-248

Franque S., PP-MO-383

Frascaro M., PP-TH-282, PP-WE-715

Frasson R., OC-WE-081

Frattani F. F. S., PP-TH-179

Frattani F. S., PP-MO-390

Frauchiger B., PP-TH-492

Fraysse B., PP-MO-332

Fredenburgh J. C., OC-TH-106, OC-WE-079, PP-MO-428

Freedman J. E., PP-TH-064

Freedman J., AS-TU-030, OC-MO-139, OC-WE-121, PP-MO-020, PP-WE-060, PP-MO-065

Frei C., PP-MO-469

AUTHORS INDEX

509

Freire C., PP-WE-371

Freitas V. M., PP-MO-063

Fremeaux-Bacchi V., OC-WE-012

French D. L., PP-WE-082, PP-WE-174

Frengen E., PP-TH-165

Frenkel E., PP-MO-757

Frere C., OC-MO-007, PP-MO-773, PP-MO-774, PP-WE-775

Freson K., PP-MO-059, PP-WE-041, PP-WE-085

Fressinaud E., PP-MO-626,PP-TH-623

Fretigny M., OC-TU-073, PP-MO-645, PP-TH-144, PP-WE-533

Freund M., AS-TU-047, OC-TH-033, OC-TH-034, OC-TH-035, OC-TU-049, OC-WE-150

Freyburger G. F., PP-MO-196

Freyburger G., PP-MO-195,PP-TH-432, PP-WE-673

Freyssinet J., PP-WE-787

Fridrich J., PP-TH-438

Friedman K. D., AS-WE-038,OC-TU-071

Friedman R. J., PP-MO-167

Friedman R., PP-MO-247, PP-TH-167

Friedman S., PP-TH-087

Friedrich W., PP-MO-029

Frieling J., PP-TH-414, PP-WE-405

Fries D. M., PP-MO-034

Fries M., PP-WE-557

Friese K., PP-WE-784

Frijling B., PP-WE-475

Friso S., OC-TH-030, PP-MO-342, PP-TH-347

Frith D., OC-TH-067

Fritsch S., PP-TH-585, PP-TH-586

Fritsche I., PP-MO-357

Fritsma G. A., PP-MO-102, PP-WE-235

Froesner G., PP-WE-578

Frölich L., PP-WE-182

Frölich M., PP-MO-782

Frontoni R., OC-TH-075

Frontroth J. P., OC-WE-134,PP-WE-637

Frontroth J., OC-TU-064, PP-MO-687

Frost C. E., PP-MO-407

Fruhwald M., OC-WE-106

Fruth K., PP-WE-488

Fryer H. J. L., PP-MO-296, PP-MO-319, PP-MO-502, PP-MO-709

Frykman V., PP-TH-469

Fu J., PP-MO-830

Fu Q., PP-MO-510

Fu X., PP-TH-092, AS-MO-011

Fu Y., PP-WE-674

Fuchs B., PP-WE-624

Fuentes P., PP-WE-175

Fuerll B., OC-TH-024

Fuhr U., PP-WE-183

Fujieda Y., PP-WE-269, PP-WE-271

Fujii T., PP-TH-592, PP-WE-606

Fujii W., PP-MO-084

Fujimori Y., PP-MO-138, PP-TH-081, PP-WE-671

Fujimoto D. E., PP-MO-521

Fujimoto H., OC-WE-038

Fujimoto T., PP-TH-168, PP-WE-398, PP-WE-400

Fujimura Y., OC-WE-008, PP-MO-717

Fujino K., PP-TH-689

Fujioka M., PP-WE-090

Fujiwara A., OC-WE-038

Fujiwara H., PP-MO-511, PP-WE-011

Fujiwara M., PP-WE-090

Fukasawa I., PP-MO-734

Fukuda T., PP-MO-864

Fukushima H., PP-WE-090

Fukutake K., PP-MO-546, PP-MO-577, PP-TH-576, PP-TH-592, PP-WE-516, PP-WE-579, PP-WE-606, PP-WE-666

Funaro D., PC-030

Funes C., PP-MO-536

Funk K., PP-TH-095, PP-WE-006

Funk R. T., OC-TH-104

Furby D., PP-WE-609

Furenes E. B., PP-WE-344

Furie B. C., AS-MO-043, AS-TU-022, OC-MO-057, OC-MO-108, OC-WE-072

Furie B., AS-MO-043, AS-TU-022, OC-MO-057, OC-MO-108, OC-WE-072

Furlan-Freguia C., AS-TU-043

Fürle T., PP-MO-112

Fürll B., AS-TH-007, OC-TH-023

Furmedge J., PP-WE-531

Furtmüller M., OC-TU-081, PP-MO-189

Furugohri T., PP-TH-195

Furukawa S., PP-TH-689, PP-WE-025

Furukoji E., PP-MO-111, PP-MO-127

Fuse I., PP-TH-689

Fusegawa K., PP-WE-348

Fuset M. P., PP-WE-796

Fuster V., PP-MO-834

Fynn A., PP-TH-606

Gaarder C., OC-TH-067

Gabazza E. C., OC-WE-038,PP-WE-222

Gabbeta J., PP-TH-200

Gaborit B., PP-MO-773, PP-MO-774

Gachet C., AS-MO-058, AS-WE-030, OC-MO-008, OC-MO-124, OC-TH-033, OC-TH-034, OC-TH-035, OC-TU-049, OC-WE-150, PP-MO-033, PP-MO-416, PP-TH-010, PP-WE-891, AS-TH-021

Gadaeva Z., PP-TH-380

AUTHORS INDEX

510

Aut

hors

Inde

x

Gadelha T., PP-MO-333, PP-MO-334, PP-MO-335, PP-MO-346, PP-WE-360

Gadisseur A. P. A., PP-MO-383

Gafou A. J., PP-WE-314

Gafsou B., OC-TH-046

Gage B. F., PP-TH-357

Gagliano F., PC-015, PP-MO-634, PP-MO-635, PP-MO-750

Gagnon F., OC-MO-021

Gahl W. A., AS-WE-034

Gahunia H., PP-MO-518

Gailani D., SA-WE-013, AS-TH-039, OC-MO-103, OC-MO-104, PL-TU-003, PP-TH-037

Gajardo R., PP-WE-575, PP-WE-576

Gajeck H., PC-043

Gajek H., PP-MO-567, PP-WE-574, PP-WE-617

Galajda P., PP-WE-220

Galan A. M., PP-MO-053, PP-TH-047, PP-WE-237

Galan P., OC-MO-021

Galanakis D. K., PP-MO-211

Galanaud J., OC-TH-081, PP-TH-288

Galand P., PP-TH-309

Galanter W., PP-MO-464

Galar M., PP-MO-868, PP-WE-491, PP-WE-492

Galassi N., PP-WE-618

Galasso R., PP-MO-176, PP-TH-573, PP-WE-249

Galea V., PP-TH-485, PP-TH-486, PP-WE-490

Galimanis A., OC-WE-034

Galleguillos T., OC-WE-090

Galligan A., PP-TH-255

Gallinaro L., PP-TH-259, PP-WE-641, PP-WE-645

Gallo R., PP-MO-061

Gallo U., OC-MO-015

Gallus A. S., LB-MO-005, OC-TU-010

Galmes B., PP-MO-590

Galstyan G. M., PP-MO-218,PP-MO-668, PP-WE-170

Galy-Fauroux I., OC-TH-046,OC-TH-048, PP-MO-862

Gamba G., AS-TU-032, PP-MO-684

Gambaryan S., PP-WE-077

Gambert S., PP-WE-043

Gamble G., PP-TH-315

Gamra H., PP-TH-343

Gan E., PP-MO-713

Ganci A., PP-MO-016

Gando S., PP-MO-669, PP-WE-687

Gandrille S., OC-TH-022, OC-TU-032, PP-TH-189, OC-TH-082

Gannon C., PP-TH-549, PP-WE-685

Gansevoort R. T., OC-MO-082

Gansevoort R., OC-MO-001

Gao C., AS-TH-009

Gao D., OC-TH-108

Gao J., PP-MO-686

Gao W., PP-MO-464

Garagiola I., OC-WE-132, PP-MO-092

Garai B., PP-MO-228

Garand M., OC-WE-109, PP-WE-241

Garaulet M., AS-TH-018

Garbaraviciene J., PP-MO-705

Garbarini L. L., PP-TH-452

Garbiero S., PP-TH-060

Garcia A. A., OC-MO-004, OC-WE-023

Garcia A. B., OC-WE-023

Garcia A., AS-MO-036

Garcia Barbera N., PP-TH-481

Garcia C., OC-MO-099

Garcia Candel F., PP-MO-601

García Candel F., PP-MO-536

Garcia D. A., PP-MO-462, PP-MO-463

Garcia D., PP-MO-308

Garcia De Frutos P., AS-TU-060, PP-WE-821, PP-WE-822

García- Estañ J., PP-TH-003

Garcia Iglesias L., PP-MO-637

García J. J., PP-MO-279

Garcia M., PP-TH-311, PP-WE-560, PP-WE-765

García M., PP-TH-572, PP-WE-551

Garcia N., PP-WE-821, PP-WE-822

Garcia R., PP-MO-227, PP-WE-436

Garcia Rodriguez P., AS-MO-035, AS-WE-019

Garcia V., AS-WE-010

Garcia-Candel F., PP-MO-566

García-Dabrio C., AS-MO-003

García-Latorre E., PP-WE-264

García-Mouriz A., PP-MO-472

Garcia-Pagan J., PP-TH-314

Garcia-Pagán J., PP-MO-224

Garcia-Rodrigues P., PP-WE-497

Garcia-Rodriguez M., PC-048,PP-TH-603, PP-TH-604

Garcia-Talavera J., PP-WE-665

Garcin I., PP-WE-008

Gardiner C., PP-TH-263

Gardiner E. E., AS-TU-039,OC-MO-110

Gardiner E., AS-WE-032

Gardsvoll H., PP-WE-225

Gårdsvoll H., AS-WE-047

Garmer S. F., PP-WE-585

Garner S. F., AS-MO-037, OC-TH-093

Garofalo J., PP-MO-464

Garraud O., OC-TH-021, PP-WE-165

Garrido C., PP-MO-526

Gartner T. K., PP-MO-082, PP-WE-051

Garwood C. L., PP-WE-479

Gasbarrini A., PP-MO-328

Gascoigne E. W., PP-MO-568

AUTHORS INDEX

511

Gasparini D., PP-TH-420, PP-WE-424

Gastineau D. A., PP-MO-487

Gasto C., PP-TH-047

Gatenholm P., PP-MO-430

Gatt A., PP-MO-524, PP-TH-106, PP-TH-679, PP-WE-192, PP-WE-649

Gattis J., PP-WE-065

Gatzoulis M., PP-WE-805

Gau J. P., PP-MO-330, PP-TH-620

Gaucherand P., PP-TH-385,PP-TH-386

Gaussem P., AS-TH-023, AS-TH-035, OC-TH-022, OC-TU-032, OC-TU-090, OC-WE-089, PP-MO-835, PP-TH-349, PP-WE-263

Gautam N., PP-TH-330

Gautier P., PP-WE-600

Gavalaki M., PP-TH-609, PP-MO-679

Gavasso S. S. G., OC-TH-026

Gavasso S., OC-MO-005, OC-MO-119, OC-MO-121, PL-TU-004, PP-MO-242, PP-MO-243, PP-MO-348, PP-MO-765, PP-TH-382, PP-TH-383, PP-TH-420, PP-TH-487, PP-TH-488, PP-WE-080, PP-WE-248, PP-WE-384

Gavish D., PP-MO-338

Gavrylyuk S. P., PP-MO-401

Gay S., PP-WE-787

Gaydukova S. M., PP-TH-479

Gayen-Betal S., PP-WE-894

Gayol S., PP-MO-416

Gazikalovic S., PP-WE-867

Ge J., PP-TH-078, PP-WE-706,PP-WE-707

Gear A. R. L., OC-TU-027

Gebbink M. F. B. G., AS-TH-038, PP-WE-216

Gebbink M., OC-MO-112

Gebhard S., OC-TU-026

Gebuis E. P. A., LB-MO-001

Geerts W., PL-MO-002

Geetha N. M., PP-MO-848

Geetha N., PP-WE-842

Geierova V., PP-MO-583, PP-TH-083

Geiger M., OC-TU-081, PP-MO-189

Geisel J., OC-MO-126

Geisen C., OC-WE-076, OC-WE-077, PP-MO-128, PP-TH-661, PP-WE-210

Geissen C., AS-TU-054

Geiter S., PP-MO-711, PP-TH-148, PP-WE-777

Gelderman M. P., PP-TH-016

Gemmati D., AS-WE-039, PP-WE-657

Genc S., PP-MO-744

Gennaro N., PP-TH-304

Gensbittel M., PP-MO-530

Gensini G. F., OC-WE-102, PP-MO-340, PP-MO-341, PP-MO-743, PP-MO-818, PP-TH-352, PP-TH-353, PP-WE-745, PP-WE-746, PP-WE-747, PP-WE-748

Gensini G., AS-TH-034, OC-MO-010, OC-TH-047, OC-WE-031, OC-WE-032, PP-MO-013, PP-MO-217, PP-MO-303, PP-MO-304, PP-MO-339, PP-MO-799, PP-MO-800, PP-MO-801, PP-MO-802, PP-MO-803, PP-MO-804, PP-MO-805, PP-MO-836, PP-TH-163, PP-TH-340, PP-TH-341, PP-WE-002, PP-WE-003

Gent M., OC-WE-004, PP-TH-415, PP-TH-430, PP-WE-404, PP-WE-421

George J. N., OC-WE-009, PP-TH-079, PP-WE-729

Georgescu A., PP-MO-855

Georgiou G., PP-MO-679

Gerard-Blanluet M., PP-TH-074

Gerdes C., OC-TH-058

Gerdes N., PP-WE-890

Gerdes V. E. A., OC-TU-010,PP-MO-221, PP-MO-292, PP-MO-293, PP-TH-286, PP-TH-293, PP-TH-517, PP-WE-336, OC-MO-039, PP-MO-659

Gerhardt H., AS-MO-061

Gerlach H. E., PP-MO-509

Gerlach H., PP-TH-312

Gerlofs-Nijland M. E., PP-TH-122

Germani A., PP-WE-688

Gerometta M., OC-TU-009

Gerotziafas G. T., PP-MO-477,PP-MO-478, PP-MO-777, PP-MO-778, PP-MO-779, PP-TH-485, PP-TH-486, PP-WE-490

Gerotziafas G., PP-TH-343

Gerrits A. J., PP-MO-007, PP-WE-024

Gersh K. C., OC-WE-112

Gersh K., OC-TH-055, PP-WE-212

Gershkovich K., PP-TH-219,PP-TH-227

Gertler F. B., OC-MO-068

Gertow K., OC-TU-025

Gertz M. A., PP-MO-487, PP-WE-723

Gesell-Salazar M., OC-TU-026

Gesheff M., PP-WE-797

Gesheff T., PP-WE-798

Geskus R. B., PP-MO-597

Gessner C. R., OC-TU-095

Gessner J. E., AS-TU-005

Getz T. M., PP-TH-040

Getz T., OC-TH-098

Geyer M., PP-MO-244

Ghanayem N. S., OC-TU-065

Ghenu O., PP-WE-737

Gheras M., PP-TH-276

Ghirarduzzi A., OC-MO-013,OC-TH-003, OC-TH-006, OC-TH-011, PP-MO-285, PP-MO-290, PP-MO-291, PP-WE-403

Ghiselli L., PP-MO-802

Ghomchi H., PP-WE-737

Ghorbani R., PP-TH-124

Ghosh K., PP-TH-295, PP-TH-659, PP-TH-660, PP-TH-668

Giacomelli M., PP-MO-611

AUTHORS INDEX

512

Aut

hors

Inde

x

Giacomelli S., OC-TU-074, OC-WE-136, PP-WE-626, PP-WE-627, PP-WE-628, PP-WE-629, PP-WE-630

Gialeraki A. E., PP-TH-338

Giambene B., OC-WE-031,OC-WE-032, PP-MO-217

Gianellini S., PP-WE-868

Gianfagna F., PP-TH-249, PP-WE-246

Giangrande P., AS-MO-028,OC-WE-119, PP-TH-540, PP-TH-541, PP-WE-542

Giannarelli C., PP-MO-834

Giannattasio E. R., OC-WE-101

Giannini S., OC-TH-032, OC-WE-087, PP-MO-085, PP-TH-402

Giansily-Blaizot M., PP-MO-656, PP-MO-657, PP-WE-659

Giaya K., PP-WE-782

Gibbins J. M., OC-TH-037, OC-TH-093, OC-TH-100, PP-MO-032, PP-TH-014, PP-TH-031, PP-WE-040, PP-WE-809

Gibbs H., PP-TH-471, PP-TH-472, PP-WE-409

Gibbs J., PP-TH-471, PP-TH-472

Gibson A., PP-TH-538

Gibson N. S., OC-MO-039, OC-TU-010, PP-TH-293

Giebl A., OC-WE-119, PP-WE-039, PP-WE-542

Gierczak R. F., PP-TH-175

Giermasz A., PP-MO-066

Giese C., PP-MO-420

Giesen P. L. A., OC-WE-060

Giessen P., OC-TH-057

Giglioli C., PP-MO-013

Gijsen S., PP-MO-621

Gil Bernabe P., PP-WE-222

Gilabert J., PP-TH-627, PP-MO-215

Gilabert-Estelles J., PP-MO-215

Gilbert G. E., OC-TU-095, PP-MO-131, PP-TH-159, PP-WE-153, PP-WE-674

Gilbert J. C., AS-WE-014, OC-WE-011, OC-WE-129, PP-MO-622

Gilbert J., OC-WE-007

Gil-Campos I., PP-WE-563

Gilet H., PP-WE-425

Gilio K., AS-TU-037, OC-WE-123, PP-TH-007, PP-WE-260

Gill J. C., AS-WE-038, OC-TU-071, PP-MO-600, PP-WE-601

Gill K., AS-WE-003, PP-WE-553

Gill N., OC-MO-033

Gillanders K. R., PP-MO-568

Gilles J. G., PP-MO-605, PP-WE-610

Gilmore G., PP-MO-019

Gilmore R. M., PP-TH-549, PP-WE-685

Gilmore R., AS-MO-028, PP-MO-593

Gilmour L., PP-WE-472

Gils A., OC-TH-114, PP-MO-219, PP-MO-225

Gimenez F., PP-MO-566, PP-MO-590

Ginsberg J. J. S., PP-MO-086

Ginsberg J. S., OC-TU-009,PP-MO-515, PP-TH-522, PP-TH-523

Ginsberg J., PP-MO-310

Ginsberg M., AS-MO-046

Ginsburg D., SA-TU-008, AS-TU-058, OC-TH-061, OC-WE-039, OC-WE-072, PP-TH-398, PP-WE-047, PP-WE-640

Giolo E., PP-WE-460

Giordano A. V., PP-TH-694

Giordano G., PP-WE-823

Giordano L., PP-TH-048, PP-TH-248

Giordano P., PP-MO-448, PP-TH-493, PP-WE-878

Giorgi Pierfranceschi M., OC-MO-092

Giptner A., PP-MO-083

Giraldo R., OC-TU-082

Girard P., PP-TH-307

Girault S., PP-TH-593

Girelli D., OC-TH-028, OC-TH-030, PP-MO-342, PP-TH-347

Girisch M., PP-TH-450, PP-TH-575

Girndt M., OC-MO-126, PP-MO-809

Girodon E., PP-MO-529

Giroud M., PP-TH-349

Gissel M., OC-MO-003, OC-TU-003, PP-TH-196, PP-WE-358, PP-WE-362

Githanga J. W., PP-MO-452

Gitz E., PP-MO-007

Giubilato S., PP-WE-789

Giuffrida A., AS-TU-032

Giugliano R., OC-WE-003

Giuseppe C., PP-WE-866

Giusti B., AS-TH-034, OC-MO-010, PP-TH-341, PP-WE-003

Gladysheva V. G., PC-010, PC-011, PC-051

Glatz J. F., PP-TH-012

Glazer S., OC-TH-057

Glechikov A. V., PP-TH-514

Gleiter C., PP-WE-183

Glennane T., PP-WE-409

Gloanec P., PP-MO-382, PP-WE-396

Glover S., OC-TH-020

Goddijn M., PP-TH-373

Godier A., PP-MO-391, PP-MO-835, PP-TH-394

Godino C., PP-MO-775

Godoi L. C., PP-MO-871, PP-TH-218, PP-WE-869

Goekoop R. J., OC-MO-037

Goerlinger K., PP-TH-207, PP-TH-208

Goffin V., PP-MO-022

AUTHORS INDEX

513

Goico F. J., PC-050

Goker H., PP-MO-394

Golanski J., PP-TH-099

Goldenberg N. A., PP-TH-265,PP-WE-255, AS-TU-051

Goldenberg N., OC-WE-117

Golder M., AS-MO-018, AS-MO-020, PP-TH-631

Goldford M. D., PP-WE-195

Goldhaber S. Z., OC-TU-004,PP-TH-424

Goldhaber S., SA-MO-002, OC-MO-054

Goldmann G., PP-TH-537

Goldsmith R. E., PP-WE-431,PP-WE-541

Goli N., PP-TH-161

Golmard J. L., PP-TH-429

Golmard J., PP-WE-412

Golubeva M., PP-MO-256

Gomes K. B., PP-MO-335, PP-MO-346, PP-MO-363, PP-MO-364, PP-MO-816, PP-TH-490, PP-WE-310, PP-WE-347, PP-WE-364, PP-WE-365, PP-WE-814, PP-WE-815

Gomez K., PP-TH-551, PP-TH-657

Gómez N., PP-MO-144

Gomez P., AS-TH-018

Gomez-Lechon M., PP-MO-215

Gomez-Vidales V., PP-MO-865

Gomis R., AS-TH-018

Gomperts E. D., OC-MO-086

Gomperts E., PP-WE-597

Gonçalves E., PP-WE-730

Goncalves L. R., PP-TH-444

Gonczol E., OC-TU-051, PP-WE-836

Gonen R., PP-WE-272

Gong H., PP-WE-004

Gonidec M., PP-MO-112, PP-TH-183

Gonsalves C., PP-MO-460

Gonzalez Conejero R., OC-TH-120, PP-TH-481

Gonzalez G., PP-MO-865

Gonzalez M., PP-MO-766

González O., OC-TH-036

González-Conejero R., AS-MO-054, AS-TH-052, OC-TH-027, PP-MO-144, PP-WE-123

González-Manchón C., PP-WE-764

Goodall A. H., AS-MO-037, OC-TH-093, OC-TU-029, OC-WE-126

Goodeve A. C., AS-MO-019,OC-TU-077, OC-WE-135, PP-TH-638

Goodeve A., PP-MO-199, PP-MO-534

Goodwin C., OC-WE-024

Goossens M., PP-MO-529, PP-WE-600

Gorbacheva L. R., PP-MO-882

Gorbacheva L., OC-WE-143,PP-WE-155

Gorbatenko A. S., PP-MO-182

Gorczyca M., AS-WE-014

Gordon B., PP-WE-215

Gordon S. P., PP-TH-393

Gordon W., PP-TH-315

Gori A. M., PP-MO-743, PP-WE-745, PP-WE-747, PP-WE-748

Gori A., AS-TH-034, OC-MO-010, OC-TH-047, PP-MO-799, PP-MO-800, PP-MO-801, PP-MO-802, PP-MO-803, PP-MO-836, PP-TH-341, PP-WE-002, PP-WE-003

Gorkun O. V., OC-WE-147

Görlinger K., PP-WE-697

Gorodetsky V. M., PP-MO-218,PP-MO-668, PP-WE-170

Gorog D., PP-TH-061, PP-WE-751

Gorska M., PP-WE-433

Gosens I., PP-TH-122

Gosic V., PC-028

Goslings C., OC-TH-067

Goto S., PP-MO-111, PP-TH-004

Gottenberg J., PP-WE-787

Gottsäter A., OC-TH-078, PP-WE-328

Gottstein S., PP-MO-357, PP-TH-588, PP-WE-620

Gouault-Heilman M., PP-TH-189

Goudemand J., OC-TU-073,PP-MO-530, PP-MO-618, PP-MO-626, PP-TH-583, PP-TH-593, PP-TH-623

Goudsmit J., PP-WE-150, PP-WE-151

Gouider E., PP-MO-649, PP-MO-650

Gouin-Thibault I., PP-WE-412,PP-TH-429

Gourhant L., PP-WE-186

Goussetis E., OC-TH-044

Goux D., OC-WE-111

Govaert P., OC-TU-063

Govers-Riemslag J. W. P., AS-TH-038, OC-TU-085, OC-WE-036, PP-MO-433, PP-TH-122, PP-TH-131, PP-WE-126, PP-WE-219, PP-WE-352

Goyal A., PP-TH-231, PP-TH-232

Goyal P., PP-MO-008

Grabell J., PP-TH-639

Gräber S., PP-MO-809

Grabhorn E., PP-TH-215

Grace J., PP-WE-474

Graf M., PP-MO-711, PP-TH-148, PP-WE-777

Graf N., PP-TH-614, PP-WE-648

Graham I. G., PP-TH-034

Graham R. M., OC-TU-054

Grailly S. Y., PP-WE-610

Grainger J. D., PP-MO-690

Gram J., PP-MO-164, PP-WE-282, PP-WE-515

Grancha S., PP-TH-591

Grandchamp B., PP-MO-077

Grandi A. M., PP-MO-309

Grandone E. E. G., AS-WE-023, PP-MO-372

AUTHORS INDEX

514

Aut

hors

Inde

x

Grandone E., PP-MO-822, PP-WE-366, PP-WE-367, OC-TU-035

Grange C., PP-WE-483

Granier C., PP-TH-172

Granier D., PP-MO-079

Grant P. J., AS-TH-019, OC-MO-115, OC-TH-055, OC-TH-089, OC-TU-054, OC-WE-114, OC-WE-125, PP-MO-250, PP-TH-028, PP-TH-351, PP-WE-231, PP-WE-258, PP-WE-259

Grassi M., PP-MO-448, PP-TH-493, PP-WE-878

Gratacap M., OC-MO-099, PP-WE-019

Grau E., PP-MO-226, PP-MO-227, PP-WE-436

Gray A., PP-MO-136, PP-TH-137, PP-WE-481

Gray E., PP-WE-133

Gray J. T., AS-TU-011

Gray L., PP-TH-655

Greaves P., PP-MO-680

Greco L., PP-WE-367

Green D., AS-WE-060, PP-WE-530

Green K., PP-WE-782

Green M., OC-WE-003

Green S. P., PP-WE-298

Green S., PP-MO-550

Greenfield R. S., PP-MO-296,PP-MO-319, PP-MO-502, PP-MO-709

Greensmith H., PP-TH-683

Greenway A. L., PP-MO-438

Greenway A., PP-MO-437, PP-WE-531

Gregorová K., PP-TH-306

Gregory G. D., AS-TH-042

Greig J. A., PP-WE-150

Greinacher A., PL-WE-001, AS-TH-007, OC-TH-023, OC-TH-024, OC-TH-102, OC-TU-026, PP-TH-425

Grelac F., AS-TH-023, OC-TH-022, PP-MO-748

Grenegård M., PP-MO-021

Grenga I., PP-TH-494

Grenner Y., OC-MO-126, PP-MO-809

Gresele P., OC-MO-028, OC-TH-032, OC-TU-047, OC-WE-087, PP-MO-085, PP-TH-008, PP-TH-069, PP-TH-094, PP-TH-402, PP-WE-823

Gretener S., PP-WE-211

Gretler D., PP-TH-027, PP-WE-801

Grgurevich S., PP-MO-054

Gribkova I. V., PP-MO-182

Gridelli B., PP-MO-070

Griesshammer M., PP-TH-550

Griest A., PP-MO-522

Griffin J. H., AS-TU-043, PP-MO-880, PP-MO-881

Griffioen A., PP-WE-192

Griffith M., OC-MO-086

Griffiths A. E., PP-MO-155

Grifoni E., OC-WE-102, PP-MO-303, PP-MO-304, PP-MO-339, PP-MO-340, PP-MO-341, PP-WE-283

Grifoni S., OC-TH-014

Grigoriev S. V., PP-TH-250

Grigorjeva M., PP-MO-256, PP-WE-397

Grigorov A., PP-MO-551

Grilli P., PP-MO-457

Grimaux M., PP-MO-514

Gringeri A., OC-MO-034, OC-WE-119, PP-MO-560, PP-MO-585, PP-MO-586, PP-MO-591, PP-MO-604, PP-TH-558, PP-WE-542, PP-WE-597

Grion A., OC-MO-015

Gris J. C., OC-WE-099

Gris J., OC-TH-081, PP-MO-783

Grisaru D., PP-TH-070

Gritsch H., PP-MO-640, PP-TH-641

Gritsenko P. G., PP-MO-212

Grobbee D. E., OC-TU-070,PP-WE-534

Groenendaal F., OC-TU-063

Gröner A., PP-MO-556, PP-MO-557

Gröning A., OC-TH-101

Groot A. P., OC-WE-105, PP-MO-489

Groot E., AS-WE-037, OC-TU-072, PP-MO-091

Grosbrois S., PP-TH-172

Groschup M., PP-MO-556

Gross P. L., AS-WE-042, OC-TH-060, PP-TH-009

Grosser M., PP-MO-824

Grossmann R., PP-TH-651

Grosso S. H., PC-047

Grosso S., PP-MO-204, PP-MO-613

Grove E. L., PP-WE-788

Gruber A., AS-TH-039, OC-MO-104, PP-TH-037, PP-WE-097

Gruber F. X., PP-MO-808, PP-TH-237, PP-WE-110

Gruber T., PP-TH-231, PP-TH-232

Gruel Y., OC-TH-022, OC-TU-073, PP-MO-527, PP-MO-664, PP-TH-172, PP-TH-365

Gruhler A., PP-MO-558

Grundt H., PP-MO-433, PP-TH-131, PP-WE-126, PP-WE-829, PP-WE-830, PP-WE-831

Grunebaum L., PP-MO-611,PP-WE-655

Grünhage F., PP-TH-537

Grunzke M. L., PP-WE-255

Gruppo R. A., OC-WE-012

Gruzdev A., PP-WE-743

Grzyb A., PP-TH-381

Grzywacz A. M., PP-WE-307

Gu C., OC-MO-013, PC-043

Gu D., OC-WE-068, PP-TH-078, PP-WE-706, PP-WE-707

Gu H., PP-MO-810, PP-WE-009

Gu J., PP-MO-810, PP-WE-009

Gu X., PP-WE-009

AUTHORS INDEX

515

Guadagni F., PP-MO-379, PP-MO-380, PP-TH-494, PP-WE-824

Guarini P., OC-TH-030, PP-MO-342, PP-TH-347

Guasch J. F., PP-TH-520, PP-WE-270

Guazzaloca G., AS-TH-029,OC-TH-075, PP-MO-503, PP-WE-359

Gubensek M., PP-MO-404

Guechi Z., PC-018, PP-MO-445

Gueguen P., AS-TH-015, OC-MO-060

Guella I., PP-MO-648, PP-TH-670, PP-WE-657

Gueret P., PP-TH-423

Guerin V., PP-MO-645

Guerrero F., PP-MO-188, PP-WE-169

Guerrero J. A., PP-MO-082,PP-MO-134

Guerrero J., PP-WE-033

Guest J. F., PP-WE-676

Guglielmini G., OC-WE-087,PP-MO-085, PP-TH-008

Guglielmone H. A., PP-MO-547, PP-TH-568, PP-WE-511

Gui T., AS-WE-042

Guida A., PP-MO-336, PP-WE-320, PP-WE-325

Guidetti G. F., PP-MO-018

Guidi G. C., OC-MO-096

Guidi G., OC-MO-097, OC-TH-030, PP-MO-540, PP-MO-541, PP-WE-140

Guido G., PP-WE-870

Guido R., PP-MO-634, PP-MO-635

Guil M., PP-MO-226

Guillaizeau F., OC-TH-018

Guillet B., OC-TU-073, PP-TH-172, PP-MO-833

Guilliatt A. M., PP-MO-614, PP-MO-623

Guillo P., PP-MO-508, PP-WE-510

Guillot K., OC-WE-017, PP-TH-288

Guimaraes A. H., PP-MO-224

Guimarães D. A. M., PP-MO-363, PP-MO-364, PP-WE-364, PP-WE-365

Guimarães D. A., PP-WE-092,PP-WE-310, PP-WE-347

Guinet C., PP-WE-198, PP-WE-199

Guinto E. R., PP-MO-709

Guinto E., PP-MO-296, PP-MO-319

Guizzardi G., PP-MO-015

Guldiken S., PP-TH-221, PP-TH-222, PP-WE-876

Guler S., PP-MO-537, PP-MO-538

Gulin D., PC-005, PP-TH-227

Gumustekin C., PP-MO-797

Guney B., PP-MO-858

Guney S. B., PP-TH-686, PP-WE-880

Gunja N., PP-MO-326

Gunnarsson M., PP-MO-540

Günther A., AS-TH-037

Guo C., OC-MO-136, OC-MO-137

Guo L. J., OC-MO-096

Guo Z., PP-TH-078

Gupalo E. M., PP-WE-058

Gupta S., PP-WE-523

Guralnik J., PP-WE-311

Gurbel P. A., PP-MO-739, PP-MO-771, PP-TH-026, PP-TH-101, PP-WE-043, PP-WE-757, PP-WE-794, PP-WE-797, PP-WE-798, PP-WE-799, PP-WE-801, PP-WE-802, PP-WE-803

Gurbel P., PP-WE-797

Gurbuz A., PP-TH-511

Gurewich V., AS-WE-050

Gurgey A., OC-WE-132

Gurney D. A., PP-MO-166

Gurniak C., AS-WE-029

Gussoni G., OC-MO-018

Gustafsson T., PP-MO-845

Gut R., PP-WE-602

Guthold M., PP-WE-861

Gutierrez M. J., PP-MO-590

Gutiérrez-Gallego R., OC-TU-082

Gutte H., OC-MO-040

Gutti R. K., PP-TH-067, PP-WE-083

Gutti R., PP-TH-073

Guy C., PP-TH-076

Guzmán A., PP-TH-607

Gyenes M., AS-TH-060, PP-MO-001, PP-WE-862

Gyrgy A. A., PP-TH-346

Gyulkhandanyan A. V., PP-MO-065

H.C.D.C. A., PP-TH-628, PP-TH-639

Ha J. R., PP-WE-238

Ha Noh J., PP-MO-567

Haahr K., PP-WE-383

Haaning J., OC-WE-057, OC-WE-059

Haas S., PP-TH-425

Habas R., AS-WE-035

Haberichter S. L., AS-MO-017,AS-WE-038, OC-WE-133, PP-TH-128

Haberstock-Debic H., PP-MO-045, PP-TH-027

Habib A., PP-WE-738

Hachelaf M., OC-TH-018

Hachem A., PP-MO-012

Hach-Wunderle V., PP-MO-509, PP-TH-312

Hackeng C. M., OC-MO-133,OC-MO-135, PP-MO-780, PP-MO-781, PP-MO-788, PP-WE-741, PP-WE-742

Hackeng T. M., OC-MO-005,PP-MO-186, PP-TH-344

Hackeng T., SA-TH-016

Hacquard M., PP-TH-394, PP-TH-693, PP-WE-700

Hadadeh O., OC-TH-045

Haderer C., PP-MO-615

Hadj-Ali A., PP-TH-680

Hadonou M., PP-MO-628, PP-WE-635

Hadzi-Pecova L. B., PP-WE-769

AUTHORS INDEX

516

Aut

hors

Inde

x

Hafez F. M., PP-WE-202

Hagedorn I., AS-TH-040, AS-TU-040, AS-WE-030

Hagemeyer C. E., PP-MO-100

Haggag S., PP-WE-281

Hagihara K., PP-MO-096, PP-WE-348

Hagiwara N., PP-WE-342, PP-WE-418

Hahnfeld S., LB-MO-003

Haider S., PP-WE-382

Haidl H., PP-WE-439

Haiko J., OC-TH-064

Hajduk B., AS-TH-028

Hajjar K. A., PP-WE-264, AS-WE-046

Hajjar K., OC-MO-026

Hajsmanova Z., PP-TH-368,PP-WE-070

Halaris A., PP-MO-857

Halimeh S., OC-WE-117, PP-MO-377, PP-MO-607, PP-TH-575, PP-TH-646, PP-TH-647, PP-WE-370, PP-WE-633, PP-WE-653, PP-WE-669, PP-WE-670, PP-WE-756

Hall A. J., PP-WE-161

Hall K. J., OC-WE-123

Hallam S., PP-MO-680

Hamaguchi Y., PP-MO-119

Hamahata A., PP-MO-516, PP-TH-319, PP-WE-463

Hamaia S. W., PP-MO-041, PP-MO-058, PP-MO-852

Hamamoto T., PP-TH-689, PP-WE-605

Hamdi S., PP-TH-343

Hamed F., PP-WE-043

Hamed M. S., PP-WE-798

Hamed M., PP-TH-026, PP-WE-043

Hamers S., AS-MO-030

Hamiel C., PP-TH-408

Hamilton J. R., OC-MO-110,OC-WE-044

Hammamy B., PP-MO-664

Hammarström P., AS-TH-038

Hammelburger J., PP-WE-115

Hammer D., PP-WE-030

Hammerschmidt S., OC-TH-059

Hammerstingl C., PP-MO-409

Hammerstrom J., OC-WE-013

Hammond G. C., PP-WE-537

Hampshire D. J., AS-MO-019,OC-TU-077, OC-WE-135, PP-TH-638

Hampton K. K., PP-MO-199,PP-TH-664, PP-WE-766

Hamsten A., PP-MO-108

Hamulyak K., PP-MO-286, PP-MO-337, PP-TH-007, PP-TH-181, PP-WE-017, PP-WE-219

Hamulyák K., AS-WE-058, OC-MO-125, OC-TH-001, OC-WE-100, PP-MO-670, PP-WE-352, PP-WE-457

Han F. Y., PP-TH-364

Han H., PP-WE-844

Han K., PP-WE-112

Han Y., PP-TH-335, PP-WE-773

Han Z., OC-WE-068

Hanabusa H., PP-TH-576, PP-TH-592, PP-WE-606

Hanau D., PP-WE-891

Hanazawa S., PP-TH-229

Hancer V., PP-TH-270

Hang M. X., PP-WE-553

Hanke A. A., PP-WE-697

Hankey G., PP-MO-019

Hanley J. P., PP-WE-372

Hanley J., PP-WE-298

Hann A., PP-MO-397

Hannah M. J., OC-MO-067

Hansen A., PP-MO-014

Hansen J. B., OC-MO-058, PP-MO-177, PP-MO-813

Hansen J. J., PP-WE-572

Hansen J., OC-TU-005, OC-TU-006, OC-WE-137, OC-WE-140, PP-MO-808, PP-TH-237, PP-WE-110, PP-WE-304, PP-WE-305

Hansen K. J., PP-WE-854

Hansen L., OC-MO-085, PP-MO-575, PP-TH-150, PP-TH-151, PP-TH-579

Hansen T. B., PC-042

Hanslik A., PP-MO-436

Hanson E., OC-WE-115, PP-MO-343

Hanson S. J., OC-TU-065, PP-TH-457

Hanson S. R., PP-WE-097

Hanson S., PP-TH-310

Hanssen T., PP-TH-443

Hansson G. K., PP-WE-890

Hansson G., SA-WE-008

Hansson M., PP-MO-762

Hantel S., PP-WE-204

Hantgan R. R., PP-TH-105, PP-WE-703, PP-WE-861

Hanzu F., AS-TH-018

Hara H., PP-MO-070

Harada A., PP-MO-127

Harada T., PP-TH-521

Haramura G., PP-MO-205

Harashima M., PP-TH-229

Haratian Z., PC-049

Harbrecht U., PP-WE-210

Hardwardt M., PP-MO-185

Harenberg J., PP-MO-420, PP-WE-182, PP-WE-183

Harhouri K., AS-MO-060

Harmon S., PP-TH-549, PP-WE-685

Harpell L., AS-TU-014, OC-TH-085

Harper A. G. S., PP-MO-003

Harper J., PP-WE-116

Harper M. T., AS-WE-035, OC-MO-045, OC-WE-123, PP-WE-020

Harper P. L., OC-TU-079

Harper P., PP-MO-493

Harries C., PP-WE-805

Harrington L. S., AS-WE-052

Harris G. A., OC-TH-112

Harris S., PP-WE-530

Harrison P., OC-MO-009, OC-TU-056, PP-MO-759

AUTHORS INDEX

517

Harsfalvi J., PP-WE-049

Hársfalvi J., PP-TH-633

Hart D. P., PP-MO-708

Hart E., PP-WE-239

Hart G., PP-TH-197

Hartman D., OC-MO-100

Hartmann R., PP-WE-557

Hartwell E., PP-MO-767

Hartwig J. H., PL-TU-002, PP-WE-077, AS-WE-026

Harustiakova D., PP-MO-259

Harvey E. J., PP-MO-820

Harvey S., AS-MO-049

Harwardt M., PP-MO-184

Hasan I., PP-MO-638

Hasebe Y., PP-TH-229

Hasegawa M., PP-MO-096, PP-TH-054

Haselböck J., PP-WE-663

Haselboeck J., OC-TU-013

Hashemi A., PP-TH-210

Hashemi Soteh M., PP-TH-636,PP-WE-558

Hashiguchi T., PP-MO-884

Hashimoto M., PP-MO-096

Hass M., PP-TH-397, PP-WE-159

Hassairi N., PP-MO-280

Hassan M. U., PP-MO-710

Hassanien A. S., PP-TH-506

Hassanzadeh G. H., OC-TH-114

Hasse M., AS-TH-060, PP-WE-862

Hassenpflug W. A., PP-TH-215

Hassine M., PP-TH-343, PP-TH-343

Hasslacher M., AS-WE-015,PP-MO-087, PP-MO-150

Hasstedt S. J., OC-MO-024,OC-TU-001

Hasumi K., PP-TH-226

Hatala R., PP-TH-433, PP-TH-437

Hatemi A., PP-MO-858

Hatfield M. L., PP-MO-004

Hathaway H. A., PP-WE-255

Hathaway W. E., PP-WE-255

Hatmi M., PP-TH-343, PP-TH-485, PP-TH-486, PP-WE-490

Hato T., PP-MO-511, PP-WE-011

Hattori K., PP-MO-123, PP-MO-127

Hau C. M., AS-WE-017, PP-MO-109

Haubelt H., OC-WE-077

Haubold K., PP-MO-603, PP-MO-647

Hauer A., OC-WE-046, PP-WE-439

Haumer M., PP-MO-436

Hauroeder B., PP-TH-440, PP-WE-190

Hauschner H., OC-TH-042

Hauser C. J., OC-TH-069

Haushner H., PP-TH-084

Hausl C., OC-TH-054

Havens P. L., OC-TU-065

Hawley A. E., OC-TU-060, PP-MO-388, PP-MO-400

Hay C. R. M., OC-TU-078, PP-TH-645

Hay J. W., PP-TH-600, PP-WE-612

Haya S., PP-MO-589, PP-MO-590, PP-TH-544, PP-TH-627, PP-WE-668

Hayafuji K., PP-TH-689

Hayakawa K., PP-WE-090

Hayakawa M., PP-WE-687

Hayashi A., OC-TH-088, OC-TU-041, PP-MO-232

Hayashi H., PP-TH-051

Hayashi T., OC-WE-054, PP-TH-143, PP-WE-032, PP-WE-882, PP-TH-057, PP-WE-278

Hayashida Y., PP-WE-411

Haynes R., PP-WE-429

Hayun Y., PP-WE-847

Hayward C. P. M., AS-TH-045,OC-MO-134, PP-TH-663, AS-TH-031

Hazen S., SA-TU-010

Hazenberg B. P. C., AS-TH-038

Hazenoot T. A., PP-WE-322

Haznedaroglu I. C., PC-003,PP-MO-394

He C., OC-WE-098

He S., PP-TH-141, PP-TH-186,PP-WE-846, PP-TH-146, PP-TH-114

He X., PP-WE-846, PP-TH-146,PP-TH-114

He Y., PP-MO-854, PP-WE-732

Head M. W., OC-MO-032

Heaney N. B., PP-TH-538

Heath S., OC-MO-021, PP-TH-309

Heath V. L., OC-MO-069

Heath V., PP-WE-638

Hebbagodi S., PP-MO-811, PP-MO-812, PP-WE-828

Hechler B., AS-MO-058, OC-TH-033, OC-TH-034, OC-TH-035, OC-TU-049

Hecking C., PP-MO-501

Hedayatiasl A., PP-TH-124

Heddle N., PP-TH-663

Hedner U., OC-WE-061, PP-WE-237

Hedstrom L., PP-WE-218

Heeb M. J., OC-MO-055

Heegaard C. W., PP-MO-131

Heemskerk J. W. M., AS-TU-029, AS-TU-037, AS-WE-044, OC-MO-044, OC-WE-123, PL-TU-003, PP-MO-670, PP-TH-007, PP-TH-012, PP-WE-260

Heemskerk J., PP-TH-104

Heeneman S., AS-WE-058, OC-MO-125

Hegadorn C., AS-MO-018, AS-MO-020, AS-TU-014, OC-TH-085, OC-TH-086, PP-TH-631, PP-TH-639

Heidinger K. S., PP-MO-083

Heidinger K., PP-MO-513

Heijnen H. F. G., PP-MO-042,PP-TH-055, PP-WE-061

Heilmann C., PP-MO-030

AUTHORS INDEX

518

Aut

hors

Inde

x

Heim V., PP-WE-891

Heine G. H., OC-MO-126, PP-MO-809

Heine S. I., PP-TH-614, PP-WE-648

Heiniger A. I., PP-TH-572

Heiniger A., PP-WE-550, PP-WE-551

Heisel-Kurth M. A., PP-MO-586

Heistinger M., OC-WE-077

Heit J. A., AS-TH-003, PP-MO-284, PP-MO-629, PP-MO-678, PP-MO-760, PP-WE-292

Hejazi S., PP-MO-539, PP-TH-318

Helal O., OC-TU-087

Helgestad J., PP-TH-455

Helinska M., PP-TH-098, PP-TH-099

Heller C., PP-MO-592, PP-WE-210, PP-WE-434

Helley D., OC-TH-046, PP-MO-862

Hellweg A., AS-WE-053

Helmerhorst F. M., AS-TH-002

Hemapriya K., OC-TH-118

Hemche H., PP-TH-608, PP-WE-701

Hemker C. H., PP-TH-155

Hemker C., PP-TH-107, PP-TH-176, PP-TH-177

Hemker H. C., PP-MO-251, PP-MO-582, PP-TH-246, PP-WE-683

Hemker P. W., PP-MO-251

Hemmeryckx B., PP-MO-819

Hemostasis Research LabMembers M., PP-TH-628

Hendrickx B., OC-TU-008

Hendriks D. F., PP-MO-327

Hendriks D., PP-MO-229, PP-MO-230

Hendriks H. G. D., PP-WE-771

Henig I., PP-TH-387

Henk J., OC-MO-051

Henke P. K., OC-TU-060, PP-MO-388

Henkens I. R., PP-WE-322

Henley K. J., AS-WE-032

Henneke I., AS-TH-037

Hennessy E. M., OC-TU-002

Henriet C., PP-MO-618

Henriksson P., OC-WE-104,PP-MO-374

Henry H., PP-MO-686

Henschler R., PP-MO-029

Henskens Y. M. C., PP-WE-017

Hentrich J., PP-MO-700, PP-WE-739

Hepner M. D., PP-WE-637

Hepner M., OC-TU-064, PP-MO-687

Heptinstall S., OC-MO-100,PP-MO-101, PP-WE-045, PP-WE-755

Heras M., PP-MO-254

Herault J., PP-WE-388

Herbel P., PP-TH-120

Herbert J. M. J., OC-MO-069

Herbert S., PP-WE-522

Herbiniaux U., AS-WE-002

Herczenik E., PP-TH-616

Hergenroeder G. W., OC-TH-104

Herlea O., OC-TH-065

Herman A., PP-MO-338

Herman J. H., PP-MO-756

Hermanides J., PP-MO-298

Hermann C., OC-WE-063

Hermann D., OC-MO-100

Hermanowicz J. M., PP-MO-234

Hermans C., PP-MO-220, PP-MO-560, PP-TH-566, PP-TH-578, PP-WE-532

Hermida J., PP-MO-178

Hermit M. B., PP-MO-118, PP-MO-575, PP-TH-579, PP-WE-154

Hernan N., PP-WE-665

Hernandez F., PP-TH-059, PP-WE-560, PP-WE-765

Hernandez I., PP-MO-880, PP-MO-881

Hernandez J., PP-WE-284

Hernandez M., PP-MO-737,PP-WE-692

Hernández M., PP-TH-675

Hernández R., OC-TH-036

Hernandez Romero D., OC-TH-120

Hernández-Espinosa D., OC-WE-107

Hernandez-Navarro F., PC-048, PP-TH-603, PP-TH-604

Herr A. B., OC-WE-048

Herrera M., PP-WE-665

Hers I., PP-WE-007

Hersemeyer K., AS-TH-058

Hersi A., PP-WE-163

Hertfelder H. J., PP-MO-253

Herzog R. W., SA-TU-013, AS-TU-015, PP-TH-618, OC-TH-049, PP-WE-798, PP-WE-802

Herzog W., PP-WE-802

Hesham M., PP-TH-445

Hess K. A., AS-TH-019

Hess K., PP-TH-351

Hessner M. J., PP-MO-880

Hewlett L., OC-MO-067

Heylen E., PP-MO-229, PP-MO-230, PP-MO-327

Heyndrickxs G., PP-WE-416

Hickey K. P., PP-MO-199, PP-TH-679, PP-WE-144

Hickey K., PP-WE-302

Hickson N., AS-MO-019, PP-TH-638

Hidalgo P., OC-WE-086, PP-MO-860

Hiebert L. M., PP-WE-392, PP-WE-393

Hierso S., PP-TH-386

Hiestand B., PP-MO-470, PP-WE-284

Higasa A., PP-TH-592

Higasa S., PP-WE-606

Higashihara M., PP-MO-084,PP-WE-025

Higgerson R. A., PP-TH-310,PP-TH-457

AUTHORS INDEX

519

Higgins J. R., PP-MO-381

Higgins-Gruber S. L., OC-WE-075

High K. A., AS-TU-015

Hijjawi S. B., PP-WE-504

Hilbig A., LB-MO-003

Hildebrand R. B., OC-WE-046

Hilden I., OC-MO-058, PP-MO-177, PP-TH-529, PP-WE-589

Hill C. E., OC-WE-109

Hill F. G. H., OC-MO-032, OC-MO-033

Hill G., PP-MO-090

Hill M., PP-MO-534, PP-WE-214, PP-WE-215

Hill S. N., PP-MO-054, PP-TH-097

Hillarp A., OC-TH-050, PP-MO-258, PP-MO-615, PP-WE-758

Hillege H., OC-MO-001

Hills J., PP-TH-263

Himmer K., PP-TH-652

Hinckley J., PP-WE-636

Hinrichs A., PP-WE-620

Hintenberger R., PP-MO-829

Hirabayashi K., PP-TH-358

Hiramoto J., PP-WE-562

Hirata K., PP-MO-429

Hirmerova J., PP-WE-287

Hiroe K., PP-MO-201, PP-TH-168, PP-WE-400

Hirsch A. M., PP-WE-462

Hirsch J., AS-TH-008

Hitchen C., PP-TH-224

Hitos K., PP-MO-326, PP-WE-300, PP-WE-301

Hiura H., OC-WE-008

Hizroeva D. H., PP-TH-278

Hjemdahl P., AS-WE-024, PP-WE-890

Hjortdal V., PP-WE-677

Hla T., AS-WE-056

Hlawaty M., PP-WE-107

Hlusi A., PC-022, PP-MO-689,PP-WE-142, PP-WE-273

Hlusí A., PP-WE-378

Ho C. H., PP-TH-620

Ho D., OC-MO-025

Hobbs H., PL-MO-001

Hobbs W., PP-WE-887

Hochstrasser D., OC-TH-073

Hocini H., PP-WE-483

Hockin M. F., OC-TU-003

Hockings P. D., PP-MO-385

Hoebbel-Schnell T., PP-MO-693, PP-WE-644

Hoecke C. J., PP-MO-296, PP-MO-319, PP-MO-502, PP-MO-709

Hoefer I., OC-TH-031

Hoefman S., AS-TH-024

Hoeg T. S., PP-WE-586

Höehr N. F., PP-MO-145

Hoekstra J. B. L., PP-MO-298

Hoekstra J., PP-MO-224, PP-TH-314

Hoelscherman H., OC-WE-128

Hoes A. W., OC-TH-017, OC-TU-012

Hofbeck M., PP-TH-450

Hoffman B. E., AS-TU-015

Hoffman M., OC-WE-061, PP-MO-300, PP-TH-205

Hoffman S., OC-MO-134

Hoffmann T., PP-MO-745

Hoffmeister M., PP-MO-480

Hofman T., PP-WE-128

Hofstee H. M. A., PP-TH-517

Hofstra J. H., PP-MO-190

Hofstra J. J. H., PP-MO-191

Hogan W. J., PP-MO-487

Hogg M. M., OC-TU-007, PP-TH-505, PP-WE-414

Hogg P. J., OC-MO-056

Hogg P., PL-TU-000

Hogwood J., PP-WE-133

Hoibraaten E., AS-TH-004

Hoit B., OC-MO-128

Holada K., PP-TH-016

Holbrook J. B., PP-WE-854

Holbrook L., OC-TH-037

Holcomb J. B., OC-TH-069,PP-MO-767

Holcroft C., PP-TH-322

Hollenbach S. J., OC-TH-107

Hollenbach S., AS-TH-022

Hollestelle M. J., PP-WE-339,PP-WE-355

Holliday B. A., OC-MO-117

Holloway D., PP-WE-623

Holly’ P., PP-TH-305, PP-TH-598, PP-WE-220

Holm P. K., PP-MO-118, PP-MO-575, PP-MO-578, PP-TH-579

Holmberg H. L., OC-WE-056

Holmberg M., PP-WE-200, PP-WE-201

Holme P. A., PP-MO-581, PP-TH-539

Holme P., PP-MO-560

Holmes C. E., AS-MO-032, AS-MO-033, AS-MO-034

Holmström M., AS-TU-034, PP-MO-533, PP-WE-643

Holstein K., PP-TH-578

Höltje H. D., PP-TH-094

Holy E. W., OC-TU-052

Holz J., AS-TH-024, PP-WE-416

Hölzenbein T., PP-MO-561

Holzhauer S., OC-TU-062, OC-WE-117, PP-MO-607

Homann J., PP-MO-253

Homer-Vanniasinkam S., PP-MO-024

Homma S., AS-WE-006

Honauer G., PP-WE-519

Honda S., PP-TH-015

Honda Y., PP-TH-406

Hong B., PP-WE-783

Hong H., PP-WE-535

Hong M. H., PP-TH-634

Hong S., PP-TH-294, PP-WE-783

Hong W., AS-TH-042, OC-TH-095

AUTHORS INDEX

520

Aut

hors

Inde

x

Hong Y. C., PP-MO-330, PP-TH-620

Hoogerwerf J., PP-TH-153

Hooper C., PP-MO-596, PP-WE-613

Hooper N. M., AS-TH-019

Hooper W. C., PP-TH-324, PP-TH-325, PP-TH-326, PP-TH-327, PP-TH-328

Hoots K., PP-MO-586

Hoots W. K., PP-WE-610

Hoover-Plow J. L., OC-TU-036,PP-WE-239

Hopkins B. J., PP-MO-702

Hoppensteadt D., OC-TH-019,OC-TH-103, PP-MO-136, PP-MO-139, PP-MO-140, PP-MO-143, PP-MO-152, PP-MO-153, PP-MO-154, PP-MO-396, PP-MO-399, PP-MO-703, PP-MO-857, PP-TH-137, PP-TH-138, PP-TH-142, PP-TH-145, PP-TH-166, PP-TH-201, PP-TH-389, PP-TH-390, PP-TH-391, PP-WE-143

Hoque G., PP-MO-710

Horblyuk R. V., PP-MO-283,PP-MO-473, PP-WE-466

Horchani R., PP-MO-650

Horellou M., PP-WE-316, PP-WE-412

Horie S., PP-TH-051

Horio T., PP-WE-872

Horita T., PP-MO-842, PP-WE-269, PP-WE-271

Horiuchi H., PP-MO-789

Horne M. K., PP-TH-225

Horneff S., PP-TH-537

Hortelano G., AS-TH-012, AS-TU-012

Horvath A. J., PP-TH-224

Horvath A., OC-TU-079, OC-TU-084

Horvathova D., PP-WE-656

Hoshi A., PP-WE-501

Hoshino H., PP-WE-015, PP-WE-031

Hoskins P., OC-MO-017

Hossain N., PP-TH-648, PP-WE-382

Hossain S. R., PP-TH-476

Hosseini Khah Z., PP-WE-558

Hostetler K., PP-WE-672

Hou J., PP-WE-674

Hou M., OC-MO-136, OC-MO-137, PP-MO-695, PP-WE-731

Hough C., AS-TU-014, OC-TH-085, OC-TH-086

Houng A. K., PP-WE-218

Hourani R., PP-TH-456

Houska M., PP-TH-213

Houweling A., PP-WE-462

Houwing-Duistermaat J. J.,PL-TU-001

Hovatta O., PP-MO-374

Hovens M. M. C., PP-MO-782,PP-WE-851

Howard A. G., PP-WE-819

Howes J., PP-WE-028

Hoylaerts M. F., OC-MO-044,PP-WE-085, PP-WE-268, OC-WE-043, OC-TH-057, PP-MO-398, PP-MO-795, PP-MO-819

Hrachovinova I. V., PP-MO-583

Hrachovinová I. V., PP-WE-345

Hrachovinova I., PP-MO-551,PP-TH-083

Hrncir Z., PP-WE-068

Hron G., AS-MO-004

Hsiao S., AS-WE-032

Hsu C., PP-MO-879

Hsu H. C., PP-MO-330, PP-TH-620

Hu C. Y., PP-MO-180

Hu G., OC-WE-064

Hu H., PP-MO-105, PP-WE-818

Hu J., PP-WE-732, PP-WE-846,PP-TH-114

Hu L., PP-TH-022

Hu S., PP-MO-555, PP-TH-653

Hu Y., PP-WE-101

Hu Z., PP-WE-083

Hua B., PP-MO-642, PP-TH-334

Hua M., AS-WE-032

Huang C., PP-WE-079

Huang D. C. S., AS-WE-032

Huang D., PP-MO-646

Huang F., PP-WE-217

Huang J., OC-MO-070, PP-WE-838

Huang L. L. H., PP-MO-159

Huang L., PP-TH-586

Huang M., AS-WE-047, PP-WE-225

Huang T., PP-MO-840, PP-MO-844, PP-MO-846, PP-MO-878, PP-MO-879, PP-TH-653, PP-WE-895, PP-WE-895

Huang X., PP-WE-857

Huang Y., AS-TU-055

Huang Z., PP-MO-105

Hubbuch A., PP-WE-519

Hubel E., PP-TH-070

Huber K., PP-MO-829

Huber S., OC-TH-117

Hug M., OC-TU-061

Huge A., AS-TU-053, OC-TU-062

Hughes J., PP-TH-473

Huijgen R., PP-MO-298

Huisman M. V., AS-MO-035,AS-TU-010, OC-MO-037, OC-TH-008, PP-MO-506, PP-MO-507, PP-MO-782, PP-TH-413, PP-WE-322, PP-WE-341, PP-WE-512, PP-WE-513, PP-WE-521, PP-WE-851

Huisman M., SA-MO-003

Hulkower B., PP-MO-768, PP-TH-655

Hull R. D., OC-TU-021

Hulot J., OC-MO-007

Humphries J. E., OC-TH-031

Humphries J., PP-MO-384

Hunt B. J., OC-TU-039, PP-MO-371, PP-WE-727

Hunt J., PP-TH-230, PP-TH-231

Hunter R. W., PP-WE-007

AUTHORS INDEX

521

Hunter R., PP-WE-065

Huntington J. A., AS-MO-025,AS-TH-049, OC-WE-081, OC-WE-098

Huntington J., SA-TH-017

Huo M., PP-MO-247

Hurbin F., PP-WE-388

Hurevich H. L., PP-MO-873,PP-MO-874, PP-WE-863, PP-WE-864

Hurst S., PP-WE-097

Hursting M. J., OC-TH-104

Hurtado B., PP-WE-821, PP-WE-822

Hurtado J., PP-MO-732

Hurtaud-Roux M., PP-TH-074

Hurwitz J., PP-MO-722

Husain M. F., PP-MO-057

Husova L., PP-WE-596

Hussain M., PP-MO-030

Hussein A. H., PP-MO-037, PP-WE-067

Hussein M. A., OC-TH-016

Hussein M., PP-WE-465

Hussein N. A., PP-TH-506

Hutabarat R. M., PP-WE-569

Hutabarat R., AS-WE-014, PP-MO-622

Hutchaleelaha A., OC-TH-107,PP-WE-801

Huth - Kühne A., PP-MO-513

Huth-Kuehne A., PP-MO-662,PP-TH-575

Huth-Kuhne A., PP-MO-609,PP-WE-604

Huth-Kühne A., OC-WE-058,PP-TH-421

Hutspardol S., PC-052, PP-WE-710

Huyck J., PP-TH-256

Hvas A., PP-MO-386, PP-WE-788

Hvitfeldt Poulsen L., OC-MO-036

Hwa J., PP-TH-364

Hwang S., PP-TH-190

Hylek E. M., PP-MO-462, PP-MO-463

Hyllner M., PP-MO-652, PP-WE-206

Hynes E., PP-WE-298, PP-WE-372

Hyseni A. A., PP-WE-355

Hyun J., PP-TH-149

Iaboni S., PP-MO-457, PP-MO-458

Iacobelli M., OC-WE-108, PP-TH-389

Iacobellis N., PL-TU-004

Iacoviello L., PP-MO-481, PP-MO-876, PP-TH-048, PP-TH-248, PP-TH-249, PP-WE-246, PP-WE-498

Iakova P., PP-TH-439

Iannaccaro P., PP-MO-432, PP-TH-546, PP-TH-547

Iannaccone A., PP-WE-367

Iannuzzi F., PP-MO-673

Iasella M., PC-034

Iatmanen S., OC-WE-070

Iba T., PP-TH-198

Ibarra A., OC-TU-038

Ibghi D., PP-WE-423

Ibrahim B., PP-WE-691

Ichikawa H., AS-WE-045

Ichinose A., OC-WE-073

Ido M., PP-WE-032

Ieko M., PP-MO-842

Iglesias Varela M. L., PP-TH-333

Iglesias Varela M., PP-MO-275

Ignjatovic V., OC-WE-093, PP-MO-381, PP-MO-437, PP-MO-438, PP-MO-449, PP-MO-450, PP-MO-451, PP-MO-674, PP-TH-442, PP-TH-461, PP-TH-462, PP-TH-475, PP-WE-437, PP-WE-438, PP-WE-480, PP-WE-531

Iijima K., PP-TH-143

Ikeda R., PP-TH-173

Ikeda T., PP-MO-789

Ikeda Y., SA-WE-016

Ikenaga H., PP-WE-348

Ikram N., PP-TH-643

Ilic V., PP-WE-634

Iliceto S., OC-TH-075

Iliescu V., PP-WE-737

Iliuta L., PP-WE-737

Ilonczai P., PP-MO-359

Imaeda Y., PP-MO-201, PP-TH-168, PP-WE-398, PP-WE-400

Imai M., PP-WE-149

Imamura T., PP-MO-111

Imanishi D., PP-WE-666

Imanishi T., PP-MO-429

Imbergamo S., PP-WE-866

Imberti D., OC-MO-092, OC-TH-011, PP-WE-403

Imfeld K. L., PP-MO-823, PP-TH-065

Immenschuh S., OC-MO-072

Inaba H., PP-MO-546, PP-WE-666

Inagaki M., AS-TH-022, OC-TH-107

Inami N., PP-WE-781, PP-WE-827

Inbal A., PP-MO-749

Incampo F., PP-WE-249

Ingalls R., PP-TH-064

Ingerslev J., AS-MO-028, OC-MO-036, PP-MO-386, PP-MO-543, PP-TH-545, PP-WE-658, PP-WE-677, PP-WE-698, PP-WE-702, PP-WE-740

Ingle A., PP-MO-068, PP-WE-672

Ingram A. J., OC-TH-009

Ingratti M., PC-047

Innocenti M., PP-MO-542

Innocenti P., PP-WE-856

Inoue H., PP-WE-196

Inoue M., PP-TH-358

Inoue O., OC-TH-099, PP-TH-005

Inoue Y., PP-WE-005

Interthal C., PP-MO-373

Inwards D. J., PP-MO-487

Inzitari D., OC-TH-047

AUTHORS INDEX

522

Aut

hors

Inde

x

Iommi P., PP-TH-060

Ionescu-Zanetti C., PP-WE-860

Ionita H., PP-WE-549

Iorio A., AS-TH-005, AS-TU-032, AS-TU-033, OC-MO-035, OC-TH-002, OC-TH-004, OC-TU-075, PP-MO-282, PP-MO-457, PP-MO-458, PP-MO-542, PP-TH-412, PP-TH-654, PP-WE-286, PP-WE-529, PP-WE-688

Iorio M., PP-MO-758

Iotti M., PP-MO-285

Ippolito L., PP-WE-598

Iqbal O., OC-TH-019, OC-WE-088, PP-MO-072, PP-MO-136, PP-MO-140, PP-MO-143, PP-MO-154, PP-MO-857, PP-TH-137, PP-TH-138, PP-TH-166, PP-WE-143, PP-WE-261, PP-WE-387, PP-WE-482, PP-WE-866

Irigoyen M. B., PP-WE-618

Ironside J. W., OC-MO-032

Ironside J., OC-MO-033

Isaev V. A., PP-WE-422

Isarria S., PP-MO-227

Isbister G. K., PP-MO-249

Isbister G., PP-WE-118

Iscoe S., PP-TH-393

Iserbyt B. F., PP-MO-049, PP-MO-050

Isermann B., AS-MO-059, AS-TH-048, AS-WE-053

Ishibashi T., PP-WE-875

Ishida H., PP-TH-004

Ishida N., PP-TH-051

Ishihara C., OC-TH-088

Ishii H., PP-TH-061, PP-MO-252

Ishii M., PP-WE-025

Ishiwata A., OC-TH-051, PP-TH-054

Ishiwata S., OC-WE-143, PP-MO-875, PP-MO-882

Iskas M. S., PP-WE-131

Isma N., PP-WE-328

Isonishi A., OC-WE-008

Israel-Biet D., OC-TU-090

Israels S. J., PP-TH-032

Israels S., AS-WE-003, OC-MO-134, OC-TU-068, PP-WE-553

Italiano - Jr J., AS-WE-026

Italiano J. E., PL-TU-002, PP-WE-077

Italiano J., SA-MO-006

Itani M., PP-WE-281

Ithychanda S., OC-MO-047

Ito H., PP-TH-041, PP-TH-042

Ito M., PP-TH-526

Ito N., PP-MO-717, PP-TH-526,PP-WE-411

Ito T., PP-MO-884

Ito Y., PP-TH-081, PP-TH-229

Itoh H., PP-WE-349

Ittah M., PP-WE-787

Itzhar N., PP-TH-623

Ivanciu L., AS-TH-013, OC-TH-112, AS-TH-046

Ivandic B. T., PP-TH-421

Ivaskevicius V., PP-TH-671

Iversen N., PP-TH-164, PP-TH-165, PP-WE-191, PP-WE-487

Iversen P. O., PP-WE-486, PP-WE-487

Iwade K., PP-TH-416

Iwade M., PP-TH-416

Iwahashi H., PP-WE-411

Iwai T., PP-WE-005

Iwaki T., OC-TU-050

Iwaniec T., PP-MO-206, PP-MO-269, PP-MO-270, PP-MO-271, PP-MO-329, PP-TH-381, PP-WE-651, PP-WE-883, PP-WE-884

Iwasaka T., PP-WE-781

Iwata H., OC-WE-073

Iyu D., PP-MO-101

Izaguirre R. A., PP-MO-345,PP-MO-362

Izzi B., PP-MO-059, PP-WE-048

J. Hansen J., PP-MO-565

Jaax M. E., OC-TH-023

Jablonska E., AS-TH-037

Jackson C. J., AS-TH-017

Jackson C. L., OC-TU-054, PP-WE-813

Jackson S. C., PP-WE-546,PP-WE-695

Jackson S. P., AS-WE-032,OC-MO-110, OC-WE-044, OC-WE-122, OC-WE-124, PP-WE-391

Jackson S., PL-WE-002

Jacobi P. M., AS-WE-038

Jacobs G., OC-MO-128

Jacobsen A. F., PP-MO-288,PP-WE-332

Jacobsen B., PP-WE-225

Jacobsen C., PP-MO-122

Jacobsen E. M., PP-MO-288

Jacobson B. F., PP-TH-370,PP-TH-371

Jacobson J. O., PP-TH-424

Jacobson L. J., PP-WE-255

Jacquemin L., OC-MO-008

Jacquemin M. G., PP-MO-605,PP-WE-153, PP-WE-610

Jacquemin M., OC-TH-057,PP-WE-614

Jadaon M. M., PP-WE-724

Jadhav M. A., PP-WE-156

Jaenisch R., PL-TH-002

Jagadeeswaran P., OC-TH-105, OC-WE-052, PP-TH-156

Jagannathan I., AS-WE-045

Jager D., OC-TH-109

Jahan R., PP-TH-232

Jahangiri M., PP-WE-852

Jaimovich R., OC-WE-086

Jain M. K., OC-TU-042

Jain S., OC-WE-020, AS-MO-031

Jaïs X., PP-MO-376

Jakiela B., PP-MO-784

Jakobsson L., AS-MO-061

Jakovljevic B., PP-TH-296, PP-WE-369

AUTHORS INDEX

523

Jakovljevic G., PP-WE-442

Jakubowski J. A., OC-MO-012,PP-MO-096, PP-MO-733, PP-MO-787, PP-TH-030

Jalagadugula G. S., AS-TH-044, PP-MO-078

Jallad S. G., PP-WE-504

Jallu V., AS-MO-053, PP-MO-079

Jambor C., PP-WE-038

Jámbor L., PP-MO-359

James A. H., PP-TH-206

James E. A., PP-TH-616

James P. D., AS-MO-017, AS-MO-019, AS-TH-053, OC-WE-133, PP-MO-639, PP-TH-638

James P., PP-TH-628, PP-TH-639

James R., PP-MO-852, PP-TH-364

Jamrozek-Jedlinska M. M.,PP-WE-307

Janata K., PP-TH-676

Janco R., PP-MO-541

Jandrot Perrus M., PP-WE-018

Jandrot-Perrus M., AS-TU-024,OC-WE-070, PP-MO-077, PP-MO-786, PP-TH-119

Janes J., PP-MO-238

Jang M., PP-MO-301

Jang S., PP-MO-727, PP-TH-509, PP-WE-343

Jankovicova D., PP-WE-656

Jansen M., PP-MO-163, PP-TH-589

Janssen H. L. A., PP-TH-314

Janssen H. L., PP-MO-224

Januszek R., PP-MO-355, PP-WE-883, PP-WE-884

Jarchau T., AS-MO-038

Jarchum G., PP-MO-547, PP-WE-511

Jardín I., PP-TH-003

Jarvis G. E., PP-MO-041, PP-MO-048

Jasuja R., AS-TU-022

Jauhiainen M., OC-TU-096

Javela K. M., AS-TH-010

Javela K., PP-MO-742, PP-WE-279

Javier R., PC-050

Jawien A., PP-WE-433

Jayachandran M., PP-WE-780

Jayakodi D., PP-WE-171

Jayo A., PP-WE-764

Jazebi M., PP-TH-124, PP-TH-318, PP-TH-636

Jeandriens A., PP-MO-617

Jeanpierre E., PP-MO-814, PP-MO-815, PP-WE-762

Jelicic Z. D., PP-WE-369

Jenei A., PP-WE-049

Jeng J. H., PP-MO-869, PP-TH-058

Jenkins P. V., PP-TH-549

Jenkins V., PP-MO-593

Jenkinson H. F., OC-WE-047,PP-MO-051

Jennersjö C., PP-WE-334

Jennings I., PP-MO-116, PP-MO-320, PP-MO-534, PP-WE-716, PP-MO-115

Jennings L. K., PP-MO-054,PP-TH-097, PP-WE-103

Jenny N. S., AS-WE-060, OC-TH-117, OC-WE-103

Jensen A. L., PP-WE-401

Jensen C. V., OC-MO-040

Jensen E., PP-WE-172

Jensen M. B., PP-TH-577

Jensen O. E., PC-042

Jensen T. J., OC-TH-057

Jeon W. K., PP-TH-405

Jeppsson A., PP-MO-652, PP-WE-206

Jepsen T., PP-WE-585

Jerczynska H., PP-WE-879

Jerling J. C., PP-WE-228

Jern C., OC-WE-115, PP-MO-343

Jeschke U., PP-WE-784

Jeske W. P., PP-MO-399, PP-TH-201, PP-TH-391, PP-TH-404, PP-WE-262

Jeske W., PP-MO-140, PP-MO-396, PP-WE-143, PP-WE-385, PP-WE-481

Jeskins G., PP-TH-330

Jespersen J., OC-MO-090, PP-MO-164, PP-WE-515

Jessen G., PP-TH-094

Jessen S., AS-MO-050

Jevtic D. M., PP-WE-867

Ji Q., PP-WE-818

Ji S., PP-TH-399, PP-TH-400,PP-WE-099

Ji X., OC-MO-136

Ji Y., PP-MO-358

Jia F., OC-WE-124

Jia J., AS-TU-041

Jia S., PP-MO-880

Jiang H., AS-TU-028, OC-WE-059, PP-WE-030, OC-WE-057

Jiang M., PP-MO-859, PP-MO-883, PP-TH-399

Jiang N., OC-WE-109

Jilma B., AS-WE-014, OC-TH-068, OC-WE-011, PP-MO-622, PP-MO-718, PP-TH-676, PP-WE-675

Jilma P., AS-WE-014

Jilwan F., PP-MO-376

Jiménez D., PP-MO-299

Jimenez V., PP-MO-566, PP-MO-579, PP-WE-560, PP-WE-765

Jiménez V., PP-TH-596

Jiménez Yuste V., PP-MO-601

Jimenez-Yuste V., PC-048, PP-MO-590, PP-TH-059, PP-TH-603, PP-TH-604

Jin J., OC-TH-040, PP-MO-106,PP-TH-022, PP-WE-012

Jin M., OC-WE-129, OC-WE-130

Jin S., AS-MO-015, PP-TH-080

Jin Y., OC-TH-095, OC-WE-045

Jinca C., PP-MO-532, PP-WE-552

Jindal K. K., OC-TH-009

Jing D., PP-MO-531

Jing H., OC-TH-109

AUTHORS INDEX

524

Aut

hors

Inde

x

Jirgård L., PP-WE-758

Jirouskova M., PP-WE-082

Jlizi A., PP-MO-649

Jobe S. M., OC-TU-048

Joch C., PP-WE-697

Jochmans K., PP-MO-173, PP-MO-174, PP-WE-188

Joglekar M., PP-WE-051

Johansson P. I., OC-TH-067

John E., PP-WE-662

John S., OC-WE-139, PP-MO-791, PP-MO-792, PP-MO-793, PP-MO-811, PP-WE-828

Johne J., PP-MO-603, PP-MO-647

Johns S., PP-TH-632

Johnsen J., AS-TU-058

Johnsen S. P., PP-TH-455, PP-WE-315

Johnsen S., OC-WE-137, OC-WE-140

Johnson A. J., PP-WE-045

Johnson B. H., OC-WE-018,PP-WE-466

Johnson D. J. D., AS-TH-049,OC-WE-081, OC-WE-098

Johnson G. J., PP-MO-314

Johnson S. C., PP-TH-477

Johnston L., PP-MO-449, PP-MO-450, PP-MO-451, PP-WE-437, PP-WE-438

Johnston M., PP-MO-200, PP-TH-522, PP-TH-523, PP-WE-115, PP-WE-520

Joimel U., PP-TH-174

Jones C. I., AS-MO-037, OC-TH-037, OC-TH-093, OC-TH-100, PP-WE-040

Jones K. L., OC-TH-037

Jones L., PP-TH-350, PP-WE-354

Jones M. L., OC-MO-045

Jones N., PP-MO-561, PP-TH-242, PP-WE-240

Jones R., PP-MO-199

Jones S., PP-MO-026

Jong G., OC-TH-119, PC-037

Jonhsson H., PP-TH-141

Jonj B. B., PP-MO-147

Jood K., OC-WE-115, PP-MO-343

Joore M., OC-TH-017

Jordanova K., AS-MO-063

Jørgensen L., PP-TH-443

Jørgensen M., AS-MO-008, PP-WE-383

Jörneskog G., OC-TH-079,OC-WE-104

Jorquera J. I., PP-TH-591, PP-WE-575, PP-WE-576

Josefsson E. C., AS-WE-032

Joseph J. E., PP-MO-747, PP-WE-776

Joshi S. S., PP-TH-108

Joshua D., PP-WE-171

Jourde-Chiche N., PP-WE-850

Joutsi-Korhonen L., PP-MO-170

Jovanoska V. V., PC-029, PP-WE-565

Jovanoski I. I. J., PC-029, PP-WE-565

Jover S., PP-WE-665

Jovic M., PP-WE-254

Jozwiak M., PP-TH-128

Jubelirer S. J., PP-MO-661,PP-TH-354

Judd P., PP-TH-629

Jude B., PP-MO-814, PP-MO-815, PP-TH-189, PP-TH-583,PP-WE-762, PP-WE-858

Judge H. M., OC-MO-012, PP-TH-030

Jugder B., PP-TH-029

Juhan Vague I., OC-WE-099

Juhan-Vague I., OC-MO-021,OC-TH-045, PP-TH-309, PP-WE-775

Jukema J. W., PP-WE-346

Jukema W., OC-TH-110

Julian D., OC-MO-017

Julian J. A., PP-MO-515

Julian J., OC-MO-016, OC-MO-017, PP-WE-489

Jun P., PP-MO-691

Jung H., PP-WE-800

Jung S. M., PP-TH-035, PP-TH-036

Jungel A., PP-WE-787

Junqueira D. R. G., PP-MO-698, PP-MO-699

Junqueira P. L., PP-MO-755,PP-TH-542, PP-WE-705

Jünschke A., PP-TH-120

Jurak Begonja A., PP-WE-077

Jurek M., PP-TH-027, PP-WE-801

Jurisic D., PP-WE-369

Jurk K., PP-MO-029, PP-WE-734

Just B., PP-MO-128

Just S., AS-MO-008

Juthier F., PP-MO-814, PP-MO-815

Juutistenaho S., PP-TH-068

K. Klausen N., PP-MO-565

Kaandorp S. P., PP-TH-373

Kaatz S. S., OC-TU-009

Kaatz S., PP-TH-357

Kabrhel C., OC-TU-004, PP-MO-512

Kaci Z., PP-TH-204

Kaczor M., PP-MO-355

Kadar J. G., OC-WE-077, PP-MO-128

Kadar J., PP-WE-633

Kaden T., PP-MO-700, PP-WE-739

Kadioglu A., OC-WE-047

Kadir R. A., AS-MO-026

Kadohira Y., PP-TH-057, PP-WE-278

Kaech A., OC-MO-129

Kagoma P., PP-TH-315

Kahn M. L., AS-TU-038

Kahn S. R., OC-TH-084, PP-TH-315, PP-TH-323, PP-WE-461, PP-WE-462, OC-TU-011, AS-TU-006

Kahr W. H. A., AS-WE-028, OC-TU-028, OC-WE-121, PP-TH-459, PP-TH-463

Kahr W. H., OC-TH-060

Kahraman R., PP-TH-270

AUTHORS INDEX

525

Kaida M., PP-WE-025

Kaider A., AS-MO-003, PP-MO-422

Kaiser W. J., OC-TH-093, PP-TH-014, PP-TH-031, PP-WE-040

Kajiura T., PP-WE-781

Kakkar A. K., OC-WE-004, OC-WE-024, PP-TH-415, PP-TH-430, PP-WE-404, PP-WE-421

Kakkar A., OC-MO-054

Kakkar V. V., AS-WE-059, LB-MO-002, OC-TH-118, OC-WE-139, PP-MO-791, PP-MO-792, PP-MO-793, PP-MO-811, PP-MO-812, PP-MO-817, PP-WE-828, PP-WE-832, PP-WE-833, PP-WE-834

Kakkar V., OC-TU-051, PP-MO-796, PP-WE-836

Kaku S., PP-TH-184

Kala P., PP-WE-804

Kalantar G., PP-WE-855

Kalashnyk O. M., PP-MO-872

Kalathara R., PP-TH-632

Kalia N., AS-WE-033

Kalish Y., AS-TU-058

Kalka C., PP-TH-417, PP-TH-492

Kallel H., PP-TH-297, PP-TH-298, PP-WE-455

Kallel L., PP-TH-298

Kallner A., PP-WE-114

Kalnins J., PP-TH-559

Kalpodimou C., PP-MO-707

Kalus U., PP-MO-240

Kam A. W., PP-TH-225

Kameda S., PP-TH-320

Kamide K., PP-WE-872

Kaminska M., PP-MO-071

Kamisato-Matsumoto C., PP-TH-195, PP-TH-406

Kamocka M., PP-WE-394

Kamp S., OC-TU-033

Kampf L., PP-WE-570

Kämpfert C., PP-TH-656

Kamphuisen P. W., AS-MO-030, OC-MO-042, OC-MO-091, OC-TU-008, OC-WE-014, OC-WE-035, PP-MO-298, PP-MO-597, PP-MO-720, PP-TH-348, PP-TH-356, PP-TH-517, PP-TH-518, PP-WE-548

Kamphuisen P., OC-TH-014,PP-MO-763

Kamps M. P., AS-TU-020

Kanagasabapathy P., PP-TH-683

Kanai S., PP-MO-864

Kanakura Y., PP-MO-080

Kanayama N., OC-TH-111

Kane J. P., AS-WE-010

Kane W. H., PP-TH-261

Kaneko C., PP-MO-704

Kanellopoulou G., PP-MO-679,PP-MO-715

Kang C., PP-WE-810

Kang H., PP-WE-759

Kang J., AS-WE-060

Kang S. Y., PP-WE-595

Kang S., PP-WE-783

Kannan M., PP-MO-638, PP-WE-037

Kannicht C., PP-MO-574, PP-WE-624

Kanse S. M., AS-TH-058, OC-TH-070, OC-TH-110

Kanse S., OC-WE-128

Kansiz E., PP-MO-858

Kanz R., OC-TU-013

Kao C. Y., PP-MO-158

Kapelak B., PP-MO-798

Kapiotis S., PP-WE-200, PP-WE-201

Kaplan C., AS-MO-053, PP-MO-079

Kappas N. C., AS-WE-051

Kappel A., PP-MO-107

Kappelmayer J., PP-MO-009,PP-MO-359, PP-WE-774

Kappert G., PP-MO-377, PP-TH-647, PP-WE-370, PP-WE-669

Kaprinis I., PP-MO-777, PP-MO-778, PP-MO-779

Kapur D., PP-TH-477

Kapustin S. I., PP-TH-313, PP-TH-321, PP-TH-346, PP-WE-361

Kara E., PP-TH-511

Kara M., PP-WE-709

Karabay, PP-TH-511

Karabocuoglu M., PP-MO-440

Karacelik M., PP-TH-511

Karafoulidou A., PP-MO-585,PP-MO-715, PP-TH-609, PP-WE-693, PP-MO-679, PP-TH-467

Karagun B. S., PP-MO-644

Karakas Z., PP-MO-222

Karaman I., PP-MO-683

Karami-Djurabi R., PP-MO-506

Karapetian H., PP-MO-436

Karatas A., PP-MO-222

Karatela R. A., PP-WE-825,PP-WE-826

Karavokiros I., PP-MO-715

Karbovskyy V. L., PP-TH-160

Kardkasam P., PP-MO-354

Karimi M., PC-044, PP-MO-655, PP-TH-534, PP-TH-535, PP-WE-459, PP-WE-518

Karimi N., PP-WE-545

Karimi S., PP-WE-518

Karimipoor M., PP-WE-545

Karlman M., PP-WE-646

Karlsson J., PP-MO-565

Karlsson M., PP-MO-652, PP-WE-206

Karovitch A., PP-MO-460

Karpf D. M., PP-MO-569, PP-MO-570, PP-WE-154

Karpova I. S., PP-MO-873, PP-MO-874

Karst A., PP-MO-162

Kartsios H., PP-MO-305

Karumanchi A., AS-WE-021

Kase M. T., PP-MO-719

Kashanian M., PP-WE-074

AUTHORS INDEX

526

Aut

hors

Inde

x

Kashif M., AS-MO-059, AS-WE-053

Kashiwagi H., PP-MO-080, PP-TH-081

Kashiwakura Y., OC-TH-051,PP-TH-054

Kassab Chahmi D., PP-TH-497

Kassak P., OC-MO-125

Kastelan D., PP-MO-519

Kastelein J. J. P., PP-MO-022

Kasthuri R. S., OC-TH-020

Kasthuri R., OC-TU-017

Kastrikina I., PP-WE-062

Kastrissios H., OC-WE-003

Kaszuba M., PP-WE-884

Katabami K., PP-WE-687

Kataoka H., PP-MO-842, PP-WE-269, PP-WE-271

Katayama N., PP-TH-526

Katayama Y., PP-TH-358

Katerchi A., PP-WE-768

Kato M., PP-WE-269, PP-WE-271

Kato S., OC-WE-008

Katona É., PP-MO-205, PP-MO-228, PP-TH-216, PP-TH-366

Katsamouris A., PP-MO-778

Katsaros K., PP-MO-829

Katsarou O., PP-MO-715, PP-TH-609, PP-WE-693

Katsiki N., PP-MO-777, PP-MO-778

Katsman Y., OC-MO-102

Katsuhiko H., PP-WE-398

Katsutani S., PP-MO-050

Katz B., PP-TH-070

Katzenell S., OC-TU-058

Kaufman R. J., AS-WE-043,OC-WE-062

Kaufmann R., PP-MO-705

Kaufmann V., PP-WE-777

Kauke T., PP-WE-039

Kauling M., PP-MO-476

Kaun C., PP-MO-829

Kaur G., AS-TH-044, PP-MO-078

Kaur J., PP-TH-242, PP-WE-240

Kaushansky K., SA-WE-017

Kauskot A., OC-WE-043

Kautzner J., PP-WE-345

Kavakli K., PP-MO-606, PP-WE-577

Kavanagh G. F., PP-MO-735

Kavanagh M., PP-WE-615

Kavas E., PP-WE-308

Kaveri S. V., OC-MO-064, PP-WE-614

Kaveri S., OC-WE-066, PP-MO-588, PP-TH-619

Kawahara K., PP-MO-884

Kawai T., PP-WE-349

Kawai Y., PP-WE-196

Kawajiri H., PP-TH-194

Kawamura M., PP-MO-201,PP-TH-168, PP-WE-398, PP-WE-400

Kawanami D., OC-TU-042

Kawano Y., PP-WE-872

Kawasaki T., PP-TH-041, PP-TH-042

Kawasugi K., PP-MO-669, PP-WE-420

Kay S., PP-TH-070

Kazanjian S. N., PP-TH-376

Kazantzidou E., PP-MO-302

Kazazian H. H., AS-TU-013

Kazi M., PP-WE-522

Kazlauskas A., AS-TU-038

Kazui M., PP-WE-348

Keane C., OC-WE-047, PP-MO-051

Keane G., PP-WE-685

Kearney E., PP-WE-474

Kearney M. T., OC-TH-055

Kearney-Schwartz A., PP-TH-362

Kearon C., PP-MO-282, PP-MO-310, PP-MO-515, PP-WE-462, SA-TH-003

Kebir A., AS-MO-060

Keegan M. B., PP-WE-430

Keeling D. M., OC-MO-032

Keeling D., PP-TH-540, PP-TH-541, PP-WE-638, PP-WE-716

Keeney S., OC-TU-078, PP-TH-645

Kehrel B. E., PP-MO-029, PP-MO-030, PP-MO-031, PP-TH-574, PP-WE-734

Kehrel B., AS-MO-050

Keil B., PP-TH-611

Kekilli M., PC-003, PP-MO-394

Kekomäki R., AS-TH-010, PP-TH-068

Keleidari B., PP-MO-517

Keller G., PP-WE-082

Keller L., PP-MO-610, PP-MO-831, PP-MO-832, PP-TH-350, PP-WE-089, PP-WE-093

Keller M. K., PP-MO-240, PP-MO-241

Keller P., PP-MO-736, PP-MO-753

Kelley J., AS-WE-009

Kelly I., PP-WE-615

Kelly L. A., PP-WE-373

Kelly N., PP-WE-474

Kemkes - Matthes B., PP-MO-513

Kemkes-Matthes B., OC-WE-077

Kemp B., OC-MO-101

Kempfer A. C., PP-MO-610,PP-MO-831, PP-MO-832, PP-TH-044, PP-TH-350, PP-WE-089, PP-WE-093, PP-WE-094, PP-WE-402

Kempton C. L., PP-MO-587

Kenet G., AS-TU-052, OC-WE-106, OC-WE-117, PP-MO-434, PP-MO-685, PP-WE-036

Kennedy D. R., OC-MO-057

Kennedy M., PP-WE-082, PP-WE-274

Kennedy R., PP-MO-396

Kenny D. J., AS-MO-048

Kenny D., AS-TU-039, OC-TH-095, PP-MO-735, PP-TH-052, PP-TH-053, PP-WE-059

AUTHORS INDEX

527

Kent N., PP-TH-052, PP-WE-059

Kentner T. A., PP-WE-177

Kentouche K., PP-TH-086, PP-TH-087, PP-WE-651

Kerachian M. A., PP-MO-820

Kerbiriou-Nabias D., PP-WE-008

Kercret G., PP-TH-508

Kerdelo S., PP-TH-113

Kerdélo S., PP-MO-112, PP-TH-183

Keresztes Z., PP-MO-851

Kern A., OC-WE-051

Kerrigan S. W., OC-WE-047,PP-MO-051

Kerrigan S., PP-TH-056

Kerschen E. J., PP-MO-880,PP-MO-881

Kershaw G. W., PP-WE-171,PP-WE-547

Kerspern H., PP-TH-291

Kervran D., AS-MO-053

Kessel C., PP-MO-592

Kessler C. M., PP-MO-598, PP-MO-600, PP-WE-601

Kessler P., PP-TH-422

Keßler W., AS-TH-007

Kesteven P., PP-WE-298, PP-WE-372

Key N. S., OC-TU-017, PP-MO-768, PP-TH-262, PP-TH-655, PP-WE-299, PP-WE-785

Key N., OC-TH-020

Khair K., PP-TH-605

Khalafallah A. A., PP-MO-233

Khaled E. A. A., PP-MO-037,PP-TH-506, PP-WE-067

Khalfi K., PP-WE-505

Khalil T., PP-TH-666

Khan A., AS-TH-050

Khan M. I., PP-WE-817

Khan N., PP-WE-382

Khanbhai M., OC-TH-055

Khandoga A. L., PP-MO-008

Khanna S., PP-TH-538

Khare R. K., PP-TH-283, PP-WE-467

Khaterchi A., PP-TH-485, PP-TH-486, PP-WE-490

Khawaji M. M., PP-TH-580

Khazanov N. A., AS-MO-027

Kheirabadi B. S., PP-WE-399

Khizroeva J., PP-WE-265

Khoo L. T., PP-WE-547

Khorana A. A., OC-TU-018,PP-MO-492

Khoury A., PP-WE-281

Kieffer N., PP-WE-013

Kiely D. G., PP-TH-679

Kienast A., PP-WE-453

Kierzek G., PP-MO-514, PP-TH-211

Kijac A. Z., OC-TU-091

Kijlstra A., PP-TH-246

Kiklevich V., PP-MO-754

Kikukawa Y., PP-WE-516

Kile B. T., AS-WE-032, PP-WE-258

Kile B., SA-TH-014

Kilicaslan I., PC-039

Kilicoglu O., PP-WE-568

Kilic-Okman T., PP-TH-221,PP-WE-876

Kilinc E., PP-TH-122

Kilinc Y., PP-MO-644, PP-WE-607

Kim B., PP-WE-069, PP-WE-069

Kim H. C., PP-TH-190

Kim H. J., PP-TH-190

Kim H., PP-MO-213, PP-TH-149, PP-TH-190, PP-TH-504, PP-WE-069, PP-WE-112, PP-WE-496, PP-WE-759

Kim I., PP-WE-027, PP-WE-069

Kim J., OC-WE-059, PP-TH-149, PP-WE-027, PP-WE-027, PP-WE-112, PP-WE-496, PP-WE-783

Kim K., PP-TH-504, PP-WE-112, PP-WE-463

Kim M., PP-TH-504

Kim N., PP-MO-353, PP-TH-294, PP-WE-877

Kim O., PP-MO-353

Kim P. Y., OC-MO-061, OC-MO-095, OC-TU-067

Kim S. N., PP-WE-595

Kim S., OC-MO-043, OC-TH-094, OC-TH-098, OC-WE-052, OC-WE-122, PP-MO-106, PP-TH-011, PP-TH-156, PP-TH-504

Kim T., PP-WE-844

Kim Y., AS-TU-034, PP-MO-301, PP-TH-519, PP-WE-419, PP-WE-496, PP-WE-844

Kimura Y., PP-WE-793

Kinasewitz G. T., OC-TH-112

Kindler S., PP-TH-254

King S. M., PP-WE-071, PP-WE-218

Kini R. M., OC-TH-105

Kini R., PP-MO-172

Kink-Eiband M., PP-MO-347,PP-WE-181, PP-WE-390

Kinoshita A., PP-MO-439

Kinoshita T., PP-TH-015

Kirby D., OC-WE-114

Kirby R., PP-MO-370

Kirchgesner T., PP-MO-416

Kirchheiner J., PP-WE-183

Kirchhofer D., AS-MO-044

Kirchmaier C. M., PP-MO-179,PP-MO-746, PP-TH-662, PP-WE-763

Kirienko A. I., PP-TH-513, PP-WE-526

Kirwan G., PP-WE-813

Kiseleva E. V., PP-MO-882

Kishi K., PP-MO-119

Kishta S. A., PP-MO-037

Kiskinis D., PP-MO-777, PP-MO-778, PP-MO-779

Kiss L. N., PP-MO-378

Kiss R., PP-MO-772

Kissova J., PP-TH-612, PP-TH-613

Kitabata H., PP-MO-429

AUTHORS INDEX

528

Aut

hors

Inde

x

Kitamura K., PP-MO-111

Kitazawa T., PP-MO-123, PP-MO-127

Kitchen D. P., PP-MO-115, PP-MO-116, PP-MO-320, PP-WE-716

Kitchen S., PP-MO-110, PP-MO-115, PP-MO-116, PP-MO-199, PP-MO-320, PP-MO-534, PP-TH-664, PP-WE-144, PP-WE-716

Kitjakornpa S., PP-MO-681

Kitonyi G. W., PP-MO-452

Kitpoka P., PP-MO-681

Kittikalayawong Y., PP-MO-446

Kitzmüller E., PP-MO-436

Kiyak A., PP-MO-073

Kjær A., OC-MO-040

Kjær B., PP-MO-118

Kjærgaard J., OC-MO-040

Kjaergaard K., PP-MO-565,PP-WE-572

Kjalke M., PP-MO-558, PP-MO-565, PP-MO-569, PP-MO-570, PP-MO-580, PP-TH-594, PP-WE-401, PP-WE-581, PP-WE-582, PP-WE-589, PP-WE-591

Klaassen R., AS-WE-003, OC-WE-132, PP-WE-553

Klajnbard A., PP-WE-383

Klamroth R., OC-WE-077, PP-MO-357, PP-MO-591, PP-MO-746, PP-TH-578, PP-TH-587, PP-TH-588, PP-WE-593, PP-WE-594, PP-WE-620

Klare M. O. G., PC-024

Klausen N. K., PP-MO-580

Kleber F., OC-MO-053

Klein E., PP-MO-313

Klein Gebbinck J. W. T. M.,OC-TU-083

Kleine Budde I., PP-MO-571

Kleinjan A., PP-MO-763

Kleinow M. E., PP-WE-479

Kleinridders A., OC-WE-076

Kleinschnitz C., AS-TH-040,OC-WE-040

Klekowski N. T., OC-TU-007,PP-TH-505

Klenkova N. A., PP-TH-346,PP-WE-361

Klich K., PP-MO-592

Kliem P., PP-TH-254

Kline J. A., OC-TU-007, PP-MO-470, PP-MO-512, PP-TH-505, PP-TH-510, PP-WE-284, PP-WE-323, PP-WE-414

Klingebiel T., PP-TH-162, PP-WE-434

Klintman J., OC-TH-050, PP-WE-611

Klinzing S., PP-WE-684

Kloczko J., PP-MO-868, PP-WE-491, PP-WE-492

Klok F. A., AS-TU-010, OC-MO-037, PP-MO-506, PP-MO-507, PP-WE-341, PP-WE-512, PP-WE-513

Klompas A., PP-WE-238

Klose G., PP-MO-141

Kløw N. E., AS-MO-007

Kluft C., OC-MO-090

Kluin-Nelemans H. C., OC-WE-098, PP-TH-515, PP-TH-516

Kluin-Nelemans H., AS-MO-002

Kluin-Nelemans J. C., PP-TH-332

Klukowska A., PP-MO-163,PP-MO-608, PP-WE-722

Klungel O. H., OC-WE-035

Knaggs K., PP-WE-298, PP-WE-372

Knapp S., PP-TH-148

Knetsch M. L., PL-TU-003

Knight S., PP-MO-272, PP-TH-599

Knipe L., OC-MO-067

Knirsch W., OC-TU-061

Knobl P., PP-MO-609

Knöbl P., OC-WE-011, PP-MO-622

Knoche J., PP-MO-066

Knoebl P. N., PP-TH-077

Knoebl P., AS-WE-014, OC-WE-058, PP-MO-666, PP-WE-604

Knoefler R., AS-TH-055, PP-TH-671

Knol H. M., PP-MO-677

Knoll C., PP-MO-596, PP-TH-265, PP-WE-613

Knottnerus I. L. H., OC-TU-085, PP-WE-219

Knowlton W., PP-TH-586

Knudsen T., PP-TH-116, PP-WE-401

Ko B. S., PP-TH-405

Kobalava Z., PP-TH-223

Kobayashi A., PP-WE-418

Kobayashi E., OC-TH-051

Kobayashi K., PP-MO-842

Kobayashi T., PP-TH-411, PP-WE-793

Kobilyanskaya V. A., PP-TH-268, PP-TH-313

Koch G. G., PP-WE-299

Kodali L., PP-TH-180

Koder S., OC-MO-027, OC-TU-015, PP-TH-077, PP-TH-273

Koehler-Vajta K., PP-WE-578

Koekman C. A., PP-MO-007,PP-WE-024

Koeleman B. P. C., OC-MO-024

Koenderman J. S., OC-WE-091

Koene H. R., PP-TH-373

Koenen R. R., PP-WE-892

Koenig W., OC-TU-034

Koestenberger M., PP-TH-448

Kofiady I., PP-WE-335

Koga Y., PP-TH-041, PP-TH-042

Koh C. Y., OC-TH-105, PP-MO-172

Koh Y., PP-TH-504

Kohler H. P., OC-WE-034

Kohler H., PP-TH-671

Köhler H., OC-MO-126

Koide H., PP-TH-226

Koide T., PP-TH-194

AUTHORS INDEX

529

Koike T., PP-MO-842, PP-WE-269, PP-WE-271

Kojima H., PP-MO-080, PP-TH-071

Kojima T., PP-MO-138, PP-WE-671

Kok M. G. M., OC-MO-091

Kokabee L., PP-WE-545

Kokame K., AS-MO-012, OC-WE-008, PP-MO-093, PP-MO-393, PP-WE-090

Kokoviadou K., PP-WE-484

Kokubo Y., PP-MO-726, PP-TH-320

Kolaitis N. I., PP-MO-657, PP-WE-681

Kolck U. W., PP-MO-253

Kolesnikova I. N., PP-MO-212

Kolev K., OC-MO-075, PP-MO-851, PP-WE-229

Koliakos G., PP-MO-257, PP-TH-006

Koliou P., PP-MO-657

Kolset S. O., PP-WE-487

Kolte D., PP-TH-133

Komada Y., PP-WE-032

Komarek A., PP-TH-422

Komari N., PP-TH-315

Komarov A. L., PP-WE-335

Komatsu N., OC-TH-088

Kombrinck K. W., AS-TU-045

Komine-Kobayashi M., PP-TH-358

Komisarenko S. V., PP-MO-212

Komissarova S. M., PP-WE-337

Komitopoulou A., PP-TH-597, PP-WE-440

Komorowicz E., PP-MO-851

Komorowski P., PP-WE-879

Komrska V., PP-TH-530

Komukai K., PP-MO-429

Komwilaisak P., PP-TH-459

Kondakova O. A., PP-MO-182

Kondkar A., OC-WE-045

Kondo K., PP-MO-439

Kondratieva L. V., PP-TH-277

Kondratyeva L. V., PP-MO-268

Konetschny C., PP-MO-150

Kongtim P., PP-MO-406

Königs C., PP-MO-592

Konings J., PP-TH-131

Konishi N., PP-MO-201, PP-TH-168, PP-WE-398, PP-WE-400

Konkle B., AS-TH-033

Kono T., PP-MO-516, PP-TH-071, PP-TH-319

Konopatskaya O., OC-WE-123

Konrad S., AS-TU-005

Konstantinides S., OC-TH-014

Konstantinova E. E., PP-WE-863, PP-WE-864

Koo J., PP-MO-211

Koo Y., PP-WE-027

Kooiman J., PP-MO-506, PP-WE-513

Koolwijk P., PP-MO-847

Kopferschmitt J., PP-MO-416

Kopylov K. G., PP-MO-553,PP-WE-561

Korantzis I., PP-MO-305, PP-WE-484

Koren A., PP-TH-084

Koren G., OC-TH-084

Koretsune Y., PP-WE-196

Korfi K., PP-TH-244

Korhonen T. K., OC-TH-064

Korkmaz G., PP-MO-537, PP-MO-538

Kornecki E., OC-TH-092

Körner I., PP-WE-733

Kornø H. T., PC-042

Korporaal S. J. A., OC-WE-046

Kósa K., PP-TH-366

Kosar A., PP-MO-394

Kosch M., PP-WE-593

Koschinsky M. L., OC-WE-109,PP-WE-241

Koskinen S., AS-TH-010

Kost O., PC-005

Kostál M., PP-WE-524

Koster S., AS-WE-028

Kostovska S., PC-014, PP-WE-426

Kotev S., PP-MO-771, PP-WE-797

Kotha J., PP-MO-054

Kotsi P. A., PP-MO-679, PP-TH-467

Kotsi P., PP-MO-715, PP-TH-609, PP-WE-693

Kottke-Marchant K., PP-WE-101

Kotula-Horowitz K., PP-WE-883, PP-WE-884

Kotz R., PP-TH-690

Kotze R. C. M., PP-WE-228

Kouchakji B., PP-MO-514

Koudstaal P. J., OC-MO-078

Koumarianou A., PP-WE-693

Kouraba A., PP-TH-609, PP-WE-693

Kouramba A., PP-MO-679

Koutsas C., PP-WE-129

Ková D., PP-WE-524

Kovac M., PP-TH-296, PP-WE-368, PP-WE-379

Kovacs E., PP-TH-063, PP-WE-075

Kovács G., PP-MO-359

Kovacs M. J., PP-MO-403, PP-WE-462, OC-TU-011

Kovacs M., PP-WE-517

Kowalska M. A., AS-TH-008,AS-WE-027, OC-WE-151

Koyama T., PP-MO-546, PP-MO-827, PP-WE-501

Kozak M., PP-MO-350

Kozasa T., PP-WE-004

Kozuma Y., PP-TH-071

Kragelund L., PP-TH-577

Kraiss L. W., AS-WE-028

Krajaèiæ - Karas G., PP-TH-258

Krajina A., PP-TH-438

Krajnc O., PP-MO-453

Kramaric A., OC-TH-013

Kramer M. H. H., PP-TH-517

AUTHORS INDEX

530

Aut

hors

Inde

x

Kramer M. S., OC-TH-084

Kramkowski K., PP-MO-234,PP-TH-239

Kramor R., PP-TH-219

Kramp B. K., PP-WE-892

Kranenburg O., PP-WE-216

Kranz A., PP-MO-422

Krapiec F., PP-WE-190

Krasnobrizha I., PP-TH-395

Krasnobrysha I., PP-MO-146

Kraszula £., PP-TH-099

Krauel K., AS-TH-007, OC-TH-023

Kraus J., OC-WE-138

Kraus P. S., OC-TH-074

Krause M., PP-MO-179, PP-MO-662, PP-MO-746, PP-TH-662, PP-WE-763

Krause S., PP-TH-086

Kraut E. H., OC-WE-009

Kravos A., PP-MO-350

Kravtsov D. V., OC-MO-103,OC-MO-104

Krcova V., PC-022, PP-MO-689, PP-WE-142, PP-WE-273

Krechetova A. V., PP-MO-218,PP-MO-668, PP-WE-170

Krekeler S., PP-MO-584, PP-TH-651

Krell S., OC-TH-101

Kremastinos D., PP-TH-338

Kremer Hovinga J. A., PP-TH-079, PP-TH-080

Kremer Hovinga J., PP-MO-714

Krenek P., PP-TH-433, PP-TH-437

Krenn T., PP-TH-614, PP-WE-648

Kretschmar O., OC-TU-061,PP-TH-446

Kretz C. A., OC-TH-106

Kreuz W., PP-MO-130, PP-MO-592, PP-TH-162, PP-TH-646, PP-WE-434, PP-WE-594

Krezel C., PP-MO-175, PP-TH-423

Kriegel I., PP-TH-497

Krishna R., PP-MO-199

Krishnamoorthi R., PP-MO-675

Krishnan S., PP-WE-894

Krishnan U., OC-WE-126

Krishnaswamy S., AS-TH-008,AS-TH-047, AS-TH-050, OC-WE-080

Krisinger M. J., OC-MO-096,OC-TU-096

Kristensen A. T., PP-TH-116,PP-WE-401

Kristensen C., PP-WE-109,PP-WE-572

Kristensen S. D., PP-WE-788

Kristensen S. R., PP-MO-134,PP-TH-140, PP-TH-455, PP-WE-315

Kristoffersen U. S., OC-MO-040

Kriukov A., PP-WE-574

Kroft L. J. M., AS-TU-010, PP-MO-507, PP-WE-512

Krogh T. N., PP-MO-118, PP-MO-575

Kroh H. K., AS-TH-050, OC-WE-082

Krohne G., AS-WE-029, AS-WE-030

Kroiss R., PP-WE-380

Kroiss S., OC-TU-061, PP-TH-446

Kroll H., PP-MO-705, PP-MO-706, PP-WE-714

Kronmal R., OC-TH-117

Kronthaler U., AS-TH-040, OC-WE-120, PP-TH-130, PP-TH-561, PP-WE-652

Kroon-Batenburg L. M. J., PP-WE-216

Kropacheva E. S., PP-TH-431

Krougliak V., PP-TH-200

Kruchinsky N. G., PP-WE-820

Kruchynsky N. G., PC-025,PC-026, PP-TH-023, PP-WE-046

Krudysz-Amblo J., AS-TU-023,PP-WE-152

Krueger T., OC-TU-053

Kruempel A., PP-TH-647

Kruger T., AS-WE-045

Krugluger W., PP-MO-141

Kruip M. J. H. A., PP-TH-518,PP-WE-548

Kruip M. J., OC-MO-078

Kruit A., OC-MO-133, PP-MO-781

Kruithof E. K. O., OC-TU-037,OC-WE-110

Krumpel A., OC-WE-094

Krümpel A., PP-WE-453

Krupinski J., AS-MO-065, PP-WE-821, PP-WE-822

Krusche C., PP-TH-086

Krych M., PP-MO-694

Krystofiak E. S., PP-MO-039

Ku D. N., AS-MO-040, PP-MO-722

Kubicek C., PP-MO-357

Kubisz P., PP-TH-305, PP-TH-306, PP-TH-598, PP-WE-220

Kubo K., PP-MO-201, PP-TH-168, PP-WE-398, PP-WE-400

Kubota N., PP-WE-687

Kuca P., PP-TH-279, PP-TH-280, PP-WE-433

Kucher N., PP-MO-318, PP-TH-417, PP-TH-492, PP-WE-329

Kuderer N. M., OC-TU-018, PP-MO-492

Kudryk B., PP-MO-211

Kueter T. J., PP-TH-097

Kufaas-Braekkan S., OC-TU-005, OC-TU-006, PP-WE-304, PP-WE-305

Kuhelj R., PP-TH-589, PP-WE-624

Kuhle S., OC-TU-066, PP-MO-454, PP-TH-531, PP-WE-450

Kuhn J. G., PP-TH-567

Kuhn T., PP-MO-563

Kuijpers M. J. E., AS-TU-029,AS-TU-037, PP-TH-012

AUTHORS INDEX

531

Kuint J., PP-MO-434, PP-MO-685

Kuiper J., OC-WE-046

Kuivenhoven J. A., OC-WE-046

Kulharia M., PP-WE-157

Kulkarni B., PP-TH-295

Kulkarni V., OC-WE-052, PP-TH-156

Kulman J. D., PP-TH-092

Kulsum S., PP-WE-014

Kumanogoh A., PP-WE-030

Kumanongoh A., AS-TU-028

Kumar K., PP-MO-817

Kumar S. K., PP-MO-487

Kumar S., OC-TH-105, PP-WE-327

Kunapuli S. P., OC-TH-040,OC-TH-098, OC-WE-030, OC-WE-122, PP-MO-028, PP-TH-011, PP-TH-022, PP-WE-888, PP-WE-896

Kunapuli S. S. P. K., PP-TH-040

Kunapuli S., OC-TH-094, PP-MO-106, PP-WE-012

Kung C., PP-MO-548, PP-TH-200

Kunishima S., PP-MO-084, PP-TH-081

Kunitada S., PP-MO-198

Kuo S. F., PP-TH-634

Kuo S., PP-MO-877, PP-TH-123

Kuperman A., PC-053

Kupesiz A., PP-MO-606

Kurata A., PP-MO-864

Kurihara A., PP-MO-096, PP-WE-348

Kuritsch I., PP-MO-347, PP-WE-181, PP-WE-390

Kurnik K., OC-WE-117, PP-MO-607, PP-TH-533, PP-TH-587, PP-WE-453

Kurosaki H., OC-TH-088

Kurt M., PC-003, PP-MO-394

Kurt O. K., PP-MO-394

Kurth A. A., PP-MO-167, PP-WE-204, PP-WE-205

Kurth A., PP-TH-169, PP-TH-170

Kurtoglu M., PP-WE-197

Kurz J. C., PP-WE-168, PP-WE-569

Kushimoto S., PP-MO-669

Kusnierova M., PP-TH-422

Kusumoto E., PP-WE-605

Kutlar A., PP-MO-768, PP-TH-655

Kutlu S. T., PP-TH-511

Kuttler B., OC-TU-026

Kuwahara G., PP-WE-411

Kuwatjanakul P., PP-MO-446

Kuziej J., PP-MO-396, PP-WE-262

Kuzmanovic M., PP-TH-269

Kuznetsov Y. V., PP-MO-182

Kwak B. R., AS-TU-018

Kwon H., PP-WE-783

Kwon J. H., PP-MO-576

Kwon S., PP-WE-543

Kwong L. M., PP-WE-478

Kwong L., PP-MO-247, PP-WE-473

Kyndt X., OC-WE-017

Kyriakidis D. A., PP-WE-131

Kyrle P. A., AS-MO-004, PP-MO-422, PP-TH-690, PP-WE-309

Kyselovic J., PP-TH-433, PP-TH-437

L. Nørby P., PP-MO-565

La Farina F., PP-MO-379, PP-MO-380

La Greca A., PP-TH-316

La Heij E. C., PP-TH-246

La Marca S., PP-WE-625

La Rosa L., OC-TH-075

Labalette M., PP-TH-508

Labar B., PP-MO-630

Labarere J., PP-MO-315

Labarthe B., PP-MO-060, PP-MO-061

Labat V., PP-MO-664

Labelle A., OC-TH-085, OC-TH-086

Labro S., OC-WE-085

Labrouche S., PP-MO-195, PP-MO-196, PP-TH-432, PP-WE-673

Labruyere C., PP-MO-783

Lacatusu A., PP-MO-532, PP-WE-549, PP-WE-552

Lacerda S. H., PP-TH-016

Lacerda-Alves J., PP-WE-098

Lacolley P., PP-TH-362

Lacreta F., PP-MO-407

Lacroix R., AS-WE-050, PP-MO-486, PP-WE-785

Lacroix-Desmazes S., OC-MO-064, OC-WE-066, PP-MO-588, PP-TH-172, PP-TH-619, PP-WE-614

Lacut K., PP-MO-500, PP-TH-483, PP-WE-508, PP-MO-508, PP-TH-291, PP-WE-186

Laczkovics C., PP-TH-317, PP-WE-663

Ladislau R., PP-WE-552

Ladurner G., OC-WE-138

Laemmle B., PP-MO-711, PP-TH-692, PP-WE-211, PP-WE-717

Laferriere N., AS-WE-003, PP-WE-553

Laffan M. A., OC-MO-065, PP-MO-231, PP-MO-397

Laffan M., PP-WE-635

Lages G. F. G., PP-MO-349

Lages G. G., PP-MO-333

Lages P., OC-WE-077, PP-MO-662

Laggner A. N., PP-TH-676

Laguna P., PP-MO-163, PP-MO-608

Lahav J., PP-MO-749, PP-WE-010

Lahood B. D., PP-MO-113

Lairon D., OC-TU-087

Lak M., PP-MO-552

Lakhani P., PP-WE-012

Lakoski S. G., OC-WE-103

Lally C., PP-TH-324, PP-TH-325, PP-TH-326, PP-TH-327

AUTHORS INDEX

532

Aut

hors

Inde

x

Lalouschek W., AS-WE-010

Lam S., PP-WE-004

Lambert C., PP-MO-220, PP-TH-566, PP-WE-532

Lambert M. P., AS-WE-027,OC-WE-151

Lambert T., OC-TU-073, PP-MO-591, PP-TH-578, PP-TH-593, PP-TH-623

Lambrechts D., PL-TU-006

Lame M. W., PP-MO-389

Lami D., PP-MO-217, PP-TH-474, PP-WE-745

Lämmle B., PP-TH-079, PP-TH-080

Lamy E., AS-WE-050

Lance M. D., PP-WE-017

Lancé M. D., PP-MO-670

Lancellotti S., AS-MO-013, PP-MO-328, PP-TH-085, PP-WE-647

Landau M., OC-MO-105, OC-TH-042, PP-TH-075

Landford C., OC-TU-029

Landgraf H., PP-MO-357

Landini F., PP-MO-285, PP-WE-403

Landolfi R., OC-MO-094, PP-MO-328, PP-WE-647

Landowska J., PP-WE-474

Lands L. T., PP-WE-103

Lane D. A., AS-TU-019, AS-WE-012, PP-MO-089, PP-MO-091, PP-TH-089, PP-TH-090

Lane G., PP-MO-449, PP-MO-450, PP-MO-451, PP-WE-437, PP-WE-438

Lang J., AS-MO-003

Lang L. A., AS-WE-009

Lang S., AS-TU-030, OC-WE-121, PP-WE-060

Lang W., OC-WE-120, PP-TH-561

Langer C., PP-WE-528

Langer F., PP-MO-014, PP-TH-482, PP-WE-001, PP-WE-485

Langford C., OC-WE-126

Langlet P., PP-MO-224

Langlet S., PP-WE-619

Lanier R., PP-WE-414

Lanir N., PP-MO-850

Lanning L., PP-WE-192, PP-WE-649

Lannoy N., PP-WE-532

Lanois I., AS-MO-058

Lanza F., AS-TU-047, OC-TH-033, OC-TH-034, OC-TH-035, OC-TU-049, OC-WE-150, PP-MO-033, PP-MO-416, PP-TH-010, PP-WE-891

Lanzi P., AS-MO-028

Lap P., PP-TH-260

Lapadatescu M., OC-TH-061

Lapalud P., PP-TH-172

Lapecorella M., AS-TU-032,PP-MO-525, PP-MO-654, PP-TH-694

Lapini I., PP-MO-801, PP-WE-745

Laporte S., OC-MO-050, OC-MO-053, OC-WE-002, PP-TH-076, PP-TH-426

Laranjeira C., PP-WE-374

Larina L. E., PP-TH-454

Laros-Vangorkom B., PP-WE-555

Larsen A., PP-MO-433

Larsen K. S., AS-TH-049

Larsen L. F., PP-MO-580, PP-WE-589

Larsen O. H., PP-WE-702

Larsen S. B., PP-WE-788

Larsen S., OC-TH-061

Larson J., PP-WE-292

Larusch G., OC-TH-056, OC-MO-128

Lasne D., OC-TH-022, PP-MO-077, PP-MO-748

Lassen M. R., LB-MO-005, OC-WE-004, PP-MO-405, PP-TH-415, PP-TH-430, PP-WE-404, PP-WE-421, PP-WE-454

Lass-Flörl C., PP-MO-031

Lassila R., PP-MO-170

Latal B., OC-TU-061

Latella M., PP-MO-481

Lathrop M., OC-MO-021, PP-TH-309

Latib A., PP-MO-775

Latif L., PP-WE-045

Latinne D., PP-MO-220

Latorre A., PP-MO-027, PP-WE-096

Latour C. C. L., PP-MO-594

Lattanzio S., AS-TU-049, PP-MO-015, PP-MO-016, PP-WE-738

Lau C., PP-MO-667

Lau J. T. Y., PP-WE-893

Laudisi A., PP-TH-494

Laufs U., PP-MO-809

Laughlin S., PP-TH-463

Launay J., PP-WE-408

Laurén A., OC-WE-055

Laurent M., PP-TH-174

Lauricella A., PP-WE-210

Laurie A., PP-MO-631

Laurie J., PP-TH-615

Lauritzen B., PP-MO-564

Lauro R., PP-MO-016

Lauw M. N., PP-TH-373

Lauwereys M., AS-TH-024

Lauzon M., PP-WE-115

Laverty K., AS-MO-018, AS-MO-020, PP-TH-631

Lavigne Lissalde G., OC-WE-099

Lavigne-Lissalde G., AS-TH-054, PP-MO-527, PP-TH-172, PP-TH-578

Lawal L., PP-MO-771, PP-TH-026, PP-WE-794, PP-WE-797

Lawrence D. A., PP-MO-244,PP-TH-252

Lawrence D., SA-WE-002

Lawrie A. S., OC-TU-056, PP-MO-325, PP-MO-759, PP-WE-125

Laws H., PP-MO-595, PP-TH-575, PP-TH-646

AUTHORS INDEX

533

Lawson K. A., PP-TH-310, PP-TH-457

Layman R., OC-MO-031

Lazarski E. A., PP-MO-502

Lazarus A., SA-TU-005

Lazo-Langner A., PP-MO-403,PP-WE-517

Lazzari M. A., PP-MO-038, PP-MO-274, PP-MO-613, PP-MO-831, PP-MO-832, PP-TH-044, PP-TH-100, PP-TH-350, PP-WE-089, PP-WE-093, PP-WE-094, PP-WE-145, PP-WE-146, PP-WE-354, PP-WE-402, PP-WE-498

Lazzari M., PC-047, PP-MO-204, PP-MO-610

Lazzeri C., PP-MO-013

Lazzerini G., PP-MO-828

Le Beller C., PP-TH-464

Le Bonniec B. F., PP-MO-237

Le Bonniec B., PP-MO-391,PP-MO-837

Le Cam-Duchez V., PP-TH-144

Le Cessie S., AS-MO-005

Le D. T., OC-MO-025

Le Duc-Pennec A., PP-MO-508, PP-WE-510

Le Flem L., PP-WE-073

Le Gal G., OC-MO-038, OC-MO-041, OC-TH-073, PP-MO-500, PP-MO-505, PP-TH-292, PP-TH-483, PP-TH-489, PP-TH-524, PP-WE-508, PP-WE-510, OC-MO-087, OC-TH-012, OC-TU-011, PP-MO-499, PP-TH-508, PP-TH-518, PP-MO-508

Le Grand B., AS-TH-023

Le Guillou J., PP-TH-307

Le Guludec D., PP-MO-786

Le J., PP-WE-887

Le Moigne E., PP-TH-483

Lê P., PP-MO-441, PP-TH-666

Le Querrec A., OC-TH-082, AS-WE-025

Le Sache F., PP-MO-391

Le Tourneau T., PP-MO-815,PP-WE-858

Leal S., OC-WE-045

Lebel B., OC-TU-022

Leblebisatan G., PP-MO-644,PP-WE-607

Lebra E., PP-MO-112, PP-TH-235

Lebret M., PP-MO-074

Lebuisson A., PP-TH-307

Lecam-Duchez V., PP-TH-174

Lecchi A., AS-WE-020

Lecher B., OC-TH-059

Lechner D., PP-MO-666, PP-TH-690

Lechner K., PP-WE-621

Lecompte T., OC-MO-029, PP-MO-402, PP-TH-362, PP-TH-394, PP-TH-693, PP-WE-133, PP-WE-700

Lecumberri R. R., PP-TH-308

Lecumberri R., PP-MO-472,PP-TH-675, PP-WE-141

Lee A. C. W., PP-TH-441

Lee A. Y., OC-MO-016, OC-MO-017, PP-TH-489

Lee B., PP-WE-783

Lee C., PP-TH-266

Lee D., PP-WE-030, PP-WE-069

Lee E. K., AS-TU-028

Lee H., OC-WE-044, PP-TH-190, PP-WE-844

Lee J., PP-MO-353, PP-MO-731, PP-TH-294, PP-TH-504, PP-WE-069, PP-WE-242, PP-WE-496, PP-WE-877

Lee K., PP-MO-712, PP-WE-496

Lee L. P., PP-WE-059

Lee M., OC-MO-086, PP-TH-504, PP-WE-543

Lee N., PP-TH-504, PP-WE-595

Lee S., PP-MO-213, PP-MO-353, PP-MO-493, PP-TH-519, PP-WE-573

Lee T. K., PP-TH-109

Lee T. S., PP-MO-330

Lee T., PP-MO-301

Lee Y., PP-WE-759

Leebeek F. W. G., OC-MO-042,OC-MO-133, OC-TH-029, PP-MO-633, PP-MO-781, PP-TH-314, PP-WE-346, PP-WE-355

Leebeek F. W., PP-MO-224

Leenders L., PP-TH-666

Leenders P., AS-WE-058, PP-TH-181

Lees M., OC-WE-005, PP-MO-468, PP-WE-472, PP-WE-473

Lefrançois A., PP-WE-642

Lefrandt J. D., PP-WE-554

Legal G., PP-TH-497

Legall C., OC-TH-018

Legge L., PP-MO-435

Leggo J., OC-WE-134

Legnani C. C. L., PP-MO-372

Legnani C., AS-TH-029, OC-MO-028, OC-TH-003, OC-TH-006, PP-MO-290, PP-MO-291, PP-MO-351, PP-MO-503, PP-MO-504, PP-TH-282, PP-WE-351, PP-WE-359, PP-WE-509, PP-WE-715

Leguet P., PP-WE-425

Lehmann-Kopydlowska A.,PP-MO-216

Lehmeyer S., PP-MO-501

Lei Y., PP-MO-691

Leiber F., OC-TU-052

Leibovitz E., PP-MO-338

Leibson C. L., AS-TH-003, PP-MO-284

Leikauf M., OC-MO-129

Lein V. C., PP-WE-498

Leis L. A., PP-MO-314

Leissinger C., PP-MO-625, PP-WE-597

Leitges M., OC-WE-123

Leitner J. M., PP-TH-676

Leitner J., PP-MO-718

Leizorovicz A., PP-WE-410

Leker R., PP-WE-847

Lely R., PP-TH-517

Lemesle G., PP-WE-858

AUTHORS INDEX

534

Aut

hors

Inde

x

Leng B., PP-TH-191

Lenicek Krleza J., PP-WE-435,PP-WE-442

Lenk H., PP-TH-569, PP-WE-594

Lennemann K., PP-MO-693

Lennon D., PL-TU-005

Lenormand B., PP-TH-345

Lent M. P., PP-TH-419

Lenti M., PP-WE-823

Lenting P. J., AS-WE-037, OC-TU-072, OC-WE-042, PP-MO-091, PP-TH-642, PP-WE-339, PP-WE-355, AS-MO-016

Lenting P., PP-WE-056, PP-WE-887

Leo A., PP-WE-789

Leon A., PP-WE-665

Léon C., OC-MO-008, OC-WE-150

Leone B., PP-MO-380

Leone M., OC-WE-087, PP-TH-094

Leontyev D., OC-MO-102

Leporace A., PP-MO-210

Leppaniemi A. K., OC-TH-069

Lereun C., OC-WE-005

Lerolle N., PP-MO-090

Leroyer C., PP-MO-310, PP-WE-510, PP-MO-508

Lesavre N., OC-TU-087

Leschnik B., OC-WE-138, PP-TH-448, PP-WE-439

Leslie B. A., OC-WE-079

Lessiani G., AS-TH-029, AS-TU-049

Lester W. A., OC-MO-131

Lester W., PP-TH-330

Letellier T., PP-WE-008

Lethagen S., OC-MO-036, PP-WE-589, PP-WE-590, PP-WE-591

Letley L., OC-TU-002

Letourneau S., PP-MO-529

Levashov M. Y., PP-TH-219

Levels J. H. M., PP-MO-262

Levenkova N., AS-MO-027

Levesque H., PP-MO-609, PP-TH-144, PP-TH-172, PP-WE-604, PP-WE-483, OC-WE-058

Levi M. M., OC-TH-062, OC-TH-066, OC-WE-144, PP-MO-190, PP-MO-191

Levi M., SA-TH-012, OC-TH-031, PP-MO-710, PP-TH-388, PP-WE-407

Levine M. N., PP-WE-489

Levine M., OC-MO-016, OC-MO-017

Levine R. L., OC-TH-104

Levis J. E., AS-MO-032

Levy C., PP-WE-412

Levy J. H., PP-MO-776, PP-WE-187

Levy M., OC-WE-089

Levy P. J., PP-WE-854

Levy R. A., PP-MO-483

Levy-Shraga Y., PP-MO-685

Lewandrowski U., AS-MO-038

Lewis D. A., OC-MO-002

Lewis H., PP-WE-111

Leymarie V., AS-TH-043

Leyte A., PP-TH-436, PP-WE-778, PP-WE-779

Leytin V., PP-MO-065

Li C., AS-TU-030, PP-TH-230,PP-WE-060

Li D., SA-WE-011, AS-WE-031

Li G. G. L., PP-MO-159

Li H., PP-TH-174, PP-WE-674

Li J., PP-WE-640

Li L., OC-WE-121, PP-TH-112

Li N., PP-MO-105, PP-WE-818,PP-WE-890, PP-TH-146

Li R. C. H., PP-TH-441

Li R., OC-TU-043, OC-TU-046,PP-TH-045

Li S., PP-TH-252

Li T., PP-WE-536, PP-WE-540

Li Thiao Te V., PP-MO-125

Li W., AS-MO-025, AS-TU-025,OC-MO-107, OC-WE-074, PP-WE-674

Li X., PP-TH-147, PP-TH-147,PP-WE-005

Li Y. G., PP-MO-733

Li Z., PP-TH-400

Liakopulu M., PP-WE-129

Liang H. H. P., OC-MO-056

Liang N., OC-MO-022

Liang X., PP-TH-261

Liang Y., PP-MO-642

Liao C., PP-MO-877

Liao M., PP-MO-665

Liao W., OC-WE-068

Liaw P. C. Y., AS-MO-022

Liaw P. C., PP-MO-490, PP-WE-245

Liaw W., PP-MO-665

Libby P., AS-WE-057

Liberman C., OC-WE-090

Libraire J., PP-MO-237

Librè L., AS-WE-007

Licari V., PP-TH-453

Licastro G., PC-015

Lichman I., PP-MO-338

Licht C., OC-TU-028

Liebaers I., PP-MO-173, PP-MO-174, PP-WE-188

Liebe V., PP-MO-238

Lieberman J., PP-MO-248

Liebing U., PP-TH-561

Liebman H., OC-TU-017, PP-WE-489

Liesner R., PP-TH-088, PP-TH-605

Lievens D., AS-MO-047

Lighezan D., PP-MO-532, PP-WE-552

Lijfering W. M., OC-WE-100,PP-MO-286, PP-TH-329, PP-TH-332, PP-WE-554

Lijfering W., AS-MO-002, OC-MO-082, PP-WE-326

Lijnen H. R., OC-TH-065, PP-MO-219, PP-TH-039, PP-MO-819, OC-WE-122

AUTHORS INDEX

535

Lillicrap D., AS-MO-017, AS-MO-018, AS-MO-020, AS-TH-053, AS-TU-012, AS-TU-013, AS-TU-014, AS-WE-003, OC-TH-053, OC-TH-085, OC-TH-086, OC-TU-068, OC-TU-076, OC-WE-133, OC-WE-134, OC-WE-135, PP-MO-639, PP-TH-628, PP-TH-631, PP-TH-639, PP-WE-553, SA-MO-009

Lillo-Le Louet A., PP-TH-464

Lim Y., PP-WE-844

Lima A. S., PP-TH-672, PP-TH-673, PP-TH-674, PP-WE-689

Lima E. M., PP-WE-092

Lima L. G., PP-TH-499

Lima L. M., PP-MO-390, PP-WE-226, PP-WE-812

Lima L., PP-WE-374

Limaye S., PP-WE-676

Li-Mcleod J. M., PP-TH-571,PP-WE-537, PP-WE-538

Limonov E., PP-WE-091

Lin B. D., PP-TH-634

Lin C. N., PP-MO-158

Lin C., PP-MO-070, PP-WE-079

Lin E., PP-TH-064

Lin H. Y., PP-TH-634

Lin H., PP-WE-207

Lin J. C., PP-MO-156

Lin J. H., PP-WE-241

Lin J. S., PP-TH-634

Lin J., OC-WE-018, PP-MO-465, PP-MO-466, PP-TH-123, PP-WE-465, PP-WE-661

Lin K., PP-MO-840

Lin L., PP-WE-225

Lin S. R., PP-MO-158

Lin S. W., PP-MO-158

Lin S., OC-WE-009, OC-WE-130, PP-MO-877, PP-TH-401, PP-TH-401

Linares A., PP-MO-160

Lincoln B., PP-WE-059

Lincz L. F., PP-WE-118

Lindahl T. L., PP-MO-021, PP-MO-133, PP-MO-430, PP-TH-018, PP-WE-014, PP-WE-334

Lindblad B., OC-TH-078, PP-WE-328

Linde T., PP-WE-190

Linden J., OC-TU-027

Linder H., OC-TU-081

Lindgren P., PP-MO-606

Lindhoff-Last E., OC-WE-077,PP-MO-295, PP-MO-307, PP-MO-501, PP-MO-705, PP-MO-706, PP-MO-730, PP-WE-376, PP-WE-714, PP-WE-792

Lindner J. R., OC-MO-123

Lindsey D. A., PP-WE-232

Lindstrom K., PP-WE-749, PP-WE-750

Lindvall K., PP-WE-570

Ling M., PP-TH-092

Linhardt R. J., PP-MO-165

Link A., PP-MO-238

Linnemann B., PP-MO-295,PP-MO-730, PP-WE-376, PP-WE-792

Lins P., OC-TH-079, OC-WE-104

Liotier J., OC-MO-053

Lip G. Y. H., PP-WE-172, PP-WE-345

Lipets E. N., PP-WE-253

Lippi G., OC-MO-096, OC-MO-097, PP-MO-540, PP-MO-541, PP-WE-140

Lisboa T. A., PP-MO-387

Lischetzki G. R., PP-MO-544

Lisman T., OC-TU-001, OC-WE-016, PP-MO-126, PP-MO-352, PP-WE-771

Lison S., PP-WE-039

Lissalde-Lavigne G., OC-TH-081

Lissens W., PP-MO-173, PP-MO-174, PP-WE-188

Litinas E., PP-MO-072, PP-MO-139, PP-MO-140, PP-MO-396, PP-MO-857, PP-TH-145, PP-TH-201,

PP-TH-391, PP-WE-166, PP-WE-262, PP-WE-385

Littenberg B., AS-MO-033

Litvinov R. I., AS-MO-039, OC-WE-146, PP-TH-214

Litzow M. R., PP-MO-487

Liu C. Y., PP-MO-330

Liu C., PP-MO-010

Liu F., OC-MO-070

Liu J., AS-TH-013, PP-WE-857,AS-TH-046

Liu K., AS-WE-060

Liu M., OC-WE-068

Liu P., OC-WE-068

Liu R. D., PP-TH-484

Liu S., PP-TH-392

Liu T., OC-WE-057, OC-WE-059

Liu W., PP-WE-711

Liu X. X. L., PP-MO-159

Liu X., PP-WE-394

Liu Y., PP-TH-663

Liu Z., PP-TH-067, PP-TH-073,PP-WE-083

Ljatifi A., PP-TH-557, PP-WE-769

Ljung R., OC-WE-119, PP-WE-542, PP-WE-570

Llanto L., PP-TH-180

Llobet D., PP-WE-175

Llop E., OC-TU-082

Lloyd J. V., PP-MO-148

Lloyd J., PP-TH-626, PP-WE-544, PP-WE-662

Lloyd N. S., PP-WE-429

Llugaliu B., PP-MO-584, PP-TH-644, PP-TH-651

Lo Coco L., AS-TH-030, PP-TH-527

Lo H., PP-WE-845

Lo Manto G., PP-TH-282

Lobo J., PP-MO-299

Lochowski R., PP-TH-537

Lockwood C., PP-WE-382

Lodder J., OC-TU-085, PP-WE-219

AUTHORS INDEX

536

Aut

hors

Inde

x

Lodigiani C., AS-WE-007

Loffredo L., PP-WE-105, PP-WE-753

Loffredo M., PP-WE-325

Löfgren E., PP-MO-021

Lofthus C. M., AS-TH-004

Lohmann C., OC-TU-052

Lojik M., PP-TH-438

Lokajczyk A., OC-TH-046, OC-TH-048, OC-TU-032

Lokar L., PP-MO-453, PP-WE-308

Lokhorst H. M., AS-TH-038

Loktionova S. A., PP-MO-856

Lollar P., AS-TU-016

Lomakin N. V., PP-WE-743

Lombardi G., PP-WE-321

Lombardi M., PP-MO-294, PP-WE-598

Lombardi R., PP-MO-092, AS-WE-011

Lombardo D., PP-MO-485, PP-MO-486

Long C., PP-MO-070

Longo S. S., PP-TH-452

Longstaff C., OC-MO-075, OC-MO-116, PP-WE-229

Longstreth W. T., AS-WE-009

Loof A., OC-TH-052, PP-TH-260

Lopatina E., OC-MO-036

Lopes L., PP-MO-034

Lopes R., PP-WE-374

Lopez E., PP-MO-656

Lopez Fernandez F., PP-MO-637

López Fernández F., PP-MO-601

Lopez J. A., PP-MO-002, PP-TH-468, PP-WE-023, PP-WE-056, PP-WE-887, AS-MO-011, PP-TH-045, PP-TH-092

Lopez M. F., PP-MO-590

López M., PP-TH-596

Lopez S., PP-WE-209

López S., PP-TH-289

Lopez-Alonso A., PP-TH-053

Lopez-Fernàndez F M., PP-MO-591

López-Fernandez M., PP-MO-566

Lopez-Fernández M., PP-MO-560

López-Fernández M., PP-MO-585

Lopez-Miranda J., OC-TU-087

Lopez-Sagaseta J., PP-MO-178

Lopez-Vilchez I., PP-MO-053,PP-TH-047, PP-WE-237

Lorand-Metze I., PP-MO-870

Lord S. T., OC-MO-117, OC-WE-145

Lorenzet R., PP-MO-202, PP-MO-481, PP-TH-048, PP-TH-248, PP-TH-249, PP-WE-246, PP-WE-502

Loreth R. M., PP-MO-141

Loriot M. A., PP-TH-429

Lorut C., AS-TU-009

Losche W., PP-TH-086, PP-TH-087, PP-WE-684

Lospalluti M., PC-015

Lothrop - Jr C. D., OC-TH-087

Lotta L. A., OC-WE-132, AS-WE-011

Loubele S. T. B. G., PP-TH-181

Louedec L., PP-MO-786

Loughney A. D., PP-WE-372

Louis P., PP-TH-508

Loukidhs K., PP-MO-305, PP-WE-484

Louzada M. L., PP-WE-500

Lova P., PP-MO-018

Lovegrove J. A., PP-MO-032

Lovegrove J., OC-TU-087

Lovis C., PP-MO-318

Lowe G. D. O., OC-WE-116

Lowe G., OC-TH-080, OC-WE-033, PP-WE-353

Lowe R., PP-MO-674

Lowenberg E. C., PP-MO-710,PP-TH-388, PP-WE-407

Loyau S., AS-TU-024, PP-MO-786

Lozano M. L., AS-MO-054

Lozano M., AS-TH-052, PP-MO-055, PP-MO-732, PP-TH-096, PP-WE-033, PP-WE-764

Lozier J. N., AS-MO-010, PP-TH-225

Lu B., OC-TU-084, PP-TH-224

Lu G., OC-TH-107

Lu J., AS-TU-027, PP-MO-131,PP-WE-153

Lu S., OC-WE-068

Lu T., PP-MO-307

Lu X., OC-TU-051, PP-MO-796,PP-MO-817, PP-WE-836

Lu Y., PP-TH-562, PP-TH-563,PP-TH-564, PP-TH-565, PP-WE-770, PP-MO-646, PP-MO-531

Luan P., OC-TH-107

Lubetsky A., PP-MO-434

Lubetzky A., PP-WE-036

Lubkowski J., PP-WE-065

Lucarini L., PP-MO-818

Lucas R. C., PP-WE-156

Lucas S. B., PP-WE-727

Lucas-Junior F., PP-MO-063

Lucchesi A., PP-MO-654, PP-TH-694

Lucchesi B. R., PP-MO-400

Luchian M., PP-WE-737

Luciani M., PC-030

Lucking A. J., PP-TH-212

Luddington R., PP-MO-289,PP-MO-551, PP-TH-240, PP-WE-133, PP-WE-556

Ludovici G., PP-MO-380, PP-WE-824

Ludwig A., OC-MO-110

Ludwig R. J., PP-MO-705, PP-MO-706

Luetjohann D., PP-WE-159

Lugovskaya N. E., PP-MO-212

Lugovskoy E. V., PP-MO-212

Lühn S., PP-TH-192, PP-TH-193

AUTHORS INDEX

537

Luke K., AS-WE-003, PP-WE-553

Luke M. M., AS-WE-010

Luken B. M., AS-TU-019, AS-WE-012, PP-MO-089

Luksza E., PP-WE-492

Lunacsek O. E., PP-MO-283

Lunardi J., PP-MO-748

Lund P., PP-TH-428

Lunde K., PP-TH-427

Lundin B., OC-MO-034

Lunghi B., OC-TH-028

Luo J., PP-MO-733

Luo M. P., PP-TH-570

Luo R., PP-WE-179

Luo Y., OC-MO-021

Lupu C., AS-MO-045, OC-TH-065, OC-TH-112, OC-WE-028

Lupu F., AS-MO-045, OC-TH-065, OC-TH-112, OC-WE-028

Luque A., AS-MO-065, PP-MO-526

Lüscher T. F., OC-TU-052, PP-WE-329

Lusher J. M., PP-TH-180

Lussana F., PP-TH-348

Lütjohann D., PP-MO-809

Luu H., PP-MO-602, PP-WE-574

Luxembourg B., OC-WE-077,PP-MO-295, PP-MO-307, PP-MO-501, PP-WE-376, PP-WE-714

Luzak B., PP-MO-097

Lv B., OC-WE-027

Lwaleed B. A., PP-MO-871,PP-TH-217, PP-TH-218, PP-WE-869

Lyapina L. A., PC-012

Lyman G. H., OC-TU-018, PP-MO-492

Lyutova L. V., PP-WE-422

M. Petersen J., PP-MO-565

Ma A. C., OC-TU-067

Ma D. D. F., PP-WE-776

Ma D., PP-WE-731

Ma H., PP-WE-728

Ma J. Y., PP-TH-405

Ma T., OC-TH-119, PC-037

Ma Y. Q., OC-MO-048

Ma Y. T., PP-TH-112

Ma Z., PP-TH-093, PP-WE-088

Maek G., AS-TH-028

Maas C., AS-TH-038, AS-TU-017, OC-MO-112, PP-WE-216

Maas Enriquez M., PP-TH-584

Maayan-Metzger A., PP-MO-685

Macaulay I. C., AS-MO-037,AS-WE-035

Maccallum P. K., OC-TU-002,PP-TH-476, PP-WE-377

Macchi S., PP-MO-523

Maccraith B. D., PP-WE-059

Macdonald V., PP-MO-708

Macey M. G., PP-WE-377

Mach E. S., PP-MO-268

Mach F., AS-TH-032, OC-MO-132, PP-WE-744

Machado A. B. C., PP-MO-311

Machado T. F. G. S., PP-MO-725

Machado T. M., PP-TH-157

Machherndl-Spandl S., PP-MO-666

Machin S. J., OC-MO-138, PP-MO-325, PP-MO-708, PP-MO-759, PP-TH-088, PP-TH-263, PP-WE-125

Machlus K. R., PP-TH-119, PP-WE-299

Machovich R., PP-MO-851

Mack G., PP-WE-451

Mackie I. J., OC-MO-138, PP-MO-325, PP-MO-759, PP-TH-088, PP-WE-125

Mackinnon B., PP-MO-515

Mackman N., SA-TU-009, AS-MO-042, AS-MO-043, AS-MO-044, AS-TU-044, OC-TH-020, OC-TU-017, PL-TU-003, PP-MO-768, PP-TH-119, PP-TH-502, PP-TH-677, PP-TH-678, PP-TH-691

Maclean R. M., PP-MO-199,PP-TH-664

Maclean R. N., PP-WE-766

Maclean R., PP-MO-110

Macleod A. R., OC-TH-108

Madan B., PP-MO-166, PP-WE-623, PP-WE-635

Maddox B. D., PP-MO-048

Madeira C. L., OC-MO-031

Madeira H. S., PP-MO-871, PP-TH-218, PP-WE-869

Mäder G., PP-TH-079

Madhani M., PP-MO-680, PP-TH-476

Madoiwa S., OC-TH-051, PP-MO-669, PP-TH-054

Madon J., OC-MO-129

Madonna R., OC-WE-071, PP-MO-828, PP-WE-856

Madronio E. B., PP-WE-428

Maeda Y., PP-TH-015

Maegdefessel L., PP-TH-440,PP-WE-190

Maegele M., OC-TH-067

Maekawa M., PP-TH-057, PP-WE-278

Maes P., PP-MO-619

Maffei F. H. A., PP-MO-311

Magari Y., PP-TH-233

Mager J., PP-WE-777

Maggini N., PP-MO-743, PP-MO-818, PP-TH-352, PP-TH-353, PP-WE-745, PP-WE-746, PP-WE-747, PP-WE-748

Magic Z., PP-WE-368

Magnenat S., OC-TH-033, OC-TH-034

Maguire P. B., AS-WE-035

Maguy A., PP-MO-060, PP-MO-061

Mah C., OC-TH-049

Mahaldar A., PP-MO-757

Mahan C. E., OC-TH-016

Mahdi F., OC-MO-128, PP-TH-133

Mahe I., PP-TH-429, PP-WE-483

AUTHORS INDEX

538

Aut

hors

Inde

x

Mahé I., PP-WE-412

Mahfouz R., PP-MO-135, PP-MO-273

Mahjoub S., PP-TH-297, PP-TH-298, PP-WE-455

Mahla E., PP-TH-101, PP-WE-757, PP-WE-799

Mahlangu J. N., PP-MO-471,PP-MO-471

Mahmoodi B. K., AS-MO-002,OC-MO-001, OC-MO-082

Mahmoodi B., PP-WE-326

Maier H., PP-WE-519

Mainwaring J., PP-TH-615

Maiorana A., PP-MO-635

Mairuhu R., PP-WE-106

Maitra A., OC-WE-139, PP-MO-791, PP-MO-792, PP-MO-793

Maître B., PP-WE-891

Maj R., OC-WE-128

Majado M., PP-MO-536

Majcen Vivod B., PP-WE-308

Majdalani M. M., PP-WE-686

Majdalani M., PP-TH-456

Majeed A., AS-TU-034

Majeed H. H. M., PP-WE-500

Majeed H., OC-TH-012

Makatsaria A. A. D., PP-WE-265

Makatsaria A. D., PP-MO-378,PP-TH-367

Makatsaria A., PP-MO-474, PP-WE-381

Makatsariya A. D., PC-017, PP-MO-360, PP-MO-361, PP-TH-278, PP-TH-378, PP-TH-379, PP-TH-380

Makatsarya A. D., PP-TH-669

Mäkelburg A. B. U., PP-MO-286

Makhoul B., PP-MO-313

Makinde Y. O., PP-MO-278,PP-WE-330

Makita K., PP-MO-138

Makkonen P., PP-WE-276

Makris M. P., PP-MO-257, PP-TH-006, PP-WE-129

Makris M., PP-MO-075, PP-MO-076, PP-MO-199, PP-TH-664, PP-TH-679, PP-WE-252, PP-WE-302, PP-WE-766

Makris P. E., PP-MO-257, PP-TH-006, PP-WE-129, PP-WE-131

Makris P., PP-WE-252

Malan E., PP-MO-713

Malara A., PP-MO-067

Malato A., AS-TH-030, OC-MO-092, PP-MO-308, PP-TH-527

Malaver E., PP-WE-042

Malcorra J. J., PP-MO-590

Male C., PP-MO-436, PP-MO-561

Malecot J., PP-TH-291

Malek G., PP-TH-279, PP-TH-280, PP-WE-433

Maleki A., PP-MO-214

Malendowicz-Portala L., PP-WE-213

Malfliet J. J., PP-MO-224, PP-WE-228

Malhotra J. D., AS-WE-043

Malhotra P., PP-MO-324

Malincarne L., OC-WE-087

Malinin N., PL-TU-005

Mallela J., PP-MO-885

Mallett S., PP-TH-242, PP-WE-240

Mallik A., PP-WE-718

Mallouk N., PP-MO-783

Mallouli F., PP-WE-455

Malloy M. J., AS-WE-010

Malmstrom J., PP-WE-585,PP-WE-586

Maloney S. F., AS-TU-028, AS-TU-038, OC-WE-049

Maloney S., PP-WE-030

Malovichko M. V., PP-WE-158

Maly’ J. J. M., PP-TH-369

Maly J., PP-WE-068

Maly’ J., PP-WE-524

Maly’ R. R. M., PP-TH-369

Maly R., PP-TH-438, PP-WE-068

Mameli A., PP-MO-266, PP-MO-267

Mammo L., PP-MO-425, PP-TH-465, PP-WE-285

Manai Z., PP-TH-297

Manakov M. Y., PP-MO-182

Manarini S., AS-TH-059, AS-TU-042

Manavifar L., PP-WE-632

Manco-Johnson M. J., PP-MO-596, PP-TH-265, PP-WE-255, PP-WE-613

Mancuso G., AS-TU-032, OC-TU-075, PP-MO-750, PP-WE-567, PP-WE-599

Mancuso M. E., AS-WE-005,OC-TU-075, PP-WE-555

Mancuso M., AS-WE-020, OC-TU-074, PP-MO-542, PP-WE-567

Mandalà M., PP-MO-476

Mandelbrot L., OC-TH-082, AS-WE-025

Mandic V., PP-WE-379

Manfredi A. A., OC-WE-127,PP-MO-056

Manfredi E., OC-TH-011

Manga P., PP-TH-370, PP-TH-371

Mangieri E., PP-WE-105

Mangin P., AS-TU-047, OC-WE-122, PP-TH-010, PP-WE-891

Mangolini F. G., OC-WE-023

Mani A., OC-TH-118, PP-MO-812

Mani H., PP-MO-730, PP-WE-792

Manina G., OC-TU-024

Manion C. V., PP-WE-267

Manithody C., OC-TU-093

Manjunath G. B., PP-MO-808,PP-TH-237, PP-WE-110

Manly D. A., OC-TU-017, PP-TH-119

Manly D., AS-MO-044, PP-TH-677, PP-TH-678, PP-TH-691

AUTHORS INDEX

539

Mann K. G., AS-TU-023, OC-MO-003, OC-MO-006, OC-TU-003, PP-TH-154, PP-TH-196, PP-WE-152, PP-WE-358, PP-WE-362

Mann K., PP-MO-244

Manner D., OC-TU-062, OC-WE-117, PP-MO-607

Mannhalter C., AS-WE-010,PP-MO-322, PP-MO-821, PP-WE-621

Manning R. A., PP-MO-397

Manning S. L., OC-WE-039,PP-TH-398

Mannini L., OC-WE-031, OC-WE-102, PP-MO-013, PP-MO-340, PP-MO-341, PP-MO-802, PP-MO-803, PP-MO-804, PP-TH-353

Manns J. M., OC-WE-030

Manns K., OC-MO-138, PP-TH-088

Mannucci P. M., AS-TU-033,OC-MO-034, OC-MO-081, PP-MO-321, PP-MO-648, PP-MO-673, PP-TH-300, PP-TH-301, PP-TH-670, PP-WE-132, PP-WE-230, PP-WE-339, PP-WE-625, PP-WE-657

Mannucci P., AS-WE-005, AS-WE-020, OC-MO-035, OC-TU-074, OC-TU-075, PP-MO-375, PP-MO-542, PP-MO-716, PP-TH-085, PP-TH-558, PP-WE-691, AS-WE-011

Manolopoulos P., PP-WE-045

Manotti C., PP-MO-461

Mansmann U., PP-MO-660

Mansour A. H., PP-MO-488

Mansour W., PP-TH-084

Mansouri Taleghani B., OC-WE-077

Mansouritorghabeh H., PP-MO-552, PP-WE-632

Mantovani L. G., OC-MO-034

Mantovani L., OC-WE-119, PP-WE-542

Manuel M., PP-WE-360

Manuel R., OC-MO-061

Manwani D., PP-MO-180

Manyak S., PP-TH-231

Manzato F., OC-TH-028

Manzino A., PP-MO-641

Mao G., AS-TH-044, PP-MO-078

Mao Y., PP-MO-106, PP-WE-896

Maraèiè I., PP-WE-308

Marathe D. D., PP-WE-893

Maraveyas A., PP-MO-479, PP-WE-503

Marbet G. A., PP-TH-199

Marcato P. D., PP-MO-145

March L., AS-TH-017

Marchena Yglesias P., PP-TH-299

Marcher C., AS-MO-055

Marchese P., OC-TU-044

Marchesi M., PP-WE-688

Marchesini E., OC-MO-035,PP-WE-688

Marchetti G., OC-TH-028

Marchetti M., AS-TU-048, AS-TU-050, AS-WE-058, PP-MO-476, PP-MO-482, PP-MO-867, PP-WE-499

Marchetti P., PP-WE-858

Marchick M. R., PP-MO-512,PP-WE-323

Marchie T. T., PC-009

Marchioli R., OC-MO-094

Marchiori A., PP-TH-303

Marco P., PP-MO-609, PP-WE-604

Marcone S., PP-TH-048

Marconi M., PP-WE-791

Marcoux L., PP-MO-611

Marcucci M., AS-TH-005, OC-MO-035, OC-TH-002, OC-TH-004, PP-MO-282, PP-TH-412, PP-WE-286, PP-WE-529

Marcucci R., AS-TH-034, OC-MO-010, OC-TH-047, OC-WE-031, OC-WE-032, OC-WE-102, PP-MO-013, PP-MO-217, PP-MO-303, PP-MO-304, PP-MO-339, PP-MO-340, PP-MO-341, PP-MO-743, PP-MO-801,

PP-TH-341, PP-TH-353, PP-WE-002, PP-WE-003, PP-WE-747, PP-WE-748

Marcus M. A. E., PP-WE-017

Marcus M. A., PP-MO-670

Mardaraz C., PP-TH-316

Marder V. J., PP-TH-231, PP-TH-232

Maréchaux S., PP-MO-815

Marek G., PP-WE-107

Marenzi G., OC-TU-025

Marés P., OC-TH-081

Marfisi R., OC-MO-094

Margaglione M., AS-WE-005,OC-TU-075, PP-MO-822, PP-WE-366, PP-WE-367, OC-TU-035, AS-WE-023, PP-MO-372

Margeli A., OC-TH-044

Margue C., PP-WE-013

Mari D., AS-WE-007

Maria Annichino-Bizzacchi J.,PP-WE-066

Mariani G., PP-MO-654, PP-TH-694, PP-WE-658

Mariani M., AS-WE-011

Marie J., PP-WE-855

Mariette X., PP-WE-787

Marin C., OC-TU-087

Marín F., OC-TH-027, OC-TH-120, PP-MO-732

Marin S., PP-WE-737

Marinaccio C., PP-TH-453

Marinaki A., PP-MO-715

Maringhini A., PC-015

Marino P., PP-MO-616

Marino R., PP-TH-573

Marinova M., PP-TH-397, PP-WE-159

Markakis K., PP-MO-715, PP-TH-609, PP-WE-693, PP-MO-679, PP-TH-467

Markart P., AS-TH-037

Marks M., PP-MO-460

Marmur J. D., OC-TH-092

Maroney S. A., AS-MO-024

Marongiu F., OC-MO-028, PP-MO-266, PP-MO-267

AUTHORS INDEX

540

Aut

hors

Inde

x

Marosi A., PP-WE-774

Marosi C., PP-MO-322

Marotta H., OC-WE-088

Marquart J. A., PP-MO-262

Marques D., PP-WE-730

Marqués M., PP-MO-472

Marques-Verdier A., PC-021

Marquès-Verdier A., PC-013

Marrero C., PP-WE-665

Marret E., PP-MO-477, PP-MO-478

Marro M., PP-WE-022

Marschall T., OC-TH-023

Marsden K., PP-MO-724

Marsden P. A., AS-TU-056

Marsh J. J., OC-MO-022

Marsh M. S., OC-MO-088, OC-MO-089

Marshall D., PP-TH-449

Martageix C., AS-MO-053

Martelli N., AS-TH-059

Marti D., PP-MO-299

Marti E., PP-MO-413

Martí E., PP-MO-323

Martin E. J., PP-TH-567, PP-TH-682

Martin J., OC-TU-002, PP-MO-421

Martín J., PP-TH-290

Martin K. J., AS-WE-018, PP-WE-782

Martin M., PP-TH-059, PP-WE-765

Martin Toutain I., PP-WE-333

Martin V., OC-MO-099, PP-WE-019

Martineau J., PP-TH-315

Martineau N., PP-WE-619

Martinelli I., OC-MO-081, PP-MO-321, PP-TH-300, PP-TH-301, PP-WE-132

Martinelli N., OC-TH-028, OC-TH-030, PP-MO-342, PP-TH-347

Martinelli P., PP-WE-367

Martinez A., PP-WE-768

Martínez Á., PP-WE-243

Martínez C., AS-MO-054, AS-TH-052, OC-TU-082, PP-MO-055, PP-MO-134, PP-MO-732, PP-TH-096, PP-TH-247, PP-WE-033, PP-WE-141, PP-WE-764

Martinez De Lizarrondo S.,OC-MO-130

Martinez I., OC-TH-005, OC-WE-017

Martinez M. A., PP-WE-371

Martinez M., PP-TH-606

Martinez P., PP-TH-060, PP-TH-060

Martinez S., PP-WE-699

Martinez Trabal J. L., PP-TH-376

Martinez-Colomer J., PP-WE-415

Martinez-Gonzalez J., LB-MO-002, OC-MO-130, PP-WE-178, PP-WE-415

Martínez-Martínez I., OC-TU-080, OC-TU-082, OC-WE-107, PP-MO-134, PP-MO-144, PP-TH-247, PP-TH-287, PP-WE-141

Martinez-Saguer I., PP-MO-130, PP-TH-162, PP-WE-434

Martinez-Sales V., PP-TH-363

Martínez-Sales V., PP-WE-885

Martínez-Sánchez E., PP-MO-323, PP-TH-285

Martinho P., PP-WE-730

Martini F., PP-MO-379, PP-TH-494, PP-WE-824

Martini G., PP-TH-301

Martini W. Z., PP-TH-687, PP-WE-399

Martino L., OC-TH-018

Martinod E., PP-MO-723

Martinoli J., PP-WE-198

Martins N., PP-WE-730

Martins P., PP-MO-387

Martin-Salces M., PC-048, PP-TH-603, PP-TH-604, PP-WE-560

Martins-Filho O. A., PP-MO-063

Martinuzzo M. E., PP-MO-275,PP-TH-333, PP-TH-681

Martorana A., PP-MO-634

Martorell M., PP-MO-528, PP-WE-761

Martorell T., PP-MO-254

Martret Redrado X., PP-TH-299

Maruff P., OC-WE-129

Maruyama I., PP-MO-884

Marx G., PP-TH-086, PP-WE-684

Marx I., OC-WE-042, PP-MO-395, PP-TH-642

Marx P. F., OC-TH-064, PP-MO-221, PP-WE-336

Marzac C., PP-WE-855

Marzec U. M., PP-WE-097

Marzolo M., PP-WE-338

Maseri A., OC-WE-127, PP-MO-775

Mason K. D., AS-WE-032

Masood S., PP-TH-137, PP-TH-138, PP-TH-142

Massardo T., OC-WE-086, OC-WE-090, PP-MO-860

Massberg S., PP-MO-005

Massey G., PP-MO-596, PP-WE-613

Massicotte M. P., OC-TU-066,PP-MO-454, PP-MO-455, PP-MO-456, PP-TH-531, PP-WE-450, PP-WE-451, PP-WE-452

Massicotte M., PP-MO-435

Massicotte P., PP-WE-238

Masson F., PP-TH-432

Massons J., PP-WE-234

Mast A. E., AS-MO-024

Masuda Y., PP-MO-252

Masurat S., PP-MO-603

Matafonov A., AS-TH-039, OC-MO-104

Mateo J., PP-MO-413, PP-WE-175

Materazzi M., PP-WE-688

Matero D., PP-TH-408

Matevosyan K., PP-MO-757

AUTHORS INDEX

541

Matheron J., PP-MO-862

Mathias M. C., PP-TH-605

Mathias M., PP-TH-551

Mathiesen E., OC-TU-005, OC-TU-006, OC-WE-137, OC-WE-140, PP-MO-813, PP-WE-304, PP-WE-305

Matijevic N., PP-MO-767, PP-WE-819

Matisic D., PP-WE-275

Matos R., PP-MO-667

Matsubara Y., PP-TH-072, PP-WE-015, PP-WE-031, PP-WE-349

Matsuda J., PP-MO-864, PP-TH-051

Matsuda K., PP-WE-400

Matsuda S., PP-MO-111, PP-MO-123

Matsui H., AS-TU-012, AS-TU-014, OC-TH-085, OC-TH-086

Matsui T., OC-TH-088, OC-TU-041

Matsumoto A., PP-WE-501

Matsumoto K., PP-WE-015

Matsumoto M., OC-WE-008,PP-MO-717, PP-WE-196

Matsumoto S., OC-TH-088,OC-TU-041

Matsumoto T., PP-TH-526, PP-MO-497

Matsumura K., PP-TH-689

Matsuo M., PP-MO-704

Matsuo T., PP-MO-704

Matsushima H., PP-MO-704

Matsushita T., PP-TH-592, PP-WE-606, PP-WE-671

Matsuura E., PP-MO-842

Matta K. L., PP-WE-893

Matta M. A. P., PP-WE-535

Matter C. M., OC-TU-052

Mattew L. G., PP-TH-275

Matthews A., OC-MO-001

Matthews S., PP-WE-547

Matthijsen R. A., PP-TH-181

Mattle H. P., OC-WE-034

Mattoscio D., AS-TU-049, PP-TH-082

Matus V., OC-WE-026, PP-MO-064, PP-TH-024, PP-TH-043, PP-WE-057, PP-WE-121, PP-WE-654

Matyja-Bednarczyk A., PP-MO-270, PP-MO-271

Matysiak M., PP-MO-608

Matyskova M., PP-TH-612, PP-TH-613

Maude R. J., PP-MO-710

Mauer A. C., AS-MO-027

Maufus M., PP-MO-499, PP-MO-500

Mauge L., OC-TU-090, OC-WE-089

Maugeri N., OC-WE-127, PP-MO-056

Maurer G., PP-MO-829

Maurer M. C., PP-MO-250, PP-WE-156, PP-WE-158

Maurissen L. F., OC-MO-005

Maurizi F., PP-WE-527

Mauser-Bunschoten E. P., PP-MO-571, PP-MO-633

Mavri A., OC-TH-013, PP-MO-404, PP-TH-418

Mavrogiorgos N., PP-TH-064

Max J., PP-MO-402, PP-TH-362

May F., OC-TH-039

May J. A., OC-MO-100, PP-WE-755

Mayanglambam A., PP-MO-028

Mayer B., AS-MO-055

Mayer G., AS-TH-048, PP-WE-180

Mayne P., PP-TH-034

Mazgajska-Barczyk K., PP-WE-491

Mazharian A., AS-WE-033, PP-WE-076

Mazoyer E., PP-MO-723, OC-WE-099

Mazur M., PP-TH-337

Mazurov A. V., PP-MO-856

Mazzarelli L., PP-WE-367

Mazzolai L., PP-TH-492

Mazzotta C., PP-MO-654

Mazzucato M., PP-TH-008, PP-WE-018

Mazzucconi G., AS-TU-032

Mazzucconi M., AS-TU-033,PP-MO-210, PP-MO-287, PP-MO-542

Mbemba E., PP-TH-485, PP-TH-486

Mbemba M., PP-WE-490

Mcalindon M., PP-WE-766

Mcallister E., PP-TH-201

Mcardle W. L., OC-TU-034

Mcarthur J., PP-TH-310, PP-TH-457

Mcbride E., PP-MO-686

Mccall M., PP-MO-738

Mccallum P., PP-MO-680

Mccarty O. J. T., PP-TH-037

Mccarty O. J., AS-WE-044

Mccarty O., OC-MO-123

Mcclintock R. A., OC-TH-096

Mcclung W. G., PP-TH-435

Mcclure L. A., OC-WE-103

Mccool K. H., PP-MO-463

Mccool K., PP-MO-308

Mccorkell S., PP-MO-562

Mccourt S., PP-WE-372

Mccrae K. R., OC-TU-042

Mcdonald H., OC-MO-051, OC-TU-020, OC-WE-005, PP-MO-468

Mcdonald V., OC-MO-138

Mceachron T., PP-TH-502

Mcewan P. A., OC-MO-103,OC-TU-043, PP-TH-045

Mcewen B., PP-MO-411

Mcewen N., PP-WE-520

Mcfarland R., PP-MO-300

Mcgarrigle S. A., PP-TH-034

Mcgeehan E., PP-MO-396

Mcginness K., PP-WE-569

Mcglasson D. L., PP-MO-102,PP-MO-103, PP-WE-235

Mcgrath J., PP-MO-200, PP-MO-494

Mcinerney M., PP-WE-474

AUTHORS INDEX

542

Aut

hors

Inde

x

Mcjunkin B., PP-MO-661

Mckinley S., PP-MO-410

Mckinnon T. A. J., OC-MO-065,PP-MO-231

Mclaren G. D., PP-TH-424

Mclean K., OC-WE-057, OC-WE-059

Mclean M. A., PP-WE-119

Mcleod A., PP-TH-315

Mclimont M., AS-WE-003, PP-WE-553

Mcmahon C., PP-WE-615

Mcmanus A., OC-TH-076

Mcmichael M., PP-TH-255

Mcmillan-Ward E. M., PP-TH-032

Mcmonagle J., OC-TU-087

Mcmurray M., AS-TU-014

Mcnamara H., OC-TH-084

Mcnamee R. A., PP-WE-071,PP-WE-218

Mcrae S. J., PP-TH-188, PP-WE-427

Mcrae S., OC-TU-010, PP-TH-626, PP-WE-544

Mcsorley A., PP-WE-522, PP-WE-523

Mcvey J. H., OC-TH-043, OC-WE-067, PP-WE-150, PP-WE-151, PP-WE-848, PP-WE-849

Md. Afandi F., PP-MO-636

Mead J. R., PP-WE-662

Meade G. R., PP-WE-059

Meade G., PP-TH-052

Mecawi A. S., PP-TH-178

Mechurová A., PP-WE-378

Meddeb B., AS-TU-002, PP-MO-649

Medina P., PP-MO-192, PP-MO-193

Meeks S. L., PP-MO-587

Meena A., PP-MO-208, PP-WE-327

Meens J., PP-TH-631

Megens R., PP-TH-104

Mehrvar A., PP-TH-124

Mehta H., PP-WE-071

Mehta Z., OC-MO-009

Meier N., OC-WE-034

Meijer A. B., OC-TU-083, OC-WE-084

Meijer K., PP-MO-633, PP-MO-677, PP-WE-419, PP-WE-554

Meijer P., OC-MO-134, PP-MO-168

Meijers J. C. M., AS-TU-017,AS-TU-035, OC-MO-030, OC-TH-064, OC-TU-059, OC-WE-016, PP-MO-221, PP-MO-262, PP-MO-293, PP-MO-298, PP-MO-352, PP-MO-710, PP-TH-139, PP-TH-388, PP-WE-336, PP-WE-407

Meijers J. C., OC-TH-031

Meiring M., PP-TH-637, PP-WE-650, PP-WE-726

Meissner M., PP-TH-279, PP-TH-280

Meixner S. C., OC-MO-118

Melado M., PP-WE-234

Melamed E., OC-TU-057

Melazzini F., AS-TU-004

Melchior C., PP-WE-013

Melenovsky’ V., PP-WE-345

Melikian C., PP-TH-242, PP-WE-240

Melinyshyn A., OC-TH-007

Mellars G., PP-TH-551, PP-TH-657

Mello T. B. T., PP-WE-296

Mellors G., PP-MO-624

Melo T. M., PP-WE-295

Melot C., PP-MO-498

Melton Iii L. J., AS-TH-003

Melton L. J., PP-MO-284

Meltzer M. E., OC-TU-001, OC-WE-016, PP-MO-352

Menahem M., AS-TU-008

Menashku S., AS-TU-052

Menchen H., OC-WE-022

Menchini U., OC-WE-031, OC-WE-032, PP-MO-217

Mende M., AS-WE-004

Mendelboum Raviv S., PP-WE-049

Mendell J., OC-WE-003, PP-MO-198, PP-WE-179

Mendelsohn M. E., AS-TH-016

Menditto L. A., PP-MO-283

Mendolicchio G. L., PP-WE-791

Mendolicchio L., PP-MO-775

Menegatti M., AS-MO-028, PP-MO-210

Meneguzzi A., PP-MO-015

Meneveau N., AS-TU-009

Mengatti J., PP-WE-535

Mengi N., PP-TH-686

Menke L. A., PP-MO-597

Mennecier P., PP-MO-382

Mensi N., OC-TH-073

Meola A., PP-WE-321

Mercier E., OC-TH-081

Merhi Y., OC-WE-007, PP-MO-012

Merkouri E., PP-TH-338

Merli G. J., PP-WE-465

Merlini P., PP-WE-339

Merricks E. P., PP-MO-570,PP-TH-579

Merrill J. T., OC-TU-033

Merrill-Skoloff G., AS-MO-043,AS-TU-022, OC-MO-057, OC-MO-108, OC-WE-072

Merriman E. G., PP-MO-631

Mertens K., OC-MO-111, OC-MO-112, OC-TU-083, OC-WE-084

Mesa M., PP-WE-665

Meschengieser S. S., PP-MO-613, PP-TH-350

Meschengieser S., PC-047,PP-MO-204, PP-MO-274, PP-TH-100, PP-WE-145, PP-WE-146, PP-WE-354

Mesli M. N., PP-WE-564

Mesli N., PP-TH-608, PP-WE-701, PP-TH-608

Meslier Y., OC-MO-064, OC-WE-066, PP-MO-588

Messano L., PP-WE-048

AUTHORS INDEX

543

Messina M., OC-TU-075

Messmore H., PP-MO-143, PP-TH-390, PP-WE-385

Mesters R., OC-TU-062

Mesterton J., PP-MO-606

Metassan S., PP-TH-212

Metelin V., PP-MO-729, PP-WE-062

Metin A., OC-WE-132

Metjian A., OC-MO-002

Metzger K. E., PP-WE-640

Metzger U., PP-TH-417

Metzner H. J., OC-WE-120, PP-TH-561

Metzner H., PP-TH-130

Meulemans A., PP-MO-786

Meurs I., OC-WE-046

Mewburn J., PP-TH-631

Mewhort-Buist T. A., OC-MO-074, PP-WE-173

Meyer B., PP-MO-332

Meyer D., PP-TH-623

Meyer G., AS-TU-009, OC-MO-041, OC-TH-018, PP-MO-376, PP-WE-483

Meyer J. P., PP-TH-103

Meyer J., PP-MO-004

Meyer M., PP-TH-215

Meyer S. C., PP-TH-079, PP-TH-080

Meyer T., PP-MO-004, PP-WE-001

Mezzano D., AS-MO-054, AS-TH-052, OC-WE-026, OC-WE-086, PP-MO-064, PP-MO-860, PP-TH-024, PP-TH-043, PP-WE-057, PP-WE-121, PP-WE-123, PP-WE-654, AS-MO-041

Mezzasoma A., PP-MO-085

Mialhe A., AS-WE-050

Miao C. H., OC-WE-062

Miao H. Z., OC-WE-062, PP-WE-153

Miao H., AS-WE-043

Miccio A., AS-TH-042

Miccoli R., PP-MO-016

Miceli-Richard C., PP-WE-787

Michel J., PP-MO-786

Michel-Behnke I., PP-MO-436

Michell B., OC-MO-101

Michielsen P., PP-MO-383

Michno A., PP-MO-024

Micic D., PP-TH-269

Micucci J. A., AS-TH-047

Miculschi G., PP-WE-552

Miczák A., OC-TU-051, PP-WE-836

Middeldorp S., AS-MO-030,OC-WE-100, PP-MO-286, PP-TH-139, PP-TH-373, AS-MO-001

Miesbach W., AS-MO-003, PP-MO-584, PP-TH-644, PP-TH-651, PP-TH-652, PP-WE-210

Mihailov D., PP-WE-549

Mihailov M., PP-MO-532, PP-WE-552

Mihaly J., PP-MO-838, PP-MO-848, PP-WE-842

Mijares M., PP-MO-663

Mikati M., PP-TH-456

Mikhail N. E., PP-TH-506

Mikhalovska L. I., PP-MO-872

Mikhalovsky S. V., PP-MO-872

Mikheeva Y. A., PP-TH-431

Mikovic D., AS-TU-033, PP-MO-533, PP-TH-296, PP-WE-379

Mikovic Z., PP-WE-379

Mikulenkova D., PP-TH-083

Milanov P., AS-TH-014

Miles L. A., AS-TU-020

Milio G., AS-TH-030

Miljic P. S., PP-MO-327

Miljic P., PP-MO-599

Millar C. M., OC-MO-032, PP-MO-624

Millar C., OC-MO-033

Miller C. D., OC-TU-007, PP-TH-505, PP-WE-414

Miller C. H., PP-MO-596, PP-WE-613, PP-WE-749, PP-WE-750

Miller C. M., OC-TH-077

Miller C., PP-TH-328

Miller E., PP-MO-518

Miller J. L., PP-WE-029

Miller R., PP-WE-292

Miller V. M., PP-WE-780

Milli B., PP-MO-294

Mills G. B., PP-TH-392

Mills N. L., PP-TH-212

Mills S., AS-TH-022, PP-MO-045

Milos M., PP-MO-223, PP-WE-275, PP-WE-435

Milosevic Jovcic N., PP-WE-634

Milyutina D. A., PP-WE-863,PP-WE-864

Mimaya J., PP-TH-592, PP-WE-606

Mimikakou G. E., PP-WE-131

Mimuro J., OC-TH-051, PP-TH-054

Min P., PP-WE-783

Min S., PP-MO-727, PP-WE-343

Minagawa Y., PC-040

Miñano A., OC-TH-027, OC-TU-080, OC-WE-107, PP-MO-134, PP-MO-144, PP-TH-247, PP-TH-287, PP-WE-141

Minaudo M., AS-WE-007

Ming H., PP-MO-691

Mingot E., PP-MO-566, PP-MO-601, PP-TH-596

Mingot M. E., PP-TH-572, PP-WE-550, PP-WE-551

Minhas N., AS-TH-017

Miniati M., PP-MO-303, PP-MO-304, PP-WE-283

Minibeck E., PP-TH-640

Minkin S. C., PP-TH-439

Minoldo S., PP-MO-547, PP-WE-511

Minotto I., PP-TH-304, PP-WE-527

Minou A. F., PP-TH-234

Minuk L., PP-WE-517

Minuz P., PP-MO-015

AUTHORS INDEX

544

Aut

hors

Inde

x

Miqueo C., OC-TU-080

Miranda A., PP-WE-167

Miranda C. G., PP-MO-346

Miranda M., PP-MO-667, PP-MO-743, PP-WE-748

Miranda P., PP-TH-385

Miras F., PP-MO-637

Mirault T., PP-MO-748

Miron M., PP-TH-315

Mironova E. V., PP-WE-863,PP-WE-864

Mirshahi M., PP-MO-214, PP-WE-139, PP-WE-505, PP-WE-855

Mirshahi P., PP-WE-855

Mirshahi S., PP-MO-514, PP-TH-174, PP-TH-185, PP-TH-211, PP-WE-139, PP-WE-505

Mishima K., PP-WE-090

Mishra G., PP-MO-233

Mismetti P., OC-MO-050, OC-MO-053, OC-TH-021, OC-TU-022, OC-WE-002, PC-023, PP-TH-076, PP-TH-426, PP-WE-165, PP-WE-483

Misquith R., PP-MO-675

Missenard J., PP-TH-649

Miszalski-Jamka T., PP-MO-207

Mitchell B., PP-WE-078

Mitchell J. A., AS-WE-052, PP-MO-740, PP-MO-741

Mitchell J., PP-WE-539

Mitchell L. G., AS-TU-054, OC-WE-092, OC-WE-096, PP-WE-448, PP-WE-449

Mitchell L., OC-WE-094, OC-WE-106

Mitchell M. J., PP-MO-628, PP-WE-635

Mitchell M., PP-MO-562, PP-TH-152, PP-WE-616

Mitic G., PP-WE-368, PP-WE-369, PP-WE-379

Mitragorti S., AS-MO-049

Mitri Z., PP-MO-135

Mitsopoulou K., PP-MO-302

Mitsuguro M., PP-TH-320

Mitterer A., PP-MO-150

Miyajima Y., PP-TH-081

Miyamoto E., PP-WE-269, PP-WE-271

Miyamoto S., PP-MO-393

Miyashita K., PP-MO-704

Miyata K., PP-TH-184

Miyata S., PP-MO-093, PP-WE-720

Miyata T., AS-MO-012, OC-WE-008, PP-MO-093, PP-MO-393, PP-MO-726, PP-TH-015, PP-TH-320, PP-WE-090, PP-WE-872

Miyawaki Y., PP-MO-138, PP-WE-671

Miyazaki H., PP-WE-605

Miyazaki K., PP-MO-084

Miyazaki Y., PP-WE-666

Miyazawa Y., PP-WE-420

Mizukoshi M., PP-MO-429

Mo X., OC-TU-046, PP-TH-045

Moazed B., PP-WE-393

Mobalegh A., PP-WE-632

Mobarrez F., OC-TH-079, OC-WE-104, PP-MO-374, PP-MO-761, PP-MO-762

Moeller F., PP-MO-573

Moessmer G., PP-MO-132

Moffat K. A., OC-MO-134

Mogami H., OC-WE-054

Moghimi B., AS-TU-015, OC-TH-049

Moghrabi A., PP-MO-494, PP-WE-507

Mogielnicki A., PP-MO-234,PP-TH-239

Mohler E. R., AS-TH-033

Mohlke K. L., PP-TH-398

Mohseni R., PP-WE-558

Molad Y., PP-MO-749

Molderings G. J., PP-MO-253

Mole J. P., PP-WE-655

Molenaar P. J., PP-TH-436, PP-WE-778

Molina P., AS-TH-018, PP-MO-053, PP-WE-871

Molina R., PP-MO-227

Molinari A. C., PP-MO-525, PP-MO-616

Molinaro R. J., PP-MO-137,PP-MO-676, PP-TH-136

Molino-Lova R., PP-WE-311

Molins B., AS-MO-049

Molkentin J. D., OC-WE-123

Moll F. L., OC-TU-030

Mollah S. A., AS-MO-027

Møller B., PP-WE-740

Momi S., OC-TH-032, PP-TH-094, PP-TH-402

Monagle P. T., PP-MO-438

Monagle P., OC-WE-093, PP-MO-381, PP-MO-437, PP-MO-449, PP-MO-450, PP-MO-451, PP-TH-442, PP-TH-461, PP-TH-462, PP-TH-475, PP-WE-437, PP-WE-438, PP-WE-480, PP-WE-531

Monahan P. E., AS-WE-042,OC-TH-087, OC-WE-064

Monassier J. P., OC-MO-008

Monatte T., PP-TH-076

Monavari A., PP-TH-034

Mondorf W., PP-WE-593

Mongiat M., PP-WE-527

Monia B. P., OC-TH-108, PP-TH-388

Monkman K., PP-MO-403

Mono M., OC-WE-034

Monreal M. M., PP-TH-308

Monreal M., PP-MO-299, PP-TH-288, PP-WE-178, PP-WE-415

Monroe D. M., AS-WE-042, OC-WE-061, PP-MO-392, PP-TH-205

Montalescot G., OC-MO-008

Montalvão S. A. L., PP-MO-145, PP-MO-521, PP-TH-157, PP-TH-554

Montalvo A., PL-TU-002

Montani N., PP-MO-684

Montano N., OC-TH-010

Montavão S. A. L., PP-WE-296

Monteagudo E., PP-WE-436

AUTHORS INDEX

545

Monteagudo J., PP-MO-254,PP-WE-371

Montebello E., PP-MO-828

Monteiro R. Q., PP-TH-499

Monteiro R. R. Q., PP-TH-179

Montero F., PC-050

Montes R., PP-MO-178

Montgomery For Canadian -Vicenza - And Zpmcb-VwdStudy Groups R. R., AS-MO-017

Montgomery For TheCanadian Type 1 Vwd AndZpmcb-Vwd Study R. R., OC-WE-133

Montgomery R. R., AS-WE-038, OC-TU-071, PP-TH-128

Montiel-Manzano G., OC-MO-026

Montsch P., PP-TH-611

Moodley S., PP-TH-370

Moons K. G. M., OC-TH-017

Moons K. M. G., OC-TU-012

Moore C. L., PP-MO-512

Moore C., PP-MO-062

Moore G. C., PP-TH-330

Moore G. W., PP-MO-166

Moore G., PP-MO-543

Moore L. C., PP-WE-854

Moores L., PP-MO-299

Moorthi C., PP-MO-603, PP-MO-647

Mor Cohen R., PP-WE-010

Moraes L. A., OC-TH-093, OC-TH-100, PP-WE-040, PP-WE-809

Morag I., PP-MO-434

Morais S., PP-MO-667, PP-WE-374

Moraleda J., PP-MO-536

Morales A., PP-MO-536

Morales J., PP-WE-065

Moran N., PP-MO-043, PP-MO-044, PP-TH-034

Morange P. E., OC-WE-099,PP-MO-774, PP-TH-309

Morange P., OC-MO-007, OC-MO-021, PP-MO-773, PP-WE-165, PP-WE-775

Morateck P. A., OC-TU-071

Morcillo S., PP-WE-768

Mor-Cohen R., PP-TH-013

Mordasini A., PP-TH-692

Moreau C., PP-TH-429

Moreau P., PP-TH-593

Moreira L., PP-WE-374

Morel O., PP-MO-416

Morel-Kopp M. C., PP-MO-410,PP-MO-411, PP-WE-221

Morel-Kopp M., PP-WE-547

Morenghi E., AS-WE-007

Moreno M., PP-MO-536

Moreno N., OC-WE-086

Moret A., PP-MO-589, PP-MO-590, PP-TH-544, PP-TH-627, PP-WE-668

Morfini M., PP-MO-542, PP-TH-584, PP-TH-622, PP-WE-599

Mörgelin M., PP-MO-221

Morgret M. L., PP-WE-120

Mori F., PP-MO-246

Moriarty R., PP-MO-043

Moride Y., PP-TH-323

Moriguchi-Goto S., PP-MO-123, PP-MO-127

Morikawa C., PP-TH-173

Morimoto M., PP-MO-439

Morin K. A., PP-TH-520, PP-WE-267, PP-WE-270

Morishige N., PP-WE-411

Morishima Y., PP-TH-195, PP-TH-406

Morishita E., PP-TH-057, PP-WE-278

Morissey J., SA-TH-018

Morita T., PP-WE-150

Moritani Y., PP-TH-041, PP-TH-042

Moroi M., PP-MO-080, PP-TH-035, PP-TH-036

Moroi R., PP-TH-521

Moroz G. I., PP-TH-479

Morozov Y. A., PC-010, PC-011, PC-051

Morrell C. N., PP-MO-011

Morris A. J., PP-TH-392

Morris T. A., OC-MO-022, OC-TU-009

Morrissey J. H., AS-WE-034,OC-TU-091, PP-MO-113, PP-TH-255, PP-TH-256, PP-WE-120

Morrrissey J. H., PP-WE-256

Morse M., PP-MO-233

Morser J., OC-WE-038, PP-WE-222

Mortensen J., OC-MO-040

Mortensen S. B., PP-WE-788

Mos I. C. M., OC-MO-037, PP-WE-341, PP-WE-512, PP-WE-513

Moscardo A., PP-MO-027, PP-WE-096

Moscardó A., PP-WE-796

Moses P. D., PP-TH-275

Moshou M., PP-MO-257, PP-TH-006

Mosialos L., PP-MO-777, PP-MO-778, PP-MO-779

Moskowitz K. A., PP-TH-677,PP-TH-678, PP-TH-691

Mosnier I., PP-MO-332

Mosnier L. O., AS-TU-043, OC-WE-142, PP-MO-880, PP-MO-881

Møss J., OC-WE-055

Mostafa . Z., PP-MO-277

Mota L., PP-TH-659, PP-TH-660, PP-TH-668

Mota R., OC-WE-107

Mota-Vieira L., PP-MO-297

Mothabeng S. M., PP-WE-650

Motta G., PP-MO-124

Motte S., PP-MO-498

Motterlini R., PP-TH-239

Mottier D., PP-MO-310, PP-MO-500, PP-TH-483, PP-WE-186, PP-WE-508, PP-WE-510, PP-TH-291, PP-TH-508, PP-MO-508

AUTHORS INDEX

546

Aut

hors

Inde

x

Motto D. G., OC-WE-041, PP-MO-090, PP-WE-389

Möttönen S., PP-TH-068

Moubarik C., PP-MO-833

Mouhsine E., PP-TH-417

Moulard M., PP-MO-787

Moulin N., PP-TH-076

Mouquet F., PP-TH-583, PP-WE-858

Mourad W., OC-WE-007, PP-MO-012

Mourão P. A. S., PP-TH-178

Mousavi H., PC-049

Mowinckel M. C., AS-TH-004

Mowinckel M., PP-WE-486

Moya C., PP-TH-568

Moyna N., AS-TU-059

Mt-Isa S., OC-TU-002

Mu J., PP-WE-394

Mucci L., PP-TH-082

Much E. S., PP-TH-267

Muchitsch E. M., OC-TH-054,OC-WE-063, PP-MO-150, PP-MO-640, PP-WE-557

Muehlberger E., OC-TH-070

Mueller F., AS-WE-034

Mueller M., PP-WE-519

Mueller-Esterl W., OC-TH-059

Muenzel T., OC-MO-068

Mughal S., PP-TH-351

Muhl L., AS-TH-058, OC-TH-110

Mühle C., PP-TH-556

Mukai H. Y., PP-TH-071

Mukhametova L. I., PC-005

Mukhametova L., PP-TH-227

Mukherjee M. S., PP-TH-108,PP-WE-811

Mukhopadhyay R., AS-TU-041

Mukon M., PP-TH-477

Muladzanov A., PP-WE-462

Mulder A. B., OC-WE-098, PP-TH-332, PP-TH-515, PP-TH-516

Mulder R., OC-WE-098, PP-TH-515, PP-TH-516

Muleo G., PP-MO-432, PP-TH-546, PP-TH-547

Müller J., AS-TH-048, PP-WE-180

Muller P., PP-TH-392

Müller S., OC-TH-023

Müller-Reible C., OC-WE-076

Mullier F., PP-MO-040

Mullins E. S., AS-TU-045, OC-TH-063

Mumford A. D., OC-MO-131,OC-TH-041

Mumford A., PP-MO-076

Mun H., PP-WE-783

Mun Y., PP-TH-504

Munday A. D., PP-MO-002, PP-WE-023, PP-WE-056

Mundell S. J., OC-MO-131,OC-TH-041

Mundkur L. A., OC-TH-118,PP-MO-817

Munier A., PP-MO-723

Munnix I. C. A., AS-WE-044,OC-MO-044, OC-WE-123, PP-TH-012

Muñoz I., PC-048, PP-TH-603,PP-TH-604, PP-WE-560, PP-WE-765

Muñoz S., PP-WE-236

Muñoz X., PP-WE-821, PP-WE-822

Munroe S., PP-MO-115, PP-MO-116

Münster A. B., PP-MO-164, PP-WE-282

Muntean W., OC-WE-138, PP-TH-448, PP-WE-439

Murad S. D., PP-MO-224

Murakami Y., PP-WE-875

Murasaki K. M., PP-WE-418

Murasaki K., PP-WE-342

Murat E., PP-MO-858

Murata M., PP-MO-717, PP-TH-072, PP-WE-015, PP-WE-031, PP-WE-349

Murate T., PP-MO-138

Murayama S., PP-MO-119

Murphy A., AS-TU-059

Murphy D., PP-MO-044, PP-TH-033

Murphy J. E., OC-WE-057, OC-WE-059

Murphy K. K., PP-WE-306

Murphy M., OC-TU-056

Murphy R. P., AS-TU-059

Murray H., OC-WE-033

Murray J., PP-WE-636

Murray-Segal L., OC-MO-127

Murugappan S., PP-TH-011

Murugesan G., PP-WE-101

Musallam K. M., PP-TH-336

Musallem K. M., PP-WE-686

Musial J., PP-MO-269, PP-MO-270, PP-MO-271, PP-MO-329, PP-MO-784, PP-TH-381, PP-WE-267, PP-WE-270

Musil P., PP-TH-433, PP-TH-437

Musso M., PP-TH-590, PP-WE-870

Musso R. R. M., PP-TH-590

Musso R., AS-TU-032, OC-TU-075, PP-MO-577, PP-TH-622, PP-WE-567, PP-WE-579, PP-WE-870

Mussoni L., PP-WE-050

Mustonen P., PP-MO-742, PP-WE-276, PP-WE-279

Muszbek L., PP-MO-009, PP-MO-205, PP-MO-228, PP-TH-216, PP-TH-366, PP-WE-350, PP-WE-774

Mutch Mueller N. J., AS-WE-034

Mutch N. J., OC-MO-076, PP-WE-130

Muth A., PP-TH-241

Muthny F., PP-MO-459

Mutlu A., PP-MO-065

Muto S., PP-MO-439, PP-WE-562

Mutoh S., PP-TH-041, PP-TH-042

Mutucumarana V. P., OC-WE-075

Muwakkit S. A., PP-TH-456,PP-WE-686

AUTHORS INDEX

547

Muyldermans S., OC-TH-114

Muzard J., PP-MO-786

Muzykantov V., OC-WE-112

Mwanda W. O., PP-MO-452

Myers B., PP-MO-370, PP-WE-760

Myers H. R., AS-MO-063

Myers Jr D. D., OC-TU-060,PP-MO-388, PP-MO-400

Myers L., PP-MO-136

Mykhaylov S., PP-MO-065

Myklebust C. F., PP-TH-164

Myojin K., PP-WE-720

Mysliwiec M., PP-MO-114, PP-WE-223

N. Krogh T., PP-MO-565

Nadal-Wollbold F., AS-TH-023

Nadir Y., PP-TH-387

Næsgaard P., PP-MO-433

Naess I., OC-WE-013

Nagae C., PP-MO-439, PP-WE-562

Nagai R., OC-TH-009

Nagalla S., OC-WE-045, PP-MO-756, PP-WE-752

Nagam N., AS-TH-027

Nagao T., PP-TH-358

Nagaraj S., PP-MO-792, PP-MO-793

Nagaswami C., AS-WE-048

Nagaya H., PP-MO-119

Nagpal S., PP-WE-495

Nagy - Jr B., OC-MO-043

Nagy B., OC-TH-094, OC-TH-098, PP-MO-009

Nagy J., PP-WE-049

Nahal A., PP-MO-820

Nahrendorf M., AS-WE-057

Naidu S., OC-MO-072

Naik M. U., OC-MO-046, OC-MO-071, OC-TH-038, PP-WE-053

Naik U. P., OC-MO-046, OC-MO-071, OC-TH-038, PP-WE-053

Naina H. V. K., PP-MO-487,PP-TH-220, PP-WE-723

Nair S. C., PP-TH-275

Naito S., PP-WE-148

Najid S., OC-WE-093

Nakadate H., PP-WE-025

Nakagaki T., OC-WE-073, PP-WE-605

Nakagawa H., PP-MO-842

Nakagawa P. A., PP-TH-065,PP-TH-066

Nakajima Y., PP-MO-704

Nakajo Y., PP-MO-393

Nakamura H., PP-WE-005

Nakamura N., PP-MO-429

Nakanishi K., PP-WE-032

Nakao S., PP-TH-057, PP-WE-278

Nakashima H., PP-TH-229

Nakashima T., PP-WE-605

Nakatani K., PP-TH-526

Nakatomi Y., PP-WE-605

Nakaya S. M., PP-MO-156

Nakic M., PP-WE-442

Nakkinkun Y., PP-WE-772

Nanba T., PP-WE-348

Nandurkar H., AS-TH-025, OC-MO-101, OC-MO-127

Nanna C., AS-TH-034

Nanni L., PP-WE-246

Naparstek E., PP-TH-070

Napoleone E., PP-MO-202, PP-MO-481, PP-TH-248, PP-TH-249, PP-WE-246, PP-WE-502

Napoleone M., OC-WE-051,PP-MO-620

Napolitano M., PP-MO-654,PP-TH-694

Narasaki R., PP-TH-226

Nardi A., PP-TH-591

Nardi M., PP-WE-338

Nardini I., PP-MO-246

Naseem K. M., PP-MO-023,PP-MO-024, PP-TH-020

Naseem K., OC-TH-055

Naseem S., PP-TH-272, PP-WE-266, PP-WE-456

Nasirikenari M., PP-WE-893

Näslin D., PP-WE-643

Nasonov E. L., PP-MO-268,PP-TH-267, PP-TH-277

Nasreddine W., PP-TH-336

Natesha B. K., AS-WE-059, PP-WE-832, PP-WE-833, PP-WE-834

Nathwani A. C., AS-TU-011

Natorska J., PP-WE-107

Navajas R., PP-TH-591

Navalon F., PP-MO-053, PP-TH-047, PP-WE-871

Navaneetham D., PP-MO-181

Navarrete A., OC-WE-066, PP-MO-588

Navarro D., PP-TH-568

Navarro F., PP-MO-579

Navarro M., PP-WE-816

Navarro N., AS-MO-054

Navarro S., PP-MO-192, PP-MO-193

Navarro-Fernández J., OC-TU-082

Navarro-Núñez L., AS-MO-054,AS-TH-052, PP-MO-055, PP-MO-732, PP-TH-096, PP-WE-033, PP-WE-764

Navis G., OC-MO-001, PP-WE-326

Nawroth P. P., AS-MO-059, AS-WE-053

Nayak S., AS-TU-015, OC-TH-049, PP-TH-618

Nayiager T., PP-MO-494

Nayiger T., PP-WE-507

Nayir A., PP-MO-440

Naz A. A. N., PP-TH-648

Neceva V., PC-014, PC-027,PC-028, PP-TH-271, PP-WE-426

Needham J., PP-MO-272, PP-TH-599, PP-WE-111

Neelamegham S., OC-WE-050,PP-WE-893

Neerman-Arbez M., PP-MO-206, PP-WE-213

Neeves K. B., AS-TU-028, AS-TU-038, OC-WE-053

AUTHORS INDEX

548

Aut

hors

Inde

x

Neeves K., PP-WE-030

Neff A. T., PP-MO-596, PP-WE-613

Negaard H. F. S., PP-WE-486,PP-WE-487

Negrier C., OC-TU-073, PP-MO-263, PP-MO-264, PP-MO-567, PP-MO-586, PP-MO-645, PP-MO-658, PP-TH-385, PP-TH-386, PP-WE-133, PP-WE-493, PP-WE-533, OC-WE-021, OC-MO-062, PP-MO-604, PP-TH-593, AS-TH-011

Negro F., PP-TH-316

Negrotto S., PP-WE-042

Neiva T. J. C., PP-MO-034

Nekkal S., PP-WE-639

Nelli P. J., PP-WE-861

Nemecz M., PP-MO-855

Nemekh A., PP-TH-029

Nemery B., PP-MO-398

Nemes L., OC-WE-058, OC-WE-119, PP-MO-609, PP-WE-542, PP-WE-604

Nencini P., OC-TH-047

Nendaz M. R., PP-MO-318

Nendaz M., PP-WE-375

Nepal S., PP-MO-407

Nergiz-Unal R., AS-TU-029

Nergiz-Ünal R., PP-TH-012

Neri C., PP-TH-507

Neri T., PP-MO-758

Nerlich C., PP-TH-130

Nesbitt W. S., OC-WE-124

Nesheim M. E., OC-MO-061,OC-MO-095, OC-TH-071, OC-TH-072, OC-TU-067, OC-TU-069

Neubert U., PP-WE-755

Neufeld E. J., PP-MO-535, PP-MO-600

Neuhart E., PP-MO-175, PP-TH-423

Neuhaus D., OC-TU-061

Nevière R., PP-WE-858

Newall F. H., PP-MO-449, PP-MO-450, PP-MO-451, PP-TH-442, PP-WE-437, PP-WE-438

Newall F., OC-WE-093, PP-MO-437, PP-MO-438, PP-TH-461, PP-TH-475

Newby D. E., PP-TH-212

Newell J. L., PP-MO-157

Newman D. K., AS-TH-009

Newman D., SA-TU-002

Newman P. J., AS-MO-052, AS-TH-009

Newman P., AS-MO-057

Newton A. S., PP-MO-435

Ngo J., AS-WE-041

Ngo M., PP-TH-133

Nguyen N. X., OC-TU-046, PP-TH-045

Nguyen P., OC-MO-050, OC-WE-002

Nguyen Y., AS-WE-027, OC-WE-151

Ni H., AS-TU-030, AS-WE-042,OC-MO-139, OC-WE-121, PP-WE-060

Ni R., PP-TH-009

Nicham F., PP-MO-766

Nichols T. C., AS-TU-013, PP-MO-570, PP-TH-579

Nichols T., OC-MO-086

Nichols W. L., PP-MO-629, PP-MO-678

Nickerson D. A., AS-WE-009

Nicklin S. A., PP-WE-150, PP-WE-151

Nicolaes G. A. F., PP-WE-157

Nicole O., OC-WE-111

Nicolescu A., PP-MO-069, PP-TH-063

Niekrens C., PP-TH-575

Nieland A., OC-TH-076

Nielsen A. D., PP-MO-559, PP-WE-585, PP-WE-586

Nielsen H. M., PP-MO-121

Nielsen M., PP-MO-118

Nieman M. T., OC-TH-056

Nieman M., OC-MO-128

Niemann B., PP-TH-537

Niemann S., PP-MO-030, PP-MO-031, PP-WE-734

Nienhuis A. W., AS-TU-011

Niers T. M. H., OC-WE-019,PP-TH-484

Niessen F., AS-TU-043

Niesters H. G. M., PP-TH-332

Nieswandt B., SA-WE-005, AS-TH-040, AS-TU-005, AS-TU-037, AS-TU-040, AS-WE-029, AS-WE-030, OC-TH-039, OC-WE-040

Nieuwdorp M., PP-MO-221

Nieuwkoop A. J., OC-TU-091

Nieuwland R., AS-WE-017, OC-TU-055, OC-TU-059, PP-MO-022, PP-MO-109, PP-MO-763, PP-MO-769, PP-WE-784

Niewiadomska E., PP-WE-722

Niewiarowska J., PP-MO-839,PP-MO-843

Niglio A. A., PP-TH-308

Nigro C., PP-MO-379, PP-MO-380

Niitsu Y., PP-MO-096

Nijhuis S., PP-TH-155

Nijkeuter M., AS-MO-035, PP-MO-506

Nikoloska I., PC-014, PC-027,PC-028, PP-TH-271, PP-WE-426

Nikolskaya I., PC-005

Nikookhesal E., PP-TH-104

Niladri S., PP-WE-833

Nilsen D. W. T., PP-MO-433,PP-TH-131, PP-TH-344, PP-WE-072, PP-WE-126, PP-WE-830, PP-WE-831

Nilsen D., PP-WE-829

Nilsson B., OC-MO-106

Nilsson Ekdahl K., OC-MO-106

Nilsson S., OC-WE-115, PP-MO-343

Ninet J., PP-TH-385

Ninomiya H., PP-TH-071

Nishihira K., PP-MO-111

Nishimi M., PP-WE-411

Nishimura S., PP-WE-605

Nishino Y., PP-TH-014

Nishio K., PP-WE-090

AUTHORS INDEX

549

Nishio M., PP-MO-827, PP-WE-501

Nishiya K., PP-MO-255, PP-WE-250, PP-WE-516

Nitti C., OC-MO-092, OC-TH-014

Nixon B., PP-WE-636

Nixon J., PP-TH-230

Njerve I. U., PP-MO-719

Njolstad I., OC-TU-005, OC-TU-006, PP-WE-304, PP-WE-305

Njølstad I., OC-WE-137, OC-WE-140

Nkujani T., PP-MO-471

Noack H., PP-MO-167, PP-TH-167, PP-TH-169, PP-TH-170, PP-WE-205

Nobel D., PP-TH-492

Nobori T., PP-TH-526, PP-MO-497

Nogami A., PP-TH-358

Nogami K., PP-MO-255, PP-WE-250, PP-WE-516

Nohara C., PP-TH-358

Nokes T., OC-TH-076

Nolan B., PP-MO-593, PP-WE-615

Nolli S., AS-TH-032, OC-MO-132, PP-WE-744

Nolte M. E., PP-TH-567

Nomikou E., PP-WE-314

Nomura M., PP-TH-416

Nomura S., PP-WE-781, PP-WE-827, AS-WE-016

Nonne C., OC-TH-034

Noordermeer K., PP-WE-072

Norberg E., PP-MO-703

Nord E., PP-WE-643

Norda R., PP-MO-672

Nordenholz K. E., PP-MO-512,PP-TH-408

Nordstrom S. M., OC-MO-077

Norenberg C., PP-MO-577, PP-WE-579

Norengaard L., PP-WE-658

Noris M., PL-TU-006

Noris P., PP-MO-085, AS-TU-004

Normann S., PP-WE-528

Norris J. W., PP-MO-389

Norris L. A., PP-WE-373

Norstrom E. A., OC-MO-098

North P., OC-TH-097

Notet V., PP-TH-394

Notheaux Micheli J., PP-MO-125

Notley C., AS-MO-020, OC-TU-076, OC-WE-134

Noto A., PP-TH-303

Noto D., OC-TU-088

Noubouossié D., PP-MO-617

Nougier C., PP-MO-263, PP-MO-264

Nourani Khojaste H., PP-WE-459

Novak M., OC-WE-138, PP-TH-448, PP-WE-439

Novakov Mikic A., PP-WE-368

Nováková I. R. O., PP-MO-571

Novakova I., PP-TH-260, PP-WE-735

Nováková I., PP-MO-633

Novakovic V. A., PP-TH-159

Noveck R. J., PP-WE-179

Noventa F., OC-MO-015

Novikov A. A., PP-MO-268, PP-TH-267, PP-TH-277

Novokhatny V., PP-TH-230,PP-TH-231

Nowak A. A., PP-MO-231

Nowak G., PP-MO-700, PP-WE-739

Nowak Göttl And U., PP-TH-074

Nowak Gottl U., AS-TU-054

Nowak-Goettl U., OC-WE-117,PP-TH-647

Nowak-Gottl U., AS-TU-053,OC-WE-094, OC-WE-106, PP-MO-607, PP-TH-360, PP-WE-528, PP-WE-756

Nowak-Göttl U., OC-TU-062,PP-WE-453, PP-WE-633, PP-WE-653

Nowakowski G. S., PP-MO-487

Noya G., OC-TU-024

Nozaki M., PP-WE-463

Nuchsongsin F., PP-MO-710

Nugent D. J., PP-MO-823, PP-TH-065, PP-TH-066

Nugent D., PP-MO-625

Numa A., PP-TH-458

Nuñez R. J., PP-WE-767

Nuñez R., PP-MO-566, PP-MO-601, PP-TH-596

Nur E., PP-MO-292

Nurden A. T., OC-TH-097

Nurden A., SA-MO-013, AS-TH-043, PP-TH-074

Nurden P., AS-TH-043, OC-TH-097

Nutescu E. A., PP-MO-464

Nutescu E., PP-WE-406

Nuti R., PP-TH-301

Nyatanga P., PP-TH-449

Nyhus K., PP-TH-539

Nylander M., PP-MO-021

Nylander S., PP-TH-018

O Neill S., PP-TH-033, PP-TH-034

O’Donnell J., PP-TH-053

O’Beirne J., PP-WE-649

Öberg K. V., PP-WE-014

Obergan T., PC-012, PP-WE-397

Oberkanins C., PP-MO-141

Oborna I., PC-022

O’Brien M. C., PP-WE-489

O’Brien S., PP-TH-052, PP-WE-059

Obser T., OC-WE-136, PP-MO-638, PP-WE-629, PP-WE-630

Ocak G., PP-MO-316

Ockelford P. A., PP-MO-493

Ockelford P., OC-TU-079

O’Connor M. N., AS-MO-037

Odone-Filho V., PP-WE-444

O’Donnell C. J., OC-TU-034

AUTHORS INDEX

550

Aut

hors

Inde

x

O’Donnell J. S., PP-TH-549,PP-WE-685

O’Donnell J., PP-MO-593

O∂uz E., PP-TH-511

Oelenberg S., OC-TU-053

Oestergaard H., OC-MO-084,PP-MO-573, PP-MO-578

Oettle H., LB-MO-003

Offenberg H., PP-MO-578

Ofosu F. A., PP-MO-017

Oganova E. G., PP-WE-337

Ogawa S., PP-WE-196

Ogawa T., PP-MO-096

Ogbata O. U., PP-WE-127

Oger E., PP-MO-500, PP-TH-483, PP-WE-508, PP-MO-508, PP-TH-291

Ogiwara K., PP-MO-255, PP-WE-250

O’Gorman D., AS-TU-059

Oh D., PP-MO-301, PP-MO-353, PP-WE-877

Oh H. J., PP-WE-595

Oh M., PP-TH-585

Ohashi K., PP-WE-244, PP-WE-580

Ohayon T., PP-TH-070

Ohishi K., PP-TH-526

Ohkita Y., PP-WE-720

Ohkubo Y. Z., OC-TU-094, PP-WE-162

Ohkura N., PP-TH-051, PP-MO-864

Ohlmann P., PP-MO-416

Ohmori T., OC-TH-051, PP-TH-054

Ohsugi T., PP-TH-228, PP-WE-148

Ohtake T., PP-TH-358

Øie C., OC-MO-058, PP-MO-177

Oikawa Y., PP-WE-349

Oikonomou A., PP-WE-681

Oishi K., PP-TH-051

Ojeokun F. A., PP-TH-500, PP-TH-501

Oka T., PP-TH-592, PP-WE-606

Okada H., PP-MO-726

Okada Y., OC-MO-128

Okamoto A., PP-TH-320

Okamoto K., PP-MO-669

Okamoto T., PP-TH-143, PP-WE-882

Okamura M., PP-TH-358

Okamura T., PP-MO-669, PP-MO-726

Okano T., PP-WE-244, PP-WE-580

Okazaki E., PP-MO-755, PP-TH-542, PP-WE-705

Okazaki H., PP-WE-736

Okazaki O., PP-WE-348

Oku K., PP-WE-269, PP-WE-271

Okuchi K., PP-WE-090

Okuda M., PP-MO-119

Okuda T., PP-MO-393

Okumura N., OC-WE-145, PP-TH-229

Okuyama Y., PP-TH-143

Oláh Z., PP-MO-359

Oldenburg J., AS-TH-048, AS-WE-002, AS-WE-004, OC-WE-076, OC-WE-077, PP-MO-128, PP-MO-253, PP-MO-513, PP-TH-397, PP-TH-537, PP-TH-569, PP-TH-575, PP-TH-619, PP-TH-658, PP-TH-661, PP-TH-671, PP-TH-696, PP-WE-159, PP-WE-210, PP-WE-574, PP-WE-594, PP-WE-660

Oldgren J., PP-MO-408, PP-TH-407

O’Leary J. J., PP-WE-373

O’Leary M. A., PP-WE-118

Oleksiuk J., PP-WE-492

Olesen J. B., PP-MO-386

Olie V., OC-TH-005

Olié V., PP-WE-316

Oliva A., PP-WE-665

Olivares P., OC-WE-086, OC-WE-090, PP-MO-860

Oliveira D. G. L., PP-MO-475,PP-WE-167

Oliveira Di Migueli C., PP-WE-631

Oliveira Duarte V., PP-WE-066

Oliveira F., PP-WE-374

Oliveira S. M. C. G., PP-TH-178

Oliveira V., PP-MO-034

Oliver J. A., PP-MO-039, PP-WE-122

Olivieri M., AS-TH-055, PP-MO-607, PP-TH-533, PP-WE-453

Olivieri O., OC-TH-028, OC-TH-030, PP-MO-342, PP-TH-347

Olivieri S., OC-MO-113, PP-TH-274

Olivo G., PP-TH-352

Ollieuz S., PP-TH-684

Ollivier V., AS-TU-024, PP-MO-077, PP-TH-119

Olorunju S., PP-WE-124

Olsen J. O., OC-MO-025

Olsen J., OC-WE-025, PP-MO-795

Olson J., OC-WE-134

Olsson B., PP-WE-172

Olszynski P., PP-WE-704

Olteanu G., PP-MO-532

Omar S. Z., PP-MO-367

O’Meara E., AS-WE-009

Omer B., PP-MO-744

Omnes S., AS-WE-025

Omolade O. A., PP-MO-278,PP-WE-330

Omori H., PP-WE-342, PP-WE-418

Omoto S., PP-WE-781, PP-WE-827

Omran H., PP-MO-029, PP-MO-409

On Behalf Of The EclaxirStudy ., OC-TH-082

Oney S., PP-WE-189

Ong A. C., PP-MO-075

Ong E., PP-TH-639

Ong S., PP-MO-442

Onimaru M., PP-WE-875

AUTHORS INDEX

551

Onisai M., PP-MO-069, PP-WE-075

Onishi K., PP-TH-526

Ono A., AS-WE-032, OC-WE-044

Ono M., PP-TH-072

Ono N., PP-MO-232

Ooe E., PP-TH-194

Oosterkamp T. H., AS-WE-019

Opitz B., LB-MO-003

Oppermann J., PP-TH-656

Opstad T. B., PP-TH-118

Orantes V., PP-TH-285

Orbe J., OC-MO-130, OC-TH-113

Orden A., PP-WE-236

Ordóñez A., OC-TH-027, OC-TU-080, OC-TU-082, OC-WE-107, PP-MO-134, PP-MO-144, PP-TH-247, PP-TH-287, PP-WE-141

Ordoñez J., PP-TH-289

Orebaugh C., PP-WE-703

O’Reilly L. A., AS-WE-032

Orel E. B., PP-MO-218, PP-MO-668

Orfeo T., AS-TU-023, OC-MO-003, OC-TU-003, PP-TH-196

Orford N., OC-TH-015

Orje J. N., AS-MO-049

Orlando C., PP-MO-173, PP-MO-174, PP-WE-188

Orlemans E., PP-WE-803

Orlovic M., PP-MO-357

Orosz Z. Z., PP-TH-216

Orset C., OC-TH-113

Orsi F. A., PP-TH-466, PP-TH-532, PP-WE-295, PP-WE-476

Orsi F. L. A., PP-MO-870, PP-WE-294

Orsi F., PP-MO-725

Ortel T. L., OC-MO-002, PP-MO-492

Ortner E., OC-WE-034

Osakue J., PC-008, PC-009

Osanto S., AS-MO-035, AS-WE-019, PP-WE-497

Oschatz C., OC-TH-059

O’Shaughnessy D., OC-TH-076

Oshea S., PP-MO-414

Oshimura M., OC-TH-088

Oslakovic C., OC-TU-096

Osman A., PP-MO-133

Ostapchenko L. I., PP-MO-401

Ostasevski Fernandez N., OC-TH-013, PP-TH-418

Østenstad B., PP-WE-486, PP-WE-487

Oster K., OC-MO-126

Ostergaard H., OC-MO-085,PP-MO-118, PP-WE-590

Østergaard H., PP-MO-575,PP-TH-579

Östergren-Ludén G., AS-WE-054

Ostermann H., PP-MO-694

Osterud B., OC-WE-025

Østerud B., OC-MO-025, PP-MO-795, PP-MO-808, PP-TH-237, PP-WE-110

Osthaus A., PP-TH-207, PP-TH-208

Osto E., OC-WE-088

Ostryakova E. V., PP-MO-268,PP-TH-277

Ota S., PP-TH-526

Otegui M., PP-WE-575, PP-WE-576

Otero R., PP-MO-299

Otgontaij S. B., PP-TH-017

Othman M., OC-TH-053, OC-TU-076, OC-WE-134, PP-MO-632, PP-TH-393

Otomo K., PP-WE-269, PP-WE-271

Otrock Z., PP-TH-456

Ott J., OC-WE-098

Otten J. M. M. B., OC-MO-014,PP-MO-484

Otzen D. E., PP-TH-140

Ouarhlent Y., PC-045

Ouchchane L., PC-021

Oude Egbrink M. G. A., AS-TU-029

Oude Egbrink M., PP-TH-104

Oudega R., OC-TH-017, OC-TU-012

Oudemans - Van Straaten H.M., PP-TH-436

Ouvina S. M., PP-WE-203

Ouviña S. M., PP-TH-316

Ouviña S., PP-TH-607, PP-TH-681

Ouwehand W. H., AS-MO-037,OC-TH-037, OC-TH-093, OC-TU-029, OC-WE-126

Ouwehand W., SA-TU-016

Ou-Yang J., PP-TH-667

Ovali F., PP-MO-683

Ovanesov M. V., PP-TH-109,PP-WE-253

Overberg D., PP-MO-603, PP-MO-647

Overmyer K. A., OC-MO-073

Overvad K., PP-WE-315

Oviedo-Orta E., PP-WE-873

Øvlisen K., PP-WE-581

Owaidah T. M., PP-TH-062, PP-WE-280

Owczarska K., PP-TH-658

Owen B. A., PP-MO-760

Owen W. G., PP-TH-161, PP-WE-292, PP-WE-780

Oyen F., PP-MO-638, PP-WE-722

Ozaki Y., SA-TU-003, OC-TH-099, PP-MO-734, PP-TH-005, PP-WE-793

Ozdemir N., PC-039

Ozdemir O., PP-MO-394

Ozdenkaya Y., PP-WE-197

Ozel Demiralp D. F., PP-MO-797

Ozelci A. B., PP-TH-511

Ozelo M. C., AS-TU-013, AS-TU-014, OC-WE-134, PP-MO-520, PP-MO-521, PP-TH-157, PP-TH-466, PP-TH-532, PP-TH-554, PP-WE-295, PP-WE-535

AUTHORS INDEX

552

Aut

hors

Inde

x

Ozelo M., OC-TH-085, PP-WE-631

Ozkilic H., PP-WE-577

Ozturk E., PP-MO-841, PP-WE-889

Ozturk G., PP-MO-222

Öztürk Y’., PP-TH-284

Ozulker T., PP-WE-571

Ozyurek E., PP-WE-806

Pabinger I., AS-MO-003, OC-MO-027, OC-TU-013, OC-TU-015, OC-TU-016, PP-MO-322, PP-TH-273, PP-TH-569, PP-WE-594, PP-WE-663

Pabinger-Fasching I., PP-TH-317, PP-WE-621

Paccamiccio E., PP-MO-458

Pacheco P. R., PP-MO-297

Packard R. R., PP-MO-835

Pacouret G., AS-TU-009

Padayattil S., OC-MO-015, OC-MO-028

Padeh S., AS-TU-052

Padickakudi J., PP-WE-813

Padilla J., PP-MO-144, PP-WE-141

Padrini R., PP-WE-641

Pagana L., PP-TH-453

Paganelli F., PP-MO-785

Page M. J., OC-WE-083

Pagella F., PP-MO-684

Pagliuca M., PP-TH-474

Pagnan A., OC-MO-049, OC-TU-086, PP-MO-424, PP-TH-259, PP-TH-302, PP-TH-304, PP-WE-527, PP-WE-641, PP-WE-645

Pagnano R. G., PP-WE-535

Pai C., PP-TH-401

Pai M., AS-WE-003, PP-TH-663, PP-WE-429, PP-WE-553

Pai N., PP-TH-295

Paidas M. J., PP-TH-414, PP-WE-405

Paidas M., PP-WE-382

Paiva Palomino J. H., PP-MO-831, PP-MO-832, PP-TH-044, PP-WE-402

Paiva S. G., PP-MO-364, PP-WE-364

Paiva-Palomino J., PP-MO-610

Paiva-Patiño J., PP-TH-350

Paixão D. S. P., PP-WE-296

Pak Y., AS-TH-022, PP-MO-045

Pakola S., OC-TH-057

Palareti G. G. P., AS-WE-023,PP-MO-372

Palareti G., AS-MO-003, AS-TH-005, AS-TH-029, OC-TH-002, OC-TH-003, OC-TH-004, OC-TH-006, PP-MO-282, PP-MO-290, PP-MO-291, PP-MO-351, PP-MO-503, PP-MO-504, PP-TH-282, PP-TH-412, PP-WE-286, PP-WE-351, PP-WE-359, PP-WE-509, PP-WE-715

Palekar S., PP-MO-427

Palla A., PP-TH-303

Palla R., AS-MO-028, OC-WE-131, OC-WE-132, PP-MO-716, PP-TH-085, PP-WE-339, AS-WE-011

Pallavicini J., OC-WE-086, PP-MO-860

Palm L., PP-WE-585, PP-WE-586

Palma M., PP-TH-493

Palmieri V., PP-WE-321

Palmirotta R., PP-MO-379, PP-MO-380, PP-WE-824

Paloma M. J., PP-MO-590

Paloma M., PP-MO-566, PP-MO-601, PP-TH-596

Palomo A., PP-WE-550, PP-WE-551

Palomo M., AS-TH-018, PP-WE-871

Palumbo J. S., AS-TU-045, OC-TH-063

Palumbo V., OC-TH-047

Pampuch A., PP-WE-048

Pamuk G. E., PP-MO-841, PP-WE-889

Pamuklar Z., AS-TH-059

Pan J., OC-WE-057, OC-WE-059

Panagiotakopoulos V., PP-WE-693

Panchenko E. P., PP-TH-431,PP-TH-513, PP-WE-526

Panchenko E., PP-WE-335

Panchenko V. M., PP-WE-422

Pancotti S., PC-030

Pandey A., AS-TH-022

Panduro L., AS-MO-008

Paneesha S., OC-TH-076

Panes O., AS-MO-054, OC-WE-026, OC-WE-086, OC-WE-090, PP-MO-064, PP-TH-024, PP-TH-043, PP-WE-057, PP-WE-121, PP-WE-654, AS-MO-041

Pang J., PP-TH-037

Panholzer E., PP-WE-557

Paniccia R., AS-TH-034, PP-MO-013, PP-MO-743, PP-MO-818, PP-TH-352, PP-TH-353, PP-TH-474, PP-WE-002, PP-WE-003, PP-WE-745, PP-WE-746, PP-WE-747, PP-WE-748

Panicot-Dubois L., AS-TH-015,PP-MO-485, PP-MO-486

Panizo E., PP-MO-472, PP-TH-675

Panizzi P. R., AS-WE-057

Panizzi P., AS-TH-050

Pankiv S., PP-TH-237

Pannell R., AS-WE-050

Panova M., PP-MO-867

Panova-Noeva M., AS-TU-048,AS-TU-050

Pansini V., PC-030

Pantazatos D., OC-TU-095

Panteleev M. A., PP-MO-235,PP-WE-253

Pantovic S. M., PC-002, PP-WE-881

Pantziarela E., PP-MO-302

Panzer S., OC-MO-027, PP-TH-273

Paoletti O., PP-MO-496, PP-TH-374, PP-TH-375, PP-WE-682

AUTHORS INDEX

553

Paoloski G. B., PP-WE-203

Papadakis E., PP-MO-305, PP-WE-484

Papageorgiou C., PP-MO-477,PP-MO-478

Papageorgiou P. C., PP-TH-125

Papajik T., PP-MO-689

Papalardo E., OC-MO-026, OC-MO-114, OC-TU-038

Paparella D., PP-MO-423

Papassotiriou I., OC-TH-044

Papayan L. P., PP-MO-431, PP-MO-495, PP-TH-268, PP-TH-346, PP-WE-361

Papi R. M., PP-WE-131

Papiewska-Pajak I., PP-MO-861

Pappo A., PP-TH-445

Para A. N., AS-MO-040, PP-MO-722

Paraboschi E. M., PP-MO-648,PP-WE-657

Paradela A., PP-TH-591

Paradis A. K., PP-MO-721

Parahuleva M., OC-WE-128

Paramo J. A., OC-MO-130, OC-TH-113

Páramo J. A., PP-MO-472, PP-TH-675

Parent F., AS-TU-009, PP-MO-376

Pareyn I., PP-MO-049, PP-MO-050, PP-MO-094, PP-WE-013

Parfitt L. A., PP-WE-805

Pargalava N., PC-019

Parhami-Seren B., PP-TH-154

Parienti J., OC-TU-022

Parisi Q., PP-WE-048

Parizkova E., PP-MO-682

Parizzi L. P., PP-MO-825, PP-MO-826

Park C., PP-MO-727, PP-TH-509, PP-WE-343

Park D., PP-WE-496

Park E., PP-MO-213, PP-WE-027

Park G., PP-MO-213

Park J., PP-TH-595, PP-WE-069, PP-WE-573, PP-WE-805

Park R., PP-MO-213, PP-MO-712, PP-TH-519

Park S., PP-MO-213, PP-MO-727, PP-TH-149, PP-TH-509, PP-WE-027, PP-WE-027, PP-WE-069, PP-WE-343

Park Y., PP-WE-573, PP-TH-595

Parker A. L., PP-WE-150, PP-WE-151

Parker J. L., PP-WE-569

Parker W. A., PP-WE-430

Parmar K., OC-TU-039

Parmer R. J., AS-TU-020

Parpia S., OC-MO-016, OC-MO-017, PP-MO-515

Parr M. J. A., OC-TH-069

Parra R., PP-MO-528, PP-MO-590, PP-WE-234, PP-WE-761

Parry C., PP-MO-514

Parsi K., PP-MO-671, PP-WE-786

Parthasarathi L., PP-MO-043

Pascale S., PP-TH-082

Paschke M., OC-TH-059

Pascual M., OC-WE-058

Pascual T., PP-WE-360

Pascual Z., PP-TH-520, PP-TH-625

Pasdelou M., PP-WE-388

Pasetto L., PP-MO-424

Pasha S. M., OC-MO-037, PP-MO-782

Pasi J., PP-TH-685

Pasic S., PP-TH-269

Paskavitz J., OC-WE-129

Pasowicz M., PP-MO-207

Pasquier E., OC-WE-113

Passamonti F., AS-TU-004

Passamonti S., OC-MO-081,PP-WE-132

Passaro A., PP-TH-372

Passlow C., OC-TH-015

Pasta G., PP-MO-542

Pasterkamp G., OC-TH-031

Pastor F., PP-MO-732

Pastorova V., PC-012

Patel B., OC-MO-067

Patel H., PP-MO-548

Patel Hett S., PP-WE-077

Patel K. P., PP-WE-468

Patel K. V., PP-TH-014

Patel R. K., OC-MO-088, OC-MO-089

Patel S. R., PL-TU-002

Patel Y. M., PP-TH-014

Patel-Hett S., AS-WE-026

Paterno M. D., PP-TH-424

Paterson A., AS-TH-045

Paterson C., PP-MO-412

Pathak A. S., PP-MO-790

Pathak A., PP-TH-243

Pathare A. V., PP-MO-675

Pati S., PP-MO-767

Patil S. B. G., OC-MO-012

Patino G., PP-MO-103

Patkar N. V., PP-TH-275

Patnaik M. M., PP-TH-220

Patno T., PP-TH-182

Patrizia R., PP-MO-056

Patrono C., SA-TH-006, PP-MO-015, PP-MO-016, PP-WE-738

Patsialas K., PP-WE-129

Pattacini C., PP-MO-461, PP-MO-523

Pattarini E., PP-MO-261

Patton J. M., PP-WE-071

Patton W. F., PP-TH-424

Pattyn P., PP-WE-176

Paty I., OC-WE-006, PP-MO-418, PP-TH-409, PP-WE-413, PP-WE-423

Paudice N., PP-TH-353

Paul P., OC-TU-089

Paula G. M. M., PP-MO-063

Paulsson M., OC-WE-076

AUTHORS INDEX

554

Aut

hors

Inde

x

Pautard B., PP-MO-125

Pautard Muchemble B., PP-MO-125

Pautas E., PP-TH-429, PP-WE-412

Pauzner R., OC-TH-102

Pavic M., PP-TH-497

Pavicic M., PP-MO-736, PP-MO-753

Pavlik T., PP-TH-613

Pavlík T., PP-TH-543

Pavlova A., AS-WE-004, PP-MO-513, PP-TH-619, PP-WE-660

Pavord S., PP-WE-760

Pawlak D., PP-MO-114, PP-MO-234, PP-WE-223

Pawlak K., PP-MO-114, PP-WE-223

Pawlik C., PP-MO-441

Pawlinski R., AS-MO-042, AS-MO-044, AS-TU-044, PL-TU-003

Pawlowska Z., PP-WE-879

Payne C. D., PP-MO-733

Payrastre B., OC-MO-099, PP-WE-019

Paysant J., PP-MO-395

Paytubí Garí C., PP-TH-299

Paz B., PP-MO-850

Pazzini C., PP-MO-145

Peace A. J., PP-MO-735

Peace A., PP-MO-738

Peake I. R., AS-MO-019, OC-MO-131, OC-TU-077, OC-WE-135, PP-TH-638

Pearlman N., PP-TH-408

Pearse R. M., OC-TH-067

Pearse R., PP-TH-685

Pearson D., PP-MO-075

Pease R. J., OC-MO-115, OC-TU-054, OC-WE-125, PP-TH-028, PP-WE-258

Pecce R., AS-TH-059

Pecci A., AS-TU-004, PP-MO-067

Pecka M., PP-WE-068

Peden A., OC-MO-032

Pedersen A. A., PP-MO-118,PP-MO-575

Pedersen J., PP-MO-565

Pedersen S., PP-MO-134, PP-TH-140

Pedrazzi P., PP-MO-523

Pedrinelli R., OC-WE-029, PP-MO-758

Peebles D., PP-TH-384

Peel S. A. F., PP-MO-518

Peerlinck K., OC-WE-058, PP-MO-609, PP-WE-041, PP-WE-086, PP-WE-268

Peerlink K., AS-MO-028

Peerschke E. E. I. B., PP-MO-129

Peeters K., PP-WE-085

Peeters L. L., PP-TH-377

Peeters M., PP-MO-225, PP-WE-176

Peetz D., PP-MO-317, PP-MO-373, PP-WE-488

Peffault De Latour R., PP-MO-862

Pegenaute C., PP-MO-472, PP-TH-675

Pegoraro V., PP-MO-321

Pehrsson S., PP-MO-385

Peiretti F., OC-TH-045

Pejovic E. M., PC-002

Pejovic E., PP-WE-881

Pekcelen Y., PP-MO-653

Pekun F., PP-MO-344, PP-MO-537, PP-MO-538, PP-WE-571

Pellechia D., PP-WE-533

Pellegrini V. D., PP-MO-248

Pellequer J. L., PP-WE-659

Pelzer H., PP-MO-569, PP-MO-570, PP-TH-594, PP-WE-154

Pelzer U., LB-MO-003

Pen P., PP-TH-112

Peña E., AS-WE-055, OC-TH-090, PP-MO-209

Peña M., PP-MO-794

Penaloza A., PP-MO-498

Pendergast W., PP-TH-424

Pendleton R. C., PP-TH-424

Pendleton R., PP-MO-470, PP-WE-284

Pendu R., AS-TH-015, OC-MO-060, OC-WE-042, PP-TH-642

Peng J., OC-MO-136, OC-MO-137, PP-MO-695, PP-WE-731

Pengo V., OC-MO-013, OC-MO-015, OC-MO-028, OC-MO-113, OC-TH-003, OC-TH-006, OC-TH-075, OC-TU-040, PP-MO-282, PP-MO-290, PP-MO-291, PP-MO-331, PP-TH-274, PP-TH-303, PP-TH-304

Penka M., PP-MO-259, PP-TH-612, PP-TH-613, PP-WE-596, PP-WE-804

Penkala R. A., PP-MO-002, PP-WE-056

Pennings M., OC-MO-114

Penz S., OC-MO-124

Peoc’H K., PP-WE-408

Pepler L., PP-WE-245

Peppelenbosch M. P., OC-WE-105, PP-MO-489

Peppelenbosch M., PP-WE-839

Pera M. G., PP-TH-494

Perarnau J., PP-MO-664

Perchuc A. M., PP-MO-025

Perchuc A., PP-WE-039

Percic I., PP-WE-680

Pereboom I. T. A., PP-WE-771

Perederyaeva E. B., PP-TH-380

Pereira F. G., PP-MO-870

Pereira G. A. G., PP-MO-825,PP-MO-826

Pereira G. J. C., PP-MO-311

Pereira J., AS-MO-054, OC-WE-026, OC-WE-086, OC-WE-090, PP-MO-064, PP-MO-860, PP-TH-024, PP-TH-043, PP-WE-057, PP-WE-121, PP-WE-123, PP-WE-654

Pereira M. S., PP-MO-725, PP-TH-157, PP-TH-532, PP-WE-476

AUTHORS INDEX

555

Pereira M., PP-WE-374

Pereirinha T., PP-MO-297

Perés Wingeyer S., PP-WE-236

Pérez Andreu V., OC-TH-120,PP-TH-481

Perez Bianco R., PP-WE-618

Perez Cuadra A., PP-MO-362

Pérez Más J., PP-TH-299

Perez R., PP-MO-590, PP-TH-578

Perez-Casal M., PP-TH-197

Perez-Garrido R., PP-WE-767

Pérez-Lara Á., OC-TU-082

Perez-Ontiveros J., PP-WE-217

Pergantou H., AS-MO-028, PP-TH-597, PP-WE-440

Perina F., PP-TH-304

Perini E., PP-MO-698, PP-MO-699

Perkins S. J., PP-TH-657

Perkmann T., PP-WE-777

Perlati M. M. P., OC-TH-026

Perlati M., OC-MO-049, PP-MO-242, PP-TH-382, PP-WE-247

Perlingeiro Beltrame M., PP-WE-066

Perneby C., AS-WE-024

Perneger T., OC-TH-073, PP-MO-505

Pernod G., OC-MO-021, PP-MO-315, PP-TH-309

Perret C., OC-MO-021

Perret-Guillaume C., OC-MO-029

Perrier A., AS-TU-009, OC-MO-038, OC-MO-041, OC-TH-018, OC-TH-073, PP-MO-505, PP-TH-518, PP-TH-524, PP-WE-375, OC-TU-011

Perry D. J., PP-MO-534, PP-TH-657, PP-WE-690

Persdotter Eberg K., PP-MO-374

Persichillo M., PP-MO-876

Persson E., PP-MO-117, PP-TH-529, PP-WE-589

Peruhype-Magalhães V., PP-MO-063

Perutelli P., PP-MO-616

Perveen R., PP-TH-095, PP-WE-006

Perzborn E., PP-MO-162, PP-MO-183, PP-MO-184, PP-MO-185, PP-WE-198, PP-WE-199

Pesantes E., PP-TH-299

Pesavento R., PP-TH-303, PP-TH-304, PP-WE-527

Pescott M., PP-TH-384

Pessina A. C., PP-MO-331

Pestilci F., PP-TH-284

Petakov M., PP-TH-296

Peter K., PP-MO-100, PP-WE-211

Peternel P., PP-WE-251

Peters A., OC-TU-034

Peters J., OC-TU-026

Peters M. P., PP-MO-036

Peters M., PP-MO-597, PP-TH-356, PP-WE-548

Peters R. J., PP-TH-348

Peters R. T., OC-MO-083

Petersen C. L., OC-MO-040

Petersen H., PP-MO-051

Petersen J. M., PP-MO-118,PP-MO-575

Petersen K., PP-MO-244

Petersen L. C., PP-MO-575,PP-TH-116, PP-TH-237, PP-WE-154

Peterse-Stienissen I., PP-MO-169

Peterson C., OC-TH-116, PP-TH-510

Petit L., PP-TH-432

Petitou M., PP-MO-175, PP-TH-423

Petkovic M., PP-WE-369

Petrera N. S., OC-WE-079

Petrides P., PP-TH-671

Petrini P., PP-TH-569

Petros S., PP-TH-253, PP-TH-254

Petrov V. Y., PP-MO-688

Petruk O. A., PP-WE-337

Pettersen A., PP-MO-719, PP-TH-118

Petterson T. M., AS-TH-003,PP-MO-284, PP-WE-292

Pettersson F., PP-TH-018

Petteway - Jr S. R., PP-TH-231

Petteway S. R., PP-TH-230,PP-TH-403

Pettinella C., OC-TU-088, PP-MO-015, PP-WE-738

Peutz-Kootstra C. J., PP-TH-181

Peynaud-Debayle E., AS-WE-025, OC-TH-082

Peyrafitte M., PP-MO-419

Peyvandi F., AS-MO-028, AS-TU-033, OC-WE-131, OC-WE-132, PP-MO-092, PP-MO-648, PP-MO-716, PP-TH-085, PP-TH-670, PP-WE-086, PP-WE-339, PP-WE-657, AS-WE-011

Pezzullo S., PP-WE-321

Pfaffenberger S., PP-MO-829

Pfammatter T., PP-MO-643

Pfannkuche H., PP-WE-022

Pfeiff M., PP-TH-241

Pfenniger A., AS-TU-018

Pfrang J., PP-WE-886

Philippe P., PC-021

Philippou H., OC-MO-076, OC-MO-115, PP-MO-250, PP-WE-130, PP-WE-231, PP-WE-259

Phillips D. R., OC-TH-107, PP-MO-045, PP-TH-027, AS-TU-026

Phillips D., AS-TH-022

Phillips J. K., PP-WE-297

Phillott A., PP-WE-609

Philpot M. A., PP-WE-430

Phng L., AS-MO-061

Phoenix F. P., PP-WE-212

AUTHORS INDEX

556

Aut

hors

Inde

x

Phoenix F., OC-TH-055, PP-TH-351

Piacente L., PP-WE-878

Piazza G., PP-TH-424

Picard V., PP-MO-187

Picardi N., PP-WE-856

Piccioli A., OC-MO-013

Piccoli A., AS-TH-059

Pichlmaier M., PP-TH-207, PP-TH-208

Pickard A., PP-MO-545

Pieculewicz M., PP-TH-337

Pieczanski P., PP-TH-100

Piepenbrock S., PP-TH-207,PP-TH-208

Pierangeli S. S., OC-MO-026,OC-MO-114, OC-TU-038

Pierce G. F., OC-WE-057, OC-WE-059

Piercecchi-Marti M., PP-MO-833

Piermarocchi S., PP-MO-424,PP-TH-302

Pieroni G., OC-TU-064, PP-MO-687, PP-WE-637

Pieters M., PP-WE-228

Pietrangelo L., PP-WE-738

Piga M., PP-MO-266

Pignatelli P., PP-TH-050, PP-WE-105, PP-WE-753

Pignoloni P., PP-MO-287

Pijl H., PP-MO-782

Pijoan J., PP-WE-371

Pileri P., PP-MO-375

Piletz J., PP-MO-857

Pilgrimm A., PP-MO-746

Pili C., PP-TH-282, PP-WE-359

Pilka R., PP-WE-378

Pillitteri D., PP-MO-179, PP-MO-746, PP-TH-662, PP-WE-763

Pillot J., PP-WE-673

Pilon D., OC-TU-023

Pilotto E., PP-MO-424, PP-TH-302

Pilz G., OC-WE-138

Pineda J., OC-TH-027

Pinelis V., OC-WE-143, PP-WE-155

Pineo G. F., LB-MO-005, OC-MO-053

Pineo G., PP-MO-465, PP-MO-466

Ping T., PP-WE-392

Pinheiro P. S., PP-MO-816, PP-WE-347

Pinho N., PP-MO-667

Pink R., PP-WE-150

Pino M., PP-TH-047

Piñol M., PP-TH-635

Pinotti M., AS-WE-039, OC-TH-028, PP-MO-654

Pintao M. C., OC-MO-004, OC-MO-019, OC-WE-023

Pintão M. C., PP-TH-139

Pinto A., AS-TH-030

Pinto B. L., OC-TH-074

Pintó X., PP-WE-816

Pinzon E., PP-MO-865

Pio S. F., PP-TH-556

Piot M., OC-TH-021, PP-WE-165

Piovella C., PP-MO-415

Piovella F., AS-MO-009, OC-TU-010, PP-MO-415

Pipe S. W., AS-WE-043, OC-WE-062, PP-TH-617, PP-WE-153

Piran S., AS-TU-030

Pirck M., PP-WE-617

Pisanelli D., PP-MO-822, PP-WE-366, OC-TU-035

Pisani F., PP-MO-654

Pisano P., PP-MO-833

Piscitelli L., PP-MO-503

Piseddu G., PP-WE-567

Pitocco D., PP-WE-789

Pittens C. A. C., PP-MO-788

Pittet M., AS-WE-057

Pizzinelli S., PP-TH-654

Pizzo G., AS-TH-030

Pizzolo F., OC-TH-030, PP-MO-342, PP-TH-347

Pizzuti M., PP-MO-716

Plachuta T. G., PP-MO-688,PP-TH-454

Plaimauer B., AS-WE-015, PP-MO-087

Plamenová I., PP-TH-306, PP-TH-598

Planchetka J., PP-WE-803

Plançon S., PP-WE-013

Planken E. V., OC-TH-008

Plantavid M., PP-WE-019

Plantier J. L., OC-WE-021

Plantier J., OC-MO-062

Plasenzotti R., PP-WE-675

Plat E., PP-MO-500

Platè M., PP-MO-210, PP-TH-630

Platokouki H., PP-TH-597, PP-WE-440, PP-MO-619

Platt R., OC-TH-084

Platt S. J., PP-WE-613

Platzer C., OC-TH-101

Plawinski L., AS-WE-050, OC-WE-111, PP-TH-039

Plebani A., PP-TH-050

Plehn A., PP-TH-440

Pleines I., AS-TH-040, AS-WE-029, AS-WE-030

Plénat F., PP-TH-394

Plesch W., PP-TH-120

Plessier A., PP-MO-224

Plompen E. P. C., OC-TH-008

Ploplis V. A., OC-TU-050, OC-WE-022

Ploug M., AS-WE-047, PP-WE-225

Plow E. F., OC-MO-047, OC-MO-048

Plow E., PL-TU-005

Plu-Bureau G., PP-WE-316

Plug I., OC-TU-070

Plumb J. M., PP-WE-469, PP-WE-470, PP-WE-471

Plumhoff E., OC-MO-134

Pluthero F. G., OC-TH-060,OC-TU-028

Plyuchsh O. P., PC-041

Plyushch O. P., OC-MO-036

AUTHORS INDEX

557

Plyushch O., PP-WE-608

Pock K., PP-MO-615

Podda G., OC-TH-010

Podolak-Dawidziak M., PP-MO-692

Podolec P., PP-TH-337

Podorolskaya L. V., PP-TH-158, PP-TH-257, PP-WE-224

Podrez E., PL-TU-005, SA-TH-015

Poenaru D., PP-WE-549

Poenitz V., PP-TH-344, PP-WE-072

Poettler M., OC-WE-069

Poggi M., PP-MO-503, PP-WE-715

Poggio R., OC-TH-014

Pohar-Perme M., PP-MO-350

Pohl S., PP-MO-030

Pohlreichova V., PP-MO-583

Polack B., PP-TH-172

Polanowska-Grabowska R. K.,OC-TU-027

Polanski S., PP-WE-884

Poldermans D. D., OC-TH-029

Polenewen R., PP-WE-735

Poli D., AS-TH-005, OC-TH-002, OC-TH-003, OC-TH-004, OC-WE-102, PP-MO-290, PP-MO-291, PP-MO-303, PP-MO-304, PP-MO-339, PP-MO-340, PP-MO-341, PP-TH-412, PP-TH-474, PP-WE-283, PP-WE-286

Poli G., PP-MO-540

Polipoli D., OC-TH-006

Politou M., PP-TH-338

Polkinghorne V., OC-TH-089

Pollack C. V., PP-WE-284

Pollmann H., OC-WE-077, PP-MO-459, PP-TH-575, PP-WE-593, PP-WE-594, PP-WE-670

Pollola J. A., PP-WE-203

Poloczek M., PP-WE-804

Pombo M., PP-MO-389

Pomin V. H., PP-TH-178

Pompili M., PP-MO-328, PP-WE-823

Poncelet P., PP-MO-766, PP-WE-785

Poncz M., AS-TH-008, AS-TH-042, AS-WE-027, OC-WE-151, SA-TU-006

Pongrácz E., PP-WE-350

Poniewierski M. S., PP-MO-492

Pönitz V., PP-MO-433, PP-TH-131, PP-WE-126, PP-WE-829

Ponniahpillai Subramanian H.,PP-MO-821

Pons D., OC-TH-110

Pontara E., PP-TH-259, PP-WE-641, PP-WE-645

Pool R., PP-WE-124

Poole A. W., OC-MO-045, OC-WE-123, PP-WE-020

Poole A., AS-WE-035

Poon M. C., AS-WE-003

Poon M., OC-TU-068, PP-WE-546, PP-WE-553, PP-WE-695

Pop L., PP-MO-532, PP-WE-549, PP-WE-552

Popescu N. I., AS-MO-045, OC-TH-065, OC-WE-028

Poplavsky J. L., PP-WE-655

Popov D., PP-MO-855, PP-TH-003

Popov V. I., PP-WE-075

Popov V., PP-TH-063

Popovic S., PP-TH-296, PP-WE-680

Porcar L., OC-WE-050

Porcher R., PP-MO-862

Porche-Sorbet R., PP-TH-473

Porco A., PP-TH-555

Pordes G., OC-TH-054

Poredos P., PP-MO-350

Porntrasertsud N., PP-MO-354

Porreca E., OC-WE-014, PP-WE-311

Portarena I., PP-TH-494

Porte R. J., PP-WE-771

Pos W., AS-WE-012, AS-WE-013, PP-TH-080

Post M., PP-WE-193

Post Marketing Study Group .,PP-MO-618, PP-MO-619

Postma S., PP-WE-742

Postmus P. E., PP-WE-322

Potaczek D., PP-TH-337

Potapova G. N., PP-MO-806

Potgieter J. J., PP-WE-124

Pötschke C., AS-TH-007

Pottecher J., PP-TH-649

Potthoff C. M., PP-MO-595

Pötzsch B., AS-TH-048, PP-MO-409, PP-WE-180

Poul H., PP-TH-422

Poulhazan E., PP-WE-186

Pounder E., PP-TH-265

Pouplard C., OC-TH-022, PP-MO-527, PP-TH-365, AS-TH-043

Pourfathollah A., PP-MO-214

Pourmohamadi K., PP-TH-535

Pourmohammadi K., PP-TH-534

Povazan L., PP-WE-368, PP-WE-369

Powazniak Y. P., PP-MO-831,PP-MO-832, PP-TH-044, PP-WE-089, PP-WE-094

Powell L., PP-WE-873

Powell S., AS-TU-014, OC-TH-085

Poyet R., PP-MO-773

Pozgaj R., OC-TH-039

Pozner R., PP-WE-042

Pozzi N., AS-MO-013, OC-MO-113, OC-TU-040, OC-WE-081, PP-TH-085

Pracucci G., OC-TH-047

Pradella P., OC-MO-121

Pradier O., PP-WE-013

Prager G. W., OC-WE-069, PP-MO-838, PP-MO-848, PP-WE-843

AUTHORS INDEX

558

Aut

hors

Inde

x

Prandoni P., LB-MO-002, OC-MO-013, OC-MO-015, OC-MO-049, PP-MO-424, PP-TH-302, PP-TH-303, PP-TH-304, PP-WE-403, PP-WE-410, PP-WE-460, PP-WE-527

Pratesi C., PP-MO-804, PP-MO-805, PP-MO-836

Pratesi G., PP-MO-804, PP-MO-805, PP-MO-836

Prathibha B., PP-TH-496

Praticò D., OC-WE-046

Pratt K. P., PP-MO-156

Pratt K., PP-TH-616

Prechel M., PP-MO-703, PP-TH-404, PP-WE-395

Préda I., PP-MO-772

Preiss J. R., PP-WE-569

Preissner K. T., AS-TH-037,AS-TH-058, OC-TH-023, OC-TH-070, OC-TH-110, PP-MO-827

Prejanò S., PP-MO-432, PP-TH-546, PP-TH-547

Prengel C., PP-TH-485, PP-TH-486, PP-WE-490

Presbitero P., PP-WE-791

Presles E., OC-MO-050, OC-WE-002, PP-TH-076

Presnyakova M. V., PP-WE-678

Prestidge T., PP-MO-493

Preudhomme C., PP-WE-762

Prévost C., OC-WE-021

Prezoti A., PP-WE-631

Prezoto B. C., PP-MO-124

Price L., OC-MO-002

Price V., AS-WE-003, PP-MO-686, PP-WE-447, PP-WE-553

Priepke H., PP-WE-390

Prieto M., PP-MO-566, PP-MO-590, PP-MO-601, PP-TH-596

Primiani L., PP-WE-618

Primignani M., PP-MO-224,PP-MO-673, PP-TH-300

Prins M. H., LB-MO-004, OC-TH-001, OC-TH-017, OC-TU-012, OC-WE-100, PP-MO-286, PP-MO-337, PP-WE-317, PP-WE-318, PP-WE-425, PP-WE-457, PP-WE-475

Prins M., OC-MO-016, PP-WE-352

Prinsloo A., PP-WE-124

Prisco D., OC-TH-003, OC-TH-006, OC-TH-075, OC-WE-031, OC-WE-032, OC-WE-102, PP-MO-217, PP-MO-291, PP-MO-303, PP-MO-304, PP-MO-339, PP-MO-340, PP-MO-341, PP-MO-743, PP-TH-352, PP-TH-474, PP-WE-283, PP-WE-746, PP-WE-747, PP-WE-748

Prisyazhnaya N., PP-TH-227

Pritchard D., PP-MO-433

Privalov D., PP-WE-743

Procházka M., PP-WE-378

Prochazkova J., PP-WE-142,PP-WE-273

Procházková J., PP-WE-378

Prochnow S., PP-MO-730

Prock A., AS-TU-057

Profumo A., OC-WE-148

Proietti M., PP-MO-379, PP-WE-824

Prorok M., AS-WE-049

Protonotariou E., PP-MO-302

Proulle V., PP-TH-470, PP-TH-623, PP-TH-649, PP-TH-650, PP-WE-787, PP-TH-074

Provaznikova D., PP-TH-083

Pruss A., PP-MO-240

Pruss C. M., AS-MO-018, AS-MO-020, PP-TH-631

Pruthi R. K., PP-MO-487, PP-MO-629, PP-MO-678

Pryzdial E. L. G., OC-MO-118

Przyklenk K., PP-WE-102

Psaty B. M., OC-TH-117

Psaty B., SA-TU-017

Pshenichnikova T. B., PP-TH-380

Ptoszkova H., PP-MO-563

Pucci N., PP-MO-799, PP-MO-800, PP-TH-340

Puchta A., OC-MO-059

Puck M., PP-WE-329

Puehringer H., PP-MO-141

Pugh N., PP-WE-028, PP-WE-052

Puig J., PP-WE-267, PP-WE-270

Pujade-Lauraine E., PP-WE-505

Pulanic D., PP-MO-630

Pulanic R., PP-MO-630

Pulcinelli F. M., PP-MO-104,PP-WE-789

Pulizzi N., PP-MO-016

Pullan S., PP-WE-416

Pullen G., PP-MO-756

Pullenayegum E., PP-WE-553

Pulli R., PP-MO-804, PP-MO-805, PP-MO-836

Pullinger C. R., AS-WE-010

Puntes M., PP-WE-178

Punzalan R. C., OC-TU-065

Punzo M., OC-TU-072

Pure E., AS-TU-028

Purihit P. K., OC-WE-146

Purroy N., PP-WE-761

Purvis J. E., PP-TH-049, PP-WE-063

Puttarajappa C., PP-WE-495

Puurunen M., PP-WE-276

Puy C., PP-MO-178

Pyle M., PP-TH-326, PP-TH-327

Qadura M., OC-TH-053

Qayyum S., OC-WE-092, OC-WE-096, PP-WE-448, PP-WE-449

Qi G., OC-TU-051, PP-WE-836

Qi Y., OC-MO-123

Qin J., OC-MO-047, OC-MO-048

Qin L., PP-WE-222

Qin P., PP-MO-695

Qing P., OC-MO-136

AUTHORS INDEX

559

Qing Y., PP-MO-691

Qiu Y., PP-WE-857

Quehe P., PP-MO-500, PP-WE-508, PP-MO-499

Quehenberger P., OC-MO-027,OC-TU-016, PP-MO-422, PP-TH-077, PP-TH-273, PP-WE-663

Queijo I. M. I., PP-MO-641

Quenet S., PP-TH-288

Quentin G., PP-MO-112, PP-TH-235

Quere G., PP-MO-310

Quere I., PP-TH-497

Quéré I., OC-TH-081, PP-TH-288

Querellou S., PP-WE-510, PP-MO-508

Quero F., PC-050

Quesnel B., PP-MO-814

Quijada A., PP-MO-737, PP-WE-692

Quilici J., PP-WE-775, PP-MO-773

Quinart A., PP-WE-673

Quinlan D. J., PP-TH-413

Quinn-Allen M., PP-TH-261

Quintana J. C., OC-WE-086

Quintana M., PC-031, PC-032,PC-033, PP-MO-579, PP-MO-590, PP-WE-699

Quintanar L., PP-WE-874

Quintavalla R., PP-MO-294

Quintavalle G., PP-MO-336

Quintella F. F., PP-MO-483

Quiroga T., AS-MO-054, AS-TH-052, PP-WE-123

Qureshi S. H., OC-TU-093

Raab M., PP-MO-043, PP-MO-044

Raaz U., PP-TH-440, PP-WE-190

Rabe E., PP-MO-509, PP-TH-312

Rabelink T. J., PP-WE-851

Rabinovich O., PP-WE-135,PP-WE-293

Rachman A., OC-MO-072

Rachmilewitz E., PP-MO-338

Radaelli T., PP-WE-691

Radesi S., PP-MO-069, PP-TH-063

Radhakrishnan R., PP-WE-063

Radojkovic D., PP-TH-460, PP-WE-379

Radossi P., PP-MO-542

Radovanovic N., PP-TH-296

Radu C., OC-MO-005, OC-MO-119, OC-MO-121, OC-TU-086, PL-TU-004, PP-MO-242, PP-MO-243, PP-MO-765, PP-WE-080, PP-WE-081, PP-WE-247, PP-WE-248, PP-WE-384

Radulovic V., PP-MO-652

Rafailovich M., PP-MO-211

Raffini L. J., AS-TU-055

Rafi S., OC-WE-014, PP-TH-356, PP-WE-548

Rafiee Khoshnood E., PP-WE-074

Rafii A., PP-WE-855

Rafii S., SA-TH-008

Ragab M. ., PP-WE-202

Ragni M. V., OC-MO-031, PP-MO-627

Rago L., PP-MO-876

Ragoonanan V., PP-WE-432

Rahayu P., OC-MO-072

Rahe-Meyer N., PP-TH-207,PP-TH-208

Rahman S., PP-TH-014

Rahmani M., PP-TH-124

Rajab J. A., PP-MO-452

Rajic N. V., PP-WE-680, PP-WE-680

Rajnavölgyi É., PP-MO-359

Rajpurkar M., PP-TH-180

Rajpurohit S., PP-TH-156

Raju N. C., PP-WE-800

Rakicevic L., PP-TH-460, PP-WE-379

Ralevic V., PP-WE-045

Rallidis L., PP-TH-338

Ramacciotti E., OC-TU-060,PP-MO-388

Raman S. V., PP-WE-729

Ramasamy S. M., PP-WE-503

Rambaldi A., AS-TU-048, AS-TU-050

Ramirez A. E., PP-MO-345

Ramirez L. M., PP-WE-489

Ramirez L., PP-MO-528

Ramon L. A., PP-MO-215

Ramos C. D., PP-WE-535

Ramos O. H., PP-WE-160

Ramos-Nino M. E., AS-MO-033

Rampini M. R., PP-MO-380

Rampini M., PP-MO-379

Ramroop N., PP-TH-090

Ramström M., PP-MO-574

Ramstrom S., PP-TH-053

Ramström S., PP-WE-014

Ramzi M., PP-WE-459

Rancan E., PP-MO-659

Rand J. H., OC-TU-039, PP-WE-468

Rand M. L., AS-TH-053, OC-TH-060, PP-MO-020, PP-MO-639, PP-TH-009

Randell E., PP-TH-364

Randolph G., SA-TU-011

Rangarajan S., PP-MO-272,PP-MO-371, PP-MO-543, PP-MO-562, PP-TH-014, PP-TH-599, PP-TH-615, PP-WE-111, PP-WE-539, PP-WE-609, PP-WE-616

Ranjan R., PP-MO-208, PP-WE-327

Rank A., PP-WE-784

Rankin A., OC-TH-093

Rannou O., AS-TH-058

Rans D., PP-MO-617

Rao A. K., AS-TH-044, PP-MO-078

Rao A., PP-WE-894

Rao V. S., AS-WE-059, OC-TH-118, OC-WE-139, PP-MO-791, PP-MO-792, PP-MO-793, PP-MO-811, PP-MO-812, PP-WE-828, PP-WE-832, PP-WE-833, PP-WE-834

AUTHORS INDEX

560

Aut

hors

Inde

x

Rapaccini G., PP-MO-328

Raparelli V., PP-MO-379, PP-MO-380, PP-WE-824

Rapoport T., AS-TU-025, OC-WE-074

Rapson D., PP-TH-639

Rasheed N., PP-TH-062

Raskob G. E., LB-MO-005

Rasmussen J. K., PP-MO-580

Rasmussen J. T., PP-MO-131

Rasmussen L. H., PP-WE-172

Rassoulzadegan M., PP-MO-539, PP-TH-553

Rastegarlari G., PP-MO-539,PP-TH-553

Rastegar-Lari G., PP-TH-636

Rasul F., OC-WE-005

Rateri D. L., OC-TH-077

Rathgen K., PP-TH-134

Rathnam V., PP-TH-117

Ratignier C., PP-MO-530

Raubal B., PP-MO-561

Rauch R., PP-TH-450

Rauh M., PP-MO-544

Rauova L., AS-TH-008

Raupach J., PP-TH-438

Raval S. R., PP-WE-195

Ravanat C., OC-MO-124, OC-TH-034, PP-MO-033

Ravanbod S., PP-MO-539, PP-TH-553, PP-TH-636

Ravenhill L., PP-MO-853

Ravi Kumar V., OC-TH-118

Ravid B., PP-MO-434, PP-MO-685

Ravnefjord A., PP-MO-095,PP-MO-385

Rawlins P., PP-TH-206

Ray L., PP-WE-450

Ray M. J., PP-WE-021

Ray P. S., AS-TU-041

Raymer R. A., PP-MO-570, PP-TH-579

Rázsó K., PP-MO-359

Razzaq T., OC-WE-024

Razzari C., PP-WE-136

Rea C. J., PP-MO-371

Rea C., PP-WE-623

Reakatanan W., PP-MO-354

Reale D., PP-MO-104

Reati R., PP-TH-300

Reaves A., PP-MO-471

Reber G., OC-TU-037, PP-TH-520, PP-WE-267, PP-WE-270

Rebeyka I., OC-WE-096, PP-WE-449

Rebrikov D., PP-WE-335

Recchiuti A., AS-TU-049, PP-WE-738

Receveur N., PP-TH-010

Recher C., OC-MO-099

Recke P. V. D., OC-MO-040

Recknagel P., PP-TH-087

Rector W. G., PP-MO-463

Reddy C. D., PP-MO-028

Redfors P., OC-WE-115

Redondo M., PP-MO-711

Redossi P., PP-TH-527

Redou P., PP-TH-113

Redzic D., PP-WE-254

Reed G. L., PP-WE-071, PP-WE-218

Reed M., OC-TH-015

Reekers J. A., OC-TH-031

Regan I., PP-WE-615

Reganon E., PP-TH-363, PP-WE-885

Reghis A., PP-TH-276

Regina S., PP-MO-527, PP-TH-365

Regnault V., OC-MO-029, PP-MO-402, PP-WE-133, PP-TH-362

Rego E. M., OC-WE-023

Rehberg S., PP-MO-556

Reheman A., AS-WE-042, PP-WE-060

Reiber J. H. C., PP-WE-303

Reid R., PP-WE-462

Reiff E., AS-TH-060, PP-WE-055

Rein C. M., PP-MO-239

Reiner A. P., AS-WE-009

Reinhardt C., AS-WE-054

Reinhart K., PP-WE-684

Reininger A. J., AS-TH-057,OC-MO-124, OC-WE-051, PP-MO-620

Reipert B. M., OC-TH-054, OC-WE-063, OC-WE-065

Reipert B., SA-TU-014

Reis D., PP-WE-310

Reis E. M., PP-MO-475, PP-TH-495

Reiser G., OC-WE-143, PP-WE-155

Reiss U., AS-TU-011

Reiter M., PP-MO-150

Reitsma P. H., AS-MO-005, AS-MO-063, AS-WE-040, OC-MO-004, OC-MO-019, OC-MO-020, PP-MO-236, PP-MO-764, PP-TH-139, PP-TH-484

Reitter S. E., PP-TH-317, PP-WE-621

Reizig P., LB-MO-003

Remandet B., PP-WE-388

Remones V., OC-TH-005

Remuzzi G., PL-TU-006

Renaudin J., PP-WE-483

Rendu F., PP-MO-837, PP-WE-408

Renna F., PP-WE-856

Renné T., SA-WE-014, AS-TH-037, AS-TH-039, AS-WE-034, OC-MO-068, OC-TH-059, PL-TU-003

Renneville A., PP-WE-762

Reny J. L., OC-MO-132, OC-TU-032, PP-MO-783

Reny J., AS-TH-032, PP-WE-744

Repesse Y., OC-WE-066, PP-MO-588, PP-TH-619, PP-WE-600

Resh M., PP-WE-326

Reshetnyak T. M., PP-MO-268,PP-TH-267, PP-TH-277

Reshetnyak T., PP-WE-062

AUTHORS INDEX

561

Rettig R., OC-TU-026

Reuken P., PP-TH-086, PP-WE-684

Reusser M., PP-MO-736

Reutelingsperger C. P., OC-TU-053

Reuwer A. Q., PP-MO-022

Revel A., PP-WE-696

Revel P., PP-WE-673

Revel-Vilk S., AS-TU-008, PP-WE-696

Reverter J. C., OC-MO-130,PP-MO-254, PP-WE-371

Rey I., PC-047

Rey Santos R., PP-TH-299

Reyes C., PP-MO-663, PP-MO-737, PP-WE-692

Reyes E., OC-MO-134, PP-TH-482, PP-WE-264

Reynaud J. J. R., PP-MO-594

Reynaud J., PP-WE-165

Rezaie A. R., OC-TU-093

Rezende S. M., AS-TU-019, PP-TH-556

Rezende S., PP-WE-312

Rezende-Neto J. B., PP-MO-387

Rezzonico F., OC-TU-072, PP-WE-625

Rhee K., PP-TH-504

Rhemtula H. A., PP-TH-370,PP-TH-371

Rhomdhane M., AS-WE-030

Rib L., PP-WE-209, PP-WE-243

Riba R., PP-MO-023, PP-TH-020

Ribeiro D. D., PP-MO-333, PP-MO-334, PP-MO-335, PP-MO-387, PP-TH-672, PP-TH-673, PP-TH-674, PP-WE-364, PP-WE-689

Ribeiro L. M., PP-TH-444

Ribeiro M. A., PP-TH-490

Ribeiro M., PP-WE-730

Ribó Crusat F., PP-TH-299

Ricafort R., PP-MO-180

Riccardi A., PP-TH-374

Riccardi F., PP-MO-523, PP-WE-598

Ricci I., PP-TH-353, PP-TH-474

Riccioni M., PP-WE-647

Ricco A. J., PP-TH-052, PP-TH-053, PP-WE-059

Riccò M., PP-MO-294

Rice A., PP-WE-749, PP-WE-750

Ricevuto E., PP-TH-694

Richard V., PP-WE-859

Richards M., AS-TH-054, PP-MO-560, PP-TH-578

Richardson J. L., PL-TU-002

Richardson J., PP-WE-168

Richardson P. G., OC-WE-108

Richel D. J., OC-WE-019, PP-TH-484

Richter E. K., OC-TU-052

Ricker L. J. A. G., PP-TH-246

Rickles F., OC-MO-016

Rico M. C., OC-WE-030, PP-WE-888

Rico S., PP-WE-178, PP-WE-415

Riddell A. F., PP-MO-524, PP-MO-624, PP-TH-106, PP-TH-528, PP-WE-713

Riddell A., PP-TH-242, PP-WE-192, PP-WE-240

Ridker P., SA-WE-009

Riedel T., PP-TH-213

Rieke M., PP-MO-693, PP-WE-644

Rienstra C. M., OC-TU-091,PP-MO-113

Riera A., PP-MO-226

Ries M., PP-TH-575

Riess H. B., LB-MO-003, PP-MO-509

Riess H., PP-TH-312, PP-TH-425

Riewald M., AS-TH-020

Righini M., OC-MO-038, OC-MO-041, OC-TH-073, PP-MO-505, PP-TH-518, PP-TH-524, PP-WE-375, OC-TU-011, PP-TH-508

Rigolli A., PP-TH-374

Rijken D. C., PP-MO-224, PP-TH-314, PP-WE-228

Rijnders A. J. M., OC-TU-008

Rim D., PP-MO-353

Rim S., PP-WE-783

Rimm E., OC-TU-004

Rimoldi V., PP-TH-670

Riondino S., PP-MO-379, PP-TH-494, PP-WE-789, PP-WE-824

Rios D. R. A., PP-MO-363, PP-MO-364, PP-TH-217, PP-WE-092, PP-WE-310

Rios M., PP-WE-665

Riou B., PC-023

Ris C., OC-TU-055

Risberg B., PP-MO-430

Rischel C., PP-MO-559

Risco L., OC-WE-090

Riserus U., OC-TU-087

Rishavy M. A., OC-WE-078

Rishavy M., OC-WE-072

Risse F., PP-MO-385

Ritchie K., PP-TH-349

Ritli L., PP-MO-532, PP-WE-549

Rittich S., PP-MO-583, PP-TH-083

Rivard G. E., AS-TH-045, AS-WE-003, OC-TU-069, PP-WE-553

Rivard G., OC-TU-068

Rivas I., PC-048, PP-TH-603,PP-TH-604, PP-WE-560, PP-WE-765

Rivera J., AS-MO-054, AS-TH-052, PP-MO-055, PP-MO-732, PP-TH-096, PP-WE-033, PP-WE-764

Rivera L., OC-TH-036

Rives S., PP-TH-451

Rivolta G. F., PP-MO-525

Rivolta G., PP-MO-523, PP-WE-567, PP-WE-598

Rivron-Guillot K., PP-WE-165

Rizoli S. B., PP-MO-387

Rizza V., PP-MO-654

Robert F., PP-WE-768

AUTHORS INDEX

562

Aut

hors

Inde

x

Robert S., AS-WE-050, OC-TU-087, PP-MO-040, PP-WE-785, OC-TU-089

Roberts A. W., AS-WE-032

Roberts H. R., OC-WE-061

Roberts J. R., OC-TH-096, OC-TU-044

Roberts L., OC-MO-088, OC-MO-089

Roberts W., PP-MO-024, PP-TH-020

Robertson I., PP-MO-233

Robertson J. D., PP-MO-639,PP-WE-443

Robertson M., OC-WE-033,OC-WE-116

Robier A., PP-MO-332

Robinson M., PP-TH-536, PP-WE-608

Robinson S., AS-WE-003, OC-TU-068, PP-WE-553

Robinson-Cohen C., OC-TU-023

Robles L., PP-TH-482, PP-WE-001

Robles-Carillo L., PP-MO-004

Robson S., AS-TH-025, OC-MO-127

Rocca A., PP-TH-654

Rocca B., AS-TU-049, PP-TH-082, PP-TH-085, PP-WE-738

Rocchetti L., PP-WE-688

Rocci A., PP-MO-294

Rocco M., OC-WE-148

Rocha M. M., PP-MO-124

Rocha P. R. S., PP-TH-672

Rocha T. R. F., PP-MO-124,PP-TH-542, PP-WE-444, PP-MO-034

Roche H., OC-TU-087

Rochon J., PP-MO-295

Rocino A., AS-WE-005, OC-TU-075, PP-MO-591

Rodeghiero F., AS-MO-029,OC-TU-074, OC-WE-136, PP-MO-612, PP-WE-626, PP-WE-627, PP-WE-628, PP-WE-629, PP-WE-630

Roden R. C., PP-WE-016

Rodewald L., PP-WE-697

Rodger M. A., AS-WE-022, OC-MO-037, PP-TH-292, PP-TH-489, PP-WE-462

Rodger M., OC-MO-087, OC-TH-012, OC-TU-011, PP-MO-460

Rodgers G. M., PP-WE-306,PP-WE-725

Rodgers S., PP-TH-188, PP-TH-626, PP-WE-544

Rodorigo G., AS-TH-029, PP-MO-523, PP-MO-542, PP-WE-509

Rodrigues C. A., PP-MO-862

Rodrigues K. F., PP-MO-816,PP-WE-347

Rodrigues Pereira R., OC-WE-091

Rodrigues V., PP-TH-217

Rodriguez A., PC-047

Rodriguez C., OC-MO-130

Rodriguez J. A., OC-MO-130,OC-TH-113

Rodriguez J., PP-MO-209

Rodriguez Moncalvo J., PP-TH-100

Rodríguez-Otero P., PP-MO-472, PP-TH-675

Roelofs J. J. T. H., PP-MO-190, PP-MO-191

Roemisch J., PP-MO-615

Roessle M., OC-WE-148

Roest M., AS-WE-008, OC-TH-025, PP-TH-055, PP-WE-357

Rogacev K. S., OC-MO-126,PP-MO-809

Rohatagi S., OC-WE-003

Roheghiero F., AS-MO-017

Rojas M., PP-MO-790

Rojnuckarin P., PP-TH-245

Roldan V. V., PP-TH-308

Roldan V., OC-TH-120, PP-TH-481

Roldán V., AS-TH-052, OC-TH-027, PP-MO-732, PP-WE-123, PP-WE-764

Rolfes E., PP-MO-317, PP-MO-373

Rolli V., OC-MO-062

Romagnuolo I., PP-MO-743,PP-MO-805

Romanenko O., PP-WE-010

Romaniuk M. A., PP-WE-035,PP-WE-042

Romano E., PP-MO-818, PP-WE-745, PP-WE-746, PP-WE-747

Romano M., AS-TU-049

Romano P. S., PP-TH-311

Romanov A. N., PP-MO-182

Romanov Y. A., PP-MO-856

Romay- Penabad Z., OC-MO-026

Romay-Penabad Z., OC-MO-114, OC-TU-038

Romeih S., PP-MO-507

Romero J., PP-MO-579

Romey-Chatelain M. C., PP-MO-656

Romijn F., PP-WE-497

Romijn J. A., PP-TH-238, PP-TH-286

Rommens J., AS-TH-045

Ronca E., PP-TH-374

Roncon L. L. R., PP-MO-312

Rondelli F., OC-TU-024

Roodt J., AS-TH-024

Roos Y. B. W. E., AS-TU-035

Roque M., PP-MO-254

Rosa J., OC-WE-043

Rosado J. A., PP-TH-003

Rosano C., OC-WE-148

Rosario P. W., PP-MO-349

Rose H., PP-WE-468

Rose K., PP-WE-022

Rose P., OC-TH-076

Roselli M., PP-TH-494

Rosen E. D., OC-TU-031, PP-WE-394

Rosen H., AS-TU-043

Rosenbaum E. J., PP-TH-424

AUTHORS INDEX

563

Rosenberg N., OC-MO-105,OC-TH-042, PP-TH-013, PP-TH-075, PP-WE-010

Rosenbreg N., PP-TH-084

Rosencher N., OC-MO-050,OC-WE-002, PP-TH-167, PP-TH-169, PP-TH-170, PP-WE-204, PP-WE-205

Rosencrance J. G., PP-TH-354

Rosendaal F. R., AS-MO-003,AS-MO-005, AS-MO-034, AS-TH-002, AS-TH-035, AS-WE-008, LB-MO-001, OC-MO-003, OC-MO-004, OC-MO-020, OC-MO-023, OC-MO-024, OC-MO-079, OC-TH-025, OC-TU-001, OC-TU-070, OC-WE-013, OC-WE-015, OC-WE-016, OC-WE-036, OC-WE-091, PP-MO-289, PP-MO-316, PP

Rosendaal F., SA-TU-018

Rosenkranz A., PP-WE-439

Rosenqvist M., PP-TH-469

Rosenstein R., PP-MO-038

Rosenthal C., PP-MO-240, PP-MO-241

Rosenthal E., PP-MO-749

Roshani S., AS-MO-030, PP-TH-139

Roshdy Elsafy U., PP-TH-445

Rosholm A., OC-WE-055

Rosing J., OC-MO-005, OC-MO-119, OC-WE-097, PP-MO-186, PP-MO-337, PP-TH-377, PP-WE-157, PP-WE-352, PP-WE-499

Roskell N. S., PP-WE-469, PP-WE-470, PP-WE-471

Ross D. A., AS-WE-010

Ross D., OC-WE-096, PP-WE-449

Rossetti G., AS-TU-032

Rossetto V., OC-TU-086, PP-MO-348, PP-TH-382, PP-TH-383, PP-TH-487, PP-TH-488, PP-WE-147, PP-WE-247

Rossi E. E. R., PP-MO-372

Rossi E., PP-WE-366

Rossi J., PP-WE-694

Rossi L., PP-MO-818, PP-WE-746

Rossi M., PP-WE-791

Rossi V., PP-MO-572

Rosso F., PP-WE-338

Rosso M., PP-WE-870

Rota L. L., AS-WE-007

Rota L., PP-WE-791

Roth I., AS-TU-018

Rother R. P., OC-WE-012

Rothschild C., PP-MO-077,PP-MO-530, PP-TH-593, PP-TH-619, PP-WE-592

Rothwell P., OC-MO-009

Rotilio D., PP-TH-048, PP-TH-248

Rotmans J. I., OC-TH-031

Rotschild C., PP-TH-172

Rott H., PP-MO-377, PP-TH-646, PP-TH-647, PP-TH-671, PP-WE-370, PP-WE-669, PP-WE-670

Rottensteiner H., PP-MO-640,PP-TH-641, PP-WE-619

Rough J. J., OC-WE-030, PP-WE-888

Rouhl R. P. W., OC-TU-085,PP-WE-219

Roullet S., PP-WE-673

Roumenina L. T., PP-WE-614

Roumeque L., PP-TH-060

Rouse J., PP-WE-703

Rousseau A., PP-MO-368, PP-MO-369, PP-MO-491, PP-TH-345, PP-TH-447, PP-TH-483, PP-WE-508

Roussel B., PP-MO-125

Roussel-Robert V., PP-WE-533, AS-TH-043

Routledge M. N., PP-TH-212

Rovere-Querini P., OC-WE-127

Roveri R. G., PP-WE-535

Rovin B. H., PP-WE-729

Rovira N., AS-MO-065

Rowland C. M., AS-WE-010

Roy A., PP-TH-599, PP-WE-111, PP-WE-609

Roy P. M., PP-TH-518

Roy P., AS-TU-009, OC-MO-038, OC-MO-041, OC-TH-018, PC-023, PP-TH-524

Royer B., AS-TH-043

Rozalski M., PP-TH-098, PP-TH-099

Ruan C., PP-MO-830, PP-MO-854, PP-MO-859, PP-MO-883, PP-TH-093, PP-TH-399, PP-TH-400, PP-TH-621, PP-WE-088, PP-WE-099, PP-WE-711, PP-TH-335, PP-WE-773

Ruan J., PP-MO-883

Ruano M., PP-WE-796

Rubal B. J., PP-MO-103

Rubbi F., OC-TH-011

Rubboli A. A. R., PP-MO-312

Rubets I., PP-WE-179

Rubichek O., PP-MO-313

Rubin M. S., PP-MO-825, PP-MO-826

Rubini V., PP-WE-625

Ruchutrakool T., PP-MO-406,PP-WE-772

Rudd C. E., PP-MO-041

Rudd-Scott L., OC-TH-007

Rudez G., OC-MO-133

Rudez G., PP-MO-781

Rudigoz C. R., PP-TH-385

Rudzki Z., PP-WE-544

Ruf A., PP-TH-681

Ruf W., SA-MO-011, AS-MO-063, AS-TU-043, AS-WE-054, OC-MO-129, OC-TH-110

Ruffatti A., OC-MO-028, OC-MO-113, OC-TU-040, PP-TH-274

Rugeri L., PP-MO-645, PP-MO-658, PP-TH-385, PP-TH-386

Ruggeri Z. M., AS-MO-049,OC-TH-096, OC-TU-044, PP-WE-018, PP-WE-791, AS-WE-036

Ruggeri Z., AS-TU-030, PP-MO-775, PP-WE-060

Ruggiero L., OC-TU-025

AUTHORS INDEX

564

Aut

hors

Inde

x

Rugin A., OC-TU-057

Ruinemans-Koerts J., PP-MO-169

Ruivard M., PC-013, PC-021

Ruiz N., PP-WE-267, PP-WE-270

Ruiz Nodar J., OC-TH-120

Ruiz-Saez A., PP-MO-526, PP-MO-663, PP-MO-737, PP-WE-692

Rumley A., OC-TH-080, OC-WE-033, OC-WE-116, PP-WE-353

Rumph B., PP-MO-776

Rundgren M., PP-WE-721

Rupin A., PP-MO-382, PP-MO-395, PP-WE-396

Rupwate M., PP-MO-200

Rusanova A., PP-MO-875

Rusconi A., OC-TH-010

Rusicke E., PP-MO-130, PP-TH-162, PP-WE-434

Russell S. J., PP-TH-458

Russell S., OC-WE-020, PP-MO-082, AS-MO-031

Russin M. P., PP-WE-704

Russmüller G., PP-MO-718

Russo A., PP-WE-653

Russo L., AS-TU-050, PP-MO-476, PP-WE-499

Russolillo A., PP-MO-336

Rutella S., PP-TH-085

Ruven H. J. T., OC-MO-133,PP-MO-781

Ruzza L., PP-MO-331

Ryan C., PP-WE-443

Ryan F., PP-MO-414

Ryan K., PP-WE-802

Rybakova L. P., PP-WE-835

Rybaltowski M., OC-WE-054

Rychli K., PP-MO-829

Rychlik B., PP-TH-098, PP-WE-034

Ryland J. K., PP-MO-325, PP-WE-125

Ryoo H., PP-TH-504

Ryser R., PP-MO-279

Rysz J., PP-MO-097

Ryttberg L., PP-WE-472

Rywaniak J., PP-MO-097, PP-WE-034

Rzeszutko M., PP-MO-355

S. Sen H., PP-TH-121

Sa Q., OC-TU-036

Saab R., PP-TH-456, PP-WE-686

Sabaie S. E., PP-TH-506

Sabater-Lleal M., PP-TH-290,PP-WE-208, PP-WE-209

Sabatier F., AS-WE-050, OC-TU-087, PP-MO-833, PP-WE-850

Sabatino D. E., AS-TU-013

Sabino A. P., PP-MO-333, PP-MO-334, PP-MO-335, PP-MO-346, PP-MO-363, PP-WE-364, PP-WE-815

Sabo T. M., PP-WE-158

Sabovic M., PP-MO-350

Sabrina G., PP-WE-147

Saccullo G., AS-TH-030, PP-TH-527

Sacewicz I., PP-MO-839

Sachdev S., PP-MO-427

Sachs U. J. H., AS-MO-050

Sachs U., PP-MO-083

Sack B., OC-TH-049

Saczewicz I., PP-MO-843

Sadeghi B., PP-TH-311

Sadler E., OC-MO-070

Sadler J. E., AS-MO-014

Sadler J., PL-TH-001

Sadowski J., PP-MO-798, PP-WE-107

Saenz D., PP-MO-038

Sáez A., PP-TH-555

Sáez C. G., OC-WE-086, OC-WE-090, PP-MO-860, PP-TH-043, PP-WE-057

Safa O., PP-MO-200

Safadi F. F., OC-MO-043, PP-WE-888

Saftoiu C., PP-TH-063

Sage S. O., PP-MO-003

Saggiorato G., OC-WE-088,PP-TH-302, PP-TH-420, PP-WE-866

Saggioro F. P., OC-WE-023

Sahin T., PP-WE-571

Sahlab S., PP-MO-277

Sahuquillo J., PP-MO-226

Said J. M., PP-MO-381

Saillant D., AS-MO-053

Sainani G., PP-WE-825, PP-WE-826

Saint-Remy J. R., PP-MO-605,PP-WE-610

Saint-Remy J., OC-TH-057,PP-WE-614

Saito H., PP-MO-138, PP-TH-081, PP-WE-671

Saito J., PP-WE-148

Saka B., PP-MO-744

Sakai M., PP-TH-592, PP-WE-606

Sakariassen K. S., PP-TH-103

Sakata C., PP-TH-041, PP-TH-042

Sakata T., PP-MO-726, PP-TH-320

Sakata Y., OC-TH-051, PP-TH-054

Sakellaridis T., PP-WE-693

Sakon M., PP-TH-410, PP-TH-411

Saksela K., AS-TU-038

Saksena R., PP-MO-180

Sakurai H., PP-MO-516, PP-TH-319, PP-WE-463

Sakurai Y., PP-WE-244

Sala N., PP-WE-821, PP-WE-822

Salaj P., PP-MO-583, PP-TH-083, PP-TH-543

Salameh P., PP-WE-281

Salatic I., PP-WE-368

Salaun P., PP-WE-510, PP-MO-508

Salazar D. E., PP-MO-733

Salazar D., OC-WE-003, PP-WE-179

AUTHORS INDEX

565

Salcioglu Z., PP-MO-073, PP-TH-121, PP-WE-571

Saleh M. N., AS-MO-055, AS-TU-002

Salem H. H., AS-WE-032, OC-WE-044

Salem H., PP-WE-391

Salerno F., PP-MO-673

Sales M., PP-TH-635, PP-WE-525

Salgado V., PP-WE-874

Salguero M., PP-MO-279

Salhi N., PP-MO-611

Salido E., PP-MO-536

Salido G. M., PP-TH-003

Salifu M. O., OC-TH-092

Saller F., OC-WE-037

Salles I. I., AS-MO-037, PP-WE-084, PP-WE-085

Salles I. S., PP-MO-049

Sallmon H., PP-TH-067, PP-TH-073

Salmela B., PP-MO-170

Salmoiraghi S., AS-TU-050

Salomon R., PP-MO-748

Saltykova N. B., PP-TH-313,PP-TH-346

Salvado R., PP-WE-730

Salvadori M., PP-WE-002

Salvagno G., OC-MO-096, OC-MO-097, PP-MO-540, PP-MO-541, PP-WE-140

Salvaris E., OC-MO-127

Salvi A., OC-MO-092, OC-TH-014

Salzer-Muhar U., PP-MO-436

Samama C. M., PP-MO-391

Samama C., OC-WE-002, PC-023

Samama M. M., PP-MO-185,PP-WE-198, PP-WE-199

Sambo A. L. A., PP-WE-535

Sambrook P. N., AS-TH-017

Samel M., PP-MO-149

Samis J. A., OC-TH-071, OC-TH-072

Samkova A., PP-MO-682

Samonte M., PP-WE-277

Samoylenko V., PP-MO-863,PP-TH-236, PP-WE-138

Samudra A., OC-MO-101

Samulski R. J., OC-TH-087

Sanabria P., PP-WE-065

Sanak M., PP-MO-270, PP-MO-329, PP-MO-784

Sanchez C., OC-WE-099

Sánchez Casado M., PC-031,PC-032, PC-033, PP-WE-699

Sanchez D., PP-MO-265, PP-TH-281

Sanchez J., OC-MO-106, OC-TH-073, PP-MO-227

Sanchez Luceros A., PC-047,PP-MO-204, PP-MO-274

Sánchez Luceros A., PP-WE-089, PP-WE-093, PP-WE-094, PP-WE-402

Sanchez Munoz-Torrero J.,PP-TH-288

Sanchez O., AS-TU-009, OC-MO-041, OC-TU-090, PP-MO-376, PP-TH-524

Sanchez R., PP-MO-226

Sánchez T., PP-TH-635, PP-WE-525

Sanchez-Lazaro I., PP-TH-363

Sánchez-Lázaro I., PP-WE-885

Sanchez-Luceros A., PP-MO-610, PP-MO-613

Sánchez-Vega B., AS-TH-052,PP-TH-247, PP-TH-287

Sanclemente C., PP-WE-360

Sanda N., PP-MO-138

Sandberg H., PP-MO-574

Sander M., PP-MO-240

Sanderink G., OC-WE-006, PP-WE-423

Sandhu M., PP-MO-427

Sandhu R. K., PP-TH-498

Sandoval E. P. N., PP-TH-542

Sandoval-Cooper M. J., OC-TU-050, OC-WE-022

Sandset P. M., AS-MO-007, AS-TH-004, PP-MO-288, PP-WE-332, PP-WE-486, PP-WE-487

Sandset P., PP-TH-164, PP-TH-165, PP-WE-191

Sandy B., PP-TH-396

Sane D. C., PP-WE-861

Sanguigni V., PP-TH-050

Sani G., PP-TH-352

Sanjay A., PP-TH-011, PP-WE-012

Sanna S., OC-TU-074

Sannappa P. R., OC-WE-139,PP-MO-791, PP-MO-792, PP-MO-793

Sano M., PP-TH-320, PP-WE-671

Santacroce R., PP-WE-366

Santagostino E., AS-TU-032,AS-WE-005, AS-WE-020, OC-TU-074, OC-TU-075, PP-MO-542, PP-TH-558, PP-WE-555, PP-WE-599

Santamaria A., PP-MO-413

Santamaría A., PP-MO-323

Santamaria M., PP-WE-048

Santana Sorensen A., PP-TH-103

Santana-Lemos B. A. A., OC-WE-023

Santesson P., OC-WE-104

Santilli F., AS-TU-049, OC-TU-088, PP-MO-015, PP-MO-016, PP-WE-738

Santoro C., PP-MO-210, PP-MO-525, PP-MO-542, PP-MO-572, PP-WE-567

Santoro M. L., PP-MO-034

Santoro N., PP-MO-448, PP-TH-493

Santoro R., AS-TU-032, PP-MO-432, PP-MO-525, PP-TH-546, PP-TH-547

Santos A. O., PP-WE-535

Santos A. V., PP-TH-217

Santos A., PP-MO-520, PP-MO-521, PP-WE-066, PP-WE-588, PP-WE-631

Santos C. G. M., PP-MO-335

Santos E. C., PP-WE-428

Santos G. A. S., OC-WE-023

Santos I. R., PP-WE-347, PP-WE-814

AUTHORS INDEX

566

Aut

hors

Inde

x

Santos M. S., PP-MO-333, PP-MO-334, PP-MO-363, PP-MO-364, PP-WE-364, PP-WE-365

Santos M. T., PP-MO-027, PP-WE-096, PP-WE-796

Santos M., PP-MO-227, PP-WE-436

Santoso S., AS-MO-050, AS-MO-052, AS-MO-057, OC-MO-072, PP-MO-083

Sanz-Rosa D., PP-MO-026

Saotome T., PP-TH-689

Saour J., PP-MO-425, PP-TH-465, PP-WE-285

Saour T., PP-TH-465, PP-WE-285

Saposnik B., AS-TH-043, OC-TH-082, PP-TH-074, OC-TU-032, PP-TH-189

Sarabi A., PP-WE-892

Saracco P., PP-TH-453, PP-TH-452

Saracini C., AS-TH-034, PP-MO-818

Saraf S., PP-TH-061, PP-WE-751

Saraniti J., PP-WE-239

Sarda-Mantel L., PP-MO-786

Sargent I., OC-TU-056

Sarig G., PP-MO-313

Sarlon G., OC-TH-048

Sarmiento I., PP-MO-160

Sarode R., PP-MO-757

Sarper N., PP-WE-571

Sartorello F., PP-TH-259, PP-WE-641, PP-WE-645

Sartori M. T., PP-MO-424, PP-TH-302, PP-TH-420, PP-WE-424

Sartori M., AS-TH-029, PP-MO-351, PP-WE-359

Sartori R., PP-MO-542

Sasamata M., PP-TH-184

Sasanakul W., PC-052, PP-WE-566

Sask K. N., PP-TH-435

Sasmaz I., PP-MO-606, PP-MO-644, PP-WE-607

Satake M., PP-WE-736

Sato K., PP-WE-793

Sato Y., PP-MO-123

Satoh D., PP-WE-781

Satoh K., PP-MO-734

Satta N., OC-TU-037

Sattar N., OC-WE-033, OC-WE-116

Saucedo J. F., PP-WE-794

Sauerbruch T., PP-TH-537

Sauls D. L., PP-MO-300

Saunders B., PP-MO-471

Saunders R. E., PP-TH-657

Saut N., OC-MO-021, PP-TH-309

Sautet A., PC-023

Savchuk A. N., PP-TH-160

Savchuk O. M., PP-MO-146,PP-MO-401

Savchuk O., PP-TH-395

Savic A., PP-WE-680

Savic I., PP-WE-680

Savinkova I., OC-WE-143

Savion N., PP-WE-044, PP-WE-049

Savoia A., PP-MO-085

Savonarola A., PP-MO-380,PP-WE-824

Savopol T., PP-TH-063, PP-WE-075

Savushkin A. V., PC-004, PC-006, PC-007

Sawada K., PP-TH-229

Sawamura A., PP-WE-687

Saxena R., PP-MO-208, PP-MO-638, PP-WE-037, PP-WE-327

Sayer R., PP-MO-708

Sazonova I. Y., PP-WE-218

Sbraccia P., PP-MO-016

Scannapieco G., OC-TH-011

Scarabin P., OC-TH-005, OC-WE-017, PP-TH-349, AS-TH-001

Scaraggi A., PP-MO-542

Scaraggi F. A., PP-TH-573, PP-WE-599

Scaraggi F., OC-TU-075

Scarno A., PP-WE-824

Scarvelis D., PP-MO-504

Scekic M., PP-WE-369

Scepansky E., PP-MO-632

Schaap M. C. L., OC-TU-059,PP-MO-022

Schachnik N. C. C., PP-MO-063

Schade A. E., PP-MO-006, PP-WE-095

Schadinger S. L., OC-TH-115

Schadinger S., PP-WE-241

Schadmand-Fischer S., PP-WE-488

Schaefer A., PP-MO-005, PP-TH-019, PP-WE-886

Schaefer-Prokop C., PP-TH-517

Schäfer H., PP-TH-215

Schäfer W., PP-MO-556, PP-MO-557

Schaffner F., AS-WE-054

Schambeck C. M., PP-MO-295,PP-MO-307

Schapira M., OC-WE-037

Scharf R. E., AS-TH-060, PP-MO-001, PP-MO-745, PP-TH-355, PP-WE-054, PP-WE-055, PP-WE-862, PP-WE-865

Scharrer I., PP-WE-087, PP-WE-633, PP-WE-653

Schattner M., PP-WE-035, PP-WE-042

Schaub R. G., PP-WE-168, PP-WE-569

Schaub R., OC-WE-007

Scheele J. S., PP-MO-029

Scheffler B., PP-TH-120

Scheiflinger F., AS-WE-015,PP-MO-087, PP-MO-150, PP-WE-557

Schejter-Dinur Y., PP-WE-696

Schellong S. M., OC-TU-010,PP-MO-509, PP-TH-312

Schellong S., PP-TH-425

Schellongowski P., PP-TH-077

Schenk W. A., AS-WE-034

AUTHORS INDEX

567

Schenka A. A. A. S., PC-046

Scherer M. R., PP-WE-399

Scheucher P. S., OC-WE-023

Schiavon F., OC-TU-086

Schiavone D., OC-WE-071

Schiavoni M., PC-034

Schiavulli M., PP-WE-599

Schiemann S., PP-WE-506

Schiff E., PP-WE-272

Schifferdecker T., PP-MO-030

Schiks B., AS-TH-038

Schimanski S., PP-MO-295

Schinco P., OC-TU-075, PP-MO-525

Schindewolf M., PP-MO-501,PP-MO-705, PP-MO-706, PP-WE-376, PP-WE-714

Schinzel H., PP-MO-317, PP-MO-373, PP-WE-488

Schiviz A., PP-WE-557

Schlachterman A., AS-TH-013

Schlegel N., AS-TH-043, PP-TH-074

Schliamser L., PP-WE-272

Schlitt A., OC-MO-126, PP-TH-440, PP-WE-190

Schluckebier L., PP-MO-483

Schluter J., PP-TH-471, PP-TH-472

Schmaier A. A., AS-TU-038

Schmaier A. H., OC-MO-128,OC-TH-056, AS-TH-036

Schmid J., OC-TU-081

Schmid M. L., PP-MO-550

Schmid P., PP-TH-692

Schmid R., PP-MO-422

Schmidbauer S., PP-TH-130,PP-TH-561

Schmidt J., OC-TH-018

Schmidt M., PP-MO-087

Schmidt-Woell T., OC-TH-070

Schmugge M., OC-TU-061, PP-TH-446

Schnee J. M., PP-MO-167, PP-WE-204

Schneider D., OC-WE-059

Schneider M. F., AS-TH-057,OC-WE-051, PP-MO-620

Schneider P., PP-MO-491, PP-TH-447

Schneider T., PP-TH-253, PP-TH-693

Schneiter S., PP-WE-717

Schneppenheim R., OC-TU-077, OC-WE-136, PP-MO-638, PP-TH-215, PP-WE-629, PP-WE-630, PP-WE-651, PP-WE-722

Schobess R., OC-WE-106

Schoenefeld H., PP-MO-240

Schoenfisch M. H., OC-WE-147

Schoenwaelder S. M., AS-WE-032

Schols S. E. M., AS-WE-044,PP-MO-670, PP-WE-260

Scholz T., PP-MO-179, PP-MO-746, PP-TH-662, PP-WE-763

Scholz U., PP-MO-365, PP-TH-656, PP-WE-233, PP-WE-622, PP-WE-733

Schoolmeester A., AS-TH-024

Schosser R., PP-MO-660

Schott U., PP-MO-258, PP-MO-672, PP-TH-359, PP-TH-428, PP-TH-695, PP-WE-721, PP-WE-758

Schouten J., PP-MO-383

Schouten M., OC-TH-062, OC-TH-066, OC-WE-144

Schramm W., OC-WE-118, OC-WE-119, PP-MO-532, PP-WE-542, PP-WE-549, PP-WE-552, PP-WE-594

Schranz S., OC-WE-011, PP-MO-622

Schreiber S., PP-MO-307

Schreibner D., PP-MO-470,PP-MO-470

Schreiner J., PP-TH-641

Schreiner P. J., AS-WE-060

Schrenk G., PP-WE-619

Schreyer B., PP-MO-141

Schrieber D., PP-WE-284

Schröder J., PP-TH-537

Schroeder C., PP-TH-404

Schroeder V., OC-TH-089, OC-WE-034, PP-TH-671

Schroth P., PP-TH-585, PP-TH-586

Schuemann M., OC-TH-070

Schuepbach R. A., AS-TH-020

Schuerholz T., PP-WE-684

Schuettrumpf J., AS-TH-014

Schuh K., OC-MO-068

Schuhler S., PP-MO-033

Schulman K. L., OC-WE-018

Schulman S., AS-TU-025, AS-TU-034, OC-TH-007, OC-WE-074, PP-MO-515, PP-TH-315, PP-TH-413, PP-WE-419

Schulte A., PP-MO-030

Schulte S., OC-WE-120, PP-TH-130, PP-TH-561

Schulte-Merker S., OC-TU-030

Schultz M. J., PP-MO-190, PP-MO-191

Schulz A. S., PP-MO-029

Schulz C., PP-MO-005

Schulze H., PP-MO-029, PP-WE-077

Schumacher M., OC-TH-058

Schumacher W. A., PP-TH-202, PP-WE-100

Schuman J., PP-MO-156

Schunemann H. J., PP-MO-876, PP-WE-429

Schurgers L. J., OC-MO-044,OC-TU-053, PP-WE-808

Schuster M., OC-WE-063, PP-MO-241

Schutgens R. E. G., OC-TU-010, PP-MO-036, PP-WE-317, PP-WE-318, PP-WE-475

Schuttenberg V., PP-TH-606

Schüttrumpf J., PP-TH-651

Schütz B., PP-TH-587

Schützer K., PP-WE-200, PP-WE-201

Schved J., AS-TH-032, OC-MO-021, OC-MO-132, PP-MO-657, PP-TH-172, PP-TH-309, PP-WE-744

AUTHORS INDEX

568

Aut

hors

Inde

x

Schwaab R., AS-WE-004, PP-TH-696

Schwartz D., PP-WE-495

Schwartz J., PP-MO-321

Schwartz K. A., PP-WE-495

Schwartz L., PP-TH-584

Schwartz M. A., AS-TH-056

Schwartz M., PP-WE-860

Schwarz H. P., OC-TH-054,OC-WE-065, PP-MO-640, PP-TH-611, PP-TH-640, PP-TH-641, PP-WE-619

Schwarz H., OC-MO-090, OC-WE-063

Schwarz M., PP-MO-100

Schwarz N., PP-WE-714

Schwarz T., OC-WE-040, PP-WE-594

Schwarzman A. L., PP-TH-025

Schweintzger S., PP-TH-448

Schwertz H., AS-WE-028

Schwonberg J., PP-MO-501,PP-MO-730, PP-WE-792

Scianname’ N., OC-TU-035

Sciuccati G., OC-TU-064, PP-MO-687, PP-WE-637

Scoazec J. Y., PP-WE-493

Scorizello B. A., OC-WE-101

Scott D. M., OC-TH-043

Scott J. A., PP-TH-212

Scott P., OC-TH-116

Scott R., PP-TH-615

Scrascia G., PP-MO-423

Scriven N., OC-TH-076

Scroboachi M., PP-TH-497

Scroyen I., PP-MO-219

Scuderi P., PP-TH-230, PP-TH-231, PP-TH-403

Scully M. A., OC-MO-138

Scully M. F., OC-WE-024

Scully M., PP-MO-708, PP-TH-088

Searle E. J., PP-MO-690

Seary M. E., PP-TH-629, PP-WE-587

Seaton D., PP-MO-233

Sebastian S., AS-WE-037

Sedano C., PP-MO-566, PP-MO-590, PP-MO-601, PP-TH-596

Sedding D. G., AS-TU-057

Sedding D., AS-TH-058

Sedlmeier R., OC-TH-059

See B. H., PP-MO-172

Seehafer T., PP-TH-360

Seehaus S., AS-MO-059

Seested Johansen T., PP-MO-121, PP-MO-122

Segal H., OC-MO-009

Segbefia C. I., PP-MO-443

Segel S., PP-WE-589, PP-WE-590, PP-WE-591

Segers O., OC-WE-097

Séguin C., PP-MO-820

Seibt S., PP-WE-620

Seidel H., PP-MO-253

Seidlerova J., PP-WE-287

Seifert S., OC-MO-068

Seifried E., AS-TH-014, OC-WE-076, OC-WE-077, PP-MO-128, PP-MO-295, PP-TH-661, PP-WE-210

Seitz R., PP-WE-841

Sekaran M., PP-MO-366, PP-MO-367

Seki T., PP-TH-229

Seki Y., PP-MO-669, PP-TH-688

Seksarn P., PP-MO-446

Selan C., AS-TH-025, OC-MO-101

Selby R., OC-MO-051, OC-TU-020

Seldon M., PP-WE-118

Selfa S., PP-MO-227

Seligsohn U., SA-WE-015, OC-MO-105, OC-TH-042, OC-TH-102, PP-TH-013, PP-TH-084

Selim T. S., PP-WE-257

Selime A., PP-MO-858

Seljeflot I., PP-MO-719, PP-TH-118, PP-TH-427, PP-WE-026, PP-WE-344

Sellam J., PP-WE-787

Sellborn A., PP-MO-430

Selleng K., OC-TH-102

Sellink E., OC-WE-084

Selton-Suty C., OC-MO-029

Semberova J., PP-TH-016

Semenova O. N., PP-TH-361

Semeraro F., PP-MO-176, PP-MO-245, PP-MO-423, PP-WE-249

Semeraro N., PP-MO-176, PP-MO-245, PP-MO-423, PP-TH-573, PP-WE-249

Sen H., PP-MO-073, PP-WE-571

Sen M., PP-TH-511

Sengupta N., PP-WE-473, PP-WE-478

Sengupta R., AS-TU-012

Senis Y. A., AS-WE-033, PP-TH-021, AS-MO-036

Senis Y., AS-TU-036

Senzolo M., PP-TH-420, PP-WE-424

Seo Y., PP-TH-519

Sepanski D. M., PP-TH-376

Sephton P., PP-TH-679

Sequeria A., PP-WE-757

Serafimidou O., PP-MO-302

Serban M., OC-WE-119, PP-MO-532, PP-WE-542, PP-WE-549, PP-WE-552

Serbic O. M., PP-TH-269

Serbic O., PP-WE-254

Serebruany V. L., PP-WE-022

Serebryakova T. N., PP-TH-158, PP-TH-257

Seredavkina N. V., PP-TH-267, PP-TH-277

Seredkina N., PP-MO-808

Serhan C., SA-MO-016

Serin K., PP-WE-197

Serino M., PP-MO-523

Sermon A. M., PP-MO-110

Seroski W. M., PP-WE-431

Serra J., PP-TH-520, PP-TH-625, PP-WE-267

AUTHORS INDEX

569

Serrano R., OC-TH-113

Serre A. F., PC-013

Sert C., PP-TH-511

Sessa W., SA-MO-017

Setlaba P., PP-TH-637

Setty Y. B. N., PP-WE-894

Setty Y. B., PP-TH-262

Sevde U., PP-MO-858

Severin K., PP-TH-575

Severin S., PP-WE-019

Severinsen M. T., PP-WE-315

Sevestre M., PP-MO-315

Sevilla J., PC-033

Sevivas T., PP-MO-144, PP-WE-730

Seyed Mortaz L., PP-WE-324

Shah A. D., PP-MO-103

Shah A., PP-WE-755

Shahidi M., PP-WE-873

Shahrour N., PP-WE-281

Shahzad K., AS-MO-059, AS-WE-053

Shakhmatova O., PP-WE-335

Shakhovskaya E. N., PP-TH-367

Shams Eldin A., PP-MO-277

Shamsi T., PP-TH-648, PP-WE-382

Shan N., PP-MO-695

Shang X., PP-WE-006

Shanker J., OC-TH-118, OC-WE-139, PP-MO-791, PP-MO-792, PP-MO-793, PP-MO-811, PP-MO-812, PP-WE-828

Shanley C., PP-WE-135, PP-WE-293

Shapiro A. D., PP-MO-596, PP-WE-613

Shapiro A., PP-MO-522, PP-WE-636

Shapiro S., PP-WE-462

Shaposhnikov S. A., PP-TH-251

Sharathkumar A. A., PP-MO-522

Shariat-Madar Z., OC-MO-128,PP-TH-133, PP-MO-885

Sharifian R. A., PP-MO-552

Sharkova T. S., PP-TH-158,PP-TH-257

Sharma A., OC-MO-101, PP-WE-327

Sharma S., PP-WE-751, PP-TH-061

Sharp A., PP-MO-775

Sharpless N., PP-WE-290

Sharrack B., PP-WE-302

Sharrett R., PP-WE-819

Shashaani T., PP-TH-124, PP-TH-318

Shattil S., SA-WE-006

Shaughnessy S. G., PP-WE-817

Shaw C., OC-WE-045

Shaw M. A., AS-TU-045

Sheehan J. P., PP-WE-184

Sheereen A., PP-TH-465, PP-WE-285

Sheffield W. P., OC-MO-059,PP-MO-161, PP-TH-175

Shemirani A. H., PP-WE-350

Shen F., PP-MO-854

Shen M. C., PP-TH-634

Shen M., PP-TH-123

Shen X., PP-WE-846, PP-TH-114, PP-TH-146

Shen Y., AS-TU-039, PP-MO-757

Sheng Y., PP-WE-540

Shenkman B., OC-TH-102, PP-WE-044, PP-WE-049

Shentu W., OC-MO-123

Shepherd J., OC-WE-116

Sheptovitsky V., PP-WE-010

Sheridan D., PP-MO-550

Shermock K. M., OC-TH-074

Sherwood R., OC-MO-088,OC-MO-089

Sheth S., PP-TH-243

Shetty K. R., PP-TH-108, PP-WE-811

Shetty S., PP-TH-295, PP-TH-659, PP-TH-660, PP-TH-668

Shi G. Y., PP-MO-158

Shi J., PP-MO-131, PP-WE-674

Shi M., PP-MO-198, PP-WE-179

Shi Q., PP-TH-128

Shi Y., OC-MO-136, OC-MO-137

Shibamiya A., OC-TH-070

Shibano T., PP-TH-072, PP-TH-195, PP-TH-406, PP-WE-015

Shibeko A. M., PP-MO-235

Shibhu J., OC-TH-118

Shibu J., AS-WE-059, PP-WE-832, PP-WE-833

Shick E., PP-MO-006, PP-WE-095

Shida Y., PP-WE-090

Shidham G. B., PP-WE-729

Shigenaga T., PP-TH-042

Shikata K., PP-TH-051

Shilagard T., OC-MO-026, OC-MO-114

Shiller E. A., PP-TH-454

Shiltagh N., PP-TH-657

Shim S., PP-WE-877

Shima M., PP-MO-255, PP-TH-576, PP-TH-592, PP-WE-244, PP-WE-250, PP-WE-516, PP-WE-580, PP-WE-606

Shimada A., PP-WE-349

Shimazu C., PP-WE-420

Shimazu T., PP-WE-781

Shimokawa T., PP-WE-720

Shin D. J., PP-WE-595

Shin D., PP-TH-294

Shin H., PP-TH-504

Shin J., PP-TH-519

Shin S., PP-WE-877

Shinhmar S. K., PP-TH-002

Shinozawa E., PP-MO-201, PP-WE-400

Shinozawa K., PP-MO-546,PP-WE-516, PP-WE-666

Shipolini A., AS-WE-052

Shirafuji N., PP-WE-420

AUTHORS INDEX

570

Aut

hors

Inde

x

Shirahata A., PP-TH-576, PP-TH-592, PP-WE-606

Shiraishi H., PP-TH-226

Shirasaki R., PP-WE-420

Shirokova T. E., PP-MO-770

Shirotani-Ikejima H., PP-TH-015

Shivadasani R., SA-MO-014

Shlaen M., PP-WE-542

Shlaen R., PP-MO-694

Shmeleva V. M., PP-MO-431,PP-MO-495, PP-TH-268, PP-TH-313, PP-TH-321, PP-TH-346, PP-TH-361, PP-WE-361, PP-WE-835

Shmirev I. I., PP-MO-235

Shofuda K., PP-WE-400

Shoji T., PP-MO-439, PP-WE-562

Shokunbi W. A., PP-MO-276

Shomer E., OC-TU-058

Shorbagi A., PP-MO-394

Shorr A. F., PP-MO-283, PP-MO-473, PP-WE-466

Shoukri M., PP-WE-285

Shouzu A., PP-WE-781, PP-WE-827

Shoya Y., PP-TH-194

Shpilberg O., PP-MO-749

Shrier I., PP-WE-462

Shrivastava S., OC-TH-043

Shtivelband I. B., PP-MO-268,PP-TH-277

Shubina T., PC-012

Shuldiner A., PP-WE-802

Shuman H., AS-MO-039

Shurin S., PL-TU-005

Shustova O. N., PP-MO-856

Shworak N. W., PP-MO-165

Siami E., PP-WE-558

Sibi K., OC-TH-118, PP-MO-812, PP-WE-828

Siboni S. M., AS-MO-028, AS-TU-033

Siboni S., PP-TH-558

Sichev D. A., PP-TH-431

Siciliano S., PP-TH-503

Siddiqui A., PP-MO-845

Sidelmann J. J., OC-MO-090,PP-MO-164, PP-WE-282, PP-WE-515

Sidorkin V. G., PP-WE-678

Sidorkina A. N., PP-WE-678

Sié P., OC-MO-099, PP-MO-188, PP-MO-618, PP-WE-169

Siebenrock K., PP-TH-417

Sieber M. W., PP-TH-087

Siegbahn A., PP-MO-408, PP-TH-407

Siegemund A., PP-MO-128,PP-MO-365, PP-TH-656, PP-WE-133, PP-WE-233, PP-WE-622, PP-WE-733

Siegemund R., PP-TH-253, PP-TH-254

Siegemund T., PP-MO-365,PP-TH-253, PP-TH-254, PP-WE-133, PP-WE-233, PP-WE-622

Siegerink B., AS-WE-008, OC-WE-036, PP-TH-339

Siegmund B., PP-MO-459, PP-WE-593, PP-WE-670

Siemieniak D. R., OC-WE-039

Siemieniak D., PP-WE-640

Siess W., OC-MO-124, PP-MO-008

Sigaud M., PP-WE-642

Sigl-Kraetzig M., PP-WE-453,PP-WE-653

Siguret V., PP-TH-429, PP-WE-412

Sigutova P., PP-TH-368

Siigur E., PP-MO-149

Siigur J., PP-MO-149

Sijpkens Y. W. J., PP-WE-513

Silasi-Mansat R., OC-TH-112,OC-WE-028

Siller J., AS-WE-014

Siller-Matula J. M., PP-WE-675

Siller-Matula J., PP-MO-718

Silva A. C. S., PP-WE-092

Silva C. L. A., OC-WE-023

Silva C. S. S. S., PP-MO-124,PP-TH-542, PP-WE-444, PP-MO-034

Silva J. B. J., PP-WE-535

Silva M., PP-WE-229

Silva Pinto C., PP-WE-730

Silvani C., PP-WE-688

Silveira A., PP-MO-108

Silveira J. R., OC-MO-066

Silver L., OC-MO-009

Silver R. M., PP-MO-194

Silverstein R., OC-MO-107

Silverstrim C., PP-MO-502

Sim D., OC-WE-057, OC-WE-059

Simak J., PP-TH-016

Simakova O., PP-TH-016

Simanek R., OC-TU-015, OC-TU-016, PP-MO-322, PP-WE-663

Simansour M., OC-TH-082,PP-TH-074

Simchen M., AS-TU-052

Simetka O., PP-WE-378

Simionecu M., PP-TH-003

Simionescu M., PP-MO-855

Simioni P. P. S., AS-WE-023,OC-TH-026, PP-MO-372

Simioni P., OC-MO-005, OC-MO-049, OC-MO-119, OC-MO-121, OC-TU-086, PL-TU-004, PP-MO-186, PP-MO-242, PP-MO-243, PP-MO-348, PP-MO-765, PP-TH-382, PP-TH-383, PP-TH-420, PP-TH-487, PP-TH-488, PP-WE-080, PP-WE-081, PP-WE-147, PP-WE-247, PP-WE-248, PP-WE-384, PP-WE-460

Simões E Silva A. C., PP-TH-217

Simon A., PP-WE-408

Simon J., OC-TH-036

Simon Z., PP-MO-009

Simonneau G., PP-MO-376

Simons S. M., PP-TH-495, PP-MO-475

Simowchenko G. S., PP-WE-422

Simpson A. M. C., PP-MO-058

Simpson H., PP-MO-658

AUTHORS INDEX

571

Simpson V. M. A., PP-TH-384

Sinauridze E. I., PP-MO-182,PP-WE-170

Sinclair G. D., OC-TU-068

Singh A., PP-MO-326

Singh I., OC-WE-050

Singh P. R., PP-WE-811

Singh P., PP-MO-756

Singh S., PP-TH-272, PP-WE-266, PP-WE-456

Singhi P., PP-WE-456

Singla A., PP-MO-739, PP-MO-771, PP-TH-026, PP-WE-043, PP-WE-794, PP-WE-797, PP-WE-801

Singleton E. E., PP-MO-593

Sinha D., PP-MO-181

Sinha U., OC-TH-107, AS-TU-026

Sinkov S. V., PP-TH-250, PP-TH-251

Sion M., PP-WE-484

Sionis A., PP-MO-254

Sipos T., PP-MO-359

Siqueira L. H. S., PP-WE-296

Siqueira L. H., PP-MO-520, PP-MO-521, PP-WE-066, PP-WE-294

Siqueira L., PP-WE-631

Sirachainan N., PC-052, PP-MO-354

Siragusa S. M., AS-TH-030,OC-MO-093, PP-TH-527

Siragusa S., OC-MO-037, OC-MO-092, PP-MO-308, PP-TH-622, PP-WE-403

Siregar B., OC-MO-112

Siripattanapong P., PP-WE-710

Sirisena T., PP-WE-021

Sirotkina O. V., PP-TH-025

Sisler I., AS-TH-039

Sittinger K., OC-WE-077, PP-TH-661, PP-WE-210

Siu G., OC-TH-107

Siwkowski A., OC-TH-108

Själander A., PP-TH-469

Skalicky S., AS-WE-015, PP-MO-087

Skalka V. N., PP-TH-160

Skeith L. A., PP-WE-546

Skenderi K., OC-TH-044

Skjeldestad F. E., PP-MO-288,PP-WE-332

Skoda R., AS-TU-047

Skok M. V., PP-MO-872

Skotnicki A. B., PP-WE-651

Skotnicki A., PP-MO-206

Skouby S. O., OC-MO-090

Skouri H., PP-MO-135

Skrahina A. M., PP-WE-863

Skretting G., PP-TH-164, PP-TH-165, PP-WE-191

Skrtic S., PP-WE-206

Skubiszak A., PP-MO-216

Skutnitskaya L., PP-TH-223

Slagboom P. E., PL-TU-001

Slagsvold C. E., AS-MO-007

Slama A., PP-TH-608

Slater B. C. S., PP-TH-110

Slater D. E., PP-TH-477

Slattery D., PP-MO-470, PP-WE-284

Slavik L., PC-022, PP-WE-142,PP-WE-273

Slavík L., PP-WE-378

Slayton W., PP-WE-083

Slechtova J., PC-020, PP-TH-368, PP-WE-070

Slechtova M., PP-TH-612, PP-TH-613

Sletten M., PP-TH-165

Slevin M., AS-MO-065

Slichter S. J., AS-MO-051

Sligar S. G., OC-TU-091, PP-WE-119

Sloane D. D., PP-MO-086

Slowik A., PP-WE-358

Smadja D. M., OC-TU-090, OC-WE-089, PP-MO-835, PP-TH-464, PP-WE-263

Small D. S., PP-MO-733

Smedsrød B., OC-MO-058, PP-MO-177

Smejkal P., PP-TH-612, PP-TH-613, PP-WE-804

Smethurst P., OC-MO-124

Smid M., OC-TH-080, PP-MO-337, PP-WE-352, PP-WE-353

Smilevska T., PP-TH-557, PP-WE-769

Smirnov M., PP-MO-200, PP-MO-709

Smirnova O. A., PP-MO-431,PP-TH-268, PP-WE-361

Smit A. J., PP-WE-554

Smit J. W. A., PP-TH-238, PP-TH-286

Smith A., PP-MO-384

Smith E. L., PP-MO-250, PP-WE-259

Smith H., OC-WE-134, PP-MO-632

Smith J. M., PP-MO-110

Smith J., AS-MO-049

Smith K. A., OC-MO-115

Smith K. J., PP-MO-627

Smith L., PP-MO-233

Smith M., PP-MO-631

Smith N. L., OC-TU-034

Smith P. L., PP-WE-100

Smith S. A., PP-TH-255, PP-TH-256

Smith T. S., PP-MO-549, PP-WE-291

Smithline H. A., OC-TU-007,PP-TH-505, PP-WE-414

Smock K. J., PP-WE-306

Smolewski P., PP-MO-752

Smrtka M. P., PP-TH-206

Smurygina V. V., PP-TH-669

Smyth S. S., AS-TH-059, PP-TH-392

Smyth S., SA-MO-018

Snijder R. J., PP-WE-318

Snir A., PP-MO-850

Snoep J. D., AS-MO-034, AS-TH-035, OC-MO-037, OC-TH-025, PP-MO-782, PP-WE-851

Snyder M. L., PP-TH-136

AUTHORS INDEX

572

Aut

hors

Inde

x

Snyder M., PP-WE-477

Soares A., PP-MO-349

Sobas F., PP-MO-263, PP-MO-264

Sobieraj-Teague M., PP-MO-086

Sobol A., PP-MO-071

Soboleva E. L., PP-MO-806

Sobreira M. L., PP-MO-311

Socié G., PP-MO-862

Socoliuc C., PP-WE-075

Sodi A., OC-WE-031, OC-WE-032, PP-MO-217

Soeda T., PP-MO-127, PP-WE-250

Soejima K., PP-MO-516, PP-TH-319, PP-WE-463

Soep J., PP-TH-265

Sofi F., OC-MO-010, OC-TH-047, OC-WE-031, OC-WE-032, PP-MO-799, PP-MO-800, PP-MO-801, PP-MO-802, PP-MO-803, PP-MO-804, PP-MO-805, PP-MO-836, PP-TH-163, PP-TH-340, PP-TH-341, PP-WE-002, PP-WE-003, PP-WE-746

Sofian T., OC-TU-084, PP-TH-224

Sohne M., OC-MO-039, OC-MO-042

Söhne M., PP-TH-518

Sohrabi N., PP-WE-074

Soisamrong A., PC-052

Sokolikova B., OC-TU-081,PP-MO-189

Sokolowski J., PP-MO-868,PP-WE-491

Solar M., PP-TH-438

Sola-Visner M. C., PP-TH-067

Sola-Visner M., PP-TH-073,PP-WE-083

Soldati M., PC-030

Solheim S., PP-TH-427

Solimando M., OC-TU-072

Solimeno L., PP-MO-542

Solimeno P., PP-TH-527

Solman L., PP-MO-453

Solomon A. B., PP-MO-026

Solomon C., PP-TH-207, PP-TH-208

Solymoss S., OC-TU-011, PP-WE-489

Somaini S., OC-WE-108

Soman T., PP-TH-463

Somma J., PP-WE-468

Sommer C., PP-MO-578

Sommer J. M., OC-WE-057,OC-WE-059

Sonesson E., OC-TH-057

Song J., PP-MO-712, PP-WE-242

Song M., PP-WE-844

Song Y., PP-MO-017

Sonnek M., PP-MO-467

Soonsawad S., PP-WE-710

Sooriyakumar T., PP-WE-297

Sorensen B. B., PP-WE-590,PP-WE-591

Sørensen B. B., PP-TH-116,PP-WE-589

Sorensen B., PP-WE-616, PP-WE-698

Sørensen B., PP-MO-386, PP-MO-543, PP-MO-562, PP-MO-581, PP-TH-545, PP-WE-539, PP-WE-658, PP-WE-677, PP-WE-702, PP-WE-740

Sørensen C., PP-MO-405

Sorensen H. T., PP-TH-304

Soria C., PP-MO-514, PP-TH-174, PP-TH-185, PP-TH-211, PP-TH-680, PP-WE-505, PP-WE-855

Soria J. M., OC-TH-027

Soria J., PP-MO-514, PP-TH-174, PP-TH-185, PP-TH-211, PP-TH-289, PP-TH-290, PP-WE-208, PP-WE-209, PP-WE-243, PP-WE-505, PP-WE-855

Soria N., PP-MO-279

Soroka S. D., OC-TH-009

Sos B. C., OC-MO-077

Soskov G. I., PP-MO-688

Sosnovik D. E., AS-WE-057

Sosothikul D., PP-MO-446

Sotirova T., PP-TH-557, PP-WE-769

Soto I., PP-MO-566, PP-MO-590, PP-MO-601, PP-TH-596

Sottilotta G., AS-TU-033

Soucie J. M., PP-MO-596, PP-WE-613

Soucie M., PP-MO-522

Soukup T., PP-WE-068

Souri M., OC-WE-073

Sousa M. O., PP-MO-335, PP-MO-349, PP-MO-363, PP-MO-816, PP-WE-226, PP-WE-227, PP-WE-347, PP-WE-365, PP-WE-812, PP-WE-814, PP-WE-815, PP-WE-816

Soutari N. M. H., PP-WE-114

Souto J. C., PP-MO-413

Souto J., PP-TH-285, PP-TH-289, PP-TH-290, PP-WE-208, PP-WE-209, PP-WE-243

Souto L. L. R. S., PC-046

Souverein P. C., OC-WE-014,OC-WE-035

Souza R. A., PP-WE-092

Sovershaev M., PP-MO-808,PP-TH-237, PP-WE-110

Spada C., PP-WE-647

Spalton J. C., OC-TH-041

Spannagl M., OC-WE-077, PP-MO-307, PP-MO-620, PP-WE-038, PP-WE-039

Spath B., PP-MO-014, PP-WE-485

Speich H. E., PP-TH-097, PP-WE-103

Spek A. C., AS-MO-063, PP-TH-181

Spek A., OC-WE-105, PP-MO-489, PP-WE-839

Spek C. A., OC-WE-019, PP-TH-484

Speletas M., PP-WE-484

Spena S., PP-TH-670

Spencer F. A., PP-WE-429

Spengler U., PP-TH-537

AUTHORS INDEX

573

Sperandio O., PP-WE-157

Speroni J., PP-MO-204

Spiel A. O., PP-MO-718, PP-TH-676

Spiel A., AS-WE-014

Spies C., PP-MO-240, PP-MO-241

Spiezia L., AS-TU-032, OC-MO-005, OC-MO-119, OC-MO-121, OC-TU-086, PL-TU-004, PP-MO-242, PP-MO-243, PP-MO-348, PP-MO-765, PP-TH-382, PP-TH-383, PP-TH-487, PP-TH-488, PP-WE-080, PP-WE-147, PP-WE-247, PP-WE-248, PP-WE-384, PP-WE-460

Spila A., PP-TH-494

Spinar J., PP-WE-804

Spira J., PP-WE-608

Spirk D., PP-MO-318, PP-TH-417, PP-TH-492, PP-WE-329

Spiropoulos A., OC-TH-044

Spitzer C., PP-WE-695

Spohn G., OC-WE-076, OC-WE-077

Sponagle K., AS-MO-018, AS-MO-020, PP-TH-631

Spotti E., PP-MO-496

Spotts G., PP-MO-602, PP-TH-585, PP-WE-574, PP-WE-617

Spreafico M., AS-MO-028, OC-WE-131, PP-MO-716

Spring C. M., OC-WE-121

Springer T. A., PP-WE-013

Spronk H. M. H., OC-TH-001,OC-TH-080, OC-TU-085, OC-WE-060, PL-TU-003, PP-MO-337, PP-MO-484, PP-TH-122, PP-TH-181, PP-TH-516, PP-WE-219, PP-WE-352, PP-WE-353

Spronk H. M., PP-WE-779

Spronk H., AS-TU-048, AS-WE-058, OC-MO-125, PP-TH-344

Spyridon M., PP-WE-040, PP-WE-809

Spyropoulos A. C., OC-MO-052, OC-TH-016, PP-MO-248, PP-WE-406

Spyrou A., PP-MO-305

Squizzato A., PP-MO-292, PP-MO-293, PP-MO-309, PP-MO-659, PP-TH-507, PP-WE-340

Squizzqato A., OC-MO-039

Srámek A., PP-WE-303

Sreeram G., PP-MO-676

Sridhara H., AS-WE-059, OC-TH-118, PP-MO-791, PP-MO-792, PP-MO-793, PP-WE-832, PP-WE-833

Srivastava A., AS-WE-001

Srour M., PP-TH-696

Staals J., OC-TU-085, PP-WE-219

Stadler M., PP-MO-615

Staelens S., PP-MO-049, PP-MO-050

Staels B., PP-MO-814

Stafford A. R., OC-TH-106, OC-WE-079, PP-MO-428

Stafford D. W., AS-WE-042,OC-WE-075

Stahle M. C., PP-TH-105, PP-WE-703

Stain A. M., PP-TH-629, PP-WE-587

Staines H., PP-TH-131, PP-WE-829

Stalker T. J., AS-TU-028, PP-TH-038, PP-WE-030

Stalls C., PP-WE-694

Stambolsky D., PP-WE-335

Stamos T., PP-MO-464

Stancu P., PP-MO-532, PP-WE-549

Stanczyk L., PP-MO-097

Standeven K. F., AS-TH-019,OC-TH-055, OC-TH-089, PP-TH-351, PP-WE-212, PP-WE-231, PP-WE-259

Stanford T., PP-TH-188

Stang L., PP-WE-448

Stangier J., PP-TH-134

Stankovic M., PP-TH-460

Stankovic S., PP-TH-557, PP-WE-769

Stanley R. G., PP-TH-031

Stanssens P., AS-TH-024

Stanworth S., OC-TH-067

Stare J., PP-MO-350

Staritz P., PP-MO-513, PP-MO-662, PP-TH-421

Starostova L., PP-MO-689

Stashenko G., OC-MO-002

Stasiak M., PP-MO-071

Stasko J., PP-TH-598, PP-WE-220

Stasko J., PP-TH-305, PP-TH-306

Stassen J., OC-TH-057

Staubitz A., OC-WE-128

Stavenuiter F., OC-WE-084

Stavik B., PP-TH-164, PP-TH-165

Stebbings Y., PP-TH-599

Steele B. M., AS-WE-035

Steele M., AS-WE-003, PP-WE-553

Steen Carlsson K., PP-WE-570

Steenstrup T. D., PP-MO-569,PP-WE-109, PP-WE-572, PP-WE-589

Stefanini L., PP-WE-016

Stefanska-Windyga E., PP-MO-714

Stegnar M., PP-MO-350, PP-WE-251

Stegner D., AS-TU-005, AS-TU-037

Stehle S., PP-WE-183

Stehouwer A., AS-MO-030

Steil L., OC-TU-026

Stein S. F., PP-WE-749, PP-WE-750

Steiner T., AS-TU-031

Steinitz K. N., OC-WE-065

Steinseifer U., PP-WE-190

Stemkowski S., PP-WE-465

Stemmelin G., PP-WE-135, PP-WE-293

Stemple D. L., AS-MO-037

AUTHORS INDEX

574

Aut

hors

Inde

x

Stender S., PP-WE-319, PP-WE-383

Sten-Linder M., PP-MO-703,PP-WE-114

Stenlund P., PP-MO-574

Stennicke H. R., PP-TH-116

Stennicke H., AS-TH-049

Steno B., PP-WE-656

Stensballe A., PP-TH-140

Stepanian A., AS-WE-025, PP-MO-332, OC-TH-082

Stephan F., PP-TH-153

Stephan J. J. L. S., PP-MO-594

Stephens D., PP-MO-567, PP-MO-602, PP-WE-574

Stephens G., PP-TH-027, PP-WE-801

Stepien E., PP-MO-206, PP-MO-207, PP-MO-798

Stepinska J., PP-WE-795

Sterkers O., PP-MO-332

Stern L., PP-MO-465, PP-MO-466

Sterz F., PP-TH-676

Sterzing D., PP-TH-417

Steuerwald M. T., PP-TH-510

Stevens S. M., PP-TH-424

Stevic I., PP-WE-177

Steward M., AS-MO-037

Stewart A. B., PP-TH-202

Stewart K. A., OC-TH-071, OC-TH-072

Sticchi E., PP-MO-805, PP-MO-818, PP-WE-003

Stieler J., LB-MO-003

Stieltjes N., PP-WE-533

Stockschlaeder M., PP-WE-652

Stoffers H. E. J. H., OC-TH-017, OC-TU-012

Stojanovic A., PP-TH-557

Stojanovic B., PP-TH-296

Stojanovska Z., PC-027

Stojanovska-Trajkovska L.,PP-TH-271

Stojanovski Z., PP-TH-557

Stokol T., PP-TH-117

Stoldt V. R., AS-TH-060, PP-MO-001, PP-TH-355, PP-WE-054, PP-WE-055, PP-WE-862, PP-WE-865

Stoll G., AS-TH-040, OC-WE-040

Stoll M., AS-TU-053, OC-TU-062, PP-TH-360

Stoll P., PP-MO-100

Stone N. L., AS-MO-055

Storey R. F., OC-MO-012, PP-TH-030

Stormer J., OC-TU-005, OC-TU-006, PP-WE-304, PP-WE-305

Storrie B., PP-MO-082

Storti S., PP-WE-498

Stott D. J., OC-WE-116

Stott D., OC-WE-033

Stouffer G. A., PP-TH-243, PP-WE-838

Stouffer G., PP-MO-790, PP-WE-694

Strachan D., OC-TU-034

Strahler J. R., OC-TU-060

Straight D. L., OC-WE-075

Straka E., PP-TH-462

Stramezzi M., PP-TH-375, PP-WE-682

Strandberg K., PP-MO-258,PP-WE-758, PP-WE-514

Strassberger V., AS-MO-038

Strassel C., AS-TU-047, OC-TU-049, OC-WE-150, PP-MO-033

Strater R., PP-WE-528

Strauch M., LB-MO-003

Strauss T., AS-TU-052, PP-MO-434, PP-MO-685

Strawn W. B., PP-WE-854

Streif W., AS-TH-055

Streiff M. B., OC-TH-074

Streiter D., OC-MO-100

Strengers P. F. W., PP-MO-571

Streva A., PP-MO-521

Strickland S., SA-WE-003

Strike K. L., PP-WE-541

Strobel U., OC-TH-024

Stroes E. S. G., OC-TH-031

Stroes E. S., PP-TH-388

Strogolov V., PP-WE-122

Ström J., PP-WE-586

Stroobants A. K., PP-MO-720

Strukova S. M., PP-MO-882

Strukova S., OC-WE-143, PP-MO-875, PP-WE-155

Strulovitch C., PP-TH-315

Struve S., OC-WE-077, PP-TH-550

Stuart M. J., PP-TH-262

Stuart M., PP-WE-894

Stuart-Smith S., OC-TU-039

Sturgeon S. A., OC-WE-044

Sturgeon S., PP-WE-391

Sturk A., AS-WE-017, OC-TU-055, OC-TU-059, PP-MO-109, PP-MO-769

Sturm D., PP-TH-258

Su E. J., PP-MO-244

Su H., PP-MO-467

Suarez T. A., PP-MO-739, PP-WE-757, PP-WE-798

Suarez T., PP-TH-026, PP-WE-801

Subbarayal B., PP-MO-821

Subbi J., PP-MO-149

Subrahmanian T., PP-MO-465,PP-MO-466

Subrt I., PP-WE-287

Sucker C., PP-WE-210

Sudo A., PP-MO-497, PP-TH-526

Sudo Y., PP-TH-051

Sueishi K., PP-WE-875

Sugamele R., AS-TU-018

Sugano M., PP-WE-687

Suggett N., PP-TH-330

Sugidachi A., PP-MO-096, PP-MO-787, PP-TH-030

Sugimoto K., PP-MO-252

Sugimoto M., PP-WE-090

Sugimura H., PP-MO-111

Sugita C., PP-MO-123, PP-MO-127

AUTHORS INDEX

575

Sugita M., PP-MO-717

Sugiyama T., PP-TH-526

Sukchanova G. A., PP-TH-454

Sukhu K., PP-WE-638

Sulc P., PP-WE-345

Sulimov V. B., PP-MO-182

Sullenger B. A., PP-WE-189

Sullivan K., PP-WE-116

Sulpice E., OC-WE-043

Sultan E., PP-MO-418

Sultanaliev T., PP-WE-281

Sulzer I., PP-TH-079, PP-WE-717

Sumarokov A. A. B., PP-WE-058

Sumarokov A. B., PP-MO-770,PP-WE-091

Sumathipala R. N., PP-TH-014

Sumi H., PP-TH-228, PP-WE-148, PP-WE-149

Sumi T., PP-MO-111

Sumida E., PP-TH-228

Summerhayes R., OC-WE-093,PP-MO-437, PP-MO-438, PP-MO-449, PP-MO-450, PP-MO-451, PP-MO-674, PP-TH-461, PP-TH-462, PP-TH-475, PP-WE-438, PP-WE-480, PP-WE-531

Sun A., PP-TH-335, PP-WE-773

Sun G., PP-TH-364

Sun H., OC-TH-061, OC-WE-072, PP-MO-011

Sun J., OC-MO-136, OC-MO-137, OC-TH-087, OC-WE-064, PP-MO-203, PP-MO-554, PP-TH-203, PP-WE-800

Sun M., AS-TH-039, OC-MO-103, OC-MO-104

Sun Y., OC-MO-098

Sunder-Plassmann R., PP-WE-621

Supina D., PP-WE-478

Suri D., PP-TH-272, PP-WE-266

Surie S., PP-TH-293

Susen S., PP-MO-814, PP-TH-583, PP-WE-858

Suslov V., PP-MO-863, PP-TH-236, PP-WE-137, PP-WE-138

Sussman I. I., PP-WE-468

Sutherland J. S., PP-TH-175

Sutherland M. S., OC-TU-078,PP-TH-645

Suttnar J., PP-TH-213

Suvajac N., OC-TH-068, PP-MO-238

Suwanawiboon B., PP-MO-406, PP-WE-772

Suzan F., AS-MO-028, PP-MO-530

Suzuki A., PP-MO-497, PP-MO-138, PP-WE-671

Suzuki H., PP-WE-005

Suzuki K., PP-TH-143, PP-TH-184, PP-TH-526, PP-WE-032, PP-WE-882

Suzuki N., PP-WE-015, PP-WE-031

Suzuki T., PP-WE-666

Suzuki Y., OC-TH-111, OC-WE-054

Suzuki-Inoue K., OC-TH-099,PP-TH-005

Suzumiya J., PP-TH-081

Svennevig K., PP-WE-487

Svensson P. J., AS-MO-003,PP-TH-469, PP-WE-328, PP-WE-514

Sverre J., PP-TH-539

Svirin P. V., PP-MO-688, PP-TH-454

Swadzba J., PP-MO-269, PP-MO-270, PP-MO-271

Swaim A., PP-MO-011

Swaminathan K., OC-TH-105

Swanson K., PP-TH-255

Swanson P. L., OC-TH-116,PP-WE-238

Swirski F. K., AS-WE-057

Swystun L. L., PP-MO-490

Syed A., OC-MO-009

Syed S. N., AS-TU-005

Synder M. L., PP-MO-137

Szabó L., OC-MO-075

Szarvas M., PP-MO-359

Szczeklik A., PP-MO-355, PP-MO-784, PP-WE-883, PP-WE-884

Szecsi P. B., PP-WE-383

Szekeres-Csiki K., PP-TH-633,PP-WE-049

Szlam F., PP-MO-676, PP-MO-776, PP-WE-187

Sztark F., PP-WE-673

Sztukowska M., PP-WE-645

Szucs G., PP-MO-205

Szymanski J., PP-MO-071

Tabares A. H., PP-MO-279, PP-WE-464

Tabatabaii M., PP-WE-324

Tabbers M. M., PP-MO-444

Taberna M., PC-031, PC-032

Tablin F., PP-MO-389

Tabrizian M., PP-MO-012

Tacheuchi K., PP-WE-411

Tachibana M., PP-MO-198

Tadokoro K., PP-WE-736

Tadokoro S., PP-TH-015

Tagalakis V., OC-TU-023, PP-TH-322, PP-TH-323

Tagariello G., PP-MO-542, PP-TH-527

Tagliaferri A., AS-TU-032, AS-WE-005, OC-TU-075, PP-MO-523, PP-MO-525, PP-TH-527, PP-TH-558, PP-TH-569, PP-WE-567, PP-WE-598, PP-WE-599

Taguchi O., OC-WE-038, PP-WE-222

Tagzirt M., PP-MO-237

Taher A., PP-MO-135, PP-MO-273, PP-TH-336, PP-WE-281

Tait C., AS-TH-005, OC-TH-002,OC-TH-004, PP-TH-412, PP-TH-414, PP-WE-286, PP-WE-405

Tait R. C., PP-WE-214

Tajkhorshid E., OC-TU-094,PP-WE-162

Takada K., PP-MO-252

Takagi A., PP-MO-138, PP-WE-671

AUTHORS INDEX

576

Aut

hors

Inde

x

Takagi J., AS-MO-012

Takagi T., OC-WE-038, PP-WE-222

Takahashi M., PP-MO-123, PP-MO-127

Takaki A., PP-WE-605

Takamatsu J., PP-TH-576, PP-TH-592, PP-WE-606

Takamatsu Y., PP-TH-081

Takami E., PP-WE-605

Takamura F., PP-TH-041

Takano K., PP-WE-793

Takarada S., PP-MO-429

Takasaki J., PP-TH-041, PP-TH-042

Takata N., PP-TH-592, PP-WE-606

Takayama S., PP-MO-439

Takeda M., PP-TH-521

Takeda S., AS-MO-012

Takedani H., PP-TH-592, PP-WE-606

Takei Y., OC-WE-038, PP-WE-222

Takeya H., OC-TH-088, OC-TU-041, PP-MO-232

Takeyama M., PP-MO-255, PP-WE-250

Taki M., PP-MO-439, PP-TH-576, PP-TH-592, PP-WE-562, PP-WE-606

Takubo H., PP-TH-358

Talalaeva I. N., PP-MO-378

Talbot K., OC-MO-118

Talens S., PP-TH-314

Talks K. L., PP-MO-550, PP-WE-298

Talmage K. E., AS-TU-045

Tam B. H. L., PP-WE-445

Tamburrelli C., PP-MO-099,PP-TH-048, PP-WE-048, PP-WE-246

Tamsma J. T., PP-MO-782, PP-WE-341, PP-WE-513, PP-WE-851

Tamura N., PP-TH-004

Tamura S., PP-MO-127

Tan F., PP-WE-047

Tan M., PP-WE-521

Tanaka A., OC-TH-111, PP-MO-429, PP-WE-666

Tanaka I., PP-TH-592, PP-WE-606

Tanaka K. A., PP-MO-676, PP-MO-776, PP-WE-187

Tanaka K., PP-TH-207, PP-TH-208

Tanaka Y., PP-TH-143

Tanck M. W., PP-TH-139

Tancredi D., PP-TH-311

Tang H., OC-TH-065

Tang M., PP-WE-677

Tang W., OC-TU-034

Tang Y., OC-WE-027

Tange J. I., PP-MO-629

Tangnararatchakit K., PP-MO-681

Tanguay J. F., OC-WE-007

Tani Y., PP-WE-736

Taniguchi R., PP-MO-789

Taniguchi T., PP-MO-119

Tanimoto T., PP-MO-429

Tankere F., PP-MO-332

Tanner F. C., OC-TU-052

Tans G., PP-TH-377

Tantry U. S., PP-MO-739, PP-TH-026, PP-TH-101, PP-WE-757, PP-WE-794, PP-WE-797, PP-WE-798, PP-WE-799

Tantry U., PP-MO-771, PP-WE-043, PP-WE-801, PP-WE-802

Tanzilli G., PP-WE-105

Tao M. H., PP-MO-158

Taouli K., PP-TH-608, PP-WE-701

Taouli T. K., PP-WE-564

Tapaneya-Olarn, PP-MO-354

Tapon-Bretaudière J., PP-MO-656

Tapson V., OC-MO-052, OC-MO-054

Tarantino A., PP-TH-666

Tarantino M. D., AS-TU-003

Tarantino M., PP-MO-596, PP-WE-613

Tardy B., AS-TU-009, OC-TH-021, PP-TH-189, PP-WE-165

Tardy- Poncet B., OC-TH-021,PP-WE-165

Tas P., AS-MO-038

TascıOglu C., PP-MO-744

Taser O., PP-WE-568

Tashiro H., PP-WE-420

Tashiro T., PP-WE-411

Taskiran B., PP-TH-221, PP-WE-876

Tassies D., PP-MO-254, PP-WE-371

Tateno C., PP-WE-580

Tatsumi K., PP-WE-244, PP-WE-580

Taubert D., OC-MO-135

Taubman M. B., OC-TH-077

Taveras M., PC-050

Tavoosi N., PP-WE-256

Tay L. H., PP-TH-626, PP-WE-544

Taylor - Jr F. B., OC-TH-071,OC-TH-072

Taylor F. B., OC-TH-112

Taylor S. M., AS-WE-051

Tchaikovski S. N., PP-TH-377

Tcherniantchouk O., PP-WE-277

Tea M. M., PP-WE-380

Teague M., PP-WE-800

Tebbe U., PP-MO-420

Tedesco A. F., PP-MO-735, PP-MO-738

Tehrani S., OC-TH-079, OC-WE-104

Teigelkamp S., PP-TH-241

Teitel J., PP-WE-597

Teixeira G. S., PP-MO-363, PP-MO-364, PP-WE-365

Tekgunduz E., PP-MO-841, PP-WE-889

Telega D., PP-MO-442

Tello Montoliu A., OC-TH-120

AUTHORS INDEX

577

Telnova E. A., PP-MO-553, PP-TH-581, PP-WE-561

Ten Berg J. M., PP-WE-741,OC-MO-133, OC-MO-135, PP-MO-780, PP-MO-781, PP-MO-788, PP-WE-742

Ten Cate H., AS-TH-038, AS-TU-048, AS-TU-050, AS-WE-058, OC-MO-125, OC-TH-001, OC-TH-080, OC-WE-036, OC-WE-097, PL-TU-003, PP-MO-337, PP-MO-433, PP-MO-482, PP-MO-484, PP-MO-670, PP-TH-122, PP-TH-131, PP-TH-181, PP-TH-344, PP-TH-516, PP-WE-072, PP-WE-126, PP-WE-352

Ten Cate-Hoek A. J., OC-TH-001, OC-TH-017, OC-TU-012, PP-WE-457, PP-WE-683

Ten Kate M. K., OC-WE-098,PP-TH-515, PP-TH-516

Ten Kate M., AS-MO-002

Ten Wolde M., OC-TU-008

Tengborn L., OC-WE-058, PP-MO-609, PP-WE-604

Tenias J., PP-MO-226, PP-MO-227, PP-WE-436

Tentsova I., OC-MO-036

Teplyakov A., PC-025, PC-026

Terada C., PP-WE-736

Ternisien C., PP-MO-626, PP-TH-189, PP-TH-623, PP-WE-642

Ternström L., PP-MO-652, PP-WE-206

Terpstra W. E., PP-WE-778,PP-WE-779

Teruel R., AS-MO-054, PP-MO-134, PP-TH-247, PP-TH-287, PP-WE-141

Teruya J., PP-TH-445

Tesic R., PP-WE-369

Tesselaar M. E. T., AS-MO-035,PP-WE-497

Testa S., OC-MO-028, OC-TH-003, OC-TH-006, OC-TH-075, PP-MO-290, PP-MO-496, PP-TH-374, PP-TH-375, PP-WE-682

Tewhatu L., PP-TH-471, PP-TH-472

Teyssandier M., OC-MO-064,OC-WE-066, PP-MO-588

Thabane L., PP-TH-503, PP-WE-429, PP-WE-507

Thachil J., OC-TH-091, PP-TH-129, PP-WE-116

Thai Trung King M., PP-TH-056, PP-TH-102

Thakur S., PP-TH-376

Thaler C., PP-WE-784

Thaler J., OC-TU-015

Thames B. H., PP-TH-206

Thapa B., PP-WE-456

Thati M., AS-MO-059, AS-WE-053

The Riete Investigators A., PP-TH-288

Thedieck S., AS-TU-053, OC-TU-062, PP-TH-360, PP-WE-756

Theill C., PP-TH-150, PP-TH-151

Thelwell C., OC-MO-116, PP-WE-229

Themistou E., OC-WE-050

Theodoridis T., PP-MO-707

Theodosiadis G., PP-WE-314

Theophilus B. D. M., PP-MO-614

Theophilus B. D., PP-MO-623

Théorêt J. F., OC-WE-007, PP-MO-012

Theroux P., PP-MO-060, PP-MO-061

Theunissen H. M. S., PP-WE-017

Thieme F., PP-MO-307

Thiemermann C., OC-TH-067,PP-TH-685

Thijs T., PP-WE-084

Thim L., PP-MO-565, PP-MO-570

Thim T., PP-WE-810

Thiruchelvam A., PP-MO-366,PP-MO-367

Thom J., PP-MO-019

Thom K., PP-MO-436, PP-MO-561

Thomas C., PP-WE-642

Thomas D. H., OC-TH-040

Thomas D., OC-WE-085, PP-MO-028

Thomas G. M., PP-MO-485,PP-MO-486

Thomas K., OC-TU-033

Thomas S., PP-MO-521, PP-TH-554, PP-WE-754

Thomas W. E., PP-MO-002

Thomas W., PP-WE-056

Thomas-Dewing R. R., PP-WE-727

Thomassen M. L. G. D., PP-TH-377

Thompson N., PP-WE-215

Thompson P., OC-TH-085, OC-TH-086

Thomsen M., PP-TH-140

Thomson G., PP-MO-543

Thomson R., PP-TH-665

Thon J. N., PL-TU-002

Thon J., AS-WE-026

Thong B., PP-MO-197

Thongtanyong N., PP-WE-772

Thornton S., OC-TH-063

Thouvenin S. S. T., PP-MO-594

Thuerlemann C., PP-MO-753

Thuillez C., PP-WE-859

Thul J., PP-TH-180

Thuraisingham R., PP-WE-377

Thys C., PP-WE-041

Thys F., PP-TH-524

Thys J., PP-WE-084

Tichelaar Y. I. G. V., PP-TH-332

Tiede A., PP-WE-670

Tieken C., PP-TH-139

Tien L., OC-TH-119, PC-037

Tierney S., OC-TH-012, PP-TH-489

Tigchelaar Gutter W., OC-WE-019

Tillmanns H., AS-TU-057, OC-WE-128

AUTHORS INDEX

578

Aut

hors

Inde

x

Tillyer L., PP-MO-120, PP-WE-232

Timur C., PP-WE-571

Tincani E., PP-MO-306

Tinel H., PP-MO-183

Tinot T., PP-MO-125

Tipton H., OC-WE-022

Tirado A. A., PP-TH-308

Tirado I., PP-MO-323, PP-TH-285, PP-WE-175

Tiret L., PP-TH-309

Tiscia G. L., OC-TU-035

Tiscia G., PP-MO-822

Tisseau J., PP-TH-113

Titaeva E. V., PP-TH-513

Tizzano E., PP-MO-536

Tjeldhorn L., PP-WE-191

Tjia I., PP-TH-445

Tjønnfjord G., PP-TH-539

Tobin E., PP-MO-857

Toby G., OC-MO-083

Tocchet A., PP-TH-453

Toda M., OC-WE-038

Todd T., PP-WE-690

Todesco S., OC-TU-086

Todo K., PP-MO-080

Toennes S. W., PP-WE-792

Tofler G., PP-MO-410

Tognin G., OC-MO-121, PL-TU-004, PP-MO-243, PP-MO-348, PP-WE-080

Toh C. H., PP-TH-129, PP-WE-116

Toh C., OC-TH-091, PP-TH-197

Toledo V. P. C., PP-WE-226

Tolenaar D., PP-MO-567

Toll D. B., OC-TH-017, OC-TU-012

Toll T., PP-TH-451

Tolley N., OC-TU-047

Tolosa C., PP-TH-288

Toltl L. J., AS-MO-022

Tomaiuolo M., PP-MO-822

Tomer A., PP-WE-712

Tomin D., PP-WE-634

Tomita A., PP-MO-232

Tomiyama Y., PP-MO-080, PP-TH-015, PP-TH-081

Tomkowski W. Z., AS-TH-028,PP-TH-279, PP-TH-280, PP-WE-433

Tomlin M. E., PP-MO-733

Tomlinson M. G., AS-WE-033,OC-MO-069, PP-TH-021

Tomlinson S., OC-TH-015

Tomoike H., PP-WE-720

Tomokiyo K., PP-WE-605

Tomonaga M., PP-WE-666

Tona F., OC-WE-088

Tonello M., OC-TU-040, PP-TH-274

Tong C. H., AS-WE-010, OC-MO-020

Tonismagi K., PP-MO-149

Tonn T., AS-TH-014

Tonnesen E., PP-WE-698

Tonoyan A. A., PP-MO-553,PP-TH-581, PP-WE-561

Topalidou M., PP-MO-305

Topf H., PP-MO-544

Topor-Madry R., PP-MO-207

Torchet M., PP-WE-592

Tordoir J., PP-WE-457

Toril J., PP-WE-360

Tormene D., AS-WE-023, OC-MO-005, OC-MO-049, OC-TH-026, PL-TU-004, PP-MO-186, PP-MO-242, PP-MO-372, PP-WE-147, PP-WE-247, PP-WE-460

Tornai I., PP-MO-228

Tornvall J., PP-MO-095

Torpier G., PP-MO-814

Torres A., PP-MO-663

Torres E., PP-TH-043

Torres I., PP-MO-865

Torres O., PP-TH-607

Torres-Alcantara S., PP-WE-217

Tortella B. J., OC-TH-069

Torti M., PP-MO-018, PP-MO-046

Tosato F., PP-MO-331

Tosetto A. A. T., AS-WE-023,PP-MO-372

Tosetto A., AS-MO-029, AS-TH-005, OC-TH-002, OC-TH-003, OC-TH-004, PP-MO-291, PP-MO-612, PP-TH-412, PP-WE-286

Tosi M., PL-TU-005

Toso R., AS-TH-013, AS-TH-046

Totani L., AS-TH-059, OC-WE-127

Totapally B., PP-TH-310, PP-TH-457

Toth B., PP-WE-784

Tóth J., PP-MO-359, PP-WE-774

Tóth-Zsámboki E., PP-MO-772

Toti F., OC-WE-111, PP-WE-787

Touchrift C., PC-018, PP-MO-445

Toulon P. A., PP-TH-470, PP-WE-333

Toulon P., PP-MO-504

Tournoij E., OC-TU-030

Tous J., PP-TH-625

Toussaint-Martinez De Castro.,PP-WE-217

Toweel G., PP-TH-370

Tözün R., PP-TH-284

Trabattoni D., PP-WE-356

Traby L., PP-MO-422

Tracy P. B., OC-MO-066, OC-MO-120, OC-TU-092

Tracy R. P., AS-WE-060, OC-TH-117

Tracz W., PP-MO-207, PP-MO-216, PP-TH-337, PP-WE-107

Tradati F., PP-TH-558

Tradler T., OC-TH-059

Traisci G., PP-MO-015

Trajkova S., PP-TH-557, PP-WE-769

Tran A., AS-TU-028, PP-WE-030

Tran S., OC-MO-063

AUTHORS INDEX

579

Tran T. H., PP-TH-199

Tranholm M., OC-MO-084, OC-MO-085, OC-WE-056, PP-MO-564, PP-MO-573, PP-MO-575, PP-MO-578, PP-TH-579, PP-TH-594, PP-WE-401, PP-WE-581

Trappenburg M. C., PP-WE-778, PP-WE-779

Travlou A., PP-TH-338

Trawinski B., PP-MO-522

Trawnicek L., PP-WE-624

Trbic A., OC-TH-054

Trbojevic B., PP-TH-296

Trebicka J., PP-MO-224

Treepongkarune S., PP-MO-354

Tregouet D., OC-MO-021, PP-TH-309

Treish I. M., PP-MO-488

Trelinski J., PP-MO-752

Trellu M., OC-WE-006, PP-MO-418, PP-TH-409, PP-WE-388, PP-WE-413, PP-WE-423

Tremoli E., OC-TU-025, PP-WE-050, PP-WE-356, PP-WE-868

Trenchfield S., PP-MO-543

Treumann A., PP-MO-044

Tribulatti M. V., PP-WE-035

Triche E., PP-WE-382

Trichet C., AS-TH-043

Trifiro’ E., PP-MO-104, PP-WE-789

Trillot N., PP-TH-583, PP-WE-762

Trinchero A., PP-MO-684

Trinquart L., AS-TU-009

Tripodi A., OC-TH-003, OC-TH-006, PP-MO-290, PP-MO-291, PP-MO-673

Triscott M. X., PP-TH-264, PP-WE-117

Triscott M., PP-MO-200, PP-MO-265, PP-MO-548, PP-TH-200, PP-TH-281, PP-WE-115, PP-WE-207

Trobo R., PP-WE-236

Tromp E. A. M., PP-WE-317,PP-WE-318

Trossaert M., PP-TH-172, PP-TH-623

Trossaërt M., PP-TH-593, PP-WE-642

Trujillo M., PP-WE-665

Trummal K., PP-MO-149

Truss N. J., PP-MO-740, PP-TH-001, PP-TH-002

Trzeciak M. C., PP-TH-385

Tsai H., PP-MO-665, OC-WE-010

Tsai W., PP-TH-634

Tsatsaris V., AS-WE-025

Tseng C., PP-MO-877, PP-WE-079

Tseu I., PP-WE-193

Tsevrenis V., PP-WE-314

Tsianos E. V., PP-WE-681

Tsikopoulou F., PP-MO-302

Tsimerman G., OC-TU-057

Tsironi M., OC-TH-044

Tsoukala C., PP-TH-467

Tsuji A., PP-TH-526

Tsuji M., PP-WE-605

Tsujita Y., PP-TH-689

Tsukada Y., PP-WE-349

Tsutsumi Y., PP-TH-320

Tsuyoshi H., PP-MO-669

Tsygankov A. Y., OC-TH-040

Tu A., PP-WE-056

Tucker A. T., PP-MO-740, PP-MO-741

Tucker E. I., AS-TH-039, OC-MO-104, PP-TH-037, PP-WE-097

Tuckuviene R., PP-TH-455

Tuddenham E. G. D., PP-MO-642, AS-TU-011

Tuddenham E. G., PP-TH-106,PP-TH-657

Tudini M., PP-TH-694

Tufano A., PP-MO-336, PP-WE-320, PP-WE-325

Tuganbekova S., PP-WE-281

Tugcu D., PP-MO-073, PP-MO-222, PP-TH-121, PP-WE-571

Tugrul A., PP-TH-221, PP-TH-222

Tuischer J., PP-WE-593

Tuma R. F., PP-WE-896

Turck N., OC-TH-073

Turecek P. L., PP-MO-640, PP-TH-611, PP-TH-640, PP-TH-641, PP-WE-619

Turenhout E. A. M., AS-WE-013

Turgut B., PP-TH-221

Turhan N., PC-003

Turkkan E., PP-MO-344, PP-MO-537, PP-MO-538, PP-WE-571

Turner N., PP-MO-120

Turoczi T., AS-TH-008

Turpie A. G. G., OC-WE-004,PP-TH-415, PP-TH-430, PP-WE-404, PP-WE-421

Turpie A. G., PP-MO-248

Turu M. M., AS-MO-065, PP-MO-834

Tusell J., PP-WE-237

Tushuizen J. M., PP-MO-769

Tuttle A., PP-TH-628

Tutun U., PP-WE-880

Tveit A., PP-WE-026, PP-WE-172

Twickler M. T. H. B., PP-MO-292

Twickler M., PP-MO-022

Tybura M., PP-MO-752

Tychinsky V., PP-MO-729

Tylko G., PP-MO-798

Tymvios C., PP-MO-062

Tzeng C. H., PP-MO-330, PP-TH-620

Tzourio C., PP-TH-349

Uchida A., PP-TH-526

Uchitel I. A., PP-MO-770, PP-WE-091

Uchiyama S., PP-WE-196

Uchiyama T., PP-MO-669

AUTHORS INDEX

580

Aut

hors

Inde

x

Udomchaisakun R., PP-MO-681

Udvardy M. L., PP-TH-633

Udvardy M., PP-MO-359

Ueba T., PP-WE-827

Uekötter A., PP-MO-031

Uemura T., PP-TH-041, PP-TH-042

Uetsuka Y., PP-WE-342, PP-WE-418

Ueyama T., PP-WE-090

Uh S., PP-TH-519

Uitte De Willige S., OC-MO-076, PP-WE-231

Ulcova-Gallova Z., PP-TH-368

Ulehlova J., PC-022, PP-WE-142, PP-WE-273

Úlehlová J., PP-WE-378

Ulimoen S., PP-WE-026

Uljanov A., PC-012

Ulrich C. K., PP-MO-809

Ulrich C., OC-MO-126

Ulrich D., PP-TH-448

Ulrichts H., AS-TH-024

Ulus T. A., PP-WE-880

Umeda M., PP-WE-005

Umesato N., PP-TH-358

Unadkat S., PP-WE-649

Undas A., PP-MO-206, PP-MO-207, PP-MO-216, PP-MO-798, PP-TH-154, PP-TH-337, PP-WE-107, PP-WE-213, PP-WE-358, PP-WE-362

Unger K., PP-TH-588

Unseld M., PP-MO-838

Unterthurner S., OC-WE-063

Unuvar A., PP-MO-222, PP-MO-440

Uprichard J., PP-MO-397

Urano T., OC-TH-111, OC-WE-054

Urban L., PP-TH-433, PP-TH-437

Urbanus R. T., AS-TU-017, AS-WE-008, OC-MO-030, PP-TH-037

Urbanus R., OC-MO-114

Uresandi F., PP-MO-299

Urlep Salinoviæ V., PP-MO-453, PP-WE-308

Urosevic I., PP-WE-680

Ursu E., PP-MO-532, PP-WE-549, PP-WE-552

Usami A., PP-MO-119

Uscatescu V., PP-WE-549, PP-WE-737

Useini S., PC-027, PP-WE-426

Uslu O., AS-TH-058

Usluer S., PP-MO-653

Ustundag B., PP-WE-708, PP-WE-709

Uthman I., PP-MO-273

Uvaraj P., OC-TH-105

Vacher Coponat H., OC-TU-089

Vafafar A., PP-MO-655

Vagdatli E., PP-MO-302

Vagg M., OC-TH-015

Vahter M., AS-WE-024

Vaillant H., PC-021

Vainchenker W., SA-WE-018

Valarche V., PP-TH-650

Valdés M., PP-MO-732

Valdre L. L. V., AS-WE-023

Valdre L., PP-WE-351

Valdre’ L., PP-WE-359

Valdrè L., PP-MO-523, PP-WE-509, PP-WE-567

Vale Lopez A., PP-MO-637

Valente B., PP-MO-794, PP-WE-874

Valente E., PP-WE-374

Valente S., PP-MO-013

Valentijn K. M., AS-WE-040

Valentin N., OC-TH-097

Valentin S., PP-WE-585

Valentino L. A., PP-TH-601,PP-TH-602, PP-WE-583, PP-WE-584

Valenzuela G., OC-WE-026

Valéra M., OC-MO-099

Vali Zadeh F., PP-WE-558

Valla D. C., PP-MO-224, PP-TH-314

Valles J., PP-MO-027, PP-WE-096, PP-WE-796

Vallez M. O., PP-MO-382, PP-MO-395, PP-WE-396

Valls Serón M., OC-TH-064

Vallvé C., PP-WE-175

Valsami S., OC-MO-129

Valsecchi C., OC-WE-131, AS-WE-011

Valsecchi L., OC-TH-083

Van Beers E. J., OC-TU-059,PP-MO-769

van Belle E., PP-MO-814, PP-TH-583, PP-WE-858

Van Berkel M., OC-MO-112

van Berkel T. J. C., OC-WE-046

Van Bladel E. R., PP-WE-318,PP-WE-475

Van Buul M. M. C., PP-WE-317

van Damme N., PP-WE-176

van de Craen B., PP-MO-219

Van De Wal R. M. A., PP-WE-741

van de Walle G. R., PP-MO-049

van de Water N., OC-TU-079

Van Den Berg H., PP-TH-616

van den Berg M., SA-TU-015

Van Den Berg Y. W., AS-MO-063

Van Den Biggelaar M., OC-TU-083

Van Den Blink B., OC-WE-105

Van Den Boogaard F. E., PP-MO-190, PP-MO-191

Van Den Born B., PP-MO-710

Van Den Dool E. J., PP-MO-720

Van Den Goor J. M., PP-MO-769

Van Den Hengel L. G., AS-MO-063, PP-MO-764

Van Der Bijl N., AS-TU-010

Van Der Bom J. G., AS-MO-034, AS-TH-035, OC-TH-025, OC-TU-070, PP-MO-633

AUTHORS INDEX

581

Van Der Griend R., PP-WE-475

Van Der Kley-Corssmit N.P.M.,PP-TH-238

van der Lee J. H., PP-MO-597

van der Linden I. K., PP-MO-236

Van Der Linden I., PP-WE-497

Van Der Linden P. W. G., PP-MO-571

van der Linden P., PP-MO-617

Van Der Meer F. J. M., LB-MO-001, OC-TH-008, PP-MO-571

Van Der Meer J., AS-MO-002,OC-MO-001, OC-MO-082, OC-WE-098, OC-WE-100, PP-MO-286, PP-MO-677, PP-TH-356, PP-TH-515, PP-TH-516, PP-WE-326, PP-WE-554

Van Der Meijden P. E. J., AS-TU-037, PP-TH-007

Van Der Meijden P. J. E., AS-TU-029

Van Der Neut E., PP-MO-720

van der Planken M., PP-MO-383

van der Poll T., OC-TH-062,OC-TH-066, OC-WE-144, PP-MO-190, PP-MO-191, PP-TH-153, PP-WE-407

Van Der Post J. M., AS-MO-030

Van Der Schoot C., PP-TH-373

van der Sluijs K., OC-TH-066

Van Der Steege G., OC-WE-098

Van Der Veen F., PP-TH-373

Van Der Velde E., OC-TH-017,OC-TU-012

Van Der Voort R. G. J., OC-MO-023

Van Der Wal D. E., PP-MO-035,PP-MO-036, PP-TH-046

Van Der Zee A. G. J., PP-MO-677

Van Dijk S. M., PP-MO-042

Van Doormaal F. F., OC-MO-014, OC-TU-059, PP-MO-763, PP-MO-769

van Dreden P., PP-MO-369,PP-TH-447, PP-TH-483, PP-WE-508

van Dyke M., PP-WE-703

van Eck M., OC-WE-046

Van Eck-Smit B. L. F., PP-TH-293

Van Eimeren V. F., PP-TH-463

van Geet C., PP-MO-059, PP-MO-094, PP-WE-041, PP-WE-085, SA-MO-015

Van Geffen M., OC-TH-052,PP-WE-555

Van Geloven N., AS-TU-035

Van Giersbergen P. L. M., PP-TH-423

Van Giezen J. J. J., PP-MO-095, PP-TH-104

Van Haren B., PP-MO-621

Van Haren S. D., PP-TH-616

Van Heerde W. L., PP-TH-260,PP-WE-064, PP-WE-555

Van Heerde W., OC-TH-052

Van Helden P. M., OC-WE-063,OC-WE-065

van Hoorelbeke K., PP-WE-726

Van Hylckama Vlieg A., AS-TH-002, OC-MO-023, OC-MO-079, OC-WE-015, PP-MO-289

Van Kraaij M., PP-TH-260

Van Kruchten R., AS-TU-037

Van Langevelde K., PP-WE-303

Van Leeuwen Y., LB-MO-001, PP-WE-771

Van Loon J. E., OC-TH-029,PP-WE-346

Van Marion V., PL-TU-001

Van Minkelen R., OC-MO-019,PL-TU-001

Van Nispen Tot Pannerden H.E., PP-MO-042, PP-WE-061

Van Noorden C. J. F., OC-WE-019, PP-TH-484

Van Oerle R., AS-WE-058, OC-MO-125, OC-TH-001, OC-TH-080, OC-TU-085, OC-WE-060,

OC-WE-097, PP-MO-337, PP-MO-433, PP-MO-484, PP-TH-122, PP-TH-344, PP-TH-516, PP-WE-017, PP-WE-072, PP-WE-219, PP-WE-352, PP-WE-353

Van Ommen C. H., PP-MO-444,PP-MO-597

Van Ommen C., OC-TU-063

Van Oostenbrugge R. J., PP-WE-219

Van Oostenbrugge R., OC-TU-085

Van Os G. M. A., OC-MO-030

Van Pampus E. C. M., PP-MO-670

Van Rooden C. J., PP-WE-521

van Rooijen N., PP-WE-151

van Russelt M., PP-WE-267

Van Ryn J., PP-MO-347, PP-TH-134, PP-WE-181, PP-WE-190, PP-WE-390

Van Schie M. C., OC-TH-029,PP-WE-355

Van Schilfgaarde M., PP-TH-436, PP-WE-778, PP-WE-779

Van Schouwenburg I. M., OC-MO-082, OC-WE-098

Van Sluis G. L., OC-MO-042,OC-WE-019, PP-MO-484, PP-TH-484

van Staden B., PP-WE-726

Van Stralen K. J., PP-MO-316

Van ‘T Veer C., PP-MO-190,PP-MO-191, OC-TH-062, OC-TH-066, OC-WE-144

van Thiel D., PP-TH-142

Van Tiel C. M., PP-MO-022

Van Veen J. J., PP-MO-702,PP-TH-664, PP-WE-766

Van Veen J., PP-MO-199

Van Velzen J., PP-WE-064

van Vlijmen B. J. M., PP-MO-236

Van Vlijmen B., PP-TH-377

Van Waesberghe J. H. T. M.,PP-TH-517

van Walderveen M. C., PP-TH-135

AUTHORS INDEX

582

Aut

hors

Inde

x

Van Weert H. C., OC-TH-017

Van Weert H., OC-TU-012

Van Werkum J. W., OC-MO-133, OC-MO-135, PP-MO-780, PP-MO-781, PP-MO-788, PP-WE-741, PP-WE-742

Van Westerloo D. J., PP-WE-407

Van Wijngaarden A., PP-MO-151

Van Zaane B., PP-MO-292, PP-MO-293, PP-TH-238, PP-TH-286, PP-MO-659

Van Zanten A. P., PP-TH-286

Van Zonneveld A., PP-WE-851

Vanacore R., PP-MO-758

Vancraenenbroeck R., PP-MO-094

Vandahl B. S., PP-MO-565

Vandahl B., PP-MO-558

Vandeberg P., PP-TH-396

Vandenbroucke J. P., AS-TH-002

Vandeputte N., PP-MO-050,PP-WE-086

Vanderelst L. A., PP-MO-605

Vandreden P., PP-MO-368, PP-MO-491, PP-TH-345

Vangenechten I., PP-MO-383

Vanhoorelbeke K., AS-MO-014,OC-WE-040, PP-MO-049, PP-MO-050, PP-MO-088, PP-MO-094, PP-TH-091, PP-WE-013, PP-WE-084, PP-WE-086

Vanni S., OC-TH-014

Vannier J. P., PP-TH-447

Vannier J., PP-MO-491

Vannini M., PP-MO-267

Vannucchi A. M., AS-TU-046

Vanrusselt M., PP-TH-520, PP-TH-625, PP-TH-635

Varadi K., PP-MO-640, PP-TH-611, PP-TH-641, PP-WE-619

Vardosanidze R., PP-WE-281

Varela L., PP-MO-641

Varfaj F., PP-WE-289

Varfolomeyev S., PP-TH-219,PP-TH-227

Vargas G., OC-MO-026, OC-MO-114

Varga-Szabo D., AS-TU-005,OC-TH-039

Varga-Szabó D., AS-TU-040

Vargová K., PP-MO-772

Varin R., PP-MO-514, PP-TH-174, PP-TH-211, PP-WE-505, PP-WE-855

Varma G., PP-TH-476

Varma M., PP-MO-817

Varma N., PP-MO-324, PP-WE-456

Varma S., PP-MO-324

Varon D., PP-WE-847

Varpio L., PP-MO-460

Varraso R., OC-TU-004

Vartholomatos G., PP-MO-657,PP-WE-681

Varughese J. I., PP-MO-427

Vaschuk I., PP-MO-863

Vasco B., PP-MO-226

Vasey S., AS-MO-055

Vasheghani A., PP-WE-281

Vasileiadou D., PP-MO-257

Vasilenko I., PP-MO-729, PP-MO-863, PP-TH-236, PP-WE-062, PP-WE-137, PP-WE-138

Vasiliev S. A., PP-MO-218, PP-MO-668, PP-WE-170

Vasquez J., PP-MO-265, PP-WE-117

Vassallo J. J. V., PC-046

Vassara C., PP-MO-777, PP-MO-778, PP-MO-779

Vasse M., PP-MO-491, PP-TH-345, PP-TH-447

Vauthier C., PP-MO-112

Vavilova T. V., PP-TH-025

Vayá A., PP-MO-192, PP-MO-193

Vaysse N., OC-WE-085

Vaz R., PP-TH-444

Vazzana N., OC-TU-088

Vdovin V. V., PP-TH-454

Vecchio V., PP-MO-802

Vecchioli M., PP-MO-457, PP-MO-458

Vecchione G., PP-MO-822, PP-WE-367

Vedantham S., AS-TH-026

Vedovati M. C., OC-TH-014,PP-WE-313

Veeger N. J. G. M., OC-MO-082, OC-WE-100, PP-MO-286,PP-TH-332

Veeger N., AS-MO-002, OC-MO-001, PP-WE-326

Vega-Ostertag M., PP-TH-661,PP-WE-210

Vegting I. L., PP-MO-444

Veiga M., PP-MO-521

Vejda S., PP-MO-640, PP-TH-641

Velasco F., PP-MO-566

Velázquez L., PP-MO-134, PP-WE-141

Veldman A., PP-MO-660

Veljkovic D., PP-TH-269, PP-WE-867

Vellicce A., PP-TH-044

Velthuis S. I., PP-MO-506, PP-WE-521

Vely F., AS-MO-060

Venisse L., AS-TU-024

Venter C. S., PP-WE-228

Ventura J. S., PP-MO-475, PP-MO-849

Verbeek K., PP-TH-260

Verberne L. M., OC-MO-091

Verbeuren T. J., PP-MO-382,PP-MO-395, PP-WE-396

Verbruggen B., OC-TH-052,PP-MO-168, PP-MO-169, PP-MO-621, PP-TH-260, PP-TH-665, PP-WE-555, PP-WE-735

Vercauteren E., PP-MO-225

Vercruysse K., PP-WE-416

Verduijn M., PP-MO-316

Veréb Z., PP-MO-359

Vergeer M., OC-WE-046

Verghese L., PP-WE-377

AUTHORS INDEX

583

Vergnes C., PP-MO-195, PP-MO-196, PP-TH-189

Vergnes M. C., PP-TH-385

Vergnes M., OC-WE-017

Vergouwen M. D. I., AS-TU-035

Vergura P., PP-MO-822, PP-WE-367

Verhagen H. J. M., OC-TH-031

Verhamme P., OC-TH-057

Verheugt F. W. A., PP-WE-741

Verhoef S., PP-MO-035, PP-MO-036

Verkleij C. J. N., PP-MO-221,PP-WE-336

Verlato F., PP-WE-338

Verlato G., PP-WE-338

Vermeer C., OC-TU-053, PP-WE-808

Vermeulen M., AS-TU-035

Vermylen C., PP-WE-532

Vernois J., PP-MO-530

Verro P., PP-MO-356

Verschuren F., AS-TU-009, OC-TH-073, PP-TH-524

Verschurren F., OC-MO-041

Verso M., OC-MO-018

Versteeg H. H., AS-MO-063,PP-MO-764, PP-TH-484

Verstuyft C., PP-WE-186

Verzijlbergen J. F., PP-WE-317

Veselova S. P., PP-MO-806

Vestrini A., AS-TH-034, PP-WE-748

Veth J., OC-MO-019

Veth R., PP-TH-665

Vetr H., PP-MO-711, PP-TH-148, PP-WE-777

Veyradier A., PP-MO-626, PP-TH-623

Vianello F., OC-WE-088, PP-MO-867

Vicente C. P., PP-TH-499

Vicente V., AS-MO-054, AS-TH-052, OC-TH-027, OC-TH-120, OC-TU-080, OC-TU-082, OC-WE-107, PP-MO-055, PP-MO-134, PP-MO-144, PP-MO-732,

PP-TH-096, PP-TH-247, PP-TH-287, PP-TH-481, PP-WE-033, PP-WE-123, PP-WE-141, PP-WE-764

Vickars L., OC-TU-011, OC-TU-068

Vickerman M., PP-MO-051

Vickers M. R., OC-TU-002

Vidal F., PP-MO-528

Vidovic A., PP-WE-634

Vidovic N., PP-TH-537

Vidwan P., PP-TH-243, PP-WE-694

Vielpeau C. H., OC-TU-022

Vielpeau C., OC-WE-002

Viertel A., PP-MO-317

Viesti U., PP-MO-616

Viganò M., AS-MO-009

Vigh T., PP-WE-087

Vigneron C., PP-MO-530

Vignoli A., AS-TU-050, PP-MO-476, PP-MO-867, PP-WE-499

Vija H., PP-MO-149

Vik A., OC-WE-137, OC-WE-140

Vila K., PP-WE-065

Vila V., PP-TH-363, PP-WE-885

Villa D., PP-WE-356

Villa R., PP-WE-264

Villaca P. R., PP-MO-755, PP-TH-542, PP-WE-705

Villalta S., PP-WE-460

Villamil F., PP-TH-681

Villanueva C., PP-MO-413

Villaume K., PP-WE-493

Villaverde C. A., PP-MO-209

Villoutreix B. O., PP-WE-157

Vincent J. L., OC-TH-069

Vincent L., PP-WE-855

Vincentelli A., PP-MO-815

Vincenzi D., PP-MO-523

Vinciguerra C., OC-TU-073,PP-MO-645, PP-TH-619, PP-WE-533

Vinícius De Paula E., PP-WE-066

Vinnikov I., AS-MO-059

Vinther K., PP-MO-118

Violi F., PP-TH-050, PP-WE-105, PP-WE-753

Vishenskaya T., PP-MO-729

Vishnevskaya S., PP-TH-023,PP-WE-046

Visonà A. A., PP-TH-308

Visonà A., PP-TH-303

Vissac A. M., PP-MO-419, PP-MO-697, PP-MO-701

Visser M. M., OC-MO-082

Visseren F. L., PP-MO-007

Visvikis-Siest S., OC-MO-021

Viswanathan S., PP-WE-729

Vitale J., OC-MO-092

Vitali M., PP-TH-568

Vittorini R., PP-TH-453

Vitzthum F., OC-MO-090

Viuff D., PP-WE-589, PP-WE-590, PP-WE-591

Vivien D., OC-TH-113

Vladareanu A., PP-MO-069,PP-TH-063, PP-WE-075

Vladareanu R., PP-MO-069

Vlahovic G., PP-TH-269

Vlaisavljevic N., PP-WE-680

Vlasova E., PP-MO-863, PP-TH-236, PP-WE-137, PP-WE-138

Vlckova E., PP-TH-422

Vliegen H. W., PP-WE-322

Vlodavsky I., PP-TH-387

Vodickova L., PP-TH-438

Vohnout B., PP-TH-249, PP-WE-246

Voican I., PP-MO-069

Voisin S., PP-MO-188, PP-WE-169

Vojacek J., PP-TH-438

Völker U., OC-TU-026

Volkmann N., OC-WE-148

Volkov G. L., PP-MO-146, PP-MO-401, PP-TH-160

Volkov G., PP-TH-395

Volovyk Z., PP-TH-205

AUTHORS INDEX

584

Aut

hors

Inde

x

Volpato S., PP-TH-372

Von Depka M., PP-MO-693

Von Depka Prondzinski M.,PP-WE-633, PP-WE-644

Von Der Thusen J., OC-WE-105

Von Eiff C., PP-MO-031

Von Eller-Eberstein H., PP-MO-307

Von Heymann C., PP-MO-240,PP-MO-241

Von Kügelgen I., PP-MO-253

Von Mackensen S., OC-MO-034, OC-WE-119, PP-TH-558, PP-TH-559, PP-WE-542, PP-WE-563

Von Pape K., PP-WE-038

Vondrakova J., PP-MO-689

Vonk Noordegraaf A., PP-WE-322

Voorberg J., AS-WE-012, AS-WE-013, OC-MO-111, PP-TH-080, PP-TH-616, PP-WE-157

Vormittag R., OC-MO-027, OC-TU-013, OC-TU-016, PP-MO-322, PP-TH-273

Vorobev A., PP-MO-474

Vorobiova E., PC-019

Vorobyev P. A., PP-MO-553,PP-TH-581, PP-WE-561

Vorobyeva N. A., PP-TH-512,PP-WE-679

Vorobyeva N. M., PP-TH-513,PP-WE-526

Vorpahl F., PP-MO-592

Vorster H. H., PP-WE-228

Vos H. L., AS-TH-035, OC-MO-019, OC-MO-078, OC-MO-122, PL-TU-001, PP-MO-151

Voscresenskaya O., PP-MO-256

Vosmaer A., OC-WE-091

Vossen C. Y., AS-MO-003, OC-MO-024, PP-MO-316, PP-MO-480

Vossough P., PP-TH-124

Vowles J., PP-MO-550

Voyno-Yasenetskaya T., PP-WE-004

Vrbacky’ F. F. V., PP-TH-369

Vucemilo T., PP-TH-258

Vuilleumier N., OC-TH-073

Vujic D., PP-WE-867

Vukovich T., OC-TU-013

Vutuc C., PP-TH-317

Vydyborets S. V., PP-TH-479

Wada H., PP-MO-497, PP-MO-669, PP-MO-717, PP-TH-526

Wada T., PP-WE-687

Waddington S. N., OC-TU-076,PP-WE-150, PP-WE-151

Wadoodi A., PP-MO-384

Waelkens E., PP-WE-041

Wågberg F., PP-WE-185

Wagenvoord R. J., PP-TH-176,PP-TH-177

Wagenvoord R., PP-TH-107

Wagner B., PP-MO-075

Wagner D. D., AS-MO-047, OC-TH-063, OC-TU-045, PP-MO-093

Wagner L., PP-MO-551

Wagner O., OC-TU-015

Wagner T., PP-WE-380

Wagstaff L., PP-MO-853

Waha R., AS-MO-028

Wahi R., PP-MO-152, PP-MO-153, PP-MO-154, PP-TH-390

Wahl D., OC-MO-029, PP-MO-402

Wahl M., PP-MO-244

Wahlander K., PP-WE-200, PP-WE-201

Wåhlander K., PP-WE-172, PP-WE-185

Wahlmüller F., OC-TU-081, PP-MO-189

Wain G. V., PP-WE-300

Waite C., PP-WE-547

Wajih N., PP-WE-861

Wajima T., PP-MO-249

Wakabayashi H., PP-MO-155,PP-WE-289

Wakagi K., PP-TH-688

Waked E. A., PP-WE-067

Waked M., PP-WE-281

Wakefield C. D., AS-TH-053

Wakefield T. W., OC-TU-060,PP-MO-388, AS-MO-006

Waldhoer T., PP-TH-317

Walenga J. M., OC-TH-019,PP-MO-139, PP-MO-399, PP-TH-390, PP-TH-391, PP-TH-404, PP-WE-262, PP-WE-387, PP-WE-395, PP-WE-481

Walenga J., OC-TH-103, PP-MO-140, PP-WE-143, PP-WE-385

Walker A., AS-MO-037

Walker I. D., PP-MO-320, PP-WE-716

Walker I., PP-MO-115, PP-MO-116, PP-MO-534, PP-WE-541

Walker M. B., PP-MO-469

Walker S. P., PP-MO-381

Walkowiak B., PP-MO-071, PP-WE-879

Wallace K., OC-TU-027

Wallace S., PP-TH-632

Wallace T., PP-TH-442

Wallen H., PP-TH-141

Wallén H., OC-WE-104, PP-MO-374, PP-MO-761, PP-MO-762, PP-TH-186

Wallen N., OC-TH-079

Wallentin L., PP-MO-408, PP-TH-407, PP-TH-469

Walsh C. E., PP-WE-584

Walsh M. T., OC-TU-045

Walsh P. N., PP-MO-181

Waltenberger J., PP-MO-337,PP-WE-352

Walter L., PP-MO-317

Walter U., AS-MO-038, PP-WE-077

Walters D., PP-WE-021

Waltham M., PP-MO-384

Wanachiwanawin W., PP-MO-406, PP-WE-772

AUTHORS INDEX

585

Wanaka K., PP-MO-704

Wang A., PP-TH-093

Wang C., PP-MO-695

Wang D., PP-WE-707

Wang G. T., PP-TH-663

Wang G., OC-TH-091, PP-TH-129, PP-TH-197

Wang H., AS-MO-059, OC-TH-060, OC-WE-027, PP-MO-020, PP-MO-203, PP-MO-510, PP-TH-127, PP-TH-203, PP-TH-331, PP-TH-562, PP-TH-563, PP-TH-564, PP-TH-565, PP-WE-770, PP-WE-846, PP-MO-531, PP-TH-114, PP-MO-646

Wang J. W., AS-WE-040

Wang J., AS-MO-044, OC-TU-017, PP-MO-510, PP-TH-119

Wang K., PP-WE-636

Wang L., OC-MO-136, OC-TH-077, PP-WE-478, PP-WE-009

Wang M., AS-WE-049, PP-TH-265, PP-TH-564

Wang Q., PP-TH-334, PP-WE-101, PP-WE-857

Wang R., PP-TH-112

Wang S., PP-TH-334

Wang W., PP-WE-819

Wang X., PP-MO-203, PP-MO-510, PP-MO-554, PP-TH-127, PP-TH-203, PP-TH-331, PP-TH-562, PP-TH-563, PP-TH-564, PP-TH-565, PP-WE-536, PP-WE-770, PP-MO-531, PP-WE-667, PP-MO-646, PP-TH-126

Wang Y. C., PP-TH-634

Wang Y., AS-TH-042, AS-WE-027, PP-TH-092

Wang Z., PP-TH-335, PP-WE-773

Wanivenhaus H. A., PP-TH-690

Wannemacher K. M., PP-WE-030

Ward C. M., PP-MO-410, PP-MO-411, PP-WE-221

Ward K. R., PP-TH-682

Ward V. A., OC-TU-067

Wardrop J., PP-MO-754

Ware J., AS-TU-030, OC-WE-020, PP-MO-082, PP-WE-051, PP-WE-060, AS-MO-031

Warner T. D., AS-WE-052, PP-MO-740, PP-MO-741, PP-TH-001, PP-TH-002

Warnock M., PP-MO-244, PP-TH-252

Warwick D., PP-MO-248

Waschke J., OC-MO-068

Washington A., OC-TH-036,PP-WE-065

Wasserman B., PP-WE-819

Watala C., PP-MO-097, PP-TH-098, PP-TH-099, PP-WE-034

Watanabe G., PP-TH-229, PP-WE-015

Waterman P., AS-WE-057

Waters B., OC-TH-053

Waters E. K., PP-WE-168, PP-WE-569

Watkins N. A., AS-MO-037,OC-TH-037, OC-TU-029, OC-WE-126

Watkins T. R., PP-TH-468

Watson C. A., PP-TH-171

Watson C. C., PP-MO-702

Watson H. G., PP-WE-676

Watson S. P., AS-WE-033, OC-MO-069, OC-MO-131, OC-TH-041, PP-TH-021, PP-WE-076, AS-TU-036

Watson S., PP-MO-076

Wattanatittan S., PP-WE-710

Watzka M., OC-WE-076, OC-WE-077, PP-TH-397, PP-TH-658, PP-WE-159

Waye J. S., AS-TH-045

Webb I. G., PP-TH-014

Weber A., PP-MO-640, PP-TH-640

Weber C., SA-TU-012, PP-WE-892

Weber G. J., OC-TU-030

Webert K. E., PP-TH-663

Weck K., PP-TH-466

Weeterings C., AS-TU-017, PP-MO-126

Wegrzyn W., PP-MO-784

Wei Z., AS-MO-023

Weickardt S., AS-TH-055

Weidow B. L., PP-WE-494

Weijers E. M., PP-MO-847

Weiler H., SA-MO-012, AS-TH-008, AS-TU-043, AS-WE-058, OC-TH-068, PP-MO-880, PP-MO-881

Weilitz J., PP-MO-095

Weimer T., OC-WE-120, PP-TH-130, PP-TH-561

Weinberger J., PP-MO-615

Weingärtner O., PP-MO-809

Weinspach S., PP-MO-595

Weinstein B., SA-WE-012

Weintraub M., AS-TU-008

Weise-Kelly L., PP-WE-489

Weisel J. W., AS-MO-039, AS-WE-048, OC-TH-055, OC-WE-112, OC-WE-146, PP-TH-214, PP-WE-212

Weiss A., AS-WE-033, PP-TH-021

Weiss C., PP-MO-420, PP-WE-182, PP-WE-183

Weiss D., PP-WE-210

Weiss E. J., OC-MO-077

Weiss R., PP-MO-518

Weiss T., PP-WE-344

Weisser H., PP-WE-038

Weissleder R., AS-WE-057

Weissman P., PP-WE-172

Weitz J. I., OC-TH-106, OC-WE-079, PP-MO-428, PP-TH-009

Weitz J. J. I., PP-MO-086

Weksler B. B., PP-WE-868

Welland M. E., PP-MO-058

Wells P., OC-MO-051, OC-TU-020, OC-WE-005, PP-MO-460, PP-MO-468, PP-WE-500, OC-TH-012, OC-TU-011, OC-MO-021, PP-TH-292, PP-WE-462

AUTHORS INDEX

586

Aut

hors

Inde

x

Welsh P., OC-WE-033, OC-WE-116

Wen B. Z., PP-TH-112

Wen J., AS-TH-012, AS-TU-012

Wen N., PP-TH-400

Wen Z. B., PP-TH-146

Wen Z., PP-WE-846, PP-TH-114

Werdan K., PP-TH-440, PP-WE-190

Werstuck G. H., PP-WE-817

Werth S., AS-MO-057

Westein E., OC-WE-124, PP-TH-642

Westenberg J. J. M., PP-MO-507

Westendorp R., OC-WE-033,OC-WE-116

Westenfeld R., OC-TU-053

Wester J. P. J., PP-TH-436

Westerbeek R. E., PP-WE-521

Westerga J., PP-MO-484

Westerlund E., PP-MO-374

Westfeld M., PP-TH-575, PP-WE-593, PP-WE-594

Westhofen P., PP-TH-397, PP-WE-159

Westrich G., PP-MO-248

Westrick L. G., PP-WE-122

Westrick R. J., OC-WE-039,PP-TH-398

Westrup D., PP-MO-179, PP-MO-746, PP-TH-662, PP-WE-763

Wetzel K., PP-TH-134

Weyrich A. S., AS-WE-028,OC-TU-047

Wheatcroft S. B., AS-TH-019

Wheeler M., PP-MO-713

Wheeler R. B., PP-TH-152

Whelchel K., PP-TH-473

Whelihan M. F., AS-TU-023,OC-MO-006

Whinna H. C., PP-MO-392

Whinna H., PP-WE-290

Whiss P. A., PP-MO-047

White - Md J. G., PP-MO-081

White A. E., PP-WE-045

White B., PP-MO-593, PP-TH-549, PP-WE-685

White J., PP-MO-057

White M. J., AS-WE-032

White M. M., PP-TH-097

White N. J., PP-TH-682

White R. H., OC-MO-080, OC-TU-009, OC-TU-014, PP-MO-356, PP-TH-311, PP-TH-357, PP-TH-498, OC-TU-011

White-Adams T. C., PP-TH-037

Whitehead M., OC-MO-088,OC-MO-089

Whiteheart S., OC-WE-045

Whitsett C., PP-TH-328

Whittaker P., PP-WE-102, PP-WE-479

Whyte K., OC-TU-002

Wibaut B., PP-TH-583

Wice S. M., PP-WE-392

Wichers I. M., PP-TH-139

Wichterle D., PP-WE-345

Wickert T., PP-TH-120

Wicklund B. M., PP-MO-596,PP-WE-613

Wiedebusch S., PP-MO-459

Wiegand G., PP-TH-450

Wieland K., OC-WE-152

Wielders S., PP-WE-157

Wieloch A., PP-TH-559

Wienen W., PP-MO-347, PP-TH-134, PP-WE-181, PP-WE-390

Wiens L., PP-MO-551

Wierdak J., PP-MO-420

Wiertz N. R., PP-TH-436

Wiesel M. L., PP-MO-416

Wijeyeratne Y. D., PP-WE-045

Wijmenga C., OC-WE-098

Wiklund B., PP-MO-761

Wiktorska M., PP-MO-839, PP-MO-843

Wilcox D. A., AS-TH-009, OC-TH-097

Wilde J., PP-MO-076

Wildes M. T., PP-MO-722

Wilhelm S., OC-MO-068, PL-TU-003

Wilk R., PP-MO-097

Wilke C. T., PP-MO-545, PP-MO-600

Wilkieson T. J., OC-TH-009

Will A. M., PP-MO-690

Will A., OC-TU-078, PP-TH-645

Willcox A., AS-WE-032

Willemse J. L., PP-MO-327

Willemse J., PP-MO-229, PP-MO-230

Williams G. D., PP-TH-458

Williams H., OC-TU-054

Williams M. D., OC-TH-041,PP-MO-614, PP-MO-623, PP-TH-449

Williams M., PP-WE-214, PP-WE-215

Williams S. A., PP-MO-823,PP-TH-065

Williams S., OC-MO-116, PP-MO-426, PP-MO-443, PP-MO-447, PP-TH-459, PP-TH-463, PP-WE-288, PP-WE-443, PP-WE-445, PP-WE-446, PP-WE-719

Williams Z., OC-TU-068

Wilmer M., PP-WE-519

Wilsgaard T., OC-TU-005, OC-TU-006, OC-WE-137, OC-WE-140, PP-WE-304, PP-WE-305

Wilson A. R., PP-WE-306, PP-WE-725

Wilson D. W., PP-MO-389

Wiman B., PP-WE-646

Winckers K., PP-TH-344, PP-WE-072

Winder A., PP-MO-338

Windyga J., PP-MO-692, PP-MO-714, PP-TH-658, PP-WE-660

Winkens M., PP-MO-337

Winkler A. M., PP-MO-137, PP-TH-136

Winkler A., PP-MO-068, PP-WE-672

AUTHORS INDEX

587

Winkler S., PP-WE-892

Winkler U., OC-MO-090

Winn L. Y. N., PP-MO-089

Winship P. R., AS-MO-019, OC-WE-135, PP-MO-052, PP-TH-244, PP-TH-638, PP-WE-161

Winstedt D., PP-TH-359, PP-TH-695

Winter L., PP-TH-629

Winters K. J., PP-MO-733

Wipfler P., OC-WE-138

Wischmeyer P., PP-TH-408

With Notø A., PP-MO-813

Witke W., AS-WE-029

Witkoff L., OC-WE-009, OC-WE-129

Witmer C., AS-TU-055

Witt - D., PP-MO-308

Witt D. M., PP-MO-462, PP-MO-463

Witteman J. C. M., OC-TU-034

Wittig I., PP-MO-365

Wizowski L., PP-WE-431

Wlian L., PP-MO-849

Woda M., AS-WE-018

Wohlfeil M., PP-TH-652

Wohner N., PP-MO-851

Wojta J., PP-MO-829

Wolberg A. S., OC-MO-073,PP-TH-119, PP-TH-655, PP-WE-299

Wolf H., AS-MO-030

Wolf M., PP-MO-376, PP-MO-626

Wolfsegger M., AS-WE-015,OC-WE-065

Wolowacz S. E., PP-WE-469,PP-WE-470, PP-WE-471

Wolter M., PP-MO-706

Wolzt M., PP-WE-200, PP-WE-201

Won J., PP-TH-504

Wong A., PP-TH-188

Wong I., AS-TH-045

Wong M. L. G., PP-TH-441

Wong P. C., PP-TH-171, PP-TH-202

Wood J. P., OC-MO-066, OC-MO-120

Woodhams B. J., OC-TU-033,PP-MO-108, PP-MO-112, PP-MO-368, PP-MO-369, PP-MO-491, PP-MO-514, PP-MO-533, PP-MO-766, PP-TH-115, PP-TH-183, PP-TH-185, PP-TH-211, PP-TH-235, PP-TH-345, PP-WE-164, PP-WE-232, PP-WE-505

Woodhams B., PP-MO-348,PP-TH-487, PP-TH-488, PP-TH-684

Woodley-Cook J., PP-TH-434

Woods A. I., PP-MO-610, PP-MO-613, PP-TH-350, PP-WE-089

Woods D., PP-WE-118

Woods T. A. L., PP-MO-320,PP-WE-716

Woods T., PP-MO-115, PP-MO-116

Woods V. L., OC-MO-022, OC-TU-095

Woodward M., OC-TH-080, PP-WE-353

Woollard K. J., PP-WE-391

Worms B., PP-MO-530

Wort S. J., PP-WE-805

Woulfe D. S., AS-WE-031

Woulfe D., OC-TH-094, OC-TH-095

Wright B., PP-MO-032, PP-TH-031

Wright J. R., OC-TU-029, OC-WE-126

Wright M. J., PP-WE-541

Wrobleski S. K., OC-TU-060,PP-MO-388, PP-MO-400

Wu C., PP-MO-665

Wu D., PP-TH-335, PP-WE-773

Wu H. L., PP-MO-158

Wu H. M., OC-WE-009, OC-WE-129, OC-WE-130, PC-036, PP-WE-729

Wu J. K. M., AS-WE-003, OC-TU-068, PP-WE-553

Wu J. R., PP-MO-319, PP-MO-549, PP-WE-291, PP-WE-299

Wu J., AS-MO-062, OC-WE-059, PP-MO-171, PP-MO-203, PP-MO-504, PP-MO-554, PP-TH-038, PP-TH-203, PP-WE-536, PP-WE-540

Wu K. K., PP-WE-819

Wu M., PP-WE-845

Wu R., PP-TH-548, PP-WE-728

Wu W., PP-WE-183, PP-WE-845

Wu X., PP-TH-548, AS-WE-030,OC-TU-039

Wu Y. P., PP-TH-046

Wu Y., PP-TH-331, PP-WE-216

Wulf S., PP-TH-095

Wulffen B., PP-WE-180

Wun T., OC-TU-014, PP-TH-498

Wunderlich F. T., OC-WE-076

Wurtz V., PP-MO-033, PP-TH-010

Wuttke W., PP-WE-373

Wygrecka M., AS-TH-037

Wysocki T., PP-MO-839, PP-MO-843

Xafaki P., PP-TH-597, PP-WE-440

Xhaja K. J., AS-WE-018

Xi X., PP-TH-331, PP-TH-562,PP-TH-563, PP-TH-564, PP-TH-565, PP-WE-770

Xia J., PP-MO-548

Xia M., OC-TU-051, PP-WE-836

Xiao Q., PP-WE-852

Xiao X., OC-WE-027

Xie A., OC-MO-123

Xie B., PP-TH-564

Xie X., PP-MO-830

Xie Y. G., PP-TH-364

Ximenes B., PP-WE-870

Xin B., PP-TH-202

Xing W., OC-WE-068

Xiong S., PP-WE-857

Xu G., PP-MO-646, PP-TH-331

Xu J., OC-WE-068, PP-WE-707

Xu L., PC-036

Xu Q., PP-WE-852

AUTHORS INDEX

588

Aut

hors

Inde

x

Xu X., AS-WE-047

Xu Y., OC-TH-061

Xu Z., PP-WE-394

Xue A., PP-WE-292

Xue F., PP-WE-707

Xue J., PP-WE-893

Xue M., AS-TH-017

Yacoub D., PP-MO-012

Yada H., PP-WE-516

Yadav B. K., PP-MO-208, PP-WE-037

Yadav S., PP-WE-794, PP-WE-798

Yago H., PP-MO-497, PP-TH-173

Yaguchi A., PP-TH-521

Yahalom V., PP-WE-036

Yahorava N. V., PP-MO-873,PP-MO-874, PP-WE-863, PP-WE-864

Yakoubi M., PP-TH-680

Yakura Y., OC-TH-088, OC-TU-041

Yakushijin Y., PP-MO-511, PP-WE-011

Yalcin Atay D., PP-MO-344,PP-WE-571

Yamada K., PP-WE-781

Yamada N., PP-TH-526, PP-WE-720, PP-MO-497

Yamada T., PP-MO-138, PP-WE-671

Yamaguchi T., PP-WE-196

Yamaji K., PP-WE-031

Yamaki T., PP-MO-516, PP-TH-319, PP-TH-521, PP-WE-463

Yamamoto H., PP-MO-393, PP-WE-720

Yamamoto J., PP-TH-061

Yamanouchi J., PP-MO-511,PP-WE-011

Yamashita A., PP-MO-111, PP-MO-123, PP-MO-127, PP-MO-439, PP-WE-562

Yamashita T., PP-WE-196

Yamauchi T., OC-TH-051

Yamazaki M., PP-TH-057, PP-WE-278

Yamazaki S., PP-MO-439, PP-WE-562

Yamori Y., PP-TH-061

Yan J., PP-WE-732

Yan Y., AS-MO-023

Yanagisawa Y., PP-WE-149

Yanamoto H., PP-MO-393

Yanar H., PP-WE-197

Yang H., OC-WE-121

Yang J. Y. K., PP-MO-426, PP-TH-441, PP-WE-288

Yang J., PP-MO-093, PP-MO-885, PP-TH-399, PP-WE-099

Yang L., OC-TU-093

Yang M., PP-TH-147

Yang R., PP-MO-203, PP-MO-554, PP-TH-078, PP-TH-203, PP-WE-706, PP-WE-707

Yang S., OC-WE-009, OC-WE-068, OC-WE-130, PC-036, PP-TH-123

Yang W., PP-WE-732

Yanni D., PP-MO-440

Yao Y., AS-WE-032

Yarbrough K., PP-TH-396

Yarlas A. S., PP-WE-537, PP-WE-538

Yasaka M., PP-WE-196

Yastrubinetskaya O., OC-MO-036

Yasuda S., PP-MO-842, PP-WE-269, PP-WE-271

Yasui Y., AS-TU-054

Yasukawa M., PP-MO-511, PP-WE-011

Yatagai C., PP-WE-148

Yates Iii J. R., AS-TU-020

Yatuv R., PP-WE-608

Yatzenko E. A., PP-TH-454

Yau J. W., PP-MO-428

Yavarian M., PP-MO-655, PP-WE-459, PP-WE-518

Yazdani-Abyaneh M., PP-WE-078

Yazihan N., PP-MO-797

Yc C., PP-TH-552

Ye X., PP-TH-132

Yee A., PP-WE-047

Yee C. K., PP-WE-817

Yee T. T., PP-MO-624

Yee T., PP-MO-567, PP-TH-528

Yenson P. R., PP-MO-639, PP-WE-719

Yeo E. L., PP-TH-125

Yesilipek A., PP-MO-606

Yhap M., PP-WE-447

Yildirmak Y., PP-WE-571

Yilmaz D., PP-MO-606, PP-WE-577

Yilmaz E., PC-001

Yin F., AS-WE-042

Yin H., AS-TU-027

Yiu E., PP-TH-463

Ynineb Y., PP-MO-477, PP-MO-478

Yoder M., SA-TH-009

Yokochi M., PP-TH-358

Yokoyama K., PP-WE-015, PP-WE-349

Yoksan S., PP-MO-681

Yong J., PP-MO-577

Yoo B. K., PP-TH-405

Yoo H., PP-WE-844

Yoo K. Y., PP-WE-543

Yoo K., PP-TH-190

Yoon H., PP-TH-504

Yoon S., PP-TH-504, PP-TH-519, PP-WE-027, PP-WE-069

Yoon Y., PP-WE-783

Yoshida K., PP-TH-143

Yoshimura N., PP-TH-358

Yoshioka A., PP-TH-592, PP-WE-606

Yoshizato K., PP-WE-580

You J. Y., PP-MO-330, PP-TH-620

Young G. A., PP-MO-545, PP-WE-602

Young G., PP-MO-604, PP-TH-600, PP-WE-597

Young J., PP-WE-579, PP-WE-661

AUTHORS INDEX

589

Young L., OC-TU-079, PP-MO-493

Younis K. A., PP-WE-067

Ypma P., PP-MO-571

Yu I. S., PP-MO-158

Yu I., PP-TH-401

Yu M., PP-MO-554

Yu P., OC-TH-039

Yu T., PP-MO-510, PP-TH-127,PP-WE-770, PP-MO-646

Yu X., OC-MO-128, PP-TH-022

Yu Y. B., PP-MO-330, PP-TH-620

Yu Z., PP-TH-621

Yuan Y., AS-WE-032

Yuana Y., AS-WE-019

Yuce H., PP-WE-708, PP-WE-709

Yuldasheva N. Y., AS-TH-019

Yun Y., PP-WE-844

Yun-Choi H., PP-WE-027

Yunus E. B., PP-MO-710

Yusen R. D., OC-TU-009, OC-TU-021

Yusen R., PP-MO-299

Yves-Line D., PP-WE-507

Z Omar S., PP-MO-366

Za T., PP-WE-366

Zaatari G., PP-MO-135

Zabolotskikh I. B., PP-TH-250,PP-TH-251

Zacchi E., PP-WE-868

Zäch D., PP-TH-559

Zacharias C., PP-TH-569, PP-TH-587

Zachoval R., PP-WE-578

Zachrisson H., PP-WE-386

Zadro R., PP-MO-223, PP-WE-275, PP-WE-435, PP-WE-442

Zaehringer M., OC-MO-008

Zafar T., PP-TH-560, PP-TH-643

Zafiri C., PP-WE-314

Zafreen L., OC-WE-052

Zaidat O. O., PP-MO-442

Zain Z. N. M., PP-MO-740

Zaitsev S., OC-WE-112

Zajicek J., AS-WE-049

Zakai N. A., AS-WE-009

Zakarija A., PP-WE-530

Zakernia M., PP-WE-459

Zaki Zadeh R., PP-WE-558

Zaman A., OC-MO-033

Zamboni W., PP-MO-099, PP-WE-502

Zamfir C., PP-MO-855

Zampolli A., OC-TH-096, OC-TU-044

Zanardelli S., PP-MO-091

Zanazzi M., PP-TH-353, PP-WE-002

Zanon E., AS-TU-032, AS-TU-033, OC-TU-075, PP-MO-525, PP-TH-569, PP-TH-622, PP-WE-567

Zapata V. A., PP-MO-832, PP-TH-044, PP-WE-093, PP-WE-094, PP-WE-402

Zapfl C., PP-MO-615

Zapletal O., PP-TH-530

Zappelli C., OC-MO-112

Zarifis J., PP-MO-777, PP-MO-778, PP-MO-779

Zarpellon A., OC-TH-096

Zaucke F., OC-WE-076

Zavalloni D., PP-WE-791

Zavazava N., PP-WE-594

Zavrelova J., PP-MO-259, PP-WE-596, PP-WE-804

Zawadzki C., OC-TU-073, PP-MO-814, PP-MO-815, PP-TH-623

Zawilska K. M., PP-WE-307

Zawilska K., PP-MO-216, PP-WE-213

Zawilska On Behalf OfHaemostasis Group Of Phit K.M., PP-MO-692

Zbikowski P., PP-MO-608

Zborilova R., PP-MO-689

Zdziarska J., PP-MO-206, PP-MO-692, PP-WE-651

Zeadin M. G., PP-WE-817

Zecca M., AS-TU-004

Zecevic Z., PP-WE-867

Zeerleder S., PP-TH-153

Zeinad A. K., PP-MO-755, PP-TH-542, PP-WE-705

Zeinali S., PP-WE-545

Zekas E., OC-WE-080

Zelenika D., OC-MO-021, PP-TH-309

Zeller W., PP-TH-559

Zemani F., OC-TH-048

Zemanova M., PP-WE-345

Zemljic E., PP-WE-251

Zeng F., PP-WE-857

Zeng G., AS-WE-051

Zeravica B., PP-WE-680

Zerbinati P., PP-MO-243, PP-WE-248

Zerr Fouineau M., OC-TH-035

Zerr-Fouineau M., AS-MO-058

Zgheib N., PP-MO-135

Zgouras D., PP-MO-501

Zhai Z., OC-WE-121

Zhang H., OC-TH-108, PP-TH-388

Zhang J., PP-TH-093, PP-WE-088, PP-WE-731

Zhang L., PL-TU-005, PP-MO-165, PP-MO-859, PP-TH-621, PP-WE-101, PP-WE-706, OC-WE-068

Zhang M., PP-WE-896

Zhang N., PP-TH-548

Zhang S., PP-TH-022

Zhang T., PP-MO-854

Zhang W., OC-WE-073, PP-TH-621

Zhang X., AS-TH-025, OC-MO-101, OC-MO-127, OC-MO-136, OC-MO-137, OC-WE-057, OC-WE-059, PP-MO-203, PP-TH-203, PP-WE-674

Zhang Y., OC-MO-109, PP-TH-022, PP-WE-732, PP-MO-810

Zhao C., OC-TH-108

Zhao H., PP-TH-078, PP-WE-706, PP-WE-707

AUTHORS INDEX

590

Aut

hors

Inde

x

Zhao L., PP-TH-548

Zhao X., OC-WE-057, OC-WE-059

Zhao Y., AS-WE-033, OC-MO-123, PP-MO-105, PP-MO-203, PP-MO-554, PP-MO-642, PP-MO-854, PP-TH-203, PP-TH-334, PP-TH-399, PP-TH-621, PP-WE-076, PP-WE-732

Zheng C., PP-MO-171, PP-WE-536

Zheng L., PP-WE-857

Zheng X. L., PP-TH-080

Zheng X., AS-MO-015, OC-TH-063, OC-TU-043, PP-TH-045

Zheng Y., PP-WE-006, PP-WE-674

Zhmurov A., PP-TH-214

Zhong A., PP-MO-518

Zhong D., PP-TH-112

Zhou A., AS-MO-023

Zhou B., OC-WE-068

Zhou J., PP-WE-674

Zhou M., PP-TH-147

Zhou R., PP-TH-667

Zhou S., AS-TU-013, AS-TU-015

Zhou W., OC-WE-010

Zhou Y., OC-MO-128, OC-TH-056

Zhou Z., PP-TH-078, PP-TH-600, PP-WE-612

Zhu D., OC-WE-059

Zhu G., AS-TU-030, OC-MO-139, OC-WE-039, PP-TH-398, PP-WE-060

Zhu H., OC-TH-103, OC-WE-028, PP-MO-152, PP-MO-153, PP-MO-154, PP-TH-389

Zhu J., AS-WE-033, PP-TH-021

Zhu L., AS-TU-028, PP-MO-105, PP-WE-030, PP-WE-818

Zhu M., PP-MO-859

Zhu T., OC-TH-005, OC-WE-017

Zhu W., PP-MO-171

Zhu X., OC-MO-136, PP-MO-695, PP-WE-731

Zhukova A. I., PP-MO-146, PP-MO-872

Zhulev U. A., PP-MO-553, PP-TH-581, PP-WE-561

Ziaja K., PP-WE-433

Zidane M., OC-TH-008

Zidani N., PP-WE-639, PP-TH-204

Ziegelin M., OC-MO-126

Zieger B., PP-MO-029, PP-MO-128, PP-WE-210

Zielinski C. C., OC-WE-069,PP-MO-838

Zielinski C., OC-TU-013, OC-TU-015, OC-TU-016, PP-MO-322

Zilberberg M. D., PP-MO-473

Zimmerman G. A., AS-WE-028

Zimmermann A., PP-MO-496,PP-TH-374, PP-TH-375, PP-WE-682

Zimmermann R., OC-WE-077,PP-MO-513, PP-MO-662, PP-TH-421, PP-TH-587, PP-WE-594

Zingali R. B., PP-MO-390, PP-TH-179

Zipfel P. F., OC-TU-028

Zito F., PP-MO-876

Zivelin A., OC-MO-105, PP-MO-434

Zocco M., PP-MO-328

Zogg M., PP-MO-880, PP-MO-881

Zoghlami C., PP-TH-273

Zolfaghari S., PP-WE-324

Zolotukhina S. F., PP-WE-337

Zomer C. A., PP-WE-741

Zon L. I., OC-TU-030

Zonzin P. P. Z., PP-MO-312

Zorenko V. U., PP-TH-581

Zorio E., OC-TH-027

Zou Z., AS-TU-038

Zouain D., PP-TH-556

Zouaoui Boudjeltia K., PP-TH-684

Zozulya N. I., PC-041, PP-MO-553, PP-TH-581, PP-TH-582, PP-WE-561

Zozulya N., PP-WE-608

Zrelak P., PP-TH-311

Zrinski Topic R., PP-WE-435

Zu J., PP-WE-732

Zuber M., PP-TH-417

Zubova N. V., PP-MO-260

Zucker M., OC-MO-105

Zufferey P., OC-MO-050, PP-TH-426

Zuily S., OC-MO-029

Zulfikar B., PP-MO-683, PP-WE-568

Zupancic Salek S., PP-MO-630

Zupancic-Salek S., PP-MO-519

Zurlo F., PP-MO-481, PP-TH-248, PP-TH-249, PP-WE-246

Zwaginga J. J., AS-TH-035

Zwaginga J., AS-MO-037

Zwiauer K., PP-MO-561

Zwiers M., PP-TH-356, PP-WE-554

Zybin K. D., PP-TH-250

AUTHORS INDEX

591

The International Society on Thrombosis and Haemostasis

Documents

Transcript of The International Society on Thrombosis and Haemostasis